FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Howie, S
   Guy, M
   Fleming, L
   Bailey, W
   Noyes, H
   Faye, JA
   Pepin, J
   Greenwood, B
   Whittle, H
   Molyneux, D
   Corrah, T
AF Howie, Stephen
   Guy, Malcolm
   Fleming, Louise
   Bailey, Wendi
   Noyes, Harry
   Faye, Joseph Axel
   Pepin, Jacques
   Greenwood, Brian
   Whittle, Hilton
   Molyneux, David
   Corrah, Tumani
TI A Gambian infant with fever and an unexpected blood film
SO PLOS MEDICINE
LA English
DT Editorial Material
ID SLEEPING SICKNESS; MELARSOPROL; GAMBIENSE; TRIAL
C1 MRC Labs, Banjul, Gambia.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
   Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada.
   London Sch Hyg & Trop Med, London WC1, England.
RP Howie, S (reprint author), MRC Labs, Banjul, Gambia.
EM showie@mrc.gm
RI Noyes, Harry/B-1151-2010
OI Noyes, Harry/0000-0002-0656-200X
FU Medical Research Council [MC_U190088478]
CR Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6
   Bray R. S., 1964, Bull Inst franY Afr noire, V26A, P238
   Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3
   JOHNSON P. D., 1933, TRANS ROY SOC TROP MED AND HYG [LONDON], V26, P467, DOI 10.1016/S0035-9203(33)90105-4
   Linardi PM, 2002, MEM I OSWALDO CRUZ, V97, P411, DOI 10.1590/S0074-02762002000300024
   MOLYNEUX D, 1983, T R SOC TROP MED HYG
   Molyneux D.H., 1976, P285
   Noyes HA, 1999, INT J PARASITOL, V29, P331, DOI 10.1016/S0020-7519(98)00167-2
   Noyes HA, 2002, PARASITOLOGY, V124, P185, DOI 10.1017/S0031182001001019
   PEPIN J, 1989, LANCET, V1, P1246
   Picozzi K, 2005, BRIT MED J, V331, P1238, DOI 10.1136/bmj.331.7527.1238
   SHRIVASTAVA KK, 1974, T ROY SOC TROP MED H, V68, P143, DOI 10.1016/0035-9203(74)90188-6
   SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520
   STERNER G, 1977, SCAND J INFECT DIS, V9, P154
   Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461
   Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632
   WHITTLE HC, 1972, ANN TROP MED PARASIT, V66, P7
   *WHO, 2006, MOTH TO CHILD TRANSM
   WHO, 1998, CONTR SURV AFR TRYP
NR 19
TC 22
Z9 26
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD SEP
PY 2006
VL 3
IS 9
BP 1508
EP 1512
AR e355
DI 10.1371/journal.pmed.0030355
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 103YT
UT WOS:000241923800018
PM 17002503
OA gold
DA 2017-08-15
ER

PT J
AU Coleman, R
   Morison, L
   Paine, K
   Powell, RA
   Walraven, G
AF Coleman, Rosalind
   Morison, Linda
   Paine, Katie
   Powell, Richard A.
   Walraven, Gijs
TI Women's reproductive health and depression - A community survey in the
   Gambia, West Africa
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE depression; common mental disorders (CMD); Africa; reproductive health
ID COMMON MENTAL-DISORDERS; RURAL GAMBIA; POSTNATAL DEPRESSION;
   DEVELOPING-WORLD; PRIMARY-CARE; RISK-FACTORS; ZIMBABWE; ASSOCIATIONS;
   PERSPECTIVE; MORTALITY
AB Background: Depression is the commonest mental illness in developing countries and impoverished women are most at risk. Formal mental health services in these situations are rare. Depression commonly co-presents with physical symptoms or else is unspectacular, so the condition often goes unrecognised. To strengthen the prevention and management of depression, information is required on easily recognisable correlates of depression. This study explored associations between depression and reproductive health conditions in rural African women of reproductive age. Methods: A community-based reproductive health survey among rural women aged 15-54 years in The Gambia, West Africa, included screening with a modified Edinburgh Depression Scale (EDS), a reproductive health questionnaire and a gynaecological examination. Depression was then assessed clinically and data for 565 women were used to estimate the prevalence of depression and examine associations with reproductive health conditions and demographic factors. Results: The weighted prevalence of depression was 10.3% (95% CI 8.3-12.7). Being depressed was most significantly associated with widowhood or divorce (adjusted Odds Ratio (aOR) 8.42, 2.77-25.57), infertility (3.69, 1.42-9.65) and severe menstrual pain (3.94, 1.52-10.27). There were significant differences between ethnic groups. Being in the postpartum period was not associated with an increased likelihood of depression. Conclusion: This study points to the importance of reproductive potential and reproductive health in maintaining women's mental well-being across different strata of a rural and resource-poor society. It could provide an initial focus for the management of women with depression as well as directing future research in reproductive health and psychiatry.
C1 Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   MRC Labs, Farafenni Field Stn, Banjul, Gambia.
   Sainsbury Ctr Mental Hlth, Policy & Res Directorate, London, England.
RP Morison, L (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM linda.morison@lshtm.ac.uk
RI Morison, Linda/H-9738-2013
CR ABAS M, 1994, BRIT J PSYCHIAT, V164, P293, DOI 10.1192/bjp.164.3.293
   ABAS M, 1994, BRIT MED J, V308, P1052
   ADERIBIGBE YA, 1993, BRIT J PSYCHIAT, V163, P645, DOI 10.1192/bjp.163.5.645
   BLEDSOE CH, 1994, POPUL DEV REV, V20, P81, DOI 10.2307/2137631
   Cooper PJ, 1999, BRIT J PSYCHIAT, V175, P554, DOI 10.1192/bjp.175.6.554
   COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782
   Cox JL, 1999, INT REV PSYCHIATR, V11, P103, DOI 10.1080/09540269974258
   Cox JL, 1996, J AFFECT DISORDERS, V39, P185, DOI 10.1016/0165-0327(96)00008-0
   COX JL, 1979, BRIT J PSYCHIAT, V134, P401, DOI 10.1192/bjp.134.4.401
   DESJARLAIS R, 1995, WORLD MNTAL HLTH PRO
   Ellsberg M, 2001, STUD FAMILY PLANN, V32, P1, DOI 10.1111/j.1728-4465.2001.00001.x
   Gureje O, 1997, AM J PSYCHIAT, V154, P989
   HARRIS B, 1989, BRIT J PSYCHIAT, V154, P813, DOI 10.1192/bjp.154.6.813
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   HOBFALL S, 1998, PSYCHOL PHILOS STRES
   Morison L, 2001, TROP MED INT HEALTH, V6, P643, DOI 10.1046/j.1365-3156.2001.00749.x
   Nhiwatiwa S, 1998, J EPIDEMIOL COMMUN H, V52, P262
   ORLEY J, 1979, ARCH GEN PSYCHIAT, V36, P513
   Patel V, 2001, BRIT MED J, V322, P482, DOI 10.1136/bmj.322.7284.482
   Patel V, 2006, ARCH GEN PSYCHIAT, V63, P404, DOI 10.1001/archpsyc.63.4.404
   Patel V, 1997, BRIT J PSYCHIAT, V171, P60, DOI 10.1192/bjp.171.1.60
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Sartorius N, 1996, BRIT J PSYCHIAT, V168, P38
   SINGHATEH SK, 1985, FEMALE CIRCUMCISION
   Turkson S N, 1996, West Afr J Med, V15, P85
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   World Health Organization, 1993, ICD 10 CLASS MENT BE
   WING J, 1974, MEASUREMENT CLASSIFI, P190
   1996, DIAGNOSTIC MANAGEMEN
NR 30
TC 17
Z9 17
U1 3
U2 9
PU DR DIETRICH STEINKOPFF VERLAG
PI DARMSTADT
PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY
SN 0933-7954
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD SEP
PY 2006
VL 41
IS 9
BP 720
EP 727
DI 10.1007/s00127-006-0085-8
PG 8
WC Psychiatry
SC Psychiatry
GA 083CF
UT WOS:000240432800007
PM 16794765
OA No
DA 2017-08-15
ER

PT J
AU Dunyo, S
   Milligan, P
   Edwards, T
   Sutherland, C
   Targett, G
   Pinder, M
AF Dunyo, Samuel
   Milligan, Paul
   Edwards, Tansy
   Sutherland, Colin
   Targett, Geoffrey
   Pinder, Margaret
TI Gametocytaemia after drug treatment of asymptomatic Plasmodium
   falciparum
SO PLOS CLINICAL TRIALS
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; INTERMITTENT PREVENTIVE TREATMENT;
   SULFADOXINE-PYRIMETHAMINE; GAMBIAN CHILDREN; DOUBLE-BLIND; MOSQUITO
   TRANSMISSION; UNCOMPLICATED MALARIA; PLUS PYRIMETHAMINE;
   ANTIMALARIAL-DRUGS; RISK-FACTORS
AB Objectives: Treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine (SP) is followed by a sharp rise in the prevalence and density of gametocytes. We did a randomized trial to determine the effect of treatment of asymptomatic infections with SP or SP plus one dose of artesunate (SP+AS) on gametocyte carriage.
   Design: The study was a three-arm open-label randomized trial. We randomized asymptomatic carriers of P. falciparum to receive antimalarial treatment or placebo, and recorded the prevalence and density of gametocytes over the next 2 mo.
   Setting: The trial was conducted during the dry ( low malaria transmission) season in four rural villages in Gambia.
   Participants: Participants were adults and children aged over 6 mo with asexual P. falciparum infection and confirmed free of clinical symptoms of malaria over a 2-d screening period.
   Interventions: Participants were randomized to receive a single dose of SP or SP+AS or placebo.
   Outcome Measures: The outcome measures were the presence of gametocytes 7 and 56 d after treatment, and the duration and density of gametocytaemia over 2 mo.
   Results: In total, 372 asymptomatic carriers were randomized. Gametocyte prevalence on day 7 was 10.5% in the placebo group, 11.2% in the SP group ( risk difference to placebo 0.7%, 95% confidence interval - 7.4% to 8.7%, p = 0.87), and 7.1% in the SP+AS group ( risk difference to placebo 4.1%, 95% confidence interval - 3.3% to 12%, p = 0.28). By day 56, gametocyte prevalence was 13% in the placebo group and 2% in both drug-treated groups. Gametocyte carriage ( the area under the curve of gametocyte density versus time), was reduced by 71% in the SP group, and by 74% in the SP+AS group, compared to placebo. Gametocyte carriage varied with age and was greater among children under 15 than among adults.
   Conclusions: Treatment of asymptomatic carriers of P. falciparum with SP does not increase gametocyte carriage or density. Effective treatment of asexual parasitaemia in the dry season reduces gametocyte carriage to very low levels after 4 wk.
C1 London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Banjul, Gambia.
RP Milligan, P (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM paul.milligan@lshtm.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
FU Medical Research Council [G0700837]
CR Bousema JT, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-18
   Buckling A, 1999, PARASITOLOGY, V118, P339, DOI 10.1017/S0031182099003960
   Butcher GA, 1997, INT J PARASITOL, V27, P975, DOI 10.1016/S0020-7519(97)00079-9
   Chandramohan D, 2005, BRIT MED J, V331, P727, DOI 10.1136/bmj.331.7519.727
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112
   Doherty JF, 1999, T ROY SOC TROP MED H, V93, P543, DOI 10.1016/S0035-9203(99)90376-0
   Drakeley CJ, 2004, TROP MED INT HEALTH, V9, P53, DOI 10.1046/j.1365-3156.2003.01169.x
   Enosse S, 2000, T ROY SOC TROP MED H, V94, P77, DOI 10.1016/S0035-9203(00)90447-4
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1988, LANCET, V1, P1121
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   Hommel M, 2002, ESSENTIAL MALARIOLOG, P35
   MCGREGOR IA, 1987, ANN TROP MED PARASIT, V81, P647
   Nacher M, 2004, ANTIMICROB AGENTS CH, V48, P2751, DOI 10.1128/AAC.48.7.2751-2752.2004
   Price R, 1999, AM J TROP MED HYG, V60, P1019
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Robert V, 2000, AM J TROP MED HYG, V62, P210
   Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964
   Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217
   von Seidlein L, 2003, TRENDS PARASITOL, V19, P452, DOI 10.1016/j.pt.2003.08.003
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   von Seidlein L, 2001, AM J TROP MED HYG, V65, P523
NR 27
TC 53
Z9 53
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1555-5887
J9 PLOS CLIN TRIALS
JI PLos Clin. Trials
PD AUG 18
PY 2006
VL 1
IS 4
AR e20
DI 10.1371/journal.pctr.0010020
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 150SM
UT WOS:000245238300002
PM 17013431
OA gold
DA 2017-08-15
ER

PT J
AU Jukes, MCH
   Pinder, M
   Grigorenko, EL
   Smith, HB
   Walraven, G
   Bariau, EM
   Sternberg, RJ
   Drake, LJ
   Milligan, P
   Cheung, YB
   Greenwood, BM
   Bundy, DAP
AF Jukes, Matthew C. H.
   Pinder, Margaret
   Grigorenko, Elena L.
   Smith, Helen Banos
   Walraven, Gijs
   Bariau, Elisa Meier
   Sternberg, Robert J.
   Drake, Lesley J.
   Milligan, Paul
   Cheung, Yin Bun
   Greenwood, Brian M.
   Bundy, Donald A. P.
TI Long-term impact of malaria chemoprophylaxis on cognitive abilities and
   educational attainment: Follow-up of a controlled trial
SO PLOS CLINICAL TRIALS
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; PRIMARY-HEALTH-CARE; CEREBRAL MALARIA;
   NEUROLOGICAL SEQUELAE; SCHOOL-ACHIEVEMENT; EARLY-CHILDHOOD; ENDEMIC
   AREAS; CHILDREN; BURDEN; PERFORMANCE
AB Objectives: We investigated the long-term impact of early childhood malaria prophylaxis on cognitive and educational outcomes.
   Design: This was a household-based cluster-controlled intervention trial.
   Setting: The study was conducted in 15 villages situated between 32 km to the east and 22 km to the west of the town of Farafenni, the Gambia, on the north bank of the River Gambia.
   Participants: A total of 1,190 children aged 3 - 59 mo took part in the trial. We traced 579 trial participants ( 291 in the prophylaxis group and 288 in the placebo group) in 2001, when their median age was 17 y 1 mo ( range 14 y 9 mo to 19 y 6 mo).
   Interventions: Participants received malaria chemoprophylaxis (dapsone/pyrimethamine) or placebo for between one and three malaria transmission seasons from 1985 to 1987 during the controlled trial. At the end of the trial, prophylaxis was provided for all children under 5 y of age living in the study villages.
   Outcome Measures: The outcome measures were cognitive abilities, school enrolment, and educational attainment ( highest grade reached at school).
   Results: There was no significant overall intervention effect on cognitive abilities, but there was a significant interaction between intervention group and the duration of post-trial prophylaxis ( p = 0.034), with cognitive ability somewhat higher in the intervention group among children who received no post-trial prophylaxis ( treatment effect = 0.2 standard deviations [SD], 95% confidence interval [CI] - 0.03 to 0.5) and among children who received less than 1 y of post-trial prophylaxis ( treatment effect = 0.4 SD, 95% CI 0.1 to 0.8). The intervention group had higher educational attainment by 0.52 grades ( 95% CI = -0.041 to 1.089; p = 0.069). School enrolment was similar in the two groups.
   Conclusions: The results are suggestive of a long-term effect of malaria prophylaxis on cognitive function and educational attainment, but confirmatory studies are needed.
C1 Imperial Coll Sch Med, Dept Infect Dis Epidemiol, Partnership Child Dev, London, England.
   MRC Labs, Banjul, Gambia.
   Yale Univ, Ctr Psychol Abil Competencies & Expertise, New Haven, CT USA.
   Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
   London Sch Hyg & Trop Med, London WC1, England.
   World Bank, Human Dev Network, Washington, DC 20433 USA.
RP Jukes, MCH (reprint author), Harvard Univ, Grad Sch Educ, Cambridge, MA 02138 USA.
EM jukesma@gse.harvard.edu
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
FU Medical Research Council [G0700837]; Wellcome Trust
CR Agresti A., 2002, CATEGORICAL DATA ANA
   Al Serouri AW, 2000, PARASITOLOGY, V121, P337, DOI 10.1017/S0031182099006502
   Alderman H, 2001, J HUM RESOUR, V36, P185, DOI 10.2307/3069675
   ALLEN SJ, 1990, J TROP MED HYG, V93, P313
   Bartlett MS, 1937, B J PSYCHOL-GEN SECT, V28, P97
   Berkman DS, 2002, LANCET, V359, P564, DOI 10.1016/S0140-6736(02)07744-9
   BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588
   Boivin MJ, 2002, J DEV BEHAV PEDIATR, V23, P353
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211
   Breman JG, 2001, AM J TROP MED HYG, V64, P1
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   Brooker S, 2000, PARASITOL TODAY, V16, P183, DOI 10.1016/S0169-4758(00)01663-X
   Bundy DAP, 2000, PARASITOL TODAY, V16, P181, DOI 10.1016/S0169-4758(00)01658-6
   Carter JA, 2006, DEV MED CHILD NEUROL, V48, P51
   Carter JA, 2005, TROP MED INT HEALTH, V10, P3, DOI 10.1111/j.1365-3156.2004.01345.x
   CATTELL RB, 1943, PSYCHOL BULL, V3, P618
   Chandramohan D, 2005, BRIT MED J, V331, P727, DOI 10.1136/bmj.331.7519.727
   Chang SM, 2002, J CHILD PSYCHOL PSYC, V43, P775, DOI 10.1111/1469-7610.00088
   Fernando D, 2003, T ROY SOC TROP MED H, V97, P161, DOI 10.1016/S0035-9203(03)90107-6
   Fernando SD, 2003, AM J TROP MED HYG, V69, P582
   Grantham-McGregor S, 2001, J NUTR, V131, P649
   GRANTHAMMCGREGOR S, 1994, CHILD DEV, V65, P428
   Greenwood B, 2004, AM J TROP MED HYG, V70, P1
   GREENWOOD BM, 1988, LANCET, V1, P1121
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   Holding PA, 1999, T ROY SOC TROP MED H, V93, P529, DOI 10.1016/S0035-9203(99)90368-1
   Holding PA, 2001, AM J TROP MED HYG, V64, P68
   Johnson Richard, 2002, APPL MULTIVARIATE ST
   Jukes Matthew, 2005, Food and Nutrition Bulletin, V26, pS193
   Jukes MCH, 2002, TROP MED INT HEALTH, V7, P104
   Kihara M, 2006, TROP MED INT HEALTH, V11, P386, DOI 10.1111/j.1365-3156.2006.01579.x
   LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004
   Lozoff B., 2000, PEDIATRICS, V105, P51
   MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L
   Mung'Ala-Odera V, 2004, AM J TROP MED HYG, V71, P64
   Murphy SC, 2001, AM J TROP MED HYG, V64, P57
   POLLITT E, 1995, J NUTR, V125, pS1111
   Raven J., 1998, RAVENS PROGR MATRICE
   Royston P., 2004, STATA J, V4, P227, DOI DOI 10.1037//1082-989X.7.2.147
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   SIMEON DT, 1989, AM J CLIN NUTR, V49, P646
   Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624
   Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R
   Walker SP, 2000, J PEDIATR-US, V137, P36, DOI 10.1067/mpd.2000.106227
   Wechsler D., 1997, WECHSLER ADULT INTEL, V3
NR 46
TC 26
Z9 27
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1555-5887
J9 PLOS CLIN TRIALS
JI PLos Clin. Trials
PD AUG 18
PY 2006
VL 1
IS 4
AR e19
DI 10.1371/journal.pctr.0010019
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 150SM
UT WOS:000245238300001
PM 17013430
OA gold
DA 2017-08-15
ER

PT J
AU Dhollander, S
   Jallow, A
   Mbodge, K
   Kora, S
   Sanneh, M
   Gaye, M
   Bos, J
   Leak, S
   Berkvens, D
   Geerts, S
AF Dhollander, S.
   Jallow, A.
   Mbodge, K.
   Kora, S.
   Sanneh, M.
   Gaye, M.
   Bos, J.
   Leak, S.
   Berkvens, D.
   Geerts, S.
TI Equine trypanosomosis in the Central River Division of the Gambia: A
   study of veterinary gate-clinic consultation records
SO PREVENTIVE VETERINARY MEDICINE
LA English
DT Article
DE trypanosomosis; equines; Gambia; epidemiology; gate-clinic; prevalence
ID TSETSE CHALLENGE; AFRICAN TRYPANOSOMIASIS; CATTLE; PREVALENCE;
   DIAGNOSIS; DONKEYS
AB The objective of this,study was to provide epidemiological information of equine trypanosomosis in the Central River Division (CRD) of The Gambia. Therefore, 2285 consultations records of equines, admitted in a gate-clinic at Sololo in CRD, were studied retrospectively. The data were recorded in the period between September 1995 and July 2002 and comprised consultations of 2113 horses and 172 donkeys.
   'Trypanosome infection' was the most frequently diagnosed condition and accounted for 61% of the cases. Horses were more frequently diagnosed with trypanosome infections than donkeys (p < 0.001), with an occurrence of 63% compared to 43% in donkeys. In both horses and donkeys, trypanosome infections were mainly due to Trypanosoma congolense (64%) and T vivax (32%). There was no difference observed in the occurrence of trypanosome infections in male or female donkeys (p = 0.585), but there were more female (67.8%) horses observed with trypanosome infections than male horses (60.7%; p = 0.003). There was no difference observed in the occurrence of trypanosome infections in donkeys older or younger than I year (p = 0.130), but more older horses (63.2% > 1 year) were observed with trypanosome infections than young horses (54.5% < 1 year; p = 0.033).
   The number of donkeys and horses with trypanosome infections decreased during the rainy season (June-September).
   The majority of equines that were admitted with trypanosome infections were severely anaemic. The average packed cell volume (PCV) declined with increasing parasitaemia (p = 0.006).
   Seventy-four percent of the farmers' predictions of trypanosome infections in their equines were confirmed by darkground-microscopy. That proved that farmers had a fairly accurate knowledge of the diseases affecting their equines.
   The treatments executed at the gate-clinic were generally effective. The few (0.4%) relapses of the T vivax infections that were previously treated with diminazene aceturate in this study were not sufficient to prove drug resistance.
   The study showed that the analysis of consultation records at a gate-clinic can provide complementary information to conventional epidemiological studies in the same research area. (c) 2005 Elsevier B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Wageningen & Res Ctr, Wageningen, Netherlands.
   Inst Trop Med, B-2000 Antwerp, Belgium.
RP Dhollander, S (reprint author), Int Agr Sci S Vietnam, 121 Nguyen Binh Khiem St,Dist 1, Ho Chi Minh City, Vietnam.
EM sofiedhollander@yahoo.co.uk
CR BARROWMAN PR, 1991, DONKEYS, MULES AND HORSES IN TROPICAL AGRICULTURAL DEVELOPMENT, P106
   Catley A, 2001, PREV VET MED, V49, P95, DOI 10.1016/S0167-5877(01)00171-4
   Catley A, 2001, PREV VET MED, V51, P161, DOI 10.1016/S0167-5877(01)00240-9
   Catley A, 2002, MED VET ENTOMOL, V16, P1
   Fall A, 1999, VET PARASITOL, V81, P235, DOI 10.1016/S0304-4017(98)00213-1
   Faye D, 2001, VET PARASITOL, V101, P101, DOI 10.1016/S0304-4017(01)00503-9
   KAUFMANN J, 1996, DIAGNOSTIC MANUAL
   LEAK SGA, 1993, ACTA TROP, V53, P121, DOI 10.1016/0001-706X(93)90024-6
   LOUM B, 1989, INCIDENCE EQUINE TRY
   MacLennan K. J. R., 1970, P751
   MARINER JC, 2000, 10 FAO AN HLTH MAN
   MATTILI RC, 1994, TROP ANIM HEALTH PRO, V26, P102, DOI 10.1007/BF02239909
   MILLIGAN PJM, 1988, PARASITOLOGY, V96, P211
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   PARIS J, 1982, ACTA TROP, V39, P307
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   SECKA A, 2003, NARI ITC DLS COLLABO, P17
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   SOWE J, 1987, FOALING MORTALITY EQ
   STARKEY P, 1990, P 3 WORKSH W AFR AN, P90
   Stephen L. E., 1970, P774
   Sumberg J., 1992, African Livestock Research, V1, P1
   WACHER TJ, 1993, ANN TROP MED PARASIT, V87, P517
NR 23
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-5877
EI 1873-1716
J9 PREV VET MED
JI Prev. Vet. Med.
PD AUG 17
PY 2006
VL 75
IS 3-4
BP 152
EP 162
DI 10.1016/j.prevetmed.2005.11.009
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA 069TV
UT WOS:000239472100002
PM 16814418
OA No
DA 2017-08-15
ER

PT J
AU West, SK
   Emerson, PM
   Mkocha, H
   Mchiwa, W
   Munoz, B
   Bailey, R
   Mabey, D
AF West, Sheila K.
   Emerson, Paul M.
   Mkocha, Harran
   Mchiwa, Wilson
   Munoz, Beatriz
   Bailey, Robin
   Mabey, David
TI Intensive insecticide spraying for fly control after mass antibiotic
   treatment for trachoma in a hyperendemic setting: a randomised trial
SO LANCET
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS; CENTRAL TANZANIA; INFECTION; COMMUNITY; DIARRHEA;
   TRANSMISSION; VECTOR; IMPACT
AB Background There are no data on the cumulative effect of fly control and antibiotic distribution on trachoma in hyperendemic communities. We sought to determine whether insecticide spray intervention after mass antibiotic treatment could reduce trachoma and ocular infection with Chlamydia trachomatis in hyperendemic neighbourhoods in Tanzania.
   Methods We did a single-blind, randomised clinical trial in 16 neighbourhoods (balozi) in Kongwa, Tanzania. All children aged 1-7 years were enrolled, with 119 children in the eight balozi of the intervention group and 183 in the eight control balozi. Children were examined at baseline, 6 months, and 1 year for clinical trachoma and ocular C trachomatis infection. one dose of azithromycin was offered to all residents of both intervention and control balozi after the baseline survey. Households (and surrounding areas) in the intervention group were then sprayed with insecticide throughout the ensuing year and monitored for reductions in fly counts. This study is registered at ClinicalTrials.gov, number NCT00347763.
   Findings The intervention balozi had significantly lower fly counts than controls at all monitored weeks (p < 0.05), apart from weeks 7-9. The trachoma rate did not differ significantly in the intervention and control balozi at 6 months post-treatment (20% vs 33%, p = 0.07), nor did it at 1 year (43% vs 44%, p = 0.90). Infection with C trachomatis did not differ between groups at 6 months post-treatment (9% vs 7%, p = 0.45).
   Interpretation Intensive insecticide spraying reduced flies in the environment, but our results suggest that fly reduction after mass antibiotic treatment has no added benefit on reduction of trachoma.
C1 Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   MRC, Fajara, Gambia.
   Kongwa Trachoma Project, Kongwa, Tanzania.
   London Sch Hyg & Trop Med, London WC1, England.
RP West, SK (reprint author), Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.
EM shwest@jhmi.edu
FU Wellcome Trust
CR Chavasse DC, 1999, LANCET, V353, P22, DOI 10.1016/S0140-6736(98)03366-2
   COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N
   COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   West ES, 2005, INVEST OPHTH VIS SCI, V46, P83, DOI 10.1167/iovs.04-0327
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0
   West SK, 2004, PROG RETIN EYE RES, V23, P381, DOI 10.1016/j.preteyeres.2004.04.001
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   World Health Assembly, 1998, WHA5111
NR 18
TC 27
Z9 27
U1 0
U2 2
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 12
PY 2006
VL 368
IS 9535
BP 596
EP 600
DI 10.1016/S0140-6736(06)69203-9
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 074OF
UT WOS:000239821000033
PM 16905024
OA No
DA 2017-08-15
ER

PT J
AU Cooke, GS
   Campbell, SJ
   Sillah, J
   Gustafson, P
   Bah, B
   Sirugo, G
   Bennett, S
   McAdam, KPWJ
   Sow, O
   Lienhardt, C
   Hill, AVS
AF Cooke, Graham S.
   Campbell, Sarah J.
   Sillah, Jackson
   Gustafson, Per
   Bah, Boubacar
   Sirugo, Georgio
   Bennett, Steve
   McAdam, Keith P. W. J.
   Sow, Oumou
   Lienhardt, Christian
   Hill, Adrian V. S.
TI Polymorphism within the Interferon-gamma/Receptor complex is associated
   with pulmonary tuberculosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE interferon-gamma; polymorphism; receptor; tuberculosis
ID GAMMA RECEPTOR-1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; IFN-GAMMA;
   MYCOBACTERIUM-TUBERCULOSIS; TRANSCRIPTIONAL RESPONSES; LINKAGE
   DISEQUILIBRIUM; PROMOTER VARIANT; RISK-FACTORS; 1ST INTRON; INFECTION
AB Rationale: Interferon-gamma (IFN-gamma) is of central interest in the study of tuberculosis. A number of single-gene mutations have been identified in the IFN-gamma signaling pathway that predispose to severe mycobacterial disease, but the relevance of polymorphism within these genes to the common phenotype of tuberculosis remains unclear.
   Methods: A total of 1,301 individuals were included in a large, detailed study of West African populations with pulmonary tuberculosis. We investigated disease association with the genes encoding IFN-gamma and its receptor subunits (IFNG, IFNGR1, and IFNGR2).
   Results: Within the IFNG gene, two promoter variants showed evidence of novel disease association: -1616GG (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.11-2.00; p = 0.008) and +3234TT (OR, 1.40; 95% CI, 1.09-1.80; p = 0.009). The +874AA genotype was not significantly more frequent among cases over control subjects (OR, 1.16; 95%CI, 0.89-1.51; p = 0.25). In addition, novel disease association was also found with the -56CC genotype of the IFNGR1 promoter (OR, 0.75; 95% CI, 0.57-0.99; p = 0.041). No disease association was seen with the IFNGR2 locus.
   Conclusions: These results provide evidence of a significant role for genetic variation at the IFNG locus and provide detailed understanding of the genetic mechanisms underlying this association. The disease association with IFNGR1 is novel, and together these findings support the hypothesis that genetically determined variation in both IFN-gamma production and responsiveness influences the risk of developing tuberculosis.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Fajara, Gambia.
   CHU Ignace Deen, Conakry, Guinea.
   Danish Epidemiol Sci Ctr, Bissau, Guinea Bissau.
   IRD, Dakar, Senegal.
RP Cooke, GS (reprint author), Churchill Hosp, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM graham.cooke@st-marys.nhs.uk
RI HILL, Adrian/C-1306-2008
FU Wellcome Trust
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   An P, 2003, J INFECT DIS, V188, P228, DOI 10.1086/376455
   Aoki M, 2003, INT J MOL MED, V12, P185
   Awomoyi AA, 2004, THORAX, V59, P291, DOI 10.1136/thx.2003.013029
   Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   Bellamy R., 1998, Tubercle and Lung Disease, V79, P83, DOI 10.1054/tuld.1998.0009
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   Bream JH, 2002, GENES IMMUN, V3, P165, DOI 10.1038/sj/gene.6363870
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Collins HL, 2001, IMMUNOLOGY, V103, P1, DOI 10.1046/j.1365-2567.2001.01236.x
   Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526
   Dupuis S, 2000, IMMUNOL REV, V178, P129, DOI 10.1034/j.1600-065X.2000.17810.x
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Fraser DA, 2003, SCAND J IMMUNOL, V57, P480, DOI 10.1046/j.1365-3083.2003.01253.x
   Gao PS, 1999, BIOCHEM BIOPH RES CO, V263, P425, DOI 10.1006/bbrc.1999.1368
   GREENLUND AC, 1993, J BIOL CHEM, V268, P18103
   Henri S, 2002, GENES IMMUN, V3, P1, DOI 10.1038/sj/gene/6363809
   Juliger S, 2003, IMMUNOGENETICS, V54, P675, DOI 10.1007/s00251-002-0516-y
   Kincaid EZ, 2003, J IMMUNOL, V171, P2042
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   KOTENKO SV, 1995, J BIOL CHEM, V270, P20915
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Lin YG, 1996, INFECT IMMUN, V64, P1351
   Lio D, 2002, EUR J IMMUNOGENET, V29, P371, DOI 10.1046/j.1365-2370.2002.00327.x
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC
   Mohamed HS, 2003, GENES IMMUN, V4, P351, DOI 10.1038/sj.gene.6363977
   Moreira AL, 2000, MICROB PATHOGENESIS, V29, P175, DOI 10.1006/mpat.2000.0382
   Nakashima H, 1999, FEBS LETT, V453, P187, DOI 10.1016/S0014-5793(99)00701-2
   Newport MJ, 2003, SCAND J IMMUNOL, V58, P383, DOI 10.1046/j.1365-3083.2003.01328.x
   Ottenhoff THM, 2002, NAT GENET, V32, P97, DOI 10.1038/ng0902-97
   Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1
   Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Thye T, 2003, AM J HUM GENET, V72, P448, DOI 10.1086/367714
   Ting LM, 1999, J IMMUNOL, V163, P3898
   ZHANG M, 1995, INFECT IMMUN, V63, P3231
NR 43
TC 71
Z9 74
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD AUG 1
PY 2006
VL 174
IS 3
BP 339
EP 343
DI 10.1164/rccm.200601-088OC
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 068ZW
UT WOS:000239415200019
PM 16690980
OA No
DA 2017-08-15
ER

PT J
AU de Bone, S
   Laskey, MA
   Ceesay, M
   Mendy, M
   Schoenmakers, I
   Prentice, A
AF de Bone, S.
   Laskey, M. A.
   Ceesay, M.
   Mendy, M.
   Schoenmakers, I
   Prentice, A.
TI Influence of birth weight on bone size and mineral content in young
   Gambian adults
SO EARLY HUMAN DEVELOPMENT
LA English
DT Meeting Abstract
C1 MRC, Human Nutr Res, London W1N 4AL, England.
   MRC, Keneba, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-3782
J9 EARLY HUM DEV
JI Early Hum. Dev.
PD AUG
PY 2006
VL 82
IS 8
BP 506
EP 506
PG 1
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 082FJ
UT WOS:000240371800039
OA No
DA 2017-08-15
ER

PT J
AU Ibango, HB
   Brookes, RH
   Hill, PC
   Owiafe, PK
   Fletcher, HA
   Lienhardt, C
   Hill, AVS
   Adegbola, RA
   McShane, H
AF Ibango, Hannah B.
   Brookes, Roger H.
   Hill, Philip C.
   Owiafe, Patrick K.
   Fletcher, Helen A.
   Lienhardt, Christian
   Hill, Adrian V. S.
   Adegbola, Richard A.
   McShane, Helen
TI Early clinical trials with a new tuberculosis vaccine, MVA85A, in
   tuberculosis-endemic countries: issues in study design
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID MYCOBACTERIUM-BOVIS BCG; PROTECTIVE IMMUNITY; SKIN-TEST; INFECTION;
   PROTEIN; GAMBIA; SENSITIVITY; IMMUNOLOGY; DIAGNOSIS; RESPONSES
AB Tuberculosis remains a substantial global health problem despite effective drug treatments. The efficacy of BCG, the only available vaccine, is variable, especially in tuberculosis-endemic regions. Recent advances in the development of new vaccines against tuberculosis mean that the first of these are now entering into early clinical trials. A recombinant modified vaccinia virus Ankara expressing a major secreted antigen from Mycobacterium tuberculosis, antigen 85A, was the first new tuberculosis vaccine to enter into clinical trials in September 2002. This vaccine is known as MVA85A. In a series of phase I clinical trials in the UK, MVA85A had an excellent safety profile and was highly immunogenic. MVA85A was subsequently evaluated in a series of phase I trials in The Gambia, a tuberculosis-endemic area in west Africa. This vaccine is the only new subunit tuberculosis vaccine to enter into clinical trials in Africa to date. Here, we discuss some of the issues that were considered in the protocol design of these studies including recruitment, inclusion and exclusion criteria, reimbursement of study participants, and HIV testing. These issues are highly relevant to early clinical trials with all new tuberculosis vaccines in the developing world.
C1 Univ Oxford, Ctr Clin Vaccinol & Trop Med, Churchill Hosp, Oxford OX3 7LJ, England.
   MRC Labs, Fajara, Gambia.
   Inst Rech Dev, Dakar, Senegal.
RP McShane, H (reprint author), Univ Oxford, Ctr Clin Vaccinol & Trop Med, Churchill Hosp, S Parks Rd, Oxford OX3 7LJ, England.
EM helen.mcshane@ndm.ox.ac.uk
RI HILL, Adrian/C-1306-2008; Fletcher, Helen/D-1470-2011
OI Fletcher, Helen/0000-0002-0435-1006; Kwasi Owiafe,
   Patrick/0000-0002-4287-3577
FU Medical Research Council [MC_U190071468]; Wellcome Trust [, 076943]
CR Barnes PF, 2004, AM J RESP CRIT CARE, V170, P5, DOI 10.1164/rccm.2404004
   Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002
   COMSTOCK GW, 1966, AM REV RESPIR DIS, V94, P553
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   EDWARDS LB, 1958, AM J HYG, V68, P213
   Ellner JJ, 2000, CLIN INFECT DIS, V30, pS279, DOI 10.1086/313874
   Emanuel EJ, 2005, LANCET, V366, P336, DOI 10.1016/S0140-6736(05)66992-9
   EPSTEIN PR, 1990, LANCET, V335, P1536, DOI 10.1016/0140-6736(90)93087-6
   Fine PE., 1989, REV INFECT DIS S2, V11, P353
   FINE PEM, 1999, ISS REL US BCG IMM P
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   GODFREYFAUSSETT P, 1995, T ROY SOC TROP MED H, V89, P354, DOI 10.1016/0035-9203(95)90005-5
   GRINDULIS H, 1984, ARCH DIS CHILD, V59, P614
   Harboe M, 1996, INFECT IMMUN, V64, P16
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   HOROWITZ HW, 1995, AM J INFECT CONTROL, V23, P181, DOI 10.1016/0196-6553(95)90039-X
   Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397
   Horwitz MA, 2005, MICROBES INFECT, V7, P947, DOI 10.1016/j.micinf.2005.04.002
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558
   Koch R., 1891, DEUT MED WOCHENSCHR, V171, P101, DOI [DOI 10.1055/S-0029-1206198, 10.1055/s-0029-1206198]
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lee E, 2002, CLIN INFECT DIS, V34, P365, DOI 10.1086/338149
   Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC
   MARKOWITZ N, 1993, ANN INTERN MED, V119, P185
   McShane H, 2005, TUBERCULOSIS, V85, P47, DOI 10.1016/j.tube.2004.09.015
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   *NAT COMM PROT HUM, 1988, 887809 GPO NAT COMM
   *NAT I ALL INF DIS, PREV TB CLOS LONG RO
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X
   Pollock JM, 1997, J INFECT DIS, V175, P1251
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710
   Taylor JL, 2003, INFECT IMMUN, V71, P2192, DOI 10.1128/IAI.71.4.2192.2198.2003
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Vekemans J, 2004, INFECT IMMUN, V72, P381, DOI 10.1128/IAI.72.1.381-388.2004
   von Reyn CF, 2005, LANCET INFECT DIS, V5, P132
   WHO, 1994, TB GLOB EM
   *WHO REG OFF AFR, TB EM DECL
NR 46
TC 36
Z9 39
U1 1
U2 4
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD AUG
PY 2006
VL 6
IS 8
BP 522
EP 528
DI 10.1016/S1473-3099(06)70552-7
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 067ZM
UT WOS:000239341300023
PM 16870530
OA No
DA 2017-08-15
ER

PT J
AU Faal, N
   Bailey, RL
   Jeffries, D
   Joof, H
   Sarr, I
   Laye, M
   Mabey, DCW
   Holland, MJ
AF Faal, Nkoyo
   Bailey, Robin L.
   Jeffries, David
   Joof, Hassan
   Sarr, Isatou
   Laye, Mass
   Mabey, David C. W.
   Holland, Martin J.
TI Conjunctival FOXP3 expression in trachoma: Do regulatory T cells have a
   role in human ocular Chlamydia trachomatis infection?
SO PLOS MEDICINE
LA English
DT Article
ID IMMUNE-RESPONSES; GENE-EXPRESSION; CYTOKINE; ANTIGENS; LEISHMANIASIS;
   INTERFERON; VACCINE; IL-10; AGE
AB Background Trachoma, caused by ocular infection with Chlamydia trachomatis, remains the leading infectious cause of blindness and in 2002 was responsible for 3.6% of total global blindness. Although transmission can be successfully interrupted using antibiotics and improvements in public and personal hygiene, the long-term success of the control programmes advocated by the World Health Organization are still uncertain. For the complete control and prevention of trachoma, a vaccine would be highly desirable. Currently there are no licensed vaccines for trachoma, and no human vaccine trials have been conducted since the 1960s. A barrier to new attempts to design and introduce a vaccine is the identification of immunologic correlates of protective immunity or immunopathology. We studied important correlates of the immune response in a trachoma-endemic population in order to improve our knowledge of this disease. This is essential for the successful development of a vaccine against both ocular and genital C. trachomatis infection.
   Methods and Findings We used quantitative real-time PCR for C. trachomatis 16S rRNA to identify conjunctival infection. The expression of IFN-gamma, IDO, IL-10, and FOXP3 mRNA transcripts was measured. We evaluated the role of immune effector and regulatory responses in the control of chlamydial infection and in the resolution of clinical signs of trachoma in endemic communities in Gambia. All host transcripts examined were detectable even in normal conjunctiva. The levels of these transcripts were increased, compared to normal uninfected conjunctiva, when infection was detected, with or without clinical disease signs. Interestingly, when clinical disease signs were present in the absence of infection, the expression of a regulatory T cell transcription factor, FOXP3, remained elevated.
   Conclusions There is evidence of an increase in the magnitude of the local anti-chlamydial cytokine immune responses with age. This increase is coupled to a decline in the prevalence of infection and active trachoma, suggesting that effective adaptive immunity is acquired over a number of years. The anti-chlamydial and inflammatory immune response at the conjunctival surface, which may control chlamydial replication, is closely matched by counter inflammatory or regulatory IL-10 expression. Differences in the level of FOXP3 expression in the conjunctiva may indicate a role for regulatory T cells in the resolution of the conjunctival immune response, which is important in protection from immunopathology. However, the expression of cytokines that control chlamydial replication and those that regulate the conjunctival immune response is not simply juxtaposed; the interaction between the infection and the clinical disease process is therefore more complex.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   Kerewan Dist Hlth Ctr, Natl Eye Care Programme, Kerewan, Gambia.
RP Holland, MJ (reprint author), MRC Labs, Banjul, Gambia.
EM Martin.Holland@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Medical Research Council [MC_U190081961]
CR ALTMAN DG, 1983, BRIT MED J, V286, P1489
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BEATTY WL, 1994, INFECT IMMUN, V62, P3705
   Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI 10.1172/JCI200317993
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Faal N, 2005, CLIN EXP IMMUNOL, V142, P347, DOI 10.1111/j.1365-2249.2005.02917.x
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495
   Fisher R. A., 1948, STAT METHODS RES WOR
   Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x
   Groux H, 1997, NATURE, V389, P737
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   JAWETZ E, 1965, J AMER MED ASSOC, V194, P620
   Krzanowski W., 1988, PRINCIPLES MULTIVARI
   Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816
   Maul J, 2005, GASTROENTEROLOGY, V128, P1868, DOI 10.1053/j.gastro.2005.03.043
   Miller K, 2004, OPHTHAL EPIDEMIOL, V11, P255, DOI 10.1080/09286580490514577
   MIMS C, 1988, PATHOGENESIS INFECT
   Morrison RP, 2002, INFECT IMMUN, V70, P2741, DOI 10.1128/IAI.70.6.2741-2751.2002
   NATIVIDAD A, 2005, GENES IMMUN, P1
   Pop SM, 2005, J EXP MED, V201, P1333, DOI 10.1084/jem.20042398
   RAPOZA PA, 1991, INVEST OPHTH VIS SCI, V32, P2919
   Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x
   Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x
   SOWA S, 1969, J HYG-CAMB, V67, P699
   Suvas S, 2005, J VIROL, V79, P11935, DOI 10.1128/JVI.79.18.11935-11942.2005
   Suvas S, 2004, J IMMUNOL, V172, P4123
   TAYLOR HR, 1989, INVEST OPHTH VIS SCI, V30, P1823
   Wang CB, 2005, J INFECT DIS, V191, P1084, DOI 10.1086/428592
   Wang SH, 1999, EUR J IMMUNOL, V29, P3782, DOI 10.1002/(SICI)1521-4141(199911)29:11<3782::AID-IMMU3782>3.0.CO;2-B
   WANG SP, 1967, AM J OPHTHALMOL, V63, P1615
   Westfall PH, 1993, RESAMPLING BASED MUL
   Yang X, 1999, J IMMUNOL, V162, P1010
   Yang X, 1996, J IMMUNOL, V156, P4338
   [Anonymous], 2005, LANCET, V365, P630
NR 42
TC 33
Z9 33
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2006
VL 3
IS 8
BP 1292
EP 1301
AR e266
DI 10.1371/journal.pmed.0030266
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 079YG
UT WOS:000240213200023
PM 16881731
OA gold
DA 2017-08-15
ER

PT J
AU Moore, SE
   Collinson, AC
   N'Gom, PT
   Aspinall, R
   Prentice, AM
AF Moore, Sophie E.
   Collinson, Andrew C.
   N'Gom, Pa Tamba
   Aspinall, Richard
   Prentice, Andrew M.
TI Early immunological development and mortality from infectious disease in
   later life
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Joint Meeting of the
   Nutrition-Society/British-Society-for-Immunology-Development-Immunology-
   Group
CY DEC   09, 2005
CL Harogate, ENGLAND
SP Nutr Soc, British Soc Immunol Dev Immunol Grp
DE Gambia; immune function; programming; thymus; vaccine response
ID BREAST-FED INFANTS; THYMIC FUNCTION; BIRTH-WEIGHT; HUMAN-MILK; PRENATAL
   UNDERNUTRITION; POSTNATAL ENVIRONMENTS; INTRAUTERINE GROWTH; GAMBIAN
   WOMEN; FETAL GROWTH; RURAL GAMBIA
AB In rural Gambia the risk of mainly infection-related mortality is 10-fold higher for adults born in the nutritionally-debilitating 'hungry' season, suggesting that immune function may be compromised by events early in life. The current programme of research focuses on the biological mechanisms underlying this hypothesis, exploring early-life environmental influences on immune development and the long-term functional consequences these influences may have. Results obtained to date show that thymus development during infancy is critically sensitive to environmental exposures, with smaller thymuses observed in the hungry season. Measurement of the frequency of T-cell receptor excision circles indicate that thymus function is also sensitive to seasonal influences, with further studies implicating variations in breast-milk IL-7 as a possible mediator of these effects. Studies in adults have shown that size at birth is positively correlated with antibody responses to vaccination with polysaccharide antigens, thus providing evidence for long-term functional deficits. The present paper will review progress made to date within this field of research.
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp,Dept Epidemiol & Populat Hlth, Nutr & Publ Hlth Intervent Res Unit, London WC1E 7HT, England.
   MRC, MRC Labs, Keneba, Gambia.
   Royal Devon & Exeter Hosp, Directorate Child & Womens Hlth, Exeter EX2 5DW, Devon, England.
   Chelsea & Westminster Hosp, Imperial Coll London, Dept Immunol, London SW10 9NH, England.
RP Moore, SE (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp,Dept Epidemiol & Populat Hlth, Nutr & Publ Hlth Intervent Res Unit, Keppel St, London WC1E 7HT, England.
EM Sophie.Moore@lshtm.ac.uk
RI Aspinall, Richard/E-4924-2013
OI Aspinall, Richard/0000-0002-1648-1887
CR Aaby P, 2002, ACTA PAEDIATR, V91, P698, DOI 10.1080/080352502760069142
   Ashworth A, 1998, EUR J CLIN NUTR S1, V52, P34
   Barker DJP, 2004, ACTA PAEDIATR, V93, P26, DOI 10.1080/08035320410022730
   BARKER DJP, 1986, LANCET, V1, P1077
   Barker DJP, 1994, MOTHERS BABIES DIS L
   BEACH RS, 1982, SCIENCE, V218, P469, DOI 10.1126/science.7123244
   Benn CS, 2001, CLIN EXP ALLERGY, V31, P1862, DOI 10.1046/j.1365-2222.2001.01128.x
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   COLLINSON AC, 2002, THESIS U BRISTOL
   Douek DC, 1998, NATURE, V396, P690
   Eysteinsdottir JH, 2004, CLIN EXP IMMUNOL, V136, P349, DOI 10.1111/j.1365-2249.2004.02437.x
   Garofalo RP, 1998, BIOL NEONATE, V74, P134, DOI 10.1159/000014019
   GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x
   Hanson LA, 2003, ANN NY ACAD SCI, V987, P199
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x
   Hawkes JS, 1999, PEDIATR RES, V46, P194, DOI 10.1203/00006450-199908000-00012
   Hazenberg MD, 2003, NAT IMMUNOL, V4, P97, DOI 10.1038/ni0203-97
   Houseknecht KL, 1997, BIOCHEM BIOPH RES CO, V240, P742, DOI 10.1006/bbrc.1997.7736
   Jalil F, 1989, Acta Paediatr Scand Suppl, V350, P44
   Jeppesen DL, 2004, PEDIATR ALLERGY IMMU, V15, P127, DOI 10.1111/j.1399-3038.2004.00032.x
   Klein J, 1997, IMMUNOLOGY
   MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303
   Madhok AB, 2005, CLIN DIAGN LAB IMMUN, V12, P563, DOI 10.1128/CDLI.12.5.563-565.2005
   McDade TW, 2004, CLIN EXP ALLERGY, V34, P44, DOI 10.1111/j.1365-2222.2004.01834.x
   McDade TW, 2001, J NUTR, V131, P1225
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   MORRISSEY PJ, 1994, CELL IMMUNOL, V157, P118, DOI 10.1006/cimm.1994.1210
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   Owens JA, 1989, ADV FETAL PHYSL, P263
   PHILLIPS DIW, 1993, Q J MED, V86, P247
   PITTARD WB, 1984, CLIN IMMUNOL IMMUNOP, V30, P178, DOI 10.1016/0090-1229(84)90052-7
   PRENTICE A, 1984, ACTA PAEDIATR SCAND, V73, P803, DOI 10.1111/j.1651-2227.1984.tb17779.x
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Prentice AM, 1999, FETAL PROGRAMMING IN, P399
   Rayco-Solon P, 2005, AM J OBSTET GYNECOL, V192, P1133, DOI 10.1016/j.ajog.2004.10.636
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   SINGH J, 1989, BRIT J NUTR, V62, P315, DOI 10.1079/BJN19890033
   SUDA T, 1991, J IMMUNOL, V146, P3068
   Ulijaszek S.J., 1993, SEASONALITY HUMAN EC
   VICTORA CG, 1988, PEDIATRICS, V81, P807
   WINICK M, 1966, J NUTR, V89, P300
NR 47
TC 42
Z9 42
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 2RU CAMBRIDGE, ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD AUG
PY 2006
VL 65
IS 3
BP 311
EP 318
DI 10.1079/PNS2006503
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 076PY
UT WOS:000239971400010
PM 16923314
OA No
DA 2017-08-15
ER

PT J
AU New, M
   Hewitson, B
   Stephenson, DB
   Tsiga, A
   Kruger, A
   Manhique, A
   Gomez, B
   Coelho, CAS
   Masisi, DN
   Kululanga, E
   Mbambalala, E
   Adesina, F
   Saleh, H
   Kanyanga, J
   Adosi, J
   Bulane, L
   Fortunata, L
   Mdoka, ML
   Lajoie, R
AF New, Mark
   Hewitson, Bruce
   Stephenson, David B.
   Tsiga, Alois
   Kruger, Andries
   Manhique, Atanasio
   Gomez, Bernard
   Coelho, Caio A. S.
   Masisi, Dorcas Ntiki
   Kululanga, Elina
   Mbambalala, Ernest
   Adesina, Francis
   Saleh, Hemed
   Kanyanga, Joseph
   Adosi, Juliana
   Bulane, Lebohang
   Fortunata, Lubega
   Mdoka, Marshall L.
   Lajoie, Robert
TI Evidence of trends in daily climate extremes over southern and west
   Africa
SO JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES
LA English
DT Article
ID INTERANNUAL VARIABILITY; HEAVY PRECIPITATION; TEMPERATURE TRENDS;
   RAINFALL; 20TH-CENTURY; INDEXES; PROBABILITY; FREQUENCY; INTENSITY;
   ZIMBABWE
AB [ 1] There has been a paucity of information on trends in daily climate and climate extremes, especially from developing countries. We report the results of the analysis of daily temperature ( maximum and minimum) and precipitation data from 14 south and west African countries over the period 1961 - 2000. Data were subject to quality control and processing into indices of climate extremes for release to the global community. Temperature extremes show patterns consistent with warming over most of the regions analyzed, with a large proportion of stations showing statistically significant trends for all temperature indices. Over 1961 to 2000, the regionally averaged occurrence of extreme cold ( fifth percentile) days and nights has decreased by - 3.7 and - 6.0 days/decade, respectively. Over the same period, the occurrence of extreme hot (95th percentile) days and nights has increased by 8.2 and 8.6 days/decade, respectively. The average duration of warm ( cold) has increased ( decreased) by 2.4 (0.5) days/decade and warm spells. Overall, it appears that the hot tails of the distributions of daily maximum temperature have changed more than the cold tails; for minimum temperatures, hot tails show greater changes in the NW of the region, while cold tails have changed more in the SE and east. The diurnal temperature range (DTR) does not exhibit a consistent trend across the region, with many neighboring stations showing opposite trends. However, the DTR shows consistent increases in a zone across Namibia, Botswana, Zambia, and Mozambique, coinciding with more rapid increases in maximum temperature than minimum temperature extremes. Most precipitation indices do not exhibit consistent or statistically significant trends across the region. Regionally averaged total precipitation has decreased but is not statistically significant. At the same time, there has been a statistically significant increase in regionally averaged daily rainfall intensity and dry spell duration. While the majority of stations also show increasing trends for these two indices, only a few of these are statistically significant. There are increasing trends in regionally averaged rainfall on extreme precipitation days and in maximum annual 5-day and 1-day rainfall, but only trends for the latter are statistically significant.
C1 Univ Oxford, Ctr Environm, Oxford OX1 3QY, England.
   Univ Cape Town, Dept Geog & Environm Sci, ZA-7925 Cape Town, South Africa.
   Univ Reading, Dept Meteorol, Reading RG6 6BB, Berks, England.
   Natl Meteorol Serv, Harare, Zimbabwe.
   S Africa Weather Serv, ZA-0001 Pretoria, South Africa.
   Natl Meteorol Serv, Maputo, Mozambique.
   Dept Water Resources, Banjul, Gambia.
   Natl Meteorol Serv, Bechuanaland, Botswana.
   Natl Meteorol Serv, Chileka, Malawi.
   Obafemi Awolowo Univ, Dept Geog, Ife, Nigeria.
   Tanzanian Meteorol Agcy, Dar Es Salaam, Tanzania.
   Zambia Meteorol Dept, Lusaka 10101, Zambia.
   Lesotho Meteorol Serv, Maseru 100, Lesotho.
   Uganda Meteorol Dept, Kampala, Uganda.
   Natl Meteorol Serv, Victoria, Seychelles.
RP New, M (reprint author), Univ Oxford, Ctr Environm, S Parks Rd, Oxford OX1 3QY, England.
EM mark.new@ouce.ox.ac.uk
RI Stephenson, David/A-9903-2011; New, Mark/A-7684-2008; Coelho,
   Caio/G-4275-2012; Hewitson, Bruce/B-3295-2014
OI New, Mark/0000-0001-6082-8879; Hewitson, Bruce/0000-0001-7546-4430
CR Aguilar E, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006119
   Alexander LV, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006290
   Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364
   EASTERLING DR, 2003, B AM METEOROL SOC, V8, P1403
   Fauchereau N, 2003, NAT HAZARDS, V29, P139, DOI 10.1023/A:1023630924100
   Frei C, 2001, J CLIMATE, V14, P1568, DOI 10.1175/1520-0442(2001)014<1568:DPOTIR>2.0.CO;2
   Frich P, 2002, CLIMATE RES, V19, P193, DOI 10.3354/cr019193
   Groisman PY, 1999, CLIMATIC CHANGE, V42, P243, DOI 10.1023/A:1005432803188
   Haylock MR, 2006, J CLIMATE, V19, P1490, DOI 10.1175/JCLI3695.1
   Hollander M., 1973, NONPARAMETRIC STAT I
   Hulme M, 2001, CLIMATE RES, V17, P145, DOI 10.3354/cr017145
   Karl TR, 1998, B AM METEOROL SOC, V79, P231, DOI 10.1175/1520-0477(1998)079<0231:STOPAF>2.0.CO;2
   KARL TR, 1995, NATURE, V377, P217, DOI 10.1038/377217a0
   Kiktev D, 2003, J CLIMATE, V16, P3560, DOI 10.1175/1520-0442(2003)016<3560:COMAOT>2.0.CO;2
   Kruger AC, 2004, INT J CLIMATOL, V24, P1929, DOI 10.1002/joc.1096
   Mahe G, 2001, HYDROLOG SCI J, V46, P211, DOI 10.1080/02626660109492817
   Malhi Y, 2004, PHILOS T ROY SOC B, V359, P311, DOI 10.1098/rstb.2003.1433
   Manton MJ, 2001, INT J CLIMATOL, V21, P269, DOI 10.1002/joc.610
   Mason SJ, 1999, CLIMATIC CHANGE, V41, P249, DOI 10.1023/A:1005450924499
   Misra V, 2003, J CLIMATE, V16, P2408, DOI 10.1175/2785.1
   Moberg A, 2005, NATURE, V433, P613, DOI 10.1038/nature03265
   Moron V, 1997, INT J CLIMATOL, V17, P785, DOI 10.1002/(SICI)1097-0088(19970630)17:8<785::AID-JOC153>3.0.CO;2-I
   Nicholls N, 1996, CLIMATE CHANGE 1995, P133
   Osborn TJ, 2000, INT J CLIMATOL, V20, P347, DOI 10.1002/(SICI)1097-0088(20000330)20:4<347::AID-JOC475>3.0.CO;2-C
   Paeth H, 2002, CLIM RES, V22, P189, DOI 10.3354/cr022189
   Peterson TC, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002251
   Peterson TC, 2005, CLIVAR EXCHANGES, V10, P6
   Schreck CJ, 2004, INT J CLIMATOL, V24, P681, DOI 10.1002/joc.1019
   Sen Roy S, 2004, INT J CLIMATOL, V24, P457, DOI 10.1002/joc.995
   Tadross MA, 2005, J CLIMATE, V18, P3356, DOI 10.1175/JCLI3423.1
   Unganai LS, 2001, S AFR J SCI, V97, P425
   Vincent LA, 2005, J CLIMATE, V18, P5011, DOI 10.1175/JCLI3589.1
   Wang XL, 2003, J CLIMATE, V16, P3383, DOI 10.1175/1520-0442(2003)016<3383:CODOUC>2.0.CO;2
   *WMO, 2005, WMO PUBL, V9
NR 34
TC 214
Z9 233
U1 3
U2 43
PU AMER GEOPHYSICAL UNION
PI WASHINGTON
PA 2000 FLORIDA AVE NW, WASHINGTON, DC 20009 USA
SN 2169-897X
J9 J GEOPHYS RES-ATMOS
JI J. Geophys. Res.-Atmos.
PD JUL 21
PY 2006
VL 111
IS D14
AR D14102
DI 10.1029/2005JD006289
PG 11
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 071DU
UT WOS:000239579100001
OA No
DA 2017-08-15
ER

PT J
AU Dunyo, S
   Ord, R
   Hallett, R
   Jawara, M
   Walraven, G
   Mesa, E
   Coleman, R
   Sowe, M
   Alexander, N
   Targett, GAT
   Pinder, M
   Sutherland, CJ
AF Dunyo, Samuel
   Ord, Rosalynn
   Hallett, Rachel
   Jawara, Musa
   Walraven, Gijs
   Mesa, Eduardo
   Coleman, Rosalind
   Sowe, Maimuna
   Alexander, Neal
   Targett, Geoffrey A. T.
   Pinder, Margaret
   Sutherland, Colin J.
TI Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian
   children with malaria: Impact against multidrug-resistant P-falciparum
SO PLOS CLINICAL TRIALS
LA English
DT Article
ID SULFADOXINE-PYRIMETHAMINE; UNCOMPLICATED MALARIA; DIHYDROPTEROATE
   SYNTHASE; DIHYDROFOLATE-REDUCTASE; COMBINATION THERAPY; DOUBLE-BLIND;
   CHLOROQUINE; ARTESUNATE; TRANSMISSION; DRUG
AB Objectives: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP.
   Design: We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone.
   Setting: The study took place in the town of Farafenni and surrounding villages in the Gambia.
   Participants: Participants were children aged 12 mo to 10 y presenting as outpatients with uncomplicated P. falciparum malaria.
   Interventions: 500 children were randomised to receive CQ, SP, or CQ/SP as supervised treatment and actively followed over 28 d.
   Outcome Measures: Primary outcome was parasitaemia at any time during follow-up. Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures, and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from 161 patients were tested for the presence of resistance-associated genetic markers.
   Results: The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP ( odds ratio [ OR], 0.106; 95% confidence interval [CI], 0.057 - 0.194; p < 0.001) and 13.9% for CQ/SP ( OR versus CQ, 0.140; 95% CI, 0.078 - 0.250; p < 0.001). There was no difference between the SP and CQ/SP groups ( OR, 1.324; 95% CI, 0.705 - 2.50). The projected prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/ SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common, with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of multidrug-resistant parasite genotypes was associated with treatment failure in the SP group, but not in the CQ or CQ/ SP groups.
   Conclusions: The combination of CQ/ SP was an efficacious treatment for uncomplicated malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant parasites suggests that this observed efficacy is not sustainable.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1, England.
   MRC Labs, Farafenni Field Stn, Fajara, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, London WC1, England.
RP Sutherland, CJ (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1, England.
EM Colin.Sutherland@lshtm.ac.uk
FU Medical Research Council [G0700837]; Wellcome Trust
CR Bojang KA, 1998, T ROY SOC TROP MED H, V92, P73, DOI 10.1016/S0035-9203(98)90962-2
   Cattamanchi A, 2003, AM J TROP MED HYG, V68, P133
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   Dorsey G, 2004, AM J TROP MED HYG, V71, P758
   Drakeley CJ, 2004, TROP MED INT HEALTH, V9, P53, DOI 10.1046/j.1365-3156.2003.01169.x
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   Hallett RL, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010015
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   Kahn HA, 1989, STAT METHODS EPIDEMI
   MCINTOSH HM, 2005, COCHRANE DB SYST REV, P386
   Meerman L, 2005, J INFECT DIS, V192, P1651, DOI 10.1086/496887
   Mendez F, 2002, AM J EPIDEMIOL, V156, P230, DOI 10.1093/aje/kwf030
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3
   Pearce RJ, 2003, ANTIMICROB AGENTS CH, V47, P1347, DOI 10.1128/AAC.47.4.1347-1354.2003
   PLOWE CV, 1995, AM J TROP MED HYG, V52, P565
   Schwab U, 2005, CLIN INFECT DIS, V40, P493, DOI 10.1086/427152
   Snounou G, 1998, PARASITOL TODAY, V14, P462, DOI 10.1016/S0169-4758(98)01340-4
   Staedke SG, 2004, LANCET, V364, P1950, DOI 10.1016/S0140-6736(04)17478-3
   Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
   WHO, 1993, WHO TECHN REP SER, V839
   *WHO, 2003, WHOCDSMAL20031093 UN
NR 29
TC 25
Z9 25
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1555-5887
J9 PLOS CLIN TRIALS
JI PLos Clin. Trials
PD JUL 21
PY 2006
VL 1
IS 3
AR e14
DI 10.1371/journal.pctr.0010014
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 150SK
UT WOS:000245237900001
PM 16871319
OA gold
DA 2017-08-15
ER

PT J
AU Hallett, RL
   Dunyo, S
   Ord, R
   Jawara, M
   Pinder, M
   Randall, A
   Alloueche, A
   Walraven, G
   Targett, GAT
   Alexander, N
   Sutherland, CJ
AF Hallett, Rachel L.
   Dunyo, Samuel
   Ord, Rosalynn
   Jawara, Musa
   Pinder, Margaret
   Randall, Anna
   Alloueche, Ali
   Walraven, Gijs
   Targett, Geoffrey A. T.
   Alexander, Neal
   Sutherland, Colin J.
TI Chloroquine/sulphadoxine-pyrimethamine for Gambia children with malaria:
   Transmission to mosquitoes of multidrug-resistant Plasmodium falciparum
SO PLOS CLINICAL TRIALS
LA English
DT Article
ID UNCOMPLICATED MALARIA; SULFADOXINE-PYRIMETHAMINE; DIHYDROPTEROATE
   SYNTHASE; DIHYDROFOLATE-REDUCTASE; COMBINATION THERAPY; CHLOROQUINE;
   ARTESUNATE; MUTATIONS; TRIAL; DRUG
AB Objectives: In the Gambia, chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP) is the first-line antimalarial treatment. Plasmodium falciparum parasites carrying mutations associated with resistance to each of these drugs were present in 2001 but did not cause a significant loss of therapeutic efficacy among children receiving the combination CQ/SP. We measured their effect on parasite transmission to Anopheles gambiae mosquitoes.
   Design: We conducted a single-blind, randomised, controlled trial with follow-up over 28 d. Mosquito feeding experiments were carried out 7, 10, or 14 d after treatment.
   Setting: The study took place in the town of Farafenni and surrounding villages in the Gambia.
   Participants: Participants were 500 children aged 6 mo to 10 y with uncomplicated P. falciparum malaria.
   Interventions: Children were randomised to receive CQ, SP, or CQ/SP.
   Outcome Measures: Outcomes related to transmission were determined, including posttreatment gametocyte prevalence and density. Infectiousness was assessed by membrane-feeding A. gambiae mosquitoes with blood from 70 gametocyte-positive patients. Mutations at seven loci in four genes associated with drug resistance were measured pre- and posttreatment and in the midguts of infected mosquitoes.
   Results: After SP treatment, the infectiousness of gametocytes was delayed, compared to the other two treatment groups, despite comparable gametocyte densities. Among bloodmeal gametocytes and the midguts of infected mosquitoes, the presence of the four-locus multidrug-resistant haplotype TYRG ( consisting of mutations pfcrt-76T, pfmdr1-86Y, pfdhfr-59R, and pfdhps-437G) was associated with significantly higher oocyst burdens after treatment with the combination CQ/SP.
   Conclusions: Parasites with a multidrug-resistant genotype had a substantial transmission advantage after CQ/SP treatment but did not have a significant impact on in vivo efficacy of this drug combination. Protocols that include measuring transmission endpoints as well as therapeutic outcomes may be a useful strategy when monitoring the evolution of drug resistance in malaria parasites in vivo.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, London WC1, England.
   MRC Labs, Farafenni Field Stn, Fajara, Gambia.
RP Sutherland, CJ (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1, England.
EM Colin.Sutherland@lshtm.ac.uk
FU Medical Research Council [G0700837]; Wellcome Trust
CR Bell D, 2004, BRIT MED BULL, V71, P29, DOI 10.1093/bmb/ldh031
   Bojang KA, 1998, T ROY SOC TROP MED H, V92, P73, DOI 10.1016/S0035-9203(98)90962-2
   Brockman A, 2000, T ROY SOC TROP MED H, V94, P537, DOI 10.1016/S0035-9203(00)90080-4
   Butcher GA, 1997, INT J PARASITOL, V27, P975, DOI 10.1016/S0020-7519(97)00079-9
   Dorsey G, 2004, AM J TROP MED HYG, V71, P758
   Drakeley CJ, 2004, TROP MED INT HEALTH, V9, P53, DOI 10.1046/j.1365-3156.2003.01169.x
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   Hayward R, 2005, MOL MICROBIOL, V55, P1285, DOI 10.1111/j.1365-2958.2004.04470.x
   Meerman L, 2005, J INFECT DIS, V192, P1651, DOI 10.1086/496887
   Mendez F, 2002, AM J EPIDEMIOL, V156, P230, DOI 10.1093/aje/kwf030
   Pearce RJ, 2003, ANTIMICROB AGENTS CH, V47, P1347, DOI 10.1128/AAC.47.4.1347-1354.2003
   PLOWE CV, 1995, AM J TROP MED HYG, V52, P565
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876
   Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   WALSH PS, 1991, BIOTECHNIQUES, V10, P506
NR 21
TC 45
Z9 45
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1555-5887
J9 PLOS CLIN TRIALS
JI PLos Clin. Trials
PD JUL 21
PY 2006
VL 1
IS 3
AR e15
DI 10.1371/journal.pctr.0010015
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 150SK
UT WOS:000245237900002
PM 16871318
OA gold
DA 2017-08-15
ER

PT J
AU Cutts, FT
   Enwere, G
   Zaman, SMA
   Yallop, FG
AF Cutts, F. T.
   Enwere, G.
   Zaman, S. M. A.
   Yallop, F. G.
TI Operational challenges in large clinical trials: Example lessons learned
   from the Gambia pneumococcal vaccine
SO PLOS CLINICAL TRIALS
LA English
DT Article
ID CONJUGATE VACCINE; EFFICACY; DISEASE; INFANTS
C1 MRC Labs, Fajara, Gambia.
RP Cutts, FT (reprint author), World Hlth Org, Geneva, Switzerland.
EM cuttsf@who.int
CR Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Emanuel EJ, 2005, LANCET, V366, P336, DOI 10.1016/S0140-6736(05)66992-9
   GREENWOOD BM, 2005, GRAND CHALLENGE FUTU, P249, DOI 10.1007/3-7643-7381-4_12
   Jaffar S, 2003, INT J EPIDEMIOL, V32, P430, DOI 10.1093/ije/dyg082
   Jaffar S, 1999, VACCINE, V18, P633, DOI 10.1016/S0264-410X(99)00277-7
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Leach A, 1996, PEDIATR INFECT DIS J, V15, P333, DOI 10.1097/00006454-199604000-00010
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   [Anonymous], 1996, INT C HARM
NR 10
TC 13
Z9 13
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1555-5887
J9 PLOS CLIN TRIALS
JI PLos Clin. Trials
PD JUL 14
PY 2006
VL 1
IS 3
AR e16
DI 10.1371/journal.pctr.0010016
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 150SJ
UT WOS:000245237800001
PM 16871317
OA gold
DA 2017-08-15
ER

PT J
AU Howie, S
   Howie, R
AF Howie, S
   Howie, R
TI Valuing children
SO LANCET
LA English
DT Letter
ID SURVIVAL
C1 MRC Labs, Banjul, Gambia.
RP Howie, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM showie@mrc.gm
CR Horton R, 2005, LANCET, V365, P821, DOI 10.1016/S0140-6736(05)71015-1
   Lawn JE, 2006, LANCET, V367, P1541, DOI 10.1016/S0140-6736(06)68587-5
   Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5
   Stanton C, 2006, LANCET, V367, P1487, DOI 10.1016/S0140-6736(06)68586-3
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 8
PY 2006
VL 368
IS 9530
BP 117
EP 118
DI 10.1016/S0140-6736(06)68999-X
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 062AR
UT WOS:000238917200022
PM 16829293
OA No
DA 2017-08-15
ER

PT J
AU Tosh, K
   Campbell, SJ
   Fielding, K
   Sillah, J
   Bah, B
   Gustafson, P
   Manneh, K
   Lisse, I
   Sirugo, G
   Bennett, S
   Aaby, P
   McAdam, KPWJ
   Bah-Sow, O
   Lienhardt, C
   Kramnik, I
   Hill, AVS
AF Tosh, Kerrie
   Campbell, Sarah J.
   Fielding, Katherine
   Sillah, Jackson
   Bah, Boubacar
   Gustafson, Per
   Manneh, Kebba
   Lisse, Ida
   Sirugo, Giorgio
   Bennett, Steve
   Aaby, Peter
   McAdam, Keith P. W. J.
   Bah-Sow, Oumou
   Lienhardt, Christian
   Kramnik, Igor
   Hill, Adrian V. S.
TI Variants in the SP110 gene are associated with genetic susceptibility to
   tuberculosis in West Africa
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE association study; murine genetics; macrophage
ID LINKAGE DISEQUILIBRIUM; INTERFERON-GAMMA; RISK-FACTORS; TECHNOLOGY;
   RESISTANCE; INFECTION; IMMUNITY; RECEPTOR
AB The sst1 locus has been identified in a mouse model to control resistance and susceptibility of Mycobacterium tuberculosis infection. Subsequent studies have now identified Ipr1 (intracellular pathogen resistance 1) to be the gene responsible. Ipr1 is encoded within the sst1 locus and is expressed in the tuberculosis lung lesions and macrophages of sst1-resistant, but not sst1-susceptible mice. We have therefore examined the closest human homologue of Ipr1, SP110, for its ability to control susceptibility to M. tuberculosis infection in humans. In a study of families from The Gambia we have identified three polymorphisms that are associated with disease. On examination of additional families from Guinea-Bissau and the Republic of Guinea, two of these associations were independently replicated. These variants are in strong linkage disequilibrium with each other and lie within a 31-kb block of low haplotypic diversity, suggesting that a polymorphism within this region has a role in genetic susceptibility to tuberculosis in humans.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Programme Natl Lutte Anti TB, Conakry, Guinea.
   Statens Serum Inst, Projecto Saude Bandim, Danish Epidemiol Serv Ctr, Bissau, Guinea Bissau.
   Natl TB Leprosy Control Program, Banjul, Gambia.
   Inst Rech Dev, Dakar, Senegal.
   Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Hill, AVS (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM adrian.hill@imm.ox.ac.uk
RI HILL, Adrian/C-1306-2008
OI Kramnik, Igor/0000-0001-6511-9246
FU Wellcome Trust
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Bellamy R, 2003, GENES IMMUN, V4, P4, DOI 10.1038/sj.gene.6363915
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000
   Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Jurinke Christian, 2002, Methods Mol Biol, V187, P179
   Jurinke Christian, 2002, Adv Biochem Eng Biotechnol, V77, P57
   Kramnik I, 2000, P NATL ACAD SCI USA, V97, P8560, DOI 10.1073/pnas.150227197
   Kruglyak L, 1998, J COMPUT BIOL, V5, P1, DOI 10.1089/cmb.1998.5.1
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Lio D, 2002, EUR J IMMUNOGENET, V29, P371, DOI 10.1046/j.1365-2370.2002.00327.x
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC
   Maniatis N, 2002, P NATL ACAD SCI USA, V99, P2228, DOI 10.1073/pnas.042680999
   Pan H, 2005, NATURE, V434, P767, DOI 10.1038/nature03419
   Saito T, 2004, BIOCHEM BIOPH RES CO, V317, P335, DOI 10.1016/j.bbrc.2004.03.056
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D
   Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003
   World Health Organization, 2002, WORLD HLTH REP 2002
NR 21
TC 63
Z9 73
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 5
PY 2006
VL 103
IS 27
BP 10364
EP 10368
DI 10.1073/pnas.0603340103
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 064DM
UT WOS:000239069400039
PM 16803959
OA No
DA 2017-08-15
ER

PT J
AU Munday, K
   Ginty, F
   Fulford, A
   Bates, CJ
AF Munday, K.
   Ginty, F.
   Fulford, A.
   Bates, C. J.
TI Relationships between biochemical bone turnover markers, season, and
   inflammatory status indices in prepubertal Gambian boys
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Gambian boys; seasonal difference; procollagen type IN-propeptide;
   C-terminal telopeptide of type I collagen; acute phase marker
ID ACUTE-PHASE PROTEIN; C-REACTIVE PROTEIN; MINERAL CONTENT; GROWTH;
   CHILDREN; WOMEN; SUPPLEMENTATION; NUTRITION; HORMONE
AB Seasonal and interindividual differences in food availability and illnesses cause variations in growth, including bone growth, in children in developing countries. We investigated seasonal differences in biochemical (serum) markers of bone metabolism and relationships between these markers (procollagen type I N propeptide [P1NP], serum C-terminal telopeptide of type 1 collagen [S-CTX]) and serum markers of inflammation (alpha(1)- antichymotrypsin [ACT], C-reactive protein [CRP], sialic acid) in prepubertal Gambian boys. Three seasonal time points were chosen: August, mid-rainy season; October, late rainy season (both are associated with decreased food supply, increased prevalence of infection, reduced weight gain, and stunting); and April, late dry season, when environmental conditions are better and rates of weight gain are higher. The prevalence of raised inflammatory markers was high: 29% of ACT values > 0.40 g/L in August, 42% > 0.40 g/L in October, and 18% > 0.40 g/L in April. Of CRP values, 92-96% were > 0.47 mg/L and 30%, 46%, and 18% were > 3.95 mg/L in August, October, and April, respectively. Also, 42-52% of sialic acid values were > 648 mg/L. Of the bone markers, S-CTX exhibited the highest values in August; P1NP did not vary with season. Inverse relationships between each bone marker and the acute phase markers occurred, with the strongest relationships between P1NP and ACT or sialic acid. We conclude that bone collagen synthesis and turnover are reduced during inflammation in rural Gambian boys. Biochemical indices can provide powerful, single-time point evidence of infection and growth-faltering episodes.
C1 MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   MRC, Int Nutr Grp, Keneba, Gambia.
RP Bates, CJ (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM Chris.Bates@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960371, MC_U105960399]
CR Aspray TJ, 1996, J BONE MINER RES, V11, P1019
   Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Bradney M, 2000, J BONE MINER RES, V15, P1871, DOI 10.1359/jbmr.2000.15.10.1871
   COLE TJ, 1990, EUR J CLIN NUTR, V44, P45
   Cook DG, 2000, ATHEROSCLEROSIS, V149, P139, DOI 10.1016/S0021-9150(99)00312-3
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   DIBBA BJ, 1999, MRC HUMAN NUTR RES
   Doherty CP, 2002, CLIN ENDOCRINOL, V57, P391, DOI 10.1046/j.1365-2265.2002.01622.x
   DUAN Y, 2004, J BONE MINER RES, V18, P1766
   Ginty F, 2004, EUR J CLIN NUTR, V58, P1257, DOI 10.1038/sj.ejcn.1601959
   Gregory J., 2000, NATL DIET NUTR SURVE
   KUNDU SK, 1985, ARCH BIOCHEM BIOPHYS, V238, P388, DOI 10.1016/0003-9861(85)90179-1
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   Munday K, 2005, BRIT J NUTR, V93, P501, DOI 10.1079/BJN20041329
   Panter-Brick C, 2001, BRIT J NUTR, V85, P125, DOI 10.1079/BJN2000225
   ROBINSON GW, 1994, MECH DEVELOP, V48, P199, DOI 10.1016/0925-4773(94)90060-4
   Rooney M, 2000, J RHEUMATOL, V27, P1073
   Seibel MJ, 2002, CURR OPIN CLIN NUTR, V5, P525, DOI 10.1097/00075197-200209000-00011
   SEIBEL MJ, 2000, OSTEOPOROS INT S, V6, pS18
   Sillanaukee P, 1999, EUR J CLIN INVEST, V29, P413
   SINGH J, 1989, BRIT J NUTR, V62, P315, DOI 10.1079/BJN19890033
   STEFENELLI N, 1985, J CANCER RES CLIN, V109, P55, DOI 10.1007/BF01884255
   SUGUHARA K, 1980, CLIN CHIM ACTA, V108, P493
   THOMPSON D, 1992, ANN CLIN BIOCHEM, V29, P123
   WHICHER JT, 1985, CLIN IMMUNOL ALLERGY, V5, P425
   Wilkins J, 1998, CLIN CHEM, V44, P1358
NR 26
TC 8
Z9 8
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0171-967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUL
PY 2006
VL 79
IS 1
BP 15
EP 21
DI 10.1007/s00223-005-0276-4
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 071HH
UT WOS:000239589900003
PM 16868668
OA No
DA 2017-08-15
ER

PT J
AU de Bono, S
   Laskey, A
   Ceesay, M
   Mendy, M
   Prentice, A
AF de Bono, S
   Laskey, A
   Ceesay, M
   Mendy, M
   Prentice, A
TI Influence of birth weight on PQCT measurements of cortical bone sites in
   young Gambian adults
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Meeting Abstract
CT Annual Meeting of the Bone-Research-Society
CY JUL 05-06, 2006
CL Southampton, ENGLAND
SP Bone Res Soc
C1 MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
   MRC, Keneba, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2006
VL 21
IS 7
BP 1161
EP 1161
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 057MW
UT WOS:000238600900073
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Kuniholm, MH
   Lesi, OA
   Mendy, M
   Akano, AC
   Goedert, JJ
   Whittle, H
   Hainaut, P
   Montesano, R
AF Kirk, G. D.
   Kuniholm, M. H.
   Lesi, O. A.
   Mendy, M.
   Akano, A. C.
   Goedert, J. J.
   Whittle, H.
   Hainaut, P.
   Montesano, R.
TI Risk of cirrhosis with exposure to aflatoxin and hepatitis B and C
   viruses
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on Viral Hepatitis and Liver Disease
CY JUL 01-05, 2006
CL Paris, FRANCE
SP Pan-Amer Soc Clin Virol, European Soc Clin Virol
C1 Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
   MRC Labs, Gambia Hepatitis Intervent Study, Banjul, Gambia.
   Natl Hosp, Dept Radiodiag, Abuja, Nigeria.
   NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
   IARC, Gambia Hepatitis Intervent Study, Lyon, France.
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2006
VL 36
SU 2
BP S37
EP S38
DI 10.1016/S1386-6532(06)80119-8
PG 2
WC Virology
SC Virology
GA 064CR
UT WOS:000239067300110
OA No
DA 2017-08-15
ER

PT J
AU Le Roux, E
   Villar, S
   Friesen, MD
   Mendy, M
   Van der Sande, M
   Waight, P
   McConkey, S
   Whittle, H
   Hainaut, R
AF Le Roux, E.
   Villar, S.
   Friesen, M. D.
   Mendy, M.
   Van der Sande, M.
   Waight, P.
   McConkey, S.
   Whittle, H.
   Hainaut, R.
TI TP53 mutation at codon 249 in circulating DNA of healthy patients
   exposed to aflatoxin: relation with HBV infection and significance for
   assessment of carcinogen exposure
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on Viral Hepatitis and Liver Disease
CY JUL 01-05, 2006
CL Paris, FRANCE
SP Pan-Amer Soc Clin Virol, European Soc Clin Virol
C1 Int Agcy Res Canc, MCB, F-69372 Lyon, France.
   Johns Hopkins Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA.
   MRC, Viral Dis Programme, Banjul, Gambia.
   Natl Inst Publ Hlth & Environm, Ctr Infect Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands.
   Hlth Protect Agcy, Healthcare Associate Infect & Antimicrobial Resis, London, England.
   Royal Coll Surg, Infect Dis Team, Dublin, Ireland.
RI Friesen, Marlin/D-7328-2012; McConkey, Samuel/E-7307-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2006
VL 36
SU 2
BP S176
EP S177
DI 10.1016/S1386-6532(06)80550-0
PG 2
WC Virology
SC Virology
GA 064CR
UT WOS:000239067300540
OA No
DA 2017-08-15
ER

PT J
AU Mendy, ME
   Kirk, G
   Jeng-Barry, A
   Kaye, S
   McConkey, S
   Le Roux, E
   Hainaut, P
   Whittle, H
   Rowland-Jones, S
AF Mendy, M. E.
   Kirk, G.
   Jeng-Barry, A.
   Kaye, S.
   McConkey, S.
   Le Roux, E.
   Hainaut, P.
   Whittle, H.
   Rowland-Jones, S.
TI Novel oligonucleotide assay detects HBV pre-core and basal core
   mutations in HBV-infected Gambians
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on Viral Hepatitis and Liver Disease
CY JUL 01-05, 2006
CL Paris, FRANCE
SP Pan-Amer Soc Clin Virol, European Soc Clin Virol
C1 MRC, Viral Dis Programme, Banjul, Gambia.
   Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
   IARC, Mol Carcinogenesis, Lyon, France.
RI McConkey, Samuel/E-7307-2012; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2006
VL 36
SU 2
BP S177
EP S177
DI 10.1016/S1386-6532(06)80551-2
PG 1
WC Virology
SC Virology
GA 064CR
UT WOS:000239067300541
OA No
DA 2017-08-15
ER

PT J
AU Taylor, T
   Olola, C
   Valim, C
   Agbenyega, T
   Kremsner, P
   Krishna, S
   Kwiatkowski, D
   Newton, C
   Missinou, M
   Pinder, M
   Wypij, D
AF Taylor, T
   Olola, C
   Valim, C
   Agbenyega, T
   Kremsner, P
   Krishna, S
   Kwiatkowski, D
   Newton, C
   Missinou, M
   Pinder, M
   Wypij, D
CA SMAC Network
TI Standardized data collection for multi-center clinical studies of severe
   malaria in African children: establishing the SMAC network
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; severe malaria; Plasmodium falciparum; children; clinical
   trials; Africa
ID CEREBRAL MALARIA
AB The Severe Malaria in African Children (SMAC) network was established to conduct mortality-based trials. Although falciparum malaria kilts more than one million children each year, single centers cannot enroll enough patients to detect reductions of 20-30% in mortality rates. Our aim was to quantify and describe severe malaria across a variety of epidemiological settings so that we could design intervention studies with more precise sample size estimates. We used a standardized surveillance mechanism to capture clinical, laboratory and outcome data on all parasitemic children admitted to hospital. Between December 2000 and December 2003, 20333 patients were enrolled at five sites. The frequency of severe malaria syndromes (cerebral malaria, severe malarial anemia and acidosis) differed between sites, as did the syndrome-specific mortality rates. Intervention studies targeted at reducing mortality in one or a combination of severe malaria syndromes would require 3-4 years to complete within the existing network. These data provide more accurate estimates of the disease burden of children hospitalized for malaria in sub-Saharan Africa. Networks are required to recruit enough patients for mortality-based studies and to encompass the epidemiological diversity of malaria in sub-Saharan Africa. SMAC represents the first effort to develop this capacity. (C) 2006 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
   Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya.
   Childrens Hosp, Clin Res Program, Boston, MA 02115 USA.
   Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Physiol, Kumasi, Ghana.
   Albert Schweitzer Hosp, Lambarene, Gabon.
   Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany.
   St George Hosp, Sch Med, Dept Cellular & Mol Sci Infect Dis, London SW17 0RE, England.
   Wellcome Ctr Human Genet, Oxford OX3 7BN, England.
   Inst Child Hlth, London, England.
   MRC Labs, Malaria Res Programme, Banjul, Gambia.
RP Taylor, T (reprint author), Michigan State Univ, Coll Osteopath Med, Dept Internal Med, B309-B W Fee Hall, E Lansing, MI 48824 USA.
EM taylort@msu.edu
RI Newton, Charles/C-6222-2009; Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507; Krishna, Sanjeev/0000-0003-0066-0634;
   Kwiatkowski, Dominic/0000-0002-5023-0176
FU Medical Research Council [G19/9, G9505090]; NIAID NIH HHS [AI 45955, U01
   AI045955, U19 AI045955]; Wellcome Trust
CR Bruno JM, 1997, NATURE, V386, P541
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Newton CRJC, 1998, AM J TROP MED HYG, V58, P673
   PLANCHE T, 2001, AM J TROP MED HYG, V65, P500
   Snow R. W., 1994, African Journal of Health Sciences, V1, P71
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   World Health Organisation, 2000, T R SOC TROP MED S1, V94
NR 10
TC 50
Z9 50
U1 0
U2 3
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL
PY 2006
VL 100
IS 7
BP 615
EP 622
DI 10.1016/j.trstmh.2005.09.021
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 049IZ
UT WOS:000238011000003
PM 16551469
OA No
DA 2017-08-15
ER

PT J
AU Mbaye, A
   Richardson, K
   Balajo, B
   Dunyo, S
   Shulman, C
   Milligan, P
   Greenwood, B
   Walraven, G
AF Mbaye, A.
   Richardson, K.
   Balajo, B.
   Dunyo, S.
   Shulman, C.
   Milligan, P.
   Greenwood, B.
   Walraven, G.
TI A randomized, placebo-controlled trial of intermittent preventive
   treatment with sulphadoxine-pyrimethamine in Gambian multigravidae
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE intermittent preventive treatment in pregnancy; malaria; anaemia;
   birthweight; multigravidae; The Gambia
ID PREGNANT-WOMEN; PLASMODIUM-FALCIPARUM; MALARIA TRANSMISSION; WESTERN
   KENYA; AREA; INFECTION; MORBIDITY; MORTALITY; MALAWI; CHLOROQUINE
AB We investigated the ability of intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine/pyrimethamine to prevent anaemia and low birthweight in Gambian multigravidae. Between July 2002 and February 2004, 2688 multigravidae living in a rural area of The Gambia received SP (1346 women) or placebo (1342 women) up to four times during pregnancy and were followed until 6-weeks postpartum. Shortly after delivery, 10.7% of women in the intervention group and 8.8% in the control group were severely anaemic [Hb < 7 g/dl, risk difference = 0.02 (95% CI 0.01, 0.04), P = 0.17]. The overall mean birthweight of infants born to women who had received SP ( 3103 g) was very similar to that observed in infants born to women in the control group [3075 g; difference = 28 g (95% CI 11 g, 67 g), P = 0.16]. However, among women who did not use a bednet (either insecticide treated or untreated), infants born to women who had received SP weighed more than infants born to women in the control group [3147 g vs. 3044 g; difference 143 g (95% CI 53 g, 232 g), interaction test P < 0.001]. This study did not show that IPTp with SP benefited Gambian multigravidae overall but that it may benefit a sub-group of women who do not use a bednet. In areas such as The Gambia, provision of insecticide-treated bednets to multigravidae may provide an adequate means of protection against malaria in pregnancy without the need for additional IPTp.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Govt Gambia, Dept Hlth, Banjul, Senegal.
   MRC Labs, Fajara, Gambia.
   Aga Khan, Secretariat His Highness, Aiglemont, France.
RP Greenwood, B (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM brian.greenwood@lshtm.acv.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Brabin B, 1991, 1 WHO
   Diagne N, 2000, NEW ENGL J MED, V343, P598, DOI 10.1056/NEJM200008313430901
   GREENWOOD AM, 1994, T ROY SOC TROP MED H, V88, P861
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Guyatt H, 2003, LANCET, V362, P1549, DOI 10.1016/S0140-6736(03)14744-7
   Hammerich A, 2002, TROP MED INT HEALTH, V7, P573, DOI 10.1046/j.1365-3156.2002.00898.x
   LeHesran JY, 1997, AM J EPIDEMIOL, V146, P826
   Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459
   MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0
   MORLEY D, 1964, BRIT MED J, V1, P667
   Njagi JK, 2003, T ROY SOC TROP MED H, V97, P277, DOI 10.1016/S0035-9203(03)90141-6
   Parise ME, 1998, AM J TROP MED HYG, V59, P813
   Rogerson SJ, 2000, T ROY SOC TROP MED H, V94, P549, DOI 10.1016/S0035-9203(00)90083-X
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Sirugo G, 2004, AM J MED GENET A, V128A, P104, DOI 10.1002/ajmg.a.30080
   Staalsoe T, 2004, INFECT IMMUN, V72, P5027, DOI 10.1128/IAI.72.9.5027-5030.2004
   ter Kuile FO, 2003, AM J TROP MED HYG, V68, P50
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van Eijk AM, 2004, TROP MED INT HEALTH, V9, P351, DOI 10.1111/j.1365-3156.2004.01196.x
   Verhoeff FH, 1998, ANN TROP MED PARASIT, V92, P141
   von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x
NR 22
TC 41
Z9 41
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2006
VL 11
IS 7
BP 992
EP 1002
DI 10.1111/j.1365-3156.2006.01649.x
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 060FQ
UT WOS:000238788300003
PM 16827700
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Hill, PC
   Secka, O
   Ikumapayi, UN
   Lahai, G
   Greenwood, BM
   Corrah, T
AF Adegbola, Richard A.
   Hill, Philip C.
   Secka, Ousman
   Ikumapayi, Usman N.
   Lahai, George
   Greenwood, Brian M.
   Corrah, Tumani
TI Serotype and antimicrobial susceptibility patterns of isolates of
   Streptococcus pneumoniae causing invasive disease in The Gambia
   1996-2003
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Streptococcus pneumoniae; serotype; antimicrobial sensitivity; The
   Gambia
ID PNEUMOCOCCAL CONJUGATE VACCINE; RESISTANT PNEUMOCOCCI; CHILDREN;
   SEROGROUPS; EPIDEMIOLOGY; PREVENTION; SURVEILLANCE; ANTIBIOTICS;
   MENINGITIS; INFECTIONS
AB OBJECTIVES To describe the characteristics of pneumococcal isolates obtained from patients with invasive pneumococcal disease in The Gambia.
   METHODS Pneumococcal isolates were obtained from children aged <= 6 years with invasive pneumococcal disease during a Haemophilus influenzae vaccine effectiveness study (1997-2002) and from patients with invasive pneumococcal disease admitted to the MRC hospital, Fajara, for routine care (1996-2003). Isolates were identified, serotyped and tested for antibiotic susceptibility.
   RESULTS Five hundred and thirty one pneumococcal isolates were obtained from 518 patients; 55 (10.6%) patients died; 415 isolates (79%) were from blood culture, 84 (16%) from CSF, and 42 (8%) from lung aspirates. Forty serogroups and serotypes were identified; six accounted for 64% and 16 for 86% of all episodes; 33.7% were of serotypes 1 and 5. 23.5% were of a 7-valent vaccine serotype, 57.1% were of a 9-valent vaccine serotype; 56% were of a 7-valent serogroup and 78% were of a 9-valent serogroup. There was a significant increase in the proportion of isolates of non-vaccine serogroup with increasing age (P < 0.0001). Antibiotic resistance had not significantly increased over time; but intermediate non-susceptibility to penicillin had risen and resistance to chloramphenicol had fallen in isolates of vaccine serotype compared with those of non-vaccine serotype.
   CONCLUSIONS The majority of invasive pneumococcal disease in The Gambia is caused by pneumococci of relatively few serogroups. A conjugate vaccine would be expected to reduce the pneumococcal disease burden substantially and to have a beneficial effect on pneumococcal antibiotic resistance to penicillins.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Adegbola, RA (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM radegbola@mrc.gm
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   ALONSODEVELASCO E, 1995, MICROBIOL REV, V59, P591
   Babl FE, 2001, CLIN INFECT DIS, V32, P1155, DOI 10.1086/319750
   Benbachir M, 2001, ANTIMICROB AGENTS CH, V45, P627, DOI 10.1128/AAC.45.2.627-629.2001
   Bergemann A, 1996, QJM-MON J ASSOC PHYS, V89, P499
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Byington CL, 2005, CLIN INFECT DIS, V41, P21, DOI 10.1086/430604
   Campbell JD, 2004, PEDIATR INFECT DIS J, V23, P642, DOI 10.1097/01.inf.0000130951.85974.79
   CreweBrown HH, 1997, CLIN INFECT DIS, V25, P1165
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2003, PEDIATR INFECT DIS J, V22, P532, DOI 10.1097/00006454-200306000-00009
   Dowell SF, 1997, AM FAM PHYSICIAN, V55, P1647
   FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920
   Ghaffar F, 2004, CLIN INFECT DIS, V39, P930, DOI 10.1086/423379
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Hortal M, 2000, Int J Infect Dis, V4, P91, DOI 10.1016/S1201-9712(00)90100-0
   Klugman KP, 2001, CLIN INFECT DIS, V33, P489, DOI 10.1086/322736
   KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171
   KLUGMAN KP, 2003, NEW ENGL J MED, V349, P1312
   Lakshmy A, 1997, ADV EXP MED BIOL, V418, P273
   Leowski J, 1986, World Health Stat Q, V39, P138
   *NATK COMM CLIN ST, 2004, M100S14 NAT COM CLIN
   Neufeld F, 1902, Z HYG INFEKTIONSKR, V40, P54, DOI 10.1007/BF02140530
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51
   Paul J, 1996, J INFECTION, V32, P139, DOI 10.1016/S0163-4453(96)91374-2
   Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729
   SALO P, 1995, J INFECT DIS, V171, P479
   SNIADACK DH, 1995, PEDIATR INFECT DIS J, V14, P503, DOI 10.1097/00006454-199506000-00007
   Spratt BG, 2000, LANCET, V356, P1210, DOI 10.1016/S0140-6736(00)02779-3
   STEPHENS DS, 2004, ISPPD4
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   Watt JP, 2004, CLIN INFECT DIS, V38, P496, DOI 10.1086/381198
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
NR 38
TC 53
Z9 53
U1 2
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2006
VL 11
IS 7
BP 1128
EP 1135
DI 10.1111/j.1365-3156.2006.01652.x
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 060FQ
UT WOS:000238788300016
PM 16827713
OA No
DA 2017-08-15
ER

PT J
AU Jallow, S
   Kaye, S
   Alabi, A
   Aveika, A
   Sarge-Njie, R
   Sabally, S
   Corrah, T
   Whittle, H
   Vanham, G
   Rowland-Jones, S
   Janssens, W
   McConkey, SJ
AF Jallow, Sabelle
   Kaye, Steve
   Alabi, Abraham
   Aveika, Akum
   Sarge-Njie, Ramu
   Sabally, Saihou
   Corrah, Tumani
   Whittle, Hilton
   Vanham, Guido
   Rowland-Jones, Sarah
   Janssens, Wouter
   McConkey, Samuel J.
TI Virological and immunological response to Combivir and emergence of drug
   resistance mutations in a cohort of HIV-2 patients in The Gambia
SO AIDS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-2; ANTIRETROVIRAL THERAPY; ZIDOVUDINE;
   POLYMORPHISM; GENE
C1 MRC Labs, Banjul, Gambia.
   Inst Trop Med, Dept Microbiol, HIV Virol Unit, B-2000 Antwerp, Belgium.
RP Jallow, S (reprint author), MRC Labs, Fajara POB 273, Banjul, Gambia.
EM sjallow@mrc.gm
RI McConkey, Samuel/E-7307-2012
FU Medical Research Council [MC_U190081962, MC_U190085854]
CR Adje-Toure CA, 2003, AIDS, V17, pS49
   Berry N, 1998, J Hum Virol, V1, P457
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Boyer PL, 2006, PLOS PATHOG, V2, P101, DOI 10.1371/journal.ppat0020010
   Brandin E, 2003, AIDS RES HUM RETROV, V19, P543, DOI 10.1089/088922203322230905
   Colson P, 2004, J CLIN MICROBIOL, V42, P570, DOI 10.1128/JCM.42.2.570-577.2004
   Descamps D, 1997, J VIROL, V71, P8893
   ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502
   Gallego O, 2002, AIDS RES HUM RETROV, V18, P857, DOI 10.1089/08892220260190335
   Kaye S, 2003, CLIN CHEM, V49, P325, DOI 10.1373/49.2.325
   Kemp SD, 1998, J VIROL, V72, P5093
   Mullins C, 2004, CLIN INFECT DIS, V38, P1771, DOI 10.1086/421390
   Nkengasong JN, 2004, AIDS REV, V6, P4
   Reid P, 2005, VIROLOGY, V336, P251, DOI 10.1016/j.virol.2005.03.030
   Rodes B, 2000, J CLIN MICROBIOL, V38, P1370
NR 15
TC 25
Z9 25
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 26
PY 2006
VL 20
IS 10
BP 1455
EP 1458
DI 10.1097/01.aids.0000233582.64467.8e
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 068FM
UT WOS:000239358100014
PM 16791023
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Jackson-Sillah, D
   Donkor, SA
   Otu, J
   Adegbola, RA
   Lienhardt, C
AF Hill, Philip C.
   Jackson-Sillah, Dolly
   Donkor, Simon A.
   Otu, Jacob
   Adegbola, Richard A.
   Lienhardt, Christian
TI Risk factors for pulmonary tuberculosis: a clinic-based case control
   study in The Gambia
SO BMC PUBLIC HEALTH
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS; SOCIOECONOMIC-STATUS; GLOBAL EPIDEMIOLOGY;
   SUSCEPTIBILITY; SURVEILLANCE; INFECTION; EXPOSURE; SMOKING; DISEASE; HIV
AB Background : The tuberculosis (TB) epidemic in Africa is on the rise, even in low-HIV prevalence settings. Few studies have attempted to identify possible reasons for this. We aimed to identify risk factors for pulmonary tuberculosis in those attending a general outpatients clinic in The Gambia, a sub-Saharan African country with relatively low HIV prevalence in the community and in TB patients.
   Methods: We conducted a case control study at the Medical Research Council Outpatients' clinic in The Gambia. Pulmonary TB cases were at least 15 years old, controls were age and sex matched clinic attendees. Participants were interviewed using a structured questionnaire.
   Results: 100 sputum smear positive TB cases and 200 clinic controls were recruited. HIV prevalence was 6.1% in cases and 3.3% in controls. Multivariable assessment of host factors showed that risk of TB was increased among the Jola ethnic group and smokers, and decreased in those in a professional occupation. Assessment of environmental factors showed an increased risk with household crowding, history of household exposure to a known TB case, and absence of a ceiling in the house. In a combined multivariable host-environment model, the risk of TB increased with crowding, exposure to a known TB case, as well as amongst the Jola ethnic group.
   Conclusion: In The Gambia, household crowding and past household exposure to a known TB case are the standout risk factors for TB disease. Further research is needed to identify why risk of TB seems to differ according to ethnicity.
C1 MRC Labs, TB DIv, Banjul, Gambia.
   Inst Rech Dev, Programme TB, UMR 145, Montpellier, France.
RP Hill, PC (reprint author), MRC Labs, TB DIv, Banjul, Gambia.
EM phill@mrc.gm; dolly.jackson-sillah@lshtm.ac.uk; sdonkor@mrc.gm;
   jotu@mrc.gm; radegbola@mrc.gm; lienhardt@ird.sn
FU Medical Research Council [MC_U190071468]
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Alcaide J, 1996, TUBERCLE LUNG DIS, V77, P112, DOI 10.1016/S0962-8479(96)90024-6
   *BRIT THOR TUB ASS, 1971, TUBERCLE, V52, P1
   Cantwell MF, 1998, AM J RESP CRIT CARE, V157, P1016
   COKER R, 2006, BRIT MED J, V322, P85
   Crampin AC, 2001, T ROY SOC TROP MED H, V95, P481, DOI 10.1016/S0035-9203(01)90009-4
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767
   Glynn JR, 2000, T ROY SOC TROP MED H, V94, P500, DOI 10.1016/S0035-9203(00)90065-8
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96
   *KNVC, 2004, 5 KNCV
   Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964
   KUSHIGEMACHI M, 1984, J CHRON DIS, V37, P853, DOI 10.1016/0021-9681(84)90018-3
   Lienhardt C, 2005, INT J EPIDEMIOL, V34, P914, DOI 10.1093/ije/dyi100
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009
   MANGTANI P, 1995, BRIT MED J, V310, P963
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   *WHO, 2005, WHOHTMTB205349
NR 20
TC 31
Z9 32
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUN 19
PY 2006
VL 6
AR 156
DI 10.1186/1471-2458-6-156
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 074HH
UT WOS:000239802800001
PM 16784521
OA gold
DA 2017-08-15
ER

PT J
AU Frodsham, AJ
   Zhang, L
   Dumpis, U
   Taib, NAM
   Best, S
   Durham, A
   Hennig, BJW
   Hellier, S
   Knapp, S
   Wright, M
   Chiaramonte, M
   Bell, JI
   Graves, M
   Whittle, HC
   Thomas, HC
   Thursz, MR
   Hill, AVS
AF Frodsham, AJ
   Zhang, L
   Dumpis, U
   Taib, NAM
   Best, S
   Durham, A
   Hennig, BJW
   Hellier, S
   Knapp, S
   Wright, M
   Chiaramonte, M
   Bell, JI
   Graves, M
   Whittle, HC
   Thomas, HC
   Thursz, MR
   Hill, AVS
TI Class II cytokine receptor gene cluster is a major locus for hepatitis B
   persistence
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE complex trait; IL-10; interferon; susceptibility; virus
ID PEDIGREE DISEQUILIBRIUM TEST; AUSTRALIA ANTIGEN;
   TRANSMISSION/DISEQUILIBRIUM TEST; INTERLEUKIN-10 RECEPTOR; LINKAGE
   ANALYSIS; DENDRITIC CELLS; DOWNS-SYNDROME; T-CELLS; IDENTIFICATION;
   COMPLEX
AB Persistent hepatitis B virus infection is a major risk factor for hepatocellular carcinoma, the most frequent cancer in some developing countries. Up to 95% of those infected at birth and 15% of those infected after the neonatal period fail to clear hepatitis B virus, together resulting in approximate to 350 million persistent carriers worldwide. Via a whole genome scan in Gambian families, we have identified a major susceptibility locus as a cluster of class 11 cytokine receptor genes on chromosome 21q22. Coding changes in two of these genes, the type I IFN receptor gene, IFN-AR2, and the IL-10RB gene that encodes a receptor chain for IL-10-related cytokines including the IFN-lambda s, are associated with viral clearance (haplotype P value = 0.0003), and in vitro assays support functional roles for these variants in receptor signaling.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   MRC Labs, Fajara, Gambia.
   Univ London Imperial Coll Sci Technol & Med, Sch Med, St Marys Hosp, London W2 1PG, England.
   Roche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England.
   Univ Aquila, I-67100 Laquila, Italy.
RP Thursz, MR (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, St Marys Campus,Norfolk Pl, London W2 1NY, England.
EM m.thursz@imperial.ac.uk
RI HILL, Adrian/C-1306-2008; Thomas, Howard/A-3152-2009; Best,
   Steve/A-7531-2012; Hennig, Branwen/M-6444-2014
OI Durham, Andrew/0000-0003-2372-4688; Talbot, Angela/0000-0002-0386-8070
FU Medical Research Council [G0200250]
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   BAYER ME, 1968, NATURE, V218, P1057, DOI 10.1038/2181057a0
   BLUMBERG BS, 1966, AM J HUM GENET, V18, P594
   BLUMBERG BS, 1969, P NATL ACAD SCI USA, V62, P1108, DOI 10.1073/pnas.62.4.1108
   Buelens C, 2002, BLOOD, V99, P993, DOI 10.1182/blood.V99.3.993
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487
   DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0
   FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082
   Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4
   Hennig BJW, 2002, GENES IMMUN, V3, P359, DOI 10.1038/sj.gene.6363883
   Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X
   INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764
   Josephson K, 2001, IMMUNITY, V15, P35, DOI 10.1016/S1074-7613(01)00169-8
   Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124
   Koeleman BPC, 2000, ANN HUM GENET, V64, P207, DOI 10.1046/j.1469-1809.2000.6430207.x
   Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894
   Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   Manavalan JS, 2003, TRANSPL IMMUNOL, V11, P245, DOI 10.1016/S0966-3274(03)00058-3
   MARCHANT A, 1994, LANCET, V343, P707, DOI 10.1016/S0140-6736(94)91584-9
   Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521
   Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957
   Martin ER, 2001, AM J HUM GENET, V68, P1065, DOI 10.1086/319525
   MAYANS MV, 1994, LANCET, V343, P761
   Nyholt DR, 2000, AM J HUM GENET, V67, P282, DOI 10.1086/303029
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622
   REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390
   RUNDLE AT, 1975, CLIN GENET, V8, P1
   Satsangi J, 1996, NAT GENET, V14, P199, DOI 10.1038/ng1096-199
   Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571
   Suciu-Foca N, 2003, TRANSPL IMMUNOL, V11, P235, DOI 10.1016/S0966-3274(03)00052-2
   Thursz M, 2001, ANTIVIR RES, V52, P113, DOI 10.1016/S0166-3542(01)00175-9
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200
NR 39
TC 63
Z9 65
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 13
PY 2006
VL 103
IS 24
BP 9148
EP 9153
DI 10.1073/pnas.0602800103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 054ID
UT WOS:000238369100046
PM 16757563
OA No
DA 2017-08-15
ER

PT J
AU Levine, OS
   O'Brien, KL
   Knoll, M
   Adegbola, RA
   Black, S
   Cherian, T
   Dagan, R
   Goldblatt, D
   Grange, A
   Greenwood, B
   Hennessy, T
   Klugman, KP
   Madhi, SA
   Mulholland, K
   Nohynek, H
   Santosham, M
   Saha, SK
   Scott, JA
   Sow, S
   Whitney, CG
   Cutts, F
AF Levine, Orin S.
   O'Brien, Katherine L.
   Knoll, Maria
   Adegbola, Richard A.
   Black, Steven
   Cherian, Thomas
   Dagan, Ron
   Goldblatt, David
   Grange, Adenike
   Greenwood, Brian
   Hennessy, Tom
   Klugman, Keith P.
   Madhi, Shabir A.
   Mulholland, Kim
   Nohynek, Hanna
   Santosham, Mathuram
   Saha, Samir K.
   Scott, J. Anthony
   Sow, Samba
   Whitney, Cynthia G.
   Cutts, Felicity
TI Pneumococcal vaccination in developing countries
SO LANCET
LA English
DT Editorial Material
ID CONJUGATE VACCINE; CHILDREN; DISEASE; PNEUMONIA; FORMULATION;
   INFECTIONS; SEROGROUPS; IMPACT; TRIAL
C1 Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.
   MRC Labs, Fajara, Gambia.
   Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA.
   WHO, CH-1211 Geneva, Switzerland.
   Soroka Univ, Med Ctr, Paediat Infect Dis Unit, Beer Sheva, Israel.
   Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
   UCL, Inst Child Hlth, London, England.
   Great Ormond St Hosp Sick Children, London WC1N 3JH, England.
   Int Paediat Assoc, Lagos, Nigeria.
   London Sch Hyg & Trop Med, London WC1, England.
   Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Infect Dis, Anchorage, AK USA.
   Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   Natl Publ Hlth Inst, Helsinki, Finland.
   Dhaka Shishu Hosp, Bangladesh Inst Child Hlth, Dept Microbiol, Dhaka, Bangladesh.
   Wellcome Trust Kenya Med Res Inst, Ctr Geog Med Res Coast, Kilifi, Kenya.
   Ctr Dev Vaccins Mali, Bamako, Mali.
RP Levine, OS (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.
EM olevine@jhsph.edu
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
FU Wellcome Trust [061089, 081835]
CR Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Campbell JD, 2004, PEDIATR INFECT DIS J, V23, P642, DOI 10.1097/01.inf.0000130951.85974.79
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P893
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P122, DOI 10.1086/313609
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828
   Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004
   OBRIEN KL, 2006, 5 INT S PNEUM PNEUM, P189
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   World Health Organization, 2003, WKLY EPIDEMIOL REC, V14, P110
   *WHO, 1999, MEN PNEUM DIS VACC
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0
   *WYETH, 2006, WYETH ANN M STOCKH D
NR 16
TC 109
Z9 120
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 10
PY 2006
VL 367
IS 9526
BP 1880
EP 1882
DI 10.1016/S0140-6736(06)68703-5
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 051XG
UT WOS:000238194400006
PM 16765742
OA No
DA 2017-08-15
ER

PT J
AU Mutapi, F
   Mduluza, T
   Gomez-Escobar, N
   Gregory, WF
   Fernandez, C
   Midzi, N
   Maizels, RM
AF Mutapi, Francisca
   Mduluza, Takafira
   Gomez-Escobar, Natalia
   Gregory, William F.
   Fernandez, Cecilia
   Midzi, Nicholas
   Maizels, Rick M.
TI Immuno-epidemiology of human Schistosoma haematobium infection:
   preferential IgG3 antibody responsiveness to a recombinant antigen
   dependent on age and parasite burden
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID RECENTLY EXPOSED COMMUNITY; EGG OUTPUT STABILITY; HUMORAL RESPONSES;
   THEORETICAL FRAMEWORK; HELMINTH INFECTION; ADULT SCHISTOSOMES; MANSONI;
   IMMUNOEPIDEMIOLOGY; INTENSITY; SEX
AB Background: Schistosomiasis is a major parasitic disease affecting over 200 million people in the developing world with a further 400 million people at risk of infection. The aim of this study was to identify a single antigen from adult Schistosoma haematobium worms and subsequently use this antigen to study the development of schistosome-acquired immunity in a human population.
   Methods: The full-length cDNA sequence of a S. haematobium protein, a putative orthologue of the S. mansoni tegumental antigen Sm13, was obtained from a cDNA library of adult S. haematobium worms and named Sh13 following a small-scale expressed sequence tags ( EST) project. The recombinant Sh13 protein expressed in E. coli, was used to investigate immuno-epidemiological patterns in 147 Zimbabweans ( 7 - 18 years old) exposed to S. haematobium.
   Results: Sequence analysis of the full-length cDNA sequence of the S. haematobium protein Sh13, indicated that the protein has an N-terminal signal peptide and encodes an 85-amino acid mature protein with a highly conserved predicted transmembrane domain (86% identity with the S. mansoni tegumental antigen Sm13). The recombinant Sh13 protein was used in ELISA assays to determine the reactivity of sera from the study participants. Antibody responses against Sh13 were predominantly IgG3 isotype compared to responses against crude worm antigens which were predominantly IgG1 and IgG4. The relationship between anti-Sh13 IgG3 levels and infection intensity varied significantly with host age. The youngest children ( 7 - 10 years old) had relatively low levels of both infection and anti-Sh13 IgG3. In older children ( 11 - 12 years old) rising infection levels were accompanied by a significant increase in anti-Sh13 IgG3 levels. Subsequently, infection intensity declined significantly in 13 - 18 year olds but levels of the antibody continued to rise. The changing relationship between infection intensity and anti-Sh13 IgG3 levels with host age is consistent with the profile of a protective immune response predicted from theoretical work.
   Conclusion: We have identified and characterised a novel S. haematobium antigen Sh13, a putative tegumental protein, and shown that it is recognised predominantly by IgG3 antibodies from people infected with/exposed to S. haematobium parasites. We have also shown that, the anti-Sh13 IgG3 response is maximal in older individuals with the lowest infection intensity, and that the age profile of the relationship between anti-Sh13 IgG3 and infection intensity is consistent with that predicted by theoretical work for a protective response stimulated by and directed against adult worms.
C1 Univ Edinburgh, Sch Biol Sci, Ashworth Labs, Inst Immunol & Infect Res, Edinburgh EH9 3J, Midlothian, Scotland.
   Univ Republica, Fac Quim, Catedra Inmunol, Montevideo, Uruguay.
   MRC, Banjul, Gambia.
   Natl Inst Hlth Res, Harare, Zimbabwe.
   Univ Zimbabwe, Dept Biochem, Harare, Zimbabwe.
RP Mutapi, F (reprint author), Univ Edinburgh, Sch Biol Sci, Ashworth Labs, Inst Immunol & Infect Res, W Mains Rd,Kings Bldg, Edinburgh EH9 3J, Midlothian, Scotland.
EM f.mutapi@ed.ac.uk; tmduluza@yahoo.com; ngescobar@mrc.gm;
   b.gregory@ed.ac.uk; cfernan@fq.edu.uy; nmidzi@nihr.co.zw;
   r.maizels@ed.ac.uk
FU Wellcome Trust
CR Abath FGC, 2000, PARASITOL RES, V86, P745, DOI 10.1007/PL00008562
   Abebe F, 2001, APMIS, V109, P816, DOI 10.1034/j.1600-0463.2001.091203.x
   Acosta LP, 2002, ACTA TROP, V84, P137, DOI 10.1016/S0001-706X(02)00177-8
   AGNEW AM, 1993, PARASITE IMMUNOL, V15, P261, DOI 10.1111/j.1365-3024.1993.tb00609.x
   AGNEW AM, 1992, MEM I OSWALDO CRUZ, V87, P87
   Al-Sherbiny M, 2003, ACTA TROP, V88, P117, DOI 10.1016/S0001-706X(03)00195-5
   BRADLEY DJ, 1973, T ROY SOC TROP MED H, V67, P491, DOI 10.1016/0035-9203(73)90080-1
   CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823
   Chan MS, 2000, PARASITOLOGY, V120, P161, DOI 10.1017/S003118209900534X
   Chan MS, 1997, VACCINE, V15, P1545, DOI 10.1016/S0264-410X(97)00071-6
   CHAN MS, 1995, EPIDEMIOL INFECT, V115, P325
   CHANDIWANA SK, 1991, PARASITOLOGY, V102, P73
   Clarke V D, 1966, Cent Afr J Med, V12, P1
   Fernandez C, 2002, MOL BIOCHEM PARASIT, V122, P171, DOI 10.1016/S0166-6851(02)00098-1
   FISHER A. C., 1934, TRANS ROY SAC TROP MED AND HYG, V28, P277, DOI 10.1016/S0035-9203(34)90066-3
   GOLL PH, 1984, T ROY SOC TROP MED H, V78, P222, DOI 10.1016/0035-9203(84)90282-7
   GRYSEELS B, 1995, MEM I OSWALDO CRUZ, V90, P271
   Hagan P, 2003, EXPERT OPIN BIOL TH, V3, P1271, DOI 10.1517/14712598.3.8.1271
   HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V347, P166
   Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397
   MCCULLOUGH FS, 1973, T ROY SOC TROP MED H, V67, P475, DOI 10.1016/0035-9203(73)90079-5
   MONTRESOR A, 1998, GUIDELINE EVALUATION
   MOTT KE, 1983, B SOC PATHOL EXOT, V76, P101
   Mutapi F, 2005, J INFECT DIS, V192, P1108, DOI 10.1086/432553
   Mutapi F, 1997, PARASITE IMMUNOL, V19, P255, DOI 10.1046/j.1365-3024.1997.d01-206.x
   Mutapi F, 2002, LANCET INFECT DIS, V2, P219, DOI 10.1016/S1473-3099(02)00240-2
   Mutapi F, 2001, TRENDS PARASITOL, V17, P518, DOI 10.1016/S1471-4922(01)02118-3
   Naus CWA, 2003, TROP MED INT HEALTH, V8, P561, DOI 10.1046/j.1365-3156.2003.01056.x
   Ndhlovu P, 1996, PARASITE IMMUNOL, V18, P181, DOI 10.1046/j.1365-3024.1996.d01-78.x
   Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1
   *ORG WH, 1993, WHO TECHN REP SER, P3
   *ORG WH, IN VACC RES PAR DIS
   Quinnell RJ, 2004, PARASITE IMMUNOL, V26, P443, DOI 10.1111/j.0141-9838.2004.00727.x
   QUINNELL RJ, 1995, PARASITE IMMUNOL, V17, P313, DOI 10.1111/j.1365-3024.1995.tb00897.x
   SAMBROOK J, 2001, MOL CLONNING LAB MAN, V3
   vanDam GJ, 1996, J INFECT DIS, V173, P1232
   Webster M, 1998, TROP MED INT HEALTH, V3, P318, DOI 10.1046/j.1365-3156.1998.00234.x
   Webster M, 1997, PARASITOLOGY, V114, P383, DOI 10.1017/S003118209600858X
   WOOLHOUSE MEJ, 1992, PARASITE IMMUNOL, V14, P563, DOI 10.1111/j.1365-3024.1992.tb00029.x
   WOOLHOUSE MEJ, 1994, T ROY SOC TROP MED H, V88, P520, DOI 10.1016/0035-9203(94)90144-9
   WOOLHOUSE MEJ, 1991, NATURE, V351, P757, DOI 10.1038/351757a0
   Woolhouse MEJ, 1999, NAT MED, V5, P1225, DOI 10.1038/15169
   WOOLHOUSE MEJ, 1994, PARASITOL TODAY, V10, P196, DOI 10.1016/0169-4758(94)90030-2
   WOOLHOUSE MEJ, 1993, PARASITE IMMUNOL, V15, P583
   Woolhouse MEJ, 2000, PARASITOLOGY, V120, P37, DOI 10.1017/S0031182099005156
   Zar JH, 1998, BIOSTATISTICAL ANAL
NR 46
TC 13
Z9 16
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 9
PY 2006
VL 6
AR 96
DI 10.1186/1471-2334-6-96
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 068XR
UT WOS:000239408600001
PM 16764709
OA gold
DA 2017-08-15
ER

PT J
AU Kasse, Y
   Jasseh, M
   Corrah, T
   Donkor, SA
   Antonnio, M
   Jallow, A
   Adegbola, RA
   Hill, PC
AF Kasse, Yaya
   Jasseh, Momodou
   Corrah, Tumani
   Donkor, Simon A.
   Antonnio, Martin
   Jallow, Adama
   Adegbola, Richard A.
   Hill, Philip C.
TI Health seeking behaviour, health system experience and tuberculosis case
   finding in Gambians with cough
SO BMC PUBLIC HEALTH
LA English
DT Article
ID PULMONARY TUBERCULOSIS; GLOBAL EPIDEMIOLOGY; DIAGNOSIS; DELAYS;
   PREVALENCE; DISTRICT; PATIENT; AFRICA
AB Background: Studies in Africa investigating health-seeking behaviour by interviewing tuberculosis patients have revealed patient knowledge issues and significant delays to diagnosis. We aimed to study health-seeking behaviour and experience of those with cough in The Gambia and to identify whether they had tuberculosis.
   Methods: During a round of a population under 3-monthly demographic surveillance, we identified people > 10 years old who had been coughing >= 3 weeks. A questionnaire was administered concerning demographic data, cough, knowledge, health seeking, and experience at health facilities. Case finding utilised sputum smear and chest X-ray.
   Results: 122/29,871 coughing individuals were identified. Of 115 interviewed, 93 (81%) had sought treatment; 76 (81.7%) from the health system. Those that visited an alternative health provider first were significantly older than those who visited the health system first ( p = 0.03). The median time to seek treatment was 2 weeks ( range 0 - 106). 54 (58.1%) made their choice of provider because they believed it was right. Of those who left the health system to an alternative provider (n = 13): 7 believed it was the best place, 3 cited cost and 2 failure to improve. 3 cases were identified by sputum analysis, 11 more by X-ray; all had visited the health system first. Total 'excess' cough time was 1079 person weeks.
   Conclusion: The majority of people with cough in this population seek appropriate help early. Improved case detection might be achieved through the use of chest X-ray in addition to sputum smear.
C1 MRC Labs, TB Div, Banjul, Gambia.
   Natl Leprosy & TB Control Programme, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Labs, TB Div, Banjul, Gambia.
EM yayak25@hotmail.com; mjasseh@mrc.gm; tcorrah@mrc.gm; sdonkor@mrc.gm;
   mantonio@mrc.gm; adamahaddyjatou@hotmail.com; radegbola@mrc.gm;
   phill@mrc.gm
FU Medical Research Council [MC_U190071468, MC_UP_A900_1123]
CR ALUOCH JA, 1982, T ROY SOC TROP MED H, V76, P679, DOI 10.1016/0035-9203(82)90240-1
   CASSELS A, 1982, TUBERCLE, V63, P173
   Collins C. H., 1997, TUBERCULOSIS BACTERI
   DeRiemer K, 2005, LANCET, V365, P1239, DOI 10.1016/S0140-6736(05)74812-1
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767
   Eastwood SV, 2004, INT J TUBERC LUNG D, V8, P70
   GOTHI GD, 1976, INDIAN J MED RES, V64, P1150
   Guneylioglu D, 2004, MED SCI MONITOR, V10, pCR62
   HARPER M, 2004, INT J TUBERC LUNG D, V10, P1266
   Harries AD, 1997, T ROY SOC TROP MED H, V91, P416, DOI 10.1016/S0035-9203(97)90262-5
   Heifets Leonid B., 1994, P85
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   *KNCV, 2004, 5 KNCV
   Lawn SD, 1998, INT J TUBERC LUNG D, V2, P635
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009
   Paynter S, 2004, INT J TUBERC LUNG D, V8, P180
   Pronyk PM, 2001, INT J TUBERC LUNG D, V5, P611
   Rajeswari R, 2002, INT J TUBERC LUNG D, V6, P789
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   SMITH PG, 1977, TUBERCLE, V58, P157, DOI 10.1016/0041-3879(77)90018-6
   Steen TW, 1998, INT J TUBERC LUNG D, V2, P627
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   VANCLEEF MRA, 2005, BMC INFECT DIS, P111
   WANDWALO ER, 2000, INT J TUBERC LUNG D, V4, P627
   Global tuberculosis control: surveillance planning financing, 2005, WHOHTMTB2005349
   YIMER S, BMC INFECT DIS, V5, P112
NR 27
TC 10
Z9 10
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUN 5
PY 2006
VL 6
AR 143
DI 10.1186/1471-2458-6-143
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 064RT
UT WOS:000239107500001
PM 16753057
OA gold
DA 2017-08-15
ER

PT J
AU Mbaye, A
   Richardson, K
   Balajo, B
   Dunyo, S
   Shulman, C
   Milligan, P
   Greenwood, B
   Walraven, G
AF Mbaye, A
   Richardson, K
   Balajo, B
   Dunyo, S
   Shulman, C
   Milligan, P
   Greenwood, B
   Walraven, G
TI Lack of inhibition of the anti-malarial action of
   sulfadoxine-pyrimethamine by folic acid supplementation when used for
   intermittent preventive treatment in Gambian primigravidae
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM; MALARIA; PREGNANCY; ANEMIA; AREA; EFFICACY;
   AFRICA; KENYA; INFECTION; REDUCTION
AB Folic acid is frequently given to pregnant women at the same time as intermittent preventive treatment (IPTp) with sulfadoxine/pyrimethamine (SP), but it is not known if it interferes with the anti-malarial activity of SP. To investigate this concern, 1,035 Gambian primigravidae were randomized to receive either folic acid (500-1,500 mu g/day) together with oral iron (522) or oral iron alone (513) for 14 days at the same time as they received IPTp with SP. On presentation, 261 women (25%) had Plasmodium falciparum asexual parasitemia. Prevalences of parasitemia on day 14 after treatment were similar in both groups: 5.7% (26 of 458) in the iron plus folic acid group and 4.9% (22 of 446) in the iron alone group (risk difference = 0.74%, 95% confidence interval [CI] = -2.2% to 3.7%). Parasitologic cure was observed in 116 (91%) of 128 of women who were parasitemic on presentation and who received iron and folic acid and in 122 (92%) of 133 women who received iron alone (difference = 1.1%, 95% CI = -5.6% to 8.0%). Women who received folic acid and iron had a slightly higher mean hemoglobin concentration at day 1.4 than women who had received iron alone (difference = 0.14 g/dL, 95% CI = 0.01-0.27 g/dL). The results of this study suggest that in an area of low SP resistance, administration of folic acid to pregnant women in a dose of 500-1,500 mu g/day will not interfere with the protective effect of SP when used for IPTp.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Govt Gambia, Dept Hlth, Banjul, Gambia.
   MRC Labs, Banjul, Gambia.
RP Greenwood, B (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM brian.greenwood@lshtm.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Brabin B, 1991, 1 WHO
   Carter JY, 2005, AM J TROP MED HYG, V73, P166
   FLEMING AF, 1986, ANN TROP MED PARASIT, V80, P211
   FLEMING AF, 1989, T ROY SOC TROP MED H, V83, P441, DOI 10.1016/0035-9203(89)90241-1
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Guyatt HL, 2001, T ROY SOC TROP MED H, V95, P569, DOI 10.1016/S0035-9203(01)90082-3
   HAMILTON PJ, 1972, T ROY SOC TROP MED H, V66, P594, DOI 10.1016/0035-9203(72)90305-7
   Hyde JE, 2005, ACTA TROP, V94, P191, DOI 10.1016/j.actatropica.2005.04.002
   MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0
   Nacher M, 2003, T ROY SOC TROP MED H, V97, P273, DOI 10.1016/S0035-9203(03)90140-4
   Parise ME, 1998, AM J TROP MED HYG, V59, P813
   Rogerson SJ, 2000, T ROY SOC TROP MED H, V94, P549, DOI 10.1016/S0035-9203(00)90083-X
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515
   Shulman CE, 1996, T ROY SOC TROP MED H, V90, P535, DOI 10.1016/S0035-9203(96)90312-0
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   ter Kuile FO, 2003, AM J TROP MED HYG, V68, P50
   vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7
NR 17
TC 15
Z9 15
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2006
VL 74
IS 6
BP 960
EP 964
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 051ZT
UT WOS:000238200900007
PM 16760504
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Gopalakrishna, G
   Awomoyi, A
   Cunningham, A
   Adegbola, RA
   Falade, AG
   Ogunlesi, OO
   Whittle, HC
   Mulholland, EK
AF Weber, MW
   Gopalakrishna, G
   Awomoyi, A
   Cunningham, A
   Adegbola, RA
   Falade, AG
   Ogunlesi, OO
   Whittle, HC
   Mulholland, EK
TI The role of Chlamydia pneumoniae in acute respiratory tract infections
   in young children in The Gambia, West Africa
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID DEVELOPING-COUNTRIES; INFANTS; PREVALENCE; ETIOLOGY; ANTIBODIES;
   DISEASE; GENE
AB Background: Little is known about the role of Chlamydia pneumoniae in the aetiology of acute respiratory tract infections (ARI) in children in developing countries.
   Aims: To obtain better information, we studied the presence of C. pneumoniae and its association with clinical signs and symptoms of ARI in children under 5 years of age in The Gambia.
   Methods: C. pneumoniae was sought by polymerase chain reaction in nasopharyngeal secretions and/or lung puncture aspirates from 324 infants under 3 months of age and 325 children between 3 months and 5 years of age with malnutrition, with or without pneumonia, and in control children. Clinical signs and symptoms for ARI and the spectrum of other viral and bacterial organisms were compared between those positive for C. pneumoniae and those negative.
   Results: Of 324 young infants, ten (3.1%) showed the presence of C. pneumoniae whereas in the older children 50 of 325 (15%) were positive for C. pneumoniae. There was no significant association between clinical signs and symptoms of ARI and C. pneumoniae positivity in the young infants. Among older infants and children, there was a trend to more frequent lobar alveolar changes in those positive for C. pneumoniae. No bacterial pathogens were found to be significantly associated with C. pneumoniae infection. However, there was an association with measles in the malnutrition group and with RSV in the young infants group.
   Conclusions: In this study, C. pneumoniae was not associated with any particular clinical syndrome. We found no evidence that the organism plays a major role in ARI in young children in developing countries such as The Gambia.
C1 MRC Labs, Fajara, Gambia.
   Royal Victoria Hosp, Banjul, Gambia.
RP Weber, MW (reprint author), WHO, CAH, Av Appia, CH-1211 Geneva 27, Switzerland.
EM weberm@who.int
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BENYAAKOV M, 1994, J CLIN PATHOL, V47, P232, DOI 10.1136/jcp.47.3.232
   BERMAN S, 1991, REV INFECT DIS, V13, pS454
   CARTER MW, 1991, J GEN MICROBIOL, V137, P465
   Chaudhry R., 1998, Indian Journal of Pediatrics, V65, P717, DOI 10.1007/BF02731050
   CUNNINGHAM A, 1995, THESIS U SOUTHAMPTON
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   GAYDOS CA, 1992, J CLIN MICROBIOL, V30, P796
   Hahn DL, 1999, ANN ALLERG ASTHMA IM, V83, P271, DOI 10.1016/S1081-1206(10)62666-X
   Hahn DL., 1999, ANN ALLERG ASTHMA IM, V83, P291
   HERRING AJ, 1992, J INFECTION, V25, P1, DOI 10.1016/0163-4453(92)91851-2
   JANTOS CA, 1995, PEDIATR INFECT DIS J, V14, P117, DOI 10.1097/00006454-199502000-00007
   MONTALBAN GS, 1994, J CLIN MICROBIOL, V32, P1406
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   SAIKKU P, 1988, J INFECT DIS, V158, P1095
   Sambrook J., 1989, MOL CLONING LAB MANU
   Schmidt SM, 2002, PEDIATR INFECT DIS J, V21, P758, DOI 10.1097/inf.0000023964.47743.ca
   VANRENTERGHEM L, 1990, EUR J CLIN MICROBIOL, V9, P347
   Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS23
   Yang YG, 2001, PEDIATR INFECT DIS J, V20, P52, DOI 10.1097/00006454-200101000-00010
   YEUNG SM, 1993, EUR J CLIN MICROBIOL, V12, P850, DOI 10.1007/BF02000406
   2003, CHILD HLTH EPIDEMIOL
NR 23
TC 4
Z9 4
U1 0
U2 2
PU MANEY PUBLISHING
PI LEEDS
PA HUDSON RD, LEEDS LS9 7DL, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD JUN
PY 2006
VL 26
IS 2
BP 87
EP 94
DI 10.1179/146532806X107412
PG 8
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 054LJ
UT WOS:000238377900002
PM 16709325
OA No
DA 2017-08-15
ER

PT J
AU Owens, S
   Harper, G
   Amuasi, J
   Offei-Larbi, G
   Ordi, J
   Brabin, BJ
AF Owens, S
   Harper, G
   Amuasi, J
   Offei-Larbi, G
   Ordi, J
   Brabin, BJ
TI Placental malaria and immunity to infant measles
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID ANTIBODIES
AB The efficiency of transplacental transfer of measles specific antibody was assessed in relation to placental malaria. Infection at delivery was associated with a 30% decrease in expected cord measles antibody titres. Uninfected women who received anti-malarial drugs during pregnancy transmitted 30% more antibody than those who received no antimalarial drugs.
C1 Univ Liverpool Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5AQ, Merseyside, England.
   MRC Labs, Fajara, Gambia.
   Univ Barcelona, Dept Anat Patol, Barcelona, Spain.
   Komfo Anokye Teaching Hosp, Kumsai, Ghana.
   Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, NL-1105 AZ Amsterdam, Netherlands.
RP Brabin, BJ (reprint author), Univ Liverpool Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Pembroke Pl, Liverpool L3 5AQ, Merseyside, England.
EM b.j.brabin@liv.ac.uk
CR Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   Caceres VM, 2000, CLIN INFECT DIS, V31, P110, DOI 10.1086/313926
   Scott S, 2005, J INFECT DIS, V191, P1854, DOI 10.1086/429963
   Yamaguchi S, 2002, EPIDEMIOL INFECT, V129, P361, DOI 10.1017/S0950268802007458
NR 5
TC 9
Z9 10
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD JUN
PY 2006
VL 91
IS 6
BP 507
EP 508
DI 10.1136/adc.2005.085274
PG 2
WC Pediatrics
SC Pediatrics
GA 044RR
UT WOS:000237690600016
PM 16714721
OA No
DA 2017-08-15
ER

PT J
AU Hanchard, N
   Diakite, M
   Koch, O
   Keating, B
   Pinder, M
   Jallow, M
   Sisay-Joof, F
   Nijnik, A
   Wilson, J
   Udalova, I
   Kwiatkowski, D
   Rockett, K
AF Hanchard, N
   Diakite, M
   Koch, O
   Keating, B
   Pinder, M
   Jallow, M
   Sisay-Joof, F
   Nijnik, A
   Wilson, J
   Udalova, I
   Kwiatkowski, D
   Rockett, K
TI Implications of inter-population linkage disequilibrium patterns on the
   approach to a disease association study in the human MHC class III
SO IMMUNOGENETICS
LA English
DT Article
DE population; linkage disequilibrium; MHC class III
ID MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN-CHROMOSOME 6P; SUSCEPTIBILITY
   LOCUS; HAPLOTYPIC STRUCTURE; HUMAN GENOME; MAP; REGION; TNF
AB There is presently much interest in utilizing patterns of linkage disequilibrium (LD) to further genetic association studies. This is particularly pertinent in the class III region of the human major histocompatibility complex (MHC), which has been extensively studied as a disease susceptibility locus in a number of ethnic groups. To date, however, few studies of LD in the MHC have considered non-Caucasian populations. With the advent of large-scale haplotyping of the human genome, the question of utilizing LD patterns across populations has come to the fore. We have previously used LD mapping to direct an MHC class III association study in a UK Caucasian population. As an extension of this, we sought to determine to what extent the pattern of LD observed in that study could be used to conduct a similar study in a West African Gambian population. We found that broad patterns of LD were similar in the two populations, resulting in similar candidate region delineations, but at a higher resolution, marker-specific patterns of LD and population-dependent allele frequencies confounded the choice of regional tagging SNPs. Our results have implications for the applicability of large-scale haplotype maps such as the HapMap to complex regions like the MHC.
C1 Univ W Indies, Res Inst Trop Med, Trop Metab Res Unit, Kingston 7, Jamaica.
   Wellcome Trust Ctr Human Genet, Oxford, England.
   Univ Oxford, Dept Paediat, Oxford, England.
   MRC Labs, Fajara, Gambia.
RP Hanchard, N (reprint author), Univ W Indies, Res Inst Trop Med, Trop Metab Res Unit, Kingston 7, Jamaica.
EM neil.hanchard@green-oxford.com
RI Koch, Oliver/A-9480-2016
OI Kwiatkowski, Dominic/0000-0002-5023-0176
FU Medical Research Council [G19/9, G9505090]
CR Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24
   Ackerman HC, 2003, GENES IMMUN, V4, P476, DOI 10.1038/sj.gene.6364008
   Ahmad T, 2003, HUM MOL GENET, V12, P647, DOI 10.1093/hmg/ddg066
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   DEGLIESPOSTI MA, 1992, HUM IMMUNOL, V34, P242, DOI 10.1016/0198-8859(92)90023-G
   Evans DM, 2005, AM J HUM GENET, V76, P681, DOI 10.1086/429274
   Goldstein D, 2001, CURR BIOL, V11, P576
   Hanchard N, 2006, GENES IMMUN, V7, P51, DOI 10.1038/sj.gene.6364277
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   LUONI G, 2005, GENES IMMUN
   Miretti MM, 2005, AM J HUM GENET, V76, P634, DOI 10.1086/429393
   Mueller JC, 2005, AM J HUM GENET, V76, P387, DOI 10.1086/427925
   Okamoto K, 2003, AM J HUM GENET, V72, P303, DOI 10.1086/346067
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Stenzel A, 2004, HUM GENET, V114, P377, DOI 10.1007/s00439-003-1075-5
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Walsh EC, 2003, AM J HUM GENET, V73, P580, DOI 10.1086/378101
   Wei J, 2004, AM J MED GENET B, V125B, P43, DOI 10.1002/ajmg.b.20093
   Wilson JN, 2005, GENES IMMUN, V6, P462, DOI 10.1038/sj.gene.6364227
   Yu HX, 2005, IMMUNOGENETICS, V57, P559, DOI 10.1007/s00251-005-0002-4
NR 21
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0093-7711
J9 IMMUNOGENETICS
JI Immunogenetics
PD JUN
PY 2006
VL 58
IS 5-6
BP 465
EP 470
DI 10.1007/s00251-006-0118-1
PG 6
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 049KK
UT WOS:000238014900015
PM 16738941
OA No
DA 2017-08-15
ER

PT J
AU Duvall, MG
   Jaye, A
   Dong, T
   Brenchley, JM
   Alabi, AS
   Jeffries, DJ
   van der Sande, M
   Togun, TO
   McConkey, SJ
   Douek, DC
   McMichael, AJ
   Whittle, HC
   Koup, RA
   Rowland-Jones, SL
AF Duvall, Melody G.
   Jaye, Assan
   Dong, Tao
   Brenchley, Jason M.
   Alabi, Abraham S.
   Jeffries, David J.
   van der Sande, Marianne
   Togun, Toyin O.
   McConkey, Samuel J.
   Douek, Daniel C.
   McMichael, Andrew J.
   Whittle, Hilton C.
   Koup, Richard A.
   Rowland-Jones, Sarah L.
TI Maintenance of HIV-specific CD4(+) T cell help distinguishes HIV-2 from
   HIV-1 infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE CHAIN-REACTION; PLASMA VIRAL
   LOAD; WEST-AFRICA; HIV-2-INFECTED INDIVIDUALS; GASTROINTESTINAL-TRACT;
   CD8-T-CELL MEMORY; GAMBIAN PATIENTS; CD4-T-CELL HELP; PROVIRAL LOAD
AB Unlike HIV-1-infected people, most HIV-2-infected subjects maintain a healthy CD4(+) T cell count and a strong HIV-specific CD4(+) T cell response. To define the cellular immunological correlates of good prognosis in HIV-2 infection, we conducted a crosssectional study of HIV Gag-specific T cell function in HIV-1- and HIV-2-infected Gambians. Using cytokine flow cytometry and lymphoproliferation assays, we show that HIV-specific CD4(+) T cells from HIV-2-infected individuals maintained proliferative capacity, were not terminally differentiated (CD57(-)), and more frequently produced IFN-gamma or IL-2 than CD4(+) T cells from HIV-1-infected donors. Polyfunctional (1FN-gamma(+)/1L-2(+)) HIV-specific CD4(+) T cells were found exclusively in HIV-2(+) donors. The disparity in CD4(+) T cell responses between asymptomatic HIV-1- and HIV-2-infected subjects was not associated with differences in the proliferative capacity of HIV-specific CD8(+) T cells. This study demonstrates that HIV-2-infected donors have a well-preserved and functionally heterogeneous HIV-specific memory CD4(+) T cell response that is associated with delayed disease progression in the majority of infected people.
C1 MRC Labs, Banjul, Gambia.
   Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit,MRC, Oxford, England.
   NIAID, Vaccine Res Ctr, Bethesda, MD 20892 USA.
RP Rowland-Jones, SL (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM srowland-jones@mrc.gm
RI McConkey, Samuel/E-7307-2012
FU Medical Research Council [MC_U137884180, MC_U190081958, MC_U190081962]
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Andersson S, 1999, VIROLOGY, V262, P312, DOI 10.1006/viro.1999.9867
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Arien KK, 2005, J VIROL, V79, P8979, DOI 10.1128/JVI.79.14.8979-8990.2005
   Ariyoshi K, 1999, AIDS, V13, P1145, DOI 10.1097/00002030-199906180-00023
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Berry N, 2001, AIDS RES HUM RETROV, V17, P263, DOI 10.1089/088922201750063197
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Bertoletti A, 1998, J VIROL, V72, P2439
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Blaak H, 2004, JAIDS-J ACQ IMM DEF, V36, P777, DOI 10.1097/00126334-200407010-00003
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
   Cham F, 2000, AIDS RES HUM RETROV, V16, P1915, DOI 10.1089/08892220050195874
   CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Harari A, 2005, J IMMUNOL, V174, P1037
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   Iyasere C, 2003, J VIROL, V77, P10900, DOI 10.1128/JVI.77.20.10900-10909.2003
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   MCCLURE MO, 1987, NATURE, V330, P487, DOI 10.1038/330487a0
   Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
   Musey LK, 1999, J INFECT DIS, V180, P278, DOI 10.1086/314868
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   PINTO LA, 1995, J MED VIROL, V47, P139, DOI 10.1002/jmv.1890470206
   PINTO LA, 1993, AIDS, V7, P1389, DOI 10.1097/00002030-199310000-00016
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   ROBERTGUROFF M, 1992, J VIROL, V66, P3602
   Roederer M, 2004, CLIN IMMUNOL, V110, P199, DOI 10.1016/j.clim.2003.11.015
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Sarr AD, 1999, J HUMAN VIROL, V2, P45
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804
   Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317
   Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105
   van der Loeff MFS, 2002, AIDS, V16, P1775
   Whittle HC, 1998, CURR OPIN IMMUNOL, V10, P382, DOI 10.1016/S0952-7915(98)80108-8
   Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 58
TC 59
Z9 61
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2006
VL 176
IS 11
BP 6973
EP 6981
PG 9
WC Immunology
SC Immunology
GA 045PN
UT WOS:000237754200065
PM 16709858
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Waight, P
   Mendy, M
   Rayco-Solon, P
   Hutt, P
   Fulford, T
   Doherty, C
   McConkey, SJ
   Jeffries, D
   Hall, AJ
   Whittle, HC
AF van der Sande, MAB
   Waight, P
   Mendy, M
   Rayco-Solon, P
   Hutt, P
   Fulford, T
   Doherty, C
   McConkey, SJ
   Jeffries, D
   Hall, AJ
   Whittle, HC
TI Long-term protection against carriage of hepatitis B virus after infant
   vaccination
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID 2 GAMBIAN VILLAGES; 15-YEAR FOLLOW-UP; EXPANDED PROGRAM; CHILDREN;
   EFFICACY; IMMUNIZATION; IMMUNITY; INFECTION; ANTIBODY; 10-YEAR
AB Background. Carriage of hepatitis B virus (HBV) is a major risk factor for liver cirrhosis and hepatocellular carcinoma. Infant vaccination has been effective in preventing horizontal transmission during early childhood. It is unknown whether protection is maintained into early adulthood.
   Methods. In 1984, early childhood vaccination was introduced in 2 rural Gambian villages. In 2003, serological assessment of 81.5% of 1350 eligible participants 1-24 years old was done, to determine vaccine efficacy against infection and carriage.
   Results. Overall vaccine efficacy against infection and carriage was 83.4% (95% confidence interval [CI], 79.8% - 86.6%) and 96.5% (85% CI, 93.9% - 98.9%), respectively. Vaccine efficacy against infection was similar when restricted to primary responders (85.3%), but a significant effect of peak antibody concentration was found. Both vaccine efficacy and levels of hepatitis B surface antibody (anti-HBs) decreased with age, resulting in a vaccine efficacy against infection and carriage among 20-24-year-old participants of 70.9% ( 95% CI, 60.4% - 80.5%) and 91.1% ( 95% CI, 75.8%-100%), respectively. Fifteen years after vaccination, fewer than half of the vaccinees had detectable anti-HBs. The prevalence of carriage in the unvaccinated population was similar to the prevalence 20 years earlier.
   Conclusions. HBV vaccination early during life can provide long-lasting protection against carriage, despite decreasing antibody levels. The role played by subclinical boosting and the necessity of a booster need to be evaluated.
C1 MRC, Fajara, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP van der Sande, MAB (reprint author), Natl Inst Publ Hlth & Environm, Ctr Infect Dis Epidemiol, POB 1-PB 75, NL-3580 BA Bilthoven, Netherlands.
EM marianne.van.der.sande@rivm.nl
RI McConkey, Samuel/E-7307-2012
FU Medical Research Council [MC_U190071516]
CR Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Banatvala J, 2000, LANCET, V355, P561
   Banatvala J, 2000, VACCINE, V19, P877, DOI 10.1016/S0264-410X(00)00224-3
   Barin F, 1981, Prog Med Virol, V27, P148
   Chadha M S, 2000, Indian J Gastroenterol, V19, P168
   CHOTARD J, 1992, J INFECT DIS, V166, P764
   COURSAGET P, 1994, J HEPATOL, V21, P250, DOI 10.1016/S0168-8278(05)80404-0
   Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   FitzSimons D, 2005, VACCINE, V23, P4158, DOI 10.1016/j.vaccine.2005.03.017
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   FORTUIN M, 1994, J INFECT DIS, V169, P1374
   Harbarth S, 2000, EUR J EPIDEMIOL, V16, P173, DOI 10.1023/A:1007624415699
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Liao SS, 1999, VACCINE, V17, P2661, DOI 10.1016/S0264-410X(99)00031-6
   Lu CY, 2004, HEPATOLOGY, V40, P1415, DOI 10.1002/hep.20490
   McMahon BJ, 2005, ANN INTERN MED, V142, P333
   Medley GF, 2001, NAT MED, V7, P619, DOI 10.1038/87953
   Petersen KM, 2004, PEDIATR INFECT DIS J, V23, P650, DOI 10.1097/01.inf.0000130952.96259.fd
   Poovorawan Y, 2000, ANN TROP MED PARASIT, V94, P615
   Resti M, 1997, VACCINE, V15, P1338, DOI 10.1016/S0264-410X(97)00028-5
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Wainwright RB, 1997, J INFECT DIS, V175, P674
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHO, 2000, HEP B FACT SHEET
   Yen MF, 2004, CLIN GASTROENTEROL H, V2, P941
NR 31
TC 75
Z9 76
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2006
VL 193
IS 11
BP 1528
EP 1535
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 038SS
UT WOS:000237246700009
PM 16652281
OA No
DA 2017-08-15
ER

PT J
AU Marchant, A
   Pihlgren, M
   Goetghebuer, T
   Weiss, HA
   Ota, MOC
   Schlegel-Hauter, SE
   Whittle, H
   Lambert, PH
   Newport, MJ
   Siegrist, CA
AF Marchant, A
   Pihlgren, M
   Goetghebuer, T
   Weiss, HA
   Ota, MOC
   Schlegel-Hauter, SE
   Whittle, H
   Lambert, PH
   Newport, MJ
   Siegrist, CA
CA Med Res Council Gambia Twin Study
TI Predominant influence of environmental determinants on the persistence
   and avidity maturation of antibody responses to vaccines in infants
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; LIVED PLASMA-CELLS; MEMORY B-CELLS;
   IMMUNE-RESPONSE; MEASLES-VACCINE; HEPATITIS-B; EARLY-LIFE; SOMATIC
   HYPERMUTATION; IMMUNOLOGICAL MEMORY; YOUNG AGE
AB Background. Immune responses are complex traits influenced by genetic and environmental factors. We previously reported that genetic factors control early antibody responses to vaccines in Gambian infants. For the present study, we evaluated the determinants of the memory phase of immunoglobulin G (IgG) responses.
   Methods. Antibody responses to tetanus toxoid ( TT), measles vaccines, and environmental antigens ( total IgG levels) were measured in 210 Gambian twin pairs recruited at birth. Intrapair correlations for monozygous and dizygous pairs were compared to estimate the environmental and genetic components of variations in response.
   Results. In contrast to antibody responses measured in infants at age 5 months, 1 month after immunization, no significant contribution of genetic factors to anti-TT antibody and total IgG levels was detected at age 12 months. Genetic factors controlled measles antibody responses in 12-month-old infants, which indicates that the increasing influence of environmental determinants on anti-TT responses was not related to the older age of the children but, rather, to the time elapsed since immunization. Environmental factors also predominantly controlled affinity maturation and the production of high-avidity antibodies to TT.
   Conclusions. Genetic determinants control the early phase of the vaccine antibody response in Gambian infants, whereas environmental determinants predominantly influence antibody persistence and avidity maturation.
C1 Univ Geneva, WHO Collaborating Ctr Vaccinol, Dept Pathol Immunol, CMU, CH-1211 Geneva 4, Switzerland.
   Univ Geneva, Dept Pediat, CH-1211 Geneva, Switzerland.
   Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium.
   Hop St Pierre & Erasme, Dept Pediat, Brussels, Belgium.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, MRC, Trop Epidemiol Grp, London WC1, England.
   Univ Sussex, Div Clin Med, Brighton & Sussex Med Sch, Brighton, E Sussex, England.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Siegrist, CA (reprint author), Univ Geneva, WHO Collaborating Ctr Vaccinol, Dept Pathol Immunol, CMU, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.
EM Claire-Anne.Siegrist@medecine.unige.ch
FU Medical Research Council [G0700837]; Wellcome Trust
CR Becker A, 1997, J REPROD MED, V42, P260
   Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   FINK CW, 1962, J CLIN INVEST, V41, P1422, DOI 10.1172/JCI104597
   FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060
   Gans H, 2001, J INFECT DIS, V184, P817, DOI 10.1086/323346
   Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527
   Giuliano M, 1998, J PEDIATR-US, V132, P983, DOI 10.1016/S0022-3476(98)70395-6
   Goldblatt D, 1999, J INFECT DIS, V180, P538, DOI 10.1086/314901
   GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P756, DOI 10.1016/0035-9203(80)90195-9
   GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0
   GUPTA RK, 1994, BIOLOGICALS, V22, P215, DOI 10.1006/biol.1994.1031
   HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151
   Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X
   Hunziker L, 2003, NAT IMMUNOL, V4, P343, DOI 10.1038/ni911
   Joseph H, 2001, J INFECT DIS, V184, P661, DOI 10.1086/322790
   KLEIN U, 1994, J EXP MED, V180, P1383, DOI 10.1084/jem.180.4.1383
   KONRADSEN HB, 1993, CLIN EXP IMMUNOL, V92, P532
   Kosco-Vilbois MH, 2003, NAT REV IMMUNOL, V3, P764, DOI 10.1038/nri1179
   Lewis D, 2001, INFECT DIS FETUS NEW, P25
   LIEBERMAN JM, 1995, J PEDIATR-US, V126, P198, DOI 10.1016/S0022-3476(95)70545-7
   Mallet E, 2004, VACCINE, V22, P1343, DOI 10.1016/j.vaccine.2003.09.039
   Manz RA, 2002, CURR OPIN IMMUNOL, V14, P517, DOI 10.1016/S0952-7915(02)00356-4
   Marchant A, 2000, CURR OPIN INFECT DIS, V13, P241
   MCGREGOR IA, 1970, CLIN EXP IMMUNOL, V7, P51
   MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295
   MONJOUR L, 1988, PATHOL BIOL, V36, P235
   Neale MC, 1997, BEHAV GENET, V27, P113, DOI 10.1023/A:1025681223921
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Paunio M, 2000, EPIDEMIOL INFECT, V124, P263, DOI 10.1017/S0950268899003222
   Pichichero ME, 1999, J INFECT DIS, V180, P1390, DOI 10.1086/314989
   Pollard AJ, 2000, LANCET, V356, P2065, DOI 10.1016/S0140-6736(00)03405-X
   Posthuma D, 2005, BEHAV GENET, V35, P499, DOI 10.1007/s10519-005-2791-5
   Redd SC, 1999, VACCINES, P222
   Ridings J, 1998, CLIN EXP IMMUNOL, V114, P33
   Schallert N, 2002, EUR J IMMUNOL, V32, P752, DOI 10.1002/1521-4141(200203)32:3<752::AID-IMMU752>3.0.CO;2-5
   Schmitt HJ, 2003, VACCINE, V21, P3653, DOI 10.1016/S0264-410X(03)00389-X
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Slifka MK, 1998, CURR OPIN IMMUNOL, V10, P252, DOI 10.1016/S0952-7915(98)80162-3
   SMITH DH, 1973, PEDIATRICS, V52, P637
   Tan PL, 2001, VACCINE, V19, P2434, DOI 10.1016/S0264-410X(00)00468-0
   Tiru M, 2000, VACCINE, V18, P2295, DOI 10.1016/S0264-410X(99)00539-3
   Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001
   Wassilak SGF, 1999, VACCINES, V3rd, P441
   Weitkamp JH, 2005, HUM IMMUNOL, V66, P666, DOI 10.1016/j.humimm.2005.02.008
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
   WHITTLE H, 1988, LANCET, V2, P811
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WILLIAMSON WA, 1978, LANCET, V1, P1328
   Wuorimaa T, 2001, J INFECT DIS, V184, P1211, DOI 10.1086/323648
NR 51
TC 29
Z9 29
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2006
VL 193
IS 11
BP 1598
EP 1605
DI 10.1086/503775
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 038SS
UT WOS:000237246700018
PM 16652290
OA No
DA 2017-08-15
ER

PT J
AU Newton, PN
   McGready, R
   Fernandez, F
   Green, MD
   Sunjio, M
   Bruneton, C
   Phanouvong, S
   Millet, P
   Whitty, CJM
   Talisuna, AO
   Proux, S
   Christophel, EM
   Malenga, G
   Singhasivanon, P
   Bojang, K
   Kaur, H
   Palmer, K
   Day, NPJ
   Greenwood, BM
   Nosten, F
   White, NJ
AF Newton, Paul N.
   McGready, Rose
   Fernandez, Facundo
   Green, Michael D.
   Sunjio, Manuela
   Bruneton, Carinne
   Phanouvong, Souly
   Millet, Pascal
   Whitty, Christopher J. M.
   Talisuna, Ambrose O.
   Proux, Stephane
   Christophel, Eva Maria
   Malenga, Grace
   Singhasivanon, Pratap
   Bojang, Kalifa
   Kaur, Harparkash
   Palmer, Kevin
   Day, Nicholas P. J.
   Greenwood, Brian M.
   Nosten, Francois
   White, Nicholas J.
TI Manslaughter by fake artesunate in Asia - Will Africa be next?
SO PLOS MEDICINE
LA English
DT Editorial Material
ID SOUTHEAST-ASIA; MALARIA; ANTIMALARIALS; ARTEMETHER; DRUGS
C1 Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX1 2JD, England.
   Mahosot Hosp, Wellcome Trust, Oxford Trop Med Res Collaborat, Viangchan, Laos.
   Shoklo Malaria Res Unit, Mae Sot, Tak, Thailand.
   Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand.
   Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.
   Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Parasit Dis, Atlanta, GA 30333 USA.
   Univ Victor Segalen, EA3677 Bases Therapeut Inflammat & Infect, Bordeaux, France.
   Reseau Medicaments & Dev, Paris, France.
   US Pharmacopeia, Drug Qual & Informat Program, Global Assistance Initiat, Rockville, MD USA.
   Univ London, London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HU, England.
   WHO, Western Pacific Reg Off, Manila, Philippines.
   Malaria Alert Ctr, Bantyre, Malawi.
   MRC Labs, Banjul, Gambia.
RP Newton, PN (reprint author), Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX1 2JD, England.
EM paul@tropmedres.ac
RI Fernandez, Facundo/B-7015-2008; Whitty, Christopher/C-7740-2012; White,
   Nicholas/I-4629-2012
OI Whitty, Christopher/0000-0002-6076-5027; Bojang,
   Kalifa/0000-0001-7506-0938; Singhasivanon, Pratap/0000-0002-9759-1702;
   McGready, Rose/0000-0003-1621-3257; Nosten, Francois/0000-0002-7951-0745
FU Wellcome Trust
CR Alter K, 2004, EUR PHARM REV, V3, P1
   Arrow K. J., 2004, SAVING LIVES BUYING
   ASHLEY EA, 2005, 15 INT C TROP MED MA
   Basco LK, 2004, AM J TROP MED HYG, V70, P245
   *BETT LIF PHARM, 2006, DUNATE ART
   Cody RB, 2005, ANAL CHEM, V77, P2297, DOI 10.1021/ac050162j
   Davis TME, 2005, MED J AUSTRALIA, V182, P181
   Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x
   FERNANDEZ M, 2006, IN PRESS CHEM MED CH
   Green MD, 2001, TROP MED INT HEALTH, V6, P980, DOI 10.1046/j.1365-3156.2001.00793.x
   Jambou R, 2005, LANCET, V366, P1960, DOI 10.1016/S0140-6736(05)67787-2
   Newton P, 2001, LANCET, V357, P1948, DOI 10.1016/S0140-6736(00)05085-6
   Newton PN, 2003, LANCET, V362, P169, DOI 10.1016/S0140-6736(03)13872-X
   Newton PN, 2002, BRIT MED J, V324, P800, DOI 10.1136/bmj.324.7341.800
   Phanouvong S, 2005, 7 INT C AIDS AS PAC
   Rozendaal J, 2000, B MEKONG MALARIA FOR, V7, P62
   SMITH G, 2006, BEFORE YOU GO IMMUNI
   *WHO ROLL BACK MAL, RBM UPD
   2001, FAKE MALARIA DRUGS
   2000, NEWS ITEM SIHANOUK H
NR 20
TC 105
Z9 106
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD JUN
PY 2006
VL 3
IS 6
BP 752
EP 755
AR e197
DI 10.1371/journal.pmed.0030197
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 069WK
UT WOS:000239479600013
PM 16752952
OA gold
DA 2017-08-15
ER

PT J
AU Aaby, P
   Jensen, H
   Walraven, G
AF Aaby, P
   Jensen, H
   Walraven, G
TI Age-specific changes in the female-male mortality ratio related to the
   pattern of vaccinations: An observational study from rural Gambia
SO VACCINE
LA English
DT Article
DE BCG; diphtheria-tetanus-pertussis vaccine; DTP; hepatitis B vaccine;
   measles vaccine; non-specific effects of vaccines; sex-differential
   mortality
ID DIPHTHERIA-TETANUS-PERTUSSIS; TITER MEASLES IMMUNIZATION; GUINEA-BISSAU;
   ROUTINE VACCINATIONS; CHILDHOOD MORTALITY; WEST-AFRICA; BCG VACCINATION;
   PEDIATRIC WARD; SURVIVAL; CHILDREN
AB Background: According to studies from Guinea-Bissau and Senegal, live vaccines may reduce the female-male mortality ratio (MR) whereas inactivated vaccines increase this ratio. We used data from The Gambia to examine whether similar tendencies could be found in a different setting.
   Setting: Forty villages in the Farafenni area in rural Gambia.
   Subjects: A population of 17,000 was followed with demographic surveillance between 1998 and 2002; 537 children less than 5 years of age died in this period.
   Methods: We used two vaccination surveys and community mortality data to examine, first, the female-male mortality ratio (MR) in the age groups in which DTP and MV are recommended and have a high coverage. Second, using vaccination cards seen post-mortem, we examined the distribution of live or inactivated vaccines as last vaccination in different age groups. Third, we examined the effect of DTP and MV administered simultaneously.
   Main outcome measures: The female-male MR in different age groups and for different vaccines.
   Results: Vaccination coverage was high for BCG, third dose of DTP (DTP3) and MV, reaching a level of 80-90% within a few months of the recommended age of vaccination. First, the female-male MR was 0.93 (0.63-1.38) in the first 2 months of life when children had received no vaccination or the combination of BCG, HBV and OPV. From 2 to 8 months of age, with DTP and HBV being the main vaccinations, the female-male MR was 1.28 (0.86-1.89). Between 9 and 17 months of age, with MV as the main vaccination, this ratio dropped to 0.73 (0.50-1.07), a significant inversion of the female-male MR (p = 0.045). Second, using information from vaccination cards of dead children, boys who died at 2-4 months of age were more likely to have received live BCG and girls to have received inactivated DTP and HBV as last vaccination (p < 0.001). At 5-8 months of age, essentially all dead children had received DTP as last vaccination and the female-male MR was 1.68 (0.96-2.93), whereas the MR was 0.70 (0.43-1.15) at 12-17 months of age when nearly all dead children had received MV (p = 0.022). Third, compared with the general population of children who had received MV, dead children who had received MV were more likely to have received DTP3 simultaneously with MV (relative risk (RR) = 5.59 (2.10-14.8)) or after MV (RR = 2.61 (1.13-6.05)).
   Conclusion: Most children dying at a specific age had received the recommended vaccines. BCG and MV as last vaccination was associated with a low female-male MR, whereas DTP as last vaccination was associated with a high female-male MR. These trends are consistent with observations from other African countries. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Statens Serum Inst, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark.
   MRC Labs, Farafenni, Gambia.
   Bandim Hlth Project, Bissau, Guinea Bissau.
RP Aaby, P (reprint author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM p.aaby@bandim.org
CR AABY P, 1993, AM J EPIDEMIOL, V138, P746
   Aaby P, 2005, VACCINE, V23, P1746, DOI 10.1016/j.vaccine.2004.02.054
   Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, PEDIATR INFECT DIS J, V22, P798, DOI 10.1097/01.inf.0000083821.33187.b5
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, UNPUB PIDJ
   AABY P, 2003, VACCINE
   Aaby P, 2002, BMJ
   AABY P, 2003, SEMIN PEDIAT INFECT, P14
   Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   Ashorn P, 2002, ARCH DIS CHILD, V87, P386, DOI 10.1136/adc.87.5.386
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   Garly ML, 2004, PEDIATR INFECT DIS J, V23, P1086, DOI 10.1097/01.inf.0000145700.77286.94
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Global Advisory Committee on vaccine Safety, 2002, WKLY EPIDEMIOL REC, V77, P393
   Hill AG, 1998, LANCET, V352, P1909, DOI 10.1016/S0140-6736(05)60400-X
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   Jason J, 2002, INFECT IMMUN, V70, P6188, DOI 10.1128/IAI.70.11.6188-6195.2002
   Kabir Z, 2002, J TROP PEDIATRICS, V48, P178, DOI 10.1093/tropej/48.3.178
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Lehmann D, 2005, INT J EPIDEMIOL, V34, P138, DOI 10.1093/ije/dyh262
   Moulton LH, 2005, TROP MED INT HEALTH, V10, P947, DOI 10.1111/j.1365-3156.2005.01434.x
   NYARKO P, 2001, 147 POP COUNC
   Ota MOC, 2002, J IMMUNOL, V168, P919
   ROTH A, 2005, INT J EPIDEMIOL
   Shann F, 2004, PEDIATR INFECT DIS J, V23, P555, DOI 10.1097/01.inf.0000130155.42392.04
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   VALENTINERBRATH P, 2006, VACCINE
   Vaugelade J, 2004, BRIT MED J, V329, P1309, DOI 10.1136/bmj.38261.496366.82
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
NR 38
TC 44
Z9 44
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 29
PY 2006
VL 24
IS 22
BP 4701
EP 4708
DI 10.1016/j.vaccine.2006.03.038
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 058ZV
UT WOS:000238704000003
PM 16621182
OA No
DA 2017-08-15
ER

PT J
AU Gilbert, SC
   Moorthy, VS
   Andrews, L
   Pathan, AA
   McConkey, SJ
   Vuola, JM
   Keating, SM
   Berthoud, T
   Webster, D
   McShane, H
   Hill, AVS
AF Gilbert, Sarah C.
   Moorthy, Vasee S.
   Andrews, Laura
   Pathan, Ansar A.
   McConkey, Samuel J.
   Vuola, Jenni M.
   Keating, Sheila M.
   Berthoud, Tamara
   Webster, Daniel
   McShane, Helen
   Hill, Adrian V. S.
TI Synergistic DNA-MVA prime-boost vaccination regimes for malaria and
   tuberculosis
SO VACCINE
LA English
DT Article
DE malaria; tuberculosis; prime-boost; vaccine
ID VACCINIA VIRUS ANKARA; POLYMERASE-CHAIN-REACTION; BACILLE
   CALMETTE-GUERIN; T-CELL RESPONSES; ENHANCED IMMUNOGENICITY; PROTECTIVE
   EFFICACY; IMMUNE-RESPONSES; MYCOBACTERIUM-TUBERCULOSIS; FOWLPOX-VIRUS;
   BCG VACCINE
AB T-cell-mediated responses against the liver-stage of Plasmodium falciparum are critical for protection in the human irradiated sporozoite model and several animal models. Heterologous prime-boost approaches, employing plasmid DNA and viral vector delivery of malarial DNA sequences, have proved particularly promising for maximising T-cell-mediated protection in animal models. The T-cell responses induced by this prime-boost regime, in animals and humans, are substantially greater than the sum of the responses induced by DNA or MVA vaccines used alone, leading to the term introduced here of "synergistic" prime-boost immunisation. The insert in our first generation clinical constructs is known as multiple epitope-thrombospondin-related adhesion protein (ME-TRAP). We have performed an extensive series of phase I/II trials evaluating various prime-boost combination regimens for delivery of ME-TRAP in over 500 malaria-naive and malaria-exposed individuals. The three delivery vectors are DNA, modified vaccinia virus Ankara (MVA) and, more recently, fowlpox strain 9 (FP9). Administration was intra-epidermal and intramuscular for DNA and intradermal for MVA and FP9. Doses of DNA ranged from 4 mu g to 2 mg. Doses of MVA were up to 1.5 x 10(8) plaque forming units (pfu) and of FP9, up to 1.0 x 10(8) pfu. Further trials employing bacille Calmette-Guerin (BCG) as the priming agent and MVA expressing antigen 85A of Mycobacterium tuberculosis as the boosting agent has extended the scope of synergistic prime-boost vaccination. In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England.
   MRC Labs, Banjul, Gambia.
RP Gilbert, SC (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM sarah.gilbert@well.ox.ac.uk
RI HILL, Adrian/C-1306-2008; McConkey, Samuel/E-7307-2012; Keating,
   Sheila/B-1652-2013
OI McConkey, Samuel/0000-0001-9085-7793; Gilbert,
   Sarah/0000-0002-6823-9750; Keating, Sheila/0000-0002-8324-3694
FU Wellcome Trust [, 063643]
CR AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Anderson RJ, 2004, J IMMUNOL, V172, P3094
   Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Barber DL, 2003, J IMMUNOL, V171, P27
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002
   Clements-Mann ML, 1998, J INFECT DIS, V177, P1230
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003
   Ferraz JC, 2004, INFECT IMMUN, V72, P6945, DOI 10.1128/IAI.72.12.6945-6950.2004
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   Goonetilleke NP, 2003, J IMMUNOL, V171, P1602
   Hanke T, 1999, VACCINE, V17, P589, DOI 10.1016/S0264-410X(98)00238-2
   Harari A, 2005, J IMMUNOL, V174, P1037
   Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052
   Laidlaw SM, 2004, J GEN VIROL, V85, P305, DOI 10.1099/vir.0.19568-0
   LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Moorthy VS, 2003, VACCINE, V21, P2004
   Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785
   Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9
   Palmowski MJ, 2002, J IMMUNOL, V168, P4391
   ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Skinner MA, 2003, INFECT IMMUN, V71, P4901, DOI 10.1128/IAI.71.9.4901-4907.2003
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   SUTTER G, 1995, DEV BIOL STAND, V84, P195
   SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847
   Vordermeier HM, 2004, IMMUNOLOGY, V112, P461, DOI 10.1046/j.1365-2567.2004.01903.x
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   *WHO, 1996, 94 WHO
   Williams A, 2005, INFECT IMMUN, V73, P3814, DOI 10.1128/IAI.73.6.3814-3816.2005
NR 42
TC 90
Z9 91
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 22
PY 2006
VL 24
IS 21
BP 4554
EP 4561
DI 10.1016/j.vaccine.2005.08.048
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 056JI
UT WOS:000238518400016
PM 16150517
OA No
DA 2017-08-15
ER

PT J
AU Enosse, S
   Dobano, C
   Quelhas, D
   Aponte, JJ
   Lievens, M
   Leach, A
   Sacarlal, J
   Greenwood, B
   Milman, J
   Dubovsky, F
   Cohen, J
   Thompson, R
   Ballou, WR
   Alonso, PL
   Conway, DJ
   Sutherland, CJ
AF Enosse, Sonia
   Dobano, Carlota
   Quelhas, Diana
   Aponte, John J.
   Lievens, Marc
   Leach, Amanda
   Sacarlal, Jahit
   Greenwood, Brian
   Milman, Jessica
   Dubovsky, Filip
   Cohen, Joe
   Thompson, Ricardo
   Ballou, W. Ripley
   Alonso, Pedro L.
   Conway, David J.
   Sutherland, Colin J.
TI RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope
   selection and reduces multiplicity of infection
SO PLOS CLINICAL TRIALS
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; PAPUA-NEW-GUINEA; CIRCUMSPOROZOITE
   PROTEIN VACCINE; RANDOMIZED CONTROLLED-TRIAL; TANZANIAN CHILDREN;
   CROSS-REACTIVITY; FOLLOW-UP; EFFICACY; RESPONSES; DISEASE
AB Objective: The candidate malaria vaccine RTS, S/AS02A is a recombinant protein containing part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a recent trial conducted in children younger than age five in southern Mozambique, the vaccine demonstrated significant and sustained efficacy against both infection and clinical disease. In a follow-up study to the main trial, breakthrough infections identified in the trial were examined to determine whether the distribution of csp sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes.
   Design: P. falciparum DNA from isolates collected during the trial was used for genotype studies.
   Setting: The main trial was carried out in the Manhica district, Maputo province, Mozambique, between April 2003 and May 2004.
   Participants: Children from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection.
   Outcome: Divergence of DNA sequence encoding the CSP T cell-epitope region sequence from that of the vaccine sequence was measured in 521 isolates. The number of distinct P. falciparum genotypes was also determined.
   Results: We found no evidence that parasite genotypes from children in the RTS, S/AS02A arm were more divergent than those receiving control vaccines. For Cohort 1 ( survey at study month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer genotypes than those in the control group, ( p = 0.035, p = 0.006), respectively, for the two cohorts. This was not the case for children in Cohort 1 who were admitted to hospital ( p = 0.478).
   Conclusions: RTS, S/AS02A did not select for genotypes encoding divergent T cell epitopes in the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the mean number of parasite genotypes harboured by vaccinated children compared with controls, but only among those with asymptomatic infections.
C1 London Sch Hyg & Trop Med, HPA Malaria Reference Lab, London WC1, England.
   Minist Saude, Ctr Invest Saude Manhica, Maputo, Mozambique.
   Minist Saude, Inst Nacl Saude, Maputo, Mozambique.
   Univ Barcelona, Ctr Salut Int, Hosp Clin IDIBAPS, Barcelona, Spain.
   GlaxoSmithKline Biol, Rixensart, Belgium.
   London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1, England.
   PATH Malaria Vaccine Initiat, Bethesda, MD USA.
   MRC Labs, Fajara, Gambia.
RP Sutherland, CJ (reprint author), London Sch Hyg & Trop Med, HPA Malaria Reference Lab, London WC1, England.
EM colin.sutherland@lshtm.ac.uk
RI Dobano, Carlota/N-4119-2014
OI Dobano, Carlota/0000-0002-6751-4060
FU Medical Research Council [MC_U190081993]
CR Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2
   Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   ALONSO PL, 1994, LANCET, V344, P1175
   Beck HP, 1997, J INFECT DIS, V175, P921, DOI 10.1086/513991
   Bojang KA, 1998, VACCINE, V16, P62, DOI 10.1016/S0264-410X(97)00159-X
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Breman JG, 2004, AM J TROP MED HYG, V71, P1
   Cortes A, 2004, EXP PARASITOL, V106, P22, DOI 10.1016/j.exppara.2004.01.010
   Farnert A, 1999, J INFECT DIS, V179, P989, DOI 10.1086/314652
   Geels MJ, 2005, J VIROL, V79, P11247, DOI 10.1128/JVI.79.17.11247-11258.2005
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Graves P, 2003, COCHRANE DB SYST REV, V1
   Haywood M, 1999, Trans R Soc Trop Med Hyg, V93 Suppl 1, P65, DOI 10.1016/S0035-9203(99)90330-9
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   KUMKHAEK C, 2005, IMMUNOLOGY, V175, P3965
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   Mayor A, 2003, TROP MED INT HEALTH, V8, P3, DOI 10.1046/j.1365-3156.2003.00968.x
   Ofosu-Okyere A, 2001, PARASITOLOGY, V123, P113, DOI 10.1017/S0031182001008162
   Pinder M, 2004, CLIN EXP IMMUNOL, V135, P286, DOI 10.1111/j.1365-2249.2004.02371.x
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   SHI YP, 1992, AM J TROP MED HYG, V47, P844
   Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Sun PF, 2003, J IMMUNOL, V171, P6961
   Sutherland CJ, 2002, AM J TROP MED HYG, V66, P700
   Williams OM, 2002, J VIROL, V76, P7418, DOI 10.1128/JVI.76.15.7418-7429.2002
   Yu XG, 2005, AIDS, V19, P1449, DOI 10.1097/01.aids.0000183126.32077.c8
NR 29
TC 51
Z9 52
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1555-5887
J9 PLOS CLIN TRIALS
JI PLos Clin. Trials
PD MAY 19
PY 2006
VL 1
IS 1
AR e5
DI 10.1371/journal.pctr.0010005
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 150HJ
UT WOS:000245206100003
PM 16871327
OA gold
DA 2017-08-15
ER

PT J
AU Lee, EAM
   Flanagan, KL
   Minigo, G
   Reece, WHH
   Bailey, R
   Pinder, M
   Hill, AVS
   Plebanski, M
AF Lee, EAM
   Flanagan, KL
   Minigo, G
   Reece, WHH
   Bailey, R
   Pinder, M
   Hill, AVS
   Plebanski, M
TI Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes
   turn off memory T cells and interfere with T cell priming
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE altered peptide ligands; antagonism; immune interference; polyclonal;
   population dimorphism
ID CARBOXYL-TERMINAL FRAGMENT; HUMORAL IMMUNE-RESPONSES; ALTERED PEPTIDE
   LIGANDS; CIRCUMSPOROZOITE PROTEIN; GENETIC DIVERSITY; IN-VITRO; MALARIA;
   ANTIGEN; PROTECTION; POPULATION
AB The leading blood-stage malaria vaccine candidate antigen, Plasmodium falciparum merozoite surface protein-1 (MSP-1) occurs in two major allelic types worldwide. The molecular basis promoting this stable dimorphism is unknown. In this study, we have shown that allelic altered peptide ligand (APL) T cell epitopes of MSP-1 mutually inhibited IFN-gamma secretion as well as proliferation of CD4(+) T cells in 27/34 malaria exposed Gambian volunteers. Besides this inhibition of malaria-specific immunity, the same variant epitopes were also able to impair the priming of human T cells in malaria naive individuals. Epitope variants capable of interfering with T cell priming as well as inhibiting memory T cell effector functions offer a uniquely potent combination for immune evasion. Indeed, enhanced co-habitation of parasites bearing such antagonistic allelic epitope regions was observed in a study of 321 West African children, indicating a survival advantage for parasites able to engage this inhibitory immune interference mechanism.
C1 Austin Res Inst, Vaccine & Infect Dis Unit, Burnet Res Inst, Melbourne, Vic 3084, Australia.
   Univ Oxford, Mol Immunol Grp, Weatherall Inst Mol Med, Nuffield Dept Med,John Radcliffe Hosp, Oxford, England.
   MRC Labs, Banjul, Gambia.
RP Plebanski, M (reprint author), Austin Res Inst, Vaccine & Infect Dis Unit, Burnet Res Inst, Studley Rd, Melbourne, Vic 3084, Australia.
EM mplebans@ari.unimelb.edu.au
RI HILL, Adrian/C-1306-2008
FU Wellcome Trust
CR BABIKER HA, 1991, T ROY SOC TROP MED H, V85, P572, DOI 10.1016/0035-9203(91)90347-2
   Berenzon D, 2003, J IMMUNOL, V171, P2024
   BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0
   CONWAY DJ, 1992, INFECT IMMUN, V60, P1122
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816
   FERRANTE A, 1990, IMMUNOL LETT, V25, P179, DOI 10.1016/0165-2478(90)90112-4
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173
   Good MF, 2005, ANNU REV IMMUNOL, V23, P69, DOI 10.1146/annurev.immunol.23.021704.115638
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Hirunpetcharat C, 1999, J IMMUNOL, V162, P7309
   Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400
   HUGHES AL, 1992, MOL BIOL EVOL, V9, P381
   JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302
   Keitel WA, 1999, VACCINE, V18, P531, DOI 10.1016/S0264-410X(99)00221-2
   KIMURA E, 1990, GENE, V91, P57, DOI 10.1016/0378-1119(90)90162-K
   KNOWLES G, 1984, AM J TROP MED HYG, V33, P204
   Lee EAM, 2001, AM J TROP MED HYG, V64, P194
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   MINIGO G, 2004, DRUG DESIGN REV, V1, P145, DOI 10.2174/1567269043480627
   MUELLER DL, 1995, CURR OPIN IMMUNOL, V7, P375, DOI 10.1016/0952-7915(95)80113-8
   O'Donnell RA, 2000, NAT MED, V6, P91
   OCKENHOUSE CF, 1984, J IMMUNOL, V133, P1601
   PETERSON MG, 1988, MOL CELL BIOL, V8, P2664
   PLEBANSKI M, 1994, J IMMUNOL METHODS, V170, P15, DOI 10.1016/0022-1759(94)90241-0
   Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3
   Plebanski M, 1999, NAT MED, V5, P565, DOI 10.1038/8444
   Plebanski M, 1997, PARASITOLOGY, V115, pS55
   PLEBANSKI M, 1992, EUR J IMMUNOL, V22, P2353, DOI 10.1002/eji.1830220926
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Read S, 1998, EUR J IMMUNOL, V28, P3435, DOI 10.1002/(SICI)1521-4141(199811)28:11<3435::AID-IMMU3435>3.0.CO;2-P
   Recker M, 2004, NATURE, V429, P555, DOI 10.1038/nature02486
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   Sedegah M, 2004, GENES IMMUN, V5, P553, DOI 10.1038/sj.gene.6364125
   SOKAL RR, 1995, ANAL PROPORTION BIOM, P68
   STEVENSON MM, 1989, PARASITE IMMUNOL, V11, P529, DOI 10.1111/j.1365-3024.1989.tb00687.x
   TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8
   Tian JH, 1998, PARASITE IMMUNOL, V20, P263, DOI 10.1046/j.1365-3024.1998.00138.x
   Wipasa J, 2002, J IMMUNOL, V169, P944
NR 43
TC 19
Z9 20
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAY
PY 2006
VL 36
IS 5
BP 1168
EP 1178
DI 10.1002/eji.200526010
PG 11
WC Immunology
SC Immunology
GA 046BB
UT WOS:000237785300012
PM 16619284
OA No
DA 2017-08-15
ER

PT J
AU Walther, M
   Thompson, FM
   Dunachie, S
   Keating, S
   Todryk, S
   Berthoud, T
   Andrews, L
   Andersen, RF
   Moore, A
   Gilbert, SC
   Poulton, I
   Dubovsky, F
   Tierney, E
   Correa, S
   Huntcooke, A
   Butcher, G
   Williams, J
   Sinden, RE
   Hill, AVS
AF Walther, M
   Thompson, FM
   Dunachie, S
   Keating, S
   Todryk, S
   Berthoud, T
   Andrews, L
   Andersen, RF
   Moore, A
   Gilbert, SC
   Poulton, I
   Dubovsky, F
   Tierney, E
   Correa, S
   Huntcooke, A
   Butcher, G
   Williams, J
   Sinden, RE
   Hill, AVS
TI Safety, immunogenicity, and efficacy of prime-boost immunization with
   recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the
   full-length Plasmodium falciparum circumsporozoite protein
SO INFECTION AND IMMUNITY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; T-CELL IMMUNOGENICITY; MALARIA SPOROZOITES;
   PROTECTIVE IMMUNITY; THERAPEUTIC VACCINATION; DNA; INFECTION; RESPONSES;
   REGIMENS; EPITOPE
AB Heterologous prime-boost immunization with DNA and various recombinant poxviruses encoding malaria antigens is capable of inducing strong cell-mediated immune responses and partial protection in human sporozoite challenges. Here we report a series of trials assessing recombinant fowlpox virus and modified vaccinia virus Ankara encoding the Plasmodium falciparum circumsporozoite protein in various prime-boost combinations, doses, and application routes. For the first time, these vaccines were administered intramuscularly and at doses of up to 5 x 10(8) PFU. Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge.
C1 Univ Oxford, Nuffield Dept Clin Med, Ctr Clin Vaccinol & Trop Med, Churchill Hosp, Oxford OX3 7LJ, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Clin Med, Oxford OX3 7BN, England.
   Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England.
   PATH Malaria Vaccine Initiat, Bethesda, MD 20814 USA.
   Walter Reed Army Inst Res, Silver Spring, MD 20910 USA.
RP Walther, M (reprint author), MRC Labs, Fajara POB 273, Banjul, Gambia.
EM mwalther@mrc.gm
RI HILL, Adrian/C-1306-2008; Keating, Sheila/B-1652-2013
OI Gilbert, Sarah/0000-0002-6823-9750; Moore , Anne/0000-0003-3656-4230
FU Medical Research Council [G84/6323]
CR Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   AMARRA RR, 2001, SCIENCE, V296, P69
   Anderson RJ, 2004, J IMMUNOL, V172, P3094
   Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Bruna-Romero O, 2004, VACCINE, V22, P3575, DOI 10.1016/j.vaccine.2004.03.050
   CHULAY JD, 1986, AM J TROP MED HYG, V35, P66
   CLYDE DF, 1975, AM J TROP MED HYG, V24, P397
   Cosma A, 2003, VACCINE, V22, P21, DOI 10.1016/S0264-410X(03)00538-3
   Doolan DL, 2000, J IMMUNOL, V165, P1453
   Gilbert SC, 2002, VACCINE, V20, P1039, DOI 10.1016/S0264-410X(01)00450-9
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   Harrer E, 2005, ANTIVIR THER, V10, P285
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   HOFFMAN SL, 1989, J IMMUNOL, V142, P1299
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Marshall E, 2000, SCIENCE, V290, P428, DOI 10.1126/science.290.5491.428
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5
   MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333
   NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0
   Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P
   Ramirez JC, 2000, J VIROL, V74, P7651, DOI 10.1128/JVI.74.16.7651-7655.2000
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   Robinson HL, 1999, NAT MED, V5, P526, DOI 10.1038/8406
   Rochlitz C, 2003, J GENE MED, V5, P690, DOI 10.1002/jgm.397
   RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   Scheiblhofer S, 2001, EUR J IMMUNOL, V31, P692, DOI 10.1002/1521-4141(200103)31:3<692::AID-IMMU692>3.0.CO;2-Y
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x
   Terajima M, 2003, J EXP MED, V197, P927, DOI 10.1084/jem.20022222
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   WEHSTER DP, IN PRESS VACCINE
   WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573
NR 44
TC 49
Z9 51
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 2006
VL 74
IS 5
BP 2706
EP 2716
DI 10.1128/IAI.74.5.2706-2716.2006
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 039MX
UT WOS:000237311200023
PM 16622207
OA No
DA 2017-08-15
ER

PT J
AU Pinder, M
   Sutherland, CJ
   Sisay-Joof, F
   Ismaili, J
   McCall, MBB
   Ord, R
   Hallett, R
   Holder, AA
   Milligan, P
AF Pinder, M
   Sutherland, CJ
   Sisay-Joof, F
   Ismaili, J
   McCall, MBB
   Ord, R
   Hallett, R
   Holder, AA
   Milligan, P
TI Immunoglobulin G antibodies to merozoite surface antigens are associated
   with recovery from chloroquine-resistant Plasmodium falciparum in
   gambian children
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MOLECULAR MARKER; PROTECTIVE IMMUNITY; MALARIA MORBIDITY; SERUM
   ANTIBODIES; PARASITE DENSITY; PROTEIN-1; RESPONSES; SURVEILLANCE;
   SPECIFICITY; ARTESUNATE
AB We examined the hypothesis that recovery from uncomplicated malaria in patients carrying drug-resistant Plasmodium falciparum is a measure of acquired functional immunity and may therefore be associated with humoral responses to candidate vaccine antigens. Gambian children with malaria were treated with chloroquine in 28-day trials, and recovery was defined primarily as the absence of severe clinical malaria at any time and absence of parasitemia with fever after 3 days. Plasma samples from these children were assayed by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) to recombinant merozoite antigens: apical membrane antigen 1 (AMA-1) and the 19-kDa C-terminal region of merozoite surface protein 1 (MSP-1(19)), including antigenic variants of MSP-1(19) with double and triple substitutions. Antigen-specific IgG was more frequent in children who recovered, particularly that for MSP-1(19) (age-adjusted odds ratios: 0.32 [95% confidence interval, 0.05, 1.87; P = 0.168] for AMA-1, 0.19 [0.03, 1.11; P = 0.019] for recombinant MSP-1(19), 0.24 [0.04, 1.31; P = 0.032] for the recombinant MSP-1(19) double variant, and 0.18 [0.03, 0.97; P = 0.013] for the triple variant). IgG titers to MSP-1(19) and to the triple variant were higher in plasma samples taken 7 days after chloroquine treatment from children who carried resistant parasites but recovered and remained parasite free. Moreover, in children who were parasitemic on day 14 or day 28, there was an age-independent relationship between parasite density and IgG to both MSP-1(19) and the triple variant (coefficients of -0.550 and -0.590 and P values of 0.002 and 0.001, respectively). The results validate the use of this approach to identify antigens that are associated with protection from malaria.
C1 MRC Labs, Banjul, Gambia.
   Univ Nijmegen, Nijmegen, Netherlands.
   London Sch Hyg & Trop Med, London WC1, England.
   Natl Inst Med Res, Div Parasitol, London NW7 1AA, England.
RP Pinder, M (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mpinder@qanet.gm
RI Holder, Anthony/A-7554-2013; Milligan, Paul/D-8985-2017
OI Holder, Anthony/0000-0002-8490-6058; Milligan, Paul/0000-0003-3430-3395
FU Medical Research Council [MC_U117532067]; Wellcome Trust
CR AlYaman F, 1996, AM J TROP MED HYG, V54, P443
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   Bolad A, 2005, SCAND J IMMUNOL, V61, P380, DOI 10.1111/j.1365-3083.2005.01587.x
   Branch OH, 1998, AM J TROP MED HYG, V58, P211
   Cabrera G, 2005, J INFECT DIS, V191, P1631, DOI 10.1086/429832
   Cavanagh DR, 2001, INFECT IMMUN, V69, P1207, DOI 10.1128/IAI.69.2.1207-1211.2001
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
   Djimde A, 2001, LANCET, V358, P890, DOI 10.1016/S0140-6736(01)06040-8
   Djimde AA, 2003, AM J TROP MED HYG, V69, P558
   Dodoo D, 1999, INFECT IMMUN, V67, P2131
   Dorsey G, 2004, AM J TROP MED HYG, V71, P531
   Drakeley CJ, 2004, TROP MED INT HEALTH, V9, P53, DOI 10.1046/j.1365-3156.2003.01169.x
   Egan AF, 1996, J INFECT DIS, V173, P765
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709
   Hoffman Stephen H., 1996, P1
   Holder A. A., 1999, Parassitologia (Rome), V41, P409
   JARRA W, 1986, PARASITE IMMUNOL, V8, P239
   KOCKEN CH, 2005, INFECT IMMUN, V70, P4471
   Kocken CHM, 2002, INFECT IMMUN, V70, P5901, DOI 10.1128/IAI.70.10.5901.2002
   Mawili-Mboumba DP, 2003, J INFECT DIS, V187, P1137, DOI 10.1086/368414
   Mayxay M, 2001, AM J TROP MED HYG, V65, P918
   McGREGOR I. A., 1963, TRANS ROY SOC TROP MED AND HYG, V57, P170, DOI 10.1016/0035-9203(63)90058-0
   Meerman L, 2005, J INFECT DIS, V192, P1651, DOI 10.1086/496887
   Migot-Nabias F, 1999, AM J TROP MED HYG, V61, P488
   Mita T, 2003, AM J TROP MED HYG, V68, P413
   Moorthy VS, 2004, LANCET, V363, P150, DOI 10.1016/S0140-6736(03)15267-1
   Nwuba RI, 2002, INFECT IMMUN, V70, P5328, DOI 10.1128/IAI.70.9.5328-5331.2002
   Okech BA, 2004, INFECT IMMUN, V72, P1557, DOI 10.1128/IAI.72.3.1557-1567.2004
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   Robert V, 2000, PARASITE IMMUNOL, V22, P589, DOI 10.1046/j.1365-3024.2000.00340.x
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P551, DOI 10.1016/S0035-9203(02)90439-6
   Uthaipibull C, 2001, J MOL BIOL, V307, P1381, DOI 10.1006/jmbi.2001.4574
   *WHO, 2002, WHOCDSEPH200217
NR 41
TC 14
Z9 14
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 2006
VL 74
IS 5
BP 2887
EP 2893
DI 10.1128/IAI.74.5.2887-2893.2006
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 039MX
UT WOS:000237311200043
PM 16622227
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Hill, PC
   Brookes, RH
   Gagneux, S
   Jeffries, DJ
   Otu, JK
   Donkor, SA
   Fox, A
   McAdam, KPWJ
   Small, PM
   Adegbola, RA
AF de Jong, BC
   Hill, PC
   Brookes, RH
   Gagneux, S
   Jeffries, DJ
   Otu, JK
   Donkor, SA
   Fox, A
   McAdam, KPWJ
   Small, PM
   Adegbola, RA
TI Mycobacterium africanum elicits an attenuated T cell response to early
   secreted antigenic target, 6 kDa, in patients with tuberculosis and
   their household contacts
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Keystone Symposium on Tuberculosis - Integrating Host and Pathogen
   Biology
CY APR 02-07, 2005
CL Whistler, CANADA
SP Natl Inst Hlth
ID INFECTION; DIAGNOSIS; ASSAY; INDIVIDUALS; EVOLUTION; VIRULENCE;
   PROTEINS; DISEASE; COMPLEX; FAMILY
AB Background. Mycobacterium africanum, a member of the M. tuberculosis complex that is infrequently found outside of western Africa, is the cause of up to half of the tuberculosis cases there.
   Methods. We genotyped mycobacterial isolates obtained from a study of patients with tuberculosis and their household contacts and compared T cell responses and tuberculin skin test results by infecting genotype.
   Results. The T cell response to early secreted antigenic target, 6 kDa ( ESAT-6), was attenuated in patients with tuberculosis ( odds ratio [ OR], 0.41 [ 95% confidence interval {CI}, 0.19-0.89]; p = .024) and household contacts ( OR, 0.56 [ 95% CI, 0.38-0.83]; P = .004) infected with M. africanum, compared with the response in those infected with M. tuberculosis. In these same groups, responses to culture filtrate protein, 10 kDa ( CFP-10), were nonsignificantly attenuated (P = .22 and P = .16, respectively), as were tuberculin skin test results (p = .30 and P = .46, respectively). Sequencing of region of difference 1 of M. africanum revealed that Rv3879c is a pseudogene in M. africanum; however, this finding does not provide an obvious mechanism for the attenuated ESAT-6 response.
   Conclusions. This is the first evidence, to our knowledge, that strain differences affect interferon-gamma-based T cell responses. Our findings highlight the need to test new diagnostic candidates against different strains of mycobacteria. Integrating additional immunologic and genomic comparisons of M. tuberculosis and M. africanum into further studies may provide fundamental insights into the interactions between humans and mycobacteria.
C1 MRC Labs, Banjul, Gambia.
   Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA.
   Inst Syst Biol, Seattle, WA USA.
RP MRC Labs, POB 273, Banjul, Gambia.
EM bdejong@mrc.gm; phill@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; Gagneux,
   Sebastien/0000-0001-7783-9048
FU FIC NIH HHS [TW006083]; Medical Research Council [MC_U190071468,
   MC_U190081982]
CR Brodin P, 2004, TRENDS MICROBIOL, V12, P500, DOI 10.1016/j.tim.2004.09.007
   CASTETS M, 1969, Bulletin de la Societe Medicale d'Afrique Noire de Langue Francaise, V14, P693
   Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008
   de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41
   Desmond E, 2004, EMERG INFECT DIS, V10, P921
   Godkin AJ, 2002, J IMMUNOL, V169, P2210
   Gutierrez M. Cristina, 2005, PLoS Pathogens, V1, P55, DOI 10.1371/journal.ppat.0010005
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Inwald J, 2003, TUBERCULOSIS, V83, P387, DOI 10.1016/j.tube.2003.08.018
   Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   KREMER K, 2001, MYCOBACTERIUM TUBERC, P359
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2
   Liu XQ, 2004, INFECT IMMUN, V72, P2574, DOI 10.1128/IAI.72.5.2574-2581.2004
   Malik AN, 2005, LANCET INFECT DIS, V5, P174, DOI 10.1016/S1473-3099(05)01310-1
   Marmiesse M, 2004, MICROBIOL-SGM, V150, P483, DOI 10.1099/mic.0.26662-0
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   *NAT LEPR TUB PROG, 2004, KON NED CENTR VER KN
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X
   Pathan AA, 2001, J IMMUNOL, V167, P5217
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859
   Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640
   Sester M, 2004, KIDNEY INT, V65, P1826, DOI 10.1111/j.1523-1755.2004.00586.x
   Skjot RLV, 2000, INFECT IMMUN, V68, P214
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
NR 27
TC 52
Z9 53
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2006
VL 193
IS 9
BP 1279
EP 1286
DI 10.1086/502977
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 036EH
UT WOS:000237053300014
PM 16586366
OA No
DA 2017-08-15
ER

PT J
AU Fulford, AJC
   Rayco-Solon, P
   Prentice, AM
AF Fulford, AJC
   Rayco-Solon, P
   Prentice, AM
TI Statistical modelling of the seasonality of preterm delivery and
   intrauterine growth restriction in rural Gambia
SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY
LA English
DT Article
DE preterm delivery; intrauterine growth restriction; seasonality; Fourier
   series; seemingly unrelated regression; biprobit; deconvolution
ID BIRTH-WEIGHT DISTRIBUTION; MALARIA INFECTION; PLACENTAL MALARIA;
   GESTATIONAL-AGE; PREGNANCY; RETARDATION; TANZANIA; CHILDREN; INFANT;
   IMPACT
AB We have developed a methodology for comparing the seasonal influences on two outcomes, when those influences may act cumulatively or instantaneously. We have used this to compare the seasonal pattern of intrauterine growth retardation (IUGR, as reflected by weight-for-gestational-age) and preterm delivery (as assessed by Dubowitz scoring) among 1718 infants born in rural Gambia. Both outcomes were analysed as binary variables: small-for-gestational-age (SGA, < 10th centile of reference standard) and preterm (< 37 weeks) respectively. Percentages of preterm and SGA babies show divergent seasonal patterns that might indicate separate aetiologies. However, seasonal effects influencing intrauterine growth are likely to be cumulative over the last few months of pregnancy. By modelling seasonality with truncated Fourier series we were able to deconvolve the underlying seasonal influences on fetal growth from the pattern for SGA. This enabled us to use seemingly unrelated biprobit regression to compare the underlying seasonal pattern of intrauterine growth with that governing the incidence of preterm delivery.
   We conclude that, if the seasonal factors affecting intrauterine growth operate over more than the last 2 months of pregnancy, then the seasonal patterns of the factors causing IUGR and preterm delivery are indistinguishable if the factors are assumed to trigger preterm delivery immediately, but differ if preterm delivery is assumed to be programmed by factors acting at conception.
C1 London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, London WC1 7HT, England.
   MRC Keneba, Med Res Council Labs, Banjul, Gambia.
RP Fulford, AJC (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, Keppel St, London WC1 7HT, England.
EM tony.fulford@lshtm.ac.uk
CR AITKEN IW, 1990, INT J GYNECOL OBSTET, V33, P103, DOI 10.1016/0020-7292(90)90581-5
   Armson B Anthony, 2003, J Obstet Gynaecol Can, V25, P209
   Balaka B, 2002, B SOC PATHOL EXOT, V95, P280
   BANTJE H, 1983, J TROP PEDIATRICS, V29, P50
   BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   Bloomfield FH, 2003, SCIENCE, V300, P606, DOI 10.1126/science.1080803
   BRANCA F, 1993, EUR J CLIN NUTR, V47, P840
   Clayton DG, 1993, STAT MODELS EPIDEMIO
   deOnis M, 1996, AM J CLIN NUTR, V64, P650
   Dorman EK, 2002, ULTRASOUND OBST GYN, V19, P165, DOI 10.1046/j.0960-7692.2001.00545.x
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Escriba-Aguir V, 2001, INT ARCH OCC ENV HEA, V74, P583
   Hardin J. W., 1996, STATA TECHNICAL B, V33, P15
   HORT KP, 1987, ANN TROP PAEDIATR, V7, P66
   KINABO J, 1993, E AFR MED J, V70, P752
   Lawoyin T O, 1992, Afr J Med Med Sci, V21, P33
   Lima M, 1999, INT J EPIDEMIOL, V28, P469, DOI 10.1093/ije/28.3.469
   Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459
   Marin CM, 1996, T ROY SOC TROP MED H, V90, P442, DOI 10.1016/S0035-9203(96)90541-6
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449
   Moutquin JM, 2003, BJOG-INT J OBSTET GY, V110, P56, DOI 10.1016/S1470-0328(03)00031-4
   Okoko BJ, 2002, J HEALTH POPUL NUTR, V20, P4
   Rayco-Solon P, 2005, AM J OBSTET GYNECOL, V192, P1133, DOI 10.1016/j.ajog.2004.10.636
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   ROBERTS SB, 1982, T ROY SOC TROP MED H, V76, P668, DOI 10.1016/0035-9203(82)90239-5
   Rousham EK, 1998, AUST NZ J PUBL HEAL, V22, P669, DOI 10.1111/j.1467-842X.1998.tb01467.x
   Sullivan AD, 1999, J INFECT DIS, V179, P1580, DOI 10.1086/314752
   WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624
   ZELLNER A, 1962, J AM STAT ASSOC, V57, P348, DOI 10.2307/2281644
NR 30
TC 21
Z9 21
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0269-5022
J9 PAEDIATR PERINAT EP
JI Paediatr. Perinat. Epidemiol.
PD MAY
PY 2006
VL 20
IS 3
BP 251
EP 259
DI 10.1111/j.1365-3016.2006.00714.x
PG 9
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
GA 030ZB
UT WOS:000236672800009
PM 16629700
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Brookes, RH
   Adetifa, IMO
   Fox, A
   Jackson-Sillah, D
   Lugos, MD
   Donkor, SA
   Marshall, RJ
   Howie, SRC
   Corrah, T
   Jeffries, DJ
   Adegbola, RA
   McAdam, KPWJ
AF Hill, PC
   Brookes, RH
   Adetifa, IMO
   Fox, A
   Jackson-Sillah, D
   Lugos, MD
   Donkor, SA
   Marshall, RJ
   Howie, SRC
   Corrah, T
   Jeffries, DJ
   Adegbola, RA
   McAdam, KPWJ
TI Comparison of enzyme-linked immunospot assay and tuberculin skin test in
   healthy children exposed to Mycobacterium tuberculosis
SO PEDIATRICS
LA English
DT Article
DE tuberculin skin test; ELISPOT; tuberculosis; Mycobacterium tuberculosis
ID CALMETTE-GUERIN VACCINATION; T-CELLS; PEDIATRIC TUBERCULOSIS; HOUSEHOLD
   CONTACTS; INFECTION; POPULATION; DIAGNOSIS; RESPONSES; GAMBIA;
   SENSITIVITY
AB OBJECTIVE. To compare the enzyme-linked immunospot (ELISPOT) assay with the tuberculin skin test (TST) in children for the diagnosis of Mycobacterium tuberculosis infection in the Gambia.
   METHODS. We divided child contacts of sputum smear-positive tuberculosis cases into 3 age categories (< 5, 5 - 9, and 10 - 14 years) and assessed agreement between the 2 tests plus their relationship to prior Bacille Calmette-Guerin ( BCG) vaccination. We categorized a child's level of M tuberculosis exposure according to where he/she slept relative to a case: the same room, same house, or a different house. The relationship between exposure and test result was assessed by multiple logistic regression.
   RESULTS. In child contacts of 287 cases, 225 (32.5%) of 693 were positive by TST and 232 (32.3%) of 718 by ELISPOT. The overall agreement between tests was 83% and the discordance was not significant. Both tests responded to the M tuberculosis exposure gradient in each age category. The percentage of those who were TST positive/ELISPOT negative increased with increasing exposure. At the lowest exposure level, the percentage of ELISPOT-positive children who were TST negative was increased compared with the highest exposure level. Neither test had evidence of false positive results because of BCG.
   CONCLUSIONS. In Gambian children, the ELISPOT is slightly less sensitive than the TST in the diagnosis of M tuberculosis infection from recent exposure, and neither test is confounded by prior BCG vaccination. Evidence of reduced TST sensitivity in subjects with the lowest known recent M tuberculosis exposure suggests that, when maximal sensitivity is important, the 2 tests may be best used together.
C1 Mulago Hosp Complex, TB Div, Kampala, Uganda.
   Mulago Hosp Complex, Bacterial Dis Programme, Kampala, Uganda.
   Mulago Hosp Complex, Infectious Dis Inst, Kampala, Uganda.
   Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
RP Hill, PC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM phill@mrc.gm
OI Marshall, Roger/0000-0001-8278-167X
FU Medical Research Council [MC_U190088478, MC_U190071468]
CR Almeida LMD, 2001, PEDIATR INFECT DIS J, V20, P1061, DOI 10.1097/00006454-200111000-00011
   BLACK GF, 2002, LANCET, V359, P304
   Demissie A, 1999, INFECT IMMUN, V67, P5967
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Fortune SM, 2005, P NATL ACAD SCI USA, V102, P10676, DOI 10.1073/pnas.0504922102
   Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227
   Haile Y, 2002, MICROBIOL-SGM, V148, P3881
   Heifets Leonid B., 1994, P85
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968
   JASMER RM, 2002, NEW ENGL J MED, V359, P1393
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC
   LIENHARDT C, 2003, PEDIATRICS, V111
   Marshall RJ, 2001, STAT MED, V20, P1077, DOI 10.1002/sim.747
   Mudido PM, 1999, INT J TUBERC LUNG D, V3, P891
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746
   Pathan AA, 2001, J IMMUNOL, V167, P5217
   Starke JR, 2003, TUBERCULOSIS, V83, P208, DOI 10.1016/S1472-9792(02)00088-4
   STARKE JR, 1993, TUBERCULOSIS COMPREH, P329
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   Walls T, 2004, J INFECTION, V48, P13, DOI 10.1016/S0163-4453(03)00121-X
   Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804
   World Health Organization, 2003, TREATM TUB GUID NAT
   YOUNG TK, 1992, TUBERCLE LUNG DIS, V73, P94, DOI 10.1016/0962-8479(92)90062-O
NR 30
TC 79
Z9 83
U1 0
U2 1
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD MAY
PY 2006
VL 117
IS 5
BP 1542
EP 1548
DI 10.1542/peds.2005-2095
PG 7
WC Pediatrics
SC Pediatrics
GA 038GO
UT WOS:000237207300039
PM 16651307
OA No
DA 2017-08-15
ER

PT J
AU Atkinson, SH
   Rockett, K
   Sirugo, G
   Bejon, PA
   Fulford, A
   O'Connell, MA
   Bailey, R
   Kwiatkowski, DP
   Prentice, AM
AF Atkinson, Sarah H.
   Rockett, Kirk
   Sirugo, Giorgio
   Bejon, Philip A.
   Fulford, Anthony
   O'Connell, Maria A.
   Bailey, Robin
   Kwiatkowski, Dominic P.
   Prentice, Andrew M.
TI Seasonal childhood anaemia in West Africa is associated with the
   haptoglobin 2-2 genotype
SO PLOS MEDICINE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; HEMOGLOBIN SCAVENGER RECEPTOR; IRON
   STATUS; IN-VITRO; SERUM HAPTOGLOBIN; OXIDATIVE STRESS; 2-2 PHENOTYPE;
   POLYMORPHISM; CHILDREN; SUSCEPTIBILITY
AB Background Anaemia is a major cause of morbidity and mortality for children in Africa. The plasma protein haptoglobin (Hp) binds avidly to free haemoglobin released following malaria-induced haemolysis. Haptoglobin polymorphisms result in proteins with altered haemoglobin-binding capacity and different antioxidant, iron-recycling, and immune functions. Previous studies examined the importance of haptoglobin polymorphism in malaria and iron homeostasis, but it is unknown whether haptoglobin genotype might be a risk factor for anaemia in children in a malaria-endemic area.
   Methods and Findings A cohort of 780 rural Gambian children aged 2-6 y was surveyed at the start and end of the malaria season. Samples were taken to assess haemoglobin (Hb) concentration, iron status (ferritin, zinc protoporphyrin, transferrin saturation, and soluble transferrin receptor concentration), haptoglobin concentration, alpha-1-antichymotrypsin (a measure of inflammation), and malaria parasites on blood film. We extracted DNA and genotyped for haptoglobin, sickle cell, and glucose-6-phosphate (G6PD) deficiency. Mean Hb levels fell over the malaria season. Children with the haptoglobin 2-2 genotype (17%) had a greater mean drop in Hb level over the malaria season (an 8.9 g/l drop; confidence interval [CI] 5.7, 12.1) compared to other children (a 5.1 g/l drop; CI 3.8, 6.4). In multivariate regression analysis, controlling for baseline Hb level, age group, village, malaria parasites on blood film, iron status, haptoglobin concentration, and G6PD deficiency, haptoglobin genotype predicted Hb level at the end of the malaria season (p = 0.0009, coefficient = -4.2). Iron status was not influenced by haptoglobin genotype.
   Conclusions The finding that haptoglobin 2-2 genotype is a risk factor for anaemia in children in a malaria-endemic area may reflect the reduced ability of the Hp2-2 polymer to scavenge free haemoglobin-iron following malaria-induced haemolysis. The magnitude of the effect of haptoglobin genotype (4 g/l Hb difference, p = 0.0009) was comparable to that of G6PD deficiency or HbAS (3 g/l difference, p = 0.03; and 2 g/l difference, p = 0.68, respectively).
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Med Res Council Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, London WC1, England.
   MRC, Cambridge, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
RP Atkinson, SH (reprint author), MRC Labs, Banjul, Gambia.
EM satkinson@kilifi.mimcom.net
OI Kwiatkowski, Dominic/0000-0002-5023-0176
FU Medical Research Council [G0600230, G19/9, MC_U105960399, MC_U190081961]
CR Arredouani M, 2003, IMMUNOLOGY, V108, P144, DOI 10.1046/j.1365-2567.2003.01569.x
   Arredouani MS, 2005, IMMUNOLOGY, V114, P263, DOI 10.1111/j.1365-2567.2004.02071.x
   Asleh R, 2005, CIRC RES, V96, P435, DOI 10.1161/01.RES.0000156653.05853.b9
   Aucan C, 2002, T ROY SOC TROP MED H, V96, P327, DOI 10.1016/S0035-9203(02)90114-8
   Awadallah SM, 2003, CLIN CHIM ACTA, V334, P71, DOI 10.1016/S0009-8981(03)00164-5
   Beutler E, 2002, CLIN CHEM, V48, P2232
   Bienzle U, 2005, TROP MED INT HEALTH, V10, P668, DOI 10.1111/j.1365-3156.2005.01444.x
   BOREHAM PFL, 1981, T ROY SOC TROP MED H, V75, P193, DOI 10.1016/0035-9203(81)90316-3
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Brouwers A, 2004, ATHEROSCLEROSIS, V176, P189, DOI 10.1016/j.atherosclerosis.2004.05.005
   Carter K, 2003, BRIT J HAEMATOL, V122, P326, DOI 10.1046/j.1365-2141.2003.04436.x
   Crawley J, 2004, AM J TROP MED HYG, V71, P25
   CURTAIN CC, 1965, AM J PHYS ANTHROPOL, V23, P363, DOI 10.1002/ajpa.1330230410
   Das BS, 1997, BRIT J NUTR, V78, P751, DOI 10.1079/BJN19970192
   Das BS, 1999, T ROY SOC TROP MED H, V93, P58, DOI 10.1016/S0035-9203(99)90180-3
   Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009
   Elagib AA, 1998, T ROY SOC TROP MED H, V92, P309, DOI 10.1016/S0035-9203(98)91025-2
   FERRALI M, 1992, BIOCHEM J, V285, P295
   Griffiths MJ, 2001, BRIT J HAEMATOL, V113, P486, DOI 10.1046/j.1365-2141.2001.02758.x
   Kasvosve I, 2000, CLIN CHIM ACTA, V296, P163, DOI 10.1016/S0009-8981(00)00225-4
   Kasvosve I, 2002, CLIN CHEM LAB MED, V40, P810, DOI 10.1515/CCLM.2002.140
   KAY MMB, 1986, P NATL ACAD SCI USA, V83, P2463, DOI 10.1073/pnas.83.8.2463
   Kremsner PG, 2000, LANCET, V355, P40, DOI 10.1016/S0140-6736(99)04761-3
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Kwiatkowski D, 2000, CURR OPIN GENET DEV, V10, P320, DOI 10.1016/S0959-437X(00)00087-3
   Langlois MR, 2000, CLIN CHEM, V46, P1619
   Langlois MR, 1997, AM J CLIN NUTR, V66, P606
   Langlois MR, 1996, CLIN CHEM, V42, P1589
   Lim SK, 1998, BLOOD, V92, P1870
   MAEDA N, 1984, NATURE, V309, P131, DOI 10.1038/309131a0
   MCGREGOR IA, 1966, T ROY SOC TROP MED H, V60, P650, DOI 10.1016/0035-9203(66)90011-3
   MELAMEDFRANK M, 2001, BLOOD, V98, P3692
   Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Minang JT, 2004, ACTA TROP, V90, P107, DOI 10.1016/j.actatropica.2003.10.016
   Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171
   Okazaki T, 1997, CLIN CHEM, V43, P2012
   Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9
   Quaye IKE, 2000, T ROY SOC TROP MED H, V94, P216, DOI 10.1016/S0035-9203(00)90281-5
   *REP GAMB, 2001, NAT SURV PREV VIT A
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   SINGH IP, 1986, HUM HERED, V36, P31, DOI 10.1159/000153596
   SRICHAIKUL T, 1969, ARCH INTERN MED, V124, P623, DOI 10.1001/archinte.124.5.623
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P430, DOI 10.1016/0035-9203(85)90053-7
   Van Vlierberghe H, 2001, J HEPATOL, V35, P707, DOI 10.1016/S0168-8278(01)00203-3
   WEATHERALL DJ, 1982, BRIT MED BULL, V38, P147
   WEISS G, 1995, IMMUNOL TODAY, V16, P495, DOI 10.1016/0167-5699(95)80034-4
   Yano A, 1998, ACTA MED OKAYAMA, V52, P173
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 49
TC 30
Z9 32
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD MAY
PY 2006
VL 3
IS 5
BP 652
EP 658
AR e172
DI 10.1371/journal.pmed.0030172
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 057VS
UT WOS:000238623900020
PM 16637741
OA gold
DA 2017-08-15
ER

PT J
AU Natividad, A
   Cooke, G
   Holland, MJ
   Burton, MJ
   Joof, HM
   Rockett, K
   Kwiatkowski, DP
   Mabey, DCW
   Bailey, RL
AF Natividad, Angels
   Cooke, Graham
   Holland, Martin J.
   Burton, Matthew J.
   Joof, Hassan M.
   Rockett, Kirk
   Kwiatkowski, Dominic P.
   Mabey, David C. W.
   Bailey, Robin L.
TI A coding polymorphism in matrix metalloproteinase 9 reduces risk of
   scarring sequelae of ocular Chlamydia trachomatis infection
SO BMC MEDICAL GENETICS
LA English
DT Article
ID MATRIX METALLOPROTEINASES; TNF-ALPHA; GELATINASE; EXPRESSION; 92-KDA;
   TRICHIASIS; MURIDARUM; SURGERY; GENE; MICE
AB Background: Trachoma, an infectious disease of the conjunctiva caused by Chlamydia trachomatis, is an important global cause of blindness. A dysregulated extracellular matrix (ECM) proteolysis during the processes of tissue repair following infection and inflammation are thought to play a key role in the development of fibrotic sequelae of infection, which ultimately leads to blindness. Expression and activity of matrix metalloproteinase 9 (MMP-9), a major effector of ECM turnover, is up-regulated in the inflamed conjunctiva of trachoma subjects. Genetic variation within the MMP9 gene affects in vitro MMP9 expression levels, enzymatic activity and susceptibility to various inflammatory and fibrotic conditions.
   Methods: We genotyped 651 case-control pairs from trachoma endemic villages in The Gambia for coding single nucleotide polymorphisms (SNPs) in the MMP9 gene using the high-throughput Sequenom((R)) system. Single marker and haplotype conditional logistic regression (CLR) analysis for disease association was performed.
   Results: The Q279R mutation located in exon 6 of MMP9 was found to be associated with lower risk for severe disease sequelae of ocular Chlamydia trachomatis infection. This mutation, which leads to a nonsynonymous amino-acid change within the active site of the enzyme may reduce MMP-9-induced degradation of the structural components of the ECM during inflammatory episodes in trachoma and its associated fibrosis.
   Conclusion: This work supports the hypothesis that MMP-9 has a role in the pathogenesis of blinding trachoma.
C1 Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   MRC Labs, Fajara, Gambia.
RP Natividad, A (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM angels.natividad-sancho@lshtm.ac.uk; grahamscooke@hotmail.com;
   mholland@mrc.gm; matthew.burton@lshtm.ac.uk; hmjoof@yahoo.co.uk;
   Kirk.rockett@well.ox.ac.uk; dominic.kwiatkowski@paediatrics.ox.ac.uk;
   david.mabey@lshtm.ac.uk; robin.bailey@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [MC_U190081961]
CR Abu el-Asrar A M, 2001, Bull Soc Belge Ophtalmol, P73
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   COLLIER IE, 1992, J BIOL CHEM, V267, P6776
   Daniels JT, 2003, INVEST OPHTH VIS SCI, V44, P1104, DOI 10.1167/iovs.02-0412
   El-Asrar A M, 2000, Br J Ophthalmol, V84, P85, DOI 10.1136/bjo.84.1.85
   GEARING AJH, 1995, J LEUKOCYTE BIOL, V57, P774
   Leonardi A, 2003, INVEST OPHTH VIS SCI, V44, P3052, DOI 10.1167/iovs.02-0766
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Neely AN, 1999, WOUND REPAIR REGEN, V7, P166, DOI 10.1046/j.1524-475X.1999.00166.x
   Ramsey KH, 2005, INFECT IMMUN, V73, P6962, DOI 10.1128/IAI.73.10.6962-6973.2005
   Saren P, 1996, J IMMUNOL, V157, P4159
   Shah AA, 2005, SEX TRANSM DIS, V32, P49, DOI 10.1097/01.olq.0000148299.14513.11
   Shipley JM, 1996, J BIOL CHEM, V271, P4335
   Wong TTL, 2003, INVEST OPHTH VIS SCI, V44, P1097, DOI 10.1167/iovs.02-0366
   Wong TTL, 2002, SURV OPHTHALMOL, V47, P239, DOI 10.1016/S0039-6257(02)00287-4
   Zhang BP, 1999, CIRCULATION, V99, P1788
NR 18
TC 46
Z9 47
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD APR 27
PY 2006
VL 7
AR 40
DI 10.1186/1471-2350-7-40
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 068VX
UT WOS:000239403700001
PM 16643654
OA gold
DA 2017-08-15
ER

PT J
AU Mendy, ME
   Kaye, S
   van der Sande, M
   Rayco-Solon, P
   Waight, PA
   Shipton, D
   Awi, D
   Snell, P
   Whittle, H
   McConkey, SJ
AF Mendy, Maimuna E.
   Kaye, Steve
   van der Sande, Marianne
   Rayco-Solon, Pura
   Waight, Pauline A.
   Shipton, Deborah
   Awi, Dorka
   Snell, Paul
   Whittle, Hilton
   McConkey, Samuel J.
TI Application of real-time PCR to quantify hepatitis B virus DNA in
   chronic carriers in The Gambia
SO VIROLOGY JOURNAL
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; HBV-DNA; E-ANTIGEN; ANTIVIRAL THERAPY;
   POSITIVE PATIENTS; LAMIVUDINE; INFECTION; SERUM; QUANTITATION;
   INTERFERON
AB Background/Aim: The study aimed at developing a real-time quantitative PCR assay to monitor HBV serum virus load of chronic carriers enrolled in therapeutic trials.
   Method: Quantitative real-time PCR assay was carried out using SYBR-Green signal detection and primers specific to the S gene. Thermal cycling was performed in an ABi 5700 sequence detection system. The assay was calibrated against an international HBV DNA standard and inter- and intra-assay reproducibility determined. Levels of viral load were monitored for 1-year in lamivudine treated carriers. Correlation between HBV DNA levels and HBeAg sero-status was determined in untreated carriers.
   Results: The qPCR assay showed good intra- and inter-assay reproducibility over a wide dynamic range (1.5 x 10(8) copies/ml) and correlated well with those from a commercial assay (r = 0.91, (p < 0.001). Viral load levels dropped dramatically but temporarily during and after a short course of lamivudine therapy. HBV DNA was a more reliable indicator of the presence of virus than HBe antigen and was detected in 77.0% (161/209) of HBeAg negative and in all HBeAg positive carriers.
   Conclusion: This method is reliable, accurate, and reproducible, HBV DNA Quantification by qPCR can be used to monitor the efficacy of HBV therapy and useful in understanding the natural history of HBV in an endemic area.
C1 MRC, Viral Dis Programme, Banjul, Gambia.
   Univ London Imperial Coll Sci & Technol, London, England.
   RIVM, Bilthoven, Netherlands.
   Natl Protect Agcy, London, England.
   Royal Coll Surgeons Ireland, Dublin 2, Ireland.
RP Mendy, ME (reprint author), MRC, Viral Dis Programme, Atlantic Blvd,POB 273, Banjul, Gambia.
EM mmendy@mrc.gm; stevekayegambia@yahoo.com;
   Marianne.van.der.Sande@rivm.nl; Pura.Solon@lshtm.ac.uk;
   Pauline.Kaye@HPA.org.uk; shiptondeb@hotmail.com; dorka_awi@yahoo.co.uk;
   psnell@mrc.gm; hwhitle@mrc.gm; sammcconkey@rcsi.ie
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Medical Research Council [MC_U190071516]
CR Abdel-Fattah S, 1991, J Egypt Public Health Assoc, V66, P427
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BAKER BL, 1991, HEPATOLOGY, V13, P632, DOI 10.1016/0270-9139(91)92556-N
   Barbaro G, 2001, J HEPATOL, V35, P406, DOI 10.1016/S0168-8278(01)00145-3
   BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213
   Fattovich G, 1997, HEPATOLOGY, V26, P1338
   Garson JA, 2005, J VIROL METHODS, V126, P207, DOI 10.1016/j.jviromet.2005.03.001
   Gerken G, 1998, J VIROL METHODS, V74, P155, DOI 10.1016/S0166-0934(98)00081-0
   HENDRICKS DA, 1995, AM J CLIN PATHOL, V104, P537
   Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X
   Janssen HLA, 2005, LANCET, V365, P123, DOI 10.1016/S0140-6736(05)17701-0
   Jardi R, 1996, J HEPATOL, V24, P680, DOI 10.1016/S0168-8278(96)80263-7
   Kohmoto M, 2003, HEPATOL RES, V26, P125, DOI 10.1016/S1386-6346(03)00018-4
   KROGSGAARD K, 1985, HEPATOLOGY, V5, P10, DOI 10.1002/hep.1840050104
   KUHNS MC, 1989, J MED VIROL, V27, P274, DOI 10.1002/jmv.1890270404
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   Lok ASF, 2001, HEPATOLOGY, V34, P1225, DOI 10.1053/jhep.2001.29401
   Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34
   Mphahlele MJ, 2006, J CLIN VIROL, V35, P14, DOI 10.1016/j.jcv.2005.04.003
   PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   Yeh SH, 2004, J HEPATOL, V41, P659, DOI 10.1016/j.jhep.2004.06.031
   ZARSKI JP, 1989, RES VIROLOGY, V140, P283, DOI 10.1016/S0923-2516(89)80108-6
NR 24
TC 21
Z9 23
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD APR 4
PY 2006
VL 3
AR 23
DI 10.1186/1743-422X-3-23
PG 7
WC Virology
SC Virology
GA 182HQ
UT WOS:000247496100001
PM 16594999
OA gold
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Yamuah, LK
AF Okoko, BJ
   Yamuah, LK
TI Household decision-making process and childhood cerebral malaria in the
   Gambia
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE malaria; culture; health-seeking; cerebral malaria; Gambia; caregivers
ID CHILDREN; MOTHERS
AB Mortality from childhood cerebral malaria remains unacceptably high in endemic regions. This survey was conducted between June and December 2001 among 69 primary c aregivers of children admitted for cerebral malaria in Bansang Hospital, Central River Division (CRD), The Gambia to describe decision-making process at the family level that could have impact on malaria mortality. Thirty two percent of children presented in coma after 24 h of onset of illness. The eldest person in the compound or the father was responsible for taking decision on when hospital treatment was necessary in 85% of the cases. Mothers who were the primary caregivers made such decisions only ill 7% of the cases. Cultural norms in a community are important factors affecting preferences at the house-hold level and could influence important medical decisions. This survey suggests that patriarchs and/or fathers are important target groups for health education and project implementation programs. (c) 2006 IMSS. Published by Elsevier Inc.
C1 Kings Coll London, Dept Publ Hlth Sci, London SE1 3QD, England.
   MRC, Fajara, Gambia.
RP Okoko, BJ (reprint author), Kings Coll London, Dept Publ Hlth Sci, 5th Floor,Capital House, London SE1 3QD, England.
EM jacob_brown.okoko@kcl.ac.uk
CR AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   Duffy Lynne, 2005, J Transcult Nurs, V16, P23, DOI 10.1177/1043659604270962
   Jaffar S, 1997, AM J TROP MED HYG, V57, P20
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P151, DOI 10.1016/0035-9203(95)90472-7
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Mugisha F, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-40
   MWENESI H, 1995, SOC SCI MED, V40, P1271, DOI 10.1016/0277-9536(94)00250-W
   Ofovwe GE, 2002, J NEUROL SCI, V200, P49, DOI 10.1016/S0022-510X(02)00128-4
   World Health Organization, 2000, T R SOC TROP MED HYG, V94, P11
   [Anonymous], 2003, MOL ENTOMOLOGY, P1
NR 10
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0188-4409
J9 ARCH MED RES
JI Arch. Med. Res.
PD APR
PY 2006
VL 37
IS 3
BP 399
EP 402
DI 10.1016/j.arcmed.2005.07.007
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 024HA
UT WOS:000236184900018
PM 16513493
OA No
DA 2017-08-15
ER

PT J
AU Siervo, M
   Grey, P
   Nyan, OA
   Prentice, AM
AF Siervo, M
   Grey, P
   Nyan, OA
   Prentice, AM
TI Urbanization and obesity in The Gambia: a country in the early stages of
   the demographic transition
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE Africans; overweight; body composition; socio-behavioural factors;
   westernization
ID BODY-COMPOSITION; NUTRITION TRANSITION; EATING-DISORDERS;
   AFRICAN-AMERICAN; WOMEN; HEALTH; IMAGE; TELEVISION; ELECTRODES;
   BEHAVIORS
AB Objective: To investigate the distribution of overweight and obesity and its relationship with socio-economic and behavioural factors in a developing-country population undergoing rapid nutritional transition.
   Design: Cross-sectional house-to-house survey in urban Gambia.
   Subjects: Four groups of 50 subjects were sampled as follows: young men (YM, 14 - 25 years), young women (YW, 14 - 25 years), older men ( OM, 35 - 50 years) and older women (OW, 35 - 50 years).
   Measurements: Several socio-economic and behavioural factors were investigated. Composite indices for socio-economic status, education, healthy lifestyle and western influences were created. Body weight, height, waist and hip circumferences were measured and body mass index (BMI) was calculated. Body composition was assessed by leg-to-leg bioimpedance. Overweight was defined as BMI 25.0 - 29.9 kg/m(2) and obesity as BMI >= 30.0 kg/m(2).
   Results: There were highly significant gender and age differences in overweight ( YM 0%, YW 10%, OM = 6% and OW = 34%) and obesity (YM = 0%, YW = 4%, OM = 6% and OW = 50%). Only 16% of OW were neither overweight nor obese compared to 88% of OM. OW had a higher fat mass percent (38.4%) than other groups, while fat-free mass ( kg) was significantly higher in males than females with YW having the lowest value. Young generations were more educated and more influenced by western ideals than OM and OW. Weight gain was not always associated with weight concern and many overweight/obese subjects did not perceive themselves as overweight.
   Conclusion: Social and behavioural changes are already creating a perceptible 'generational gap' among this population undergoing rapid transition. The improved education and current lean status of the younger adults offers opportunities for preventative interventions. These need to be specially targeted at women.
C1 Elsie Widdowson Lab, Nutr & Hlth Grp, MRC Human Nutr Res, Cambridge CB1 9NL, England.
   Univ Durham, Dept Anthropol, Durham DH1 3HP, England.
   Univ Gambia, Banjul, Gambia.
   London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London, England.
   MRC Labs, MRC Keneba, Keneba, Gambia.
RP Siervo, M (reprint author), Elsie Widdowson Lab, Nutr & Hlth Grp, MRC Human Nutr Res, Fulbourn Rd, Cambridge CB1 9NL, England.
EM mario.siervo@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960389]
CR Anderson-Fye EP, 2004, CULT MED PSYCHIAT, V28, P561, DOI 10.1007/s11013-004-1068-4
   Becker A, 2004, CULT MED PSYCHIAT, V28, P533, DOI 10.1007/s11013-004-1067-5
   Becker AE, 2002, BRIT J PSYCHIAT, V180, P509, DOI 10.1192/bjp.180.6.509
   BROWN PJ, 1987, ANN NY ACAD SCI, V499, P29, DOI 10.1111/j.1749-6632.1987.tb36195.x
   Caldwell JC, 2001, B WORLD HEALTH ORGAN, V79, P159
   *CDC, 2000, BMI GROWTH CHARTS 2
   *CENTR STAT DEP, 1996, POP HOUS CENS GAMB 1
   Cole Tim J., 2000, BRIT MED J, V320, P1, DOI DOI 10.1136/BMJ.320.7244.1240
   Delpeuch F, 1997, Med Trop (Mars), V57, P380
   Deurenberg P, 1999, BEST PRACT RES CL EN, V13, P1, DOI 10.1053/beem.1999.0003
   Frankenfield DC, 2001, NUTRITION, V17, P26, DOI 10.1016/S0899-9007(00)00471-8
   Gunewardene A, 2001, INT J EAT DISORDER, V29, P289, DOI 10.1002/eat.1020
   Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371
   Holdsworth M, 2004, INT J OBESITY, V28, P1561, DOI 10.1038/sj.ijo.0802739
   Jebb SA, 2000, BRIT J NUTR, V83, P115
   KUMANYIKA S, 1993, J AM DIET ASSOC, V93, P416, DOI 10.1016/0002-8223(93)92287-8
   Lean MEJ, 1998, LANCET, V351, P853, DOI 10.1016/S0140-6736(97)10004-6
   Lean MEJ, 2000, P NUTR SOC, V59, P331, DOI 10.1017/S0029665100000379
   Lovejoy M, 2001, GENDER SOC, V15, P239, DOI 10.1177/089124301015002005
   Martorell R, 2000, EUR J CLIN NUTR, V54, P247, DOI 10.1038/sj.ejcn.1600931
   Nasser M, 2001, EATING DISORDERS CUL
   *NIH, 1998, AM J CLIN NUTR, V64, P685
   Nunez C, 1997, MED SCI SPORT EXER, V29, P524
   Popkin BM, 1999, WORLD DEV, V27, P1905, DOI 10.1016/S0305-750X(99)00094-7
   Popkin BM, 2002, PUBLIC HEALTH NUTR, V5, P205, DOI 10.1079/PHN2001295
   Prentice A M, 2001, Obes Rev, V2, P141, DOI 10.1046/j.1467-789x.2001.00031.x
   Reddy KS, 2002, PUBLIC HEALTH NUTR, V5, P231, DOI 10.1079/PHN2001298
   SOLOMONS NW, 1995, NUTR REV, V53, P90
   Tsui EYL, 1998, DIABETIC MED, V15, P125, DOI 10.1002/(SICI)1096-9136(199802)15:2<125::AID-DIA532>3.3.CO;2-E
   Utter AC, 1999, AM J CLIN NUTR, V69, P603
   van der Sande MAB, 2001, B WORLD HEALTH ORGAN, V79, P133
   van der Sande MAB, 2001, AM J PUBLIC HEALTH, V91, P1641, DOI 10.2105/AJPH.91.10.1641
   Wagner DR, 2000, AM J CLIN NUTR, V71, P1392
   Walker ARP, 2002, NUTRITION, V18, P71, DOI 10.1016/S0899-9007(01)00694-3
   Walker ARP, 2001, PUBLIC HEALTH, V115, P368, DOI 10.1038/sj.ph.1900790
   WHO, 2004, WORLD HLTH REP 2004
   *WHO, 1998, WHONUTNCD98I
   Wildes JE, 2001, CLIN PSYCHOL REV, V21, P521, DOI 10.1016/S0272-7358(99)00071-9
   Williamson L, 1998, SOC WORK HEALTH CARE, V28, P61
NR 39
TC 27
Z9 28
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD APR
PY 2006
VL 60
IS 4
BP 455
EP 463
DI 10.1038/sj.ejcn.1602337
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 029AL
UT WOS:000236530100002
PM 16306924
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Goetghebuer, T
   Vekemans, J
   Okoko, BJ
   Newport, MJ
   McAdam, KPWJ
   Marchant, A
AF Ota, MOC
   Goetghebuer, T
   Vekemans, J
   Okoko, BJ
   Newport, MJ
   McAdam, KPWJ
   Marchant, A
TI Dissociation between tuberculin skin test and in vitro IFN-gamma
   responses following neonatal BCG vaccination
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID BACILLUS-CALMETTE-GUERIN; INTERFERON-GAMMA; MYCOBACTERIUM-TUBERCULOSIS;
   PROTECTIVE IMMUNITY; INFECTION; CHILDREN; SUSCEPTIBILITY; MUTATION;
   RECEPTOR; BIRTH
AB The in vitro IFN-gamma response to tuberculin was recently proposed as a correlate of vaccine-induced immunity to tuberculosis. IFN-gamma also plays a central role in the tuberculin skin test (TST), commonly used as a marker of mycobacterial infection. However, the use of TST as a marker of immunity to tuberculosis is limited for reasons ascribed mainly to interference by environmental mycobacteria. We prospectively investigated the relationship between the TST and cytokine responses to BCG in early infancy, a cohort with relatively low exposure to environmental mycobacteria. Neonatal BCG vaccination induced positive TST responses and predominant IFN-gamma responses to tuberculin in most newborns. However, the production of IFN-gamma, IL-5 and IL-13 was similar in TST responders and non-responders, and there was no significant correlation between the size of TST response and cytokine production. These results indicate that the IFN-gamma assay provides different information than TST in BCG-vaccinated newborns and could be a better marker of vaccine-induced immunity.
C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
   MRC Labs, Fajara, Gambia.
RP Ota, MOC (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.
EM mota@jhsph.edu
CR ALKASSIMI FA, 1995, AM J RESP CRIT CARE, V152, P1575
   BAHR GM, 1986, TUBERCLE, V67, P205, DOI 10.1016/S0041-3879(86)80027-7
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X
   Fjallbrant H, 2001, EUR RESPIR J, V18, P376, DOI 10.1183/09031936.01.00086901
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   GRINDULIS H, 1984, ARCH DIS CHILD, V59, P614
   Johnson CM, 1998, INFECT IMMUN, V66, P1666
   KARALLIEDDE S, 1987, TUBERCLE, V68, P33, DOI 10.1016/0041-3879(87)90005-5
   LIFSCHITZ M, 1965, PEDIATRICS, V36, P624
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Orme IM, 1999, IMMUNOL TODAY, V20, P307, DOI 10.1016/S0167-5699(98)01438-8
   Ota MOC, 2002, J IMMUNOL, V168, P919
   REICHMAN LB, 1979, CHEST, V76, P764, DOI 10.1378/chest.76.6.764
   SHAABAN MA, 1990, EUR RESPIR J, V3, P187
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   WAKSMAN BH, 1971, IMMUNOLOGIC DISEASES, P220
   Weir RE, 2003, CLIN EXP IMMUNOL, V134, P285, DOI 10.1046/j.1365-2249.2003.02272.x
NR 21
TC 10
Z9 11
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD APR
PY 2006
VL 52
IS 2
BP 136
EP 140
DI 10.1093/tropej/fmi087
PG 5
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 030DT
UT WOS:000236614200014
PM 16126802
OA No
DA 2017-08-15
ER

PT J
AU Quiroga, I
   Sweeney, D
   Sutton, PM
   Ahmad, T
   Walton, R
   Barnardo, MCNM
   Fuggle, SV
AF Quiroga, I
   Sweeney, D
   Sutton, PM
   Ahmad, T
   Walton, R
   Barnardo, MCNM
   Fuggle, SV
TI The identification of three novel MICA alleles by sequence-based typing
SO TISSUE ANTIGENS
LA English
DT Article
DE MICA; nucleotide sequence; PCR-SSP; SBT
ID T-CELLS; RECEPTOR; NKG2D
AB During a study of MICA frequency in a healthy population and a cohort of patients suffering with inflammatory bowel disease, three DNA samples produced unusual reactivity patterns using polymerase chain reaction sequence-specific primers (PCR-SSP). These samples were subsequently characterized by sequence-based typing (SBT). Here, we report the sequence of these three novel MICA alleles.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England.
   Churchill Hosp, Oxford Transplant Ctr, Transplant Immunol Lab, Oxford OX3 7LJ, England.
   Univ Oxford, Gibson Labs, Gastroenterol Unit, Radcliffe Infirm, Oxford, England.
   MRC Labs, Dept Pharmacogenet, Fajara, Gambia.
RP Fuggle, SV (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, S Parks Rd, Oxford OX3 9DU, England.
EM susan.fuggle@nds.ox.ac.uk
CR Ahmad T, 2002, TISSUE ANTIGENS, V60, P164, DOI 10.1034/j.1399-0039.2002.600207.x
   BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259
   Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727
   Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4
   Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879
   Marsh Steven G. E., 2002, Human Immunology, V63, P1213, DOI 10.1016/S0198-8859(02)00769-3
   Perez-Rodriguez M, 2002, EUR J IMMUNOGENET, V29, P35, DOI 10.1046/j.0960-7420.2001.00275.x
   Quiroga I, 2004, TISSUE ANTIGENS, V63, P466, DOI 10.1111/j.0001-2815.2004.00195.x
NR 8
TC 4
Z9 5
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD APR
PY 2006
VL 67
IS 4
BP 321
EP 325
DI 10.1111/j.1399-0039.2006.00574.x
PG 5
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 036IQ
UT WOS:000237065200008
PM 16634869
OA No
DA 2017-08-15
ER

PT J
AU Jaitner, J
   Njie, M
   Corr, N
   Dempfle, L
AF Jaitner, J
   Njie, M
   Corr, N
   Dempfle, L
TI Milk production of West African dwarf goats in the Gambia
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
DE West African dwarf goats; milk; milking pattern
ID YIELD
AB Goats are important in the low-input systems of West Africa and their main importance lies in their role for income and saving. In addition, it is known that milk offtake for home consumption is also important. In order to obtain information about the real importance of milk offtake, a recording scheme was operated in 27 villages in the Central River Division of The Gambia from July 1998 until January 2000. Detailed information was obtained from about 1500 kiddings. In the recording scheme, any sheep being milked as well as the goats of the International Trypanotolerance Centre nucleus flock were also recorded. In the villages, 36% of all lactations were used for milk offtake, but the fraction milked was lower for the first two lactations. The average length of lactation was 127 days and the average daily milk offtake was 0.18 L. Goats are milked once a day and the residual milk is left for the kids. Milking starts about one week after parturition and stops when the goat becomes pregnant or the kid(s) die or the goat is drying off. The repeatability of the 90-day milk offtake was 0.24 +/- 0.09. Sixty-five percent of goat owner were women and a large fraction of goat owners also owned cattle. Goat milk was used exclusively for home consumption. It is concluded that in breeding and extension work more attention should be given to aspects of milk production.
C1 ITC, Banjul, Gambia.
   Tech Univ Munich, Dept Tierwissensch, D-8050 Freising Weihenstephan, Germany.
RP Jaitner, J (reprint author), ITC, Banjul, Gambia.
EM Jutta.Jaitner@t-online.de
CR Bennison JJ, 1997, AGR SYST, V55, P425, DOI 10.1016/S0308-521X(97)00002-4
   El-Saied UM, 1998, SMALL RUMINANT RES, V27, P209, DOI 10.1016/S0921-4488(97)00061-8
   Goonewardene LA, 1999, SMALL RUMINANT RES, V32, P181, DOI 10.1016/S0921-4488(98)00179-5
   *ICAR, 1995, REC GUID SECT 2 1, P1
   Jaitner J, 2004, TROP ANIM HEALTH PRO, V36, P169, DOI 10.1023/B:TROP.0000012101.26523.d9
   Jaitner J, 2001, SMALL RUMINANT RES, V40, P101, DOI 10.1016/S0921-4488(00)00221-2
   Knights M, 1997, SMALL RUMINANT RES, V26, P203, DOI 10.1016/S0921-4488(96)00977-7
   MONTALDO H, 1995, SMALL RUMINANT RES, V16, P97, DOI 10.1016/0921-4488(95)00624-T
   PATTERSON HD, 1971, BIOMETRIKA, V58, P545, DOI 10.2307/2334389
NR 9
TC 5
Z9 6
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD APR
PY 2006
VL 38
IS 3
BP 261
EP 266
DI 10.1007/s11250-006-4364-x
PG 6
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA 050PH
UT WOS:000238099900009
PM 16986773
OA No
DA 2017-08-15
ER

PT J
AU Wiseman, V
   McElroy, B
   Conteh, L
   Stevens, W
AF Wiseman, V
   McElroy, B
   Conteh, L
   Stevens, W
TI Malaria prevention in The Gambia: patterns of expenditure and
   determinants of demand at the household level
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE malaria prevention; household expenditure; determinants of expenditure;
   policy; economics
ID TREATED BED NETS; SUB-SAHARAN AFRICA; PERMETHRIN-IMPREGNATED BEDNETS;
   RANDOMIZED CONTROLLED-TRIAL; KASSENA-NANKANA DISTRICT;
   COST-EFFECTIVENESS; WEST-AFRICA; TARGETED CHEMOPROPHYLAXIS; PERSONAL
   PROTECTION; CHILD-MORTALITY
AB OBJECTIVE To provide a better understanding of (1) the amounts households in The Gambia spend on a wide variety of malaria prevention measures, (2) how expenditure fluctuates throughout the year and (3) the main determinants of expenditure.
   METHODS A random sample of 1700 households from the Farafenni region were interviewed about their expenditure on malaria prevention over the past 2 weeks. Interviews were staggered over 12 months. Expenditure was measured for bed nets, treating and repairing bed nets, aerosols, coils, indoor spraying, smoke and other prevention strategies such as drinking herbs and cleaning the outside environment.
   RESULTS Expenditure on bed nets, including treatment and repair, constituted only 10% of total expenditure on malaria prevention. Every fortnight, households spent an average of 8.40 Dalasis (D) on coils, 4.20 D on indoor sprays, 3.09 D on smoke and 3.06 D on aerosols, together making up 81% of total fortnightly expenditure. Of the 442 households that did not own a bed net, 68% said it was because they could not afford one. Every 2 months, the same households spent an average of US$5, the equivalent to the cost of an insecticide treated bed net, on other forms of prevention. Total expenditure was 42% higher during the wet season than for the rest of the year. For every month of the year, coils were the dominant form of prevention expenditure. Wealth, age, occupation of household head, location of residence and month of the year were significant determinants of prevention expenditure.
   CONCLUSIONS Households in The Gambia spend considerable amounts on a range of malaria prevention products and activities throughout the year. Bed nets represent a relatively small proportion of this expenditure even though they are perceived to be the most efficient and effective method of malaria control. A more concerted effort is needed to develop appropriate targeting strategies to encourage bed net use especially for children < 5 years of age. Equal emphasis should be given to addressing barriers to purchasing nets such as their relative high upfront cost.
C1 London Sch Hyg & Trop Med, Gates Malaria Partnership & Hlth Policy Unit, London WC1B 3DP, England.
   Natl Univ Ireland Univ Coll Cork, Dept Econ, Cork, Ireland.
   MRC, Fajara, Gambia.
RP Wiseman, V (reprint author), London Sch Hyg & Trop Med, Gates Malaria Partnership & Hlth Policy Unit, 50 Bedford Sq, London WC1B 3DP, England.
EM virginia.wiseman@lshtm.ac.uk
CR Agyepong IA, 1999, J BIOSOC SCI, V31, P79, DOI 10.1017/S0021932099000796
   Ahorlu CK, 1997, TROP MED INT HEALTH, V2, P488, DOI 10.1046/j.1365-3156.1997.d01-298.x
   Aikins MK, 1998, SOC SCI MED, V46, P181, DOI 10.1016/S0277-9536(97)00145-7
   AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   Alaii JA, 2003, AM J TROP MED HYG, V68, P137
   Alilio MS, 2004, AM J TROP MED HYG, V71, P205
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   ANSARI M A, 1990, Indian Journal of Malariology, V27, P57
   Anya SE, 2004, AM J TROP MED HYG, V70, P510
   ASANTE FA, 2004, COMMUNICABLE DIS B A, V2, P1
   BASSETT G, 1978, J AM STAT ASSOC, V73, P618, DOI 10.2307/2286611
   Binka FN, 1996, TROP MED INT HEALTH, V1, P147
   Binka FN, 1997, HEALTH POLICY, V41, P229, DOI 10.1016/S0168-8510(97)00035-3
   BIRLEY MH, 1987, ANN TROP MED PARASIT, V81, P163
   Bogh C, 2002, T ROY SOC TROP MED H, V96, P593, DOI 10.1016/S0035-9203(02)90320-2
   BUCHINSKY M, 1994, ECONOMETRICA, V62, P405, DOI 10.2307/2951618
   COENE J, 1989, T ROY SOC TROP MED H, V83, P568, DOI 10.1016/0035-9203(89)90299-X
   CONTEH L, 2005, INT HLTH EC C JUL 10
   Curtis CF, 1996, MED VET ENTOMOL, V10, P1, DOI 10.1111/j.1365-2915.1996.tb00075.x
   D'Alessandro U, 1997, T ROY SOC TROP MED H, V91, P638, DOI 10.1016/S0035-9203(97)90502-2
   DEATON A., 2000, ANAL HOUSEHOLD SURVE
   Deaton A. S., 1997, ANAL HOUSEHOLD SURVE
   DESFONTAINE M, 1989, B SOC PATHOL EXOT, V82, P558
   Donnelly MJ, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-12
   Drakeley CJ, 2000, T ROY SOC TROP MED H, V94, P472, DOI 10.1016/S0035-9203(00)90056-7
   Elphick H, 2003, Cent Afr J Med, V49, P87
   ETTLING M, 1994, TROP MED PARASITOL, V45, P74
   FEILDEN RM, 1996, NET GAIN NEW METHOD, P55
   FILMER D, 2001, DEMOGRAPHY, V38, P155
   Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8
   Goodman CA, 1999, HEALTH POLICY PLANN, V14, P301, DOI 10.1093/heapol/14.4.301
   Goodman CA, 2000, EC ANAL MALARIA CONT
   Greenwood B, 2004, AM J TROP MED HYG, V70, P1
   GUIGUEMDE TR, 1994, T ROY SOC TROP MED H, V88, P285, DOI 10.1016/0035-9203(94)90079-5
   Guillet P, 2001, B WORLD HEALTH ORGAN, V79, P998
   Habluetzel A, 1997, TROP MED INT HEALTH, V2, P855, DOI 10.1046/j.1365-3156.1997.d01-413.x
   Hanson K, 2004, EC MALARIA CONTROL I
   Hewitt SE, 1996, ANN TROP MED PARASIT, V90, P337
   Keiser J, 2004, AM J TROP MED HYG, V71, P118
   KLEIN RE, 1995, AM J TROP MED HYG, V52, P383
   KOENKER R, 1982, ECONOMETRICA, V50, P43, DOI 10.2307/1912528
   Kumar UD, 2001, IETE TECH REV, V18, P5
   MACINTYRE K, 2002, MALAR J, V15, P14
   Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8
   MCELROY B, 2004, DEMAND MALARIA PREVE
   McKenzie D, 2003, MEASURING INEQUALITY
   *MED RES COUNC, 2004, FAR DEM SURV SYST PR
   MOSHA FW, 1992, MED VET ENTOMOL, V6, P44, DOI 10.1111/j.1365-2915.1992.tb00033.x
   Muela SH, 2000, HEALTH POLICY PLANN, V15, P296, DOI 10.1093/heapol/15.3.296
   Mugisha F, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-40
   Mulla MS, 2001, J AM MOSQUITO CONTR, V17, P153
   Nevill CG, 1996, TROP MED INT HEALTH, V1, P139
   Nuwaha F, 2001, AM J TROP MED HYG, V65, P877
   Nuwaha F, 2002, TROP MED INT HEALTH, V7, P462, DOI 10.1046/j.1365-3156.2002.00877.x
   Oguonu T, 2005, PUBLIC HEALTH, V119, P409, DOI 10.1016/j.puhe.2004.05.008
   PATES HV, 1997, T ROY SOC TROP MED H, V91, P251
   Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23
   PICARD J, 1993, T ROY SOC TROP MED H, V87, P53, DOI 10.1016/0035-9203(93)90176-Q
   Rashed S, 2000, AM J TROP MED HYG, V62, P181
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   *RBM, 2004, ROLL BACK MAL PARTN
   Robert V, 2003, AM J TROP MED HYG, V68, P169
   Rowland M, 2004, TROP MED INT HEALTH, V9, P343
   Samuelsen H, 2004, SOC SCI MED, V59, P2361, DOI 10.1016/j.socscimed.2004.03.031
   SCOTT K, 1990, EFFECT RECALL DURATI
   Simon JL, 2002, B WORLD HEALTH ORGAN, V80, P892
   Snehalatha KS, 2003, ACTA TROP, V88, P3, DOI 10.1016/S0001-706X(03)00155-4
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   Snow RW, 1998, T ROY SOC TROP MED H, V92, P381, DOI 10.1016/S0035-9203(98)91056-2
   SONGSORE J, 1993, ENVIRON URBAN, V5, P10, DOI 10.1177/095624789300500203
   STEPHENS C, 1995, B WORLD HEALTH ORGAN, V73, P97
   Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0
   Turner AG, 2001, MEASURE EVALUATION M
   *UNICEF, 2003, SCAL US INS TREAT NE
   VANDERGEEST S, 1992, SOC SCI MED, V34, P667, DOI 10.1016/0277-9536(92)90194-U
   Warren M, 1999, EHP ACTIVITY REPORT, P71
   WINCH PJ, 1994, SOC SCI MED, V39, P63, DOI 10.1016/0277-9536(94)90166-X
   Wiseman V, 2003, AM J TROP MED HYG, V68, P161
   WORRALL E, 2003, 0103 HEFP
   Yap H. H., 1996, Tropical Biomedicine, V13, P101
   Yohannes K, 2000, ACTA TROP, V75, P173, DOI 10.1016/S0001-706X(00)00055-3
NR 82
TC 20
Z9 20
U1 3
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD APR
PY 2006
VL 11
IS 4
BP 419
EP 431
DI 10.1111/j.1365-3156.2006.01586.x
PG 13
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 024TY
UT WOS:000236220300005
PM 16553925
OA No
DA 2017-08-15
ER

PT J
AU Aiken, AM
   Hill, PC
   Fox, A
   McAdam, KPWJ
   Jackson-Sillah, D
   Lugos, MD
   Donkor, SA
   Adegbola, RA
   Brookes, RH
AF Aiken, Alexander M.
   Hill, Philip C.
   Fox, Annette
   McAdam, Keith P. W. J.
   Jackson-Sillah, Dolly
   Lugos, Moses D.
   Donkor, Simon A.
   Adegbola, Richard A.
   Brookes, Roger H.
TI Reversion of the ELISPOT test after treatment in Gambian tuberculosis
   cases
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID SECRETORY ANTIGENIC TARGET-6; LINKED IMMUNOSPOT ASSAY;
   MYCOBACTERIUM-TUBERCULOSIS; GLOBAL EPIDEMIOLOGY; IFN-GAMMA; T-CELLS;
   RESPONSES; INDIVIDUALS; DIAGNOSIS
AB Background: New tools are required to improve tuberculosis ( TB) diagnosis and treatment, including enhanced ability to compare new treatment strategies. The ELISPOT assay uses Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the immune response to pathogen. We hypothesized that TB patients in The Gambia would have reduced ELISPOT counts after successful treatment.
   Methods: We recruited Gambian adults with sputum smear and culture positive tuberculosis for ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart, comparing within and between subject variation.
   Results: We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive, 77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment: 44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a mean decline of 25, 44 and 47 SFU/2 x 10(5) cells for CFP-10, ESAT-6 and PPD respectively ( p < 0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all 4 not cured subjects ( 3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months.
   Conclusion: Successful tuberculosis treatment is accompanied by a significant reduction in the M. tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is warranted.
C1 MRC Labs, TB Div, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Labs, TB Div, Banjul, Gambia.
EM aaiken@mrc.gm; phill@mrc.gm; afox@pacific.net.au; kmcadam@idi.co.ug;
   Dolly.Jackson-Sillah@lshtm.ac.uk; mlugos@mrc.gm; sdonkor@mrc.gm;
   radegbola@mrc.gm; roger.brookes@sanofipasteur.com
FU Medical Research Council [MC_U190071468]
CR CARRARA S, 2004, CLIN INFECT DIS, V38, P757
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767
   Ferrand RA, 2005, INT J TUBERC LUNG D, V9, P1034
   Fortune SM, 2004, J IMMUNOL, V172, P6272
   GODKIN AJ, 2000, J IMMUNOL, V38, P754
   Heifets Leonid B., 1994, P85
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009
   Nicol MP, 2005, CLIN INFECT DIS, V40, P1301, DOI 10.1086/429245
   Pathan AA, 2001, J IMMUNOL, V167, P5217
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Vekemans J, 2004, INFECT IMMUN, V72, P381, DOI 10.1128/IAI.72.1.381-388.2004
   *WHO, WHO REP MON PROGR MI
   Global tuberculosis control: surveillance planning financing, 2005, WHOHTMTB2005349
   Wu-Hsieh BA, 2001, CLIN INFECT DIS, V33, P1336, DOI 10.1086/323044
NR 18
TC 88
Z9 97
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAR 30
PY 2006
VL 6
AR 66
DI 10.1186/1471-2334-6-66
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 083GV
UT WOS:000240445300001
PM 16573826
OA gold
DA 2017-08-15
ER

PT J
AU Jarjou, LM
   Prentice, A
   Sawo, Y
   Laskey, MA
   Bennett, J
   Goldberg, GR
   Cole, TJ
AF Jarjou, LM
   Prentice, A
   Sawo, Y
   Laskey, MA
   Bennett, J
   Goldberg, GR
   Cole, TJ
TI Randomized, placebo-controlled, calcium supplementation study in
   pregnant Gambian women: effects on breast-milk calcium concentrations
   and infant birth weight, growth, and bone mineral accretion in the first
   year of life
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE bone mineral accretion; breast milk; calcium; Gambia; infants; pregnancy
ID HUMAN FETUS; WHOLE-BODY; LACTATION; BRITISH; MOTHERS; TRIAL;
   HOMEOSTASIS; PHOSPHORUS; DENSITY; NEWBORN
AB Background: Growth and bone mineral accretion in Gambian infants are poorer than those in Western populations. The calcium intake of Gambian women is low, typically 300-400 mg Ca/d, and they have low breast-milk calcium concentrations, which result in low calcium intakes for their breastfed infants. A low maternal calcium supply in pregnancy may limit fetal mineral accretion and breast-milk calcium concentrations and thereby affect infant growth and bone mineral accretion.
   Objective: We investigated the effects of calcium supplementation in Gambian women during pregnancy on breast-milk calcium concentrations and infant birth weight, growth, and bone mineral accretion.
   Design: A randomized, double-blind, placebo-controlled supplementation study was conducted in 125 Gambian women who received 1500 mg Ca/d (as calcium carbonate) or placebo from 20 wk of gestation until delivery. Infant birth weight and gestational age were recorded. Breast milk was collected, and infant anthropometric and bone measurements were performed at 2, 13, and 52 wk after delivery. Infant bone mineral status was assessed by using single-photon absorptiometry of the radius and whole-body dual-energy X-ray absorptiometry.
   Results: Compliance with the supplement was high. No significant differences were detected between the groups in breast-milk calcium concentration, infant birth weight, or growth or bone mineral status during the first year of life. A slower rate of increase in infant whole-body bone mineral content and bone area was found in the supplement group than in the placebo group (group x time interaction: P = 0.03 and 0.02, respectively).
   Conclusion: Calcium supplementation of pregnant Gambian women had no significant benefit for breast-milk calcium concentrations or infant birth weight, growth, or bone mineral status in the first year of life.
C1 MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   MRC, Keneba, Gambia.
   Ctr Paediat Epidemiol & Biostat, Inst Child Hlth, London, England.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
OI Cole, Tim/0000-0001-5711-8200
FU Medical Research Council [MC_U105960371, G9827821, G9827821(62595)]
CR APTE SV, 1972, BRIT J NUTR, V27, P305, DOI 10.1079/BJN19720095
   BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002
   Chang SC, 2003, AM J CLIN NUTR, V77, P1248
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   Cole TJ, 1997, ARCH DIS CHILD, V76, P47
   CROSS NA, 1995, AM J CLIN NUTR, V61, P514
   Department of Health, 1998, NUTR BON HLTH PART R
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   FORBES GB, 1976, PEDIATRICS, V57, P976
   FREEMAN JV, 1990, ARCH DIS CHILD, V73, P17
   GLEERUP A, 1995, AM J CLIN NUTR, V61, P97
   Godfrey K, 2001, J BONE MINER RES, V16, P1694, DOI 10.1359/jbmr.2001.16.9.1694
   Heaney RP, 2001, NUTR REV, V59, P327
   Institute of Medicine Food and Nutrition Board, 1997, DIET REF INT CALC PH
   JARJOU LMA, 1996, THESIS ANGLIA POLYTE
   Kalkwarf HJ, 1997, NEW ENGL J MED, V337, P523, DOI 10.1056/NEJM199708213370803
   Koo WWK, 1998, J AM COLL NUTR, V17, P65
   Koo WWK, 2003, PEDIATRICS, V111, P1017, DOI 10.1542/peds.111.5.1017
   Koo WWK, 1999, OBSTET GYNECOL, V94, P577, DOI 10.1016/S0029-7844(99)00371-3
   Laskey MA, 1999, BRIT J RADIOL, V72, P967
   LASKEY MA, 1990, ACTA PAEDIATR SCAND, V79, P507, DOI 10.1111/j.1651-2227.1990.tb11504.x
   LASKEY MA, 1991, ANN CLIN BIOCHEM, V28, P49
   Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3
   Ortega RM, 1998, BRIT J NUTR, V79, P501, DOI 10.1079/BJN19980088
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1990, BONE MINER, V10, P211, DOI 10.1016/0169-6009(90)90263-F
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   PRENTICE A, 1991, BONE MINER, V12, P201, DOI 10.1016/0169-6009(91)90033-V
   Prentice A, 2003, J NUTR, V133, p1693S
   PRENTICE A, 1987, HUM NUTR-CLIN NUTR, V41C, P319
   PRENTICE A, 1994, ADV EXP MED BIOL, V352, P243
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   PRENTICE A, 1994, LANCET, V344, P411, DOI 10.1016/S0140-6736(94)91440-0
   Prentice A, 1997, NEW ENGL J MED, V337, P558, DOI 10.1056/NEJM199708213370809
   Prentice A., 1999, NUTR BONE DEV, P127
   PRENTICE A, 1990, HUMAN LACTATION, V4, P87
   Prentice A, 1994, EUR J CLIN NUTR, V48S, P161
   Prentice A., 2004, PUBLIC HEALTH NUTR, V7, P237
   Price GM, 1995, J HUM NUTR DIET, V8, P417, DOI 10.1111/j.1365-277X.1995.tb00337.x
   Prynne CJ, 2002, J FOOD COMPOS ANAL, V15, P349, DOI 10.1006/jfca.2002.1074
   RAMAN L, 1978, AM J CLIN NUTR, V21, P466
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Ritchie LD, 1998, AM J CLIN NUTR, V67, P693
   VILLAR J, 1987, OBSTET GYNECOL, V70, P317
   Weiler H, 2005, CAN MED ASSOC J, V172, P757, DOI 10.1503/cmaj.1040508
NR 47
TC 70
Z9 72
U1 0
U2 9
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAR
PY 2006
VL 83
IS 3
BP 657
EP 666
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 022RJ
UT WOS:000236073100019
PM 16522914
OA No
DA 2017-08-15
ER

PT J
AU Flanagan, KL
   Plebanski, M
   Odhiambo, K
   Sheu, E
   Mwangi, T
   Gelder, C
   Hart, K
   Kortok, M
   Lowe, B
   Robson, KJ
   Marsh, K
   Hill, AVS
AF Flanagan, KL
   Plebanski, M
   Odhiambo, K
   Sheu, E
   Mwangi, T
   Gelder, C
   Hart, K
   Kortok, M
   Lowe, B
   Robson, KJ
   Marsh, K
   Hill, AVS
TI Cellular reactivity to the P-falciparum protein trap in adult Kenyans:
   Novel epitopes, complex cytokine patterns, and the impact of natural
   antigenic variation
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID SPOROZOITE SURFACE PROTEIN-2; VACCINIA VIRUS ANKARA; CD8+ T-CELLS;
   CIRCUMSPOROZOITE PROTEIN; INTERFERON-GAMMA; ADHESIVE PROTEIN;
   IMMUNE-RESPONSE; HLA-B; MALARIA; PROTECTION
AB Malaria vaccines based oil thrombospondin-related adhesive protein of Plasmodium falciparum (PfTRAP) are currently undergoing clinical trials in humans. This study was designed to investigate naturally acquired cellular immunity to PfTRAP in adults from a target population for future trials of TRAP-based vaccines in Kilifi, Kenya. We first tested reactivity to a panel of 53 peptides spanning PfTRAP and identified 26 novel T-cell epitopes. A panel of naturally occurring polymorphic variant epitope peptides were made to the most commonly recognized epitope regions and tested for ability to elicit IFN-gamma, IL-4, and IL-10 production. These data provide for the first time a complex cytokine matrix mapping naturally induced T-cell responses to TRAP and suggest that T-cell responses boosted by vaccination with PfTRAP could stimulate the release of competing pro- and anti-inflammatory cytokines. They further define polymorphic variants able to boost specific Th1, Th2, and possibly Tr1 reactivity.
C1 Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   KEMRI, Ctr Geog Med, Kilifi, Kenya.
   Univ Wales Coll Cardiff, Coll Med, Cardiff, Wales.
RP Flanagan, KL (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM kflanagan@mrc.gm
RI HILL, Adrian/C-1306-2008
FU Wellcome Trust
CR Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   DELACRUZ VF, 1988, J IMMUNOL, V141, P2456
   Doolan DL, 2000, J IMMUNOL, V165, P1123
   Doolan DL, 1997, IMMUNITY, V7, P97, DOI 10.1016/S1074-7613(00)80513-0
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Flanagan KL, 2003, AM J TROP MED HYG, V68, P421
   Flanagan KL, 2001, J IMMUNOL, V167, P4729
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   HOFFMAN SL, 1989, J IMMUNOL, V142, P1299
   KABILAN L, 1988, P NATL ACAD SCI USA, V85, P5659, DOI 10.1073/pnas.85.15.5659
   KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210
   KHUSMITH S, 1994, INFECT IMMUN, V62, P2979
   Kurtis JD, 1999, INFECT IMMUN, V67, P3424
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   MELLOUK S, 1994, INFECT IMMUN, V62, P4043
   MELLOUK S, 1991, J IMMUNOL, V146, P3971
   Migot-Nabias F, 2000, T ROY SOC TROP MED H, V94, P557, DOI 10.1016/S0035-9203(00)90086-5
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283
   Perlaza BL, 2001, EUR J IMMUNOL, V31, P2200, DOI 10.1002/1521-4141(200107)31:7<2200::AID-IMMU2200>3.0.CO;2-L
   Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   Robson K.J.H., 1993, Parassitologia (Rome), V35, P91
   ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126
   Robson KJH, 1998, AM J TROP MED HYG, V58, P81
   ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHOFIELD L, 1987, J IMMUNOL, V139, P2020
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   SEGUIN MC, 1994, J EXP MED, V180, P353, DOI 10.1084/jem.180.1.353
   UDHAYAKUMAR V, 1995, J IMMUNOL, V154, P6022
   Vanderlugt CL, 1998, IMMUNOL REV, V164, P63, DOI 10.1111/j.1600-065X.1998.tb01208.x
   Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724
   *WHO, 2000, MAL GLOB CRIS
   ZEVERING Y, 1994, EUR J IMMUNOL, V24, P1418, DOI 10.1002/eji.1830240627
NR 39
TC 18
Z9 18
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAR
PY 2006
VL 74
IS 3
BP 367
EP 375
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 020PY
UT WOS:000235923300005
PM 16525093
OA No
DA 2017-08-15
ER

PT J
AU Simpson, JA
   Hughes, D
   Manyando, C
   Bojang, K
   Aarons, L
   Winstanley, P
   Edwards, G
   Watkins, WA
   Ward, S
AF Simpson, JA
   Hughes, D
   Manyando, C
   Bojang, K
   Aarons, L
   Winstanley, P
   Edwards, G
   Watkins, WA
   Ward, S
TI Population pharmacokinetic and pharmacodynamic modelling of the
   antimalarial chemotherapy chlorproguanil/dapsone
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE chlorcycloguanil; chlorproguanil; dapsone; pharmacodynamics; Plasmodium
   falciparum; population pharmacokinetics
ID PLASMODIUM-FALCIPARUM MALARIA; SULFADOXINE-PYRIMETHAMINE;
   YOUNG-CHILDREN; DAPSONE; AFRICA; GLUCURONIDATION; EFFICACY
AB Aims
   To determine the population pharmacokinetics of chlorproguanil, dapsone and the active metabolite of chlorproguanil, chlorcycloguanil; and to estimate the duration of parasitocidal activity for chlorpoguanil/dapsone against Plasmodium falciparum isolates of varying sensitivity.
   Methods
   Rich and sparse pharmacokinetic data were collected prospectively from: healthy volunteers (n = 48) and adults (n = 65) and children (n = 68) suffering from P. falciparum malaria. All subjects received 2.0 mg kg(-1) of chlorproguanil and 2.5 mg kg(-1) of dapsone.
   Results
   The population pharmacokinetic parameter estimates for chlorproguanil were k(a) = 00.09 h(-1) (intersubject variability was 44%), CL/F = 51.53 l h(-1) (57%), CLD/F = 54.67 l h(-1), V-1/F = 234.40 l (50%) and V-2/F = 1612.75 l; for dapsone were k(a) = 00.93 h(-1), CL/F = 1.99 l h(-1) (72%) and V/F = 76.96 l (48%); and for chlorcycloguanil were CLm/F-m = 3.72 l h(-1) kg(-1) (67%) and V-m/F-m = 12.76 l kg(-1) (64%). For dapsone, CL/F and V/F were both significantly positively correlated with body weight. For a 10-kg child, the mean duration of parasitocidal activity for chlorproguanil/dapsone against the three most susceptible P. falciparum strains was 4.5 days [5(th) and 95(th) percentiles 2.4, 7.3] for W282; 5.9 days (3.6, 9.7) for ItG2F6; and 6.1 days (3.7, 10.1) for K39. For an isolate with the ile-164-leu mutation, V1/S, activity ranged from 0.8 days (0.0, 3.3) for a 10-kg child to 1.8 days (0.0, 4.0) for a 60-kg adult.
   Conclusions
   Plasmodium falciparum malaria has no effect on the pharmacokinetic parameters for chlorproguanil, dapsone or chlorcycloguanil. Chlorproguanil/dapsone will probably prove to be ineffective against parasite strains with the mutation ile-164-leu, were these to become prevalent in Africa.
C1 Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic 3053, Australia.
   Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England.
   Univ Wales, Inst Med & Social Care Res, Bangor, Gwynedd, Wales.
   Trop Dis Res Ctr, Ndola, Zambia.
   MRC Labs, Banjul, Gambia.
   Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England.
   Univ Liverpool, Liverpool Sch Trop Med, Div Mol & Biochem Parasitol, Liverpool L3 5QA, Merseyside, England.
RP Simpson, JA (reprint author), Canc Council Victoria, Canc Epidemiol Ctr, 1 Rathdowne St, Carlton, Vic 3053, Australia.
EM Julie.Simpson@cancervic.org.au
RI Hughes, Dyfrig/H-5252-2012; Simpson, Julie/P-7299-2014
OI Hughes, Dyfrig/0000-0001-8247-7459; Ward, Steve/0000-0003-2331-3192;
   Bojang, Kalifa/0000-0001-7506-0938; Simpson, Julie/0000-0002-2660-2013
CR Adedoyin A, 1998, CANCER CHEMOTH PHARM, V41, P133
   Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2
   Bates SJ, 2004, J INFECT DIS, V190, P1783, DOI 10.1086/425078
   Frye RF, 1997, CLIN PHARMACOL THER, V62, P365, DOI 10.1016/S0009-9236(97)90114-4
   GRECO WR, 1995, PHARMACOL REV, V47, P331
   Green MD, 1998, DRUG METAB DISPOS, V26, P860
   LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087
   Mirochnick M, 2001, CLIN PHARMACOL THER, V70, P24, DOI 10.1067/mcp.2001.115891
   Mirochnick M, 1999, ANTIMICROB AGENTS CH, V43, P2586
   PETERSEN E, 1991, J TROP MED HYG, V94, P199
   PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018
   Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860
   Simpson JA, 2001, T ROY SOC TROP MED H, V95, P347, DOI 10.1016/S0035-9203(01)90178-6
   Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624
   Strassburg CP, 2002, GUT, V50, P259, DOI 10.1136/gut.50.2.259
   Veenendaal J R, 1988, Chemotherapy, V34, P275
   WATKINS WM, 1987, J PHARM PHARMACOL, V39, P261
   Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1
   *WHO, 2000, 200133 WHOCDSRBM
   *WHO, 2001, ANT DRUG COMB THER R
   Winstanley P, 1997, T ROY SOC TROP MED H, V91, P322, DOI 10.1016/S0035-9203(97)90093-6
   WINSTANLEY PA, 1992, BRIT J CLIN PHARMACO, V33, P143
   2000, T R SOC TROP MED H S, V1, P94
NR 23
TC 19
Z9 20
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0306-5251
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD MAR
PY 2006
VL 61
IS 3
BP 289
EP 300
DI 10.1111/j.1365-2125.2005.02567.x
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 013PH
UT WOS:000235420800007
PM 16487222
OA No
DA 2017-08-15
ER

PT J
AU Holland, MJ
   Faal, N
   Sarr, I
   Joof, H
   Laye, M
   Cameron, E
   Pemberton-Pigott, F
   Dockrell, HM
   Bailey, RL
   Mabey, DCW
AF Holland, MJ
   Faal, N
   Sarr, I
   Joof, H
   Laye, M
   Cameron, E
   Pemberton-Pigott, F
   Dockrell, HM
   Bailey, RL
   Mabey, DCW
TI The frequency of Chlamydia trachomatis major outer membrane
   protein-specific CD8(+) T lymphocytes in active trachoma is associated
   with current ocular infection
SO INFECTION AND IMMUNITY
LA English
DT Article
ID HLA-CLASS-I; ENDEMIC POPULATION; CD8-T-CELL MEMORY; CD4-T-CELL HELP;
   GENE-EXPRESSION; CELLS RECOGNIZE; GENITAL-TRACT; RESPONSES; PEPTIDES;
   ANTIGENS
AB Chlamydia-specific cytotoxic T lymphocytes are able to control model infections but may be implicated in disease pathogenesis. HLA-A2 peptide tetramers to Chlamydia trachomatis major outer membrane protein 258-266 (MOMP258-266) and MOMP260-268 were used to characterize HLA class I-restricted CD8(+) T cells in Gambian children aged 4 to 15 years with clinical signs of active trachoma and/or infection with C. trachomatis. The frequencies of circulating HLA-A2 tetramer binding cells (TBC) were determined in whole blood samples by flow cytometric analysis. Initial screening of subjects with an anti-HLA-A2 antibody confirmed the presence of either HLA-A2 or HLA-A28. These were subsequently further divided by molecular subtyping. The C. trachomatis-specific HLA-A2 peptide tetramers were able to bind T cells with receptors from subjects which were restricted by either the HLA-A2 or the HLA-A28 restriction element. In this population, the median value of C. trachomatis-specific CD8(+) T cells was 0.02%, with frequencies of up to 3.71% of CD8(+) T cells reactive with a single tetramer in a minority of subjects. TBC were detected more often in subjects who were infected at the ocular surface, and their presence was associated with infection episodes of longer duration. Detection of C. trachomatis-specific TBC was not associated with the presence of disease or with the estimated load of ocular C. trachomatis infection at the time of sample collection. High frequencies of C. trachomatis-specific cells did not predict subsequent appearance or resolution of the clinical disease signs of active trachoma.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Kerewan Dist Hlth Ctr, Natl Eye Care Programme, Kerewan, Gambia.
RP London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM Martin.Holland@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Dockrell, Hazel/0000-0003-1869-9107
FU Medical Research Council [MC_U190081961]
CR ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Appel H, 2004, ARTHRITIS RES THER, V6, pR521, DOI 10.1186/ar122
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BEATTY PR, 1994, J IMMUNOL, V153, P4588
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Carralot JP, 2005, INT IMMUNOL, V17, P591, DOI 10.1093/intimm/dxh240
   Chen SF, 2004, J INFECT DIS, V189, P1619, DOI 10.1086/383249
   Conway DJ, 1996, J INFECT DIS, V174, P643
   Doytchinova I, 2003, ORG BIOMOL CHEM, V1, P2648, DOI 10.1039/b300707c
   Fling SP, 2001, P NATL ACAD SCI USA, V98, P1160, DOI 10.1073/pnas.98.3.1160
   Gervassi AL, 2004, J IMMUNOL, V173, P6905
   Gervassi AL, 2003, J IMMUNOL, V171, P4278
   Ho TD, 2005, INFECT IMMUN, V73, P905, DOI 10.1128/IAI.73.2.905-911.2005
   Holland MJ, 1997, CLIN EXP IMMUNOL, V107, P44, DOI 10.1046/j.1365-2249.1997.2511129.x
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Kim SK, 2000, J IMMUNOL, V165, P7285
   Kim SK, 1999, J IMMUNOL, V162, P6855
   Kim SK, 2001, CURR OPIN IMMUNOL, V13, P429, DOI 10.1016/S0952-7915(00)00237-5
   Kuon W, 2001, J IMMUNOL, V167, P4738
   Lampe MF, 1998, INFECT IMMUN, V66, P5457
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   MacDonald KS, 2001, IMMUNOL LETT, V79, P151, DOI 10.1016/S0165-2478(01)00277-2
   Mahdi OSM, 2001, CLIN EXP IMMUNOL, V123, P68, DOI 10.1046/j.1365-2249.2001.01416.x
   Mathews SA, 1999, FEBS LETT, V458, P354, DOI 10.1016/S0014-5793(99)01182-5
   Matyszak MK, 2004, INFECT IMMUN, V72, P4357, DOI 10.1128/IAI.72.8.4357-4367.2004
   REACHER MH, 1991, OPHTHALMOLOGY, V98, P334
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Sidney J, 2001, HUM IMMUNOL, V62, P1200, DOI 10.1016/S0198-8859(01)00319-6
   STARNBACH MN, 1994, J IMMUNOL, V153, P5183
   Steele LN, 2004, J IMMUNOL, V173, P6327
   Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317
   Suvas S, 2004, J IMMUNOL, V172, P4123
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   VanVoorhis WC, 1996, J INFECT DIS, V174, P647
   Wong P, 2003, ANNU REV IMMUNOL, V21, P29, DOI 10.1146/annurev.immunol.21.120601.141114
NR 36
TC 9
Z9 10
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 2006
VL 74
IS 3
BP 1565
EP 1572
DI 10.1128/IAI.74.3.1565-1572.2006
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 019ED
UT WOS:000235817500014
PM 16495527
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Bowman, RJC
   Faal, H
   Aryee, EAN
   Ikumapayi, UN
   Alexander, NDE
   Adegbola, RA
   Mahey, DCW
   Foster, A
   Johnson, GJ
   Bailey, RL
AF Burton, MJ
   Bowman, RJC
   Faal, H
   Aryee, EAN
   Ikumapayi, UN
   Alexander, NDE
   Adegbola, RA
   Mahey, DCW
   Foster, A
   Johnson, GJ
   Bailey, RL
TI The long-term natural history of trachomatous trichiasis in the Gambia
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SURGERY; COMMUNITY; INFECTION; TRIAL
AB PURPOSE. Trachoma is the leading infectious cause of blindness. However, there are few data on the natural history of trachomatous trichiasis to guide program planning or that investigate its pathogenesis.
   METHODS. A cohort of Gambians with trichiasis in one or both eyes who had declined surgery was observed. Clinical examinations were performed at baseline and 4 years later. Conjunctival swab samples were collected for Chlamydia trachomatis PCR and bacteriology.
   RESULTS. One hundred fifty-four people were examined at baseline and 4 years later (241 nonsurgical eyes). At baseline 124 (52%) eyes had major trichiasis (5+ lashes), 75 (31%) minor trichiasis (1-4 lashes), and 42 (17%) no trichiasis. By 4 years, trichiasis had developed in 12 (29%) of 42 previously unaffected eyes. Minor trichiasis progressed to major in 28 (37%) of 75 eyes. New corneal opacification more commonly developed in eyes that had major (10%) compared to minor (5%) trichiasis at baseline. Bacterial infection was common (23%), becoming more frequent with increasing trichiasis. C. trachomatis infection was rare (1%). Conjunctival inflammation was common (29%) and was associated with progressive trichiasis and corneal opacification.
   CONCLUSIONS. Trichiasis progressed in the long-term in this environment, despite a low prevalence of C trachomatis. Blinding corneal opacification develops infrequently, unless major trichiasis is present. Epilation and early surgery need to be formally compared for the management of minor trichiasis. The pathologic correlates and promoters of conjunctival inflammation need to be investigated.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   CCBRT Disabil Hosp, Dar Es Salaam, Tanzania.
   Inst Ophthalmol, Div Epidemiol & Int Eye Hlth, London, England.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [G0700837]; Wellcome Trust
CR Bowman RJC, 2000, TROP MED INT HEALTH, V5, P528, DOI 10.1046/j.1365-3156.2000.00605.x
   Bowman RJC, 2002, INVEST OPHTH VIS SCI, V43, P936
   Bowman RJC, 2002, BRIT J OPHTHALMOL, V86, P339, DOI 10.1136/bjo.86.3.339
   Bowman RJC, 2001, OPHTHALMOLOGY, V108, P2219, DOI 10.1016/S0161-6420(01)00645-5
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P575, DOI 10.1136/bjo.2004.055996
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   BURTON MJ, 2005, IN PRESS BR J OPHTHA
   DAWSON CR, 1990, WHAT CLIN SIGNS ARE, P271
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   EL-ASRAR A M A, 1989, British Journal of Ophthalmology, V73, P276, DOI 10.1136/bjo.73.4.276
   Leonardi A, 2003, INVEST OPHTH VIS SCI, V44, P3052, DOI 10.1167/iovs.02-0766
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   Smith VA, 2001, BRIT J OPHTHALMOL, V85, P147, DOI 10.1136/bjo.85.2.147
   TAYLOR HR, 1987, B WORLD HEALTH ORGAN, V65, P485
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   West ES, 2005, INVEST OPHTH VIS SCI, V46, P447, DOI 10.1167/iovs.04-0600
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   World_Health_Organization, 1998, GLOB EL BLIND TRACH
   Xue ML, 2003, INVEST OPHTH VIS SCI, V44, P2020, DOI 10.1167/iovs.02-0565
NR 23
TC 28
Z9 28
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2006
VL 47
IS 3
BP 847
EP 852
DI 10.1167/iovs.05-0714
PG 6
WC Ophthalmology
SC Ophthalmology
GA 020FR
UT WOS:000235894300014
PM 16505016
OA No
DA 2017-08-15
ER

PT J
AU Nuvor, SV
   van der Sande, M
   Rowland-Jones, S
   Whittle, H
   Jaye, A
AF Nuvor, SV
   van der Sande, M
   Rowland-Jones, S
   Whittle, H
   Jaye, A
TI Natural killer cell function is well preserved in asymptomatic human
   immunodeficiency virus type 2 (HIV-2) infection but similar to that of
   HIV-1 infection when CD4 T-cell counts fall
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INDIVIDUALS; DISEASE; CYTOTOXICITY; LYMPHOCYTES; PROGRESSION;
   INTERFERON; CHEMOKINES; RESISTANCE; PHENOTYPE; RESPONSES
AB Natural killer (NK) cells are potent effectors of natural immunity and their activity prevents human immunodeficiency virus type I (HIV-1) viral entry and viral replication. We sought to determine whether NK immune responses are associated with different clinical course of HIV-1 and HIV-2 infections. A cross-sectional analysis of NK cell responses was undertaken in 30 HIV-1 and 30 HfV-2 subjects in each of three categories of CD4(+)-T-cell counts (> 500, 200 to 500, and < 200 cells/mu l) and in 50 HIV-uninfected control subjects. Lytic activity and gamma interferon (IFN-gamma) secretion were measured by chromium release and enzyme-linked immunospot assays, respectively. Flow cytometry was used to assess intracellular cytokines and chemokines. Levels of NK cytotoxicity were significantly higher in HIV-2 than in HIV-1 infections in subjects with high CD4(+)-T-cell counts and were similar to that of the healthy controls. In these HIV-2 subjects, cytolytic activity was positively correlated to NK cell count and inversely related to plasma viremia. Levels of intracellular MIP-1 beta, RANTES, tumor necrosis factor alpha, and IFN-gamma produced by NK CD56(bright) cells were significantly higher in HIV-2- than HIV-1-infected subjects with high CD4(+)-T-cell counts but fell to similar levels as CD4 counts dropped. The data suggest efficient cytolytic and chemokine-suppressive activity of NK cells early in HIV-2 infection, which is associated with high CD4(+) T-cell counts. Enhancement of these functions may be important in immune-based therapy to control HIV disease.
C1 MRC Labs, Banjul, Gambia.
RP Jaye, A (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM ajaye@mrc.gm
FU Medical Research Council [MC_U190081958, MC_U190085854]
CR AHMAD A, 1995, J ACQ IMMUN DEF SYND, V10, P115
   Ahmad R, 2001, J CLIN IMMUNOL, V21, P227, DOI 10.1023/A:1011087132180
   Berry N, 1998, J Hum Virol, V1, P457
   Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189
   Bonaparte MI, 2003, AIDS, V17, P487, DOI 10.1097/01.aids.0000050814.06065.23
   Bruunsgaard H, 1997, SCAND J IMMUNOL, V46, P91, DOI 10.1046/j.1365-3083.1997.d01-98.x
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
   DUVALL MG, UNPUB DELAEYED DIS P
   Fehniger TA, 1998, J IMMUNOL, V161, P6433
   Harrison AM, 1999, AM J RESP CRIT CARE, V159, P1918
   HU PF, 1995, J ACQ IMMUN DEF SYND, V10, P331
   Hultstrom AL, 2004, IMMUNOL LETT, V91, P155, DOI 10.1016/j.imlet.2003.11.012
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   KHATTAK A, 1998, J PUBLIC TRANSPORTAT, V2, P1
   Kottilil S, 2003, J INFECT DIS, V187, P1038, DOI 10.1086/368222
   LANDAY AL, 1993, CLIN IMMUNOL IMMUNOP, V69, P106, DOI 10.1006/clin.1993.1157
   LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100
   Meier UC, 2005, J VIROL, V79, P12365, DOI 10.1128/JVI.79.19.12365-12374.2005
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004
   Oliva A, 1998, J CLIN INVEST, V102, P223, DOI 10.1172/JCI2323
   RATCLIFFE LT, 1994, CLIN EXP IMMUNOL, V97, P373
   SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567
   SchartonKersten TM, 1997, CURR OPIN IMMUNOL, V9, P44, DOI 10.1016/S0952-7915(97)80157-4
   SCHICK A, 1999, STAT INFERENCE STOCH, V2, P69, DOI 10.1023/A:1009950813472
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Scott-Algara D, 2003, J IMMUNOL, V171, P5663
   Scott-Algara Daniel, 2002, Current Molecular Medicine (Hilversum), V2, P757, DOI 10.2174/1566524023361781
   TRINCHIERI G, 1978, J EXP MED, V147, P1314, DOI 10.1084/jem.147.5.1314
   van der Loeff MFS, 2002, AIDS, V16, P1775
   vanderEnde ME, 1996, AIDS, V10, P1649
   Weber K, 2000, IMMUNOBIOLOGY, V202, P172
   WHITE DJG, 1994, XENOTRANSPLANTATION, V2, P1
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 38
TC 19
Z9 19
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAR
PY 2006
VL 80
IS 5
BP 2529
EP 2538
DI 10.1128/JVI.80.5.2529-2538.2006
PG 10
WC Virology
SC Virology
GA 013CY
UT WOS:000235388400045
PM 16474159
OA No
DA 2017-08-15
ER

PT J
AU Archer, HA
   van der Sande, M
   Hoyer, P
   Goetghebuer, T
   McAdam, KPWJ
   Vester, U
   Newport, MJ
AF Archer, HA
   van der Sande, M
   Hoyer, P
   Goetghebuer, T
   McAdam, KPWJ
   Vester, U
   Newport, MJ
TI Oedema with proteinuria in Gambian children - a descriptive study
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE nephrotic syndrome; haematuria; nephritis; outcome; sub-Saharan Africa
ID CHILDHOOD NEPHROTIC SYNDROME; AFRICAN CHILDREN; DISEASE;
   GLOMERULONEPHRITIS; MANAGEMENT; STATEMENT
AB The clinical syndrome of oedema with proteinuria is an important cause of paediatric morbidity in sub-Saharan Africa. The aim of this study was to assess its prevalence, clinical presentation and outcome in The Gambia, where the syndrome is perceived to be common but has not previously been studied. All children admitted with oedema and proteinuria to three hospitals in the Western region of The Gambia between January 1995 and June 1998 were identified retrospectively. Hospital records were retrieved to assess admission characteristics. All traceable children were clinically reviewed, and urinalysis was performed between 3 months and 4 years after admission. Two hundred and two children who presented with proteinuria and oedema were identified, accounting for 1.2% of paediatric hospital admissions in The Gambia. Haematuria on dipstick testing was common (76.5%). Of 39 children who were traced, four (10.3%) were dead. Eighteen of the remaining 35 (51.4%) had proteinuria at follow up. Older age at first presentation was significantly associated with increased long-term morbidity. These preliminary data suggest that oedema with proteinuria may be common and could cause long-term morbidity and mortality in Gambian children. Further studies on its aetiology and treatment are warranted.
C1 Univ Sussex, Brighton & Sussex Med Sch, Brighton BN1 9XP, E Sussex, England.
   MRC Labs, Banjul, Gambia.
   Univ Essen Gesamthsch, Dept Paediat Nephrol, Essen, Germany.
RP Newport, MJ (reprint author), Univ Sussex, Brighton & Sussex Med Sch, Brighton BN1 9XP, E Sussex, England.
EM m.j.newport@bsms.ac.uk
CR ABDURRAHMAN MB, 1990, Q J MED, V75, P563
   ADHIKARI M, 1983, J TROP MED HYG, V86, P223
   BARRATT TM, 1994, ARCH DIS CHILD, V70, P151
   Brodehl J, 1996, CLIN IMMUNOTHER, V5, P175
   COOVADIA HM, 1993, ANN TROP PAEDIATR, V13, P79
   COOVADIA HM, 1999, PEDIAT NEPHROLOGY, P1362
   HENDRICKSE R G, 1963, East Afr Med J, V40, P186
   Hofmann W, 1989, LAB MED, V13, P470
   KINUTHIA DMW, 1981, E AFR MED J, V58, P818
   Lehrnbecher T, 1998, PEDIATR NEPHROL, V12, P290
   MCADAM KPWJ, 1978, PAPUA NEW GUINEA MED, V21, P69
   MCGREGOR IA, 1987, PARASITOLOGY, V94, pS159
   MORELMAROGER I, 1975, BRIT MED J, V1, P541
   Pham PTT, 2000, KIDNEY INT, V57, P1, DOI 10.1046/j.1523-1755.2000.00806.x
   POWELL KC, 1977, AUST NZ J MED, V7, P243, DOI 10.1111/j.1445-5994.1977.tb03680.x
   SEGGIE J, 1984, Q J MED, V53, P109
   Thomson PD, 1997, PEDIATR NEPHROL, V11, P508
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   WHITE RHR, 1973, NEPHRON, V11, P147, DOI 10.1159/000180227
   Williams CL, 2002, CIRCULATION, V106, P143, DOI 10.1161/01.CIR.0000019555.61092.9E
   WING AJ, 1972, T R SOC TROP MED HYG, V65, P543
NR 21
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0931-041X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD MAR
PY 2006
VL 21
IS 3
BP 339
EP 343
DI 10.1007/s00467-005-2123-2
PG 5
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 013ZN
UT WOS:000235448600007
PM 16404628
OA No
DA 2017-08-15
ER

PT J
AU Junge, S
   Palmer, A
   Greenwood, BM
   Mulholland, EK
   Weber, MW
AF Junge, S
   Palmer, A
   Greenwood, BM
   Mulholland, EK
   Weber, MW
TI The spectrum of hypoxaemia in children admitted to hospital in The
   Gambia, West Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE hypoxaemia; acute lower respiratory infection; malaria; outcome
   predictor; the Gambia
ID RESPIRATORY-TRACT INFECTION; DEVELOPING-COUNTRIES; MENINGITIS;
   ADMISSIONS; PREDICTORS; OXYGEN
AB Hypoxia predicts mortality in children with acute lower respiratory infections (ALRIs). We investigated the prevalence and predictive value of hypoxia in ALRI and other acute infectious diseases.
   We studied the spectrum of hypoxaemia in 4047 children admitted to a tertiary hospital in The Gambia. Oxygen saturation was measured shortly after admission. Severe hypoxaemia was defined as an oxygen saturation below 90%.
   5.8% of all admissions had severe hypoxaemia. Prevalence of hypoxaemia varied between disease groups: it was 11.7% in ALRI cases, 16.5% in neonates; 2.9% in malaria cases overall but 6.5% in cerebral malaria patients; and 2.7% in children with meningitis. Hypoxaemia predicted a poor outcome; the odds ratio for death among paediatric admissions overall was 7.45 [95% confidence intervals (CI) 5.40-10.29]. Surprisingly, it was lowest for children with ALRI [OR 3.53 (95% CI 1.13-10.59)], and higher for those with malaria 9.90 [95% CI 4.39-22.35].
   Hypoxaemia is common among Gambian children admitted to hospital and it is often associated with a poor outcome. A similar situation is likely in many other developing countries. Thus, equipment for measuring oxygen saturation, and facilities and equipment for effective oxygen delivery need to be made available in developing countries.
C1 Univ Zurich, Childrens Hosp, Zurich, Switzerland.
   Royal Victoria Hosp, Banjul, Gambia.
   MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   Childrens Hosp, Hannover Med Sch, Hannover, Germany.
RP Weber, MW (reprint author), WHO, CAH, Av Appia 20, CH-1211 Geneva, Switzerland.
EM weberm@who.int
CR Duke T, 2003, ARCH DIS CHILD, V88, P536, DOI 10.1136/adc.88.6.536
   Duke T, 2002, ARCH DIS CHILD, V86, P108, DOI 10.1136/adc.86.2.108
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   Lozano JM, 2001, INT J TUBERC LUNG D, V5, P496
   Maitland K, 2003, QJM-INT J MED, V96, P427, DOI 10.1093/qjmed/hcg077
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   O'Donovan DJ, 2004, ANTIOXID REDOX SIGN, V6, P169, DOI 10.1089/152308604771978471
   Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51
   Usen S, 2001, INT J TUBERC LUNG D, V5, P505
   Usen S, 1999, BRIT MED J, V318, P86
   WEBER MW, 1995, J PEDIATR-US, V127, P378, DOI 10.1016/S0022-3476(95)70067-6
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   Weber MW, 1997, ARCH DIS CHILD, V76, P310
   Weber MW, 1998, LANCET, V351, P1589, DOI 10.1016/S0140-6736(05)61160-9
   World Health Organization, 2004, MAJ CAUS DEATH CHILD
   World Health Organization, 1993, WHOARI9328
NR 16
TC 15
Z9 15
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2006
VL 11
IS 3
BP 367
EP 372
DI 10.1111/j.1365-3156.2006.01570.x
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 019NG
UT WOS:000235843200014
PM 16553917
OA No
DA 2017-08-15
ER

PT J
AU Gagneux, S
   DeRiemer, K
   Van, T
   Kato-Maeda, M
   de Jong, BC
   Narayanan, S
   Nicol, M
   Niemann, S
   Kremer, K
   Gutierrez, MC
   Hilty, M
   Hopewell, PC
   Small, PM
AF Gagneux, S
   DeRiemer, K
   Van, T
   Kato-Maeda, M
   de Jong, BC
   Narayanan, S
   Nicol, M
   Niemann, S
   Kremer, K
   Gutierrez, MC
   Hilty, M
   Hopewell, PC
   Small, PM
TI Variable host-pathogen compatibility in Mycobacterium tuberculosis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE coevolution; deletions; lineage; polymorphism; population
ID GENOMIC DELETIONS; GENETIC-STRUCTURE; COMPLEX STRAINS; SAN-FRANCISCO;
   BORN PERSONS; BCG; POPULATIONS; VACCINES; MARKERS; IMMUNITY
AB Mycobacterium tuberculosis remains a major cause of morbidity and mortality worldwide. Studies have reported human pathogens to have geographically structured population genetics, some of which have been linked to ancient human migrations. However, no study has addressed the potential evolutionary consequences of such longstanding human-pathogen associations. Here, we demonstrate that the global population structure of M. tuberculosis is defined by six phylogeographical lineages, each associated with specific, sympatric human populations. In an urban cosmopolitan environment, mycobacterial lineages were much more likely to spread in sympatric than in allopatric patient populations. Tuberculosis cases that did occur in allopatric hosts disproportionately involved high-risk individuals with impaired host resistance. These observations suggest that mycobacterial lineages are adapted to particular human populations. If confirmed, our findings have important implications for tuberculosis control and vaccine development.
C1 Inst Syst Biol, Seattle, WA 98103 USA.
   Stanford Univ, Med Ctr, Div Infect Dis & Geog Med, Stanford, CA 94305 USA.
   Univ Calif Davis, Sch Med, Davis, CA 95616 USA.
   San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA.
   Univ Calif San Francisco, San Francisco, CA 94110 USA.
   MRC Labs, Fajara, Gambia.
   Tuberculosis Res Ctr, Dept Immunol, Madras 600031, Tamil Nadu, India.
   Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   Natl Reference Ctr Mycobacteria, Forschungszentrum, D-23848 Borstel, Germany.
   Natl Inst Publ Hlth & Environm, Mycobacteria Reference Unit, NL-3720 BA Bilthoven, Netherlands.
   Swiss Trop Inst, CH-4002 Basel, Switzerland.
   Inst Pasteur, Mycobacteria Reference Lab, F-75724 Paris, France.
   Bill & Melinda Gates Fdn, Seattle, WA 98102 USA.
RP Gagneux, S (reprint author), Inst Syst Biol, 1441 N 34th St, Seattle, WA 98103 USA.
EM sgagneux@systemsbiology.org
RI Gutierrez, Cristina/B-5597-2012; Niemann, Stefan/C-9327-2011; de Jong,
   Bouke/A-3636-2013
OI Gutierrez, Cristina/0000-0002-5567-5908; de Jong,
   Bouke/0000-0002-1017-4675; DeRiemer, Kathryn/0000-0002-8375-7505; Nicol,
   Mark/0000-0002-1366-4805; Gagneux, Sebastien/0000-0001-7783-9048
FU FIC NIH HHS [K01 TW000001, K01 TW000001-07]; Wellcome Trust
CR Agostini HT, 1997, P NATL ACAD SCI USA, V94, P14542, DOI 10.1073/pnas.94.26.14542
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211
   Baker L, 2004, EMERG INFECT DIS, V10, P1568
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Burgos M, 2003, J INFECT DIS, V188, P1878, DOI 10.1086/379895
   Chin DP, 1998, AM J RESP CRIT CARE, V158, P1797
   Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Gagneux SP, 2002, J INFECT DIS, V185, P618, DOI 10.1086/339010
   Gutierrez C, 2005, PLOS PATHOG, V1, P1, DOI DOI 10.1371/JOURNAL.PPAT.0010005
   Hirsh AE, 2004, P NATL ACAD SCI USA, V101, P4871, DOI 10.1073/pnas.0305627101
   Jasmer RM, 1999, ANN INTERN MED, V130, P971
   Jasmer RM, 1997, INT J TUBERC LUNG D, V1, P536
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607
   Marmiesse M, 2004, MICROBIOL-SGM, V150, P483, DOI 10.1099/mic.0.26662-0
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Monot M, 2005, SCIENCE, V308, P1040, DOI 10.1126/science.1109759
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   MUSSER JM, 1990, REV INFECT DIS, V12, P75
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666
   Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311
   SELVIN S, 1998, MONOGRAPHS EPIDEMIOL, V28, P385
   Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869
   Tsolaki AG, 2005, J CLIN MICROBIOL, V43, P3185, DOI 10.1128/JCM.43.7.3185-3191.2005
   Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101
   van Loo IHM, 2002, MICROBIOL-SGM, V148, P2011
   World Health Organization, 2005, GLOB TUB CONTR SURV
   Wirth T, 2004, P NATL ACAD SCI USA, V101, P4746, DOI 10.1073/pnas.0306629101
   Woolhouse MEJ, 2002, NAT GENET, V32, P569, DOI 10.1038/ng1202-569
NR 32
TC 505
Z9 516
U1 6
U2 59
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 21
PY 2006
VL 103
IS 8
BP 2869
EP 2873
DI 10.1073/pnas.0511240103
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015MG
UT WOS:000235554900070
PM 16477032
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Holland, MJ
   Jeffries, D
   Mabey, DCW
   Bailey, RL
AF Burton, MJ
   Holland, MJ
   Jeffries, D
   Mabey, DCW
   Bailey, RL
TI Conjunctival chlamydial 16S ribosomal RNA expression in trachoma: Is
   chlamydial metabolic activity required for disease to develop?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID SEQUENCE-BASED AMPLIFICATION; POLYMERASE CHAIN-REACTION;
   ANTIBIOTIC-TREATMENT; GAMBIAN COMMUNITY; GENE-EXPRESSION; INFECTION;
   DIAGNOSIS; AZITHROMYCIN; PATHOGENESIS
AB Background. Nucleic acid amplification testing frequently detects conjunctival Chlamydia trachomatis infection in subjects without clinical signs of trachoma. It is unclear whether such subjects are actually infected. We measured chlamydial 16S ribosomal RNA ( rRNA) expression, a marker of chlamydial metabolic activity, in comparison with the quantitation of a chlamydial DNA target in subjects exposed to trachoma.
   Methods. Subjects from 2 Gambian villages where trachoma was endemic were examined. Conjunctival samples were tested for the presence of C. trachomatis DNA using a quantitative real-time polymerase chain reaction ( PCR) assay for the omp1 gene and for the expression of C. trachomatis 16S rRNA using a 1-step, real-time reverse-transcriptase PCR assay.
   Results. A total of 248 people were examined. The prevalence of clinically active trachoma was 16.9%. C. trachomatis was detected in 19.8% and 6.8% of subjects by the omp1 and 16S rRNA assays, respectively. For subjects with positive results for both tests, the number of copies of 16S rRNA was similar to 100-fold greater than the number of copies of the omp1 gene. In samples from subjects in whom the omp1 gene was detected in the absence of 16S rRNA, typically only a few copies of omp1 were present. The expression of 16S rRNA was strongly associated with the presence of clinical signs of active trachoma.
   Conclusions. The use of 16S rRNA expression for the detection of chlamydial metabolic activity appears to usefully discriminate established infections from the inoculation of the conjunctiva with dead or subviable organisms, which probably occurs frequently in settings in which trachoma is endemic. The data support conclusions from primate challenge studies that live Chlamydiae species or antigens derived from them are needed to provoke the clinical signs of disease.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Dept Trop & Infect Dis, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Dept Trop & Infect Dis, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
FU Medical Research Council [MC_U190081961]; Wellcome Trust
CR AN Q, 1992, J CLIN MICROBIOL, V30, P2814
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743
   BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   CHEEMA MA, 1991, AM J MED SCI, V302, P261, DOI 10.1097/00000441-199111000-00001
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   ENGEL JN, 1987, J BACTERIOL, V169, P5678
   HUDSON AP, 1992, CURR EYE RES, V11, P279, DOI 10.3109/02713689209001780
   Mathews SA, 1999, FEBS LETT, V458, P354, DOI 10.1016/S0014-5793(99)01182-5
   Miller K, 2004, OPHTHAL EPIDEMIOL, V11, P255, DOI 10.1080/09286580490514577
   Morre SA, 1996, J CLIN MICROBIOL, V34, P3108
   Morre SA, 1998, J CLIN PATHOL-MOL PA, V51, P149
   MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   TAYLOR HR, 1987, J IMMUNOL, V138, P3023
   TAYLOR HR, 1990, INFECT IMMUN, V58, P3061
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Ward ME, 1995, APMIS, V103, P769
   WHO, GLOB EL BLIND TRACH
NR 29
TC 14
Z9 15
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2006
VL 42
IS 4
BP 463
EP 470
DI 10.1086/499814
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 004HO
UT WOS:000234742800005
PM 16421789
OA No
DA 2017-08-15
ER

PT J
AU Flanagan, KL
   Buckley-Sharp, M
   Doherty, T
   Whitty, CJM
AF Flanagan, KL
   Buckley-Sharp, M
   Doherty, T
   Whitty, CJM
TI Quinine levels revisited: the value of routine drug level monitoring for
   those on parenteral therapy
SO ACTA TROPICA
LA English
DT Article
DE quinine; levels; monitoring; toxicity; P falciparum malaria
ID SEVERE FALCIPARUM-MALARIA; ACUTE-RENAL-FAILURE; CEREBRAL MALARIA;
   AFRICAN CHILDREN; ALPHA-1-ACID GLYCOPROTEIN; PLASMA-CONCENTRATION;
   INTRAVENOUS QUININE; PHARMACOKINETICS; BINDING; REGIMENS
AB Parenteral quinine is the most frequently used first line treatment for severe Plasmodium falciparum malaria in the developed world. Quinine is known to have a number of toxic side effects including cardiotoxicity, ototoxicity and ocular toxicity. Many therefore advocate routine monitoring of quinine levels for patients receiving parenteral therapy. This paper reviews current evidence oil the usefulness of quinine level monitoring in the context of 73 adult patients with severe P. falciparum malaria managed by the Hospital for Tropical Diseases in London. Combining data from these patients with a comprehensive literature review, we conclude that routine quinine level monitoring in all patients receiving parenteral therapy is seldom appropriate. (c) 2005 Elsevier B.V. All rights reserved.
C1 UCL Hosp, Hosp Trop Dis, London, England.
   UCL Hosp, Dept Biochem Med, London, England.
RP Flanagan, KL (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM kflanagan@mrc.gm
RI Whitty, Christopher/C-7740-2012
OI Whitty, Christopher/0000-0002-6076-5027
CR Assimadi JK, 2002, ARCH PEDIATRIE, V9, P587, DOI 10.1016/S0929-693X(01)00925-3
   Bethell DB, 1996, T ROY SOC TROP MED H, V90, P266, DOI 10.1016/S0035-9203(96)90241-2
   Bonington A, 1996, T ROY SOC TROP MED H, V90, P305, DOI 10.1016/S0035-9203(96)90264-3
   Claessen FAP, 1998, TROP MED INT HEALTH, V3, P482
   KARLSSON KK, 1990, T ROY SOC TROP MED H, V84, P765, DOI 10.1016/0035-9203(90)90069-Q
   Langford NJ, 2003, BRIT J CLIN PHARMACO, V56, P576, DOI 10.1046/j.1365-2125.2003.01921.x
   Lochhead J, 2003, J INFECT DIS, V187, P1342, DOI 10.1086/374058
   Lockwood DNJ, 2004, BRIT MED J, V329, P1020, DOI 10.1136/bmj.329.7473.1020
   MANSOR SM, 1991, BRIT J CLIN PHARMACO, V32, P317
   Newton P, 1999, T ROY SOC TROP MED H, V93, P69, DOI 10.1016/S0035-9203(99)90184-0
   PASVOL G, 1991, AM J TROP MED HYG, V45, P702
   Prasad RS, 2003, EUR J EMERG MED, V10, P353, DOI 10.1097/01.mej.0000092270.10491.42
   RHEEDER P, 1991, S AFR MED J, V79, P563
   SCHAPIRA A, 1993, T ROY SOC TROP MED H, V87, P299, DOI 10.1016/0035-9203(93)90136-E
   SHANN F, 1985, J PEDIATR-US, V106, P506, DOI 10.1016/S0022-3476(85)80692-2
   SILAMUT K, 1991, BRIT J CLIN PHARMACO, V32, P311
   SILAMUT K, 1985, AM J TROP MED HYG, V34, P681
   Sukontason K, 1996, TROP MED INT HEALTH, V1, P236
   Viera J, 2001, THER DRUG MONIT, V23, P612
   WHITE NJ, 1983, AM J TROP MED HYG, V32, P456
   WHITE NJ, 1982, AM J MED, V73, P564, DOI 10.1016/0002-9343(82)90337-0
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   WINSTANLEY P, 1993, T ROY SOC TROP MED H, V87, P201, DOI 10.1016/0035-9203(93)90494-B
   WINSTANLEY PA, 1992, BRIT J CLIN PHARMACO, V33, P575
NR 24
TC 10
Z9 11
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD FEB
PY 2006
VL 97
IS 2
BP 233
EP 237
DI 10.1016/j.actatropica.2005.11.006
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 009IL
UT WOS:000235105000016
PM 16387280
OA No
DA 2017-08-15
ER

PT J
AU Demissie, A
   Leyten, EMS
   Abebe, M
   Wassie, L
   Aseffa, A
   Abate, G
   Fletcher, H
   Owiafe, P
   Hill, PC
   Brookes, R
   Ottenhoff, THM
   Andersen, P
   Doherty, TM
AF Demissie, A
   Leyten, EMS
   Abebe, M
   Wassie, L
   Aseffa, A
   Abate, G
   Fletcher, H
   Owiafe, P
   Hill, PC
   Brookes, R
   Ottenhoff, THM
   Andersen, P
   Doherty, TM
CA VACSEL Study Grp
TI Recognition of stage-specific mycobacterial antigens differentiates
   between acute and latent infections with Mycobacterium tuberculosis
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID T-CELL RESPONSES; ACTIVE TUBERCULOSIS; ALPHA-CRYSTALLIN; PROTEIN;
   ESAT-6; CONTACTS; ENUMERATION; DIAGNOSIS; ANTIBODY; GENE
AB Mycobacterium tuberculosis is estimated to infect 80 to 100 million people annually, the majority of whom do not develop clinical tuberculosis (TB) but instead maintain the infection in a latent state. These individuals generally become positive in response to a tuberculin skin test and may develop clinical TB at a later date, particularly if their immune systems are compromised. Latently infected individuals are interesting for two reasons. First, they are an important reservoir of M. tuberculosis, which needs to be considered for TB control. Second, if detected prior to recrudescence of the disease, they represent a human population that is making a protective immune response to M. tuberculosis, which is very important for defining correlates of protective immunity. In this study, we show that while responsiveness to early secretory antigenic target 6 is a good marker for M. tuberculosis infection, a strong response to the 16-kDa Rv2031c antigen (HspX or alpha-crystallin) is largely restricted to latently infected individuals, offering the possibility of differential immunodiagnosis of, or therapeutic vaccination against, TB.
C1 Armauer Hansen Res Inst, Addis Ababa, Ethiopia.
   Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Infect Dis, NL-2333 ZA Leiden, Netherlands.
   MRC Labs, TB Div, Fajara, Gambia.
   UCL Royal Free & Univ Coll Med Sch, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, London, England.
   Statens Serum Inst, Dept TB Immunol, DK-2300 Copenhagen, Denmark.
RP Doherty, TM (reprint author), Statens Serum Inst, Dept Infect Dis Immunol, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM TMD@ssi.dk
RI Fletcher, Helen/D-1470-2011; Aseffa, Abraham/J-3248-2016
OI Aseffa, Abraham/0000-0002-8028-1150; Rook, Graham/0000-0002-8041-8110;
   Zumla, Alimuddin/0000-0002-5111-5735; Fletcher,
   Helen/0000-0002-0435-1006; Kwasi Owiafe, Patrick/0000-0002-4287-3577
CR Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448
   BOTHAMLEY GH, 1992, THORAX, V47, P270, DOI 10.1136/thx.47.4.270
   Bothamley GH, 2004, CLIN DIAGN LAB IMMUN, V11, P942, DOI 10.1128/CDLI.11.5.942-951.2004
   BOTHAMLEY GH, 1992, J INFECT DIS, V166, P182
   Brock I, 2001, INT J TUBERC LUNG D, V5, P462
   Brodin P, 2004, TRENDS MICROBIOL, V12, P500, DOI 10.1016/j.tim.2004.09.007
   Cahn Pedro, 2003, J Int Assoc Physicians AIDS Care (Chic), V2, P106, DOI 10.1177/154510970300200303
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008
   Cole ST, 1998, NATURE, V393, P537
   Davidow A, 2005, INFECT IMMUN, V73, P6846, DOI 10.1128/IAI.73.10.6846-6851.2005
   Demissie A, 2004, J IMMUNOL, V172, P6938
   Demissie A, 1999, INFECT IMMUN, V67, P5967
   Doherty TM, 2005, J IMMUNOL METHODS, V298, P129, DOI 10.1016/j.jim.2005.01.013
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002
   Fletcher HA, 2004, IMMUNOLOGY, V112, P669, DOI 10.1111/j.1365-2567.2004.01922.x
   Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0
   Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100
   Hu YM, 1999, J BACTERIOL, V181, P1380
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1
   LEE BY, 1992, INFECT IMMUN, V60, P2066
   Manca C, 2004, INFECT IMMUN, V72, P5511, DOI 10.1128/IAI.72.9.5511-5514.2004
   Mehrotra J, 2001, INT J MED MICROBIOL, V291, P171, DOI 10.1078/1438-4221-00113
   Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001
   Ordway DJ, 2004, J INFECT DIS, V190, P756, DOI 10.1086/422532
   Ormerod LP, 2004, THORAX, V59, P921, DOI 10.1136/thx.2004.029991
   Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640
   Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200
   Seah GT, 2001, SCAND J INFECT DIS, V33, P106, DOI 10.1080/003655401750065472
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498
   Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710
   THEISEN M, 1995, CLIN DIAGN LAB IMMUN, V2, P30
   Ulrichs T, 2000, INFECT IMMUN, V68, P6073, DOI 10.1128/IAI.68.10.6073-6076.2000
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205
   *WHO, 2002, WHOCDSTB2001287
   Wilkinson RJ, 1998, SCAND J IMMUNOL, V48, P403
   Yuan Y, 1998, P NATL ACAD SCI USA, V95, P9578, DOI 10.1073/pnas.95.16.9578
   Yuan Ying, 1996, Journal of Bacteriology, V178, P4484
   Zu Bentrup Kerstin Honer, 2001, Trends in Microbiology, V9, P597
NR 45
TC 133
Z9 147
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD FEB
PY 2006
VL 13
IS 2
BP 179
EP 186
DI 10.1128/CVI.13.2.179-186.2006
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 015GG
UT WOS:000235539300003
PM 16467323
OA No
DA 2017-08-15
ER

PT J
AU Walther, M
AF Walther, Michael
TI Advances in vaccine development against the pre-erythrocytic stage of
   Plasmodium falciparum malaria
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE DNA; liver stage; malaria; pre-erythrocytic; prime-boost; vaccine; viral
   vector
ID HEPATITIS-B-VIRUS; T-CELL EPITOPE; CIRCUMSPOROZOITE PROTEIN VACCINE;
   RANDOMIZED CONTROLLED-TRIAL; SEMI-IMMUNE ADULTS; PHASE-I TRIAL;
   PROTECTIVE IMMUNITY; CORE PARTICLES; DNA VACCINE; ANTIBODY-RESPONSES
AB With approximately 2.4 billion people at risk, Plasmodium falciparum malaria infection caused by an infectious bite of an Anopheles mosquito continues to be a major cause of mortality and morbidity, mainly in the tropics and subtropics. Measures to control the mosquito vector on a broad scale are expensive and need to be maintained continuously. The rapid emergence of parasite strains that are resistant to affordable drugs highlights the urgent need for a cheap and effective vaccine. Candidate vaccines that have been developed to date target different stages of the parasite life cycle. This review describes the recent advances in the development of a vaccine that aims to terminate the infection at its first stage in the liver. The candidate vaccines that are currently under clinical evaluation are introduced and the results from recent trials discussed. The review aims to explain the immunologic challenges a successful vaccine has to meet, as well as the different strategies that are currently employed in an attempt to induce a protective immune response. Furthermore, an outline of available options to be tested in the near future will be presented.
C1 MRC Labs, Banjul, Gambia.
RP Walther, M (reprint author), MRC Labs, Fajara POB 273, Banjul, Gambia.
EM mwalther@mrc.gm
CR Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Anderson RJ, 2004, J IMMUNOL, V172, P3094
   Ballou W Ripley, 2005, Expert Opin Emerg Drugs, V10, P489, DOI 10.1517/14728214.10.3.489
   Ballou WR, 2004, AM J TROP MED HYG, V71, P239
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   Birkett A, 2002, INFECT IMMUN, V70, P6860, DOI 10.1128/IAI.70.12.6860-6870.2002
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Bojang KA, 2005, VACCINE, V23, P4148, DOI 10.1016/j.vaccine.2005.03.019
   Calvo-Calle JM, 2005, J IMMUNOL, V175, P7575
   CalvoCalle JM, 1997, J IMMUNOL, V159, P1362
   Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166
   Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660
   CHULAY JD, 1986, AM J TROP MED HYG, V35, P66
   CLYDE DF, 1975, AM J TROP MED HYG, V24, P397
   DAVIS JR, 1989, T ROY SOC TROP MED H, V83, P748, DOI 10.1016/0035-9203(89)90315-5
   Doherty JF, 1999, AM J TROP MED HYG, V61, P865
   Doolan DL, 2000, J IMMUNOL, V165, P1453
   Doolan DL, 2001, INT J PARASITOL, V31, P753, DOI 10.1016/S0020-7519(01)00184-9
   DUNACHIE SJ, 2006, IN PRESS VACCINE
   Epstein JE, 2004, VACCINE, V22, P1592, DOI 10.1016/j.vaccine.2004.01.031
   Epstein JE, 2002, HUM GENE THER, V13, P1551, DOI 10.1089/10430340260201644
   FAIRLEY NH, 1949, BRIT MED J, V2, P891
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   GARNHAM PCC, 1966, MIL MED, V131, P961
   Gilbert SC, 2002, VACCINE, V20, P1039, DOI 10.1016/S0264-410X(01)00450-9
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   Hafalla JCR, 2002, P NATL ACAD SCI USA, V99, P11819, DOI 10.1073/pnas.182189999
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   HOFFMAN SL, 1989, J IMMUNOL, V142, P1299
   Kaiser K, 2004, MOL MICROBIOL, V51, P1221, DOI 10.1046/j.1365-2958.2004.03909.x
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Kursar M, 2002, J EXP MED, V196, P1585, DOI 10.1084/jem.20011347
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   Langermans JAM, 2005, VACCINE, V23, P4935, DOI 10.1016/j.vaccine.2005.05.036
   Lawrence GW, 1997, VACCINE, V15, P176, DOI 10.1016/S0264-410X(96)00150-8
   LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214
   Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7<1989::AID-IMMU1989>3.3.CO;2-D
   Marshall E, 2000, SCIENCE, V290, P428, DOI 10.1126/science.290.5491.428
   Matuschewski K, 2002, J BIOL CHEM, V277, P41948, DOI 10.1074/jbc.M207315200
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   Meraldi V, 2005, VACCINE, V23, P2801, DOI 10.1016/j.vaccine.2004.10.044
   MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425
   Milich DR, 2001, VACCINE, V20, P771, DOI 10.1016/S0264-410X(01)00400-5
   MILICH DR, 1987, J IMMUNOL, V139, P1223
   MILLER KD, 1988, J INFECT DIS, V158, P868
   Molano A, 2000, J IMMUNOL, V164, P5005
   Moore AC, 2004, IMMUNOL REV, V199, P126, DOI 10.1111/j.0105-2896.2004.00138.x
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2004, LANCET, V363, P150, DOI 10.1016/S0140-6736(03)15267-1
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5
   MOORTHY VS, 2004, PLOS MED, V1, pE33
   MORENO A, 1993, J IMMUNOL, V151, P489
   Morrot A, 2005, J EXP MED, V202, P551, DOI 10.1084/jem.20042463
   Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785
   Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141
   Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188
   Mueller AK, 2005, P NATL ACAD SCI USA, V102, P3022, DOI 10.1073/pnas.0408442102
   Nardin EH, 2004, INFECT IMMUN, V72, P6519, DOI 10.1128/IAI.72.11.6519-6529.2004
   Nardin EH, 2001, J IMMUNOL, V166, P481
   NARDIN EH, 1979, SCIENCE, V206, P597, DOI 10.1126/science.386511
   NARDIN EH, 1989, SCIENCE, V246, P1603, DOI 10.1126/science.2480642
   Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871
   Nevill CG, 1996, TROP MED INT HEALTH, V1, P139
   NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0
   NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5
   Ocana-Morgner C, 2003, J EXP MED, V197, P143, DOI 10.1084/jem.20021072
   Oliveira GA, 2005, INFECT IMMUN, V73, P3587, DOI 10.1128/IAI.73.6.3587-3597.2005
   Pinder M, 2004, CLIN EXP IMMUNOL, V135, P286, DOI 10.1111/j.1365-2249.2004.02371.x
   Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3
   Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P
   PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N
   Prieur E, 2004, P NATL ACAD SCI USA, V101, P290, DOI 10.1073/pnas.0307158101
   Pumpens P, 1999, FEBS LETT, V442, P1, DOI 10.1016/S0014-5793(98)01599-3
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHODEL F, 1992, J VIROL, V66, P106
   Schodel F, 1997, Behring Inst Mitt, P114
   SCHODEL F, 1994, J EXP MED, V180, P1037, DOI 10.1084/jem.180.3.1037
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   Shibui A, 2005, VACCINE, V23, P4359, DOI 10.1016/j.vaccine.2005.03.036
   Simpson JA, 2002, PARASITOLOGY, V124, P247, DOI 10.1017/S0031182001001202
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x
   Sun PF, 2003, J IMMUNOL, V171, P6961
   Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2
   Tongren JE, 2004, TRENDS PARASITOL, V20, P604, DOI 10.1016/j.pt.2004.09.005
   Ulrich R, 1998, ADV VIRUS RES, V50, P141, DOI 10.1016/S0065-3527(08)60808-8
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2005, VACCINE, V23, P857, DOI 10.1016/j.vaccine.2004.08.020
   Wang RB, 2004, J IMMUNOL, V172, P5561
   Wang RB, 2005, INFECT IMMUN, V73, P2863, DOI 10.1128/IAI.73.5.2863-2872.2005
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573
   *WHO, 2002, 20 WHO EXP COMM MAL
   ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947
NR 112
TC 11
Z9 11
U1 0
U2 3
PU FUTURE DRUGS LTD
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1476-0584
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD FEB
PY 2006
VL 5
IS 1
BP 81
EP 93
DI 10.1586/14760584.5.1.81
PG 13
WC Immunology
SC Immunology
GA 089ZW
UT WOS:000240921400012
PM 16451110
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
AF Prentice, AM
TI The emerging epidemic of obesity in developing countries
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Review
ID CARDIOVASCULAR RISK-FACTORS; NUTRITION TRANSITION; WEIGHT-GAIN; CHINESE
   ADULTS; BODY-SIZE; DIET; PREVENTION; TRENDS; HYPERINSULINEMIA;
   UNDERNUTRITION
AB Thirty years ago international nutritionists were focussing on childhood malnutrition, the 'protein gap' and how to feed the world's burgeoning population, and medical services in the developing world were concentrated on the fight against infectious diseases. Today the World Health Organization (WHO) finds itself needing to deal with the new pandemic of obesity and its accompanying non-communicable diseases (NCDs) while the challenge of childhood malnutrition has far from disappeared, TB and malaria rates are escalating, and the scourge of AIDS has emerged. This has created a 'double burden' of disease that threatens to overwhelm the health services of many resource-poor countries. WHO warns that the greater future burden of obesity and diabetes will affect developing countries, and the projected numbers of new cases of diabetes run into the hundreds of millions within the next 2 decades. The obesity pandemic originated in the US and crossed to Europe and the world's other rich nations before, remarkably, it penetrated even the world's poorest countries especially in their urban areas. The pandemic is transmitted through the vectors of subsidized agriculture and multinational companies providing cheap, highly refined fats, oils, and carbohydrates, labour-saving mechanized devices, affordable motorized transport, and the seductions of sedentary pastimes such as television. This paper briefly reviews these macro-environmental trends as well as considering some of the socio-behavioural influences on weight gain in traditional societies. It concludes, pessimistically, that the pandemic will continue to spread for the foreseeable future, and that, apart from educational campaigns, the governments and health services of poor countries will have few effective public health levers with which they can try to arrest the trend.
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.prentice@lshtm.ac.uk
CR Bell AC, 2002, OBES RES, V10, P277, DOI 10.1038/oby.2002.38
   Bell AC, 2001, INT J OBESITY, V25, P1079, DOI 10.1038/sj.ijo.0801651
   Brewis AA, 1998, INT J OBESITY, V22, P185, DOI 10.1038/sj.ijo.0800562
   Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824
   Drewnowski A, 1997, NUTR REV, V55, P31
   Egger G, 1997, BRIT MED J, V315, P477
   Fernald LC, 2004, JAMA-J AM MED ASSOC, V291, P2544, DOI 10.1001/jama.291.21.2544
   Flynn KJ, 1998, ANN BEHAV MED, V20, P13, DOI 10.1007/BF02893804
   Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5
   Holdsworth M, 2004, INT J OBESITY, V28, P1561, DOI 10.1038/sj.ijo.0802739
   HORTON R, 2005, LANCET
   James PT, 2004, EUR J CARDIOV PREV R, V11, P3, DOI 10.1097/01.hjr.0000114707.27531.48
   James PT, 2001, OBES RES, V9, p228S, DOI 10.1038/oby.2001.123
   Joffe B, 1998, ENDOCRINE, V9, P139, DOI 10.1385/ENDO:9:2:139
   Kruger HS, 2005, PUBLIC HEALTH NUTR, V8, P491, DOI 10.1079/PHN2005785
   KUMANYIKA S, 1993, J AM DIET ASSOC, V93, P416, DOI 10.1016/0002-8223(93)92287-8
   Lanningham-Foster L, 2003, OBES RES, V11, P1178, DOI 10.1038/oby.2003.162
   Littlewood R, 2004, CULT MED PSYCHIAT, V28, P597, DOI 10.1007/s11013-004-1069-3
   Lobstein T., 2005, SCN NEWS, V29, P33
   Nielsen SJ, 2002, PREV MED, V35, P107, DOI 10.1006/pmed.2002.1037
   Nielsen SJ, 2002, OBES RES, V10, P370, DOI 10.1038/oby.2002.51
   Nishida C, 2005, SCN NEWS, V29, P5
   Paeratakul S, 1998, INT J OBESITY, V22, P424, DOI 10.1038/sj.ijo.0800603
   Popkin B. M., 2003, Development Policy Review, V21, P581, DOI 10.1111/j.1467-8659.2003.00225.x
   Popkin BM, 1998, PUBLIC HEALTH NUTR, V1, P5, DOI 10.1079/PHN19980004
   Popkin BM, 2005, PUBLIC HEALTH NUTR, V8, P724, DOI 10.1079/PHN2005776
   Popkin BM, 2004, NUTR REV, V62, pS140, DOI 10.1301/nr.2004.jul.S140-S143
   Popkin BM, 2004, INT J OBESITY, V28, pS2, DOI [10.1038/sj.ijo.0802804, 10.1038/sj.ijo.0802557]
   Popkin BM, 2002, PUBLIC HEALTH NUTR, V5, P947, DOI 10.1079/PHN2002370
   Popkin BM, 2003, OBES RES, V11, P1325, DOI 10.1038/oby.2003.179
   Popkin B. M., 2001, J NUTR, V131, P871
   Prentice AM, 2005, P NUTR SOC, V64, P153, DOI 10.1079/PNS2005421
   Prentice AM, 2005, ARCH DIS CHILD, V90, P429, DOI 10.1136/adc.2004.059030
   Prentice AM, 2003, BRIT MED J, V327, P880, DOI 10.1136/bmj.327.7420.880
   PRENTICE AM, 1995, BRIT MED J, V311, P437
   PRENTICE AM, 2005, IN PRESS PHYSL BEHAV
   SAWAYA AL, 1995, OBES RES, V3, pS107
   Schmidhuber J, 2005, SCN NEWS, V29, P13
   Sichieri R, 2000, INT J OBESITY, V24, P614, DOI 10.1038/sj.ijo.0801205
   SIERVO M, 2005, IN PRESS BODY IMAGE
   STRONG K, 2005, LANCET
   Stunkard AJ, 1996, CIBA F SYMP, V201, P174
   Swinburn B, 2004, BRIT MED J, V329, P736, DOI 10.1136/bmj.329.7468.736
   Swinburn BA, 2004, PUBLIC HEALTH NUTR, V7, P123, DOI 10.1079/PHN2003585
   van der Sande MAB, 2001, AM J PUBLIC HEALTH, V91, P1641, DOI 10.2105/AJPH.91.10.1641
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   WANG L, 2005, LANCET
   WEBB FM, 2006, INT J EPIDEMIOL, V35, P24
   World Health Organization, 2003, WHO TECHN REP SER, V916
   WHO, 2005, PREV CHRON DIS VIT I
   Organization WH, 2000, WHO TECHN REP SER, V894
   Yajnik CS, 2003, INT J OBESITY, V27, P173, DOI 10.1038/sj.ijo.802219
   Yajnik CS, 2002, J CLIN ENDOCR METAB, V87, P5575, DOI 10.1210/jc.2002-020434
NR 54
TC 493
Z9 510
U1 2
U2 104
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD FEB
PY 2006
VL 35
IS 1
BP 93
EP 99
DI 10.1093/ije/dyi272
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 011PX
UT WOS:000235281700024
PM 16326822
OA No
DA 2017-08-15
ER

PT J
AU Awomoyi, A
   Sirugo, G
   Newport, MJ
   Tishkoff, S
AF Awomoyi, A
   Sirugo, G
   Newport, MJ
   Tishkoff, S
TI Global distribution of a novel trinucleotide microsatellite polymorphism
   (ATA)(n) in intron 8 of the SLC11A1 gene and susceptibility to pulmonary
   tuberculosis
SO INTERNATIONAL JOURNAL OF IMMUNOGENETICS
LA English
DT Article
ID HUMAN NRAMP1 GENE; MACROPHAGE PROTEIN GENE; NATURAL-RESISTANCE;
   RHEUMATOID-ARTHRITIS; FORMERLY NRAMP1; WEST AFRICANS; LINKAGE; VARIANTS;
   PROMOTER; LOCUS
AB We identified a novel trinucleotide (ATA)(n) repeat polymorphism in intron 8 of SLC11AI, a candidate gene for susceptibility to tuberculosis (TB) infection. We characterized the frequency of this polymorphism in 485 individuals originating from eight globally diverse human populations and compared the distribution of (ATA)(n) alleles in 146 adults and in 80 cord blood samples from newborns in the Gambian population. Lastly, we tested for association of this microsatellite with pulmonary TB in 318 TB cases and 146 controls in the Gambian population. We found no significant difference in frequency or distribution of alleles in adult and cord blood samples, and we found no significant association between this marker and pulmonary TB.
C1 Univ Maryland, Dept Biol, College Pk, MD 20742 USA.
   Univ Maryland, Dept Microbiol, Baltimore, MD 21201 USA.
   MRC Labs, Banjul, Gambia.
   Dept Med, Brighton, E Sussex, England.
   Univ Sussex, Sussex Med Sch, Brighton BN1 9PS, E Sussex, England.
RP Tishkoff, S (reprint author), Univ Maryland, Dept Biol, Bldg 144, College Pk, MD 20742 USA.
EM tishkoff@umd.edu
CR Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   BUU NT, 1995, IMMUNOGENETICS, V42, P428
   Cervino ACL, 2000, ANN HUM GENET, V64, P507, DOI 10.1046/j.1469-1809.2000.6460507.x
   Dunstan SJ, 2001, J INFECT DIS, V183, P1156, DOI 10.1086/319289
   El Baghdadi J, 2003, INT J TUBERC LUNG D, V7, P599
   Gao PS, 2000, CLIN GENET, V58, P74, DOI 10.1034/j.1399-0004.2000.580113.x
   Goswami T, 2001, BIOCHEM J, V354, P511, DOI 10.1042/0264-6021:3540511
   GOVONI G, 1995, GENOMICS, V27, P9, DOI 10.1006/geno.1995.1002
   Greenwood CMT, 2000, AM J HUM GENET, V67, P405, DOI 10.1086/303012
   Hofmeister A, 1997, SURGERY, V122, P173, DOI 10.1016/S0039-6060(97)90006-4
   John S, 1997, J RHEUMATOL, V24, P452
   Kim JH, 2003, INT J TUBERC LUNG D, V7, P370
   Kojima Y, 2001, TISSUE ANTIGENS, V58, P379, DOI 10.1034/j.1399-0039.2001.580606.x
   Lewis LA, 1996, IMMUNOGENETICS, V44, P309, DOI 10.1007/BF02602562
   Li YC, 2004, MOL BIOL EVOL, V21, P991, DOI 10.1093/molbev/msh073
   LIU J, 1995, AM J HUM GENET, V56, P845
   Liu W, 2004, INT J TUBERC LUNG D, V8, P428
   Marquet S, 1999, J INFECT DIS, V180, P1521, DOI 10.1086/315091
   Meisner SJ, 2001, AM J TROP MED HYG, V65, P733
   Mohamed HS, 2004, EUR J HUM GENET, V12, P66, DOI 10.1038/sj.ejhg.5201089
   Roger M, 1997, INT J LEPROSY, V65, P197
   Ryu S, 2000, INT J TUBERC LUNG D, V4, P577
   Sanjeevi CB, 2000, ARTHRITIS RHEUM, V43, P1397, DOI 10.1002/1529-0131(200006)43:6<1397::AID-ANR25>3.0.CO;2-6
   Schneider S, 2000, ARLEQUIN SOFTWARE PO
   Searle S, 1999, J MED GENET, V36, P295
   Shaw MA, 1997, TUBERCLE LUNG DIS, V78, P35, DOI 10.1016/S0962-8479(97)90014-9
   Siddiqui MR, 2001, NAT GENET, V27, P439, DOI 10.1038/86958
   Singal DP, 2000, TISSUE ANTIGENS, V55, P44, DOI 10.1034/j.1399-0039.2000.550107.x
   VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655
   Wheeler DL, 2001, NUCLEIC ACIDS RES, V29, P11, DOI 10.1093/nar/29.1.11
   WICKER LS, 2004, J IMMUNOL, V73, P164
   Yang YS, 2000, J KOREAN MED SCI, V15, P83
   Yip SP, 2003, GENES IMMUN, V4, P212, DOI 10.1038/sj/gene.6363944
   ZAAHL MG, 2002, AJ494846 GENBANK
NR 36
TC 4
Z9 4
U1 1
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1744-3121
J9 INT J IMMUNOGENET
JI Int. J. Immunogenet.
PD FEB
PY 2006
VL 33
IS 1
BP 11
EP 15
DI 10.1111/j.1744-313X.2006.00547.x
PG 5
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 003RA
UT WOS:000234698100003
PM 16426236
OA No
DA 2017-08-15
ER

PT J
AU Jeffries, DJ
   Hill, PC
   Fox, A
   Lugos, M
   Jackson-Sillah, DJ
   Adegbola, RA
   Brookes, RH
AF Jeffries, DJ
   Hill, PC
   Fox, A
   Lugos, M
   Jackson-Sillah, DJ
   Adegbola, RA
   Brookes, RH
TI Identifying ELISPOT and skin test cut-offs for diagnosis of
   Mycobacterium tuberculosis infection in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article; Proceedings Paper
CT 35th World Conference on Lung Health of the
   International-Union-Against-Tuberculosis-and-Lung-Disease
CY OCT 28-NOV 01, 2004
CL Paris, FRANCE
SP Int Union Against Tuberculosis & Lung Dis
DE ELISPOT; PPD skin test; cut-off; sensitivity; specificity
ID T-CELL RESPONSES; LINKED IMMUNOSPOT ASSAY; ANTIGENS; PROTEIN; ESAT-6;
   ENUMERATION; CONTACTS; CFP-10
AB SETTING: An urban area, The Gambia.
   OBJECTIVE: To identify ELISPOT and PPD skin test cut-offs, targeting sensitivity and specificity equivalence.
   DESIGN: Tuberculosis cases > 15 years of age and their household contacts underwent ELISPOT, HIV and PPD skin tests. Cases and contacts sleeping in a different house were used to estimate sensitivity and specificity, providing two planes for estimating cut-offs. Specificity was adjusted for infection from previous exposure using a multivariate discrimination algorithm.
   RESULTS: The point on the line of intersection of the planes that maximised sensitivity and specificity equivalence occurred at 4 spots (95% confidence interval [Cl] 3.5-5, multiplier = 0) for CFP-10 and 5.5 spots (4.5-8, multiplier = 0 for ESAT-6), yielding a sensitivity and specificity of 76% for both antigens. Combining ESAT-6 and CFP- 10 using an 'or' statement yielded a maximum equivalence sensitivity and specificity of 76.5% at 6 spots for ESAT-6 and 11.5 spots for CFP-10. For the PPD skin test sensitivity and specificity, an equivalence of 78% occurred at 11 mm induration (9-13 mm).
   CONCLUSION: An ELISPOT cut-off for ESAT-6 or CFP-10 could be set at 4-8 spot forming units (20-40 spots per million), with little benefit from combining the results. A cut-off of 9-13 mm for the PPD skin test is reasonable when comparing with the ELISPOT.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM phill@mrc.gm
FU Medical Research Council [MC_U190071468]
CR Arend SM, 2001, CLIN DIAGN LAB IMMUN, V8, P1089, DOI 10.1128/CDLI.8.6.1089-1096.2001
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448
   Berkel GM, 2005, INT J TUBERC LUNG D, V9, P310
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008
   Demissie A, 1999, INFECT IMMUN, V67, P5967
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Floyd S, 2002, J INFECT DIS, V186, P807, DOI 10.1086/342416
   Heifets Leonid B., 1994, P85
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   *KNCV, 2003, NAT LEPR TUB PROGR A
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   MARDIA KV, 1979, MULTIVARIATE ANAL, P318
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC
   Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
NR 20
TC 21
Z9 25
U1 0
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD FEB
PY 2006
VL 10
IS 2
BP 192
EP 198
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 010XZ
UT WOS:000235232600014
PM 16499260
OA No
DA 2017-08-15
ER

PT J
AU Dineen, B
   Foster, A
   Faal, H
AF Dineen, B
   Foster, A
   Faal, H
TI A proposed rapid methodology to assess the prevalence and causes of
   blindness and visual impairment
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE blindness prevalence; blindness etiology; visual impairment;
   methodology; underdeveloped countries; The Gambia; aphakia; trachoma;
   phthisis bulbi; cataract
ID CATARACT BLINDNESS
AB Purpose : To determine whether a sample of the 50-year-old and above population would provide comparable information to a total population-based survey. Methods : In 1996, a national eye survey of the total population in The Gambia was undertaken and the results concerning the prevalence and distribution of blindness and low vision have been reported. The same data set was used to analyse the prevalence and causes of blindness and low vision in people aged 50 years and above, and to compare the findings with the total population. Results : Of 55 bilaterally blind people in the total population, 83.6% were 50 years of age or older. The distribution by cause of blindness was similar for the total population and for those aged 50 years and above. Cataract and uncorrected aphakia accounted for 46% and 13%, respectively, in the total population and 48% and 15% in the 50 year and above age group. Trachoma accounted for 5% and 4%, and other corneal opacities for 16% and 13%, respectively. Phthisis bulbi, which may follow perforated corneal ulcers, ocular trauma/surgery or occasionally severe uveitis, accounted for 4% in both age groups, and glaucoma accounted for 9% in the total population and 11% in the 50 year plus group. Conclusion : Assessment of the 50 year and above age group proved to be a good indicator for the causes of blindness and visual impairment in the total population and for determining those causes of blindness that are avoidable. Such an assessment requires a much smaller sample size, less than 20% of the sample size for the total population, and is likely to be less expensive.
C1 London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London, England.
   Gambia Eye Care Programme, Banjul, Gambia.
RP Foster, A (reprint author), London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London, England.
EM allen.foster@lshtm.ac.uk
CR Duerksen R, 2003, OPHTHAL EPIDEMIOL, V10, P349, DOI 10.1076/opep.10.5.349.17326
   Eloff J, 2000, Ophthalmic Epidemiol, V7, P219, DOI 10.1076/0928-6586(200009)7:3;1-V;FT219
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Limburg H, 1997, INT J EPIDEMIOL, V26, P1049, DOI 10.1093/ije/26.5.1049
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   World Health Organization, 1997, WHOPBL9761
NR 7
TC 33
Z9 35
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2006
VL 13
IS 1
BP 31
EP 34
DI 10.1080/09286580500473787
PG 4
WC Ophthalmology
SC Ophthalmology
GA 017UW
UT WOS:000235719800005
PM 16510344
OA No
DA 2017-08-15
ER

PT J
AU Byass, P
   Fottrell, E
   Huong, DL
   Berhane, Y
   Corrah, T
   Kahn, K
   Muhe, L
   Van, DD
AF Byass, P
   Fottrell, E
   Huong, DL
   Berhane, Y
   Corrah, T
   Kahn, K
   Muhe, L
   Van, DD
TI Refining a probabilistic model for interpreting verbal autopsy data
SO SCANDINAVIAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE verbal autopsy; Bayes' theorem; mortality surveillance; probability;
   cause of death
ID DELPHI TECHNIQUE; DEATH; VALIDATION; MISCLASSIFICATION; METHODOLOGY;
   MORTALITY; VIETNAM
AB Objective: To build on the previously reported development of a Bayesian probabilistic model for interpreting verbal autopsy ( VA) data, attempting to improve the model's performance in determining cause of death and to reassess it. Design: An expert group of clinicians, coming from a wide range geographically and in terms of specialization, was convened. Over a four-day period the content of the previous probabilistic model was reviewed in detail and adjusted as necessary to reflect the group consensus. The revised model was tested with the same 189 VA cases from Vietnam, assessed by two local clinicians, that were used to test the preliminary model. Results: The revised model contained a total of 104 indicators that could be derived from VA data and 34 possible causes of death. When applied to the 189 Vietnamese cases, 142 ( 75.1%) achieved concordance between the model's output and the previous clinical consensus. The remaining 47 cases ( 24.9%) were presented to a further independent clinician for reassessment. As a result, consensus between clinical reassessment and the model's output was achieved in 28 cases ( 14.8%); clinical reassessment and the original clinical opinion agreed in 8 cases ( 4.2%), and in the remaining 11 cases ( 5.8%) clinical reassessment, the model, and the original clinical opinion all differed. Thus overall the model was considered to have performed well in 170 cases ( 89.9%). Conclusions: This approach to interpreting VA data continues to show promise. The next steps will be to evaluate it against other sources of VA data. The expert group approach to determining the required probability base seems to have been a productive one in improving the performance of the model.
C1 Umea Univ, Umea Int Sch Publ Hlth, SE-90185 Umea, Sweden.
   Minist Hlth, Hlth Strategy & Policy Inst, Hanoi, Vietnam.
   Univ Addis Ababa, Dept Community Hlth, Addis Ababa, Ethiopia.
   MRC Labs, Banjul, Gambia.
   Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa.
   WHO, CH-1211 Geneva, Switzerland.
   Viet Duc Surg Hosp, Hanoi, Vietnam.
RP Byass, P (reprint author), Umea Univ, Umea Int Sch Publ Hlth, SE-90185 Umea, Sweden.
EM peterbyass@aol.com
OI Byass, Peter/0000-0001-5474-4361
FU Wellcome Trust [069683]
CR Anker M, 1997, INT J EPIDEMIOL, V26, P1090, DOI 10.1093/ije/26.5.1090
   Byass P, 2003, SCAND J PUBLIC HEALT, V31, P32, DOI 10.1080/14034950310015086
   BYASS P, 1989, MEDINFO 89
   Chandramohan D, 1998, STUD FAMILY PLANN, V29, P414, DOI 10.2307/172253
   Chandramohan D, 2001, INT J EPIDEMIOL, V30, P509, DOI 10.1093/ije/30.3.509
   Chandramohan D, 1998, TROP MED INT HEALTH, V3, P436
   Hoj L, 1999, INT J EPIDEMIOL, V28, P70, DOI 10.1093/ije/28.1.70
   Huong DL, 2003, SCAND J PUBLIC HEALT, V31, P19, DOI 10.1080/14034950310015068
   *IND NETW, 2002, POP HLTH DEV COUNTR, V1
   Kahn K, 2000, TROP MED INT HEALTH, V5, P824, DOI 10.1046/j.1365-3156.2000.00638.x
   Keeney S, 2001, INT J NURS STUD, V38, P195, DOI 10.1016/S0020-7489(00)00044-4
   KONG A, 1986, NEW ENGL J MED, V315, P740, DOI 10.1056/NEJM198609183151206
   Okosun Ike S., 2001, Ethnicity and Disease, V11, P575
   Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x
   Quigley MA, 1999, INT J EPIDEMIOL, V28, P1081, DOI 10.1093/ije/28.6.1081
   Reeves BC, 1997, INT J EPIDEMIOL, V26, P1080, DOI 10.1093/ije/26.5.1080
NR 16
TC 58
Z9 58
U1 0
U2 4
PU TAYLOR & FRANCIS AS
PI OSLO
PA PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY
SN 1403-4948
J9 SCAND J PUBLIC HEALT
JI Scand. J. Public Health
PD FEB
PY 2006
VL 34
IS 1
BP 26
EP 31
DI 10.1080/14034940510032202
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 007WP
UT WOS:000235002200005
PM 16449041
OA No
DA 2017-08-15
ER

PT J
AU Somda, J
   Kamuanga, M
   Tollens, E
AF Somda, J
   Kamuanga, M
   Tollens, E
TI Prospective analysis for community participation in trypanosomosis
   control in The Gambia
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
DE demand; trypanosomosis control; livestock; community participation; The
   Gambia
ID FARMERS PERCEPTIONS; BURKINA-FASO; ADOPTION; TSETSE; TECHNOLOGY; AFRICA
AB The shift towards community participation in the eradication of trypanosomosis calls for investigation the underlying incentive structure for individuals in the community to cooperate in the provision of various control methods. Survey data were used to assess patterns of the community's demand for insecticide pour-ons and trypanocidal drugs and factors affecting individual} demand in The Gambia. The results show that insecticide pour-on is strongly preferred. Similarly, farmers revealed a preference for community-based provision scheme. Factors affecting an individual farmer's decision to invest in either pour-on or trypanocidal drugs were highlighted. While there are many factors associated with farmer's decisions to invest in trypanosomosis control methods and to participate in collective actions, the results indicate that farmers} are ready to anticipate complete privatization of veterinary services through community-based schemes.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Katholieke Univ Leuven, Dept Agr & Environm Econ, Louvain, Belgium.
   Int Livestock Res Inst, Doulasso, Burkina Faso.
   Katholieke Univ Leuven, Dept Agr & Envirnonm Econ, Louvain, Belgium.
RP Somda, J (reprint author), Int Trypanotolerance Ctr, Banjul, Gambia.
EM jacquesomda@yahoo.com
CR ADESINA AA, 1995, AGR ECON, V13, P1, DOI 10.1016/0169-5150(95)01142-8
   ADESINA AA, 1993, AGR ECON, V9, P297, DOI 10.1016/0169-5150(93)90019-9
   AGYEMANG K, 1997, VILLAGE DAMA CATTLE
   BAUER B, 1999, SUSTAINABLE INTEGRAT
   BISHOP RC, 1979, AM J AGR ECON, V61, P926, DOI 10.2307/3180348
   Blanc F., 1991, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V44, P301
   Brightwell B., 2001, Agriculture and Human Values, V18, P219, DOI 10.1023/A:1011131826919
   CARSON RT, 1999, INCENTIVE INFORMATIO
   Clarke E., 1971, PUBLIC CHOICE, V11, P17, DOI DOI 10.1007/BF01726210
   GROVES T, 1973, ECONOMETRICA, V41, P617, DOI 10.2307/1914085
   Groves T., 1987, ESSAYS HONOR L HURWI
   Kamuanga M, 2001, TROP ANIM HEALTH PRO, V33, P141, DOI 10.1023/A:1005286631470
   KAMUANGA M, 2004, PAKISTAN J SOCIAL SC, V2, P162
   KOMA LM, 2003, AFRICAS CHANGING MAR
   Laughland A. S., 1994, Agricultural and Resource Economics Review, V23, P29
   LEONARD DK, 1993, DEV CHANGE, V24, P227, DOI 10.1111/j.1467-7660.1993.tb00485.x
   LY C, 2003, AFRICAS CHANGING MAR
   Mattioli RC, 1998, ACTA TROP, V71, P57, DOI 10.1016/S0001-706X(98)00051-5
   MCCARTHY N, 103 INT EPTD INT FOO
   McDermott JJ, 2001, INT J PARASITOL, V31, P603, DOI 10.1016/S0020-7519(01)00148-5
   MCDONALD JF, 1980, REV ECON STAT, V62, P318, DOI 10.2307/1924766
   Mitchell R. C., 1989, USING SURVEYS VALUE
   Mugalla CI, 2000, THESIS PENNSYLVANIA
   NIEWIJK RK, 2003, CATO REV BUSINESS GO
   Savadogo K, 1998, AGR SYST, V58, P441, DOI 10.1016/S0308-521X(98)00040-7
   Snow WF, 1999, PREV VET MED, V42, P67, DOI 10.1016/S0167-5877(99)00072-0
   SWALLOW BM, 1994, ECOL ECON, V11, P153, DOI 10.1016/0921-8009(94)90025-6
   TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382
   Uphoff N., 1996, LEARNING GAL OYA POS
   Varian H., 1992, MICROECONOMIC ANAL
   WHITE KJ, 1993, SHAZAM USERS REFEREN
   WHITEHEAD JC, 2000, PRACTITIONERS PRIMER
   WILLIAMSON OE, 1985, EC INSTITUTIONS CAPI
NR 33
TC 1
Z9 1
U1 2
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD FEB
PY 2006
VL 38
IS 2
BP 103
EP 111
DI 10.1007/s11250-006-4308-5
PG 9
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA 039SN
UT WOS:000237327300002
PM 17682594
OA No
DA 2017-08-15
ER

PT J
AU Hanchard, NA
   Rockett, KA
   Spencer, C
   Coop, G
   Pinder, M
   Jallow, M
   Kimber, M
   McVean, G
   Mott, R
   Kwiatkowski, DP
AF Hanchard, NA
   Rockett, KA
   Spencer, C
   Coop, G
   Pinder, M
   Jallow, M
   Kimber, M
   McVean, G
   Mott, R
   Kwiatkowski, DP
TI Screening for recently selected alleles by analysis of human haplotype
   similarity
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID RECENT POSITIVE SELECTION; LINKAGE DISEQUILIBRIUM; STATISTICAL-METHOD;
   HUMAN GENOME; HISTORY; GENE
AB There is growing interest in the use of haplotype- based methods for detecting recent selection. Here, we describe a method that uses a sliding window to estimate similarity among the haplotypes associated with any given single-nucleotide polymorphism ( SNP) allele. We used simulations of natural selection to provide estimates of the empirical power of the method to detect recently selected alleles and found it to be comparable in power to the popular long-range haplotype test and more powerful than methods based on nucleotide diversity. We then applied the method to a recently selected allele-the sickle mutation at the HBB locus-and found it to have a signal of selection that was significantly stronger than that of simulated models both with and without strong selection. Using this method, we also evaluated 14,000 SNPs on chromosome 20, indicating the applicability of the method to regional data sets.
C1 Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   Univ Oxford, Dept Paediat, Oxford, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   MRC Labs, Banjul, Gambia.
   Tessella, Abingdon, Oxon, England.
RP Hanchard, NA (reprint author), Univ W Indies, Trop Metab Res Unit, Trop Med Res Inst, Kingston 7, Jamaica.
EM neil.hanchard@green-oxford.com
FU Medical Research Council [G9505090, G19/9]
CR Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24
   Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051
   Currat M, 2002, AM J HUM GENET, V70, P207, DOI 10.1086/338304
   Fay JC, 2000, GENETICS, V155, P1405
   FU YX, 1993, GENETICS, V133, P693
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HUDSON RR, 1994, GENETICS, V136, P1329
   Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337
   Ke XY, 2004, HUM MOL GENET, V13, P577, DOI 10.1093/hmg/ddh060
   Nordborg M, 2002, TRENDS GENET, V18, P83, DOI 10.1016/S0168-9525(02)02557-X
   Ohashi J, 2004, AM J HUM GENET, V74, P1198, DOI 10.1086/421330
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Spencer CCA, 2004, BIOINFORMATICS, V20, P3673, DOI 10.1093/bioinformatics/bth417
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   TAJIMA F, 1989, GENETICS, V123, P585
   Thompson EA, 1997, AM J HUM GENET, V60, P197
   Toomajian C, 2003, GENETICS, V165, P287
NR 17
TC 34
Z9 36
U1 1
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JAN
PY 2006
VL 78
IS 1
BP 153
EP 159
DI 10.1086/499252
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 993CN
UT WOS:000233930400016
PM 16385459
OA No
DA 2017-08-15
ER

PT J
AU Mboto, CI
   Davies, A
   Fielder, M
   Jewell, AP
AF Mboto, CI
   Davies, A
   Fielder, M
   Jewell, AP
TI Human immunodeficiency virus and hepatitis C co-infection in sub-Saharan
   West Africa
SO BRITISH JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Review
DE co-infection; hepatitis C; HIV
ID SEXUALLY-TRANSMITTED INFECTIONS; INTRAVENOUS-DRUG-USERS; BLOOD-DONORS;
   HEPATOCELLULAR-CARCINOMA; HIV-INFECTION; RISK-FACTORS; TRADITIONAL
   MEDICINE; PREGNANT-WOMEN; COTE-DIVOIRE; PREVALENCE
AB Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is becoming a major global problem, leading to increased morbidity and mortality in developed countries. Co-existence in sub-Saharan West Africa of a high prevalence of HIV and HCV, which share similar behavioural risk factors and modes of transmission, must be seen in the broader context of an emerging third epidemic of HIV and HCV co-infection, as many factors that may affect the spread of HIV and HCV co-infection are endemic in the continent, including host factors such as sexual behaviour, presence of other sexually transmitted diseases, female and male circumcision status, percutaneous and perinatal exposure, and poverty. This review examines the epidemiology, risk factors and transmission of HIV and HCV co-infection and draws attention to the possible emergence of an epidemic of HIV and HCV co-infection in the region.
C1 Kingston Univ, Fac Hlth & Social Care Sci, Kingston upon Thames KT1 2EE, Surrey, England.
   St Georges Univ London, Kingston upon Thames KT1 2EE, Surrey, England.
   Royal Victoria Hosp, Banjul, Gambia.
   Kingston Univ, Sch Life Sci, Kingston upon Thames KT1 2EE, Surrey, England.
RP Jewell, AP (reprint author), Kingston Univ, Fac Hlth & Social Care Sci, Penrhyn Rd, Kingston upon Thames KT1 2EE, Surrey, England.
EM ajewell@hscs.sgul.ac.uk
CR Afdhal NH, 2004, SEMIN LIVER DIS, V24, P3, DOI 10.1055/s-2004-832922
   Ahmed SD, 1998, J INFECTION, V37, P248, DOI 10.1016/S0163-4453(98)91983-1
   Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802
   Ampofo W, 2002, J CLIN MICROBIOL, V40, P3523, DOI 10.1128/JCM.40.9.3523-3525.2002
   Auvert B, 2001, AIDS, V15, pS15, DOI 10.1097/00002030-200108004-00003
   Awoyemi O B, 2002, Afr J Med Med Sci, V31, P329
   Ayele W, 2002, J MED VIROL, V68, P12, DOI 10.1002/jmv.10164
   BAILEY AC, 1984, LANCET, V1, P1318
   Bertherat E, 1998, INT J STD AIDS, V9, P31
   BISHAW M, 1991, SOC SCI MED, V33, P193, DOI 10.1016/0277-9536(91)90180-K
   BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547
   Bozdayi AM, 2004, ARCH VIROL, V149, P2115, DOI 10.1007/s00705-004-0363-2
   Centers for Disease Control and Prevention, 1998, MMWR-MORBID MORTAL W, V47, P1
   *CDCP, 1999, HIV AIDS SURV REP
   CHIWUZIE J, 1987, World Health Forum, V8, P240
   CLUMECK N, 1985, NEW ENGL J MED, V313, P182
   COHEN D, 1992, EC IMPACT HIV EPIDEM
   Combe P, 2001, T ROY SOC TROP MED H, V95, P493, DOI 10.1016/S0035-9203(01)90015-X
   De Cock KM, 2001, PHILOS T ROY SOC B, V356, P795
   Debonne J M, 1999, Med Trop (Mars), V59, P508
   DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013
   DIETERICH DT, 1999, SEMIN LIVER DIS, V19, P8794
   Dodig M, 2001, J CLIN GASTROENTEROL, V33, P367, DOI 10.1097/00004836-200111000-00005
   DONAHUE JG, 1991, AM J EPIDEMIOL, V134, P1206
   EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P60210
   Fan Wen-mei, 2004, Zhonghua Yi Xue Za Zhi, V84, P392
   FASSIN D, 1988, SOC SCI MED, V27, P353, DOI 10.1016/0277-9536(88)90269-9
   Filippini P, 2001, SEX TRANSM DIS, V28, P725, DOI 10.1097/00007435-200112000-00010
   FRETZ C, 1995, J MED VIROL, V47, P435, DOI 10.1002/jmv.1890470423
   GARCIASAMANIEGO J, 1997, AM J GASTROENTEROL, V92, P11304
   Gillett James, 2002, J Assoc Nurses AIDS Care, V13, P17, DOI 10.1016/S1055-3290(06)60198-2
   Gisselquist D, 2004, INT J STD AIDS, V15, P145, DOI 10.1258/095646204322916560
   Goldmann DA, 2002, J ALLERGY CLIN IMMUN, V110, pS21, DOI 10.1067/mai.2002.125337
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   GREEN EC, 1995, SOC SCI MED, V40, P503, DOI 10.1016/0277-9536(94)E0105-2
   Gretch DR, 1997, HEPATOLOGY, V26, P43
   Halim NKD, 2000, E AFR MED J, V77, P410
   Harder J, 2004, CLIN MICROBIOL INFEC, V10, P768, DOI 10.1111/j.1469-0691.2004.00934.x
   Hardy DB, 1987, REV INFECT DIS, V9, P1109
   Harlow L L, 1998, Womens Health, V4, P407
   Hassan MM, 2001, J CLIN GASTROENTEROL, V33, P123, DOI 10.1097/00004836-200108000-00006
   Hodges M, 1998, West Afr J Med, V17, P36
   HUGHES A, 1990, BLOOD REV, V4, P158, DOI 10.1016/0268-960X(90)90043-R
   Jeannel D, 1998, J MED VIROL, V55, P92
   KINGSLEY LA, 1987, LANCET, V1, P345
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   KIYOSAWA K, 1991, ANN INTERN MED, V115, P3679
   Leynaert B, 1998, AM J EPIDEMIOL, V148, P88
   LUSAMIJARULKUL P, 2004, SE ASIAN J TROP MED, V35, P147
   Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   McHutchison JG, 2004, AM J MANAG CARE, V10, pS21
   Menendez C, 1999, J MED VIROL, V58, P215, DOI 10.1002/(SICI)1096-9071(199907)58:3<215::AID-JMV5>3.0.CO;2-K
   METS T, 1993, SCAND J GASTROENTERO, V28, P331, DOI 10.3109/00365529309090251
   Monga HK, 2001, CLIN INFECT DIS, V33, P240, DOI 10.1086/321819
   Monteiro-Grillo M, 1993, Eur J Ophthalmol, V3, P13
   Mwangi JW, 1999, E AFR MED J, V76, P35
   Ndjomou J, 2002, J MED VIROL, V66, P179, DOI 10.1002/jmv.2128
   Ng H, 2000, Harv AIDS Rev, P2
   NGBICHI JM, 1995, AIDS, V9, P951, DOI 10.1097/00002030-199508000-00018
   Njouom R, 2003, J MED VIROL, V71, P219, DOI 10.1002/jmv.10473
   Okonofua FE, 1999, SEX TRANSM DIS, V26, P184, DOI 10.1097/00007435-199903000-00010
   OPPONG ACK, 1989, SOC SCI MED, V28, P605, DOI 10.1016/0277-9536(89)90255-4
   Owusu-Ofori S, 2005, TRANSFUSION, V45, P133, DOI 10.1111/j.1537-2995.2004.04279.x
   Patrick DM, 2000, CAN J PUBLIC HEALTH, V91, pS18
   Peeters M, 1998, AIDS RES HUM RETROV, V14, P51, DOI 10.1089/aid.1998.14.51
   POYNARD T, 1997, LANCET, V349, P82532
   Quintana M, 2003, HAEMOPHILIA, V9, P605, DOI 10.1046/j.1365-2516.2003.00804.x
   Renjifo B, 2004, AIDS, V18, P1629, DOI 10.1097/01.aids.0000131392.68597.34
   Rockstroh JK, 2004, LANCET INFECT DIS, V4, P437, DOI 10.1016/S1473-3099(04)01059-X
   ROUDOTTHORAVAL F, 1997, HEPATOLOGY, V26, P48590
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   SHATTOCK RJ, 2003, NATURE REV MICROBIOL, V1, P26
   Sherifi J, 2005, DRUG DISCOV TODAY, V10, P1, DOI 10.1016/S1359-6446(04)03301-X
   Sherman KE, 2002, CLIN INFECT DIS, V34, P831, DOI 10.1086/339042
   Stauber R, 2000, Wien Med Wochenschr, V150, P460
   SULKOWSKI MS, 2000, JAMA-J AM MED ASSOC, V283, P7480
   THOMAS DL, 1995, J INFECT DIS, V171, P76875
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van der Sande MAB, 2004, AIDS, V18, P1933, DOI 10.1097/00002030-200409240-00009
   VANDERSANDE MA, 2004, AIDS, V18, P19332
   Vardas E, 1999, B WORLD HEALTH ORGAN, V77, P965
   VENTO S, 1998, AIDS, V12, P1167
   VIRELINK H, 1995, LANCET, V345, P95
   WAINBERG, 2004, AIDS S3, V18, pS63
   Wake DJ, 1998, TROP DOCT, V28, P4
   *WHO, 1999, WKLY EPIDEMIOL REC, V74, P4218
   *WHO, 1997, WKLY EPIDEMIOL REC, V46, P343
   *WHO AFRO, 2001, ENS BLOOD TRANSF SAF
   Yerly S, 2001, J INFECT DIS, V184, P369, DOI 10.1086/322036
   Zein Nizar N, 2003, Cleve Clin J Med, V70 Suppl 4, pS2
   ZYLBERBERG H, 1998, CLIN INFECT DIS, V27, P12558
NR 92
TC 4
Z9 5
U1 1
U2 6
PU STEP PUBLISHING LTD
PI TUNBRIDGE WELLS
PA SUBSCRIPTION DEPT, NORTH FARM RD, TUNBRIDGE WELLS TN2 3DR, KENT, ENGLAND
SN 0967-4845
J9 BRIT J BIOMED SCI
JI Br. J. Biomed. Sci.
PY 2006
VL 63
IS 1
BP 29
EP 37
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 030CT
UT WOS:000236611600009
PM 16613141
OA No
DA 2017-08-15
ER

PT J
AU Van der Sande, MAB
   Kaye, S
   Miles, D
   Waight, P
   Ojuola, OO
   Savage, S
   Whittle, HC
   Marchant, A
AF Van der Sande, M. A. B.
   Kaye, S.
   Miles, D.
   Waight, P.
   Ojuola, O. O.
   Savage, S.
   Whittle, H. C.
   Marchant, A.
TI Congenital CMV infection in a west-African birth cohor
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 RIVM, Bilthoven, Netherlands.
   Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.
   MRC, Fajara, Gambia.
   Hlth Policy Agcy, London, England.
   Minist Hlth, Banjul, Gambia.
   Univ Libre Bruxelles, Brussels, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0393-2990
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PY 2006
VL 21
SU S
MA 369
BP 114
EP 114
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 066QP
UT WOS:000239245500379
OA No
DA 2017-08-15
ER

PT J
AU Fairhead, J
   Leach, M
   Small, M
AF Fairhead, J
   Leach, M
   Small, M
TI Public engagement with science? Local understandings of a vaccine trial
   in the Gambia
SO JOURNAL OF BIOSOCIAL SCIENCE
LA English
DT Article
ID CONJUGATE VACCINE
AB This paper considers how parents engage with a large, internationally supported childhood pneumococcal vaccine trial in The Gambia. Current analysis and professional reflection on public engagement is strongly shaped by the imperatives of public health and research institutions, and is thus couched in terms of acceptance and refusal, and 'informed consent'. In contrast Gambian parents' perspectives on the trial are couched in conceptual and experiential terms that are linked to their wider dilemmas of raising infants amidst the hazards of globally connected village life. Ethnographic research reveals how for most parents, longer-term experiences of the organization managing the research (the UK Medical Research Council Laboratories in The Gambia) as a health-providing institution override their reflection on trial-specific aims. A decision to participate in the trial involves a perceived balance of benefit and danger-in the extreme, of free medical treatment, versus one's child being drained of blood for sale to Europe. Social relations (especially gender relations) shape this calculus and study participation. This case suggests how the idea of 'public engagement with science' in a globalized context might be recast, with implications for debates in biomedical ethics, and the sustainability of public participation in medical research.
C1 Univ Sussex, Dept Anthropol, Brighton BN1 9RH, E Sussex, England.
   Univ Sussex, Inst Dev Studies, Brighton BN1 9RH, E Sussex, England.
   Gambia Comm Tradit Practices, Bakau, Gambia.
RP Fairhead, J (reprint author), Univ Sussex, Dept Anthropol, Brighton BN1 9RH, E Sussex, England.
CR Anderson W, 2002, SOC STUD SCI, V32, P643, DOI 10.1177/030631202128967361
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Feldman-Savelsberg P, 2000, MED ANTHROPOL Q, V14, P159, DOI 10.1525/maq.2000.14.2.159
   GOTTLIEB A, 2000, WORLD BABIES
   Leach A, 1999, SOC SCI MED, V48, P139, DOI 10.1016/S0277-9536(98)00317-7
   LEACH M, 2005, SCI CITIZEN GLOBALIZ
   Long A., 1994, BATTLEFIELDS KNOWLED
   *MRC, 2002, ANN REP UK MED RES C
   NUFFIELD, 2002, ETHICS RES RELATED H
   Streefland P, 1999, SOC SCI MED, V49, P1705, DOI 10.1016/S0277-9536(99)00239-7
   Vaughan Megan, 1991, CURING THEIR ILLS CO
   WHITE S, 2000, SPEAKING VAMPIRES RU
NR 12
TC 31
Z9 31
U1 0
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA
SN 0021-9320
J9 J BIOSOC SCI
JI J. Biosoc. Sci.
PD JAN
PY 2006
VL 38
IS 1
BP 103
EP 116
DI 10.1017/S0021932005000945
PG 14
WC Demography; Public, Environmental & Occupational Health; Social
   Sciences, Biomedical
SC Demography; Public, Environmental & Occupational Health; Biomedical
   Social Sciences
GA 008OR
UT WOS:000235050800008
PM 16266443
OA No
DA 2017-08-15
ER

PT J
AU Acharya, A
   de Lima, ATF
   Moore, M
AF Acharya, A
   de Lima, ATF
   Moore, M
TI Proliferation and fragmentation: Transactions costs and the value of aid
SO JOURNAL OF DEVELOPMENT STUDIES
LA English
DT Article
AB The problem of the proliferation of the number of aid donors and aid channels continues to worsen. It is widely and plausibly believed that this significantly; reduces the value of aid by increasing direct and indirect transactions costs. We contribute to the existing literature by: (a) categorising the apparent adverse effects of proliferation; (b) producing a reliable and fair indicator of the relative degree to which the main bilateral donors proliferate or concentrate their aid; (c) giving some explanation of why some donors proliferate more than others; (d) constructing a reliable measure of the extent to to which recipients suffer from the problem of fragmentation in the sources of their aid; and (e) demonstrating that the worst proliferators among the aid donors are especially likely); to be suppliers of aid to recipients suffering most from fragmentation. There are significant implications for aid policy.
C1 Res Triangle Inst, Washington, DC 20036 USA.
   Concern Universal, Serekunda, Gambia.
   Univ Sussex, Brighton, E Sussex, England.
RP Acharya, A (reprint author), Res Triangle Inst, 1615 M St NW, Washington, DC 20036 USA.
EM aacharya@rti.org; ana_teresa_lima@hotmail.com; M.P.Moore@ids.ac.uk
CR BIRDSALL N, 2004, 50 CGD CTR GLOB DEV
   BRAUTIGAM D, 1999, AID DEPENDENCE GOVER
   BURNELL P, 2002, J LEGISLATIVE STUDIE, V7, P34
   Cassen R. H., 1986, DOES AID WORK REPORT
   COHEN J, 1991, PUBLIC ADMIN DEVELOP, V12, P493
   Collier P, 1997, WORLD DEV, V25, P1399, DOI 10.1016/S0305-750X(97)00053-3
   DIALLO AS, 1991, CAPACITY BUILDING AI
   DOLLAR D, 1998, ASSESSING AID WORKS
   *DON GROUP, 2001, UNPUB HARM DON PROC
   Ehrenpreis D., 2003, DAC J, V4, P7
   Jacoby Neil, 1966, US AID TAIWAN STUDY
   Kanbur R., 1999, FUTURE DEV ASSISTANC
   KNACK S, 2003, UNPUB AID INTENSITY
   Lecomte Bernard J, 1986, PROJECT AID LIMITATI
   LEONARD DK, 1987, WORLD DEV, V15, P899, DOI 10.1016/0305-750X(87)90041-6
   Martens B., 2002, I EC FOREIGN AID
   MOORE M, 1992, IDS BULL-I DEV STUD, V23, P65
   MORSS ER, 1984, WORLD DEV, V12, P465, DOI 10.1016/0305-750X(84)90024-X
   O'Connell SA, 2001, WORLD DEV, V29, P1527, DOI 10.1016/S0305-750X(01)00050-X
   Ostrom E., 2002, SIDA STUDIES EVALUAT
   PAVIGNANI E, 2002, 39 ECDPM
   Toye J., 1995, NEW I EC 3 WORLD DEV
   *VIETN DEV INF CTR, 2001, PUTT PARTN WORK VIET
   WILSON LS, 1993, PUBLIC ADMIN DEVELOP, V13, P489, DOI 10.1002/pad.4230130504
   World Bank, 2003, WORLD DEV REP 2004 M
   World Bank, 2001, WORLD DEV REP 2000 2
NR 26
TC 79
Z9 79
U1 0
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0022-0388
J9 J DEV STUD
JI J. Dev. Stud.
PD JAN
PY 2006
VL 42
IS 1
BP 1
EP 21
DI 10.1080/00220380500356225
PG 21
WC Economics; Planning & Development
SC Business & Economics; Public Administration
GA 011RA
UT WOS:000235284600001
OA No
DA 2017-08-15
ER

PT J
AU Kennedy, C
   Bowman, R
   Fariza, N
   Ackuaku, E
   Ntim-Amponsah, C
   Murdoch, I
AF Kennedy, C
   Bowman, R
   Fariza, N
   Ackuaku, E
   Ntim-Amponsah, C
   Murdoch, I
TI Audit of Web-based telemedicine in ophthalmology
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
ID TELE-OPHTHALMOLOGY
AB A Web-based service was set up to link subspecialist ophthalmologists with those seeking advice on particular clinical problems in ophthalmology. The service operated between countries, with centres in Malaysia, Ghana, Tanzania, South Africa and Gambia seeking advice from Moorfields Eye Hospital in the UK. It also operated within country, where a rural clinic in The Gambia sought advice from the central hospital on difficult cases or cases for possible referral. Provision of Web access and training in image capture and manipulation were undertaken in each participating centre. During the first 12 months, 132 cases were posted to the Website from five of the six centres participating. The rate of case referral rose to about 12-14 cases per month by the end of the study. Overall, 24% of referrals did not use images. In the first four months the response time was 13 days, and in the last four months it was three days. Most cases were answered with a single response from the specialist. The main problem was the amount of Internet down-time in each of the locations. The main benefit was safe and reliable access to specialist advice for practitioners.
C1 UCL, Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, London EC1V 9EL, England.
   CCBRT Disabil Hosp, Dar Es Salaam, Tanzania.
   Selayang Hosp, Selayang, Malaysia.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
   Korle Bu Teaching Hosp, Accra, Ghana.
   Moorfields Eye Hosp, London, England.
   Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.
RP Murdoch, I (reprint author), UCL, Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, Bath St, London EC1V 9EL, England.
EM i.murdoch@ucl.ac.uk
CR Beaglehole R, 2004, LANCET, V363, P2084, DOI 10.1016/S0140-6736(04)16461-1
   Blomdahl S, 2001, J Telemed Telecare, V7 Suppl 1, P25, DOI 10.1258/1357633011936598
   Bowman RJC, 2003, EYE, V17, P743, DOI 10.1038/sj.eye.6700489
   Chen LS, 2004, J TELEMED TELECARE, V10, P337, DOI 10.1258/1357633042602035
   Hersh D., 2003, Journal of Telemedicine and Telecare, DOI 10.1258/135763303322596174
   Johnston K, 2004, HEALTH POLICY PLANN, V19, P302, DOI 10.1093/heapol/czh035
   Lamminen H, 1999, J TELEMED TELECARE, V5, P118, DOI 10.1258/1357633991933422
   *SOC COMP APPL RAD, UND IM COMPR 1997
   Taylor P, 2003, J TELEMED TELECARE, V9, P140, DOI 10.1258/135763303767149933
   Thylefors B, 1998, Community Eye Health, V11, P1
NR 10
TC 4
Z9 5
U1 0
U2 3
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 1357-633X
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PY 2006
VL 12
IS 2
BP 88
EP 91
DI 10.1258/135763306776084356
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 028CG
UT WOS:000236462800008
PM 16539756
OA No
DA 2017-08-15
ER

PT J
AU Olola, CHO
   Missinou, MA
   Issifou, S
   Anane-Sarpong, E
   Abubakar, I
   Gandi, JN
   Chagomerana, M
   Pinder, M
   Agbenyega, T
   Kremsner, PG
   Newton, CRJC
   Wypij, D
   Taylor, TE
AF Olola, C. H. O.
   Missinou, M. A.
   Issifou, S.
   Anane-Sarpong, E.
   Abubakar, I.
   Gandi, J. N.
   Chagomerana, M.
   Pinder, M.
   Agbenyega, T.
   Kremsner, P. G.
   Newton, C. R. J. C.
   Wypij, D.
   Taylor, T. E.
CA SMAC Network
TI Medical Informatics in medical research - The Severe Malaria in African
   Children (SMAC) network's experience
SO METHODS OF INFORMATION IN MEDICINE
LA English
DT Article
DE medical informatics computing; malaria; multi-center studies
ID CLINICAL-RESEARCH; PATIENT RECORD; DATA-ENTRY
AB Objectives: Computers are widely used for data management in clinical trials in the developed countries, unlike in developing countries. Dependable systems are vital for data management, and medical decision making in clinical research. Monitoring and evaluation of data management is critical. In this paper we describe database structures and procedures of systems used to implement, coordinate, and sustain data management in Africa. We outline major lessons, challenges and successes achieved, and recommendations to improve medical informatics application in biomedical research in sub-Saharan Africa.
   Methods: A consortium of experienced research units at five sites in Africa in studying children with disease formed a new clinical trials network, Severe Malaria in African Children. In December 2000, the network introduced on observational study involving these hospital-based sites. After prototyping, relational database management systems were implemented for data entry and verification, data submission and quality assurance monitoring.
   Results: Between 2000 and 2005, 25,858 patients were enrolled. Failure to meet data submission deadline and data entry errors correlated positively (correlation coefficient, r = 0.82), with more errors occuring when data was submitted late. Data submission lateness correlated inversely with hospital admissions (r = -0.62).
   Conclusions: Developing and sustaining dependable DBMS, ongoing modifications to optimize data management is crucial for clinical studies. Monitoring and communication systems are vital in multi-center networks for good data management. Data timeliness is associated with data quality and hospital admissions.
C1 KEMRI, Wellcome Trust Res Labs, Kilifi Dist Hosp, Ctr Geog Med Res, Kilifi 80108, Kenya.
   Albert Schweitzer Hosp, Tubingen, Germany.
   Univ Tubingen, Inst Trop Med, Dept Parasitol, Tubingen, Germany.
   Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Physiol, Kumasi, Ghana.
   Komfo Anokye Teaching Hosp, Kumasi, Ghana.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
   Childrens Hosp, Clin Res Program, Boston, MA 02115 USA.
   Michigan State Univ, Dept Internal Med, Coll Osteopath Med, E Lansing, MI 48824 USA.
RP Olola, CHO (reprint author), KEMRI, Wellcome Trust Res Labs, Kilifi Dist Hosp, Ctr Geog Med Res, POB 230, Kilifi 80108, Kenya.
EM c_olola@yahoo.com
RI Newton, Charles/C-6222-2009; Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507
FU NIAID NIH HHS [AI45955]
CR Booman Marlize, 2003, Malar J, V2, P13, DOI 10.1186/1475-2875-2-13
   Caloto T, 2001, BMC Med Res Methodol, V1, P14, DOI 10.1186/1471-2288-1-14
   Clarke K, 2003, METHOD INFORM MED, V42, P345
   Faber MG, 2003, METHOD INFORM MED, V42, P371
   *FILEMAKER INC, 1984, FIL MAKERPRO
   Goundry P, 1995, Health Libr Rev, V12, P261, DOI 10.1046/j.1365-2532.1995.1240261.x
   *HIMAL, 2002, INT WORKSH NEW DISTR
   Kawado M, 2003, CONTROL CLIN TRIALS, V24, P560, DOI 10.1016/S0197-2456(03)00089-8
   KENDALL M, 2000, SCI RES, V10, P1058
   Kobayashi J, 2004, ACTA TROP, V89, P299, DOI 10.1016/j.actatropica.2003.10.009
   Lorenzi NM, 2000, J AM MED INFORM ASSN, V7, P116
   *MICR CORP, 1999, MICR OFF 97
   Missinou MA, 2005, AM J TROP MED HYG, V72, P301
   Pogash RM, 2001, CONTROL CLIN TRIALS, V22, p168S, DOI 10.1016/S0197-2456(01)00170-2
   *STATA, 2004, STATA 8 WIND
   TAYLOR TE, 2005, T ROY SOC TROP MED H, V100, P615
   Timmons S, 2003, METHOD INFORM MED, V42, P471
   Tuttle MS, 1997, J AM MED INFORM ASSN, V4, P322
   Webster C, 2002, INT J MED INFORM, V68, P39, DOI 10.1016/S1386-5056(02)00062-X
   Yourdon E., 1989, MODERN STRUCTURED AN
NR 20
TC 5
Z9 5
U1 0
U2 1
PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI STUTTGART
PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY
SN 0026-1270
J9 METHOD INFORM MED
JI Methods Inf. Med.
PY 2006
VL 45
IS 5
BP 483
EP 491
PG 9
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA 093EA
UT WOS:000241149400003
PM 17019501
OA No
DA 2017-08-15
ER

PT J
AU Bah, G
   Jaye, A
AF Bah, Gibril
   Jaye, Assan
TI Haematological measurements and iron levels in HIV-infected Gambian
   subjects
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Bah, Gibril; Jaye, Assan] MRC Labs, Dept Haematol, Fajara, Gambia.
EM gbah@mrc.gm
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2006
VL 3
SU 1
MA P4
PG 1
WC Virology
SC Virology
GA V52ZS
UT WOS:000203582000114
OA gold
DA 2017-08-15
ER

PT J
AU Jallow, S
   Kaye, S
   Brandin, E
   Albert, J
   Vanham, G
   Whittle, H
   Rowland-Jones, S
   Janssens, W
AF Jallow, Sabelle
   Kaye, Steve
   Brandin, Eleanor
   Albert, Jan
   Vanham, Guido
   Whittle, Hilton
   Rowland-Jones, Sarah
   Janssens, Wouter
TI Development and evaluation of the oligonucleotide ligation assay (OLA)
   for the detection of drug resistance mutations in HIV-2 patients on
   antiretroviral therapy
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Jallow, Sabelle; Kaye, Steve; Whittle, Hilton; Rowland-Jones, Sarah] MRC, Banjul, Gambia.
   [Jallow, Sabelle; Vanham, Guido; Janssens, Wouter] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
   [Brandin, Eleanor; Albert, Jan] Swedish Inst Infect Dis Control, Dept Virol, Solna, Sweden.
EM sjallow@itg.be
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2006
VL 3
SU 1
MA P29
PG 1
WC Virology
SC Virology
GA V52ZS
UT WOS:000203582000138
OA gold
DA 2017-08-15
ER

PT J
AU Leligdowicz, A
   Yindom, LM
   Jaye, A
   Dong, T
   Alabi, A
   Sarge-N'jie, R
   Njai, H
   McMichael, A
   Whittle, H
   Rowland-Jones, S
AF Leligdowicz, Aleksandra
   Yindom, Louis-Marie
   Jaye, Assan
   Dong, Tao
   Alabi, Abraham
   Sarge-N'jie, Ramu
   Njai, Harr
   McMichael, Andrew
   Whittle, Hilton
   Rowland-Jones, Sarah
TI HIV-2 gene product-specific T cell responses and viraemia control
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Leligdowicz, Aleksandra; Yindom, Louis-Marie; Jaye, Assan; Alabi, Abraham; Sarge-N'jie, Ramu; Njai, Harr; Whittle, Hilton; Rowland-Jones, Sarah] MRC Labs, Fajara, Gambia.
   [Leligdowicz, Aleksandra; Dong, Tao; McMichael, Andrew; Rowland-Jones, Sarah] Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2006
VL 3
SU 1
MA S35
PG 2
WC Virology
SC Virology
GA V52ZS
UT WOS:000203582000036
OA gold
DA 2017-08-15
ER

PT J
AU Ondondo, B
   Yang, H
   Dong, T
   de Gleria, K
   Suttill, A
   Conlon, C
   Brown, D
   Williams, P
   Bowness, P
   Rowland-Jones, SL
   Hanke, T
   McMichael, A
   Dorrell, L
AF Ondondo, Beatrice
   Yang, Hongbing
   Dong, Tao
   de Gleria, Kati
   Suttill, Annie
   Conlon, Christopher
   Brown, Denise
   Williams, Patricia
   Bowness, Paul
   Rowland-Jones, Sarah L.
   Hanke, Tomas
   McMichael, Andrew
   Dorrell, Lucy
TI Detection of broad functional gag-specific CD4+T cell responses in
   HIV-1-infected subjects following therapeutic immunization with rMVA
   expressing an HIV-1 gag immunogen
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Ondondo, Beatrice; Yang, Hongbing; Dong, Tao; de Gleria, Kati; Suttill, Annie; Conlon, Christopher; Brown, Denise; Williams, Patricia; Bowness, Paul; Rowland-Jones, Sarah L.; Hanke, Tomas; McMichael, Andrew; Dorrell, Lucy] Univ Oxford, Weatheral Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.
   [Ondondo, Beatrice; Rowland-Jones, Sarah L.] MRC Labs, Viral Dis Program, Banjul, Gambia.
EM beatrice.ondondo@wolfson.oxford.ac.uk
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2006
VL 3
SU 1
MA S36
PG 1
WC Virology
SC Virology
GA V52ZS
UT WOS:000203582000037
OA gold
DA 2017-08-15
ER

PT J
AU Nwakanma, D
   Duny, S
   Jawara, M
   Kheir, A
   Pinder, M
   Mackinnon, M
   Milligan, P
   Walliker, D
   Babiker, HA
AF Nwakanma, Davis
   Duny, Sam
   Jawara, Musa
   Kheir, Amani
   Pinder, Margaret
   Mackinnon, Margaret
   Milligan, Paul
   Walliker, David
   Babiker, Hamza A.
TI Plasmodium falciparum in the gambia: Persistance in the dry season and
   increased complexity in mosquitoes in the wet season
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Nwakanma, Davis; Duny, Sam; Jawara, Musa; Pinder, Margaret; Milligan, Paul] MRC Labs, Banjul, Gambia.
   [Kheir, Amani; Mackinnon, Margaret; Walliker, David] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   [Babiker, Hamza A.] Sultan Qaboos Univ, Al Khoud, Oman.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2005
VL 73
IS 6
SU S
MA 316
BP 104
EP 104
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA V44GA
UT WOS:000202990000315
OA No
DA 2017-08-15
ER

PT J
AU Wootton, D
   Opara, H
   Nyirenda, M
   Blencoe, H
   Kanjala, M
   Baldeh, I
   Woessners, M
   Neate, C
   Duparc, S
   Kirby, P
   Milligan, P
   Molyneux, M
   Dunyo, S
   Winstanley, P
AF Wootton, Dan
   Opara, Hyginus
   Nyirenda, Maggie
   Blencoe, Hannah
   Kanjala, Maxwell
   Baldeh, Ignatius
   Woessners, Mary
   Neate, Colin
   Duparc, Stephan
   Kirby, Paula
   Milligan, Paul
   Molyneux, Malcolm
   Dunyo, Sam
   Winstanley, Peter
TI An open, dose-ranging, phase II trial of chlorproguanil/dapsone with
   three doses of artesunate for the treatment of acute uncomplicated
   Plasmodium Falciparum malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Wootton, Dan] Royal Liverpool Univ Hosp, Trop & Infect Dis Unit, Liverpool, Merseyside, England.
   [Opara, Hyginus; Baldeh, Ignatius; Dunyo, Sam] MRC Labs, Fajara, Gambia.
   [Nyirenda, Maggie; Blencoe, Hannah] Coll Med, Blantyre, Malawi.
   [Kanjala, Maxwell] Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre, Malawi.
   [Woessners, Mary] GlaxoSmithKline Inc, Philadelphia, PA USA.
   [Neate, Colin; Duparc, Stephan; Kirby, Paula] GlaxoSmithKline Inc, London, England.
   [Milligan, Paul] London Sch Hyg & Trop Med, London, England.
   [Winstanley, Peter] Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2005
VL 73
IS 6
SU S
MA 670
BP 222
EP 222
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA V44GA
UT WOS:000202990001093
OA No
DA 2017-08-15
ER

PT J
AU Lleonart, ME
   Kirk, GD
   Villar, S
   Lesi, OA
   Dasgupta, A
   Goedert, JJ
   Mendy, M
   Hollstein, MC
   Montesano, R
   Groopman, JD
   Hainaut, P
   Friesen, MD
AF Lleonart, ME
   Kirk, GD
   Villar, S
   Lesi, OA
   Dasgupta, A
   Goedert, JJ
   Mendy, M
   Hollstein, MC
   Montesano, R
   Groopman, JD
   Hainaut, P
   Friesen, MD
TI Quantitative analysis of plasma TP53 249(Ser)-mutated DNA by
   electrospray ionization mass spectrometry
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA PATIENTS; CELL-FREE DNA; HEPATITIS-B; P53 GENE;
   AFLATOXIN B-1; WEST-AFRICA; CODON-249 MUTATIONS; PROSTATE-CANCER;
   GAMBIA; INFECTION
AB A mutation in codon 249 of the TP53 gene (249(Ser)), related to aflatoxin B, exposure, has previously been associated with hepatocellular carcinoma risk. Using a novel internal standard plasmid, plasma concentrations of 249(Ser)-mutated DNA were quantified by electrospray ionization mass spectrometry in 89 hepatocellular carcinoma cases, 42 cirrhotic patients, and 131 nonliver diseased control subjects, all from highly aflatoxin-exposed regions of The Gambia. The hepatocellular carcinoma cases had higher median plasma concentrations of 249 Se, (2,800 copies/mL; interquartile range: 500-11,000) compared with either cirrhotic (500 copies/mL; interquartile range: 500-2,600) or control subjects (500 copies/mL; interquartile range: 500-2,000; P < 0.05). About half (52%) of the hepatocellular carcinoma cases had >2,500 copies of 249(Ser)/mL plasma, corresponding to the prevalence of this mutation in liver tumors in The Gambia. In comparison, only 15% of control group and 26% of cirrhotic participants exceeded this level (P < 0.05). Further subset analysis revealed a statistically significant, quantitative relation between diagnosis of hepatocellular carcinoma and levels of 249(Ser) detected at 2,501 to 10,000 copies/mL plasma (odds ratio, 3.8; 95% confidence interval, 1.3-10.9) and at >10,000 copies/mL plasma (odds ratio, 62; 95% confidence interval, 4.7-820) when compared with control subjects and after adjusting for age, gender, recruitment site, hepatitis B and C serologic status, and total DNA concentration. Levels of >10,000 copies of 249(Ser)/mL plasma were also significantly associated with the diagnosis of hepatocellular carcinoma (odds ratio, 15; 95% confidence interval, 1.6-140) when compared with cirrhotic patients. Potential applications for the quantification of 249(Ser) DNA in plasma include estimation of long-term, cumulative aflatoxin exposure and selection of appropriate high-risk individuals for targeted intervention.
C1 Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
   IARC, Lyon, France.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
   NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
   MRC, Banjul, Gambia.
   German Canc Res Ctr, Dept Genet Alterat Carcinogenesis, Heidelberg, Germany.
RP Friesen, MD (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room E7032, Baltimore, MD 21205 USA.
EM mfriesen@jhsph.edu
RI Kirk, Gregory/A-8484-2009; Friesen, Marlin/D-7328-2012; Hainaut, Pierre
   /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
FU NCI NIH HHS [N02 CP 40521]; NIEHS NIH HHS [P01 ES 06052]
CR Allen D, 2004, ANN NY ACAD SCI, V1022, P76, DOI 10.1196/annals.1318.013
   Anker P, 2000, ANN NY ACAD SCI, V906, P5
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   Bruix J, 2003, LIVER TRANSPLANT, V9, P700, DOI 10.1053/jlts.2003.50124
   Bruix J, 2003, HEPATOLOGY, V37, P507, DOI 10.1053/jhep.2003.50142
   Gormally E, 2004, INT J CANCER, V111, P746, DOI 10.1002/ijc.20327
   Hainaut P, 2000, ADV CANCER RES, V77, P81
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   The International Agency for Research on Cancer (IARC), 2002, IARC MONOGR EVAL CAR, V82, P1
   Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101
   Jackson PE, 2001, CANCER RES, V61, P33
   Jung K, 2004, CANCER LETT, V205, P173, DOI 10.1016/j.canlet.2003.11.023
   Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076
   Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x
   Kew MC, 2002, TOXICOLOGY, V181, P35, DOI 10.1016/S0300-483X(02)00251-2
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352
   LLEONART ME, 2004, NUCLEIC ACIDS RES, V32, P53
   Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080
   Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   Qian GS, 2002, CANCER EPIDEM BIOMAR, V11, P1126
   Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699
   Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P617
   STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5
   Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   Taback B, 2004, CURR OPIN MOL THER, V6, P273
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8
NR 36
TC 22
Z9 22
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD DEC
PY 2005
VL 14
IS 12
BP 2956
EP 2962
DI 10.1158/1055-9965.EPI-05-0612
PG 7
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 994UB
UT WOS:000234055600022
PM 16365016
OA No
DA 2017-08-15
ER

PT J
AU Owens, S
   Chamley, LW
   Ordi, J
   Brabin, BJ
   Johnson, PM
AF Owens, S
   Chamley, LW
   Ordi, J
   Brabin, BJ
   Johnson, PM
TI The association of anti-phospholipid antibodies with parity in placental
   malaria
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE anti-phospholipid antibody; beta(2) glycoprotein I; cardiolipin; malaria
   placenta
ID TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM MALARIA; ANTICARDIOLIPIN
   ANTIBODIES; BIRTH-WEIGHT; BETA-2-GLYCOPROTEIN-I; PREVALENCE; INFECTION;
   PREGNANCY; CYTOKINES; MALAWI
AB Anti-phospholipid antibodies (aPL) are autoantibodies associated with both infections and the pathogenesis of certain pregnancy complications. In the latter, but not the former, aPL are dependent on a co-factor, beta(2) glycoprotein I (beta 2GPI), which can also be used as an antigen for detection of such aPL in pregnancy. A cross-sectional study was carried out on serum samples from Kumasi, Ghana, to determine the occurrence and beta 2GPI-dependence of aPL in placental malaria. Anti-cardiolipin, anti-phosphatidylserine and anti-beta 2GPI enzyme-linked immunosorbent assays (ELISAs) were performed on sera from 103 HIV-non-infected gravid women. Placental malaria, both active and past infection, was diagnosed in 33/103 (32%) based on placental histology. In multiparae, beta 2GPI-independent IgM antibodies to cardiolipin (P = 0(.)018) and phosphatidylserine (P = 0(.)009) were observed, which were most pronounced in past placental malaria infection. In primiparae, no association emerged between aPL and placental malaria. Trends for improved clinical parameters were identified in infected women with levels of anticardiolipin beyond the 99th multiple of the median for a healthy, non-malarious population. This study in placental malaria reports parity associations of beta 2GPI-independent aPL profiles, and does not support a role for beta 2GPI-dependent aPL. It is of significance in the context of the known parity differences in pregnancy malaria immunity.
C1 Univ Liverpool, Div Immunol, Liverpool L69 3BX, Merseyside, England.
   MRC Labs, Fajara, Gambia.
   Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   Univ Auckland, Fac Med & Hlth Sci, Dept Obstet & Gynaecol, Auckland 1, New Zealand.
   Univ Barcelona, Dept Anat Patol, Barcelona, Spain.
   Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, NL-1105 AZ Amsterdam, Netherlands.
RP Johnson, PM (reprint author), Univ Liverpool, Div Immunol, Duncan Bldg,POB 147, Liverpool L69 3BX, Merseyside, England.
EM mq22@liv.ac.uk
OI Chamley, Lawrence/0000-0002-7501-1340
CR BATE CAW, 1993, IMMUNOLOGY, V79, P138
   Brabin BJ, 2004, ANN TROP PAEDIATR, V24, P311, DOI 10.1179/027249304225019136
   Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019
   BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   Chamley LW, 2002, J REPROD IMMUNOL, V57, P185, DOI 10.1016/S0165-0378(02)00041-4
   Chamley LW, 1998, LANCET, V352, P1037, DOI 10.1016/S0140-6736(05)60080-3
   Chamley LW, 1997, PLACENTA, V18, P403, DOI 10.1016/S0143-4004(97)80040-9
   Cockerill KA, 2004, CLIN IMMUNOL, V112, P129, DOI 10.1016/j.clim.2004.02.001
   Consigny PH, 2002, CLIN EXP IMMUNOL, V127, P158, DOI 10.1046/j.1365-2249.2002.01722.x
   Daniel-Ribeiro CT, 2000, ACTA TROP, V76, P205, DOI 10.1016/S0001-706X(00)00099-1
   de Laat HB, 2004, CLIN IMMUNOL, V112, P161, DOI 10.1016/j.clim.2004.02.012
   Fried M, 1998, J IMMUNOL, V160, P2523
   HUNT JE, 1992, LUPUS, V1, P75, DOI 10.1177/096120339200100204
   Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8
   JAKOBSEN PH, 1993, IMMUNOLOGY, V79, P653
   Kutteh WH, 1999, AM J REPROD IMMUNOL, V41, P133
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   le Cessie S., 2002, Archives of Disease in Childhood, V86, pF182, DOI 10.1136/fn.86.3.F182
   McGuire W, 1998, T ROY SOC TROP MED H, V92, P50, DOI 10.1016/S0035-9203(98)90951-8
   Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449
   Meroni PL, 2004, CLIN IMMUNOL, V112, P169, DOI 10.1016/j.clim.2004.02.015
   Ordi J, 1998, AM J SURG PATHOL, V22, P1006, DOI 10.1097/00000478-199808000-00011
   Richards AL, 1997, INT J PARASITOL, V27, P1251, DOI 10.1016/S0020-7519(97)00122-7
   Rogerson SJ, 2003, INFECT IMMUN, V71, P267, DOI 10.1128/IAI.71.1.267-270.2003
   Romagosa C, 2004, ACTA TROP, V90, P277, DOI 10.1016/j.actatropica.2004.02.003
   Stern C, 1998, FERTIL STERIL, V70, P938, DOI 10.1016/S0015-0282(98)00312-4
   Suguitan AL, 2004, INFECT IMMUN, V72, P5267, DOI 10.1128/IAI.72.9.5267-5273.2004
   Verhoeff FH, 2004, ANN TROP PAEDIATR, V24, P161, DOI 10.1179/027249304225013448
NR 28
TC 4
Z9 4
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2005
VL 142
IS 3
BP 512
EP 518
DI 10.1111/j.1365-2249.2005.02936.x
PG 7
WC Immunology
SC Immunology
GA 982EC
UT WOS:000233139700015
PM 16297164
OA No
DA 2017-08-15
ER

PT J
AU Luoni, G
   Forton, J
   Jallow, M
   Akha, ES
   Sisay-Joof, F
   Pinder, M
   Hanchard, N
   Herbert, M
   Kimber, M
   Mott, R
   Hull, J
   Rockett, K
   Kwiatkowski, D
AF Luoni, G
   Forton, J
   Jallow, M
   Akha, ES
   Sisay-Joof, F
   Pinder, M
   Hanchard, N
   Herbert, M
   Kimber, M
   Mott, R
   Hull, J
   Rockett, K
   Kwiatkowski, D
TI Population-specific patterns of linkage disequilibrium in the human 5q31
   region
SO GENES AND IMMUNITY
LA English
DT Article
ID HUMAN GENOME; CHROMOSOME 5Q31-Q33; HAPLOTYPE STRUCTURE; LOCUS; GENE;
   POLYMORPHISM; ASSOCIATION; INFECTION; SELECTION; ASTHMA
AB Linkage disequilibrium across the human genome is generally lower in West Africans than Europeans. However in the 5q31 region, which is rich in immune genes, we find significantly more examples of apparent nonrecombination between distant marker pairs in West Africans. Much of this effect is due to SNPs that are absent in Europeans, possibly reflecting recent positive selection in the West African population.
C1 Wellcome Trust Ctr Human Genet, Univ Dept Paediat, Oxford OX3 7BN, England.
   MRC Labs, Fajara, Gambia.
RP Kwiatkowski, D (reprint author), Wellcome Trust Ctr Human Genet, Univ Dept Paediat, Roosevelt Dr, Oxford OX3 7BN, England.
EM dominic@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176
CR Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24
   Ahmadi KR, 2005, NAT GENET, V37, P84, DOI 10.1038/ng1488
   Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616
   Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777
   Bamshad M, 2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436
   Howard TD, 2001, AM J RESP CELL MOL, V25, P377
   Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1
   Luoni G, 2001, GENES IMMUN, V2, P411, DOI 10.1038/sj.gene.6363797
   Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181
   MOTT R, 2003, MARKER SELECTION MAX
   Noguchi E, 2001, HUM IMMUNOL, V62, P1251, DOI 10.1016/S0198-8859(01)00338-X
   Rihet P, 1998, AM J HUM GENET, V63, P498, DOI 10.1086/301967
   Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Zhang K, 2003, BIOINFORMATICS, V19, P1300, DOI 10.1093/bioinformatics/btg142
NR 19
TC 4
Z9 4
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD DEC
PY 2005
VL 6
IS 8
BP 723
EP 727
DI 10.1038/sj.gene.6364250
PG 5
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 989EX
UT WOS:000233656800012
PM 16052173
OA No
DA 2017-08-15
ER

PT J
AU Hill, RC
   Stevens, W
   Hill, S
   Bah, J
   Donkor, SA
   Jallow, A
   Lienhardt, C
AF Hill, RC
   Stevens, W
   Hill, S
   Bah, J
   Donkor, SA
   Jallow, A
   Lienhardt, C
TI Risk factors for defaulting from tuberculosis treatment: a prospective
   cohort study of 301 cases in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE The Gambia; tuberculosis; defaulting; cost; knowledge
ID SMEAR-POSITIVE TUBERCULOSIS; DOTS PROGRAM; SOUTH-INDIA; DETERMINANTS;
   ETHIOPIA; DISTRICT; AFRICA; MALAWI; TRIAL
AB SETTING: An urban tuberculosis (TB) clinic, The Gambia.
   OBJECTIVE: To identify patient characteristics associated with increased rates of defaulting from treatment, specifically knowledge and cost factors amenable to intervention.
   DESIGN: Prospective cohort study of TB cases at least 15 years of age commencing treatment, interviewed by semi-structured questionnaire and followed for attendance at thrice-weekly directly observed treatment (DOT).
   RESULTS: Of 301 patients, 76 (25.2%) defaulted from treatment and 25 did not return for treatment. The defaulting rate was higher among those who said they were uncertain that their treatment would work (HR 3.64; 95%CI 1.42-9.31, P = 0.007) and among those who incurred significant time or money costs travelling to receive treatment (HR 2.67; 95%CI 1.05-6.81; P 0.04). These factors had differing effects with respect to time: uncertainty over treatment success was important in the first 90 days of treatment, while increased cost of travelling to the clinic was important after 90 days.
   CONCLUSION: In The Gambia, risk groups for defaulting can be recognised at the start of treatment and are at highest risk at different times. Home-based self-admimstration of medications after 3 months of DOT should be considered as confidence in treatment success rises, and the costs of travelling to receive treatment start to take their toll.
C1 MRC Labs, Dept Tuberculosis, Banjul, Gambia.
   Gambia Govt, Dept Dis Control, Banjul, Gambia.
   Inst Rech Dev, Tuberculosis Unit, Dakar, Senegal.
RP Hill, RC (reprint author), MRC Labs, Dept Tuberculosis, POB 273, Banjul, Gambia.
EM phill@mrc.gm
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Balasubramanian R, 2004, INT J TUBERC LUNG D, V8, P323
   Borgdorff MW, 2000, EUR RESPIR J, V16, P209, DOI 10.1034/j.1399-3003.2000.16b05.x
   Chin DP, 2000, INT J TUBERC LUNG D, V4, P744
   Comolet TM, 1998, INT J TUBERC LUNG D, V2, P891
   Connolly C, 1999, INT J TUBERC LUNG D, V3, P1081
   DEMISSIE M, 1994, ETHIOPIAN MED J, V32, P97
   Eastwood SV, 2004, INT J TUBERC LUNG D, V8, P70
   Harper M, 2003, T ROY SOC TROP MED H, V97, P506, DOI 10.1016/S0035-9203(03)80007-X
   Harries AD, 1998, T ROY SOC TROP MED H, V92, P343, DOI 10.1016/S0035-9203(98)91036-7
   *KNVC, 2004, 4 KNVC
   Liam CK, 1999, INT J TUBERC LUNG D, V3, P300
   Liefooghe R, 1999, INT J TUBERC LUNG D, V3, P1073
   Lienhardt C, 1998, INT J TUBERC LUNG D, V2, P712
   Mitike G, 1997, E AFR MED J, V74, P154
   Nyirenda TE, 2003, INT J TUBERC LUNG D, V7, pS21
   Rathman G, 2003, INT J TUBERC LUNG D, V7, P942
   Santha T, 2002, INT J TUBERC LUNG D, V6, P780
   Tam C. M., 2003, Hong Kong Medical Journal, V9, P83
   Tekle B, 2002, INT J TUBERC LUNG D, V6, P573
   Wobeser W, 1999, CAN MED ASSOC J, V160, P789
   Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7
NR 22
TC 20
Z9 20
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD DEC
PY 2005
VL 9
IS 12
BP 1349
EP 1354
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 007PJ
UT WOS:000234981300009
PM 16466057
OA No
DA 2017-08-15
ER

PT J
AU Howie, S
   Voss, L
   Baker, M
   Calder, L
   Grimwood, K
   Byrnes, C
AF Howie, S
   Voss, L
   Baker, M
   Calder, L
   Grimwood, K
   Byrnes, C
TI Tuberculosis in New Zealand, 1992-2001: a resurgence
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article; Proceedings Paper
CT International Conference of the
   American-Thoracic-Society/American-Lung-Association
CY 2003
CL Seattle, WA
SP Amer Thorac Soc, Amer Lung Assoc
ID PEDIATRIC TUBERCULOSIS; CLINICAL PRESENTATION; CHILDREN; EPIDEMIOLOGY;
   POPULATION; TRENDS; BURDEN
AB Objective: To describe the recent epidemiology and clinical features of paediatric tuberculosis ( TB) in New Zealand ( NZ).
   Methods: A retrospective review was conducted of clinical, laboratory, and radiology records of children < 16 years old diagnosed with TB between January 1992 and June 2001 in nine NZ health districts.
   Results: A total of 274 patients,16 years old were identified; the average annual TB rate was 4.8 per 100 000. Rates rose over time reaching a peak of 10.1 in 1999. Rates were highest in under-5 year olds, at 6.2 per 100 000, and varied by ethnicity: African 575.2, Pacific Island 15.2, Maori 6.4, Asian 5.6, and European 0.6. Seventy two cases ( 26%) were foreign born. Thirty six per cent of cases were not detected until they presented with symptoms and of these 44% had no known TB contact. Most cases were identified by contact tracing (48%) or immigrant screening (11%); 43% were part of outbreaks. Miliary TB or meningitis occurred in 8% of patients, two of whom died. Drug resistance was found in 7% of culture positive cases and no HIV co-infection was found.
   Conclusions: A resurgence of TB occurred among children in NZ between 1992 and 2001 predominantly involving non-European and immigrant groups. Despite established contact tracing and immigrant screening programmes, many cases were part of outbreaks, remained unidentified until symptoms arose, or had no known TB contact. These findings point to an unrecognised burden of adult disease, ongoing community transmission, and missed opportunities for prevention. Further study is required to confirm these hypotheses.
C1 Univ Auckland, Div Paediat, Auckland 1, New Zealand.
   Starship Childrens Hlth, Auckland, New Zealand.
   Univ Otago, Wellington Sch Med & Hlth Sci, Wellington, New Zealand.
   Inst Environm Sci & Res, Porirua, New Zealand.
   Auckland Dist Hlth Board, Publ Hlth, Auckland, New Zealand.
RP Howie, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM showie@mrc.gm
RI Grimwood, Keith/F-9334-2011
CR *AM AC PED, 2003, 2003 REP COMM INF DI, P642
   Balasegaram S, 2003, ARCH DIS CHILD, V88, P772, DOI 10.1136/adc.88.9.772
   BERGGREN P, 2004, ACTA PAEDIATR, V93, P311
   Burroughs M, 1999, PEDIATR INFECT DIS J, V18, P440, DOI 10.1097/00006454-199905000-00008
   Calder L, 2000, NEW ZEAL MED J, V113, P71
   CARR H, 2002, GUIDELINES TUBERCULO, P12
   Chaulk CP, 1997, PUBLIC HEALTH REP, V112, P146
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Correa AG, 1997, CLIN CHEST MED, V18, P89, DOI 10.1016/S0272-5231(05)70358-0
   Crampton P SC, 1997, SOC POLICY J N Z, V9, P186
   *DEP STAT, EXT MIGR DEC 2003 YE
   *DEP STAT, 1996, NZ CENS POP DWELL
   De Zoysa R, 2001, N Z PUBLIC HLTH REP, V8, P1
   DRIVER CR, 1995, PEDIATR INFECT DIS J, V14, P112, DOI 10.1097/00006454-199502000-00006
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Harrison A, 1999, NEW ZEAL MED J, V112, P363
   HARRISON A, 2003, GUIDELINES TUBERCULO
   HILL P, 2000, NZ PUBLIC HLTH REP, V7, P41
   Martin P, 2000, NEW ZEAL MED J, V113, P68
   Milburn HJ, 2000, ARCH DIS CHILD, V82, P386, DOI 10.1136/adc.82.5.386
   *MIN HLTH, 1996, TUB IMM HDB, P114
   *MIN HLTH, 2004, NEW MIGR HLTH DIS SC
   *MIN HLTH, 1996, GUID TUB CONTR NZ 19
   Nelson LJ, 2004, PEDIATRICS, V114, P333, DOI 10.1542/peds.114.2.333
   Palme IB, 2002, PEDIATR INFECT DIS J, V21, P1053, DOI 10.1097/01.inf.0000036090.75121.f3
   Parslow R, 2001, ARCH DIS CHILD, V84, P109, DOI 10.1136/adc.84.2.109
   SALMOND C, 1998, 8 NZDEP HLTH SERV RE
   STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3
   STARKE JR, 1989, PEDIATRICS, V84, P28
   TURNBULL F, 2003, GUIDELINES TUBERCULO
   VALLEJO JG, 1994, PEDIATRICS, V94, P1
   Walls T, 2004, J INFECTION, V48, P13, DOI 10.1016/S0163-4453(03)00121-X
   WHO, 2003, GLOB TUB CONTR SURV
   World Health Organization, 1983, PROV GUID DIAGN CLAS, P83
   WOODHOUSE A, 2003, GUIDELINES TUBERCULO
NR 35
TC 17
Z9 19
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD NOV
PY 2005
VL 90
IS 11
BP 1157
EP 1161
DI 10.1136/ADC.2005.066415
PG 5
WC Pediatrics
SC Pediatrics
GA 976HI
UT WOS:000232723500018
PM 16243871
OA No
DA 2017-08-15
ER

PT J
AU Faal, N
   Bailey, RL
   Sarr, I
   Joof, H
   Mabey, DCW
   Holland, MJ
AF Faal, N
   Bailey, RL
   Sarr, I
   Joof, H
   Mabey, DCW
   Holland, MJ
TI Temporal cytokine gene expression patterns in subjects with trachoma
   identify distinct conjunctival responses associated with infection
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE chlamydia; conjunctiva; cytokine; immunity; trachoma
ID GENITAL-TRACT INFECTION; REGULATORY T-CELLS; CHLAMYDIA-TRACHOMATIS;
   TNF-ALPHA; PROTECTIVE IMMUNITY; DENDRITIC CELLS; IFN-GAMMA; IL-10; MICE;
   RESOLUTION
AB Ocular chlamydial disease is clinically diagnosed by the appearance of characteristic inflammatory changes and development of lymphoid follicles in the conjunctiva. Nucleic acid amplification tests and relatively non-invasive methods of sampling the conjunctival surface can be used to quantify the expression of chlamydial and host genes. Using quantitative real-time polymerase chain reaction to detect the presence of Chlamydia trachomatis (CT) 16S rRNA and human interleukin (IL)-1 beta, IL-10, IL-12p40, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha transcripts we examined the immune response at the conjunctival surface in a cohort of children living in a trachoma-endemic village in The Gambia. Elevated cytokine transcript levels were associated with the presence of CT 16S rRNA. Subclinical infection (CT infection without clinical signs of disease) elicited an immune response that is proinflammatory in nature, with elevations in the transcription of IL-1 beta, IFN-gamma and IL-12p40. Clinically apparent infections were associated with the elevation of mRNA for the multi-functional cytokine TNF-alpha (fibrotic, type 1 inflammatory and regulatory) and the counter regulatory cytokine, IL-10, in addition to the other proinflammatory cytokines. A positive correlation between IFN-gamma transcript levels and the amount of CT 16S rRNA expressed in conjunctiva was found.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Faal, N (reprint author), MRC Labs, POB 273,Atlantic Rd, Banjul, Gambia.
EM nfaal@mrc.gm
OI Mabey, David/0000-0002-0031-8276
FU Medical Research Council [MC_U190081961]
CR Abu El-Asrar AM, 1998, EYE, V12, P453
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BEATTY WL, 1994, INFECT IMMUN, V62, P3705
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   Bobo LD, 1997, J INFECT DIS, V176, P1524
   Brignole-Baudouin F, 2004, EXP EYE RES, V78, P473, DOI 10.1016/j.exer.2003.08.005
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI 10.1172/JCI200317993
   Chou DHI, 1996, J IMMUNOL, V156, P4354
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Darville T, 2001, INFECT IMMUN, V69, P3556, DOI 10.1128/IAI.69.6.3556-3561.2001
   DAWSON CR, 1981, GUIDE TRACHOMA CONTR, P56
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003
   Hoffmann KF, 2000, J IMMUNOL, V164, P6406
   Kelly KA, 2003, INT REV IMMUNOL, V22, P3, DOI 10.1080/08830180390156756
   Knop N, 2000, INVEST OPHTH VIS SCI, V41, P1270
   Lampe MF, 1998, INFECT IMMUN, V66, P5457
   Lu H, 1999, INFECT IMMUN, V67, P1763
   MABEY DCW, 1987, LANCET, V2, P1491
   Mellor AL, 2004, INT IMMUNOL, V16, P1391, DOI 10.1093/intimm/dxh140
   Mittrucker HW, 2004, EUR J IMMUNOL, V34, P306, DOI 10.1002/eji.200324578
   Morrison SG, 2001, INFECT IMMUN, V69, P2643, DOI 10.1128/IAI.69.4.2643-2649.2001
   Rottenberg ME, 2002, CURR OPIN IMMUNOL, V14, P444, DOI 10.1016/S0952-7915(02)00361-8
   Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Yang X, 1999, J IMMUNOL, V162, P1010
   Yang X, 2003, CURR PHARM DESIGN, V9, P67, DOI 10.2174/1381612033392486
   Yang X, 1996, J IMMUNOL, V156, P4338
   Zganiacz A, 2004, J CLIN INVEST, V113, P401, DOI 10.1172/JCI200418991
NR 30
TC 22
Z9 23
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD NOV
PY 2005
VL 142
IS 2
BP 347
EP 353
DI 10.1111/j.1365-2249.2005.02917.x
PG 7
WC Immunology
SC Immunology
GA 975JF
UT WOS:000232657300018
PM 16232223
OA No
DA 2017-08-15
ER

PT J
AU Meerman, L
   Ord, R
   Bousema, JT
   van Niekerk, M
   Osman, E
   Hallett, R
   Pinder, M
   Walraven, G
   Sutherland, CJ
AF Meerman, L
   Ord, R
   Bousema, JT
   van Niekerk, M
   Osman, E
   Hallett, R
   Pinder, M
   Walraven, G
   Sutherland, CJ
TI Carriage of chloroquine-resistant parasites and delay of effective
   treatment increase the risk of severe malaria in Gambian children
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 53rd Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 07-11, 2004
CL Miami Beach, FL
SP Amer Soc Trop Med & Hyg
ID PEDIATRIC CEREBRAL MALARIA; FALCIPARUM-MALARIA; AFRICAN CHILDREN;
   INDICATORS; TRANSMISSION; MOSQUITOS
AB Two hundred thirty-four Gambian children with severe falciparum malaria who were admitted to the pediatric ward of a rural district hospital each were matched for age with a same-sex control subject presenting as an outpatient with uncomplicated falciparum malaria. Severe malarial anemia (SMA) was the most common presentation ( 152 cases), followed by cerebral malaria ( 38 cases) and hyperparasitemia ( 26 cases). Children presenting with SMA were significantly younger and more likely to carry gametocytes than were children with other severe presentations. Alleles of the genes pfcrt and pfmdr1 associated with chloroquine-resistant parasites occurred together among cases presenting with SMA alone more often than among their matched controls (odds ratio, 2.08 [95% confidence interval, 1.04 - 4.38]; P = .039). Costs of travel to the hospital of more than US $0.20, use of mosquito repellents, and carriage of resistant parasites were identified as independent risk factors for severe malaria in the case-control analysis. We conclude that, in this setting, poor access to the hospital and a high prevalence of chloroquine-resistant parasites lead to a delay of adequate treatment for young children with malaria, who may then develop SMA.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   St Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands.
   MRC Labs, Banjul, Gambia.
RP Sutherland, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM colin.sutherland@lshtm.ac.uk
RI Bousema, Teun/N-3574-2014
CR Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2
   CARME B, 1994, AM J TROP MED HYG, V50, P131
   Cooke GS, 2003, AM J TROP MED HYG, V69, P565
   Genton B, 1997, INT J EPIDEMIOL, V26, P670, DOI 10.1093/ije/26.3.670
   Greenwood BM, 1997, ANN TROP MED PARASIT, V91, P763
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P151, DOI 10.1016/0035-9203(95)90472-7
   Luckner D, 1998, T ROY SOC TROP MED H, V92, P478, DOI 10.1016/S0035-9203(98)90882-3
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MARSH K, 1992, PARASITOLOGY, V104, P53
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Modiano D., 1999, Parassitologia (Rome), V41, P251
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Nacher M, 2001, ACTA TROP, V78, P139, DOI 10.1016/S0001-706X(00)00184-4
   Price R, 1999, AM J TROP MED HYG, V60, P1019
   RANGIT MR, 2004, TROP MED INT HEALTH, V9, P857
   Snow RW, 1998, T ROY SOC TROP MED H, V92, P381, DOI 10.1016/S0035-9203(98)91056-2
   Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Trape JF, 2001, AM J TROP MED HYG, V64, P12
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
NR 23
TC 34
Z9 34
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2005
VL 192
IS 9
BP 1651
EP 1657
DI 10.1086/496887
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 970TR
UT WOS:000232333000020
PM 16206082
OA No
DA 2017-08-15
ER

PT J
AU Mendy, M
   Kirk, GD
   van der Sande, M
   Jeng-Barry, A
   Lesi, OA
   Hainaut, P
   Sam, O
   McConkey, S
   Whittle, H
AF Mendy, M
   Kirk, GD
   van der Sande, M
   Jeng-Barry, A
   Lesi, OA
   Hainaut, P
   Sam, O
   McConkey, S
   Whittle, H
TI Hepatitis B surface antigenaemia and alpha-foetoprotein detection from
   dried blood spots: applications to field-based studies and to clinical
   care in hepatitis B virus endemic areas
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE alpha-foetoprotein; chronic hepatitis B virus infection; dried blood
   spot; hepatitis B surface antigen; hepatocellular carcinoma
ID CHRONIC LIVER-DISEASE; 2 GAMBIAN VILLAGES; HEPATOCELLULAR-CARCINOMA;
   WEST-AFRICA; PLASMA DNA; SERUM; DIAGNOSIS; INFECTION; MARKER; CANCER
AB In many resource-limited regions with endemic hepatitis B virus (HBV), there is limited infrastructure to collect, process, transport, and store blood samples for identification of persons with chronic HBV infection or with hepatocellular carcinoma (HCC). We describe the application of a simple technique using commercially available kits for detection of HBV surface antigen (HBsAg) and alpha-foetoprotein (AFP) in dried blood spots (DBS) collected on filter paper. Study participants included subjects with and without chronic HBV infection and subjects with HCC or cirrhosis. Three to five blood drops were dried on filter paper. Dried blood (equivalent to 20 mu L) was eluted and tested for HBsAg by Determine(TM) HBsAg and for AFP by counter-current immuno-electrophoresis and radio-immunoassay (RIA). The primary analysis focused on comparison of DBS results to serum testing results as the gold standard. The sensitivity of DBS for detecting chronic HBV infection was 96% (98-98) with specificity of 100% (CI 99-100). Sensitivity of DBS in detecting AFP compared with serum RIA was 73% (60-86) with specificity of 90% (81-98). Both HBsAg and AFP recovery were unaffected when DBS were left at room temperature (30-33 degrees C) and under humid conditions for up to 28 days prior to elution. We conclude that DBS can be reliably used as an economical and logical alternative for detection of HBsAg in chronically infected patients and for AFP-based diagnosis of HCC in clinical situations which preclude adequate collection and processing of blood samples. Both research-oriented field studies and routine clinical care may benefit from application of these techniques in resource-limited settings.
C1 MRC Fajara, Banjul, Gambia.
   MRC, IARC, Gambia Hepatitis Intervent Study, Banjul, Gambia.
   Int Agcy Res Canc, F-69372 Lyon, France.
   Govt Gambia, Dept Hlth & Social Welf, Banjul, Gambia.
   NCI, Viral Epidemiol Branch, NIH, DHHS, Bethesda, MD 20892 USA.
RP Mendy, M (reprint author), MRC Fajara, POB 273, Banjul, Gambia.
EM mmendy@mrc.gm
RI Kirk, Gregory/A-8484-2009; McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
CR ALPERT ME, 1968, NEW ENGL J MED, V278, P984, DOI 10.1056/NEJM196805022781804
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BEHETS F, 1992, J CLIN MICROBIOL, V30, P1179
   Bosch FX, 1997, LIVER CANC, P13
   Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9
   Cedrone A, 2000, HEPATO-GASTROENTEROL, V47, P1654
   Cui R, 2003, BRIT J CANCER, V88, P1878, DOI 10.1038/sj.bjc.6601018
   KIRBY LT, 1981, CLIN CHEM, V27, P678
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Marrero JA, 2003, HEPATOLOGY, V37, P1114, DOI 10.1053/jhep.2003.50195
   McMahon BJ, 2000, HEPATOLOGY, V32, P842, DOI 10.1053/jhep.2000.17914
   Nakatsura T, 2003, BIOCHEM BIOPH RES CO, V306, P16, DOI 10.1016/S0006-291X(03)00908-2
   OBRIEN TR, IN PRESS CANC J
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Parkinson A J, 1996, Arctic Med Res, V55, P123
   Poon TCW, 2003, CLIN CHEM, V49, P752, DOI 10.1373/49.5.752
   RUOSLAHTI E, 1971, INT J CANCER, V8, P374
   Song BC, 2002, CANCER, V94, P175, DOI 10.1002/cncr.10170
   Soresi M, 2003, ANTICANCER RES, V23, P1747
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   TAKASHIMA T, 1982, RADIOLOGY, V145, P635
   TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625
   Tong MJ, 2001, J GASTROEN HEPATOL, V16, P553, DOI 10.1046/j.1440-1746.2001.02470.x
   Trevisani F, 2001, J HEPATOL, V34, P570, DOI 10.1016/S0168-8278(00)00053-2
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1983, LANCET, V1, P1203
   *WHO, 2001, BCTBTS014 WHO
   WU JC, 1988, LIVER, V8, P100
NR 32
TC 20
Z9 21
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1352-0504
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD NOV
PY 2005
VL 12
IS 6
BP 642
EP 647
DI 10.1111/j.1365-2893.2005.00641.x
PG 6
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 975JX
UT WOS:000232659300011
PM 16255766
OA No
DA 2017-08-15
ER

PT J
AU Enwere, G
AF Enwere, G
TI A review of the quality of randomized clinical trials of adjunctive
   therapy for the treatment of cerebral malaria
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Review
DE quality randomized controlled trial; adjunctive treatment; cerebral
   malaria
ID IRON CHELATION-THERAPY; CONSORT STATEMENT; DOUBLE-BLIND; SAMPLE-SIZE;
   CHILDREN; DEXAMETHASONE; BIAS
AB BACKGROUND Randomized controlled clinical trials (RCTs) of adjunctive treatment to reduce the high-mortality associated with cerebral malaria (CM) have so far failed to show any benefit. This may be due in part to improperly designed and/or conducted trials. Therefore a systematic review of quality of RCTs for the treatment of CM with mortality as either primary or secondary outcome published between 1980 and 2000, was conducted.
   METHODS RCTs from the peer-reviewed literature using electronic searches. Methodological quality was assessed using an individual component approach (adequacy of concealment of allocation schedule, generation of allocation sequence, double blinding and analysis of participant as randomized). Sample sizes were recalculated for the ability of reviewed trials to detect 25% and 50% reductions in mortality.
   RESULTS Nine trials satisfied the inclusion criteria and were reviewed. Only two had sufficient power to detect a 50% reduction in mortality, and none could detect a 25% reduction. All the trials had inadequate methodological quality in one or more of the components, although in two trials these deficiencies were few.
   CONCLUSION There is a need for researchers and donors to ensure proper planning and implementation of RCTs in developing countries. In CM, demonstration of worthwhile reduction in mortality by a single intervention will require a large number of subjects, which a single centre may not be able to recruit.
C1 MRC Labs, Basse Field Stn, Banjul, Gambia.
RP Enwere, G (reprint author), MRC Labs, Basse Field Stn, POB 273, Banjul, Gambia.
EM genwere4@yahoo.co.uk
CR ALTMAN DG, 1995, BRIT MED J, V311, P485
   Altman DG, 2001, ANN INTERN MED, V134, P663
   CRAWLEY J, 2000, LANCET, V355, P710
   DIPERRI G, 1995, J INFECT DIS, V171, P1317
   FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304
   GILLMAN MW, 1984, NEW ENGL J MED, V310, P1610
   GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101
   HOFFMAN SL, 1988, J INFECT DIS, V158, P325
   Hoffman SL, 1996, NEW ENGL J MED, V335, P124, DOI 10.1056/NEJM199607113350209
   Junker CA, 1998, JAMA-J AM MED ASSOC, V280, P247, DOI 10.1001/jama.280.3.247
   KOCHAR DI, 1997, Q J MED, V90, P601
   Kunz R, 1998, BRIT MED J, V317, P1185
   Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001
   MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122
   Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X
   Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3
   MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W
   MULROW CD, 1994, BRIT MED J, V309, P597
   Newell ML, 2000, T ROY SOC TROP MED H, V94, P1, DOI 10.1016/S0035-9203(00)90413-9
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   Thuma PE, 1998, T ROY SOC TROP MED H, V92, P214, DOI 10.1016/S0035-9203(98)90753-2
   vanHensbroek MB, 1996, J INFECT DIS, V174, P1091
   WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601
   WHITE NJ, 1988, LANCET, V2, P64
NR 25
TC 15
Z9 17
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD NOV
PY 2005
VL 10
IS 11
BP 1171
EP 1175
DI 10.1111/j.1365-3156.2005.01505.x
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 978IW
UT WOS:000232867800011
PM 16262742
OA No
DA 2017-08-15
ER

PT J
AU Wall, SR
   Scherf, CF
   Morison, L
   Hart, KW
   West, B
   Ekpo, G
   Fiander, AN
   Man, S
   Gelder, CM
   Walraven, G
   Borysiewicz, LK
AF Wall, SR
   Scherf, CF
   Morison, L
   Hart, KW
   West, B
   Ekpo, G
   Fiander, AN
   Man, S
   Gelder, CM
   Walraven, G
   Borysiewicz, LK
TI Cervical human papillomavirus infection and squamous intraepithelial
   lesions in rural Gambia, West Africa: viral sequence analysis and
   epidemiology
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE HPV; SIL; DNA sequence; unselected; rural; Africa; vaccination
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; CONTROLLED-TRIAL; WORLDWIDE
   PERSPECTIVE; DEVELOPING-COUNTRIES; CANCER PREVENTION; TYPE-16 VACCINE;
   WOMEN; PREVALENCE; HIV
AB The development of effective strategies against cervical cancer in Africa requires accurate type specific data on human papillomavirus (HPV) prevalence, including determination of DNA sequences in order to maximise local vaccine efficacy. We have investigated cervical HPV infection and squamous intraepithelial lesions (SIL) in an unselected cohort of 1061 women in a rural Gambian community. Squamous intraepithelial lesions was diagnosed using cytology and histology, HPV was typed by PCR-ELISA of DNA extracts, which were also DNA sequenced. The prevalence of cervical HPV infection was 13% and SIL were observed in 7% of subjects. Human papillomavirus- 16 was most prevalent and most strongly associated with SIL. Also common were HPV-18, - 33, - 58 and, notably, - 35. Human papillomavirus DNA sequencing revealed HPV-16 samples to be exclusively African type 1 (Af1). Subjects of the Wolof ethnic group had a lower prevalence of HPV infection while subjects aged 25 - 44 years had a higher prevalence of cervical precancer than older or younger subjects. This first report of HPV prevalence in an unselected, unscreened rural population confirms high rates of SIL and HPV infection in West Africa. This study has implications for the vaccination of Gambian and other African populations in the prevention of cervical cancer.
C1 Cardiff Univ, Wales Coll Med, Henry Wellcome Res Inst, Cardiff CF14 4XX, Wales.
   Cardiff Univ, Wales Coll Med, Cardiff CF14 4XN, Wales.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs Farafenni, Banjul, Gambia.
   Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.
RP Wall, SR (reprint author), Cardiff Univ, Univ Wales Hosp, Wales Coll Med, Dept Child Hlth, 5th Floor,Heath Pk, Cardiff CF14 4XN, Wales.
EM wallsr@cf.ac.uk
RI Man, Stephen/D-1391-2009; Morison, Linda/H-9738-2013
OI Man, Stephen/0000-0001-9103-1686; 
CR Astori G, 1999, INTERVIROLOGY, V42, P221, DOI 10.1159/000024981
   Baay MFD, 2004, J MED VIROL, V73, P481, DOI 10.1002/jmv.20115
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Baud D, 2004, J VIROL, V78, P12901, DOI 10.1128/JVI.78.23.12901-12909.2004
   Bayo S, 2002, INT J EPIDEMIOL, V31, P202, DOI 10.1093/ije/31.1.202
   Berg M, 2005, P NATL ACAD SCI USA, V102, P4590, DOI 10.1073/pnas.0500933102
   Bernard HU, 2005, J CLIN VIROL, V32, P1, DOI 10.1016/j.jcv.2004.10.021
   BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Bosch FX, 2001, JNCI-J NATL CANCER I, V93, P1349, DOI 10.1093/jnci/93.17.1349
   Burk RD, 1996, SEX TRANSM DIS, V23, P333, DOI 10.1097/00007435-199607000-00013
   Castellsague X, 2001, LANCET, V358, P1429, DOI 10.1016/S0140-6736(01)06523-0
   Chabaud M, 1996, J MED VIROL, V49, P259, DOI 10.1002/(SICI)1096-9071(199608)49:4<259::AID-JMV1>3.0.CO;2-2
   CHAN SY, 1995, J VIROL, V69, P3074
   Christensen Neil D, 2005, Expert Opin Emerg Drugs, V10, P5, DOI 10.1517/14728214.10.1.5
   Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688
   Da Costa P, 1994, Afr Rep, V39, P52
   De Vuyst H, 2003, SEX TRANSM DIS, V30, P137, DOI 10.1097/00007435-200302000-00009
   FEINGOLD AR, 1990, J ACQ IMMUN DEF SYND, V3, P896
   Franceschi S, 2005, RECENT RES CANCER, V166, P277
   Giuliano AR, 2001, CANCER EPIDEM BIOMAR, V10, P1129
   Gravitt PE, 2002, INT J CANCER, V100, P729, DOI 10.1002/ijc.10538
   Gravitt PE, 2005, CURR INFECT DIS REP, V7, P125, DOI 10.1007/s11908-005-0072-3
   Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4
   Herrero R, 2000, J NATL CANCER I, V92, P464, DOI 10.1093/jnci/92.6.464
   HERRERO R, 1999, INFECT HUMAN CANC, V33
   *IARC, 1995, IARC MON, V64
   Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791
   Kitchener HC, 1999, LANCET, V353, P856, DOI 10.1016/S0140-6736(98)00417-6
   Koulibaly M, 1997, INT J CANCER, V70, P39, DOI 10.1002/(SICI)1097-0215(19970106)70:1<39::AID-IJC6>3.0.CO;2-7
   Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586
   Koutsky Laura, 1997, American Journal of Medicine, V102, P3
   La Ruche G, 1998, INT J CANCER, V76, P480, DOI 10.1002/(SICI)1097-0215(19980518)76:4<480::AID-IJC6>3.0.CO;2-N
   Lazcano-Ponce EC, 1999, ARCH MED RES, V30, P240, DOI 10.1016/S0188-0128(99)00006-8
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Levi Jose E, 2002, Braz J Infect Dis, V6, P129, DOI 10.1590/S1413-86702002000300005
   Maclean J, 2005, EXPERT REV ANTICANC, V5, P97, DOI 10.1586/14737140.5.1.xxx
   Matos E, 2003, SEX TRANSM DIS, V30, P593, DOI 10.1097/01.OLQ.0000085181.25063.6C
   Mayaud P, 2001, SEX TRANSM INFECT, V77, P248, DOI 10.1136/sti.77.4.248
   Morison L, 2001, TROP MED INT HEALTH, V6, P643, DOI 10.1046/j.1365-3156.2001.00749.x
   Moscicki AB, 2004, J INFECT DIS, V190, P37, DOI 10.1086/421467
   Moscicki AB, 2004, J INFECT DIS, V190, P1413, DOI 10.1086/424466
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Munoz N, 1996, Bull Pan Am Health Organ, V30, P362
   Nardelli-Haefliger D, 2003, J NATL CANCER I, V95, P1128, DOI 10.1093/jnci/djg018
   Naucler P, 2004, J GEN VIROL, V85, P2189, DOI 10.1099/vir.0.80001-0
   Qu WM, 1997, J CLIN MICROBIOL, V35, P1304
   RAMSAY S, 1993, LANCET, V341, P366, DOI 10.1016/0140-6736(93)90159-E
   Sasagawa T, 2005, VIRUS RES, V110, P81, DOI 10.1016/j.virusres.2005.02.001
   Sellors JW, 2000, CAN MED ASSOC J, V163, P503
   SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931
   Stanczuk GA, 2003, ACTA OBSTET GYN SCAN, V82, P762, DOI 10.1034/j.1600-0412.2003.00245.x
   Svare EI, 1998, INT J CANCER, V75, P1
   Taira AV, 2004, EMERG INFECT DIS, V10, P1915
   Thomas JO, 2004, BRIT J CANCER, V90, P638, DOI 10.1038/sj.bjc.6601515
   Tomson Todd T, 2004, Curr Opin Investig Drugs, V5, P1247
   UNAIDS, 2004, 2004 REP GLOB AIDS E
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   WALBOOMERS JM, 1995, HUMAN PAPILLOMAVIRUS, P41
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   WOLFENDALE MR, 1987, BRIT MED J, V294, P33
   Xi LF, 2003, INT J CANCER, V103, P803, DOI 10.1002/ijc.10876
   Yamada T, 1997, J VIROL, V71, P2463
   zur Hausen H, 1977, Curr Top Microbiol Immunol, V78, P1
NR 64
TC 29
Z9 29
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 31
PY 2005
VL 93
IS 9
BP 1068
EP 1076
DI 10.1038/sj.bjc.6602736
PG 9
WC Oncology
SC Oncology
GA 977MK
UT WOS:000232807700019
PM 16106268
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Hill, PC
   Brookes, RH
   Otu, JK
   Peterson, KL
   Small, PM
   Adegbola, RA
AF de Jong, BC
   Hill, PC
   Brookes, RH
   Otu, JK
   Peterson, KL
   Small, PM
   Adegbola, RA
TI Mycobacterium africanum: a new opportunistic pathogen in HIV infection?
SO AIDS
LA English
DT Letter
ID SAN-DIEGO COUNTY; TUBERCULOSIS; BOVIS; CALIFORNIA
C1 MRC Labs, Banjul, Gambia.
   Stanford Univ, Div ID & Geograph Med, Stanford, CA 94305 USA.
   Inst Syst Biol, Seattle, WA USA.
RP de Jong, BC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU FIC NIH HHS [TW06083-01]
CR Desmond E, 2004, EMERG INFECT DIS, V10, P921
   Grange JM, 2001, TUBERCULOSIS, V81, P71, DOI 10.1054/tube.2000.0263
   Kato-Maeda M, 2001, GENOME RES, V11, P547, DOI 10.1101/gr.166401
   LoBue PA, 2005, INT J TUBERC LUNG D, V9, P333
   LoBue PA, 2003, INT J TUBERC LUNG D, V7, P180
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   Samper S, 1997, AIDS, V11, P1237, DOI 10.1097/00002030-199710000-00006
   Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632
NR 9
TC 27
Z9 28
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA
SN 0269-9370
J9 AIDS
JI Aids
PD OCT 14
PY 2005
VL 19
IS 15
BP 1714
EP 1715
DI 10.1097/01.aids.0000185991.54595.41
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 976VX
UT WOS:000232762700030
PM 16184053
OA No
DA 2017-08-15
ER

PT J
AU West, SK
   Munoz, B
   Mkocha, H
   Holland, MJ
   Aguirre, A
   Solomon, AW
   Foster, A
   Bailey, RL
   Mabey, DCW
AF West, SK
   Munoz, B
   Mkocha, H
   Holland, MJ
   Aguirre, A
   Solomon, AW
   Foster, A
   Bailey, RL
   Mabey, DCW
TI Infection with Chlamydia trachomatis after mass treatment of a trachoma
   hyperendemic community in Tanzania: a longitudinal study
SO LANCET
LA English
DT Article
ID AZITHROMYCIN
AB Background Data from studies done in communities where trachoma is mesoendemic suggest that ocular infection with Chlamydia trachomatis can be eliminated after one mass treatment with antibiotics. However, there are no comparable long-term data from trachoma hyperendemic communities. Our aim, therefore, was two-fold: first, to ascertain the disease pattern of trachoma and ocular infection with C trachomatis in a trachoma hyperendemic community after mass treatment; and, second, to ascertain the risk factors for incident infection.
   Methods We did a longitudinal study of a trachoma hyperendemic community (n=1017) in Tanzania. We did surveys, including ocular swabs, at baseline, 2, 6, 12, and 18 months to identify the presence, and quantity, of C trachomatis after single mass treatment of all individuals aged 6 months or older with azithromycin 20 mg per kg; pregnant women without clinical disease received topical tetracycline.
   Findings Mass treatment (coverage 86%) significantly reduced the prevalence of infection from 57% (495 of 871) to 12% (85 of 705) at 2 months. infection remained fairly constant to 12 months, with evidence of increasing numbers and load of infection by 18 months post-treatment. Incident infection at 6 months was 3.5-times more likely if another member of the household had more than 19 organisms per swab at 2 months. Travel outside the village, and visitors to the household, did not increase the risk of infection within households up to 12 months.
   Interpretation In this trachoma hyperendemic community, infection levels after high antibiotic coverage persisted at a low level to 18 months, with evidence for re-emergence after 1 year. Fairly light loads of infection were associated with household transmission. Yearly mass treatment over a few years could be sufficient to eliminate infection.
C1 Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   Kongwa Trachoma Project, Kongwa, Tanzania.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Banjul, Gambia.
RP West, SK (reprint author), Johns Hopkins Sch Med, Wilmer Eye Inst, Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.
EM shwest@jhmi.edu
FU Medical Research Council [MC_U190081961]; Wellcome Trust
CR Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Melese M, 2004, JAMA-J AM MED ASSOC, V292, P721, DOI 10.1001/jama.292.6.721
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Smith A, 2001, Ophthalmic Epidemiol, V8, P127, DOI 10.1076/opep.8.2.127.4164
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   West SK, 1996, AM J EPIDEMIOL, V143, P73
   *WHO, 1993, PREV BLINDN PRIM HLT, P16
NR 10
TC 85
Z9 85
U1 0
U2 2
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 8
PY 2005
VL 366
IS 9493
BP 1296
EP 1300
DI 10.1016/S0140-6736(05)67529-0
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 971ST
UT WOS:000232405700028
PM 16214600
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Kinteh, F
   Jallow, O
   Sillah, A
   Bah, M
   Faye, M
   Aryee, EAN
   Ikumapayi, UN
   Alexander, NDE
   Adegbola, RA
   Faal, H
   Mabey, DCW
   Foster, A
   Johnson, GJ
   Bailey, RL
AF Burton, MJ
   Kinteh, F
   Jallow, O
   Sillah, A
   Bah, M
   Faye, M
   Aryee, EAN
   Ikumapayi, UN
   Alexander, NDE
   Adegbola, RA
   Faal, H
   Mabey, DCW
   Foster, A
   Johnson, GJ
   Bailey, RL
TI A randomised controlled trial of azithromycin following surgery for
   trachomatous trichiasis in the Gambia
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMMUNITY; BLINDNESS; SUCCESS
AB Background/aim: Trachomatous trichiasis frequently returns following surgery. Several factors may promote recurrence: preoperative disease severity, surgeon ability, surgical procedure, healing responses, and infection. This study investigates whether enhanced control of infection, both of Chlamydia trachomatis and other bacteria, with azithromycin can improve surgical outcome in a trachoma control programme.
   Methods: Individuals with trachomatous trichiasis were examined and operated. After surgery patients were randomised to the azithromycin or control group. The azithromycin group and children in their household were given a dose of azithromycin. Antibiotic treatment was repeated at 6 months. All patients were reassessed at 6 months and 12 months. Samples were collected for C trachomatis polymerase chain reaction and general microbiology at each examination.
   Results: 451 patients were enrolled. 426 (94%) were reassessed at 1 year, of whom 176 (41.3%) had one or more lashes touching the eye and 84 (19.7%) had five or more lashes. There was no difference in trichiasis recurrence between the azithromycin and control group. Recurrent trichiasis was significantly associated with more severe preoperative trichiasis, bacterial infection, and severe conjunctival inflammation at 12 months. Significant variability in outcome was found between surgeons. Visual acuity and symptoms significantly improved following surgery.
   Conclusion: In this setting, with a low prevalence of active trachoma, azithromycin did not improve the outcome of trichiasis surgery conducted by a trachoma control programme. Audit of trichiasis surgery should be routine.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Inst Ophthalmol, Div Epidemiol & Int Eye Hlth, London, England.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [MC_U190081961]; Wellcome Trust
CR Adamu Y, 2002, ETHIOPIAN MED J, V40, P107
   Alemayehu W, 2004, OPHTHALMOLOGY, V111, P578, DOI 10.1016/j.ophtha.2003.06.030
   BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   Bowman RJC, 2002, BRIT J OPHTHALMOL, V86, P339, DOI 10.1136/bjo.86.3.339
   Bowman RJC, 2000, EYE, V14, P864
   Burton M J, 2002, Expert Opin Pharmacother, V3, P113, DOI 10.1517/14656566.3.2.113
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P575, DOI 10.1136/bjo.2004.055996
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Chern KC, 1999, BRIT J OPHTHALMOL, V83, P1332, DOI 10.1136/bjo.83.12.1332
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dawson CR, 1990, CHLAMYDIAL INFECT, P271
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Khandekar R, 2001, Ophthalmic Epidemiol, V8, P155, DOI 10.1076/opep.8.2.155.4165
   Munoz B, 1999, INT J EPIDEMIOL, V28, P1167, DOI 10.1093/ije/28.6.1167
   Reacher M, 1993, TRICHIASIS SURG TRAC
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   REACHER MH, 1990, BRIT J OPHTHALMOL, V74, P109, DOI 10.1136/bjo.74.2.109
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Smith PG, 1991, METHODS FIELD TRIALS
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   World_Health_Organization, 1998, GLOB EL BLIND TRACH
   Zhang H, 2004, ARCH OPHTHALMOL-CHIC, V122, P511, DOI 10.1001/archopht.122.4.511
NR 25
TC 58
Z9 58
U1 1
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2005
VL 89
IS 10
BP 1282
EP 1288
DI 10.1136/bjo.2004.062489
PG 7
WC Ophthalmology
SC Ophthalmology
GA 965UD
UT WOS:000231974900015
PM 16170117
OA No
DA 2017-08-15
ER

PT J
AU Malenga, G
   Palmer, A
   Staedke, S
   Kazadi, W
   Mutabingwa, T
   Ansah, E
   Barnes, KI
   Whitty, CJM
AF Malenga, G
   Palmer, A
   Staedke, S
   Kazadi, W
   Mutabingwa, T
   Ansah, E
   Barnes, KI
   Whitty, CJM
TI Antimalarial treatment with artemisinin combination therapy in Africa -
   Desirable, achievable, but not easy
SO BRITISH MEDICAL JOURNAL
LA English
DT Editorial Material
ID FALCIPARUM-MALARIA; ARTESUNATE; TRIAL
C1 Malaria Alert Ctr, Bantyre, Malawi.
   Ctr Innovat Malaria, Banjul, Gambia.
   Makerere Univ, UCSF Malaria Res Collaborat, Kampala, Uganda.
   Malaria Consortium, W African Network Monitoring Antimalarial Treatme, Accra, Ghana.
   Dangme W Dist Hlth Directorate Res Ctr, Hlth Serv, Dodowa, Ghana.
   Univ Cape Town, Div Clin Pharmacol, ZA-7700 Rondebosch, South Africa.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1B 3DP, England.
RP Malenga, G (reprint author), Malaria Alert Ctr, Bantyre, Malawi.
EM c.whitty@lshtm.ac.uk
RI Whitty, Christopher/C-7740-2012
CR Adjuik M, 2004, LANCET, V363, P9
   Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1
   Arrow K. J., 2004, SAVING LIVES BUYING
   Marsh VM, 2004, TROP MED INT HEALTH, V9, P451, DOI 10.1111/j.1365-3156.2004.01223.x
   Muheki C, 2004, TROP MED INT HEALTH, V9, P959, DOI 10.1111/j.1365-3156.2004.01292.x
   Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Staedke SG, 2004, LANCET, V364, P1950, DOI 10.1016/S0140-6736(04)17478-3
   Zurovac D, 2005, BRIT MED J, V331, P734, DOI 10.1136/bmj.331.7519.734
NR 10
TC 20
Z9 20
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-8146
J9 BRIT MED J
JI Br. Med. J.
PD OCT 1
PY 2005
VL 331
IS 7519
BP 706
EP 707
DI 10.1136/bmj.331.7519.706
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 971XB
UT WOS:000232417100002
PM 16195260
OA No
DA 2017-08-15
ER

PT J
AU Greenaway, C
   Lienhardt, C
   Adegbola, R
   Brusasca, R
   McAdam, K
   Menzies, D
AF Greenaway, C
   Lienhardt, C
   Adegbola, R
   Brusasca, R
   McAdam, K
   Menzies, D
TI Humoral response to Mycobacterium tuberculosis antigens in patients with
   tuberculosis in the Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculosis; diagnosis; serology; 38 kDa antigen; ESAT-6; CFP-10
ID SEROLOGICAL DIAGNOSIS; EXTRAPULMONARY TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; 38 KDA; ESAT-6; PURIFICATION; ANTIBODY; SERODIAGNOSIS;
   IMMUNOASSAY; INFECTION
AB OBJECTIVE: To determine and compare the sensitivity and specificity of four common mycobacterial antigens with three RD-1 region antigens in the serological. diagnosis of active pulmonary tuberculosis (PTB) in the Gambia.
   DESIGN: Serum from 300 Gambians (100 with active PTB, 100 of their household contacts, and 100 community controls) was tested using an ELISA method to detect antibodies to seven mycobacterial antigens (three encoded in the RD-1 region [ESAT-6, CFP-10 and Rv3871] and four common [38 kDa, GLU-S, 19 kDa and 14 kDa]). Individuals with active TB were recruited from one of the National Leprosy and TB Control Program clinics in the western region of the Gambia, and neighborhood controls were an age-matched individual living within five houses of the case.
   RESULTS: The sensitivity of the RD-1 antigens ranged from 34% to 67%, while specificity ranged from 51% to 71%. The sensitivity of the common antigens ranged from 24% to 75% and specificity from 26% to 75%.
   CONCLUSION: In countries with high rates of TB, such as the Gambia, the clinical utility of serological testing to diagnose active TB remains limited, even with newer antigens encoded in the RD-1 region of Mycobacterium tuberculosis.
C1 Sir Mortimer B Davis Jewish Hosp, Div Infect Dis, Montreal, PQ H3T 1E2, Canada.
   McGill Univ, Fac Med, Dept Epidemiol & Biostat, Montreal, PQ, Canada.
   Medical Res Council Labs, Fajara, Gambia.
   Inst Rech Dev, Dakar, Senegal.
   Publ Hlth Res Inst, Newark, NJ USA.
   Montreal Chest Inst, Montreal, PQ, Canada.
RP Greenaway, C (reprint author), Sir Mortimer B Davis Jewish Hosp, Div Infect Dis, 3755 Cote St Catherine Rd,Room G-143, Montreal, PQ H3T 1E2, Canada.
EM ca.greenaway@mcgill.ca
CR Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   BOTHAMLEY G, 1988, EUR J CLIN MICROBIOL, V7, P639, DOI 10.1007/BF01964242
   BOTHAMLEY G, 1992, EUROPEAN J CLIN MICR, V11, P6
   BOTHAMLEY GH, 1995, EUR RESPIR J, V8, pS676
   Colangeli R, 1998, J CHROMATOGR B, V714, P223, DOI 10.1016/S0378-4347(98)00094-2
   Cole RA, 1996, TUBERCLE LUNG DIS, V77, P363, DOI 10.1016/S0962-8479(96)90103-3
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   CORRAH PT, 1994, THESIS U COLL LONDON
   JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313
   Kindhauser M. K., 2003, COMMUNICABLE DIS 200
   kleinbaum D. G., 1978, APPL REGRESSION ANAL
   Laszlo A, 1996, CLIN LAB MED, V16, P697
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Lyashchenko K, 1998, INFECT IMMUN, V66, P3936
   Lyashchenko KP, 2000, J IMMUNOL METHODS, V242, P91, DOI 10.1016/S0022-1759(00)00241-6
   Manca C, 1997, INFECT IMMUN, V65, P16
   Mathur ML, 1999, INT J TUBERC LUNG D, V3, P732
   McConkey SJ, 2002, INT J TUBERC LUNG D, V6, P246
   Pottumarthy S, 2000, J CLIN MICROBIOL, V38, P2227
   Silva VMC, 2003, INT J TUBERC LUNG D, V7, P478
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710
   THYBO S, 1995, TUBERCLE LUNG DIS, V76, P149, DOI 10.1016/0962-8479(95)90558-8
   van Pittius Nico C. Gey, 2002, Infection and Immunity, V70, P6509
   Vekemans J, 2004, INFECT IMMUN, V72, P381, DOI 10.1128/IAI.72.1.381-388.2004
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   VERBON A, 1993, AM REV RESPIR DIS, V148, P378
   WHO, 2003, GLOB TUB CONTR SURV
   World Health Organization, 2004, GLOB TUB CONTR
   WILKINS E, 1991, EUR J CLIN MICROBIOL, V10, P559, DOI 10.1007/BF01967273
   WILKINS EGL, 1990, LANCET, V336, P641, DOI 10.1016/0140-6736(90)92144-7
   WILKINS EGL, 1994, CLIN TUBERCULOSIS, V367
   Zhou AT, 1996, CLIN DIAGN LAB IMMUN, V3, P337
NR 33
TC 25
Z9 27
U1 0
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD OCT
PY 2005
VL 9
IS 10
BP 1112
EP 1119
PG 8
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 971YX
UT WOS:000232422100008
PM 16229222
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
AF Prentice, AM
TI Macronutrients as sources of food energy
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE energy; macronutrients; fat; carbohydrate; protein; alcohol
ID BODY-WEIGHT REGULATION; DIETARY-FAT INTAKE; AD-LIBITUM; COVERT
   MANIPULATION; CARBOHYDRATE RATIO; NUTRIENT BALANCE; SUBSTRATE FLUX;
   OBESITY; DENSITY; HUMANS
AB This background paper considers the extent to which the development of new recommendations for dietary energy requirements needs to account for the macronutrient (fat, carbohydrate, protein and alcohol) profiles of different diets. The issues are discussed from the dual perspectives of avoiding under-nutrition and obesity. It is shown that, in practice, human metabolic processes can adapt to a wide range of fuel supply by altering fuel selection. It is concluded that, at the metabolic level, only diets with the most extreme macronutrient composition would have any consequences by exceeding the natural ability to modify fuel selection. However, diets of different macronutrient composition and energy density can have profound implications for innate appetite regulation and hence overall energy consumption.
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM andrew.prentice@lshtm.ac.uk
CR Astrup A, 2000, INT J OBESITY, V24, P1545, DOI 10.1038/sj.ijo.0801453
   Astrup A, 1998, Curr Opin Clin Nutr Metab Care, V1, P573, DOI 10.1097/00075197-199811000-00016
   BLAXTER K, 1989, ENERGY METABOLISM AN
   Blundell JE, 1997, J AM DIET ASSOC, V97, pS63, DOI 10.1016/S0002-8223(97)00733-5
   BLUNDELL JE, 1995, INT J OBESITY, V19, P832
   BOLTONSMITH C, 1994, INT J OBESITY, V18, P820
   Bray GA, 1998, AM J CLIN NUTR, V68, P1157
   Cox DN, 2000, INT J OBESITY, V24, P49, DOI 10.1038/sj.ijo.0801084
   Dorosty AR, 2000, PEDIATRICS, V105, P1115, DOI 10.1542/peds.105.5.1115
   DREON DM, 1988, AM J CLIN NUTR, V47, P995
   DREWNOWSKI A, 1992, INT J OBESITY, V16, P639
   Drewnowski A, 1997, NUTR REV, V55, P31
   *FAO, 2002, FOOD EN METH AN CONV
   [WHO FAO], 1994, FATS OILS HUM NUTR R
   *FAO WHO, 1996, CARB HUM NUTR REP JO
   FAO/WHO/UNU, 1985, EN PROT REQ
   FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173
   FLATT JP, 1987, ANN NY ACAD SCI, V499, P104, DOI 10.1111/j.1749-6632.1987.tb36202.x
   FLATT JP, 1988, DIABETES METAB REV, V4, P571
   Heini AF, 1997, AM J MED, V102, P259, DOI 10.1016/S0002-9343(96)00456-1
   HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206
   HILL JO, 1995, AM J CLIN NUTR, V62, p264S
   Jebb SA, 1996, AM J CLIN NUTR, V64, P259
   Katan MB, 1997, NEW ENGL J MED, V337, P563
   KENDALL A, 1991, AM J CLIN NUTR, V53, P1124
   LANDS WEM, 1987, AM J CLIN NUTR, V45, P47
   LEIBER CS, 1991, AM J CLIN NUTR, V54, P976
   LISSNER L, 1995, EUR J CLIN NUTR, V49, P79
   LISSNER L, 1987, AM J CLIN NUTR, V46, P886
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   MCNEILL G, 1992, Proceedings of the Nutrition Society, V51, p91A
   Mela DJ, 1997, P NUTR SOC, V56, P827, DOI 10.1079/PNS19970090
   Poppitt SD, 1996, APPETITE, V26, P153, DOI 10.1006/appe.1996.0013
   Prentice AM, 1998, AM J CLIN NUTR, V67, p535S
   Prentice AM, 1996, INT J OBESITY, V20, pS18
   PRENTICE AM, 1999, PROGR OBESITY RES, V8, P453
   Prentice AM, 1995, INT J OBESITY, V19, pS44
   Prentice AM, 1995, WEIGHT CONTROL CURRE, P8
   ROLLANDCACHERA MF, 1995, INT J OBESITY, V19, P573
   SCHUTZ Y, 1985, INT J OBESITY, V9, P111
   SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307
   SHETTY PS, 1994, AM J CLIN NUTR, V60, P534
   Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867
   SKOV AR, 1996, INT J OBESITY, V20, P47
   SONKO BJ, 1994, AM J CLIN NUTR, V59, P619
   Stubbs RJ, 1998, INT J OBESITY, V22, P980, DOI 10.1038/sj.ijo.0800715
   STUBBS RJ, 1993, AM J CLIN NUTR, V57, P897
   STUBBS RJ, 1995, INT J OBESITY, V19, pS11
   Stubbs RJ, 1996, INT J OBESITY, V20, P651
   STUBBS RJ, 1995, AM J CLIN NUTR, V62, P316
   SUTER PM, 1992, NEW ENGL J MED, V326, P983, DOI 10.1056/NEJM199204093261503
   THOMAS CD, 1992, AM J CLIN NUTR, V55, P934
   VANSTRATUM P, 1978, AM J CLIN NUTR, V31, P206
   Westerterp K.R., 1999, HLTH ISSUES RELATED, V2nd, P103
NR 54
TC 8
Z9 8
U1 2
U2 7
PU CABI PUBLISHING
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, NOSWORTHY WAY, WALLINGFORD OX10 8DE, OXON,
   ENGLAND
SN 1368-9800
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD OCT
PY 2005
VL 8
IS 7A
SI SI
BP 932
EP 939
DI 10.1079/PHN2005779
PG 8
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 981OF
UT WOS:000233097200002
PM 16277812
OA No
DA 2017-08-15
ER

PT J
AU Ackerman, H
   Usen, S
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Kwiatkowski, DP
AF Ackerman, H
   Usen, S
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Kwiatkowski, DP
TI A comparison of case-control and family-based association methods: The
   example of sickle-cell and malaria
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE disease association; transmission/disequilibrium test; TDT; case
   control; sickle cell; hemoglobin; beta-globin; malaria; plasmodium
   falciparum; segregation distortion
ID TRANSMISSION-RATIO DISTORTION; DISEQUILIBRIUM; CHILDREN; COMPLEX
AB There has been much debate about the relative merits of population- and family-based strategies for testing genetic association, yet there is little empirical data that directly compare the two approaches. Here we compare case-control and transmission/disequilibrium test (TDT) study designs using a well-established genetic association, the protective effect of the sickle-cell trait against severe malaria. We find that the two methods give similar estimates of the level of protection (case-control odds ratio = 0.10, 95% confidence interval 0.03-0.23; family-based estimate of the odds ratio = 0.11, 95% confidence interval 0.04-0.25) and similar statistical significance of the result (case-control: chi(2)= 41.26, p= 10(-10), TDT: chi(2)= 39.06, p= 10(-10)) when 315 TDT cases are compared to 583 controls. We propose a family plus population control study design, which allows both case-control and TDT analysis of the cases. This combination is robust against the respective weaknesses of the case-control and TDT study designs, namely population structure and segregation distortion. The combined study design is especially cost-effective when cases are difficult to ascertain and, when the case-control and TDT results agree, offers greater confidence in the result.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   MRC Labs, Fajara, Gambia.
RP Ackerman, H (reprint author), 64 Linnaean St, Cambridge, MA 02138 USA.
EM ackerman@fas.harvard.edu
OI Kwiatkowski, Dominic/0000-0002-5023-0176
CR ALLISON AC, 1954, BRIT MED J, V1, P290
   BACANU SA, 1998, AM J HUM GENET, V63, P935
   Eaves IA, 1999, NAT GENET, V22, P324
   EWENS WJ, 1995, AM J HUM GENET, V57, P455
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Kwiatkowski D, 2000, CURR OPIN GENET DEV, V10, P320, DOI 10.1016/S0959-437X(00)00087-3
   Lie BA, 2000, AM J HUM GENET, V66, P740, DOI 10.1086/302780
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   NAUMOVA AK, 1995, DEV GENET, V17, P198, DOI 10.1002/dvg.1020170304
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   THOMSON G, 1995, AM J HUM GENET, V57, P487
NR 14
TC 38
Z9 39
U1 1
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0003-4800
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD SEP
PY 2005
VL 69
BP 559
EP 565
DI 10.1111/j.1529-8817.2005.00180.x
PN 5
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 961MS
UT WOS:000231667100007
PM 16138914
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
   Blum, J
   Dampha, Y
   Sowe, M
   Morison, L
   Winikoff, B
   Sloan, N
AF Walraven, G
   Blum, J
   Dampha, Y
   Sowe, M
   Morison, L
   Winikoff, B
   Sloan, N
TI Misoprostol in the management of the third stage of labour in the home
   delivery setting in rural Gambia: a randomised controlled trial
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article
ID POSTPARTUM HEMORRHAGE; MORTALITY
AB Objective To assess the effectiveness of 600 mu g oral misoprostol on postpartum haemorrhage (PPH) and postpartum anaemia in a low income country home birth situation.
   Design Double blind randomised controlled trial.
   Setting Twenty-six villages in rural Gambia with 52 traditional birth attendants (TBAs).
   Sample One thousand, two hundred and twenty-nine women delivering at home under the guidance of a trained TBA.
   Methods Active management of the third stage of labour using three 200-mu g misoprostol tablets and placebo or four 0.5-mg ergometrine tablets (standard treatment) and placebo. Tablets were taken orally immediately after delivery.
   Main outcome measures Measured blood loss, postpartum haemoglobin (Hb), difference between Hb at the last antenatal care visit and three to five days postpartum.
   Results The misoprostol group experienced lower incidence of measured blood loss >= 500 mL and postpartum Hb < 8 g/dL, but the differences were not statistically significant. The reduction in postpartum (compared with pre-delivery) Hb >= 2 g/dL was 16.4% with misoprostol and 21.2% with ergometrine [relative risk 0.77; 95% confidence interval (CI) 0.60-0.98; P= 0.02]. Shivering was significantly more common with misoprostol, while vomiting was more common with ergometrine. Only transient side effects were observed.
   Conclusions Six hundred micrograms of oral misoprostol is a promising drug to prevent life-threatening PPH in this setting.
C1 MRC Labs, Farafenni Field Stn, Farafenni, Gambia.
   Populat Council, New York, NY 10021 USA.
   London Sch Hyg & Trop Med, London WC1, England.
   Gynuity Hlth Projects, New York, NY USA.
RP Walraven, G (reprint author), Secretariat Son Altesse Aga Khan, F-60270 Gouvieux, France.
RI Morison, Linda/H-9738-2013
CR AbouZahr C, 1998, GLOBAL BURDEN DIS IN, VIII, P111
   American College of Obstetricians and Gynecologists. Postpartum hemorrhage, 1998, ACOG ED B, V243
   de Vaate AB, 2002, MIDWIFERY, V18, P3, DOI 10.1054/midw.2001.0289
   DEGROOT ANJ, 1995, EUR J OBSTET GYN R B, V2, P101
   DEGROOT ANJA, 1995, INT J CLIN PHARM TH, V33, P328
   deGroot ANJA, 1996, ACTA OBSTET GYN SCAN, V75, P464, DOI 10.3109/00016349609033355
   Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4
   GULMEZOGLU AM, 2004, COCHRANE DB SYST REV, V1, DOI UNSP CD002855
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   International Confederation of Midwives and International Federation of Gynaecologists and Obstetricians, 2004, J MIDWIFERY WOM HEAL, V49, P76
   MENENDEZ C, 1993, TROP MED HYG, V96, P175
   Telfer Michelle L, 2002, Afr J Reprod Health, V6, P74, DOI 10.2307/3583148
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   World Health Organization, 1997, COV MAT CAR LIST AV
   World Health Organization, 2003, MAN COMPL PREGN CHIL
NR 15
TC 85
Z9 86
U1 0
U2 6
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1470-0328
J9 BJOG-INT J OBSTET GY
JI BJOG
PD SEP
PY 2005
VL 112
IS 9
BP 1277
EP 1283
DI 10.1111/j.1471-0528.2005.00711.x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 952GP
UT WOS:000230992300020
PM 16101608
OA No
DA 2017-08-15
ER

PT J
AU Wilson, JN
   Rockett, K
   Jallow, M
   Pinder, M
   Sisay-Joof, F
   Newport, M
   Newton, J
   Kwiatkowski, D
AF Wilson, JN
   Rockett, K
   Jallow, M
   Pinder, M
   Sisay-Joof, F
   Newport, M
   Newton, J
   Kwiatkowski, D
TI Analysis of IL10 haplotypic associations with severe malaria
SO GENES AND IMMUNITY
LA English
DT Article
DE interleukin 10; malaria; anemia; cerebral malaria; transmission
   disequilibrium test
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
   INTERLEUKIN-10 PROMOTER POLYMORPHISM; LINKAGE DISEQUILIBRIUM;
   RHEUMATOID-ARTHRITIS; PLASMODIUM-CHABAUDI; IL-10 LOCUS; GENE;
   TRANSMISSION; DISEASE
AB We investigated the association between severe malaria and genetic variation of IL10 in Gambian children, as several lines of evidence indicate that IL10 is protective against severe malaria and that IL10 production is genetically determined. We began by identifying five informative SNPs in the Gambian population that were genotyped in a combined case-control and intrafamilial study including 654 cases of severe malaria, 579 sets of parents and 459 ethnically matched controls. No significant associations were identified with individual SNPs. One haplotype of frequency 0.11 was strongly associated with protection against severe malaria in the case-control analysis (odds ratio 0.52, P = 0.00002), but the transmission disequilibrium test in families showed no significant effect. These findings raise the question of whether IL10 associations with severe malaria might be confounded by foetal survival rates or other sources of transmission bias.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
RP Wilson, JN (reprint author), Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
EM jwilson@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176
CR Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24
   Asadullah K, 2001, J INVEST DERMATOL, V116, P975, DOI 10.1046/j.1523-1747.2001.01350.x
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y
   Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1
   D'Alfonso S, 2000, ARTHRITIS RHEUM, V43, P120, DOI 10.1002/1529-0131(200001)43:1<120::AID-ANR15>3.0.CO;2-3
   Eskdale J, 1999, GENES IMMUN, V1, P151, DOI 10.1038/sj.gene.6363656
   Eskdale J, 1998, LANCET, V352, P1282, DOI 10.1016/S0140-6736(05)70489-X
   Eskdale J, 1997, IMMUNOGENETICS, V46, P120, DOI 10.1007/s002510050250
   Gibson AW, 2001, J IMMUNOL, V166, P3915
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   Kwiatkowski D., 1999, Parassitologia (Rome), V41, P233
   Lazarus R, 2002, GENOMICS, V80, P223, DOI 10.1006/geno.2002.6820
   Li C, 1999, INFECT IMMUN, V67, P4435
   Lin M, 2003, NEW ENGL J MED, V349, P2201, DOI 10.1056/NEJMoa022060
   Mantel N, 1959, N NATL CANC I, V22, P719, DOI DOI 10.1016/0021-9681(79)90031-6
   May J, 2000, J INFECT DIS, V182, P1570, DOI 10.1086/315857
   Mok CC, 1998, ARTHRITIS RHEUM, V41, P1090, DOI 10.1002/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   OZORNEK MH, 1995, J ASSIST REPROD GEN, V12, P590, DOI 10.1007/BF02212580
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   Sanni LA, 2004, INFECT IMMUN, V72, P3054, DOI 10.1128/IAI.72.5.3054-3058.2004
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   Westendorp RGJ, 2001, NAT MED, V7, P873, DOI 10.1038/90868
   Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6
   Zollner S, 2004, AM J HUM GENET, V74, P62, DOI 10.1086/381131
NR 28
TC 39
Z9 41
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD SEP
PY 2005
VL 6
IS 6
BP 462
EP 466
DI 10.1038/sj.gene.6364227
PG 5
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 960EI
UT WOS:000231572600002
PM 15933743
OA No
DA 2017-08-15
ER

PT J
AU Tetteh, KKA
   Cavanagh, DR
   Corran, P
   Musonda, R
   McBride, JS
   Conway, DJ
AF Tetteh, KKA
   Cavanagh, DR
   Corran, P
   Musonda, R
   McBride, JS
   Conway, DJ
TI Extensive antigenic polymorphism within the repeat sequence of the
   Plasmodium falciparum merozoite surface protein 1 block 2 is
   incorporated in a minimal polyvalent immunogen
SO INFECTION AND IMMUNITY
LA English
DT Article
ID APICAL MEMBRANE ANTIGEN-1; PNEUMOCOCCAL CONJUGATE VACCINE;
   ANTIBODY-RESPONSES; CLINICAL MALARIA; IN-VITRO; SELECTION; CANDIDATE;
   POPULATIONS; DIVERSITY; CHILDREN
AB Polymorphism in pathogen antigens presents a complex challenge for vaccine design. A prime example is the N-terminal block 2 region of the Plasmodium falciparum merozoite surface protein 1 (MSP1), to which allele-specific antibodies have been associated with protection from malaria. In a Zambian population studied here, 49 of 91 alleles sampled were of the KI-like type (the most common of three block 2 types in all African populations), and most of these had unique sequences due to variation in tri- and hexapeptide repetitive motifs. There were significant negative correlations between allelic sequence lengths of different regions of the repeats, so the complete repeat sequence had less length variation than its component parts, suggesting a constraint on overall length. Diverse epitopes recognized by three murine monoclonal antibodies and 24 individual human sera were then mapped by using a comprehensive panel of synthetic peptides, revealing epitopes in all regions of the repeats. To incorporate these different epitopes in a single molecule, a composite sequence of minimal overall length (78 amino acids) was then designed and expressed as a recombinant antigen. More human immune sera reacted with this "K1-like Super Repeat" antigen than with proteins consisting of single natural allelic sequences, and immunization of mice elicited antibodies that recognized a range of five cultured parasite lines with diverse K1-like MSP1 block 2 repeat sequences. Thus, complex allelic polymorphism was deconstructed and a minimal composite polyvalent antigen was engineered, delivering a designed candidate sequence for inclusion in a malaria vaccine.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England.
   Univ Edinburgh, Inst Immunol & Infect Res, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland.
   Trop Dis Res Ctr, Ndola, Zambia.
   MRC Labs, Banjul, Gambia.
RP Tetteh, KKA (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.
EM kevin.tetteh@lshtm.ac.uk
RI Cavanagh, David/A-1828-2008
OI Conway, David/0000-0002-8711-3037
CR ALYAMAN F, 1995, PARASITE IMMUNOL, V17, P493, DOI 10.1111/j.1365-3024.1995.tb00920.x
   Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921
   Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5
   Cavanagh DR, 2004, INFECT IMMUN, V72, P6492, DOI 10.1128/IAI.72.11.6492.6502.2004
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Ekala MT, 2002, ACTA TROP, V81, P33, DOI 10.1016/S0001-706X(01)00188-7
   Ferreira MU, 2003, GENE, V304, P65, DOI 10.1016/S0378-1119(02)01180-0
   FRANK R, 1997, IMMUNOLOGY METHODS M, V2, P763
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001
   Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
   Jones TR, 2002, VACCINE, V20, P1675, DOI 10.1016/S0264-410X(01)00513-8
   Jouin H, 2001, EUR J IMMUNOL, V31, P539, DOI 10.1002/1521-4141(200102)31:2<539::AID-IMMU539>3.0.CO;2-1
   Kennedy MC, 2002, INFECT IMMUN, V70, P6948, DOI 10.1128/IAI.70.12.6948-6960.2002
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002
   Kreitman M, 2000, ANNU REV GENOM HUM G, V1, P539, DOI 10.1146/annurev.genom.1.1.539
   LIPSITCH M, 2002, ADAPTIVE DYNAMICS IN, P362, DOI 10.1017/CBO9780511525728.033
   Locher CP, 1996, EXP PARASITOL, V84, P74, DOI 10.1006/expr.1996.0091
   Martin SL, 2000, VACCINE, V18, P2476, DOI 10.1016/S0264-410X(00)00047-5
   Mawili-Mboumba DP, 2003, J INFECT DIS, V187, P1137, DOI 10.1086/368414
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Polley SD, 2003, GENETICS, V165, P555
   Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003
   Polley SD, 2001, GENETICS, V158, P1505
   Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   Tine JA, 1996, INFECT IMMUN, V64, P3833
NR 35
TC 16
Z9 16
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD SEP
PY 2005
VL 73
IS 9
BP 5928
EP 5935
DI 10.1128/IAI.73.9.5928-5935.2005
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 958PK
UT WOS:000231460000070
PM 16113313
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
AF Prentice, AM
TI Starvation in humans: Evolutionary background and contemporary
   implications
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE caloric restriction; starvation; famine; human longevity
ID LONGEVITY; THERMOGENESIS; REPRODUCTION; SENESCENCE; MORTALITY; HISTORY;
   OBESITY; LIFE
AB Although there is extensive evidence that caloric restriction (CR) extends lifespan in several species the evidence base for humans is weak. We are still at the stage of applying inductive reasoning and of framing hypotheses to be tested. It is known that a genetic background contributes about 25% to the variation in human longevity, but thought unlikely that any genes conferring longer lifespan have been positively selected to do so. It is more likely that any such benefits are unintended consequences arising from other adaptations. If there is an association between CR and longevity in humans it may have been selected by previous exposures to famine. This paper briefly reviews the historical evidence on the extent and frequency of famines in human history. It is concluded that starvation has been one of the major selective pressures on the human genome and has left abundant evidence of adaptive survival traits. Many of these are mediated through effects on reproduction. However, interpretation of the possible links between these energy-sparing mechanisms and any association between CR and ageing is handicapped by an absence of data on the latter and will remain a matter of debate for many years to come. Published by Elsevier Ireland Ltd.
C1 Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   MRC, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.prentice@lshtm.ac.uk
CR Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2
   COMPSTON J, 1993, MANAGEMENT COMMON ME
   Cournil A, 2001, TRENDS GENET, V17, P233, DOI 10.1016/S0168-9525(01)02306-X
   Darwin Charles, 1989, ORIGIN SPECIES
   DIAMOND J, 1993, 3 CHIMPANZEE, P180
   Doblhammer G, 2000, POP STUD-J DEMOG, V54, P169, DOI 10.1080/713779087
   DOBLHAMMER G, 2003, P ROY SOC LOND B BIO, V7, P1541
   Dulloo AG, 2001, INT J OBESITY, V25, pS22, DOI 10.1038/sj.ijo.0801907
   Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412
   Fagan B., 2000, FLOODS FAMINES EMPER
   Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187
   FRISCH RE, 1982, SCIENCE, V215, P1272, DOI 10.1126/science.7199206
   Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1
   Hughes KA, 2005, ANNU REV ENTOMOL, V50, P421, DOI 10.1146/annurev.ento.50.071803.130409
   Jordan William Chester, 1996, GREAT FAMINE NO EURO
   Keys A, 1950, BIOL HUMAN STARVATIO
   Kirkwood TBL, 1996, BIOESSAYS, V18, P1009, DOI 10.1002/bies.950181211
   Kirkwood TBL, 2003, TRENDS ENDOCRIN MET, V14, P345, DOI 10.1016/j.tem.2003.08.003
   KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0
   Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682
   Korpelainen H, 2000, P ROY SOC B-BIOL SCI, V267, P1765, DOI 10.1098/rspb.2000.1208
   Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991
   Lycett JE, 2000, P ROY SOC B-BIOL SCI, V267, P31
   MCCANCE RA, 1975, P NUTR SOC, V34, P161, DOI 10.1079/PNS19750033
   Medawar PB, 1952, UNSOLVED PROBLEM BIO
   POPPITT SD, 1994, AM J OBSTET GYNECOL, V171, P118
   Prentice A. M., 2001, BNF Nutrition Bulletin, V26, P13, DOI 10.1046/j.1467-3010.2001.00100.x
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P283
   Prentice AM, 1997, BRIT MED BULL, V53, P229
   Prentice AM, 1987, S ZOOLOGICAL SOC LON, V57, P275
   PRENTICE AM, IN PRESS P NUTR SOC
   Prentice AM, 1996, EUR J CLIN NUTR S1, V50, P82
   PRENTICE AM, 1991, P NUTR SOC, V50, P451
   Sear R, 2002, DEMOGRAPHY, V39, P43, DOI 10.1353/dem.2002.0010
   WEINERT BT, 2003, J APPL PHYSIOL, V95, P605
   Westendorp RGJ, 1998, NATURE, V396, P743, DOI 10.1038/25519
   World Health Organization, 1998, WHONUTNCD981
   WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.2307/2406060
NR 38
TC 35
Z9 37
U1 5
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD SEP
PY 2005
VL 126
IS 9
BP 976
EP 981
DI 10.1016/j.mad.2005.03.018
PG 6
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 956YC
UT WOS:000231335000009
PM 15907972
OA No
DA 2017-08-15
ER

PT J
AU Walton, R
   Kimber, M
   Rockett, K
   Trafford, C
   Kwiatkowski, D
   Sirugo, G
AF Walton, R
   Kimber, M
   Rockett, K
   Trafford, C
   Kwiatkowski, D
   Sirugo, G
TI Haplotype block structure of the cytochrome P450CYP2C gene cluster on
   chromosome 10
SO NATURE GENETICS
LA English
DT Letter
C1 MRC Labs, Fajara, Gambia.
   Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Tessella Support Serv Plc, Abingdon, Oxon, England.
RP Walton, R (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM rwalton@mrc.gm
OI Walton, Robert/0000-0001-7700-1907; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Medical Research Council [MC_U190081977]
CR Ahmadi KR, 2005, NAT GENET, V37, P84, DOI 10.1038/ng1488
NR 1
TC 21
Z9 22
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 2005
VL 37
IS 9
BP 915
EP 916
DI 10.1038/ng0905-915
PG 2
WC Genetics & Heredity
SC Genetics & Heredity
GA 960LK
UT WOS:000231591900003
PM 16132042
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Lesi, OA
   Mendy, M
   Szymanska, K
   Whittle, H
   Goedert, JJ
   Hainaut, P
   Montesano, R
AF Kirk, GD
   Lesi, OA
   Mendy, M
   Szymanska, K
   Whittle, H
   Goedert, JJ
   Hainaut, P
   Montesano, R
TI 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and
   risk of hepatocellular carcinoma
SO ONCOGENE
LA English
DT Article
DE hepatocellular carcinoma; aflatoxin; hepatitis B virus; TP53 gene;
   plasma DNA
ID AFLATOXIN-ALBUMIN ADDUCTS; CIRCULATING NUCLEIC-ACIDS; LIVER-CANCER RISK;
   REPUBLIC-OF-CHINA; WEST-AFRICA; P53 GENE; MOLECULAR PATHOGENESIS;
   VIRUS-INFECTION; STEM-CELLS; E-ANTIGEN
AB Hepatocellular carcinoma (HCC) from regions with high dietary exposure to aflatoxins and endemic for hepatitis B virus (HBV) often contain a specific mutation at codon 249 in TP53 (249(ser); AGG to AGT, Arg to Ser). This mutation is also detectable in circulating cell-free DNA from the plasma of HCC patients and healthy subjects in these regions. We have examined the joint effect of plasma 249(ser) and HBV infection in a case-control study design involving 348 control, 98 cirrhotic, and 186 HCC participants from The Gambia, West Africa, an area of high HCC incidence. The 249(ser) mutation was detected in 3.5% of controls, 15.3% of cirrhotics, and 39.8% of HCC cases (adjusted odds ratios (OR): 4.83, (95% confidence interval (CI): 1.71-13.7) for cirrhosis and 20.3 (8.19-50.0) for HCC). HBsAg positivity along with plasma 249(ser) was observed in 45/183 (24.6%) HCC cases compared to only one (0.3%) control. Risk for HCC was associated with markers of HBV alone (OR: 10.0, 95% CI: 5.16-19.6), 249(ser) alone (OR: 13.2, 95% CI: 4.99-35.0), and both markers present (OR: 399, 95% CI: 48.6-3270). These results suggest a multiplicative effect on HCC risk resulting from the mutational effect of aflatoxin on TP53, as monitored by detection of plasma 249(ser), with concomitant chronic infection with HBV.
C1 Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, Baltimore, MD 21205 USA.
   Gambia Hepatitis Intervent Study, Banjul, Gambia.
   NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
   MRC Labs, Banjul, Gambia.
   Int Agcy Res Canc, F-69372 Lyon, France.
RP Kirk, GD (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, 615 N Wolfe St,E-6533, Baltimore, MD 21205 USA.
EM gkirk@jhsph.edu
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
CR AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284
   Anker P, 2003, INT J CANCER, V103, P149, DOI 10.1002/ijc.10791
   AUTRUP H, 1987, CANCER RES, V47, P3430
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BANNASCH P, 1995, CANCER RES, V55, P3318
   Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   Chen CJ, 1996, HEPATOLOGY, V24, P38
   COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258
   Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200
   Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411
   Groopman JD, 1996, PROG CLIN BIOL RES, V395, P211
   HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808
   Hainaut P, 2000, ADV CANCER RES, V77, P81
   Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208
   Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6
   IARC, 2002, MON EV CARC RISKS HU, V82
   International Agency for Research on Cancer (IARC), 1994, MON EV CARC RISKS HU, V59
   Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101
   Jackson PE, 1999, BEST PRACT RES CL GA, V13, P545, DOI 10.1053/bega.1999.0047
   Jackson PE, 2001, CANCER RES, V61, P33
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Liang TJ, 2002, NEW ENGL J MED, V347, P208, DOI 10.1056/NEJMe020060
   LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502
   Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900
   Mandishona E, 1998, HEPATOLOGY, V27, P1563, DOI 10.1002/hep.510270614
   Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34
   MENDY ME, 1998, BRIT J BIOMED SCI, V55, P92
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   Olubuyide I O, 1993, Afr J Med Med Sci, V22, P89
   Omer RE, 2001, CANCER CAUSE CONTROL, V12, P23, DOI 10.1023/A:1008943200826
   Omer RE, 1998, NUTR CANCER, V32, P174
   OZTURK M, 1991, LANCET, V338, P1356
   Payne RJH, 1996, P NATL ACAD SCI USA, V93, P6542, DOI 10.1073/pnas.93.13.6542
   Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387
   PONCHEL F, 1994, CANCER RES, V54, P2064
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   SELL S, 1993, INT J DEV BIOL, V37, P189
   Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699
   Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535
   Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P617
   Strain AJ, 2000, GUT, V46, P743, DOI 10.1136/gut.46.6.743
   Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   Taback B, 2004, CURR OPIN MOL THER, V6, P273
   Thorgeirsson S S, 1995, Princess Takamatsu Symp, V25, P163
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   Vall MM, 1990, LANCET, V336, P1107
   van Rensburg S J, 1990, J Environ Pathol Toxicol Oncol, V10, P11
   Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5<620::AID-IJC5>3.3.CO;2-V
   Wang XW, 2002, TOXICOLOGY, V181, P43, DOI 10.1016/S0300-483X(02)00253-6
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   Wild CP, 1996, CANCER EPIDEM BIOMAR, V5, P179
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   WILD CP, 1987, INT J CANCER, V40, P328, DOI 10.1002/ijc.2910400308
   WILD CP, 1992, TOXICOL LETT, V64-5, P455, DOI 10.1016/0378-4274(92)90219-A
   Wogan GN, 2000, SEMIN CANCER BIOL, V10, P201, DOI 10.1006/scbi.2000.0320
   Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8
   Yan R Q, 1989, Zhonghua Bing Li Xue Za Zhi, V18, P19
   Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215
NR 64
TC 71
Z9 76
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD SEP
PY 2005
VL 24
IS 38
BP 5858
EP 5867
DI 10.1038/sj.onc.1208732
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 960KW
UT WOS:000231590400008
PM 16007211
OA No
DA 2017-08-15
ER

PT J
AU Somda, J
   Tollens, E
   Kamuanga, M
AF Somda, J
   Tollens, E
   Kamuanga, M
TI Transaction costs and the marketable surplus of milk in smallholder
   farming systems of The Gambia
SO OUTLOOK ON AGRICULTURE
LA English
DT Article
DE transaction-cost factors; market participation; smallholders; milk; The
   Gambia
ID BEHAVIOR; AFRICA
AB The neoclassical economic paradigm views market linkages as efficient mechanisms for trading. However, the validity of this position is questionable, as markets frequently do not possess the structural conditions necessary for perfect competition. In subsistence-farming systems,factors that prevent greater participation of smallholders in markets can be found from the production level to the access to markets themselves. This study investigates the transaction-cost factors operating in smallholder dairy farms in The Gambia. The results indicate that access to market at the farm gate, the number of local cows and the distance to the nearest city increase the likelihood of market participation by producers and the marketing of surpluses of dairy products. Increases in home consumption lead to decreases in sales and of farmers' participation in milk marketing. To achieve pro-poor rural growth, it is therefore essential to address explicitly the low productivity of dairy cattle, low capital endowments and market accessibility for smallholder farmers.
C1 ITC, Banjul, Gambia.
   Katholieke Univ Leuven, Dept Agr & Environm Econ, Louvain, Belgium.
   CIRDES, Int Livestock Res Inst, Bobo Dioulasso, Burkina Faso.
RP Somda, J (reprint author), INERA, 04 BP 8645, Ouagadougou 04, Burkina Faso.
EM Jacques.somda@inera.bf
CR AGYEMANG K, 2000, 8 ILRI
   AGYEMANG K, 1997, J DAIRY SCI, V80, P231
   BARJE PP, 1995, EVALUATION PERI URBA
   BROKKEN RF, 1992, P S HELD 26 30 NOV 1
   COULIBALY MD, 1995, EVALUATION SYSTEMES
   Debrah S., 1991, 19 ILCA
   DEFLY A, 1998, PRODUCTION LAITIERE
   DEJANVRY A, 1991, ECON J, V101, P1400, DOI 10.2307/2234892
   DELGADO C, 1999, J AGR EC ASS S AFR A, V38, P165
   Eggertson T, 1990, EC BEHAV I
   FAFCHAMPS M, 1995, INDUCED INNOVATION I
   GOETZ SJ, 1992, AM J AGR ECON, V74, P444, DOI 10.2307/1242498
   HELTBERG R, 2001, 2001114 WIDER UN U
   HOLLOWAY G, 2000, 28 ILRI
   JAFFEE S., 1994, MARKETING AFRICAS HI, P199
   KOPEL B, 1995, INDUCED INNOVATION I
   MCDONALD JF, 1980, REV ECON STAT, V62, P318, DOI 10.2307/1924766
   NWOSU AO, 1991, DAIRY STUDIES SE ZON
   SADOULET E, 1995, QUALTATIVE DEV POLIC
   SHAPIRO K, 1992, DAIRY MARKETING SUBS
   Staal S, 1997, WORLD DEV, V25, P779, DOI 10.1016/S0305-750X(96)00138-6
   STRAUSS J, 1984, AM J AGR ECON, V66, P321, DOI 10.2307/1240799
   Tangka F. K., 2000, 27 ILRI
   Wagenaar KT, 1986, 13 ILCA
   Walshe MJ, 1991, 135 WORLD BANK
   WHITE KJ, 1993, SHAZAM USERS REFEREC
   Zaibet LT, 1998, ECON DEV CULT CHANGE, V46, P831, DOI 10.1086/452376
NR 27
TC 1
Z9 1
U1 0
U2 1
PU I P PUBLISHING LTD
PI LONDON
PA COLERIDGE HOUSE, 4-5 COLERIDGE GARDENS, LONDON NW6 3QH, ENGLAND
SN 0030-7270
J9 OUTLOOK AGR
JI Outlook Agric.
PD SEP
PY 2005
VL 34
IS 3
BP 189
EP 195
PG 7
WC Agriculture, Multidisciplinary
SC Agriculture
GA 978OE
UT WOS:000232882100008
OA No
DA 2017-08-15
ER

PT J
AU Ghattas, H
   Darboe, BM
   Wallace, DL
   Griffin, GE
   Prentice, AM
   Macallan, DC
AF Ghattas, H
   Darboe, BM
   Wallace, DL
   Griffin, GE
   Prentice, AM
   Macallan, DC
TI Measuring lymphocyte kinetics in tropical field settings
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE T-lymphocyte; kinetics; stable isotope labelling; cell sorting; MACS;
   The Gambia
ID T-CELL KINETICS; REFERENCE RANGES; RAPID TURNOVER; IN-VIVO; DNA; HUMANS;
   BLOOD; PROLIFERATION; ETHIOPIANS
AB Studies involving in-vivo labelling of lymphocyte DNA with 6,6-(2)H2-glucose to track T-cell turnover have contributed to understanding lymphocyte homeostasis in health and disease. Applying such studies in tropical settings (where diseases that affect T-cells are prevalent) requires protocol modifications including non-intravenous label administration, applicability in outpatient facilities, and T-cell sorting methods independent of a fluorescence activated cell sorter (FACS). Such protocols were validated in UK pilot studies and applied in The Gambia. Healthy adult subjects (n = 12) were recruited from three Gambian villages. 6,6-H-2(2)-glucose was administered orally in an outpatient clinic and T-cell subpopulations isolated from peripheral blood using plastic adherence, and Multisort (TM) magnetic cell sorting (MACS (TM)) to obtain CD8 + CD45RO+, CD8-CD45RO+, CD8 + CD45RO- and CD8-CD45RO- subsets. To achieve high cell purity and yield, CD45RO- cells were reincubated with CD45R0 beads. T-cell proliferation and disappearance were quantified using gas chromatography mass spectrometry. Results were consistent with those of other studies showing higher turnover in memory (CD45RO+) than in naive (CD45RO-) T-cell subsets, and an association between recent cell proliferation and susceptibility to cell death. Cell kinetics research is applicable in tropical settings, and can contribute to further understanding the regulation of adaptive immunity in response to infections and other insults. (c) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England.
   MRC Labs, Keneba, Gambia.
   Edward Jenner Inst Vaccine Res, Newbury RG20 7NN, Berks, England.
   Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
RP Macallan, DC (reprint author), St George Hosp, Sch Med, Dept Cellular & Mol Med, Cranmer Terrace, London SW17 0RE, England.
EM macailan@sghms.ac.uk
RI Ghattas, Hala/K-5661-2016
OI Macallan, Derek/0000-0002-3014-7148
CR Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2
   Busch R, 2004, J IMMUNOL METHODS, V286, P97, DOI 10.1016/j.jim.2003.12.012
   Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772
   Hellerstein MK, 1999, IMMUNOL TODAY, V20, P438, DOI 10.1016/S0167-5699(99)01529-7
   Macallan DC, 2004, J EXP MED, V200, P255, DOI 10.1084/jem.20040341
   Macallan DC, 2003, EUR J IMMUNOL, V33, P2655, DOI 10.1002/eji.200324295
   Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763
   Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708
   McCune JM, 2000, J CLIN INVEST, V105, pR1, DOI 10.1172/JCI8647
   MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0
   Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499
   Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375
   Partington KM, 1999, J IMMUNOL METHODS, V223, P195, DOI 10.1016/S0022-1759(98)00219-1
   Tsegaye A, 1999, CLIN DIAGN LAB IMMUN, V6, P410
   Tsegaye A, 2003, CLIN IMMUNOL, V109, P338, DOI 10.1016/j.clim.2003.08.008
   TUGUME SB, 1995, CLIN DIAGN LAB IMMUN, V2, P233
   Wallace DL, 2004, J IMMUNOL, V173, P1787
   WHO, 2004, WORLD HLTH REP 2004
   Worku S, 1997, T ROY SOC TROP MED H, V91, P618, DOI 10.1016/S0035-9203(97)90051-1
NR 19
TC 13
Z9 13
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP
PY 2005
VL 99
IS 9
BP 675
EP 685
DI 10.1016/j.trstmh.2005.02.005
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 950TV
UT WOS:000230881700006
PM 15985275
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Fielding, K
   Sillah, JS
   Bah, B
   Gustafson, P
   Warndorff, D
   Palayew, M
   Lisse, I
   Donkor, S
   Diallo, S
   Manneh, K
   Adegbola, R
   Aaby, P
   Bah-Sow, O
   Bennett, S
   McAdam, K
AF Lienhardt, C
   Fielding, K
   Sillah, JS
   Bah, B
   Gustafson, P
   Warndorff, D
   Palayew, M
   Lisse, I
   Donkor, S
   Diallo, S
   Manneh, K
   Adegbola, R
   Aaby, P
   Bah-Sow, O
   Bennett, S
   McAdam, K
TI Investigation of the risk factors for tuberculosis: a case-control study
   in three countries in West Africa
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE tuberculosis; risk factors; epidemiology; developing countries
ID SUB-SAHARAN AFRICA; PULMONARY TUBERCULOSIS; SOCIOECONOMIC-STATUS;
   NORTHERN MALAWI; BCG SCARS; SUSCEPTIBILITY; SMOKING; HIV; EPIDEMIOLOGY;
   DEPRIVATION
AB Background Host-related and environment-related factors have been shown to play a role in the development of tuberculosis (TB), but few studies were carried out to identify their respective roles in resource-poor countries.
   Methods A multicentre case-control study was conducted in Guinee, Guinea Bissau, and The Gambia, from January 1999 to March 2001. Cases were newly detected smear positive TB patients. TWO controls were recruited for each case, one within the household of the case, and one in the community.
   Results Regarding host-related factors, univariate analysis by conditional logistic regression of 687 matched pairs of cases and household controls showed that TB was associated with male sex, family history of TB, absence of a BCG scar, smoking, alcohol, anaemia, HIV infection, and history and treatment of worm infection. In a multivariable model based on 601 matched pairs, male sex, family history of TB, smoking, and HIV infection were independent risk factors of TB. The investigation of environmental factors based on the comparison of 816 cases/community control pairs showed that the risk of TB was associated with single marital status, family history of TB, adult crowding, and renting the house. In a final model assessing the combined effect of host and environmental factors, TB was associated with male sex, HIV infection, smoking (with a dose-effect relationship), history of asthma, family history of TB, marital status, adult crowding, and renting the house.
   Conclusion TB is a multifactorial disorder, in which environment interacts with host-related factors. This study provided useful information for the assessment of host and environmental factors of TB for the improvement of TB control activities in developing countries.
C1 Inst Rech Dev, Dakar, Senegal.
   MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   CHU Ignace Deen, Programme Natl Lutte AntiTuberculeuse, Serv Pneumol, Conakry, Guinea.
   Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau.
   McGill Univ, Jewish Gen Hosp, Div Pulm Med, Montreal, PQ H3A 2T5, Canada.
RP Lienhardt, C (reprint author), Inst Rech Dev, UR 36,BP 1386, Dakar, Senegal.
EM lienhardt@dakar.ird.sn
CR Alcaide J, 1996, TUBERCLE LUNG DIS, V77, P112, DOI 10.1016/S0962-8479(96)90024-6
   ANDERSEN S, 1960, Bull World Health Organ, V22, P39
   Aubry MC, 2000, CLIN CHEST MED, V21, P11, DOI 10.1016/S0272-5231(05)70005-8
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   BHATTI N, 1995, BRIT MED J, V310, P967
   Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732
   BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P7415
   BUSKIN SE, 1994, AM J PUBLIC HEALTH, V84, P1750, DOI 10.2105/AJPH.84.11.1750
   Cantwell MF, 1998, AM J RESP CRIT CARE, V157, P1016
   COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   DECOCK KM, 1994, TUBERCULOSIS BACK FU
   Diwan VK, 1999, LANCET, V353, P1000, DOI 10.1016/S0140-6736(99)01318-5
   DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7
   Dubos R, 1987, WHITE PLAGUE TUBERCU
   FINE PEM, 1981, INT J LEPROSY, V49, P437
   Fine PEM, 1996, LANCET, V348, P17
   FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
   Frost WH, 1933, AM J PUBLIC HEALTH N, V23, P426, DOI 10.2105/AJPH.23.5.426
   GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527
   Glynn JR, 2000, T ROY SOC TROP MED H, V94, P500, DOI 10.1016/S0035-9203(00)90065-8
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   Harper M, 2003, T ROY SOC TROP MED H, V97, P506, DOI 10.1016/S0035-9203(03)80007-X
   Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96
   Hudelson P, 1996, TUBERCLE LUNG DIS, V77, P391, DOI 10.1016/S0962-8479(96)90110-0
   KASS EH, 1971, J INFECT DIS, V123, P110
   Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964
   Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC
   Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   MANGTANI P, 1995, BRIT MED J, V310, P963
   Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011
   Rieder HL, 1999, EPIDEMIOLOGICAL BASI
   SCHOEMAN JH, 1991, INT J EPIDEMIOL, V20, P435, DOI 10.1093/ije/20.2.435
   SHIRAKAWA T, 1997, SCIENCE, V275, P7
   SPENCE DPS, 1993, BRIT MED J, V307, P759
   Stein L, 1952, BR J SOC MED, V6, P1
   Tocque K, 1998, INT J TUBERC LUNG D, V2, P213
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602
   von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449
   World Health Organization, 2001, WHOCDSTB2001287
   [Anonymous], 2003, WHO FRAM CONV TOB CO
NR 46
TC 84
Z9 90
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 2005
VL 34
IS 4
BP 914
EP 923
DI 10.1093/ije/dyi100
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 957HG
UT WOS:000231360300038
PM 15914505
OA No
DA 2017-08-15
ER

PT J
AU Simms, VM
   Makalo, P
   Bailey, RL
   Emerson, PM
AF Simms, VM
   Makalo, P
   Bailey, RL
   Emerson, PM
TI Sustainability and acceptability of latrine provision in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE trachoma; Musca sorbens; hygiene promotion; sanitation; The Gambia
ID TRACHOMA; EPIDEMIOLOGY; FLIES; RISK
AB All households in 32 villages were provided with improved pit latrines as part of a trachoma control programme in a rural part of The Gambia. Latrine provision was externally driven and was not in response to a request from the communities involved. Materials were provided for free and tabour was paid for. To assess durability and acceptability we conducted a follow-up study 25-47 months after construction. Before the intervention only 32% of households in these villages had access to any type of latrine; at follow-up this had risen to 95%. On visual inspection 585/666 latrines (87.3%) were usable and 510 (87.2% of those usable) were currently used. During interviews 566/637 Latrine owners (89%) said they were either happy or very happy with their latrines, and 620 (97.3%) reported that they would make a new latrine of some kind when the current one was full or unusable. We interpret these data to suggest that externally driven Latrine provision, without additional health education, to an area with poor latrine coverage can result in high, sustainable Levels of uptake and generate future demand for sanitation. (c) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 MRC Labs, Banjul, Gambia.
   Univ Durham, Dept Biol & Biomed Sci, Durham DH1 3LE, England.
   London Sch Hyg & Trop Med, Clin Res Unit, London W1E 5HT, England.
RP Emerson, PM (reprint author), Carter Ctr, 1 Copenhill,453 Freedom Pkwy, Atlanta, GA 30307 USA.
EM paul.emerson@emory.edu
RI Simms, Victoria/C-3278-2009
OI Simms, Victoria/0000-0002-4897-458X
FU Medical Research Council [MC_U190081961]
CR Cairncross S., 1992, 9 WORLD BANK
   COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P23
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2002, OPHTHALMIC EPIDEMIOL, V9, P105, DOI 10.1076/opep.9.2.105.1522
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   EMERSON PM, 2000, TROP MED INT HEALTH, V5, P250
   Jenkins M, 2004, WHO BUYS LATRINES WH
   LUNA EJA, 1992, INT J EPIDEMIOL, V21, P169, DOI 10.1093/ije/21.1.169
   Saywell D., 1999, SANITATION PROGRAMME
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   TIELSCH JM, 1988, AM J TROP MED HYG, V38, P393
   WELL, 1998, GUID MAN WAT SUPPL S
   World Health Organization, 1997, STRAT PREV BLINDN NA
   WHO, 1997, WHOPBLGET971
   Zerihun N, 1997, TROP MED INT HEALTH, V2, P1115, DOI 10.1046/j.1365-3156.1997.d01-211.x
NR 18
TC 18
Z9 18
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD AUG
PY 2005
VL 99
IS 8
BP 631
EP 637
DI 10.1016/j.trstmh.2004.10.004
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 942OR
UT WOS:000230292200010
PM 15927217
OA No
DA 2017-08-15
ER

PT J
AU Howie, S
   Adegbola, R
   Corrah, T
AF Howie, S
   Adegbola, R
   Corrah, T
TI Migration of health professionals
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Howie, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM showie@mrc.gm
CR Eastwood JB, 2005, LANCET, V365, P1893, DOI 10.1016/S0140-6736(05)66623-8
NR 1
TC 0
Z9 0
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 16
PY 2005
VL 366
IS 9481
BP 199
EP 200
DI 10.1016/S0140-6736(05)66898-5
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 945RG
UT WOS:000230519200017
PM 16023500
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Olodude, F
   Pinder, M
   Ofori-Anyinam, O
   Vigneron, L
   Fitzpatrick, S
   Njie, F
   Kassanga, A
   Leach, A
   Milman, J
   Rabinovich, R
   McAdam, KPWJ
   Kester, KE
   Heppner, DG
   Cohen, JD
   Tornieporth, N
   Milligan, PJM
AF Bojang, KA
   Olodude, F
   Pinder, M
   Ofori-Anyinam, O
   Vigneron, L
   Fitzpatrick, S
   Njie, F
   Kassanga, A
   Leach, A
   Milman, J
   Rabinovich, R
   McAdam, KPWJ
   Kester, KE
   Heppner, DG
   Cohen, JD
   Tornieporth, N
   Milligan, PJM
TI Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in
   Gambian children
SO VACCINE
LA English
DT Article
DE RTS,S/AS02A; Phase I paediatric vaccine trials
ID CIRCUMSPOROZOITE PROTEIN VACCINE; PLASMODIUM-FALCIPARUM INFECTION;
   WEST-AFRICA; EFFICACY; TRIAL; INFANTS; SPF66
AB RTS,S/AS02A is a pre-erythrocytic malaria vaccine candidate in which a portion of the circumsporozoite surface protein (CSP) of Plasmodium falciparum is genetically linked to hepatitis B surface antigen (HBsAg) coexpressed in yeast with unfused HBsAg. The resulting particulate antigen is formulated with the adjuvant system AS02A. We have initiated the paediatric clinical development of this vaccine by conducting two sequential Phase I studies in children: a study in older children (6-11 years), followed by a second study in younger children (1-5 years). In each study, a double-blind, randomised controlled, staggered, dose-escalation design was used to evaluate 10 mu g RTS,S dose (10 mu g RTS,S in 0.1 mL AS02A), 25 mu g dose (25 mu g RTS,S in 0.25 mL AS02A) and finally a 50 mu g dose (50 mu g RTS,S in 0.5 mL AS02A) of the RTS,S/AS02A candidate malaria vaccine administered according to a 0-, 1- and 3-month vaccination schedule. Safety and reactogenicity were evaluated before moving to a higher dose level.
   The RTS,S/AS02A vaccine was safe at all dose levels, in both age groups. No serious adverse events related to vaccination were reported. The frequency of local Grade 3 symptoms was low but tended to increase with increasing dose level. Grade 3 general adverse events in the RTS,S/AS02A groups were infrequent and of short duration. The majority of local and general Grade 3 symptoms resolved or decreased in intensity within 48 h. The pattern and intensity of reactogenicity seen in these studies are similar to those of previous studies with RTS,S/AS02A. All doses were highly immunogenic for anti-CSP and anti-HBsAg antibodies. The pooled anti-CSP antibody data from the two studies showed that the 25 mu g dose and 50 mu g dose anti-CSP antibody response were similar at both dose levels. However, the immunogenicity of the 10 mu g dose anti-CSP response was significantly lower than that of either the 50 mu g or 25 mu g dose. The 25 mu g dose was selected for future studies of RTS,S/AS02A in paediatric populations. (c) 2005 Elsevier Ltd. All rights reserved.
C1 MRC Labs, Banjul, Gambia.
   GlaxoSmithKline Biol, Rixensart, Belgium.
   PATH, Malaria Vaccine Initiat, Rockville, MD USA.
   Walter Reed Army Inst Res, Washington, DC 20307 USA.
RP Bojang, KA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM kbojang@mrc.gm
RI Kester, Kent/A-2114-2011; Milligan, Paul/D-8985-2017
OI Kester, Kent/0000-0002-5056-0802; Milligan, Paul/0000-0003-3430-3395
CR Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   Doherty JF, 1999, AM J TROP MED HYG, V61, P865
   GORDON DM, 1995, J INFECT DIS, V171, P1576
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   LEACH A, 1995, PARASITE IMMUNOL, V17, P441, DOI 10.1111/j.1365-3024.1995.tb00912.x
   Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485
   Smith PG, 1991, METHODS FIELD TRIALS
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   World Bank, 1993, WORLD DEV REP 1993 I
NR 14
TC 71
Z9 73
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL 14
PY 2005
VL 23
IS 32
BP 4148
EP 4157
DI 10.1016/j.vaccine.2005.03.019
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 943EB
UT WOS:000230334000008
PM 15964483
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Secka, O
   Lahai, G
   Lloyd-Evans, N
   Njie, A
   Usen, S
   Oluwalana, C
   Obaro, S
   Weber, M
   Corrah, T
   Mulholland, K
   McAdam, K
   Greenwood, B
   Milligan, PJM
AF Adegbola, RA
   Secka, O
   Lahai, G
   Lloyd-Evans, N
   Njie, A
   Usen, S
   Oluwalana, C
   Obaro, S
   Weber, M
   Corrah, T
   Mulholland, K
   McAdam, K
   Greenwood, B
   Milligan, PJM
TI Elimination of Haemophilus influenzae type b (Hib) disease from The
   Gambia after the introduction of routine immunisation with a Hib
   conjugate vaccine: a prospective study
SO LANCET
LA English
DT Article
ID WEST-AFRICA; MENINGITIS; CHILDREN; TRIAL; INFECTIONS; INFANTS;
   EPIDEMIOLOGY; PNEUMONIA; COUNTRIES; EFFICACY
AB Background Routine immunisation of infants in The Gambia with a Haemophilus influenzae type b (Hib) polysaccharide-tetanus toxoid conjugate vaccine began in May, 1997. We investigated the effectiveness of the vaccine when delivered through the expanded programme on immunisation and the effect of national immunisation. on incidence of Hib disease.
   Methods Surveillance for Hib disease was maintained in the western half of The Gambia using standard methods with an emphasis on meningitis. We estimated vaccine efficacy using the case control method, and vaccine coverage and population denominators for incidence rates using a cluster sample survey. Prevalence of Hib carriage in a sample of 1-2-year old children attending health centres for vaccination was ascertained with oropharyngeal swabs plated onto antiserum agar.
   Findings Between May, 1997, and April, 2002, a total of 5984 children were examined for possible Hib infections. 49 children had Hib disease, 36 of whom had meningitis. The annual incidence rates of Hib meningitis before any use of the vaccine (1990-93) dropped from over 200 per 100 000 children aged younger than 1 year to none per 100 000 in 2002, and from 60 to no cases per 100 000 in children younger than 5 years. The prevalence of Hib carriage decreased from 12% to 0.25% (p<0.0001). Two doses of vaccine were needed for direct protection from Hib disease (vaccine efficacy 94%, 95% CI 62-99). Since most children received a protective dose after the age of greatest disease risk, indirect effects were important in reducing disease incidence.
   Interpretation The Gambian Hib immunisation programme reduced the occurrence of Hib disease despite irregular vaccine supply. The effect of the programme in The Gambia has important implications for the introduction of the vaccine into routine immunisation. programmes of other developing countries.
C1 MRC Labs, Banjul, Gambia.
   Natl Hlth Lab, Banjul, Gambia.
   Dept State Hlth, Banjul, Gambia.
   Royal Childrens Hosp, Parkville, Vic 3052, Australia.
   London Sch Hyg & Trop Med, Dept Infect Dis, London WC1, England.
RP Adegbola, RA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM radegbola@mrc.gm
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440
   Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   BAER M, 1995, LANCET, V345, P661, DOI 10.1016/S0140-6736(95)90570-7
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BIJLMER HA, 1991, VACCINE S, V9, P5
   BULKOW LR, 1993, PEDIATR INFECT DIS J, V12, P484, DOI 10.1097/00006454-199306000-00006
   COCHI SL, 1988, PEDIATRICS, V81, P166
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 1999, VACCINE, V17, P134, DOI 10.1016/S0264-410X(98)00165-0
   DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X
   Garner D, 2003, LANCET, V361, P395, DOI 10.1016/S0140-6736(03)12385-9
   GIESECHE J, 1997, LANCET, V349, P670
   Goetghebuer T, 2000, TROP MED INT HEALTH, V5, P207, DOI 10.1046/j.1365-3156.2000.00535.x
   GREENWOOD B, 1992, J INFECT DIS, V165, pS26
   Jordens JZ, 1995, EUR J CLIN MICROBIOL, V14, P935, DOI 10.1007/BF01691374
   Lagos R, 1998, PEDIATR INFECT DIS J, V17, pS139, DOI 10.1097/00006454-199809001-00010
   Milligan P, 2004, INT J EPIDEMIOL, V33, P469, DOI 10.1093/ije/dyh096
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X
   Ramsay ME, 2003, J INFECT DIS, V188, P481, DOI 10.1086/376997
   WAGGONERFOUNTAIN LA, 1995, CLIN INFECT DIS, V21, P1322, DOI 10.1093/clinids/21.5.1322
   Ward JJ, 1996, CLIN INFECT DIS, V22, P1077
   WENGER JD, 2000, VACCINE, V18, P736
NR 25
TC 178
Z9 182
U1 0
U2 5
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 9
PY 2005
VL 366
IS 9480
BP 144
EP 150
DI 10.1016/S0140-6736(05)66788-8
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 943JH
UT WOS:000230349200033
PM 16005337
OA No
DA 2017-08-15
ER

PT J
AU Somda, J
   Kamuanga, M
   Tollens, E
AF Somda, J
   Kamuanga, M
   Tollens, E
TI Characteristics and economic viability of milk production in the
   smallholder farming systems in The Gambia
SO AGRICULTURAL SYSTEMS
LA English
DT Article
DE The Gambia; milk production; farming systems; discriminant analysis;
   viability
ID CATTLE
AB Domestic milk production has been for a long time hindered by many factors including lack of interest from decision makers, distorted economic policy and biotechnical constraints. For the last 20 years, many developing countries have been attempting to develop the domestic milk production sector. However, research on the basic realities and the viability status of enterprises within this sector remain largely unproved in many developing countries. This study focuses on the characteristic of smallholder milk producers in The Gambia. Data were collected from 90 smallholder farm households to characterise milk producers and evaluate the profitability and viability status of this activity. Based on current typology of farms and gross margin analyses at farm level, the study identified two resource-based types of smallholder farms. The current milk production system is surely viable. Constraints to increased productivity include lack of improved technology at farm level and weak institutional support. Despite the low viability status, it is shown that milk production generates reliable incomes, which could be a departure for most farmers to intensify farming systems, particularly in areas where no loan schemes exist for purchasing agricultural inputs. (c) 2004 Elsevier Ltd. All rights reserved.
C1 ITC, Banjul, Gambia.
   Katholieke Univ Leuven, Dept Agr & Environm Econ, Louvain, Belgium.
   CIRDES, ILRI, Bobo Dioulasso 01, Burkina Faso.
RP Somda, J (reprint author), ITC, PMB 14, Banjul, Gambia.
EM j.somda@itc.gm
CR ABOAGYE GS, 1998, P 75 ANN S S AFR STU, P30
   AGYEMANG K, 1997, VILLAGE NDAMA CATTLE, P131
   BATZ JF, 1998, THESIS HUMBOLDT U BE
   Delgado C., 1999, 28 IFPRI FAO ILRI
   DUBE L, 1995, THESIS U ZIMBABWE
   FERGUSON W, 1988, P ILCA ILRAD NOV 198, P187
   Hanyani-Mlambo BT, 1998, LIVESTOCK RES RURAL, V10
   Hazel P., 2001, 34 INT FOOD POL RES
   HILL B, 1990, INTRO EC STUDENT AGR, P381
   HOLLOWAY G, 2000, 28 ILRI
   Itty P., 1993, Quarterly Journal of International Agriculture, V32, P293
   Itty P, 1996, AGR ECON, V14, P33, DOI 10.1016/0169-5150(95)01170-6
   JOHNSON DT, 1985, BUSINESS FARMING GUI
   KLECKA WR, 1981, SAGE U PAPER SERIES, P71
   Rushton J, 1999, REV SCI TECH OIE, V18, P315
   SCOBIE GM, 1995, AGR RES ERA ADJ POL, P1
   Sere C., 1995, GLOBAL AGENDA LIVEST, P11
   SOMDA J, 2003, 1 ITC SOC RES
   STARKEY PH, 1984, WORLD ANIM REV, P2
   TABOR SR, 1992, OIL BOOM INDONESIAN
   WAITHAKA M, 1998, INTEGRATION USER PRE
   WATERSBAYER A, 1988, FARMING SYSTEMS RESO, V4
   Williams TO, 1999, PROPERTY RIGHTS, RISK, AND LIVESTOCK DEVELOPMENT IN AFRICA, P132
   *WINR INT, 1992, ASS AN AGR SUB SAH A, P162
NR 24
TC 22
Z9 24
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-521X
J9 AGR SYST
JI Agric. Syst.
PD JUL
PY 2005
VL 85
IS 1
BP 42
EP 58
DI 10.1016/j.agsy.2004.07.011
PG 17
WC Agriculture, Multidisciplinary
SC Agriculture
GA 937UN
UT WOS:000229951400003
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Onipede, A
   Pym, AS
   Gagneux, S
   Aga, RS
   DeRiemer, K
   Small, PM
AF de Jong, BC
   Onipede, A
   Pym, AS
   Gagneux, S
   Aga, RS
   DeRiemer, K
   Small, PM
TI Does resistance to pyrazinamide accurately indicate the presence of
   Mycobacterium bovis?
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID TUBERCULOSIS; EPIDEMIOLOGY
AB Mycobacterium bovis is best identified by screening those isolates of the Mycobacterium tuberculosis complex that have any pyrazinamide-(PZA) resistance, using a confirmatory test such as spoligotyping, biochemical testing, or genomic deletion analysis. The sensitivity for detection of M. bovis is lowered to 82% when only PZA-monoresistant isolates are screened.
C1 MRC Labs, Fajara, Banjul, Gambia.
   Stanford Univ, Div Infect Dis, Stanford, CA 94305 USA.
   Bill & Melinda Gates Fdn, Seattle, WA USA.
RP de Jong, BC (reprint author), MRC Labs, POB 273, Fajara, Banjul, Gambia.
EM bouke@stanford.edu
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; DeRiemer,
   Kathryn/0000-0002-8375-7505; Gagneux, Sebastien/0000-0001-7783-9048;
   Pym, Alexander/0000-0002-6260-8180
FU FIC NIH HHS [K01 TW000001, K01 TW000001-06, K01 TW006083, TW 06083-01];
   NIAID NIH HHS [R01 AI034238, AI 34238]
CR Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Chaves F, 1996, J CLIN MICROBIOL, V34, P1118
   Hannan MM, 2001, J CLIN MICROBIOL, V39, P647, DOI 10.1128/JCM.39.2.647-650.2001
   Jasmer RM, 1999, ANN INTERN MED, V130, P971
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Kent PT, 1985, PUBLIC HLTH MYCOBACT
   LoBue PA, 2003, INT J TUBERC LUNG D, V7, P180
   LUTZ B, 1992, CLIN MICROBIOLOGY PR
   Rhee JT, 2000, INT J TUBERC LUNG D, V4, P1111
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
NR 10
TC 23
Z9 23
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 2005
VL 43
IS 7
BP 3530
EP 3532
DI 10.1128/JCM.43.7.3530-3532.2005
PG 3
WC Microbiology
SC Microbiology
GA 947AR
UT WOS:000230614900089
PM 16000498
OA No
DA 2017-08-15
ER

PT J
AU Garbusinski, JM
   van der Sande, MAB
   Bartholome, EJ
   Dramaix, M
   Gaye, A
   Coleman, R
   Nyan, OA
   Walker, RW
   McAdam, KPWJ
   Walraven, GE
AF Garbusinski, JM
   van der Sande, MAB
   Bartholome, EJ
   Dramaix, M
   Gaye, A
   Coleman, R
   Nyan, OA
   Walker, RW
   McAdam, KPWJ
   Walraven, GE
TI Stroke presentation and outcome in developing countries - A prospective
   study in The Gambia
SO STROKE
LA English
DT Article
DE Africa; developing countries; prognosis; recovery of function; social
   support; stroke; stroke outcome
ID ACUTE ISCHEMIC-STROKE; EARLY ASPIRIN USE; INTRACEREBRAL HEMORRHAGE;
   CONTROLLED-TRIAL; MORTALITY; SCORE; INFARCTION
AB Background and Purpose - Despite increasing burden of stroke in Africa, prospective descriptive data are rare. Our objective was to describe, in The Gambia, the clinical outcome of stroke patients admitted to the Royal Victoria Teaching Hospital in the capital Banjul, to assess mortality and morbidity, and propose preventive and therapeutic measures.
   Methods - Prospective data were collected on consecutive patients older than 15 years old admitted between February 2000 and February 2001 with the diagnosis of nonsubarachnoid stroke. Risk factors, clinical characteristics, and social consequences were assessed using a modified National Institutes of Health Stroke Scale (mNIHSS), the Barthel Activity in Daily Living scale, the Siriraj score for subtypes, and the Bamford criteria for location/extension. Patients were followed-up at home up to 1 year after discharge.
   Results - Ninety-one percent (148/162) of eligible patients were enrolled and followed-up. Hypertension and smoking were the most prevalent risk factors. Severity was high at admission, especially in women, and was strongly correlated to the outcome. mNIHSS and consciousness level on admission were strong predictors of the mortality risk. Swallowing difficulties at admission, fever, lung infection, and no aspirin treatment were, independently, risk factors for a lethal outcome susceptible to being addressed by treatment. Mortality was 41 % in-hospital and 62 % after 1 year. In survivors, autonomy levels improved over time. Drug compliance was poor. At home, family members provided care. Long-term socioeconomic and cultural activities were affected in most patients.
   Conclusions - Case-fatality was high compared with Western cohorts. Preventive measures can be developed. Rational treatment, in the absence of head imaging for initial assessment, requires adapted protocols. Providers should be trained, both at hospital and community levels.
C1 MRC Labs, Fajara, Gambia.
   Univ Libre Bruxelles, Ecole Sante Publ, Hop Erasme, Lab Stat Med,Serv Neurol, Brussels, Belgium.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
RP Garbusinski, JM (reprint author), 130 Rue Allies, B-1190 Brussels, Belgium.
EM jgarbusinski@hotmail.com
CR Akpunonu BE, 1998, AM J MED SCI, V315, P194, DOI 10.1097/00000441-199803000-00009
   BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373
   BROTT T, 1989, STROKE, V20, P864
   Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5
   Chen ZM, 2000, STROKE, V31, P1240
   Cheung RTF, 2003, STROKE, V34, P1717, DOI 10.1161/01.STR.0000078657.22835.B9
   Johnston KC, 2000, STROKE, V31, P448
   Kahn K, 1999, S AFR MED J, V89, P63
   Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9
   Kissela B, 2004, STROKE, V35, P426, DOI 10.1161/01.STR.0000110982.74967.39
   Lisk D R, 1993, Stroke, V24, P139
   MAHONEY F I, 1965, Md State Med J, V14, P61
   MBuyambaKabangu JR, 1995, J HYPERTENS, V13, P1863
   Murray CJ, 1996, GLOBAL BURDEN DIS CO
   Nyame PK, 1998, E AFR MED J, V75, P637
   POUNGVARIN N, 1991, BRIT MED J, V302, P1565
   van der Sande MAB, 2001, B WORLD HEALTH ORGAN, V79, P133
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   Walker RW, 2000, LANCET, V355, P1684, DOI 10.1016/S0140-6736(00)02240-6
   Walker RW, 2003, STROKE, V34, P1604, DOI 10.1161/01.STR.0000077943.63718.67
NR 20
TC 43
Z9 45
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUL
PY 2005
VL 36
IS 7
BP 1388
EP 1393
DI 10.1161/01.STR.0000170717.91591.7d
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 941BW
UT WOS:000230190600013
PM 15947255
OA No
DA 2017-08-15
ER

PT J
AU Emerson, PM
   Simms, VM
   Makalo, P
   Bailey, RL
AF Emerson, PM
   Simms, VM
   Makalo, P
   Bailey, RL
TI Household pit latrines as a potential source of the fly Musca sorbens -
   a one year longitudinal study from The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Chrysomya albiceps; domestic flies; hygiene; pit latrines; Musca
   domestica; Musca sorbens; The Gambia; toilet facilities; trachoma
ID TRACHOMA; VECTOR
AB OBJECTIVES To assess whether the trachoma vector Musca sorbens was breeding in household latrines in a trachoma-endemic part of The Gambia.
   METHODS Longitudinal study of flies emerging from 16 sentinel household latrines selected at random from a list of all latrines present in four Gambian villages. Latrines were surveyed and fly traps were set over the drop hole for 24 h once per month for a year.
   RESULTS All the sentinel latrines were of the 'Gambian improved household latrine' design, which has a cement slab but is not ventilated or fly-proofed. The latrines were all in regular use by a family, mean number of users per latrine 14.8 (SD 8.0, range 2-29). Of 55 351 flies caught in 192 catches 54 130 (97.8%) were Chrysomya albiceps, 690 (1.2%) Musca domestica, 466 (0.8%) Chrysomya regalis and 65 (0.1%) M. sorbens. Of the M. sorbens caught 61 (93.8%) were female.
   CONCLUSIONS Gambian improved household pit latrines cannot be considered a source of the trachoma vector M. sorbens, and the promotion of pit latrines as a method to reduce M. sorbens is warranted. A large number of C. albiceps were caught emerging from the latrines, but this species is not considered to be of medical importance.
C1 Univ Durham, Sch Biol & Biomed Sci, Durham, England.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Emerson, PM (reprint author), Carter Ctr, 1 Copenhill, Atlanta, GA 30307 USA.
EM paul.emerson@emory.edu; victoria.simms@lshtm.ac.uk;
   pateh_makalo@yahoo.co.uk; robin.bailey@lshtm.ac.uk
RI Simms, Victoria/C-3278-2009
FU Medical Research Council [MC_U190081961]
CR CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1
   de Andrade JB, 2002, MEM I OSWALDO CRUZ, V97, P1137, DOI 10.1590/S0074-02762002000800013
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P83
   Hall Martin J. R., 1993, P429
   Omar Aziza H., 1995, Journal of the Egyptian Society of Parasitology, V25, P729
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Verves YG, 2004, MED VET ENTOMOL, V18, P308, DOI 10.1111/j.0269-283X.2004.00512.x
   WHO, 1997, WHOPBLGET971
   Zimin LS, 1948, OPRED FAUNA USSR, V28, P1
NR 12
TC 22
Z9 22
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2005
VL 10
IS 7
BP 706
EP 709
DI 10.1111/j.1365-3156.2005.01432.x
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 936DZ
UT WOS:000229837000011
PM 15960710
OA No
DA 2017-08-15
ER

PT J
AU Dhollander, S
   Bos, J
   Kora, S
   Sanneh, M
   Gaye, M
   Leak, S
   Berkvens, D
   Geerts, S
AF Dhollander, S
   Bos, J
   Kora, S
   Sanneh, M
   Gaye, M
   Leak, S
   Berkvens, D
   Geerts, S
TI Susceptibility of West African Dwarf goats and WAD x Saanen crosses to
   experimental infection with Trypanosoma congolense
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trypanosoma congolense; goat; genetic resistance; West African Dwarf
   goat; Saanen goat; trypanotolerance
ID GLOSSINA-MORSITANS-SUBMORSITANS; ZEBU CATTLE; TSETSE CHALLENGE; SHEEP;
   NDAMA; BREEDS; TRYPANOTOLERANCE; PERFORMANCE; ANTIBODIES; DIAGNOSIS
AB West African Dwarf goats (WADs) and their Saanen crosses were experimentally infected with Trypanosoma congolense. No significant differences were found between trypanosome parasitaemia and antibody response of the crossbred and WAD goats. Neither the WAD goats nor the Saanen crosses were able to control the drop in PCV following trypanosome infection. The level of anaemia caused by the trypanosome infection was similar in the two breeds during the trial. Based on these findings, no difference in tolerance or susceptibility to T congolense could be demonstrated between the WAD goats and their Saanen crosses.
   Although the weight of all goats increased during the trial, the crosses gained significantly more weight than the WAD goats. The trypanosome infection reduced the growth rate of both breeds, but this reduction was not statistically significant.
   Crossbreeding trypanotolerant WADs with trypanosusceptible Saanen goats might, therefore, be an effective means of increasing productivity. (c) 2005 Published by Elsevier B.V.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Wageningen & Res Ctr, Wageningen, Netherlands.
   Inst Trop Med, B-2000 Antwerp, Belgium.
RP Dhollander, S (reprint author), Lepelstr 63, B-9140 Temse, Belgium.
EM sofiedhollander@yahoo.co.uk
CR CLAUSEN PH, 1993, TROP MED PARASITOL, V44, P99
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   Faye D, 2002, VET PARASITOL, V108, P117, DOI 10.1016/S0304-4017(02)00184-X
   Goossens B, 1999, VET PARASITOL, V85, P25, DOI 10.1016/S0304-4017(99)00087-4
   Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X
   GRIFFIN L, 1979, J COMP PATHOL, V89, P457, DOI 10.1016/0021-9975(79)90037-9
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KatungukaRwakishaya E, 1997, TROP ANIM HEALTH PRO, V29, P7, DOI 10.1007/BF02632337
   LEAK S, 2003, ISCTRC C PRET
   LEAK S, 2002, ICPTV, V6, P36
   Lejon V, 2003, VET PARASITOL, V116, P87, DOI 10.1016/S0304-4017(03)00257-7
   Mattioli RC, 1998, ACTA TROP, V71, P57, DOI 10.1016/S0001-706X(98)00051-5
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   PARIS J, 1982, ACTA TROP, V39, P307
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   Rebeski DE, 2000, VET PARASITOL, V89, P187, DOI 10.1016/S0304-4017(00)00194-1
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   TOURE SM, 1981, DAKAR
   WHITELAW DD, 1985, TROP ANIM HEALTH PRO, V17, P155, DOI 10.1007/BF02355876
NR 23
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUN 10
PY 2005
VL 130
IS 1-2
BP 1
EP 8
DI 10.1016/j.vetpar.2004.11.012
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 931LB
UT WOS:000229485700001
PM 15893063
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Van der Loeff, MS
   Eugen-Olsen, J
   Vincent, T
   Sarje-Njie, R
   Ngom, P
   Meyer, AM
   Berry, N
   Aaby, P
   Whittle, H
AF Jaffar, S
   Van der Loeff, MS
   Eugen-Olsen, J
   Vincent, T
   Sarje-Njie, R
   Ngom, P
   Meyer, AM
   Berry, N
   Aaby, P
   Whittle, H
TI Immunological predictors of survival in HIV type 2-infected rural
   villagers in Guinea-Bissau
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID PLASMA VIRAL LOAD; DISEASE PROGRESSION; GAMBIAN PATIENTS; SERUM LEVEL;
   RNA LEVELS; INFECTION; MARKERS; ACTIVATION; BETA-2-MICROGLOBULIN;
   RECEPTOR
AB We investigated the association between beta(2)-microglobulin, neopterin, serum levels of soluble urokinase-type plasminogen activator receptor (suPAR), CD4 count, and plasma viremia with survival in 133 HIV-2-infected villagers and 160 controls living in rural Guinea-Bissau. Subjects were recruited in 1991 and visited at home every 3-6 months until 1998. Median beta(2)-microglobulin, neopterin, and suPAR were significantly higher and CD4% significantly lower among HIV-2-infected individuals than controls. Thirty-one HIV-2-infected individuals died and 7 were lost to follow-up. beta(2)-Microglobulin, CD4%, and plasma viral load were associated independently with survival in multivariate analyses. Neopterin and suPAR did not reach statistical significance. These findings suggest that immune activation is central to the pathogenesis of HIV. They also have important implications for resource-poor settings where CD4 count and plasma viral load are unaffordable.
C1 London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Hvidovre Univ Hosp, Dept Infect Dis, Hvidovre, Denmark.
   Hvidovre Univ Hosp, Clin Res Unit, Hvidovre, Denmark.
   Danish Epidemiol Sci Ctr, Proj Saude Bandim, Bissau, Guinea Bissau.
   Natl Inst Biol Stand & Controls, Div Retrovirol, S Mimms, Herts, England.
RP Jaffar, S (reprint author), London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Dept Infect & Trop Dis, London WC1E 7HT, England.
EM shabbar.jaffar@lshtm.ac.uk
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   BROWN AE, 1990, CLIN EXP IMMUNOL, V82, P97
   Eugen-Olsen J, 2002, INT J TUBERC LUNG D, V6, P686
   Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724
   Hosp M, 2000, HIV Med, V1, P125, DOI 10.1046/j.1468-1293.2000.00016.x
   Iuliano R, 1997, J ACQ IMMUN DEF SYND, V14, P408
   LAFEUILLADE A, 1994, J ACQ IMMUN DEF SYND, V7, P1028
   Lawn SD, 2004, J INFECTION, V48, P1, DOI 10.1016/j.jinf.2003.09.001
   Mellors JW, 1997, ANN INTERN MED, V126, P946
   Messele T, 2001, CLIN IMMUNOL, V98, P212, DOI 10.1006/clim.2000.4958
   Moodley D, 1996, ANN TROP PAEDIATR, V16, P155
   Nkengasong JN, 2001, J INFECT DIS, V183, P1405, DOI 10.1086/319855
   Poppa A, 2004, HIV MED, V5, P46, DOI 10.1111/j.1468-1293.2004.00215.x
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Sehgal S., 2002, Methods in Cell Science, V24, P107, DOI 10.1023/A:1024109624370
   Sidenius N, 2000, BLOOD, V96, P4091
   Ullum H, 2000, SCAND J INFECT DIS, V32, P371
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 21
TC 18
Z9 18
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2005
VL 21
IS 6
BP 560
EP 564
DI 10.1089/aid.2005.21.560
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 946CU
UT WOS:000230550500006
PM 15989461
OA No
DA 2017-08-15
ER

PT J
AU Koch, O
   Rockett, K
   Jallow, M
   Pinder, M
   Sisay-Joof, F
   Kwiatkowski, D
AF Koch, O
   Rockett, K
   Jallow, M
   Pinder, M
   Sisay-Joof, F
   Kwiatkowski, D
TI Investigation of malaria susceptibility determinants in the
   IFNG/IL26/IL22 genomic region
SO GENES AND IMMUNITY
LA English
DT Article
DE interferon-gamma; IFNG; IL22; IL26; malaria; anaemia; cerebral malaria;
   microsatellite
ID HUMAN INTERFERON-GAMMA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR-NECROSIS
   FACTOR; CEREBRAL MALARIA; 1ST INTRON; PLASMODIUM-FALCIPARUM; GENE
   POLYMORPHISMS; INNATE IMMUNITY; IN-VITRO; INTERLEUKIN-12
AB Interferon-gamma, encoded by IFNG, is a key immunological mediator that is believed to play both a protective and a pathological role in malaria. Here, we investigate the relationship between IFNG variation and susceptibility to malaria. We began by analysing West African and European haplotype structure and patterns of linkage disequilibrium across a 100 kb genomic region encompassing IFNG and its immediate neighbours IL22 and IL26. A large case - control study of severe malaria in a West Africa population identified several weak associations with individual single-nucleotide polymorphisms in the IFNG and IL22 genes, and defined two IL22 haplotypes that are, respectively, associated with resistance and susceptibility. These data provide a starting point for functional and genetic analysis of the IFNG genomic region in malaria and other infectious and inflammatory conditions affecting African populations.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
RP Rockett, K (reprint author), Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
EM Kirk.Rockett@well.ox.ac.uk
RI Koch, Oliver/A-9480-2016
OI Kwiatkowski, Dominic/0000-0002-5023-0176
CR Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24
   Awad M, 1999, HUM IMMUNOL, V60, P343, DOI 10.1016/S0198-8859(98)00133-5
   Bream JH, 2000, IMMUNOGENETICS, V51, P50, DOI 10.1007/s002510050008
   Cavet J, 2001, BLOOD, V98, P1594, DOI 10.1182/blood.V98.5.1594
   CHEHIMI J, 1994, J CLIN IMMUNOL, V14, P149, DOI 10.1007/BF01533364
   Chevillard C, 2002, EUR J IMMUNOGENET, V29, P53, DOI 10.1046/j.0960-7420.2001.00281.x
   GRAU GE, 1989, IMMUNOL REV, V112, P49, DOI 10.1111/j.1600-065X.1989.tb00552.x
   GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572
   GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0
   Hoffman SL, 1997, NAT MED, V3, P80, DOI 10.1038/nm0197-80
   JOHNSON JK, 1993, J INFECT DIS, V167, P698
   Khani-Hanjani A, 2000, LANCET, V356, P820, DOI 10.1016/S0140-6736(00)02657-X
   KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827
   Lio D, 2002, EUR J IMMUNOGENET, V29, P371, DOI 10.1046/j.1365-2370.2002.00327.x
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Nagarkatti R, 2002, J ALLERGY CLIN IMMUN, V110, P410, DOI 10.1067/mai.2002.127859
   Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573
   Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622
   Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1
   Pravica V, 1999, EUR J IMMUNOGENET, V26, P1, DOI 10.1046/j.1365-2370.1999.00122.x
   RILEY EM, 1991, EUR J IMMUNOL, V21, P1019, DOI 10.1002/eji.1830210424
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   SCHOFIELD L, 1987, J IMMUNOL, V139, P2020
   SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P10700, DOI 10.1073/pnas.91.22.10700
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311
   VANNUCCHI AM, 1994, BRIT J HAEMATOL, V87, P18, DOI 10.1111/j.1365-2141.1994.tb04864.x
   Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007
NR 30
TC 22
Z9 23
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUN
PY 2005
VL 6
IS 4
BP 312
EP 318
DI 10.1038/sj.gene.6364214
PG 7
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 931DI
UT WOS:000229465600006
PM 15858598
OA No
DA 2017-08-15
ER

PT J
AU Natividad, A
   Wilson, J
   Koch, O
   Holland, MJ
   Rockett, K
   Faal, N
   Jallow, O
   Joof, HM
   Burton, MJ
   Alexander, NDE
   Kwiatkowski, DP
   Mabey, DCW
   Bailey, RL
AF Natividad, A
   Wilson, J
   Koch, O
   Holland, MJ
   Rockett, K
   Faal, N
   Jallow, O
   Joof, HM
   Burton, MJ
   Alexander, NDE
   Kwiatkowski, DP
   Mabey, DCW
   Bailey, RL
TI Risk of trachomatous scarring and trichiasis in Gambians varies with SNP
   haplotypes at the interferon-gamma and interleukin-10 loci
SO GENES AND IMMUNITY
LA English
DT Article
DE human; Chlamydia trachomatis; interferon gamma; interleukin 10;
   single-nucleotide polymorphism; haplotype
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
   CHLAMYDIA-TRACHOMATIS; GENE PROMOTER; MYCOBACTERIAL INFECTION; ENDEMIC
   POPULATION; DISEASE; IL-10; RESPONSES; ANTIGENS
AB Experimental evidence implicates interferon gamma (IFN gamma) in protection from and resolution of chlamydial infection. Conversely, interleukin 10 (IL10) is associated with susceptibility and persistence of infection and pathology. We studied genetic variation within the IL10 and IFN gamma loci in relation to the risk of developing severe complications of human ocular Chlamydia trachomatis infection. A total of 651 Gambian subjects with scarring trachoma, of whom 307 also had potentially blinding trichiasis and pair-matched controls with normal eyelids, were screened for associations between single-nucleotide polymorphisms ( SNPs), SNP haplotypes and the risk of disease. MassEXTEND (Sequenom) and MALDI-TOF mass spectrometry were used for detection and analysis of SNPs and the programs PHASE and SNPHAP used to infer haplotypes from population genetic data. Multivariate conditional logistic regression analysis identified IL10 and IFN gamma SNP haplotypes associated with increased risk of both trachomatous scarring and trichiasis. SNPs in putative IFNg and IL10 regulatory regions lay within the disease-associated haplotypes. The IFN gamma +874A allele, previously linked to lower IFN gamma production, lies in the IFN gamma risk haplotype and was more common among cases than controls, but not significantly so. The promoter IL10-1082G allele, previously associated with high IL10 expression, is in both susceptibility and resistance haplotypes.
C1 Univ London London Sch Hyg & Trop Med, Infect Trop Dis Dept, Clin Res Unit, London WC1E 7HT, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Childhood Infect Grp, Oxford OX3 7BN, England.
   MRC Labs, Fajara, Gambia.
   Natl Eye Care Program, Banjul, Gambia.
RP Natividad, A (reprint author), Univ London London Sch Hyg & Trop Med, Infect Trop Dis Dept, Clin Res Unit, Keppel St, London WC1E 7HT, England.
EM angels.natividad-sancho@lshtm.ac.uk
RI Koch, Oliver/A-9480-2016
OI Mabey, David/0000-0002-0031-8276; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [MC_U190081961]
CR Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24
   Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432
   Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY R, 1998, CHLAMYDIAL INFECT, P474
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   Beatty Wandy L., 1994, Trends in Microbiology, V2, P94, DOI 10.1016/0966-842X(94)90542-8
   BEATTY WL, 1995, INFECT IMMUN, V63, P199
   BEATTY WL, 1994, INFECT IMMUN, V62, P3705
   Bobo LD, 1997, J INFECT DIS, V176, P1524
   Bream JH, 2000, IMMUNOGENETICS, V51, P50, DOI 10.1007/s002510050008
   BRUNHAM RC, 1994, INFECT AGENT DIS, V3, P218
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Chevillard C, 2002, EUR J IMMUNOGENET, V29, P53, DOI 10.1046/j.0960-7420.2001.00281.x
   CICCARONE VC, 1990, J IMMUNOL, V144, P725
   CLARK JG, 1989, J CLIN INVEST, V83, P1505, DOI 10.1172/JCI114045
   Cohen CR, 1999, AIDS, V13, P327, DOI 10.1097/00002030-199902250-00004
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Conway DJ, 1996, J INFECT DIS, V174, P643
   Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y
   DAWSON CR, 1989, EYE, V3, P204
   Eskdale J, 1998, P NATL ACAD SCI USA, V95, P9465, DOI 10.1073/pnas.95.16.9465
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gibson AW, 2001, J IMMUNOL, V166, P3915
   Goddard KAB, 2000, AM J HUM GENET, V66, P216, DOI 10.1086/302727
   Griffin TJ, 2000, TRENDS BIOTECHNOL, V18, P77, DOI 10.1016/S0167-7799(99)01401-8
   Henri S, 2002, GENES IMMUN, V3, P1, DOI 10.1038/sj/gene/6363809
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   Igietseme JU, 1998, MICROBIOL IMMUNOL, V42, P617
   Jouanguy E, 1999, NAT GENET, V21, P370
   Kinnunen AH, 2002, HUM REPROD, V17, P2073, DOI 10.1093/humrep/17.8.2073
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   KURKINEN M, 1980, LAB INVEST, V43, P47
   Kurreeman FAS, 2004, HUM MOL GENET, V13, P1755, DOI 10.1093/hmg/ddh187
   LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286
   Lim S, 2000, AM J RESP CRIT CARE, V162, P1355
   Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6
   Llorente L, 1997, ARTHRITIS RHEUM, V40, P1429, DOI 10.1002/art.1780400810
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   MORRISON RP, 1989, J EXP MED, V170, P1271, DOI 10.1084/jem.170.4.1271
   Mozzato-Chamay N, 2001, GENES IMMUN, V2, P153, DOI 10.1038/sj.gene.6363753
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Peeling RW, 1998, J INFECT DIS, V177, P256, DOI 10.1086/517367
   Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1
   Pravica V, 1999, EUR J IMMUNOGENET, V26, P1, DOI 10.1046/j.1365-2370.1999.00122.x
   Ramsey KH, 2001, INFECT IMMUN, V69, P7374, DOI 10.1128/IAI.69.12.7374-7379.2001
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   Wang SH, 1999, EUR J IMMUNOL, V29, P3782, DOI 10.1002/(SICI)1521-4141(199911)29:11<3782::AID-IMMU3782>3.0.CO;2-B
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6
   Yang X, 1999, J IMMUNOL, V162, P1010
   Yang X, 1996, J IMMUNOL, V156, P4338
NR 62
TC 46
Z9 48
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUN
PY 2005
VL 6
IS 4
BP 332
EP 340
DI 10.1038/sj.gene.6364182
PG 9
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 931DI
UT WOS:000229465600008
PM 15789056
OA No
DA 2017-08-15
ER

PT J
AU Scott, S
   Cumberland, P
   Shulman, CE
   Cousens, S
   Cohen, BJ
   Brown, DWG
   Bulmer, JN
   Dorman, EK
   Kawuondo, K
   Marsh, K
   Cutts, F
AF Scott, S
   Cumberland, P
   Shulman, CE
   Cousens, S
   Cohen, BJ
   Brown, DWG
   Bulmer, JN
   Dorman, EK
   Kawuondo, K
   Marsh, K
   Cutts, F
TI Neonatal measles immunity in rural Kenya: The influence of HIV and
   placental malaria infections on placental transfer of antibodies and
   levels of antibody in maternal and cord serum samples
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; WEST-AFRICAN POPULATION; LOW-BIRTH-WEIGHT;
   TETANUS ANTIBODIES; GESTATIONAL-AGE; VACCINATION; CHILDREN; WOMEN;
   INFANTS; HYPERGAMMAGLOBULINEMIA
AB Introduction. Young infants are protected from measles infection by maternal measles antibodies. The level of these antibodies at birth depends on the level of antibodies in the mother and the extent of placental transfer. We investigated predictors of levels of measles antibodies in newborns in rural Kenya.
   Methods. A total of 747 paired maternal-cord serum samples (91 from human immunodeficiency virus [HIV]-infected and 656 from HIV-uninfected mothers) were tested for measles immunoglobulin G antibodies. Placental malaria infection was determined by biopsy. Data on pregnancy history, gestational age, and anthropometric and socioeconomic status were collected.
   Results. Infants born to HIV-infected mothers were more likely (odds ratio, 4.6 [95% confidence interval {CI}, 2.2-9.7]) to be seronegative and had 35.1% (95% CI, 9.8%-53.2%) lower levels of measles antibodies than did those born to HIV-uninfected mothers. Preterm delivery, early maternal age, and ethnic group were also associated with reduced levels of measles antibodies. There was little evidence that placental malaria infection was associated with levels of measles antibodies in newborns.
   Conclusion. Our results suggest that maternal HIV infection may reduce levels of measles antibodies in newborns. Low levels of measles antibodies at birth render children susceptible to measles infection at an early age. This is of concern in sub-Saharan African countries, where not only is the prevalence of HIV high, but measles is the cause of much morbidity and mortality.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England.
   Hlth Protect Agcy, Specialist & Reference Microbiol Div, Enter Resp & Neurol Virus Lab, Colindale, England.
   Homerton Univ Hosp NHS Fdn Trust, London, England.
   Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sch Clin & Lab Sci Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya.
   MRC Labs, Banjul, Gambia.
RP Scott, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM Susana.Scott@lshtm.ac.uk
CR Asamoah-Odei E, 2004, LANCET, V364, P35, DOI 10.1016/S0140-6736(04)16587-2
   ATKINSON WL, 1991, SEMIN PEDIATR INFECT, V2, P100
   BLACK FL, 1986, AM J EPIDEMIOL, V124, P442
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   Brugha R, 1996, EPIDEMIOL INFECT, V117, P519
   CHRISTIE CD, 1990, INT J EPIDEMIOL, V19, P698, DOI 10.1093/ije/19.3.698
   Crowe JE, 2001, CLIN INFECT DIS, V33, P1720, DOI 10.1086/322971
   De Milito A, 2004, BLOOD, V103, P2180, DOI 10.1182/blood-2003-07-2375
   de Moraes-Pinto MI, 1998, ARCH DIS CHILD, V79, pF202
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077
   DEMORAESPINTO MI, 1993, ACTA PAEDIATR, V82, P1034
   DESERRES G, 1997, VACCINE, V15, P650
   EREGIE CO, 1991, DEV MED CHILD NEUROL, V33, P146
   GALBRAITH RM, 1980, T ROY SOC TROP MED H, V74, P61, DOI 10.1016/0035-9203(80)90012-7
   GENDREL D, 1990, J TROP PEDIATRICS, V36, P279
   Goncalves G, 1999, EPIDEMIOL INFECT, V122, P273, DOI 10.1017/S0950268899002046
   Hartter HK, 2000, PEDIATR INFECT DIS J, V19, P635, DOI 10.1097/00006454-200007000-00010
   KACICA MA, 1995, J MED VIROL, V45, P227, DOI 10.1002/jmv.1890450220
   KAUR G, 1982, INDIAN J MED RES, V76, P407
   LENNON JL, 1986, J PEDIATR-US, V108, P671, DOI 10.1016/S0022-3476(86)81039-3
   LEPAGE P, 1992, AM J DIS CHILD, V146, P550
   Linder N, 2004, VACCINE, V22, P1509, DOI 10.1016/j.vaccine.2003.10.009
   Markowitz LE, 1996, PEDIATRICS, V97, P53
   Okoko BJ, 2001, J HEALTH POPUL NUTR, V19, P59
   Okoko JB, 2001, TROP MED INT HEALTH, V6, P529, DOI 10.1046/j.1365-3156.2001.00741.x
   PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004
   *PAN AM HLTH ORG, EPI NEWSLETTER, V26
   Rau A T K, 2002, Indian Pediatr, V39, P282
   SATO H, 1979, AM J DIS CHILD, V133, P1240
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Shulman CE, 2001, TROP MED INT HEALTH, V6, P770, DOI 10.1046/j.1365-3156.2001.00786.x
   Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7
   Singh N, 1998, J FOOD ENG, V35, P91, DOI 10.1016/S0260-8774(98)00002-8
   Siringi S, 2002, LANCET, V359, P2175, DOI 10.1016/S0140-6736(02)09193-6
   Wanyama C, 2002, B WORLD HEALTH ORGAN, V80, P989
   Wesumperuma HL, 1999, ANN TROP MED PARASIT, V93, P169
   *WHO, 2002, WKLY EPIDEMIOL REC, V7, P50
   WHO, 1977, B WORLD HEALTH ORGAN, V55, P21
   *WHO UNICEF, REV NAT IMM COV 1980
   Zanetta RAC, 2001, VACCINE, V20, P226, DOI 10.1016/S0264-410X(01)00267-5
NR 40
TC 59
Z9 60
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2005
VL 191
IS 11
BP 1854
EP 1860
DI 10.1086/429963
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 923AN
UT WOS:000228881100011
PM 15871118
OA No
DA 2017-08-15
ER

PT J
AU Lack, N
   West, B
   Jeffries, D
   Ekpo, G
   Morison, L
   Soutter, WP
   Walraven, G
   Borysiewicz, L
AF Lack, N
   West, B
   Jeffries, D
   Ekpo, G
   Morison, L
   Soutter, WP
   Walraven, G
   Borysiewicz, L
TI Comparison of non-invasive sampling methods for detection of HPV in
   rural African women
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; HIGH-RISK; WORLDWIDE
AB Background: The prevalence of cervical cancer is extremely high in low income countries, primarily because of a lack of cytological screening. The link between human papillomavirus (HPV) and cervical cancer has long been recognised, and it has been suggested that isolated HPV testing in women who do not participate in existing screening programmes may be used to identify women at higher risk of developing cervical cancer. This community based study compares two self administered techniques for detecting HPV ( tampons and self administered swabs) with a clinician directed technique, the cervical cytobrush.
   Methods: 377 rural women were interviewed and of these 210 women had full gynaecological examination, and accepted all three sampling methods for HPV. HPV typing of DNA extracts was performed using polymerase chain reaction and enzyme linked immunosorbent assay techniques.
   Results: Using the cervical cytobrush as the gold standard, self administered swabs ( SAS) showed a sensitivity of 63.9%, and tampons showed a sensitivity of 72.4%. The acceptability of these two tests was 97.1% and 84.6% respectively. When combining acceptability with sensitivity, the SAS detected 61.9% and the tampons detected 60.9% of the true positives.
   Conclusion: In a setting where women are at a considerable risk of developing cervical cancer, with no access to a formal screening programme, self directed HPV testing could be a useful screening tool in identifying those women at increased risk who may require further investigation.
C1 MRC Labs, Banjul, Gambia.
   Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.
   London Sch Hyg & Trop Med, London WC1, England.
RP Lack, N (reprint author), MRC Labs, Atlantic Blvd,POB 273, Banjul, Gambia.
EM nikkilack@hotmail.com
RI Morison, Linda/H-9738-2013
CR BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Cuzick J, 2003, LANCET, V362, P1871, DOI 10.1016/S0140-6736(03)14955-0
   CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7
   Harper DM, 2002, AM J OBSTET GYNECOL, V186, P365, DOI 10.1067/mob.2002.121076
   Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791
   Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X
   Parkin DM, 1999, INT J CANCER, V80, P827
   Salmeron J, 2003, CANCER CAUSE CONTROL, V14, P505, DOI 10.1023/A:1024806707399
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   ZURHAUSEN H, 1976, CANCER RES, V36, P794
NR 11
TC 19
Z9 20
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD JUN 1
PY 2005
VL 81
IS 3
BP 239
EP 241
DI 10.1136/sti.2004.010413
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 930RN
UT WOS:000229434100013
PM 15923294
OA No
DA 2017-08-15
ER

PT J
AU Morison, L
   Ekpo, G
   West, B
   Demba, E
   Mayaud, P
   Coleman, R
   Bailey, R
   Walraven, G
AF Morison, L
   Ekpo, G
   West, B
   Demba, E
   Mayaud, P
   Coleman, R
   Bailey, R
   Walraven, G
TI Bacterial vaginosis in relation to menstrual cycle, menstrual protection
   method, and sexual intercourse in rural Gambian women
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
ID VAGINAL FLORA; PREGNANT-WOMEN; INFECTIONS; POPULATION; PREVALENCE;
   MICROFLORA; MORPHOLOGY; TANZANIA; SMEARS
AB Objective: To examine the occurrence of bacterial vaginosis (BV) over the menstrual cycle and in relation to menstrual protection materials and sexual intercourse in a rural African setting.
   Methods: Married, regularly menstruating female volunteers were asked to collect self administered swabs on alternate days through four menstrual cycles. BV was assessed using Nugent scores. Menstruation and reported sexual intercourse data were recorded contemporaneously. A crossover design comparing traditional and modern menstrual protection methods was incorporated. Multivariate logistic regression was used to examine associations with BV.
   Results: 30 women completed four menstrual cycles in the study. Completeness and validity of data from the self administered swabs was high. Greater frequencies of BV were found for all women in the second week of the menstrual cycle relative to days 14+, and markedly higher frequencies of BV were found in the first week in women with infrequent BV. BV was (non-significantly) more frequent when modern pads were used compared with traditional cloths. No association was found between BV and intercourse reported in the previous 4 days; or between the frequency of reported intercourse in one menstrual cycle and BV in either the same menstrual cycle or the next.
   Conclusions: Similar transient fluctuations over the menstrual cycle were found to those in industrialised countries. We found no evidence that sexual intercourse was associated with increased frequency of BV. Our data do not support hypotheses that menstrual hygiene materials might explain the high prevalences of BV found in sub-Saharan Africa compared to industrialised countries.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, MRC, Trop Epidemiol Grp, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
RP Morison, L (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, MRC, Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
EM linda.morison@lshtm.ac.uk
RI Morison, Linda/H-9738-2013
FU Medical Research Council [MC_U190081961]
CR Armitage P., 1994, STAT METHODS MED RES
   BARTLETT JG, 1977, J INFECT DIS, V136, P271
   Boskey ER, 2004, WOMEN HEALTH ISS, V14, P14, DOI 10.1016/j.whi.2003.12.001
   Bulut A, 1997, STUD FAMILY PLANN, V28, P35, DOI 10.2307/2137969
   Cristiano L, 1996, EUR J EPIDEMIOL, V12, P383, DOI 10.1007/BF00145302
   Delaney ML, 2001, OBSTET GYNECOL, V98, P79, DOI 10.1016/S0029-7844(01)01402-8
   Eschenbach DA, 2000, CLIN INFECT DIS, V30, P901, DOI 10.1086/313818
   Govender L, 1996, INT J GYNECOL OBSTET, V55, P23, DOI 10.1016/0020-7292(96)02744-0
   GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   Haiman CA, 2002, BRIT J CANCER, V86, P367, DOI 10.1038/sj/bjc/6600098
   Hay PE, 1997, INT J STD AIDS, V8, P603, DOI 10.1258/0956462971918850
   HAY PE, 1994, BRIT J OBSTET GYNAEC, V101, P1048, DOI 10.1111/j.1471-0528.1994.tb13580.x
   Holzman C, 2001, AM J PUBLIC HEALTH, V91, P1664, DOI 10.2105/AJPH.91.10.1664
   Keane FEA, 2000, INT J STD AIDS, V11, P356
   Keane FEA, 1997, INT J STD AIDS, V8, P489, DOI 10.1258/0956462971920631
   Kilic AO, 2001, CLIN DIAGN LAB IMMUN, V8, P31, DOI 10.1128/CDLI.8.1.31-39.2001
   Klebanoff MA, 2004, AM J OBSTET GYNECOL, V190, P363, DOI 10.1016/j.ajog.2003.08.020
   Mayaud P, 1998, SEX TRANSM INFECT, V74, pS139
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297
   ONDERDONK AB, 1986, APPL ENVIRON MICROB, V51, P333
   SAUTTER RL, 1980, J CLIN MICROBIOL, V11, P479
   Schwebke JR, 1999, J INFECT DIS, V180, P1632, DOI 10.1086/315065
   Schwebke JR, 1997, SEX TRANSM DIS, V24, P236, DOI 10.1097/00007435-199704000-00009
   Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5
   Smart S, 2004, SEX TRANSM INFECT, V80, P58, DOI 10.1136/sti.2003.004978
   Sonnex C, 1998, SEX TRANSM INFECT, V74, P11
   Taylor-Robinson D., 1999, International Journal of Gynecology and Obstetrics, V67, pS35, DOI 10.1016/S0020-7292(99)00137-X
   TRELOUR AE, 1967, INT J FERTIL, V13, P77
   Ugwumadu A, 2004, OBSTET GYNECOL, V104, P114, DOI 10.1097/01.AOG.0000130068.21566.4e
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   WASSERHEIT JN, 1989, STUD FAMILY PLANN, V20, P69, DOI 10.2307/1966461
   Woods MN, 1996, J NATL CANCER I, V88, P1369, DOI 10.1093/jnci/88.19.1369
   YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232
NR 33
TC 27
Z9 27
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD JUN 1
PY 2005
VL 81
IS 3
BP 242
EP 247
DI 10.1136/sti.2004.011684
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 930RN
UT WOS:000229434100014
PM 15923295
OA No
DA 2017-08-15
ER

PT J
AU Stevens, W
   Wiseman, V
   Ortiz, J
   Chavasse, D
AF Stevens, W
   Wiseman, V
   Ortiz, J
   Chavasse, D
TI The costs and effects of a nationwide insecticide-treated net programme:
   the case of Malawi
SO MALARIA JOURNAL
LA English
DT Article
ID RESOURCE-ALLOCATION; MALARIA CONTROL; TANZANIA; TRANSMISSION; COVERAGE;
   AREA
AB Background: Insecticide-treated nets (ITNs) are a proven intervention to reduce the burden of malaria, yet there remains a debate as to the best method of ensuring they are universally utilized. This study is a cost-effectiveness analysis of an intervention in Malawi that started in 1998, in Blantyre district, before expanding nationwide. Over the 5-year period, 1.5 million ITNs were sold.
   Methods: The costs were calculated retrospectively through analysis of expenditure data. Costs and effects were measured as cost per treated-net year (cost/TNY) and cost per net distributed.
   Results: The mean cost/TNY was calculated at $4.41, and the mean cost/ITN distributed at $2.63. It also shows evidence of economies of scale, with the cost/TNY falling from $7.69 in year one ( 72,196 ITN) to $3.44 in year five (720,577 ITN). Cost/ITN distributed dropped from $5.04 to $1.92.
   Conclusion: Combining targeting and social marketing has the potential of being both cost-effective and capable of achieving high levels of coverage, and it is possible that increasing returns to scale can be achieved.
C1 MRC Labs, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England.
   UNICEF, Lilongwe 3, Malawi.
   PSI, Malaria Dept, Nairobi, Kenya.
RP Stevens, W (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM wstevens@mrc.gm; virginia.wiseman@lshtm.ac.uk; jortiz@unicef.org;
   chavasse@psikenya.org
CR Aikins MK, 1998, SOC SCI MED, V46, P181, DOI 10.1016/S0277-9536(97)00145-7
   Alcalay Rina, 2000, PROMOTING NUTR PHYS
   Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217
   Brandeau ML, 2003, J HEALTH ECON, V22, P575, DOI 10.1016/S0167-6296(03)00043-2
   Chavasse D, 2001, ESSENTIAL DRUGS MONI, V30, P1
   *COMM MACR HLTH, 2001, 19 COMM MACR HLTH
   *CTR SOC RES CTR D, 2004, MAL PREV TREATM COMM
   Elbasha EH, 2004, HEALTH ECON, V13, P21, DOI 10.1002/hec.793
   Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8
   Hanson K, 2003, B WORLD HEALTH ORGAN, V81, P269
   Howard N, 2003, TROP MED INT HEALTH, V8, P1043, DOI 10.1046/j.1365-3156.2003.01163.x
   Karlsson G, 1998, SOC SCI MED, V46, P1183, DOI 10.1016/S0277-9536(97)10046-6
   Kikumbih N, 2005, SOC SCI MED, V60, P369, DOI 10.1016/j.socscimed.2004.05.005
   Kroeger Axel, 2002, Malar J, V1, P15, DOI 10.1186/1475-2875-1-15
   Lengeler C., 1996, Bulletin of the World Health Organization, V74, P325
   Lines J, 2003, LANCET INFECT DIS, V3, P465, DOI 10.1016/S1473-3099(03)00717-5
   Mushi AK, 2003, HEALTH POLICY PLANN, V18, P163, DOI 10.1093/heapol/czg021
   OVER M, 1998, SOC SCI MED, V22, P351
   Rowland M, 2004, TROP MED INT HEALTH, V9, P343
   Wiseman V, 2000, HEALTH CARE ANAL, V8, P217, DOI 10.1023/A:1009458714162
   Wiseman V, 2003, AM J TROP MED HYG, V68, P161
   Wouters A, 1993, Health Econ, V2, P31, DOI 10.1002/hec.4730020105
NR 22
TC 36
Z9 36
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 10
PY 2005
VL 4
AR 22
DI 10.1186/1475-2875-4-22
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 931JF
UT WOS:000229480900001
PM 15885143
OA gold
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Bowman, RJC
   Faal, H
   Aryee, EAN
   Ikumapayi, UN
   Alexander, NDE
   Adegbola, RA
   West, SK
   Mabey, DCW
   Foster, A
   Johnson, GJ
   Bailey, RL
AF Burton, MJ
   Bowman, RJC
   Faal, H
   Aryee, EAN
   Ikumapayi, UN
   Alexander, NDE
   Adegbola, RA
   West, SK
   Mabey, DCW
   Foster, A
   Johnson, GJ
   Bailey, RL
TI Long term outcome of trichiasis surgery in the Gambia
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TRACHOMATOUS TRICHIASIS; TRIAL; PREVENTION; BLINDNESS; SUCCESS
AB Background: Trichiasis surgery is believed to reduce the risk of losing vision from trachoma. There are limited data on the long term outcome of surgery and its effect on vision and corneal opacification. Similarly, the determinants of failure are not well understood.
   Methods: A cohort of people in the Gambia who had undergone surgery for trachomatous trichiasis 3 4 years earlier was re-assessed. They were examined clinically and the conjunctiva was sampled for Chlamydia trachomatis polymerase chain reaction (PCR) and general bacterial culture.
   Results: In total, 141/162 people were re-examined. Recurrent trichiasis was found in 89/214 (41.6%) operated eyes and 52 (24.3%) eyes had five or more lashes touching the globe. Corneal opacification improved in 36 of 78 previously affected eyes. There was a general deterioration in visual acuity between surgery and follow up, which was greater if new corneal opacification developed or trichiasis returned. Recurrent trichiasis was associated with severe conjunctival inflammation and bacterial infection. C trachomatis was detected in only one individual.
   Conclusions: Recurrent trichiasis following surgery is a common potentially sight threatening problem. Some improvement in the cornea can occur following surgery and the rate of visual loss tended to be less in those without recurrent trichiasis. The role of conjunctival inflammation and bacterial infection needs to be investigated further. Follow up of patients is advised to identify individuals needing additional surgical treatment.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Natl Eye Care Programme, Banjul, Gambia.
   CCBRT Disabil Hosp, Dar Es Salaam, Tanzania.
   Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   Inst Ophthalmol, Div Epidemiol, London, England.
   Inst Ophthalmol, Int Eye Hlth, London, England.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [MC_U190081961]
CR Adamu Y, 2002, ETHIOPIAN MED J, V40, P107
   BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   Bowman RJC, 2000, TROP MED INT HEALTH, V5, P528, DOI 10.1046/j.1365-3156.2000.00605.x
   Bowman RJC, 2002, BRIT J OPHTHALMOL, V86, P339, DOI 10.1136/bjo.86.3.339
   Bowman RJC, 2000, EYE, V14, P864
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   JONES BR, 1975, T OPHTHAL SOC UK, V95, P16
   Khandekar R, 2001, Ophthalmic Epidemiol, V8, P155, DOI 10.1076/opep.8.2.155.4165
   REACHER MH, 1991, OPHTHALMOLOGY, V98, P334
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   REACHER MH, 1990, BRIT J OPHTHALMOL, V74, P109, DOI 10.1136/bjo.74.2.109
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   TAYLOR HR, 1987, B WORLD HEALTH ORGAN, V65, P485
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   World Health Organization, 1997, GLOB SCI M GEN 17 20
   Zhang H, 2004, ARCH OPHTHALMOL-CHIC, V122, P511, DOI 10.1001/archopht.122.4.511
NR 17
TC 41
Z9 41
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2005
VL 89
IS 5
BP 575
EP 579
DI 10.1136/bjo.2004.055996
PG 5
WC Ophthalmology
SC Ophthalmology
GA 917GN
UT WOS:000228444600018
PM 15834088
OA No
DA 2017-08-15
ER

PT J
AU Helfand, RF
   Moss, WJ
   Harpaz, R
   Scott, S
   Cutts, F
AF Helfand, RF
   Moss, WJ
   Harpaz, R
   Scott, S
   Cutts, F
TI Evaluating the impact of the HIV pandemic measures control and
   elimination
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE HIV infections/complications; measles vaccine;
   measles/immunology/epidemiology; antigen-antibody reactions; child;
   models; statistical; Africa south of the Sahara (source : MeSH, NLM)
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INFECTED
   CHILDREN; MEASLES ANTIBODY; TRANSMISSION; IMMUNIZATION; TYPE-1;
   ERADICATION; IMMUNITY; INFANTS
AB Objective To estimate the impact of the HIV pandemic on vaccine-acquired population immunity to measles virus because high levels of population immunity are required to eliminate transmission of measles virus in large geographical areas, and HIV infection can reduce the efficacy of measles vaccination.
   Methods A literature review was conducted to estimate key parameters relating to the potential impact of HIV infection on the epidemiology of measles in sub-Saharan Africa; parameters included the prevalence of HIV, child mortality, perinatal HIV transmission rates and protective immune responses to measles vaccination. These parameter estimates were incorporated into a simple model, applicable to regions that have a high prevalence of HIV, to estimate the potential impact of HIV infection on population immunity against measles.
   Findings Tie model suggests that the HIV pandemic should not introduce an insurmountable barrier to measles control and elimination, in part because higher rates of primary and secondary vaccine failure among HIV-infected children are counteracted by their high mortality rate. The HIV pandemic could result in a 2-3% increase in the proportion of the birth cohort susceptible to measles, and more frequent supplemental immunization activities (SIAs) may be necessary to control or eliminate measles. In the model the optimal interval between SIAs was most influenced by the coverage rate for routine measles vaccination. The absence of a second opportunity for vaccination resulted in the greatest increase in the number of susceptible children.
   Conclusion These results help explain the initial success of measles elimination efforts in southern Africa, where measles control has been achieved in a setting of high HIV prevalence.
C1 Ctr Dis Control & Prevent, Med Off Resp & Enter Viruses Branch, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, Med Epidemiol, Natl Immunizat Program, Atlanta, GA USA.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Banjul, Gambia.
RP Helfand, RF (reprint author), Ctr Dis Control & Prevent, Med Off Resp & Enter Viruses Branch, 1600 Clifton Rd NE,Mailstop A-30, Atlanta, GA 30333 USA.
EM rzh7@cdc.gov
CR ALATTAR I, 1995, PEDIATR INFECT DIS J, V14, P149
   Arpadi SM, 1996, PEDIATRICS, V97, P653
   Berkelhamer S, 2001, CLIN INFECT DIS, V32, P1090, DOI 10.1086/319591
   Biellik R, 2002, LANCET, V359, P1564, DOI 10.1016/S0140-6736(02)08517-3
   BRENA AE, 1993, J ACQ IMMUN DEF SYND, V6, P1125
   BRUNELL PA, 1995, J ACQ IMMUN DEF SYND, V10, P540, DOI 10.1097/00042560-199510050-00007
   Buve A, 2002, LANCET, V359, P2011, DOI 10.1016/S0140-6736(02)08823-2
   Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2
   DABIS F, 1992, AIDS, V7, P1139
   De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175
   DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V
   Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6
   Eshleman SH, 2002, JAIDS, V31, P327
   FINE PEM, 1993, EPIDEMIOL REV, V15, P265
   FRENKEL L, 1994, ARCH PEDIAT ADOL MED, V148, P540
   GUAY L, 1993, 9 INT AIDS C GEN INT
   Halsey NA, 1983, RECENT ADV IMMUNIZAT, P4
   JASON J, 1994, AM J HEMATOL, V46, P29, DOI 10.1002/ajh.2830460106
   KRASINSKI K, 1989, JAMA-J AM MED ASSOC, V261, P2512, DOI 10.1001/jama.261.17.2512
   LALLEMANT M, 1989, AIDS, V3, P643, DOI 10.1097/00002030-198910000-00004
   Marum L H, 1997, AIDS, V11 Suppl B, pS125
   Marum Lawrence H., 1996, P25
   Mbori-Ngacha D, 2001, JAMA-J AM MED ASSOC, V286, P2413, DOI 10.1001/jama.286.19.2413
   Melvin AJ, 2003, PEDIATRICS, V111, pE641, DOI 10.1542/peds.111.6.e641
   Moss WJ, 1999, CLIN INFECT DIS, V29, P106, DOI 10.1086/520136
   Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167
   NOKES DJ, 1995, VET MICROBIOL, V44, P333
   Nokes DJ, 1997, TRENDS MICROBIOL, V5, P14, DOI 10.1016/S0966-842X(97)81769-6
   OXTOBY M, 1989, EP INT SERV C ATL GA, P31
   PALUMBO P, 1992, PEDIATR INFECT DIS J, V11, P1008
   Permar SR, 2001, J INFECT DIS, V183, P532, DOI 10.1086/318533
   RUDY BT, 1994, J PEDIATR-US, V125, P72, DOI 10.1016/S0022-3476(94)70125-3
   RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501
   Taha T E, 2000, Pediatrics, V106, pE77, DOI 10.1542/peds.106.6.e77
   Taha TE, 2000, AIDS, V14, P453, DOI 10.1097/00002030-200003100-00021
   Thaithumyanon P, 2000, Southeast Asian J Trop Med Public Health, V31, P658
   *UNAIDS, 2001, UNAIDS0174E WHO
   *UNAIDS, AIDS EP UPD DEC 2003
   UNAIDS, 2000, UNAIDS0013E
   *UNAIDS, 2002, GLOB HIV AIDS STD SU
   WALTER EB, 1994, PEDIATR AIDS HIV INF, V5, P300
   *WHO, 2003, SO AFR INT DIS SURV
   *WHO, 2001, WHOVB0115
   *WHO, 2000, SO AFR INT DIS SURV
   *WHO, 2002, SO AFR INT DIS SURV
   [Anonymous], 1998, MMWR RECOMMENDATIONS, V47, P1
   2003, WEEKLY EPIDEMIOLOGIC, V21, P184
   2003, WEEKLY EPIDEMIOLOGIC, V49, P417
   2001, WEEKLY EPIDEMIOLOGIC, V49, P381
   2004, WEEKLY EPIDEMIOLOGIC, V39, P20
NR 50
TC 18
Z9 20
U1 0
U2 1
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD MAY
PY 2005
VL 83
IS 5
BP 329
EP 337
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 925MH
UT WOS:000229056700006
PM 15976873
OA No
DA 2017-08-15
ER

PT J
AU Gillespie, GMA
   Pinheiro, S
   Sayeid-Al-Jamee, M
   Alabi, A
   Kaye, S
   Sabally, S
   Sarge-Njie, R
   Njai, H
   Joof, K
   Jaye, A
   Whittle, H
   Rowland-Jones, S
   Dorrell, L
AF Gillespie, GMA
   Pinheiro, S
   Sayeid-Al-Jamee, M
   Alabi, A
   Kaye, S
   Sabally, S
   Sarge-Njie, R
   Njai, H
   Joof, K
   Jaye, A
   Whittle, H
   Rowland-Jones, S
   Dorrell, L
TI CD8(+) T cell responses to human immunodeficiency viruses type 2 (HIV-2)
   and type 1 (HIV-1) gag proteins are distinguishable by magnitude and
   breadth but not cellular phenotype
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE HIV-2; HIV-1; CD8(+); T cell; IFN-gamma; perforin
ID VIRAL LOAD; ANTIRETROVIRAL THERAPY; IMMUNE-RESPONSES; LYMPHOCYTES;
   INFECTION; EFFECTOR; EPITOPE; DIFFERENTIATION; INDIVIDUALS; FREQUENCY
AB The mechanisms underlying the relatively slow progression of human immunodeficiency virus type 2 (HIV-2) compared with HIV-1 infection are undefined and could be a result of more effective immune responses. We used HIV-2 and HIV-1 IFN-&gamma; enzyme-linked immunospot assays to evaluate CD8(+) T cell responses in antiretroviral-naive HIV-2('HIV-2(+)') and HIV-1(+) infected ('HIV-1(+)') individuals. Gag-specific responses were detected in the majority of HIV-2(+) and HIV-1(+) subjects. Overlapping gag peptide analysis indicated a significantly greater magnitude and breadth of responses in the HIV-1(+) cohort, and this difference was attributable to low responses in HIV-2(+) subjects with undetectable viral load (medians 2107 and 512 spot-forming units per 10(6) PBMC, respectively, p=0.007). We investigated the phenotype of viral epitope-specific CD8(+) T cells identified with HLA-B53- and HLA-B58-peptide tetramers (8 HIV-2(+), 11 HIV-1(+) subjects). HIV-2-specific CD8(+) T cells were predominantly CD27(+) CD45RA(-), and only a minority expressed perforin. The limited breadth and low frequency of CD8(+) T cell responses to HIV-2 gag in aviremic HIV-2(+) subjects suggests that these responses reflect antigen load in plasma, as is the case in HIV-1 infection. Immune control of HIV-2 does not appear to be related to the frequency of perforin-expressing virus-specific CD8(+) T cells.
C1 John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Grp, Oxford OX3 9DU, England.
   MRC Labs, Banjul, Gambia.
RP Dorrell, L (reprint author), Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England.
EM ldorrell@gwmail.jr2.ox.ac.uk
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Berry N, 1998, J Hum Virol, V1, P457
   Bertoletti A, 1998, J VIROL, V72, P2439
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.0.CO;2-L
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Draenert R, 2004, AIDS, V18, P871, DOI 10.1097/01.aids.0000111400.02002.db
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Goulder PJR, 1996, AIDS RES HUM RETROV, V12, P1691, DOI 10.1089/aid.1996.12.1691
   Gray CM, 1999, J IMMUNOL, V162, P1780
   Hamann D, 1999, INT IMMUNOL, V11, P1027, DOI 10.1093/intimm/11.7.1027
   Hess C, 2004, LANCET, V363, P863, DOI 10.1016/S0140-6736(04)15735-8
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Jin X, 2000, MOL MED, V6, P803
   Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433
   Lopes AR, 2003, J IMMUNOL, V171, P307
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Ogg GS, 1999, J VIROL, V73, P797
   Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   Sarr AD, 2001, AIDS RES HUM RETROV, V17, P1257, DOI 10.1089/088922201750461311
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969
   Sousa AE, 2002, J IMMUNOL, V169, P3400
   Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 32
TC 19
Z9 20
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAY
PY 2005
VL 35
IS 5
BP 1445
EP 1453
DI 10.1002/eji.200526007
PG 9
WC Immunology
SC Immunology
GA 926BG
UT WOS:000229097100013
PM 15832290
OA No
DA 2017-08-15
ER

PT J
AU Martin, M
   Brookes, L
   Cham, A
   Sowe, DM
   Khan, S
   Thomas, DR
   Hill, PC
AF Martin, M
   Brookes, L
   Cham, A
   Sowe, DM
   Khan, S
   Thomas, DR
   Hill, PC
TI Tuberculosis education in an endemic setting: application of
   participatory methods to video development in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE The Gambia; tuberculosis; participatory methods; video; diagnostic
   delay; access; stigma
ID HIV/AIDS; PREVENTION
AB OBJECTIVE: To produce an educational video for tuberculosis (TB) awareness in The Gambia using participatory methods and integrated formative evaluation.
   METHODS: A steering group was formed of key people working in TB research, health education, the health service and the media. They developed a script and commissioned local production of the video in three local languages and English. A formative participatory evaluation of the project was conducted using document review, attendance at rehearsals and semi-structured interviews. A pilot version of the video was evaluated through focus groups in Banjul and remote villages. Data were analysed using a general inductive approach.
   RESULTS: Five major themes emerged from evaluation of the project participatory process: collaboration, knowledge sharing, networking, ownership and a common desire to sustain the project goals for video dissemination. The video was well received and described as informative, entertaining and professional. Audiences were able to identify the key messages, prevailing attitudes about TB were challenged, and many participants expressed a desire to act on their new knowledge.
   CONCLUSION: A participatory approach to the development of a video in The Gambia proved to be empowering to local participants and led to the production of a resource well received by Gambian people.
C1 MRC Labs, Dept Tuberculosis, Banjul, Gambia.
   Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
   MRC Labs, Dept Translat Res, Banjul, Gambia.
   Govt Gambia, Dept State Hlth, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Labs, Dept Tuberculosis, POB 273, Banjul, Gambia.
EM phill@mrc.gm
CR Beeker C, 1998, SOC SCI MED, V46, P831, DOI 10.1016/S0277-9536(97)00208-6
   deKoning K., 1996, PARTICIPATORY RES HL
   Eastwood SV, 2004, INT J TUBERC LUNG D, V8, P70
   Green LW, 1995, STUDY PARTICIPATORY
   HARPER M, 2004, T ROY SOC TROP MED H, V97, P506
   Israel BA, 1995, HEALTH EDUC QUART, V22, P364
   Liefooghe R, 1997, TROP MED INT HEALTH, V2, P809, DOI 10.1046/j.1365-3156.1997.d01-380.x
   LIENHARDT C, 2001, INT J TUBERC LUNG D, V5, P1
   Lipson J M, 1991, J Am Coll Health, V39, P235
   Mitchell K, 2001, HEALTH EDUC RES, V16, P411, DOI 10.1093/her/16.4.411
   Naidoo J, 2000, HLTH PROMOTION FDN P
   Panford S, 2001, AM J PUBLIC HEALTH, V91, P1559, DOI 10.2105/AJPH.91.10.1559
   THOMAS DR, 2003, GEN INDUCTIBE APPROA
   Thompson B., 1990, HLTH PROMOTION COMMU, P45
   *UNICEF, 2000, GAMB MULT CLUST SURV
NR 15
TC 8
Z9 8
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD MAY
PY 2005
VL 9
IS 5
BP 550
EP 555
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 921PR
UT WOS:000228777300015
PM 15875928
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Jackson-Sillah, D
   Fox, A
   Franken, KLMC
   Lugos, MD
   Jeffries, DJ
   Donkor, SA
   Hammond, AS
   Adegbola, RA
   Ottenhoff, THM
   Klein, MR
   Brookes, RH
AF Hill, PC
   Jackson-Sillah, D
   Fox, A
   Franken, KLMC
   Lugos, MD
   Jeffries, DJ
   Donkor, SA
   Hammond, AS
   Adegbola, RA
   Ottenhoff, THM
   Klein, MR
   Brookes, RH
TI ESAT-6/CFP-10 fusion protein and peptides for optimal diagnosis of
   Mycobacterium tuberculosis infection by ex vivo enzyme-linked immunospot
   assay in The Gambia
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID T-CELL RESPONSES; ANTIGENS; ENUMERATION; ESAT-6; CFP-10
AB Overlapping peptides of Mycobacterium tuberculosis antigens ESAT-6 and CFP-10 offer increased specificity over the purified protein derivative skin test when they were used in an ex vivo enzyme-linked immunospot (ELISPOT) assay for gamma interferon detection for the diagnosis of M. tuberculosis infection from recent exposure. We assessed whether equivalent results could be obtained for a fusion protein of the two antigens and whether a combined readout would offer increased sensitivity in The Gambia. We studied the ELISPOT assay results for 488 household contacts of 88 sputum smear-positive tuberculosis (TB) cases. The proportions of subjects positive by each test and by the tests combined were assessed across an exposure gradient, defined according to sleeping proximity to a TB case. Eighty-eight (18%) subjects were positive for CFP-10 peptides, 148 (30%) were positive for ESAT-6 peptides, 161 (33%) were positive for both peptides, and 168 (34%) were positive for the fusion protein; 188 (39%) subjects had either a positive result for a peptide or a positive result for the fusion protein. There was reasonable agreement between the peptide and the protein results (kappa statistic = 0.78) and no significant discordance (P = 0.38). There was a strong correlation between the fusion protein and combined peptide spot counts (r = 0.9), and responses to the peptide and the proteins all increased significantly according to M. tuberculosis exposure. The proportion of subjects positive for either the pool of peptides or the fusion protein offered maximum sensitivity, being significantly higher than the proportion of subjects positive for ESAT-6 peptides alone (P = 0.007). A fusion protein of ESAT-6 and CFP-10 is equivalent to overlapping peptides for the diagnosis of latent M. tuberculosis infection. Use of a combination of peptides and fusion protein offers improved sensitivity.
C1 MRC Unit, Bacterial Dis Program, TB Div, Banjul, Gambia.
   Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands.
RP Hill, PC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM phill@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011
FU Medical Research Council [MC_U190071468]
CR Arend SM, 2001, CLIN DIAGN LAB IMMUN, V8, P1089, DOI 10.1128/CDLI.8.6.1089-1096.2001
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448
   Barnes PF, 2004, AM J RESP CRIT CARE, V170, P5, DOI 10.1164/rccm.2404004
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008
   Franken KLMC, 2000, PROTEIN EXPRES PURIF, V18, P95, DOI 10.1006/prep.1999.1162
   Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240
   Heifets Leonid B., 1994, P85
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200
   Small PM, 2000, LANCET, V356, P1048, DOI 10.1016/S0140-6736(00)02724-0
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W
   Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522
NR 15
TC 38
Z9 52
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2005
VL 43
IS 5
BP 2070
EP 2074
DI 10.1128/JCM.43.5.2070-2074.2005
PG 5
WC Microbiology
SC Microbiology
GA 925YR
UT WOS:000229090100006
PM 15872224
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Rayco-Solon, P
   Moore, SE
AF Prentice, AM
   Rayco-Solon, P
   Moore, SE
TI Insights from the developing world: thrifty genotypes and thrifty
   phenotypes
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Summer Meeting of the
   Nutrition-Society/Association-for-the-Study-of-Obesity
CY JUL 05-08, 2004
CL Trinity Coll, Dublin, IRELAND
SP Nutr Soc, Assoc Study Obes
HO Trinity Coll
DE obesity; thrifty genes; mitochondrial genes; uncoupling protein; ApoE
ID GENE VARIABLE NUMBER; DEPENDENT DIABETES-MELLITUS; HUMAN INSULIN GENE;
   LOW-BIRTH-WEIGHT; UNCOUPLING PROTEINS; TANDEM REPEATS; FETAL ORIGINS;
   INS-VNTR; METABOLISM; HYPOTHESIS
AB Few researchers would dispute that the pandemic of obesity is caused by a profound mismatch between humanity's present environmental circumstances and those that have moulded evolutionary selection. This concept was first articulated when gestational diabetes was described as being the result of a 'thrifty genotype rendered detrimental by progress'. More recently, this hypothesis has been extended to the concept of a 'thrifty phenotype' to describe the metabolic adaptations adopted as a survival strategy by a malnourished fetus; changes that may also be inappropriate to deal with a later life of affluence. Both the thrifty genotype and the thrifty phenotype hypotheses would predict that populations in some areas of the developing world would be at greater risk of obesity and its co-morbidities; a proposition to be explored in the present paper. To date thrifty genes remain little more than a nebulous concept propagated by the intuitive logic that man has been selected to survive episodic famine and seasonal hungry periods. Under such conditions those individuals who could Jay down extra energy stores and use them most efficiently would have a survival advantage. The search for candidate thrifty genes needs to cover every aspect of human energy balance from food-seeking behaviour to the coupling efficiency of oxidative phosphorylation. The present paper will describe examples of attempts to find thrifty genes in three selected candidate areas: maternally-transmitted mitochondrial genes; the uncoupling proteins; apoE4, whose geographical distribution has been linked to a possible thrifty role in lipoprotein and cholesterol metabolism.
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.prentice@lshtm.ac.uk
CR Adair LS, 2004, J NUTR, V134, P191
   Appleby A. B., 1978, FAMINE TUDOR STUART
   Argiles JM, 2002, BIOCHEM BIOPH RES CO, V293, P1145, DOI 10.1016/S0006-291X(02)00355-8
   Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268
   BAVDEKAR A, 1999, DIABETES, V48, P2242
   BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176
   Bennett AJ, 2004, DIABETES, V53, P2126, DOI 10.2337/diabetes.53.8.2126
   BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284
   Bindon JR, 1997, AM J PHYS ANTHROPOL, V104, P201, DOI 10.1002/(SICI)1096-8644(199710)104:2<201::AID-AJPA6>3.0.CO;2-0
   Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2
   Chakravarthy MV, 2004, J APPL PHYSIOL, V96, P3, DOI 10.1152/japplphysiol.00757.2003
   Corbo RM, 2004, MOL HUM REPROD, V10, P617, DOI 10.1093/molehr/gah082
   Corbo RM, 2004, FERTIL STERIL, V81, P104, DOI 10.1016/j.fertnstert.2003.05.029
   Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x
   Dalgaard LT, 2001, DIABETOLOGIA, V44, P946, DOI 10.1007/s001250100596
   Darwin Charles, 1989, ORIGIN SPECIES
   Diamond J, 2003, NATURE, V423, P599, DOI 10.1038/423599a
   DIAMOND J, 1993, 3 CHIMPANZEE, P180
   Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412
   DULLOO AG, 2001, J OBESITY S5, V25, pS22
   Dunger DB, 1998, NAT GENET, V19, P98, DOI 10.1038/ng0598-98
   Eaves IA, 1999, NAT GENET, V22, P324
   Fagan B., 2000, FLOODS FAMINES EMPER
   Forsen T, 2000, ANN INTERN MED, V133, P176
   FRISCH RE, 1982, SCIENCE, V215, P1272, DOI 10.1126/science.7199206
   HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248
   Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5
   Ibanez L, 2001, J CLIN ENDOCR METAB, V86, P5788, DOI 10.1210/jc.86.12.5788
   Joffe B, 1998, ENDOCRINE, V9, P139, DOI 10.1385/ENDO:9:2:139
   JORDAN WC, 1996, GREAT FAMINE N EUROP
   KELSEY G, 1999, INFLUENCES DEV DIS L, P73
   Keys A, 1950, BIOL HUMAN STARVATIO
   Kimm SYS, 2002, AM J CLIN NUTR, V75, P714
   KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663
   Kramer MS, 2003, J NUTR, V133, p1592S
   Lindsay RS, 2003, DIABETES, V52, P187, DOI 10.2337/diabetes.52.1.187
   Lucas A, 1999, BRIT MED J, V319, P245
   Maharatna Arap, 1996, DEMOGRAPHY FAMINE
   MCCANCE RA, 1975, P NUTR SOC, V34, P161, DOI 10.1079/PNS19750033
   Melve KK, 2003, INT J EPIDEMIOL, V32, P625, DOI 10.1093/ije/dyg163
   Mitchell SMS, 2004, J CLIN ENDOCR METAB, V89, P310, DOI 10.1210/jc.2003-030605
   Moore SE, 2001, DIABETIC MED, V18, P646, DOI 10.1046/j.1464-5491.2001.00565.x
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   NEWSHOLME EA, 1994, NUTRITION, V10, P178
   Ong KK, 2004, DIABETES, V53, P1128, DOI 10.2337/diabetes.53.4.1128
   Ong KK, 2004, J CLIN ENDOCR METAB, V89, P2647, DOI 10.1210/jc.2003-031848
   Ong KKL, 1999, NAT GENET, V21, P262
   Ong KKL, 2000, J PEDIATR ENDOCR MET, V13, P1419
   Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158
   PARRYBILLINGS M, 1991, BIOCHEM J, V279, P327
   Popkin BM, 2002, PUBLIC HEALTH NUTR, V5, P93, DOI 10.1079/PHN200180
   Popkin B. M., 2001, J NUTR, V131, P871
   Prentice A. M., 2001, BNF Nutrition Bulletin, V26, P13, DOI 10.1046/j.1467-3010.2001.00100.x
   Prentice AM, 2003, BRIT MED J, V327, P880, DOI 10.1136/bmj.327.7420.880
   Prentice AM, 2000, AM J CLIN NUTR, V71, p1226S
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   SEN AK, POVERTY FAMINE ESSAY
   Snyder EE, 2004, OBES RES, V12, P369, DOI 10.1038/oby.2004.47
   Stead JDH, 2003, GENOME RES, V13, P2101, DOI 10.1101/gr.948003
   Stein Z., 1975, FAMINE HUMAN DEV DUT
   Stocker CJ, 2005, P NUTR SOC, V64, P143, DOI 10.1079/PNS2005417
   SUSSER M, 1991, AM J CLIN NUTR, V53, P1384
   Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054
   van der Sande MAB, 2001, AM J PUBLIC HEALTH, V91, P1641, DOI 10.2105/AJPH.91.10.1641
   WEST KM, 1974, DIABETES, V23, P841
   WIDDOWSON EM, 1974, P R SOC LOND, V185, P1
   Wilcox AJ, 2001, INT J EPIDEMIOL, V30, P1233, DOI 10.1093/ije/30.6.1233
   WOLFE RR, 1990, AM J PHYSIOL, V258, pE382
   Yajnik C, 2000, P NUTR SOC, V59, P257, DOI 10.1017/S0029665100000288
   Yajnik CS, 2002, J CLIN ENDOCR METAB, V87, P5575, DOI 10.1210/jc.2002-020434
   YAJNIK CS, 2002, INT J OBESITY, V27, P173
   ZIMMET P, 1997, DIABETOLOGIA, V31, P111
NR 72
TC 91
Z9 96
U1 0
U2 23
PU CABI PUBLISHING
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, NOSWORTHY WAY, WALLINGFORD OX10 8DE, OXON,
   ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD MAY
PY 2005
VL 64
IS 2
BP 153
EP 161
DI 10.1079/PNS2005421
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 934XO
UT WOS:000229743100003
PM 15960860
OA No
DA 2017-08-15
ER

PT J
AU Greenwood, BM
   Bojang, K
   Whitty, CJM
   Targett, GAT
AF Greenwood, BM
   Bojang, K
   Whitty, CJM
   Targett, GAT
TI Malaria
SO LANCET
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; PLACEBO-CONTROLLED TRIAL; PLUS
   SULFADOXINE-PYRIMETHAMINE; RANDOMIZED CONTROLLED-TRIAL;
   PAPUA-NEW-GUINEA; CIRCUMSPOROZOITE PROTEIN VACCINE; INSECTICIDE-TREATED
   NETS; DRUG-RESISTANT MALARIA; YOUNG AFRICAN CHILDREN; SUB-SAHARAN AFRICA
AB Malaria is the most important parasitic infection in people, accounting for more than 1 million deaths a year. Malaria has become a priority for the international health community and is now the focus of several new initiatives. Prevention and treatment of malaria could be greatly improved with existing methods if increased financial and labour resources were available. However, new approaches for prevention and treatment are needed. Several new drugs are under development, which are likely to be used in combinations to slow the spread of resistance, but the high cost of treatments would make sustainability difficult. Insecticide-treated bed-nets provide a simple but effective means of preventing malaria, especially with the development of longlasting nets in which insecticide is incorporated into the net fibres. One malaria vaccine, RTS,S/AS02, has shown promise in endemic areas and will shortly enter further trials. Other vaccines are being studied in clinical trials, but it will probably be at least 10 years before a malaria vaccine is ready for widespread use.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1B 3DP, England.
   MRC Labs, Banjul, Gambia.
RP Greenwood, BM (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1B 3DP, England.
EM brian.greenwood@lshtm.ac.uk
RI Whitty, Christopher/C-7740-2012
OI Whitty, Christopher/0000-0002-6076-5027
CR Abeku TA, 2004, TRENDS PARASITOL, V20, P400, DOI 10.1016/j.pt.2004.07.005
   Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4
   Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Alphey L, 2002, SCIENCE, V298, P119, DOI 10.1126/science.1078278
   Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1
   Anderson RJ, 2004, J IMMUNOL, V172, P3094
   ARROW KJ, 2004, SAV LIV BUYING TIM E
   Barat LM, 2004, AM J TROP MED HYG, V71, P174
   Barnes KI, 2004, LANCET, V363, P1598, DOI 10.1016/S0140-6736(04)16203-X
   Bates I, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-38
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Binka FN, 2002, T ROY SOC TROP MED H, V96, P597, DOI 10.1016/S0035-9203(02)90321-4
   Bloland PB, 2003, MALARIA CONTROL MASS
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Boutlis CS, 2004, INFECT IMMUN, V72, P6932, DOI 10.1128/IAI.72.12.6932-6938.2004
   Brey PT, 2003, MOL CELLS, V15, P133
   Brooke BD, 2001, B ENTOMOL RES, V91, P265, DOI 10.1079/BER2001108
   Carter JA, 2005, TROP MED INT HEALTH, V10, P3, DOI 10.1111/j.1365-3156.2004.01345.x
   Centres for Disease Control and Prevention, MAL
   Chandramohan D, 2002, TROP MED INT HEALTH, V7, P45, DOI 10.1046/j.1365-3156.2002.00827.x
   Chen A, 2003, EMERG INFECT DIS, V9, P960
   Chima RI, 2003, HEALTH POLICY, V63, P17, DOI 10.1016/S0168-8510(02)00036-2
   CISSE B, 2004, 53 M AM SOC TROP MED
   Coleman PG, 2004, TROP MED INT HEALTH, V9, P433, DOI 10.1111/j.1365-3156.2004.01225.x
   Connor J, 2004, B WORLD HEALTH ORGAN, V82, P935
   Craig MH, 2002, T ROY SOC TROP MED H, V96, P258, DOI 10.1016/S0035-9203(02)90092-1
   Crawley J, 2001, ARCH DIS CHILD, V84, P247, DOI 10.1136/adc.84.3.247
   Curtis C, 2003, LANCET INFECT DIS, V3, P304, DOI 10.1016/S1473-3099(03)00612-1
   De Savigny D, 2004, AM J TROP MED HYG, V71, P224
   Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85
   DICKO A, 2004, 53 M AM SOC TROP MED
   DJIMDE AA, 2003, AM J TROP MED HYG, V69, P559
   Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x
   Dondorp AM, 2004, CRIT CARE MED, V32, P1683, DOI 10.1097/01.CCM.0000132901.86681.CA
   Duke T, 2004, LANCET, V363, P1922, DOI 10.1016/S0140-6736(04)16438-6
   Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002
   Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hcho93
   Felger I, 2003, TRENDS PARASITOL, V19, P60, DOI 10.1016/S1471-4922(02)00066-1
   Fernando SD, 2003, AM J TROP MED HYG, V69, P582
   French N, 2001, AIDS, V15, P899, DOI 10.1097/00002030-200105040-00010
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   Greenwood B, 2004, AM J TROP MED HYG, V70, P1
   Greenwood B, 2002, CHEM IMMUNOL, V80, P366
   Guyatt HL, 2001, T ROY SOC TROP MED H, V95, P569, DOI 10.1016/S0035-9203(01)90082-3
   Guyatt HL, 2001, AM J TROP MED HYG, V64, P36
   Hallem EA, 2004, NATURE, V427, P212, DOI 10.1038/427212a
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   Hastings IM, 2004, TRENDS PARASITOL, V20, P512, DOI 10.1016/j.pt.2004.08.006
   Hastings IM, 2002, PHILOS T ROY SOC B, V357, P505, DOI 10.1098/rstb.2001.1036
   Hawley WA, 2003, AM J TROP MED HYG, V68, P121
   Hay SI, 2002, TRENDS PARASITOL, V18, P530, DOI 10.1016/S1471-4922(02)02374-7
   Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6
   *HLTH PROT AG, MAL GUID
   *INT PREV TREATM I, INT PREV TREAT INF A
   Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274
   Jones COH, 2004, AM J TROP MED HYG, V71, P156
   Kaslow DC, 2002, CHEM IMMUNOL, V80, P287
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1
   Kremsner PG, 2004, LANCET, V364, P285, DOI 10.1016/S0140-6736(04)16680-4
   Kublin JG, 2005, LANCET, V365, P233
   Lengeler C, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000363.PUB2
   Litsios S., 1996, TOMORROW MALARIA
   *LOND SCH HYG TROP, DER MORT MORB EST CO
   Lyke KE, 2004, INFECT IMMUN, V72, P5630, DOI 10.1128/IAI.72.10.5630-5637.2004
   Mabaso MLH, 2004, TROP MED INT HEALTH, V9, P846, DOI 10.1111/j.1365-3156.2004.01263.x
   Maitland K, 2005, TRENDS PARASITOL, V21, P11, DOI 10.1016/j.pt.2004.10.010
   Makani J, 2003, QJM-INT J MED, V96, P355, DOI 10.1093/qjmed/hcg059
   Marsh VM, 2004, TROP MED INT HEALTH, V9, P451, DOI 10.1111/j.1365-3156.2004.01223.x
   Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452
   Massaga JJ, 2003, LANCET, V361, P1853, DOI 10.1016/S0140-6736(03)13504-0
   Mayxay M, 2004, CLIN INFECT DIS, V39, P1139, DOI 10.1086/424512
   Mita T, 2003, AM J TROP MED HYG, V68, P413
   Monasch R, 2004, AM J TROP MED HYG, V71, P232
   Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2004, LANCET, V363, P150, DOI 10.1016/S0140-6736(03)15267-1
   Mount AM, 2004, LANCET, V363, P1860, DOI 10.1016/S0140-6736(04)16354-X
   Muller O, 2001, BRIT MED J, V322, P1567, DOI 10.1136/bmj.322.7302.1567
   Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9
   Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3
   Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8
   Obonyo CO, 2003, T ROY SOC TROP MED H, V97, P585, DOI 10.1016/S0035-9203(03)80038-X
   OMARI AA, 2003, COCHRANE DB SYST REV, V2, P3125
   Peters RPH, 2004, TROP MED INT HEALTH, V9, P928, DOI 10.1111/j.1365-3156.2004.01288.x
   Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23
   Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1
   Planche T, 2004, PLOS MED, V1, P56, DOI 10.1371/journal.pmed.0010018
   Plowe CV, 2004, BRIT MED J, V328, P545, DOI 10.1136/bmj.37977.653750.EE
   Polley SD, 2004, TRENDS PARASITOL, V20, P99, DOI 10.1016/j.pt.2003.12.003
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a
   Rogerson SJ, 2000, T ROY SOC TROP MED H, V94, P549, DOI 10.1016/S0035-9203(00)90083-X
   Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0
   Rowland M, 2004, TROP MED INT HEALTH, V9, P335, DOI 10.1111/j.1365-3156.2004.01198.x
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   Sachs JD, 2005, LANCET, V365, P347, DOI 10.1016/S0140-6736(05)17791-5
   Schellenberg D, 1999, AM J TROP MED HYG, V61, P431
   Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Schellenberg JRMA, 2001, LANCET, V357, P1241, DOI 10.1016/S0140-6736(00)04404-4
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515
   Shankar AH, 1999, LANCET, V354, P203, DOI 10.1016/S0140-6736(98)08293-2
   Shankar AH, 2000, AM J TROP MED HYG, V62, P663
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X
   Singh B, 2004, LANCET, V363, P1017, DOI 10.1016/S0140-6736(04)15836-4
   Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Staalsoe T, 2004, LANCET, V363, P283, DOI 10.1016/S0140-6736(03)15386-X
   Staedke SG, 2004, LANCET, V364, P1950, DOI 10.1016/S0140-6736(04)17478-3
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Tanser FC, 2003, LANCET, V362, P1792, DOI 10.1016/S0140-6736(03)14898-2
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   Teklehaimanot HD, 2004, EMERG INFECT DIS, V10, P1220
   Thomson MC, 2001, TRENDS PARASITOL, V17, P438, DOI 10.1016/S1471-4922(01)02077-3
   Tran Tinh Hien, 2004, Lancet (North American Edition), V363, P18
   van Eijk AM, 2004, TROP MED INT HEALTH, V9, P351, DOI 10.1111/j.1365-3156.2004.01196.x
   Vennerstrom JL, 2004, NATURE, V430, P900, DOI 10.1038/nature02779
   Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0
   Vernick KD, 2004, NEW ENGL J MED, V351, P1901, DOI 10.1056/NEJMcibr042899
   Whitty CJM, 2004, B WORLD HEALTH ORGAN, V82, P381
   Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6
   *WHO, 2004, PORTF CAND MAL VACC
   WHO, 2003, ASS SAF ART COMP PRE
   *WHO, 2004, SCAL HOM BAS CAR MAL
   World Health Organization, WHOCDSWHOPESGCDPP200
   Zaim M, 2002, TRENDS PARASITOL, V18, P161, DOI 10.1016/S1471-4922(01)02220-6
NR 137
TC 404
Z9 418
U1 10
U2 103
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 23
PY 2005
VL 365
IS 9469
BP 1487
EP 1498
DI 10.1016/S0140-6736(05)66420-3
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 919XT
UT WOS:000228651600028
PM 15850634
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Holland, MJ
   Makalo, P
   Aryee, EAN
   Alexander, NDE
   Sillah, A
   Faal, H
   West, SK
   Foster, A
   Johnson, GJ
   Mabey, DCW
   Bailey, RL
AF Burton, MJ
   Holland, MJ
   Makalo, P
   Aryee, EAN
   Alexander, NDE
   Sillah, A
   Faal, H
   West, SK
   Foster, A
   Johnson, GJ
   Mabey, DCW
   Bailey, RL
TI Re-emergence of Chlamydia trachomatis infection after mass antibiotic
   treatment of a trachoma-endemic Gambian community: a longitudinal study
SO LANCET
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; AZITHROMYCIN; DIAGNOSIS; CHILDREN; AREA
AB Background Community-wide mass antibiotic treatment is a central component of trachoma control. The optimum frequency and duration of treatment are unknown. We measured the effect of mass treatment on the conjunctival burden of Chlamydia trachomatis in a Gambian community with low to medium trachoma prevalence and investigated the rate, route, and determinants of re-emergent infection.
   Methods 14 trachoma-endemic villages in rural Gambia were examined and conjunctival swabs obtained at baseline, 2, 6, 12, and 17 months. Mass antibiotic treatment with azithromycin was given to the community at baseline. C trachomatis was detected by qualitative PCR and individual infection load then estimated by real-time quantitative PCR.
   Findings C trachomatis was detected in 95 (7%) of 1319 individuals at baseline. Treatment coverage was 83% of the population (1328 of 1595 people). The effect of mass treatment was heterogeneous. In 12 villages all baseline infections (34 [3%] of 1062 individuals) resolved, and prevalence (three [0.3%]) and infection load remained low throughout the study. Two villages (baseline infection: 61 [24%] of 257 individuals) had increased infection 2 months after treatment (74 [30%]), after extensive contact with other untreated communities. Subsequently, this value reduced to less than half of that before treatment (25 [11%]).
   Interpretation Mass antibiotic treatment generally results in effective, longlasting control of C trachomatis in this environment. For low prevalence regions, one treatment episode might be sufficient. Infection can be reintroduced through contact with untreated populations. Communities need to be monitored for treatment failure and control measures implemented over wide geographical areas.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Natl Eye Care Programme, Banjul, Gambia.
   Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   Inst Ophthalmol, Div Epidemiol & Int Eye Hlth, London, England.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
FU Medical Research Council [MC_U190081961]
CR Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2000, TROP MED INT HEALTH, V5, P515, DOI 10.1046/j.1365-3156.2000.00603.x
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   Fraser-Hurt N, 2001, B WORLD HEALTH ORGAN, V79, P632
   Kirkwood BR, 1988, ESSENTIAL MED STAT
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   Moalic E, 2000, PEDIATR INFECT DIS J, V19, P979, DOI 10.1097/00006454-200010000-00008
   Munoz B, 2003, INVEST OPHTH VIS SCI, V44, P1464, DOI 10.1167/iovs.02-0234
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Smith A, 2001, Ophthalmic Epidemiol, V8, P127, DOI 10.1076/opep.8.2.127.4164
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Ward M, 1990, Scand J Infect Dis Suppl, V69, P137
   WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   World Health Organization, 1997, WHOPBL9656
   *WHO, 2001, 6 M WHO ALL GLOB EL
NR 25
TC 88
Z9 88
U1 0
U2 3
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 9
PY 2005
VL 365
IS 9467
BP 1321
EP 1328
DI 10.1016/S0140-6736(05)61029-X
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 914HY
UT WOS:000228219600027
PM 15823382
OA No
DA 2017-08-15
ER

PT J
AU Rayco-Solon, P
   Fulford, AJ
   Prentice, AM
AF Rayco-Solon, P
   Fulford, AJ
   Prentice, AM
TI Maternal preconceptional weight and gestational length
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE conception; pregnancy; length of gestation; nutritional status
ID AGE; BIRTH
AB Recent animal studies suggest that preconceptional undernutrition shortens gestation. We retested this idea among rural Gambian women who experience annual fluctuations in energy balance caused by the rains (with lowest weights in September to November) using records front 1918 infants. Pregnancies conceived in September to November were significantly shorter than those from better-fed months (38.6 vs 39.0 weeks; log-rank chi(2) = 17.4, P < .0001). (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   MRC Labs, MRC Keneba, Banjul, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.Prentice@lshtm.ac.uk
CR Bloomfield FH, 2003, SCIENCE, V300, P606, DOI 10.1126/science.1080803
   Cole T. J., 1993, SEASONALITY HUMAN EC
   CONSTANTINE NA, 1987, J PEDIATR-US, V110, P921, DOI 10.1016/S0022-3476(87)80416-X
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Neggers Y, 2003, J NUTR, V133, p1737S
   SANDERS M, 1991, PEDIATRICS, V88, P542
   SUSSER M, 1994, NUTR REV, V52, P84
   Vik T, 1997, AM J PERINAT, V14, P369, DOI 10.1055/s-2007-994163
NR 8
TC 28
Z9 29
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD APR
PY 2005
VL 192
IS 4
BP 1133
EP 1136
DI 10.1016/j.ajog.2004.10.636
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 916YD
UT WOS:000228421800022
PM 15846192
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Moore, SE
AF Prentice, AM
   Moore, SE
TI Early programming of adult diseases in resource poor countries
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID THRIFTY PHENOTYPE HYPOTHESIS; EARLY-LIFE ORIGINS; BIRTH-WEIGHT; FETAL
   ORIGINS; INTRAUTERINE GROWTH; INSULIN-RESISTANCE; DIABETES-MELLITUS;
   LIPID-METABOLISM; HEART-DISEASE; SOUTH-INDIA
AB Considerable evidence now exists to suggest that early exposure to nutritional deprivation can have long term consequences to health, with low birth weight now considered a risk factor for later health outcomes such as coronary heart disease, stroke, type 2 diabetes, and the metabolic syndrome. Of importance, such effects are most exaggerated when faced with over-nutrition in later life, forming the basis for the "thrifty phenotype'' hypothesis. The evidence in support of these associations comes largely from retrospective cohort studies in which adult outcomes were correlated with birth weight records. Relatively little data is available from developing countries, where long term record keeping of birth weight data has not been a high priority. Arguably however, such countries are at the greatest risk from the mismatch of early nutritional deprivation and later nutritional affluence. This paper explores the importance of the "developmental origins of health and disease'' hypothesis in resource poor countries.
C1 Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.Prentice@lshtm.ac.uk
CR Adair LS, 2004, J NUTR, V134, P191
   BARKER DJP, 1986, LANCET, V1, P1077
   Barker DJP, 1994, MOTHERS BABIES DIS L
   Bavdekar A, 1999, DIABETES, V48, P2422, DOI 10.2337/diabetes.48.12.2422
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   COLLINSON AC, 2002, THESIS U BRISTOL
   DESAI M, 1995, BIOCHEM SOC T, V23, P331
   DOWSE GK, 1991, AM J EPIDEMIOL, V133, P1093
   Fall CHD, 1998, DIABETIC MED, V15, P220, DOI 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.3.CO;2-F
   Fall CHD, 2001, BRIT MED BULL, V60, P33, DOI 10.1093/bmb/60.1.33
   Forrester T, 2004, J NUTR, V134, P211
   HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248
   Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5
   Hales CN, 1997, DIABETIC MED, V14, P189
   Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1
   Joseph KS, 1996, EPIDEMIOL REV, V18, P158
   Langley-Evans SC, 2001, P NUTR SOC, V60, P505, DOI 10.1079/PNS2001111
   Lauren L, 2003, INT J EPIDEMIOL, V32, P862, DOI 10.1093/ije/dyg201
   Lucas A, 1999, BRIT MED J, V319, P245
   MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142
   MCCANCE DR, 1994, BRIT MED J, V308, P942
   MCCANCE RA, 1974, PROC R SOC SER B-BIO, V185, P1, DOI 10.1098/rspb.1974.0001
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   McKeigue PM, 1998, DIABETOLOGIA, V41, P1133, DOI 10.1007/s001250051042
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 2001, DIABETIC MED, V18, P646, DOI 10.1046/j.1464-5491.2001.00565.x
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   Ozanne SE, 1997, AM J PHYSIOL-ENDOC M, V273, pE46
   Phillips DIW, 1999, INT J OBESITY, V23, P1025, DOI 10.1038/sj.ijo.0801050
   Prentice AM, 2003, BRIT MED J, V327, P880, DOI 10.1136/bmj.327.7420.880
   Seckl JR, 1999, BIOCHEM SOC T, V27, P74
   Singhal A, 2004, LANCET, V363, P1571, DOI 10.1016/S0140-6736(04)16198-9
   Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3
   World Health Organization (WHO), 2003, DIET NUTR PREV CHRON
   Woods LL, 2000, CURR OPIN NEPHROL HY, V9, P419, DOI 10.1097/00041552-200007000-00014
   Yajnik C, 2000, P NUTR SOC, V59, P257, DOI 10.1017/S0029665100000288
   Yajnik CS, 2003, INT J OBESITY, V27, P173, DOI 10.1038/sj.ijo.802219
   Yajnik CS, 2004, J NUTR, V134, P205
   Yajnik CS, 2002, J CLIN ENDOCR METAB, V87, P5575, DOI 10.1210/jc.2002-020434
NR 42
TC 77
Z9 80
U1 0
U2 10
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD APR
PY 2005
VL 90
IS 4
BP 429
EP 432
DI 10.1136/adc.2004.059030
PG 4
WC Pediatrics
SC Pediatrics
GA 908RA
UT WOS:000227805500031
PM 15781942
OA No
DA 2017-08-15
ER

PT J
AU Aspray, TJ
   Yan, L
   Prentice, A
AF Aspray, TJ
   Yan, L
   Prentice, A
TI Parathyroid hormone and rates of bone formation are raised in
   perimenopausal rural Gambian women
SO BONE
LA English
DT Article
DE bone formation; Gambian women; perimenopausal; PTH; osteoporosis
ID VITAMIN-D DEFICIENCY; HIP FRACTURE; POSTMENOPAUSAL WOMEN; BLACK-WOMEN;
   MINERAL CONTENT; UNITED-KINGDOM; RISK-FACTORS; PRIMARY
   HYPERPARATHYROIDISM; ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES
AB To investigate rates of bone turnover and calcium homeostasis in Gambian women, we recruited 103 peri- and postmenopausal women, aged 45 to 80+ years and 11 women of reproductive age. Fasting blood was analyzed for plasma osteocalcin, PTH, 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], total- and bone-specific alkaline phosphatase. Plasma and urinary calcium, inorganic phosphate, sodium, potassium, creatinine, and albumin and urine free deoxypyridinoline (Dpd) was also measured. Samples from 20 premenopausal and 31 postmenopausal women from Cambridge, UK were analyzed, using the same methodology for comparison.
   For the Gambian women, peak calcium excretion occurred at around 50 years of age. For women aged >= 45 years, calcium excretion decreased by 3.0% per year of age (SE 1%; P < 0.005). In this age group, 25(OH)D also decreased with age (P < 0.005). Urinary sodium output, pH, and titratable acid Output decreased (all P < 0.05) and total alkaline phosphatase (P < 0.005), osteocalcin ( P < 0.005), and PTH (P < 0.05) increased with age.
   Comparisons were made between the following groups of Gambian and British women: premenopausal, early (age 55-64 years)- and late (age 65+ years)-postmenopausal. Gambian women of all ages were lighter (P < 0.001), shorter (P < 0.01), and had higher plasma bone-specific alkaline phosphatase activity (P < 0.05) and higher concentrations of osteocalcin (P < 0.05), PTH (P < 0.001), 1,25(OH)(2)D (P < 0.001), and 25(OH)D (P < 0.001). There were no consistent differences in calcitonin, while urinary free Dpd outputs were lower in the Garribians (P < 0.001). Plasma calcium, phosphate, and albumin (P < 0.01) were significantly lower. Urinary calcium, phosphate, sodium, and potassium excretion were lower, particularly in the postmenopausal group (P < 0.001). Although Gambian urine pH was more acidic, titratable acid output was lower (P < 0.01).
   These data show that Gambian women with low dietary calcium intakes and good vitamin D status have low urinary calcium excretion and that menopausal changes in calcium and bone metabolism among Gambian women are similar to those seen in other populations.
   In addition, they demonstrate that Gambian women of all ages have raised plasma PTH and 1,25(OH)(2)D concentrations and raised markers of osteoblast activity. We postulate that high endogenous PTH concentrations may be beneficial to bone health in Gambian women, removing fatigue damage and improving bone quality. (c) 2005 Elsevier Inc. All rights reserved.
C1 MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
   MRC, Keneba, Gambia.
   Newcastle Univ, Inst Hlth & Aging, Newcastle Upon Tyne, Tyne & Wear, England.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
CR ADEBAJO AO, 1991, AGE AGEING, V20, P435, DOI 10.1093/ageing/20.6.435
   Aloia JF, 1996, CALCIFIED TISSUE INT, V59, P415, DOI 10.1007/BF00369203
   Aloia JF, 1999, CALCIFIED TISSUE INT, V65, P29, DOI 10.1007/s002239900653
   Aloia JF, 1998, J LAB CLIN MED, V132, P383, DOI 10.1016/S0022-2143(98)90109-3
   ANDERSON JJB, 1994, ADV NUTR RES, V9, P129
   ASPRAY T, 2002, OSTEOPOROSIS STUDY R, P213
   ASPRAY TJ, 1995, BONE, V17, P261, DOI 10.1016/8756-3282(95)00216-Z
   Aspray TJ, 1996, J BONE MINER RES, V11, P1018
   BARON JA, 1994, EPIDEMIOLOGY, V5, P42, DOI 10.1097/00001648-199401000-00008
   Bartl Gregor, 1996, Blutalkohol, V33, P1
   Beavan SR, 2005, EUR J CLIN NUTR, V59, P72, DOI 10.1038/sj.ejcn.1602037
   Brown EM, 2002, J BONE MINER RES, V17, pN24
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   CROSS NA, 1995, J BONE MINER RES, V10, P1312
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   DAWSONHUGHES B, 1987, AM J CLIN NUTR, V46, P685
   Dibba B, 1999, ANN HUM BIOL, V26, P229
   FALCH JA, 1992, ACTA ENDOCRINOL-COP, V126, P10
   FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374
   FENN B, 1996, DIET INTAKES CALCIUM
   Fournier A, 2001, AM J KIDNEY DIS, V38, P222, DOI 10.1053/ajkd.2001.26171
   Fraser WD, 2004, CURR OPIN NEPHROL HY, V13, P437, DOI 10.1097/01.mnh.0000133985.29880.34
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756-3282(03)00202-3
   GALLAGHER JC, 1980, J LAB CLIN MED, V95, P373
   Garnero P, 1998, OSTEOPOROSIS INT, V8, P563, DOI 10.1007/s001980050100
   Garnero P, 1996, J BONE MINER RES, V11, P337
   GRIFFIN MR, 1992, AM J EPIDEMIOL, V136, P1378
   GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202
   Heaney RP, 2001, AM J CLIN NUTR, V73, P5
   KELLIE SE, 1990, AM J PUBLIC HEALTH, V80, P326, DOI 10.2105/AJPH.80.3.326
   Khosla S, 2002, J BONE MINER RES, V17, pN103
   LeBoff MS, 1999, JAMA-J AM MED ASSOC, V281, P1505, DOI 10.1001/jama.281.16.1505
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   MEIER DE, 1991, J CLIN ENDOCR METAB, V72, P703
   Meunier P, 1996, Scand J Rheumatol Suppl, V103, P75
   Pfeifer M, 2001, EXP CLIN ENDOCR DIAB, V109, P87, DOI 10.1055/s-2001-14831
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1990, BONE MINER, V10, P211, DOI 10.1016/0169-6009(90)90263-F
   PRENTICE A, 1991, BONE MINER, V12, P201, DOI 10.1016/0169-6009(91)90033-V
   ROBINS SP, 2002, PRINCIPLES BONE BIOL, V1
   SCHNITZLER CM, 1993, CALCIFIED TISSUE INT, V53, pS27, DOI 10.1007/BF01673398
   TROTTER M, 1960, J BONE JOINT SURG AM, V42, P50
   Wu F, 2002, CLIN ENDOCRINOL, V56, P703, DOI 10.1046/j.1365-2265.2002.01534.x
   Yan L, 2003, BONE, V33, P620, DOI 10.1016/S8756-3282(03)00216-3
NR 46
TC 27
Z9 28
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD APR
PY 2005
VL 36
IS 4
BP 710
EP 720
DI 10.1016/j.bone.2005.01.002
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 924NX
UT WOS:000228986600015
PM 15780975
OA No
DA 2017-08-15
ER

PT J
AU Munday, K
   Fulford, A
   Bates, CJ
AF Munday, K
   Fulford, A
   Bates, CJ
TI Vitamin C status and collagen cross-link ratios in Gambian children
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE vitamin C; collagen; cross-links; Gambian children
ID EHLERS-DANLOS-SYNDROME; HYDROXYLYSINE-DEFICIENT COLLAGEN; SYNDROME
   TYPE-VI; URINARY-EXCRETION; LYSYL HYDROXYLASE; GUINEA-PIGS; SKIN
   FIBROBLASTS; BONE-RESORPTION; ASCORBATE; HYDROXYLYSYLPYRIDINOLINE
AB Vitamin C ( ascorbate) is essential for hydroxylation of prolyl and lysyl residues in nascent collagen, the failure of which leads to connective tissue lesions of scurvy. Of the pyridinium-type cross-links in mature collagen, pyridinoline requires more hydroxylysyl residues than does deoxypyridinoline. Our study tested the hypothesis that pyridinoline: deoxypyridinoline ratios in urinary degradation products may vary with ascorbate status in man. These ratios were compared between British and Gambian prepubertal boys, mean age 8(.)3 years, and in Gambian boys between two seasons with contrasting ascorbate availability. The mean cross-links ratio in 216 British boys was 4(.)36 (SD 0(.)71), significantly greater (P < 0(.)0001) than in sixty-two Gambian boys: 3(.)83 (SD 0(.)52). In the Gambians the cross-links ratio was significantly higher in the dry season (with high ascorbate intake and status) than in the rains (with low intake and status). A 7-week controlled intervention was carried out in Gambian boys during the rainy season (the 'hungry' season, when vitamin C-containing foods are virtually unavailable): 100 mg ascorbate/d was given to one group of thirty-two Gambian boys and placebo to another group. The intervention did not, however, significantly alter the cross-link ratio, possibly because the response time and/or intervention - response delay is > 7 weeks. If confirmed, the putative association between ascorbate and collagen cross-link ratios in man could become the basis for a functional test for adequacy of ascorbate status.
C1 MRC, Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   MRC, Int Nutr Grp, Keneba, Gambia.
RP Bates, CJ (reprint author), MRC, Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM Chris.Bates@mrc-hnr.cam.ac.uk
CR ACIL Y, 1995, J AM ACAD DERMATOL, V33, P522, DOI 10.1016/0190-9622(95)91404-8
   Acil Y, 1996, SCAND J CLIN LAB INV, V56, P275, DOI 10.3109/00365519609088617
   Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5
   Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054
   Banse X, 2002, J BONE MINER RES, V17, P1621, DOI 10.1359/jbmr.2002.17.9.1621
   Barnes M J, 1972, Vitam Horm, V30, P1, DOI 10.1016/S0083-6729(08)60793-1
   Bates Christopher J., 1999, Proceedings of the Nutrition Society, V58, p63A
   BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   BEARDSWORTH LJ, 1990, J BONE MINER RES, V5, P671
   BRANCA F, 1992, LANCET, V340, P1493, DOI 10.1016/0140-6736(92)92754-4
   Branca F, 2002, J PEDIATR ENDOCR MET, V15, P27
   DEMBURE PP, 1987, METABOLISM, V36, P687, DOI 10.1016/0026-0495(87)90155-7
   Dolan AL, 1998, ANN RHEUM DIS, V57, P630, DOI 10.1136/ard.57.10.630
   Douglas AS, 1996, J CLIN PATHOL, V49, P284, DOI 10.1136/jcp.49.4.284
   ELSAS LJ, 1978, J PEDIATR-US, V92, P378, DOI 10.1016/S0022-3476(78)80423-5
   Fraser WD, 1998, J CLIN LIGAND ASSAY, V21, P102
   Ginty F, 1998, EUR J CLIN NUTR, V52, P71, DOI 10.1038/sj.ejcn.1600502
   Gregory J., 2000, NATL DIET NUTR SURVE
   HANSON DA, 1992, J BONE MINER RES, V7, P1251
   KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245
   MILLER RL, 1979, J INVEST DERMATOL, V72, P241, DOI 10.1111/1523-1747.ep12531702
   MYLLYLA R, 1984, J BIOL CHEM, V259, P5403
   Pasquali M, 1997, P ASSOC AM PHYSICIAN, V109, P33
   PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901
   QUINN RS, 1976, J CLIN INVEST, V57, P83, DOI 10.1172/JCI108273
   RAUCH F, 1995, ACTA PAEDIATR, V84, P66, DOI 10.1111/j.1651-2227.1995.tb13486.x
   ROBINSON GW, 1994, MECH DEVELOP, V48, P199, DOI 10.1016/0925-4773(94)90060-4
   ROYCE PM, 1985, BIOCHEM J, V230, P475
   SEIBEL MJ, 1992, TRENDS ENDOCRIN MET, V3, P263, DOI 10.1016/1043-2760(92)90129-O
   Tsuchiya H, 1998, J NUTR BIOCHEM, V9, P402, DOI 10.1016/S0955-2863(98)00039-4
   Tsuchiya H, 2003, BRIT J NUTR, V89, P303, DOI 10.1079/BJN2002775
   Tsuchiya H, 1997, BRIT J NUTR, V77, P315, DOI 10.1079/BJN19970032
   VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25
   1984, NUTR REV, V42, P392
NR 34
TC 7
Z9 8
U1 0
U2 5
PU CABI PUBLISHING
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, NOSWORTHY WAY, WALLINGFORD OX10 8DE, OXON,
   ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD APR
PY 2005
VL 93
IS 4
BP 501
EP 507
DI 10.1079/BJN20041329
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 934AP
UT WOS:000229679200012
PM 15946412
OA No
DA 2017-08-15
ER

PT J
AU Faburay, B
   Munstermann, S
   Geysen, D
   Bell-Sakyi, L
   Ceesay, A
   Bodaan, C
   Jongejan, F
AF Faburay, B
   Munstermann, S
   Geysen, D
   Bell-Sakyi, L
   Ceesay, A
   Bodaan, C
   Jongejan, F
TI Point seroprevalence survey of Ehrlichia ruminantium infection in small
   ruminants in the Gambia
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article
ID LINKED-IMMUNOSORBENT-ASSAY; COWDRIA-RUMINANTIUM; AMBLYOMMA-VARIEGATUM;
   DOMESTIC RUMINANTS; FIELD SERA; ANTIBODIES; HEARTWATER; CATTLE; GHANA;
   VALIDATION
AB Using the MAP1-B enzyme-linked immunosorbent assay, we tested 1,318 serum samples collected from sheep and goats at 28 sites in the five divisions of The Gambia to determine the Ehrlichia ruminantium seroprevalence rates and to assess the risk for heartwater. About half (51.6 %) of 639 sheep were positive, with seroprevalence rates per site varying between 6.9 % and 100 %. The highest seroprevallence was detected in the western part of the country (88.1 % in the Western Division and 62.1 % in the Lower River Division). Sheep in the two easterly divisions (Central River and Upper River divisions) showed the lowest seroprevalence of 29.3 % and 32.4 %, respectively, while those in the North Bank Division showed an intermediate prevalence of 40.6 %. In goats, less than one-third (30.3 %) of 679 animals tested were positive. The highest seroprevalence was detected in goats in the North Bank Division (59 %) and Western Division (44.1 %). Goats in the Lower River Division showed an intermediate level of 21.9 %, whereas the lowest rates were found in the eastern part of the country (4.8 % in the Central River Division and 2.3 % in the Upper River Division). At nearly all sites, seroprevalence rates were higher in sheep than in goats. The results show a gradient of increasing heartwater risk for susceptible small ruminants from the east to the west of The Gambia. These findings need to be taken into consideration when future livestock-upgrading programs are implemented.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Univ Edinburgh, Royal Sch Vet Studies Dick, Ctr Trop Vet Med, Edinburgh EH25 9RG, Midlothian, Scotland.
   Univ Utrecht, Fac Med Vet, Div Parasitol & Trop Vet Med, NL-3508 TC Utrecht, Netherlands.
   Univ Pretoria, Fac Vet Sci, Dept Trop Dis, ZA-0110 Onderstepoort, South Africa.
RP Faburay, B (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
EM b.faburay@itc.gm
CR Awa DN, 1997, VET PARASITOL, V68, P165, DOI 10.1016/S0304-4017(96)01058-8
   Bekker CPJ, 2001, CLIN DIAGN LAB IMMUN, V8, P843, DOI 10.1128/CDLI.8.4.843-846.2001
   Bell-Sakyi L, 2004, VET MICROBIOL, V100, P175, DOI 10.1016/j.vetmic.2004.02.010
   Bell-Sakyi L, 2003, CLIN DIAGN LAB IMMUN, V10, P917, DOI 10.1128/CDLI.10.5.917-925.2003
   De Waal DT, 2000, ANN NY ACAD SCI, V916, P622
   Gueye A., 1993, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V46, P217
   Gueye A., 1989, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V42, P497
   Gueye A, 1994, Rev Elev Med Vet Pays Trop, V47, P39
   Gueye A, 1993, Rev Elev Med Vet Pays Trop, V46, P449
   GUEYE A, 1982, REV ELEV MED VET PAY, V35, P217
   JONGEJAN F, 1991, RES VET SCI, V51, P24, DOI 10.1016/0034-5288(91)90025-J
   JONGEJAN F, 1988, RES VET SCI, V44, P186
   Kakono O, 2003, ONDERSTEPOORT J VET, V70, P243
   Koney EBM, 2004, VET MICROBIOL, V103, P183, DOI 10.1016/j.vetmic.2004.02.017
   Mahan SM, 1998, ANN NY ACAD SCI, V849, P259, DOI 10.1111/j.1749-6632.1998.tb11057.x
   Mattioli RC, 2000, EXP APPL ACAROL, V24, P957, DOI 10.1023/A:1010645927535
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   Mboloi MM, 1999, CLIN DIAGN LAB IMMUN, V6, P66
   Mondry R, 1998, ANN NY ACAD SCI, V849, P262, DOI 10.1111/j.1749-6632.1998.tb11058.x
   Sumption KJ, 2003, CLIN DIAGN LAB IMMUN, V10, P910, DOI 10.1128/CDLI.10.5.910-916.2003
   VANVLIET AHM, 1995, J CLIN MICROBIOL, V33, P2405
   WALKER JB, 1987, ONDERSTEPOORT J VET, V54, P353
   Yunker CE, 1996, ONDERSTEPOORT J VET, V63, P159
   2000, STAT YB GAMBIAN AGR, P47
NR 24
TC 12
Z9 12
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD APR
PY 2005
VL 12
IS 4
BP 508
EP 512
DI 10.1128/CDLI.12.4.508-512.2005
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 955AL
UT WOS:000231196900006
PM 15817758
OA No
DA 2017-08-15
ER

PT J
AU Hammond, AS
   Klein, MR
   Corrah, T
   Fox, A
   Jaye, A
   McAdam, KP
   Brookes, RH
AF Hammond, AS
   Klein, MR
   Corrah, T
   Fox, A
   Jaye, A
   McAdam, KP
   Brookes, RH
TI Mycobacterium tuberculosis genome-wide screen exposes multiple CD8(+) T
   cell epitopes
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE CTL; ELISPOT; genome-wide; tuberculosis; vaccine
ID PLASMODIUM-FALCIPARUM MALARIA; PEPTIDE BINDING; HLA-B; VACCINE;
   IMMUNOLOGY; INFECTION; SEQUENCE; ANTIGENS; IMMUNOGENICITY; FREQUENCIES
AB Mounting evidence suggests human leucocyte antigen (HLA) class I-restricted CD8(+) T cells play a role in protective immunity against tuberculosis yet relatively few epitopes specific for the causative organism, Mycobacterium tuberculosis, are reported. Here a total genome-wide screen of M. tuberculosis was used to identify putative HLA-B*3501 T cell epitopes. Of 479 predicted epitopes, 13 with the highest score were synthesized and used to restimulate lymphocytes from naturally exposed HLA-B*3501 healthy individuals in cultured and ex vivo enzyme-linked immunospot (ELISPOT) assays for interferon (IFN)-gamma. All 13 peptides elicited a response that varied considerably between individuals. For three peptides CD8(+) T cell lines were expanded and four of the 13 were recognized permissively through the HLA-B7 supertype family. Although further testing is required we show the genome-wide screen to be feasible for the identification of unknown mycobacterial antigens involved in immunity against natural infection. While the mechanisms of protective immunity against M. tuberculosis infection remain unclear, conventional class I-restricted CD8(+) T cell responses appear to be widespread throughout the genome.
C1 MRC Labs, Bacterial Dis Programme, TB Div, Banjul, Gambia.
RP Brookes, RH (reprint author), MRC Labs, Bacterial Dis Programme, TB Div, Atlantic Rd,POB 273, Banjul, Gambia.
EM rbrookes@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011
CR Agger EM, 2002, VACCINE, V21, P7, DOI 10.1016/S0264-410X(02)00447-4
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Bivas-Benita M, 2004, VACCINE, V22, P1609, DOI 10.1016/j.vaccine.2003.09.044
   BLEED DWC, 2003, GLOBAL TUBERCULOSIS
   Brookes RH, 2003, EUR J IMMUNOL, V33, P3293, DOI 10.1002/eji.200324109
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006
   Cole ST, 1998, NATURE, V393, P537
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   DANIEL TM, 1980, CLIN CHEST MED, V1, P189
   Ellis JM, 2001, TISSUE ANTIGENS, V57, P339, DOI 10.1034/j.1399-0039.2001.057004339.x
   Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002
   Flower DR, 2003, TRENDS IMMUNOL, V24, P667, DOI 10.1016/j.it.2003.10.006
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Flynn JL, 2004, TUBERCULOSIS, V84, P93, DOI 10.1016/j.tube.2003.08.010
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558
   Klein MR, 2002, INFECT IMMUN, V70, P981, DOI 10.1128/IAI.70.2.981-984.2002
   Klein MR, 2001, ARCH IMMUNOL THER EX, V49, P379
   Klein MR, 2001, J INFECT DIS, V183, P928, DOI 10.1086/319267
   Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   Modigliani Y, 1996, IMMUNOL REV, V149, P155, DOI 10.1111/j.1600-065X.1996.tb00903.x
   Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331
   Ottenhoff THM, 2002, NAT GENET, V32, P97, DOI 10.1038/ng0902-97
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Pathan AA, 2000, EUR J IMMUNOL, V30, P2713, DOI 10.1002/1521-4141(200009)30:9<2713::AID-IMMU2713>3.0.CO;2-4
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   SCHONBACH C, 1995, J IMMUNOL, V154, P5951
   Serbina NV, 2001, INFECT IMMUN, V69, P4320, DOI 10.1128/IAI.69.7.4320-4328.2001
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Sidney J, 1996, J IMMUNOL, V157, P3480
   Stenger S, 1998, J IMMUNOL, V161, P3582
   Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121
   Sylvester-Hvid C, 2004, TISSUE ANTIGENS, V63, P395, DOI 10.1111/j.0001-2815.2004.00221.x
   van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4
   Voskuil MI, 2004, TUBERCULOSIS, V84, P138, DOI 10.1016/j.tube.2003.12.008
   *WHO, 104 WHO
NR 39
TC 18
Z9 20
U1 0
U2 1
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD APR
PY 2005
VL 140
IS 1
BP 109
EP 116
DI 10.1111/j.1365-2249.2005.02751.x
PG 8
WC Immunology
SC Immunology
GA 905SK
UT WOS:000227589800014
PM 15762882
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Lleonart, ME
   Villar, S
   Groopman, JD
   Mendy, M
   Hainaut, P
   Friesen, M
AF Kirk, GD
   Lleonart, ME
   Villar, S
   Groopman, JD
   Mendy, M
   Hainaut, P
   Friesen, M
TI Quantitative detection of 249ser TP53 mutations in plasma DNA and risk
   for hepatocellular carcinoma
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 40th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 13-17, 2005
CL Paris, FRANCE
C1 Johns Hopkins Univ, Baltimore, MD USA.
   Int Agcy Res Canc, Lyon, France.
   MRC Labs, Banjul, Gambia.
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2005
VL 42
SU 2
MA 249
BP 95
EP 96
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 925AN
UT WOS:000229024000250
OA No
DA 2017-08-15
ER

PT J
AU Erskine, J
AF Erskine, J
TI Oral hypotensives for severe hypertension
SO TROPICAL DOCTOR
LA English
DT Letter
C1 WEC Int, Banjul, Gambia.
RP Erskine, J (reprint author), WEC Int, POB 86, Banjul, Gambia.
EM erskinesjd@yahoo.co.uk
CR Ofor OO, 2004, TROP DOCT, V34, P32
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD APR
PY 2005
VL 35
IS 2
BP 124
EP 124
DI 10.1258/0049475054037174
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 936XI
UT WOS:000229888400033
PM 15970055
OA No
DA 2017-08-15
ER

PT J
AU Ameyaw, SK
AF Ameyaw, SK
TI Childhood skin infections and post-infective nephropathy
SO TROPICAL DOCTOR
LA English
DT Letter
C1 Atlantic Benhavard, Med Res Coucil Labs, Clin Serv Unit, Fajara, Gambia.
RP Ameyaw, SK (reprint author), Atlantic Benhavard, Med Res Coucil Labs, Clin Serv Unit, Box 273 Bajul, Fajara, Gambia.
EM skahealshandlife@yahoo.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD APR
PY 2005
VL 35
IS 2
BP 126
EP 126
DI 10.1258/0049475054036869
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 936XI
UT WOS:000229888400038
PM 15970059
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Govender, T
   Garrib, A
   Welz, T
   Grosskurth, H
   Smith, PG
   Whittle, H
   Bennish, ML
AF Jaffar, S
   Govender, T
   Garrib, A
   Welz, T
   Grosskurth, H
   Smith, PG
   Whittle, H
   Bennish, ML
TI Antiretroviral treatment in resource-poor settings: public health
   research priorities
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE HAART implementation; sub-Saharan Africa; ART delivery
ID RANDOMIZED CONTROLLED-TRIAL; AMBULATORY PERITONEAL-DIALYSIS;
   SEXUALLY-TRANSMITTED-DISEASES; RESEARCH AGENDA; HIV-INFECTION;
   TUBERCULOSIS; TRANSMISSION; THERAPY; INTERVENTIONS; INDIVIDUALS
AB Many countries in Africa are planning to provide highly active antiretroviral therapy ( HAART) to millions of people with acquired immune deficiency syndrome. This will be a highly complex therapy programme. Physician-based models of care adapted from industrialized countries will not succeed in providing treatment to the majority of those who need it in resource-constrained settings. A high priority is to identify care models for Africa that will increase coverage of HAART safely and effectively: key issues are (i) whether nursing staff or non-clinically qualified staff can take the major role in the treatment programme and reduce the workload of physicians, (ii) whether treatment and monitoring can be delivered through peripheral health centres or through home visits and achieve better adherence and be more cost-effective than delivery at hospitals and (iii) which clinical algorithms used by nursing or non-clinically qualified staff will be effective for screening, diagnosing and managing treatment-related side-effects and medical problems being incurred. Many current ART support programmes are making little or no investment in research, but answering important questions on delivery of HAART will be essential if HAART programmes are to be successful in African nations with a high burden of human immunodeficiency virus infection.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, MRC, Trop Epidmiol Grp, London WC1E 7HT, England.
   Dept Hlth, Epidemiol Unit, Pietermaritzburg, South Africa.
   Africa Ctr Hlth & Populat Studies, Mtubatuba, South Africa.
   Uganda Virus Res Inst, Med Res Council Programme AIDS Uganda, Entebbe, Uganda.
   MRC Labs, Banjul, Gambia.
   Tufts New England Med Ctr, Dept Med, Boston, MA USA.
   Univ Kwa Zulu Natal, Nelson R Mandela Sch Med, Dept Community Med, Durban, South Africa.
   Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
RP Jaffar, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, MRC, Trop Epidmiol Grp, Keppel St, London WC1E 7HT, England.
EM shabbar.jaffar@lshtm.ac.uk; govendet@dohho.kzntl.gov.za;
   Anupam.garrib@mrc.ac.za; Tanyawelz@btinternet.com;
   Heiner.grosskurth@mrcuganda.org; Peter.smith@lshtm.ac.uk;
   hwhittle@mrc.gm; michael.bennish@mrc.ac.za
FU NIAID NIH HHS [1 K24 AI/HDO1671-01]
CR Buve A, 1997, TROP MED INT HEALTH, V2, P136, DOI 10.1046/j.1365-3156.1997.d01-235.x
   Coates TJ, 2000, LANCET, V356, P103
   GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   Hayes RJ, 2000, STAT METHODS MED RES, V9, P95, DOI 10.1191/096228000670953670
   Jaffar S, 1999, VACCINE, V18, P633, DOI 10.1016/S0264-410X(99)00277-7
   Kamali A, 2003, LANCET, V361, P645, DOI 10.1016/S0140-6736(03)12598-6
   Kamolratanakul P, 1999, T ROY SOC TROP MED H, V93, P552, DOI 10.1016/S0035-9203(99)90379-6
   Katz IJ, 2001, NEPHROL DIAL TRANSPL, V16, P2395, DOI 10.1093/ndt/16.12.2395
   Kent DM, 2003, CLIN INFECT DIS, V37, pS13, DOI 10.1086/375368
   Khan MA, 2002, HEALTH POLICY PLANN, V17, P178, DOI 10.1093/heapol/17.2.178
   KITYO C, 2003, 13 INT C AIDS AFR AB
   Nolan ML, 2002, AIDS, V16, P1991, DOI 10.1097/00002030-200210180-00003
   Poppa A, 2004, HIV MED, V5, P46, DOI 10.1111/j.1468-1293.2004.00215.x
   Pozniak A, 2003, HIV Med, V4 Suppl 1, P1
   Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4
   Thorne C, 2004, CURR OPIN INFECT DIS, V17, P247, DOI 10.1097/01.qco.0000129623.46401.01
   TODD JE, 2004, XV INT AIDS C BANK
   *UNAIDS, 2003, AIDS EPID UPD, P1
   VEMUND SH, 2003, CLIN INFECT DIS, V37, P4
   Vermund SH, 2003, CLIN INFECT DIS, V37, pS4, DOI 10.1086/375367
   Volmink J, 2003, COCHRANE DATABASE SY
   Walley JD, 2001, LANCET, V357, P664, DOI 10.1016/S0140-6736(00)04129-5
   Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3
   Weller S.C., 2002, COCHRANE DATABASE SY
   ZENT R, 1994, PERITON DIALYSIS INT, V14, P48
   Zulu I, 2004, JAIDS-J ACQ IMM DEF, V36, P831, DOI 10.1097/00126334-200407010-00010
   Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7
NR 27
TC 24
Z9 24
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD APR
PY 2005
VL 10
IS 4
BP 295
EP 299
DI 10.1111/j.1365-3156.2005.01390.x
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 912FY
UT WOS:000228064200002
PM 15807791
OA No
DA 2017-08-15
ER

PT J
AU Kaye, S
   Howard, M
   Alabi, A
   Hansmann, A
   Whittle, H
   van der Loeff, MS
AF Kaye, S
   Howard, M
   Alabi, A
   Hansmann, A
   Whittle, H
   van der Loeff, MS
TI No observed effect of GB virus C coinfection on disease progression in a
   cohort of African woman infected with HIV-1 or HIV-2
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
ID HEPATITIS-G VIRUS; ASSOCIATION
AB We studied mortality among subjects with human immunodeficiency virus (HIV)-1 and HIV-2 infection in relation to GB virus (GBV)-C coinfection. No significant differences in mortality were seen between subjects with and subjects without GBV-C coinfection who also had either HIV-1 or HIV-2 infection. No association between GBV-C and HIV plasma virus loads or CD4 cell count was observed.
C1 MRC Labs, Banjul, Gambia.
   Kings Coll London, Sch Med, London SE5 9PJ, England.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Univ Munster, D-4400 Munster, Germany.
RP Kaye, S (reprint author), MRC Labs, Fajara,POB 273, Banjul, Gambia.
EM skaye@mrc.gm
CR Berry N, 1998, J Hum Virol, V1, P457
   Birk M, 2002, AIDS, V16, P2482, DOI 10.1097/01.aids.0000042584.93174.58
   Brumme ZL, 2002, AIDS, V16, P1929, DOI 10.1097/00002030-200209270-00010
   HANSMANN A, IN PRESS J AIDS
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Montavon C, 2000, J ACQ IMMUN DEF SYND, V23, P363
   Muerhoff AS, 2003, J MED VIROL, V70, P141, DOI 10.1002/jmv.10375
   Nunnari G, 2003, ANN INTERN MED, V139, P26
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2
NR 12
TC 20
Z9 20
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2005
VL 40
IS 6
BP 876
EP 878
DI 10.1086/428123
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 904JP
UT WOS:000227492800017
PM 15736023
OA No
DA 2017-08-15
ER

PT J
AU Demba, E
   Morison, L
   van der Loeff, MS
   Awasana, AA
   Gooding, E
   Bailey, R
   Mayaud, P
   West, B
AF Demba, E
   Morison, L
   van der Loeff, MS
   Awasana, AA
   Gooding, E
   Bailey, R
   Mayaud, P
   West, B
TI Bacterial vaginosis, vaginal flora patterns and vaginal hygiene
   practices in patients presenting with vaginal discharge syndrome in The
   Gambia, West Africa
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID PEROXIDE-PRODUCING LACTOBACILLI; GROUP-B STREPTOCOCCI; PREGNANT-WOMEN;
   HIV-INFECTION; MYCOPLASMA-HOMINIS; RISK-ASSESSMENT; ASSOCIATION;
   ALGORITHM; NAIROBI; KENYA
AB Background: Bacterial vaginosis (BV) - a syndrome characterised by a shift in vaginal flora - appears to be particularly common in sub-Saharan Africa, but little is known of the pattern of vaginal flora associated with BV in Africa. We conducted a study aimed at determining the prevalence of BV and patterns of BV-associated vaginal micro-flora among women with vaginal discharge syndrome (VDS) in The Gambia, West Africa.
   Methods: We enrolled 227 women with VDS from a large genito-urinary medicine clinic in Fajara, The Gambia. BV was diagnosed by the Nugent's score and Amsel's clinical criteria. Vaginal swabs were collected for T vaginalis and vaginal flora microscopy, and for Lactobacillus spp, aerobic organisms, Candida spp and BV-associated bacteria ( Gardnerella vaginalis, anaerobic bacteria, and Mycoplasma spp) cultures; and cervical swabs were collected for N gonorrhoeae culture and C trachomatis PCR. Sera were tested for HIV-1 and HIV-2 antibodies. Sexual health history including details on sexual hygiene were obtained by standardised questionnaire.
   Results: BV prevalence was 47.6% by Nugent's score and 30.8% by Amsel's clinical criteria. Lactobacillus spp were isolated in 37.8% of women, and 70% of the isolates were hydrogen-peroxide (H(2)0(2))- producing strains. Prevalence of BV-associated bacteria were: G vaginalis 44.4%; Bacteroides 16.7%; Prevotella 15.2%; Peptostretococcus 1.5%; Mobiluncus 0%; other anaerobes 3.1%; and Mycoplasma hominis 21.4%. BV was positively associated with isolation of G vaginalis (odds-ratio [ OR] 19.42, 95% CI 7.91 - 47.6) and anaerobes ( P = 0.001 [ OR] could not be calculated), but not with M hominis. BV was negatively associated with presence of Lactobacillus ( OR 0.07, 95% CI 0.03 - 0.15), and H2O2-producing lactobacilli ( OR 0.12, 95% CI 0.05 - 0.28). Presence of H2O2-producing lactobacilli was associated with significantly lower prevalence of G vaginalis, anaerobes and C trachomatis. HIV prevalence was 12.8%. Overall, there was no association between BV and HIV, and among micro-organisms associated with BV, only Bacteroides spp. and Prevotella spp. were associated with HIV. BV or vaginal flora patterns were not associated with any of the factors relating to sexual hygiene practices ( vaginal douching, menstrual hygiene, female genital cutting).
   Conclusion: In this population, BV prevalence was higher than in corresponding populations in industrialised countries, but the pattern of vaginal micro-flora associated with BV was similar. BV or vaginal flora patterns were not associated with HIV nor with any of the vaginal hygiene characteristics.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   MRC Labs, Fajara, Gambia.
RP Mayaud, P (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
EM edemba@mrc.gm; linda.morison@lshtm.ac.uk; maarten.schim@lshtm.ac.uk;
   aaveika@mrc.gm; edemba@mrc.gm; robin.bailey@lshtm.ac.uk;
   philippe.mayaud@lshtm.ac.uk; beryl_west@hotmail.com
RI Morison, Linda/H-9738-2013
FU Medical Research Council [MC_U190081961]
CR AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9
   Arya OP, 2001, SEX TRANSM INFECT, V77, P58, DOI 10.1136/sti.77.1.58
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   Boskey ER, 1999, INFECT IMMUN, V67, P5170
   Daly CC, 1998, SEX TRANSM INFECT, V74, pS50
   ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251
   Fonck K, 2000, SEX TRANSM INFECT, V76, P33, DOI 10.1136/sti.76.1.33
   Fonck K, 2001, SEX TRANSM INFECT, V77, P271, DOI 10.1136/sti.77.4.271
   Govender L, 1996, INT J GYNECOL OBSTET, V55, P23, DOI 10.1016/0020-7292(96)02744-0
   Gresenguet G, 1997, AIDS, V11, P101, DOI 10.1097/00002030-199701000-00015
   Hawes SE, 1996, J INFECT DIS, V174, P1058
   HAY PE, 1992, BRIT J OBSTET GYNAEC, V99, P63, DOI 10.1111/j.1471-0528.1992.tb14395.x
   HILL GB, 1993, AM J OBSTET GYNECOL, V169, P450
   Hillier SL, 1999, SEXUALLY TRANSMITTED, P563
   HILLIER SL, 1992, OBSTET GYNECOL, V79, P369
   Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604
   Holzman C, 2001, AM J PUBLIC HEALTH, V91, P1664, DOI 10.2105/AJPH.91.10.1664
   KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289
   Koneman EW, 1992, COLOUR ATLAS TXB DIA
   La Ruche G, 1999, SEX TRANSM DIS, V26, P191, DOI 10.1097/00007435-199904000-00001
   Ledru S, 1996, SEX TRANSM DIS, V23, P151, DOI 10.1097/00007435-199603000-00011
   Mardh PA, 1997, AM J OBSTET GYNECOL, V176, P173, DOI 10.1016/S0002-9378(97)80031-2
   Martino JL, 2002, EPIDEMIOL REV, V24, P109, DOI 10.1093/epirev/mxf004
   Mayaud P, 1998, SEX TRANSM INFECT, V74, pS139
   Mayaud P, 1998, SEX TRANSM INFECT, V74, pS77
   Morison L, 2001, TROP MED INT HEALTH, V6, P643, DOI 10.1046/j.1365-3156.2001.00749.x
   Morris MC, 2001, SEX TRANSM INFECT, V77, P63, DOI 10.1136/sti.77.1.63
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297
   Regan JA, 1996, AM J OBSTET GYNECOL, V174, P1354, DOI 10.1016/S0002-9378(96)70684-1
   Reid G, 2001, AM J CLIN NUTR, V73, p437S
   Royce RA, 1999, J ACQ IMMUN DEF SYND, V20, P382
   Royce RA, 1999, SEX TRANSM DIS, V26, P96, DOI 10.1097/00007435-199902000-00007
   Schmid G, 2000, SEX TRANSM INFECT, V76, P3, DOI 10.1136/sti.76.1.3
   Schneider H, 1998, SEX TRANSM INFECT, V74, pS147
   Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5
   SPIEGEL CA, 1991, CLIN MICROBIOL REV, V4, P485
   SUARA RO, 1994, J INFECT DIS, V170, P1316
   Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019
   Thomas T, 1996, GENITOURIN MED, V72, P334
   Thorsen P, 1998, AM J OBSTET GYNECOL, V178, P580, DOI 10.1016/S0002-9378(98)70442-9
   van der Loeff MFS, 2002, AIDS, V16, P1775
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   West B, 2003, SEX TRANSM DIS, V30, P483, DOI 10.1097/00007435-200306000-00003
NR 43
TC 27
Z9 29
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAR 9
PY 2005
VL 5
AR 12
DI 10.1186/1471-2334-5-12
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA 918IM
UT WOS:000228535500001
PM 15757510
OA gold
DA 2017-08-15
ER

PT J
AU Faye, D
   Fall, A
   Leak, S
   Losson, B
   Geerts, S
AF Faye, D
   Fall, A
   Leak, S
   Losson, B
   Geerts, S
TI Influence of an experimental Trypanosoma congolense infection and plane
   of nutrition on milk production and some biochemical parameters in West
   African Dwarf goats
SO ACTA TROPICA
LA English
DT Article
DE Trypanosoma congolense; nutrition; milk; West African Dwarf goats;
   biochemistry; lactation
ID LISTERIA-MONOCYTOGENES INFECTION; SCOTTISH BLACKFACE SHEEP; DJALLONKE
   EWE LAMBS; VIVAX INFECTION; NITROGEN-METABOLISM; DIETARY LIPIDS; NDAMA
   CATTLE; COTTON SEED; FEED-INTAKE; SUSCEPTIBILITY
AB The interactions of trypanosomosis and plane of nutrition on health and productivity of multiparous and primiparous West African Dwarf (WAD) does were studied in a multi-factorial experiment including diet (supplementation or basal diet) and infection (infected or control). Experimental does were infected with Trypanosoma congolense at the beginning of the second week post-kidding and monitored for 16 weeks after infection. Trypanosome infection significantly reduced packed cell volume (PCV) (control: 30.1 +/- 0.3% versus infected: 22.2 +/- 0.3%; P < 0.0001). Regardless of infection, the drop in PCV from the pre-infection period to the end of the experiment was more severe in animals under restricted diet (interaction diet x period, P < 0.001). Trypanosome parasitaemia tended to be higher in the supplemented group than in the basal diet group (P > 0.05) and multiparous animals had a higher parasitaemia (score: 2.6 +/- 0.1) than primiparous animals (score: 2.2 +/- 0.1) (P < 0.05). Trypanosome infection as well as dietary supplement had a significant effect on lactation length. Milk off-take from trypanosome-infected does was significantly lower than that from the uninfected control group (17.5 +/- 3.21 versus 35.5 +/- 3.21, P < 0.001) and there was a positive effect of plane of nutrition (supplemented: 32.8 +/- 3.21 and basal diet: 20.2 +/- 3.51, P = 0.01). The drop in milk off-take due to trypanosome infection was more severe in the supplemented group (control: 46.7 +/- 4.71 versus infected: 18.9 +/- 4.21) than in the group receiving a basal diet (control: 24.2 +/- 5.01 versus infected: 16.1 +/- 4.71) (interaction infection x diet, P = 0.04) due to the number of does from the supplemented group that were withdrawn from the experiment. The effect of trypanosome infection on doe's live-weight was only noticeable during the first 8 weeks of lactation and there was no significant effect on offspring growth rate unless the mother died. Plasma total protein (TP), albumin and cholesterol concentrations were significantly reduced by the infection but were significantly increased by supplementation. Supplemented does had a higher level of cholesterol and a tendency for a higher parasitaemia. Does of high parity also had a higher cholesterol level than primiparous does and, based on the number of animals that were withdrawn from the experiment, they showed a lower resistance to the infection. (c) 2005 Elsevier B.V. All rights reserved.
C1 Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Liege, Fac Vet Med, Dept Parasitol, B-4000 Cointe Ougree, Belgium.
RP Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.
EM sgeerts@itg.be
CR ADAH MI, 1993, VET PARASITOL, V47, P177, DOI 10.1016/0304-4017(93)90020-N
   AGYEMANG K, 1990, ANIM PROD, V50, P383
   AGYEMANG K, 1991, ACTA TROP, V50, P91, DOI 10.1016/0001-706X(91)90001-Z
   AKINBAMIJO OO, 1992, VET QUART, V14, P95
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P387
   ALBRIGHT JW, 1994, IMMUNOL LETT, V40, P279, DOI 10.1016/0165-2478(94)00066-2
   Andrianarivo AG, 1996, EXP PARASITOL, V82, P104, DOI 10.1006/expr.1996.0014
   ANOSA VO, 1976, TROP ANIM HLTH PROD, V8, P11
   BELIBASAKIS NG, 1995, ANIM FEED SCI TECH, V52, P227, DOI 10.1016/0377-8401(94)00725-O
   BENNISON JJ, 1997, THESIS WYE COLL U LO
   Calder PC, 2001, NUTR RES, V21, P309, DOI 10.1016/S0271-5317(00)00287-6
   Chaudhary ZI, 2000, ACTA TROP, V77, P209, DOI 10.1016/S0001-706X(00)00142-X
   Fall A, 1999, VET PARASITOL, V81, P235, DOI 10.1016/S0304-4017(98)00213-1
   Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   Hudson J. R., 1944, JOUR COMP PATH AND THERAP, V54, P108
   International Committee for Animal Recording, 2001, ICAR RUL STAND GUID
   Jarrige R., 1988, ALIMENTATION BOVINS
   KALU AU, 1991, TROP ANIM HEALTH PRO, V23, P215, DOI 10.1007/BF02357102
   Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93
   KATUNGUKARWAKISHAY, 1999, VET PARASITOL, V84, P1
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2
   KatungukaRwakishaya E, 1997, VET PARASITOL, V70, P67, DOI 10.1016/S0304-4017(96)01136-3
   KATUNGUKARWAKISHAYA E, 1992, VET PARASITOL, V45, P17, DOI 10.1016/0304-4017(92)90024-4
   LEAK S, 2002, ICPTV NEWSLETT, P36
   Leak S.G.A., 1998, TSETSE BIOL ECOLOGY
   MCDONALD P, 1978, ANIMAL NUTR
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   OKELLY JC, 1984, VET PARASITOL, V15, P151, DOI 10.1016/0304-4017(84)90030-X
   Osaer S, 1999, VET PARASITOL, V80, P215, DOI 10.1016/S0304-4017(98)00193-9
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Osaer S, 1998, RES VET SCI, V65, P65, DOI 10.1016/S0034-5288(98)90029-7
   Osaer S, 2000, ACTA TROP, V75, P229, DOI 10.1016/S0001-706X(00)00060-7
   PARIS J, 1982, ACTA TROP, V39, P307
   PAYNE JM, 1989, METABOLIC NUTR DIS C
   Puertollano MA, 2003, CLIN NUTR, V22, P313, DOI 10.1016/S0261-5614(03)00031-1
   Puertollano MA, 2001, FEMS IMMUNOL MED MIC, V32, P47, DOI 10.1016/S0928-8244(01)00270-X
   *STAT AN SYST I SA, 1999, VERS 8 1
   van Dam JTP, 1996, THESIS WAGENINGEN AG
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   WHITELAW DD, 1985, TROP ANIM HEALTH PRO, V17, P155, DOI 10.1007/BF02355876
   ZWART D, 1991, J ANIM SCI, V69, P3780
NR 45
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD MAR
PY 2005
VL 93
IS 3
BP 247
EP 257
DI 10.1016/j.actatropica.2004.10.008
PG 11
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 910JG
UT WOS:000227926700004
PM 15715994
OA No
DA 2017-08-15
ER

PT J
AU Hansmann, A
   van der Loeff, MFS
   Kaye, S
   Awasana, AA
   Sarge-Njie, R
   O'Donovan, D
   Ariyoshi, K
   Alabi, A
   Milligan, P
   Whittle, HC
AF Hansmann, A
   van der Loeff, MFS
   Kaye, S
   Awasana, AA
   Sarge-Njie, R
   O'Donovan, D
   Ariyoshi, K
   Alabi, A
   Milligan, P
   Whittle, HC
TI Baseline plasma viral load and CD4 cell percentage predict survival in
   HIV-1- and HIV-2-infected women in a community-based cohort in the
   Gambia
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-2; mortality; viral load; CD4; Africa; women; natural history; HIV-1
ID HIV-1 INFECTION; GUINEA-BISSAU; ANTIRETROVIRAL THERAPY; LYMPHOCYTE
   COUNTS; WEST-AFRICA; RNA LEVELS; MORTALITY; VIRUS; PROGRESSION;
   FERTILITY
AB Objectives: To estimate and compare the all-cause mortality rates among HIV-1-infected, HIV-2-infected, and uninfected women and to assess the predictive value of baseline Plasma viral load (PVL) and CD4 cell percentage (CD4%) for mortality. Design: Cohort study.
   Methods: At presentation to antenatal clinics in The Gambia in 1993-1995, pregnant women were screened for antibodies to HIV-1 and HIV-2. Seropositive subjects and a similar number of seronegative controls were enrolled, and baseline PVL and CD4% were measured. Participants were visited regularly by field-workers until 18 months after delivery and again 4-7 years later.
   Results: Thirty-two of 101 women infected with HIV-1, 23 of 243 infected with HIV-2, and 9 of 468 seronegative women died during a median follow-up of 6.9 years. The mortality rate was 56 deaths per 1000 person years of observation (pyo) for HIV-1-infected, 16 deaths per 1000 pyo for HIV-2-infected, and 3.1 deaths per 1000 pyo for HIV-uninfected women. After 8 years of follow-up, >50% of HIV-1 infected women were still alive. In multivariate analysis, a 1-log increase of HIV-1 PVL was associated with a 1.8-fold higher rate of mortality (95% confidence interval [CI], 0.9-3.4). In HIV-2 infection, women with a high PVL (>10,000 copies/mL) had an 8.7-fold (95% CI, 2.8-28) higher rate of mortality than did those with a low PVL (<1000 copies/mL). A 10% decrease in CD4% was associated with higher mortality rates among HIV-1-infected (1.6-fold; 95% CI, 1.1-2.3) and HIV-2-infected (1.5-fold; 95% CI, 1.0-2.3) subjects.
   Discussion: Survival of HIV-1-infected women in The Gambia is similar to that in industrialized countries before the introduction of antiretroviral treatment. Survival of HIV-2-infected women is much better. However, women with high PVLs die as quickly as their HIV-1-infected counterparts.
C1 MRC Labs, Fajara, Gambia.
   Univ Munster, D-4400 Munster, Germany.
   London Sch Hyg & Trop Med, London WC1, England.
   Univ Coll, Dept Publ Hlth, Galway, Ireland.
   Natl Inst Infect Dis, Tokyo, Japan.
RP van der Loeff, MFS (reprint author), IATEC BV, Pietersbergweg 9, NL-1105 BM Amsterdam, Netherlands.
EM m.schim@iatec.com
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Anastos K, 1999, AIDS, V13, P1717, DOI 10.1097/00002030-199909100-00016
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2001, AIDS RES HUM RETROV, V17, P263, DOI 10.1089/088922201750063197
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Boerma JT, 1998, AIDS, V12, pS3
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Collaborative Group on AIDS Incubation & HIV Survival including the CASCADE EU Concerted Action, 2000, LANCET, V355, P1131
   COX S, 1994, AIDS RES HUM RETROV, V12, P1725
   Crampin AC, 2002, AIDS, V16, P1545, DOI 10.1097/00002030-200207260-00012
   Glynn JR, 2000, J ACQ IMMUN DEF SYND, V25, P345, DOI 10.1097/00126334-200012010-00008
   Grassly NC, 1998, J VIROL, V72, P7895
   Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1
   Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502
   Kilmarx PH, 2002, BRIT MED J, V324, P197
   LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   *MIN HLTH NAT AIDS, 1995, POL GUID HIV AIDS
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   Morgan D, 2002, BRIT MED J, V324, P193, DOI 10.1136/bmj.324.7331.193
   Norrgren H, 1998, SCAND J INFECT DIS, V30, P323
   Nunn AJ, 1997, BRIT MED J, V315, P767
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703
   OBrien WA, 1997, ANN INTERN MED, V126, P939
   Ota MOC, 2000, AIDS, V14, P435, DOI 10.1097/00002030-200003100-00018
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016
   Smith NA, 2001, J INFECTION, V42, P126, DOI 10.1053/jinf.2001.0792
   Unaids, 2002, REP GLOB HIV AIDS EP
   *UNAIDS, 2002, EP UPD
   van der Loeff MFS, 2002, AIDS, V16, P1775
   vanderEnde ME, 1996, AIDS, V10, P1649
   Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006
NR 39
TC 33
Z9 33
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAR 1
PY 2005
VL 38
IS 3
BP 335
EP 341
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 903EK
UT WOS:000227408100015
PM 15735454
OA No
DA 2017-08-15
ER

PT J
AU Cutts, FT
   Zaman, SMA
   Enwere, G
   Jaffar, S
   Levine, OS
   Okoko, JB
   Oluwalana, C
   Vaughan, A
   Obaro, SK
   Leach, A
   McAdam, KP
   Biney, E
   Saaka, M
   Onwuchekwa, U
   Yallop, F
   Pierce, NF
   Greenwood, BM
   Adegbola, RA
AF Cutts, FT
   Zaman, SMA
   Enwere, G
   Jaffar, S
   Levine, OS
   Okoko, JB
   Oluwalana, C
   Vaughan, A
   Obaro, SK
   Leach, A
   McAdam, KP
   Biney, E
   Saaka, M
   Onwuchekwa, U
   Yallop, F
   Pierce, NF
   Greenwood, BM
   Adegbola, RA
CA Gambian Pneumococcal Vaccine Trial
TI Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia
   and invasive pneumococcal disease in The Gambia: randomised,
   double-blind, placebo-controlled trial
SO LANCET
LA English
DT Article
ID INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; CHILDREN; SAFETY;
   IMMUNOGENICITY; INFECTIONS; PREVENTION; DIPHTHERIA; PERTUSSIS; TETANUS
AB Background Pneumonia is estimated to cause 2 million deaths every year in children. Streptococcus pneumoniae is the most important cause of severe pneumonia. We aimed to assess the efficacy of a nine-valent pneumococcal conjugate vaccine in children.
   Methods We undertook a randomised, placebo-controlled, double-blind trial in eastern Gambia. Children age 6-51 weeks were randomly allocated three doses of either pneumococcal conjugate vaccine (n=8718) or placebo (8719), with intervals of at least 25 days between doses. Our primary outcome was first episode of radiological pneumonia. Secondary endpoints were clinical or severe clinical pneumonia, invasive pneumococcal disease, and all-cause admissions. Analyses were per protocol and intention to treat.
   Findings 529 children assigned vaccine and 568 allocated placebo were not included in the per-protocol analysis. Results of per-protocol and intention-to-treat analyses were similar. By per-protocol analysis, 333 of 8189 children given vaccine had an episode of radiological pneumonia compared with 513 of 8151 who received placebo. Pneumococcal vaccine efficacy was 37% (95% CI 27-45) against first episode of radiological pneumonia. First episodes of clinical pneumonia were reduced overall by 7% (95% CI 1-12). Efficacy of the conjugate vaccine was 77% (51-90) against invasive pneumococcal disease caused by vaccine serotypes, 50% (21-69) against disease caused by all serotypes, and 15% (7-21) against all-cause admissions. We also found an efficacy of 16% (3-28) against mortality. 110 serious adverse events arose in children given the pneumococcal vaccine compared with 131 in those who received placebo.
   Interpretation In this rural African setting, pneumococcal conjugate vaccine has high efficacy against radiological pneumonia and invasive pneumococcal disease, and can substantially reduce admissions and improve child survival. Pneumococcal conjugate vaccines should be made available to African infants.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   NIAID, NIH, Bethesda, MD 20892 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Cutts, FT (reprint author), WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland.
EM cuttsf@who.int
FU NIAID NIH HHS [N01-AI-25477]
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/01.inf.0000027926.99356.4c
   Campbell JD, 2004, PEDIATR INFECT DIS J, V23, P642, DOI 10.1097/01.inf.0000130951.85974.79
   CHERIAN T, IN PRESS B WHO
   Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Jaffar S, 2003, INT J EPIDEMIOL, V32, P430, DOI 10.1093/ije/dyg082
   Jaffar S, 1999, VACCINE, V18, P633, DOI 10.1016/S0264-410X(99)00277-7
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Lucero MG, 2004, COCHRANE DB SYST REV, V4
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   Obaro SK, 2002, PEDIATR INFECT DIS J, V21, P940, DOI 10.1097/01.inf.0000034245.88174.3c
   Obaro SK, 1997, PEDIATR INFECT DIS J, V16, P1135, DOI 10.1097/00006454-199712000-00007
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212
   SALO P, 1995, J INFECT DIS, V171, P479
   Spratt BG, 2000, LANCET, V356, P1210, DOI 10.1016/S0140-6736(00)02779-3
   Usen S, 2000, PEDIATR INFECT DIS J, V19, P444, DOI 10.1097/00006454-200005000-00010
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Weber MW, 1997, B WORLD HEALTH ORGAN, V75, P25
   Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   *WHO PNEUM VACC TR, 2001, STAND CHEST RAD DIAG
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0
NR 29
TC 554
Z9 585
U1 0
U2 17
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD MAR-APR
PY 2005
VL 365
IS 9465
BP 1139
EP 1146
DI 10.1016/S0140-6736(05)71876-6
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 910DD
UT WOS:000227909500026
PM 15794968
OA No
DA 2017-08-15
ER

PT J
AU Alexander, NDE
   Solomon, AW
   Holland, MJ
   Bailey, RL
   West, SK
   Shao, JF
   Mabey, DCW
   Foster, A
AF Alexander, NDE
   Solomon, AW
   Holland, MJ
   Bailey, RL
   West, SK
   Shao, JF
   Mabey, DCW
   Foster, A
TI An index of community ocular Chlamydia trachomatis load for control of
   trachoma
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE trachoma; Chlamydia trachomatis; control programmes; Williams mean;
   quantitative PCR; Tanzania
ID ONCHOCERCIASIS; INFECTION; AREA
AB Quantitative PCR (Q-PCR) technology has recently been applied to the measurement of ocular loads of Chlamydia trachomatis. We present an index called the community ocular C. trachomatis load (COCTL) which is similar to the community microfilarial load (CMFL) of onchocerciasis. Our index has the advantage of being scale-independent so that, for example, percentage changes are the same whether calculated per eye swab or per Q-PCR capillary. The COCTL for a population or subgroup is formed by adding the arbitrary concentration of 1 organism per ml to each individual Q-PCR quantification, calculating the geometric mean, and finally subtracting 1 per ml again. The use of the COCTL is illustrated in a study of trachoma in northern Tanzania. The COCTL is higher in people with clinical trachoma than those without (5.8 organisms per swab vs. 0.1), and in children aged six months to ten years than in the overall population (1.1 vs. 0.4). The COCTL index is potentially useful for sentinel sites, operational research and calibration of clinical measures of trachoma. (C) 2004 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Johns Hopkins Sch Med, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   Kilimanjaro Christian Med Ctr, Moshi, Tanzania.
RP Alexander, NDE (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM neal.alexander@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Solomon, Anthony/0000-0001-7101-6649
FU Medical Research Council [MC_U190081961]
CR Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P
   MARSHALL TFD, 1986, T ROY SOC TROP MED H, V80, P426
   REMME J, 1986, B WORLD HEALTH ORGAN, V64, P667
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   SOLOMON AW, 2003, THESIS LONDON SCH HY
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Williams CB, 1937, ANN APPL BIOL, V24, P404, DOI 10.1111/j.1744-7348.1937.tb05042.x
NR 8
TC 7
Z9 8
U1 0
U2 2
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR
PY 2005
VL 99
IS 3
BP 175
EP 177
DI 10.1016/j.trstmh.2004.05.003
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 896FV
UT WOS:000226920900002
PM 15653119
OA No
DA 2017-08-15
ER

PT J
AU Collinson, A
   Moore, S
   O'Connell, M
   Charalambos, C
   Prentice, A
AF Collinson, A
   Moore, S
   O'Connell, M
   Charalambos, C
   Prentice, A
TI Developmental changes in leptin as a measure of energy status in human
   infants in a natural ecologic setting(x)
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE leptin; humans; pregnancy; infancy; adipose tissue; energy flux; Gambia;
   birth weight; growth
ID CORD BLOOD LEPTIN; SERUM LEPTIN; PLASMA LEPTIN; BIRTH-WEIGHT;
   INTRAUTERINE GROWTH; REFERENCE CURVES; MATERNAL SERUM; SHORT-TERM;
   GENDER; CHILDREN
AB Background: Most human research on leptin has involved well-nourished subjects or clinical states such as anorexia nervosa or cancer cachexia.
   Objective: We studied the development of leptin as a monitor of energy status in young African infants whose growth patterns probably reflect the evolutionary norm.
   Design: We enrolled a prospective birth cohort of 138 rural Gambian mother-infant pairs. Plasma leptin was analyzed in maternal blood in late pregnancy, in cord blood, and at 8, 16, and 52 wk in the infants. Body mass index (BMI; in kg/m(2)) was used as a proxy for fatness. The mothers were lean (BMI: 21.6 +/- 2.5), and the infants grew poorly compared with Western standards (average weight-for-age z score of -1.9 at 52 wk).
   Results: Maternal and cord blood leptin and birth weight were all positively correlated. Throughout infancy, leptin was highly correlated with BMI. A strong sex difference existed at birth (ie, leptin concentrations were significantly higher in females than in males), disappeared at 8 wk, and reappeared at 16 and 52 wk. Absolute leptin concentrations declined by almost 90% from birth to 52 wk, but leptin's ability to discriminate across a range of BMI values improved with age. In early infancy, leptin concentrations were uncorrelated with recent changes in BMI, but, by 52 wk, leptin was able to assess both the size of energy stores and the direction of recent changes.
   Conclusions: Leptin concentrations signal energy status from fetal life onward. As infancy progresses, leptin's power to discriminate both chronic and dynamic energy status increases, and this discrimination is achieved at much lower circulating peptide concentrations.
C1 London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC1B 7HT, England.
   MRC Keneba, MRC Labs, Banjul, Gambia.
   MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
RP Prentice, A (reprint author), London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, Keppel St, London WC1B 7HT, England.
EM andrew.prentice@lshtm.ac.uk
CR Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   COLE TJ, 1993, SOC ST HUM, V35, P89, DOI 10.1017/CBO9780511600517.008
   Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503
   Dubowitz L M, 1980, Brain Dev, V2, P3
   Ellis KJ, 1997, PEDIATR RES, V42, P484, DOI 10.1203/00006450-199710000-00010
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Fruhbeck G, 2001, FASEB J, V15, P1996, DOI 10.1096/fj.00-0829hyp
   Fruhbeck G, 1998, CLIN PHYSIOL, V18, P399, DOI 10.1046/j.1365-2281.1998.00129.x
   Harigaya A, 1997, J CLIN ENDOCR METAB, V82, P3281, DOI 10.1210/jc.82.10.3281
   HASSINK SG, 1997, PEDIATRICS, V100, P1
   Hytinantti T, 1999, PEDIATR RES, V45, P197, DOI 10.1203/00006450-199902000-00007
   Jaquet D, 1998, J CLIN ENDOCR METAB, V83, P1243, DOI 10.1210/jc.83.4.1243
   Koistinen HA, 1997, J CLIN ENDOCR METAB, V82, P3328, DOI 10.1210/jc.82.10.3328
   Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511
   Kolaczynski JW, 1996, J CLIN ENDOCR METAB, V81, P4162, DOI 10.1210/jc.81.11.4162
   Laml T, 2001, J SOC GYNECOL INVEST, V8, P43, DOI 10.1016/S1071-5576(00)00121-0
   Maffeis C, 1999, INT J OBESITY, V23, P943, DOI 10.1038/sj.ijo.0801023
   Marchini G, 1998, PEDIATRICS, V101, P429, DOI 10.1542/peds.101.3.429
   Matsuda J, 1997, J CLIN ENDOCR METAB, V82, P1642, DOI 10.1210/jc.82.5.1642
   Matsuda J, 1999, PEDIATR RES, V45, P71, DOI 10.1203/00006450-199901000-00012
   Moore SE, 2004, INT J OBESITY, V28, P17, DOI 10.1038/sj.ijo.0802484
   Moore SE, 2001, AM J CLIN NUTR, V74, P840
   Ong K, 2002, J CLIN ENDOCR METAB, V87, P1041, DOI 10.1210/jc.87.3.1041
   Ong KKL, 1999, J CLIN ENDOCR METAB, V84, P1145, DOI 10.1210/jc.84.3.1145
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Prentice AM, 2002, NUTR REV, V60, pS56, DOI 10.1301/002966402320634940
   PRENTICE AM, 1984, CURRENT TOPICS NUTR, V2, P3
   Radunovic N, 2003, J Matern Fetal Neonatal Med, V13, P394
   Roemmich JN, 1999, ENDOCRIN METAB CLIN, V28, P749, DOI 10.1016/S0889-8529(05)70100-6
   Rump P, 2001, EUR J CLIN NUTR, V55, P244, DOI 10.1038/sj.ejcn.1601151
   Schubring C, 1997, J CLIN ENDOCR METAB, V82, P1480, DOI 10.1210/jc.82.5.1480
   Stein TP, 1998, AM J CLIN NUTR, V68, P1236
   Taylor RW, 1997, INT J OBESITY, V21, P1082, DOI 10.1038/sj.ijo.0800522
   Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P561, DOI 10.1210/jc.82.2.561
NR 35
TC 13
Z9 13
U1 1
U2 4
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD FEB
PY 2005
VL 81
IS 2
BP 488
EP 494
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 896OJ
UT WOS:000226943100022
PM 15699239
OA No
DA 2017-08-15
ER

PT J
AU Frick, KD
   Foster, A
   Bah, M
   Faal, H
AF Frick, KD
   Foster, A
   Bah, M
   Faal, H
TI Analysis of costs and benefits of the Gambian Eye Care Program
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID GLOBAL BLINDNESS; MORTALITY
AB Objective: To estimate the net benefit of the Gambian Eye Care Program (GECP) using a limited definition of benefits from a societal perspective.
   Methods: The number of cases of blindness avoided was modeled using population projections, population-based blindness survey estimates from 1986 and 1996, and reported blindness-related mortality differences. Benefits were measured as lifetime productivity gains that resulted from the cases of blindness avoided between the surveys. Costs included all contributions to GECP between the surveys.
   Results: In 1996, 1658 fewer individuals were blind than would have been without GECP. The present value of costs was US $1.28 million (1995 dollars). Although the net benefit between the blindness surveys was negative, the net lifetime benefit was US $1.01 million (1995 dollars), yielding an internal rate of return of 10%. In the primary sensitivity analysis, assuming similar benefits to Senegalese citizens, who accounted for 30% of patients, the internal rate of return was 19%. Upper bound sensitivity analyses result in internal rates of return higher than 20%.
   Conclusion: In one sub-Saharan African country with avoidable blindness due to cataract and eye infections, the internal rate of return of a national eye care program was substantial when using a limited definition of benefit.
C1 Johns Hopkins Univ, Dept Hlth Policy & Management, Hlth Serv Res, Baltimore, MD 21205 USA.
   Bloomberg Sch Publ Hlth, Dev Ctr, Baltimore, MD USA.
   Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   Johns Hopkins Univ, Dept Econ, Baltimore, MD USA.
   Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD USA.
   Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
   London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1, England.
   Minist Hlth, Natl Eye Care Program, Banjul, Gambia.
RP Frick, KD (reprint author), Johns Hopkins Univ, Dept Hlth Policy & Management, Hlth Serv Res, 624 N Broadway,Room 606, Baltimore, MD 21205 USA.
EM kfrick@jhsph.edu
CR Blohme J, 2000, ACTA OPHTHALMOL SCAN, V78, P560, DOI 10.1034/j.1600-0420.2000.078005560.x
   Boardman A.E., 1996, COST BENEFIT ANAL CO
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Gold M, 1996, COST EFFECTIVENESS H
   KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5
   MURRAY CJL, 1996, GLOBAL BURDEN DIS, P413
   Pauly MV, 2002, HEALTH ECON, V11, P221, DOI 10.1002/hec.648
   Pion SDS, 2002, ANN TROP MED PARASIT, V96, P181, DOI 10.1179/000349802125000718
   Schemann JF, 2002, OPHTHALMIC EPIDEMIOL, V9, P133, DOI 10.1076/opep.9.2.133.1519
   Shamanna B R, 1998, Indian J Ophthalmol, V46, P169
   Smith AF, 1996, BRIT J OPHTHALMOL, V80, P276, DOI 10.1136/bjo.80.4.276
   TAYLOR HR, 1991, B WORLD HEALTH ORGAN, V69, P335
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   World Bank, 2001, WORLD DEV IND 2001
NR 17
TC 24
Z9 24
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2005
VL 123
IS 2
BP 239
EP 243
DI 10.1001/archopht.123.2.239
PG 5
WC Ophthalmology
SC Ophthalmology
GA 893XS
UT WOS:000226755000014
PM 15710822
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Turner, PC
   Gong, YY
   Lesi, OA
   Mendy, M
   Goedert, JJ
   Halls, AJ
   Whittle, H
   Hainaut, P
   Montesano, R
   Wild, CP
AF Kirk, GD
   Turner, PC
   Gong, YY
   Lesi, OA
   Mendy, M
   Goedert, JJ
   Halls, AJ
   Whittle, H
   Hainaut, P
   Montesano, R
   Wild, CP
TI Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing
   and DNA repair enzymes in a population with aflatoxin exposure and
   hepatitis B virus endemicity
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GLUTATHIONE-S-TRANSFERASE; MICROSOMAL EPOXIDE HYDROLASE; GENETIC
   POLYMORPHISMS; GAMBIAN CHILDREN; LIVER-CANCER; ALBUMIN ADDUCTS; NULL
   GENOTYPES; PUBLIC-HEALTH; WEST-AFRICA; RISK
AB High rates of hepatocellular carcinoma (HCC) in The Gambia, West Africa, are primarily due to a high prevalence of chronic hepatitis B virus infection and heavy aflatoxin exposure via groundnut consumption. We investigated genetic polymorphisms in carcinogen-metabolizing (GSTM1, GSTT1, HYL1*2) and DNA repair (XRCC1) enzymes in a hospital-based case-control study. Incident HCC cases (n = 216) were compared with frequency-matched controls (n = 408) with no clinically apparent liver disease. Although the prevalence of variant genotypes was generally low, in multivariable analysis (adjusting for demographic factors, hepatitis B virus, hepatitis C virus, and TP53 status), the GSTM1-null genotype [odds ratio (OR), 2.45; 95% confidence interval (95% CI), 1.21-4.95] and the heterozygote XRCC1-399 AG genotype (OR, 3.18; 95% CI, 1.35-7.51) were significantly associated with HCC. A weak association of the HYL1*2 polymorphism with HCC was observed but did not reach statistical significance. GSTT1 was not associated with HCC. The risk for HCC with null GSTM1 was most prominent among those with the highest groundnut consumption (OR, 4.67; 95% CI, 1.45-15.1) and was not evident among those with less than the mean groundnut intake (OR, 0.64; 95% Cl, 0.20-2.02). Among participants who had all three suspected aflatoxin-related high-risk genotypes [GSTM1 null, HLY1*2 (HY/HH), and XRCC1 (AG/GG)], a significant 15-fold increased risk of HCC was observed albeit with imprecise estimates (OR, 14.7; 95% CI, 1.27-169). Our findings suggest that genetic modulation of carcinogen metabolism and DNA repair can alter susceptibility to HCC and that these effects may be modified by environmental factors.
C1 NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept HHS, Bethesda, MD 20892 USA.
   Gambia Hepatisis Intervent Study, IARC, Banjul, Gambia.
   MRC Labs, Banjul, Gambia.
   Univ Leeds, Mol Epidemiol Unit, Acad Unit Epidemiol & Hlth Serv Res, Leeds, W Yorkshire, England.
   London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
   IARC, Lyon, France.
RP Kirk, GD (reprint author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept HHS, 6120 Execut Blvd,EPS-8003,MSC-7248, Bethesda, MD 20892 USA.
EM kirkg@mail.nih.gov
RI Kirk, Gregory/A-8484-2009; Turner, Paul/A-6152-2011; Hainaut, Pierre
   /B-6018-2012; Turner, Paul/B-8131-2013; Gong, Yun/L-7094-2016
OI Hainaut, Pierre /0000-0002-1303-1610; Gong, Yun/0000-0003-4927-5526
CR ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P426, DOI 10.1016/0035-9203(92)90253-9
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Bian JC, 2000, WORLD J GASTROENTERO, V6, P228
   Chen CJ, 1996, AM J HUM GENET, V59, P128
   Chen SY, 2000, NUTR CANCER, V38, P179, DOI 10.1207/S15327914NC382_6
   Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8
   Egner PA, 2001, P NATL ACAD SCI USA, V98, P14601, DOI 10.1073/pnas.251536898
   FORRESTER LM, 1990, P NATL ACAD SCI USA, V87, P8306, DOI 10.1073/pnas.87.21.8306
   Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513
   Guengerich FP, 1998, MUTAT RES-FUND MOL M, V402, P121, DOI 10.1016/S0027-5107(97)00289-3
   Guengerich FP, 1996, ENVIRON HEALTH PERSP, V104, P557, DOI 10.2307/3432823
   HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421
   Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208
   Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005
   Johnson WW, 1997, CHEM RES TOXICOL, V10, P672, DOI 10.1021/tx960209j
   Johnson WW, 1997, BIOCHEMISTRY-US, V36, P3056, DOI 10.1021/bi962537o
   Kelly EJ, 2002, TOXICOL SCI, V65, P35, DOI 10.1093/toxsci/65.1.35
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   KIRK GD, 2003, WORLD CANC REPORT, P144
   Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882
   Lebailly P, 2002, BRIT J HAEMATOL, V116, P587, DOI 10.1046/j.0007-1048.2001.03320.x
   Lunn RM, 1999, CANCER RES, V59, P2557
   MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384
   McGlynn KA, 2003, CANCER RES, V63, P4594
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   PEMBLE S, 1994, BIOCHEM J, V300, P271
   Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387
   Shen MR, 1998, CANCER RES, V58, P604
   SHIMODA R, 1994, CANCER RES, V54, P3171
   Sonzogni L, 2002, HEPATOLOGY, V36, P195, DOI 10.1053/jhep.2002.33898
   Sun CA, 2001, CARCINOGENESIS, V22, P1289, DOI 10.1093/carcin/22.8.1289
   Tiemersma EW, 2001, CANCER EPIDEM BIOMAR, V10, P785
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   Vall MM, 1990, LANCET, V336, P1107
   Wang HF, 1998, BIOCHEMISTRY-US, V37, P12536, DOI 10.1021/bi980895g
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P555
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   Wild CP, 2002, MUTAGENESIS, V17, P471, DOI 10.1093/mutage/17.6.471
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   Wild CP, 2002, MUTAT RES-FUND MOL M, V499, P3, DOI 10.1016/S0027-5107(01)00290-1
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   Wilson MH, 2000, FASEB J, V14, P791
   Yu MW, 1999, AM J EPIDEMIOL, V149, P621
   Yu MW, 2003, J NATL CANCER I, V95, P1485, DOI 10.1093/jnci/djg051
NR 47
TC 64
Z9 73
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD FEB
PY 2005
VL 14
IS 2
BP 373
EP 379
DI 10.1158/1055-9965.EPI-04-0161
PG 7
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 898ZD
UT WOS:000227113800013
PM 15734960
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Fox, A
   Jeffries, DJ
   Jackson-Sillah, D
   Lugos, MD
   Owiafe, PK
   Donkor, SA
   Hammond, AS
   Corrah, T
   Adegbola, RA
   McAdam, KPWJ
   Brookes, RH
AF Hill, PC
   Fox, A
   Jeffries, DJ
   Jackson-Sillah, D
   Lugos, MD
   Owiafe, PK
   Donkor, SA
   Hammond, AS
   Corrah, T
   Adegbola, RA
   McAdam, KPWJ
   Brookes, RH
TI Quantitative T cell assay reflects infectious load of Mycobacterium
   tuberculosis in an endemic case contact model
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID DELAYED-TYPE HYPERSENSITIVITY; CALMETTE-GUERIN VACCINATION;
   RISK-FACTORS; SKIN-TEST; DIAGNOSIS; RESPONSES; AFRICA; GAMBIA
AB Background. Currently, reliable efficacy markers for assessment of new interventions against tuberculosis (TB) are limited to disease and death. More precise measurement of the human immune response to Mycobacterium tuberculosis infection may be important. A qualitative enzyme-linked immunospot assay (ELISPOT) result for early secretory antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) offers improved specificity over the purified protein derivative (PPD) skin test reaction in the detection of M. tuberculosis infection. We evaluated the quantitative ELISPOT and PPD skin test responses to recent M. tuberculosis exposure.
   Methods. We studied quantitative PPD skin test and PPD ELISPOT results in 1052 healthy household contacts of index patients with cases of sputum smear-positive and culture-positive TB in The Gambia, according to a positive or negative ex vivo interferon gamma ELISPOT response to M. tuberculosis-specific antigens (ESAT-6/CFP-10). We then studied the quantitative PPD skin test and PPD ELISPOT results in patient contacts who had positive ESAT-6/CFP-10 results against a natural exposure gradient according to sleeping proximity to a patient with TB.
   Results. The number of positive results was significantly greater for both PPD skin test and PPD ELISPOT in ESAT-6/CFP-10-positive subjects, compared with others (P<.0001). However, when quantitative PPD skin test P and PPD ELISPOT results were compared in ESAT-6/CFP-10-positive subjects, only the ELISPOT count was sensitive to the exposure gradient, increasing significantly according to exposure (P=.009).
   Conclusions. The quantitative ELISPOT response to PPD in specific-antigen-positive contacts of patients with TB reflects the infectious load of M. tuberculosis as a result of recent exposure. This finding offers new possibilities for assessment of the efficacy of new interventions, and adjustment should be made for it when relating the early immune response to progression to disease.
C1 MRC Labs, TB Div, Banjul, Gambia.
RP Brookes, RH (reprint author), MRC Labs, TB Div, POB 273, Banjul, Gambia.
EM rbrookes@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011
OI Kwasi Owiafe, Patrick/0000-0002-4287-3577
FU Medical Research Council [MC_U190071468]
CR Beggs CB, 2003, INT J TUBERC LUNG D, V7, P1015
   Carrara S, 2004, CLIN INFECT DIS, V38, P754, DOI 10.1086/381754
   Demissie A, 1999, INFECT IMMUN, V67, P5967
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Floyd S, 2002, J INFECT DIS, V186, P807, DOI 10.1086/342416
   GLOVER JA, 1920, MED RES COUNCIL SPEC, V50, P133
   GODKIN AJ, 2000, J IMMUNOL, V169, P2210
   Heifets Leonid B., 1994, P85
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hoft DF, 2000, CLIN INFECT DIS, V30, pS217, DOI 10.1086/313864
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x
   SCHIM, 2003, AIDS, V17, P1841
   2003, NATIONAL LEPROSY TUB
NR 20
TC 51
Z9 56
U1 0
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 15
PY 2005
VL 40
IS 2
BP 273
EP 278
DI 10.1086/427030
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 904JL
UT WOS:000227492400011
PM 15655747
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, EK
   Adegbola, RA
AF Mulholland, EK
   Adegbola, RA
TI Bacterial infections - A major cause of death among children in Africa
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 MRC Labs, Bacterial Dis Programme, Fajara, Gambia.
RP Mulholland, EK (reprint author), Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia.
CR Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   MOSLEY W. H., 1983, POPULI J U N FUND PO, V10, P41
   *WHO, OV CAH CHILD HLTH DE
   [Anonymous], 2004, LANCET, V364, P1555
NR 5
TC 42
Z9 42
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 6
PY 2005
VL 352
IS 1
BP 75
EP 77
DI 10.1056/NEJMe048306
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 884UP
UT WOS:000226112500013
PM 15635117
OA No
DA 2017-08-15
ER

PT J
AU Al-hussein, S
   Palmer, A
   Pappoe, M
   Malenga, G
   Mapunda, P
   Mathanga, D
   Sarr, E
AF Al-hussein, S.
   Palmer, A.
   Pappoe, M.
   Malenga, G.
   Mapunda, P.
   Mathanga, D.
   Sarr, E.
TI Innovation and change in capacity building for malaria control
   [MIM-GM-16300]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 Sch Publ Hlth, Ghana Malaria Ctr, Accra, Ghana.
   Ctr Innovat Malaria, Banjul, Gambia.
   Coll Med, Malaria Alert Ctr, Blantyre, Malawi.
   Ctr Enhancement Effect Malaria Intervent, Dar Es Salaam, Tanzania.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S273
EP S273
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600436
OA No
DA 2017-08-15
ER

PT J
AU Bojang, K
   Jallow, M
   Esangbedo, P
   Milligan, P
   Pinder, M
   Greenwood, B
AF Bojang, K.
   Jallow, M.
   Esangbedo, P.
   Milligan, P.
   Pinder, M.
   Greenwood, B.
TI Chemoprophylaxis with sulfadoxine-pyrimethamine to prevent recurrence of
   anaemia in Gambian children treated previously for this condition
   [MIM-KB-7502]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 MRC Labs, Banjul, Gambia.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S233
EP S233
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600370
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
AF Bojang, K. A.
TI Progress and challenges in the diagnosis of severe malaria
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 [Bojang, K. A.] MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
SU S
BP S50
EP S51
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600076
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
AF Bojang, K. A.
TI Public health campaigns' dilemma: Field experience about malaria control
   in a rural setting, north-western Tanzania [MIM-SN-36540]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 [Bojang, K. A.] MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
SU S
BP S50
EP S50
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600075
OA No
DA 2017-08-15
ER

PT J
AU Conway, D
AF Conway, D.
TI Polymorphic malaria antigens and polyvalent malaria vaccines-A challenge
   for translational research and development [MIM-DC-167760]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 [Conway, D.] MRC Labs, Banjul, Gambia.
   [Conway, D.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S55
EP S55
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600083
OA No
DA 2017-08-15
ER

PT J
AU Dunyo, S
   Sirugo, G
   Adiamo, M
   Sesay, S
   Njie, F
   Jawara, M
   Diatta, M
   Sowe, M
   Cheung, Y
   Milligan, P
AF Dunyo, S.
   Sirugo, G.
   Adiamo, M.
   Sesay, S.
   Njie, F.
   Jawara, M.
   Diatta, M.
   Sowe, M.
   Cheung, Y.
   Milligan, P.
TI Randomized trial of the effectiveness of Lapdap [MIM-FN-13390]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S256
EP S256
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600407
OA No
DA 2017-08-15
ER

PT J
AU Dunyo, S
   Njie, F
   Cheung, Y
   Jawara, M
   Olaose-Bikan, R
   Kaye, P
   Sowe, M
   Kaur, H
   Hallett, R
   Milligan, P
AF Dunyo, S.
   Njie, F.
   Cheung, Y.
   Jawara, M.
   Olaose-bikan, R.
   Kaye, P.
   Sowe, M.
   Kaur, H.
   Hallett, R.
   Milligan, P.
TI Pragmatic trial of the effectiveness of combination treatment for
   uncomplicated malaria [MIM-SD-87789]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 MRC, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S236
EP S237
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600376
OA No
DA 2017-08-15
ER

PT J
AU Hallett, R
   Alexander, N
   Jawara, M
   Ord, R
   Drakeley, C
   Dunyo, S
   Pinder, M
   Milligan, P
   Targett, G
   Sutherland, C
AF Hallett, R.
   Alexander, N.
   Jawara, M.
   Ord, R.
   Drakeley, C.
   Dunyo, S.
   Pinder, M.
   Milligan, P.
   Targett, G.
   Sutherland, C.
TI Transmission of multi-drug resistant Plasmodium falciparum after
   treatment with chloroquine and sulphadoxine-pyrimethamine in The Gambia
   [MIM-RH-22533]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
SU S
BP S347
EP S348
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600559
OA No
DA 2017-08-15
ER

PT J
AU Jawara, A
   Pinder, M
   Drakeley, C
   Nwakanma, D
   Jallow, E
   Bogh, C
   Targett, G
   Lindsay, S
   Dunyo, S
   Conway, D
AF Jawara, A.
   Pinder, M.
   Drakeley, C.
   Nwakanma, D.
   Jallow, E.
   Bogh, C.
   Targett, G.
   Lindsay, S.
   Dunyo, S.
   Conway, D.
TI Dry season ecology of members of the An. gambiae complex in an area of
   The Gambia [MIM-MJ-68152]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 MRC Labs, Fajara, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3HP, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S177
EP S177
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600276
OA No
DA 2017-08-15
ER

PT J
AU Jawara, M
   Nwakanma, D
   Jallow, E
   Dunyo, S
   Con-way, D
AF Jawara, M.
   Nwakanma, D.
   Jallow, E.
   Dunyo, S.
   Con-way, D.
TI Distribution pattern in the dry season of members of the An. gambiae
   complex in an area of The Gambia by PCR identification [MIM-MJ-318080]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 [Jawara, M.; Nwakanma, D.; Jallow, E.; Dunyo, S.; Con-way, D.] MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S176
EP S177
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600275
OA No
DA 2017-08-15
ER

PT J
AU Joof, B
   Palmer, A
   Dawson, A
   Dibba, A
   Yehuenou, S
   Devanney, B
   Ocran, C
   Kasse, Y
   Milligan, P
AF Joof, B.
   Palmer, A.
   Dawson, A.
   Dibba, A.
   Yehuenou, S.
   Devanney, B.
   Ocran, C.
   Kasse, Y.
   Milligan, P.
TI Peer health education for promoting knowledge and practice of malaria
   prevention among school children and their families [MIM-AP-59778]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 Ctr Innovat Malaria, Banjul, Gambia.
   Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   Nova Scotia Gambia Assoc, Banjul, Gambia.
   MRC Labs, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RI Dawson, Angela/A-6872-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S275
EP S275
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600439
OA No
DA 2017-08-15
ER

PT J
AU Missinou, M
   Issifou, S
   Pinder, M
   Agbenyega, T
   Newton, C
   Olola, C
   Valim, C
   Wypij, D
   Taylor, T
   Kremsner, P
AF Missinou, M.
   Issifou, S.
   Pinder, M.
   Agbenyega, T.
   Newton, C.
   Olola, C.
   Valim, C.
   Wypij, D.
   Taylor, T.
   Kremsner, P.
TI A multicenter, prospective study of intraleukocytic and
   intraerythrocytic pigment as prognostic features in African children
   with falciparum malaria [MIM-AM-33336]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
   Univ Tubingen, Inst Trop Med, Dept Parasitol, Tubingen, Germany.
   MRC, Banjul, Gambia.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
   Kwame Nkrumah Univ Sci & Technol, Sch Med, Dept Physiol, Kumasi, Ghana.
   Komfo Anokye Teaching Hosp, Kumasi, Ghana.
   Kenya Med Res Inst KEMRI, Ctr Geog Med Res Coast, Wellcome Trust Res Labs, Kilifi, Kenya.
   Childrens Hosp, Clin Res Program, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   Queen Elizabeth Cent Hosp, Blantyre Malaria Project, Blantyre, Malawi.
   Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
RI Newton, Charles/C-6222-2009
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S51
EP S52
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600078
OA No
DA 2017-08-15
ER

PT J
AU Nery, S
   Mosobo, M
   Marsh, K
   Conway, D
AF Nery, S.
   Mosobo, M.
   Marsh, K.
   Conway, D.
TI Investigating molecular mechanisms of erythrocyte invasion by Plasmodium
   falciparum in Kenya [MIM-SN-45262]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya.
   MRC Labs, Fajara, Gambia.
RI Vaz Nery, Susana/P-4518-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S142
EP S143
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600221
OA No
DA 2017-08-15
ER

PT J
AU Okoko, B
AF Okoko, B.
TI The socioeconomic dimension of cerebral malaria in The Gambia:
   Implication for research and control [MIM-BO-55744]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 [Okoko, B.] Med Res Council Fajara, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S293
EP S293
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600469
OA No
DA 2017-08-15
ER

PT J
AU Olola, C
   Missinou, M
   Issifou, S
   Anane-Sarpong, E
   Pinder, M
   Agbenyega, T
   Kremsner, P
   Newton, C
   Wypij, D
   Taylor, T
AF Olola, C.
   Missinou, M.
   Issifou, S.
   Anane-sarpong, E.
   Pinder, M.
   Agbenyega, T.
   Kremsner, P.
   Newton, C.
   Wypij, D.
   Taylor, T.
TI Medical informatics in medical research: The Severe Malaria in African
   Children (SMAC) Network's Experience [MIM-CO-454800]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 Kenya Med Res Inst CGMRC, Kilifi, Kenya.
   Albert Schweitzer Hosp, Lambarene, Gabon.
   Komfo Anokye Teaching Hosp, Kumasi, Ghana.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
   Queen Elizabeth Cent Hosp, Blantyre, Malawi.
   Childrens Hosp, Boston, MA 02115 USA.
RI Newton, Charles/C-6222-2009
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S60
EP S60
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600092
OA No
DA 2017-08-15
ER

PT J
AU Palmer, A
   Dawson, A
   Jayalashmi, J
   Kasse, Y
   Ceesay, F
   Jagne, M
   Gardner, A
   Fofana, M
   Milligan, P
AF Palmer, A.
   Dawson, A.
   Jayalashmi, J.
   Kasse, Y.
   Ceesay, F.
   Jagne, M.
   Gardner, A.
   Fofana, M.
   Milligan, P.
TI The power of radio [MIM-PM-408460]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 Ctr Innovat Against Malaria, Banjul, Gambia.
   Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.
   JayaMac Prod Ltd, Northampton, England.
   Natl Malaria Control Programme, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect Dis, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S474
EP S474
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600765
OA No
DA 2017-08-15
ER

PT J
AU Pinder, M
   Valim, C
   Bojang, K
   Olola, C
   Agbenyega, T
   Kremsner, P
   Newton, C
   Wypij, D
   Taylor, T
AF Pinder, M.
   Valim, C.
   Bojang, K.
   Olola, C.
   Agbenyega, T.
   Kremsner, P.
   Newton, C.
   Wypij, D.
   Taylor, T.
TI Heterogeneity of severe paediatric malaria in six sites across Africa: A
   prospective, hospital-based cohort study [MIM-MP-305592]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 MRC Labs, Banjul, Gambia.
   Childrens Hosp, Boston, MA 02115 USA.
   Kenya Govt Med Res Ctr, Kilifi, Kenya.
   Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana.
   Albert Schweitzer Hosp, Lambarene, Ghana.
   Michigan State Univ, E Lansing, MI 48824 USA.
RI Newton, Charles/C-6222-2009
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S395
EP S395
PG 1
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600637
OA No
DA 2017-08-15
ER

PT J
AU Thompson, F
   Keating, S
   Berthoud, T
   Imoukhuede, B
   Moorthy, V
   Todryk, S
   Hill, A
AF Thompson, F.
   Keating, S.
   Berthoud, T.
   Imoukhuede, B.
   Moorthy, V.
   Todryk, S.
   Hill, A.
TI Cellular immune responses to several pre-erythrocytic antigens correlate
   with protection from P-falciparum malaria in Gambians [MIM-FT-179394]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   Wellcome Trust Ctr Human Genet, Oxford, England.
RI Keating, Sheila/B-1652-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S14
EP S15
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600021
OA No
DA 2017-08-15
ER

PT J
AU Verra, F
   Chokejindachai, W
   Polley, S
   Marsh, K
   Conway, D
AF Verra, F.
   Chokejindachai, W.
   Polley, S.
   Marsh, K.
   Conway, D.
TI Allele frequency based tests of neutrality on eba-175 and ebl-1 in
   Plasmodium falciparum populations from Kenya and Thailand [MIM-FV-66780]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Mahidol Univ, Fac Trop Med, Bangkok, Thailand.
   Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya.
   MRC Labs, Fajara, Gambia.
RI Polley, Spencer/F-7766-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S146
EP S147
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600228
OA No
DA 2017-08-15
ER

PT J
AU Wiseman, V
   Mcelroy, B
   Conteh, L
   Matovu, F
   Stevens, W
   Mwengee, W
AF Wiseman, V.
   Mcelroy, B.
   Conteh, L.
   Matovu, F.
   Stevens, W.
   Mwengee, W.
TI Household expenditure on mosquito control in The Gambia and Tanzania: An
   analysis of patterns of expenditure and determinants of demand
   [MIM-VW-263010]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 London Sch Hyg & Trop Med, London WC1B 3DP, England.
   Natl Univ Ireland Univ Coll Cork, Dept Econ, Cork, Ireland.
   MRC, Fajara, Gambia.
   Bombo Hosp, Tanga, Tanzania.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S435
EP S436
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600704
OA No
DA 2017-08-15
ER

PT J
AU Wootton, D
   Opara, H
   Dube-Mbeye, Q
   Kanjala, M
   Neate, C
   Kirby, P
   Milligan, P
   Molyneux, M
   Dunyo, S
   Winstanley, P
AF Wootton, D.
   Opara, H.
   Dube-mbeye, Q.
   Kanjala, M.
   Neate, C.
   Kirby, P.
   Milligan, P.
   Molyneux, M.
   Dunyo, S.
   Winstanley, P.
TI A dose-ranging, phase II trial of chlorproguanildapsone with three doses
   of artesunate for the treatment of acute uncomplicated P. falciparum
   malaria [MIM-PK-392880]
SO ACTA TROPICA
LA English
DT Meeting Abstract
C1 MRC Labs, Fajara, Gambia.
   Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
   Coll Med, Blantyre, Malawi.
   Malawi Liverpool Wellcome Trust Clin Res Programm, Liverpool, Merseyside, England.
   GlaxoSmithKline Inc, London, England.
   London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PY 2005
VL 95
BP S189
EP S190
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA V80CY
UT WOS:000205415600297
OA No
DA 2017-08-15
ER

PT J
AU Rayco-Solon, P
   Fulford, AJ
   Prentice, AM
AF Rayco-Solon, P
   Fulford, AJ
   Prentice, AM
TI Differential effects of seasonality on preterm birth and intrauterine
   growth restriction in rural Africans
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE low birth weight; prematurity; intrauterine growth restriction; season;
   developing countries; pregnancy; gestational age; birth weight
ID MALARIA INFECTION; GESTATIONAL-AGE; DIETARY SUPPLEMENTATION; LACTATIONAL
   PERFORMANCE; WEIGHT DISTRIBUTION; PLACENTAL MALARIA; GAMBIAN WOMEN;
   RISK-FACTORS; PREGNANCY; RETARDATION
AB Background: Low birth weight (LBW) can result from prematurity or intrauterine growth restriction (IUGR) and result in small-forgestational-age (SGA) infants. Prematurity and IUGR may have different etiologies and consequences.
   Objective: Our objective was to analyze seasonal patterns of prematurity and SGA in a rural African community and to compare them against variations in nutritional and ecologic variables that may provide insight into likely causative factors.
   Design: Fourier series were used to compare the seasonality of prematurity (<37 wk) and SGA (<10th percentile of the reference standard) among 1916 live infants born over 26 y in 3 Gambian villages. The resultant patterns were compared against monthly variations in birth frequency, maternal energy status, maternal work, and malaria infections.
   Results: The incidence of LBW was 13.3%, of prematurity was 12.3%, and of SGA was 25.1 %. Prematurity and SGA showed divergent patterns of seasonality. Incidence of SGA was highest at the end of the annual hungry season, from August to December (peaking in November at 30.6%), with a nadir of 12.9% in June. Rates of SGA varied inversely with maternal weight changes. This pattern was not seen for rates of prematurity, which showed 2 peaks-in July (17.2%) and October (13.9%). The lowest proportion of preterm births occurred in February (5.1 %). The peaks in prematurity closely paralleled increases in agricultural labor (July) and malaria infections (October).
   Conclusion: We conclude that a reduction in LBW in such communities may require multiple interventions because of the variety of precipitating factors.
C1 Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Rayco-Solon, P (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, Keppel St, London WC1E 7HT, England.
EM pura.solon@lshtm.ac.uk
CR Armson B Anthony, 2003, J Obstet Gynaecol Can, V25, P209
   Balaka B, 2002, B SOC PATHOL EXOT, V95, P280
   BANTJE H, 1983, J TROP PEDIATRICS, V29, P50
   BARROS FC, 1992, PEDIATRICS, V90, P238
   BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   Bloomfield FH, 2003, SCIENCE, V300, P606, DOI 10.1126/science.1080803
   BRANCA F, 1993, EUR J CLIN NUTR, V47, P840
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Cole T. J., 1993, SEASONALITY HUMAN EC
   DAlessandro U, 1996, T ROY SOC TROP MED H, V90, P487, DOI 10.1016/S0035-9203(96)90289-8
   deOnis M, 1996, AM J CLIN NUTR, V64, P650
   Dorman EK, 2002, ULTRASOUND OBST GYN, V19, P165, DOI 10.1046/j.0960-7692.2001.00545.x
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Escriba-Aguir V, 2001, INT ARCH OCC ENV HEA, V74, P583
   FRISCH RE, 1990, BAILLIERE CLIN OB GY, V4, P419, DOI 10.1016/S0950-3552(05)80302-5
   FRISCH RE, 1980, FED PROC, V39, P2395
   Kaushik S L, 1998, Indian J Pediatr, V65, P429, DOI 10.1007/BF02761138
   KINABO J, 1993, E AFR MED J, V70, P752
   KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663
   KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574
   Kramer MS, 2000, COCHRANE DB SYST REV
   KRAMER MS, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000032
   LAWRENCE M, 1988, EUR J CLIN NUTR, V42, P145
   Lima M, 1999, INT J EPIDEMIOL, V28, P469, DOI 10.1093/ije/28.3.469
   Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459
   Marin CM, 1996, T ROY SOC TROP MED H, V90, P442, DOI 10.1016/S0035-9203(96)90541-6
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449
   Moutquin JM, 2003, BJOG-INT J OBSTET GY, V110, P56, DOI 10.1016/S1470-0328(03)00031-4
   NOORDEEN SK, 1995, B WORLD HEALTH ORGAN, V73, P1
   Okoko BJ, 2002, J HEALTH POPUL NUTR, V20, P4
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   PRENTICE AM, 1980, LANCET, V2, P886
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   ROBERTS SB, 1982, T ROY SOC TROP MED H, V76, P668, DOI 10.1016/0035-9203(82)90239-5
   Rousham EK, 1998, AUST NZ J PUBL HEAL, V22, P669, DOI 10.1111/j.1467-842X.1998.tb01467.x
   Simchen MJ, 2000, AM J PERINAT, V17, P187, DOI 10.1055/s-2000-9423
   Sirima SB, 2003, CLIN INFECT DIS, V36, P1374, DOI 10.1086/375077
   Steketee RW, 1996, AM J TROP MED HYG, V55, P33
   Sullivan AD, 1999, J INFECT DIS, V179, P1580, DOI 10.1086/314752
   SUSSER M, 1991, AM J CLIN NUTR, V53, P1384
   WATKINSON M, 1983, BRIT MED J, V287, P251
   WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624
   Zeitlin JA, 2001, AM J OBSTET GYNECOL, V185, P208, DOI 10.1067/mob.2001.114869
   ZELLNER A, 1962, J AM STAT ASSOC, V57, P348, DOI 10.2307/2281644
NR 45
TC 76
Z9 76
U1 3
U2 11
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JAN
PY 2005
VL 81
IS 1
BP 134
EP 139
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 886VC
UT WOS:000226259800022
PM 15640472
OA No
DA 2017-08-15
ER

PT J
AU Mboto, CI
   Davies-Russell, A
   Fielder, M
   Jewell, AP
AF Mboto, CI
   Davies-Russell, A
   Fielder, M
   Jewell, AP
TI Hepatitis C antibodies in asymptomatic first-time blood donors in The
   Gambia: prevalence and risk factors
SO BRITISH JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE blood donors; hepatitis C; risk factors; The Gambia
ID NON-B-HEPATITIS; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; SEXUAL
   TRANSMISSION; NATURAL-HISTORY; NON-A; EPIDEMIOLOGY; PARTNERS; DISEASES;
   AFRICA
AB This study evaluates the seroprevalence and risk factors for hepatitis C (HCV) antibodies in asymptomatic first-time blood donors in The Gambia. The study population includes 460 blood donors (age range: 18-40 years [mean: 27.5]) who attended the Royal Victoria Teaching Hospital from July to December 2002. Antibodies to hepatitis C are determined using and enzyme-linked immunosorbent assay (ELISA) test system. The prevalence of hepatitis C found in this study was 1.1% (95% Cl, 0.16-1.12). Previous history of sexually transmitted disease, married men in polygamous relationships, and hospital or clinic-based workers were determined to be at risk of acquiring hepatitis C. The study shows that seroprevalence of hepatitis C in The Gambia is low compared to other countries in the region.
C1 Kingston Univ, Sch Life Sci, Kingston upon Thames KT1 2EE, Surrey, England.
   Royal Victoria Hosp, Banjul, Gambia.
RP Kingston Univ, Sch Life Sci, Penrhyn Rd, Kingston upon Thames KT1 2EE, Surrey, England.
EM a.jewell@kingston.ac.uk
CR AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901
   ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702
   ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201
   Ampofo W, 2002, J CLIN MICROBIOL, V40, P3523, DOI 10.1128/JCM.40.9.3523-3525.2002
   BRETTLER DB, 1992, BLOOD, V80, P540
   Candotti D, 2003, J VIROL, V77, P7914, DOI 10.1128/JVI.77.14.7914-7923.2003
   COURSAGET P, 1992, T ROY SOC TROP MED H, V86, P552, DOI 10.1016/0035-9203(92)90107-N
   Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339
   Fathalla SE, 2003, SAUDI MED J, V24, pS120
   GABRIELLI C, 1994, J INFECTION, V29, P17, DOI 10.1016/S0163-4453(94)94952-2
   Halim NKD, 2000, E AFR MED J, V77, P410
   HALLAM NF, 1993, J MED VIROL, V40, P251, DOI 10.1002/jmv.1890400315
   HASAN F, 1990, HEPATOLOGY, V12, P589, DOI 10.1002/hep.1840120323
   Hassan MM, 2001, J CLIN GASTROENTEROL, V33, P123, DOI 10.1097/00004836-200108000-00006
   Kao JH, 1996, AM J GASTROENTEROL, V91, P2087
   Kassem AS, 2000, J TROP PEDIATRICS, V46, P231, DOI 10.1093/tropej/46.4.231
   KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467
   MacDonald M, 1996, EPIDEMIOL REV, V18, P137
   Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5
   Maida MJ, 2000, EUR J EPIDEMIOL, V16, P1183, DOI 10.1023/A:1010920426795
   Mele A, 1999, J MED VIROL, V57, P111, DOI 10.1002/(SICI)1096-9071(199902)57:2<111::AID-JMV4>3.0.CO;2-C
   Montalto G, 2002, ANN NY ACAD SCI, V963, P13
   NDUMBE PM, 1993, SCAND J INFECT DIS, V25, P689, DOI 10.3109/00365549309008564
   Ola S O, 2002, West Afr J Med, V21, P215
   Scotto G, 1996, EUR J EPIDEMIOL, V12, P241, DOI 10.1007/BF00145412
   Stauber R, 2000, Wien Med Wochenschr, V150, P460
   Terrault NA, 2002, HEPATOLOGY, V36, pS99, DOI 10.1053/jhep.2002.36797
   Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506
   Wejstal R, 1999, J HEPATOL, V31, P92, DOI 10.1016/S0168-8278(99)80382-1
NR 29
TC 3
Z9 4
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0967-4845
J9 BRIT J BIOMED SCI
JI Br. J. Biomed. Sci.
PY 2005
VL 62
IS 2
BP 89
EP 91
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 939PT
UT WOS:000230085600007
PM 15997884
OA No
DA 2017-08-15
ER

PT J
AU Payne, RB
   Barlow, CR
   Balakrishnan, CN
   Sorenson, MD
AF Payne, RB
   Barlow, CR
   Balakrishnan, CN
   Sorenson, MD
TI Song mimicry of Black-bellied Firefinch Lagonosticta rara and other
   finches by the brood-parasitic Cameroon Indigobird Vidua camerunensis in
   West Africa
SO IBIS
LA English
DT Article
ID SPECIES ASSOCIATIONS; CHALYBEATA; ORIGIN
AB Brood-parasitic finches Vidua spp. mimic songs of their foster species, with most Vidua species both mimicking songs and parasitizing nests of a single estrildid finch species. We describe a behavioural radiation in the Cameroon Indigobird Vidua camerunensis. Local populations are polymorphic in behaviour, each male mimicking songs of a single species, with certain males mimicking songs of one species and other males mimicking songs of another host species. The species most often mimicked in song are Black-bellied Firefinch Lagonosticta rara and African Firefinch L. rubricata; other species mimicked in song are Brown Twinspot Clytospiza monteiri and Dybowski's Twinspot Euschistospiza dybowskii. Indigobirds in the different mimicry song populations do not differ morphologically in plumage colour or size. The lack of morphological differences between male indigobirds with different mimicry songs is consistent with a recent behavioural radiation through host shifts, perhaps facilitated by environmental change associated with prehistoric cultivation of grain. The mimicry song populations of indigobirds, behaviourally imprinted upon different host species, support the idea of a process of speciation driven by a shift to new host species.
C1 Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.
   Birds Gambia, Banjul, Gambia.
   Boston Univ, Dept Biol, Boston, MA 02215 USA.
RP Payne, RB (reprint author), Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA.
EM rbpayne@umich.edu
RI Sorenson, Michael/D-8065-2011; Balakrishnan, Christopher/A-3043-2014
OI Sorenson, Michael/0000-0001-5375-2917; Balakrishnan,
   Christopher/0000-0002-0788-0659
CR Avise J. C., 2004, MOL MARKERS NATURAL
   CHAPIN JP, 1954, B AM MUS NAT HIST B, V75
   Chappuis C., 2000, OISEAUX AFRIQUE AFRI
   Elgood J.H., 1994, BIRDS NIGERIA
   FIELD GD, 1968, BIRDS FREETOWN AREA
   Goodwin D., 1982, ESTRILDID FINCHES WO
   IMMELMANN KJ, 1965, PRACHTFINKEN, V1
   Irvine F.R., 1969, W AFRICAN AGR, V2
   KLEIN NK, 1998, EVOLUTION, V52, P299
   MOREL MY, 1973, MEM MUS NAT HIST N A, V78
   National Research Council, 1996, LOST CROPS AFR, VI
   NEUMANN K., 1999, EXPLOITATION PLANT R, P73
   Nicolai J., 1964, Zeitschrift fuer Tierpsychologie, V21, P129
   NICOLAI J, 1972, Journal fuer Ornithologie, V113, P229, DOI 10.1007/BF01647506
   NICOLAI J, 1968, NATURWISSENSCHAFTEN, V53, P654
   Nikolaus Gerhard, 2000, Malimbus, V22, P1
   PAYNE R B, 1990, Vogelwarte, V35, P321
   Payne RB, 2000, ANIM BEHAV, V59, P69, DOI 10.1006/anbe.1999.1283
   Payne RB, 1998, ANIM BEHAV, V55, P1537, DOI 10.1006/anbe.1997.0701
   PAYNE RB, 1985, Z TIERPSYCHOL, V70, P1
   Payne RB, 2002, EVOLUTION OF BEGGING: COMPETITION, COOPERATION AND COMMUNICATION, P429, DOI 10.1007/0-306-47660-6_22
   Payne RB, 2002, IBIS, V144, P373, DOI 10.1046/j.1474-919X.2002.00065.x
   Payne RB, 2001, ANIM BEHAV, V62, P473, DOI 10.1006/anbe.2001.1773
   Payne RB, 2000, ETHOLOGY, V106, P261, DOI 10.1046/j.1439-0310.2000.00528.x
   PAYNE RB, 1994, IBIS, V136, P291, DOI 10.1111/j.1474-919X.1994.tb01098.x
   Payne RB, 1995, AUK, V112, P649
   PAYNE RB, 1982, MISC PUBL U MICH MUS, V162
   PAYNE RB, 1993, P PAN AFRICAN ORNITH, V13, P40
   PAYNE RB, 1973, ORNITHOL MONOGR, V11
   Payne Robert B., 1998, Ibis, V140, P368
   Purseglove J.W., 1972, TROPICAL CROPS MONOC
   Serle W., 1957, Ibis, V99, P371, DOI 10.1111/j.1474-919X.1957.tb01958.x
   Serle W, 1957, IBIS, V99, P628, DOI 10.1111/j.1474-919X.1957.tb03056.x
   Sorenson MD, 2002, INTEGR COMP BIOL, V42, P388, DOI 10.1093/icb/42.2.388
   Sorenson MD, 2004, SYST BIOL, V53, P140, DOI 10.1080/10635150490265021
   Sorenson MD, 2003, NATURE, V424, P928, DOI 10.1038/nature01863
   Sorenson MD, 2001, EVOLUTION, V55, P2550
NR 37
TC 10
Z9 10
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-1019
J9 IBIS
JI Ibis
PD JAN
PY 2005
VL 147
IS 1
BP 130
EP 143
DI 10.1111/j.1474-919x.2004.00378.x
PG 14
WC Ornithology
SC Zoology
GA 889XT
UT WOS:000226476900012
OA No
DA 2017-08-15
ER

PT J
AU West, ES
   Munoz, B
   Mkocha, H
   Holland, MJ
   Aguirre, A
   Solomon, AW
   Bailey, R
   Foster, A
   Mabey, D
   West, SK
AF West, ES
   Munoz, B
   Mkocha, H
   Holland, MJ
   Aguirre, A
   Solomon, AW
   Bailey, R
   Foster, A
   Mabey, D
   West, SK
TI Mass treatment and the effect on the load of Chlamydia trachomatis
   infection in a trachoma-hyperendemic community
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID EPIDEMIOLOGY; AZITHROMYCIN; TANZANIA; CHILDREN
AB PURPOSE. Trachoma remains a leading cause of blindness. Determining the most effective antibiotic treatment strategy is essential for the success of country-based trachoma control programs.
   METHODS. Baseline and 2-month follow-up examinations were performed in a trachoma-hyperendemic village. All residents were offered azithromycin for trachoma after baseline was determined. Infection with Chlamydia trachomatis and chlamydial load were determined by PCR. Clinical trachoma status was evaluated. A high chlamydial load was defined as a higher than median chlamydial load among those with infection. Risk factors were examined in multiple logistic regression models. Associations are presented as odds ratios and 95% confidence intervals.
   RESULTS. At baseline, 57% of participants were infected with C. trachomatis. Although clinical trachoma correlated with infection, 23% of participants with high chlamydial loads showed no clinical signs. Adults represented only 10% of the population with high loads. Treatment significantly decreased the proportion positive in the community and the load in the community. However, 27% of individuals with high loads at baseline who received treatment also were infected at 2 months. Of those, 93% with high loads at 2 months were aged less than or equal to 10 years.
   CONCLUSIONS. Although most of the chlamydial load in this community resided in children, 10% of the high load resided in adults, most of whom did not have follicular trachoma and in whom the infection would be missed under treatment strategies that focus on clinical disease or children. These data support a mass treatment strategy for hyperendemic communities, at least as a first approach. In addition, treatment of children age less than or equal to 2 years should be reexamined, as > 30% with high loads at baseline remained infected at 2 months, despite monitored treatment according to weight.
C1 Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   Kongwa Trachoma Project, Kongwa, Tanzania.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Fajara, Gambia.
RP West, ES (reprint author), Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Wilmer Room 121,600 N Wolfe St, Baltimore, MD 21205 USA.
EM ewest@jhsph.edu
RI Gower, Emily/A-9688-2009
OI Mabey, David/0000-0002-0031-8276; Solomon, Anthony/0000-0001-7101-6649
FU Medical Research Council [MC_U190081961]
CR BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Frick KD, 2001, B WORLD HEALTH ORGAN, V79, P201
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Melese M, 2004, JAMA-J AM MED ASSOC, V292, P721, DOI 10.1001/jama.292.6.721
   Munoz B, 2003, INVEST OPHTH VIS SCI, V44, P1464, DOI 10.1167/iovs.02-0234
   Munoz B, 1999, INT J EPIDEMIOL, V28, P1167, DOI 10.1093/ije/28.6.1167
   Negrel AD, 1998, INT J ANTIMICROB AG, V10, P259
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   WEST SK, 1991, J INFECT DIS, V163, P752
   World Health Organization, 1998, WHO 51 WORLD HLTH AS
NR 14
TC 52
Z9 52
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2005
VL 46
IS 1
BP 83
EP 87
DI 10.1167/iovs.04-0327
PG 5
WC Ophthalmology
SC Ophthalmology
GA 889UV
UT WOS:000226469100014
PM 15623758
OA No
DA 2017-08-15
ER

PT J
AU Awomoyi, AA
   Charurat, M
   Marchant, A
   Miller, EN
   Blackwell, JM
   McAdam, KPWJ
   Newport, MJ
AF Awomoyi, AA
   Charurat, M
   Marchant, A
   Miller, EN
   Blackwell, JM
   McAdam, KPWJ
   Newport, MJ
TI Polymorphism in IL1B-ILIB-511 association with tuberculosis and
   decreased lipopolysaccharide-induced IL-1 beta in IFN-gamma primed
   ex-vivo whole blood assay
SO JOURNAL OF ENDOTOXIN RESEARCH
LA English
DT Article
DE IL1B polymorphism; interleukin-1b; tuberculosis; ex-vivo whole blood
   assay
ID INTERLEUKIN-1 RECEPTOR ANTAGONIST; TUMOR-NECROSIS-FACTOR; PULMONARY
   TUBERCULOSIS; GENE POLYMORPHISM; DISEASE; CELLS; IL-1; SUSCEPTIBILITY;
   EXPRESSION; SEQUENCE
AB To determine whether variation in two interleukin 1 family genes (IL1B and interleukin 1 receptor antagonist, IL1RN) is associated with pulmonary tuberculosis (TB), two published polymorphisms at nucleotide positions -511 and +3953 in IL1B and one in the IL1RN 86 bp VNTR were genotyped in 335 smear positive Gambian TB patients, and 298 ethnically matched controls. All individuals were HIV negative. Decreased risk of pulmonary TB was associated with both heterozygosity and homozygosity for the IL1B-511-C allele (OR 0.66, P = 0.027, and OR 0.58, P = 0.015, respectively). Nonetheless, the C allele was present at a frequency of 0.66 in TB cases suggesting that whilst IL-1 beta contributes to disease susceptibility, it is not the major factor. There was no association between the IL1B+3953-T/C polymorphism or the 86 bp IL1RN pentallelic repeat and TI3 in this population. Using an ex-vivo whole blood assay, healthy Gambian individuals who are homozygous for the IL1B-511-T allele failed to exhibit a significant increase in IL-1 beta production in response to LPS after IFN-gamma priming.
C1 Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   MRC Labs, Banjul, Gambia.
   Univ Maryland Biotechnol Inst, Inst Human Virol, Baltimore, MD USA.
   Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Cambridge, England.
   Brighton & Sussex Med Sch, Dept Med, Brighton, E Sussex, England.
RP Awomoyi, AA (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, 655 W Baltimore St 13-009, Baltimore, MD 21201 USA.
EM aawomoyi@som.umaryland.edu
RI Blackwell, Jenefer/H-3015-2015
FU Wellcome Trust
CR Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   Bellamy R., 1998, Tubercle and Lung Disease, V79, P83, DOI 10.1054/tuld.1998.0009
   BLAKEMORE AIF, 1995, J CLIN ENDOCR METAB, V80, P111, DOI 10.1210/jc.80.1.111
   BLAKEMORE AIF, 1994, ARTHRITIS RHEUM, V37, P1380, DOI 10.1002/art.1780370917
   BLAND JM, 1995, BRIT MED J, V310, P170
   CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897
   Clay JS, 2001, CLASSICAL WORLD, V94, P407, DOI 10.2307/4352607
   CRUSIUS JBA, 1995, LANCET, V346, P979, DOI 10.1016/S0140-6736(95)91607-5
   DANIS VA, 1995, CLIN EXP IMMUNOL, V99, P303
   Dinarello CA, 2000, NEW ENGL J MED, V343, P732, DOI 10.1056/NEJM200009073431011
   Dinarello CA, 1996, BLOOD, V87, P2095
   El-Omar EM, 2001, NATURE, V412, P99, DOI 10.1038/35083631
   Hamajima N, 2001, JPN J CANCER RES, V92, P383
   HUNTER CA, 1995, J IMMUNOL, V155, P4347
   Juffermans NP, 2000, J INFECT DIS, V182, P902, DOI 10.1086/315771
   MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637
   Newport MJ, 2004, TUBERCULOSIS, V84, P347, DOI 10.1016/j.tube.2004.02.001
   Nicklin MJH, 2002, GENOMICS, V79, P718, DOI 10.1006/geno.2002.6751
   POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x
   Read RC, 2000, J INFECT DIS, V182, P1557, DOI 10.1086/315889
   Sambrook J., 1989, MOL CLONING LAB MANU, V2
   SICA A, 1990, J IMMUNOL, V144, P3034
   TARLOW JK, 1993, HUM GENET, V91, P403
   Tsao TCY, 2000, CHEST, V117, P103, DOI 10.1378/chest.117.1.103
   Tsukada J, 2000, BLOOD, V95, P2715
   Wilkinson RJ, 1999, J EXP MED, V189, P1863, DOI 10.1084/jem.189.12.1863
   Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200
NR 27
TC 28
Z9 28
U1 0
U2 2
PU MANEY PUBLISHING
PI LEEDS
PA HUDSON RD, LEEDS LS9 7DL, ENGLAND
SN 0968-0519
J9 J ENDOTOXIN RES
JI J. Endoxtin Res.
PY 2005
VL 11
IS 5
BP 281
EP 286
DI 10.1179/096805105X58706
PG 6
WC Biochemistry & Molecular Biology; Immunology; Medicine, Research &
   Experimental; Microbiology
SC Biochemistry & Molecular Biology; Immunology; Research & Experimental
   Medicine; Microbiology
GA 983PI
UT WOS:000233244200003
PM 16263000
OA No
DA 2017-08-15
ER

PT B
AU Gomez, B
AF Gomez, B
BE Sivakumar, MVK
   Motha, RP
   Das, HP
TI Degradation of vegetation and agricultural productivity due to natural
   disasters and land use strategies to mitigate their impacts on
   agriculture, rangelands and forestry
SO Natural Disasters and Extreme Events in Agriculture: Impacts and
   Mitigation
LA English
DT Proceedings Paper
CT Meeting on Natural Disasters and Extreme Events in Agriculture
CY FEB 16-20, 2004
CL Beijing, PEOPLES R CHINA
AB Natural disasters are known to cause severe economic losses and in many developing countries in the form of decline in agricultural production, destruction of food reserves, damage to water supplies, etc. This report focuses on land use strategies to mitigate natural disasters including tropical storms, floods, droughts, dust storms and sand storms, frosts, volcanoes, landslides, bush, and forest fires. It is important that disaster preparedness and prevention projects are built into a wider development strategy. Mitigation efforts need an integrated and concerted action by all the agencies concerned. Long term disaster reduction efforts should aim at promoting appropriate land-use in the disaster-prone areas, by harmonizing land suitability with agricultural development strategies.
C1 Dept Water Resources, Banjul, Gambia.
RP Gomez, B (reprint author), Dept Water Resources, Banjul, Gambia.
CR ADAMENKO TI, 2003, AGROMEOROLOGY RELATE
   ANDREWS PL, 1995, S FIR WILD PARK MAN, P149
   DAS HP, 2003, AGROMETEOROLOGY RELA
   DAS HP, 1995, INCIDENCE IMPACT MON
   KULIK MS, 1957, ESTIMATION EFECTS DR
   MOLGA M, 1962, AGR MET CENTRALNY I
   Pyne S. J., 1996, INTRO WILDLAND FIRE, P769
NR 7
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
BN 3-540-22490-4
PY 2005
BP 259
EP 276
DI 10.1007/3-540-28307-2_15
PG 18
WC Agriculture, Multidisciplinary; Environmental Sciences; Meteorology &
   Atmospheric Sciences
SC Agriculture; Environmental Sciences & Ecology; Meteorology & Atmospheric
   Sciences
GA BCY55
UT WOS:000231871100015
OA No
DA 2017-08-15
ER

PT J
AU Barnett, L
AF Barnett, L
TI The Darwin Field Station, The Gambia
SO ORYX
LA English
DT News Item
C1 Makasutu Wildlife Trust, Serrekunda, Gambia.
RP Barnett, L (reprint author), Makasutu Wildlife Trust, POB 2164, Serrekunda, Gambia.
EM drumohq@qanet.gm
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA
SN 0030-6053
J9 ORYX
JI Oryx
PD JAN
PY 2005
VL 39
IS 1
BP 15
EP 16
PG 2
WC Ecology
SC Environmental Sciences & Ecology
GA 896RN
UT WOS:000226951300007
OA No
DA 2017-08-15
ER

PT J
AU Jallow, S
   Kaye, S
   Alabi, A
   Aveika, A
   McConkey, S
   Rowland-Jones, S
   Janssens, W
AF Jallow, Sabelle
   Kaye, Steve
   Alabi, Abraham
   Aveika, Akum
   McConkey, Samuel
   Rowland-Jones, Sarah
   Janssens, Wouter
TI Anti-retroviral therapy (ART) monitoring and the development of the
   oligonucleotide ligation assay for detecting critical drug-resistant
   mutations in HIV-2 patients in preparation of the global fund initiative
   in the Gambia
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Jallow, Sabelle; Janssens, Wouter] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Jallow, Sabelle; Kaye, Steve; Alabi, Abraham; Aveika, Akum; McConkey, Samuel; Rowland-Jones, Sarah] MRC, Banjul, Gambia.
EM sjallow@itg.be
RI McConkey, Samuel/E-7307-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2005
VL 2
SU 1
AR S134
DI 10.1186/1742-4690-2-S1-S134
PG 1
WC Virology
SC Virology
GA V52KE
UT WOS:000203541600202
OA gold
DA 2017-08-15
ER

PT J
AU Aryee, EAN
   Bailey, RL
   Natividad-Sancho, A
   Kaye, S
   Holland, MJ
AF Aryee, Esther A. N.
   Bailey, Robin L.
   Natividad-Sancho, Angels
   Kaye, Steve
   Holland, Martin J.
TI Detection, quantification and genotyping of Herpes Simplex Virus in
   cervicovaginal secretions by real-time PCR: a cross sectional survey
SO VIROLOGY JOURNAL
LA English
DT Article
AB Background: Herpes Simplex Virus (HSV) Genital Ulcer Disease (GUD) is an important public health problem, whose interaction with HIV results in mutually enhancing epidemics. Conventional methods for detecting HSV tend to be slow and insensitive. We designed a rapid PCR-based assay to quantify and type HSV in cervicovaginal lavage (CVL) fluid of subjects attending a Genito-Urinary Medicine (GUM) clinic. Vaginal swabs, CVL fluid and venous blood were collected. Quantitative detection of HSV was conducted using real time PCR with HSV specific primers and SYBR Green I. Fluorogenic TaqMan Minor Groove Binder (MGB) probes designed around a single base mismatch in the HSV DNA polymerase I gene were used to type HSV in a separate reaction. The Kalon test was used to detect anti-HSV-2 IgG antibodies in serum. Testing for HIV, other Sexually Transmitted Infections (STI) and related infections was based on standard clinical and laboratory methods.
   Results: Seventy consecutive GUM clinic attendees were studied. Twenty-seven subjects (39%) had detectable HSV DNA in CVL fluid; HSV-2 alone was detected in 19 (70%) subjects, HSV-1 alone was detected in 4 (15%) subjects and both HSV types were detected in 4 (15%) subjects. Eleven out of 27 subjects (41%) with anti-HSV-2 IgG had detectable HSV-2 DNA in CVL fluid. Seven subjects (10%) were HIV-positive. Three of seven (43%) HIV-infected subjects and two of five subjects with GUD (40%) were secreting HSV-2. None of the subjects in whom HSV-1 was detected had GUD.
   Conclusion: Quantitative real-time PCR and Taqman MGB probes specific for HSV-1 or -2 were used to develop an assay for quantification and typing of HSV. The majority of subjects in which HSV was detected had low levels of CVL fluid HSV, with no detectable HSV-2 antibodies and were asymptomatic.
C1 [Aryee, Esther A. N.; Bailey, Robin L.; Kaye, Steve; Holland, Martin J.] MRC Labs, Fajara, Gambia.
   [Bailey, Robin L.; Natividad-Sancho, Angels; Holland, Martin J.] London Sch Hyg & Trop Med, London WC1, England.
RP Holland, MJ (reprint author), MRC Labs, Fajara, Gambia.
EM earyee@mrc.gm; Robin.Bailey@lshtm.ac.uk;
   Angels.Natividad-Sancho@lshtm.ac.uk; skaye@mrc.gm;
   Martin.Holland@lshtm.ac.uk
FU MRC training committee; MRC UK
FX The study was supported by funds from the MRC training committee and
   grants from the MRC UK. Finally we thank the study participants.
CR Afonina I, 1997, NUCLEIC ACIDS RES, V25, P2657, DOI 10.1093/nar/25.13.2657
   Aldea C, 2002, J CLIN MICROBIOL, V40, P1060, DOI 10.1128/JCM.40.3.1060-1062.2002
   ASHLEY RL, 1993, GENITOURIN MED, V69, P174
   Austin H, 1999, SEX TRANSM DIS, V26, P329, DOI 10.1097/00007435-199907000-00004
   Auvert B, 2001, AIDS, V15, P885, DOI 10.1097/00002030-200105040-00009
   Baker DA, 1999, OBSTET GYNECOL, V94, P103, DOI 10.1016/S0029-7844(99)00239-2
   Burrows J, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-12
   Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144
   GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008
   Gwanzura L, 1998, J INFECT DIS, V177, P481
   Halton K, 2003, AIDS, V17, P97, DOI 10.1097/01.aids.0000042937.55529.05
   Kinghorn GR, 1999, HERPES, V6, P4
   KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009
   KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305
   Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655
   Liew M, 2004, CLIN CHEM, V50, P1156, DOI 10.1373/clinchem.2004.032136
   Mbopi-Keou FX, 2000, J INFECT DIS, V182, P1090, DOI 10.1086/315836
   MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007
   Morrow RA, 2003, J CLIN MICROBIOL, V41, P5212, DOI 10.1128/JCM.41.11.5212-5214.2003
   Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19
   O'Farrell N, 1999, SEX TRANSM INFECT, V75, P377
   Obasi A, 1999, J INFECT DIS, V179, P16, DOI 10.1086/314555
   Ramaswamy M, 2004, SEX TRANSM INFECT, V80, P406, DOI 10.1136/sti.2003.008201
   Scoular A, 2002, SEX TRANSM INFECT, V78, P21, DOI 10.1136/sti.78.1.21
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   Stevenson J, 2005, J CLIN MICROBIOL, V43, P2391, DOI 10.1128/JCM.43.5.2391-2398.2005
   TSURUMI T, 1987, GENE, V52, P129
   Tyring SK, 1998, ARCH DERMATOL, V134, P185, DOI 10.1001/archderm.134.2.185
   Tyring SK, 2002, J INFECT DIS, V186, pS40, DOI 10.1086/342966
   Van Dyck E, 2004, J CLIN MICROBIOL, V42, P2961, DOI 10.1128/JCM.42.7.2961-2965.2004
   WAGNER HU, 1994, INT J STD AIDS, V5, P332
   Wald A, 1996, ANN INTERN MED, V124, P8
   Wald Anna, 2004, Herpes, V11 Suppl 3, p130A
   Ye S, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.17.e88
NR 34
TC 14
Z9 16
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PY 2005
VL 2
AR 61
DI 10.1186/1743-422X-2-61
PG 10
WC Virology
SC Virology
GA V26AR
UT WOS:000208519000061
PM 16095535
OA gold
DA 2017-08-15
ER

PT J
AU Scott, S
   Mossong, J
   Moss, WJ
   Cutts, FT
   Kasolo, F
   Sinkala, M
   Cousens, S
AF Scott, S
   Mossong, J
   Moss, WJ
   Cutts, FT
   Kasolo, F
   Sinkala, M
   Cousens, S
TI Estimating the force of measles virus infection from hospitalised cases
   in Lusaka, Zambia
SO VACCINE
LA English
DT Article
DE measles; force of infection; measles vaccination
ID EAST-AFRICA; VACCINATION; CHILDREN; COVERAGE; ENGLAND; RUBELLA; WALES;
   RATES
AB Estimates of the force of infection (the rate at which susceptible individuals acquire infection) are essential for modelling the transmission dynamics of infectious diseases and can be a useful toot in evaluating mass vaccination strategies. Few estimates exist of the force of infection of measles virus in sub-Saharan Africa. A mathematical model was applied to age-specific recorded hospital admissions between September 1996 and September 1999 to estimate the force of measles virus infection in Lusaka, Zambia. The average force of infection was estimated to be 20% per year (95% confidence intervals (CI) 16.5, 23.5) which was insensitive to varying assumptions about vaccine coverage. The force of infection varied from year to year (P < 0.001) reflecting the cyclic pattern of measles incidence. The estimated probability of a case being hospitalised decreased with age, consistent with less severe disease in older children. Estimates of the force of infection using routinely available data were consistent with those based upon serological surveys in other sub-Saharan African countries. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Ctr Rech Publ Sante, Luxembourg, Luxembourg.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD USA.
   MRC Labs, Banjul, Gambia.
   Univ Teaching Hosp, Virol Lab, Lusaka, Zambia.
   Lusaka Dist Hlth Management Team, Lusaka, Zambia.
RP Scott, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM Susana.Scott@lshtin.ac.uk
RI Mossong, Joel/D-4998-2009
OI Mossong, Joel/0000-0003-0717-9835
CR ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259
   ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839
   ATKINSON WL, 1991, SEMIN PEDIATR INFECT, V2, P100
   BURSTROM B, 1995, E AFR MED J, V72, P155
   Caceres VM, 2000, CLIN INFECT DIS, V31, P110, DOI 10.1086/313926
   Central Statistical Office (Zambia) Ministry of Health (Zambia) Macro International Inc, 1997, ZAMB DEM HLTH SURV 1
   Cutts FT, 1999, VACCINE, V17, pS47, DOI 10.1016/S0264-410X(99)00309-6
   Edmunds WJ, 2000, EPIDEMIOL INFECT, V125, P635, DOI 10.1017/S0950268800004672
   Enquselassie F, 2003, EPIDEMIOL INFECT, V130, P507, DOI 10.1017/S0950268803008446
   FINE PEM, 1982, INT J EPIDEMIOL, V11, P15, DOI 10.1093/ije/11.1.15
   FINE PEM, 1982, INT J EPIDEMIOL, V11, P5, DOI 10.1093/ije/11.1.5
   GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419
   Griffiths DA, 1974, APPL STATIST, V23, p330 , DOI DOI 10.2307/2347126)
   HAYES R, 1983, LANCET, P744
   Henao-Restrepo AM, 2003, J INFECT DIS, V187, pS15
   KAMBARAMI RA, 1991, B WORLD HEALTH ORGAN, V69, P213
   Moss WJ, 2002, CLIN INFECT DIS, V35, P189, DOI 10.1086/341248
   Murray CJL, 2003, LANCET, V362, P1022, DOI 10.1016/S0140-6736(03)14411-X
   Oshitani H, 1997, TROP MED INT HEALTH, V2, P612, DOI 10.1046/j.1365-3156.1997.d01-346.x
   OSHITANI H, 1995, ANN TROP PAEDIATR, V15, P167
   REMME J, 1984, INT J EPIDEMIOL, V13, P332, DOI 10.1093/ije/13.3.332
   Roberts MG, 2000, EPIDEMIOL INFECT, V124, P279, DOI 10.1017/S0950268899003556
   TAYLOR WR, 1988, AM J EPIDEMIOL, V127, P788
   *WHO, 2002, WKLY EPIDEMIOL REC, P50
   *WHO DEP VACC, IMM BIOL WHO VACC PR
   *WHO DEP VACC IMM, MEAS INC TIM SER ZAM
   Williams BG, 1995, EPIDEMIOL INFECT, V115, P603
   2001, MMWR MORB MORTAL WKL, V50, P513
NR 28
TC 7
Z9 7
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD DEC 21
PY 2004
VL 23
IS 6
BP 732
EP 738
DI 10.1016/j.vaccine.2004.07.026
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 882KC
UT WOS:000225936800002
PM 15542196
OA No
DA 2017-08-15
ER

PT J
AU Thomas, JE
   Dale, A
   Bunn, JEG
   Harding, M
   Coward, WA
   Cole, TJ
   Weaver, LT
AF Thomas, JE
   Dale, A
   Bunn, JEG
   Harding, M
   Coward, WA
   Cole, TJ
   Weaver, LT
TI Early Helicobacter pylori colonisation: the association with growth
   faltering in The Gambia
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID C-13-UREA BREATH TEST; EARLY-LIFE; INFECTION; CHILDREN; PREVALENCE;
   DIARRHEA; TRANSMISSION; POPULATION; STANDARDS; CHILDHOOD
AB Background: Helicobacter pylori is one of the commonest causes of chronic infection of mankind, yet the natural history of acute infection is poorly understood. Some studies suggest that gastric colonisation with H pylori is associated with suboptimal nutrition and growth in childhood.
   Aims: To describe the clinical features of early H pylori colonisation and assess its role in the development of infant malnutrition and growth faltering.
   Methods: Two consecutive prospective longitudinal cohort studies were conducted at the Medical Research Council Laboratories in a rural community in The Gambia, West Africa. The first birth cohort of 125 infants was followed by a second of 65 children from the same community. H pylori colonisation was detected by sequential C-13 urea breath tests, and infant growth was monitored by serial measurements.
   Results: Children with early H pylori colonisation became significantly lighter, shorter, and thinner than their peers in late infancy. The association was found in both cohorts. No socioeconomic or demographic confounding variables were identified to explain this, and the weight deficit was no longer detectable when the children were aged 5-8 years.
   Conclusions: Results suggest that H pylori colonisation in early infancy predisposes to the development of malnutrition and growth faltering, although the effect did not persist into later childhood.
C1 MRC Human Nutr Res, Cambridge, England.
   Univ Newcastle Upon Tyne, Dept Child Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   MRC Keneba, Banjul, Gambia.
   Univ Glasgow, Dept Child Hlth, Glasgow G12 8QQ, Lanark, Scotland.
RP Thomas, JE (reprint author), Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Dept Child Hlth, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM j.e.thomas@ncl.ac.uk
OI Cole, Tim/0000-0001-5711-8200
FU Medical Research Council [G9827821, G9827821(62595)]
CR Buyukgebiz A, 2001, J PEDIATR ENDOCR MET, V14, P549
   Campbell DI, 2001, HELICOBACTER, V6, P263, DOI 10.1046/j.1083-4389.2001.00047.x
   CLEMENS J, 1995, J INFECT DIS, V171, P1653
   COLE TJ, 1990, EUR J CLIN NUTR, V44, P45
   CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8
   Dale A, 1998, J PEDIATR GASTR NUTR, V26, P393, DOI 10.1097/00005176-199804000-00006
   Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290
   Kehrt R, 1997, J PEDIATR GASTR NUTR, V25, P84, DOI 10.1097/00005176-199707000-00014
   Kersulyte D, 2000, J BACTERIOL, V182, P3210, DOI 10.1128/JB.182.11.3210-3218.2000
   Malaty HM, 2002, J PEDIATR GASTR NUTR, V35, P59, DOI 10.1097/01.MPG.0000016486.73596.4E
   MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116
   Oderda G, 1998, BRIT MED J, V317, P514
   Passaro DJ, 2002, J PEDIATR GASTR NUTR, V35, P522, DOI 10.1097/00005176-200210000-00012
   PATEL P, 1994, BRIT MED J, V309, P1119
   Perri F, 1997, ARCH DIS CHILD, V77, P46
   Poskitt EME, 1999, ARCH DIS CHILD, V80, P115
   Rowland M, 1998, BRIT MED BULL, V54, P95
   Sarker SA, 1995, DIGEST DIS SCI, V40, P2669, DOI 10.1007/BF02220458
   SULLIVAN PB, 1990, ARCH DIS CHILD, V65, P189
   Thomas JE, 1999, PEDIATR RES, V46, P147, DOI 10.1203/00006450-199908000-00003
   Thomas JE, 1999, PEDIATR RES, V45, P218, DOI 10.1203/00006450-199902000-00010
   Torres J, 2000, ARCH MED RES, V31, P431, DOI 10.1016/S0188-4409(00)00099-0
   WEAVER LT, 1993, LANCET, V341, P1327, DOI 10.1016/0140-6736(93)90827-4
   WEBB PM, 1994, BRIT MED J, V308, P750
NR 24
TC 60
Z9 62
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD DEC
PY 2004
VL 89
IS 12
BP 1149
EP 1154
DI 10.1136/adc.2002.015313
PG 6
WC Pediatrics
SC Pediatrics
GA 873AI
UT WOS:000225250600021
PM 15557054
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Bailey, RL
   Jeffries, D
   Mabey, DCW
   Holland, MJ
AF Burton, MJ
   Bailey, RL
   Jeffries, D
   Mabey, DCW
   Holland, MJ
TI Cytokine and fibrogenic gene expression in the conjunctivas of subjects
   from a Gambian Community where trachoma is endemic
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MURINE CHLAMYDIA-TRACHOMATIS; GENITAL-TRACT INFECTION;
   NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; MATRIX METALLOPROTEINASES;
   GAMMA-INTERFERON; IN-VITRO; SCARRING TRACHOMA; ANTERIOR SEGMENT;
   KNOCKOUT MICE
AB The role of immunity in blinding trachoma is unclear. Conjunctival gene expression was measured in a population where trachoma is endemic. Proinflammatory (tumor necrosis factor alpha and interleukin-1beta [IL-1beta]), anti-inflammatory (IL-10), and fibrogenic (matrix metalloprotease 9) gene expression was increased in active trachoma. Markers indicative of T-cell response (gamma interferon, IL-4, IL-12p40, and perforin) were increased when chlamydial infection was present.
C1 London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
RP Burton, MJ (reprint author), London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
CR Abu El-Asrar AM, 1998, EYE, V12, P1001
   Abu El-Asrar AM, 1998, EYE, V12, P453
   Abu El-Asrar AM, 1998, EYE, V12, P735
   ALRAJHI AA, 1993, OPHTHALMOLOGY, V100, P1293
   Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   Ault KA, 2002, AM J OBSTET GYNECOL, V187, P1377, DOI 10.1067/mob.2002.126850
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   CASSATELLA MA, 1995, EUR J IMMUNOL, V25, P1, DOI 10.1002/eji.1830250102
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P1975
   Cotter TW, 1997, INFECT IMMUN, V65, P2145
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dawson CR, 1990, CHLAMYDIAL INFECT, P271
   El-Asrar A M, 2000, Br J Ophthalmol, V84, P85, DOI 10.1136/bjo.84.1.85
   Holland MJ, 1997, CLIN EXP IMMUNOL, V107, P44, DOI 10.1046/j.1365-2249.1997.2511129.x
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   Ito JI, 1999, INFECT IMMUN, V67, P5518
   Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   Mathews SA, 1999, FEBS LETT, V458, P354, DOI 10.1016/S0014-5793(99)01182-5
   Meller D, 2000, INVEST OPHTH VIS SCI, V41, P2922
   Morrison SG, 2000, INFECT IMMUN, V68, P2870, DOI 10.1128/IAI.68.5.2870-2879.2000
   Morrison SG, 2000, INFECT IMMUN, V68, P6979, DOI 10.1128/IAI.68.12.6979-6987.2000
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162
   PASQUALE LR, 1993, INVEST OPHTH VIS SCI, V34, P23
   Perry LL, 1997, J IMMUNOL, V158, P3344
   Perry LL, 1999, INFECT IMMUN, V67, P1379
   RAMSEY KH, 2002, CHLAMYDIAL INFECT, P249
   RANK RG, 1992, INFECT IMMUN, V60, P4427
   Rodel J, 1998, J RHEUMATOL, V25, P2161
   Rottenberg ME, 2002, CURR OPIN IMMUNOL, V14, P444, DOI 10.1016/S0952-7915(02)00361-8
   Sakaguchi S, 2003, NAT IMMUNOL, V4, P10, DOI 10.1038/ni0103-10
   Saren P, 1996, J IMMUNOL, V157, P4159
   Schonbeck U, 1998, J IMMUNOL, V161, P3340
   Siwik DA, 2000, CIRC RES, V86, P1259
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843
   Williams DM, 1996, RES MICROBIOL, V147, P251, DOI 10.1016/0923-2508(96)81385-4
   Williams DM, 1997, INFECT IMMUN, V65, P2876
   Wong TTL, 2003, INVEST OPHTH VIS SCI, V44, P1097, DOI 10.1167/iovs.02-0366
   Wong TTL, 2002, SURV OPHTHALMOL, V47, P239, DOI 10.1016/S0039-6257(02)00287-4
   Xue ML, 2003, INVEST OPHTH VIS SCI, V44, P2020, DOI 10.1167/iovs.02-0565
   Yang X, 1999, J IMMUNOL, V162, P1010
NR 47
TC 52
Z9 55
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2004
VL 72
IS 12
BP 7352
EP 7356
DI 10.1128/IAI.72.12.7352-7356.2004
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 875WW
UT WOS:000225453900073
PM 15557667
OA No
DA 2017-08-15
ER

PT J
AU McNulty, SL
   Mole, BM
   Dailidiene, D
   Segal, I
   Ally, R
   Mistry, R
   Secka, O
   Adegbola, RA
   Thomas, JE
   Lenarcic, EM
   Peek, RM
   Berg, DE
   Forsyth, MH
AF McNulty, SL
   Mole, BM
   Dailidiene, D
   Segal, I
   Ally, R
   Mistry, R
   Secka, O
   Adegbola, RA
   Thomas, JE
   Lenarcic, EM
   Peek, RM
   Berg, DE
   Forsyth, MH
TI Novel 180- and 480-base-pair insertions in African and African-American
   strains of Helicobacter pylori
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID EPITHELIAL-CELL CYCLE; GASTRIC-CANCER; CHILD TRANSMISSION;
   GENE-EXPRESSION; ETHNIC-GROUPS; GENOTYPES; INFECTION; ENIGMA;
   POPULATIONS; SEQUENCES
AB Helicobacter pylori is a genetically diverse bacterial species that chronically infects human stomachs and sometimes causes severe gastroduodenal disease. Studies of polymorphic DNA sequences can suggest geographic origins of individual strains. Here, we describe a 180-bp insertion (ins180), which is just after the translation stop of a gene of unknown function, near the promoter of jhp0152-jhp0151 two-component signal transduction genes in strain J99, and absent from this site in strain 26695. This ins180 insertion was found in 9 of 9 Gambian (West African), 9 of 20 (45%) South African, and 9 of 40 (23%) Spanish strains but in only 2 of 20 (10%) North American strains and none of 20 Lithuanian, 20 Indian, and 20 Japanese strains. Four South African isolates that lacked ins180 and that belonged to an unusual outlier group contained a 480-bp insertion at this site (ins480), whereas none of 181 other strains screened contained ins480. In further tests 56% (10 of 18) of strains from African Americans but only 17% (3 of 18) of strains from Caucasian Americans carried ins180 (P < 0.05). Thus, the H. pylori strains of modern African Americans seem to retain traces of African roots, despite the multiple generations since their ancestors were taken from West Africa. Fragmentary ins180-like sequences were found at numerous sites in H. pylori genomes, always between genes. Such sequences might affect regulation of transcription and could facilitate genome rearrangement by homologous recombination. Apparent differences between African-American and Caucasian-American H. pylori gene pools may bear on our understanding of H. pylori transmission and disease outcome.
C1 Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   Baragwanath Hosp, African Inst Digest Dis, Johannesburg, South Africa.
   MRC Labs, Fajara, Gambia.
   Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Vanderbilt Univ, Med Ctr, Dept Gastroenterol, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA.
   Vet Adm Med Ctr, Nashville, TN 37203 USA.
RP Forsyth, MH (reprint author), Coll William & Mary, Dept Biol, 214 Millington Hall,Landrum Dr, Williamsburg, VA 23187 USA.
EM mhfors@wm.edu
FU NCI NIH HHS [R01 CA077955, CA 77955, R29 CA077955]; NIAID NIH HHS [AI
   38166, AI 53062, R15 AI053062]; NIDDK NIH HHS [DK 53727, DK 58587, DK
   63041, R01 DK058587, R01 DK063041]
CR Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495
   American Cancer Society, 2004, CANC FACTS FIG 2004
   Ando T, 2002, J CLIN MICROBIOL, V40, P239, DOI 10.1128/JCM.40.1.239-246.2002
   Aras RA, 2003, P NATL ACAD SCI USA, V100, P13579, DOI 10.1073/pnas.1375481100
   Ausubel FM., 1994, CURRENT PROTOCOLS MO
   Campbell DI, 2001, HELICOBACTER, V6, P263, DOI 10.1046/j.1083-4389.2001.00047.x
   Chalkauskas H, 1998, HELICOBACTER, V3, P296
   Cover T. L., 2001, PRINCIPLES BACTERIAL, P509, DOI 10.1016/B978-012304220-0/50012-1
   Dailidiene D, 2004, J BACTERIOL, V186, P356, DOI 10.1128/JB.186.2.356-365.2004
   Dietz P, 2002, J BACTERIOL, V184, P350, DOI 10.1128/JB.184.2.350-362.2002
   Disotell TR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-213
   DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603
   Ernst PB, 2000, ANNU REV MICROBIOL, V54, P615, DOI 10.1146/annurev.micro.54.1.615
   Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857
   FENNERTY MB, 1992, CANCER EPIDEM BIOMAR, V1, P293
   Flores C, 2004, EUR J HUM GENET, V12, P855, DOI 10.1038/sj.ejhg.5201225
   Forsyth MH, 2002, J BACTERIOL, V184, P4630, DOI 10.1128/JB.184.16.4630-4635.2002
   FOX JG, 2000, NAT MED, V6, P535
   Ge ZM, 1999, ANNU REV MICROBIOL, V53, P353, DOI 10.1146/annurev.micro.53.1.353
   Ghose C, 2002, P NATL ACAD SCI USA, V99, P15107, DOI 10.1073/pnas.242574599
   HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9
   HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429
   Kersulyte D, 2000, J BACTERIOL, V182, P3210, DOI 10.1128/JB.182.11.3210-3218.2000
   Kivi M, 2003, J CLIN MICROBIOL, V41, P5604, DOI 10.1128/JCM.41.12.5604-5608.2003
   Kuipers EJ, 2000, EUR J GASTROEN HEPAT, V12, P601, DOI 10.1097/00042737-200012060-00003
   Louw JA, 2001, HELICOBACTER, V6, P268, DOI 10.1046/j.1523-5378.2001.00044.x
   McFarlane G, 2001, BRIT J CANCER, V85, P1322, DOI 10.1054/bjoc.2001.1994
   McFarlane GA, 2000, EUR J GASTROEN HEPAT, V12, P617, DOI 10.1097/00042737-200012060-00007
   Miwa H, 2002, AM J GASTROENTEROL, V97, P1106
   MONTANEZ C, 1986, J MOL BIOL, V191, P29, DOI 10.1016/0022-2836(86)90420-1
   Peek RM, 2000, INFECT IMMUN, V68, P5488, DOI 10.1128/IAI.68.10.5488-5495.2000
   Peek RM, 1999, CANCER RES, V59, P6124
   Peek RM, 1998, P ASSOC AM PHYSICIAN, V110, P531
   Peek RM, 2000, GASTROENTEROLOGY, V118, P48, DOI 10.1016/S0016-5085(00)70413-6
   Pflock M, 2004, FEMS MICROBIOL LETT, V234, P51, DOI 10.1016/j.femsle.2004.03.023
   Rothenbacher D, 1999, J INFECT DIS, V179, P398, DOI 10.1086/314595
   Salama N, 2000, P NATL ACAD SCI USA, V97, P14668, DOI 10.1073/pnas.97.26.14668
   Segal I, 2001, EUR J CANCER PREV, V10, P479, DOI 10.1097/00008469-200112000-00001
   Segal I, 2001, QJM-MON J ASSOC PHYS, V94, P561, DOI 10.1093/qjmed/94.10.561
   Tindberg Y, 2001, GASTROENTEROLOGY, V121, P310, DOI 10.1053/gast.2001.26282
   Wirth T, 2004, P NATL ACAD SCI USA, V101, P4746, DOI 10.1073/pnas.0306629101
NR 41
TC 12
Z9 12
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD DEC
PY 2004
VL 42
IS 12
BP 5658
EP 5663
DI 10.1128/JCM.42.12.5658-5663.2004
PG 6
WC Microbiology
SC Microbiology
GA 883SK
UT WOS:000226035800035
PM 15583296
OA No
DA 2017-08-15
ER

PT J
AU Wiart, A
   Jepson, A
   Banya, W
   Bennett, S
   Whittle, H
   Martin, NG
   Hill, AVS
AF Wiart, A
   Jepson, A
   Banya, W
   Bennett, S
   Whittle, H
   Martin, NG
   Hill, AVS
TI Quantitative association tests of immune responses to antigens of
   Mycobacterium tuberculosis: A study of twins in West Africa
SO TWIN RESEARCH
LA English
DT Article
ID T-CELL-ACTIVATION; AUTOIMMUNE-DISEASES; HASHIMOTOS-THYROIDITIS; GENE
   POLYMORPHISM; DENDRITIC CELLS; GRAVES-DISEASE; SUSCEPTIBILITY;
   DIFFERENTIATION; INTERLEUKIN-10; EXPRESSION
AB There is now considerable evidence that host genetic factors are important in determining the outcome of infection with Mycobacterium tuberculosis (MTB). The aim of this study was to assess the role of several candidate genes in the variation observed in the immune responses to MTB antigens. In-vitro assays of T-cell proliferation, an in-vivo intradermal delayed hypersensitivity response; cytokine and antibody secretions to several mycobacterial peptide antigens were assessed in healthy, but exposed, West African twins. Candidate gene polymorphisms were typed in the NRAMP1, Vitamin D receptor, IL10, IL4, IL4 receptor and CTLA-4 genes. Variants of the loci IL10 (-1082 G/A), CTLA-4 (49 A/G) and the IL4 receptor (128 A/G) showed significant associations with immune responses to several antigens. T-cell proliferative responses and antibody responses were reduced, TNF-alpha responses were increased for subjects with the CTLA-4 G allele. The T-cell proliferative responses of subjects with IL10 GA and GG genotypes differed significantly. IL4 receptor AG and GG genotypes also showed significant differences in their T-cell proliferative responses to MTB antigens. These results yield a greater understanding of the genetic mechanisms that underlie the immune responses in tuberculosis and have implications for the design of therapeutic interventions.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1, England.
   MRC Labs, Fajara, Gambia.
   Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
RP Hill, AVS (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM adrian.hill@well.ox.ac.uk
RI HILL, Adrian/C-1306-2008
OI Martin, Nicholas/0000-0003-4069-8020
CR Battifora M, 1998, J CLIN ENDOCR METAB, V83, P4130, DOI 10.1210/jc.83.11.4130
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, CURR OPIN IMMUNOL, V10, P483, DOI 10.1016/S0952-7915(98)80125-8
   BELLAMY R, 1998, THESIS OXFORD U UNIT
   Bellows RT, 2001, ANN OPHTHALMOL, V33, P8, DOI 10.1007/s12009-001-0054-5
   Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645
   Cervino ACL, 2000, ANN HUM GENET, V64, P507, DOI 10.1046/j.1469-1809.2000.6460507.x
   Clavreul A, 1998, IMMUNOLOGY, V95, P272
   Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115
   DOLAN CV, 1989, BEHAV GENET, V19, P51, DOI 10.1007/BF01065883
   Donner H, 1997, J CLIN ENDOCR METAB, V82, P4130, DOI 10.1210/jc.82.12.4130
   Eskdale J, 1998, P NATL ACAD SCI USA, V95, P9465, DOI 10.1073/pnas.95.16.9465
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Fulker DW, 1999, AM J HUM GENET, V64, P259, DOI 10.1086/302193
   Gong JH, 1996, INFECT IMMUN, V64, P913
   GONZALEZESCRIBANO, 1999, TISSUE ANTIGENS, V53, P296
   Green K, 1998, SUPPLY CHAIN MANAG, V3, P89, DOI DOI 10.1108/13598549810215405
   Haldane J. B. S., 1949, Ricerca Scientifica Suppl, P68
   Heinemann L A, 1999, Eur J Contracept Reprod Health Care, V4, P67, DOI 10.3109/13625189909064007
   Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593
   JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313
   Jepson A, 1997, INFECT IMMUN, V65, P872
   Jepson A, 2001, INFECT IMMUN, V69, P3989, DOI 10.1128/IAI.69.6.3989-3994.2001
   Kaplan G, 1996, RES IMMUNOL, V147, P565, DOI 10.1016/S0923-2494(97)85223-6
   KeaneMyers A, 1997, J IMMUNOL, V158, P2042
   Kirman J, 1999, INFECT IMMUN, V67, P3786
   Koss K, 2000, GENES IMMUN, V1, P185, DOI 10.1038/sj.gene.6363657
   Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655
   Kubo M, 1999, J IMMUNOL, V163, P2432
   Lischke A, 1998, J BIOL CHEM, V273, P31222, DOI 10.1074/jbc.273.47.31222
   LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323
   MACGREGOR B, 1999, GENET EPIDEMIOL, V16, P40
   MARTIN NG, 1987, AM J HUM GENET, V40, P267
   MEHRA V, 1992, J EXP MED, V175, P275, DOI 10.1084/jem.175.1.275
   Mitsuyasu H, 1999, J IMMUNOL, V162, P1227
   Mozo L, 1998, J ALLERGY CLIN IMMUN, V102, P968, DOI 10.1016/S0091-6749(98)70335-5
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6
   Murray PJ, 1999, INFECT IMMUN, V67, P3087
   NEALE MC, 1989, BEHAV GENET, V19, P63, DOI 10.1007/BF01065884
   Neale MC, 1999, BEHAV GENET, V29, P233, DOI 10.1023/A:1021638122693
   Neale MC, 1992, METHODOLOGY GENETIC
   O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6
   ORME IM, 1993, J INFECT DIS, V167, P1481
   PEARSON K, 1907, FIRST STUDY STAT PUL
   Penna G, 2000, J IMMUNOL, V164, P2405
   Piemonti L, 2000, J IMMUNOL, V164, P4443
   PUFFER RR, 1946, FAMILIAL SUSCEPTIBIL
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Reiser H, 1996, NEW ENGL J MED, V335, P1369
   ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x
   Rosenwasser L. J, 1995, CLIN EXP ALLERGY S2, V25, P95
   ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890
   Saha B, 1998, EUR J IMMUNOL, V28, P4213, DOI 10.1002/(SICI)1521-4141(199812)28:12<4213::AID-IMMU4213>3.0.CO;2-C
   SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920
   Schluger NW, 1999, INT J TUBERC LUNG D, V3, P281
   SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314
   Seidl C, 1998, TISSUE ANTIGENS, V51, P62, DOI 10.1111/j.1399-0039.1998.tb02947.x
   Sham PC, 2000, AM J HUM GENET, V66, P1616, DOI 10.1086/302891
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621
   WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X
   Wandstrat A, 2001, NAT IMMUNOL, V2, P802
   Whitfield JB, 2000, AM J HUM GENET, V66, P1246, DOI 10.1086/302862
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
   Yanagawa T, 1997, THYROID, V7, P843, DOI 10.1089/thy.1997.7.843
   YOUNG DB, 1987, INFECT IMMUN, V55, P1421
NR 68
TC 7
Z9 7
U1 0
U2 0
PU AUSTRALIAN ACAD PRESS
PI BOWEN HILLS
PA 32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA
SN 1369-0523
J9 TWIN RES
JI Twin Res.
PD DEC
PY 2004
VL 7
IS 6
BP 578
EP 588
DI 10.1375/1369052042663887
PG 11
WC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
SC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
GA 878BY
UT WOS:000225622700007
PM 15607008
OA No
DA 2017-08-15
ER

PT J
AU Deubzer, HE
   Obaro, SK
   Newman, VO
   Adegbola, RA
   Greenwood, BM
   Henderson, DC
AF Deubzer, HE
   Obaro, SK
   Newman, VO
   Adegbola, RA
   Greenwood, BM
   Henderson, DC
TI Colostrum obtained from women vaccinated with pneumococcal vaccine
   during pregnancy inhibits epithelial adhesion of Streptococcus
   pneumoniae
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 3rd International Symposium on Pneumococci and Pneumococcal Diseases
CY MAY 05-09, 2002
CL ANCHORAGE, AK
ID BREAST-MILK; MATERNAL IMMUNIZATION; ANTIBODY; SERUM; CELLS; ADHERENCE;
   INFANT; IGA
AB Prevention of nasopharyngeal colonization may reduce the burden of pneumococcal infection during infancy. Colostrum obtained from Gambian mothers who had been vaccinated with either Pneumovax II or Mengivax A&C (n = 8 per group) during pregnancy was examined for inhibition of adherence of Streptococcus pneumoniae serotypes 6B and 14 to pharyngeal epithelial cells in vitro. Pneumococcal adherence was significantly reduced in the presence of breast milk (P less than or equal to .0001 for S. pneumoniae serotype 14; P = .036 for serotype 6B), independent of the concentration of secretory IgA antibodies. Maternal vaccination with polyvalent pneumococcal polysaccharide vaccine boosts the capacity of colostrum to inhibit adherence of pneumococci to pharyngeal epithelial cells. In breast-feeding populations, maternal vaccination might prevent pneumococcal disease in young infants.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Immunol, Chelsea & Westminster Hosp, London, England.
   MRC Labs, Banjul, Gambia.
RP Obaro, SK (reprint author), Rhode Isl Hosp, Brown Sch Med, Div Pediat Infect Dis, 593 Eddy St, Providence, RI 02903 USA.
EM sobaro@lifespan.org
CR ANDERSSON B, 1981, INFECT IMMUN, V32, P311
   ANDERSSON B, 1986, J INFECT DIS, V153, P232
   CUNDELL DR, 1994, MICROB PATHOGENESIS, V17, P361, DOI 10.1006/mpat.1994.1082
   Finn A, 2002, J INFECT DIS, V186, P1422, DOI 10.1086/344356
   GASPARONI A, 1992, ARCH DIS CHILD, V67, P41
   Greenwood B, 2003, VACCINE, V21, P3436, DOI 10.1016/S0264-410X(03)00346-3
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Janoff EN, 1999, J CLIN INVEST, V104, P1139, DOI 10.1172/JCI6310
   Obaro SK, 2000, VACCINE, V19, P411, DOI 10.1016/S0264-410X(00)00201-2
   ODempsey TJD, 1996, VACCINE, V14, P963, DOI 10.1016/0264-410X(96)00009-6
   PETERSON WD, 1971, P SOC EXP BIOL MED, V136, P1187
   PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1
   Romero-Steiner S, 2003, CLIN DIAGN LAB IMMUN, V10, P246, DOI 10.1128/CDLI.10.2.246-251.2003
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS17, DOI DOI 10.1097/00006454-199910001-00004
   Yu JG, 2003, J INFECT DIS, V187, P1019, DOI 10.1086/368200
NR 16
TC 16
Z9 17
U1 1
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2004
VL 190
IS 10
BP 1758
EP 1761
DI 10.1086/424597
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 865KG
UT WOS:000224700800006
PM 15499530
OA No
DA 2017-08-15
ER

PT J
AU Solomon, AW
   Holland, MJ
   Alexander, NDE
   Massae, PA
   Aguirre, A
   Natividad-Sancho, A
   Molina, S
   Safari, S
   Shao, JF
   Courtright, P
   Peeling, RW
   West, SK
   Bailey, RL
   Foster, A
   Mabey, DCW
AF Solomon, AW
   Holland, MJ
   Alexander, NDE
   Massae, PA
   Aguirre, A
   Natividad-Sancho, A
   Molina, S
   Safari, S
   Shao, JF
   Courtright, P
   Peeling, RW
   West, SK
   Bailey, RL
   Foster, A
   Mabey, DCW
TI Mass treatment with single-dose azithromycin for trachoma
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Proceedings Paper
CT Meeting of the Royal-Society-of-Tropical-Medicine-and-Hygiene
CY DEC   12, 2002
CL LONDON, ENGLAND
SP Royal Soc Trop Med & Hyg
ID OCULAR CHLAMYDIAL INFECTION; CLINICAL-DIAGNOSIS; LOW-PREVALENCE;
   PREVENTION; BLINDNESS; NEPAL; AREAS
AB BACKGROUND
   Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, is an important cause of blindness. Current recommended dosing intervals for mass azithromycin treatment for trachoma are based on a mathematical model.
   METHODS
   We collected conjunctival swabs for quantitative polymerase-chain-reaction assay of C. trachomatis before and 2, 6, 12, 18, and 24 months after mass treatment with azithromycin in a Tanzanian community in which trachoma was endemic. For ethical reasons, at 6, 12, and 18 months, we gave tetracycline eye ointment to residents who had clinically active trachoma.
   RESULTS:
   At baseline, 956 of 978 residents (97.8 percent) received either one oral dose of azithromycin or (if azithromycin was contraindicated) a course of tetracycline eye ointment. The prevalence of infection fell from 9.5 percent before mass treatment to 2.1 percent at 2 months and 0.1 percent at 24 months. The quantitative burden of ocular C. trachomatis infection in the community was 13.9 percent of the pretreatment level at 2 months and 0.8 percent at 24 months. At each time point after baseline, over 90 percent of the total community burden of C. trachomatis infection was found among subjects who had been positive the previous time they were tested.
   CONCLUSIONS:
   The prevalence and intensity of infection fell dramatically and remained low for two years after treatment. One round of very-high-coverage mass treatment with azithromycin, perhaps aided by subsequent periodic use of tetracycline eye ointment for persons with active disease, can interrupt the transmission of ocular C. trachomatis infection.
C1 Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England.
   Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania.
   Huruma Hosp, Mkuu, Rombo, Tanzania.
   MRC Labs, Fajara, Gambia.
   WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland.
   Hlth Canada, Natl Microbiol Lab, Winnipeg, MB, Canada.
   Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
RP Solomon, AW (reprint author), Univ London London Sch Hyg & Trop Med, Clin Res Unit, Keppel St, London WC1E 7HT, England.
EM anthony.solomon@lshtm.ac.uk
CR BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743
   Bowman RJC, 2000, INVEST OPHTH VIS SCI, V41, P4074
   Dawson CR, 1997, CLIN INFECT DIS, V24, P363
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   Everett KDE, 1999, INT J SYST BACTERIOL, V49, P415
   FOSTER A, 1991, LANCET, V337, P1267, DOI 10.1016/0140-6736(91)92929-V
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   Jha H, 2002, CLIN INFECT DIS, V35, P765, DOI 10.1086/342298
   Kirkwood B.R, 1988, ESSENTIALS MED STAT
   Kuper H, 2003, LANCET INFECT DIS, V3, P372, DOI 10.1016/S1473-3099(03)00659-5
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Mabey Denise, 2003, Expert Rev Anti Infect Ther, V1, P209, DOI 10.1586/14787210.1.2.209
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY
   SCHACHTER J, 1983, REV INFECT DIS, V5, pS562
   SCHACHTER J, 1985, REV INFECT DIS, V7, P713
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   SCHACHTER J, 2002, CHLAMYDIAL INFECT
   Shattock RM, 1998, SEX TRANSM INFECT, V74, P289
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842
   TAYLOR HR, 1993, BRIT J OPHTHALMOL, V77, P66, DOI 10.1136/bjo.77.2.66
   Thein J, 2002, OPHTHALMIC EPIDEMIOL, V9, P263, DOI 10.1076/opep.9.4.263.1508
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1985, REV INFECT DIS, V7, P774
   Thylefors B, 1998, WORLD HEALTH FORUM, V19, P53
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
NR 32
TC 145
Z9 148
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 4
PY 2004
VL 351
IS 19
BP 1962
EP 1971
DI 10.1056/NEJMoa040979
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 867OG
UT WOS:000224851300008
PM 15525721
OA No
DA 2017-08-15
ER

PT J
AU Allen, SJ
   Thomas, JE
   Alexander, NDE
   Bailey, R
   Emerson, PM
AF Allen, SJ
   Thomas, JE
   Alexander, NDE
   Bailey, R
   Emerson, PM
TI Flies and Helicobacter pylori infection
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID HOUSEFLIES MUSCA-DOMESTICA; VECTOR
AB Houseflies have been proposed to be a reservoir and vector for Helicobacter pylori. We assessed the effect of insecticide spraying in villages in The Gambia on H. pylori infection in young children. Effective control of flies did not prevent infection with H. pylori.
C1 MRC Labs, Banjul, Gambia.
   Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
RP Allen, SJ (reprint author), Univ Coll Swansea, Sch Clin, Swansea SA2 8PP, W Glam, Wales.
EM s.j.allen@swansea.ac.uk
CR Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Grubel P, 1998, LANCET, V352, P788, DOI 10.1016/S0140-6736(05)60683-6
   Grubel P, 1997, J CLIN MICROBIOL, V35, P1300
   Mitchell H, 2002, HELICOBACTER, V7, P8, DOI 10.1046/j.1523-5378.7.s1.10.x
   Osato MS, 1998, J CLIN MICROBIOL, V36, P2786
   Thomas JE, 1999, PEDIATR RES, V46, P147, DOI 10.1203/00006450-199908000-00003
NR 6
TC 3
Z9 3
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD NOV
PY 2004
VL 89
IS 11
BP 1037
EP 1038
DI 10.1136/adc.2003.045880
PG 2
WC Pediatrics
SC Pediatrics
GA 865IU
UT WOS:000224696700013
PM 15499059
OA No
DA 2017-08-15
ER

PT J
AU Bornman, L
   Campbell, SJ
   Fielding, K
   Bah, B
   Sillah, J
   Gustafson, P
   Manneh, K
   Lisse, I
   Allen, A
   Sirugo, G
   Sylla, A
   Aaby, P
   McAdam, KPWJ
   Bah-Sow, O
   Bennett, S
   Lienhardt, C
   Hill, AVS
AF Bornman, L
   Campbell, SJ
   Fielding, K
   Bah, B
   Sillah, J
   Gustafson, P
   Manneh, K
   Lisse, I
   Allen, A
   Sirugo, G
   Sylla, A
   Aaby, P
   McAdam, KPWJ
   Bah-Sow, O
   Bennett, S
   Lienhardt, C
   Hill, AVS
TI Vitamin D receptor polymorphisms and susceptibility to tuberculosis in
   West Africa: A case-control and family study
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS; LINKAGE DISEQUILIBRIUM; PULMONARY
   TUBERCULOSIS; GENE POLYMORPHISMS; 1,25-DIHYDROXYVITAMIN D-3;
   HUMAN-MONOCYTES; RISK-FACTORS; DISEASE; ASSOCIATION; TRANSMISSION
AB Vitamin D receptor (VDR) gene polymorphisms have been implicated in susceptibility to tuberculosis ( TB), but reports have been inconsistent. We genotyped the VDR single-nucleotide polymorphisms ( SNPs) FokI, BsmI, ApaI, and TaqI in 1139 case patients and control subjects and 382 families from The Gambia, Guinea, and Guinea-Bissau. The transmission-disequilibrium test on family data showed a significant global association of TB with SNP combinations FokI-BsmI-ApaI-TaqI and FokI-ApaI that were driven by the increased transmission to affected offspring of the FokI F and ApaI A alleles in combination. The ApaI A allele was also transmitted to affected offspring significantly more often than expected. Case-control analysis showed no statistically significant association between TB and VDR variants. BsmI, ApaI, and TaqI showed strong linkage disequilibrium. The significance of the family-based associations found between TB and FokI-BsmI-ApaI-TaqI and the FA haplotype supports a role for VDR haplotypes, rather than individual genotypes, in susceptibility to TB.
C1 Rand Afrikaans Univ, Dept Chem & Biochem, Div Biochem, ZA-2006 Auckland Pk, South Africa.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   London Sch Hyg & Trop Med, London WC1, England.
   Programme Natl Lutte AntiTB, Conakry, Guinea.
   MRC Labs, Fajara, Gambia.
   Natl TB Leprosy Control Programme, Banjul, Gambia.
   Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau.
   Inst Rech Dev, Dakar, Senegal.
RP Bornman, L (reprint author), Rand Afrikaans Univ, Dept Chem & Biochem, Div Biochem, POB 524, ZA-2006 Auckland Pk, South Africa.
EM lbo@na.rau.ac.za
RI HILL, Adrian/C-1306-2008
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Bellamy R, 2000, LANCET, V355, P588, DOI 10.1016/S0140-6736(99)00426-2
   Bellamy R, 2003, GENES IMMUN, V4, P4, DOI 10.1038/sj.gene.6363915
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   CADRANEL J, 1988, AM REV RESPIR DIS, V138, P984
   Cervino ACL, 2002, HUM MOL GENET, V11, P1599, DOI 10.1093/hmg/11.14.1599
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Colin EM, 2000, CLIN ENDOCRINOL, V52, P211, DOI 10.1046/j.1365-2265.2000.00909.x
   Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577
   DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226
   Delgado JC, 2002, J INFECT DIS, V186, P1463, DOI 10.1086/344891
   DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200
   ENARSON DA, 1994, CLIN TUBERCULOSIS
   Fibla J, 2002, XIV INTERNATIONAL AIDS CONFERENCE: BASIC SCIENCES, P87
   Fine PEM, 1999, NEW ENGL J MED, V341, P1226, DOI 10.1056/NEJM199910143411609
   Gelder CM, 2000, J INFECT DIS, V181, P2099, DOI 10.1086/315489
   Hayes CE, 2003, CELL MOL BIOL, V49, P277
   Hill AVS, 2001, ANNU REV GENOM HUM G, V2, P373, DOI 10.1146/annurev.genom.2.1.373
   Ingles SA, 1997, CANCER EPIDEM BIOMAR, V6, P93
   Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Liu Wei, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P389
   Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165
   Mullighan CG, 1999, GENES IMMUN, V1, P137, DOI 10.1038/sj.gene.6363653
   Pani MA, 2000, DIABETES, V49, P504, DOI 10.2337/diabetes.49.3.504
   Rockett KA, 1998, INFECT IMMUN, V66, P5314
   ROOK GAW, 1986, IMMUNOLOGY, V57, P159
   Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536
   Sanchez F, 2003, INFECT IMMUN, V71, P126, DOI 10.1128/IAI.71.1.126-131.2003
   Selvaraj P, 2000, INDIAN J MED RES, V112, P86
   Selvaraj P, 2000, INDIAN J MED RES, V111, P172
   Sharma O P, 2000, Curr Opin Pulm Med, V6, P442, DOI 10.1097/00063198-200009000-00010
   Smith P., 1994, TUBERCULOSIS PATHOGE
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Styblo K., 1991, SELECTED PAPERS, V24
   Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865
   Uitterlinden AG, 2002, MOL CELL ENDOCRINOL, V197, P15, DOI 10.1016/S0303-7207(02)00274-5
   Whitfield GK, 2001, MOL CELL ENDOCRINOL, V177, P145
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
   Zmuda JM, 2000, EPIDEMIOL REV, V22, P203
NR 43
TC 86
Z9 90
U1 0
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2004
VL 190
IS 9
BP 1631
EP 1641
DI 10.1086/424462
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 859YA
UT WOS:000224303100015
PM 15478069
OA No
DA 2017-08-15
ER

PT J
AU Castelo, L
   Machado, MC
AF Castelo, L.
   Machado, M. C.
TI Knowledege and self-percections of androgen decrease when ageing. Study
   in an urban community
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Meeting Abstract
C1 [Castelo, L.; Machado, M. C.] Hosp Univ Manuel Fajardo, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1743-6095
J9 J SEX MED
JI J. Sex. Med.
PD NOV
PY 2004
VL 1
SU 1
BP 140
EP 140
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA V13HG
UT WOS:000207657300385
OA No
DA 2017-08-15
ER

PT J
AU Freeman, AR
   Meghen, CM
   MacHugh, DE
   Loftus, RT
   Achukwi, MD
   Bado, A
   Sauveroche, B
   Bradley, DG
AF Freeman, AR
   Meghen, CM
   MacHugh, DE
   Loftus, RT
   Achukwi, MD
   Bado, A
   Sauveroche, B
   Bradley, DG
TI Admixture and diversity in West African cattle populations
SO MOLECULAR ECOLOGY
LA English
DT Article
DE admixture; Bos indicus; Bos taurus; gene flow; microsatellite;
   trypanosomiasis
ID EUROPEAN CATTLE; BOS-INDICUS; DNA; ORIGINS; TAURINE; INTROGRESSION;
   EVOLUTION; MARKERS; TAURUS; GENES
AB We present a population genetic analysis of microsatellite variation in 16 West African cattle populations. West Africa represents a unique juxtaposition of different climatic and ecological zones in a relatively small geographical area. While more humid coastal regions are inhabited by the tsetse fly, a vector which spreads trypanosomiasis among cattle, the disease is not transmitted in the drier areas outside this zone. This is the most thorough study of genetic diversity in cattle within this area, which contains genetically important trypanotolerant Bos taurus breeds. Genetic relationships among the many breeds are examined and levels of diversity are assessed. Admixture levels were determined using a variety of methods. Ancestry informative or population-associated alleles (PAAs) were selected using populations from India, the Near East and Europe. Multivariate analysis, the ADMIX program and model-based Bayesian admixture analysis approaches were also employed. These analyses reveal the direct impact of ecological factors and the profound effect of admixture on the cattle of this region. They also highlight the importance of efforts to prevent further dilution of African taurine breeds by B. indicus cattle.
C1 Univ Dublin Trinity Coll, Smurfit Inst Genet, Dept Genet, Dublin 2, Ireland.
   Identigen Ltd, Unit 9, Trinity Enterprise Ctr, Dublin 2, Ireland.
   Natl Univ Ireland Univ Coll Dublin, Fac Agr, Dept Anim Sci & Prod, Dublin 4, Ireland.
   Natl Univ Ireland Univ Coll Dublin, Fac Agr, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.
   Wakwa Reg Ctr, Inst Agr Res Dev, Ngaoundere, Cameroon.
   FAO Reg Project, Banjul, Gambia.
   CIRDES, Bobo Dioulasso, Burkina Faso.
RP Bradley, DG (reprint author), Univ Dublin Trinity Coll, Smurfit Inst Genet, Dept Genet, Dublin 2, Ireland.
EM daniel.bradley@tcd.i.e
RI Bradley, Daniel/A-3240-2012
OI Bradley, Daniel G/0000-0001-7335-7092; MacHugh,
   David/0000-0002-8112-4704
CR Bierne N, 2003, MOL ECOL, V12, P447, DOI 10.1046/j.1365-294X.2003.01730.x
   Bradley DG, 1996, P NATL ACAD SCI USA, V93, P5131, DOI 10.1073/pnas.93.10.5131
   BRADLEY DG, 1994, ANIM GENET, V25, P7
   CAVALLISFORZA LL, 1993, HIST GEOGRAPHYRAPHY
   CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P9119, DOI 10.1073/pnas.85.23.9119
   Clutton-Brock J, 1989, WALKING LARDER PATTE, P200
   Cymbron T, 1999, P ROY SOC B-BIOL SCI, V266, P597, DOI 10.1098/rspb.1999.0678
   DEAN M, 1994, AM J HUM GENET, V55, P788
   Epstein H, 1984, EVOLUTION DOMESTICAT, P6
   Epstein H., 1971, ORIGIN DOMESTIC ANIM
   Estoup A, 1999, MOL BIOL EVOL, V16, P898
   *FAO, 2003, PROGR AFR TRYP
   Felsenstein J., 2001, PHYLIP PHYLOGENY INF
   Hanotte O, 2002, SCIENCE, V296, P336, DOI 10.1126/science.1069878
   Hanotte O, 2000, MOL ECOL, V9, P387, DOI 10.1046/j.1365-294x.2000.00858.x
   Kumar P, 2003, HEREDITY, V91, P43, DOI 10.1038/sj.hdy.6800277
   Loftus RT, 1999, MOL ECOL, V8, P2015, DOI 10.1046/j.1365-294x.1999.00805.x
   MacDonald K. C., 1998, TRANSFORMATIONS AFRI, P71
   MacDonald KC, 2000, ORIGINS DEV AFRICAN, P127
   MacHugh DE, 1997, GENETICS, V146, P1071
   MARSHALL F, 2000, J WORLD PREHISTORY, V16, P99
   MCINTOSH RJ, 1993, J AFR HIST, V34, P181
   McKeigue PM, 1997, AM J HUM GENET, V60, P188
   Minch E, 1995, MICROSAT MICROSATELL
   MOUNTAIN JL, 1992, PHILOS T ROY SOC B, V337, P159, DOI 10.1098/rstb.1992.0093
   Park SDE, 2001, THESIS U DUBLIN
   Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148
   Pritchard JK, 2000, GENETICS, V155, P945
   ROBERTS DF, 1965, HUM BIOL, V37, P38
   Rogers DJ, 1996, ANN TROP MED PARASIT, V90, P225
   Schneider S., 2000, ARLEQUIN VERSION 2 0
   Shriver MD, 1997, AM J HUM GENET, V60, P957
   Troy CS, 2001, NATURE, V410, P1088, DOI 10.1038/35074088
   ZDAREK J, 1992, J EXP BIOL, V173, P11
NR 34
TC 49
Z9 52
U1 0
U2 3
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0962-1083
J9 MOL ECOL
JI Mol. Ecol.
PD NOV
PY 2004
VL 13
IS 11
BP 3477
EP 3487
DI 10.1111/j.1365-294X.2004.02311.x
PG 11
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA 862XF
UT WOS:000224524000019
PM 15488005
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
   Deubzer, HE
   Newman, VO
   Adegbola, RA
   Greenwood, BM
   Henderson, DC
AF Obaro, SK
   Deubzer, HE
   Newman, VO
   Adegbola, RA
   Greenwood, BM
   Henderson, DC
TI Serotype-specific pneumococcal antibodies in breast milk of Gambian
   women immunized with a pneumococcal polysaccharide vaccine during
   pregnancy
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pneumococcal polysaccharide vaccine; pregnancy; breast milk; infant
ID ACUTE OTITIS-MEDIA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; CONJUGATE
   VACCINE; CHILDREN; EFFICACY; CARRIAGE; DISEASE; ADHERENCE; FAMILIES;
   AVIDITY
AB Background: In breast-feeding populations, immunization during pregnancy with pneumococcal polysaccharide offers a potentially useful approach to preventing pneumococcal disease in young infants.
   Methods: Breast milk samples were collected at 0, 2, 4 and 6 months after delivery from Gambian women vaccinated during pregnancy (24-32 weeks gestation) with Pneumovax II (n = 56) or Mengivax A&C (n = 57). Specimens were examined for secretory immunoglobulin A (s-IgA) concentration, subclass distribution and avidity specific to pneumococcal serotypes 4, 6B, 14, 19F and 23F and the antigen mixture in Pneumovax 11 by enzyme-linked immunosorbent assay. Colostral s-IgA and IgG concentrations in paired maternal sera were compared.
   Results: Colostral s-IgA concentrations specific to all pneumococcal polysaccharide antigens investigated were significantly higher (P < 0.05) among Pneumovax II vaccinees. Titers specific to serotypes 4, 6B and 14 and the vaccine formula remained significantly higher during 6 months, and those for 19F were higher during 4 months. Significantly higher concentrations of vaccine antigen-specific s-IgA antibody were sustained for 6 months after delivery (P = 0.011). Comparison of colostral s-IgA and IgG in serum revealed a significant correlation only among Mengivax A&C vaccinees for pneumococcal polysaccharide 23F (r(s) = 0.68; P less than or equal to 0.0001). Vaccination elicited trends toward increased s-IgA2, reaching significance for serotype 14 and the vaccine formula. Immunization elicited significantly higher s-IgA avidities specific to all pneumococcal polysaccharide antigens studied during 6 months.
   Conclusions: The public health value of immunization during pregnancy with pneumococcal polysaccharide vaccine in breastfeeding populations warrants further evaluation, particularly in populations with a high incidence of pneumococcal disease in early infancy.
C1 MRC Labs, Banjul, Gambia.
   Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Immunol, London, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Obaro, SK (reprint author), Brown Univ, Sch Med, Div Pediat Infect Dis, Rhode Isl Hosp, Providence, RI 02912 USA.
CR Advisory Committee on Immunization Practices, 2000, MMWR RECOMM REP, V49, P1
   ANDERSSON B, 1986, J INFECT DIS, V153, P232
   AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35
   Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/01.inf.0000027926.99356.4c
   BRANDTZAEG P, 1992, J INFECT DIS, V165, pS167
   BRANDTZAEG P, 2003, VACCINE, P3382
   CUNDELL DR, 1994, MICROB PATHOGENESIS, V17, P361, DOI 10.1006/mpat.1994.1082
   Dagan R, 2000, J INFECT DIS, V181, P1322, DOI 10.1086/315383
   Dagan R, 2000, PEDIATR INFECT DIS J, V19, pS79, DOI 10.1097/00006454-200005001-00012
   DEUBZER HE, IN PRESS J INFECT DI
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   *ET CLIN SIGN SER, 1999, PEDIAT INFECT DIS S, V1, pS1
   GASPARONI A, 1992, ARCH DIS CHILD, V67, P41
   HENDLEY JO, 1975, J INFECT DIS, V132, P55
   Hocini H, 2000, J IMMUNOL METHODS, V235, P53, DOI 10.1016/S0022-1759(99)00214-8
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Kilian M, 1996, APMIS, V104, P321
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   LUE C, 1988, J IMMUNOL, V140, P3793
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   O'Brien KL, 2003, VACCINE, V21, P1815, DOI 10.1016/S0264-410X(02)00807-1
   Obaro S, 2002, J MED MICROBIOL, V51, P98
   Obaro SK, 2003, VACCINE, V21, P1423, DOI 10.1016/S0264-410X(02)00634-5
   ODempsey TJD, 1996, VACCINE, V14, P963, DOI 10.1016/0264-410X(96)00009-6
   PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1
   SHURIN PA, 1993, J PEDIATR-US, V123, P801, DOI 10.1016/S0022-3476(05)80865-0
   TARKOWSKI A, 1990, J IMMUNOL, V144, P3770
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Usinger WR, 1999, INFECT IMMUN, V67, P2366
   Vitharsson G, 1994, J Infect Dis, V170, P592
   Weiser JN, 2003, P NATL ACAD SCI USA, V100, P4215, DOI 10.1073/pnas.0637469100
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
NR 32
TC 25
Z9 25
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2004
VL 23
IS 11
BP 1023
EP 1029
DI 10.1097/01.inf.0000143651.54880.09
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 872HD
UT WOS:000225197400008
PM 15545857
OA No
DA 2017-08-15
ER

PT J
AU Moorthy, VS
   Imoukhuede, EB
   Milligan, P
   Bojang, K
   Keating, S
   Kaye, P
   Pinder, M
   Gilbert, SC
   Walraven, G
   Greenwood, BM
   Hill, AVS
AF Moorthy, VS
   Imoukhuede, EB
   Milligan, P
   Bojang, K
   Keating, S
   Kaye, P
   Pinder, M
   Gilbert, SC
   Walraven, G
   Greenwood, BM
   Hill, AVS
TI A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA
   ME-TRAP against malaria infection in Gambian adults
SO PLOS MEDICINE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; VIRUS ANKARA; CIRCUMSPOROZOITE PROTEIN;
   PROTECTIVE EFFICACY; T-CELLS; ENHANCED IMMUNOGENICITY; DNA VACCINES;
   ASSOCIATION; CHILDREN; PARASITE
AB Many malaria vaccines are currently in development, although very few have been evaluated for efficacy in the field. Plasmodium falciparum multiple epitope (ME)- thrombospondin-related adhesion protein (TRAP) candidate vaccines are designed to potently induce effector T cells and so are a departure from earlier malaria vaccines evaluated in the field in terms of their mechanism of action. ME-TRAP vaccines encode a polyepitope string and the TRAP sporozoite antigen. Two vaccine vectors encoding ME-TRAP, plasmid DNA and modified vaccinia virus Ankara (MVA), when used sequentially in a prime-boost immunisation regime, induce high frequencies of effector T cells and partial protection, manifest as delay in time to parasitaemia, in a clinical challenge model.
   Methods and Findings A total of 372 Gambian men aged 15-45 y were randomised to receive either DNA ME-TRAP followed by MVA ME-TRAP or rabies vaccine (control). Of these men, 296 received three doses of vaccine timed to coincide with the beginning of the transmission season (141 in the DNA/MVA group and 155 in the rabies group) and were followed up. Volunteers were given sulphadoxine/pyrimethamine 2 wk before the final vaccination. Blood smears were collected weekly for 11 wk and whenever a volunteer developed symptoms compatible with malaria during the transmission season. The primary endpoint was time to first infection with asexual P. falciparum. Analysis was per protocol. DNA ME-TRAP and MVA ME-TRAP were safe and well-tolerated. Effector T cell responses to a non-vaccine strain of TRAP were 50-fold higher postvaccination in the malaria vaccine group than in the rabies vaccine group. Vaccine efficacy, adjusted for confounding factors, was 10.3% (95% confidence interval, -22% to +34%; p = 0.49). Incidence of malaria infection decreased with increasing age and was associated with ethnicity.
   Conclusions DNA/MVA heterologous prime-boost vaccination is safe and highly immunogenic for effector T cell induction in a malaria-endemic area. But despite having produced a substantial reduction in liver-stage parasites in challenge studies of non-immune volunteers, this first generation T cell-inducing vaccine was ineffective at reducing the natural infection rate in semi-immune African adults.
C1 MRC Labs, Banjul, Gambia.
   Univ Oxford, Ctr Clin Vaccinol & Trop Med, Nuffield Dept Clin Med, Oxford, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   London Sch Hyg & Trop Med, London WC1, England.
RP Moorthy, VS (reprint author), MRC Labs, Banjul, Gambia.
EM vmoorthy@malariavaccine.org
RI HILL, Adrian/C-1306-2008; Keating, Sheila/B-1652-2013; Milligan,
   Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Imoukhuede, Egeruan
   Babatunde/0000-0001-6679-0904; Gilbert, Sarah/0000-0002-6823-9750;
   Keating, Sheila/0000-0002-8324-3694
FU Wellcome Trust
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   BEJON P, 2004, IN PRESS J INFECT DI
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Coulibaly D, 2002, AM J TROP MED HYG, V67, P604
   Genton B, 2000, VACCINE, V18, P2504, DOI 10.1016/S0264-410X(00)00036-0
   Gilbert SC, 1999, BIOL CHEM, V380, P299, DOI 10.1515/BC.1999.041
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   Hanke T, 1999, J VIROL, V73, P7524
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Moorthy VS, 2003, VACCINE, V21, P2004
   Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9
   Ong'echa JMO, 2003, AM J TROP MED HYG, V68, P590
   Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P
   Prieur E, 2004, P NATL ACAD SCI USA, V101, P290, DOI 10.1073/pnas.0307158101
   ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0
   RODRIGUES M, 1992, J EXP MED, V175, P895, DOI 10.1084/jem.175.4.895
   RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579
   ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648
   Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763
NR 38
TC 122
Z9 123
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD NOV
PY 2004
VL 1
IS 2
BP 128
EP 136
AR e33
DI 10.1371/journal.pmed.0010033
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 902TG
UT WOS:000227378800013
PM 15526058
OA gold
DA 2017-08-15
ER

PT J
AU Faye, D
   Sulon, J
   Kane, Y
   Beckers, JF
   Leak, S
   Kaboret, Y
   de Sousa, NM
   Losson, B
   Geerts, S
AF Faye, D
   Sulon, J
   Kane, Y
   Beckers, JF
   Leak, S
   Kaboret, Y
   de Sousa, NM
   Losson, B
   Geerts, S
TI Effects of an experimental Trypanosoma congolense infection on the
   reproductive performance of West African Dwarf goats
SO THERIOGENOLOGY
LA English
DT Article
DE WAD goat; Trypanosoma congolense; reproduction; PAG; progesterone
ID PREGNANCY-ASSOCIATED GLYCOPROTEIN; TRYPANOTOLERANT DJALLONKE EWES; VIVAX
   INFECTION; PROGESTERONE CONCENTRATIONS; LISTERIA-MONOCYTOGENES; PLASMA
   PROGESTERONE; TOXOPLASMA-GONDII; NEOSPORA-CANINUM; ESTROUS-CYCLE;
   DIAGNOSIS
AB Thirty-six West African Dwarf (WAD) goats were used to assess the effects of an experimental Trypanosoma congolense infection on their reproductive system. Estrous cycles were synchronised and when confirmed pregnant (n = 3 1), the does were randomly allocated into control and trypanosome-infected groups. After infection, the animals were carefully observed till parturition. Trypanosome infection caused an increase of rectal temperature, a significant drop in PCV (infected: 23.3 +/- 0.3%; control: 28.5 +/- 10.4%; P < 0.0001) and abortions in 27.8% of the infected does. Kids born from infected does had a lower birth weight than kids born from control goats (0.9 +/- 0.1 kg versus 1.6 +/- 0.1 kg; P < 0.0001). Eight out of 13 kids (61.5%) that were born alive from infected does died during their first week of life. Plasma pregnancy-associated glycoprotein (PAG) and progesterone concentrations were lower in the infected animals than in the controls. In general, PAG concentration in does which aborted dropped before abortion. Our results revealed that artificial T congolense infection affected reproductive performance of WAD goats with abortions, premature births and perinatal losses being observed. Neither transplacental transmission of T congolense nor histopathological lesions of the placenta could be demonstrated. (c) 2004 Elsevier Inc. All rights reserved.
C1 Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Ecole Inter Etats Sci & Med Vet Dakar, Serv Pathol Med & Anat Pathol, Dakar, Senegal.
RP Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.
EM sgeerts@itg.be
CR BECKERS JF, 1978, ANN MED VET, V122, P579
   DOBSON H, 1993, THERIOGENOLOGY, V40, P411, DOI 10.1016/0093-691X(93)90278-D
   Dubey JP, 2002, VET PARASITOL, V110, P131, DOI 10.1016/S0304-4017(02)00320-5
   EDEGHERE H, 1992, VET PARASITOL, V43, P203, DOI 10.1016/0304-4017(92)90161-2
   ELHASSAN E, 1995, TROP ANIM HEALTH PRO, V27, P9, DOI 10.1007/BF02236327
   ELHASSAN E, 1994, TROP ANIM HEALTH PRO, V26, P213, DOI 10.1007/BF02240384
   Engeland IV, 1997, ANIM REPROD SCI, V45, P311, DOI 10.1016/S0378-4320(96)01590-4
   Engeland IV, 1996, VET PARASITOL, V67, P61, DOI 10.1016/S0304-4017(96)01025-4
   Garbayo JM, 2000, MOL REPROD DEV, V57, P311, DOI 10.1002/1098-2795(200012)57:4<311::AID-MRD2>3.0.CO;2-F
   Gonzalez F, 1999, THERIOGENOLOGY, V52, P717, DOI 10.1016/S0093-691X(99)00165-X
   Gonzalez F, 2000, REPROD DOMEST ANIM, V35, P79, DOI 10.1046/j.1439-0531.2000.00202.x
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   Green JA, 2000, BIOL REPROD, V62, P1624, DOI 10.1095/biolreprod62.6.1624
   GREENWOOD FC, 1963, BIOCHEM J, V89, P114
   HUMBLOT P, 1990, J REPROD FERTIL, V89, P205
   IKEDE BO, 1988, ACTA TROP, V45, P5
   Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93
   Leak S.G.A., 1998, TSETSE BIOL ECOLOGY
   LLEWELYN CA, 1987, BRIT VET J, V143, P423
   Moore DP, 2002, VET PARASITOL, V107, P303, DOI 10.1016/S0304-4017(02)00129-2
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MUTAYOBA BM, 1989, RES VET SCI, V47, P315
   MUTAYOBA BM, 1988, ACTA ENDOCRINOL-COP, V117, P477
   MUTAYOBA BM, 1988, ACTA TROP, V45, P225
   NARS PW, 1973, J ENDOCRINOL, V57, P47
   OGAA JS, 1991, P 21 M ISCTRC OAU 19
   OGWU D, 1986, THERIOGENOLOGY, V25, P383, DOI 10.1016/0093-691X(86)90046-4
   OKECH G, 1996, THERIOGENOLOGY, V5, P859
   Osaer S, 1999, VET PARASITOL, V82, P101, DOI 10.1016/S0304-4017(99)00011-4
   Osaer S, 1998, ANIM REPROD SCI, V51, P97, DOI 10.1016/S0378-4320(98)00067-0
   PARIS J, 1982, ACTA TROP, V39, P307
   Perenyi ZS, 2002, REPROD DOMEST ANIM, V37, P100, DOI 10.1046/j.1439-0531.2002.00341.x
   Quinn HE, 2002, TRENDS PARASITOL, V18, P391, DOI 10.1016/S1471-4922(02)02324-3
   RANILLA MJ, 1994, THERIOGENOLOGY, V42, P537, DOI 10.1016/0093-691X(94)90691-B
   RONAYNE E, 1990, IRISH J AGR RES, V29, P109
   ROWLANDS GJ, 1995, ACTA TROP, V59, P105, DOI 10.1016/0001-706X(95)00074-O
   *SAS I INC, 2000, STAT AN SYST I SAS V
   SEKONI VO, 1994, THERIOGENOLOGY, V42, P557, DOI 10.1016/0093-691X(94)90373-Q
   SHALABY AS, P 7 INT C GOATS 2000
   Sousa NM, 1999, SMALL RUMINANT RES, V32, P137, DOI 10.1016/S0921-4488(98)00171-0
   Sousa NM, 2003, THERIOGENOLOGY, V59, P1131
   TILTON JE, 1972, J ANIM SCI, V34, P605
   Zarrouk A, 1999, THERIOGENOLOGY, V52, P1095, DOI 10.1016/S0093-691X(99)00197-1
   Zarrouk A, 1999, THERIOGENOLOGY, V51, P1321, DOI 10.1016/S0093-691X(99)00076-X
   ZOLI AP, 1991, BIOL REPROD, V45, P1, DOI 10.1095/biolreprod45.1.1
NR 45
TC 12
Z9 12
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
J9 THERIOGENOLOGY
JI Theriogenology
PD NOV
PY 2004
VL 62
IS 8
BP 1438
EP 1451
DI 10.1016/j.theriogenology.2004.02.007
PG 14
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA 906RL
UT WOS:000227660000007
PM 15451252
OA No
DA 2017-08-15
ER

PT J
AU Rayco-Solon, P
   Moore, SE
   Fulford, AJ
   Prentice, AM
AF Rayco-Solon, P
   Moore, SE
   Fulford, AJ
   Prentice, AM
TI Fifty-year mortality trends in three rural African villages
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE infant mortality; neonatal mortality; under-5 mortality; early adult
   mortality; developing countries
ID YOUNG-CHILDREN; CHILDHOOD MORTALITY; GAMBIAN VILLAGES; NEONATAL CARE;
   GROWTH; INFANT; HEALTH; DEATHS
AB OBJECTIVE To determine differential improvements in mortality rates according to age, and to discuss differences in neonatal and post-neonatal mortality rates, using longitudinal data from the past 50 years in three rural Gambian villages.
   METHODS All villagers whose date of birth was recorded were followed up until death or October 1997. A Lexis expansion was performed to categorize age: early neonatal, late neonatal, infant, 1-4 years, 5-14 years and 15 or more years. Calendar time was divided into three periods - prior to 1975, 1975-1984 and after 1985, representing different levels of clinical care. Cox regression and likelihood-ratio test were used to model the hazards ratios.
   RESULTS There were 3981 subjects included in the analysis with a total of 59 002 person-years follow-up. There was a dramatic decrease in neonatal (44 to 15), infant (162 to 36) and under-five mortality rates (397-66 per 1000) from pre-1975 to the present. The disproportionate decrease in the mortality rates means that neonatal deaths accounted for a greater percentage of post-natal deaths in later years. There was a marked seasonality in mortality rates with significantly more deaths in the 'hungry' season prior to 1975 (odds = 1.87; 95% CI = 1.62-2.17) and from 1975 to 1984 (odds = 1.84; 95% CI = 1.34-2.53). This seasonality of death has diminished in recent years (odds = 1.23; 95% CI = 0.85-1.76).
   CONCLUSION Our analysis indicates a dramatic reduction in mortality rates and an attenuation in the seasonality of death. It is likely that the efficient implementation of basic currently available health measures was one of the key elements in achieving such a major reduction in mortality.
C1 MRC Labs, MRC Keneba, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
RP MRC Labs, MRC Keneba, POB 273, Banjul, Gambia.
EM pura.solon@lshtm.ac.uk; sophie.moore@lshtm.ac.uk;
   tony.fulford@lshtm.ac.uk; andrew.prentice@lshtm.ac.uk
CR AlNahedh N, 1997, J ROY SOC HEALTH, V117, P106, DOI 10.1177/146642409711700207
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Hill AG, 1998, LANCET, V352, P1909, DOI 10.1016/S0140-6736(05)60400-X
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1
   Kruger C, 2002, B WORLD HEALTH ORGAN, V80, P759
   LAMB WH, 1984, LANCET, V2, P912
   Leach A, 1999, ANN TROP PAEDIATR, V19, P33, DOI 10.1080/02724939992617
   Marsh David R, 2002, J Perinatol, V22, P572, DOI 10.1038/sj.jp.7210793
   MCGREGOR IA, 1970, T ROY SOC TROP MED H, V64, P48, DOI 10.1016/0035-9203(70)90196-3
   MCGREGOR IA, 1961, BRIT MED J, V2, P1661
   MCGREGOR IA, 1968, T ROY SOC TROP MED H, V62, P341, DOI 10.1016/0035-9203(68)90084-9
   MCGREGOR IA, 1991, DIS MORTALITY SUBSAH
   Mohan P, 2002, LANCET, V359, P1620, DOI 10.1016/S0140-6736(02)08499-4
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Poskitt EME, 1999, ARCH DIS CHILD, V80, P115
   PRENTICE AM, 1991, ACTA PAEDIATR SCAND, P67
   Preston S. H., 2001, DEMOGRAPHY MEASURING
   Rousham EK, 1997, ACTA PAEDIATR, V86, P46, DOI 10.1111/j.1651-2227.1997.tb08830.x
   ROWLAND MGM, 1981, SEASONAL DIMENSIONS, P164
   THOMPSON BARBARA, 1967, J TROP PEDIAT, V13, P124
   THOMSON AM, 1968, T ROY SOC TROP MED H, V62, P330, DOI 10.1016/0035-9203(68)90083-7
   Tully M, 1978, Nurs Times, V74, P401
   UNICEF, 2002, STAT WORLDS CHILDR 2
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Vandale S, 1997, SALUD PUBLICA MEXICO, V39, P48, DOI 10.1590/S0036-36341997000100008
   WEAVER LT, 1993, LANCET, V341, P1327, DOI 10.1016/0140-6736(93)90827-4
NR 29
TC 41
Z9 42
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD NOV
PY 2004
VL 9
IS 11
BP 1151
EP 1160
DI 10.1111/j.1365-3156.2004.01325.x
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 872DR
UT WOS:000225188100003
PM 15548310
OA No
DA 2017-08-15
ER

PT J
AU Thomas, JE
   Bunn, JEG
   Kleanthous, H
   Monath, TP
   Harding, M
   Coward, WA
   Weaver, LT
AF Thomas, JE
   Bunn, JEG
   Kleanthous, H
   Monath, TP
   Harding, M
   Coward, WA
   Weaver, LT
TI Specific immunoglobulin A antibodies in maternal milk and delayed
   Helicobacter pylori colonization in Gambian infants
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID C-13-UREA BREATH TEST; IMMUNE-RESPONSES; NATURAL-HISTORY; FELIS
   INFECTION; HUMAN-DISEASE; MOUSE MODEL; CHILDREN; UREASE; MICE;
   IMMUNIZATION
AB Background. Immunoglobulin A (IgA) in maternal milk may protect Gambian infants from early Helicobacter pylori colonization. This study sought evidence that this protection could be due to specific IgA antibodies.
   Methods. Sixty-five infants were screened from 12 weeks of age with [13C]-urea breath tests. Antibodies in maternal milk were measured to determine total IgA content and to detect specific IgA antibodies against crude whole-cell and recombinant H. pylori urease antigen preparations.
   Results. Ten children (15%) had no evidence of early H. pylori colonization, 10 (15%) had early H. pylori colonization, and 43 (66%) had mixed results. Levels of maternal circulating specific immunoglobulin G, total milk IgA, and IgA directed against crude whole-cell H. pylori antigen preparation were not significantly associated with the rate of infant H. pylori colonization. However, mothers of infants with no evidence of early colonization produced significantly higher levels of anti-recombinant urease IgA antibodies in milk than did control mothers, particularly at 8, 16, and 20 weeks postpartum (P < .01).
   Conclusions. These observations support the hypothesis that antibodies in mother's milk directed against H. pylori urease can protect against colonization in human infancy.
C1 Med Res Council Human Nutr Res, Keneba, Gambia.
   Med Res Council Human Nutr Res, Cambridge, England.
   Univ Newcastle Upon Tyne, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Univ Glasgow, Dept Child Hlth, Glasgow G12 8QQ, Lanark, Scotland.
   Univ Liverpool Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   Acambis, Cambridge, England.
RP Thomas, JE (reprint author), Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM J.E.Thomas@ncl.ac.uk
CR BLANCHARD TG, 1995, INFECT IMMUN, V63, P1394
   BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146
   Clyne M, 1997, GUT, V40, P731
   CZINN SJ, 1993, VACCINE, V11, P637, DOI 10.1016/0264-410X(93)90309-L
   Dial EJ, 1998, DIGEST DIS SCI, V43, P2750, DOI 10.1023/A:1026675916421
   Dubois A, 1996, INFECT IMMUN, V64, P2885
   FERRERO RL, 1994, INFECT IMMUN, V62, P4981
   Ferrero RL, 1997, GASTROENTEROLOGY, V113, P185, DOI 10.1016/S0016-5085(97)70094-5
   Granstrom M, 1997, J CLIN MICROBIOL, V35, P468
   GUELRUD M, 1994, J PEDIATR GASTR NUTR, V18, P461, DOI 10.1097/00005176-199405000-00010
   Kim JS, 2000, J MICROBIOL BIOTECHN, V10, P865
   Kindermann A, 2000, J PEDIATR GASTR NUTR, V30, P85, DOI 10.1097/00005176-200001000-00023
   Kleanthous H, 1998, INFECT IMMUN, V66, P2879
   Kleanthous H., 1995, Gut, V37, pA94
   KLEIN PD, 1994, AM J GASTROENTEROL, V89, P2196
   Li CF, 1996, DIGEST DIS SCI, V41, P2142, DOI 10.1007/BF02071393
   Malaty HM, 1999, CLIN INFECT DIS, V28, P279, DOI 10.1086/515105
   Malaty HM, 2002, J PEDIATR GASTR NUTR, V35, P59, DOI 10.1097/01.MPG.0000016486.73596.4E
   Malaty HM, 2001, CLIN INFECT DIS, V32, P1387, DOI 10.1086/320148
   MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456
   MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002
   Parsonnet J, 1998, INFECT DIS CLIN N AM, V12, P185, DOI 10.1016/S0891-5520(05)70417-7
   PRENTICE A, 1984, ACTA PAEDIATR SCAND, V73, P796, DOI 10.1111/j.1651-2227.1984.tb17778.x
   Rothenbacher D, 2002, INT J EPIDEMIOL, V31, P632, DOI 10.1093/ije/31.3.632
   SOMAN G, 1995, FASEB J, V9, pA1465
   SULLIVAN PB, 1990, ARCH DIS CHILD, V65, P189
   Sutton P, 2000, IMMUNOL CELL BIOL, V78, P28, DOI 10.1046/j.1440-1711.2000.00881.x
   Thomas JE, 1999, PEDIATR RES, V46, P147, DOI 10.1203/00006450-199908000-00003
   THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L
   Thomas JE, 1999, PEDIATR RES, V45, P218, DOI 10.1203/00006450-199902000-00010
   THOMAS JE, 1993, LANCET, V342, P121, DOI 10.1016/0140-6736(93)91327-I
   THOMAS JE, 1990, J CLIN MICROBIOL, V28, P2641
   Torres J, 2000, ARCH MED RES, V31, P431, DOI 10.1016/S0188-4409(00)00099-0
   Weaver LT, 1998, ARCH DIS CHILD, V78, P235
   Zevering Y, 1999, GUT, V45, P465
NR 35
TC 22
Z9 22
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2004
VL 39
IS 8
BP 1155
EP 1160
DI 10.1086/424514
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 904JF
UT WOS:000227491700009
PM 15486839
OA No
DA 2017-08-15
ER

PT J
AU Hallett, RL
   Sutherland, CJ
   Alexander, N
   Ord, R
   Jawara, M
   Drakeley, CJ
   Pinder, M
   Walraven, G
   Targett, GAT
   Alloueche, A
AF Hallett, RL
   Sutherland, CJ
   Alexander, N
   Ord, R
   Jawara, M
   Drakeley, CJ
   Pinder, M
   Walraven, G
   Targett, GAT
   Alloueche, A
TI Combination therapy counteracts the enhanced transmission of
   drug-resistant malaria parasites to mosquitoes
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; CHLOROQUINE; CHILDREN; ANTIMALARIAL;
   ARTESUNATE
AB Malaria parasites carrying genes conferring resistance to antimalarials are thought to have a selective advantage which leads to higher rates of transmissibility from the drug-treated host. This is a likely mechanism for the increasing prevalence of parasites with resistance to chloroquine (CQ) and sulfadoxine-pyrimethamine in sub-Saharan Africa. Combination therapy is the key strategy being implemented to reduce the impact of resistance, but its effect on the transmission of genetically resistant parasites from treated patients to mosquito vectors has not been measured directly. In a trial comparing CQ monotherapy to the combination CQ plus artesunate (AS) in Gambian children with uncomplicated falciparum malaria, we measured transmissibility by feeding Anopheles gambiae mosquitoes with blood from 43 gametocyte-positive patients through a membrane. In the CQ-treated group, gametocytes from patients carrying parasites with the CQ resistance-associated allele pfcrt-76T prior to treatment produced infected mosquitoes with 38 times higher Plasmodium falciparum oocyst burdens than mosquitoes fed on gametocytes from patients infected with sensitive parasites (P < 0.001). Gametocytes from parasites carrying the resistance-associated allele pfmdr1-86Y produced 14-fold higher oocyst burdens than gametocytes from patients infected with sensitive parasites (P = 0.011). However, parasites carrying either of these resistance-associated alleles pretreatment were not associated with higher mosquito oocyst burdens in the CQ-AS-treated group. Thus, combination therapy overcomes the transmission advantage enjoyed by drug-resistant parasites.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Joint Malaria Programme, Moshi, Tanzania.
RP Sutherland, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM colin.sutherland@lshtm.ac.uk
CR Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2
   DRAKELEY CJ, 2004, TROP MED INT HEALTH, V9, P1
   Duraisingh MT, 2000, PARASITOLOGY, V121, P1, DOI 10.1017/S0031182099006022
   Handunnetti SM, 1996, T ROY SOC TROP MED H, V90, P563, DOI 10.1016/S0035-9203(96)90325-9
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Robert V, 2000, AM J TROP MED HYG, V62, P210
   Sowunmi A, 2003, TROP MED INT HEALTH, V8, P783, DOI 10.1046/j.1365-3156.2003.01093.x
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
   World Health Organization/UNICEF, 2003, AFR MAL REP
NR 13
TC 52
Z9 53
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD OCT
PY 2004
VL 48
IS 10
BP 3940
EP 3943
DI 10.1128/AAC.48.10.3940-3943.2004
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 858UH
UT WOS:000224217000042
PM 15388456
OA No
DA 2017-08-15
ER

PT J
AU McConkey, SJ
   Awi, D
   Cavenaugh, JS
   Mendy, M
   Schneider, J
   Pearse, G
   Hill, AV
AF McConkey, SJ
   Awi, D
   Cavenaugh, JS
   Mendy, M
   Schneider, J
   Pearse, G
   Hill, AV
TI Safety, immunogenicity, and efficacy results of a phase II trial of
   therapeutic vaccines for chronic HBV in the Gambia.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 55th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY OCT 29-NOV 02, 2004
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 MRC Labs, Banjul, Gambia.
   Univ Oxford, Oxford, England.
   Oxxon Therapeut, Oxford, England.
RI HILL, Adrian/C-1306-2008; McConkey, Samuel/E-7307-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2004
VL 40
IS 4
SU 1
BP 676A
EP 676A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857FR
UT WOS:000224102101178
OA No
DA 2017-08-15
ER

PT J
AU Harper, ME
   Hill, PC
   Bah, AH
   Manneh, K
   McAdam, KPWJ
   Lienhardt, C
AF Harper, ME
   Hill, PC
   Bah, AH
   Manneh, K
   McAdam, KPWJ
   Lienhardt, C
TI Traditional healers participate in tuberculosis control in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE The Gambia; tuberculosis; traditional healer; diagnostic delay
ID HEALTH-SERVICES; CONTROL PROGRAM; SOUTH-AFRICA; DELAY; TANZANIA; GENDER
AB SETTING: Twenty-three Gambian villages.
   OBJECTIVE: To evaluate the feasibility of involving traditional healers in tuberculosis diagnosis and treatment in The Gambia.
   DESIGN: Twenty-eight traditional healers were educated in the recognition of signs and symptoms of tuberculosis and indications for referral. They administered medications to confirmed cases, and were revisited after 1 year to assess knowledge retention.
   RESULTS: Over 6 months, the traditional healers referred 66 suspects, from whom eight cases were diagnosed. All were successfully treated. Twenty-three of 24 traditional healers re-interviewed retained appropriate knowledge; 16 continued to refer suspects.
   CONCLUSIONS: Traditional healers can play a positive role in tuberculosis control.
C1 MRC Labs, Dept TB, Banjul, Gambia.
   Gambia Govt, Dept Dis Control, Western Div, Banjul, Gambia.
   Inst Rech Dev, Dept TB, Dakar, Senegal.
RP Hill, PC (reprint author), MRC Labs, Dept TB, POB 273, Banjul, Gambia.
EM phill@mrc.gm
CR Ajai O, 1990, Med Law, V9, P685
   Colvin M, 2003, INT J TUBERC LUNG D, V7, pS86
   Eastwood SV, 2004, INT J TUBERC LUNG D, V8, P70
   HARPER M, 2004, T ROY SOC TROP MED H, V97, P506
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233
   MANKAZANA EM, 1979, S AFR MED J, V56, P1003
   Muela SH, 2000, HEALTH POLICY PLANN, V15, P296, DOI 10.1093/heapol/15.3.296
   Needham DM, 2001, TROP MED INT HEALTH, V6, P256, DOI 10.1046/j.1365-3156.2001.00709.x
   Wandwalo ER, 2000, INT J TUBERC LUNG D, V4, P133
   Wilkinson D, 1999, INT J TUBERC LUNG D, V3, P838
NR 10
TC 11
Z9 12
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD OCT
PY 2004
VL 8
IS 10
BP 1266
EP 1268
PG 3
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 862LO
UT WOS:000224492500016
PM 15527161
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   van der Loeff, MFS
   Aveika, AA
   Sabally, S
   Togun, T
   Sarge-Njie, R
   Alabi, AS
   Jaye, A
   Corrah, T
   Whittle, HC
AF van der Sande, MAB
   van der Loeff, MFS
   Aveika, AA
   Sabally, S
   Togun, T
   Sarge-Njie, R
   Alabi, AS
   Jaye, A
   Corrah, T
   Whittle, HC
TI Body mass index at time of HIV diagnosis - A strong and independent
   predictor of survival
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE Africa; survival; HIV-1; HIV-2; body mass index; CD4(+) count; cohort
ID AIDS-DEFINING ILLNESS; INFECTED PATIENTS; PROGNOSTIC VALUE;
   COTE-DIVOIRE; WEIGHT-LOSS; MALNUTRITION; TUBERCULOSIS; PROGRESSION;
   PREVALENCE; MORTALITY
AB Background: Identification of basic prognostic indicators of HIV infection is essential before widespread antiretroviral therapy can be implemented in low-technology settings. This study assessed how well body mass index (BMI:kg/m(2)) predicts survival.
   Methods: BMI within 3 months of HIV diagnosis was obtained from 1657 patients aged greater than or equal to 15 years, recruited in a seroprevalent clinical cohort in The Garnbia since 1992 and followed up at least once. Baseline CD4(+) counts and clinical assessment at time of diagnosis were done.
   Results: The mortality hazard ratio (FIR) of those with a baseline BMI < 18 compared with those with a baseline BMI greater than or equal to 18 was 3.4 (95%, CI, 3.0-3.9). The median Survival time of those presenting with a BMI < 16 was 0.8 years, in contrast to a median survival of 8.9 years for those with a baseline BMI greater than or equal to 22. Baseline BMI < 18 remained a highly significant independent predictor of mortality after adjustment for age, sex, co-trimoxazole prophylaxis, tuberculosis, reported wasting at diagnosis, and baseline CD4(+) cell Count (aqjusted HR = 2.5 , 95% CI 2.0-3.0). Sensitivity and specificity of baseline BMI <18 was comparable to that of a CD4(+) Count < 200 in predicting mortality within 6 months of diagnosis.
   Discussion: BMI at diagnosis is a strong, independent predictor of survival in HIV-infected patients in West Africa. In the absence of sophisticated clinical and laboratory support, BMI may also prove a useful guide for deciding when to initiate antiretroviral therapy.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP van der Sande, MAB (reprint author), Labs Fajara, POB 273, Banjul, Gambia.
EM mvdsande@mrc.gm
CR ALABI AS, 2003, AIDS, V7, P1513
   Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1
   Badri M, 2002, INT J TUBERC LUNG D, V6, P231
   BAHRI M, 2001, SADJ, V56, P592
   Castetbon K, 2001, AM J EPIDEMIOL, V154, P75, DOI 10.1093/aje/154.1.75
   Harries AD, 1998, B WORLD HEALTH ORGAN, V76, P651
   KARNOFSKY DA, 1948, CANCER, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   LINDAN CP, 1992, ANN INTERN MED, V116, P320
   Maas JJ, 1998, J ACQ IMMUN DEF SYND, V19, P254
   Malvy E, 2001, J Am Coll Nutr, V20, P609
   Melchior JC, 1999, NUTRITION, V15, P865, DOI 10.1016/S0899-9007(99)00210-5
   Morgan D, 2002, BRIT MED J, V324, P193, DOI 10.1136/bmj.324.7331.193
   Niyongabo T, 1997, EUR J CLIN NUTR, V51, P637, DOI 10.1038/sj.ejcn.1600461
   PALENICK JP, 1995, J ACQ IMMUN DEF SYND, V9, P43
   Post FA, 2001, S AFR MED J, V91, P583
   Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4
   Rivera S, 1998, J ACQ IMMUN DEF SYND, V17, P411
   SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004
   van der Loeff MFS, 2002, AIDS, V16, P1775
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   Wheeler DA, 1998, J ACQ IMMUN DEF SYND, V18, P80
   Zachariah R, 2002, T ROY SOC TROP MED H, V96, P291, DOI 10.1016/S0035-9203(02)90103-3
   1993, MMWR MORB MORTAL WKL, V41, P1
NR 23
TC 78
Z9 78
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2004
VL 37
IS 2
BP 1288
EP 1294
DI 10.1097/01.qai.0000122708.59121.03
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 857ZJ
UT WOS:000224159300010
PM 15385737
OA No
DA 2017-08-15
ER

PT J
AU Ginty, F
   Prentice, A
   McKenna, L
   Bennett, J
   Dibba, B
AF Ginty, F
   Prentice, A
   McKenna, L
   Bennett, J
   Dibba, B
TI An investigation into the effects of calcium carbonate supplementation
   on markers of pubertal status and leptin in 8-12 year old Gambian girls.
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Meeting Abstract
CT 26th Annual Meeting of the
   American-Society-for-Bone-and-Mineral-Research
CY OCT 01-05, 2004
CL Seattle, WA
SP Amer Soc Bone & Mineral Res
C1 MRC Human Nutr Res, Cambridge, England.
   MRC, Keneba, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2004
VL 19
SU 1
BP S450
EP S450
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 860FB
UT WOS:000224326802513
OA No
DA 2017-08-15
ER

PT J
AU Wojnowski, L
   Turner, PC
   Pedersen, B
   Hustert, E
   Brockmoller, J
   Mendy, M
   Whittle, HC
   Kirk, G
   Wild, CP
AF Wojnowski, L
   Turner, PC
   Pedersen, B
   Hustert, E
   Brockmoller, J
   Mendy, M
   Whittle, HC
   Kirk, G
   Wild, CP
TI Increased levels of aflatoxin-albumin adducts are associated with CYP3A5
   polymorphisms in The Gambia, West Africa
SO PHARMACOGENETICS
LA English
DT Article
DE aflatoxins; hepatocellular carcinoma; CYP3A5; genetic polymorphism
ID CARCINOGEN METABOLIZING ENZYMES; HUMAN LIVER; GENETIC-DETERMINANTS;
   EPOXIDE HYDROLASE; DRUG-METABOLISM; PUBLIC-HEALTH; EXPRESSION; B-1;
   HEPATITIS; ACTIVATION
AB Objectives Major risk factors for hepatocellular carcinoma (HCC) are hepatitis viruses and exposure to aflatoxins, including aflatoxin B1 (AFB1). The mutagenic effect of AFB1 results from hepatic bioactivation to AFB1 -exo-8,9-epoxide. This is in part catalysed by CYP3A5, an enzyme expressed polymorphically. We investigated the role of CYP3A5 polymorphisms in the formation of AFB1 -exo-8,9-epoxide in The Gambia, a population exposed to high aflatoxin levels.
   Methods Common CYP3A5 polymorphisms were identified in an African-American population. Subsequently, 288 Gambian subjects were genotyped and CYP3A5 activity predicted using haplotypes of the three variant loci (CYP3A5*3, *6 and *7) associated with decreases in protein expression. CYP3A5 expression was then compared to aflatoxin-albumin (AF-alb) adduct, a biomarker of AFB1 bioactivation; data were also analysed in relation to expression of other aflatoxin-metabolizing enzymes.
   Results CYP3A5 haplotypes reflecting high CYP3A5 protein expression were associated with increased AF-alb. Compared to individuals with predicted low expression those predicted to express CYP3A5 from one allele displayed 16.1% higher AF-alb (95% CI: -2.5,38.2, P = 0.093) and homozygous expressers displayed 23.2% higher AF-alb levels (95% CI: -0.01, 52.0, P = 0.051). The effect of the CYP3A5 polymorphism was strongest in individuals with low CYP3A4 activity with a 70.1% increase in AF-alb (95% CI: 11.8,158.7, P < 0.05) in high compared to low expressers. A similar effect was observed for individuals with null alleles of GSTM1, which conjugates the AFB1 -exo-8,9-epoxide to reduced glutathione.
   Conclusions The CYP3A5 polymorphism is associated with increased levels of the mutagenic AFB1 -exo-8,9-epoxide, particularly in individuals with low CYP3A4, and this may modulate individual risk of HCC. (C) 2004 Lippincott Williams Wilkins.
C1 Univ Leeds, Ctr Biostat & Epidemiol, Mol Epidemiol Unit, Leeds Inst Genet Hlth & Therapeut, Leeds LS2 9JT, W Yorkshire, England.
   Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany.
   US Dept HHS, NCI, Viral Epidemiol Branch, NIH, Bethesda, MD USA.
   Epidauros Biotechnol AG, D-82347 Bernried, Germany.
   MRC Labs, Fajara, Gambia.
   Univ Gottingen, Dept Clin Pharmacol, D-37075 Gottingen, Germany.
RP Wild, CP (reprint author), Univ Leeds, Ctr Biostat & Epidemiol, Mol Epidemiol Unit, Leeds Inst Genet Hlth & Therapeut, Leeds LS2 9JT, W Yorkshire, England.
EM c.p.wild@leeds.co.uk
RI Turner, Paul/A-6152-2011; Turner, Paul/B-8131-2013
CR Chemin I, 1996, HEPATOLOGY, V24, P649, DOI 10.1002/hep.510240330
   Chemin I, 1999, LIVER, V19, P81, DOI 10.1111/j.1478-3231.1999.tb00015.x
   GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P374, DOI 10.1006/abbi.1995.1177
   GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P498, DOI 10.1006/abbi.1995.1259
   Guengerich FP, 1998, MUTAT RES-FUND MOL M, V402, P121, DOI 10.1016/S0027-5107(97)00289-3
   Henry SH, 1999, SCIENCE, V286, P2453, DOI 10.1126/science.286.5449.2453
   Hukkanen J, 2003, J PHARMACOL EXP THER, V304, P745, DOI 10.1124/jpet.102.038208
   Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005
   Johnson WW, 1997, CHEM RES TOXICOL, V10, P672, DOI 10.1021/tx960209j
   Kelly EJ, 2002, TOXICOL SCI, V65, P35, DOI 10.1093/toxsci/65.1.35
   KIRBY GM, 1994, MOL CARCINOGEN, V11, P74, DOI 10.1002/mc.2940110204
   Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882
   Lee SJ, 2003, PHARMACOGENETICS, V13, P461, DOI 10.1097/01.fpc.0000054117.14659.ac
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Rae JM, 2001, J PHARMACOL EXP THER, V299, P849
   Rohde K, 2001, HUM MUTAT, V17, P289, DOI 10.1002/humu.26
   Schuetz JD, 1996, MOL PHARMACOL, V49, P63
   Wang HF, 1998, BIOCHEMISTRY-US, V37, P12536, DOI 10.1021/bi980895g
   Westlind-Johnsson A, 2003, DRUG METAB DISPOS, V31, P755, DOI 10.1124/dmd.31.6.755
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   Wild CP, 2002, MUTAGENESIS, V17, P471, DOI 10.1093/mutage/17.6.471
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393
NR 23
TC 40
Z9 45
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0960-314X
J9 PHARMACOGENETICS
JI Pharmacogenetics
PD OCT
PY 2004
VL 14
IS 10
BP 691
EP 700
DI 10.1097/00008571-200410000-00007
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
GA 865FK
UT WOS:000224687700007
PM 15454734
OA No
DA 2017-08-15
ER

PT J
AU Sirugo, G
   Ashenbrenner, J
   Odunsi, KK
   Morakinyo, OO
   Page, GG
AF Sirugo, G
   Ashenbrenner, J
   Odunsi, KK
   Morakinyo, OO
   Page, GG
TI No evidence of association between the genetic predisposition for
   dizygotic twinning and schizophrenia in West Africa
SO SCHIZOPHRENIA RESEARCH
LA English
DT Letter
ID NIGERIA
C1 MRC, Lab Human Genet, Banjul, Gambia.
   Roswell Pk Canc Inst, Dept Gynecol Oncol, Buffalo, NY 14263 USA.
   Obafemi Awolowo Univ, Dept Mental Hlth, Ife, Nigeria.
   Univ Alabama, Dept Epidemiol & Biostat, Birmingham, AL USA.
RP Sirugo, G (reprint author), MRC, Lab Human Genet, Atlantic Blvd,POB 273, Banjul, Gambia.
EM gsirugo@mrc.gm
CR AABY P, 1995, EPIDEMIOLOGY, V6, P419, DOI 10.1097/00001648-199507000-00016
   ABIODUN OA, 1992, J PSYCHOSOM RES, V36, P485, DOI 10.1016/0022-3999(92)90009-Q
   JAFFAR S, 1998, ANN TROP PAEDIATR, V18, P213
   Klaning U, 2002, SCHIZOPHR RES, V58, P31, DOI 10.1016/S0920-9964(01)00343-7
   MORAKINYO O, 1995, DEV COMPREHENSIVE NA
   Nylander P P, 1978, Prog Clin Biol Res, V24 Pt B, P35
   NYLANDER PP, 1971, J BIOSOC SCI, V3, P151
   NYLANDER PP, 1969, ANN HUM GENET, V33, P41, DOI 10.1111/j.1469-1809.1969.tb01627.x
   SCHMIDT HD, 1983, ANN HUM BIOL, V4, P371
   Vogel P., 1997, HDB HUMAN GENETICS
NR 10
TC 2
Z9 2
U1 5
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD OCT 1
PY 2004
VL 70
IS 2-3
BP 343
EP 344
DI 10.1016/j.schres.2004.01.002
PG 2
WC Psychiatry
SC Psychiatry
GA 853EN
UT WOS:000223809600018
PM 15329309
OA No
DA 2017-08-15
ER

PT J
AU Burton, M
   Nyong'o, O
   Burton, K
   John, W
   Inkoom, E
   Pinder, M
   Corrah, T
   Johnson, G
   Bailey, R
AF Burton, M
   Nyong'o, O
   Burton, K
   John, W
   Inkoom, E
   Pinder, M
   Corrah, T
   Johnson, G
   Bailey, R
TI Retinopathy in Gambian children admitted to hospital with malaria
SO TROPICAL DOCTOR
LA English
DT Article
ID OCULAR FUNDUS FINDINGS; CEREBRAL MALARIA; RETINAL HEMORRHAGES;
   FALCIPARUM-MALARIA
AB A characteristic retinopathy associated with a poor prognosis has previously been described in African children with established cerebral malaria. However, relatively little is known about retinal abnormalities in children with severe non-cerebral malaria, the group most at risk of developing the cerebral complications of this disease. In this study the prevalence, pattern, clinical significance and accessibility to clinical examination of this characteristic retinopathy are described in 106 Gambian children admitted consecutively to hospital with severe malaria, including six with established cerebral malaria.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, London, England.
RP Burton, M (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
CR BELL R W, 1975, Annals of Ophthalmology, V7, P1439
   BYWATER HH, 1922, T OPHTHAL SOC UK, V42, P359
   DAVIS MW, 1982, PAPUA NEW GUINEA MED, V25, P19
   GRANT MW, 1946, ARCH OPHTHALMOL-CHIC, V35, P48
   HASLETT P, 1991, J TROP PEDIATRICS, V37, P86
   Lewallen S, 1996, T ROY SOC TROP MED H, V90, P144, DOI 10.1016/S0035-9203(96)90116-9
   Lewallen S, 1999, T ROY SOC TROP MED H, V93, P619, DOI 10.1016/S0035-9203(99)90071-8
   LEWALLEN S, 1993, OPHTHALMOLOGY, V100, P857
   LOOAREESUWAN S, 1983, AM J TROP MED HYG, V32, P911
   NEWTON CRJC, 1991, ARCH DIS CHILD, V66, P753
   Olumese PE, 1997, E AFR MED J, V74, P285
   Poncet F, 1878, ANN OCUL, V79, P201
   RUNYAN TE, 1977, ANN OPHTHALMOL, V9, P1521
   Schemann JF, 2002, AM J TROP MED HYG, V67, P61
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
NR 15
TC 9
Z9 9
U1 0
U2 1
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD OCT
PY 2004
VL 34
IS 4
BP 214
EP 218
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 863JH
UT WOS:000224557100008
PM 15510945
OA No
DA 2017-08-15
ER

PT J
AU Viviani, S
   Mendy, M
   Jack, AD
   Hall, AJ
   Montesano, R
   Whittle, HC
AF Viviani, S
   Mendy, M
   Jack, AD
   Hall, AJ
   Montesano, R
   Whittle, HC
TI EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE vaccine; DPT; polio; measles
ID HEPATITIS-B VACCINE; ORAL POLIO VACCINE; EXPANDED PROGRAM; MEASLES;
   CHILDREN; TETANUS; IMMUNIZATION; IMMUNITY; INFANTS; AFRICA
AB OBJECTIVES We evaluated antibody prevalence to measles, polio 1 and 3, and tetanus toxoid antibodies in 8-9 year-old children in The Gambia within the framework of the Gambia Hepatitis Intervention Study (GHIS), a large vaccine trial aimed at evaluating vaccine efficacy against hepatitis B virus (HBV) infection, chronic carriage and primary liver cancer in a high risk population. The results of the present survey were compared with a previous survey performed with the same objectives and same methodology but in different children at 3-4 years of age.
   METHODS Four clusters of 200 children each were sampled as representative of the whole country. Children would have received BCG, diphtheria-pertussis-tetanus vaccine (DPT), poliovirus vaccine (OPV), measles and yellow fever immunization. The measles haemoagglutination inhibition test (HAI) was used to detect measles antibody. Antibodies to polioviruses 1 and 3 were tested using the standard polio neutralization assay described in the EPI manual (WHO 1990). An enzyme-linked immuno-sorbent assay (ELISA) was used to measure tetanus toxoid antibodies.
   RESULTS A high proportion of children were fully vaccinated in both age groups. Measles antibody concentrations were less than or equal to1 : 8 in 8.2% of 8-9 year-old vaccinated children. In the previous survey of 3-4 year-old children this was 11.3%. In the present survey, GMC was lower than in the 3-4 year-old children; 88% of 3-4 year-olds and 89% of 8-9 year-olds had detectable antibody levels against poliovirus type 1. Fewer children at 8-9 years of age had antibodies against poliovirus type 3 than 3-4 year-olds (78%vs. 89%P < 0.001). A significant overall lower proportion of 8-9 year-old children had detectable tetanus toxoid antibodies compared to 3-4 year-old children (87%vs. 95%P < 0.001), as well as those who received four doses of DPT (90%vs. 97%P < 0.001).
   CONCLUSIONS High vaccine coverage is achieved in The Gambia with EPI. With time the number of vaccinated children who are not protected against measles, poliovirus 3 and tetanus increases. Besides the maintenance of high vaccine coverage in infants and young children, booster doses of some of the EPI vaccines in adolescents should be considered.
C1 Int Agcy Res Canc, WHO, Gambia Hepatitis Intervent Study, F-69372 Lyon 08, France.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC, Fajara, Gambia.
RP Viviani, S (reprint author), Via Gramsci 12,Loc Strove, Siena, Italy.
EM sviviani@hotmail.com; maimunamendy@hotmail.com; jacka@who-nigeria.org;
   andy.hall@lshtm.ac.uk; montesano@iarc.fr; hwhittle@mrc.gm
CR Brabin L, 2000, T ROY SOC TROP MED H, V94, P455, DOI 10.1016/S0035-9203(00)90139-1
   de Quadros CA, 2003, J INFECT DIS, V187, pS102, DOI 10.1086/368032
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   FORTUIN M, 1995, T ROY SOC TROP MED H, V89, P326, DOI 10.1016/0035-9203(95)90564-2
   GALAZKA A, 1993, IMMUNOLOGICAL BASI B
   HALL A J, 1987, Cancer Research, V47, P5782
   HALL AJ, 1989, LANCET, V1, P1057
   Kurtzhals JAL, 1997, AM J TROP MED HYG, V56, P576
   Maldonado YA, 1997, J INFECT DIS, V175, P545
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   SEDGWICK AK, 1983, J CLIN MICROBIOL, V18, P104
   Triki H, 1997, VACCINE, V15, P1123, DOI 10.1016/S0264-410X(97)00001-7
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   WHITTLE HC, 1984, LANCET, V2, P834
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WHO Expanded Programme on Immunization. World Health Organization. Division of communicable diseases, 1990, MAN VIR INV POL
NR 16
TC 5
Z9 5
U1 0
U2 1
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2004
VL 9
IS 10
BP 1044
EP 1049
DI 10.1111/j.1365-3156.2004.01313.x
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 862BK
UT WOS:000224464400002
PM 15482396
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   van der Loeff, MFS
   Bennett, RC
   Dowling, M
   Aveika, AA
   Togun, TO
   Sabally, S
   Jeffries, D
   Adegbola, RA
   Sarge-Njie, R
   Jaye, A
   Corrah, T
   McConkey, S
   Whittle, HC
AF van der Sande, MAB
   van der Loeff, MFS
   Bennett, RC
   Dowling, M
   Aveika, AA
   Togun, TO
   Sabally, S
   Jeffries, D
   Adegbola, RA
   Sarge-Njie, R
   Jaye, A
   Corrah, T
   McConkey, S
   Whittle, HC
TI Incidence of tuberculosis and survival after its diagnosis in patients
   infected with HIV-1 and HIV-2
SO AIDS
LA English
DT Article
DE HIV-1; HIV-2; tuberculosis; incidence; survival; CD4 cell; epidemiology;
   natural history; west Africa
ID IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY;
   PULMONARY TUBERCULOSIS; HOSPITALIZED-PATIENTS; GUINEA-BISSAU;
   COTE-DIVOIRE; MORTALITY; AFRICA; PREVALENCE; ABIDJAN
AB Background: In sub-Saharan Africa, tuberculosis (TB) is the most frequently diagnosed opportunistic infection and cause of death among HIV-infected patients. HIV-2 has been associated with less immune suppression, slower disease progression and longer survival. Objective: To examine whether the incidence of TB and survival after TB are associated with CD4 cell count rather than HIV type. Methods: Clinical and immunological data were retrospectively evaluated among an open clinic-based cohort of HIV-1- and HIV-2-infected patients to determine incidence of TB (first diagnosis > 28 days after HIV diagnosis) and subsequent mortality. Patients were grouped by CD4 cell count into those with < 200, 200-500 and > 500 x 10(6) cells/l. Results: Incident TB was diagnosed among 159 of 2012 patients, with 4973 person-years of observation time. In 105/159 (66.0%), the diagnosis was confirmed by direct microscopy or culture. Incidence of TB was highest in the group with < 200 x 10(6) cells/l (9.1/100 and 8.8/100 person-years in HIV-1 and HIV-2, respectively). Adjusted for CD4 cell count, there was no significant difference in incidence or mortality following TB between HIV-1- and HIV-2-infected patients. Mortality rate was higher inthose with incident TB and HIV infection, most markedly in the group with the highest CD4 cell count (hazard ratio, 10.0; 95% confidence interval, 5.1-19.7). Conclusion: Adjusted for CD4 cell count, incidence of TB was similar among HIV-1-and HIV-2-infected patients. Mortality rates after TB diagnosis were similar in both groups and high compared with those without TB. (C) 2004 Lippincott Williams Wilkins.
C1 MRC, Labs Fajara, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP van der Sande, MAB (reprint author), MRC, Labs Fajara, POB 273, Banjul, Gambia.
EM nivdsande@mrc.gm
RI McConkey, Samuel/E-7307-2012
CR ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7
   Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1
   Badri M, 2002, INT J TUBERC LUNG D, V6, P231
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V41, P1
   Collins Kalonji R., 2002, AIDS Reviews, V4, P165
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   DALAMO J, 2003, ACQUIR IMMUNE DEFIC, V33, P184
   Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010
   DECOCK KM, 1991, BRIT MED J, V302, P496
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   GNAORE E, 1993, T ROY SOC TROP MED H, V87, P57, DOI 10.1016/0035-9203(93)90420-U
   Harries AD, 1998, B WORLD HEALTH ORGAN, V76, P651
   Hawken MP, 2001, INT J TUBERC LUNG D, V5, P360
   KARNOFSKY DA, 1948, CANCER, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005
   Malkin JE, 1997, INT J TUBERC LUNG D, V1, P68
   Naucler A, 1996, TUBERCLE LUNG DIS, V77, P226, DOI 10.1016/S0962-8479(96)90005-2
   Norrgren H, 2001, SCAND J INFECT DIS, V33, P450
   Raviglione M C, 1997, AIDS, V11 Suppl B, pS115
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901
   Seng R, 2002, AIDS, V16, P1059, DOI 10.1097/00002030-200205030-00013
   Shafer RW, 1996, AIDS, V10, P269, DOI 10.1097/00002030-199603000-00005
   Stevens W, 2004, BRIT MED J, V328, P280, DOI 10.1136/bmj.328.7434.280
   van der Loeff MFS, 2002, AIDS, V16, P1775
   VANDERLOEFF S, 1999, AIDS, V13, pS69
   Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845
   Wolday D, 2003, Int J Tuberc Lung Dis, V7, P110
NR 30
TC 35
Z9 35
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD SEP 24
PY 2004
VL 18
IS 14
BP 1933
EP 1941
DI 10.1097/00002030-200409240-00009
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 858TK
UT WOS:000224214600008
PM 15353979
OA No
DA 2017-08-15
ER

PT J
AU Ngom, PT
   Collinson, AC
   Pido-Lopez, J
   Henson, SM
   Prentice, AM
   Aspinall, R
AF Ngom, PT
   Collinson, AC
   Pido-Lopez, J
   Henson, SM
   Prentice, AM
   Aspinall, R
TI Improved thymic function in exclusively breastfed infants is associated
   with higher interleukin 7 concentrations in their mothers' breast milk
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE breast milk; thymus; lymphocytes; immune programming; infection;
   nutritional deprivation; signal-joint T cell receptor-rearrangement
   excision circles; sjTRECs; interleukin 7
ID B-CELL PRECURSORS; DENDRITIC CELLS; GAMBIAN INFANTS; RURAL GAMBIA;
   BIRTH-WEIGHT; IN-VITRO; T-CELLS; MICE; IL-7; INFECTION
AB Background: In rural Gambians, the season of birth strongly predicts adult mortality. Those born during the harvest season have longer life spans than do those born during the hungry season, and the deaths associated with infectious diseases suggest permanent early-life influences on immunity. Thymic measurements showed significantly smaller thymuses in infants born during the hungry season than in those born during the harvest season. The differences were greatest at 8 wk of age, a time when all infants were exclusively breastfed, which suggests the involvement of breast milk factors.
   Objective: This study tested whether thymic size differences reflect thymic output and ascertained whether thymic output is associated with breast milk interleukin 7 (IL-7) concentrations.
   Design: We studied thymic size and output in a prospective cohort of 138 Gambian infants born in either the hungry or the harvest season by measuring signal-joint T cell receptor-rearrangement excision circles (sjTRECs) at birth and at 8 wk of age. IL-7 concentrations in breast milk were measured by using an enzyme-linked immunosorbent assay.
   Results: By age 8 wk, those born in the hungry season had significantly lower sjTREC counts than did those born in the harvest season(0.97 and 2.12 sjTRECs/100 T cells, respectively; P = 0.006). At 1 wk postpartum, the breast milk of mothers of infants born in the hungry season had significantly lower IL-7 than did that of mothers of infants born in the harvest season (79 and 100 pg/mL, respectively; P = 0.02). The findings were similar at 8 wk postpartum.
   Conclusion: These data show a plausible pathway linking external seasonal insults to mothers with thymic development in their infants, which suggests possible implications for long-term programming of immunity.
C1 Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Immunol, Chelsea & Westminster Hosp, London SW10 9NH, England.
   London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   Med Res Council Keneba, Keneba, Gambia.
RP Aspinall, R (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Immunol, Chelsea & Westminster Hosp, 369 Fulham Rd, London SW10 9NH, England.
EM r.aspinall@imperial.ac.uk
RI Aspinall, Richard/E-4924-2013
OI Aspinall, Richard/0000-0002-1648-1887
CR Carlsen HS, 2002, GUT, V51, P364, DOI 10.1136/gut.51.3.364
   Chandra RK, 2002, EUR J CLIN NUTR, V56, pS73, DOI 10.1038/sj.ejcn.1601492
   Chevalier P, 1996, Sante, V6, P201
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Donnet-Hughes A, 2000, IMMUNOL CELL BIOL, V78, P74, DOI 10.1046/j.1440-1711.2000.00882.x
   Douek DC, 1998, NATURE, V396, P690
   Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5
   Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892
   Fry TJ, 2001, BLOOD, V97, P1525, DOI 10.1182/blood.V97.6.1525
   GARTNER A, 1992, NUTRITION, V8, P258
   GEBERT A, 1995, ANAT REC, V241, P487, DOI 10.1002/ar.1092410406
   Goldman AS, 1996, J MAMMARY GLAND BIOL, V1, P251, DOI 10.1007/BF02018078
   GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q
   Hamosh M, 1999, SEMIN PERINATOL, V23, P242, DOI 10.1016/S0146-0005(99)80069-X
   Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x
   Hasselbalch H, 1999, EUR J PEDIATR, V158, P964, DOI 10.1007/s004310051258
   HAYNES BF, 1995, J EXP MED, V181, P1445, DOI 10.1084/jem.181.4.1445
   Hazenberg MD, 2000, NAT MED, V6, P1036
   Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135
   Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762
   ISGRO A, 2002, AIDS, V6, P2231
   Kaiserlian D, 1999, SEMIN IMMUNOL, V11, P217, DOI 10.1006/smim.1999.0177
   Korobkin M, 1996, RADIOLOGY, V200, P743
   LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224
   MIYAJI C, CELL IMMUNOL, V199, P159
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   MORRISSEY PJ, 1994, CELL IMMUNOL, V157, P118, DOI 10.1006/cimm.1994.1210
   Morrow R H Jr, 1985, IARC Sci Publ, P177
   Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   Murai M, 2003, NAT IMMUNOL, V4, P154, DOI 10.1038/ni879
   OSMOND DG, 1990, CURR TOP MICROBIOL, V166, P149
   PAUL AA, 1979, P NUTR SOC, V38, pA28
   Pido-Lopez J, 2002, EUR J IMMUNOL, V32, P2827, DOI 10.1002/1521-4141(2002010)32:10<2827::AID-IMMU2827>3.0.CO;2-X
   PRENTICE A, 1984, ACTA PAEDIATR SCAND, V73, P803, DOI 10.1111/j.1651-2227.1984.tb17779.x
   PRENTICE AM, 1983, LANCET, V1, P489
   Prentice AM, 1999, BRIT J NUTR, V81, P345
   Reinholz MM, 2002, BREAST CANCER RES TR, V74, P255, DOI 10.1023/A:1016339120506
   Saito H, 1998, SCIENCE, V280, P275, DOI 10.1126/science.280.5361.275
   SAVINO W, 1992, MEM I OSWALDO CRUZ, V87, P73
   Savino W, 2002, EUR J CLIN NUTR, V56, pS46, DOI 10.1038/sj.ejcn.1601485
   Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946
   SERRANI RE, 1989, ARCH INT PHYSIOL BIO, V97, P309, DOI 10.3109/13813458909075071
   Soares MVD, 1998, J IMMUNOL, V161, P5909
   SUDA T, 1991, J IMMUNOL, V146, P3068
   Takahata Y, 2001, PEDIATR RES, V50, P268, DOI 10.1203/00006450-200108000-00017
   Tang JH, 1997, J IMMUNOL, V159, P117
   Turner PC, 2003, ENVIRON HEALTH PERSP, V111, P217, DOI 10.1289/ehp.5753
   Wesa AK, 2001, CELL IMMUNOL, V208, P115, DOI 10.1006/cimm.2001.1773
   Wilson IG, 1997, APPL ENVIRON MICROB, V63, P3741
NR 51
TC 59
Z9 62
U1 0
U2 4
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD SEP
PY 2004
VL 80
IS 3
BP 722
EP 728
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 849SR
UT WOS:000223561500026
PM 15321814
OA No
DA 2017-08-15
ER

PT J
AU Palmer, A
   Carlin, JB
   Freihorst, J
   Gatchalian, S
   Muhe, L
   Mulholland, K
   Weber, MW
AF Palmer, A
   Carlin, JB
   Freihorst, J
   Gatchalian, S
   Muhe, L
   Mulholland, K
   Weber, MW
CA WHO Young Infant Study Grp
TI The use of CRP for diagnosing infections in young infants < 3 months of
   age in developing countries
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID C-REACTIVE PROTEIN; NEONATAL INFECTION; SEPTICEMIA; SEPSIS
AB The diagnosis of severe bacterial infection in young infants in developing countries is difficult because of the lack of sensitivity and specificity of the presenting symptoms and signs. Whether C-reactive protein (CRP) might help with the early detection of neonatal sepsis was investigated in a prospective study in The Gambia, Ethiopia and The Philippines. Infants <3 months of age with symptoms or signs of possible sepsis were evaluated; CRP was measured and assessed for its ability to predict proven invasive bacterial infection. Of 966 children <3 months of age, 54 had a positive blood culture, 13 a positive CSF culture, 15 a positive blood and CSF culture and 884 had negative cultures. Median (interquartile range) CRP values were 42 (9-173), 14 (6-36), 209 (135-286) and 8 (3-27) mg/L in the four groups, respectively. Taking a CRP cut-off of 10 mg/L, the sensitivity and specificity of an elevated CRP to predict a positive blood or CSF culture were 77% and 55%, respectively, and 55% and 82%, respectively, for a cut-off of 40 mg/L. CRP lacks the sensitivity and specificity to be used alone as a predictor of serious infections in young infants.
C1 Royal Victoria Hosp, Banjul, Gambia.
   MRC Labs, Banjul, Gambia.
   Univ Melbourne, Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Parkville, Vic 3052, Australia.
   Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.
   Childrens Hosp, Hannover, Germany.
   Res Inst Trop Med, Alabang, Philippines.
   Ethio Swedish Childrens Hosp, Dept Paediat & Child Hlth, Addis Ababa, Ethiopia.
RP Weber, MW (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
EM weberm@who.int
RI Carlin, John/B-3492-2012
OI Carlin, John/0000-0002-2694-9463; Byass, Peter/0000-0001-5474-4361
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   ADHIKARI M, 1986, ANN TROP PAEDIATR, V6, P37
   BERGER C, 1995, EUR J PEDIATR, V154, P138
   Chiu CH, 1997, PEDIATR INFECT DIS J, V16, P59, DOI 10.1097/00006454-199701000-00013
   DASILVA O, 1995, PEDIATR INFECT DIS J, V14, P362
   Jaye DL, 1997, PEDIATR INFECT DIS J, V16, P735, DOI 10.1097/00006454-199708000-00003
   MATHERS NJ, 1987, EUR J PEDIATR, V146, P147, DOI 10.1007/BF02343221
   Mulholland K, 1998, VACCINE, V16, P1360, DOI 10.1016/S0264-410X(98)00092-9
   PHILIP AGS, 1994, PEDIATRICS, V93, P693
   POTEMPA LA, 1988, INFLAMMATION, V12, P391, DOI 10.1007/BF00915774
   POURCYROUS M, 1993, PEDIATRICS, V92, P431
   SABEL KG, 1979, ACTA PAEDIATR SCAND, V68, P825
   SABEL KG, 1974, ACTA PAEDIATR SCAND, V63, P381, DOI 10.1111/j.1651-2227.1974.tb04814.x
   Sharma A, 1993, Indian Pediatr, V30, P347
   Stoll BJ, 1997, CLIN PERINATOL, V24, P1
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS17, DOI DOI 10.1097/00006454-199910001-00004
   The WHO Young Infants Study Group, 1999, PEDIAT INFECT DIS S, V18, pS8
NR 17
TC 9
Z9 9
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA HUDSON RD, LEEDS LS9 7DL, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD SEP
PY 2004
VL 24
IS 3
BP 205
EP 212
DI 10.1179/027249304225018948
PG 8
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 858UZ
UT WOS:000224218900002
PM 15479569
OA No
DA 2017-08-15
ER

PT J
AU Van Der Sande, MAB
   Luong, TN
   Van Der Loeff, MFS
   Sabally, S
   Aveika, AA
   Corrah, T
   Sarge-Njie, R
   Kaye, S
   Whittle, HC
AF Van Der Sande, MAB
   Luong, TN
   Van Der Loeff, MFS
   Sabally, S
   Aveika, AA
   Corrah, T
   Sarge-Njie, R
   Kaye, S
   Whittle, HC
TI Dual HIV-1 and HIV-2 infection in a West African infant
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Letter
ID TO-CHILD TRANSMISSION; ABIDJAN
C1 MRC Labs, Fajara, Gambia.
RP Van Der Sande, MAB (reprint author), MRC Labs, Fajara, Gambia.
EM mvdsande@mrc.gm
CR ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   DECOCK KM, 1994, BRIT MED J, V308, P441
   Jost S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMoa020263
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   van der Loeff MFS, 1999, AIDS, V13, pS69
NR 5
TC 2
Z9 2
U1 0
U2 0
PU MANEY PUBLISHING
PI LEEDS
PA HUDSON RD, LEEDS LS9 7DL, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD SEP
PY 2004
VL 24
IS 3
BP 277
EP 278
DI 10.1179/027249304225019073
PG 2
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 858UZ
UT WOS:000224218900014
PM 15479581
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
   Dampha, Y
   Bittaye, B
   Sowe, M
   Hofmeyr, J
AF Walraven, G
   Dampha, Y
   Bittaye, B
   Sowe, M
   Hofmeyr, J
TI Misoprostol in the treatment of postpartum haemorrhage in addition to
   routine management: a placebo randomised controlled trial
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article
AB Postpartum haemorrhage remains a leading cause of maternal mortality, despite treatment with conventional methods. In this randomised controlled trial, we compared misoprostol 600 mug (200 mug orally and 400 mug sublingually) with placebo in the treatment of postpartum haemorrhage in addition to routine treatment. One hundred and sixty consenting women who delivered vaginally with measured blood loss >500 mL and for whom inadequate uterine contraction was thought to be a possible factor were given either misoprostol or placebo in addition to normal treatment and after routine active management with uterotonics. Blood loss was measured by collection in a special plastic bedpan and side effects of treatment were recorded. Measured average additional blood loss was 325 mL (95% confidence interval [CI] 265 to 384 mL) with misoprostol and 410 mL (95% CI 323 to 498 mL) with placebo. No severe side effects were noted in the use of misoprostol.
C1 Aga Khan Hlth Serv, F-60270 Gouvieux, France.
   MRC Labs, Reprod Hlth Programme, Farafenni, Gambia.
   AFPRC Hosp, Matern Ward, Farafenni, Gambia.
   Univ Witwatersrand, Effect Care Res Unit, ZA-2050 Wits, South Africa.
RP Walraven, G (reprint author), Aga Khan Hlth Serv, F-60270 Gouvieux, France.
CR AbouZahr C, 1998, HLTH DIMENSIONS SEX, P111
   Driessen F, 1991, OBSTETRIC PROBLEMS P
   Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4
   HOFMEYR GJ, UNPUB BR J OBSTET
   Lokugamage AU, 2001, ACTA OBSTET GYN SCAN, V80, P835, DOI 10.1034/j.1600-0412.2001.080009835.x
   Mousa HA, 2001, CURR OPIN OBSTET GYN, V13, P595, DOI 10.1097/00001703-200112000-00008
   PRENDIVILLE WJ, 2003, COCHRANE LIB
   Villar J, 2002, OBSTET GYNECOL, V100, P1301, DOI 10.1016/S0029-7844(02)02371-2
NR 8
TC 27
Z9 29
U1 0
U2 3
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1470-0328
J9 BJOG-INT J OBSTET GY
JI BJOG
PD SEP
PY 2004
VL 111
IS 9
BP 1014
EP 1017
DI 10.1111/j.1471-0528.2004.00217.x
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 854JY
UT WOS:000223900100021
PM 15327620
OA No
DA 2017-08-15
ER

PT J
AU Mitchell, J
   Hayhurst, C
   Robinson, SM
AF Mitchell, J
   Hayhurst, C
   Robinson, SM
TI Can a senior house officer's time be used more effectively?
SO EMERGENCY MEDICINE JOURNAL
LA English
DT Article
ID EMERGENCY
AB Objectives: To determine the amount of time senior house officers (SHO) spent performing tasks that could be delegated to a technician or administrative assistant and therefore to quantify the expected benefit that could be obtained by employing such physicians' assistants (PA).
   Methods: SHOs working in the emergency department were observed for one week by pre-clinical students who had been trained to code and time each task performed by SHOs. Activity was grouped into four categories ( clinical, technical, administrative, and other). Those activities in the technical and administrative categories were those we believed could be performed by a PA.
   Results: The SHOs worked 430 hours in total, of which only 25 hours were not coded due to lack of an observer. Of the 405 hours observed 86.2% of time was accounted for by the various codes. The process of taking a history and examining patients accounted for an average of 22% of coded time. Writing the patient's notes accounted for an average of 20% of coded time. Discussion with relatives and patients accounted for 4.7% of coded time and performing procedures accounted for 5.2% of coded time. On average across all shifts, 15% of coded time was spent doing either technical or administrative tasks.
   Conclusion: In this department an average of 15% of coded SHOs working time was spent performing administrative and technical tasks, rising to 17% of coded time during a night shift. This is equivalent to an average time of 78 minutes per 10 hour shift/SHO. Most tasks included in these categories could be performed by PAs thus potentially decreasing patient waiting times, improving risk management, allowing doctors to spend more time with their patients, and possibly improving doctors' training.
C1 Addenbrookes NHS Trust, Cambridge CB1 6JD, England.
   WEC Int, Brikama, Gambia.
RP Robinson, SM (reprint author), Addenbrookes NHS Trust, Hills Rd, Cambridge CB1 6JD, England.
EM susan.robinson@addenbrookes.nhs.uk
OI Robinson, Susan/0000-0002-1796-6739
CR Australian College for Emergency Medecine (ACEM), 1994, EMERG MED FREMANTLE, V6, P145
   ALBERTI G, 2000, DAILY TELEGRAPH 0120
   BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085
   Castledine G, 1996, Br J Nurs, V5, P124
   Davidson AG, 2000, J ROY COLL PHYS LOND, V34, P503
   *DEP HLTH, 1998204 NHS HSC DEP
   Department of Health, 2000, NHS PLAN
   Fernandes C M, 1997, J Emerg Med, V15, P397, DOI 10.1016/S0736-4679(97)00030-9
   HALL C, 2000, DAILY TELEGRAPH 0407
   Hargadon J., 2000, HLTH SERVICE ALL TAL
   Hassell I, 2001, Emerg Nurse, V8, P7
   ORME M, 1999, HOSP DOCTORS PRESSUR
   Rohme K, 2001, Tidsskr Nor Laegeforen, V121, P1458
   Venning P, 2000, BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048
NR 14
TC 10
Z9 10
U1 1
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1472-0205
J9 EMERG MED J
JI Emerg. Med. J.
PD SEP 1
PY 2004
VL 21
IS 5
BP 545
EP 547
DI 10.1136/emj.2003.007088
PG 3
WC Emergency Medicine
SC Emergency Medicine
GA 849IZ
UT WOS:000223533300007
PM 15333525
OA No
DA 2017-08-15
ER

PT J
AU Bastian, M
   Bohmer, G
   Fischer, A
   Pompadre-Beigier, M
   Brookes, R
   Puzo, G
   Jachmann, M
   DeLibero, G
   Rollinghoff, M
   Stenger, S
AF Bastian, M
   Bohmer, G
   Fischer, A
   Pompadre-Beigier, M
   Brookes, R
   Puzo, G
   Jachmann, M
   DeLibero, G
   Rollinghoff, M
   Stenger, S
TI T-cell responses to lipid antigens as possible correlates of protection
   in human tuberculosis
SO INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the DGHM
CY SEP 26-29, 2004
CL Munster, GERMANY
SP DGHM
C1 Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, Erlangen, Germany.
   Bezirksklinkum Ebensfeld, Klin Erkrankungen Atemwege, Kutzenberg, Germany.
   Gesundheitsamt Bad Neustadt, Bad Neustadt an der Saale, Germany.
   Univ Buenos Aires, Natl Acad Med, Buenos Aires, DF, Argentina.
   MRC, Res Ctr Fajara, Fajara, Gambia.
   CNRS, Inst Pharmacol & Biol Struct, Toulouse, France.
   Klin Michelsberg, Abt Thoraxchirurg, Munnerstadt, Germany.
   Kantonsspital Basel, Inst Expt Immunol, Basel, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU URBAN & FISCHER VERLAG
PI JENA
PA BRANCH OFFICE JENA, P O BOX 100537, D-07705 JENA, GERMANY
SN 1438-4221
J9 INT J MED MICROBIOL
JI Int. J. Med. Microbiol.
PD SEP
PY 2004
VL 294
SU 39
BP 196
EP 197
PG 2
WC Microbiology; Virology
SC Microbiology; Virology
GA 861ZA
UT WOS:000224456000270
OA No
DA 2017-08-15
ER

PT J
AU Jeffries, DJ
   Donkor, S
   Brookes, RH
   Fox, A
   Hill, RC
AF Jeffries, DJ
   Donkor, S
   Brookes, RH
   Fox, A
   Hill, RC
TI Design and implementation of relational databases relevant to the
   diverse needs of a tuberculosis case contact study in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculosis; database; The Gambia; case contact study; ELISPOT
ID T-CELLS; MEMORY; IMMUNITY
AB The data requirements of a large multidisciplinary tuberculosis case contact study are complex. We describe an ACCESS-based relational database system that meets our rigorous requirements for data entry and validation, while being user-friendly, flexible, exportable, and easy to install on a network or stand alone system. This includes the development of a double data entry package for epidemiology and laboratory data, semi-automated entry of ELISPOT data directly from the plate reader, and a suite of new programmes for the manipulation and integration of flow cytometry data. The double entered epidemiology and immunology databases are combined into a separate database, providing a near-real-time analysis of immuno-epidemiological data, allowing important trends to be identified early and major decisions about the study to be made and acted on. This dynamic data management model is portable and can easily be applied to other studies.
C1 MRC Labs, Resp Dis Programme, TB Res Grp, Banjul, Gambia.
RP Hill, RC (reprint author), MRC Labs, Resp Dis Programme, TB Res Grp, POB 273, Banjul, Gambia.
EM phill@mrc.gm
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54
   Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407
   Heifets Leonid B., 1994, P85
   Hsieh SM, 2000, J ACQ IMMUN DEF SYND, V25, P212, DOI 10.1097/00126334-200011010-00002
   KAYE P, 2003, ACDM NEWSLETTER, V45, P14
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
NR 7
TC 11
Z9 11
U1 1
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD SEP
PY 2004
VL 8
IS 9
BP 1095
EP 1099
PG 5
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 851JB
UT WOS:000223680300009
PM 15455594
OA No
DA 2017-08-15
ER

PT J
AU Woodward, A
   Hill, S
   Blakely, T
AF Woodward, A
   Hill, S
   Blakely, T
TI Deaths caused by secondhand smoke: estimates are consistent
SO TOBACCO CONTROL
LA English
DT Letter
C1 Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
   MRC Labs, Banjul, Gambia.
   Wellington Sch Med, Dept Publ Hlth, Wellington, New Zealand.
RP Woodward, A (reprint author), Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
EM a.woodward@auckland.ac.nz
OI Woodward, Alistair/0000-0001-5425-6018
CR Hill SE, 2004, BRIT MED J, V328, P988, DOI 10.1136/bmj.38070.503009.EE
   Woodward A, 2001, TOB CONTROL, V10, P383, DOI 10.1136/tc.10.4.383
NR 2
TC 1
Z9 1
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
J9 TOB CONTROL
JI Tob. Control
PD SEP
PY 2004
VL 13
IS 3
BP 319
EP 320
DI 10.1136/tc.2004.009092
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 849IU
UT WOS:000223532700029
PM 15333892
OA No
DA 2017-08-15
ER

PT J
AU Fletcher, HA
   Owiafe, P
   Jeffries, D
   Hill, P
   Rook, GAW
   Zumla, A
   Doherty, TM
   Brookes, RH
AF Fletcher, HA
   Owiafe, P
   Jeffries, D
   Hill, P
   Rook, GAW
   Zumla, A
   Doherty, TM
   Brookes, RH
CA VACSEL Study Grp
TI Increased expression of mRNA encoding interleukin (IL)-4 and its splice
   variant IL-4 delta 2 in cells from contacts of Mycobacterium
   tuberculosis, in the absence of in vitro stimulation
SO IMMUNOLOGY
LA English
DT Article
DE ESAT-6; IL-4; IL-482; tuberculosis; vaccine
ID CD8(+) T-CELLS; HUMAN IL-4; INFECTION; RESPONSES; TH1; DISEASE; ESAT-6;
   GAMMA
AB Expression of interleukin (IL)-4 is increased in tuberculosis and thought to be detrimental. We show here that in healthy contacts there is increased expression of its naturally occurring antagonist, IL-4delta2 (IL-4delta2). We identified contacts by showing that their peripheral blood mononuclear cells (PBMC) released interferon (IFN)-gamma in response to the Mycobacterium tuberculosis-specific antigen 6 kDa early secretory antigenic target (ESAT-6). Fresh unstimulated PBMC from these contacts contained higher levels of mRNA encoding IL-4delta2 (P=0.002) than did cells from ESAT-6 negative donors (noncontacts). These data indicate that contact with M. tuberculosis induces unusual, previously unrecognized, immunological events. We tentatively hypothesize that progression to active disease might depend upon the underlying ratio of IL-4 to IL-4delta2.
C1 UCL Royal Free & Univ Coll, Sch Med, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, London W1P 6DB, England.
   MRC Labs, TB Div, Fajara, Gambia.
   Statens Serum Inst, DK-2300 Copenhagen, Denmark.
RP Rook, GAW (reprint author), UCL Royal Free & Univ Coll, Sch Med, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, Cleveland St, London W1P 6DB, England.
EM g.rook@ucl.ac.uk
RI Fletcher, Helen/D-1470-2011
OI Rook, Graham/0000-0002-8041-8110; Zumla, Alimuddin/0000-0002-5111-5735;
   Fletcher, Helen/0000-0002-0435-1006
CR Arend SM, 2002, J INFECT DIS, V186, P1797, DOI 10.1086/345760
   Atamas SP, 1996, J IMMUNOL, V156, P435
   BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227
   Demissie A, 2004, J IMMUNOL, V172, P6938
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Gautherot I, 2002, IMMUNOGENETICS, V54, P635, DOI 10.1007/s00251-002-0510-4
   Hernandez-Pando R, 2004, EUR J IMMUNOL, V34, P174, DOI 10.1002/eji.200324253
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6
   Lindblad EB, 1997, INFECT IMMUN, V65, P623
   Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200
   Seah GT, 2001, AM J RESP CRIT CARE, V164, P1016
   Seah GT, 1999, J IMMUNOL METHODS, V228, P139, DOI 10.1016/S0022-1759(99)00084-8
   Smith SM, 2002, TUBERCULOSIS, V82, P7, DOI 10.1054/tube.2001.0317
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325
   Vasiliev AM, 2003, J PROTEOME RES, V2, P273, DOI 10.1021/pr025586y
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205
   Wangoo A, 2001, J IMMUNOL, V166, P3432
NR 20
TC 56
Z9 56
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD AUG
PY 2004
VL 112
IS 4
BP 669
EP 673
DI 10.1111/j.1365-2567.2004.01922.x
PG 5
WC Immunology
SC Immunology
GA 839RG
UT WOS:000222801700019
PM 15270739
OA No
DA 2017-08-15
ER

PT J
AU Sirugo, G
   Van Der Loeff, MS
   Sam, O
   Nyan, O
   Pinder, M
   Hill, AV
   Kwiatkowski, D
   Prentice, A
   de Toma, C
   Cann, HM
   Diatta, M
   Jallow, M
   Morgan, G
   Clarke, M
   Corrah, T
   Whittle, H
   McAdam, K
AF Sirugo, G
   Van Der Loeff, MS
   Sam, O
   Nyan, O
   Pinder, M
   Hill, AV
   Kwiatkowski, D
   Prentice, A
   de Toma, C
   Cann, HM
   Diatta, M
   Jallow, M
   Morgan, G
   Clarke, M
   Corrah, T
   Whittle, H
   McAdam, K
TI A national DNA bank in The Gambia, West Africa, and genomic research in
   developing countries
SO NATURE GENETICS
LA English
DT Letter
ID MALARIA
C1 MRC Labs, Banjul, Gambia.
   Dept State Hlth, Banjul, Gambia.
   Univ Gambia, Sch Med, Banjul, Gambia.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Fdn Jean Dausset CEPH, Paris, France.
   Royal Victoria Teaching Hosp, Banjul, Gambia.
   Gambian Govt MRC Labs Joint Eth Comm, Fajara, Gambia.
RP Sirugo, G (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM gsirugo@mrc.gm
RI HILL, Adrian/C-1306-2008
OI Kwiatkowski, Dominic/0000-0002-5023-0176
CR HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Luoni G, 2001, GENES IMMUN, V2, P411, DOI 10.1038/sj.gene.6363797
   Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206
NR 4
TC 21
Z9 23
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD AUG
PY 2004
VL 36
IS 8
BP 785
EP 786
DI 10.1038/ng0804-785
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 842AG
UT WOS:000222974000004
PM 15284842
OA No
DA 2017-08-15
ER

PT J
AU Simonsen, PE
   Magesa, SM
   Dunyo, SK
   Malecela-Lazaro, MN
   Michael, E
AF Simonsen, PE
   Magesa, SM
   Dunyo, SK
   Malecela-Lazaro, MN
   Michael, E
TI The effect of single dose ivermectin alone or in combination with
   albendazole on Wuchereria bancrofti infection in primary school children
   in Tanzania
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE lymphatic filariasis; Wuchereria bancrofti; children; ivermectin;
   albendazole; Tanzania
ID LONGITUDINAL DATA-ANALYSIS; LYMPHATIC FILARIASIS; CLINICAL
   MANIFESTATIONS; NORTHEASTERN TANZANIA; CIRCULATING ANTIGENS; ENDEMIC
   COMMUNITIES; MICROFILAREMIA; PATTERNS; CHEMOTHERAPY; EFFICACY
AB Examination of 1829 children from 6 primary schools in coastal Tanzania revealed overall Wuchereria bancrofti microfilaria (mf) and circulating filarial, antigen (CFA) prevalences of 17.3% and 43.7%, respectively. A randomized double-blind field trial with a single dose of ivermectin (150-200 mug/kg body weight) atone or in combination with albendazole (400mg) was subsequently carried out among these children. Both treatment regimens resulted in a considerable decrease in mean mf intensities, with overall reductions being slightly but statistically significantly higher for the combination than for ivermectin alone. The difference in effect between the two treatment regimens was most pronounced at 6 months, whereas it was minor at 12 months after treatment. The relative effect of treatment on mean CFA units was less pronounced than on mf. For both treatment regimens, reductions in CFA intensity appeared to be higher in children who were both CFA and mf positive before treatment, which may suggest that treatment mainly affected the survival and/or production of mf, rather than the survival of adult worms. New cases of infection appeared after treatment with both regimens among the pre-treatment mf and CFA negative children. Adverse reactions were few and mild in both groups, and mainly reported from pre-treatment mf and CFA positive children. The alarmingly high prevalence of W bancrofti infection in primary school children highlights the importance of also determining the reversibility of already acquired early lesions, and the development of new measures and strategies to specifically protect children from later developing clinical disease. (C) 2004 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. Alt rights reserved.
C1 Danish Bilharziasis Lab, DK-2920 Charlottenlund, Denmark.
   Ubwari Res Stn, Muheza, Tanzania.
   MRC Labs, Banjul, Gambia.
   Natl Inst Med Res, Dar Es Salaam, Tanzania.
   Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis Epidemiol, London W2 1PG, England.
RP Simonsen, PE (reprint author), Danish Bilharziasis Lab, Jaegersborg Alle 1 D, DK-2920 Charlottenlund, Denmark.
EM pes@bilharziasis.dk; smagesa@hotmail.com; sdunyo@hotmail.com;
   mmalecela@nimr.or.tz; e.michael@imperial.ac.uk
RI Michael, Edwin/D-3388-2014
CR Addiss DG, 1997, LANCET, V350, P480, DOI 10.1016/S0140-6736(97)02231-9
   Brown KR, 2000, PARASITOLOGY, V121, P133
   Bundy DAP, 1995, CURR OPIN INFECT DIS, V8, P466, DOI 10.1097/00001432-199512000-00012
   Cao WC, 1997, TROP MED INT HEALTH, V2, P393
   Dreyer G, 1996, TROP MED INT HEALTH, V1, P427, DOI 10.1046/j.1365-3156.1996.d01-79.x
   Dunyo SK, 2000, T ROY SOC TROP MED H, V94, P437, DOI 10.1016/S0035-9203(00)90135-4
   Dunyo SK, 2000, T ROY SOC TROP MED H, V94, P205, DOI 10.1016/S0035-9203(00)90278-5
   Dunyo SK, 1996, T ROY SOC TROP MED H, V90, P634, DOI 10.1016/S0035-9203(96)90414-9
   Horton J, 2000, PARASITOLOGY, V121, P147
   Ismail MM, 2001, T ROY SOC TROP MED H, V95, P332, DOI 10.1016/S0035-9203(01)90257-3
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   MCMAHON JE, 1981, ANN TROP MED PARASIT, V75, P415
   MCMAHON JE, 1979, ANN TROP MED PARASIT, V73, P457
   Meyrowitsch DW, 1995, ANN TROP MED PARASIT, V89, P653
   Michael E, 1997, PARASITOL TODAY, V13, P472, DOI 10.1016/S0169-4758(97)01151-4
   Ottesen EA, 1999, PARASITOL TODAY, V15, P382, DOI 10.1016/S0169-4758(99)01486-6
   Ottesen EA, 1997, B WORLD HEALTH ORGAN, V75, P491
   Plaisier AP, 2000, PARASITOL TODAY, V16, P298, DOI 10.1016/S0169-4758(00)01691-4
   Ramaiah KD, 2000, ACTA TROP, V76, P197, DOI 10.1016/S0001-706X(00)00102-9
   Simonsen PE, 1995, ACTA TROP, V60, P179, DOI 10.1016/0001-706X(95)00126-Y
   Simonsen PE, 2002, AM J TROP MED HYG, V66, P550
   Simonsen PE, 1997, TROP MED INT HEALTH, V2, P153, DOI 10.1046/j.1365-3156.1997.d01-237.x
   Simonsen PE, 1996, AM J TROP MED HYG, V55, P69
   Simonsen PE, 1999, T ROY SOC TROP MED H, V93, P278, DOI 10.1016/S0035-9203(99)90022-6
   SIMONSEN PE, 2003, AM J TROP MED HYG, V70, P63
   Stokes ME, 2000, CATEGORICAL DATA ANA
   Wamae CN, 1998, PARASITOLOGY, V116, P173, DOI 10.1017/S0031182097002060
   WEGESA P, 1979, ACTA TROP, V36, P369
   Weil GJ, 1996, AM J TROP MED HYG, V55, P333
   WEIL GJ, 1987, J IMMUNOL, V138, P3035
   Witt C, 2001, TROP MED INT HEALTH, V6, P582, DOI 10.1046/j.1365-3156.2001.00765.x
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 32
TC 21
Z9 22
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD AUG
PY 2004
VL 98
IS 8
BP 462
EP 472
DI 10.1016/j.trstmh.2003.12.005
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832YD
UT WOS:000222302700003
PM 15186934
OA No
DA 2017-08-15
ER

PT J
AU Sirugo, G
   Schaefer, EA
   Mendy, A
   West, B
   Bailey, R
   Walraven, G
   Sabeti, P
   Macciardi, F
   Zonta, LA
AF Sirugo, G
   Schaefer, EA
   Mendy, A
   West, B
   Bailey, R
   Walraven, G
   Sabeti, P
   Macciardi, F
   Zonta, LA
TI Is G6PD A- deficiency associated with recurrent stillbirths in The
   Gambia?
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Letter
ID AFRICA
C1 MRC, Labs Fajara & Farafenni, Fajara, Gambia.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   Univ Milan, Dipartimento Biol & Genet, I-20122 Milan, Italy.
   Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Travers, I-27100 Pavia, Italy.
RP Sirugo, G (reprint author), MRC Gambia, Lab Human Genet, POB 273, Banjul, Gambia.
EM gsirugo@mrc.gm
RI Macciardi, Fabio/N-3768-2014
OI Macciardi, Fabio/0000-0003-0537-4266
CR BATTISTUZZI G, 1977, AM J HUM GENET, V29, P31
   BEUTLER E, 1994, BLOOD, V84, P3613
   Nicol CJ, 2000, FASEB J, V14, P111
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
NR 5
TC 3
Z9 3
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0148-7299
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JUL 1
PY 2004
VL 128A
IS 1
BP 104
EP 105
DI 10.1002/ajmg.a.30080
PG 2
WC Genetics & Heredity
SC Genetics & Heredity
GA 833HW
UT WOS:000222329000025
PM 15211670
OA No
DA 2017-08-15
ER

PT J
AU Mangtani, P
   Cumberland, P
   Hodgson, CR
   Roberts, JA
   Cutts, FT
   Hall, AJ
AF Mangtani, P
   Cumberland, P
   Hodgson, CR
   Roberts, JA
   Cutts, FT
   Hall, AJ
TI A cohort study of the effectiveness of influenza vaccine in older
   people, performed using the United Kingdom General Practice Research
   Database
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ELDERLY PERSONS; EPIDEMICS; EFFICACY; ACCURACY; DISEASE; SMOKING; DEATHS
AB Background. The effectiveness of influenza vaccination against hospitalization and death can only ethically be assessed in observational studies. A concern is that individuals who are vaccinated are healthier than individuals who are not vaccinated, potentially biasing estimates of effectiveness upward.
   Methods. We conducted a historical cohort study of individuals >64 years of age, for whom there were data available in the General Practice Research Database for 1989 to 1999 in England and Wales. Rates of admissions for acute respiratory diseases and rates of death due to respiratory disease were compared over 692,819 person-years in vaccine recipients and 1,534,280 person-years in vaccine nonrecipients.
   Results. The pooled effectiveness of vaccine against hospitalizations for acute respiratory disease was 21% (95% confidence interval [CI], 17%-26%). The rate reduction attributable to vaccination was 4.15 hospitalizations/100,000 person-weeks in the influenza season. Among vaccine recipients, no important reduction in the number of admissions to the hospital was seen outside influenza seasons. The pooled effectiveness of vaccine against deaths due to respiratory disease was 12% ( 95% CI, 8%-16%). A greater proportionate reduction was seen among people without medical disorders, but absolute rate reduction was higher in individuals with medical disorders, compared with individuals without such disorders (6.14 deaths due to respiratory disease/100,000 person-weeks vs. 3.12 deaths due to respiratory disease/100,000 person-weeks). Clear protection against death due to all causes was not seen.
   Conclusions. Influenza vaccination reduces the number of hospitalizations and deaths due to respiratory disease, after correction for confounding in individuals >64 years of age who had a high risk or a low risk for influenza. For elderly people, untargeted influenza vaccination is of confirmed benefit against serious outcomes.
C1 Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Off Natl Stat, London, England.
   MRC Labs, Banjul, Gambia.
RP Mangtani, P (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM punam.mangtani@lshtm.ac.uk
RI Research Datalink, Clinical Practice/H-2477-2013; CPRD, CPRD/B-9594-2017
CR Ashley J, 1991, POPULATION TRENDS, V62, P16
   BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85
   Christenson B, 2001, LANCET, V357, P1008, DOI 10.1016/S0140-6736(00)04237-9
   Christenson B, 2002, EPIDEMIOL INFECT, V129, P515, DOI 10.1017/S095026880200780X
   CURWEN M, 1990, BRIT MED J, V300, P896
   Dedman D J, 1998, Commun Dis Public Health, V1, P244
   Fleming D M, 2000, Commun Dis Public Health, V3, P32
   Fleming DM, 1995, EPIDEMIOL INFECT, V115, P581
   Fleming DM, 1999, EUR J EPIDEMIOL, V15, P467, DOI 10.1023/A:1007525402861
   GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550
   GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661
   GROSS PA, 1995, ANN INTERN MED, V123, P518
   Iorio AM, 1999, GERONTOLOGY, V45, P31, DOI 10.1159/000022052
   IRISH C, 1998, HLTH TRENDS, V30, P51
   JICK H, 1991, BRIT MED J, V302, P766
   Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445
   Mant J, 2000, J PUBLIC HEALTH MED, V22, P198, DOI 10.1093/pubmed/22.2.198
   MULLOOLY JP, 1994, ANN INTERN MED, V121, P947
   NAZARETH I, 1993, BRIT MED J, V307, P32
   Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028
   Nicholson KG, 1999, EPIDEMIOL INFECT, V123, P103, DOI 10.1017/S095026889900271X
   *OFF NAT STAT, 1997, MORT STAT GEN ENGL W
   Office for National Statistics, 1998, KEY HLTH STAT GEN PR
   Office for National Statistics, 2000, KEY HLTH STAT GEN PR
   Ohmit SE, 1995, INT J EPIDEMIOL, V24, P1240, DOI 10.1093/ije/24.6.1240
   Salisbury DM, 1996, IMMUNISATION INFECT
   *STAT CORP, 2001, INT STAT 7
   Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI 10.1002/pds.2630030106
   Voordouw BCG, 2003, ARCH INTERN MED, V163, P1089, DOI 10.1001/archinte.163.9.1089
   Whiting P, 1999, Commun Dis Public Health, V2, P273
   Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X
   2002, BRIT NATL FORMULARY, pCH2
   2002, BMJ, V324, P66
NR 33
TC 99
Z9 101
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2004
VL 190
IS 1
BP 1
EP 10
DI 10.1086/421274
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 828VV
UT WOS:000222002700001
PM 15195237
OA No
DA 2017-08-15
ER

PT J
AU Szymanska, K
   Lesi, OA
   Kirk, GD
   Sam, O
   Taniere, P
   Scoazec, JY
   Mendy, M
   Friesen, MD
   Whittle, H
   Montesano, R
   Hainaut, P
AF Szymanska, K
   Lesi, OA
   Kirk, GD
   Sam, O
   Taniere, P
   Scoazec, JY
   Mendy, M
   Friesen, MD
   Whittle, H
   Montesano, R
   Hainaut, P
TI Ser-249 TP53 mutation in tumour and plasma DNA of hepatocellular
   carcinoma patients from a high incidence area in the Gambia, West Africa
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE Ser-249 TP53; hepatocellular carcinoma; plasma; circulating free DNA;
   the Gambia; aflatoxin
ID SQUAMOUS-CELL CARCINOMA; LIVER-CANCER PATIENTS; P53 MUTATIONS; AFLATOXIN
   B-1; CODON 249; GENE; EXPOSURE; SERUM; CARCINOGENESIS; SPECTROMETRY
AB Hepatocellular carcinoma (HCC) is frequent in areas of high exposure to aflatoxin and high prevalence of HBV infection, such as western Africa and south-east China. A selective mutation in TP53 (AGG --> AGT at codon 249, Arg --> Ser) has been identified as a hotspot in HCCs from such areas, reflecting DNA damage caused by aflatoxin metabolites. Recent studies have shown that circulating free DNA can be retrieved from human plasma, and it is hypothesised that plasma DNA may serve as a source for biomarkers of tumorigenic processes. In our study, we have determined the prevalence of Ser-249 mutation, using a PCR-restriction digestion method, with selective use of short oligonucleotide mass spectrometry analysis (SOMA), in a series of 29 biopsy specimens of HCC from The Gambia in West Africa. Overall, we identified the Ser-249 mutation in 35% (10/29) of the tumours. In parallel, we tested 17 plasma samples from HCC patients with matching tumour tissue. The 249 status concordance between tumour tissues and matched plasma was 88.5%. These results indicate that the Ser-249 mutation is common in HCC in The Gambia (35%), although a higher prevalence has been reported in other regions with high population exposure to aflatoxin (e.g., eastern China: >50%). Moreover, our studies indicate that plasma is a convenient source of liver tumour-derived DNA, thus holding promise for earlier detection and diagnosis of cancer. (C) 2004 Wiley-Liss, Inc.
C1 Int Agcy Res Canc, F-69008 Lyon 08, France.
   Gambia Hepatitis Intervent Study, Lyon, France.
   NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA.
   Royal Victoria Hosp, Banjul, Gambia.
   Hop Edouard Herriot, Anat Pathol Lab, Lyon, France.
   MRC Labs, IARC, Gambia Hepatitis Intervent Study, Fajara, Gambia.
RP Hainaut, P (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon 08, France.
EM hainaut@iarc.fr
RI Kirk, Gregory/A-8484-2009; Friesen, Marlin/D-7328-2012; Hainaut, Pierre
   /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
FU NCI NIH HHS [N02CP40521]
CR AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586
   Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913
   Anker P, 2003, INT J CANCER, V103, P149, DOI 10.1002/ijc.10791
   Anker P, 2000, ANN NY ACAD SCI, V906, P5
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   BUCHANAN TF, 1974, AM J CLIN PATHOL, V61, P529
   COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258
   Denissenko MF, 1998, ONCOGENE, V17, P3007, DOI 10.1038/sj.onc.1202214
   Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj/onc/1205434
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.0.CO;2-1
   HAMELIN R, 1993, ONCOGENE, V8, P2213
   HOLLSTEIN MC, 1993, INT J CANCER, V53, P51, DOI 10.1002/ijc.2910530111
   Hsia CC, 2000, ONCOL REP, V7, P353
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   Jackson PE, 2001, CANCER RES, V61, P33
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   LAI CL, 1979, CANCER, V44, P1677, DOI 10.1002/1097-0142(197911)44:5<1677::AID-CNCR2820440522>3.0.CO;2-D
   Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352
   Mace K, 1997, CARCINOGENESIS, V18, P1291, DOI 10.1093/carcin/18.7.1291
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113
   OZTURK M, 1991, LANCET, V338, P1356
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   PONCHEL F, 1994, CANCER RES, V54, P2064
   SCORSONE KA, 1992, CANCER RES, V52, P1635
   Sepehr A, 2001, ONCOGENE, V20, P7368, DOI 10.1038/sj.onc.1204912
   Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699
   Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535
   Sylla A, 1999, MUTAT RES-FUND MOL M, V428, P187, DOI 10.1016/S1383-5742(99)00046-0
   Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   Wong IHN, 2000, ANN NY ACAD SCI, V906, P102
   Wong IHN, 1999, CANCER RES, V59, P71
NR 37
TC 42
Z9 47
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 20
PY 2004
VL 110
IS 3
BP 374
EP 379
DI 10.1002/ijc.20103
PG 6
WC Oncology
SC Oncology
GA 820GD
UT WOS:000221374600009
PM 15095302
OA No
DA 2017-08-15
ER

PT J
AU Moorthy, VS
   Imoukhuede, EB
   Keating, S
   Pinder, M
   Webster, D
   Skinner, MA
   Gilbert, SC
   Walraven, G
   Hill, AVS
AF Moorthy, VS
   Imoukhuede, EB
   Keating, S
   Pinder, M
   Webster, D
   Skinner, MA
   Gilbert, SC
   Walraven, G
   Hill, AVS
TI Phase 1 evaluation of 3 highly immunogenic prime-boost regimens,
   including a 12-month reboosting vaccination, for malaria vaccination in
   gambian men
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Multilateral Initiative on Malaria Conference
CY NOV 17-22, 2002
CL Arusha, TANZANIA
ID VACCINIA VIRUS ANKARA; CYTOTOXIC T-LYMPHOCYTES; PLASMODIUM-FALCIPARUM;
   CIRCUMSPOROZOITE PROTEIN; DNA VACCINES; PROTECTIVE EFFICACY;
   IMMUNE-RESPONSES; CELLS RECOGNIZE; HUMANS; SAFETY
AB Successful vaccination against intracellular pathogens, including liver-stage Plasmodium falciparum, will require induction of strong antigen-specific T lymphocyte responses. The multiple epitope (ME)-thrombospondin-related adhesion protein (TRAP) construct includes CD8(+) and CD4(+) T cell epitopes from pre-erythrocytic P. falciparum antigens fused in-frame to the entire pre-erythrocytic antigen TRAP. Three carriers for this construct-plasmid DNA and 2 recombinant nonreplicating poxviruses (modified vaccinia virus Ankara [MVA] and fowlpox strain 9 [FP9])-were administered at 3-week intervals in a heterologous prime-boost combination to 29 Gambian men aged 18-45 years. Doses of DNA ME-TRAP, MVA ME-TRAP, and FP9 ME-TRAP were 2 mg and 1.5 X 10(8) and plaque-forming units, respectively. DNA ME-TRAP was injected intramuscularly; MVA ME-TRAP and FP9 ME-TRAP were injected intradermally. There were no clinically relevant laboratory abnormalities and no severe or serious adverse events related to vaccination. DNA/MVA and FP9/MVA regimens were the most potent inducers of circulating effector T cells seen to date in sub-Saharan Africa. Twelve months after the final vaccination, a single booster vaccination expanded the effector T cell pool to a similar or higher magnitude than that after the primary vaccinations. These results highlight optimized combination regimens with general relevance to the development of vaccines targeting intracellular pathogens.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   MRC Labs, Banjul, Gambia.
   Inst Food Res, Inst Anim Hlth, Compton Lab, Newbury RG16 0NN, Berks, England.
RP Hill, AVS (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Level 7,Rm 7503, Oxford OX3 9DU, England.
EM adrian.hill@imm.ox.ac.uk
RI HILL, Adrian/C-1306-2008; Skinner, Michael/B-7112-2012; Keating,
   Sheila/B-1652-2013
OI Skinner, Michael/0000-0002-0050-4167; Gilbert,
   Sarah/0000-0002-6823-9750; Keating, Sheila/0000-0002-8324-3694
CR Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Clements-Mann ML, 1998, J INFECT DIS, V177, P1230
   Fries LF, 1996, VACCINE, V14, P428, DOI 10.1016/0264-410X(95)00171-V
   Gilbert SC, 1999, BIOL CHEM, V380, P299, DOI 10.1515/BC.1999.041
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Hanke T, 1999, J VIROL, V73, P7524
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   Lalvani A, 1996, EUR J IMMUNOL, V26, P773, DOI 10.1002/eji.1830260408
   Le TP, 2000, VACCINE, V18, P1893, DOI 10.1016/S0264-410X(99)00407-7
   MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300
   MAYR A., 1966, ZENTRALBL VETERINARMED REIHE B, V13, P1
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5
   MORENO A, 1991, INT IMMUNOL, V3, P997, DOI 10.1093/intimm/3.10.997
   Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P
   Plebanski M, 1997, J IMMUNOL, V158, P2849
   ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   TAYLOR J, 1988, VACCINE, V6, P497, DOI 10.1016/0264-410X(88)90100-4
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763
   WIZEL B, 1995, J IMMUNOL, V155, P766
NR 36
TC 81
Z9 83
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 15
PY 2004
VL 189
IS 12
BP 2213
EP 2219
DI 10.1086/421118
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 824PW
UT WOS:000221699500009
PM 15181568
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Grant, AD
   Whitworth, J
   Smith, PG
   Whittle, H
AF Jaffar, S
   Grant, AD
   Whitworth, J
   Smith, PG
   Whittle, H
TI The natural history of HIV-1 and HIV-2 infections in adults in Africa: a
   literature review
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Review
DE HIV-1/immunology; HIV-2/immunology; HIV infections/diagnosis/mortality;
   acquired immunodeficiency syndrome/diagnosis/; mortality; HIV
   seropositivity; disease progression; antiretroviral therapy, highly
   active; AIDS-related opportunistic infections; survival rate; HIV
   seroprevalence; review literature; Africa; Uganda (source, MeSH, NLM)
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SUB-SAHARAN AFRICA; FEMALE SEX-WORKERS;
   RNA VIRAL LOAD; RURAL UGANDA; OPPORTUNISTIC INFECTIONS; HIV-2-INFECTED
   PATIENTS; PNEUMOCOCCAL DISEASE; COTE-DIVOIRE; WEST-AFRICA
AB About 30 million people in Africa are estimated to be living with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), yet data about the natural history of infection on the continent are sparse. We reviewed the literature on the natural history of HIV-1 and HIV-2 infections among African adults. Only one study, conducted in rural Uganda, has reported on survival from the time of HIV-1 seroconversion: the median was 9.8 years, which is similar to that reported in developed countries in the early stages of the epidemic and consistent with the findings from the follow-up of individuals identified by serological testing during community-based prevalence studies from Africa. Progression to symptomatic disease was faster in Uganda than in developed countries, due largely to the high background level of morbidity. Various studies suggest that people infected with HIV-2 survive longer and the course of the disease is possibly more variable than in people infected with HIV-1. However no studies have investigated survival from time of seroconversion among people infected with HIV-2. The majority of patients in hospital in Africa with either HIV-1 or HIV-2 have the clinical features of AIDS just before they die, and many are severely immunosuppressed. This is similar to the situation in developed countries before the introduction of highly active antiretroviral therapy (HAART). Potentially preventable infections are the leading causes of death among individuals infected with HIV-1. Prophylactic regimens and better treatments could have some effect on survival, but major improvements in life expectancy will require HAART.
C1 Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1E 7HT, England.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Uganda Virus Res Inst, MRC, Programme AIDS, Entebbe, Uganda.
   MRC Labs, Banjul, Gambia.
RP Jaffar, S (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
EM shabbar.jaffar@lshtm.ac.uk
CR ANZALA OA, 1995, J INFECT DIS, V171, P686
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Babiker A, 2000, LANCET, V355, P1131
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Bortolotti W, 2002, AIDS, V16, P1309
   Brink AK, 2002, J INFECTION, V45, P99, DOI 10.1053/jinf.2002.1002
   Bush CE, 1996, J ACQ IMMUN DEF SYND, V13, P23, DOI 10.1097/00042560-199609000-00004
   BWAYO JJ, 1995, J ACQ IMMUN DEF SYND, V10, P457, DOI 10.1097/00042560-199512000-00009
   The CASCADE Collaboration, 2000, LANCET, V355, P1158
   Collins Kalonji R., 2002, AIDS Reviews, V4, P165
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5
   Cozzi Lepri A, 1994, BMJ, V309, P1537
   Crampin AC, 2002, AIDS, V16, P1545, DOI 10.1097/00002030-200207260-00012
   Darby SC, 1996, LANCET, V347, P1573
   DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010
   Del Amo J, 1999, AIDS, V13, P1151, DOI 10.1097/00002030-199907090-00002
   Dyer JR, 1998, J INFECT DIS, V177, P1742, DOI 10.1086/517436
   FLEGG PJ, 1994, J INFECTION, V29, P311, DOI 10.1016/S0163-4453(94)91266-1
   GHIRARDINI A, 1995, AIDS, V9, P1351, DOI 10.1097/00002030-199512000-00008
   Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8
   Gilks CF, 2001, BRIT MED BULL, V58, P171, DOI 10.1093/bmb/58.1.171
   Gordon SB, 2002, AIDS, V16, P1409, DOI 10.1097/00002030-200207050-00013
   Grant AD, 1998, INT J TUBERC LUNG D, V2, P926
   Grant AD, 2001, AM J TROP MED HYG, V65, P810
   Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010
   Grant AD, 1998, BRIT MED BULL, V54, P369
   GRANT AD, 1997, AIDS SB, V11, P43
   HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537
   Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007
   Holmes CB, 2003, CLIN INFECT DIS, V36, P652, DOI 10.1086/367655
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   JAFFAR S, 2001, THESIS LONDON U LOND
   Kaleebu P, 2002, J INFECT DIS, V185, P1244, DOI 10.1086/340130
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Kaplan JE, 2000, CLIN INFECT DIS   S1, V30, P5
   LEE CA, 1991, BRIT MED J, V303, P1093
   LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421
   Lepri AC, 1997, J INFECT DIS, V175, P775, DOI 10.1086/513970
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Mocroft A, 1997, BRIT MED J, V314, P409
   Mole L, 1997, J INFECT DIS, V176, P766
   Morgan D, 1998, AIDS, V12, P591, DOI 10.1097/00002030-199806000-00007
   Morgan D, 1997, LANCET, V350, P245, DOI 10.1016/S0140-6736(97)01474-8
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   Morgan D, 2002, BRIT MED J, V324, P193, DOI 10.1136/bmj.324.7331.193
   Morgan D, 1997, AIDS, V11, P633, DOI 10.1097/00002030-199705000-00011
   Morgan D, 2001, NAT MED, V7, P143, DOI 10.1038/84564
   Morgan D, 2000, SEX TRANSM INFECT, V76, P193, DOI 10.1136/sti.76.3.193
   Ndour M, 2000, TROP MED INT HEALTH, V5, P687, DOI 10.1046/j.1365-3156.2000.00627.x
   Nduati R, 2001, LANCET, V357, P1651, DOI 10.1016/S0140-6736(00)04820-0
   Neilson JR, 1999, J VIROL, V73, P4393
   Nunn AJ, 1997, BRIT MED J, V315, P767
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, AIDS
   Rogers P A, 1997, Commun Dis Rep CDR Rev, V7, pR93
   ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101
   SALINARI RK, 1990, TROP DOCT, V20, P169
   Semba RD, 1999, BRIT J NUTR, V81, P181, DOI 10.1017/S0007114599000379
   SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011
   Todd J, 1997, AIDS, V11, P801, DOI 10.1097/00002030-199706000-00013
   *UNAIDS WHO, AIDS EP UPD DEC 2002
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2002, AIDS, V16, P1775
   WHITMOREOVERTON SE, 1993, AIDS, V7, P415, DOI 10.1097/00002030-199303000-00017
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6
   Wolday D, 2001, MED MICROBIOL IMMUN, V190, P65
NR 70
TC 76
Z9 80
U1 0
U2 19
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD JUN
PY 2004
VL 82
IS 6
BP 462
EP 469
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 830MR
UT WOS:000222126900012
PM 15356940
OA No
DA 2017-08-15
ER

PT J
AU Stockton, JC
   Howson, JMM
   Awomoyi, AA
   McAdam, KP
   Blackwell, JM
   Newport, MJ
AF Stockton, JC
   Howson, JMM
   Awomoyi, AA
   McAdam, KP
   Blackwell, JM
   Newport, MJ
TI Polymorphism in NOD2, Crohn's disease, and susceptibility to pulmonary
   tuberculosis
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Article
DE tuberculosis; Crohn's disease; genetic susceptibility; NOD2; Gambia
ID AVIUM SUBSPECIES PARATUBERCULOSIS; VARIANTS; GENE; ASSOCIATION;
   POPULATION; MUTATION
AB The nucleotide oligomerization binding domain 2 gene (NOD2) encodes an intracellular receptor for bacterial components, which is expressed in monocytes and is associated with Crohn's Disease (CD). This finding, along with epidemiological evidence, supports a role for infection in the pathogenesis of CD. Speculation that mycobacteria, are involved in CD led us to investigate NOD2 in susceptibility to tuberculosis (TB), a global public health problem caused by Mycobacterium tuberculosis. CD-associated NOD2 variants were absent in a case-control study of 640 Gambians, where CD is rare. Novel NOD2 promoter polymorphisms were identified but showed no association with TB in this African population sample. (C) 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Cambridge CB2 2XY, England.
   Univ Cambridge, Inst Med Res, Diabet & Inflammat Lab, Cambridge CB2 2XY, England.
   MRC Labs, Banjul, Gambia.
RP Newport, MJ (reprint author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.
EM melanie.newport@cimr.cam.ac.uk
RI Blackwell, Jenefer/H-3015-2015
CR Bellamy R, 2003, GENES IMMUN, V4, P4, DOI 10.1038/sj.gene.6363915
   BELLAMY R, 1998, NEW ENGL J MED, V339, P199
   Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019
   Cavanaugh JA, 2003, ANN HUM GENET, V67, P35, DOI 10.1046/j.1469-1809.2003.00006.x
   Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7
   Hermon-Taylor J, 2001, GUT, V49, P755, DOI 10.1136/gut.49.6.755
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hulten K, 2000, DIGEST DIS SCI, V45, P445, DOI 10.1023/A:1005453409445
   Hume G, 2002, PATHOLOGY, V34, P561, DOI 10.1080/0031302021000035965
   Inoue N, 2002, GASTROENTEROLOGY, V123, P86, DOI 10.1053/gast.2002.34155
   Leong RWL, 2003, ALIMENT PHARM THERAP, V17, P1465, DOI 10.1046/j.0269-2813.2003.01607.x
   Marsh S, 2003, GUT, V52, P770, DOI 10.1136/gut.52.5.770
   Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330
   Mishina D, 1996, P NATL ACAD SCI USA, V93, P9816, DOI 10.1073/pnas.93.18.9816
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Quirke P, 2001, GUT, V49, P757, DOI 10.1136/gut.49.6.757
   Salisbury BA, 2003, MUTAT RES-FUND MOL M, V526, P53, DOI 10.1016/S0027-5107(03)00014-9
   Schwartz D, 2000, CLIN MICROBIOL INFEC, V6, P303, DOI 10.1046/j.1469-0691.2000.00093.x
NR 22
TC 29
Z9 30
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-8244
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD JUN 1
PY 2004
VL 41
IS 2
BP 157
EP 160
DI 10.1016/j.femsim.2004.02.004
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 828BS
UT WOS:000221948300009
PM 15145460
OA No
DA 2017-08-15
ER

PT J
AU Milligan, P
   Njie, A
   Bennett, S
AF Milligan, P
   Njie, A
   Bennett, S
TI Comparison of two cluster sampling methods for health surveys in
   developing countries
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Cluster sampling; Expanded Program for Immunization; segment sampling;
   survey methods; vaccination coverage
ID COMPUTER-SIMULATION
AB Background The Expanded Program for Immunization (EPI) random walk method has been widely used by the World Health Organization and others for rapid cluster sample surveys where an up-to-date household sampling frame is not available. However, it is not a probability sample, does not allow for population movement since the last census, and does not ensure objectivity in household selection or permit call-backs for non-response. Compact segment sampling avoids these problems and has been proposed as a slower but cleaner alternative.
   Methods We conducted two surveys, one using the EPI scheme and one using compact segment sampling, to estimate vaccination coverage in Western Region of The Gambia within 3 months of each other in 2000-2001.
   Results Point estimates for vaccination coverage from the two surveys rarely differed by more than 2%. Any differences were more likely to be due to household selection than to population movement. A simple mathematical model showed that even in extreme situations, ignoring population movement since the last census is unlikely to have any appreciable effect. Rates of homogeneity did not differ systematically between the surveys.
   Conclusions In situations where quality of fieldwork can be guaranteed, the EPI random walk method can give accurate and precise results. However, compact segment sampling is generally to be preferred as it ensures objectivity in household selection and permits the estimation of population totals (such as those unvaccinated), which are helpful for planning service provision.
C1 MRC Labs, Fajara, Gambia.
   Govt Gambia, Dept State Hlth & Social Welf, Banjul, Gambia.
   London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1, England.
RP Milligan, P (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM pmilligan@mrc.gm
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   BENNETT S, 1991, World Health Statistics Quarterly, V44, P98
   BENNETT S, 1994, INT J EPIDEMIOL, V23, P1282, DOI 10.1093/ije/23.6.1282
   BENNETT S, 1993, P INT STAT I 49 SESS, P21
   Brogan Donna, 1994, Annals of Epidemiology, V4, P302
   Cochran W. G., 1977, SAMPLING TECHNIQUES
   *GAMB GOV, 1999, MISS OPP IMM TAL KUN
   *GAMB GOV, 1996, NAT REP POP DEV GAMB
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   Kish L., 1995, SURVEY SAMPLING
   LEMESHOW S, 1985, INT J EPIDEMIOL, V14, P473, DOI 10.1093/ije/14.3.473
   [Anonymous], 1996, 6 MACR INT INC
   Turner AG, 1996, INT J EPIDEMIOL, V25, P198, DOI 10.1093/ije/25.1.198
   *UNICEF, 1998, EV UNICEF MULT IND C
   *UNICEF, 1997, EV MULT IND CLUST SU
   World Health Organization, 1991, WHOEPIMLM9110
NR 16
TC 67
Z9 69
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD JUN
PY 2004
VL 33
IS 3
BP 469
EP 476
DI 10.1093/ije/dyh096
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 832MR
UT WOS:000222272100010
PM 15020569
OA No
DA 2017-08-15
ER

PT J
AU Morris-Jones, S
   Weber, M
AF Morris-Jones, S
   Weber, M
TI Medical mystery: Painless ulcers - The answer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 MRC Labs, Fajara, Gambia.
RP Morris-Jones, S (reprint author), MRC Labs, Fajara, Gambia.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC/NEJM
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 27
PY 2004
VL 350
IS 22
BP 2313
EP 2313
DI 10.1056/NEJMc045252
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 823VP
UT WOS:000221641900033
PM 15163788
OA No
DA 2017-08-15
ER

PT J
AU Anya, SE
AF Anya, SE
TI Seasonal variation in the risk and causes of maternal death in the
   Gambia: Malaria appears to be an important factor
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM; PREGNANT-WOMEN; RURAL GAMBIA; WEST-AFRICA;
   MORTALITY; ANEMIA; ECLAMPSIA; SENEGAL; BURDEN; AREAS
AB An increase in maternal mortality risk during peak malaria transmission in endemic countries is thought to implicate malaria in maternal deaths. The purpose of this study was to evaluate changes in risk and causes of maternal death in relation to the malaria season at the main referral hospital in The Gambia. During the malaria season, there was a 168% increase in the maternal mortality ratio (MMR), a three-fold increase in the proportion of deaths due to anemia, and an eight-fold increase in the anemia MMR. Apart from a 5.4-fold increase in eclampsia, there was no significant change in the contribution of other causes of death. It is estimated that malaria may account for up to 93 maternal deaths per 100,000 live births.
C1 Univ Gambia, Fac Med & Allied Hlth Sci, Dept Obstet & Gynaecol, Clin Sci Div,Reprod Hlth Res Unit, Kanifing, Gambia.
   Royal Victoria Teaching Hosp, Dept Obstet & Gynaecol, Banjul, Gambia.
RP Anya, SE (reprint author), Univ Gambia, Fac Med & Allied Hlth Sci, Dept Obstet & Gynaecol, Clin Sci Div,Reprod Hlth Res Unit, POB 3530, Serrekunda, Gambia.
EM se_anya@yahoo.co.uk
CR AGOBE JT, 1981, BRIT J OBSTET GYNAEC, V88, P706, DOI 10.1111/j.1471-0528.1981.tb01269.x
   Bouvier P, 1997, AM J TROP MED HYG, V56, P378
   Brabin BJ, 2001, J NUTR, V131, p604S
   Brabib B, 2002, MATERNAL MORBIDITY M, P65
   DARE FO, 1999, TROP DOCT, V28, P92
   DORMAN E, 2000, CURR OBSTET GYNECOL, V10, P189
   Etard JF, 2003, AM J TROP MED HYG, V68, P503
   Font F, 2000, INT J EPIDEMIOL, V29, P107, DOI 10.1093/ije/29.1.107
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   Guyatt HL, 2001, AM J TROP MED HYG, V64, P36
   Hoestermann CFL, 1996, TROP MED INT HEALTH, V1, P710
   MAHLER H, 1987, LANCET, V1, P668
   OBED SA, 1994, INT J GYNECOL OBSTET, V45, P97, DOI 10.1016/0020-7292(94)90115-5
   Piper C, 2001, INT J GYNECOL OBSTET, V72, P77, DOI 10.1016/S0020-7292(00)00323-4
   Rush David, 2000, AM J CLIN NUTR, V72, P212
   Sartelet H, 1996, LANCET, V347, P1121, DOI 10.1016/S0140-6736(96)90321-9
   Shulman CE, 2002, LANCET, V360, P494, DOI 10.1016/S0140-6736(02)09662-9
   SHULMAN CE, 1999, ANN TROP MED PARASIT, V93, P59
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   Verhoeff FH, 1999, ANN TROP MED PARASIT, V93, P119
   von Seidlein L, 2002, B WORLD HEALTH ORGAN, V80, P790
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
NR 22
TC 26
Z9 26
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 2004
VL 70
IS 5
BP 510
EP 513
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 822OO
UT WOS:000221549700007
PM 15155982
OA No
DA 2017-08-15
ER

PT J
AU Cooke, GS
   Campbell, SJ
   Fielding, K
   Sillah, J
   Manneh, K
   Sirugo, G
   Bennett, S
   McAdam, KPWJ
   Lienhardt, C
   Hill, AVS
AF Cooke, GS
   Campbell, SJ
   Fielding, K
   Sillah, J
   Manneh, K
   Sirugo, G
   Bennett, S
   McAdam, KPWJ
   Lienhardt, C
   Hill, AVS
TI Interleukin-8 polymorphism is not associated with pulmonary tuberculosis
   in the Gambia
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID SUSCEPTIBILITY; VIRUS
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Churchill Hosp, Oxford OX3 7BN, England.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Fajara, Gambia.
   Natl TB Leprosy Control Programme, Banjul, Gambia.
RP Hill, AVS (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Churchill Hosp, Roosevelt Dr, Oxford OX3 7BN, England.
EM adrian.hill@well.ox.ac.uk
RI HILL, Adrian/C-1306-2008
CR Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Ma X, 2003, J INFECT DIS, V188, P349, DOI 10.1086/376559
NR 5
TC 21
Z9 22
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD APR 15
PY 2004
VL 189
IS 8
BP 1545
EP 1546
DI 10.1086/382489
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 810WW
UT WOS:000220735400027
PM 15073694
OA No
DA 2017-08-15
ER

PT J
AU Emerson, PM
   Lindsay, SW
   Alexander, N
   Bah, M
   Dibba, SM
   Faal, HB
   Lowe, K
   McAdam, KPWJ
   Ratcliffe, AA
   Walraven, GEL
   Bailey, RL
AF Emerson, PM
   Lindsay, SW
   Alexander, N
   Bah, M
   Dibba, SM
   Faal, HB
   Lowe, K
   McAdam, KPWJ
   Ratcliffe, AA
   Walraven, GEL
   Bailey, RL
TI Role of flies and provision of latrines in trachoma control:
   cluster-randomised controlled trial
SO LANCET
LA English
DT Article
ID GLOBAL ELIMINATION; BLINDNESS; TANZANIA; VECTOR; RISK
AB Background Eye-seeking flies have received much attention as possible trachoma vectors, but this remains unproved. We aimed to assess the role of eye-seeking flies as vectors of trachoma and to test provision of simple pit latrines, without additional health education, as a sustainable method of fly control.
   Methods In a community-based, cluster-randomised controlled trial, we recruited seven sets of three village clusters and randomly assigned them to either an intervention group that received regular insecticide spraying or provision of pit latrines (without additional health education) to each household, or to a control group with no intervention. Our primary outcomes were fly-eye contact and prevalence of active trachoma. Frequency of child fly-eye contact was monitored fortnightly. Whole communities were screened for clinical signs of trachoma at baseline and after 6 months. Analysis was per protocol.
   Findings Of 7080 people recruited, 6087 (86%) were screened at follow-up. Baseline community prevalence of active trachoma was 6%. The number of Musca sorbens flies caught from children's eyes was reduced by 88% (95% CI 64-100; p < 0.0001) by insecticide spraying and by 30% (7-52; p = 0.04) by latrine provision by comparison with controls. Analysis of age-standardised trachoma prevalence rates at the cluster level (n = 14) showed that spraying was associated with a mean reduction in trachoma prevalence of 56% (19-93; p = 0.01) and 30% with latrines (-81 to 22; p = 0.210) by comparison with the mean rate change in the controls.
   Interpretation Fly control with insecticide is effective at reducing the number of flies caught from children's eyes and is associated with substantially lower trachoma prevalence compared with controls. Such a finding is consistent with flies being important vectors of trachoma. Since latrine provision without health education was associated with a significant reduction in fly-eye contact by M sorbens, studies of their effect when combined with other trachoma control measures are warranted.
C1 Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   MRC Labs, Banjul, Gambia.
   Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Emerson, PM (reprint author), Univ Durham, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.
EM p.m.emerson@durham.ac.uk
CR Bailey R, 2001, B WORLD HEALTH ORGAN, V79, P233
   Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839
   COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   Dawson CR, 2002, LANCET, V359, P184, DOI 10.1016/S0140-6736(02)07463-9
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 2002, OPHTHALMIC EPIDEMIOL, V9, P105, DOI 10.1076/opep.9.2.105.1522
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   EMERSON PM, 2000, TROP MED INT HEALTH, V5, P250
   Gaynor Bruce D., 2002, International Ophthalmology Clinics, V42, P85
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P83
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P275
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   Mabey D, 1999, BRIT J OPHTHALMOL, V83, P1261, DOI 10.1136/bjo.83.11.1261
   Mabey D, 2001, BRIT MED J, V323, P218, DOI 10.1136/bmj.323.7306.218
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   Munoz B, 1997, EPIDEMIOL REV, V19, P205
   PROST A, 1989, B WORLD HEALTH ORGAN, V67, P9
   Pruss A, 2000, B WORLD HEALTH ORGAN, V78, P258
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Schemann JF, 2003, T ROY SOC TROP MED H, V97, P63, DOI 10.1016/S0035-9203(03)90025-3
   Schemann JF, 2002, INT J EPIDEMIOL, V31, P194, DOI 10.1093/ije/31.1.194
   Taylor H, 1999, NAT MED, V5, P492, DOI 10.1038/8376
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   Taylor HR, 2002, CLIN EXP OPHTHALMOL, V30, P65
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   *WHO, 2001, 5 M WHO ALL GLOB EL
   [Anonymous], 1997, 1 M WHO ALL GLOB EL
NR 32
TC 106
Z9 106
U1 0
U2 7
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 3
PY 2004
VL 363
IS 9415
BP 1093
EP 1098
DI 10.1016/S0140-6736(04)15891-1
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 808VB
UT WOS:000220595500007
PM 15064026
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Brookes, RH
   Fox, A
   Fielding, K
   Jeffries, DJ
   Jackson-Sillah, D
   Lugos, MD
   Owiafe, PK
   Donkor, SA
   Hammond, AS
   Otu, JK
   Corrah, T
   Adegbola, RA
   McAdam, KPWJ
AF Hill, PC
   Brookes, RH
   Fox, A
   Fielding, K
   Jeffries, DJ
   Jackson-Sillah, D
   Lugos, MD
   Owiafe, PK
   Donkor, SA
   Hammond, AS
   Otu, JK
   Corrah, T
   Adegbola, RA
   McAdam, KPWJ
TI Large-scale evaluation of enzyme-linked immunospot assay and skin test
   for diagnosis of Mycobacterium tuberculosis infection against a gradient
   of exposure in The Gambia
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID DELAYED-TYPE HYPERSENSITIVITY; CALMETTE-GUERIN VACCINATION; T-CELLS;
   NORTHERN MALAWI; IFN-GAMMA; RESPONSES; ESAT-6; HEALTHY; SENSITIVITY;
   POPULATION
AB The purified protein derivative (PPD) skin test for Mycobacterium tuberculosis infection lacks specificity. We assessed 2 more specific M. tuberculosis antigens (ESAT-6 and CFP-10) by enzyme-linked immunospot assay (ELISPOT) compared with PPD by ELISPOT and skin test in The Gambia. Of 735 household contacts of 130 sputum smear-positive tuberculosis cases, 476 (65%) tested positive by PPD ELISPOT, 300 (41%) tested positive by PPD skin test, and 218 (30%) tested positive by ESAT-6/CFP-10 ELISPOT. Only 15 (2%) had positive ESAT-6/CFP-10 results and negative PPD results by ELISPOT. With increasing M. tuberculosis exposure, the percentage of subjects who were PPD skin test positive/ESAT-6/CFP-10 ELISPOT negative increased (P<.001), whereas the percentage of subjects who were PPD skin test negative/PPD ELISPOT positive decreased (P=.011). Eighteen (31%) ESAT-6/CFP-10 ELISPOT-positive subjects in the lowest exposure category had negative PPD skin test results. ESAT-6/CFP-10 ELISPOT probably offers increased specificity in the diagnosis of M. tuberculosis infection in this tropical setting of endemicity, at the cost of some sensitivity.
C1 MRC Labs, TB Div, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Hill, PC (reprint author), MRC Labs, TB Div, POB 273, Banjul, Gambia.
EM phill@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011
OI Kwasi Owiafe, Patrick/0000-0002-4287-3577
FU Medical Research Council [MC_U190071468]
CR Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   ANDERSEN P, 1995, J IMMUNOL, V154, P3359
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664
   Cockle PJ, 2002, INFECT IMMUN, V70, P6996, DOI 10.1128/IAI.70.12.6996-7003.2002
   Demissie A, 1999, INFECT IMMUN, V67, P5967
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Floyd S, 2002, J INFECT DIS, V186, P807, DOI 10.1086/342416
   Godkin AJ, 2002, J IMMUNOL, V169, P2210
   Haile Y, 2002, MICROBIOL-SGM, V148, P3881
   Heifets Leonid B., 1994, P85
   Hoft DF, 2000, CLIN INFECT DIS, V30, pS217, DOI 10.1086/313864
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   LEINHARDT C, 2003, AM J RESP CRIT CARE, V168, P448
   Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740
   *NAT LEPR TUB PROG, 2003, ANN REP
   Pathan AA, 2001, J IMMUNOL, V167, P5217
   Pitman R, 2002, INT J TUBERC LUNG D, V6, P485
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498
   Small PM, 2000, LANCET, V356, P1048, DOI 10.1016/S0140-6736(00)02724-0
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W
   van Pittius Nico C. Gey, 2002, Infection and Immunity, V70, P6509
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   YOUNG TK, 1992, TUBERCLE LUNG DIS, V73, P94, DOI 10.1016/0962-8479(92)90062-O
NR 26
TC 133
Z9 137
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 1
PY 2004
VL 38
IS 7
BP 966
EP 973
DI 10.1086/382362
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 805AF
UT WOS:000220338500012
PM 15034828
OA No
DA 2017-08-15
ER

PT J
AU Njai, HF
   Van der Auwera, G
   Ngong, CA
   Heyndrickx, L
   Sawadago, S
   Whittle, H
   Nyambi, P
   Colebunders, R
   van der Groen, G
   Janssens, W
AF Njai, HF
   Van der Auwera, G
   Ngong, CA
   Heyndrickx, L
   Sawadago, S
   Whittle, H
   Nyambi, P
   Colebunders, R
   van der Groen, G
   Janssens, W
TI Development, evaluation, and validation of an oligonucleotide probe
   hybridization assay to subtype human immunodeficiency virus type 1
   circulating recombinant form CRF02_AG
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HETERODUPLEX MOBILITY ASSAY; NON-B SUBTYPES; HIV TYPE-1; MOLECULAR
   CHARACTERIZATION; GENETIC SUBTYPES; CENTRAL-AFRICA; PREDOMINANCE;
   SEQUENCES; ENV; AG
AB We have developed and validated an oligonucleotide probe hybridization assay for human immunodeficiency virus type I (HIV-1) circulating recombinant form (CRF) CRF02_AG. In the p17 coding region of the gag gene, a CRF02_AG-specific signature pattern was observed. Five working probes were designed to discriminate CRF02_AG infections from infections by all other documented subtypes and CRFs in an enzyme-linked immunosorbent assay-based oligonucleotide probe hybridization assay. Nucleic acids were extracted from a panel of HIV-1-positive plasma samples from Cameroon, Benin, Cote d'Ivoire, Kenya, Zambia, and Belgium and from blood spots from The Gambia. CRF02_AG (n = 147) and non-CRF02 (n = 100) samples were analyzed to evaluate and validate the oligonucleotide probe hybridization assay. The CRF02_AG-specific oligonucleotide probe hybridization assay has a high sensitivity and specificity, with good positive and negative predictive values in regions of high and low prevalence. A validation of the assay with West and West Central African samples indicated a sensitivity of 98.4% and a specificity of 96.7%. The oligonucleotide probe hybridization assay as a diagnostic tool will allow for rapid screening for CRF02_AG. This could be used to track the HIV epidemic in terms of documenting the real prevalence of CRF02_AG strains and will complement efforts in vaccine development. Moreover, this technology can easily be applied in laboratories in developing countries.
C1 Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
   State Univ Ghent, Dept Plant Syst Biol, B-9000 Ghent, Belgium.
   Flanders Interuniv Inst Biotechnol, Zwijnaarde, Belgium.
   Projet RETRO CI, Abidjan, Cote Ivoire.
   MRC Labs, Fajara, Gambia.
   NYU, Sch Med, Dept Pathol, New York, NY USA.
RP Janssens, W (reprint author), Inst Trop Med, Dept Microbiol, Natl Str 155, B-2000 Antwerp, Belgium.
EM janssens@itg.be
CR Andersson S, 1999, VIROLOGY, V262, P312, DOI 10.1006/viro.1999.9867
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Bredell H, 2002, AIDS RES HUM RETROV, V18, P681, DOI 10.1089/088922202760019400
   Carr JK, 1998, VIROLOGY, V247, P22, DOI 10.1006/viro.1998.9211
   Cham F, 2000, AIDS RES HUM RETROV, V16, P1915, DOI 10.1089/08892220050195874
   de Baar MP, 2001, J CLIN MICROBIOL, V39, P1895, DOI 10.1128/JCM.39.5.1895-1902.2001
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Esteves A, 2002, AIDS RES HUM RETROV, V18, P313, DOI 10.1089/088922202753519089
   Heyndrickx L, 2000, J VIROL, V74, P363
   Holguin A, 2000, AIDS RES HUM RETROV, V16, P1395, DOI 10.1089/08892220050140946
   HOWARD TM, 1994, AIDS RES HUM RETROV, V10, P1755, DOI 10.1089/aid.1994.10.1755
   Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000
   Krogstad P, 2002, AIDS RES HUM RETROV, V18, P413, DOI 10.1089/088922202753614173
   LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003
   Montavon C, 2000, J ACQ IMMUN DEF SYND, V23, P363
   Nkengasong JN, 2000, J ACQ IMMUN DEF SYND, V23, P430
   Nyambi P, 2002, AIDS, V16, P295, DOI 10.1097/00002030-200201250-00022
   Ortiz M, 2000, AIDS RES HUM RETROV, V16, P1967, DOI 10.1089/088922200750054693
   ORTIZ M, 2001, AIDS RES HUM RETROV, V9, P851
   Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184
   Peeters M, 2000, AIDS RES HUM RETROV, V16, P315, DOI 10.1089/088922200309197
   Plantier JC, 2002, J CLIN MICROBIOL, V40, P1010, DOI 10.1128/JCM.40.3.1010-1022.2002
   Preston BD, 1997, SCIENCE, V275, P228, DOI 10.1126/science.275.5297.228
   Ramratnam B, 1999, LANCET, V354, P1782, DOI 10.1016/S0140-6736(99)02035-8
   Stanojevic M, 2002, AIDS RES HUM RETROV, V18, P519, DOI 10.1089/088922202317406673
   Taniguchi Y, 2002, AIDS RES HUM RETROV, V18, P79, DOI 10.1089/088922202753394745
   Tebit DM, 2002, AIDS RES HUM RETROV, V18, P39, DOI 10.1089/088922202753394709
   Toure-Kane C, 2000, AIDS RES HUM RETROV, V16, P603, DOI 10.1089/088922200309025
   Ustina V, 2001, AIDS RES HUM RETROV, V17, P81, DOI 10.1089/088922201750056816
   VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
NR 31
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD APR
PY 2004
VL 42
IS 4
BP 1428
EP 1433
DI 10.1128/JCM.42.4.1428-1433.2004
PG 6
WC Microbiology
SC Microbiology
GA 814GK
UT WOS:000220963000007
PM 15070984
OA No
DA 2017-08-15
ER

PT J
AU Nweneka, CV
   Eneh, AU
AF Nweneka, CV
   Eneh, AU
TI Malaria parasitaemia in Neonates in Port Harcourt, Nigeria
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID CONGENITAL MALARIA
AB Malaria is thought to be rare among neonates in malaria-endemic regions. Consequently, blood film for malaria parasite is not routinely included in the sepsis screening protocol for neonates. We examined the role of malaria in perinatal morbidity among neonates admitted into our unit with a view to determining the need or otherwise of including malaria parasitaemia in the sepsis work-up in suspected neonatal septicaemia. Fourteen babies who met our preset criteria were screened for malaria parasitaemia out of which five (35.71 per cent) had positive blood smears for Plasmodium falciparum. Eighty per cent of the neonates presenting with fever had positive blood films (rates corrected chi(2)=3.9822; p=0.04). All the babies responded to an oral course of chloroquine. These data have further highlighted the importance of malaria in perinatal morbidity in our environment. We recommend a multi-centred study to define clearly the role of malaria in perinatal and neonatal morbidity and mortality in malaria endemic areas.
C1 Univ Port Harcourt, Teaching Hosp, Port Harcourt, Nigeria.
RP Nweneka, CV (reprint author), MRC Keneba, POB 273, Banful, Gambia.
CR AKINDELE JA, 1993, ANN TROP PAEDIATR, V13, P273
   Comellini L, 1998, ANN TROP PAEDIATR, V18, P41
   DISU EA, 2001, INT C PAED BEIJ CHIN
   EZEOKE AC, 1985, CENT AFR J MED, V3, P241
   Fischer PR, 1997, CLIN PEDIATR, V36, P411, DOI 10.1177/000992289703600706
   Ibhanesebhor SE, 1995, J TROP PEDIATRICS, V41, P330
   IBHANESEBHOR SE, 1992, ANN TROP PAEDIATR, V12, P297
   Olanrewaju W I, 1999, West Afr J Med, V18, P139
   *WHO, 1998, 94 WHO
NR 9
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD APR
PY 2004
VL 50
IS 2
BP 114
EP 116
DI 10.1093/tropej/50.2.114
PG 3
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 810QX
UT WOS:000220719900012
PM 15088802
OA No
DA 2017-08-15
ER

PT J
AU Reece, WHH
   Pinder, M
   Gothard, PK
   Milligan, P
   Bojang, K
   Doherty, T
   Plebanski, M
   Akinwunmi, P
   Everaere, S
   Watkins, KR
   Voss, G
   Tornieporth, N
   Alloueche, A
   Greenwood, BM
   Kester, KE
   McAdam, KPWJ
   Cohen, J
   Hill, AVS
AF Reece, WHH
   Pinder, M
   Gothard, PK
   Milligan, P
   Bojang, K
   Doherty, T
   Plebanski, M
   Akinwunmi, P
   Everaere, S
   Watkins, KR
   Voss, G
   Tornieporth, N
   Alloueche, A
   Greenwood, BM
   Kester, KE
   McAdam, KPWJ
   Cohen, J
   Hill, AVS
TI A CD4(+) T-cell immune response to a conserved epitope in the
   circumsporozoite protein correlates with protection from natural
   Plasmodium falciparum infection and disease
SO NATURE MEDICINE
LA English
DT Article
ID SPOROZOITE SURFACE PROTEIN-2; MALARIA VACCINE; EFFECTOR FUNCTIONS;
   IFN-GAMMA; EFFICACY; LYMPHOCYTES; DISTINCT; SUBSETS; RTS,S/AS02;
   ANTIBODIES
AB Many human T-cell responses specific for epitopes in Plasmodium falciparum have been described, but none has yet been shown to be predictive of protection against natural malaria infection(1). Here we report a peptide-specific T-cell assay that is strongly associated with protection of humans in The Gambia, West Africa, from both malaria infection and disease. The assay detects interferon-gamma-secreting CD4(+) T cells specific for a conserved sequence from the circumsporozoite protein, which binds to many human leukocyte antigen (HLA)-DR types(2). The correlation was observed using a cultured, rather than an ex vivo, ELISPOT assay that measures central memory-type T cells rather than activated effector T cells(3,4). These findings provide direct evidence for a protective role for CD4(+) T cells in humans, and a precise target for the design of improved vaccines against P. falciparum.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
   GlaxoSmithKline Biol, B-1330 Rixensart, Belgium.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Walter Reed Army Inst Res, Silver Spring, MD 20910 USA.
RP Hill, AVS (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
EM Adrian.Hill@ndm.ox.ac.uk
RI HILL, Adrian/C-1306-2008; Kester, Kent/A-2114-2011; Milligan,
   Paul/D-8985-2017
OI Kester, Kent/0000-0002-5056-0802; Milligan, Paul/0000-0003-3430-3395
CR Aidoo M, 2000, PARASITOL TODAY, V16, P50, DOI 10.1016/S0169-4758(99)01592-6
   Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   Baron V, 2003, IMMUNITY, V18, P193, DOI 10.1016/S1074-7613(03)00020-7
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   Flanagan KL, 2003, AM J TROP MED HYG, V68, P421
   Flanagan KL, 2001, J IMMUNOL, V167, P4729
   Godkin AJ, 2002, J IMMUNOL, V169, P2210
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   HOFFMAN SL, 1989, J IMMUNOL, V142, P1299
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   Pinder M, 2004, CLIN EXP IMMUNOL, V135, P286, DOI 10.1111/j.1365-2249.2004.02371.x
   Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Schwenk R, 2003, PARASITE IMMUNOL, V25, P17, DOI 10.1046/j.1365-3024.2003.00495.x
   SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0
   SINIGAGLIA F, 1988, EUR J IMMUNOL, V18, P633, DOI 10.1002/eji.1830180422
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657
   Sun PF, 2003, J IMMUNOL, V171, P6961
   Wang RB, 1996, J IMMUNOL, V157, P4061
   Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889
   WIZEL B, 1995, J EXP MED, V182, P1435, DOI 10.1084/jem.182.5.1435
   Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832
   ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591
NR 29
TC 182
Z9 188
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD APR
PY 2004
VL 10
IS 4
BP 406
EP 410
DI 10.1038/nm1009
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 808RU
UT WOS:000220587000033
PM 15034567
OA No
DA 2017-08-15
ER

PT J
AU Morris-Jones, S
   Weber, M
AF Morris-Jones, S
   Weber, M
TI A medical mystery - Painless ulcers
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 MRC Labs, Fajara, Gambia.
RP Morris-Jones, S (reprint author), MRC Labs, Fajara, Gambia.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC/NEJM
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 1
PY 2004
VL 350
IS 14
BP 1442
EP 1442
DI 10.1056/NEJMicm930334
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 808IJ
UT WOS:000220562500011
OA No
DA 2017-08-15
ER

PT J
AU Barnett, LK
   Emms, C
   Jallow, A
   Cham, AM
   Mortimer, JA
AF Barnett, LK
   Emms, C
   Jallow, A
   Cham, AM
   Mortimer, JA
TI The distribution and conservation status of marine turtles in The
   Gambia, West Africa: a first assessment
SO ORYX
LA English
DT Article
DE Africa; conservation status; nesting; marine turtles; The Gambia;
   threats
AB This paper reports the first systematic survey of the marine turtles of the 80 km of Gambian coastline, and brings together new data and all past records and reports of marine turtles in The Gambia. Green turtles Chelonia mydas are the most abundant turtles and this is the only species so far observed nesting in The Gambia, with peak nesting between August and October. Although 75% (60 km) of The Gambian coastline appears to be suitable for turtle nesting, most nesting activity is confined to the southern coastline. Offshore foraging habitat is apparently extensive. Strandings of green turtles, olive ridley turtles Lepidochelys olivacea, leather-back turtles Dermochelys coriacea and hawksbill turtles Eretmochelys imbricata have been recorded, but we were unable to find evidence for loggerhead turtles Caretta caretta. Threats are mainly of human origin, and include illegal harvesting of eggs, juveniles and adults, as well as mortality as fisheries bycatch, including trawling. One stranded green turtle apparently had fibropapilloma disease. The major threat to nesting habitats is erosion and unregulated development of the coast for tourism. Marine turtles are fully protected under Gambian law. Other national efforts to conserve turtles in The Gambia are described and assessed.
C1 Dept State Fisheries Nat Resources & Environm, Dept Pks & Wildlife Management, Banjul, Gambia.
   Dept Fisheries, Banjul, Gambia.
   Univ Florida, Dept Zool, Gainesville, FL 32611 USA.
RP Barnett, LK (reprint author), Makasutu Wildlife Trust, POB 2164, Serrekunda, Gambia.
EM drumohq@qanet.gm
OI Mortimer, Jeanne A./0000-0001-6318-2890
CR Barnett Linda K., 2001, Bulletin of the African Bird Club, V8, P39
   BARNETT LK, 2003, DAILY OBSERVER  0313
   BARNETT LK, 2002, DAILY OBSERVER  0627
   BARNETT LK, 2000, RAMSAR WETLAND STUDY
   BOLTEN A.B., 1999, IUCN SSC MARINE TURT, V4, P110
   CAMARA A, 1998, UNPUB DRAFT MANAGEME
   DANSO A, 1997, STATE ENV REPORT GAM, P39
   DRAMMEH F, 2002, DAILY OBSERVER  0704
   *ECOLAS, 2000, UNPUB TRAD GAT PROJ
   FATTY L, 1997, STATE ENV REPORT GAM, P61
   FRETEY J, 2001, TECHNICAL SERIES PUB, V6
   *GOV GAMB, 1999, NAT BIOD STRAT ACT P
   *GOV GAMB, 1999, BIOD WILDL POL REG 1
   GRUSCHWITZ M, 1991, HERPETOFAUNA, V74, P13
   Herbst Lawrence H., 1995, P593
   Herbst Lawrence H., 1994, Annual Review of Fish Diseases, V4, P389, DOI 10.1016/0959-8030(94)90037-X
   IUCN, 2002, IUCN RED LIST THREAT
   MAIGRET J., 1983, B SOC HERPETOLOGIQUE, V28, P22
   Mortimer J.A., 1999, Linnean Society Occasional Publication, V2, P159
   MURPHY PF, 1997, RAMSAR WETLAND STUDY
   Pauwels Olivier, 1996, British Herpetological Society Bulletin, V56, P27
   Pritchard P.C.H., 1999, IUCN SSC MARINE TURT, V4, P21
   SIEH R, 1993, DAILY OBSERVER  0407
   *UNEP CMS, 1999, MAR TURTL CONS STAT
   *UNEP CMS, 1999, INT C CONS SEA TURTL
NR 25
TC 7
Z9 9
U1 1
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA
SN 0030-6053
J9 ORYX
JI Oryx
PD APR
PY 2004
VL 38
IS 2
BP 203
EP 208
DI 10.1017/S0030605304000353
PG 6
WC Ecology
SC Environmental Sciences & Ecology
GA 823US
UT WOS:000221639400022
OA No
DA 2017-08-15
ER

PT J
AU Drakeley, CJ
   Eling, W
   Teelen, K
   Bousema, JT
   Sauerwein, R
   Greenwood, BM
   Targett, GAT
AF Drakeley, CJ
   Eling, W
   Teelen, K
   Bousema, JT
   Sauerwein, R
   Greenwood, BM
   Targett, GAT
TI Parasite infectivity and immunity to Plasmodium falciparum gametocytes
   in Gambian children
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE gametes; gametocytes; malaria; P. falciparum; Pfs230; Pfs48/45;
   transmission-blocking immunity
ID TRANSMISSION-BLOCKING IMMUNITY; SURFACE-ANTIGEN PFS230; SEXUAL STAGE
   ANTIGENS; PAPUA-NEW-GUINEA; COMPETITION ELISAS; ANTIBODY-RESPONSES;
   ANOPHELES-GAMBIAE; MALARIA; SERA; MOSQUITOS
AB Immunity to the sexual stages of Plasmodium falciparum can be induced during natural infections. Characterization of this immunity may facilitate the design of a transmission-blocking vaccine (TBV). This study aimed to assess the prevalence and serological correlates of functional transmission-blocking immunity in Gambian children (aged 1-4 years old) who were P. falciparum gametocyte carriers. Serological assays showed 100% response to fixed, whole parasites but only 42% to live gametes. Responses to the antigens Pfs230 and Pfs48/45 were 54.1% and 37.3%, respectively, in an IgG1 ELISA. 14/55 sera were capable of reducing the infectivity of laboratory isolate NF54 in a standard membrane-feeding assay (SMFA). This activity was strongly correlated with IgG1 responses to Pfs48/45 (r = 0.49, P < 0.001) and to a serological reaction with epitopes of the same molecule (r = 0.38, P = 0.003). A weaker correlation was observed with IgG1 to Pfs230 (r = 0.29, P = 0.03). In direct membrane feeding assays (DMFA) with autologous isolates, sera from 4/29 children showed transmission-blocking activity. There was no correlation with serological assays and the DMFA or between the SMFA and DMFA. This may be caused by variation in sexual stage antigens and/or alternative modes of transmission-blocking immunity, both of which have implications for vaccine implementation.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands.
RP Drakeley, CJ (reprint author), Joint Malaria Programme, Box 2228, Moshi, Tanzania.
EM chris.drakeley@lshtm.ac.uk
RI Sauerwein, Robert/C-8519-2013; Bousema, Teun/N-3574-2014
CR BILLINGSLEY PF, 1994, AM J TROP MED HYG, V51, P260
   CARTER R, 1995, MOL BIOCHEM PARASIT, V71, P203, DOI 10.1016/0166-6851(94)00054-Q
   CARTER R, 1989, J EXP MED, V169, P135, DOI 10.1084/jem.169.1.135
   Drakeley CJ, 1999, TROP MED INT HEALTH, V4, P131, DOI 10.1046/j.1365-3156.1999.00361.x
   Drakeley CJ, 1998, PARASITOLOGY, V116, P417, DOI 10.1017/S0031182098002601
   Drakeley CJ, 2004, TROP MED INT HEALTH, V9, P53, DOI 10.1046/j.1365-3156.2003.01169.x
   GRAVES PM, 1988, PARASITE IMMUNOL, V10, P209, DOI 10.1111/j.1365-3024.1988.tb00215.x
   GRAVES PM, 1991, PARASITE IMMUNOL, V13, P291, DOI 10.1111/j.1365-3024.1991.tb00283.x
   GWADZ RW, 1976, SCIENCE, V193, P1150, DOI 10.1126/science.959832
   Healer J, 1997, INFECT IMMUN, V65, P3017
   Healer J, 1999, PARASITOLOGY, V119, P425, DOI 10.1017/S0031182099005041
   Kaslow DC, 1997, INT J PARASITOL, V27, P183, DOI 10.1016/S0020-7519(96)00148-8
   KOCKEN CHM, 1995, MOL BIOCHEM PARASIT, V69, P115, DOI 10.1016/0166-6851(94)00193-Q
   Lensen A, 1996, T ROY SOC TROP MED H, V90, P20, DOI 10.1016/S0035-9203(96)90464-2
   MENDIS KN, 1991, RES IMMUNOL, V142, P687, DOI 10.1016/0923-2494(91)90150-H
   MENDIS KN, 1987, INFECT IMMUN, V55, P369
   MULDER B, 1994, T ROY SOC TROP MED H, V88, P121, DOI 10.1016/0035-9203(94)90534-7
   Mulder B, 1999, EXP PARASITOL, V92, P81, DOI 10.1006/expr.1999.4398
   NIJHOUT MM, 1978, PARASITOLOGY, V76, P39
   ONG CSL, 1990, PARASITE IMMUNOL, V12, P447, DOI 10.1111/j.1365-3024.1990.tb00980.x
   PONNUDURAI T, 1982, T ROY SOC TROP MED H, V76, P242, DOI 10.1016/0035-9203(82)90289-9
   PREMAWANSA S, 1994, PARASITE IMMUNOL, V16, P35, DOI 10.1111/j.1365-3024.1994.tb00302.x
   RANAWAKA GRR, 1994, PARASITOLOGY, V109, P11
   READ D, 1994, PARASITE IMMUNOL, V16, P511, DOI 10.1111/j.1365-3024.1994.tb00305.x
   RILEY EM, 1994, PARASITE IMMUNOL, V16, P55
   Roeffen W, 1996, PARASITE IMMUNOL, V18, P103, DOI 10.1046/j.1365-3024.1996.d01-54.x
   ROEFFEN W, 1995, EXP PARASITOL, V80, P15, DOI 10.1006/expr.1995.1003
   TARGETT GAT, 1990, IMMUNOL LETT, V25, P77, DOI 10.1016/0165-2478(90)90095-8
   Taylor RR, 1996, INT IMMUNOL, V8, P905, DOI 10.1093/intimm/8.6.905
   VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460
NR 30
TC 18
Z9 18
U1 0
U2 4
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD APR
PY 2004
VL 26
IS 4
BP 159
EP 165
DI 10.1111/j.0141-9838.2004.00696.x
PG 7
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 853XI
UT WOS:000223863500001
PM 15367293
OA No
DA 2017-08-15
ER

PT J
AU Awomoyi, AA
   Nejentsev, S
   Richardson, A
   Hull, J
   Koch, O
   Podinovskaia, M
   Todd, JA
   McAdam, KPWJ
   Blackwell, JM
   Kwiatkowski, D
   Newport, MJ
AF Awomoyi, AA
   Nejentsev, S
   Richardson, A
   Hull, J
   Koch, O
   Podinovskaia, M
   Todd, JA
   McAdam, KPWJ
   Blackwell, JM
   Kwiatkowski, D
   Newport, MJ
TI No association between interferon-gamma receptor-1 gene polymorphism and
   pulmonary tuberculosis in a Gambian population sample
SO THORAX
LA English
DT Article
ID CALMETTE-GUERIN INFECTION; MYCOBACTERIUM-TUBERCULOSIS; SUSCEPTIBILITY;
   DEFICIENCY; MUTATION; INTERLEUKIN-10; ACTIVATION; STAT1; CHILD
AB Background: Tuberculosis (TB) is a major global cause of mortality and morbidity, and host genetic factors influence disease susceptibility. Interferon-gamma mediates immunity to mycobacteria and rare mutations in the interferon-gamma receptor-1 gene (IFNGR1) result in increased susceptibility to mycobacterial infection, including TB, in affected families. The role of genetic variation in IFNGR1 in susceptibility to common mycobacterial diseases such as pulmonary TB in outbred populations has not previously been investigated.
   Methods: The association between IFNGR1 and susceptibility to pulmonary TB was investigated in a Gambian adult population sample using a case-control study design. The coding and promoter regions of IFNGR1 were sequenced in 32 patients with pulmonary TB, and the frequencies of six common IFNGR1 polymorphisms were determined using PCR based methods in 320 smear positive TB cases and 320 matched controls. Haplotypes were estimated from the genotype data using the expectation-maximisation algorithm.
   Results: There was no association between the IFNGR1 variants studied and TB in this Gambian population sample. Three common haplotypes were identified within the study population, none of which was associated with TB.
   Conclusions: These data represent an important negative finding and suggest that, while IFNGR1 is implicated in rare Mendelian susceptibility to mycobacterial disease, the common variants studied here do not have a major influence on susceptibility to pulmonary TB in The Gambian population.
C1 MRC Labs, Fajara, Gambia.
   Univ Cambridge, Cambridge Inst Med Res, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Cambridge, England.
   Wellcome Trust Ctr Human Genet, Oxford, England.
   Univ Cambridge, Cambridge Inst Med Res, Dept Med, Cambridge, England.
RP Newport, MJ (reprint author), Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England.
EM Melanie.newport@cimr.cam.ac.uk
RI Todd, John/A-3542-2010; Blackwell, Jenefer/H-3015-2015; Koch,
   Oliver/A-9480-2016
OI Todd, John/0000-0003-2740-8148; 
CR Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950
   Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999
   Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   BELLAMY R, 1998, NEW ENGL J MED, V339, P199
   de Jong R, 1998, SCIENCE, V280, P1435
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Fraser DA, 2003, SCAND J IMMUNOL, V57, P480, DOI 10.1046/j.1365-3083.2003.01253.x
   Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC
   Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330
   Newport MJ, 2003, SCAND J IMMUNOL, V58, P383, DOI 10.1046/j.1365-3083.2003.01328.x
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   NEWPORT MJ, 2004, IN PRESS PRIMARY IMM
   ROOK GAW, 1986, IMMUNOLOGY, V59, P333
   Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5
   Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034
   Tanaka Y, 1999, IMMUNOGENETICS, V49, P266, DOI 10.1007/s002510050492
   Thye T, 2003, AM J HUM GENET, V72, P448, DOI 10.1086/367714
   Ting LM, 1999, J IMMUNOL, V163, P3898
NR 26
TC 25
Z9 28
U1 1
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
J9 THORAX
JI Thorax
PD APR 1
PY 2004
VL 59
IS 4
BP 291
EP 294
DI 10.1136/thx.2003.013029
PG 4
WC Respiratory System
SC Respiratory System
GA 807CT
UT WOS:000220480300006
PM 15047947
OA No
DA 2017-08-15
ER

PT J
AU Allal, N
   Sear, R
   Prentice, AM
   Mace, R
AF Allal, N
   Sear, R
   Prentice, AM
   Mace, R
TI An evolutionary model of stature, age at first birth and reproductive
   success in Gambian women
SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE life-history trade-off evolution; age at first birth; height; father
   absence; The Gambia
ID LIFE-HISTORY TRAITS; RURAL GAMBIA; FERTILITY; MENARCHE; HEIGHT; GIRLS;
   MORTALITY; VILLAGES; MATURITY; PUBERTY
AB We have built a model to predict optimal age at first birth for women in a natural fertility population. The only existing fully evolutionary model, based on Ache hunter-gatherers, argues that as women gain weight, their fertility (rate of giving birth) increases-thus age at first birth represents a trade-off between time allocated to weight gain and greater fertility when mature. We identify the life-history implications of female age at first birth in a Gambian population, using uniquely detailed longitudinal data collected from 1950 to date. We use height rather than weight as an indicator of growth as it is more strongly correlated with age at first birth. Stature does not greatly influence fertility in this population but has a significant effect on offspring mortality. We model age at first reproduction as a trade-off between the time spent growing and reduced infant mortality after maturation. Parameters derived from this population are fitted to show that the predicted optimal mean age of first birth, which maximizes reproductive success, is 18 years, very close to that observed. The reaction norm associated with variation in growth rate during childhood also satisfactorily predicts the variation in age at first birth.
C1 UCL, Dept Anthropol, London WC1E 6BT, England.
   London Sch Econ, Dept Social Policy, London WC2A 2AE, England.
   MRC Labs Keneba, Banjul, Gambia.
RP UCL, Dept Anthropol, Gower St, London WC1E 6BT, England.
EM r.mace@ucl.ac.uk
OI Mace, Ruth/0000-0002-6137-7739
CR BELSKY J, 1991, CHILD DEV, V62, P647, DOI 10.1111/j.1467-8624.1991.tb01558.x
   BILLEWICZ WZ, 1982, ANN HUM BIOL, V9, P309, DOI 10.1080/03014468200005811
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   Bogin B., 1999, PATTERNS HUMAN GROWT
   Ellis BJ, 2003, CHILD DEV, V74, P801, DOI 10.1111/1467-8624.00569
   Georgiadis E, 1997, ANN HUM BIOL, V24, P55, DOI 10.1080/03014469700004772
   Gibson MA, 2002, CURR ANTHROPOL, V43, P631, DOI 10.1086/342428
   Hill K, 1996, ACHE LIFE HIST
   Hulanicka B, 2001, AM J HUM BIOL, V13, P771, DOI 10.1002/ajhb.1123
   Ibanez L, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.5.e72
   Kaar P, 1996, P ROY SOC B-BIOL SCI, V263, P1475, DOI 10.1098/rspb.1996.0215
   Kaplowitz PB, 2001, PEDIATRICS, V108, P347, DOI 10.1542/peds.108.2.347
   LUNN PG, 1981, LANCET, V1, P1428
   MACE R, 2004, IN PRESS GRANDMOTHER
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Mul D, 2001, PEDIATR RES, V50, P479, DOI 10.1203/00006450-200110000-00010
   Okasha M, 2001, ANN HUM BIOL, V28, P68
   QAMRA S R, 1991, Indian Pediatrics, V28, P265
   Roff Derek A., 1992
   Rush D, 2000, AM J CLIN NUTR, V72, p212S
   Sear R, 2000, P ROY SOC B-BIOL SCI, V267, P1641, DOI 10.1098/rspb.2000.1190
   Sear R, 2003, EVOL HUM BEHAV, V24, P25, DOI 10.1016/S1090-5138(02)00105-8
   SEAR R, 2004, IN PRESS J EC ANTHR
   SEAR RS, 2001, THESIS U COLL LONDON
   Silva ID, 2002, INT J EPIDEMIOL, V31, P405, DOI 10.1093/ije/31.2.405
   Simondon KB, 1998, EUR J CLIN NUTR, V52, P412, DOI 10.1038/sj.ejcn.1600577
   STEARNS SC, 1986, EVOLUTION, V40, P893, DOI 10.1111/j.1558-5646.1986.tb00560.x
   Stearns SC, 1992, EVOLUTION LIFE HIST
   Strassmann BI, 2002, P ROY SOC B-BIOL SCI, V269, P553, DOI 10.1098/rspb.2001.1912
   THOMPSON EDB, 1965, THESIS U ABERDEEN
   TRACER DP, 1991, AM J PHYS ANTHROPOL, V85, P393, DOI 10.1002/ajpa.1330850404
   WAYNFORTH D, 2002, HDB FATHER INVOLVE 4
   Zabin LS, 1998, STUD FAMILY PLANN, V29, P210, DOI 10.2307/172160
NR 33
TC 62
Z9 64
U1 0
U2 8
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8452
EI 1471-2954
J9 P ROY SOC B-BIOL SCI
JI Proc. R. Soc. B-Biol. Sci.
PD MAR 7
PY 2004
VL 271
IS 1538
BP 465
EP 470
DI 10.1098/rspb.2003.2623
PG 6
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA 779LV
UT WOS:000189299600004
PM 15129955
OA No
DA 2017-08-15
ER

PT J
AU Sear, R
   Allal, N
   Mace, R
   Mcgregor, IA
AF Sear, R
   Allal, N
   Mace, R
   Mcgregor, IA
TI Height and reproductive success among Gambian women.
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Meeting Abstract
C1 London Sch Econ, London, England.
   UCL, London, England.
   MRC Gambia, Banjul, Gambia.
NR 0
TC 4
Z9 5
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1042-0533
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD MAR-APR
PY 2004
VL 16
IS 2
MA 66
BP 223
EP 223
PG 1
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA 800CL
UT WOS:000220006400079
OA No
DA 2017-08-15
ER

PT J
AU Nwanegbo, E
   Vardas, E
   Gao, WT
   Whittle, H
   Sun, HJ
   Rowe, D
   Robbins, PD
   Gambotto, A
AF Nwanegbo, E
   Vardas, E
   Gao, WT
   Whittle, H
   Sun, HJ
   Rowe, D
   Robbins, PD
   Gambotto, A
TI Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35
   in the adult populations of The Gambia, South Africa, and the United
   States
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article
ID CELLULAR IMMUNE-RESPONSES; MEDIATED GENE-TRANSFER; RECOMBINANT
   ADENOVIRUS; PHASE-I; NONHUMAN-PRIMATES; LUNG-CANCER; VECTORS; THERAPY;
   EXPRESSION; INFECTION
AB One of the major limitations of the use of adenoviruses as gene therapy vectors is the existence of preformed immunity in various populations. Recent studies have linked failure of adenoviral gene therapy trials to the presence of antiadenoviral neutralizing antibodies (NAb). Understanding the distribution and specificity of such antibodies will assist in the design of successful recombinant adenoviral gene therapies and vaccines. To assess the prevalence of NAb to adenovirus serotypes 5 and 35 (Ad5 and Ad35), we analyzed serum samples from adult immunocompetent individuals living in The Gambia, South Africa, and the United States by using a neutralization assay. Serum samples were incubated with A549 lung carcinoma cells and adenoviruses encoding enhanced green or yellow fluorescent proteins; results were analyzed by fluorescence microscopy and flow cytometry. Using this technique, we found a high prevalence of NAb against Ad5 in Gambian, South African, and U.S. subjects at both low and high titers. Conversely, all subjects displayed a low prevalence of NAb to Ad35; when present, anti-Ad35 NAb were seen at low titers. Because of the ability of adenoviruses to elicit systemic and mucosal immune responses, Ad35 with its low NAb prevalence appears to be an attractive candidate vector for gene therapy applications.
C1 Univ Pittsburgh, Sch Med, Ctr Biotechnol & Bioengn, Dept Mol Genet & Biochem, Pittsburgh, PA 15219 USA.
   Univ Pittsburgh, Sch Med, Ctr Biotechnol & Bioengn, Dept Surg, Pittsburgh, PA 15219 USA.
   Univ Pittsburgh, Sch Med, Dept Infect Dis, Pittsburgh, PA 15219 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis, Pittsburgh, PA 15219 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Microbiol, Pittsburgh, PA 15219 USA.
   Univ Witwatersrand, Chris Hani Baragwanath Hosp, HIV AIDS Vaccine Div, Soweto, South Africa.
   MRC, Dept Virol, Banjul, Gambia.
RP Gambotto, A (reprint author), Univ Pittsburgh, Sch Med, Ctr Biotechnol & Bioengn, Dept Mol Genet & Biochem, 300 Technol Dr,Suite 211, Pittsburgh, PA 15219 USA.
EM agamb@imap.pitt.edu
OI Vardas, Eftyhia/0000-0002-7804-878X
FU NHLBI NIH HHS [U01 HL066949, U01HL66949]; NIAID NIH HHS [AI52806-01, R21
   AI052806]
CR Armentano D, 1997, J VIROL, V71, P2408
   BRODY SL, 1994, HUM GENE THER, V5, P821, DOI 10.1089/hum.1994.5.7-821
   Chen Y, 2000, HUM GENE THER, V11, P1553, DOI 10.1089/10430340050083289
   Cichon G, 2001, GENE THER, V8, P1794, DOI 10.1038/sj.gt.3301611
   De Jong JC, 1999, J CLIN MICROBIOL, V37, P3940
   FATZ W, 1985, IMMUN INFEKT, V13, P108
   FLOMENBERG P, 1995, J INFECT DIS, V171, P1090
   FLOMENBERG PR, 1987, J INFECT DIS, V155, P1127
   Foy H. M., 1976, VIRAL INFECT HUMANS, P53
   GaherySegard H, 1997, J CLIN INVEST, V100, P2218, DOI 10.1172/JCI119759
   Gao W, 2003, GENE THER, V10, P1941, DOI 10.1038/sj.gt.3302097
   GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265
   Goossens PH, 2001, ARTHRITIS RHEUM, V44, P48, DOI 10.1002/1529-0131(200101)44:1<48::AID-ANR7>3.0.CO;2-D
   Hardy S, 1997, J VIROL, V71, P1842
   Hitt MM, 2000, CURR PHARM DESIGN, V6, P613, DOI 10.2174/1381612003400551
   Huang S, 1996, J VIROL, V70, P4502
   Ilan Y, 1997, P NATL ACAD SCI USA, V94, P2587, DOI 10.1073/pnas.94.6.2587
   Jooss K, 1998, GENE THER, V5, P309, DOI 10.1038/sj.gt.3300595
   Kaplan JM, 1996, GENE THER, V3, P117
   KassEisler A, 1996, GENE THER, V3, P154
   Kay MA, 1997, P NATL ACAD SCI USA, V94, P12744, DOI 10.1073/pnas.94.24.12744
   Kozarsky K F, 1993, Curr Opin Genet Dev, V3, P499, DOI 10.1016/0959-437X(93)90126-A
   Mack CA, 1997, HUM GENE THER, V8, P99, DOI 10.1089/hum.1997.8.1-99
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244
   Mei YF, 2002, VIROLOGY, V295, P30, DOI 10.1006/viro.2002.1359
   Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121
   Pickles RJ, 1998, J VIROL, V72, P6014
   Reddy PS, 2003, VIROLOGY, V311, P384, DOI 10.1016/S0042-6822(03)00161-2
   Schnell MJ, 2001, FEMS MICROBIOL LETT, V200, P123, DOI 10.1111/j.1574-6968.2001.tb10703.x
   Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149
   TOOGOOD CIA, 1992, J GEN VIROL, V73, P1429, DOI 10.1099/0022-1317-73-6-1429
   Tursz T, 1996, J NATL CANCER I, V88, P1857, DOI 10.1093/jnci/88.24.1857
   Vogels R, 2003, J VIROL, V77, P8263, DOI 10.1128/JVI.77.15.8263-8271.2003
   WADELL G, 1999, MANUAL CLIN MICROBIO
   Walters RW, 1999, J BIOL CHEM, V274, P10219, DOI 10.1074/jbc.274.15.10219
   YANG YP, 1995, J VIROL, V69, P2004
   YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890
NR 37
TC 154
Z9 162
U1 2
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD MAR
PY 2004
VL 11
IS 2
BP 351
EP 357
DI 10.1128/CDLI.11.2.351-357.2004
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 807DV
UT WOS:000220483100020
PM 15013987
OA No
DA 2017-08-15
ER

PT J
AU Newport, MJ
   Goetghebuer, T
   Weiss, HA
   Whittle, H
   Siegrist, CA
   Marchant, A
AF Newport, MJ
   Goetghebuer, T
   Weiss, HA
   Whittle, H
   Siegrist, CA
   Marchant, A
CA MRC Gambia Twin Study Grp
TI Genetic regulation of immune responses to vaccines in early life
SO GENES AND IMMUNITY
LA English
DT Article
DE Gambia; vaccines; twins; heritability; HLA
ID MAJOR HISTOCOMPATIBILITY COMPLEX; B CONJUGATE VACCINES;
   INFECTIOUS-DISEASES; MEASLES-VACCINE; ANTIBODY; IMMUNIZATION; INFANTS;
   TUBERCULOSIS; INFLUENZAE; ANTIGENS
AB Infant immunization is the most cost-effective strategy to prevent infectious diseases in childhood, but is limited by immaturity of the immune system. To define strategies to improve vaccine immunogenicity in early life, the role of genetic and environmental factors in the control of vaccine responses in infant twins was studied. Immune responses to BCG, polio, hepatitis B, diphtheria, pertussis and tetanus vaccines were measured at 5 months of age in 207 Gambian twin pairs recruited at birth. Intrapair correlations for monozygous and dizygous pairs were compared to estimate the environmental and genetic components of variation in responses. High heritability was observed for antibody (Ab) responses to hepatitis B (77%), oral polio (60%), tetanus (44%) and diphtheria (49%) vaccines. Significant heritability was also observed for interferon-gamma and interleukin-13 responses to tetanus, pertussis and some BCG vaccine antigens (39-65%). Non-HLA genes played a dominant role in responses to Ab-inducing vaccines, whereas responses to BCG were predominantly controlled by genes within the HLA class II locus. Genetic factors, particularly non-HLA genes, significantly modulate immune responses to infant vaccination. The identification of the specific genes involved will provide new targets for the development of vaccines and adjuvants for young infants that work independently of HLA.
C1 Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   Univ Cambridge, Dept Med, Cambridge CB2 1TN, England.
   Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Unit, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Univ Geneva, WHO Collaborat Ctr Neonatal Vaccinol, CH-1211 Geneva 4, Switzerland.
   John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England.
RP Newport, MJ (reprint author), Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.
EM melanie.newport@cimr.cam.ac.uk
CR Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   Becker A, 1997, J REPROD MED, V42, P260
   Bishop GA, 2001, CURR OPIN IMMUNOL, V13, P278, DOI 10.1016/S0952-7915(00)00216-8
   Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577
   CUTTS FT, 1999, VACCINES, P1047
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   EGEA E, 1991, J EXP MED, V173, P531, DOI 10.1084/jem.173.3.531
   FINK C, 1962, J CLIN INVEST, V41, P163
   Gans H, 2001, J INFECT DIS, V184, P817, DOI 10.1086/323346
   Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527
   Gelder CM, 2002, J INFECT DIS, V185, P114, DOI 10.1086/338014
   Goldblatt D, 1998, J INFECT DIS, V177, P1112
   Goriely S, 2001, J IMMUNOL, V166, P2141
   Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X
   Jepson A, 1997, INFECT IMMUN, V65, P872
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558
   KONRADSEN HB, 1993, CLIN EXP IMMUNOL, V92, P532
   Lewis D, 2001, INFECT DIS FETUS NEW, P25
   LIEBERMAN JM, 1995, J PEDIATR-US, V126, P198, DOI 10.1016/S0022-3476(95)70545-7
   Marchant A, 2000, CURR OPIN INFECT DIS, V13, P241
   Mustafa AS, 2000, INFECT IMMUN, V68, P3933, DOI 10.1128/IAI.68.7.3933-3940.2000
   Neale MC, 1997, BEHAV GENET, V27, P113, DOI 10.1023/A:1025681223921
   NEWPORT MJ, 2003, IN PRESS PRIMARY IMM
   Ota MOC, 2002, J IMMUNOL, V168, P919
   PLEBANI A, 1989, EUR J PEDIATR, V149, P164, DOI 10.1007/BF01958271
   Poland GA, 1998, AM J HUM GENET, V62, P215, DOI 10.1086/301736
   Poland GA, 2001, VACCINE, V20, P430, DOI 10.1016/S0264-410X(01)00346-2
   Pollard AJ, 2000, LANCET, V356, P2065, DOI 10.1016/S0140-6736(00)03405-X
   Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331
   ROSEN FS, 1990, SEMIN HEMATOL, V27, P333
   Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996
   Shiokawa S, 1999, J IMMUNOL, V162, P6060
   Siegrist C A, 1998, Dev Biol Stand, V95, P133
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Singh N, 1997, EMERG INFECT DIS, V3, P41
   SJOBERG K, 1992, P NATL ACAD SCI USA, V89, P2101, DOI 10.1073/pnas.89.6.2101
   SMITH DH, 1973, PEDIATRICS, V52, P637
   Stein CM, 2003, J INFECT DIS, V187, P1679, DOI 10.1086/375249
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   VANEDEN W, 1983, CLIN EXP IMMUNOL, V52, P287
   Vekemans J, 2002, CLIN EXP IMMUNOL, V127, P495, DOI 10.1046/j.1365-2249.2002.01788.x
   Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656
NR 42
TC 105
Z9 111
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD MAR
PY 2004
VL 5
IS 2
BP 122
EP 129
DI 10.1038/sj.gene.6364051
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 780GD
UT WOS:000189363200006
PM 14737096
OA No
DA 2017-08-15
ER

PT J
AU Burgner, D
   Usen, S
   Rockett, K
   Jallow, M
   Ackerman, H
   Cervino, A
   Pinder, M
   Kwiatkowski, DP
AF Burgner, D
   Usen, S
   Rockett, K
   Jallow, M
   Ackerman, H
   Cervino, A
   Pinder, M
   Kwiatkowski, DP
TI Nucleotide and haplotypic diversity of the NOS2A promoter region and its
   relationship to cerebral malaria (vol 112, pg 379, 2003)
SO HUMAN GENETICS
LA English
DT Correction
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX2 7BN, England.
   MRC Labs, Fajara, Gambia.
   Royal Victoria Hosp, Banjul, Gambia.
RP Kwiatkowski, DP (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX2 7BN, England.
EM dominic.kwiatkowski@paediatrics.ox.ac.uk
CR Burgner D, 2003, HUM GENET, V112, P379, DOI 10.1007/s00439-002-0882-4
NR 1
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD MAR
PY 2004
VL 114
IS 4
BP 401
EP 401
DI 10.1007/s00439-003-1068-4
PG 1
WC Genetics & Heredity
SC Genetics & Heredity
GA 777VY
UT WOS:000189202200012
OA No
DA 2017-08-15
ER

PT J
AU Clausen, PH
   Grace, D
   Diall, O
   Diallo, B
   Barry, M
   Munstermann, S
   Bocoum, Z
   Diarra, B
   Sidibe, I
   Affognon, H
   Waibel, H
   Randolph, T
   McDermott, J
AF Clausen, PH
   Grace, D
   Diall, O
   Diallo, B
   Barry, M
   Munstermann, S
   Bocoum, Z
   Diarra, B
   Sidibe, I
   Affognon, H
   Waibel, H
   Randolph, T
   McDermott, J
TI Improving the management of trypanocide resistance in the cotton zone of
   West Africa: a coordinated regional study
SO INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Meeting Abstract
CT 21st Congress of the German-Society-of-Parasitology
CY MAR 17-20, 2004
CL Univ Wurzburg, Wurzburg, GERMANY
SP German Soc Parasitol
HO Univ Wurzburg
C1 Free Univ Berlin, Inst Parasitol & Int Anim Hlth, D-1000 Berlin, Germany.
   Int Crops Res Inst Semi Arid Trop, ILRI BMZ Project Chemoresistance, Bamako, Mali.
   IRAG, Inst Rech Agrnom Guinee, Conakry, Guinea.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Lab Cent Vet Bamako, Bamako, Mali.
   LCV, Unite Cent Lutte Contre Tsetse & Trypanosomose, Bamako, Mali.
   Ctr Int Rech Dev Elevage Zone Subhumide, Bobo Dioulasso, Burkina Faso.
   Leibniz Univ Hannover, Inst Hort Econ, Hannover, Germany.
   Int Livestock Res Inst, Nairobi, Kenya.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 1438-4221
J9 INT J MED MICROBIOL
JI Int. J. Med. Microbiol.
PD MAR
PY 2004
VL 293
SU 38
BP 67
EP 67
PG 1
WC Microbiology; Virology
SC Microbiology; Virology
GA 836XQ
UT WOS:000222589900061
OA No
DA 2017-08-15
ER

PT J
AU McAdam, KPWJ
AF McAdam, KPWJ
TI NRAMPI (SLCIIAI) and vitamin D receptor genes: disease associations
SO NETHERLANDS JOURNAL OF MEDICINE
LA English
DT Article
ID INTERFERON-GAMMA-RECEPTOR; MYCOBACTERIAL INFECTION; NATURAL-RESISTANCE;
   HOST-RESISTANCE; TUBERCULOSIS; SUSCEPTIBILITY; POLYMORPHISMS; AFRICANS;
   LEPROSY; MACROPHAGES
AB Resistance to infectious diseases is complex, being regulated by multiple genes, and so far no one locus has been shown to dominate the susceptibility in outbred human populations. Multi-case families have contributed greatly to defining important host immune response pathways using a candidate gene approach. It is likely that genome scans will identify novel genes for resistance to disease that could help define new approaches to drug and vaccine development.
C1 MRC Labs, Banjul, Gambia.
RP McAdam, KPWJ (reprint author), MRC Labs, Banjul, Gambia.
CR Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830
   ALLISON AC, 1954, BRIT MED J, V1, P190
   Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432
   Audi L, 1999, HORM RES, V51, P105, DOI 10.1159/000023343
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Blackwell JM, 1998, INT J PARASITOL, V28, P21, DOI 10.1016/S0020-7519(97)00175-6
   Blackwell JM, 2001, CELL MICROBIOL, V3, P773, DOI 10.1046/j.1462-5822.2001.00150.x
   BUSHMAN E, 2001, DRUG METAB DISPOS, V29, P471
   Buu N, 2000, CLIN INFECT DIS, V31, pS81, DOI 10.1086/314067
   Cervino ACL, 2000, ANN HUM GENET, V64, P507, DOI 10.1046/j.1469-1809.2000.6460507.x
   Clegg JB, 1999, P ASSOC AM PHYSICIAN, V111, P278, DOI 10.1046/j.1525-1381.1999.99235.x
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   CROWLE AJ, 1990, INFECT IMMUN, V58, P632
   Doffinger R, 2000, MICROBES INFECT, V2, P1553, DOI 10.1016/S1286-4579(00)01311-3
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   Gao PS, 2000, CLIN GENET, V58, P74, DOI 10.1034/j.1399-0004.2000.580113.x
   Greenwood CMT, 2000, AM J HUM GENET, V67, P405, DOI 10.1086/303012
   Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7
   LIU J, 1995, AM J HUM GENET, V56, P845
   LURIE MB, 1952, AM J HUM GENET, V4, P302
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259
   Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536
   Ryu S, 2000, INT J TUBERC LUNG D, V4, P577
   Selvaraj P, 2000, INDIAN J MED RES, V111, P172
   SHAW MA, 2000, J INFECT DIS, V82, P1473
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
NR 31
TC 0
Z9 0
U1 0
U2 0
PU VAN ZUIDEN COMMUNICATIONS
PI ALPHEN AAN DE RIJN
PA HENRY DUNANTWEG 40A, 2402 NR ALPHEN AAN DE RIJN, NETHERLANDS
SN 0300-2977
J9 NETH J MED
JI Neth. J. Med.
PD MAR
PY 2004
VL 62
IS 3
SU S
BP 42
EP 45
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 808TT
UT WOS:000220592100011
OA No
DA 2017-08-15
ER

PT J
AU Hamer, C
   Kvatum, K
   Jeffries, D
   Allen, S
AF Hamer, C
   Kvatum, K
   Jeffries, D
   Allen, S
TI Detection of severe protein-energy malnutrition by nurses in The Gambia
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; HEALTH-WORKERS; MORTALITY;
   CHILDREN
AB Aim: To test whether nurses can use the WHO integrated management of childhood illness (IMCI) nutrition algorithm to identify reliably severe protein-energy malnutrition in children.
   Methods: Nurses were trained to identify severe protein-energy malnutrition using IMCI training materials. They identified visible severe wasting and bipedal oedema, and categorised weight-for-age using a growth chart, in consecutive children attending outpatient clinics. Their findings were compared with weight for height Z (WHZ) score, bipedal oedema assessed by a trained observer, and weight-for-age Z score.
   Results: A total of 352 children were recruited, of whom 34 (9.7%) were severely wasted ( WHZ score,23) and 18 (5.1%) had bipedal oedema. In the detection of severe wasting, the nurses' assessments showed 56% sensitivity, 95% specificity, and 56% positive predictive value (PPV), and for bipedal oedema 22%, 99%, and 57% respectively. Overall, the nurses identified only half of 50 children with severe wasting and/or bipedal oedema and wrongly identified a further 13 children as severely malnourished. Plotting weight for age by the nurses showed 62% sensitivity, 99% specificity, and 89% PPV for the detection of children with very low weight.
   Conclusions: Severe malnutrition was both under-diagnosed and wrongly diagnosed by nurses trained in the use of the IMCI nutrition algorithm in a clinic setting in The Gambia. These guidelines for health workers and the training materials, particularly with respect to calculation of age, need further development to improve the detection of malnourished children.
C1 Royal Victoria Hosp, Banjul, Gambia.
   Univ Minnesota, Minneapolis, MN 55455 USA.
RP Hamer, C (reprint author), Univ Bristol, Ctr Child & Adoelscent Child Hlth, Hampton House,Cotham Hill, Bristol BS6 6JS, Avon, England.
EM Clare.Hamer@bristol.ac.uk
CR Bern C, 1997, B WORLD HEALTH ORGAN, V75, P87
   CHEN LC, 1980, AM J CLIN NUTR, V33, P1836
   GAYLE HD, 1988, J TROP PEDIATRICS, V34, P213
   Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7
   HILLMAN RW, 1967, AM J CLIN NUTR, V20, P118
   Man WDC, 1998, TROP MED INT HEALTH, V3, P678
   PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443
   Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223
   Simoes EAF, 1997, B WORLD HEALTH ORGAN, V75, P43
   *WHO, 1998, MAN CHILDH ILLN ASS, P9
   World Health Organisation, 1997, B WHO S1, V75, P119
   World Health Organization Working Group, 1986, B WORLD HEALTH ORGAN, V64, P929
NR 12
TC 18
Z9 19
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD FEB 1
PY 2004
VL 89
IS 2
BP 181
EP 184
DI 10.1136/adc.2002.022715
PG 4
WC Pediatrics
SC Pediatrics
GA 765UP
UT WOS:000188302500027
PM 14736639
OA No
DA 2017-08-15
ER

PT J
AU Pinder, M
   Reece, WHH
   Plebanski, M
   Akinwunmi, P
   Flanagan, KL
   Lee, EAM
   Doherty, T
   Milligan, P
   Jaye, A
   Tornieporth, N
   Ballou, R
   Mcadam, KPMJ
   Cohen, J
   Hill, AVS
AF Pinder, M
   Reece, WHH
   Plebanski, M
   Akinwunmi, P
   Flanagan, KL
   Lee, EAM
   Doherty, T
   Milligan, P
   Jaye, A
   Tornieporth, N
   Ballou, R
   Mcadam, KPMJ
   Cohen, J
   Hill, AVS
TI Cellular immunity induced by the recombinant Plasmodium falciparum
   malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE cell-mediated immunity; circumsporozoite; ELISPOT; Plasmodium
   falciparum; vaccine
ID CIRCUMSPOROZOITE PROTEIN VACCINE; EFFICACY; RESPONSES; IMMUNOGENICITY;
   RTS,S/SBAS2; RECOGNITION; INFECTION; EPITOPES; SAFETY; TRIAL
AB Vaccination of malaria-naive humans with recombinant RTS,S/AS02, which includes the C-terminus of the circumsporozoite protein (CS), has been shown to induce strong T cell responses to both the whole protein antigen and to peptides from CS. Here we show that strong T cell responses were also observed in a semi-immune population in The Gambia, West Africa. In a Phase I study, 20 adult male volunteers, lifelong residents in a malaria-endemic region, were given three doses of RTS,S/AS02 at 0, 1 and 6 months. Responses to RTS,S, hepatitis B surface antigen and peptides from CS were tested using lymphocyte proliferation, interferon (IFN)-gamma production in microcultures, and IFN-gamma ex vivo and cultured ELISPOT, before and after vaccination. Cytotoxic responses were tested only after vaccination and none were detected. Before vaccination, the majority of the volunteers (15/20) had detectable responses in at least one of the tests. After vaccination, responses increased in all assays except cytotoxicity. The increase was most marked for proliferation; all donors responded to RTS,S after the third dose and all except one donor responded to at least one peptide after the second or third dose. There was a lack of close association of peptide responses detected by the different assays, although in microcultures IFN-gamma responses were found only when proliferative responses were high, and responses by cultured ELISPOT and proliferation were found together more frequently after vaccination. We have therefore identified several peptide-specific T cell responses induced by RTS,S/AS02 which provides a mechanism to investigate potentially protective immune responses in the field.
C1 MRC Labs, Banjul, Gambia.
   Glaxo SmithKline Biol, Rixensart, Belgium.
   John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England.
   Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA.
   Austin Res Inst, Vaccine Dev & Infect Dis Unit, Melbourne, Vic, Australia.
RP Pinder, M (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mpinder@mrc.gm
RI HILL, Adrian/C-1306-2008; Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Doherty JF, 1999, AM J TROP MED HYG, V61, P865
   ELHASSAN IM, 1994, AM J TROP MED HYG, V51, P372
   Flanagan KL, 2001, J IMMUNOL, V167, P4729
   Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   GORDON DM, 1995, J INFECT DIS, V171, P1576
   Helmby H, 2000, INFECT IMMUN, V68, P1485, DOI 10.1128/IAI.68.3.1485-1490.2000
   Hoffman Stephen L., 1996, P35
   Jaye A, 1998, J INFECT DIS, V177, P1282
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Kwiatkowski D, 1997, LANCET, V350, P1696, DOI 10.1016/S0140-6736(97)03256-X
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   Sinnis Photini, 1996, P15
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657
   WHITTLE HC, 1983, LANCET, V1, P1203
   World Health Organization UNICEF, 1996, STAT WORLDS VACC IMM
NR 21
TC 54
Z9 54
U1 0
U2 2
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD FEB
PY 2004
VL 135
IS 2
BP 286
EP 293
DI 10.1111/j.1365-2249.2004.02371.x
PG 8
WC Immunology
SC Immunology
GA 766EK
UT WOS:000188353600016
PM 14738458
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Fulford, AJC
   Streatfield, PK
   Persson, LA
   Prentice, AM
AF Moore, SE
   Fulford, AJC
   Streatfield, PK
   Persson, LA
   Prentice, AM
TI Comparative analysis of patterns of survival by season of birth in rural
   Bangladeshi and Gambian populations
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE mortality; seasonality; Bangladesh; infections; maternal nutrition;
   intrauterine growth retardation
ID WEST-AFRICA; PRENATAL UNDERNUTRITION; NUTRITIONAL-STATUS; MALNUTRITION;
   CHILDREN; WEIGHT; WOMEN; SUPPLEMENTATION; VACCINATION; AFLATOXIN
AB Background Analysis of data from rural Gambia has previously shown that being born during the annual hungry season strongly influences susceptibility to mortality from infectious disease in young adulthood, possibly through an influence on immune function. In rural Bangladesh pregnancies are exposed to similar seasonality. The current paper uses data from a large demographic survey in the Matlab region of Bangladesh to retest the Gambian-derived hypothesis that early life exposures correlated with season of birth predict later patterns of mortality.
   Methods Since 1966, a continuous demographic surveillance system has been in operation in the rural Matlab region of Bangladesh. The current analysis is based on 172 228 births and 24 697 deaths between 1974 and 2000. Season of birth was defined as 'harvest' (January-June) and 'hungry' (July-December), based on monthly variations in rates of conception and neonatal mortality within the same dataset.
   Results Birth during the hungry season resulted in excess mortality during the first year of life. However, for adult mortality (deaths >15 years), there was no excess in individuals born during the annual hungry season: ratio of hazard July-December versus January-June = 1.12; 95% CI: 0.87, 1.45.
   Conclusions The current study found no excess mortality in young adults born during the 'hungry' season in rural Bangladesh. This differing pattern in survival when compared with The Gambia may be a consequence of the greatly reduced incidence of young adult deaths in Bangladesh (0.1%) compared with The Gambia (3%). Under such conditions possible differences in immune function may not be detectable with early adult death as the outcome. However, it also remains possible that our Gambian observation could be a highly discrete phenomenon localized in either time or place, and as such, will not be replicated in other populations.
C1 London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, London WC1B 3DP, England.
   MRC, Keneba, Gambia.
   Ctr Hlth & Populat Res B, Hlth & Demog Surveillance Programme, Div Publ Hlth Sci, ICDDR B, Dhaka, Bangladesh.
RP Moore, SE (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, 49-51 Bedford Sq, London WC1B 3DP, England.
EM sophie.moore@lshtm.ac.uk
CR Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   Barker DJP, 1999, ANN INTERN MED, V130, P322
   Barker DJP, 1999, ARCH DIS CHILD, V80, P305
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   BROWN KH, 1982, AM J CLIN NUTR, V36, P303
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   CHEN LC, 1979, ECOL FOOD NUTR, V8, P175
   COLLINSON AC, 2002, EARLY NUTR ENV INFLU
   COLLINSON AC, 2002, IN PRESS ACTA PAEDIA
   FRISCH RE, 1982, SCIENCE, V215, P1272, DOI 10.1126/science.7199206
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HORT KP, 1987, ANN TROP PAEDIATR, V7, P66
   HUFFMAN SL, 1985, AM J CLIN NUTR, V42, P725
   McDade TW, 2001, J NUTR, V131, P1225
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   Moore SE, 2001, AM J CLIN NUTR, V74, P840
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   Prentice AM, 1999, FETAL PROGRAMMING IN, P399
   Simondon KB, 2004, INT J EPIDEMIOL, V33, P130, DOI 10.1093/ije/dyg279
   SINGH J, 1989, BRIT J NUTR, V62, P315, DOI 10.1079/BJN19890033
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   WILD CP, 1991, LANCET, V337, P1602, DOI 10.1016/0140-6736(91)93295-K
NR 25
TC 25
Z9 26
U1 3
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD FEB
PY 2004
VL 33
IS 1
BP 137
EP 143
DI 10.1093/ije/dyh007
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 809CO
UT WOS:000220615000025
PM 15075159
OA No
DA 2017-08-15
ER

PT J
AU Jaye, A
   Sarge-Njie, R
   van der Loeff, MS
   Todd, J
   Alabi, A
   Sabally, S
   Corrah, T
   Whittle, H
AF Jaye, A
   Sarge-Njie, R
   van der Loeff, MS
   Todd, J
   Alabi, A
   Sabally, S
   Corrah, T
   Whittle, H
TI No differences in cellular immune responses between asymptomatic HIV
   type 1-and type 2-infected Gambian patients
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTE; PLASMA VIRAL LOAD;
   INFECTED INDIVIDUALS; SYNTHETIC PEPTIDES; WEST-AFRICA; CELLS; CD4(+);
   RECOGNITION; REACTIVITY
AB Fewer people infected with human immunodeficiency virus (HIV) type 2 progress to acquired immunodeficiency syndrome, compared with those infected with HIV-1. To understand the immune mechanisms leading to slow progression in HIV-2 infection, cell-mediated immune responses were compared between the 2 infections in asymptomatic subjects with a CD4 cell count greater than or equal to20%. Interferon-gamma release from T lymphocytes and the cytotoxicity of CD8(+) T lymphocytes were measured by ELISPOT and Cr-51 release assays. The level of responses and the proportion of responders were similar in the 2 infections, despite a 20-fold difference in their geometric mean plasma virus loads. The proliferation of CD4(+) T helper cells, which was evaluated by thymidine incorporation, was not different between the 2 infections. Contrary to widely held views, our results suggest that nonprogression in HIV-2 infection may not be due to more vigorous immune responses.
C1 MRC Labs, Banjul, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Jaye, A (reprint author), MRC Labs, POB 273, Banjul, Fajara, Gambia.
EM ajaye@mrc.gm
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Barouch DH, 2001, CURR OPIN IMMUNOL, V13, P479, DOI 10.1016/S0952-7915(00)00244-2
   BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   Berry N, 1998, J Hum Virol, V1, P457
   Bertoletti A, 1998, J VIROL, V72, P2439
   Betts MR, 1999, AIDS RES HUM RETROV, V15, P1219, DOI 10.1089/088922299310313
   Betts MR, 2000, J VIROL, V74, P9144, DOI 10.1128/JVI.74.19.9144-9151.2000
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   Cham F, 2000, AIDS RES HUM RETROV, V16, P1915, DOI 10.1089/08892220050195874
   CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Goulder P, 1997, IMMUNOL REV, V159, P17, DOI 10.1111/j.1600-065X.1997.tb01004.x
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Kalams SA, 1999, J VIROL, V73, P6715
   LOPES R, 2003, J IMMUNOL, V171, P307
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P45, DOI 10.1016/0022-1759(94)00327-S
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   PINTO LA, 1995, J MED VIROL, V47, P139, DOI 10.1002/jmv.1890470206
   PINTO LA, 1993, AIDS, V7, P1389, DOI 10.1097/00002030-199310000-00016
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Shanmugam V, 2000, J ACQ IMMUN DEF SYND, V24, P257
   Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804
   Whittle HC, 1998, CURR OPIN IMMUNOL, V10, P382, DOI 10.1016/S0952-7915(98)80108-8
   Wilson JDK, 2000, AIDS, V14, P225, DOI 10.1097/00002030-200002180-00003
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205
NR 36
TC 25
Z9 27
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 1
PY 2004
VL 189
IS 3
BP 498
EP 505
DI 10.1086/381185
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 767TC
UT WOS:000188467900018
PM 14745708
OA No
DA 2017-08-15
ER

PT J
AU Jaitner, J
   Corr, N
   Njie, M
   Dempfle, L
AF Jaitner, J
   Corr, N
   Njie, M
   Dempfle, L
TI Screening village N'Dama cows in The Gambia with respect to milk yield
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
DE breed; cows; milk off-take; productivity; selection
ID MANAGEMENT
C1 Tech Univ Munich, Dept Tierwissensch, D-8050 Freising Weihenstephan, Germany.
   Int Trypanotolerance Ctr, Banjul, Gambia.
RP Jaitner, J (reprint author), Walsroder Str 35, D-27238 Verden, Germany.
EM Jutta.Jaitner@t-online.de
CR AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   Bennison JJ, 1997, AGR SYST, V55, P425, DOI 10.1016/S0308-521X(97)00002-4
   Dempfle L, 2000, ICAR TECHNICAL SERIE, V3, P347
   *ICAR, 1995, INT COMM AN REC REC, P1
   Jaitner J, 2003, TROP ANIM HEALTH PRO, V35, P179, DOI 10.1023/A:1022881703918
   *LAND ERZ TIER VER, 1999, LEIST QUAL RIND BAYE
   PATTERSON HD, 1971, BIOMETRIKA, V58, P545, DOI 10.2307/2334389
NR 7
TC 4
Z9 4
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD FEB
PY 2004
VL 36
IS 2
BP 169
EP 174
DI 10.1023/B:TROP.0000012101.26523.d9
PG 6
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA 763HX
UT WOS:000188079900007
PM 14998315
OA No
DA 2017-08-15
ER

PT J
AU Stevens, W
   Kaye, S
   Corrah, T
AF Stevens, W
   Kaye, S
   Corrah, T
TI Antiretroviral therapy in Africa
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID RESISTANCE MUTATIONS; SALVAGE THERAPY; DRUG-RESISTANCE; HIV;
   TUBERCULOSIS; ADHERENCE; FAILURE
C1 MRC Labs, Banjul, Gambia.
RP Stevens, W (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM wstevens@mrc.gm
CR Ansah EK, 2001, TROP MED INT HEALTH, V6, P496, DOI 10.1046/j.1365-3156.2001.00740.x
   BANGSBERG DR, 2003, AIDS, V17, P1923
   Burger DM, 1998, ANTIVIR THER, V3, P215
   Harrigan PR, 2002, ANTIMICROB AGENTS CH, V46, P909, DOI 10.1128/AAC.46.3.909-912.2002
   Karmochkine M, 2000, ANTIVIR RES, V47, P179, DOI 10.1016/S0166-3542(00)00110-8
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001
   Moulding TS, 2002, INT J TUBERC LUNG D, V6, P313
   O'Boyle SJ, 2002, INT J TUBERC LUNG D, V6, P307
   Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/01.aids.0000060398.18106.f6
   Quinones-Mateu ME, 2002, DRUG RESIST UPDATE, V5, P224, DOI 10.1016/S1368-7646(02)00123-1
   Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625
   Schinazi RF, 2000, INT ANTIVIRAL NEWS, V8, P65
   Unaids, 2002, REP GLOB HIV AIDS EP
   World Health Organization, 2002, WHO REP 2002 GLOB TU
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7
NR 19
TC 44
Z9 46
U1 1
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD JAN 31
PY 2004
VL 328
IS 7434
BP 280
EP 282
DI 10.1136/bmj.328.7434.280
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 771LC
UT WOS:000188786000027
PM 14751902
OA No
DA 2017-08-15
ER

PT J
AU Stevens, W
   Walker, D
AF Stevens, W
   Walker, D
TI Adolescent vaccination in the developing world: time for serious
   consideration?
SO VACCINE
LA English
DT Article
DE immunisation; developing countries; adolescents
ID SCHOOL-BASED SCHISTOSOMIASIS; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B
   VACCINATION; CHILDREN; EFFICACY; COST
AB The number of vaccinations and vaccine boosters that are becoming relevant to delivery among adolescents is growing. For sexually transmitted infections (STIs) in particular, such as HIV, vaccine delivery in this (pre-sexually active) age group is going to be an integral component of the strategy to control these diseases in the future. Currently, however, adolescent vaccination does not routinely occur because the traditional method of delivery is through secondary schools, and in developing countries school attendance has historically been low. But with school attendance growing rapidly throughout the developing world, the cost of vaccines falling over time, and an increasing number of current and future vaccines targeted at adolescents, it is an ideal opportunity to place this route of delivery on the national and international health agenda. Therefore, this paper examines the rationale for adolescent vaccination, looks at the success of other adolescent-targeted health care interventions, and finally, considers the challenges associated with future adolescent vaccination programmes in developing countries. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Walker, D (reprint author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.
EM wstevens@mrc.gm; damian.walker@lshtm.ac.uk
CR Brabin L, 2000, T ROY SOC TROP MED H, V94, P455, DOI 10.1016/S0035-9203(00)90139-1
   Brisson M, 2002, VACCINE, V20, P2500, DOI 10.1016/S0264-410X(02)00180-9
   Carabin H, 2000, PARASITOLOGY, V121, P171, DOI 10.1017/S0031182099006101
   CUTTS FT, 1999, VACCINES, P1047
   ENGLAND S, 2001, CMH WORKING PAPER WG, V5
   FARIZO KM, 1992, CLIN INFECT DIS, V14, P708
   *GAVI, IMM EV CHILD GAVI ST
   Guyatt HL, 2001, B WORLD HEALTH ORGAN, V79, P695
   Guyatt HL, 1998, TROP MED INT HEALTH, V3, P425, DOI 10.1046/j.1365-3156.1998.00248.x
   Jamison D. T., 1990, Food and Nutrition Bulletin, V12, P204
   Karim SSA, 1998, S AFR MED J, V88, P693
   Magnussen P, 2001, TROP MED INT HEALTH, V6, P273, DOI 10.1046/j.1365-3156.2001.00720.x
   Martinson FEA, 1996, J MED VIROL, V48, P278
   Mbizvo EM, 2002, INT J STD AIDS, V13, P343, DOI 10.1258/0956462021925171
   Nwaorgu OC, 1998, TROP MED INT HEALTH, V3, P842, DOI 10.1046/j.1365-3156.1998.00313.x
   Talaat M, 1999, TROP MED INT HEALTH, V4, P551, DOI 10.1046/j.1365-3156.1999.00439.x
   *UNESCO, 1997, PRIM SEC ED AG SPEC
   UNICEF, 2002, STAT WORLDS CHILDR
   Vryheid RE, 2000, VACCINE, V19, P1026, DOI 10.1016/S0264-410X(00)00239-5
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   *WHO, 1999, WHO REP 1999
   World Bank, 1993, WORLD DEV REP 1993 I
   *WORLD BANK, 2000, WORLD DEV REP 2000-0
   World Bank, 1999, ED SECT STRAT
   1998, HLTH POLICY PLAN, V13, P384
NR 26
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JAN 26
PY 2004
VL 22
IS 5-6
BP 781
EP 785
DI 10.1016/j.vaccine.2003.05.001
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 775YB
UT WOS:000189087300033
PM 14741173
OA No
DA 2017-08-15
ER

PT J
AU Moorthy, VS
   Good, MF
   Hill, AVS
AF Moorthy, VS
   Good, MF
   Hill, AVS
TI Malaria vaccine developments
SO LANCET
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; CIRCUMSPOROZOITE PROTEIN VACCINE;
   PLACEBO-CONTROLLED TRIAL; B SURFACE-ANTIGEN; SPOROZOITE VACCINE; SPF66
   VACCINE; PROTECTIVE EFFICACY; ACQUIRED IMMUNITY; CLINICAL MALARIA;
   RANDOMIZED TRIAL
AB Large gains in the reduction of malaria mortality in the early 20th century were lost in subsequent decades. Malaria now kills 2-3 million people yearly. Implementation of malaria control technologies such as insecticide-treated bednets and chemotherapy could reduce mortality substantially, but an effective malaria vaccine is also needed. Advances in vaccine technology and immunology are being used to develop malaria subunit vaccines. Novel approaches that might yield effective vaccines for other diseases are being evaluated first in malaria. We describe progress in malaria vaccine development in the past 5 years: reasons for cautious optimism, the type of vaccine that might realistically be expected, and how the process could be hastened. Although exact predictions are not possible, if sufficient funding were mobilised, a deployable, effective malaria vaccine is a realistic medium-term to long-term goal.
C1 MRC Labs, Banjul, Gambia.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4006, Australia.
RP Moorthy, VS (reprint author), Malaria Vaccine Initiat, 6290 Montrose Rd, Rockville, MD 20852 USA.
RI HILL, Adrian/C-1306-2008
CR Acosta CJ, 1999, TROP MED INT HEALTH, V4, P368, DOI 10.1046/j.1365-3156.1999.00406.x
   Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   ALONSO PL, 1994, LANCET, V344, P1175
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   BALLOU WR, 1987, LANCET, V1, P1277
   Beverley PCL, 2002, BRIT MED BULL, V62, P15, DOI 10.1093/bmb/62.1.15
   Birkett A, 2002, INFECT IMMUN, V70, P6860, DOI 10.1128/IAI.70.12.6860-6870.2002
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633
   BROWN AE, 1994, VACCINE, V12, P102, DOI 10.1016/0264-410X(94)90046-9
   Cheng Q, 1997, AM J TROP MED HYG, V57, P495
   Church LWP, 1997, J INFECT DIS, V175, P915, DOI 10.1086/513990
   CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002
   COCHRANE AH, 1980, MALARIA
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   CROSNIER J, 1981, LANCET, V1, P455
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   Doolan DL, 2001, INT J PARASITOL, V31, P753, DOI 10.1016/S0020-7519(01)00184-9
   Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   GONZALEZ C, 1994, J INFECT DIS, V169, P927
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   Guerin PJ, 2002, LANCET INFECT DIS, V2, P564, DOI 10.1016/S1473-3099(02)00372-9
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052
   HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0
   HERRINGTON DA, 1992, VACCINE, V10, P841, DOI 10.1016/0264-410X(92)90047-N
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   HOFFMAN SL, 1994, AM J TROP MED HYG, V51, P603
   Holder A. A., 1999, Parassitologia (Rome), V41, P409
   KABILAN L, 1990, INFECT IMMUN, V58, P2989
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Kwiatkowski D, 1997, LANCET, V350, P1696, DOI 10.1016/S0140-6736(97)03256-X
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   leSueur D, 1996, S AFR MED J, V86, P936
   LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214
   Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7<1989::AID-IMMU1989>3.3.CO;2-D
   Makobongo MO, 2003, P NATL ACAD SCI USA, V100, P2628, DOI 10.1073/pnas.0337659100
   MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315
   Martens P, 2000, EMERG INFECT DIS, V6, P103
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   MCGREGOR IA, 1974, B WORLD HEALTH ORGAN, V50, P259
   Miyahira Y, 1998, P NATL ACAD SCI USA, V95, P3954, DOI 10.1073/pnas.95.7.3954
   Molano A, 2000, J IMMUNOL, V164, P5005
   Moorthy V, 2002, BRIT MED BULL, V62, P59, DOI 10.1093/bmb/62.1.59
   MOORTHY VS, IN PRESS J INFECT DI
   Moorthy VS, 2003, VACCINE, V21, P2004
   Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785
   Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141
   Muentener P, 1999, B WORLD HEALTH ORGAN, V77, P560
   NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20
   Nardin EH, 2001, J IMMUNOL, V166, P481
   Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871
   Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0
   Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331
   Oeuvray C, 2000, INFECT IMMUN, V68, P2617, DOI 10.1128/IAI.68.5.2617-2620.2000
   OEUVRAY C, 1994, BLOOD, V84, P1594
   Paoletti E, 1996, P NATL ACAD SCI USA, V93, P11349, DOI 10.1073/pnas.93.21.11349
   PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N
   POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504
   RICHIE TL, 2001, AM J TROP MED HYG  S, V65, P230
   Rogers WO, 2002, INFECT IMMUN, V70, P4329, DOI 10.1128/IAI.70.8.4329-4335.2002
   ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G
   Russell P., 1955, MANS MASTERY MALARIA
   Sachs JD, 2002, SCIENCE, V298, P122, DOI 10.1126/science.1077900
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Schneider J, 1999, IMMUNOL REV, V170, P29, DOI 10.1111/j.1600-065X.1999.tb01326.x
   Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937
   Shanks GD, 2000, T ROY SOC TROP MED H, V94, P253, DOI 10.1016/S0035-9203(00)90310-9
   SHERWOOD JA, 1991, T ROY SOC TROP MED H, V85, P336, DOI 10.1016/0035-9203(91)90281-3
   Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   VREDEN SGS, 1991, AM J TROP MED HYG, V45, P533
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   *WHO, 1996, MAL FACT SHEET 94
   *WHO, 2000, MAL GLOB CRIS
NR 81
TC 115
Z9 119
U1 0
U2 11
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 10
PY 2004
VL 363
IS 9403
BP 150
EP 156
DI 10.1016/S0140-6736(03)15267-1
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 761WV
UT WOS:000187939200020
PM 14726170
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Vekemans, J
   Schlegel-Haueter, SE
   Fielding, K
   Whittle, H
   Lambert, PH
   McAdam, KPWJ
   Siegrist, CA
   Marchant, A
AF Ota, MOC
   Vekemans, J
   Schlegel-Haueter, SE
   Fielding, K
   Whittle, H
   Lambert, PH
   McAdam, KPWJ
   Siegrist, CA
   Marchant, A
TI Hepatitis B immunisation induces higher antibody and memory Th2
   responses in new-borns than in adults
SO VACCINE
LA English
DT Article
DE new-borns; hepatitis B vaccine; Th1/Th2 cells
ID BACILLUS-CALMETTE-GUERIN; IFN-GAMMA PRODUCTION; T-CELL RESPONSES;
   IMMUNE-RESPONSES; DENDRITIC CELLS; VACCINE ANTIGENS; VIRUS-INFECTION;
   SURFACE-ANTIGEN; IN-VIVO; MICE
AB New-borns raise limited antibody responses to most T cell-dependent antigens but little is known about neonatal T lymphocyte responses to vaccines. In this study, we compared the immune response induced by the hepatitis B vaccine in new-borns and naive adults. Infants produced markedly higher serum anti-hepatitis B surface (HBs) antibody titres than adults. This was not associated with greater HBs Ag-specific Th2 cytokine responses but with lower primary IFN-gamma responses. At 1 year, the infant memory response to HBs Ag was characterised by higher Th2 responses than those of adults. We conclude that neonatal antibody and T cell responses to hepatitis B vaccine differ from those induced in adults. (C) 2003 Elsevier Ltd. All rights reserved.
C1 MRC Labs, Banjul, Gambia.
   John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   CMU, WHO, Ctr Vaccinol & Neonatal Immunol, CH-1211 Geneva, Switzerland.
RP Marchant, A (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM arnaud.marchant@btinternet.com
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Adkins B, 1996, J IMMUNOL, V157, P1343
   Adkins B, 1998, J IMMUNOL, V160, P4217
   Adkins B, 2001, J Immunol, V166, P918
   Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   Averhoff F, 1998, AM J PREV MED, V15, P1, DOI 10.1016/S0749-3797(98)00003-8
   Barrios C, 1996, EUR J IMMUNOL, V26, P2666, DOI 10.1002/eji.1830261118
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   Bocher WO, 1999, HEPATOLOGY, V29, P238, DOI 10.1002/hep.510290120
   Franco A, 1997, J IMMUNOL, V159, P2001
   Goriely S, 2001, J IMMUNOL, V166, P2141
   Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65
   Henderson RA, 1997, J IMMUNOL, V159, P635
   Honorati MC, 1997, GASTROENTEROLOGY, V112, P2017, DOI 10.1053/gast.1997.v112.pm9178695
   Hsu HY, 1996, HEPATOLOGY, V24, P1355, DOI 10.1002/hep.510240607
   IKEDA T, 1986, HEPATOLOGY, V6, P962, DOI 10.1002/hep.1840060525
   INABA K, 1993, J EXP MED, V178, P479, DOI 10.1084/jem.178.2.479
   Langrish CL, 2002, CLIN EXP IMMUNOL, V128, P118, DOI 10.1046/j.1365-2249.2002.01817.x
   Mahoney FJ, 1999, VACCINES, P158
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Marchant A, 2000, CURR OPIN INFECT DIS, V13, P241
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Penna A, 1996, J CLIN INVEST, V98, P1185, DOI 10.1172/JCI118902
   Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996
   SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Singh RR, 1996, J EXP MED, V183, P1613, DOI 10.1084/jem.183.4.1613
   Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   Vekemans J, 2002, CLIN EXP IMMUNOL, V127, P495, DOI 10.1046/j.1365-2249.2002.01788.x
   WIEDERMANN G, 1987, VACCINE, V5, P179, DOI 10.1016/0264-410X(87)90096-X
   WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935
   Yap G, 2000, J IMMUNOL, V165, P628
   Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837
NR 35
TC 41
Z9 43
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JAN 2
PY 2004
VL 22
IS 3-4
BP 511
EP 519
DI 10.1016/j.vaccine.2003.07.020
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 765UF
UT WOS:000188301600027
PM 14670334
OA No
DA 2017-08-15
ER

PT J
AU Albaret, JJ
   Simier, M
   Darboe, FS
   Ecoutin, JM
   Raffray, J
   de Morais, LT
AF Albaret, JJ
   Simier, M
   Darboe, FS
   Ecoutin, JM
   Raffray, J
   de Morais, LT
TI Fish diversity and distribution in the Gambia Estuary, West Africa, in
   relation to environmental variables
SO AQUATIC LIVING RESOURCES
LA English
DT Article
DE fish community; aquatic environment; estuary; Gambia; West Africa
AB The Gambia Estuary, a "normal" estuary with a decreasing salinity gradient from the mouth towards the head, is moderately exploited by small-scale fisheries and does not receive any severe pollution from either agriculture or industrial activities. Neither the Gambia River nor its estuary are artificially impounded. As the last large West African estuary free of major human disturbance, it is of considerable interest for comparative studies on the effect of major environmental perturbations in West African estuarine ecosystems. The aquatic environment and fish communities of the Gambia Estuary (about 250 km long) were studied by purse seine sampling at different periods in the river cycle, covering all hydro-climatic seasons that are characteristic of West African estuaries. Emphasis was placed on the diversity, composition, structure and distribution of fish assemblages in relation to fluctuations in physico-chemical factors such as water temperature, salinity and turbidity. Results on the aquatic environment, mainly the salinity range (from freshwater to 39) and dissolved oxygen (never a limiting factor for fish in the estuary) and on the main characteristics of the fish fauna (high diversity of life cycles, all the ecological categories represented) indicated that the Gambia Estuary was free of major climatic perturbation and reinforced the choice of this system as a reference for the study of the effects of major perturbations on estuarine tropical fish communities.
C1 IRD, Dakar, Senegal.
   IRD, Ctr Rech Halieut Mediterraneenne & Trop, F-34203 Sete, France.
   Dept Fisheries, Banjul, Gambia.
RP Albaret, JJ (reprint author), IRD, BP 1386, Dakar, Senegal.
EM albaret@ird.sn
RI Tito de Morais, Luis/B-1721-2012
OI Tito de Morais, Luis/0000-0001-8580-1808; Simier,
   Monique/0000-0002-8436-5925
CR Albaret J.-J., 1987, Revue d'Hydrobiologie Tropicale, V20, P291
   Albaret J.J., 1999, POISSONS EAUX CONTIN, P325
   Albaret J.-J., 1994, ENV RESSOURCES AQUAT, VII, P239
   ALBARET J., 1994, BIOL DIVERSITY AFRIC, P165
   BARAN E, 1995, THESIS ORSTOM PARIS
   BERRY TD, 1985, 9 U MICH, P202
   BLABER SJM, 1981, S AFR J SCI, V77, P305
   Blaber SJM, 2000, ICES J MAR SCI, V57, P590, DOI 10.1006/jmsc.2000.0723
   Blaber SJM, 2000, FISH AQUATIC RESOURC, V7
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407
   Daget J., 1960, Bull Inst franc Afr noire, V22A, P610
   Diouf PS, 1996, THESIS ORSTOM PARIS
   DORR JA, 1985, 11 U MICH GREAT LAK
   Gray JS, 2001, SCI MAR, V65, P41
   Guillard J, 2004, AQUAT LIVING RESOUR, V17, P47, DOI 10.1051/alr:2004005
   LAMAGAT JP, 1990, MONOGRAPHIE HYDROLOG
   LESACK LFW, 1984, LIMNOL OCEANOGR, V29, P816
   LESACK LFW, 1986, J FISH BIOL, V28, P679, DOI 10.1111/j.1095-8649.1986.tb05203.x
   MICHEL P, 1963, MEMOIRES ORSTOM, V63
   Panikkar N. K., 1960, AUST FISH COUN P, V32, P168
   POR FD, 1972, MAR BIOL, V14, P111, DOI 10.1007/BF00373210
   SAVENIJE HHG, 1992, J HYDROL, V135, P157, DOI 10.1016/0022-1694(92)90087-C
   Vidy G, 2004, AQUAT LIVING RESOUR, V17, P56, DOI 10.1051/alr:2004008
   WHITFIELD AK, 1994, ENVIRON BIOL FISH, V40, P37, DOI 10.1007/BF00002181
   WHITFIELD AK, 1998, MONOGRAPHS JLB SMITH, V2
   Whitfield A.K., 1994, ANN MUS R AFR CTR ZO, V275, P149
NR 26
TC 44
Z9 46
U1 1
U2 11
PU GAUTHIER-VILLARS/EDITIONS ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75015 PARIS, FRANCE
SN 0990-7440
J9 AQUAT LIVING RESOUR
JI Aquat. Living Resour.
PD JAN-MAR
PY 2004
VL 17
IS 1
BP 35
EP 46
DI 10.1051/alr:2004001
PG 12
WC Fisheries; Marine & Freshwater Biology
SC Fisheries; Marine & Freshwater Biology
GA 811FL
UT WOS:000220757700006
OA No
DA 2017-08-15
ER

PT J
AU Vidy, G
   Darboe, FS
   Mbye, EM
AF Vidy, G
   Darboe, FS
   Mbye, EM
TI Juvenile fish assemblages in the creeks of the Gambia Estuary
SO AQUATIC LIVING RESOURCES
LA English
DT Article
DE estuary; mangrove; juvenile fish; nursery; match-mismatch; West Africa
AB A tyke net survey of the juvenile and small fish assemblage of the Gambia estuary was conducted on three sampling occasions during the maximum recruitment season, from May to November 2002. This is the first detailed description of that particular component of the fish community in the Gambia estuary. The overall fyke net fish assemblage comprised 51 species, with a majority of young individuals of large and medium size species and the adults of small species. This assemblage is defined as the "small fish component of the mangrove channels". The assemblage is dominated by true estuarine and certain marine species, all able to complete their life cycle within the estuary. The sea spawning species whose juveniles use the estuary mainly as a nursery ground, are not very diverse or abundant during the recruitment season. They are limited to the lowest part of the estuary due to the low salinity prevailing in the middle and upper reaches during the rainy season. This suggests that extreme seasonal variability (river flooding) in certain West African tropical estuaries at the time of maximum recruitment by certain marine species may reduce the nursery around value for these taxa.
C1 IRD, Dakar, Senegal.
   Dept Fisheries, Banjul, Gambia.
RP Vidy, G (reprint author), IRD, BP 1386, Dakar, Senegal.
EM Guy.Vidy@dakar.ird.sn
CR Albaret JJ, 2004, AQUAT LIVING RESOUR, V17, P35, DOI 10.1051/alr:2004001
   Albaret J.J., 1999, POISSONS EAUX CONTIN, P325
   Albaret J. J., 1994, ANN MUS R AFR CENTR, V275, P165
   DAY JH, 1988, ESTUARINE ECOLOGY, P377
   DORR JA, 1985, 11 U MICH GREAT LAK
   Laegdsgaard P, 2001, J EXP MAR BIOL ECOL, V257, P229, DOI 10.1016/S0022-0981(00)00331-2
   MILLER JM, 1982, NATO C SER, V4, P209
   POTTER IC, 1990, ENVIRON BIOL FISH, V28, P143, DOI 10.1007/BF00751033
   Ross S.W., 1985, P207
   SASEKUMAR A, 1992, HYDROBIOLOGIA, V247, P195, DOI 10.1007/BF00008219
   SAVENIJE HHG, 1992, J HYDROL, V135, P157, DOI 10.1016/0022-1694(92)90087-C
   Vidy G., 2000, Wetlands Ecology and Management, V8, P37, DOI 10.1023/A:1008402905530
   Wagner CM, 1999, ESTUARIES, V22, P304, DOI 10.2307/1352986
   Whitfield AK, 1999, REV FISH BIOL FISHER, V9, P151, DOI 10.1023/A:1008994405375
   WHITFIELD AK, 1983, S AFR J SCI, V79, P362
NR 15
TC 16
Z9 17
U1 1
U2 4
PU GAUTHIER-VILLARS/EDITIONS ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75015 PARIS, FRANCE
SN 0990-7440
J9 AQUAT LIVING RESOUR
JI Aquat. Living Resour.
PD JAN-MAR
PY 2004
VL 17
IS 1
BP 56
EP 64
DI 10.1051/alr:2004008
PG 9
WC Fisheries; Marine & Freshwater Biology
SC Fisheries; Marine & Freshwater Biology
GA 811FL
UT WOS:000220757700008
OA No
DA 2017-08-15
ER

PT J
AU Lae, R
   Ecoutin, JM
   Mendy, A
   Raffray, J
   Weigel, JY
   Sadio, O
   Djobe, O
AF Lae, R
   Ecoutin, JM
   Mendy, A
   Raffray, J
   Weigel, JY
   Sadio, O
   Djobe, O
TI Effects of a targeted shrimp (Penaeus notialis) exploitation on fish
   catches in the Gambia estuary
SO AQUATIC LIVING RESOURCES
LA English
DT Article
DE artisanal fisheries; Gambia estuary; fish statistics; finfish; shrimp;
   mono-exploitation
ID WEST-AFRICA
AB Results of an annual survey of fishing activities and catches in the Gambia estuary (200 km long), carried out from June 2001 to May 2002, indicated that fishing effort targets mainly (66% of fishing trips) shrimps. As a result of the globalisation of fish markets, the fishery has become a quasi mono-exploitation of shrimp for exporting. At the opposite, fishing activities focusing on fish were low and carried out with large and medium mesh drift nets, gill nets and surrounding nets (17% of fishing trips), handlines and longlines (15%). The annual catch, estimated at 2350 tonnes for the estuarine part of the River Gambia, consisted of 1800 t of fish and 550 t of shrimp. Stownets were the most efficient gear accounting for 50% of the total production (550 t of shrimp and 600 t of fish) while other significant techniques were mainly drift nets (21%), longlines (11%) and gillnets (5%). Fish catches were composed with 55 fish species among which 16 species accounted for 90% of the annual catch. The average catch length of these first sixteen species was 295 mm, clearly demonstrating that fishing for fish was targeting large fish. The effects of the targeted shrimp exploitation resulted in a low fishing effort for fish leading to low fish landings and consequently to an under exploitation of fish resource in the Gambia estuary.
C1 IRD, Dakar, Senegal.
   Dept Fisheries, Banjul, Gambia.
RP Lae, R (reprint author), IRD, BP 1386, Dakar, Senegal.
EM lae@ird.sn
CR Albaret J.-J., 1987, Revue d'Hydrobiologie Tropicale, V20, P291
   Albaret JJ, 2004, AQUAT LIVING RESOUR, V17, P35, DOI 10.1051/alr:2004001
   Albaret J.J., 1999, POISSONS EAUX CONTIN, P325
   BLABER SJM, 2000, FISH AQUATIC RESOUR, V7
   Bousso T., 1996, THESIS U MONTPELLIER
   CHAVANCE P, 2004, ACT S INT DAK SEN 24
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407
   DIADHIOU A, 1986, ESTUAIRE CASAMANCE, P111
   DIOUF PS, 1991, PLAN ACTION FORESTIE, V1
   Diouf PS, 1996, THESIS ORSTOM PARIS
   DORR JA, 1985, 11 U MICH GREAT LAK
   ECOUTIN JM, 1999, RIVIERES SUD, P209
   Ecoutin JM, 1994, ENV RESSOURCES AQUAT, VII, P399
   *FISH DEP GAMB, 1983, FRAM SURV
   *FISH DEP GAMB, 1997, FRAM SURV
   Garcia SM, 1996, MAR FRESHWATER RES, V47, P43, DOI 10.1071/MF9960043
   Guiral D., 1999, RIVIERES SUD, P63
   KEBE M, 1994, 140 CRODT
   KING H, 1979, MIN AGR NATURAL RESO, V32
   LAMAGAT JP, 1990, MONOGRAPHIE HYDROLOG
   Le Reste Louis, 1994, Revue d'Hydrobiologie Tropicale, V27, P129
   LEENDERTSE K, 1995, FIDPINT91007 FAO
   LERESTE L, 1992, OCEANOL ACTA, V4, P327
   LERESTE L, 1984, ETUD REV CGPM, V61, P253
   LERESTE L, 1986, ESTUARIRE CASAMANCE, P245
   LESACK LFW, 1984, LIMNOL OCEANOGR, V29, P816
   LESACK LFW, 1986, J FISH BIOL, V28, P679, DOI 10.1111/j.1095-8649.1986.tb05203.x
   LESACK LFW, 1980, MIN AGR NATURAL RESO, V33
   Lhomme F., 1984, P111
   LHOMME F, 1981, BIOL DYNAMIQUE PENAE
   MARIUS C, 1985, 193 ORSTOM
   NJAI SE, 2000, TRADITIONAL FISH PRO
   REIZER C, 1974, THESIS U LIEGE
   Ronnback P, 1999, ESTUAR COAST SHELF S, V48, P223, DOI 10.1006/ecss.1998.0415
   Scherrer B, 1984, BIOSTATISTIQUE
   THAYER GW, 1987, MAR ECOL PROG SER, V35, P25, DOI 10.3354/meps035025
   VANCE DJ, 1990, ESTUAR COAST SHELF S, V31, P689, DOI 10.1016/0272-7714(90)90020-R
   Welcomme R. L., 1985, 262 FAO
NR 38
TC 9
Z9 11
U1 0
U2 4
PU GAUTHIER-VILLARS/EDITIONS ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75015 PARIS, FRANCE
SN 0990-7440
J9 AQUAT LIVING RESOUR
JI Aquat. Living Resour.
PD JAN-MAR
PY 2004
VL 17
IS 1
BP 75
EP 85
DI 10.1051/alr:2004010
PG 11
WC Fisheries; Marine & Freshwater Biology
SC Fisheries; Marine & Freshwater Biology
GA 811FL
UT WOS:000220757700010
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Lesi, OA
   Mendy, M
   Akano, AO
   Sam, O
   Goedert, JJ
   Hainaut, P
   Hall, AJ
   Whittle, H
   Montesano, R
AF Kirk, GD
   Lesi, OA
   Mendy, M
   Akano, AO
   Sam, O
   Goedert, JJ
   Hainaut, P
   Hall, AJ
   Whittle, H
   Montesano, R
TI The Gambia Liver Cancer Study: Infection with hepatitis B and C and the
   risk of hepatocellular carcinoma in West Africa
SO HEPATOLOGY
LA English
DT Article
ID VIRUS-INFECTION; CIRRHOTIC-PATIENTS; DUAL INFECTION; UNITED-STATES;
   E-ANTIGEN; ETIOLOGY; GENDER; PREVALENCE; AGE; TRANSMISSION
AB Hepatocellular carcinoma (HCC) is the most common cancer in The Gambia. Hepatitis B virus (HBV) infection is endemic, with 15% to 20% of the population being chronic carriers, whereas hepatitis C virus (HCV) prevalence is low. We recruited 216 incident cases of HCC and 408 controls from three sites. HBV carriage was present in 61% (129/211) of HCC patients and 16% (64/402) of controls, whereas 19% (36/191) of HCC patients were HCV seropositive compared with 3% (11/382) of controls. HCC patients with HCV were notably older and were more likely to be female than those with HBV. Increased HCC risk was strongly associated with chronic HBV (odds ratio, 16.7; 95% Cl, 9.7-28.7), HCV (16.7; 6.9-40.1), and dual infection (35.3; 3.9-323). We interpret the additive nature of risk with coinfection as representative of HBV and HCV acting primarily through shared steps in the multistage process of hepatocarcinogenesis. HCV infection was not observed among younger participants, suggesting a possible cohort effect. Reasons for the striking age and gender differences in HCC associated with HBV compared with HCV are unclear, but transmission patterns and age at exposure may be factors. In conclusion, in a standardized evaluation of well-characterized study participants from The Gambia, most cases of HCC are attributable to HBV (57%), but HCV adds a significant fraction (20%), especially among older patients and females. If HCV transmission is not perpetuated in future cohorts, focusing available resources on HB vaccination efforts could greatly ameliorate a major cause of cancer death in sub-Saharan Africa.
C1 NCI, Viral Epidemiol Branch, DCEG, NIH,DHHS, Bethesda, MD 20892 USA.
   Int Agcy Res Canc, Gambia Hepatitis Intervent Study, Banjul, Gambia.
   Int Agcy Res Canc, Gambia Hepatitis Intervent Study, F-69372 Lyon, France.
   MRC Labs, Banjul, Gambia.
   Govt Gambia, Royal Victoria Hosp, Dept Med Serv, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Kirk, GD (reprint author), NCI, Viral Epidemiol Branch, DCEG, NIH,DHHS, 6120 Execut Blvd,EPS-8003,MSC-7248, Bethesda, MD 20892 USA.
EM kirkg@mail.nih.gov
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
FU NCI NIH HHS [N01CP40521]
CR Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321
   Chu CJ, 2002, HEPATOLOGY, V35, P1274, DOI 10.1053/jhep.2002.33161
   CHU CM, 2000, J GASTROEN HEPATOL, V15, pS25
   Colombo M, 1999, J HEPATOL, V31, P25, DOI 10.1016/S0168-8278(99)80370-5
   Deuffic S, 1999, J VIRAL HEPATITIS, V6, P411, DOI 10.1046/j.1365-2893.1999.00178.x
   Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2
   Donato MF, 2001, HEPATOLOGY, V34, P523, DOI 10.1053/jhep.2001.26820d
   Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7
   Dumpis U, 2001, J MED VIROL, V65, P664, DOI 10.1002/jmv.2088
   Dumpis U, 2001, J HEPATOL, V35, P99, DOI 10.1016/S0168-8278(01)00064-2
   Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807
   Evans AA, 1998, CANCER EPIDEM BIOMAR, V7, P559
   Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   Ghebranious N, 1998, HEPATOLOGY, V27, P383, DOI 10.1002/hep.510270211
   HADZIYANNIS S, 1995, INT J CANCER, V60, P627, DOI 10.1002/ijc.2910600510
   Hall AJ, 2003, TROP MED INT HEALTH, V8, P1, DOI 10.1046/j.1365-3156.2003.00985.x
   International Agency for Research on Cancer (IARC), 1994, MON EV CARC RISKS HU, V59
   Ishikawa T, 2001, J GASTROEN HEPATOL, V16, P1274, DOI 10.1046/j.1440-1746.2001.02616.x
   Kaczynski J, 1996, SCAND J GASTROENTERO, V31, P809, DOI 10.3109/00365529609010357
   Kane M, 1995, VACCINE S1, V13, P47
   Kew MC, 1997, GASTROENTEROLOGY, V112, P184, DOI 10.1016/S0016-5085(97)70233-6
   KIRK GD, 2003, WORLD CANC REPORT, P144
   Lee CM, 1999, CANCER, V86, P1143, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1143::AID-CNCR7>3.0.CO;2-Z
   Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5
   MAYANS MV, 1990, LANCET, V336, P1107
   McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14
   MENDY ME, 1998, BRIT J BIOMED SCI, V55, P92
   Miyakawa H, 1996, ALCOHOL CLIN EXP RES, V20, pA91, DOI 10.1111/j.1530-0277.1996.tb01738.x
   Parkin DM, 2001, EJC SUPPL, V37, P4, DOI DOI 10.1016/S0959-8049(01)00267-2
   Payne RJH, 1996, P NATL ACAD SCI USA, V93, P6542, DOI 10.1073/pnas.93.13.6542
   Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387
   Pontisso P, 1998, ANTIVIR THER, V3, P137
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   Seeff Leonard B., 1999, American Journal of Medicine, V107, p10S
   Shiratori Y, 1997, CANCER, V80, P2060, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2060::AID-CNCR4>3.0.CO;2-0
   TARAO K, 1993, CANCER, V72, P369, DOI 10.1002/1097-0142(19930715)72:2<369::AID-CNCR2820720210>3.0.CO;2-5
   Tsai JF, 1996, BRIT J CANCER, V73, P1498, DOI 10.1038/bjc.1996.283
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHO, 1999, J VIRAL HEPATITUS, V6, P35
   Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215
   YU MW, 1994, CRIT REV ONCOL HEMAT, V17, P71, DOI 10.1016/1040-8428(94)90020-5
   YU SZ, 1997, CHIN J EPIDEMIOL, V18, P214
   Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0
NR 50
TC 95
Z9 97
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD JAN
PY 2004
VL 39
IS 1
BP 211
EP 219
DI 10.1002/hep.20027
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 805OK
UT WOS:000220375400026
PM 14752840
OA No
DA 2017-08-15
ER

PT J
AU Vekemans, J
   Ota, MOC
   Sillah, J
   Fielding, K
   Alderson, MR
   Skeiky, YAW
   Dalemans, W
   McAdam, KPWJ
   Lienhardt, C
   Marchant, A
AF Vekemans, J
   Ota, MOC
   Sillah, J
   Fielding, K
   Alderson, MR
   Skeiky, YAW
   Dalemans, W
   McAdam, KPWJ
   Lienhardt, C
   Marchant, A
TI Immune responses to mycobacterial antigens in the Gambian population:
   Implications for vaccines and immunodiagnostic test design
SO INFECTION AND IMMUNITY
LA English
DT Article
ID T-CELL RESPONSES; FILTRATE PROTEIN 10; ALPHA-CRYSTALLIN; TUBERCULOSIS
   INFECTION; PULMONARY TUBERCULOSIS; ACTIVE TUBERCULOSIS; GUERIN
   VACCINATION; EXPRESSION CLONING; MOLECULAR-CLONING; GAMMA PRODUCTION
AB Recombinant immunodominant mycobacterial antigens are needed for the development of new vaccines and immunodiagnostic tools for use against tuberculosis. Ubiquitous exposure to mycobacteria in tropical countries could influence vaccine-induced immunity and the specificity of tuberculosis immunodiagnosis. For this study conducted in The Gambia, cellular immune responses to recombinant mycobacterial antigens were characterized in Mycobacterium bovis BCG-vaccinated and nonvaccinated infants, adult community controls, household contacts, health care workers, and tuberculosis patients. Neonatal BCG vaccination induced gamma interferon (IFN-gamma) responses to Mtb8.4, Mtb32-C, Mtb39A, Mtb9.9A, and Mtb32-N, but not CFP-10 (Mtb11) and alpha-crystallin (Mtb16). Exposure to Mycobacterium tuberculosis in household contacts and health care workers was associated with high responses to CFP-10 and alpha-crystallin. Generally, low IFN-gamma responses were found in tuberculosis patients. These results suggest that Mtb8.4, Mtb32-C, Mtb39A, Mtb9.9A, and Mtb32-N may be used in a subunit vaccine to boost BCG-induced immunity. While CFP-10 and alpha-crystallin are promising candidates for the immunodiagnosis of M. tuberculosis infection or for vaccine use, disease-associated immunosuppression may prevent IFN-gamma immunodiagnosis of more advanced tuberculosis.
C1 Free Univ Brussels, B-1190 Brussels, Belgium.
   MRC Labs, Fajara, The Gambia, Gambia.
   GlaxoSmithKline Biol, Rixensart, Belgium.
   London Sch Hyg & Trop Med, London WC1, England.
   Corixa Corp, Seattle, WA USA.
RP Vekemans, J (reprint author), Free Univ Brussels, 130 Rue Allies, B-1190 Brussels, Belgium.
CR Alderson MR, 2000, J EXP MED, V191, P551, DOI 10.1084/jem.191.3.551
   Andersen P, 2001, TRENDS IMMUNOL, V22, P160, DOI 10.1016/S1471-4906(01)01865-8
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   Arend SM, 2001, INT J TUBERC LUNG D, V5, P680
   Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918
   CHAPARAS SD, 1970, AM REV RESPIR DIS, V101, P74
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   Coler RN, 2001, J IMMUNOL, V166, P6227
   Coler RN, 1998, J IMMUNOL, V161, P2356
   Cunningham AF, 1998, J BACTERIOL, V180, P801
   Dillon DC, 2000, J CLIN MICROBIOL, V38, P3285
   Dillon DC, 1999, INFECT IMMUN, V67, P2941
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   HernandezPando R, 1997, INFECT IMMUN, V65, P3317
   Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114
   Hirsch CS, 1999, J INFECT DIS, V179, P945, DOI 10.1086/314667
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Lewinsohn DM, 2001, J IMMUNOL, V166, P439
   Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Marchant A, 2001, AM J RESP CELL MOL, V24, P187
   ORME IM, 1984, INFECT IMMUN, V44, P28
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859
   Ramshaw IA, 2000, IMMUNOL TODAY, V21, P163, DOI 10.1016/S0167-5699(00)01612-1
   Skeiky YAW, 2000, J IMMUNOL, V165, P7140
   Skeiky YAW, 1999, INFECT IMMUN, V67, P3998
   Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   VERBON A, 1992, J BACTERIOL, V174, P1352
   Webb JR, 1998, INFECT IMMUN, V66, P4208
   Wilkinson RJ, 1998, SCAND J IMMUNOL, V48, P403
   Yuan Y, 1998, P NATL ACAD SCI USA, V95, P9578, DOI 10.1073/pnas.95.16.9578
NR 42
TC 41
Z9 48
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JAN
PY 2004
VL 72
IS 1
BP 381
EP 388
DI 10.1128/IAI.72.1.381-388.2004
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 758JR
UT WOS:000187631600046
PM 14688119
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Falorni, A
   Bini, V
   Fulford, AJC
   O'Connell, MA
   Prentice, AM
AF Moore, SE
   Falorni, A
   Bini, V
   Fulford, AJC
   O'Connell, MA
   Prentice, AM
TI Ethnic differences in the relationship between fasting leptin and BMI in
   children
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE leptin; BMI; body composition; children; Italy; Gambia
ID BODY-COMPOSITION; GAMBIAN CHILDREN; AFRICAN-AMERICAN; ENERGY-BALANCE;
   BIRTH-WEIGHT; SUPPLEMENTATION; GENDER; WOMEN; PUBERTY; FATNESS
AB OBJECTIVE: To compare the relationship between fasting serum leptin levels and body mass index (BMI) in children from different ethnic groups.
   SUBJECTS: Children aged 6 - 10 y from rural Gambia (n = 471) and central Italy ( n = 839).
   MEASUREMENTS: Anthropometry ( z- score of BMI) and fasting serum leptin concentrations.
   RESULTS: The Italian children had significantly higher mean BMI z- scores than the Gambian children ( males: Italy 1.58, Gambia - 1.44, Pless than or equal to0.0001; females: Italy 1.33, Gambia - 1.42, Pless than or equal to0.0001) and significantly higher serum leptin concentrations ( males: Italy 8.86 ng ml(-1), Gambia 1.78 ng ml(-1), Pless than or equal to0.0001; females: Italy 11.31 ng ml(-1), Gambia 2.22 ng ml(-1), Pless than or equal to0.0001). A significantly different relationship was observed between z- score of BMI and serum leptin levels in the Gambian and the Italian children for both boys and girls.
   CONCLUSION: A different relationship exists between z- score of BMI and leptin levels in these two groups of children from very diverse ethnic backgrounds. Future studies using detailed measures of body composition and energy balance are needed to help understand this relationship.
C1 London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC1B 3DP, England.
   MRC Keneba, MRC Labs, Fajara, Gambia.
   Univ Perugia, Dept Gynaecol Obstet & Paediat Sci, I-06100 Perugia, Italy.
   MRC, Elsie Widdowson Lab, Cambridge, England.
RP Moore, SE (reprint author), London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, 49-51 Bedford Sq, London WC1B 3DP, England.
RI Bini, Vittorio/F-5134-2010; Falorni, Alberto/E-5747-2011
OI Bini, Vittorio/0000-0001-8404-2918; 
CR Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005
   Danadian K, 1999, J PEDIATR ENDOCR MET, V12, P639
   der Merwe M T, 1999, Int J Obes Relat Metab Disord, V23, P909
   Deurenberg P, 2003, EUR J CLIN NUTR, V57, P405, DOI 10.1038/sj.ejcn.1601569
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   Ellis KJ, 1997, PEDIATR RES, V42, P484, DOI 10.1203/00006450-199710000-00010
   Falorni A, 1998, INT J OBESITY, V22, P1197, DOI 10.1038/sj/ijo/0800746
   Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410
   Luke AH, 1998, AM J CLIN NUTR, V67, P391
   Ma ZM, 1996, CLIN CHEM, V42, P942
   Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066
   Moore SE, 2001, AM J CLIN NUTR, V74, P840
   Nagy TR, 1997, J CLIN ENDOCR METAB, V82, P2148, DOI 10.1210/jc.82.7.2148
   Perry HM, 1997, METABOLISM, V46, P1399, DOI 10.1016/S0026-0495(97)90138-4
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Prentice AM, 2002, NUTR REV, V60, pS56, DOI 10.1301/002966402320634940
   TANNER JM, 1976, ARCH DIS CHILD, V51, P170
   Wells JCK, 1998, INT J OBESITY, V22, P387, DOI 10.1038/sj.ijo.0800572
NR 22
TC 10
Z9 10
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
J9 INT J OBESITY
JI Int. J. Obes.
PD JAN
PY 2004
VL 28
IS 1
BP 17
EP 21
DI 10.1038/sj.ijo.0802484
PG 5
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 760RX
UT WOS:000187849200004
PM 14652620
OA No
DA 2017-08-15
ER

PT J
AU Eastwood, SV
   Hill, PC
AF Eastwood, SV
   Hill, PC
TI A gender-focused qualitative study of barriers to accessing tuberculosis
   treatment in the Gambia, West Africa
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE the Gambia; tuberculosis; gender; diagnostic delay; traditional healers;
   access; stigma
ID CARE SEEKING BEHAVIOR; VIETNAM; HEALTH; PERCEPTION; DIAGNOSIS; DELAYS;
   WOMEN; INDIA
AB SETTING: The Medical Research Council unit in Fajara, The Gambia.
   OBJECTIVE: To explore gender differences in care seeking behaviour, access to treatment, and knowledge and perceptions about tuberculosis.
   DESIGN : Fifteen government health workers were interviewed to define the scope of the issues involved, then 15 male and 15 female tuberculosis patients were interviewed. Qualitative semi-structured questionnaires were used in health worker and patient interviews. Data were analysed using the thematic framework method. The main themes were compared between male and female patients.
   RESULTS: Patients often initially consulted traditional healers and pharmacies. Women used traditional healers more, probably because of stronger traditional beliefs, time constraints and increased confidentiality. Regardless of sex, most patients acknowledged problems affording the transport costs to access treatment. Health workers and patients highlighted negative perceptions of tuberculosis. Lack of knowledge about tuberculosis and stigma were widely reported, and were worst in female patients.
   CONCLUSIONS: Tuberculosis is a stigmatised disease in The Gambia, particularly in women, and its management is associated with access problems. Health education is required to provide basic knowledge about the disease and to reduce stigma, and further decentralisation of tuberculosis services is needed to improve access.
C1 MRC Labs, Dept TB, Western Div, Banjul, Gambia.
   Univ Birmingham, Dept Med, Birmingham, W Midlands, England.
RP Hill, PC (reprint author), MRC Labs, Dept TB, Western Div, POB 273, Banjul, Gambia.
EM phill@mrc.gm
CR BARNHOORN F, 1992, SOC SCI MED, V34, P291, DOI 10.1016/0277-9536(92)90271-Q
   CASSELS A, 1982, TUBERCLE, V63, P173
   GEORGE A, 1997, HOUSEHOLD HLTH EXPEN, P56
   Grange JM, 1999, LANCET, V353, P996, DOI 10.1016/S0140-6736(99)01196-4
   Hudelson P, 1996, TUBERCLE LUNG DIS, V77, P391, DOI 10.1016/S0962-8479(96)90110-0
   Johansson E, 2000, HEALTH POLICY, V52, P33, DOI 10.1016/S0168-8510(00)00062-2
   Johansson E, 2002, QUAL HEALTH RES, V12, P473, DOI 10.1177/104973202129120025
   Kurasawa T, 1990, Kekkaku, V65, P47
   Liefooghe R, 1997, TROP MED INT HEALTH, V2, P809, DOI 10.1046/j.1365-3156.1997.d01-380.x
   Liefooghe R, 1995, SOC SCI MED, V41, P1685, DOI 10.1016/0277-9536(95)00129-U
   LIEFOOGHE R, 1998, GENDER TUBERCULOSIS
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233
   Long NH, 1999, INT J TUBERC LUNG D, V3, P388
   MURRAY CJL, 1990, B INT UNION TUBERC, V65, P1
   Nair DM, 1997, HEALTH POLICY PLANN, V12, P77, DOI 10.1093/heapol/12.1.77
   Rajeswari R, 1999, INT J TUBERC LUNG D, V3, P869
   Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI DOI 10.4324/9780203413081_CHAPTER_9
   Salaniponi FML, 2000, INT J TUBERC LUNG D, V4, P327
   Samson K, 2001, NATL LEPROSY TUBERCU
   SHAABAN MA, 1990, EUR RESPIR J, V3, P187
   UPLEKAR M, 1993, ACCESS HLTH CARE IND
   Uplekar MW, 2001, INT J TUBERC LUNG D, V5, P220
   van der Loeff MFS, 2002, AIDS, V16, P1775
   VLASSOFF C, 1994, SOC SCI MED, V39, P1249, DOI 10.1016/0277-9536(94)90357-3
   World Health Organization, 2003, WHOCDSTB2003316
   Wilkinson D, 1999, INT J TUBERC LUNG D, V3, P838
   Yamasaki-Nakagawa M, 2001, INT J TUBERC LUNG D, V5, P24
NR 27
TC 51
Z9 54
U1 0
U2 4
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD JAN
PY 2004
VL 8
IS 1
BP 70
EP 75
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 766KT
UT WOS:000188376100009
PM 14974748
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Goetghebuer, T
   Sanneh, M
   Whittle, HC
   Weber, MW
AF van der Sande, MAB
   Goetghebuer, T
   Sanneh, M
   Whittle, HC
   Weber, MW
TI Seasonal variation in respiratory syncytial virus epidemics in The
   Gambia, West Africa
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE respiratory syncytial virus; epidemiology; seasonality; The Gambia
ID INFECTION; CHILDREN
AB Respiratory syncytial virus outbreaks tend to occur seasonally and are a major cause of childhood morbidity. In The Gambia a regular pattern of outbreaks during six consecutive annual seasons was disrupted by 2 years of irregular outbreaks, followed by another 2 years of regular seasonal outbreaks. Improved understanding of the transmission dynamics of respiratory syncytial virus is essential to design and test effective interventions.
C1 MRC Labs, Banjul, Gambia.
   John Radcliffe Hosp, Oxford OX3 9DU, England.
   WHO, CH-1211 Geneva, Switzerland.
RP van der Sande, MAB (reprint author), MRC Labs, Banjul, Gambia.
CR Cane PA, 1999, EPIDEMIOL INFECT, V122, P155, DOI 10.1017/S0950268896001872
   Chew FT, 1998, EPIDEMIOL INFECT, V121, P121, DOI 10.1017/S0950268898008905
   Doraisingham S, 1987, Ann Acad Med Singapore, V16, P243
   Krilov L. R., 2001, CURR INFECT DIS REP, V3, P242, DOI 10.1007/s11908-001-0026-3
   Piedra PA, 2003, PEDIATR INFECT DIS J, V22, pS94, DOI 10.1097/00006454-200302001-00014
   Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501
   Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   van der Sande MAB, 2002, CLIN EXP ALLERGY, V32, P1430, DOI 10.1046/j.1365-2745.2002.01521.x
   WARIS M, 1991, J INFECT DIS, V163, P464
   Weber A, 2001, MATH BIOSCI, V172, P95, DOI 10.1016/S0025-5564(01)00066-9
   Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x
   Weber MW, 1999, INT J EPIDEMIOL, V28, P157, DOI 10.1093/ije/28.1.157
NR 13
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JAN
PY 2004
VL 23
IS 1
BP 73
EP 74
DI 10.1097/01.inf.0000105183.12781.06
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 768VB
UT WOS:000188554800015
PM 14743052
OA No
DA 2017-08-15
ER

PT S
AU Jarjou, LMA
   Prentice, A
   Bennett, J
AF Jarjou, LMA
   Prentice, A
   Bennett, J
BE Pickering, LK
   Morrow, AL
   RuizPalacios, GM
   Schanler, RJ
TI Impact of calcium supplementation in the preceding pregnancy on the
   human milk calcium concentration of Gambian women
SO PROTECTING INFANTS THROUGH HUMAN MILK: ADVANCING THE SCIENTIFIC EVIDENCE
SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY
LA English
DT Article; Proceedings Paper
CT 11th International Conference of the
   International-Society-for-Research-in-Human-Milk-and-Lactation
CY OCT 04-08, 2002
CL Mexico City, MEXICO
SP Int Soc Res Human Milk & Lactat
C1 MRC Keneba, Keneba, Gambia.
   MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
RP Jarjou, LMA (reprint author), MRC Keneba, POB 273, Keneba, Gambia.
EM ann.prentice@mrc.dunn.cam.ac.uk
CR LASKEY MA, 1991, ANN CLIN BIOCHEM, V28, P49
   PRENTICE A, 1994, LANCET, V344, P411, DOI 10.1016/S0140-6736(94)91440-0
NR 2
TC 1
Z9 1
U1 0
U2 0
PU KLUWER ACADEMIC/PLENUM PUBL
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0065-2598
BN 0-306-48588-5
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2004
VL 554
BP 347
EP 349
PG 3
WC Medicine, Research & Experimental; Nutrition & Dietetics; Obstetrics &
   Gynecology; Pediatrics
SC Research & Experimental Medicine; Nutrition & Dietetics; Obstetrics &
   Gynecology; Pediatrics
GA BAU75
UT WOS:000223641000035
PM 15384598
OA No
DA 2017-08-15
ER

PT J
AU Ofor, OO
AF Ofor, OO
TI Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment
   for severe hypertension in Nigerians
SO TROPICAL DOCTOR
LA English
DT Article
ID THERAPY; NIFEDIPINE; GUIDELINES; MODERATE
AB A combination of low-dose oral enalapril, methyldopa and hydrochlorothiazide was evaluated in the acute treatment of severe hypertension. Blood pressure moved from an average 210/120 mmHg at the onset to an average 135/79 mmHg within 24 hours, without any significant side effects and at about half the cost of commonly used parenteral hydralazine.
C1 Royal Victoria Hosp, Med Unit, Banjul, Gambia.
RP Ofor, OO (reprint author), Ebonyi State Univ, Teaching Hosp, Dept Internal Med, PMB 077, Abakaliki, Ebonyi State, Nigeria.
EM okezieofor@hotmail.com
CR Ajayi AA, 1996, EUR J CLIN PHARMACOL, V51, P45, DOI 10.1007/s002280050158
   Black HR, 1997, ARCH INTERN MED, V157, P2413
   Chalmers J, 1999, J HYPERTENS, V17, P151
   CLARK R, 1998, WASHINGTON MANUAL ME, P61
   Damasceno A, 1998, J CARDIOVASC PHARM, V31, P165, DOI 10.1097/00005344-199801000-00022
   GOA KL, 1996, DRUGS, V53, P540
   GREENE CS, 1990, AM J EMERG MED, V8, P293, DOI 10.1016/0735-6757(90)90077-D
   HELLER MB, 1990, AM J EMERG MED, V8, P282, DOI 10.1016/0735-6757(90)90074-A
   Houston MC, 1998, POSTGRAD MED, V104, P167
   JAGASOTHY R, 1996, J OBSTET GYNECOL RES, V22, P21
   Karnik N D, 1996, J Assoc Physicians India, V44, P480
   LEONETTI G, 1990, J HUM HYPERTENS, V4, P5
   Ramsay LE, 1996, J HYPERTENS, V14, pS187
   Stimpel M, 1996, CARDIOLOGY, V87, P313, DOI 10.1159/000177112
NR 14
TC 2
Z9 2
U1 1
U2 1
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD JAN
PY 2004
VL 34
IS 1
BP 32
EP 33
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 769VZ
UT WOS:000188671600016
PM 14959973
OA No
DA 2017-08-15
ER

PT J
AU Drakeley, CJ
   Jawara, M
   Targett, GAT
   Walraven, G
   Obisike, U
   Coleman, R
   Pinder, M
   Sutherland, CJ
AF Drakeley, CJ
   Jawara, M
   Targett, GAT
   Walraven, G
   Obisike, U
   Coleman, R
   Pinder, M
   Sutherland, CJ
TI Addition of artesunate to chloroquine for treatment of Plasmodium
   falciparum malaria in Gambian children causes a significant but
   short-lived reduction in infectiousness for mosquitoes
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Plasmodium falciparum; malaria; gametocytes; infectivity; chloroquine;
   artesunate; combination therapy; The Gambia
ID UNCOMPLICATED MALARIA; PYRIMETHAMINE-SULFADOXINE; ATOVAQUONE-PROGUANIL;
   PLUS PYRIMETHAMINE; TRANSMISSION; MALARONE(TM); GAMETOCYTES;
   INFECTIVITY; RESISTANCE; IMPACT
AB OBJECTIVES Combination therapy using existing anti-malarials together with artesunate (AS) has been advocated as a method to slow the spread of drug resistance. We assessed the effect on Plasmodium falciparum transmissibility of the addition of AS to chloroquine (CQ) in an area of The Gambia where resistance to CQ is increasing.
   METHODS Gambian children with acute uncomplicated P. falciparum malaria were treated with either CQ monotherapy (n = 120) or the combination of CQ plus three doses of AS (CQ/AS; n = 352). Post-treatment sexual-stage parasitaemia was assessed during a 4-week follow-up period. Experimental infections of Anopheles gambiae s.s. mosquitoes were performed with blood from patients who were carrying gametocytes 7 days after starting treatment (n = 69).
   RESULTS The addition of AS significantly reduced post-treatment prevalence and mean density of gametocytes in the first 14 days (day 7: 43.7% vs. 12.4%, 62.4/mul vs. 6.2/mul; day 14: 32.9% vs. 3.7%; 21.9/mul vs. 5.2/mul; CQ vs. CQ/AS), although by day 28 the benefits of the combination were substantially less marked (40.5% vs. 21.8%; 23.0/mul vs. 63.1/mul; CQ vs. CQ/AS). The duration of gametocyte carriage over the study period was significantly tower in the CQ/AS group (5.2 days vs. 1.5 days; CQ vs. CQ/AS). The estimated infectious proportion of children at day 7 was also lower in the combination group (19.2% vs. 3.4%; CQ vs. CQ/AS), as were the proportion of mosquitoes infected and mean oocyst density (11.5% vs. 0.9%; 0.3 vs. 0.01; CQ vs. CQ/AS). Treatment failure was associated with threefold and twofold higher gametocyte carriage rates during follow-up in CQ and CQ/AS groups, respectively (P < 0.001 in both cases), and 26-fold and 2.3-fold higher intensity of infection at day 7 among CQ- and CQ/AS-treated children, respectively (P = 0.002 and 0.30, respectively).
   CONCLUSION The benefits of adding AS to CQ monotherapy in lowering gametocyte prevalence and density were transient, suggesting that the addition of AS delayed, but did not prevent, the emergence of gametocytes. This is consistent with our finding that treatment failure, and thus the presence of CQ-resistant parasites, was significantly associated with a higher gametocyte carriage rate in both treatment groups. At day 7, CQ monotherapy significantly favoured transmission of resistant infections, which showed an 11-fold greater intensity of transmission compared with infections that were successfully treated. In contrast, the combination of CQ/AS did not significantly favour resistant infections at day 7. We conclude that significant transmission-reduction is achieved by the combination but is not maintained because of the recrudescence of CQ-resistant parasites.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC, Lab Farefenni, Banjul, Gambia.
RP Drakeley, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM chris.drakeley@lshtm.ac.uk; mjawara2000@yahoo.co.uk;
   Gijs.Walraven@aiglemont.org; Gijs.WALRAVEN@aiglemont.org;
   uchenobis@yahoo.co.uk; rosalind.coleman@wanado.fr; mpinder@mrc.gm;
   colin.sutherland@lshtm.ac.uk
CR Borrmann S, 2003, ANTIMICROB AGENTS CH, V47, P901, DOI 10.1128/AAC.47.3.901-904.2003
   Butcher GA, 2000, ANN TROP MED PARASIT, V94, P429
   Drakeley CJ, 2000, ANN TROP MED PARASIT, V94, P399
   Enosse S, 2000, T ROY SOC TROP MED H, V94, P77, DOI 10.1016/S0035-9203(00)90447-4
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hogh B, 1998, AM J TROP MED HYG, V58, P176
   Lensen A, 1996, T ROY SOC TROP MED H, V90, P20, DOI 10.1016/S0035-9203(96)90464-2
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Robert V, 2000, AM J TROP MED HYG, V62, P210
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   von Seidlein L, 2001, AM J TROP MED HYG, V65, P523
   von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
NR 18
TC 53
Z9 54
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JAN
PY 2004
VL 9
IS 1
BP 53
EP 61
DI 10.1046/j.1365-3156.2003.01169.x
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 775WL
UT WOS:000189083600007
PM 14728607
OA No
DA 2017-08-15
ER

PT J
AU Newport, MJ
   Allen, A
   Awomoyi, AA
   Dunstan, SJ
   McKinney, E
   Marchant, A
   Sirugo, G
AF Newport, MJ
   Allen, A
   Awomoyi, AA
   Dunstan, SJ
   McKinney, E
   Marchant, A
   Sirugo, G
TI The toll-like receptor 4 Asp299Gly variant: no influence on LPS
   responsiveness or susceptibility to pulmonary tuberculosis in The Gambia
SO TUBERCULOSIS
LA English
DT Article
DE genetic susceptibility; tuberculosis; toll-like receptor 4; tumour
   necrosis factor; interleukin-1 beta,interleukin-10; African populations
ID MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA; LIPOPOLYSACCHARIDE;
   POLYMORPHISMS; GENE; INTERLEUKIN-10; LIPOPROTEINS; ACTIVATION; MODEL;
   TLR4
AB Setting: Tuberculosis (TB) remains a major cause of morbidity and mortality worldwide. Studies in a murine model of pulmonary TB have identified a role for Toll-like receptor 4 (TLR4) in the development of chronic lung infection with Mycobacterium tuberculosis. The Asp299Gly polymorphism in the human TLR4 gene is associated with in vivo hyporesponsiveness to lipopolysaccharide (LPS) in Caucasians.
   Objective: To determine whether TLR4 Asp299Gly influences LPS responses or susceptibility to pulmonary TB in humans in a Gambian population sample.
   Design: We compared whole blood monokine responses to LIPS in 245 healthy blood donors stratified by TLR4 Asp299Gly genotype to assess whether this polymorphism was functional in this population. A case-control study of 640 subjects was conducted to investigate whether TLR4 Asp299Gly was associated with TB.
   Results: LPS-induced tumour necrosis factor, interteukin-1beta and interleukin-10 production was not influenced by TLR4 Asp299Gly genotype. There was no association between TLR4 Asp299Gly and TB.
   Conclusion: Our data suggest that TLR4 Asp299Gly has no influence on monocyte LPS responses or susceptibility to TB in Gambians and could be an ancient neutral polymorphism. (C) 2004 Elsevier Ltd. All rights reserved.
C1 MRC Labs, Banjul, Gambia.
   Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England.
   Expt Immunol Lab, Brussels, Belgium.
RP Newport, MJ (reprint author), Addenbrookes Hosp, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.
EM melanie.newport@cimr.cam.ac.uk; gsirugo@mrc.gm
OI Dunstan, Sarah/0000-0001-7873-933X
CR Abel B, 2002, J IMMUNOL, V169, P3155
   Akahoshi M, 2003, HUM GENET, V112, P237, DOI 10.1007/s00439-002-0873-5
   Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736
   Allen A, 2003, PEDIATR INFECT DIS J, V22, P1018, DOI 10.1097/01.inf.0000095431.15606.68
   ARBOUR NC, 2000, NAT GENET, V25, P1887
   Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732
   Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851
   Delgado JC, 2002, J INFECT DIS, V186, P1463, DOI 10.1086/344891
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   FINE HA, 1994, J NEUROONCOL, V20, P11
   Kline JN, 1999, AM J RESP CRIT CARE, V160, P297
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC
   Means TK, 1999, J IMMUNOL, V163, P3920
   Means TK, 2001, J IMMUNOL, V166, P4074
   MEDZHITOV R, 2000, IMMUNOL REV, V173, P4
   Nachega JB, 2003, CLIN INFECT DIS, V36, pS24, DOI 10.1086/344657
   Orme IM, 2003, TUBERCULOSIS, V83, P112, DOI 10.1016/S1472-9792(02)00069-0
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Relethford JH, 1999, AM J PHYS ANTHROPOL, V108, P251
   Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5
   Schmitt C, 2002, CLIN CHEM, V48, P1661
   Shifman S, 2003, HUM MOL GENET, V12, P771, DOI 10.1093/hmg/ddg088
   Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000
   Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459
   von Aulock S, 2003, J INFECT DIS, V188, P938, DOI 10.1086/378095
NR 26
TC 66
Z9 75
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1472-9792
J9 TUBERCULOSIS
JI Tuberculosis
PY 2004
VL 84
IS 6
BP 347
EP 352
DI 10.1016/j.tube.2004.02.001
PG 6
WC Immunology; Microbiology; Respiratory System
SC Immunology; Microbiology; Respiratory System
GA 876DQ
UT WOS:000225476500002
PM 15525557
OA No
DA 2017-08-15
ER

PT J
AU Cooke, GS
   Aucan, C
   Walley, AJ
   Segal, S
   Greenwood, BM
   Kwiatkowski, DP
   Hill, AVS
AF Cooke, GS
   Aucan, C
   Walley, AJ
   Segal, S
   Greenwood, BM
   Kwiatkowski, DP
   Hill, AVS
TI Association of Fc gamma receptor IIa (CD32) polymorphism with severe
   malaria in West Africa
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; INFLUENZAE TYPE-B; CLINICAL IMMUNITY;
   PROTEIN; PROTECTION; BINDING; RIIA; IGG2; SUSCEPTIBILITY; MENINGITIS
AB Malaria continues to claim the lives of more children worldwide than any other infectious disease, and improved understanding of disease immunology is a priority for the development of new therapeutic and vaccination strategies. FcgammaRIIa (CD32) contains a polymorphic variant (H/R131) that has been associated with variability in susceptibility to both bacterial diseases and Plasmodium falciparum parasitemia. We investigated the role of this polymorphism in West Africans with mild and severe malarial disease. The HH131 genotype was significantly associated with susceptibility to severe malaria (P = 0.03, odds ratio = 1.40, 95% confidence interval = 1.02-1.91). In contrast to studies of parasitemia, the presence of the R131 allele, rather than the RR131 genotype, appeared to be the important factor in protection from disease. This is the first evidence for an association between CD32 polymorphism and severe malaria and provides an example of balancing selective pressures from different infectious diseases operating at the same genetic locus.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Cooke, GS (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
RI HILL, Adrian/C-1306-2008
OI Walley, Andrew/0000-0001-7707-7549
CR Aucan C, 2000, INFECT IMMUN, V68, P1252, DOI 10.1128/IAI.68.3.1252-1258.2000
   BOUHAROUNTAYOUN H, 1992, INFECT IMMUN, V60, P1473
   Braga TM, 2002, AM J TROP MED HYG, V66, P461
   BREDIUS RGM, 1993, J IMMUNOL, V151, P1463
   BREDIUS RGM, 1994, J INFECT DIS, V170, P848
   Druilhe P, 1997, ANN TROP MED PARASIT, V91, pS37
   Goetghebuer T, 2000, TROP MED INT HEALTH, V5, P207, DOI 10.1046/j.1365-3156.2000.00535.x
   Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Jiang XM, 1996, J IMMUNOL METHODS, V199, P55, DOI 10.1016/S0022-1759(96)00164-0
   Oeuvray C, 2000, INFECT IMMUN, V68, P2617, DOI 10.1128/IAI.68.5.2617-2620.2000
   Omi K, 2002, PARASITOL INT, V51, P361, DOI 10.1016/S1383-5769(02)00040-5
   PIED S, 1989, INFECT IMMUN, V57, P278
   Platonov AE, 1998, CLIN INFECT DIS, V27, P746, DOI 10.1086/514935
   Rascu A, 1997, ANN NY ACAD SCI, V815, P282, DOI 10.1111/j.1749-6632.1997.tb52070.x
   Shi YP, 2001, J INFECT DIS, V184, P107, DOI 10.1086/320999
   Stein MP, 2000, J CLIN INVEST, V105, P369, DOI 10.1172/JCI7817
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338
   Yee AMF, 2000, CLIN INFECT DIS, V30, P25, DOI 10.1086/313588
NR 20
TC 60
Z9 62
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2003
VL 69
IS 6
BP 565
EP 568
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 759JJ
UT WOS:000187734300001
PM 14740869
OA No
DA 2017-08-15
ER

PT J
AU Brookes, RH
   Pathan, AA
   McShane, H
   Hensmann, M
   Price, DA
   Hill, AVS
AF Brookes, RH
   Pathan, AA
   McShane, H
   Hensmann, M
   Price, DA
   Hill, AVS
TI CD8(+) T cell-mediated suppression of intracellular Mycobacterium
   tuberculosis growth in activated human macrophages
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE CTL; tuberculosis; macrophage; activation
ID NATURAL-KILLER-CELLS; NF-KAPPA-B; FAS LIGAND; DENDRITIC CELLS;
   INFECTION; MICE; LYMPHOCYTES; GRANULYSIN; MECHANISMS; APOPTOSIS
AB Animal models of tuberculosis point to a protective role for MHC class I-restricted CD8(+) T cells, yet it is unclear how these cells protect or whether such findings extend to humans. Here we report that macrophages infected with Mycobacterium tuberculosis, rapidly process and present an early secreted antigenic target (ESAT-6)-specific HLA class I-restricted CD8(+) T cell epitope. When cocultured with CD8(+) T cells restricted through classical HLA class I molecules the growth of bacilli within macrophages is significantly impaired after 7 days. This slow antimycobacterial activity did not correlate with macrophage lysis but required cell contact. We also found that inhibitors of apoptosis either had no effect or augmented the CD8-mediated suppressive activity, suggesting that an activation signal might be involved. Indeed we show that CD8(+) T cells were able to activate macrophages through receptors that include CD95 (Fas). Consistent with these findings the CD8-mediated suppression of mycobacterial growth was partially reversed by Fas blockade. These data identify a previously unrecognized CD8(+) T cell-mediated mechanism used to control an intracellular infection of macrophages.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   Univ Oxford, John Radcliffe Hosp, Dept Pediat, Oxford OX3 9DU, England.
RP Brookes, RH (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI HILL, Adrian/C-1306-2008; Price, David/C-7876-2013
OI Price, David/0000-0001-9416-2737
FU Wellcome Trust [063643]
CR AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Ashany D, 1999, J IMMUNOL, V163, P5303
   Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973
   Bossi G, 1999, NAT MED, V5, P90
   Brill KJ, 2001, INFECT IMMUN, V69, P1755, DOI 10.1128/IAI.69.3.1755-1765.2001
   Canaday DH, 2001, J IMMUNOL, V167, P2734
   Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812
   Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Dieli F, 2001, J INFECT DIS, V184, P1082, DOI 10.1086/323600
   Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7
   FAZAL N, 1995, CLIN EXP IMMUNOL, V99, P82
   Gonzalez-Juarrero M, 2001, INFECT IMMUN, V69, P1722, DOI 10.1128/IAI.69.3.1722-1728.2001
   Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838
   Kampmann B, 2000, J INFECT DIS, V182, P895, DOI 10.1086/315766
   Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511
   Kojima Y, 2002, BIOCHEM BIOPH RES CO, V296, P328, DOI 10.1016/S0006-291X(02)00841-0
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Laochumroonvorapong P, 1997, INFECT IMMUN, V65, P127
   Monsurro V, 2002, J IMMUNOL, V168, P5933
   Passmore JS, 2001, CLIN EXP IMMUNOL, V126, P76, DOI 10.1046/j.1365-2249.2001.01631.x
   Ruedl C, 1999, J EXP MED, V189, P1875, DOI 10.1084/jem.189.12.1875
   Silva CL, 2000, INFECT IMMUN, V68, P3269, DOI 10.1128/IAI.68.6.3269-3274.2000
   Smith SM, 2000, J IMMUNOL, V165, P7088
   Snewin VA, 1999, INFECT IMMUN, V67, P4586
   Sousa AO, 2000, P NATL ACAD SCI USA, V97, P4204, DOI 10.1073/pnas.97.8.4204
   Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121
   Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684
   Tan LC, 1999, J IMMUNOL, V162, P1827
   Turner J, 2001, AM J RESP CELL MOL, V24, P203
   Villunger A, 2000, J IMMUNOL, V165, P1337
   Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129
NR 34
TC 28
Z9 29
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD DEC
PY 2003
VL 33
IS 12
BP 3293
EP 3302
DI 10.1002/eji.200324109
PG 10
WC Immunology
SC Immunology
GA 754ZJ
UT WOS:000187363100008
PM 14635037
OA No
DA 2017-08-15
ER

PT J
AU Ariyoshi, K
   Berry, N
   Cham, F
   Jaffar, S
   van der Loeff, MS
   Jobe, O
   N'Gom, PT
   Larsen, O
   Andersson, S
   Aaby, P
   Whittle, H
AF Ariyoshi, K
   Berry, N
   Cham, F
   Jaffar, S
   van der Loeff, MS
   Jobe, O
   N'Gom, PT
   Larsen, O
   Andersson, S
   Aaby, P
   Whittle, H
TI Quantification of human T-lymphotropic virus type I (HTLV-I) provirus
   load in a rural West African population: No enhancement of human
   immunodeficiency virus type 2 pathogenesis, but HTLV-I provirus load
   relates to mortality
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID GUINEA-BISSAU; INFECTION; HIV-2; REX; COHORT
AB Human T-lymphotropic virus type I (HTLV-I) provirus load was examined in a cohort of a population in Guinea-Bissau among whom human immunodeficiency virus (HIV) type 2 is endemic. Geometric mean of HIV-2 RNA load among HTLV-I-coinfected subjects was significantly lower than that in subjects infected with HIV-2 alone (212 vs. 724 copies/mL; P=.02). Adjusted for age, sex, and HIV status, the risk of death increased with HTLV-1 provirus load; mortality hazard ratio was 1.59 for each log(10) increase in HTLV-1 provirus copies (P=.038). There is no enhancing effect of HTLV-1 coinfection on HIV-2 disease, but high HTLV-1 provirus loads may contribute to mortality.
C1 MRC Labs, Fajara, Gambia.
   Danish Epidemiol Sci Ctr, Bandim Hlth Project, Bissau, Guinea Bissau.
   UCL Royal Free & Univ Coll Med Sch, Dept Virol, London, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Orebro Univ Hosp, Dept Clin Microbiol, Orebro, Sweden.
RP Ariyoshi, K (reprint author), Natl Inst Infect Dis, AIDS Res Ctr, 4-7-1 Gakuen, Tokyo 2080011, Japan.
EM ariyoshi@nih.go.jp
CR Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Fultz PN, 1999, J INFECT DIS, V179, P600, DOI 10.1086/314627
   Harrison LH, 1997, J INFECT DIS, V175, P438
   Holmgren B, 2002, J ACQ IMMUN DEF SYND, V30, P342, DOI 10.1097/01.QAI.0000013943.86473.3E
   LEWIS N, 1990, J VIROL, V64, P1690
   Manns A, 1999, J INFECT DIS, V180, P1487, DOI 10.1086/315088
   MCGUIRE KL, 1993, J VIROL, V67, P1590
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   SAKAI H, 1990, J VIROL, V64, P5833
   Stuver SO, 1996, J INFECT DIS, V173, P584
   Taylor GP, 1999, J ACQ IMMUN DEF SYND, V22, P92
   TUKE PW, 1992, J VIROL METHODS, V40, P163, DOI 10.1016/0166-0934(92)90065-L
   van der Loeff MFS, 1999, AIDS, V13, pS69
NR 15
TC 12
Z9 12
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2003
VL 188
IS 11
BP 1648
EP 1651
DI 10.1086/379780
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 756QV
UT WOS:000187493200005
PM 14639534
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Jensen, H
   Whittle, H
AF Aaby, P
   Jensen, H
   Whittle, H
TI High-titre measles vaccine and female mortality
SO LANCET
LA English
DT Letter
ID IMMUNIZATION
C1 Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau.
   IRD, Epidemiol & Prevent Res Unit, UR 24, Dakar, Senegal.
   MRC Labs, Banjul, Gambia.
RP Aaby, P (reprint author), Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Apartado 861, Bissau, Guinea Bissau.
CR Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   Aaby Peter, 2003, Semin Pediatr Infect Dis, V14, P220, DOI 10.1016/S1045-1870(03)00037-2
   Cutts FT, 2003, LANCET, V361, P2169, DOI 10.1016/S0140-6736(03)13783-X
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
NR 5
TC 3
Z9 3
U1 1
U2 4
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 22
PY 2003
VL 362
IS 9397
BP 1765
EP 1765
DI 10.1016/S0140-6736(03)14867-2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 746VE
UT WOS:000186767700037
PM 14643138
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Hansmann, A
   Awasana, AA
   Ota, MO
   O'Donovan, D
   Sarge-Njie, R
   Ariyoshi, K
   Milligan, P
   Whittle, H
AF van der Loeff, MFS
   Hansmann, A
   Awasana, AA
   Ota, MO
   O'Donovan, D
   Sarge-Njie, R
   Ariyoshi, K
   Milligan, P
   Whittle, H
TI Survival of HIV-1 and HIV-2 perinatally infected children in The Gambia
SO AIDS
LA English
DT Article
DE HIV-2; pediatrics; cohort study; HIV-1; children; mortality; survival
   analysis; The Gambia Africa; mother-to-child transmission
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; NATURAL-HISTORY;
   WEST-AFRICA; MORTALITY; TRANSMISSION; ZIDOVUDINE; COUNTRIES; COHORT;
   RATES
AB Background: The risk of mother-to-child transmission (MTCT) of HIV-2 is much lower than that of HIV-1, but the long-term prognosis of perinatally infected HIV-2 children is unknown. We re-visited children who were part of a large MTCT study in The Gambia (conducted during 1993-1997), in order to compare the long-term survival of children perinatally infected with HIV-2 with that of seronegative and of HIV-1 infected children.
   Methods: Five to eight years' follow-up of a cohort of children born to HIV-negative, HIV-1 positive, and HIV-2 positive mothers.
   Results: Seven hundred and seventy-four children were followed up for a median of 6.6 years. Of 17 perinatally HIV-1 infected children, three were still alive on 1 July 20,01, two had been lost to follow-up, and 12 had died. The median survival was 2.5 years. Of eight HIV-2 infected children five were still alive, none were lost to follow-up and three had died. The mortality hazards ratio of both HIV-1 [9.9; 95% confidence interval (CI), 5.2-19], and of HIV-2 infected children (3.9; Cl, 1.2-12) was significantly increased compared with children of seronegative mothers. The mortality hazards ratio of HIV uninfected children of HIV-1 or HIV-2 infected mothers was not significantly increased compared to that of children of seronegative mothers (P = 0.17 and P = 0.5 respectively).
   Conclusions: Children with perinatally acquired HIV-2 infection have a higher mortality than children of seronegative mothers. Guidelines for treatment of HIV-1 infected children should be used for treatment of HIV-2 infected children. (C) 2003 Lippincott Williams Wilkins.
C1 Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Med Res Council Lib, Fajara, Gambia.
   Univ Munster, D-4400 Munster, Germany.
   Natl Hlth Lab Serv, Banjul, Gambia.
   Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan.
RP van der Loeff, MFS (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ADJETOURE CA, 2001, 12 INT C AIDS STDS A
   Andiman W, 1999, NEW ENGL J MED, V340, P977
   Bardsley-Elliot A, 2000, Paediatr Drugs, V2, P373, DOI 10.2165/00128072-200002050-00005
   Barnhart HX, 1996, PEDIATRICS, V97, P710
   BISSAGNENE E, 2001, 12 INT C AIDS STDS A
   Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2
   Dabis F, 2001, AIDS, V15, P771, DOI 10.1097/00002030-200104130-00013
   de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190
   Faye A, 1997, J PEDIATR-US, V130, P994, DOI 10.1016/S0022-3476(97)70290-7
   Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157
   Gray L, 2001, PEDIATRICS, V108, P116
   Langston C, 2001, PEDIATRICS, V107, P328, DOI 10.1542/peds.107.2.328
   Lepage P, 1998, PEDIATR INFECT DIS J, V17, P581, DOI 10.1097/00006454-199807000-00002
   Marum L H, 1997, AIDS, V11 Suppl B, pS125
   MARUM LH, 1996, 11 INT C AIDS VANC J
   McKinney RE, 1998, J PEDIATR-US, V133, P500, DOI 10.1016/S0022-3476(98)70057-5
   Mofenson LM, 2000, LANCET, V355, P2237, DOI 10.1016/S0140-6736(00)02415-6
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   Mota-Miranda A, 2001, AIDS, V15, P2460, DOI 10.1097/00002030-200112070-00018
   MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ota MOC, 2000, AIDS, V14, P435, DOI 10.1097/00002030-200003100-00018
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   ROSADO L, 1996, 11 INT C AIDS VANC J
   RYDER RW, 1994, AIDS, V8, P667, DOI 10.1097/00002030-199405000-00014
   Sharland M, 2002, HIV Med, V3, P215, DOI 10.1046/j.1468-1293.2002.00120.x
   Smith NA, 2001, J INFECTION, V42, P126, DOI 10.1053/jinf.2001.0792
   Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56
   Unaids, 2002, REP GLOB HIV AIDS EP
   van der Loeff MFS, 2002, AIDS, V16, P1775
   Walker N, 2002, LANCET, V360, P284, DOI 10.1016/S0140-6736(02)09550-8
   2003, GUIDELINES USE ANTIR
NR 32
TC 17
Z9 17
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV 7
PY 2003
VL 17
IS 16
BP 2389
EP 2394
DI 10.1097/01.aids.0000076344.42412.05
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 809YO
UT WOS:000220672200015
PM 14571192
OA No
DA 2017-08-15
ER

PT J
AU Allen, A
   Obaro, S
   Bojang, K
   Awomoyi, AA
   Greenwood, BM
   Whittle, H
   Sirugo, G
   Newport, MJ
AF Allen, A
   Obaro, S
   Bojang, K
   Awomoyi, AA
   Greenwood, BM
   Whittle, H
   Sirugo, G
   Newport, MJ
TI Variation in toll-like receptor 4 and susceptibility to group a
   meningococcal meningitis in Gambian children
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE meningitis; genetic; susceptibility; sub-Saharan Africa; epidemic;
   Toll-like receptor 4
ID INFLAMMATORY RESPONSE; GENE
AB Meningitis is an important cause of childhood mortality in sub-Saharan Africa. A case-control study investigating the role of the Toll-like receptor 4 gene in host susceptibility to Group A Neisseria meningitidis meningitis was conducted in 524 Gambian children. There was no association between a functional Toll-like receptor 4 gene polymorphism and meningitis, suggesting that this variant is not a major determinant of disease in this population.
C1 Cambridge Inst Med Res, Wellcome Trust, Addenbrookes Hosp, Cambridge CB2 2XY, England.
   Med Res Labs, Banjul, Gambia.
   Brown Med Sch, Div Pediat Infect Dis, Providence, RI USA.
   London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1, England.
   Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England.
RP Newport, MJ (reprint author), Cambridge Inst Med Res, Wellcome Trust, Addenbrookes Hosp, MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.
CR ARBOUR NC, 2000, NAT GENET, V25, P1887
   HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147
   Ingalls RR, 2001, INFECT IMMUN, V69, P2230, DOI 10.1128/IAI.69.4.2230-2236.2001
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Read RC, 2001, J INFECT DIS, V184, P640, DOI 10.1086/322798
   SPRONG T, 2002, CYTOKINE NETW, V13, P411
   Vermont CL, 2002, CRIT CARE, V6, P60
   WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859
NR 10
TC 47
Z9 50
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2003
VL 22
IS 11
BP 1018
EP 1019
DI 10.1097/01.inf.0000095431.15606.68
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 744HM
UT WOS:000186622200016
PM 14628773
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Nyong'o, O
   Burton, KJ
   John, W
   Inkoom, E
   Pinder, M
   Corrah, T
   Johnson, GJ
   Bailey, RL
AF Burton, M. J.
   Nyong'o, O.
   Burton, K. J.
   John, W.
   Inkoom, E.
   Pinder, M.
   Corrah, T.
   Johnson, G. J.
   Bailey, R. L.
TI Retinopathy in Gambian children admitted to hospital with malaria
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 MRC Labs, Fajara, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Inst Ophthalmol, Int Ctr Eye Hlth, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 2003
VL 97
IS 6
BP 626
EP 626
DI 10.1016/S0035-9203(03)80064-0
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA V43WB
UT WOS:000202964100022
OA No
DA 2017-08-15
ER

PT J
AU Moorthy, VS
   Pinder, M
   Reece, WHH
   Watkins, K
   Atabani, S
   Hannan, C
   Bojang, K
   McAdam, KPWJ
   Schneider, J
   Gilbert, S
   Hill, AVS
AF Moorthy, VS
   Pinder, M
   Reece, WHH
   Watkins, K
   Atabani, S
   Hannan, C
   Bojang, K
   McAdam, KPWJ
   Schneider, J
   Gilbert, S
   Hill, AVS
TI Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria
   vaccination in African adults
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 50th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 11-15, 2001
CL ATLANTA, GEORGIA
SP Amer Soc Trop Med & Hygiene
ID ENHANCED IMMUNOGENICITY; PLASMODIUM-FALCIPARUM; PROTECTIVE EFFICACY;
   RESPONSES; IMMUNITY; ANTIGEN; PROTEIN; CD8(+)
AB The present study is an investigation of the safety and immunogenicity of DNA and modified vaccinia virus Ankara (MVA) candidate vaccines, each encoding the malaria DNA sequence multiple epitope-thrombospondin related adhesion protein (ME-TRAP), against Plasmodium falciparum. DNA ME-TRAP and MVA ME-TRAP are safe and immunogenic for effector and memory T cell induction. MVA ME-TRAP, with or without prior DNA ME-TRAP immunization, was more immunogenic and more cross-reactive in malaria-exposed individuals than in malaria-naive individuals, a finding suggesting that recombinant MVA vaccines are particularly promising for the development of a malaria vaccine for exposed populations. Both CD4(+) and CD8(+) T cells were induced by these vaccines.
C1 MRC Labs, Banjul, Gambia.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
RP Hill, AVS (reprint author), John Radcliffe Hosp, Nuffield Dept Clin Med, Level 7, Oxford OX3 9DU, England.
RI HILL, Adrian/C-1306-2008
OI Gilbert, Sarah/0000-0002-6823-9750
CR Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Doolan DL, 2000, J IMMUNOL, V165, P1453
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950
   Klenerman P, 1998, NATURE, V394, P482
   Mayr A, 1999, BERL MUNCH TIERARZTL, V112, P322
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   Miyahira Y, 1998, P NATL ACAD SCI USA, V95, P3954, DOI 10.1073/pnas.95.7.3954
   Moorthy VS, 2003, VACCINE, V21, P2004
   MORENO A, 1991, INT IMMUNOL, V3, P997, DOI 10.1093/intimm/3.10.997
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   TSUJI M, 1990, J EXP MED, V172, P1353, DOI 10.1084/jem.172.5.1353
   *WHO, 1996, 94 WHO
NR 17
TC 77
Z9 83
U1 1
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2003
VL 188
IS 8
BP 1239
EP 1244
DI 10.1086/378515
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 730VD
UT WOS:000185850100020
PM 14551895
OA No
DA 2017-08-15
ER

PT J
AU Lejon, V
   Rebeski, DE
   Ndao, M
   Baelmans, R
   Winger, EM
   Faye, D
   Geerts, S
   Buscher, P
AF Lejon, V
   Rebeski, DE
   Ndao, M
   Baelmans, R
   Winger, EM
   Faye, D
   Geerts, S
   Buscher, P
TI Performance of enzyme-linked immunosorbent assays for detection of
   antibodies against T-congolense and T-vivax in goats
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trypanosoma congolense; Trypanosoma brucei; Trypanosoma vivax; I-TAB
   ELISA; goat; antibody; serum
ID AFRICAN TRYPANOSOMIASIS; DIAGNOSIS; CATTLE; IDENTIFICATION;
   IMMUNOASSAYS; INFECTIONS; VALIDATION; ELISAS
AB Indirect ELISAs using denatured antigen preparations of Trypanosoma (T.) congolense (TcAGd) and T vivax (TvAGd) for detection of anti-trypanosome antibodies in bovine serum (I-TAB ELISAs), were adapted for serodiagnosis in goats. The diagnostic proficiency, the cross-reactivity with sera from heterologous trypanosome infections and the operational performance of the assays were evaluated on experimentally trypanosome-infected goats.
   The I-TAB ELISA (TcAGd) detected antibodies in all T congolense infected goats (100% overall sensitivity) from 2 to 4 weeks post-infection (p.i.) until the end of the experiments. Specificity tested on 92 uninfected goats was 96.7%. Extensive cross-reactions of I-TAB ELISA (TcAGd) with sera from T vivax or T brucei infected goats were observed. The I-TAB ELISA (TvAGd) detected antibodies in 5 of the 6 T vivax infected goats, specificity tested on uninfected goats was 100%. Cross-reactivity with sera from T congolense or T brucei infected goats remained limited. Infecting species identification based on the highest percent positivity (PP) in both systems, correctly identified all T congolense infections, but misidentified in 2/19 occasions a T vivax infection as a T congolense infection. In the absence of T brucei specific antigen coated plates, T brucei infections were identified in, respectively, 7/9 and 2/9 occasions as T congolense or T vivax infections. Acceptable inter-plate repeatability was observed. The implications of results and technical requirements for ongoing applied research are discussed. (C) 2003 Elsevier B.V. All rights reserved.
C1 Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium.
   Lohmann Anim Hlth GmbH & Co KG, D-27472 Cuxhaven, Germany.
   Int Atom Energy Agny, Food & Agr Org, Anim Prod Unit, Agr & Biotechnol Lab, A-1400 Vienna, Austria.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med, Vet Dept, B-2000 Antwerp, Belgium.
RP Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Nationalstr 155, B-2000 Antwerp, Belgium.
RI Buscher, Philippe/B-9956-2012
OI Buscher, Philippe/0000-0002-1926-7472; Lejon, Veerle/0000-0002-6795-0962
CR Desquesnes M, 2001, INT J PARASITOL, V31, P610
   Desquesnes M, 2001, ANN TROP MED PARASIT, V95, P141, DOI 10.1080/00034980120050251
   Eisler MC, 1998, VET PARASITOL, V79, P187, DOI 10.1016/S0304-4017(98)00173-3
   *IAEA, 2000, RES FAO IAEA COORD R
   Jacobson RH, 1998, REV SCI TECH OIE, V17, P469
   MORZARIA S, 1998, P WORKSH HELD ILRI N
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   NANTULYA VM, 1989, TROP MED PARASITOL, V40, P267
   NDAO M, 1998, THESIS I MED TROP PR, P1
   PARIS J, 1982, ACTA TROP, V39, P307
   Rebeski DE, 1999, PARASITOL RES, V85, P550, DOI 10.1007/s004360050594
   Rebeski DE, 2000, VET PARASITOL, V89, P187, DOI 10.1016/S0304-4017(00)00194-1
   Rebeski DE, 2001, VET PARASITOL, V96, P11, DOI 10.1016/S0304-4017(00)00422-2
   REBESKI DE, 2001, THESIS U UTRECHT NET, P5
   Wright P F, 1993, Rev Sci Tech, V12, P435
NR 15
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT 8
PY 2003
VL 116
IS 2
BP 87
EP 95
DI 10.1016/S0304-4017(03)00257-7
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 729LP
UT WOS:000185775300001
PM 14519314
OA No
DA 2017-08-15
ER

PT J
AU Ackerman, HC
   Ribas, G
   Jallow, M
   Mott, R
   Neville, M
   Sisay-Joof, F
   Pinder, M
   Campbell, RD
   Kwiatkowski, DP
AF Ackerman, HC
   Ribas, G
   Jallow, M
   Mott, R
   Neville, M
   Sisay-Joof, F
   Pinder, M
   Campbell, RD
   Kwiatkowski, DP
TI Complex haplotypic structure of the central MHC region flanking TNF in a
   West African population
SO GENES AND IMMUNITY
LA English
DT Article
DE haplotype; power; association; haplotype-tagging; linkage;
   disequilibrium; htSNP
ID TUMOR-NECROSIS-FACTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; ALPHA GENE
   PROMOTER; HUMAN GENOME; LINKAGE DISEQUILIBRIUM; LYMPHOTOXIN-BETA;
   CEREBRAL MALARIA; CELL-SURFACE; POLYMORPHISM; SUSCEPTIBILITY
AB TNF polymorphisms have been associated with susceptibility to malaria and other infectious and inflammatory conditions. We investigated a sample of 150 West African chromosomes to determine linkage disequilibrium (LD) between 25 SNP markers located in an 80 kb segment of the MHC Class III region encompassing TNF and eight neighbouring genes. We observed 45 haplotypes, and 22 of them comprise 80% of the sample. The pattern of LD is remarkably patchy, such that many markers show no LD with adjacent markers but high LD with markers that are much further away. We introduce a method of examining the implications of LD data for disease association studies based on sample size considerations: this shows that certain TNF polymorphisms would be likely to yield positive associations if the true disease allele resided in LTA or BAT1. We conclude that detailed marker maps are needed to resolve the causal origin of disease associations observed at the TNF locus.
C1 Wellcome Trust Ctr Human Genet, Oxford, England.
   Fdn Ctr Nacl Invest Oncol Carlos III, Dept Patol Mol, Lab Gennet Humana, Madrid, Spain.
   Radcliffe Infirm, Gen Practice Res Grp, Canc Res UK, Oxford OX2 6HE, England.
   Royal Victoria Hosp, Banjul, Gambia.
   MRC Labs, Fajara, Gambia.
   MRC UK HGMP Resource Ctr, Cambridge, England.
   Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
RP Ackerman, HC (reprint author), 64 Linnaean St, Cambridge, MA 02138 USA.
RI Ribas, Gloria/M-6190-2017
OI Ribas, Gloria/0000-0001-6883-4130; Kwiatkowski,
   Dominic/0000-0002-5023-0176
CR ACKERMAN H, 2002, GENOME BIOL, V4, pR24
   AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0
   ALBERTELLA MR, 1994, HUM MOL GENET, V3, P793, DOI 10.1093/hmg/3.5.793
   Autieri MV, 1998, J BIOL CHEM, V273, P14731, DOI 10.1074/jbc.273.24.14731
   Beck S, 1999, NATURE, V401, P921
   BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Dunstan SJ, 2001, J INFECT DIS, V183, P261, DOI 10.1086/317940
   Fernandez-Arquero M, 1999, NEUROLOGY, V53, P1361
   Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864
   Fleiss J. L., 1981, STAT METHODS RATES P, P38
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0
   HOLZINGER I, 1995, IMMUNOGENETICS, V42, P315
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649
   Knight JC, 1999, P ASSOC AM PHYSICIAN, V111, P290, DOI 10.1046/j.1525-1381.1999.99237.x
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551
   Nadel S, 1996, J INFECT DIS, V174, P878
   NAKAMURA T, 1995, GENOMICS, V30, P312, DOI 10.1006/geno.1995.9872
   NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611
   Negoro K, 1999, GASTROENTEROLOGY, V117, P1062, DOI 10.1016/S0016-5085(99)70390-2
   NEI M, 1974, GENETICS, V76, P379
   Nei M, 1987, MOL EVOLUTIONARY GEN, P176
   Neville MJ, 1997, DNA SEQUENCE, V8, P155, DOI 10.3109/10425179709034067
   Neville MJ, 1999, J IMMUNOL, V162, P4745
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   Nordborg M, 2002, TRENDS GENET, V18, P83, DOI 10.1016/S0168-9525(02)02557-X
   OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   PEELMAN LJ, 1995, GENOMICS, V26, P210, DOI 10.1016/0888-7543(95)80203-X
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Ribas G, 2001, IMMUNOGENETICS, V53, P369, DOI 10.1007/s002510100343
   Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789
   Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223
   Rollinger-Holzinger I, 2000, J IMMUNOL, V164, P3169
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Schneider S, 2000, ARLEQUIN VER 2 000 S
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Thompson EA, 1997, AM J HUM GENET, V60, P197
   Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   Zhang K, 2002, P NATL ACAD SCI USA, V99, P7335, DOI 10.1073/pnas.102186799
NR 47
TC 20
Z9 21
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD OCT
PY 2003
VL 4
IS 7
BP 476
EP 486
DI 10.1038/sj.gene.6364008
PG 11
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 732XH
UT WOS:000185970500003
PM 14551600
OA No
DA 2017-08-15
ER

PT J
AU Burgner, D
   Rockett, K
   Ackermann, H
   Hull, J
   Usen, S
   Pinder, M
   Kwiatkowski, DP
AF Burgner, D
   Rockett, K
   Ackermann, H
   Hull, J
   Usen, S
   Pinder, M
   Kwiatkowski, DP
TI Haplotypic relationship between SNP and microsatellite markers at the
   NOS2A locus in two populations
SO GENES AND IMMUNITY
LA English
DT Article
DE linkage disequilibrium; single nucleotide polymorphism; microsatellite;
   inducible nitric oxide synthase
ID NITRIC-OXIDE SYNTHASE; SINGLE-NUCLEOTIDE POLYMORPHISMS; MODERN HUMAN
   ORIGINS; COMMON DISEASE GENES; LINKAGE DISEQUILIBRIUM; CEREBRAL MALARIA;
   PROMOTER POLYMORPHISMS; FUNCTIONAL-ANALYSIS; MYOTONIC-DYSTROPHY;
   SEQUENCE VARIATION
AB The density of genetic markers required for successful association mapping of complex diseases depends on linkage disequilibrium (LD)between non-functional markers and functional variants. The haplotypic relationship between stable markers and potentially unstable but highly informative markers (e.g. microsatellites) indicates that LD might be maintained over considerable genetic distance in non-African populations, supporting the use of such 'mixed marker haplotypes' in LD-based mapping, and allowing inferences to be drawn about human origins. We investigated sequence variation in the proximal 2.6 kb of the inducible nitric oxide synthase (NOS2A) promoter and the relationship between SNP haplotypes and a pentanucleotide microsatellite (the 'NOS2A(-2.6) microsatellite') in Gambians and UK Caucasians. UK Caucasians exhibited a subset of sequence diversity observed in Gambians, sharing four of 11 SNPs and a similar haplotypic structure. Five SNPs were found in the sequence of interspersed repetitive DNA elements. In both populations, there was dramatic loss of LD between SNP haplotypes and microsatellite alleles across a very short physical distance, suggesting a high intrinsic mutation rate of the NOS2A(-2.6) microsatellite, the SNP haplotypes are relatively ancient, or that this was a region of frequent recombination. Understanding locus- and population-specific LD is essential when designing and interpreting genetic association studies.
C1 Univ Western Australia, Princess Margaret Med Ctr, Sch Paediat & Child Hlth, Perth, WA 6840, Australia.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   MRC Labs, Fajara, Gambia.
RP Burgner, D (reprint author), Univ Western Australia, Princess Margaret Med Ctr, Sch Paediat & Child Hlth, GPO Box D184, Perth, WA 6840, Australia.
OI Kwiatkowski, Dominic/0000-0002-5023-0176
CR ANGGARD E, 1994, LANCET, V343, P1199
   ARCOT SS, 1995, GENOMICS, V29, P136, DOI 10.1006/geno.1995.1224
   Armour JAL, 1996, NAT GENET, V13, P154, DOI 10.1038/ng0696-154
   Barcellos LF, 1997, AM J HUM GENET, V61, P734, DOI 10.1086/515512
   Boehnke M, 2000, NAT GENET, V25, P246, DOI 10.1038/76980
   BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0
   BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5
   Burgner D, 1999, ARCH DIS CHILD, V81, P185
   Burgner D, 2003, HUM GENET, V112, P379, DOI 10.1007/s00439-002-0882-4
   Burgner D, 1998, LANCET, V352, P1193, DOI 10.1016/S0140-6736(05)60531-4
   Cargill M, 1999, NAT GENET, V22, P231
   Chakraborty R, 1997, P NATL ACAD SCI USA, V94, P1041, DOI 10.1073/pnas.94.3.1041
   Chambers GK, 2000, COMP BIOCHEM PHYS B, V126, P455, DOI 10.1016/S0305-0491(00)00233-9
   Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   Davoodi-Semiromi A, 2002, DIABETES, V51, P2334, DOI 10.2337/diabetes.51.7.2334
   deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054
   Eaves IA, 2000, NAT GENET, V25, P320
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   FREIMER NB, 1996, CIBA F SYMP, V197, P51
   Halushka MK, 1999, NAT GENET, V22, P239
   Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961
   Hartl D. L., 1997, PRINCIPLES POPULATIO
   Hobbs MR, 2002, LANCET, V360, P1468, DOI 10.1016/S0140-6736(02)11474-7
   HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R
   JORDE LB, 1995, AM J HUM GENET, V56, P11
   Kayser M, 2000, AM J HUM GENET, V66, P1580, DOI 10.1086/302905
   Kidd KK, 1998, HUM GENET, V103, P211, DOI 10.1007/s004390050809
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   Konno S, 2001, J ALLERGY CLIN IMMUN, V108, P810, DOI 10.1067/mai.2001.119030
   Kruglyak L, 1999, P NATL ACAD SCI USA, V96, P1170, DOI 10.1073/pnas.96.4.1170
   Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21
   Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642
   Kun JFJ, 1998, LANCET, V351, P265, DOI 10.1016/S0140-6736(05)78273-8
   Merriman TR, 1998, HUM MOL GENET, V7, P517, DOI 10.1093/hmg/7.3.517
   Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3
   Mohlke KL, 2001, GENOME RES, V11, P1221, DOI 10.1101/gr.173201
   Muijsers RBM, 1997, LIFE SCI, V60, P1833, DOI 10.1016/S0024-3205(96)00651-0
   Nadir E, 1996, P NATL ACAD SCI USA, V93, P6470, DOI 10.1073/pnas.93.13.6470
   Nakajima T, 2002, AM J HUM GENET, V70, P108, DOI 10.1086/338454
   Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782
   Nei M, 1982, Prog Clin Biol Res, V103 Pt A, P167
   Nickerson DA, 2000, GENOME RES, V10, P1532, DOI 10.1101/gr.146900
   Oates JC, 2003, J RHEUMATOL, V30, P60
   Ohashi J, 2002, J INFECT DIS, V186, P578, DOI 10.1086/341779
   Ota M, 1999, AM J HUM GENET, V64, P1406, DOI 10.1086/302364
   Phillips MS, 2003, NAT GENET, V33, P382, DOI 10.1038/ng1100
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   ROGERS AR, 1995, HUM BIOL, V67, P1
   Rutherford S, 2001, HUM GENET, V109, P408, DOI 10.1007/s004390100565
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Sawcer S, 2002, BRAIN, V125, P1337, DOI 10.1093/brain/awf143
   Spitsin SV, 1996, MOL MED, V2, P226
   SWOFFORD D, 1997, PAUP STAR PHYLOGENTI
   Taillon-Miller P, 2000, NAT GENET, V25, P324
   Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148
   Terwilliger JD, 1998, CURR OPIN BIOTECH, V9, P578, DOI 10.1016/S0958-1669(98)80135-3
   Tishkoff SA, 2000, AM J HUM GENET, V67, P901, DOI 10.1086/303068
   Tishkoff SA, 1998, AM J HUM GENET, V62, P1389, DOI 10.1086/301861
   Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380
   WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0
   Warpeha KM, 1999, FASEB J, V13, P1825
   WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123
   Weiss KM, 2002, TRENDS GENET, V18, P19, DOI 10.1016/S0168-9525(01)02550-1
   Wilson JF, 2000, AM J HUM GENET, V67, P926, DOI 10.1086/303083
   Xu WM, 1997, GENE, V204, P165, DOI 10.1016/S0378-1119(97)00538-6
   Xu WM, 2000, NEUROREPORT, V11, P297, DOI 10.1097/00001756-200002070-00015
   Zabetian CP, 2003, AM J HUM GENET, V72, P1389, DOI 10.1086/375499
NR 71
TC 38
Z9 40
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD OCT
PY 2003
VL 4
IS 7
BP 506
EP 514
DI 10.1038/sj.gene.6364022
PG 9
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 732XH
UT WOS:000185970500007
PM 14551604
OA No
DA 2017-08-15
ER

PT J
AU Campbell, SJ
   Sabeti, P
   Fielding, K
   Sillah, J
   Bah, B
   Gustafson, P
   Manneh, K
   Lisse, I
   Sirugo, G
   Bellamy, R
   Bennett, S
   Aaby, P
   McAdam, KPWJ
   Bah-Sow, O
   Lienhardt, C
   Hill, AVS
AF Campbell, SJ
   Sabeti, P
   Fielding, K
   Sillah, J
   Bah, B
   Gustafson, P
   Manneh, K
   Lisse, I
   Sirugo, G
   Bellamy, R
   Bennett, S
   Aaby, P
   McAdam, KPWJ
   Bah-Sow, O
   Lienhardt, C
   Hill, AVS
TI Variants of the CD40 ligand gene are not associated with increased
   susceptibility to tuberculosis in West Africa
SO IMMUNOGENETICS
LA English
DT Article
DE tuberculosis; genetic susceptibility; polymorphism; CD40 ligand
ID RISK-FACTORS; CD154; EXPRESSION
AB Evidence for linkage between tuberculosis and human chromosomal region Xq26 has previously been described. The costimulatory molecule CD40 ligand, encoded by TNFSF5 and located at Xq26.3, is a promising positional candidate. Interactions between CD40 ligand and CD40 are involved in the development of humoral- and cell-mediated immunity, as well as the activation of macrophages, which are the primary host and effector cells for Mycobacterium tuberculosis. We hypothesised that common variation within TNFSF5 might affect susceptibility to tuberculosis disease and, thus, might be responsible for the observed linkage to Xq26. Sequencing 32 chromosomes from a Gambian population identified nine common polymorphisms within the coding, 3' and 5' regulatory sequences of the gene. Six single nucleotide polymorphisms (SNPs) and a 3' microsatellite were genotyped in 121 tuberculosis patients and their available parents. No association with tuberculosis was detected for these variants using a transmission disequilibrium test, although one SNP at -726 showed some evidence of association in males. This finding, however, did not replicate in a separate case control study of over 1,200 West African individuals. We conclude that common genetic variation in TNFSF5 is not likely to affect tuberculosis susceptibility in West Africa and the linkage observed in this region is not due to variation in TNFSF5.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Programme Natl Lutte Anti TB, Conakry, Guinea.
   Statens Serum Inst, Danish Epidemiol Serv Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau.
   Natl TB Leprosy Control Programme, Banjul, Gambia.
RP Hill, AVS (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Henry Wellcome Bldg Genom Med, Oxford OX3 7BN, England.
RI HILL, Adrian/C-1306-2008
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Barnhart B, 2000, IMMUNOLOGY, V99, P54, DOI 10.1046/j.1365-2567.2000.00943.x
   Barnhart B, 2000, J IMMUNOL, V165, P4478
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   Campos-Neto A, 1998, J Immunol, V160, P2037
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Hinds DR, 1999, ASPEX PACKAGE AFFECT
   Hopewell Philip C., 1994, P25
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   Larkin R, 2002, INFECT IMMUN, V70, P4716, DOI 10.1128/IAI.70.8.4716-4720.2002
   Li CM, 2002, J INFECT DIS, V186, P1458, DOI 10.1086/344351
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Sabeti P, 2002, GENES IMMUN, V3, P286, DOI 10.1038/sj.gene.636877
   Samten B, 2000, INFECT IMMUN, V68, P3002, DOI 10.1128/IAI.68.5.3002-3006.2000
   SHIMADZU M, 1995, BBA-GENE STRUCT EXPR, V1260, P67, DOI 10.1016/0167-4781(94)00179-7
   Siddiqa A, 2001, NATURE, V410, P383, DOI 10.1038/35066602
   SINGH SPN, 1983, J INFECT DIS, V148, P676
   Soler P, 1999, CLIN EXP IMMUNOL, V116, P332
   van Kooten C, 2000, FRONT BIOSCI, V5, pD880, DOI 10.2741/kooten
   Yamauchi PS, 2000, J IMMUNOL, V165, P1506
NR 25
TC 12
Z9 12
U1 0
U2 1
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0093-7711
J9 IMMUNOGENETICS
JI Immunogenetics
PD OCT
PY 2003
VL 55
IS 7
BP 502
EP 507
DI 10.1007/s00251-003-0602-9
PG 6
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 736YQ
UT WOS:000186201200009
PM 12955358
OA No
DA 2017-08-15
ER

PT J
AU Tanara, G
   Falugi, C
   Cesario, A
   Margaritora, S
   Russo, P
   Cosimi, A
AF Tanara, G
   Falugi, C
   Cesario, A
   Margaritora, S
   Russo, P
   Cosimi, A
TI TP53 codon 72 polymorphism does not affect risk of cervical cancer in
   patients from The Gambia
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
LA English
DT Article
ID TYPE-16 E6 VARIANTS; HUMAN-PAPILLOMAVIRUS; P53 POLYMORPHISM;
   HYBRIDIZATION
AB Aims: A case-control study was performed to investigate the relationship between cervical cancer and TP53 polymorphism at codon 72 in young black African women from The Gambia. Materials and methods: The TP53 polymorphism at codon 72 was examined by PCR amplification and SSCP analysis in 40 patients with primary cervical cancer and in 20 healthy women of the same age and from the same geographical area. The occurrence of TP53 polymorphism in combination with the HPV-16 E6 genotype (assayed by PCR) was evaluated. Results: The distribution of TP53 genotypes in cervical cancer patients and in the control group was not statistically different (p=0.45) and homozygosity for argine at residue 72 was not associated with cervical cancer (odds ratio: 1.24; 95% confidence interval 0.21-9.16). Similarly, a different genotype distribution, cervical cancer and presence of HPV-16 E6 were not observed. Conclusions: These results cannot rule out an association between TP53 polymorphism at codon 72, HPV infection and the etiology of cervical cancer in this population sample.
C1 Natl Inst Canc Res, Expt Oncol Lab, Mol Pathol Sect, I-16132 Genoa, Italy.
   Univ Genoa, Dept Biol, I-16126 Genoa, Italy.
   Catholic Univ Rome, Div Thorac Surg, Rome, Italy.
   Royal Victoria Hosp, Banjul, Gambia.
RP Russo, P (reprint author), Natl Inst Canc Res, Expt Oncol Lab, Mol Pathol Sect, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.
RI CESARIO, Alfredo/O-4215-2015
OI CESARIO, Alfredo/0000-0003-4687-0709
CR Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228
   Bertorelle R, 1999, INT J CANCER, V82, P616, DOI 10.1002/(SICI)1097-0215(19990812)82:4<616::AID-IJC24>3.0.CO;2-7
   Brady CS, 1999, J GEN VIROL, V80, P3233
   BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486
   Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093
   ELSA K, 2000, MODERN PATHOL, V13, P373
   Giannoudis A, 2001, J PATHOL, V193, P295
   Herrero R, 1999, CANCER SURV, V33, P75
   Meda N, 1997, GENITOURIN MED, V73, P188
   Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7
   Tenti P, 2000, CANCER EPIDEM BIOMAR, V9, P435
   Thomas M, 1999, MOL CELL BIOL, V19, P1092
   Tong D, 2000, CLIN CHEM, V46, P124
   van Duin M, 2000, J GEN VIROL, V81, P317
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wheeler CM, 1997, J CLIN MICROBIOL, V35, P11
   ZEBBE I, 2001, CANCER RES, V61, P608
NR 18
TC 6
Z9 6
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 0393-6155
J9 INT J BIOL MARKER
JI Int. J. Biol. Markers
PD OCT-DEC
PY 2003
VL 18
IS 4
BP 280
EP 283
PG 4
WC Biotechnology & Applied Microbiology; Oncology
SC Biotechnology & Applied Microbiology; Oncology
GA 762KV
UT WOS:000187971600005
PM 14756543
OA No
DA 2017-08-15
ER

PT J
AU Lagarde, E
   van der Loeff, MS
   Enel, C
   Holmgren, B
   Dray-Spira, R
   Pison, G
   Piau, JP
   Delaunay, V
   M'Boup, S
   Ndoye, I
   Coeuret-Pellicer, M
   Whittle, H
   Aaby, P
AF Lagarde, E
   van der Loeff, MS
   Enel, C
   Holmgren, B
   Dray-Spira, R
   Pison, G
   Piau, JP
   Delaunay, V
   M'Boup, S
   Ndoye, I
   Coeuret-Pellicer, M
   Whittle, H
   Aaby, P
TI Mobility and the spread of human immunodeficiency virus into rural areas
   of West Africa
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Africa; HIV infection; migration; Senegal; Guinea-Bissau; prevention
ID HIV-INFECTION; SEXUAL-BEHAVIOR; GUINEA-BISSAU; RISK-FACTORS; TANZANIA;
   SENEGAL; EPIDEMIOLOGY; PREVALENCE; DETERMINANTS; COMMUNITY
AB Background In eastern and southern Africa, the human immunodeficiency virus (HIV) epidemic appeared first in urban centres and then spread to rural areas. Its overall prevalence is lower in West Africa, with the highest levels still found in cities. Rural areas are also threatened, however, because of the population's high mobility. We conducted a study in three different communities with contrasting infection levels to understand the epidemiology of HIV infection in rural West Africa.
   Method A comparative cross-sectional study using a standardized questionnaire and biological tests was conducted among samples in two rural communities of Senegal (Niakhar and Bandafassi, 866 and 952 adults, respectively) and a rural community of Guinea-Bissau (Caio, 1416 adults). We compared the distribution of population characteristics and analysed risk factors for HIV infection in Caio at the individual level.
   Results The level of HIV infection was very low in Niakhar (0.3%) and Bandafassi (0.0%), but 10.5% of the adults in Caio were infected, mostly with HIV type 2 (HIV-2). Mobility was very prevalent in all sites. Short-term mobility was found to be a risk factor for HIV infection among men in Caio (adjusted odds ratio (aOR) = 2.06; 95% CI: 1.06-3.99). Women from Caio who reported casual sex in a city during the past 12 months were much more likely to be infected with HIV (aOR = 5.61 95% CI: 1.56-20.15). Short-term mobility was associated with risk behaviours at all sites.
   Conclusions Mobility appears to be a key factor for HIV spread in rural areas of West Africa, because population movement enables the virus to disseminate and also because of the particularly risky behaviours of those who are mobile. More prevention efforts should be directed at migrants from rural areas who travel to cities with substantial levels of HIV infection.
C1 Hop Natl St Maurice, IFR69, INSERM, U88, F-94410 St Maurice, France.
   MRC Labs, Fajara, Gambia.
   Inst Natl Etud Demog, F-75675 Paris, France.
   Inst Rech & Dev, Programme Rech SIDA, Montpellier, France.
   Univ Aix Marseille 1, Lab Populat Environm Dev UME IRD 151, Marseille, France.
   Hop Dantec, Lab Virol Bacteriol, Dakar, Senegal.
   Com Natl Lutte SIDA, Dakar, Senegal.
   Projecto Saude Bandim, Bissan, Guinea Bissau.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen, Denmark.
RP Lagarde, E (reprint author), Hop Natl St Maurice, IFR69, INSERM, U88, 14 Rue Val Osne, F-94410 St Maurice, France.
RI Lagarde, Emmanuel/F-7132-2013
OI Lagarde, Emmanuel/0000-0001-8031-7400
CR BARONGO LR, 1992, AIDS, V6, P1521, DOI 10.1097/00002030-199212000-00016
   Boerma JT, 1999, AIDS, V13, P1233, DOI 10.1097/00002030-199907090-00013
   Buckner M, 1999, VIVRE PENSER SIDA AF, P389
   Colvin M, 2000, SEX TRANSM INFECT, V76, P39, DOI 10.1136/sti.76.1.39
   DELAUNAY V, 1998, SITUATION DEMOGRAPHI
   Diop OM, 2000, AIDS, V14, P1671, DOI 10.1097/00002030-200007280-00031
   FERRY B, 1995, SOC AS AIDS, P10
   Gregson S, 1998, SOC SCI MED, V46, P321, DOI 10.1016/S0277-9536(97)00165-2
   KANE F, 1993, AIDS, V7, P1261, DOI 10.1097/00002030-199309000-00017
   KANKI P, 1992, AM J EPIDEMIOL, V136, P895
   Konde-Lule J K, 1997, Health Transit Rev, V7 Suppl, P89
   LAGARDE E, 1995, AM J EPIDEMIOL, V141, P1194
   Lagarde E, 1996, AIDS, V10, P327, DOI 10.1097/00002030-199603000-00012
   Lagarde E, 1997, REV EPIDEMIOL SANTE, V45, P271
   Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018
   Mnyika KS, 1997, INT J STD AIDS, V8, P176, DOI 10.1258/0956462971919840
   Morris M, 2000, AIDS, V14, P733, DOI 10.1097/00002030-200004140-00013
   NUNN AJ, 1995, AIDS, V9, P503
   PISON G, 1993, J ACQ IMMUN DEF SYND, V6, P196
   POULSEN AG, 1989, LANCET, V1, P827
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   Quigley M, 1997, AIDS, V11, P237, DOI 10.1097/00002030-199702000-00015
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY
   SODERBERG S, 1994, AIDS, V8, P971
   UNAIDS, 2000, REP GLOB HIV AIDS EP
   Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2001, AIDS EP UPD
   van der Loeff MFS, 1999, AIDS, V13, pS69
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 28
TC 77
Z9 79
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD OCT
PY 2003
VL 32
IS 5
BP 744
EP 752
DI 10.1093/ije/dyg111
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 735ZY
UT WOS:000186146300016
PM 14559743
OA No
DA 2017-08-15
ER

PT J
AU Rathman, G
   Sillah, J
   Hill, PC
   Murray, JF
   Adegbola, R
   Corrah, T
   Lienhardt, C
   McAdam, KPWJ
AF Rathman, G
   Sillah, J
   Hill, PC
   Murray, JF
   Adegbola, R
   Corrah, T
   Lienhardt, C
   McAdam, KPWJ
TI Clinical and radiological presentation of 340 adults with smear-positive
   tuberculosis in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculosis; chest X-ray; clinical findings; HIV/TB co-infection; The
   Gambia
ID IMMUNODEFICIENCY-VIRUS INFECTION; PULMONARY TUBERCULOSIS; RADIOGRAPHIC
   ABNORMALITIES; SPECTRUM; RISK; EXPERIENCE; SYMPTOMS; FEATURES; COUNTRY
AB SETTING: Four clinics in The Gambia.
   OBJECTIVE: To document clinical and radiographic presentations of sputum smear-positive tuberculosis in adults.
   DESIGN: Newly diagnosed acid-fast bacilli (AFB) smear, culture-positive tuberculosis patients aged greater than or equal to15 years were interviewed and examined, and underwent tuberculin skin testing, HIV testing and chest X-ray reviewed by a chest physician using set criteria.
   RESULTS: Of 340 patients enrolled (median age 29 years; males 73%), 8.3% were HIV-positive. One-third reported haemoptysis, >90% reported weight loss and fever, and wasting was the most common sign (69%). Crepitations were the most frequent auscultatory finding (41%). The most common radiological lesion was a patchy infiltrate (>90%). Cavitation was present in 206 patients (60.6%), most frequently occurred in the upper lung fields, was associated with increasing bacterial load in the sputum, and was less prevalent in HIV-positivc patients (45% vs. 62%; P = 0.07). Auscultatory and chest X-ray findings matched only one-third of the time.
   CONCLUSION: In our setting, wasting is the most common clinical sign of sputum smear-positive tuberculosis. Auscultatory findings correlate poorly with radiological abnormalities. Cavitation is associated with increasing bacterial load in the sputum, and is therefore a strong indicator for early treatment.
C1 MRC Labs, Dept TB, Banjul, Gambia.
   Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
   Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Rathman, G (reprint author), MRC Labs, Dept TB, POB 273, Banjul, Gambia.
FU Medical Research Council [MC_U190071468]
CR BARNES PF, 1991, NEW ENGL J MED, V324, P1644
   BRETT W, 1986, NEW ZEAL MED J, V99, P705
   BUCKNER CB, 1990, J THORAC IMAG, V5, P28, DOI 10.1097/00005382-199004000-00006
   Cohen R, 1996, CHEST, V109, P420, DOI 10.1378/chest.109.2.420
   GREENBAUM M, 1980, AM REV RESPIR DIS, V121, P477
   HADLOCK FP, 1980, AM J ROENTGENOL, V134, P1015
   Iseman M, 2000, CLIN GUIDE TUBERCULO, P129
   Jones BE, 1997, AM J RESP CRIT CARE, V156, P1270
   KHAN MA, 1977, AM J MED, V62, P31, DOI 10.1016/0002-9343(77)90346-1
   *KNCV, 2001, NAT LEPR TUB CONTR P
   KRYSL J, 1994, CAN ASSOC RADIOL J, V45, P101
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233
   MACGREGOR RR, 1975, AM J MED, V58, P221, DOI 10.1016/0002-9343(75)90573-2
   MILLER W T, 1978, AJR (American Journal of Roentgenology), V130, P867
   MLIKACABANNE N, 1995, AM J RESP CRIT CARE, V152, P794
   MLIKACABANNE N, 1995, AM J RESP CRIT CARE, V152, P786
   STEAD WW, 1968, ANN INTERN MED, V68, P731
   TEKLU B, 1993, TUBERCLE LUNG DIS, V74, P126, DOI 10.1016/0962-8479(93)90039-Z
   THEUER CP, 1990, J INFECT DIS, V162, P8
   TYTLE TL, 1984, SOUTHERN MED J, V77, P1223
   Wilcke JTR, 1998, RESP MED, V92, P493, DOI 10.1016/S0954-6111(98)90297-9
   WOODRING JH, 1986, AM J ROENTGENOL, V146, P497
NR 23
TC 24
Z9 25
U1 1
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD OCT
PY 2003
VL 7
IS 10
BP 942
EP 947
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 727LE
UT WOS:000185659100005
PM 14552563
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Holland, MJ
   Faal, N
   Aryee, EAN
   Alexander, NDE
   Bah, M
   Faal, H
   West, SK
   Foster, A
   Johnson, GJ
   Mabey, DCW
   Bailey, RL
AF Burton, MJ
   Holland, MJ
   Faal, N
   Aryee, EAN
   Alexander, NDE
   Bah, M
   Faal, H
   West, SK
   Foster, A
   Johnson, GJ
   Mabey, DCW
   Bailey, RL
TI Which members of a community need antibiotics to control trachoma?
   Conjunctival Chlamydia trachomatis infection load in Gambian villages
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; AZITHROMYCIN; DIAGNOSIS; BLINDNESS; TANZANIA;
   VECTOR; MODELS
AB PURPOSE. Trachoma is the leading cause of infectious blindness worldwide. Control strategies target antibiotic therapy to individuals likely to be infected with Chlamydia trachomatis on the basis of clinical signs. However, many studies have found chlamydial infection in the absence of clinical disease. It has been unclear whether such individuals represent a significant reservoir of infection. In the current study, a quantitative polymerase chain reaction (PCR) assay was used to investigate the distribution and determinants of chlamydial infection load in an endemic community, and the findings were used to evaluate the potential effectiveness of different control strategies.
   METHODS. Members of a trachoma-endemic community (n = 1319) in a rural area of The Gambia were examined for signs of disease, and tarsal conjunctival swab samples were collected. C trachomatis was initially detected by qualitative PCR. The load of infection was then estimated by real-time quantitative PCR.
   RESULTS. Chlamydial infection was detected in 7.2% of the population. The distribution of infection load was skewed, with a few individuals having high loads. Only 24% of infected individuals had signs of active trachoma. Infection loads were higher in those with clinically active disease and were highest among those with severe inflammatory trachoma. High infection loads were associated with having no accessible latrine and living with a person with active disease.
   CONCLUSIONS. In this low-prevalence setting, infected individuals without signs of active trachoma constitute a significant reservoir of infection. Treatment of a defined unit of people who live with someone with clinically active trachoma would effectively target antibiotic treatment to infected people without signs of disease.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   Inst Ophthalmol, Div Epidemiol & Inst Eye Hlth, London, England.
   Natl Eye Care Program, Banjul, Gambia.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [MC_U190081961]
CR Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L
   Bobo LD, 1997, J INFECT DIS, V176, P1524
   Burton M J, 2002, Expert Opin Pharmacother, V3, P113, DOI 10.1517/14656566.3.2.113
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   JONES BR, 1975, T OPHTHAL SOC UK, V95, P16
   KATZ J, 1988, INT J EPIDEMIOL, V17, P865, DOI 10.1093/ije/17.4.865
   MABEY D, 2003, COCHRANE LIB
   Moulton LH, 2002, STAT METHODS MED RES, V11, P317, DOI 10.1191/0962280202sm292ra
   PICKETT MA, 2000, P 4 M EUR SOC CHLAM, P45
   Ridout MS, 1999, BIOMETRICS, V55, P137, DOI 10.1111/j.0006-341X.1999.00137.x
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   [Anonymous], 1997, 1 M WHO ALL GLOB EL
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 25
TC 85
Z9 86
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2003
VL 44
IS 10
BP 4215
EP 4222
DI 10.1167/iovs.03-0107
PG 8
WC Ophthalmology
SC Ophthalmology
GA 727BT
UT WOS:000185636700009
PM 14507864
OA No
DA 2017-08-15
ER

PT J
AU Nicholson, SE
   Some, B
   McCollum, J
   Nelkin, E
   Klotter, D
   Berte, Y
   Diallo, BM
   Gaye, I
   Kpabeba, G
   Ndiaye, O
   Noukpozounkou, JN
   Tanu, MM
   Thiam, A
   Toure, AA
   Traore, AK
AF Nicholson, SE
   Some, B
   McCollum, J
   Nelkin, E
   Klotter, D
   Berte, Y
   Diallo, BM
   Gaye, I
   Kpabeba, G
   Ndiaye, O
   Noukpozounkou, JN
   Tanu, MM
   Thiam, A
   Toure, AA
   Traore, AK
TI Validation of TRMM and other rainfall estimates with a high-density
   gauge dataset for West Africa. Part I: Validation of GPCC rainfall
   product and pre-TRMM satellite and blended products
SO JOURNAL OF APPLIED METEOROLOGY
LA English
DT Article
ID PRECIPITATION CLIMATOLOGY PROJECT; GLOBAL PRECIPITATION; VARIABILITY
AB Gauge data over North Africa are used to provide an assessment of satellite and blended rainfall products for 1988-94 and for 1998. A comparison is also made with the Global Precipitation Climatology Center (GPCC) gauge dataset. For the 1988-94 period, mean fields and latitudinal transects for the June-July-August season are presented, based on a 515-station gauge dataset, the GPCC gauge data, the Global Precipitation Climatology Project (GPCP) blended data, the infrared-based Geostationary Operational Environmental Satellite precipitation index (GPI), and the Special Sensor Microwave Imager (SSM/I) microwave estimates. Error calculations are also presented. The mean fields derived from the dense gauge network, the GPCC gauge-only analysis, and the GPCP are remarkably similar. The bias, with reference to the seasonal rainfall field based on the denser network, is about 3%-4% for either GPCC or GPCP. Agreement is relatively good, even in individual years. The rms error associated with these datasets is 12% for seasonal rainfall totals; thus, the error is largely random. In contrast, there are large systematic errors in the satellite-only analyses of GPI and SSM/I, with biases of 20% and 40% for the mean rain field as a whole and much larger biases in individual years. The rms errors are nearly 2 times as great. For 1998, a 920-station gauge dataset was available for a smaller section of West Africa. The comparison confirmed the superior performance of GPCP and demonstrated the lower level of performance of both GPCP and GPCC at the monthly scale as compared with the seasonal scale. Overall, the results of this study underscore the continued need for extensive gauge networks to describe adequately the large-scale precipitation field over Africa.
C1 Florida State Univ, Dept Meteorol, Tallahassee, FL 32306 USA.
   Serv Meteorol Natl, Ouagadougou, Burkina Faso.
   Ctr Reg AGRHYMET, Niamey, Niger.
   NOAA, NESDIS, ORA, Camp Springs, MD USA.
   NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.
   SODEXAM, Direct Meteorol Natl, Abidjan, Cote Ivoire.
   Direct Natl Meteorol, Conakry, Guinea.
   Dept Water Resources, Banjul, Gambia.
   Direct Meteorol Natl, Lome, Togo.
   Direct Natl Meteorol, Dakar, Senegal.
   Direct Meteorol Natl, Cotonou, Benin.
   Meteorol Serv Dept, Legon, Ghana.
   Univ Arizona, Arizona Remote Sensing Ctr, Off Arid Lands Studies, Tucson, AZ USA.
   Direct Natl Meteorol, Bamako, Mali.
   Direct Meteorol Natl, Serv Climatol, Niamey, Niger.
RP Nicholson, SE (reprint author), Florida State Univ, Dept Meteorol, Tallahassee, FL 32306 USA.
CR ARKIN PA, 1994, B AM METEOROL SOC, V75, P401, DOI 10.1175/1520-0477(1994)075<0401:TGPCPF>2.0.CO;2
   BA MB, 1995, J APPL METEOROL, V34, P411, DOI 10.1175/1520-0450(1995)034<0411:SDIVOW>2.0.CO;2
   Cook KH, 1997, J CLIMATE, V10, P1137, DOI 10.1175/1520-0442(1997)010<1137:LSADAS>2.0.CO;2
   DUVEL JP, 1990, MON WEATHER REV, V118, P1855, DOI 10.1175/1520-0493(1990)118<1855:COTAAT>2.0.CO;2
   Ferraro RR, 1997, J GEOPHYS RES-ATMOS, V102, P16715, DOI 10.1029/97JD01210
   GRIFFITHS JF, 1972, CLIMATES AFRICA, V10
   GRIFFITHS JF, 1964, MEMOIRS, V3
   HOLLINGER J, 1991, DMSP SSM I CALIBRA 1
   HOLLINGER J, 1991, DMSP SSM I CALIBRA 2
   Huffman GJ, 1997, B AM METEOROL SOC, V78, P5, DOI 10.1175/1520-0477(1997)078<0005:TGPCPG>2.0.CO;2
   HUFFMAN GJ, 1995, J CLIMATE, V8, P1284, DOI 10.1175/1520-0442(1995)008<1284:GPEBOA>2.0.CO;2
   JANOWIAK JE, 1991, J GEOPHYS RES-OCEANS, V96, P3359
   Krajewski WF, 2000, J APPL METEOROL, V39, P1071, DOI 10.1175/1520-0450(2000)039<1071:IVOTGP>2.0.CO;2
   Kummerow C, 2000, J APPL METEOROL, V39, P1965, DOI 10.1175/1520-0450(2001)040<1965:TSOTTR>2.0.CO;2
   LAING AG, 1993, MON WEATHER REV, V121, P2254, DOI 10.1175/1520-0493(1993)121<2254:MCCIA>2.0.CO;2
   LEGATES DR, 1990, INT J CLIMATOL, V10, P111, DOI 10.1002/joc.3370100202
   Leroux M., 1983, CLIMAT AFRIQUE TROPI, V2
   McCollum JR, 2000, J APPL METEOROL, V39, P666, DOI 10.1175/1520-0450-39.5.666
   Mohr KI, 1996, MON WEATHER REV, V124, P2417, DOI 10.1175/1520-0493(1996)124<2417:MCSDBT>2.0.CO;2
   MORRISSEY ML, 1993, J APPL METEOROL, V32, P411, DOI 10.1175/1520-0450(1993)032<0411:COTSBR>2.0.CO;2
   MORRISSEY ML, 1995, WATER RESOUR RES, V31, P2111, DOI 10.1029/95WR01233
   NICHOLSON SE, 1986, J CLIM APPL METEOROL, V25, P1365, DOI 10.1175/1520-0450(1986)025<1365:TSCOAR>2.0.CO;2
   Nicholson SE, 1996, J CLIMATE, V9, P1673, DOI 10.1175/1520-0442(1996)009<1673:RITSD>2.0.CO;2
   NICHOLSON SE, 1979, MON WEATHER REV, V107, P620, DOI 10.1175/1520-0493(1979)107<0620:RRSFTW>2.0.CO;2
   Nicholson SE, 2000, J CLIMATE, V13, P2628, DOI 10.1175/1520-0442(2000)013<2628:AAORRC>2.0.CO;2
   Nicholson SE, 2003, J APPL METEOROL, V42, P1355, DOI 10.1175/1520-0450(2003)042<1355:VOTAOR>2.0.CO;2
   Nicholson S.E., 1988, ATLAS AFRICAN RAINFA
   NICHOLSON SE, 2000, P INT WORKSH W AFR M, P7
   Rudolf B, 1994, GLOBAL PRECIPITATION, P173
   Rudolf B., 1993, P INT WMO IAHS ETH S, P69
   Sevruk B., 1982, 21 WMO
   TREWARTHA GT, 1970, EARTHS PROBLEM CLIMA
   XIE PP, 1995, J APPL METEOROL, V34, P1143, DOI 10.1175/1520-0450(1995)034<1143:AIOGOA>2.0.CO;2
   Xie PP, 1996, J CLIMATE, V9, P840, DOI 10.1175/1520-0442(1996)009<0840:AOGMPU>2.0.CO;2
NR 34
TC 87
Z9 89
U1 0
U2 14
PU AMER METEOROLOGICAL SOC
PI BOSTON
PA 45 BEACON ST, BOSTON, MA 02108-3693 USA
SN 0894-8763
J9 J APPL METEOROL
JI J. Appl. Meteorol.
PD OCT
PY 2003
VL 42
IS 10
BP 1337
EP 1354
DI 10.1175/1520-0450(2003)042<1337:VOTAOR>2.0.CO;2
PG 18
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 727NP
UT WOS:000185665200001
OA No
DA 2017-08-15
ER

PT J
AU Nicholson, SE
   Some, B
   McCollum, J
   Nelkin, E
   Klotter, D
   Berte, Y
   Diallo, BM
   Gaye, I
   Kpabeba, G
   Ndiaye, O
   Noukpozounkou, JN
   Tanu, MM
   Thiam, A
   Toure, AA
   Traore, AK
AF Nicholson, SE
   Some, B
   McCollum, J
   Nelkin, E
   Klotter, D
   Berte, Y
   Diallo, BM
   Gaye, I
   Kpabeba, G
   Ndiaye, O
   Noukpozounkou, JN
   Tanu, MM
   Thiam, A
   Toure, AA
   Traore, AK
TI Validation of TRMM and other rainfall estimates with a high-density
   gauge dataset for West Africa. Part II: Validation of TRMM rainfall
   products
SO JOURNAL OF APPLIED METEOROLOGY
LA English
DT Article
ID GLOBAL PRECIPITATION; SATELLITE; INFORMATION; MICROWAVE; ORBIT
AB Gauge data from a West African network of 920 stations are used to assess Tropical Rainfall Measuring Mission (TRMM) satellite and blended rainfall products for 1998. In this study, mean fields, scattergrams, and latitudinal transects for the months of May-September and for the 5-month season are presented. Error statistics are also calculated. This study demonstrates that both the TRMM-adjusted Geostationary Observational Environmental Satellite precipitation index (AGPI) and TRMM-merged rainfall products show excellent agreement with gauge data over West Africa on monthly-to-seasonal timescales and 2.5degrees x 2.5degrees latitude/longitude space scales. The root-mean-square error of both is on the order of 0.6 mm day(-1) at seasonal resolution and 1 mm day(-1) at monthly resolution. The bias of the AGPI is only 0.2 mm day(-1), whereas the TRMM-merged product shows no bias over West Africa. Performance at 1.0degrees x 1.0degrees latitude/longitude resolution is also excellent at the seasonal scale and good for the monthly scale. A comparison with standard rainfall products that predate TRMM shows that AGPI and the TRMM-merged product perform as well as, or better than, those products. The AGPI shows marked improvement when compared with the GPI, in reducing the bias and in the scatter of the estimates. The TRMM satellite-only products from the precipitation radar and the TRMM Microwave Imager do not perform well over West Africa. Both tend to overestimate gauge measurements.
C1 Florida State Univ, Dept Meteorol, Tallahassee, FL 32306 USA.
   Serv Meteorol Natl, Ouagadougou, Burkina Faso.
   Ctr Reg AGRHYMET, Niamey, Niger.
   NOAA, NESDIS, ORA, Camp Springs, MD USA.
   NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.
   Direct Meteorol Natl, SODEXAM, Abidjan, Cote Ivoire.
   Direct Natl Meteorol, Conakry, Guinea.
   Dept Water Resources, Banjul, Gambia.
   Direct Meteorol Natl, Lome, Togo.
   Direct Natl Meteorol, Dakar, Senegal.
   Direct Meteorol Natl, Cotonou, Benin.
   Meteorol Serv Dept, Legon, Ghana.
   Univ Arizona, Arizona Remote Sensing Ctr, Off Arid Lands Studies, Tucson, AZ USA.
   Direct Natl Meteorol, Bamako, Mali.
   Direct Meteorol Natl, Serv Climatol, Niamey, Niger.
RP Nicholson, SE (reprint author), Florida State Univ, Dept Meteorol, Tallahassee, FL 32306 USA.
CR ADLER RF, 1993, J APPL METEOROL, V32, P335, DOI 10.1175/1520-0450(1993)032<0335:EOMROJ>2.0.CO;2
   Adler RF, 2000, J APPL METEOROL, V39, P2007, DOI 10.1175/1520-0450(2001)040<2007:TRDDUT>2.0.CO;2
   Adler R. F., 1994, REMOTE SENS REV, V11, P125, DOI 10.1080/02757259409532262
   ARKIN PA, 1987, MON WEATHER REV, V115, P51, DOI 10.1175/1520-0493(1987)115<0051:TRBLSC>2.0.CO;2
   Ferraro RR, 1997, J GEOPHYS RES-ATMOS, V102, P16715, DOI 10.1029/97JD01210
   Huffman GJ, 1997, B AM METEOROL SOC, V78, P5, DOI 10.1175/1520-0477(1997)078<0005:TGPCPG>2.0.CO;2
   HUFFMAN GJ, 1995, J CLIMATE, V8, P1284, DOI 10.1175/1520-0442(1995)008<1284:GPEBOA>2.0.CO;2
   Kummerow C, 2000, J APPL METEOROL, V39, P1965, DOI 10.1175/1520-0450(2001)040<1965:TSOTTR>2.0.CO;2
   LEGATES DR, 1990, INT J CLIMATOL, V10, P111, DOI 10.1002/joc.3370100202
   MORRISSEY ML, 1993, J APPL METEOROL, V32, P411, DOI 10.1175/1520-0450(1993)032<0411:COTSBR>2.0.CO;2
   MORRISSEY ML, 1995, WATER RESOUR RES, V31, P2111, DOI 10.1029/95WR01233
   *NCAR, 1993, NCAR GRAPH FUND UNIX
   Nicholson SE, 2003, J APPL METEOROL, V42, P1337, DOI 10.1175/1520-0450(2003)042<1337:VOTAOR>2.0.CO;2
   Rosenfeld D, 1999, GEOPHYS RES LETT, V26, P3105, DOI 10.1029/1999GL006066
   Rudolf B, 1994, GLOBAL PRECIPITATION, P173
   Rudolf B., 1993, P INT WMO IAHS ETH S, P69
   Sevruk B., 1982, 21 WMO
   XIE PP, 1995, J APPL METEOROL, V34, P1143, DOI 10.1175/1520-0450(1995)034<1143:AIOGOA>2.0.CO;2
NR 18
TC 141
Z9 145
U1 1
U2 21
PU AMER METEOROLOGICAL SOC
PI BOSTON
PA 45 BEACON ST, BOSTON, MA 02108-3693 USA
SN 0894-8763
J9 J APPL METEOROL
JI J. Appl. Meteorol.
PD OCT
PY 2003
VL 42
IS 10
BP 1355
EP 1368
DI 10.1175/1520-0450(2003)042<1355:VOTAOR>2.0.CO;2
PG 14
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 727NP
UT WOS:000185665200002
OA No
DA 2017-08-15
ER

PT J
AU Newport, MJ
   Awomoyi, AA
   Blackwell, JM
AF Newport, MJ
   Awomoyi, AA
   Blackwell, JM
TI Polymorphism in the interferon-gamma receptor-1 gene and susceptibility
   to pulmonary tuberculosis in the Gambia
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Editorial Material
ID CALMETTE-GUERIN INFECTION; DEFICIENCY
C1 Addenbrookes Hosp, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2XY, England.
   MRC Labs, Banjul, Gambia.
   Univ Maryland, Dept Microbiol, Baltimore, MD 21201 USA.
RP Newport, MJ (reprint author), Addenbrookes Hosp, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2XY, England.
RI Blackwell, Jenefer/H-3015-2015
CR Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   Fraser DA, 2003, SCAND J IMMUNOL, V57, P480, DOI 10.1046/j.1365-3083.2003.01253.x
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   NEWPORT MJ, 2003, IN PRESS PRIMARY IMM
   Ottenhoff THM, 1998, IMMUNOL TODAY, V19, P491, DOI 10.1016/S0167-5699(98)01321-8
   Shifman S, 2003, HUM MOL GENET, V12, P771, DOI 10.1093/hmg/ddg088
NR 9
TC 25
Z9 25
U1 0
U2 1
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD OCT
PY 2003
VL 58
IS 4
BP 383
EP 385
DI 10.1046/j.1365-3083.2003.01328.x
PG 3
WC Immunology
SC Immunology
GA 722HM
UT WOS:000185369400001
PM 14507301
OA No
DA 2017-08-15
ER

PT J
AU Faye, D
   Leak, S
   Nouala, S
   Fall, A
   Losson, B
   Geerts, S
AF Faye, D
   Leak, S
   Nouala, S
   Fall, A
   Losson, B
   Geerts, S
TI Effects of gastrointestinal helminth infections and plane of nutrition
   on the health and productivity of F1 (West African Dwarf x Sahelian)
   goat crosses in The Gambia
SO SMALL RUMINANT RESEARCH
LA English
DT Article
DE goats; Sahelian; West African Dwarf; F1 crosses; nutrition; helminths;
   productivity
ID HAEMONCHUS-CONTORTUS; NEMATODES
AB A two by two factorial design including natural helminth infections (dewormed 'D' or not dewormed 'ND') and different levels of diet (basal 'B' or basal diet plus supplement 'S') was used to assess the effect of helminth infections and plane of nutrition on health and productivity of F1 (West African Dwarf (WAD) x Sahelian) crosses. The pasture composed the basal diet and supplemented animals received cottonseed and rice bran. Feed composition analysis revealed that the pasture did not provide sufficient nutrients for reproduction requirements. Feed supplementation had a significant effect on weight gain of does during pregnancy and lactation, and milk off-take was significantly higher in supplemented does compared to non-supplemented ones (31.3 +/- 2.5 1 versus 17.7 +/- 2.5 1 respectively, P < 0.01). A peri-parturient rise in strongyle egg output was noted, and diet supplementation tended to reduce faecal egg count and to increase packed cell volume (PCV), mainly during the dry season.
   Deworming had a significant effect on red blood cell (RBC) count, PCV and haemoglobin (Hb) concentration, mainly during the period of peak strongyle egg output (season x deworming: P < 0.001 for RBC and PCV and P < 0.05 for Hb). Helminth infections combined with a basal diet seriously affected weight gain but the interaction of deworming and diet was not significant. In groups receiving the basal diet, dewormed animals had a significantly higher milk yield than those that were not dewormed (23.5 +/- 3.31 versus 12.0 +/- 3.71, respectively; interaction diet x deworming: P < 0.05). The higher daily weight gains of offspring born from dewormed does might be explained by the fact that, in addition to the effect of deworming on milk yield in animals receiving basal diet, the kids were less exposed to helminth eggs, whereas does that were not dewormed constituted a greater source of helminth infection for their kids. (C) 2003 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Liege, Fac Vet Med, B-4000 Sart Tilman Par Liege, Belgium.
   Inst Trop Med, B-2000 Antwerp, Belgium.
RP Faye, D (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR BLACKBURN HD, 1991, VET PARASITOL, V40, P99, DOI 10.1016/0304-4017(91)90086-B
   CHARTIER C, 1994, VET RES, V25, P450
   Chiejina SN, 2002, VET PARASITOL, V104, P229, DOI 10.1016/S0304-4017(01)00636-7
   CISSE M, 1994, P 3 BIENN C AFR SMAL, P303
   COBON DH, 1992, J AGR SCI, V118, P245
   Coop RL, 1999, VET PARASITOL, V84, P187, DOI 10.1016/S0304-4017(99)00070-9
   Faye D, 2002, VET PARASITOL, V108, P117, DOI 10.1016/S0304-4017(02)00184-X
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   *INT COMM AN REC, 2001, ICAR RULES STAND GUI
   Ishler V, 1996, 422 PENNS STAT U
   KAUFMANN J, 1996, DIAGNOSTIC MANUAL
   MAFF (Ministry of Agriculture Fisheries and Food), 1984, EN ALL FEED SYST RUM
   MCDONALD P, 1978, ANIMAL NUTR, P543
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   NDTVEDT A, 2002, VET PARASITOL, V105, P191
   Osaer S, 2000, ACTA TROP, V74, P13, DOI 10.1016/S0001-706X(99)00042-X
   RIVEROS E, 1986, IN VITRO NEWS LETT, V3, P11
   Riviere R., 1977, MANUEL ALIMENTATION
   *STAT AN SYST I, 2000, VERS 8 01
   THIENPONT D, 1995, DIAGNOSTIC VERMINOSE
   Vlassoff A, 1999, VET PARASITOL, V84, P113, DOI 10.1016/S0304-4017(99)00072-2
NR 21
TC 11
Z9 12
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-4488
J9 SMALL RUMINANT RES
JI Small Ruminant Res.
PD OCT
PY 2003
VL 50
IS 1-2
BP 153
EP 161
DI 10.1016/S0921-4488(03)00108-1
PG 9
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 719RF
UT WOS:000185217600017
OA No
DA 2017-08-15
ER

PT J
AU Clarke, SE
   Rowley, J
   Bogh, C
   Walraven, GEL
   Lindsay, SW
AF Clarke, SE
   Rowley, J
   Bogh, C
   Walraven, GEL
   Lindsay, SW
TI Home treatment of 'malaria' in children in rural Gambia is uncommon
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE antimalarials; economic cost; health services; home treatment; malaria;
   The Gambia; treatment patterns
ID WEST-AFRICA; HEALTH-CARE; PLASMODIUM-FALCIPARUM; ANTIMALARIAL-DRUGS;
   CHILDHOOD MALARIA; PREVENTION; DISTRICT; TRIAL; GHANA; MORTALITY
AB Home treatment with antimalarials is a common practice in many countries, and may save lives by ensuring that more malaria cases receive prompt treatment. Through retrospective surveys we found that home treatment of young children with antimalarials was uncommon in rural Gambia. Few families kept medicines in the home in case of illness, 28% kept paracetamol and only 8% kept chloroquine. Less than 10% of cases of childhood 'malaria' had been treated with chloroquine at home, and 69% of those giving home medication did not know the correct dosage for a child. The most common course of treatment was the use of paracetamol and/or tepid sponging to reduce fever, before the child was taken to a government health facility. Treating a child with antimalarials at home was more costly than other forms of treatment. The low cost associated with the use of health services for children and the limited availability of antimalarials outside major towns contribute to the high use of government health services. This shows that that home treatment cannot be assumed to be the predominant mode of malaria treatment throughout Africa, and highlights the need for country-specific policies based on accurate local knowledge of treatment practices in both rural and urban areas.
C1 London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1B 3DP, England.
   Minist Hlth, Intensified Communicable Dis Control Project, Jakarta 10560, Indonesia.
   MRC Labs, Fajara Farafenni, Gambia.
   Univ Durham, Sch Biol & Biomed Sci, Sci Labs, Durham, England.
RP Clarke, SE (reprint author), London Sch Hyg & Trop Med, Gates Malaria Partnership, 50 Bedford Sq, London WC1B 3DP, England.
CR Adome R. O., 1996, POPULAR PILLS COMMUN
   AGYEPONG IA, 1994, ACTA TROP, V58, P317, DOI 10.1016/0001-706X(94)90025-6
   Ahorlu CK, 1997, TROP MED INT HEALTH, V2, P488, DOI 10.1046/j.1365-3156.1997.d01-298.x
   AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   Baume C, 2000, SOC SCI MED, V51, P1491, DOI 10.1016/S0277-9536(00)00049-6
   BREMAN JG, 1988, B WORLD HEALTH ORGAN, V66, P611
   BRINKMANN U, 1991, TROP MED PARASITOL, V42, P204
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   DEMING MS, 1989, B WORLD HEALTH ORGAN, V67, P695
   *DOS, 1976, GAMB
   FASSIN D, 1988, TROP GEOGR MED, V40, P166
   FOSTER SDF, 1991, MALARIA : WAITING FOR THE VACCINE, P123
   GLIK DC, 1989, J HEALTH SOC BEHAV, V30, P421, DOI 10.2307/2136990
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0
   KROEGER A, 1983, SOC SCI MED, V17, P147, DOI 10.1016/0277-9536(83)90248-4
   MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
   McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7
   MENON A, 1988, J TROP MED HYG, V91, P49
   Molyneux CS, 2002, J BIOSOC SCI, V34, P109
   Muller O, 1997, SOC SCI MED, V44, P1903, DOI 10.1016/S0277-9536(96)00299-7
   Nshakira N, 2002, TROP MED INT HEALTH, V7, P309, DOI 10.1046/j.1365-3156.2002.00858.x
   Nyamongo IK, 2002, SOC SCI MED, V54, P377, DOI 10.1016/S0277-9536(01)00036-3
   NYAMONGO IK, 1998, THESIS U FLORIDA
   Snow RW, 1999, HEALTH POLICY PLANN, V14, P18, DOI 10.1093/heapol/14.1.18
   SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S
   VANDERGEEST S, 1987, SOC SCI MED, V25, P293, DOI 10.1016/0277-9536(87)90232-2
   von Seidlein L, 2002, B WORLD HEALTH ORGAN, V80, P790
   WADDINGTON CJ, 1989, INT J HEALTH PLAN MA, V4, P17, DOI 10.1002/hpm.4740040104
NR 30
TC 9
Z9 10
U1 0
U2 2
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2003
VL 8
IS 10
BP 884
EP 894
DI 10.1046/j.1365-3156.2003.01095.x
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 727BD
UT WOS:000185635400006
PM 14516299
OA No
DA 2017-08-15
ER

PT J
AU Ronsmans, C
   Etard, JF
   Walraven, G
   Hoj, L
   Dumont, A
   de Bernis, L
   Kodio, B
AF Ronsmans, C
   Etard, JF
   Walraven, G
   Hoj, L
   Dumont, A
   de Bernis, L
   Kodio, B
TI Maternal mortality and access to obstetric services in West Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE maternal mortality; process indicators; evaluation; developing countries
ID FERTILITY; SENEGAL; IMPACT; CARE
AB Objectives Process evaluation has become the mainstay of safe motherhood evaluation in developing countries, yet the extent to which indicators measuring access to obstetric services at the population level reflect levels of maternal mortality is uncertain. In this study we examine the association between population indicators of access to obstetric care and levels of maternal mortality in urban and rural West Africa.
   Methods In this ecological study we used data on maternal mortality and access to obstetric services from two population-based studies conducted in 16 sites in eight West African countries: the Maternal Mortality and Obstetric Care in West Africa (MAMOCWA) study in rural Senegal, Guinea-Bissau and The Gambia and the Morbidite Maternelle en Afrique de l'Ouest (MOMA) study in urban Burkina Faso, Cote d'Ivoire, Mali, Mauritanie, Niger and Senegal.
   Results In rural areas, maternal mortality, excluding early pregnancy deaths, was 601 per 100 000 live births, compared with 241 per 100 000 for urban areas [RR = 2.49 (CI 1.77-3.59)]. In urban areas, the vast majority of births took place in a health facility (83%) or with a skilled provider (69%), while 80% of the rural women gave birth at home without any skilled care. There was a relatively close link between levels of maternal mortality and the percentage of births with a skilled attendant (r = -0.65), in hospital (r = -0.54) or with a Caesarean section (r = -0.59), with marked clustering in urban and rural areas. Within urban or rural areas, none of the process indicators were associated with maternal mortality.
   Conclusion Despite the limitations of this ecological study, there can be little doubt that the huge rural-urban differences in maternal mortality are due, at least in part, to differential access to high quality maternity care. Whether any of the indicators examined here will by themselves be good enough as a proxy for maternal mortality is doubtful however, as more than half of the variation in mortality remained unexplained by any one of them.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, Maternal Hlth Programme, London WC1E 7HT, England.
   Inst Rech Dev, Dakar, Senegal.
   MRC Labs, Fajara, Gambia.
   Projecto Saude Bandim, Bissau, Guinea Bissau.
   WHO, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland.
RP Ronsmans, C (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, Maternal Hlth Programme, Keppel St, London WC1E 7HT, England.
RI Etard, Jean-Francois/A-9630-2008; Sandall, Jane/D-4146-2009; Dumont,
   Alexandre/I-9429-2016
OI Etard, Jean-Francois/0000-0002-4873-0788; Sandall,
   Jane/0000-0003-2000-743X; Dumont, Alexandre/0000-0003-3826-0193
CR AbouZahr C, 2001, B WORLD HEALTH ORGAN, V79, P561
   Bouillin D., 1994, Cahiers d'Etudes et de Recherches Francophones/Sante, V4, P399
   Bouvier-Colle MH, 2001, ACTA OBSTET GYN SCAN, V80, P113
   Bouvier-Colle MH, 1998, MORBIDITE MATERNELLE
   CISSE CT, 1998, CAHIERS SANTE, V8, P369
   de Bernis L, 2000, BRIT J OBSTET GYNAEC, V107, P68
   De Brouwere V, 1998, BESOINS OBSTET NON C
   DELAUNAY V, 2002, INDEPTH NETWORK POPU, V1, P279
   du Lou AD, 1999, POPULATION, V54, P427, DOI 10.2307/1534985
   Dumont A, 2001, LANCET, V358, P1328, DOI 10.1016/S0140-6736(01)06414-5
   Enel C, 1993, CAHIERS SANTE, V3, P441
   FAYE EO, 1996, ARCH PUBL HLTH, V53, P50
   Filippi V, 2000, STUD FAMILY PLANN, V31, P309, DOI 10.1111/j.1728-4465.2000.00309.x
   FORTNEY JA, 1987, STUD FAMILY PLANN, V18, P109, DOI 10.2307/1966702
   Graham WJ, 1996, HEALTH POLICY PLANN, V11, P16, DOI 10.1093/heapol/11.1.16
   Graham WJ, 2002, LANCET, V359, P701, DOI 10.1016/S0140-6736(02)07817-0
   Graham WJ, 2001, STUDIES HLTH SERVICE, V17, P97
   Hill K, 2001, B WORLD HEALTH ORGAN, V79, P182
   Hoj L, 1999, INT J EPIDEMIOL, V28, P70, DOI 10.1093/ije/28.1.70
   HOJ L, 2002, THESIS U AARHUS
   Kodio B, 2002, TROP MED INT HEALTH, V7, P499, DOI 10.1046/j.1365-3156.2002.00892.x
   Loudon I., 1992, DEATH CHILDBIRTH INT
   Maine D, 1997, DESIGN EVALUATION MA
   *MIN SANT SERDHA M, 1999, ENQ SEN IND SANT 199
   PISON G, 2002, INDEPTH NETWORK POPU, V1, P271
   The Prevention of Maternal Mortality Network, 1995, SOC SCI MED, V40, P657
   Ronsmans C, 2002, B WORLD HEALTH ORGAN, V80, P317
   RONSMANS C, 2000, NUTR HLTH DEV COUNTR, P31
   Telfer Michelle L, 2002, Afr J Reprod Health, V6, P74, DOI 10.2307/3583148
   TRUSSELL J, 1984, STUD FAMILY PLANN, V15, P267, DOI 10.2307/1966071
   *UNICEF WHO UNFPA, 1997, GUID MON AV US OBSTE
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   West KP, 1999, BRIT MED J, V318, P570
   WHO (World Health Organization), 1998, WHORHTMSM9716
   World Health Organization, 1997, WHORHTHRP9726
   World Health Organization, 1995, WHOFHEMSM9515
NR 36
TC 77
Z9 79
U1 0
U2 2
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2003
VL 8
IS 10
BP 940
EP 948
DI 10.1046/j.1365-3156.2003.01111.x
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 727BD
UT WOS:000185635400013
PM 14516306
OA No
DA 2017-08-15
ER

PT J
AU Collinson, AC
   Moore, SE
   Cole, TJ
   Prentice, AM
AF Collinson, AC
   Moore, SE
   Cole, TJ
   Prentice, AM
TI Birth season and environmental influences on patterns of thymic growth
   in rural Gambian infants
SO ACTA PAEDIATRICA
LA English
DT Article
DE Gambia; infancy; programming; seasonality; thymus
ID GUINEA-BISSAU; FETAL GROWTH; SIZE; INVOLUTION; INFECTION; PREVALENCE;
   MORTALITY; CHILDREN; LIFE; MILK
AB Aim: In rural Gambia, birth season predicts infection-related adult mortality. Seasonal factors in early life may programme the immune system, possibly via an effect on thymic development. This study tested whether thymus size in rural Gambian infants is affected by birth season, defined as January-June (harvest, few infections) versus July-December (hungry, high infectious load). Methods: Thymic volume (thymic index) was assessed sonographically at 1, 8, 24 and 52 wk in 138 singleton infants born over 14 consecutive months. Growth and morbidity were regularly assessed. Results: Mean thymic index increased from 19.9 at 1 wk to 30.9 at 8 wk and 35.7 at 24 wk, then fell to 32.0 at 52 wk. Thymic index was associated with each preceding thymic index up to 24 wk. This tracking persisted after correcting for infant weight and month of measurement ( p < 0.01). Thymic index at 1 wk was marginally but non-significantly lower in hungry season births ( p = 0.06). Thymic index was lower in hungry season measurements; this effect persisted after adjusting for current weight and infection markers, and was strongest at 8 wk ( p = 0.001).
   Conclusion: These results describe a pattern of thymic growth followed by diminution in size. An infant's thymic index tracks despite changes in body weight and season. Thymic index was lower in the hungry season. This appears not to be explained by infection or nutritional status. A possible influence of trophic factors in breast milk merits investigation.
C1 London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   MRC Labs, MRC Keneba, Keneba, Gambia.
   Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England.
RP Collinson, AC (reprint author), Royal Devon & Exeter Hosp Wonford, Barrack Rd, Exeter EX2 5DW, Devon, England.
OI Cole, Tim/0000-0001-5711-8200
FU Medical Research Council [G9827821, G9827821(62595)]
CR Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   Aaby P, 2002, ACTA PAEDIATR, V91, P698, DOI 10.1080/080352502760069142
   Aspinall R, 2000, J CLIN IMMUNOL, V20, P250, DOI 10.1023/A:1006611518223
   Benn CS, 2001, CLIN EXP ALLERGY, V31, P1862, DOI 10.1046/j.1365-2222.2001.01128.x
   Boyd E, 1927, AM J DIS CHILD, V33, P867
   CLARKE AG, 1986, IMMUNOL TODAY, V7, P204, DOI 10.1016/0167-5699(86)90105-2
   Dubowitz L M, 1980, Brain Dev, V2, P3
   FREEMAN JV, 1990, ARCH DIS CHILD, V73, P17
   Garofalo RP, 1998, BIOL NEONATE, V74, P134, DOI 10.1159/000014019
   GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x
   Hasselbalch H, 1997, ACTA RADIOL, V38, P222
   Hasselbalch H, 1999, ACTA RADIOL, V40, P41
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x
   Kizilcan M, 1995, EUR RADIOL, V5, P55
   Lisse IM, 1997, J PEDIATR-US, V130, P77, DOI 10.1016/S0022-3476(97)70313-5
   McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834
   Moore SE, 2001, AM J CLIN NUTR, V74, P840
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   NAEYE RL, 1971, PEDIATR RES, V5, P17, DOI 10.1203/00006450-197101000-00004
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   OWENS JA, 1989, ADV FETAL PHYSL REV
   PHILLIPS DIW, 1993, Q J MED, V86, P247
   Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479
   PRENTICE A, 1984, ACTA PAEDIATR SCAND, V73, P803, DOI 10.1111/j.1651-2227.1984.tb17779.x
   Prentice AM, 2000, ACTA PAEDIATR, V89, P8, DOI 10.1080/080352500750028979
   Prentice AM, 1999, FETAL PROGRAMMING IN, P399
   Smith KY, 2000, J INFECT DIS, V181, P141, DOI 10.1086/315169
   van Baarlen J, 1989, Pediatr Pathol, V9, P261
   VANBAARLEN J, 1988, HUM PATHOL, V19, P1155, DOI 10.1016/S0046-8177(88)80146-1
NR 31
TC 52
Z9 52
U1 0
U2 7
PU TAYLOR & FRANCIS AS
PI OSLO
PA CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD SEP
PY 2003
VL 92
IS 9
BP 1014
EP 1020
DI 10.1080/08035250310004379
PG 7
WC Pediatrics
SC Pediatrics
GA 720CK
UT WOS:000185243800009
PM 14599061
OA No
DA 2017-08-15
ER

PT J
AU Ismaili, J
   Van der Sande, M
   Holland, MJ
   Sambou, I
   Keita, S
   Allsopp, C
   Ota, MO
   McAdam, KPWJ
AF Ismaili, J
   Van der Sande, M
   Holland, MJ
   Sambou, I
   Keita, S
   Allsopp, C
   Ota, MO
   McAdam, KPWJ
TI Plasmodium falciparum infection of the placenta affects newborn immune
   responses
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE APC; IL-12; placenta; plasmodium; Th1/Th2
ID CHONDROITIN SULFATE-A; HOLOENDEMIC MALARIA; DENDRITIC CELLS;
   BIRTH-WEIGHT; CORD SERA; PREGNANCY; EXPRESSION; MATURATION; WOMEN; BORN
AB The effects of exposure to placental malaria infection on newborn immunological responses, in particular Th1/Th2 cytokines and antigen-presenting cell (AFC) function, were compared between cord blood mononuclear cells (CBMC) from parasitized and non-parasitized placentas of Gambian women. Cells were analysed in vitro for their ability to respond to mitogens [phorbol myristate acetate (PMA)/ ionomycin, phytohaemagglutinin (PHA)], a malaria-unrelated test antigen [purified protein derivative of Mycobacterium tuberculin [purified protein derivative (PFD)] and Plasmodium falciparum schizont extracts. Mitogens induced strong proliferation and secretion of high concentrations of both IL-13 and sCD30 in CBMC from both groups. Conversely, significantly lower amounts of IFN-gamma were induced in the parasitized group in response to low doses of PHA. Protein antigens induced very low amounts of all tested cytokines, in particular IFN-gamma. However, a significantly higher release of sCD30 was observed in response to schizont extracts in the parasitized group. Addition of LPS to activate APC to low doses of PHA or schizont extracts increased the IFN-gamma production in both groups but levels remained lower in CBMC from the parasitized group. This result correlates with the lower production of IL-12 found following lipopolysaccharide (LPS) stimulation in this group. Taken together, these data show that placental infection with P. falciparum affects Th1 differentiation and sCD30 priming of neonatal lymphocytes and that the probable mode of action is via APC.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Ismaili, J (reprint author), Med Council Labs, POB 273, Banjul, Gambia.
CR Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   BRABIN B, 1991, INT J EPIDEMIOL, V20, P276, DOI 10.1093/ije/20.1.276
   BREMAN JG, 2001, AM J TROP MED HYG, V614, P1
   Chougnet C, 2000, J INFECT DIS, V181, P1590, DOI 10.1086/315458
   Delespesse G, 1998, VACCINE, V16, P1415, DOI 10.1016/S0264-410X(98)00101-7
   DESOWITZ RS, 1993, INFECT IMMUN, V61, P988
   DESOWITZ RS, 1989, T ROY SOC TROP MED H, V83, P478, DOI 10.1016/0035-9203(89)90254-X
   DESOWITZ RS, 1988, ANN TROP MED PARASIT, V82, P121
   ERTEL W, 1991, BLOOD, V78, P1781
   FAIRLAMB AH, 1985, ANN TROP MED PARASIT, V79, P379
   Fievet N, 1996, PARASITE IMMUNOL, V18, P483, DOI 10.1046/j.1365-3024.1996.d01-19.x
   Fried M, 1998, J IMMUNOL, V160, P2523
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   FUCHAROEN S, 1988, T ROY SOC TROP MED H, V82, P209, DOI 10.1016/0035-9203(88)90413-0
   Goriely S, 2001, J IMMUNOL, V166, P2141
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HARTE PG, 1983, CLIN EXP IMMUNOL, V51, P157
   Hassan J, 2000, IMMUNOL TODAY, V21, P107, DOI 10.1016/S0167-5699(99)01571-6
   Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x
   Jakobsen PH, 1998, IMMUNOLOGY, V93, P264
   King CL, 2002, J IMMUNOL, V168, P356
   Krampera M, 1999, CLIN EXP IMMUNOL, V117, P291
   LANDEWE RBM, 1992, J RHEUMATOL, V19, P1353
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   Meeusen ENT, 2001, AM J REPROD IMMUNOL, V46, P169, DOI 10.1111/j.8755-8920.2001.460208.x
   Ota MOC, 1999, AIDS, V13, P996, DOI 10.1097/00002030-199905280-00020
   POMBO D, 1988, J IMMUNOL, V140, P3594
   Rescigno M, 1997, J LEUKOCYTE BIOL, V61, P415
   Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789
   Ricke CH, 2000, J IMMUNOL, V165, P3309
   RILEY EM, 1989, AM J TROP MED HYG, V40, P141
   Snow RW, 1999, PARASITOL TODAY, V15, P99, DOI 10.1016/S0169-4758(99)01395-2
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   URBAN BC, 1999, NATURE, V400, P71
NR 36
TC 39
Z9 39
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD SEP
PY 2003
VL 133
IS 3
BP 414
EP 421
DI 10.1046/j.1365-2249.2003.02243.x
PG 8
WC Immunology
SC Immunology
GA 717AL
UT WOS:000185063400017
PM 12930369
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Garly, ML
   Bale, C
   Martins, C
   Jensen, H
   Lisse, I
   Whittle, H
AF Aaby, P
   Garly, ML
   Bale, C
   Martins, C
   Jensen, H
   Lisse, I
   Whittle, H
TI Survival of previously measles-vaccinated and measles-unvaccinated
   children in an emergency situation: an unplanned study
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE measles vaccine; nonspecific protection; mortality; war
ID BACILLUS-CALMETTE-GUERIN; GUINEA-BISSAU; CHILDHOOD MORTALITY; RURAL
   BANGLADESH; IMMUNIZATION; COMMUNITY; RESPONSES; INFECTION; COVERAGE;
   ANTIBODY
AB Background. Previous studies have suggested that standard measles vaccine may reduce mortality by more than the number of deaths thought to be caused by measles infection in areas with high mortality. However, these observations have not been based on randomized trials.
   Methods. During the recent war in Guinea-Bissau, most children fled from the city of Bissau and immunization services in the country broke down for several months. We were performing a trial in which children were randomized at 6 months of age to receive either measles vaccine or inactivated polio vaccine. Because of the war many children did not receive the dose of measles vaccine planned for 9 months of age. We were able to monitor mortality during the war and after.
   Results. Included in the study were 433 children 6 to 11 months of age. Fifteen children died (3.6%) during the first 3 months of the war before vaccination programs were resumed, 4 of 214 measles-vaccinated children and 11 of 219 children who had received inactivated polio vaccine. The effect of measles vaccine was marked for girls [mortality rate ratio (MR), 0.00; 95% confidence limits, 0.0 to 0.37], whereas there was no difference for boys (MR = 1.02; 95% confidence limits, 0.25 to 3.88). In a combined analysis controlling for factors that differed between the two groups, the MR for measles-vaccinated children was 0.30 (95% confidence limits, 0.08 to 0.87). Prolonging the period of observation to the end of 1998 or including the prewar period did not modify the significant beneficial effect of measles vaccine for girls. Twenty-two of the children in the cohort were reported to have had measles, 8 cases occurring during the 3 months of the war. Exclusion of measles cases in the analysis did not change the results; children who had received measles vaccine had a AM of 0.28 (95% confidence limits, 0.06 to 0.89) during the first 3 months of the war.
   Conclusions. Consistent with previous observational studies, measles vaccination was associated with a reduction in mortality that cannot be explained by the prevention of measles infection. This nonspecific beneficial effect was particularly strong for girls. Further studies are needed to examine the extent of nonspecific effects in settings with high mortality.
C1 Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark.
   Bandim Hlth Project, Bissau, Guinea Bissau.
   MRC Labs, Fajara, Gambia.
RP Aaby, P (reprint author), Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
CR AABY P, 1989, PEDIATR INFECT DIS J, V8, P197
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005
   Aaby P, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60575-2
   Aaby P, 1996, AM J EPIDEMIOL, V143, P1035
   Aaby P, 1999, BRIT MED J, V319, P878
   Aaby P, 1996, PEDIATR INFECT DIS J, V15, P39, DOI 10.1097/00006454-199601000-00009
   AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X
   Ashorn P, 2002, ARCH DIS CHILD, V87, P386, DOI 10.1136/adc.87.5.386
   Cox D. R., 1984, ANAL SURVIVAL DATA
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Garly ML, 2001, VACCINE, V19, P1951, DOI 10.1016/S0264-410X(00)00431-X
   Garly ML, 2001, VACCINE, V20, P468, DOI 10.1016/S0264-410X(01)00339-5
   GRAHAM BS, 1993, J IMMUNOL, V151, P2032
   HOLT EA, 1990, PEDIATRICS, V85, P188
   KIRSTENSEN I, 2000, BRIT MED J, V321, P1435
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Moran TM, 1999, J INFECT DIS, V180, P579, DOI 10.1086/314952
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Pabst HF, 1997, VACCINE, V15, P10, DOI 10.1016/S0264-410X(96)00124-7
   Paquet C, 1999, VACCINE, V17, pS116, DOI 10.1016/S0264-410X(99)00305-9
   Polack FP, 1999, NAT MED, V5, P629
   Salama P, 2001, JAMA-J AM MED ASSOC, V286, P563, DOI 10.1001/jama.286.5.563
   VANBALEN H, 1981, LANCET, V1, P764
NR 29
TC 37
Z9 37
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD SEP
PY 2003
VL 22
IS 9
BP 798
EP 805
DI 10.1097/01.inf.0000083821.33187.b5
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 727XP
UT WOS:000185686400010
PM 14506371
OA No
DA 2017-08-15
ER

PT J
AU Campbell, DI
   Murch, SH
   Elia, M
   Sullivan, PB
   Sanyang, MS
   Jobarteh, B
   Lunn, PG
AF Campbell, DI
   Murch, SH
   Elia, M
   Sullivan, PB
   Sanyang, MS
   Jobarteh, B
   Lunn, PG
TI Chronic T cell-mediated enteropathy in rural west African children:
   Relationship with nutritional status and small bowel function
SO PEDIATRIC RESEARCH
LA English
DT Article
ID TROPICAL ENTEROPATHY; PERSISTENT DIARRHEA; INTERFERON-GAMMA; GAMBIAN
   INFANTS; SMALL-INTESTINE; CELIAC-DISEASE; LAMINA PROPRIA; IFN-GAMMA;
   GROWTH; MALNUTRITION
AB Previous studies from The Gambia have shown that poor childhood growth is resistant to all but the most intense nutritional intervention and highly dependent on small bowel permeability related to enteropathy. We thus aimed to characterize the mucosal inflammatory response in rural Gambian children in relation to intestinal permeability and nutritional status. Small bowel biopsies were taken from 38 rural Gambian children (age, 0.5-3 y) with a range of nutritional and clinical states (median weight z score, -4.6; range, 0.5 to -6.4), 75% of whom had diarrhea. Morphometry was performed with immunohistochemical analysis for a range of lineage and activation markers, including proinflammatory and regulatory cytokines, and related to current clinical status and gut permeability. Comparison was made with 19 age-matched U.K. controls. All Gambian children, regardless of nutritional status, had evidence of chronic cell-mediated enteropathy with crypt hyperplasia, villous stunting, and high numbers of intraepithelial lymphocytes. CD25+ cells were 20-fold higher than in U.K. controls. Although small bowel architecture was independent of nutritional status, T cell numbers rose and B cell numbers fell with worsening nutrition, and mucosal cytokine production became biased toward a proinflammatory response, with progressive decrease of transforming growth factor-P expression. Tropical enteropathy predates the onset of marasmus and is characterized by a cell-mediated T,I response. Protein-energy malnutrition is associated with reduction of regulatory immune responses in the mucosal microenvironment, potentially impairing the mechanisms of oral tolerance.
C1 UCL Royal Free & Univ Coll, Sch Med, Ctr Paediat Gastroenterol, London NW3 2PF, England.
   MRC, Keneba, Gambia.
   Univ Southampton, Southampton Gen Hosp, Inst Human Nutr & Metab, Southampton, Hants, England.
   Univ Oxford, Univ Dept Paediat, Oxford, England.
   Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne, Tyne & Wear, England.
   Univ Cambridge, Dept Biol Anthropol, Cambridge CB2 3DZ, England.
RP Murch, SH (reprint author), UCL Royal Free & Univ Coll, Sch Med, Ctr Paediat Gastroenterol, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.
EM s.murch@rfc.ac.uk
CR ADAMS RB, 1993, J IMMUNOL, V150, P2356
   BEATTIE RM, 1995, ARCH DIS CHILD, V73, P354
   BOIVIN GP, 1995, AM J PATHOL, V146, P276
   BREESE EJ, 1994, DIGEST DIS SCI, V39, P2243, DOI 10.1007/BF02090378
   FAGUNDESNETO U, 1984, J TROP PEDIATRICS, V30, P204
   Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769
   FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688
   GARCIA S, 1968, AM J CLIN NUTR, V21, P1066
   Groux H, 1997, NATURE, V389, P737
   Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8
   HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203
   Hoare S, 1996, BRIT J NUTR, V76, P479, DOI 10.1079/BJN19960057
   IYNGKARAN N, 1989, J GASTROEN HEPATOL, V4, P127, DOI 10.1111/j.1440-1746.1989.tb00816.x
   Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394
   JUBY LD, 1989, GASTROENTEROLOGY, V96, P79
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P
   LIFSHITZ F, 1990, J AM COLL NUTR, V9, P231
   LIONETTI P, 1993, GASTROENTEROLOGY, V105, P373
   LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093
   Lunn PG, 1999, J NUTR, V129, P872
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Madsen KL, 1997, GASTROENTEROLOGY, V113, P151, DOI 10.1016/S0016-5085(97)70090-8
   MALUENDA C, 1984, J PEDIATR GASTR NUTR, V3, P349, DOI 10.1097/00005176-198406000-00008
   MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705
   MURCH SH, 1993, LANCET, V341, P711, DOI 10.1016/0140-6736(93)90485-Y
   Murch SH, 1997, BAILLIERE CLIN GASTR, V11, P413, DOI 10.1016/S0950-3528(97)90025-7
   Pender SLF, 1996, GUT, V39, P284, DOI 10.1136/gut.39.2.284
   Pender SLF, 1998, J IMMUNOL, V160, P4098
   Planchon SM, 1994, J IMMUNOL, V153, P5370
   Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669
   ROWLAND MGM, 1978, T ROY SOC TROP MED H, V72, P95, DOI 10.1016/0035-9203(78)90308-5
   ROWLAND MGM, 1981, T ROY SOC TROP MED H, V75, P215, DOI 10.1016/0035-9203(81)90319-9
   Savidge TC, 1996, GUT, V39, P185, DOI 10.1136/gut.39.2.185
   SCHNEIDER RE, 1972, AM J CLIN NUTR, V25, P1092
   SCHROEDER DG, 1994, B WORLD HEALTH ORGAN, V72, P569
   Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1
   SULLIVAN PB, 1991, ACTA PAEDIATR SCAND, V80, P1025
   SULLIVAN PB, 1992, J PEDIATR GASTR NUTR, V14, P208, DOI 10.1097/00005176-199202000-00016
   Thompson FM, 1996, GASTROENTEROLOGY, V111, P37, DOI 10.1053/gast.1996.v111.pm8698223
   Ulloa L, 1999, NATURE, V397, P710
   Veitch AM, 2001, EUR J GASTROEN HEPAT, V13, P1175, DOI 10.1097/00042737-200110000-00009
   Walker J, 1999, DOCUMENT DELIVERY BEYOND 2000, P45
   WALKERSMITH JA, 1999, DIS SMALL INTESTINE, P29
   WALKERSMITH JA, 1999, DIS SMALL INTESTINE, P235
   WALKERSMITH JA, 1999, DIS SMALL INTESTINE, P119
NR 45
TC 77
Z9 78
U1 0
U2 8
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD SEP
PY 2003
VL 54
IS 3
BP 306
EP 311
DI 10.1203/01.PDR.0000076666.16021.5E
PG 6
WC Pediatrics
SC Pediatrics
GA 714BC
UT WOS:000184891600003
PM 12788978
OA No
DA 2017-08-15
ER

PT J
AU Harper, M
   Abmadu, FA
   Ogden, JA
   McAdam, KP
   Lienhardt, C
AF Harper, M
   Abmadu, FA
   Ogden, JA
   McAdam, KP
   Lienhardt, C
TI Identifying the determinants of tuberculosis control in resource-poor
   countries: insights from a qualitative study in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE tuberculosis; Mycobacterium tuberculosis; control; compliance;
   treatment; The Gambia
ID RANDOMIZED CONTROLLED-TRIAL; GENDER; DISTRICT; HEALTH; INDIA; DOTS; SEX
AB Despite the availability of effective treatment, tuberculosis (TB) remains a major cause of death from an infectious disease in the world, particularly in resource-poor countries. Among the chief reasons for this are deficiencies in case tracing and in adherence to treatment. In order to investigate the contribution of non-biological factors to these deficiencies, we carried out a qualitative study in The Gambia, West Africa, from October 2000 to March 2001. The methods used were focus group discussions, interviews, participant and non-participant observation, and case histories. Four domains were distinctively investigated: the TB patients, the community, the health care providers (including programme staff), and the donors and policy makers. Analysis of the data from all these sources indicated the contribution of a wide range of socio-anthropological factors which influence the success or otherwise of the TB control programme in The Gambia, i.e. gender, urban/rural residence, recourse to traditional healers, adherence to national health policies, knowledge about TB, migration, and socio-economic factors. It is concluded that all these factors must be taken into account in formulating interventions to improve detection of TB cases and patient adherence to treatment within the framework of the national TB control programmes, and proposals have been made for targeted interventions.
C1 Inst Rech Dev, Dakar, Senegal.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Lienhardt, C (reprint author), Inst Rech Dev, BP 1386, Dakar, Senegal.
EM lienhardt@dakar.ird.sn
CR Banerjee A, 2000, INT J TUBERC LUNG D, V4, P1047
   BARNHOORN F, 1992, SOC SCI MED, V34, P291, DOI 10.1016/0277-9536(92)90271-Q
   Diwan VK, 1999, LANCET, V353, P1000, DOI 10.1016/S0140-6736(99)01318-5
   Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7
   Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8
   Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96
   Hudelson P, 1996, TUBERCLE LUNG DIS, V77, P391, DOI 10.1016/S0962-8479(96)90110-0
   *IUATLD, 1996, TUB GUID HIGH PREV C
   Johansson E, 2000, HEALTH POLICY, V52, P33, DOI 10.1016/S0168-8510(00)00062-2
   Kamolratanakul P, 1999, T ROY SOC TROP MED H, V93, P552, DOI 10.1016/S0035-9203(99)90379-6
   Liefooghe R, 1997, TROP MED INT HEALTH, V2, P809, DOI 10.1046/j.1365-3156.1997.d01-380.x
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233
   Lienhardt C, 1998, INT J TUBERC LUNG D, V2, P712
   LIENHARDT C, 2002, RETURN WHITE PLAGUE, P195
   Mushtaque A, 1999, Lancet, V353, P1003
   Ogden J, 1999, INT J TUBERC LUNG D, V3, P855
   Ogden J, 2000, T ROY SOC TROP MED H, V94, P135, DOI 10.1016/S0035-9203(00)90249-9
   Porter J, 1999, HEALTH POLICY PLANN, V14, P322, DOI 10.1093/heapol/14.4.322
   Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9
   SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311
   Walley JD, 2001, LANCET, V357, P664, DOI 10.1016/S0140-6736(00)04129-5
   World Health Organization, 1997, WHOTB97220
   World Health Organization, 1994, WHOTB94179
   World Health Organization, 2000, WHOCDSTB2000275
   Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7
NR 25
TC 21
Z9 22
U1 0
U2 3
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 2003
VL 97
IS 5
BP 506
EP 510
DI 10.1016/S0035-9203(03)80007-X
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 844RE
UT WOS:000223176500005
PM 15307411
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Sarge-Njie, R
   Ceesay, S
   Awasana, AA
   Jaye, P
   Sam, O
   Jaiteh, KO
   Cubitt, D
   Milligan, P
   Whittle, HC
AF van der Loeff, MFS
   Sarge-Njie, R
   Ceesay, S
   Awasana, AA
   Jaye, P
   Sam, O
   Jaiteh, KO
   Cubitt, D
   Milligan, P
   Whittle, HC
TI Regional differences in HIV trends in The Gambia: results from sentinel
   surveillance among pregnant women
SO AIDS
LA English
DT Article; Proceedings Paper
CT 12th International Conference on AIDS/STD in Africa
CY DEC 09-13, 2001
CL OUAGADOUGOU, BURKINA FASO
DE Africa; dried blood spot; HIV-1; HIV-2; pregnant women; risk factors;
   sentinel surveillance; The Gambia
ID INFECTION RATES; GUINEA-BISSAU; WEST-AFRICA; AIDS; EPIDEMIOLOGY;
   PREVALENCE; SENEGAL; TYPE-2; RISK
AB Objective: To monitor HIV-1 and HIV-2 trends in The Gambia, West Africa.
   Methods: In 1993-1995 a nationwide survey among 29 670 pregnant women attending eight antenatal clinics estimated the seroprevalence of HIV-1 at 0.6%, and of HIV-2 at 1.1%. Five years later, sentinel surveillance in pregnant women was established, using unlinked anonymous testing in four clinics. A dried blood spot on filter paper was obtained and tested for HIV antibodies.
   Results: Between May 2000 and August 2001, 8054 analysable samples were collected at four sites. The prevalence of HIV-1 rose sharply in one rural area from 0.6 to 3.0% (P < 0.0001), but the increase was small and non-significant in two other rural sites and in the urban site. The prevalence of HIV-2 did not change significantly at any of the sites. The overall prevalence of HIV-1 was 1.0% [95% confidence interval (CI) 0.8-1.3%], and of HIV-2 0.8% (CI 0.6-1.0%). Site, nationality and higher age were significantly associated with HIV-1 infection, and higher parity and site were significantly associated with HIV-2 infection.
   Conclusion: Fifteen years after the first case of HIV-1 was described in The Gambia, the epidemic is still at a low level. There is heterogeneity within the country, with one rural area experiencing a fivefold increase in 6 years. The prevalence of HIV-2 in The Gambia is stable. (C) 2003 Lippincott Williams & Wilkins.
C1 Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Inst Child Hlth, London, England.
RP van der Loeff, MFS (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR BEHETS F, 1992, J CLIN MICROBIOL, V30, P1179
   Bouckenooghe A, 1999, J INFECTION, V39, P122, DOI 10.1016/S0163-4453(99)90003-8
   *CENTR STAT DEP DE, 1996, POP HOUS CENS 1993
   CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P529
   DECOCK KM, 1991, AIDS, V5, pS21
   DJOMAND G, 1995, J ACQ IMMUN DEF SYND, V10, P358
   ENEL C, 1995, SOCIAL BEHAV RISK FA
   Ishikawa K, 1998, AIDS, V12, P1419, DOI 10.1097/00002030-199812000-00003
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   MARLINK R, 1998, 12 WORLD AIDS C GEN
   Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Obasi A, 1999, J INFECT DIS, V179, P16, DOI 10.1086/314555
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   UNAIDS, 1999, ACT EARL PREV AIDS C
   *UNAIDS WHO, EP FACT SHEETS COUNT
   *UNAIDS WHO, 2001, 2 GEN SURV HIV
   van der Loeff MFS, 2000, AIDS, V14, P1276
   van der Loeff MFS, 1999, AIDS, V13, pS69
   Walker N, 2001, AIDS, V15, P1545, DOI 10.1097/00002030-200108170-00012
   Weiss HA, 2001, AIDS, V15, pS97, DOI 10.1097/00002030-200108004-00011
   Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018
   *WHO, 1989, GPASFI893 WHO
NR 24
TC 51
Z9 53
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD AUG 15
PY 2003
VL 17
IS 12
BP 1841
EP 1846
DI 10.1097/01.aids.0000076303.76477.49
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 713BH
UT WOS:000184835100014
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Fielding, K
   Sillah, J
   Tunkara, A
   Donkor, S
   Manneh, K
   Warndorff, D
   McAdam, KP
   Bennett, S
AF Lienhardt, C
   Fielding, K
   Sillah, J
   Tunkara, A
   Donkor, S
   Manneh, K
   Warndorff, D
   McAdam, KP
   Bennett, S
TI Risk factors for tuberculosis infection in sub-Saharan Africa - A
   contact study in The Gambia
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE tuberculosis infection; tuberculin skin test; Mantoux test; contact
   investigation
ID MYCOBACTERIUM-TUBERCULOSIS; BCG VACCINATION; CALMETTE-GUERIN;
   SUSCEPTIBILITY; POPULATION; SENSITIVITY; REACTIVITY; CHILDREN;
   IMMUNIZATION; TRANSMISSION
AB Few studies have investigated the risk factors for tuberculosis (TB) infection in highly endemic countries. We conducted a household study in The Gambia, in which a tuberculin skin test (TST) was performed in members of the households of 315 smear-positive pulmonary TB cases and 305 community control subjects. The risk of being TST positive (10 mm or more) was higher in contacts of cases than in contacts of control subjects. It increased with age male sex, and duration of stay in the household but was not associated with the presence of a bacille de Calmette-Guerin scar. Within the households of the TB cases, the risk of TST positivity was higher in males and was increased with age, social proximity to the case, and the radiologic extent of the disease in the case's chest X-ray. Adjusting on these, the risk of TST positivity was higher in first-degree relatives compared with more distant relatives and nongenetically related household members, but the effect was not statistically significant. In highly endemic areas, the risk of TB infection in contacts of TB infectious cases is associated with age, sex, intensity of exposure to the case, and severity of disease in the case, but it is possible that genetic factors contribute to the susceptibility to Mycobacterium tuberculosis infection.
C1 MRC Labs, Fajara, Gambia.
   Natl TB Control Programme, Banjul, Gambia.
   Inst Rech Dev, Dakar, Senegal.
   London Sch Hyg & Trop Med, London WC1, England.
RP Lienhardt, C (reprint author), IRD,BP 1386, Dakar, Senegal.
CR Abel L, 2000, AM J HUM GENET, V67, P274, DOI 10.1086/303033
   Almeida LMD, 2001, PEDIATR INFECT DIS J, V20, P1061, DOI 10.1097/00006454-200111000-00011
   American Thoracic Society, 1981, AM REV RESPIR DIS, V124, P356
   ANDERSEN S, 1960, Bull World Health Organ, V22, P39
   Barnes PF, 2001, AM J RESP CRIT CARE, V163, P807
   Bellamy RJ, 1998, NOVART FDN SYMP, V217, P3, DOI 10.1002/0470846526.ch2
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   CHAPMAN JS, 1964, AM REV RESPIR DIS, V90, P48
   Cohn DL, 2001, AM J RESP CRIT CARE, V164, P915
   COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   ELLIOTT A, 1985, ANN TROP PAEDIATR, V5, P185
   FINE PEM, 1981, INT J LEPROSY, V49, P437
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Fine PEM, 1994, TUBERCULOSIS BACK FU, P53
   GONZALEZ B, 1994, TUBERCLE LUNG DIS, V75, P144, DOI 10.1016/0962-8479(94)90044-2
   GRINDULIS H, 1984, ARCH DIS CHILD, V59, P614
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90
   HOGE CW, 1994, AM J EPIDEMIOL, V139, P520
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968
   *IN UN TUB LUNG DI, 1996, TUB GUID HIGH PREV C
   Jepson A, 2001, INFECT IMMUN, V69, P3989, DOI 10.1128/IAI.69.6.3989-3994.2001
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Lockman S, 1999, INT J TUBERC LUNG D, V3, P23
   LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109
   Menzies RI., 2000, TUBERCULOSIS COMPREH, P279
   NARAIN R, 1966, B WORLD HEALTH ORGAN, V34, P639
   National Tuberculosis Institute Bangalore, 1974, B WORLD HEALTH ORGAN, V51, P473
   Neuenschwander BE, 2002, AM J EPIDEMIOL, V155, P654, DOI 10.1093/aje/155.7.654
   RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9
   ROELSGAARD E., 1964, BULL WORLD HEALTH ORGAN, V30, P459
   Saiman L, 2001, PEDIATRICS, V107, P999, DOI 10.1542/peds.107.5.999
   SEPULVEDA RL, 1994, TUBERCLE LUNG DIS, V75, P138, DOI 10.1016/0962-8479(94)90043-4
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724
   SNIDER DE, 1985, JAMA-J AM MED ASSOC, V253, P3438, DOI 10.1001/jama.253.23.3438
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   Weiss K. M., 1995, GENETIC VARIATION HU
   YOUNG TK, 1992, TUBERCLE LUNG DIS, V73, P94, DOI 10.1016/0962-8479(92)90062-O
NR 40
TC 81
Z9 83
U1 0
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD AUG 15
PY 2003
VL 168
IS 4
BP 448
EP 455
DI 10.1164/rccm.200212-1483OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 709ZC
UT WOS:000184655600011
PM 12773322
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Carlin, JB
   Gatchalian, S
   Lehmann, D
   Muhe, L
   Mulholland, EK
AF Weber, MW
   Carlin, JB
   Gatchalian, S
   Lehmann, D
   Muhe, L
   Mulholland, EK
CA WHO Young Infants Study Grp
TI Predictors of neonatal sepsis in developing countries
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE bacterial infection; neonatal sepsis; clinical signs; developing
   countries
ID YOUNG INFANTS; MANAGEMENT; PNEUMONIA; INFECTION
AB Background. Neonatal infections are a major cause of death worldwide. Simple procedures for identifying infants with infection that need referral for treatment are therefore of major public health importance.
   Methods. We investigated 3303 infants <2 months of age presenting with illness to health facilities in Ethiopia, The Gambia, Papua New Guinea and The Philippines, using a standardized approach. Historical factors and clinical signs predicting sepsis, meningitis, hypoxemia, deaths and an ordinal scale indicating severe disease were investigated by logistic regression, and the performance of simple combination rules was explored.
   Results. In multivariable analysis, reduced feeding ability, no spontaneous movement, temperature >38degreesC, being drowsy/unconscious, a history of a feeding problem, history of change in activity, being agitated, the presence of lower chest wall indrawing, respiratory rate >60 breaths/min, grunting, cyanosis, a history of convulsions, a bulging fontanel and slow digital capillary refill were independent predictors of severe disease. The presence of any 1 of these 14 signs had a sensitivity for severe disease (defined as sepsis, meningitis, hypoxemia, or radiologically proven pneumonia) of 87% and a specificity of 54%. More stringent combinations, such as demanding 2 signs from the list, resulted in a considerable loss of sensitivity. By contrast only slight loss of sensitivity and considerable gain of specificity resulted from reducing the list to 9 signs. Requiring the presence of fever and any other sign produced a diagnostic rule with extremely low sensitivity (25%).
   Conclusions. Physical signs can be used to identify young infants at risk of severe disease, however with limited specificity, resulting in large numbers of unnecessary referrals. Further studies are required to validate and refine the prediction of severe disease, especially in the first week of life, but there appear to be limits on the accuracy of prediction that is achievable.
C1 MRC Labs, Fajara, Gambia.
   Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   Univ Melbourne, Melbourne, Vic, Australia.
   Res Inst Trop Med, Alabang, Philippines.
   Papua New Guinea Inst Med Res, Goroka, Papua N Guinea.
   Univ Addis Ababa, Addis Ababa, Ethiopia.
RP Weber, MW (reprint author), WHO, Div Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
RI Carlin, John/B-3492-2012
OI Carlin, John/0000-0002-2694-9463
CR Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9
   Bhandari N, 1996, LANCET, V347, P1774, DOI 10.1016/S0140-6736(96)90856-9
   CRAIN EF, 1982, J PEDIATR-US, V101, P686, DOI 10.1016/S0022-3476(82)80291-6
   DAGAN R, 1985, J PEDIATR-US, V107, P855, DOI 10.1016/S0022-3476(85)80175-X
   Harrell FE, 1998, STAT MED, V17, P909, DOI 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>3.3.CO;2-F
   KLEIN JO, 1984, PEDIATR INFECT DIS J, V3, P75, DOI 10.1097/00006454-198401000-00018
   MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100
   MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004
   NYHAN WL, 1958, PEDIATRICS, V22, P268
   Schafer JL., 1997, ANAL INCOMPLETE MULT
   Stoll BJ, 1997, CLIN PERINATOL, V24, P1
   World Health Organization, 1995, TREATM DIARRH MAN PH
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS17, DOI DOI 10.1097/00006454-199910001-00004
   The WHO Young Infants Study Group, 1999, PEDIAT INFECT DIS S, V18, pS8
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS23
NR 15
TC 63
Z9 66
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2003
VL 22
IS 8
BP 711
EP 716
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 714JX
UT WOS:000184911300007
PM 12913772
OA No
DA 2017-08-15
ER

PT J
AU Goetghebuer, T
   Ota, MOC
   Kebbeh, B
   John, M
   Jackson-Sillah, D
   Vekemans, J
   Marchant, A
   Newport, M
   Weiss, HA
AF Goetghebuer, T
   Ota, MOC
   Kebbeh, B
   John, M
   Jackson-Sillah, D
   Vekemans, J
   Marchant, A
   Newport, M
   Weiss, HA
TI Delay in motor development of twins in Africa: A prospective cohort
   study
SO TWIN RESEARCH
LA English
DT Article
ID COGNITIVE-DEVELOPMENT; GESTATIONAL-AGE; BIRTH-WEIGHT; PREMATURITY;
   DEPRESSION; MORTALITY; INFANTS; GROWTH; SEX
AB Twins are prone to developmental delay due to prematurity and low birthweight. However it is unknown if twinning is an independent risk factor for developmental delay. The objective of this study was to compare the attainment of a set of gross motor milestones in a cohort of twins and singletons in The Gambia. Eighty-four pairs of twins and 72 singletons were enrolled at birth and followed up until 18 months of age. The mean age at achieving milestones was higher in twins for each development outcome and the difference between twins and singletons was significant after adjustment for confounders for maintaining head, sitting without support and walking. In twins, we found a highly significant correlation within pairs for most milestones. When monozygotic and dizygotic twins were compared, a significant heritability was observed for crawling, sitting, standing and walking, with over 90% of population variance observed due to genetic factors rather than environmental factors. There was little evidence for a genetic contribution towards very early milestones. In conclusion, our data suggest that twinning is an independent risk factor for developmental delay in early life in The Gambia, and that genetic factors contribute strongly to certain motor development outcomes.
C1 Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
   Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge, England.
   London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, MRC, Trop Epidemiol Grp, London WC1, England.
RP Goetghebuer, T (reprint author), Univ Oxford, John Radcliffe Hosp, Dept Paediat, Headley Way, Oxford OX3 9DU, England.
CR Angelsen NK, 2001, ARCH DIS CHILD, V85, P183, DOI 10.1136/adc.85.3.183
   Becker A, 1997, J REPROD MED, V42, P260
   BHARGAVA A, 2000, AM J PHYS ANTHROPOL, V111, P98
   CAPUTE AJ, 1985, DEV MED CHILD NEUROL, V27, P635
   CAPUTE AJ, 1985, AM J DIS CHILD, V139, P940
   Chrzanowska D, 1974, Acta Genet Med Gemellol (Roma), V22 suppl, P129
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Fox PW, 1996, NATURE, V384, P356, DOI 10.1038/384356a0
   FRANCISWILLIAMS J, 1974, DEV MED CHILD NEUROL, V16, P709
   FRANKENBURG WK, 1967, J PEDIATR-US, V71, P181, DOI 10.1016/S0022-3476(67)80070-2
   GROSS AD, 1991, PAPUA NEW GUINEA MED, V34, P238
   Hediger ML, 2002, PAEDIATR PERINAT EP, V16, P33, DOI 10.1046/j.1365-3016.2002.00393.x
   ILOEJE SO, 1991, ANN TROP PAEDIATR, V11, P33
   Jaffar S, 1998, ANN TROP PAEDIATR, V18, P231
   Koeppen-Schomerus G, 2000, J PEDIATR-US, V137, P527, DOI 10.1067/mpd.2000.108445
   LARGO RH, 1985, DEV MED CHILD NEUROL, V27, P183
   MORLEY R, 1989, ARCH DIS CHILD, V64, P1042
   Morris SS, 1998, INT J EPIDEMIOL, V27, P242, DOI 10.1093/ije/27.2.242
   Murphy M, 1997, J BIOSOC SCI, V29, P235, DOI 10.1017/S0021932097002356
   Murray L, 1997, ARCH DIS CHILD, V77, P99
   MYIANTHOPOULOS NC, 1976, ACTA GENETICAE MED G, V25, P376
   NEALE MC, 1997, MX STAT MODELING
   Okogbo M E, 1997, Afr J Med Med Sci, V26, P5
   Ostfeld B M, 2000, Twin Res, V3, P234, DOI 10.1375/136905200320565201
   Peter I, 1999, Twin Res, V2, P1, DOI 10.1375/twin.2.1.1
   Pison Gilles, 1992, MORTALITY SOC SUBSAH, P253
   Rutter M, 2003, J CHILD PSYCHOL PSYC, V44, P326, DOI 10.1111/1469-7610.00125
   Sherriff A, 2001, ARCH DIS CHILD, V84, P480, DOI 10.1136/adc.84.6.480
   STLIS S, 1974, ACTA GENETICAE MED S, V22, P129
   THORPE K, 1991, BRIT MED J, V302, P875
   Vestergaard M, 1999, ACTA PAEDIATR, V88, P1327, DOI 10.1080/080352599750030022
NR 31
TC 16
Z9 18
U1 0
U2 0
PU AUSTRALIAN ACAD PRESS
PI BOWEN HILLS
PA 32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA
SN 1369-0523
J9 TWIN RES
JI Twin Res.
PD AUG
PY 2003
VL 6
IS 4
BP 279
EP 284
DI 10.1375/136905203322296629
PG 6
WC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
SC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
GA 715GE
UT WOS:000184962100007
PM 14511433
OA No
DA 2017-08-15
ER

PT J
AU Solomon, AW
   Holland, MJ
   Burton, MJ
   West, SK
   Alexander, NDE
   Aguirre, A
   Massae, PA
   Mkocha, H
   Munoz, B
   Johnson, GJ
   Peeling, RW
   Bailey, RL
   Foster, A
   Mabey, DCW
AF Solomon, AW
   Holland, MJ
   Burton, MJ
   West, SK
   Alexander, NDE
   Aguirre, A
   Massae, PA
   Mkocha, H
   Munoz, B
   Johnson, GJ
   Peeling, RW
   Bailey, RL
   Foster, A
   Mabey, DCW
TI Strategies for control of trachoma: observational study with
   quantitative PCR
SO LANCET
LA English
DT Article
ID SINGLE-DOSE AZITHROMYCIN; CHLAMYDIA-TRACHOMATIS; MASS TREATMENT; ORAL
   AZITHROMYCIN; CHILDREN; BLINDNESS; IMPACT; NEPAL
AB Background Antibiotics are an important part of WHO's strategy to eliminate trachoma as a blinding disease by 2020. At present, who needs to be treated is unclear. We aimed to establish the burden of ocular Chlamydia trachomatis in three trachoma-endemic communities in Tanzania and The Gambia with real-time quantitative PCR.
   Methods Conjunctival swabs were obtained at examination from 3146 individuals. Swabs were first tested by the qualitative Amplicor PCR, which is known to be highly sensitive. In positive samples, the number of copies of omp1 (a single-copy C trachomatis gene) was measured by quantitative PCR.
   Findings Children had the highest ocular loads of C trachomatis, although the amount of pooling in young age groups was less striking at the site with the lowest trachoma frequency. Individuals with intense inflammatory trachoma had higher loads than did those with other conjunctival signs. At the site with the highest prevalence of trachoma, 48 of 93 (52%) individuals with conjunctival scarring but no sign of active disease were positive for ocular chlamydiae.
   Interpretation Children younger than 10 years old, and those with intense inflammatory trachoma, probably represent the major source of ocular C trachomatis infection in endemic communities. Success of antibiotic distribution programmes could depend on these groups receiving effective treatment.
C1 Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England.
   Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania.
   Huruma Hosp, Rombo Dist, Tanzania.
   MRC Labs, Fajara, Gambia.
   Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   Kongwa Trachoma Project, Kongwa, Tanzania.
   WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland.
   Hlth Canada, Natl Microbiol Lab, Winnipeg, MB, Canada.
RP Mabey, DCW (reprint author), Univ London London Sch Hyg & Trop Med, Clin Res Unit, Keppel St, London WC1E 7HT, England.
CR BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L
   Bowman RJC, 2000, INVEST OPHTH VIS SCI, V41, P4074
   Chern KC, 1999, BRIT J OPHTHALMOL, V83, P1332, DOI 10.1136/bjo.83.12.1332
   Dawson CR, 1997, CLIN INFECT DIS, V24, P363
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Frick KD, 2001, B WORLD HEALTH ORGAN, V79, P201
   Fry AM, 2002, CLIN INFECT DIS, V35, P395, DOI 10.1086/341414
   Holm SO, 2001, B WORLD HEALTH ORGAN, V79, P194
   Laming AC, 2000, MED J AUSTRALIA, V172, P163
   Leach AJ, 1997, CLIN INFECT DIS, V24, P356
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   Munoz B, 1999, INT J EPIDEMIOL, V28, P1167, DOI 10.1093/ije/28.6.1167
   PICKETT MA, 2000, P 4 M EUR SOC CHLAM, P45
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   SMITH IW, 1993, J CLIN PATHOL, V46, P822, DOI 10.1136/jcp.46.9.822
   STEPHENS RS, 1982, J CLIN MICROBIOL, V16, P4
   Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842
   Taylor K, 1999, BRIT J OPHTHALMOL, V83, P134, DOI 10.1136/bjo.83.2.134
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Verkooyen RP, 1996, J CLIN MICROBIOL, V34, P3072
   Whitty CJM, 1999, PEDIATR INFECT DIS J, V18, P955, DOI 10.1097/00006454-199911000-00003
   *WORLD HLTH ASS, 1998, 51 WORLD HLTH ASS RE
   World Medical Association, 2000, DECL HELS ETH PRINC
NR 25
TC 125
Z9 125
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 19
PY 2003
VL 362
IS 9379
BP 198
EP 204
DI 10.1016/S0140-6736(03)13909-8
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 702PJ
UT WOS:000184232000010
PM 12885481
OA No
DA 2017-08-15
ER

PT J
AU Alabi, AS
   Jaffar, S
   Ariyoshi, K
   Blanchard, T
   van der Loeff, MS
   Awasana, AA
   Corrah, T
   Sabally, S
   Sarge-Njie, R
   Cham-Jallow, F
   Jaye, A
   Berry, N
   Whittle, H
AF Alabi, AS
   Jaffar, S
   Ariyoshi, K
   Blanchard, T
   van der Loeff, MS
   Awasana, AA
   Corrah, T
   Sabally, S
   Sarge-Njie, R
   Cham-Jallow, F
   Jaye, A
   Berry, N
   Whittle, H
TI Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1,
   HIV-2, and dually infected Gambian patients
SO AIDS
LA English
DT Article
DE Africa; CD4 cell percentage; cohort; HIV-1; HIV-2; HLA; mortality rate;
   plasma viral load; survival; The Gambia
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOTOXIC T-CELLS; GUINEA-BISSAU;
   WEST-AFRICA; RNA LEVELS; HIV-2-ASSOCIATED MORTALITY; HIV-2-INFECTED
   PATIENTS; LYMPHOCYTE COUNTS; PROVIRAL LOAD; PROTECTION
AB Objective: To examine baseline plasma viral loads according to the CD4 cell percentage (CD4%) in HIV-1, HIV-2 and dually infected patients (HIV-D), and to relate these measurements to survival.
   Patients and methods: A total of 119 HIV-1, 137 HIV-2 and 81 HIV-D-infected patients attending the Medical Research Council clinic in The Gambia were recruited from 1991 according to baseline CD4%, and followed until death or the end of December 2000. HIV-1 and HIV-2 RNA levels were measured by in-house reverse transcriptase polymerase chain reaction assays.
   Results: The plasma viral load, which varied inversely with CD4%, was similar in HIV-1 singly and dually infected patients, but was significantly higher in HIV-1 than in HIV-2 singly infected patients, except in those with a CD4% less than 14%. HIV-2 plasma viral load in dually infected patients did not vary significantly with CD4%, but was significantly lower than in HIV-2 singly infected patients with CD4% less than 14%. Multivariate analysis showed that only CD4% was independently associated with survival in HIV-1 and HIV-D infections; whereas both CD4% and plasma viral load were independently associated with survival in HIV-2 infections. The mortality rate of HIV-D-infected patients was not significantly different from that of HIV-1-infected patients, but was significantly higher in the absence of HLA B58.
   Conclusion: HIV-2 infection does not alter HIV-1 replication or prolong survival in dually infected patients. In a clinical setting in Africa, where many patients present with advanced disease, CD4% may be a more important predictor of prognosis than plasma viral load. (C) 2003 Lippincott Williams Wilkins.
C1 Nigerian Inst Med Res, Div Microbiol, Lagos, Nigeria.
   London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1, England.
   Natl Inst Infect Dis, Ctr AIDS Res, Tokyo, Japan.
   Natl Inst Biol Stand & Controls, Div Retrovirol, S Mimms, Herts, England.
   UCL, Dept Virol, Windeyer Inst Med Sci, London, England.
   MRC Labs, Banjul, Gambia.
RP Whittle, H (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM hwhittle@mrc.gm
CR Aaby P, 1997, AIDS, V11, P939
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   Ariyoshi K, 1997, AIDS, V11, P1053
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Bertoletti A, 1998, J VIROL, V72, P2439
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.0.CO;2-L
   Greenberg AE, 2001, AIDS, V15, P2319, DOI 10.1097/00002030-200111230-00015
   Lepri AC, 1998, AIDS, V12, P1639, DOI 10.1097/00002030-199813000-00011
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Mellors JW, 1997, ANN INTERN MED, V126, P946
   Nkengasong JN, 2000, AIDS RES HUM RETROV, V16, P1371, DOI 10.1089/08892220050140919
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014
   Nunn AJ, 1997, BRIT MED J, V315, P767
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   OBrien WA, 1997, ANN INTERN MED, V126, P939
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Sarr AD, 1999, J HUMAN VIROL, V2, P45
   SMITH PG, 1996, FIELD TRIALS HLTH IN
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
NR 32
TC 44
Z9 46
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUL 4
PY 2003
VL 17
IS 10
BP 1513
EP 1520
DI 10.1097/01.aids.0000060410.18106.46
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 705XB
UT WOS:000184420900012
PM 12824789
OA No
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Enwere, G
   Ota, MOC
AF Okoko, BJ
   Enwere, G
   Ota, MOC
TI The epidemiology and consequences of maternal malaria: a review of
   immunological basis
SO ACTA TROPICA
LA English
DT Review
DE maternal malaria; cytokines; pregnancy; placenta; chondroitin sulphate A
ID FALCIPARUM-INFECTED ERYTHROCYTES; INTRAUTERINE GROWTH-RETARDATION;
   TUMOR-NECROSIS-FACTOR; HELPER 1-TYPE IMMUNITY; SUB-SAHARAN AFRICA;
   PAPUA-NEW-GUINEA; PLASMODIUM-FALCIPARUM; PLACENTAL MALARIA; CHONDROITIN
   SULFATE; BIRTH-WEIGHT
AB Millions of women who become pregnant in malaria-endemic areas are at increased risk of contracting malaria infection that jeopardises the outcome of pregnancy. The complication of this infection for mother and baby are considerable. In absence of any other reason, it was thought that the increased risk of infection during pregnancy was related to suppression of pre-existing malaria immunity. Although this concept is plausible, the significantly higher risk of maternal malaria and consequences in primigraviae compared with multigravidae suggests that there are more to mere immunosuppression in pregnancy. The mechanisms underlying some of the striking epidemiological and clinical features of malaria in pregnancy could be related to differences in the strains of parasite populations infecting pregnant women occasioned by the cyto-adherent properties of human placenta, presence or absence of anti-adhesion antibodies acquired from previous pregnancies or the elevated production of some pro-inflammatory cytokines in response to parasitisation of human placenta. Malaria infection of placenta causes a shift from Th2 to Th1 cytokine profile that may be detrimental to pregnancy. The increased susceptibility in the first pregnancy can be explained by the absence of anti-adhesion antibody in the primigravida that is being exposed for the first time to a different strain of malaria parasite sub-population that adhere exclusively to chondroitin sulphate A and hyaluronic acid (HA) in the placenta. In reviewing the epidemiology and consequences of maternal malaria, we have highlighted possible immunological and molecular basis that could account for the higher impact of malaria in pregnancy especially among primigravidae. These factors could be the basis for future research and vaccine formulation. (C) 2003 Elsevier Science B.V. All rights reserved.
C1 Med Res Labs, Banjul, Gambia.
RP Okoko, BJ (reprint author), Med Res Labs, POB 273, Banjul, Gambia.
CR Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200
   BEER AE, 1988, CIBA F SYMP, V64, P292
   Beeson JG, 2002, CELL MOL LIFE SCI, V59, P258, DOI 10.1007/s00018-002-8421-y
   Beeson JG, 2001, TRENDS PARASITOL, V17, P331, DOI 10.1016/S1471-4922(01)01917-1
   Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899
   Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582
   BILLEWICZ WZ, 1965, T R SOC MED HYG, V59, P395
   BLACKLOCK DB, 1925, ANN TROP MED PARASIT, V19, P327
   BLOLAND PB, 1995, AIDS, V9, P721, DOI 10.1097/00002030-199507000-00009
   Brabin B, 1997, Afr Health, V19, P19
   BRABIN B, 1992, ANN TROP PAEDIATR, V12, P303
   BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1
   BRAY RS, 1979, T ROY SOC TROP MED H, V73, P427, DOI 10.1016/0035-9203(79)90170-6
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x
   Chai WG, 2002, J BIOL CHEM, V277, P22438, DOI 10.1074/jbc.M111401200
   Chaisavaneeyakorn S, 2002, J INFECT DIS, V185, P127, DOI 10.1086/338013
   Chaiyaroj SC, 1996, AM J TROP MED HYG, V55, P76
   CHAOUAT G, 1990, J REPROD FERTIL, V89, P447
   CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8
   Conrad KP, 1996, FASEB J, V10, P760
   DOLAN G, 1994, T R SOC TROP MED HYG, V87, P621
   Duffy PE, 1999, BIOCHEM SOC T, V27, P478
   ENDESHAW Y, 1991, ETHIOPIAN MED J, V29, P103
   FLEMING FA, 1989, T R SOC TROP MED HYG, V8, P441
   Fried M, 2000, EXP PARASITOL, V95, P75, DOI 10.1006/expr.2000.4510
   Fried M, 1998, J IMMUNOL, V160, P2523
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570
   GALBRAITH RM, 1980, T ROY SOC TROP MED H, V74, P52, DOI 10.1016/0035-9203(80)90011-5
   GILLES HM, 1984, AM J TROP MED HYG, V33, P517
   Gowda DC, 1999, BIOSCIENCE REP, V19, P261, DOI 10.1023/A:1020542206916
   Granja ACL, 2001, J ADOLESCENT HEALTH, V28, P303, DOI 10.1016/S1054-139X(00)00205-6
   Guyatt HL, 2001, T ROY SOC TROP MED H, V95, P569, DOI 10.1016/S0035-9203(01)90082-3
   Hill JA, 1995, HUM REPROD, V10, P114
   HILL JA, 1995, JAMA-J AM MED ASSOC, V273, P1933, DOI 10.1001/jama.273.24.1933
   HUNG L, 1951, REV PALUDISME MED TR, V83, P75
   IBANESEBHOR SE, 1992, INT J GYNECOL OBSTET, V37, P247
   JELKMANN WEB, 1994, ANN NY ACAD SCI, V718, P300
   Kasumba IN, 2000, ANN TROP MED PARASIT, V94, P7, DOI 10.1080/00034980057563
   Khan M M, 2001, J Ayub Med Coll Abbottabad, V13, P38
   Khattab A, 2001, J INFECT DIS, V183, P1165, DOI 10.1086/319288
   Krishnan L, 1996, J IMMUNOL, V156, P653
   KWAK JYH, 1995, AM J REPROD IMMUNOL, V34, P93
   LeHesran JY, 1997, AM J EPIDEMIOL, V146, P826
   Leopardi O, 1996, PATHOL RES PRACT, V192, P892
   LOGIE DE, 1973, B WORLD HEALTH ORGAN, V49, P547
   LUXEMBERGER C, 2001, AM J EPIDEMIOL, V154, P465
   Luxemburger C, 1997, T ROY SOC TROP MED H, V91, P256, DOI 10.1016/S0035-9203(97)90066-3
   Marzi M, 1996, CLIN EXP IMMUNOL, V106, P127, DOI 10.1046/j.1365-2249.1996.d01-809.x
   MAY HO, 1980, MALARIA, V3, P33
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   MCGREGOR IA, 1952, T ROY SOC TROP MED H, V46, P403, DOI 10.1016/0035-9203(52)90058-8
   MCGREGOR IA, 1969, ANN TROP MED PARASIT, V63, P245
   MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0
   Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449
   Moore JM, 1999, J INFECT DIS, V179, P1218, DOI 10.1086/314737
   Moore JM, 2000, J INFECT DIS, V182, P960, DOI 10.1086/315755
   Moormann AM, 1999, J INFECT DIS, V180, P1987, DOI 10.1086/315135
   NAIR LS, 1993, INDIAN J MALARIOL, V30, P204
   Newbold C, 1997, AM J TROP MED HYG, V57, P389
   NOSTEN F, 1991, T R SOC TROP MED HYG, V85, P421
   Okoko BJ, 2002, J HEALTH POPUL NUTR, V20, P4
   Okoko BJ, 2001, J INFECT DIS, V184, P627, DOI 10.1086/322808
   ONEILDUNNE I, 2001, INFECT IMMUN, V69, P487
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   Pouvelle B, 2000, NAT MED, V6, P1264
   Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4
   RASHEED FN, 1993, AM J TROP MED HYG, V48, P154
   Richards AL, 1997, INT J PARASITOL, V27, P1251, DOI 10.1016/S0020-7519(97)00122-7
   Ricke CH, 2000, J IMMUNOL, V165, P3309
   Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X
   ROBERTSON SA, 1994, CRIT REV IMMUNOL, V14, P239
   ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15
   Rogerson SJ, 1999, ANN TROP MED PARASIT, V93, pS35, DOI 10.1080/00034989957727
   Scherf A, 2001, CELL MICROBIOL, V3, P125, DOI 10.1046/j.1462-5822.2001.00109.x
   Shulman CE, 2001, TROP MED INT HEALTH, V6, P770, DOI 10.1046/j.1365-3156.2001.00786.x
   Singh N, 2001, ANN TROP MED PARASIT, V95, P19, DOI 10.1080/00034980020035889
   Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1
   Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624
   Staalsoe T, 2001, J INFECT DIS, V184, P618, DOI 10.1086/322809
   Steketee RW, 1996, AM J TROP MED HYG, V55, P2
   Steketee RW, 1996, AM J TROP MED HYG, V55, P33
   Steketee RW, 1996, AM J TROP MED HYG, V55, P42
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   STIMSON WH, 1980, CLIN EXP IMMUNOL, V40, P157
   Sullivan AD, 1999, J INFECT DIS, V179, P1580, DOI 10.1086/314752
   Udupa KB, 1996, AM J HEMATOL, V52, P178
   Verhoeff FH, 2001, EUR J CLIN NUTR, V55, P682, DOI 10.1038/sj.ejcn.1601200
   WATTKINSON AM, 1983, BRIT MED J, V287, P251
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   WICKRAMASURIYA GAW, 1937, MALARIA ANKYLOSTOMIA, P5
   ZUCKER JR, 1994, T ROY SOC TROP MED H, V88, P173, DOI 10.1016/0035-9203(94)90283-6
NR 94
TC 40
Z9 43
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD JUL
PY 2003
VL 87
IS 2
BP 193
EP 205
DI 10.1016/S0001-706X(03)00097-4
PG 13
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 699FL
UT WOS:000184046000001
PM 12826295
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, CJ
   Drakeley, CJ
   Obisike, U
   Coleman, R
   Jawara, M
   Targett, GAT
   Milligan, P
   Pinder, M
   Walraven, G
AF Sutherland, CJ
   Drakeley, CJ
   Obisike, U
   Coleman, R
   Jawara, M
   Targett, GAT
   Milligan, P
   Pinder, M
   Walraven, G
TI The addition of artesunate to chloroquine for treatment of Plasmodium
   falciparum malaria in Gambian children delays, but does not prevent
   treatment failure
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID UNCOMPLICATED MALARIA; PYRIMETHAMINE-SULFADOXINE; RANDOMIZED TRIAL;
   RESISTANCE; AMODIAQUINE; ARTEMISININ; EFFICACY
AB In a randomized controlled trial, chloroquine monotherapy was compared with the combination of artesunate and chloroquine for treating uncomplicated Plasmodium fialciparum malaria in 536 Gambian children. Chloroquine-treated children exhibited a 28-day clinical failure rate of 15% (95% confidence interval [CI] = 9.2-22%) compared with 11% (7.8-15%) among children receiving the combination (P = 0.08, by Wilcoxon test). Seventy-three percent of chloroquine-treated children exhibited parasitemia during follow-up compared with 49% of children receiving the combination (relative risk = 1.5, 95% CI - 1.3-1.7; chi(2) = 21.18, P < 0.001). A significant reduction in clinical and parasitologic treatment failure in the combination group occurred in the first two weeks following treatment, but this was eroded over weeks three and four of follow-up. The impact of combination therapy on the transmission of chloroquine-resistant parasites is discussed. Chloroquine plus artesunate is not sufficiently efficacious to justify its introduction as a replacement for chloroquine monotherapy in The Gambia.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Fajara Med Res Council Labs, Banjul, Gambia.
   Farafenni Field Stn, Farafenni, Gambia.
   Joint Malaria Programme, Moshi, Tanzania.
RP Sutherland, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4
   Collet D., 1994, MODELLING SURVIVAL D
   Dollery C., 1999, THERAPEUTIC DRUGS
   Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6
   Fivelman QL, 1999, T ROY SOC TROP MED H, V93, P429, DOI 10.1016/S0035-9203(99)90147-5
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hoshen MB, 2000, PARASITOLOGY, V121, P237, DOI 10.1017/S0031182099006332
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   Nwanyanwu OC, 2000, TROP MED INT HEALTH, V5, P355, DOI 10.1046/j.1365-3156.2000.00554.x
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Sutherland CJ, 2002, AM J TROP MED HYG, V66, P700
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x
   vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9
   Warhurst DC, 2001, T ROY SOC TROP MED H, V95, P345, DOI 10.1016/S0035-9203(01)90177-4
   WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P1, DOI 10.1016/0035-9203(94)90458-8
   *WHO, 1999, PRACT HDB ANT DRUG T
NR 22
TC 25
Z9 26
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2003
VL 69
IS 1
BP 19
EP 25
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 706WC
UT WOS:000184477200006
PM 12932091
OA No
DA 2017-08-15
ER

PT J
AU Bogh, C
   Clarke, SE
   Jawara, M
   Thomas, CJ
   Lindsay, SW
AF Bogh, C
   Clarke, SE
   Jawara, M
   Thomas, CJ
   Lindsay, SW
TI Localized breeding of the Anopheles gambiae complex (Diptera :
   Culicidae) along the River Gambia, West Africa
SO BULLETIN OF ENTOMOLOGICAL RESEARCH
LA English
DT Article
ID TREATED BED NETS; MALARIA TRANSMISSION; TARGETED CHEMOPROPHYLAXIS; RURAL
   AREA; MOSQUITOS; CHILDREN; BEDNETS; NIGER
AB A study was undertaken to identify the major larval habitats of the Anopheles gambiae (Giles) complex in rural Gambia. Mosquito larvae and pupae were sampled along transects and in specific habitats in the central region of the country during the rainy seasons of 1996 and 1997. The sampling showed that the major breeding sites were located on the flooded alluvial soils bordering the river. The largest numbers of larvae were found during September, one month after the peak rains. Polymerase chain reaction analysis of specimens showed that Anopheles melas (Theobald) was the dominant species in the flooded areas (81.5%), followed by A. gambiae sensu stricto (Giles) (18.0%) and A. arabiensis (Patton) (0.5%). By sampling in specific habitats it was evident that A. arabiensis was mainly breeding in rain-fed rice fields along the edge of the alluvial soils. Anopheles melas and A. gambiae s.s. often coexisted but whereas A. melas were found in water with a salinity of up to 72% sea water (25.2 g NaCl l(-1)), A. gambiae s.s. only occurred in water with up to 30% sea water (10.5 g NaCl l(-1)). Anopheles melas larvae were found in association with plant communities dominated by sedges and grasses (Eleocharis sp., Paspalum sp., Sporobolus sp.) and sea-purslane Sesuvium portulacastrum (L.) and the presence of cattle hoof prints, whereas A. gambiae s.s. larvae mainly occurred in association with Paspalum sp. and Eleocharis sp. The study showed that even during the peak rainy season, breeding of the A. gambiae complex is almost entirely restricted to the extensive alluvial areas along the river.
C1 Danish Bilharziasis Lab, DK-2920 Charlottenlund, Denmark.
   MRC Labs, Fajara, Gambia.
   Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
RP Bogh, C (reprint author), Apartment 505,Apartment Regency Menteng,Jalan Soe, Jakarta 10310, Indonesia.
CR ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U
   BARBER M. A., 1931, ANN TROP MED AND PARASITOL, V25, P461
   BERTRAM D. S., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P135, DOI 10.1016/0035-9203(58)90035-X
   Bogh C, 2001, J MED ENTOMOL, V38, P822
   BOGH C, 1999, THESIS U COPENHAGEN
   BOGH C, 1999, THESIS U COPENHAGEN, P88
   BRYAN JH, 1982, GENETICA, V59, P167, DOI 10.1007/BF00056539
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   Chwatt L. J., 1945, Journal of Tropical Medicine and Hygiene, V48, P22
   CHWATT LEONARD JAN, 1949, MOSQUITO NEWS, V9, P56
   CLARKE S, 2001, THESIS U COPENHAGEN
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   GELFAND H. M., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P508, DOI 10.1016/0035-9203(55)90023-7
   GIGLIOLL MARCO E. C., 1965, J APPL ECOL, V2, P81, DOI 10.2307/2401695
   Gillies MT, 1987, ANOPHELINAE AFRICA S
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   HEMINGWAY J, 1995, B ENTOMOL RES, V85, P229
   JULVEZ J, 1992, ANN SOC BELG MED TR, V72, P163
   Julvez J, 1997, B SOC PATHOL EXOT, V90, P94
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   Muirhead-Thomson RC, 1945, B ENTOMOL RES, V36, P185
   RIBBANDS MCR, 1944, ANN TROP MED PARASIT, V38, P87
   RIBBANDS MCR, 1944, B ENTOMOL RES, V35, P271
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   SYLLA M, 1995, AGR ECOSYST ENVIRON, V54, P1, DOI 10.1016/0167-8809(95)00594-I
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0
   Toure YT, 1996, MED VET ENTOMOL, V10, P197, DOI 10.1111/j.1365-2915.1996.tb00731.x
   TREDRE RF, 1946, ANN TROP MED PARASIT, V40, P380
   TROLLDALEN JM, 1991, NORAGRIC OCCASIONA C, V10
   VERCRUYSSE J, 1985, ANN SOC BELG MED TR, V65, P171
NR 33
TC 32
Z9 33
U1 0
U2 3
PU C A B I PUBLISHING
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, WALLINGFORD OX10 8DE, OXON, ENGLAND
SN 0007-4853
J9 B ENTOMOL RES
JI Bull. Entomol. Res.
PD JUL
PY 2003
VL 93
IS 4
BP 279
EP 287
DI 10.1079/BER2003239
PG 9
WC Entomology
SC Entomology
GA 747CM
UT WOS:000186787700002
PM 12908913
OA No
DA 2017-08-15
ER

PT J
AU Zimmerman, PA
   Fitness, J
   Moulds, JM
   McNamara, DT
   Kasehagen, LJ
   Rowe, JA
   Hill, AVS
AF Zimmerman, PA
   Fitness, J
   Moulds, JM
   McNamara, DT
   Kasehagen, LJ
   Rowe, JA
   Hill, AVS
TI CR1 Knops blood group alleles are not associated with severe malaria in
   the Gambia
SO GENES AND IMMUNITY
LA English
DT Article; Proceedings Paper
CT 27th Congress of the ISBT
CY AUG 24-28, 2002
CL VANCOUVER, CANADA
SP ISBT
DE malaria; blood groups; single-nucleotide polymorphisms; complement
   receptor 1 (CR1); evolution
ID FALCIPARUM-INFECTED ERYTHROCYTES; INTERCELLULAR-ADHESION MOLECULE-1;
   HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; ROSETTE FORMATION;
   COMPLEMENT RECEPTOR-TYPE-1; UNCOMPLICATED MALARIA; ENDOTHELIAL RECEPTOR;
   MEMBRANE PROTEIN-1; MALAWIAN CHILDREN
AB The Knops blood group antigen erythrocyte polymorphisms have been associated with reduced falciparum malaria-based in vitro rosette formation (putative malaria virulence factor). Having previously identified single-nucleotide polymorphisms (SNPs) in the human complement receptor 1 (CR1/CD35) gene underlying the Knops antithetical antigens SI1/SI2 and McC(a)/McC(b), we have now performed genotype comparisons to test associations between these two molecular variants and severe malaria in West African children living in the Gambia. While SNPs associated with SI:2 and McC(b+) were equally distributed among malaria-infected children with severe malaria and control children not infected with malaria parasites, high allele frequencies for SI 2 (0.800, 136511706) and McC(b) (0.385, 658/1706) were observed. Further, when compared to the SI 1/McC(a) allele observed in all populations, the African SI 2/McC(b) allele appears to have evolved as a result of positive selection (modified Nei-Gojobori test Ka-Ks/s.e. = 1.77, P-value < 0. 05). Given the role of CR1 in host defense, our findings suggest that SI 2 and McC(b) have arisen to confer a selective advantage against infectious disease that, in view of these case-control study data, was not solely Plasmodium falciparum malaria. Factors underlying the lack of association between SI 2 and Mc(C)b with severe malaria may involve variation in CR1 expression levels.
C1 Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19129 USA.
   Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland.
   MRC Labs, Fajara, Gambia.
RP Zimmerman, PA (reprint author), Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, W147D,2109 Adelbert Rd, Cleveland, OH 44106 USA.
RI HILL, Adrian/C-1306-2008
FU NIAID NIH HHS [AI R01 42367]; Wellcome Trust [067431]
CR ALYAMAN F, 1995, T ROY SOC TROP MED H, V89, P55, DOI 10.1016/0035-9203(95)90658-4
   Barragan A, 2000, BLOOD, V95, P3594
   Barragan A, 2000, INFECT IMMUN, V68, P2971, DOI 10.1128/IAI.68.5.2971-2975.2000
   Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497
   Bellamy R, 1998, T ROY SOC TROP MED H, V92, P312, DOI 10.1016/S0035-9203(98)91026-4
   BIRMINGHAM DJ, 1994, J IMMUNOL, V153, P691
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   Clough B, 1998, EXP PARASITOL, V89, P129, DOI 10.1006/expr.1998.4275
   Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503
   Heddini A, 2001, INFECT IMMUN, V69, P5849, DOI 10.1128/IAI.69.9.5849-5856.2001
   Herrera AH, 1998, CLIN IMMUNOL IMMUNOP, V87, P176, DOI 10.1006/clin.1998.4529
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HUSAIN SM, 1995, INDIAN J MED RES, V101, P273
   Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x
   Kumar S, 2001, MEGA2 MOL EVOLUTIONA
   Kun JFJ, 1998, T ROY SOC TROP MED H, V92, P110, DOI 10.1016/S0035-9203(98)90979-8
   MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Moulds JM, 2000, GENES IMMUN, V1, P325, DOI 10.1038/sj.gene.6363676
   Moulds JM, 2002, TRANSFUSION, V42, P251, DOI 10.1046/j.1537-2995.2002.00002.x
   Moulds JM, 2001, BLOOD, V97, P2879, DOI 10.1182/blood.V97.9.2879
   MOULDS MK, 1981, AM J MED TECHNOL, V47, P789
   Newbold C, 1997, AM J TROP MED HYG, V57, P389
   RINGWALD P, 1993, INFECT IMMUN, V61, P5198
   Rogerson SJ, 1999, AM J TROP MED HYG, V61, P467
   ROWE A, 1995, INFECT IMMUN, V63, P2323
   Rowe JA, 2000, J IMMUNOL, V165, P6341
   Rowe JA, 2002, GENES IMMUN, V3, P497, DOI 10.1038/sj.gene.6363899
   Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888
   ROWE JA, IN PRESS AM J TROP M
   Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Scholander C, 1996, NAT MED, V2, P204, DOI 10.1038/nm0296-204
   Somner EA, 2000, BLOOD, V95, P674
   Treutiger CJ, 1998, AM J TROP MED HYG, V59, P202
   TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503
   Treutiger CJ, 1997, NAT MED, V3, P1405, DOI 10.1038/nm1297-1405
   Zimmerman PA, 1997, MOL MED, V3, P23
NR 40
TC 36
Z9 40
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2003
VL 4
IS 5
BP 368
EP 373
DI 10.1038/sj.gene.6363980
PG 6
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 702CC
UT WOS:000184206900008
PM 12847553
OA No
DA 2017-08-15
ER

PT J
AU Lopes, AR
   Jaye, A
   Dorrell, L
   Sabally, S
   Alabi, A
   Jones, NA
   Flower, DR
   De Groot, A
   Newton, P
   Lascar, RM
   Williams, I
   Whittle, H
   Bertoletti, A
   Borrow, P
   Maini, MK
AF Lopes, AR
   Jaye, A
   Dorrell, L
   Sabally, S
   Alabi, A
   Jones, NA
   Flower, DR
   De Groot, A
   Newton, P
   Lascar, RM
   Williams, I
   Whittle, H
   Bertoletti, A
   Borrow, P
   Maini, MK
TI Greater CD8(+) TCR heterogeneity and functional flexibility in HIV-2
   compared to HIV-1 infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CYTOTOXIC T-LYMPHOCYTES; PRIMARY IMMUNE-RESPONSE; EPSTEIN-BARR-VIRUS;
   CELL-RECEPTOR; EPITOPE VARIANTS; VIRAL ESCAPE; RECOGNITION; PEPTIDE;
   IMMUNODOMINANT; ANTIGEN
AB Virus-specific CD8(+) T cells are known to play an important role in the control of HIV infection. In this study we investigated whether there may be qualitative differences in the CD8(+) T cell response in HIV-1- and HIV-2-infected individuals that contribute to the relatively efficient control of the latter infection. A molecular comparison of global TCR heterogeneity showed a more oligoclonal pattern of CD8 cells in HIV-1- than HIV-2-infected patients. This was reflected in restricted and conserved TCR usage by CD8(+) T cells recognizing individual HLA-A2- and HLA-B57-restricted viral epitopes in HIV-1, with limited plasticity in their response to amino acid substitutions within these epitopes. The more diverse TCR usage observed for HIV-2-specific CD8(+) T cells was associated with an enhanced potential for CD8 expansion and IFN-gamma production on cross-recognition of variant epitopes. Our data suggest a mechanism that could account for any possible cross-protection that may be mediated by HIV-2-specific CD8+ T cells against HIV-1 infection. Furthermore, they have implications for HIV vaccine development, demonstrating an association between a polyclonal, virus-specific CD8(+) T cell response and an enhanced capacity to tolerate substitutions within T cell epitopes.
C1 UCL, Inst Hepatol, London WC1 E6HX, England.
   UCL, Dept Sexually Transmitted Dis, London WC1 E6HX, England.
   MRC Labs, Fajara, Gambia.
   John Radcliffe Hosp, Med Res Council Human Immunol Grp, Oxford OX3 9DU, England.
   Edward Jenner Inst Vaccine Res, Compton, Berks, England.
   Brown Univ, TB HIV Res Lab, Providence, RI 02912 USA.
RP Maini, MK (reprint author), UCL, Inst Hepatol, 69-75 Chenies Mews, London WC1 E6HX, England.
EM m.maini@ucl.ac.uk
RI Flower, Darren/F-1263-2010
OI Flower, Darren/0000-0002-8542-7067; Bertoletti,
   Antonio/0000-0002-2942-0485; De Groot, Annie/0000-0001-5911-1459
FU NIAID NIH HHS [AI37430, AI41530]
CR ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335
   Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a
   Berman HM, 2000, NAT STRUCT BIOL, V7, P957, DOI 10.1038/80734
   Berry N, 1998, J Hum Virol, V1, P457
   Bertoletti A, 1998, J VIROL, V72, P2439
   BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0
   Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405
   Busch DH, 1999, J EXP MED, V189, P701, DOI 10.1084/jem.189.4.701
   Buseyne F, 2001, INT IMMUNOL, V13, P941, DOI 10.1093/intimm/13.7.941
   Buseyne F, 2001, J VIROL, V75, P4941, DOI 10.1128/JVI.75.10.4941-4946.2001
   Campos-Lima P O, 1997, J Exp Med, V186, P83, DOI 10.1084/jem.186.1.83
   Charini WA, 2001, J IMMUNOL, V167, P4996
   Chen ZW, 2001, J IMMUNOL, V166, P4525
   Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4
   Dorrell L, 1999, J VIROL, V73, P1708
   Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.0.CO;2-L
   Douek DC, 2002, J IMMUNOL, V168, P3099
   Durali D, 1998, J VIROL, V72, P3547
   Garbe TR, 1996, MOL MED, V2, P134
   GILLESPIE GM, 2002, AIDS, V16, P691
   Gotch F, 1998, CURR OPIN IMMUNOL, V10, P388, DOI 10.1016/S0952-7915(98)80109-X
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   HORWITZ MS, 1994, J VIROL, V68, P352
   KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Klenerman P, 1998, NATURE, V394, P482
   Maini MK, 2000, J IMMUNOL, V165, P5729
   Maini MK, 2000, EUR J IMMUNOL, V30, P3067, DOI 10.1002/1521-4141(200011)30:11<3067::AID-IMMU3067>3.0.CO;2-L
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658
   Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660
   NANDA NK, 1992, J EXP MED, V176, P297, DOI 10.1084/jem.176.1.297
   NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002
   NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0
   O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493
   Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254
   PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   Putkonen P, 1997, J VIROL, V71, P4981
   PUTKONEN P, 1995, NAT MED, V1, P914, DOI 10.1038/nm0995-914
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   STUBER G, 1992, EUR J IMMUNOL, V22, P2697, DOI 10.1002/eji.1830221033
   Valitutti S, 1996, J EXP MED, V183, P1917, DOI 10.1084/jem.183.4.1917
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   Whittle HC, 1998, CURR OPIN IMMUNOL, V10, P382, DOI 10.1016/S0952-7915(98)80108-8
   Wilson JDK, 1998, J EXP MED, V188, P785, DOI 10.1084/jem.188.4.785
NR 52
TC 34
Z9 36
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUL 1
PY 2003
VL 171
IS 1
BP 307
EP 316
PG 10
WC Immunology
SC Immunology
GA 692RQ
UT WOS:000183674400039
PM 12817012
OA No
DA 2017-08-15
ER

PT J
AU Price, P
   Bolitho, P
   Jaye, A
   Glasson, M
   Yindom, LM
   Sirugo, G
   Chase, D
   McDermid, J
   Whittle, H
AF Price, P
   Bolitho, P
   Jaye, A
   Glasson, M
   Yindom, LM
   Sirugo, G
   Chase, D
   McDermid, J
   Whittle, H
TI A gambian TNF haplotype matches the european HLA-A1,B8,DR3 and chinese
   HLA-A33,B58,DR3 haplotypes
SO TISSUE ANTIGENS
LA English
DT Article
DE Africa; ancestral haplotype; MHC; tumour necrosis factor
ID CENTRAL MHC GENE; ALPHA PROMOTER; DISEASE; BAT1; SUSCEPTIBILITY;
   TRANSCRIPTION; POLYMORPHISM; ASSOCIATION; ALLELES
AB Caucasians carry TNFA-308*2 in the 8.1 ancestral haplotype (AH) (HLA-A1,B8,DR3). In Gambians, TNFA-308*2 occurs without HLA-B8 or -DR3, suggesting an independent effect of TNFA-308 on disease. Hence we sought a segment of the 8.1 AH in Gambians. BAT1 (intron 10)*2 was selected as a specific marker of the haplotype and was found with TNFA-308*2 in Gambians. Samples homozygous at TNFA-308 and BAT1 (intron 10) demonstrated identity between the African TNFA-308*2 haplotype, the 8.1AH and the Asian diabetogenic 58.1AH (HLA-A33,B58,DR3) across a region spanning BAT1, ATP6G, IKBL, LTA, TNFA, LTB, LST-1 and AIF-1 . Conservation of this block in geographically distinct populations suggests a common evolutionary origin and challenges current views of the role of TNFA-308*2 in disease.
C1 Royal Perth Hosp, Dept Clin Immunol & Biochem Genet, Perth, WA 6000, Australia.
   Univ Western Australia, Sch Pathol & Surg, Nedlands, WA 6009, Australia.
   MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
RP Price, P (reprint author), Royal Perth Hosp, Dept Clin Immunol & Biochem Genet, Perth, WA 6000, Australia.
CR Allcock RJN, 2001, IMMUNOGENETICS, V52, P289
   Allcock RJN, 2001, GENES CELLS, V6, P487, DOI 10.1046/j.1365-2443.2001.00435.x
   ArnaizVillena A, 1997, IMMUNOGENETICS, V47, P37, DOI 10.1007/s002510050324
   Bayley JP, 2001, CYTOKINE, V14, P316, DOI 10.1006/cyto.2001.0902
   CEONG KYM, 2002, HUMAN IMMUNOL, V62, P1363
   CHAN SH, 1995, HUMAN IMMUNOL, V44, P15
   CrouauRoy B, 1996, IMMUNOGENETICS, V43, P255, DOI 10.1007/s002510050061
   Cruciani F, 2002, AM J HUM GENET, V70, P1197, DOI 10.1086/340257
   Ikaheimo I, 1996, EUR J IMMUNOGENET, V23, P321, DOI 10.1111/j.1744-313X.1996.tb00128.x
   Knight JC, 1999, P ASSOC AM PHYSICIAN, V111, P290, DOI 10.1046/j.1525-1381.1999.99237.x
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   Leung JY, 2000, P NATL ACAD SCI USA, V97, P6614, DOI 10.1073/pnas.97.12.6614
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   McManus R, 1996, EUR J IMMUNOL, V26, P2113, DOI 10.1002/eji.1830260923
   Moghaddam PH, 1998, DIABETES, V47, P263
   Momose F, 2001, J VIROL, V75, P1899, DOI 10.1128/JVI.75.4.1899-1908.2001
   PEELMAN LJ, 1995, GENOMICS, V26, P210, DOI 10.1016/0888-7543(95)80203-X
   Price P, 1999, IMMUNOL REV, V167, P257, DOI 10.1111/j.1600-065X.1999.tb01398.x
   Quasney MW, 2001, ANN NEUROL, V50, P157, DOI 10.1002/ana.1284
   Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789
   Van Dooren S, 2001, MOL BIOL EVOL, V18, P661
   Witt CS, 2002, TISSUE ANTIGENS, V60, P474, DOI 10.1034/j.1399-0039.2002.600602.x
   Wong AML, 2003, GENES CELLS, V8, P403, DOI 10.1046/j.1365-2443.2002.00641.x
NR 23
TC 14
Z9 14
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD JUL
PY 2003
VL 62
IS 1
BP 72
EP 75
DI 10.1034/j.1399-0039.2003.00083.x
PG 4
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 700JA
UT WOS:000184107800006
PM 12859597
OA No
DA 2017-08-15
ER

PT J
AU Cutts, FT
   Fine, PEM
AF Cutts, FT
   Fine, PEM
TI Caution - mortality ratios ahead
SO LANCET
LA English
DT Editorial Material
ID TITER MEASLES IMMUNIZATION
C1 MRC Labs, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Cutts, FT (reprint author), MRC Labs, Banjul, Gambia.
CR AABY P, 1995, BRIT MED J, V311, P481
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   *EXP PROGR IMM, 1991, WEEKLY EPIDEMIOL REC, V66, P249
   HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777
   HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002
   Holt EA, 1993, J INFECT DIS, V168, P1987
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
NR 7
TC 6
Z9 6
U1 0
U2 3
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 28
PY 2003
VL 361
IS 9376
BP 2169
EP 2170
DI 10.1016/S0140-6736(03)13783-X
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 695DJ
UT WOS:000183815600003
PM 12842364
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Jensen, H
   Samb, B
   Cisse, B
   Sodemann, M
   Jakobsen, M
   Poulsen, A
   Rodrigues, A
   Lisse, IM
   Simondon, F
   Whittle, H
AF Aaby, P
   Jensen, H
   Samb, B
   Cisse, B
   Sodemann, M
   Jakobsen, M
   Poulsen, A
   Rodrigues, A
   Lisse, IM
   Simondon, F
   Whittle, H
TI Differences in female-male mortality after high-titre measles vaccine
   and association with subsequent vaccination with
   diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of
   West African studies
SO LANCET
LA English
DT Article
ID EDMONSTON-ZAGREB; CHILD-MORTALITY; RURAL SENEGAL; ROUTINE VACCINATIONS;
   IMMUNE-RESPONSES; GUINEA-BISSAU; IMMUNIZATION; SURVIVAL; TERM; COMMUNITY
AB Background Females given high-titre measles vaccine (HTMV) have high mortality; diphtheria-tetanus-pertussis (DTP) vaccination might be associated with increased female mortality. We aimed to assess whether IDTP or inactivated poliovirus (IPV) administered after HTMV was associated with increased female-male mortality ratio.
   Methods In three trials from West Africa, 2000 children were randomised to HTMV or control vaccine at 4-5 months of age; a second vaccination was given at age 9-10 months (standard measles vaccine). Children in high-titre groups were given IPV or DTP-IPV. Another 944 children received HTMV as routine vaccination in Senegal.
   Findings When we compared high-titre and control groups, no difference in mortality between the first and the second vaccination was noted. After the second vaccination, the female-male mortality ratio was 1.84 (95% CI 1.19-2.84) in children in the high-titre groups who received DTP-IPV or IPV, and 0.59 (0.34-1.04) in controls who received standard measles vaccine (p=0.007). Children who received HTMV but no additional DTP-IPV or IPV had a female-male mortality ratio of 0.83 (0.41-1.67). This ratio was 2.22 (1.04-4.71) for children who received DTP-IPV after routine HTMV and 1.00 (0.68-1.47) for those who did not. When we combined the results from all trials, the female-male mortality ratio was 1.93 (1.33-2.81) for those who received DTP or IPV after HTMV, and 0.96 (0.69-1.34) for those who did not (p=0.006).
   Interpretation A change in sequence of vaccinations, rather than HTMV itself, may have been the cause of increased female mortality in these trials.
C1 Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau.
   IRD, UR 24, Epidemiol & Prevent Res Unit, Dakar, Senegal.
   MRC Labs, Banjul, Gambia.
RP Aaby, P (reprint author), State Serum Inst, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
CR Aaby P, 1996, T ROY SOC TROP MED H, V90, P326, DOI 10.1016/S0035-9203(96)90275-8
   AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 1996, AM J EPIDEMIOL, V143, P1035
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, ROUTINE VACCINATIONS
   Aaby Peter, 1998, METHODS USES ANTHR D, P223
   Akramuzzaman SM, 2000, AM J EPIDEMIOL, V151, P723
   CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185
   CUTTS FT, 1994, VACCINE, V12, P1311, DOI 10.1016/S0264-410X(94)80057-7
   Dollimore N, 1997, AM J EPIDEMIOL, V146, P646
   Expanded Programme on Immunization, 1992, WKLY EPIDEMIOL REC, V67, P357
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   GARENNE M, 1994, INT J EPIDEMIOL, V23, P632, DOI 10.1093/ije/23.3.632
   GARLY ML, IN PRESS VACCINE
   *GLOB ADV GROUP, 1990, WKLY EPIDEMIOL REC, V65, P5
   GRAHAM BS, 1993, J IMMUNOL, V151, P2032
   Holt EA, 1993, J INFECT DIS, V168, P1987
   Hussey GD, 1996, J INFECT DIS, V173, P1320
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Libman MD, 2002, PEDIATR INFECT DIS J, V21, P112, DOI 10.1097/00006454-200202000-00006
   Lindblad EB, 1997, INFECT IMMUN, V65, P623
   Ota MOC, 2002, J IMMUNOL, V168, P919
   PITTMAN PR, 2002, VACCINE, V20, P48
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
NR 30
TC 127
Z9 127
U1 0
U2 2
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 28
PY 2003
VL 361
IS 9376
BP 2183
EP 2188
DI 10.1016/S0140-6736(03)13771-3
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 695DJ
UT WOS:000183815600010
PM 12842371
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
AF Walraven, G
TI Prevention of cervical cancer in resource-poor settings
SO LANCET
LA English
DT Letter
ID HUMAN-PAPILLOMAVIRUS
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
RP Walraven, G (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
CR BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Denny L, 2000, CANCER, V89, P826, DOI 10.1002/1097-0142(20000815)89:4<826::AID-CNCR15>3.0.CO;2-5
   Gaffikin L, 2003, LANCET, V361, P814
   Goldie SJ, 2001, JAMA-J AM MED ASSOC, V285, P3107, DOI 10.1001/jama.285.24.3107
   Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 21
PY 2003
VL 361
IS 9375
BP 2160
EP 2160
DI 10.1016/S0140-6736(03)13712-9
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 692GY
UT WOS:000183654200037
PM 12826462
OA No
DA 2017-08-15
ER

PT J
AU Garly, ML
   Martins, CL
   Bale, C
   Balde, MA
   Hedegaard, KL
   Gustafson, P
   Lisse, IM
   Whittle, HC
   Aaby, P
AF Garly, ML
   Martins, CL
   Bale, C
   Balde, MA
   Hedegaard, KL
   Gustafson, P
   Lisse, IM
   Whittle, HC
   Aaby, P
TI BCG scar and positive tuberculin reaction associated with reduced child
   mortality in West Africa - A non-specific beneficial effect of BCG?
SO VACCINE
LA English
DT Article
DE BCG scar; tuberculin reaction; child mortality
ID CELL-MEDIATED-IMMUNITY; BACILLUS-CALMETTE-GUERIN; DELAYED CUTANEOUS
   HYPERSENSITIVITY; GUINEA-BISSAU; MULTITEST CMI; VACCINATION; ANERGY;
   RESPONSES; MEASLES; INFANTS
AB Previous studies have suggested that the bacille Calmette-Guerin (BCG) vaccine may have a non-specific beneficial effect on childhood survival in areas with high mortality. We examined whether BCG-vaccinated children with a BCG scar or a positive tuberculin reaction had better survival than children without such reactions. As part of an ongoing two-dose measles vaccine trial for which children were recruited at 6 months of age, we examined 1813 children for BCG scar at 6 months of age and 813 BCG-vaccinated children were skin-tested for delayed hypersensitivity to tuberculin, tetanus and diphtheria. We found that BCG-vaccinated children with a BCG scar had significantly lower mortality compared with BCG scar-negative children, the mortality ratio in the first 12 months of follow-up being 0.41 (0.25-0.67). BCG-vaccinated children with a positive tuberculin test had a mortality ratio of 0.45 (0.24-0.85) compared with tuberculin negative children. These results were unchanged by control for potential confounders or using different cut-off points for a tuberculin-positive response. Exclusion of dead children who had HIV antibodies did not modify the estimate (mortality rate (MR) = 0.46 (0.23-0.94)). After censoring for tuberculosis (TB) exposure at home, the mortality ratios for having a scar and being tuberculin-positive were 0.46 (0.27-0.79) or 0.42 (0.21-0.84), respectively. Children positive to tetanus or diphtheria in the skin test had the same mortality as children not responding to these vaccine-related antigens. Thus, BCG scar and a positive tuberculin reaction were associated with better survival in early childhood in an area with high mortality. Since nothing similar was found for responders to diphtheria-tetanus-pertussis (DTP) vaccine, and the effect could not be explained by protection against tuberculosis, the effect of BCG vaccination could be due to non-specific immune-stimulation protecting against other infections. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Projecto Saude Bandim, Bissau, Guinea Bissau.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark.
   MRC Labs, Banjul, Gambia.
RP Garly, ML (reprint author), Projecto Saude Bandim, Apartado 861, Bissau, Guinea Bissau.
CR Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   Aaby P, 1999, BRIT MED J, V319, P878
   Aggarwal Anju, 2002, Indian Pediatr, V39, P404
   Alexandroff AB, 1999, LANCET, V353, P1689, DOI 10.1016/S0140-6736(98)07422-4
   Aronson JD, 1935, AM J DIS CHILD, V50, P1117
   BAGSHAWE A, 1989, B WORLD HEALTH ORGAN, V67, P389
   BERKOVICH S, 1966, NEW ENGL J MED, V274, P67, DOI 10.1056/NEJM196601132740203
   BLACK RE, 1989, PEDIATR INFECT DIS J, V8, P210
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Cox D. R., 1984, ANAL SURVIVAL DATA
   DELPRETE G, 1992, ALLERGY, V47, P450
   Expanded Programme On Immunization, 1992, WKLY EPIDEMIOL REC, V67, P357
   FANG JWS, 1993, CHILD CARE HLTH DEV, V19, P37, DOI 10.1111/j.1365-2214.1993.tb00711.x
   FINE PEM, 1995, CLIN INFECT DIS, V20, P11
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Floyd S, 2002, J INFECT DIS, V186, P807, DOI 10.1086/342416
   Garcia-Garcia MD, 2000, INT J EPIDEMIOL, V29, P369
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Garly ML, 2001, VACCINE, V20, P468, DOI 10.1016/S0264-410X(01)00339-5
   GRANGE JM, 1990, TUBERCLE, V71, P61, DOI 10.1016/0041-3879(90)90063-E
   Gustafson P, 2001, JAMA-J AM MED ASSOC, V286, P599, DOI 10.1001/jama.286.5.599
   ILDIRIM I, 1992, ARCH DIS CHILD, V67, P80
   KNIKER WT, 1985, AM J DIS CHILD, V139, P840
   KNIKER WT, 1979, ANN ALLERGY, V43, P73
   KNIKER WT, 1984, ANN ALLERGY, V52, P75
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V
   Lobato MN, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.6.e75
   MAHER J, 1992, RESP MED, V86, P481, DOI 10.1016/S0954-6111(96)80006-0
   Mallol J, 1990, Rev Chil Pediatr, V61, P252
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Mulholland K, 2000, CLIN INFECT DIS, V30, pS206, DOI 10.1086/313863
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Norrgren H, 1999, ACTA TROP, V72, P309, DOI 10.1016/S0001-706X(99)00006-6
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Ota MOC, 1999, AIDS, V13, P996, DOI 10.1097/00002030-199905280-00020
   Rani S H, 1998, Indian Pediatr, V35, P123
   Raszka WV, 1996, J PEDIATR-US, V129, P245, DOI 10.1016/S0022-3476(96)70249-4
   Ravikumar M., 1999, Tubercle and Lung Disease, V79, P309, DOI 10.1054/tuld.1999.0213
   Shaheen SO, 1996, BRIT MED J, V313, P969
   SHELLDUNCAN B, 1993, AM J HUM BIOL, V5, P225, DOI 10.1002/ajhb.1310050212
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   Sivarajah N, 1990, Ceylon Med J, V35, P75
   Slovis BS, 2000, JAMA-J AM MED ASSOC, V283, P2003, DOI 10.1001/jama.283.15.2003
   SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013
   STARR S, 1964, NEW ENGL J MED, V270, P386, DOI 10.1056/NEJM196402202700802
   Testa J, 1991, Med Trop (Mars), V51, P313
   Wayne S.J., 1990, J GERONTOL, V45, P45
   WEILLHALLE MB, 1931, B ACAD NATL MED, V106, P45
NR 52
TC 90
Z9 90
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN 20
PY 2003
VL 21
IS 21-22
BP 2782
EP 2790
DI 10.1016/S0264-410X(03)00181-6
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 693GT
UT WOS:000183709300015
PM 12798618
OA No
DA 2017-08-15
ER

PT J
AU Ghattas, H
   Fulford, T
   Prentice, A
AF Ghattas, H
   Fulford, T
   Prentice, A
TI Effect of moderate anaemia on later mortality in rural African children
SO LANCET
LA English
DT Article
ID ANEMIA
AB Severe anaemia in childhood is associated with increased mortality, although evidence relating moderate anaemia to child survival is scarce. We aimed to investigate this association. We did a case-control study of children with moderate anaemia, and compared haemoglobin concentrations measured up to a year before death for 403 children (age range 28 days to 15 years) with those from children who survived (matched for age and sex). Data were obtained from long-term health records (1950-97) of a rural Gambian research centre. Excluding an acute effect In this last week of life, no evidence was recorded of lower haemoglobin concentrations in the children who died than in survivors, or of any general or disease-specific effects of non-severe anaemia (70-110 g/L) on mortality.
C1 St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, London WC1B 3DP, England.
RP Ghattas, H (reprint author), St George Hosp, Sch Med, Dept Infect Dis, Cranmer Terrace, London SW17 0RE, England.
RI Ghattas, Hala/K-5661-2016
CR BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   Brabin BJ, 2001, J NUTR, V131, p636S
   Gonzalez MA, 2000, B WORLD HEALTH ORGAN, V78, P97
   SMITH AW, 1989, ANN TROP PAEDIATR, V2, P6
   Stoltzfus RJ, 2001, J NUTR, V131, p697S
NR 5
TC 7
Z9 7
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 14
PY 2003
VL 361
IS 9374
BP 2048
EP 2050
DI 10.1016/S0140-6736(03)13617-3
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 689JT
UT WOS:000183488900015
PM 12814719
OA No
DA 2017-08-15
ER

PT J
AU Burton, KJ
   Allen, S
AF Burton, KJ
   Allen, S
TI A review of neurological disorders presenting at a paediatric neurology
   clinic and response to anticonvulsant therapy in Gambian children
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Review
ID PHENYTOIN; EPILEPSY
AB A clinical review of 128 children presenting at the paediatric neurology clinic of the Royal Victoria Hospital, The Gambia was conducted between July 2001 and January 2002. The aim was to assess the spectrum and burden of neurological disease presenting at this tertiary-level clinic and to evaluate the effectiveness of anticonvulsant therapy. The principal clinical diagnoses most frequently made were seizures (57%), neuromotor problems (15%) and developmental delay (11%,). Many children also had associated developmental delay or learning difficulties (55%), speech and language problems (42%) and physical disability (36%). Although 65% were considered to need assistance in the community, only 11% were receiving such help. There were 73 children with seizures, 80% of whom had a greater than 50% reduction in seizure frequency following the start of simple anticonvulsant medication. Of the children who had experienced more than 100 convulsions during the previous year, only 50% responded similarly to treatment. This review emphasises the need for improved community services and accessible medical care for children with neurological problems in West Africa.
C1 MRC Labs, Fajara, Banjul, Gambia.
   John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
RP Burton, KJ (reprint author), MRC Labs, POB 273, Fajara, Banjul, Gambia.
CR ARALI JA, 1997, J NEUROL SCI, V145, P3
   deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4
   FEKSI AT, 1991, LANCET S3, V46, P406
   Mani KS, 2001, LANCET, V357, P1316, DOI 10.1016/S0140-6736(00)04516-5
   Singhal BS, 1998, ARCH NEUROL-CHICAGO, V55, P1019, DOI 10.1001/archneur.55.7.1019
NR 5
TC 5
Z9 5
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA HUDSON RD, LEEDS LS9 7DL, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD JUN
PY 2003
VL 23
IS 2
BP 139
EP 143
DI 10.1179/027249303235002215
PG 5
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 683MV
UT WOS:000183154100006
PM 12803744
OA No
DA 2017-08-15
ER

PT J
AU Ghaem-Maghami, S
   Ratti, G
   Ghaem-Maghami, M
   Comanducci, M
   Hay, PE
   Bailey, RL
   Mabey, DCW
   Whittle, HC
   Ward, ME
   Lewis, DJM
AF Ghaem-Maghami, S
   Ratti, G
   Ghaem-Maghami, M
   Comanducci, M
   Hay, PE
   Bailey, RL
   Mabey, DCW
   Whittle, HC
   Ward, ME
   Lewis, DJM
TI Mucosal and systemic immune responses to plasmid protein pgp3 in
   patients with genital and ocular Chlamydia trachomatis infection
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE chlamydia; B cell; ELISPOT; pgp3; trachoma
ID ANTIBODY-SECRETING CELLS; DIAGNOSTIC-VALUE; ANTIGENS; IMMUNOGLOBULIN;
   EXPRESSION; ENUMERATION; VACCINATION; SEROLOGY; HUMANS; GENE
AB The circulating and cervical B cell responses to Chlamydia trachomatis plasmid protein pgp3 were characterized in children and adults with ocular or genital chlamydial infection using the enzyme-linked immunospot assay (ELISPOT) and ELISA. No pgp3-specific ASCs were detected in healthy controls, but predominantly IgA ASCs were detected in UK adults with uncomplicated cervicitis or urethritis (P = 0.03, 0.019). In patients with extragenital complications or pelvic inflammatory disease a mixed response with more IgG and IgM ASCs was evident, suggesting a breach of mucosal immune compartmentalization with more extensive infection. In women with chlamydial cervicitis, ASCs secreting predominantly IgA, but also IgG, to pgp3 were present in cervix at presentation, with a frequency 30-50 times higher than blood. Cervical ASC numbers, especially IgG, fell markedly six weeks after antibiotic treatment. We detected principally IgA pgp3-specific antibody secreting cells (ASCs) in children resident in a Gambian endemic area, with a trend towards suppression of IgA responses during intense trachomatous inflammation (P = 0.06), as previously reported for other chlamydial antigens, and in keeping with the findings in genital disease. These data provide a rationale for further studies of immune responses to pgp3 in humans and animal models of chlamydia-induced disease, and its potential use in diagnostic assays and protective immunization strategies.
C1 St George Hosp, Sch Med, Div Infect Dis, London SW17 0RE, England.
   St George Hosp, Sch Med, Div Genitourinary Med, London SW17 0RE, England.
   Chiron SpA, IRIS Res Ctr, Siena, Italy.
   London Sch Hyg & Trop Med, Dept Clin Sci, London, England.
   MRC Labs, Fajara, Gambia.
   Univ Southampton, Southampton Gen Hosp, Dept Mol Microbiol, Southampton SO9 5NH, Hants, England.
RP Lewis, DJM (reprint author), St George Hosp, Sch Med, Div Infect Dis, Cranmer Terrace, London SW17 0RE, England.
OI Lewis, David JM/0000-0003-3105-9075
CR Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   Bas S, 2001, J CLIN MICROBIOL, V39, P4082, DOI 10.1128/JCM.39.11.4082-4085.2001
   Bas S, 2001, J CLIN MICROBIOL, V39, P1368, DOI 10.1128/JCM.39.4.1368-1377.2001
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   BRUNHAM RC, 1994, INFECT AGENT DIS, V3, P218
   COMANDUCCI M, 1994, INFECT IMMUN, V62, P5491
   COMANDUCCI M, 1993, J GEN MICROBIOL, V139, P1083
   COMANDUCCI M, 1988, MOL MICROBIOL, V2, P531, DOI 10.1111/j.1365-2958.1988.tb00060.x
   COMANDUCCI M, 1990, PLASMID, V23, P149, DOI 10.1016/0147-619X(90)90034-A
   CROWLEYNOWICK PA, 1995, AM J REPROD IMMUNOL, V34, P241
   Czerkinsky C, 1999, IMMUNOL REV, V170, P197, DOI 10.1111/j.1600-065X.1999.tb01339.x
   CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3
   Dong-Ji Zhang, 2000, Infection and Immunity, V68, P3074, DOI 10.1128/IAI.68.6.3074-3078.2000
   FUJIHASHI K, 1993, J PERIODONTOL, V64, P400
   Gerard HC, 1998, J RHEUMATOL, V25, P734
   GhaemMaghami S, 1997, INFECT IMMUN, V65, P4958
   KANTELE A, 1986, J INFECT DIS, V153, P1126
   KANTELE AM, 1988, J INFECT DIS, V158, P1011
   KUTTEH HK, 1999, MUCOSAL IMMUNOLOGY, P1423
   KUTTEH WH, 1988, OBSTET GYNECOL, V71, P56
   LEWIS DJM, 1991, EUR J IMMUNOL, V21, P2087, DOI 10.1002/eji.1830210917
   Manclark CR, 1986, MANUAL CLIN LABORATO, P388
   Morrison RP, 2002, INFECT IMMUN, V70, P2741, DOI 10.1128/IAI.70.6.2741-2751.2002
   MOSCICKI AB, 1995, CLIN DIAGN LAB IMMUN, V2, P40
   PAL S, 1992, INFECT IMMUN, V60, P5294
   QUIDING M, 1991, J CLIN INVEST, V88, P143, DOI 10.1172/JCI115270
   QuidingJarbrink M, 1997, J CLIN INVEST, V99, P1281, DOI 10.1172/JCI119286
   ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279
   SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1
   Xu-Amano J, 1992, Adv Exp Med Biol, V327, P107
NR 32
TC 23
Z9 25
U1 0
U2 7
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUN
PY 2003
VL 132
IS 3
BP 436
EP 442
DI 10.1046/j.1365-2249.2003.02163.x
PG 7
WC Immunology
SC Immunology
GA 693BC
UT WOS:000183693900009
PM 12780690
OA No
DA 2017-08-15
ER

PT J
AU Aucan, C
   Walley, AJ
   Hennig, BJW
   Fitness, J
   Frodsham, A
   Zhang, L
   Kwiatkowski, D
   Hill, AVS
AF Aucan, C
   Walley, AJ
   Hennig, BJW
   Fitness, J
   Frodsham, A
   Zhang, L
   Kwiatkowski, D
   Hill, AVS
TI Interferon-alpha receptor-1 (IFNAR1) variants are associated with
   protection against cerebral malaria in The Gambia
SO GENES AND IMMUNITY
LA English
DT Article
DE cerebral malaria; case-control; interferon-alpha receptor-1; genetic
   association; diplotype
ID PLASMODIUM-FALCIPARUM MALARIA; TUMOR-NECROSIS-FACTOR; GAMMA-INTERFERON;
   IMMUNE-RESPONSE; CHILDREN; SUSCEPTIBILITY; RESISTANCE; SUBUNIT; GENE;
   INHIBITION
AB The chromosome 21q22.11 cytokine receptor cluster contains four genes that encode subunits of the receptors for the cytokines interleukin-10 and interferon-alpha, -beta and -gamma that may have a role in malaria pathogenesis. A total of 15 polymorphic markers located within these genes were initially genotyped in 190 controls, and 190 severe malaria cases from The Gambia. Two interferon-alpha receptor-1 (IFNAR1) gene SNPs (17470 and L168 V) showed evidence for an association with severe malaria phenotypes and were typed in a larger series of samples comprising 538 severe malaria cases, 338 mild malaria cases and 562 controls. Both the 17470-G/G and L168V-G/G genotypes were associated with protection against severe malaria, in general, and cerebral malaria, in particular(P = 0.004 and 0.003, respectively). IFNAR1 diplotypes were then constructed for these two markers using the PHASE software package. The (17470-G L 168V-G/17470-G L168V-G) diplotype was found to be associated with a reduced risk of cerebral malaria and the (17470-C L168V-C1/17470-G L168V-G) diplotype with an increased risk of cerebral malaria (overall 3 x 2 chi(2) = 12.8, d.f. = 2, P = 0.002 and 3 x 2 chi(2) = 15.2, d.f. = 2, P = 0.0005, respectively). These data suggest a role for the type I interferon pathway in resistance to cerebral malaria.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   MRC Labs, Banjul, Gambia.
RP Aucan, C (reprint author), Wellcome Trust Ctr Human Genet, Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.
RI HILL, Adrian/C-1306-2008; Hennig, Branwen/M-6444-2014
OI Walley, Andrew/0000-0001-7707-7549; Talbot, Angela/0000-0002-0386-8070
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Aitman TJ, 2000, NATURE, V405, P1015, DOI 10.1038/35016636
   Aucan C, 2002, T ROY SOC TROP MED H, V96, P327, DOI 10.1016/S0035-9203(02)90114-8
   Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P419, DOI 10.1016/S0952-7915(00)00111-4
   Butler D, 1997, NATURE, V386, P535
   COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133
   Day DJ, 1996, HUM MOL GENET, V5, P2039, DOI 10.1093/hmg/5.12.2039
   FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   HERRERA MA, 1992, INFECT IMMUN, V60, P154
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Hill AVS, 2001, ANNU REV GENOM HUM G, V2, P373, DOI 10.1146/annurev.genom.2.1.373
   Hosmer D., 1989, APPL LOGISTIC REGRES
   Jepson A, 1997, BRIT MED J, V315, P96
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   Kurtis JD, 1999, INFECT IMMUN, V67, P3424
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359
   Lucas R, 1997, J LEUKOCYTE BIOL, V61, P551
   LUTFALLA G, 1995, EMBO J, V14, P5100
   Luty AJF, 2000, INFECT IMMUN, V68, P3909, DOI 10.1128/IAI.68.7.3909-3915.2000
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   Malaguarnera L, 2002, LANCET INFECT DIS, V2, P472, DOI 10.1016/S1473-3099(02)00344-4
   May J, 2000, J INFECT DIS, V182, P1570, DOI 10.1086/315857
   Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206
   Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   Reboul J, 1999, GENOME RES, V9, P242
   Rihet P, 1998, AM J HUM GENET, V63, P498, DOI 10.1086/301967
   RILEY EM, 1991, PARASITOL TODAY, V7, P5, DOI 10.1016/0169-4758(91)90076-Z
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   STURCHLER D, 1989, VACCINE, V7, P457, DOI 10.1016/0264-410X(89)90162-X
   Vigario AM, 2001, BLOOD, V97, P3966, DOI 10.1182/blood.V97.12.3966
   Yan H, 1996, EMBO J, V15, P1064
NR 34
TC 55
Z9 58
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUN
PY 2003
VL 4
IS 4
BP 275
EP 282
DI 10.1038/sj.gene.6363962
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 683EZ
UT WOS:000183136100006
PM 12761564
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Leach, A
   Smith, PG
   Cutts, F
   Greenwood, B
AF Jaffar, S
   Leach, A
   Smith, PG
   Cutts, F
   Greenwood, B
TI Effects of misclassification of causes of death on the power of a trial
   to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE child mortality; pneumococcal vaccines; randomized trial; sample size;
   sensitivity; specificity; post-mortern questionnaire; verbal autopsy;
   Africa
ID UPPER RIVER DIVISION; VERBAL AUTOPSIES; CHILDHOOD MORTALITY;
   GUINEA-BISSAU; WEST-AFRICA; CHILDREN; MALARIA; INFANTS; IMMUNOGENICITY;
   LIMITATIONS
AB Background A reduction in cause-specific mortality may be the most important public health measure of the efficacy of a new vaccine. However, in developing countries, assignment of causes of deaths occurring outside hospitals can be assessed often only through the questioning of relatives about the signs and symptoms leading to death ('post-mortem questionnaire'). Causes assigned in this way have poor sensitivity and specificity. We illustrate the effects of this misclassification on the power of a large trial of a pneumococcal polysaccharide/protein conjugate vaccine with a mortality endpoint.
   Methods Required sample sizes to achieve a study with specified power were calculated for all-cause and acute lower respiratory tract infection (ALRI) mortality for different levels of sensitivity and specificity of post-mortem questionnaires. Data from active community-based surveillance and post-mortem questionnaires collected 1989-1993 from the study area were used in the calculations.
   Findings The mortality rate among children aged 6-29 months from all causes was 34.2 per 1000 child-years; 19% of deaths were attributable to ALRI. Assuming that pneumococci would be responsible for 50% of ALRI deaths and that the vaccine would cover 70% of disease serotypes and would be 90% effective against these serotypes, the expected efficacy of the vaccine would be 6.0% (19% x 50% x 70% x 90%) against all causes combined and 31.5% (50% x 70% x 90%) against deaths from ALRI. If, as suggested by various reports, the sensitivity and specificity of assigning a death to ALRI by post-mortem questionnaire are about 40% and 90% respectively, then the observed vaccine efficacy against ALRI (as classified using the post-mortem questionnaire) would fall to 20%, and the power to detect this would be reduced by approximately 40%. Furthermore, low sensitivity of diagnosis would lead to a falsely low estimate of the burden of ALRI mortality in the population and the trial might have greater power to detect a reduction in mortality from all causes combined than that estimated at the outset.
   Conclusions Low sensitivity and specificity of diagnosis by post-mortem questionnaire may mean that the power of a trial to detect a reduction in all-cause mortality is similar to that to detect a reduction in ALRI mortality. Since the latter is more susceptible to bias from misclassification of cause of death, all-cause mortality may be the most suitable endpoint. Similar considerations apply to trials of interventions against other diseases for which a cause-specific endpoint is subject to Substantial misclassification.
C1 Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1E 7HT, England.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Jaffar, S (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
CR Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   AABY P, 1995, BRIT MED J, V311, P481
   Benara S. K., 1999, Indian Journal of Pediatrics, V66, P647, DOI 10.1007/BF02726242
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Chandramohan D, 1998, TROP MED INT HEALTH, V3, P436
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   DALESSANDRO U, 1996, EPIDEMIOLOGICAL EVAL
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DEFRANCISCO A, 1994, J TROP MED HYG, V97, P69
   HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777
   Jaffar S, 1999, VACCINE, V18, P633, DOI 10.1016/S0264-410X(99)00277-7
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220
   Quigley MA, 1999, INT J EPIDEMIOL, V28, P1081, DOI 10.1093/ije/28.6.1081
   Rodriguez L, 1998, Indian J Pediatr, V65, P579, DOI 10.1007/BF02730899
   Shinefield HR, 2000, PEDIATR INFECT DIS J, V19, P394, DOI 10.1097/00006454-200004000-00036
   SMITH PG, 1996, FIELD TRIAL HLTH INT
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   TODD JE, 1994, ANN TROP PAEDIATR, V14, P31
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Watson L, 2002, VACCINE, V20, P2166, DOI 10.1016/S0264-410X(02)00112-3
   1994, B WHO, V70, P707
NR 27
TC 20
Z9 21
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD JUN
PY 2003
VL 32
IS 3
BP 430
EP 436
DI 10.1093/ije/dyg082
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 696EY
UT WOS:000183874800022
PM 12777432
OA No
DA 2017-08-15
ER

PT J
AU Marchant, A
   Appay, V
   van der Sande, M
   Dulphy, N
   Liesnard, C
   Kidd, M
   Kaye, S
   Ojuola, O
   Gillespie, GMA
   Cuero, ALV
   Cerundolo, V
   Callan, M
   McAdam, KPWJ
   Rowland-Jones, SL
   Donner, C
   McMichael, AJ
   Whittle, H
AF Marchant, A
   Appay, V
   van der Sande, M
   Dulphy, N
   Liesnard, C
   Kidd, M
   Kaye, S
   Ojuola, O
   Gillespie, GMA
   Cuero, ALV
   Cerundolo, V
   Callan, M
   McAdam, KPWJ
   Rowland-Jones, SL
   Donner, C
   McMichael, AJ
   Whittle, H
TI Mature CD8(+) T lymphocyte response to viral infection during fetal life
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; HUMAN CYTOMEGALOVIRUS;
   FUNCTIONAL-HETEROGENEITY; CELL REPERTOIRE; HIV-INFECTION; PROTEIN PP65;
   CTL RESPONSE; IN-VIVO; MEMORY; IDENTIFICATION
AB Immunization of newborns against viral infections may be hampered by ineffective CD8(+) T cell responses. To characterize the function of CD8(+)T lymphocytes in early life, we studied newborns with congenital human cytomegalovirus (HCMV) infection. We demonstrate that HCMV infection in utero leads to the expansion and the differentiation of mature HCMV-specific CD8(+)T cells, which have similar characteristics to those detected in adults. High frequencies of HCMV-specific CD8(+) T cells were detected by ex vivo tetramer staining as early as after 28 weeks of gestation. During the acute phase of infection, these cells had an early differentiation phenotype (CD28(-)CD27(+)CD45RO(+), perforin(low)), and they acquired a late differentiation phenotype (CD28(-)CD27(-)CD45RA(+), perforin(high)) during the course of the infection. The differentiated cells showed potent perforin-dependent cytolytic activity and produced antiviral cytokines. The finding of a mature and functional CD8(+) T cell response to HCMV suggests that the machinery required to prime such responses is in place during fetal life and could be used to immunize newborns against viral pathogens.
C1 Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.
   John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
   John Radcliffe Hosp, Weatherall Inst Mol Med, Tumor Immunol Grp, Canc Res United Kingdom, Oxford OX3 9DU, England.
   Hop Erasme, Dept Virol, Brussels, Belgium.
   Nuffield Dept Med, Oxford, England.
   Hop Erasme, Dept Obstet & Gynecol, Brussels, Belgium.
RP Marchant, A (reprint author), Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.
OI Cerundolo, Vincenzo/0000-0003-0040-3793; Dulphy,
   Nicolas/0000-0002-1243-6456
FU Medical Research Council [G116/121]
CR Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Arvin A, 2001, INFECT DIS FETUS NEW, P425
   Barouch DH, 2001, CURR OPIN IMMUNOL, V13, P479, DOI 10.1016/S0952-7915(00)00244-2
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   EVEN J, 1995, RES IMMUNOL, V146, P65, DOI 10.1016/0923-2494(96)80240-9
   GAMADIA LE, 2002, BLOOD, V101, P2686
   Garderet L, 1998, BLOOD, V91, P340
   GAVIN MA, 1993, J IMMUNOL, V151, P3971
   GEHRZ RC, 1977, LANCET, V2, P844
   Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000
   Goulder PJR, 2001, BRIT MED BULL, V58, P89, DOI 10.1093/bmb/58.1.89
   Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   Hermann E, 2002, BLOOD, V100, P2153
   Issacs D., 1987, LANCET, V2, P769
   JONJIC S, 1989, J EXP MED, V169, P1199, DOI 10.1084/jem.169.4.1199
   Kern F, 1999, J VIROL, V73, P8179
   Khan N, 2002, J IMMUNOL, V169, P1984
   Krmpotic A, 2002, NAT IMMUNOL, V3, P529, DOI 10.1038/ni799
   Lewis D, 2001, INFECT DIS FETUS NEW, P25
   LUZURIAGA K, 1995, J IMMUNOL, V154, P433
   Mahoney FJ, 1999, VACCINES, P158
   Mbawuike IN, 2001, J INFECT DIS, V183, P687, DOI 10.1086/318815
   PASS RF, 1983, J INFECT DIS, V148, P953
   POSNETT DN, 1996, IMMUNOLOGIST, V4, P5
   Preiser W, 2001, J CLIN VIROL, V20, P59, DOI 10.1016/S1386-6532(00)00156-6
   Reddehase MJ, 2000, CURR OPIN IMMUNOL, V12, P390, DOI 10.1016/S0952-7915(00)00106-0
   Retiere C, 2000, J VIROL, V74, P3948, DOI 10.1128/JVI.74.9.3948-3952.2000
   Salio M, 2001, J IMMUNOL, V167, P1188
   Sandberg JK, 2001, J IMMUNOL, V167, P181
   Scott ZA, 2001, J IMMUNOL, V167, P7134
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Solache A, 1999, J IMMUNOL, V163, P5512
   Stagno S., 2001, INFECT DIS FETUS NEW, P389
   TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059
   Tomiyama H, 2002, J IMMUNOL, V168, P5538
   UTZ U, 1992, J IMMUNOL, V149, P214
   Wasik TJ, 1997, J IMMUNOL, V158, P6029
   Weekes MP, 1999, J VIROL, V73, P2099
   Wills MR, 2002, J IMMUNOL, V168, P5455
   Wills MR, 1996, J VIROL, V70, P7569
NR 44
TC 152
Z9 159
U1 0
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2003
VL 111
IS 11
BP 1747
EP 1755
DI 10.1172/JCI200317470
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 686GQ
UT WOS:000183313400018
PM 12782677
OA No
DA 2017-08-15
ER

PT J
AU Metzger, WG
   Okenu, DMN
   Cavanagh, DR
   Robinson, JV
   Bojang, KA
   Weiss, HA
   McBride, JS
   Greenwood, BM
   Conway, DJ
AF Metzger, WG
   Okenu, DMN
   Cavanagh, DR
   Robinson, JV
   Bojang, KA
   Weiss, HA
   McBride, JS
   Greenwood, BM
   Conway, DJ
TI Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is
   strongly associated with a reduced prospective risk of malaria
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE malaria vaccine; antigen polymorphism; merozoite; antibodies; IgG3; MSP2
ID IMMUNOGLOBULIN G3 SUBCLASS; HUMAN-ANTIBODY RESPONSE; ANTIGENIC
   POLYMORPHISM; ALLELIC VARIANTS; IN-VITRO; VACCINE; DIVERSITY;
   SURFACE-ANTIGEN-2; INFECTIONS; SELECTION
AB The merozoite surface protein 2 (MSP2) of Plasmodium falciparum is recognized by human antibodies elicited during natural infections, and may be a target of protective immunity. In this prospective study, serum IgG antibodies to MSP2 were determined in a cohort of 329 Gambian children immediately before the annual malaria transmission season, and the incidence of clinical malaria in the following 5 months was monitored. Three recombinant MSP2 antigens were used, representing each of the two major allelic serogroups and a conserved region. The prevalence of serum IgG to each antigen correlated positively with age and with the presence of parasitaemia at the time of sampling. These antibodies were associated with a reduced subsequent incidence of clinical malaria during the follow-up. This trend was seen for both IgG1 and IgG3, although the statistical significance was greater for IgG3, the most common subclass against MSP2. After adjusting for potentially confounding effects of age and pre-season parasitaemia, IgG3 reactivities against each of the major serogroups of MSP2 remained significantly associated with a lower prospective risk of clinical malaria. Individuals who had IgG3 reactivity to both of the MSP2 serogroup antigens had an even more significantly reduced risk. Importantly, this effect remained significant after adjusting for a simultaneous strong protective association of antibodies to another antigen (MSP1 block 2) which itself remained highly significant.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England.
   Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH8 9YL, Midlothian, Scotland.
   MRC Labs, Fajara, Gambia.
RP Conway, DJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.
RI Cavanagh, David/A-1828-2008; Metzger, Wolfram/A-6878-2016
OI Conway, David/0000-0002-8711-3037
CR ALYAMAN F, 1995, PARASITE IMMUNOL, V17, P493, DOI 10.1111/j.1365-3024.1995.tb00920.x
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   BOUHAROUNTAYOUN.H, 1992, INFECT IMMUN, V66, P1473
   Cavanagh DR, 2001, INFECT IMMUN, V69, P1207, DOI 10.1128/IAI.69.2.1207-1211.2001
   CLARK JT, 1989, MOL BIOCHEM PARASIT, V32, P15, DOI 10.1016/0166-6851(89)90125-4
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   Conway DJ, 2001, MOL BIOCHEM PARASIT, V115, P145, DOI 10.1016/S0166-6851(01)00278-X
   Felger I, 1997, J MOL EVOL, V45, P154, DOI 10.1007/PL00006215
   FENTON B, 1991, MOL CELL BIOL, V11, P963
   Franks S, 2003, INFECT IMMUN, V71, P3485, DOI 10.1128/IAI.71.6.3485-3495.2003
   Garraud O, 2003, TRENDS IMMUNOL, V24, P30, DOI 10.1016/S1471-4906(02)00012-1
   Garraud O, 2002, INFECT IMMUN, V70, P2820, DOI 10.1128/IAI.70.6.2820-2827.2002
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Hoffmann EHE, 2001, ANN TROP MED PARASIT, V95, P117, DOI 10.1080/00034980120045833
   Lawrence G, 2000, VACCINE, V18, P1925, DOI 10.1016/S0264-410X(99)00444-2
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Rzepczyk CM, 1997, INFECT IMMUN, V65, P1098
   SCARSELLI E, 1993, INFECT IMMUN, V61, P3490
   SMYTHE JA, 1991, P NATL ACAD SCI USA, V88, P1751, DOI 10.1073/pnas.88.5.1751
   TAYLOR RR, 1995, INFECT IMMUN, V63, P4382
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   Tebo AE, 2001, EXP PARASITOL, V98, P20, DOI 10.1006/expr.2001.4619
   Theisen M, 2001, INFECT IMMUN, V69, P5223, DOI 10.1128/IAI.69.9.5223-5229.2001
   THOMAS AW, 1990, MOL BIOCHEM PARASIT, V43, P211, DOI 10.1016/0166-6851(90)90146-D
   TOLLE R, 1993, INFECT IMMUN, V61, P40
   Tonhosolo R, 2001, J EUKARYOT MICROBIOL, V48, P556, DOI 10.1111/j.1550-7408.2001.tb00191.x
   Weisman S, 2001, INFECT IMMUN, V69, P959, DOI 10.1128/IAI.69.2.959-967.2001
NR 28
TC 77
Z9 77
U1 0
U2 4
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD JUN
PY 2003
VL 25
IS 6
BP 307
EP 312
DI 10.1046/j.1365-3024.2003.00636.x
PG 6
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 723RV
UT WOS:000185446100002
PM 14507328
OA No
DA 2017-08-15
ER

PT J
AU Collinson, AC
   N'Gom, PT
   Moore, SE
   Morgan, G
   Prentice, AM
   Keneba, MRC
AF Collinson, AC
   N'Gom, PT
   Moore, SE
   Morgan, G
   Prentice, AM
   Keneba, MRC
TI Early seasonal effects on leucocyte and lymphocyte numbers in rural
   Gambian infants
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
CT 2nd World Congress on Dietal Origins of Adult Disease
CY JUN 07-10, 2003
CL BRIGHTON, ENGLAND
C1 MRC Keneba, MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD JUN
PY 2003
VL 53
IS 6
SU S
BP 18A
EP 18A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 686RB
UT WOS:000183333800131
OA No
DA 2017-08-15
ER

PT J
AU West, B
   Morison, L
   Van der Loeff, MS
   Gooding, E
   Awasana, AA
   Demba, E
   Mayaud, P
AF West, B
   Morison, L
   Van der Loeff, MS
   Gooding, E
   Awasana, AA
   Demba, E
   Mayaud, P
TI Evaluation of a new rapid diagnostic kit (FemExam) for bacterial
   vaginosis in patients with vaginal discharge syndrome in the Gambia
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PREGNANT-WOMEN; TYPE-1; INFECTION; HIV;
   ASSOCIATION; FLORA; TRANSMISSION; ACQUISITION; EXPRESSION
AB Background: Diagnosis of bacterial vaginosis (BV) in resource-poor primary health care settings is often overlooked; there is a need for a cheap, rapid, objective point-of-care diagnostic test.
   Goal: The goal was to determine the prevalence of BV and to evaluate the performance of a new commercial diagnostic test kit in a developing country environment.
   Study Design: Vaginal and cervical swabs were collected from 230 consecutive women attending a genitourinary medicine clinic with reported symptoms of vaginal discharge and/or itching. Etiological testing was carried out. BV was diagnosed on the basis of the Nugent score, the Amsel clinical criteria, and results of FemExam card tests. Card 1 is for pH and amines, and card 2 measures proline iminopeptidase (PIP) activity.
   Results: BV prevalence was 47.9% according to the Nugent score. When compared with the Nugent score, the Amsel clinical criteria had a sensitivity of 77.9% and specificity of 58.4%, FemExam card 1 had a sensitivity of 71.4% and specificity of 72.8%, FemExam card 2 had a sensitivity of 70% and specificity of 81.0%, and FemExam cards 1 and 2 combined had a sensitivity of 91.0%, and specificity of 61.5%. Cost per patient and cost per true case detected ranged from US $0.74 and US $1.54, respectively, for Gram stain diagnosis, to US $8.32 and US $18.49 for the FemExam No-card method.
   Conclusions: In a setting where BV was frequently associated with vaginal discharge, the FemExam test compared favorably with conventional clinical diagnosis, and it has the advantage of being rapid, less subjective. and easily performed. Cutting its cost would provide wider accessibility in developing countries.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London, England.
RP West, B (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Morison, Linda/H-9738-2013
CR AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017
   Cohen CR, 1999, AIDS, V13, P327, DOI 10.1097/00002030-199902250-00004
   Cristiano L, 1996, EUR J EPIDEMIOL, V12, P383, DOI 10.1007/BF00145302
   Cu-Uvin S, 2001, CLIN INFECT DIS, V33, P894
   Dallabetta GA, 1998, SEX TRANSM INFECT S1, V74, P1
   Delaney ML, 2001, OBSTET GYNECOL, V98, P79, DOI 10.1016/S0029-7844(01)01402-8
   Fleiss JL, 1981, STAT METHODS RATES P
   Govender L, 1996, INT J GYNECOL OBSTET, V55, P23, DOI 10.1016/0020-7292(96)02744-0
   Hashemi FB, 2000, J INFECT DIS, V181, P1574, DOI 10.1086/315455
   Hillier SL, 1999, SEXUALLY TRANSMITTED, P563
   Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604
   HILLIER SL, 1997, INFECT DIS OBSTET GY, V4, P360
   KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289
   Ledru S, 1996, SEX TRANSM DIS, V23, P151, DOI 10.1097/00007435-199603000-00011
   Mabey D, 2001, SEX TRANSM INFECT, V77, P397, DOI 10.1136/sti.77.6.397
   Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127
   Mayaud P, 1998, SEX TRANSM INFECT, V74, pS139
   Mayaud P, 1998, SEX TRANSM INFECT, V74, pS77
   Mayaud P, 1997, LANCET, V350, P530, DOI 10.1016/S0140-6736(97)22034-9
   Morris MC, 2001, SEX TRANSM INFECT, V77, P63, DOI 10.1136/sti.77.1.63
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297
   Pettifor A, 2000, SEX TRANSM DIS, V27, P371, DOI 10.1097/00007435-200008000-00002
   Royce RA, 1999, J ACQ IMMUN DEF SYND, V20, P382
   Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5
   Simoes JA, 2001, J INFECT DIS, V184, P22, DOI 10.1086/321002
   Sturm-Ramirez K, 2000, J INFECT DIS, V182, P467, DOI 10.1086/315713
   Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019
   VUYLSTEKE B, 1996, CONTROL SEXUALLY TRA, P151
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   World Health Organization, 2001, GUID MAN SEX TRANSM
NR 32
TC 28
Z9 30
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2003
VL 30
IS 6
BP 483
EP 489
DI 10.1097/00007435-200306000-00003
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 685VV
UT WOS:000183285200002
PM 12782948
OA No
DA 2017-08-15
ER

PT J
AU Lindsay, SW
   Jawara, M
   Paine, K
   Pinder, M
   Walraven, GEL
   Emerson, PM
AF Lindsay, SW
   Jawara, M
   Paine, K
   Pinder, M
   Walraven, GEL
   Emerson, PM
TI Changes in house design reduce exposure to malaria mosquitoes
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE malaria; house design; screening; mosquitoes; The Gambia
ID TREATED BED NETS; GAMBIA; INSECTICIDE; TRIAL
AB House design may affect an individual's exposure to malaria parasites, and hence to disease. We conducted a randomized-controlled study using experimental huts in rural Gambia, to determine whether installing a ceiling or closing the eaves could protect people from malaria mosquitoes. Five treatments were tested against a control hut: plywood ceiling; synthetic-netting ceiling; insecticide-treated synthetic-netting ceiling (deltamethrin 12.5 mg/m(2) ); plastic insect-screen ceiling; or the eaves closed with mud. The acceptability of such interventions was investigated by discussions with local communities. House entry by Anopheles gambiae , the principal African malaria vector, was reduced by the presence of a ceiling: plywood (59% reduction), synthetic-netting (79%), insecticide-treated synthetic-netting (78%), plastic insect-screen (80%, P < 0.001 in all cases) and closed eaves (37%, ns). Similar reductions were also seen with Mansonia spp., vectors of lymphatic filariasis and numerous arboviruses. Netting and insect-screen ceilings probably work as decoy traps attracting mosquitoes into the roof space, but not the room. Ceilings are likely to be well accepted and may be of greatest benefit in areas of low to moderate transmission and when used in combination with other malaria control strategies.
C1 Univ Durham, Sci Labs, Sch Biol & Biomed Sci, Inst Ecosyst Sci, Durham DH1 3LE, England.
   Med Res Labs, Banjul, Gambia.
RP Lindsay, SW (reprint author), Univ Durham, Sci Labs, Sch Biol & Biomed Sci, Inst Ecosyst Sci, Durham DH1 3LE, England.
CR AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   BOYD MARK F., 1926, AMER JOUR TROP MED, V6, P157
   CELLI A, 2001, NEW PREVENTATIVE TRE
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Le Prince JAA, 1916, MOSQUITO CONTROL PAN
   LINDSAY SW, 1991, MED VET ENTOMOL, V5, P477, DOI 10.1111/j.1365-2915.1991.tb00576.x
   Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6
   LINDSAY SW, 1988, T ROY SOC TROP MED H, V82, P645, DOI 10.1016/0035-9203(88)90546-9
   MAJORI G, 1987, MED VET ENTOMOL, V1, P185, DOI 10.1111/j.1365-2915.1987.tb00341.x
   MANSON P, 1900, LANCET, V1, P923
   MILLER JE, 1991, MED VET ENTOMOL, V5, P465, DOI 10.1111/j.1365-2915.1991.tb00575.x
   ROSS R, 1913, BRIT MED J, V1, P1186
   SNOW RW, 1987, B ENTOMOL RES, V77, P279
NR 13
TC 91
Z9 92
U1 0
U2 13
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2003
VL 8
IS 6
BP 512
EP 517
DI 10.1046/j.1365-3156.2003.01059.x
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 686YQ
UT WOS:000183348900004
PM 12791056
OA No
DA 2017-08-15
ER

PT J
AU Moorthy, VS
   McConkey, S
   Roberts, M
   Gothard, P
   Arulanantham, N
   Degano, P
   Schneider, J
   Hannan, C
   Roy, M
   Gilbert, SC
   Peto, TEA
   Hill, AVS
AF Moorthy, VS
   McConkey, S
   Roberts, M
   Gothard, P
   Arulanantham, N
   Degano, P
   Schneider, J
   Hannan, C
   Roy, M
   Gilbert, SC
   Peto, TEA
   Hill, AVS
TI Safety of DNA and modified vaccinia virus Ankara vaccines against
   liver-stage P-falciparum malaria in non-immune volunteers
SO VACCINE
LA English
DT Article
DE malaria; vaccine; safety
ID BOOST VACCINATION REGIMEN; CYTOTOXIC T-LYMPHOCYTES;
   PLASMODIUM-FALCIPARUM; PROTECTIVE EFFICACY; INTRAMUSCULAR INJECTION;
   ENHANCED IMMUNOGENICITY; RABIES GLYCOPROTEIN; PREVENTIVE VACCINE;
   RESPONSES; GENE
AB A series of phase I clinical studies were conducted to evaluate the safety of plasmid DNA and modified vaccinia virus Ankara malaria vaccines. The vaccines each encoded a polyepitope string fused to whole Plasmodium falciparum TRAP antigen. Forty-three healthy adult volunteers received the vaccines alone or in DNA/MVA prime-boost combinations. The DNA vaccine was administered either intramuscularly by needle or intradermally by a needleless delivery device. The MVA vaccine was administered intradermally by needle. The vaccines were well-tolerated by all three routes and in various DNA/MVA immunisation regimes. There were no severe or serious adverse events. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
   Powderject Vaccines, Madison, WI 53711 USA.
RP Moorthy, VS (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI HILL, Adrian/C-1306-2008; McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793; Gilbert, Sarah/0000-0002-6823-9750
CR AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123
   CADOZ M, 1992, LANCET, V339, P1429, DOI 10.1016/0140-6736(92)92027-D
   CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403
   Clements-Mann ML, 1998, J INFECT DIS, V177, P1230
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534
   Fries LF, 1996, VACCINE, V14, P428, DOI 10.1016/0264-410X(95)00171-V
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   Han R, 2000, VACCINE, V18, P2937, DOI 10.1016/S0264-410X(00)00110-9
   Hanke T, 1999, J VIROL, V73, P7524
   Hanke T, 1998, VACCINE, V16, P426, DOI 10.1016/S0264-410X(97)00296-X
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Kanesa-thasan N, 2000, VACCINE, V19, P483, DOI 10.1016/S0264-410X(00)00191-2
   Ledwith BJ, 2000, INTERVIROLOGY, V43, P258, DOI 10.1159/000053993
   MACKETT M, 1984, J VIROL, V49, P857
   MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375
   Mayr A, 1999, BERL MUNCH TIERARZTL, V112, P322
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031
   Mor G, 1997, HUM GENE THER, V8, P293, DOI 10.1089/hum.1997.8.3-293
   Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331
   Parker SE, 1999, HUM GENE THER, V10, P741, DOI 10.1089/10430349950018508
   PIALOUX G, 1995, AIDS RES HUM RETROV, V11, P373, DOI 10.1089/aid.1995.11.373
   ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648
   Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847
   Tacket CO, 1999, VACCINE, V17, P2826, DOI 10.1016/S0264-410X(99)00094-8
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   [Anonymous], 1996, MAL FACT SHEET
   WIZEL B, 1995, J IMMUNOL, V155, P766
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
NR 40
TC 46
Z9 47
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2003
VL 21
IS 17-18
BP 1995
EP 2002
DI 10.1016/S0264-410X(02)00771-5
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 682PF
UT WOS:000183100200027
PM 12706689
OA No
DA 2017-08-15
ER

PT J
AU Campbell, DI
   Elia, M
   Lunn, PG
AF Campbell, DI
   Elia, M
   Lunn, PG
TI Growth faltering in rural Gambian infants is associated with impaired
   small intestinal barrier function, leading to endotoxemia and systemic
   inflammation
SO JOURNAL OF NUTRITION
LA English
DT Article
DE infant growth; intestinal permeability; endotoxin; inflammation;
   enteropathy
ID CHRONIC DIARRHEA; MALNUTRITION; PERMEABILITY; CHILDHOOD; INFECTION;
   ANTIBODY; CHILDREN; FAILURE
AB Growth faltering of rural Gambian infants is associated with a chronic inflammatory enteropathy of the mucosa of the small intestine that may impair both digestive/absorptive and barrier functions. The aim of this study was to determine whether the enteropathy was associated with a compromised barrier function that allowed translocation of antigenic macromolecules from the gut lumen into the body, with subsequent systemic immunostimulation, resulting in growth retardation. Rural Gambian infants were studied longitudinally at regular intervals between 8 and 64 wk of age. On each study day, each child was medically examined, anthropometric measurements were made, a blood sample was taken and an intestinal permeability test performed. Evidence of chronic immunostimulation was provided by abnormally elevated white blood cell, lymphocyte and platelet counts, and frequently raised plasma concentration of C-reactive protein. Intestinal permeability was abnormal and associated with impaired growth (r = -0.41, P < 0.001). Plasma concentrations of endotoxin and immunoglobulin (Ig)G-endotoxin core antibody were also elevated and related to both growth (r = -0.30, P < 0.02; r = -0.64, P < 0.0001, respectively) and measures of mucosal enteropathy. Plasma IgG, IgA and IgM levels increased rapidly with age toward adult concentrations. Raised values were related to poor growth but also to measures of mucosal enteropathy and the endotoxin antibody titer. The interrelationships among these variables and growth suggested that they were all part of the same growth-retarding mechanism. These data are consistent with the hypothesis of translocation of immunogenic lumenal macromolecules across a compromised gut mucosa, leading to stimulation of systemic immune/inflammatory processes and subsequent growth impairment.
C1 MRC, Keneba, Gambia.
   Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Southampton Gen Hosp, Inst Human Nutr, Dept Clin Nutr & Metab, Southampton SO9 4XY, Hants, England.
   Univ Cambridge, Dept Biol Anthropol, Cambridge CB2 3DZ, England.
RP Lunn, PG (reprint author), MRC, Keneba, Gambia.
CR BARCLAY GR, 1989, CIRC SHOCK, V29, P93
   BEATON GH, 1982, AM J CLIN NUTR, V35, P864
   BEHRENS RH, 1987, AM J CLIN NUTR, V45, P1433
   BRIEND A, 1989, LANCET, V2, P319
   BROWN KH, 1993, AM J CLIN NUTR, V58, P49
   CAMPBELL DI, 2003, IN PRESS PEDIAT RES
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897
   HUGHES E, 1996, NORMAL VALUES
   KEUSCH GT, 1990, NESTLE NUTR WORKS SE, V19, P37
   LUNN PG, 1992, CLIN CHIM ACTA, V205, P151, DOI 10.1016/S0009-8981(05)80011-7
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   MARTORELL R, 1995, J NUTR, V125, pS1127
   Meites S., 1989, PEDIAT CLIN CHEM REF
   NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N
   NorthropClewes CA, 1997, J PEDIATR GASTR NUTR, V24, P257, DOI 10.1097/00005176-199703000-00005
   Prentice A., 1993, S AFR J CLIN NUTR, V6, P33
   PRENTICE A, 1990, HUMAN LACTATION, V4, P87
   Solomons NW, 2003, J NUTR, V133, P1237
   SOLOMONS NW, 1993, NUTR REV, V51, P327
   Stephensen CB, 1999, J NUTR, V129, p534S
   SULLIVAN PB, 1991, J PEDIATR GASTR NUTR, V12, P195, DOI 10.1097/00005176-199102000-00010
   SUSKIND R, 1976, AM J CLIN NUTR, V29, P836
   TRAVIS S, 1992, CLIN SCI, V82, P471
   WEAVER LT, 1988, T ROY SOC TROP MED H, V82, P784, DOI 10.1016/0035-9203(88)90236-2
   Yao YM, 1996, EUR J CLIN INVEST, V26, P224, DOI 10.1046/j.1365-2362.1996.128257.x
NR 28
TC 136
Z9 139
U1 0
U2 11
PU AMER INST NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD MAY
PY 2003
VL 133
IS 5
BP 1332
EP 1338
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 675ZG
UT WOS:000182727000018
PM 12730419
OA No
DA 2017-08-15
ER

PT J
AU Mangtani, P
   Hall, AJ
   Cutts, F
AF Mangtani, P
   Hall, AJ
   Cutts, F
TI Efficacy of polysaccharide pneumococcal vaccine in adults in more
   developed countries: another view of the evidence - Reply
SO LANCET INFECTIOUS DISEASES
LA English
DT Letter
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Mangtani, P (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR Christenson B, 2002, EPIDEMIOL INFECT, V129, P515, DOI 10.1017/S095026880200780X
   FORRESTER HL, 1987, AM J MED, V83, P425, DOI 10.1016/0002-9343(87)90751-0
   Nichol KL, 1999, ARCH INTERN MED, V159, P2437, DOI 10.1001/archinte.159.20.2437
   Nichol KL, 1999, VACCINE, V17, pS91, DOI 10.1016/S0264-410X(99)00114-0
   SMIT P, 1977, JAMA-J AM MED ASSOC, V238, P2613, DOI 10.1001/jama.238.24.2613
NR 5
TC 0
Z9 0
U1 1
U2 1
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD MAY
PY 2003
VL 3
IS 5
BP 273
EP 274
DI 10.1016/S1473-3099(03)00605-4
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 674MM
UT WOS:000182640600021
OA No
DA 2017-08-15
ER

PT J
AU Nwanegbo, EC
   Gambotto, A
   Robbins, PD
   Gao, WT
   Whittle, H
   Vardas, E
   Sun, HJ
AF Nwanegbo, EC
   Gambotto, A
   Robbins, PD
   Gao, WT
   Whittle, H
   Vardas, E
   Sun, HJ
TI Prevalence of anti-adenovirus 5 and 35 neutralizing antibodies in The
   Gambia, South Africa and United States adult population
SO MOLECULAR THERAPY
LA English
DT Meeting Abstract
CT 6th Annual Meeting of the American-Society-of-Gene-Therapy
CY JUN 04-08, 2003
CL WASHINGTON, D.C.
SP Amer Soc Gene Therapy
C1 Univ Pittsburgh, Pittsburgh, PA USA.
   MRC Labs, Banjul, Gambia.
   Univ Witwatersrand, HIV AIDS Vaccine Div, Soweto, South Africa.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD MAY
PY 2003
VL 7
IS 5
MA 157
BP S62
EP S62
PN 2
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 676FH
UT WOS:000182740300158
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Sillah, J
   Fielding, K
   Donkor, S
   Manneh, K
   Warndorff, D
   Bennett, S
   McAdam, K
AF Lienhardt, C
   Sillah, J
   Fielding, K
   Donkor, S
   Manneh, K
   Warndorff, D
   Bennett, S
   McAdam, K
TI Risk factors for tuberculosis infection in children in contact with
   infectious tuberculosis cases in The Gambia, West Africa
SO PEDIATRICS
LA English
DT Article
DE tuberculosis infection; child; tuberculin skin test; Mantoux test
ID NEW-YORK-CITY; CALMETTE-GUERIN; BCG VACCINATION; SKIN-TESTS;
   SENSITIVITY; POPULATION; BIRTH; EPIDEMIOLOGY; HOUSEHOLD; MORTALITY
AB Objective. Tuberculosis (TB) infection is highly prevalent in developing countries. As infected children represent a large proportion of the pool from which TB cases will arise, knowledge of the factors that influence TB infection in children are of importance to evaluate transmission of infection in the community and adapt TB control activities. There are limited data on the risk of infection in child populations in developing countries.
   Methods. We performed a household contact study in The Gambia (West Africa), in which children who were living in contact with individuals who had proven smear-positive pulmonary TB cases were investigated. A questionnaire was addressed to the mother or caregiver of the child to investigate the presence of various risk factors and assess the degree of exposure of the child to the individual with TB within the household. A tuberculin skin test (TST) was performed on each child. TST sizes greater than or equal to5 and 10 mm, respectively, were considered positive.
   Results. Households of 206 TB cases were visited, and 384 children aged <5 years were examined. The median age was 2, and 48% were girls. The distribution of TST responses followed a bimodal pattern, with 135 (35%) children presenting a palpable induration. Random effects logistic regression analysis demonstrated that the risk of positive TST response in the child increased with the geographic proximity of the child to the individual with TB within the household and with the degree of activities shared with the individual with TB. It was also associated with the clinical severity of the disease in the index case. Nutritional status and presence of a bacille Calmette-Guerin (BCG) scar were not independent risk factors for TST positivity in this population. On multivariate analysis, the effect of geographic proximity to the individual with TB, household size, and duration of cough in the index case persisted for TST responses &GE;5 mm.
   Conclusions. In a highly endemic country with high BCG vaccination coverage in Africa, TB infection in children who were in contact with individual with infectious TB was directly related to the intensity of exposure of the child to the individual with TB. Our data suggest that a positive TST in a child reflects most probably TB infection rather than previous BCG vaccination. Contact tracing can play a major role in the control of TB in developing countries.
C1 Inst Rech Developpement, Dakar, Senegal.
   MRC Labs, Banjul, Gambia.
   Natl TB Control Programme, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Lienhardt, C (reprint author), Inst Rech Developpement, BP 1386, Dakar, Senegal.
CR Almeida LMD, 2001, PEDIATR INFECT DIS J, V20, P1061, DOI 10.1097/00006454-200111000-00011
   ANDERSEN S, 1960, Bull World Health Organ, V22, P39
   Beyers N, 1997, INT J TUBERC LUNG D, V1, P38
   Bleiker M A, 1989, Bull Int Union Tuberc Lung Dis, V64, P7
   *CDC, 1981, AM REV RESPIR DIS, V123, P343
   CHAPMAN JS, 1964, AM REV RESPIR DIS, V90, P48
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   DONALD PR, 1999, TUBERCULOSIS CHILDRE
   ELLIOTT A, 1985, ANN TROP PAEDIATR, V5, P185
   Fine PEM, 2001, EPIDEMIOL INFECT, V126, P379
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   GRINDULIS H, 1984, ARCH DIS CHILD, V59, P614
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90
   HARLAND P S, 1965, East Afr Med J, V42, P233
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968
   KARALLIEDDE S, 1987, TUBERCLE, V68, P33, DOI 10.1016/0041-3879(87)90005-5
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   LIENHARDT C, 2001, INT J TUBERC LUNG S1, V5, pS227
   Lockman S, 1999, INT J TUBERC LUNG D, V3, P23
   MENZIES R, 1992, AM REV RESPIR DIS, V145, P621
   MUNOZ M, 2000, TUBERCULOSIS COMPREH, P553
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6
   National Tuberculosis Institute Bangalore, 1974, B WORLD HEALTH ORGAN, V51, P473
   NYBOE J, 1960, Bull World Health Organ, V22, P5
   PALMER CE, 1968, J AMER MED ASSOC, V205, P167, DOI 10.1001/jama.205.3.167
   RAJ N, 1966, B WORLD HEALTH ORGAN, V34, P639
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9
   ROELSGAARD E., 1964, BULL WORLD HEALTH ORGAN, V30, P459
   Saiman L, 2001, PEDIATRICS, V107, P999, DOI 10.1542/peds.107.5.999
   Scholten JN, 1999, INT J TUBERC LUNG D, V3, P31
   SEPULVEDA RL, 1988, PEDIATR INFECT DIS J, V7, P578
   SINHA DP, 1976, LANCET, V2, P531
   SNIDER DE, 1985, JAMA-J AM MED ASSOC, V253, P3438, DOI 10.1001/jama.253.23.3438
   Soren K, 1999, PEDIATR INFECT DIS J, V18, P949, DOI 10.1097/00006454-199911000-00002
   Sutherland I, 1976, Adv Tuberc Res, V19, P1
   THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587
   *WHO WORK GROUP, 1996, B WORLD HEALTH ORGAN, V64, P9329
   YOUNG TK, 1992, TUBERCLE LUNG DIS, V73, P94, DOI 10.1016/0962-8479(92)90062-O
NR 41
TC 48
Z9 50
U1 0
U2 1
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD MAY 1
PY 2003
VL 111
IS 5
BP E608
EP E614
DI 10.1542/peds.111.5.e608
PG 7
WC Pediatrics
SC Pediatrics
GA 673KC
UT WOS:000182579300012
PM 12728119
OA No
DA 2017-08-15
ER

PT J
AU Burgner, D
   Usen, S
   Rockett, K
   Jallow, M
   Ackerman, H
   Cervino, A
   Pinder, M
   Kwiatkowski, DP
AF Burgner, D
   Usen, S
   Rockett, K
   Jallow, M
   Ackerman, H
   Cervino, A
   Pinder, M
   Kwiatkowski, DP
TI Nucleotide and haplotypic diversity of the NOS2A promoter region and its
   relationship to cerebral malaria
SO HUMAN GENETICS
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; COMMON DISEASE GENES; LINKAGE DISEQUILIBRIUM;
   TANZANIAN CHILDREN; PROTECTION; POLYMORPHISM; ASSOCIATION; EXPRESSION;
   TRANSMISSION; LAMBARENE
AB To assess the hypothesis that nitric oxide is critical in the pathogenesis of cerebral malaria, we analysed genetic variation in the proximal promoter region of NOS2A, the gene encoding inducible nitric oxide synthase. Sequencing 72 Gambian chromosomes revealed 11 single nucleotide polymorphisms in 2.5 kB (theta = 8.6 x 10(-4)). Genotyping 104 nuclear families identified six common haplotypes. A single haplotype, uniquely defined by the NOS2A-1659T allele, was associated with cerebral malaria by a transmission disequilibrium test of 334 affected children and their parents (P = 0.02). An independent case-control study of 505 different children from the same population replicated the allelic association with cerebral malaria (odds ratio: 1.31, P = 0.04). Taken together these data indicate a weak but significant association of the NOS2A locus with susceptibility to cerebral malaria. Despite high linkage disequilibrium across the region studied, this association would not have been detected without the initial construction of a dense marker set for haplotype tagging.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX2 7BN, England.
   MRC Labs, Fajara, Gambia.
   Royal Victoria Hosp, Banjul, Gambia.
RP Kwiatkowski, DP (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX2 7BN, England.
CR AlYaman FM, 1996, T ROY SOC TROP MED H, V90, P270, DOI 10.1016/S0035-9203(96)90243-6
   Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557
   Burgner D, 1998, LANCET, V352, P1193, DOI 10.1016/S0140-6736(05)60531-4
   Cargill M, 1999, NAT GENET, V22, P231
   Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977
   Clark I. A., 1999, Acta Physiologica Scandinavica, V167, P14
   CLARK IA, 1992, LANCET, V340, P894, DOI 10.1016/0140-6736(92)93295-X
   Clark IA, 1996, ADV PARASIT, V37, P1, DOI 10.1016/S0065-308X(08)60218-3
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   Gavrilyuk V, 2001, J NEUROCHEM, V78, P129, DOI 10.1046/j.1471-4159.2001.00375.x
   Granger DL, 1999, METHOD ENZYMOL, V301, P49
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HOFFMAN SL, 1996, MALARIA VACCINE DEV, P2005
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   IKUTA S, 1987, NUCLEIC ACIDS RES, V15, P797, DOI 10.1093/nar/15.2.797
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   Kremsner PG, 1996, T ROY SOC TROP MED H, V90, P44, DOI 10.1016/S0035-9203(96)90476-9
   Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642
   Kun JF, 2001, J INFECT DIS, V184, P330, DOI 10.1086/322037
   Kun JFJ, 1999, AM J TROP MED HYG, V61, P776
   Kun JFJ, 1998, LANCET, V351, P265, DOI 10.1016/S0140-6736(05)78273-8
   Levesque MC, 1999, J INFECT DIS, V180, P1994, DOI 10.1086/315140
   Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499
   Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Morris BJ, 2002, J MOL MED-JMM, V80, P96, DOI 10.1007/s00109-001-0287-1
   Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782
   Pance A, 2002, FASEB J, V16, P631, DOI 10.1096/fj-01-0450fje
   Povey S, 2001, HUM GENET, V109, P678, DOI 10.1007/s00439-001-0615-0
   ROCKETT KA, 1991, INFECT IMMUN, V59, P3280
   Rockett KA, 1998, INFECT IMMUN, V66, P5314
   Schaid DJ, 1996, GENET EPIDEMIOL, V13, P423, DOI 10.1002/(SICI)1098-2272(1996)13:5<423::AID-GEPI1>3.0.CO;2-3
   SCHOEDON G, 1995, CLIN INFECT DIS, V21, pS152
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Spitsin SV, 1996, MOL MED, V2, P226
   Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000
   vanHensbroek MB, 1997, J PEDIATR-US, V131, P125, DOI 10.1016/S0022-3476(97)70135-5
   VERA ME, 1996, P NATL ACAD SCI USA, V93, P1054
   WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543
   Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316
   Xu WM, 1997, GENE, V204, P165, DOI 10.1016/S0378-1119(97)00538-6
NR 42
TC 47
Z9 48
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD APR
PY 2003
VL 112
IS 4
BP 379
EP 386
DI 10.1007/s00439-002-0882-4
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 671KP
UT WOS:000182464200008
PM 12552317
OA No
DA 2017-08-15
ER

PT J
AU Polley, SD
   Tetteh, KKA
   Cavanagh, DR
   Pearce, RJ
   Lloyd, JM
   Bojang, KA
   Okenu, DMN
   Greenwood, BM
   McBride, JS
   Conway, DJ
AF Polley, SD
   Tetteh, KKA
   Cavanagh, DR
   Pearce, RJ
   Lloyd, JM
   Bojang, KA
   Okenu, DMN
   Greenwood, BM
   McBride, JS
   Conway, DJ
TI Repeat sequences in block 2 of Plasmodium falciparum merozoite surface
   protein 1 are targets of antibodies associated with protection from
   malaria
SO INFECTION AND IMMUNITY
LA English
DT Article
ID AOTUS MONKEYS; ANTIGEN GENE; T-CELL; PARASITE; RESPONSES; IMMUNE;
   EFFICACY; VACCINE; INFECTION; FRAGMENT
AB Human antibodies to the block 2 region of Plasmodium falciparum merozoite surface protein 1 (MSP1) are associated with a reduced prospective risk of clinical malaria. Block 2 is highly polymorphic, but all known alleles can be grouped into three major types. Two of these types (the K1-like and MAD20-like types) contain type-specific sequences (found in all alleles of a particular type) that flank polymorphic tripeptide repeats. These repeats contain both type-specific and subtype-specific sequences. To evaluate the antibody recognition of these parts of block 2, a new panel of six recombinant proteins was used (fused type-specific flanking sequences and two representative repeat sequences for each of the K1-like and MAD20-like types separately). Extensive testing of these antigens and full-length block 2 antigens showed that human serum immunoglobulin G antibodies induced by infection can recognize (i) type-specific epitopes in the repeats, (ii) subtype-specific epitopes in the repeats, or (iii) type-specific epitopes in flanking sequences. A large prospective study in The Gambia showed that antibodies to the repeats are strongly associated with protection from clinical malaria. The results are important for design of a vaccine to induce protective antibodies, and they address hypotheses about repeat sequences in malaria antigens.
C1 Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland.
   MRC Labs, Fajara, Gambia.
   Nigerian Inst Med Res, Lagos, Nigeria.
RP Conway, DJ (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
RI Cavanagh, David/A-1828-2008; Polley, Spencer/F-7766-2013
OI Bojang, Kalifa/0000-0001-7506-0938; Conway, David/0000-0002-8711-3037
CR AlYaman F, 1996, AM J TROP MED HYG, V54, P443
   ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409
   BOUHAROUNTAYOUN H, 1992, INFECT IMMUN, V60, P1473
   Branch OH, 2001, INFECT IMMUN, V69, P7783, DOI 10.1128/IAI.69.12.7783-7792.2001
   Branch OH, 1998, AM J TROP MED HYG, V58, P211
   Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5
   Cavanagh DR, 2001, INFECT IMMUN, V69, P1207, DOI 10.1128/IAI.69.2.1207-1211.2001
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Chang SP, 1996, INFECT IMMUN, V64, P253
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   Dodoo D, 1999, INFECT IMMUN, V67, P2131
   Egan AF, 1996, J INFECT DIS, V173, P765
   FRUH K, 1991, INFECT IMMUN, V59, P1319
   Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57
   HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0
   Jouin H, 2001, EUR J IMMUNOL, V31, P539, DOI 10.1002/1521-4141(200102)31:2<539::AID-IMMU539>3.0.CO;2-1
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Kumar S, 2000, INFECT IMMUN, V68, P2215, DOI 10.1128/IAI.68.4.2215-2223.2000
   Locher CP, 1996, EXP PARASITOL, V84, P74, DOI 10.1006/expr.1996.0091
   Millie DF, 1993, CURR TOPICS BOT RES, V1, P1
   O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Parra M, 2000, INFECT IMMUN, V68, P2685, DOI 10.1128/IAI.68.5.2685-2691.2000
   QUAKYI IA, 1994, J IMMUNOL, V153, P2082
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L
   SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014
   SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4
   TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8
   TOLLE R, 1993, INFECT IMMUN, V61, P40
   Uthaipibull C, 2001, J MOL BIOL, V307, P1381, DOI 10.1006/jmbi.2001.4574
   Verra F, 1999, MOL BIOL EVOL, V16, P627
NR 36
TC 40
Z9 40
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2003
VL 71
IS 4
BP 1833
EP 1842
DI 10.1128/IAI.71.4.1833-1842.2003
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 662BQ
UT WOS:000181926200027
PM 12654798
OA No
DA 2017-08-15
ER

PT J
AU Baum, J
   Pinder, M
   Conway, DJ
AF Baum, J
   Pinder, M
   Conway, DJ
TI Erythrocyte invasion phenotypes of Plasmodium falciparum in the Gambia
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MALARIA PARASITES; BINDING-PROTEINS; GLYCOPHORIN-A; RECEPTOR
   HETEROGENEITY; EBA-175; VIVAX; PATHWAYS; DOMAINS; ANTIBODIES; RESIDUES
AB In vitro experimentation with Plasmodium falciparum has determined that a number of different receptor-ligand interactions are involved in the invasion of erythrocytes. Most culture-adapted parasite isolates use a mechanism of invasion that depends primarily on the erythrocyte sialoglycoprotein glycophorin A (GYPA) and erythrocyte-binding antigen 175 (EBA-175) of the parasite blood-stage merozoite. However, a minority of culture-adapted parasites and a majority of Indian field isolates can apparently invade by other means. Here, erythrocyte invasion phenotypes of P. falciparum field isolates in Africa were studied. For 38 Gambian isolates, invasion of neuraminidase-treated and trypsin-treated erythrocytes was inhibited, on average, by more than 60 and 85%, respectively, indicating a high level of dependence on sialic acid and trypsin-sensitive proteins on the erythrocyte surface. These results support the hypothesis that African P. falciparum parasites use GYPA as a primary receptor for invasion. However, the considerable variation among isolates confirms the idea that alternative receptors are also used by many parasites. Three amino acid polymorphisms in the GYPA-binding region of EBA-175 (region II) were not significantly associated with invasion phenotype. There was variation among isolates in the selectivity index (i.e., a statistical tendency toward aggregation or multiple invasions of host erythrocytes), but this variation did not correlate with enzyme-determined invasion phenotype or with eba-175 alleles. Overall, these invasion phenotypes in Africa support a vaccine strategy of inhibiting EBA-175 binding to GYPA but suggest that parasites with alternative phenotypes would be selected for if this strategy were used alone.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Baum, J (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
OI Baum, Jake/0000-0002-0275-352X; Conway, David/0000-0002-8711-3037
CR Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1
   ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085
   Barnwell John W., 1998, P93
   BAUM JA, IN PRESS GENETICS
   Binks RH, 1999, MOL BIOCHEM PARASIT, V103, P123, DOI 10.1016/S0166-6851(99)00115-2
   CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497
   Chotivanich K, 2000, J INFECT DIS, V181, P1206, DOI 10.1086/315353
   DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1
   FACER CA, 1983, T ROY SOC TROP MED H, V77, P524, DOI 10.1016/0035-9203(83)90130-X
   Farnert A, 2001, T ROY SOC TROP MED H, V95, P225, DOI 10.1016/S0035-9203(01)90175-0
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178
   HOLT EH, 1989, AM J TROP MED HYG, V40, P245
   HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250
   Huang CH, 1995, BLOOD CELL BIOCH, V6, P153
   Jones TR, 2001, J INFECT DIS, V183, P303, DOI 10.1086/317933
   LAMONT G, 1981, EXP PARASITOL, V51, P74, DOI 10.1016/0014-4894(81)90043-6
   Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398
   MITCHELL GH, 1986, BLOOD, V67, P1519
   MONS B, 1988, EXP PARASITOL, V66, P183, DOI 10.1016/0014-4894(88)90089-6
   Ockenhouse CF, 2001, MOL BIOCHEM PARASIT, V113, P9, DOI 10.1016/S0166-6851(00)00375-3
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Okoyeh JN, 1999, INFECT IMMUN, V67, P5784
   Ozwara H, 2001, MOL BIOCHEM PARASIT, V116, P81, DOI 10.1016/S0166-6851(01)00298-5
   PASVOL G, 1982, NATURE, V297, P64, DOI 10.1038/297064a0
   PERKINS ME, 1988, MOL BIOCHEM PARASIT, V27, P23, DOI 10.1016/0166-6851(88)90021-7
   Ranjan A, 1999, P NATL ACAD SCI USA, V96, P14067, DOI 10.1073/pnas.96.24.14067
   Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571
   Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a
   SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226
   Simpson JA, 1999, T ROY SOC TROP MED H, V93, P165, DOI 10.1016/S0035-9203(99)90295-X
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
NR 33
TC 68
Z9 69
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2003
VL 71
IS 4
BP 1856
EP 1863
DI 10.1128/IAI.71.4.1856-1863.2003
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 662BQ
UT WOS:000181926200030
PM 12654801
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Hill, P
   Baldeh, I
   Otu, J
   Sarr, R
   Sillah, J
   Lienhardt, C
   Corrah, T
   Manneh, K
   Drobniewski, F
   McAdam, KPWJ
AF Adegbola, RA
   Hill, P
   Baldeh, I
   Otu, J
   Sarr, R
   Sillah, J
   Lienhardt, C
   Corrah, T
   Manneh, K
   Drobniewski, F
   McAdam, KPWJ
TI Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE drug resistance; Mycobacterium tuberculosis; The Gambia
AB To determine the rates of drug-resistant tuberculosis in The Gambia, Mycobacterium tuberculosis isolates obtained from 225 patients during a nationwide survey were tested against isoniazid, rifampicin, ethambutol and streptomycin using the resistance ratio method. Only nine (4%) of the patients had strains that were resistant to one or more drugs. None of the patients with drug-resistant M. tuberculosis had previously been treated for tuberculosis. Drug-resistant tuberculosis is, as yet, not common in The Gambia. Periodic surveys for drug-resistant tuberculosis are recommended to monitor changes that may emerge over time.
C1 MRC Labs, Banjul, Gambia.
   Natl TB Control Programme, Banjul, Gambia.
   Kings Coll Hosp London, Dept Microbiol, London, England.
   Kings Coll Hosp London, Dulwich Publ Hlth Lab, PHLS Mycobacterium Reference Unit, London, England.
RP Adegbola, RA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM radegbola@mrc.gm
FU Medical Research Council [MC_U190071468]
CR Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5
   Collins C. H., 1997, TUBERCULOSIS BACTERI
   Githui WA, 1998, INT J TUBERC LUNG D, V2, P499
   Heifets Leonid B., 1994, P85
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784
   MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423
   *NAT LEPR TUB PROG, 2001, ANN REP
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301
   *WHO IUATLD, 1997, WHOTB97229 IUATLD
   *WHO IUATLD, 1996, WHOTB96216 IUATLD
NR 10
TC 29
Z9 30
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD APR
PY 2003
VL 7
IS 4
BP 390
EP 393
PG 4
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 665NP
UT WOS:000182127700015
PM 12729346
OA No
DA 2017-08-15
ER

PT J
AU Munoz, B
   Solomon, AW
   Zingeser, J
   Barwick, R
   Burton, M
   Bailey, R
   Mabey, D
   Foster, A
   West, SK
AF Munoz, B
   Solomon, AW
   Zingeser, J
   Barwick, R
   Burton, M
   Bailey, R
   Mabey, D
   Foster, A
   West, SK
TI Antibiotic dosage in trachoma control programs: Height as a surrogate
   for weight in children
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DOSE ASSESSMENT; IVERMECTIN; AZITHROMYCIN
AB PURPOSE. National programs for trachoma control are implementing mass treatment programs in which azithromycin is used as part of the control strategy. Dose is determined by weight, which can be difficult to determine in field conditions. The purposes of this study were to determine whether an accurate dose could be determined by using height as. a Surrogate for weight and whether a single model of height-based dosage would be applicable in more than one setting.
   METHODS. Data on height, weight, age, and gender of 5558 children aged 6 months to 15 years were obtained from Kongwa and Rombo, Tanzania; Malakal, Sudan; Jareng, The Gambia; and Daboya, Ghana. Models for predicting weight by measuring height were developed that incorporated country-specific parameters. Doses of azithromycin assumed suspension of 40 mg/mL and 250-mg tablets that could be halved. Tolerance limits were defined as 15 to 30 mg/kg.
   RESULTS. A regression model, predicting log weight as a function of log height, was the best fit and explained 94% of the variance. In children less than 1 year of age or 60 cm in height, dose determined by weight was preferred. Dosage by height resulted in more than 97% of children receiving doses within the tolerance limits. Children aged 1 to 2 years were the group most likely to be over- or undermedicated, but this occurred in only 6% of this age group.
   CONCLUSIONS. Height-based determination of dosage of azithromycin in trachoma control programs appears to be feasible, using the height-based schedule proposed. One model was adequate for all the countries in the study. Further expansion to other countries is warranted.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   London Sch Hyg & Trop Med, London WC1, England.
   Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania.
   Huruma Hosp, Rombo, Tanzania.
   Emory Univ, Carter Ctr, Atlanta, GA 30322 USA.
   MRC Labs, Banjul, Gambia.
RP West, SK (reprint author), Johns Hopkins Univ Hosp, Dana Ctr Prevent Ophthalmol, Wilmer Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169;
   Solomon, Anthony/0000-0001-7101-6649
CR ALEXANDER NDE, 1993, B WORLD HEALTH ORGAN, V71, P361
   COUSENS SN, 1994, INT OPHTHALMOL, V18, P215
   Hall A, 1999, T ROY SOC TROP MED H, V93, P653, DOI 10.1016/S0035-9203(99)90087-1
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Shu EN, 2001, AM J TROP MED HYG, V65, P184
   Solomon AW, 2001, B WORLD HEALTH ORGAN, V79, P8
   TAYLOR HR, 1993, LANCET, V341, P50, DOI 10.1016/0140-6736(93)92524-W
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   World Health Organization, 1998, WHO 51 WORLD HLTH AS
NR 9
TC 12
Z9 12
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2003
VL 44
IS 4
BP 1464
EP 1469
DI 10.1167/iovs.02-0234
PG 6
WC Ophthalmology
SC Ophthalmology
GA 660TG
UT WOS:000181848900013
PM 12657580
OA No
DA 2017-08-15
ER

PT J
AU McConkey, SJ
   Schneider, J
   Mendy, M
   Anderson, RJ
   Nicoll, C
   Bertoletti, A
   Whittle, H
   Hill, AV
AF McConkey, SJ
   Schneider, J
   Mendy, M
   Anderson, RJ
   Nicoll, C
   Bertoletti, A
   Whittle, H
   Hill, AV
TI Therapeutic vaccination against hepatitis B virus using heterolgous
   prime boost strategy with DNA and modified vaccinia virus ankara vectors
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 38th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY MAR 29-APR 01, 2003
CL ISTANBUL, TURKEY
SP European Assoc Study Liver
C1 Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
   Oxxon Pharmaccines, Oxford, England.
   UCL, Inst Hepatol, London WC1E 6BT, England.
   MRC Labs, Fajara, Gambia.
RI HILL, Adrian/C-1306-2008; McConkey, Samuel/E-7307-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2003
VL 38
SU 2
MA 538
BP 156
EP 156
DI 10.1016/S0168-8278(03)80804-8
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 666JQ
UT WOS:000182174500531
OA No
DA 2017-08-15
ER

PT J
AU Jaye, A
   Herberts, CA
   Jallow, S
   Atabani, S
   Klein, MR
   Hoogerhout, P
   Kidd, M
   van Els, CACM
   Whittle, HC
AF Jaye, A
   Herberts, CA
   Jallow, S
   Atabani, S
   Klein, MR
   Hoogerhout, P
   Kidd, M
   van Els, CACM
   Whittle, HC
TI Vigorous but short-term gamma interferon T-Cell responses against a
   dominant HLA-A*02-restricted measles virus epitope in patients with
   measles
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HLA-A; LYMPHOCYTES; INFECTION; ANTIGENS; CHILDREN; BINDING; ADULTS
AB The absolute and relative abundance of major histocompatibility complex class I-presented viral epitopes is important in the induction and maintenance of antiviral cytotoxic-T-lymphocyte (CTL) responses. We demonstrate that the supra-abundant HLA-A*0201-restricted peptide KLWESPQEI of the measles virus nonstructural C protein induces strong gamma interferon CD8(+)-T-cell responses in children with acute measles. However, longitudinal analysis indicates that these responses are only short-lived. Thus, some viral epitopes that can be immunodominant during primary infection may fail to establish memory CTL responses.
C1 MRC Labs, Banjul, Gambia.
   Natl Inst Publ Hlth & Environm, Lab Vaccine Res, NL-3720 BA Bilthoven, Netherlands.
RP Jaye, A (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR BAROUCH D, 1995, J EXP MED, V182, P1847, DOI 10.1084/jem.182.6.1847
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   DELGUERCIO MF, 1995, J IMMUNOL, V154, P685
   Jaye A, 1998, J CLIN INVEST, V102, P1969, DOI 10.1172/JCI3290
   Jaye A, 1998, J INFECT DIS, V177, P1282
   KERNAHAN J, 1987, BRIT MED J, V295, P15
   KRAUSA P, 1995, TISSUE ANTIGENS, V45, P223, DOI 10.1111/j.1399-0039.1995.tb02444.x
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   MARKOWITZ L E, 1988, Journal of Infectious Diseases, V158, P480
   MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0
   Nanan R, 2000, J GEN VIROL, V81, P1313
   Oxenius A, 1998, IMMUNITY, V9, P449, DOI 10.1016/S1074-7613(00)80628-7
   Schneider-Schaulies Sibylle, 2001, Current Molecular Medicine (Hilversum), V1, P163, DOI 10.2174/1566524013363960
   TANIGAKI N, 1994, HUM IMMUNOL, V39, P155, DOI 10.1016/0198-8859(94)90255-0
   van Els CACM, 2000, EUR J IMMUNOL, V30, P1172, DOI 10.1002/(SICI)1521-4141(200004)30:4<1172::AID-IMMU1172>3.0.CO;2-J
   van Els CACM, 2002, VIRAL IMMUNOL, V15, P435, DOI 10.1089/088282402760312322
NR 16
TC 21
Z9 21
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD APR
PY 2003
VL 77
IS 8
BP 5014
EP 5016
DI 10.1128/JVI.77.8.5014-5016.2003
PG 3
WC Virology
SC Virology
GA 662VU
UT WOS:000181970200056
PM 12663809
OA No
DA 2017-08-15
ER

PT J
AU Akinbamijo, OO
   Nouala, S
   Sanyang, FB
   Smith, OB
AF Akinbamijo, OO
   Nouala, S
   Sanyang, FB
   Smith, OB
TI Utilisation of horticultural residues by N'Dama cattle and their crosses
   in The Gambia
SO LIVESTOCK PRODUCTION SCIENCE
LA English
DT Article
DE urban feed resources; horticultural residues; in vivo; feed conversion;
   N'Dama; crossbred
ID FEED-INTAKE REGULATION; RUMINANTS
AB In a 90-day study, the feed conversion efficiency of three cattle genotypes was tested on non-conventional feed resources with a view of widening the feed resource base for peri-urban dairy production in The Gambia. Eighteen growing bulls in three breed groups comprising of six bulls each with a mean starting weight of 157 +/- 14 kg; 230 +/- 31 kg and 194 +/- 26 kg kg for N'Dama (ND), N'Dama X Holstein-Freisian (NHF) and N'Dama X Jersey (NJ), respectively, were used in the study. Experimental diet was a composite ration based on horticultural residues consisting of 667 g/kg baby com stalk and 333 g/kg bean vines collected from commercial farms of the Greater Banjul Area. Cattle genotype had a significant effect on in vivo dry and organic matter digestibility. NHF hid a lower (P < 0.01) digestibility coefficient compared with NJ and the pure ND with 559, 602 and 615 g/kg for NHF, NJ and ND bulls, respectively. The voluntary feed intake of the experimental diet ranged between 25 and 27 g/kg LW across genotypes resulting in a positive nutrient retention in the experimental animals. Data on live weight showed that the feed allowance was good enough not only to maintain the animals but also allowing for generous average daily gains (ADGs) of 510, 640 and 680 for ND, NJ and NHF, respectively. Although the ND had the least (P < 0.05) ADG, it recorded the highest mean body condition score. In conclusion, the horticultural resides proved to be a feed resource of high biological value in terms of feed conversion to animal products if harnessed judiciously especially for the peri-urban dairy sub sector. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Int Dev Res Ctr, Ottawa, ON, Canada.
RP Akinbamijo, OO (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
EM yemi.akinbamijo@itc.gm
CR AKINBAMIJO O, 2000, IN PRESS SEM INT AIM
   Akinbamijo OO, 1997, ANIM SCI, V65, P151
   BUVANENDRAN V, 1981, ANIM PROD, V32, P165
   CISSE I, 2000, THESIS UCAD DAKAR SE
   *ILRI, 1998, LIV PEOPL ENV
   *ITC, 1999, ANN REP
   KETELAARS JJMH, 1992, LIVEST PROD SCI, V30, P269, DOI 10.1016/0301-6226(92)90039-7
   KETELAARS JJMH, 1992, LIVEST PROD SCI, V31, P235, DOI 10.1016/0301-6226(92)90020-5
   MANN DL, 1987, J ANIM SCI, V64, P880
   Nicholson MJ, 1986, GUIDE CONDITION SCOR
   NOUALA FS, 2000, THESIS I TROPICAL ME
   Nsahlai IV, 1998, ANN ARID ZONE, V37, P283
   SAS Institute Inc., 2000, SAS STAT US GUID VER, V2
   TOLKAMP BJ, 1992, LIVEST PROD SCI, V30, P297, DOI 10.1016/0301-6226(92)90040-B
   VACCARO L, 1984, TROPICAL ANIMAL PROD, V9, P86
   *WINR INT, 1992, ASS AN AGR SUB SAH A
NR 16
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-6226
J9 LIVEST PROD SCI
JI Livest. Prod. Sci.
PD APR
PY 2003
VL 80
IS 3
BP 221
EP 228
DI 10.1016/S0301-6226(02)00175-6
PG 8
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 676WK
UT WOS:000182775400005
OA No
DA 2017-08-15
ER

PT J
AU Jaitner, J
   Corr, N
   Dempfle, L
AF Jaitner, J
   Corr, N
   Dempfle, L
TI Ownership pattern and management practices of cattle herds in The
   Gambia: Implications for a breeding programme
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
DE breeding practices; cattle; herd size; management; N'Dama; ownership
ID POLICY
AB A questionnaire and a census were carried out in 1998/99 on 201 cattle herds in 44 villages located in three different areas of The Gambia, in order to obtain information about the ownership pattern, management and breeding practices for optimizing and extending a pure breeding scheme for indigenous N'Dama cattle. The herds had an average of 58.5 head, of which 39.3% were cows, and most of them were multiowner herds, having on average 5.5 owners. Overall, women represented 38.3% of the owners, but they owned only 15.9% of the cattle. Some of the senior herdsmen received no payment, as they were family members, but most of them received payment in kind, i.e. milk off-take from the herd. Payment in cash only or cash as well as milk was rare. In larger herds it was quite common for additional herdsmen to be hired throughout the year, their payment shifting towards cash only or cash and milk. Many small herds had no older bulls or breeding bull and almost all breeding bulls were born within the herd. In most cases, it was the herd owner who was responsible for the selection of the breeding bull. Traits related to the growth and milk production of the dam were considered as most important for a good breeding bull. The results are discussed with respect to the extension of a pure breeding scheme for N'Dama cattle.
C1 Tech Univ Munich, Dept Tierwissensch, D-85350 Freising Weihenstephan, Germany.
   Int Trypanotolerance Ctr, Banjul, Gambia.
RP Jaitner, J (reprint author), Walsroder Str 35, D-27283 Verden, Germany.
EM Jutta.Jaitner@t-online.de
CR Agyemang K, 1997, VILLAGE NDAMA CATTLE
   Bennison JJ, 1997, AGR SYST, V55, P425, DOI 10.1016/S0308-521X(97)00002-4
   Dempfle L., 2000, ICAR Technical Series, P347
   *DLS ITC, 1993, LIV CENS 1993
   DWINGER RH, 1994, VET QUART, V16, P81
   Itty P., 1997, Quarterly Journal of International Agriculture, V36, P268
   Itty P, 1992, EC VILLAGE CATTLE PR
   Jaitner J, 2001, SMALL RUMINANT RES, V40, P101, DOI 10.1016/S0921-4488(00)00221-2
   SUMBERG JE, 1992, TROP ANIM HEALTH PRO, V24, P193, DOI 10.1007/BF02356744
NR 9
TC 12
Z9 12
U1 0
U2 2
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD APR
PY 2003
VL 35
IS 2
BP 179
EP 187
DI 10.1023/A:1022881703918
PG 9
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA 658VM
UT WOS:000181741400008
PM 12735708
OA No
DA 2017-08-15
ER

PT J
AU Bickler, SW
   Telfer, ML
   Sanno-Duanda, B
AF Bickler, SW
   Telfer, ML
   Sanno-Duanda, B
TI Need for paediatric surgery care in an urban area of The Gambia
SO TROPICAL DOCTOR
LA English
DT Article
AB The report evaluates the need for paediatric surgical care in an urban area of sub-Saharan Africa. Seven hundred and forty-one children were treated for surgical problems from January through December 1997. The most common surgical problems were injuries (67.1%), congenital anomalies (15.0%) and surgical infections (6.7%). Forty-six per cent of children presenting with a surgical problem required a surgical procedure, 68.2% of which were classified as minor. The annual presentation rate for all surgical conditions was 543 per 10 000 children aged 0-14 years. The estimated cumulative risk for all surgical conditions is 85.4% by age 15 years.
   Our data suggest surgical diseases commonly affect children living in Banjul. Surgical care should be an essential component of child health programmes in developing countries.
C1 Royal Victoria Hosp, Dept Surg, Banjul, Gambia.
   Univ Calif San Diego, Med Ctr, Dept Surg, Div Pediat Surg, San Diego, CA 92103 USA.
RP Bickler, SW (reprint author), Royal Victoria Hosp, Dept Surg, Banjul, Gambia.
CR Bickler SW, 2000, B WORLD HEALTH ORGAN, V78, P1330
   Bickler SW, 2001, PEDIATR SURG INT, V17, P442, DOI 10.1007/s003830000516
   *GAMB CENTR STAT D, 1993, POP HOUS CENS
   *UN, 1997, UN DEV REP
   *UNICEF, 1998, STAT WOM CHILDR GAMB
NR 5
TC 18
Z9 18
U1 0
U2 1
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD APR
PY 2003
VL 33
IS 2
BP 91
EP 94
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 661ME
UT WOS:000181893700010
PM 12680542
OA No
DA 2017-08-15
ER

PT J
AU Sear, R
   Allal, N
   McGregor, IA
   Mace, R
AF Sear, R
   Allal, N
   McGregor, IA
   Mace, R
TI The relationship between reproductive success and maternal body
   condition in rural Gambia
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Meeting Abstract
C1 Univ London London Sch Econ & Polit Sci, London WC2A 2AE, England.
   UCL, London, England.
   MRC, Keneba, Gambia.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1042-0533
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD MAR-APR
PY 2003
VL 15
IS 2
MA 77
BP 284
EP 284
PG 1
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA 649GQ
UT WOS:000181199300088
OA No
DA 2017-08-15
ER

PT J
AU Walker, D
   Stevens, W
AF Walker, D
   Stevens, W
TI The economics of TB control in developing countries
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE control; cost-effectiveness analysis; costs; developing countries;
   economics; tuberculosis
ID MULTIDRUG-RESISTANT TUBERCULOSIS; POLYMERASE-CHAIN-REACTION; PULMONARY
   TUBERCULOSIS; COST-EFFECTIVENESS; MYCOBACTERIUM-TUBERCULOSIS; DIAGNOSTIC
   DELAY; CLINICAL-SAMPLES; URBAN ZAMBIA; STRATEGIES; PAKISTAN
AB Tuberculosis is one of the world's biggest killers and the burden is skewed towards developing countries, where the relative share of this disease is largest. This has much to do with poor living conditions and less developed public health systems. Nevertheless, even with these factors taken into account, the mortality from this disease is still unjustifiably high given the fact that it is treatable in the vast majority of cases with relatively inexpensive drugs. There are three main reasons for this situation: a low propensity to seek healthcare when sick, poor diagnosis upon seeking care, and high levels of non-compliance with treatment when diagnosed. Taken in combination, this means that of those who seek care, some get appropriate diagnosis at their first contact, while many do not. Unfortunately, not all of those who are diagnosed actually begin treatment and of those who do, a smaller percentage actually complete it. This article will look at each of these issues, and in particular their costs, in turn, and suggest areas in which economics can help to develop solutions to them.
C1 Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Walker, D (reprint author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.
CR AHLBURG DA, 2000, EC IMPACTS TUBERCULS
   ALUOCH JA, 1982, T ROY SOC TROP MED H, V76, P679, DOI 10.1016/0035-9203(82)90240-1
   BEYERS N, 1994, TUBERCLE LUNG DIS, V75, P260, DOI 10.1016/0962-8479(94)90130-9
   Bishai DM, 2001, INT J TUBERC LUNG D, V5, P984
   BRISSONNOEL A, 1989, LANCET, V2, P1069
   CASTELO A, 1995, PHARMACOECONOMICS, V8, P385
   Cegielski JP, 2002, INFECT DIS CLIN N AM, V16, P1, DOI 10.1016/S0891-5520(03)00045-X
   DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Enarson DA, 1994, TUBERCULOSIS GUIDE L
   Farmer P, 1998, BRIT MED J, V317, P671
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Floyd K, 2002, SCIENCE, V295, P2040, DOI 10.1126/science.1069771
   Foster S, 1999, TUBERCULOSIS INTERDI
   Foulds J, 1998, INT J TUBERC LUNG D, V2, P778
   Fryatt RJ, 1997, INT J TUBERC LUNG D, V1, P101
   Global Alliance for TB Drug Development, 2001, EC TB DRUG DEV
   Harries AD, 1997, T ROY SOC TROP MED H, V91, P416, DOI 10.1016/S0035-9203(97)90262-5
   Harries AD, 2000, INT J TUBERC LUNG D, V4, P36
   Islam MA, 2002, B WORLD HEALTH ORGAN, V80, P445
   Khan MA, 2002, HEALTH POLICY PLANN, V17, P178, DOI 10.1093/heapol/17.2.178
   Kremer L, 2002, EXPERT OPIN INV DRUG, V11, P153
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lawn SD, 1997, INT J TUBERC LUNG D, V1, P485
   Lawn SD, 1998, INT J TUBERC LUNG D, V2, P635
   LEONARD KL, 2000, AFRICAS CHANGING MAR
   Liefooghe R, 1995, SOC SCI MED, V41, P1685, DOI 10.1016/0277-9536(95)00129-U
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233
   LONROTH K, 2001, HLTH POLICY PLAN, V16, P47
   Madebo T, 1999, MED GEN MED, V18, P6
   Marsh D, 1996, TUBERCLE LUNG DIS, V77, P86, DOI 10.1016/S0962-8479(96)90082-9
   McPake B, 2000, B WORLD HEALTH ORGAN, V78, P811
   Moulding TS, 2002, INT J TUBERC LUNG D, V6, P313
   MURRAY CJ, 1993, DIS CONTROL PRIORITI
   Needham DM, 1998, INT J TUBERC LUNG D, V2, P811
   Needham DM, 1996, LANCET, V348, P134, DOI 10.1016/S0140-6736(05)64654-5
   Needham DM, 2001, TROP MED INT HEALTH, V6, P256, DOI 10.1046/j.1365-3156.2001.00709.x
   Noordhoek GT, 1996, J CLIN MICROBIOL, V34, P2522
   NSHUTI L, 1998, THESIS OHIO MAKERERE
   Pablos-Mendez A, 2002, B WORLD HEALTH ORGAN, V80, P489
   PIOT MA, WHOTBTECHINFORMATION
   Rajeswari R, 1999, INT J TUBERC LUNG D, V3, P869
   Roos BR, 1998, INT J TUBERC LUNG D, V2, P235
   Salaniponi FML, 2000, INT J TUBERC LUNG D, V4, P327
   SAUNDERSON PR, 1995, SOC SCI MED, V40, P1203, DOI 10.1016/0277-9536(94)00240-T
   SCHIRM J, 1995, J CLIN MICROBIOL, V33, P3221
   Uplekar M, 1998, INT J TUBERC LUNG D, V2, P324
   Uplekar M, 1996, TACKLING TB SEARCH S
   Vaidyanathan K, 1999, B WORLD HEALTH ORGAN, V77, P104
   Walker D, 2000, INT J TUBERC LUNG D, V4, P246
   WALKER D, 2001, INT J TUBERC LUNG DI
   *WHO, 2001, WHOCSDTB2001287
   WILSON SM, 1993, J CLIN MICROBIOL, V31, P776
   ZULMA A, 1998, BRIT MED J, V316, P1962
   Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7
NR 55
TC 11
Z9 11
U1 0
U2 1
PU ASHLEY PUBLICATIONS LTD
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1465-6566
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD MAR
PY 2003
VL 4
IS 3
BP 359
EP 368
DI 10.1517/14656566.4.3.359
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 695ZP
UT WOS:000183860500006
PM 12614188
OA No
DA 2017-08-15
ER

PT J
AU von Seidlein, L
   Walraven, G
   Milligan, PJM
   Alexander, N
   Manneh, F
   Deen, JL
   Coleman, R
   Jawara, M
   Lindsay, SW
   Drakeley, C
   De Martin, S
   Olliaro, P
   Bennett, S
   van der Loeff, MS
   Okunoye, K
   Targett, GAT
   McAdam, KPWJ
   Doherty, JF
   Greenwood, BM
   Pinder, M
AF von Seidlein, L
   Walraven, G
   Milligan, PJM
   Alexander, N
   Manneh, F
   Deen, JL
   Coleman, R
   Jawara, M
   Lindsay, SW
   Drakeley, C
   De Martin, S
   Olliaro, P
   Bennett, S
   van der Loeff, MS
   Okunoye, K
   Targett, GAT
   McAdam, KPWJ
   Doherty, JF
   Greenwood, BM
   Pinder, M
TI The effect of mass administration of sulfadoxine-pyrimethamine combined
   with artesunate on malaria incidence: a double-blind,
   community-randomized, placebo-controlled trial in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article; Proceedings Paper
CT Meeting of the Royal-Society-of-Tropical-Medicine-and-Hygiene
CY 2002
CL LONDON, ENGLAND
SP Royal Soc Trop Med & Hygiene
DE malaria; Plasmodium falciparum; chemotherapy; sulfadoxine-pyrimethamine;
   artesunate; Africa
ID PLASMODIUM-FALCIPARUM; TANZANIAN INFANTS; CHILDREN; TRANSMISSION;
   ARTEMISININ; CHLOROQUINE; ERADICATION; POPULATION; NICARAGUA; ANEMIA
AB A double-blind, community-randomized, placebo-controlled trial was conducted in a rural area of The Gambia between June and December 1999 to test whether a reduction in the infectious reservoir can reduce malaria transmission. Overall 14 017 (85%) individuals living in the study area were treated with either placebo or sulfadoxine-pyrimethamine (SP) combined with a single dose of artesunate (AS). Following the mass drug administration (MDA) 1375 children aged 6 months to 10 years were kept under surveillance for clinical malaria in 18 villages throughout the 1999 malaria transmission season. During a 20-week surveillance period 637 episodes of malaria were detected. The mean incidence rate was 2.5/100 child-weeks in the placebo villages, and 2.3/100 child-weeks in villages that received SP + AS. The mean rate ratio, adjusted for individual and village-level covariates, was 0.91 (95% CI 0.68-1.22, P = 0.49). During the first 2 months of surveillance, the malaria incidence was lower in treated villages. After 2 months the incidence was slightly higher in the MDA group but this was not statistically significant. Overall, no benefit of the MDA could be detected. The reason for the absence of an impact on malaria transmission is probably the very high basic reproductive number of malaria, and the persistence of mature gametocytes, which are not affected by AS treatment.
C1 Int Vaccine Inst, Seoul 151600, South Korea.
   MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   Dept State Hlth, Banjul, Gambia.
   Univ Durham, Durham, England.
   WHO, CH-1211 Geneva, Switzerland.
RP von Seidlein, L (reprint author), Int Vaccine Inst, POB 14, Seoul 151600, South Korea.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ALONSO PL, 1993, T ROYAL SOC TROPI S2, V87
   Anderson R, 1991, INFECT DIS HUMANS
   Barber MA, 1932, AM J HYG, V15, P601
   Behrman RE, 1996, NELSON TXB PEDIAT
   BENNETT S, 2002, INT J EPIDEMIOL, V41, P839
   BOGH C, 1999, THESIS U COPENHAGEN
   DE ZULUETA J., 1964, East African Medical Journal, V41, P102
   Deen JL, 2001, T ROY SOC TROP MED H, V95, P424, DOI 10.1016/S0035-9203(01)90204-4
   DOI H, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P341
   DOLA SK, 1974, E AFR MED J, V51, P529
   Fryauff DJ, 1997, AM J TROP MED HYG, V56, P137
   Gallup JL, 2001, AM J TROP MED HYG, V64, P85
   Garfield R, 1999, LANCET, V354, P414, DOI 10.1016/S0140-6736(99)02226-6
   GARFIELD RM, 1983, LANCET, V2, P500
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1993, T ROYAL SOC TROPI S2, V87
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   HII JLK, 1987, MED VET ENTOMOL, V1, P397, DOI 10.1111/j.1365-2915.1987.tb00370.x
   Kaneko A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5
   LINDSAY SW, 1993, T ROYAL SOC TROPI S2, V87
   MCCORMACK CP, 1983, J TROP MED HYG, V86, P99
   Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3
   Meshnick SR, 1996, MICROBIOL REV, V60, P301
   MOLINEAUX K, 1980, GARKI PROJECT RES EP
   PAYNE D, 1988, PARASITOL TODAY, V4, P112, DOI 10.1016/0169-4758(88)90042-7
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Singh MV, 1968, B INDIAN SOC MALARIA, V5, P207
   SMITH PG, 1996, FIELD TRIALS HLTH IN
   Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   von Seidlein L, 2002, B WORLD HEALTH ORGAN, V80, P790
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   Wongsrichanalai C, 2000, LANCET, V355, P2245, DOI 10.1016/S0140-6736(00)02416-8
NR 36
TC 50
Z9 51
U1 0
U2 4
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 2003
VL 97
IS 2
BP 217
EP 225
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 734AZ
UT WOS:000186034200020
PM 14584381
OA No
DA 2017-08-15
ER

PT J
AU Manirakiza, P
   Akinbamijo, O
   Covaci, A
   Pitonzo, R
   Schepens, P
AF Manirakiza, P
   Akinbamijo, O
   Covaci, A
   Pitonzo, R
   Schepens, P
TI Assessment of organochlorine pesticide residues in West African city
   farms: Banjul and Dakar case study
SO ARCHIVES OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY
LA English
DT Article
ID SOLID-PHASE EXTRACTION; GAS-CHROMATOGRAPHY; ORGANIC-CHEMICALS; SOIL;
   MODEL; WATER; BIOACCUMULATION; CONTAMINANTS; ACCUMULATION; VEGETABLES
AB Validated analytical procedures for the determination of 21 organochlorine pesticides have been applied to 74 water samples, 76 soil samples, and 160 vegetable samples from nine Sene-Gambian farms. Mean pesticide residue levels found were compared to the results of other studies. The main contaminants were DDTs in water (231.9 ng/L), in soil (71.4 ng/g), and in vegetables (5.03 ng/g). The distribution of pesticide residues in water and neighboring soils and the soil-plant transfer of these pesticides is briefly discussed. Different bioconcentration factors for sum HCHs, sum DDTs, and sum endosulfans obtained in this study allow us to confirm the complex processes already reported in the literature concerning the uptake and translocation of chemicals from soil to plant.
C1 Univ Instelling Antwerp, Toxicol Ctr, B-2610 Wilrijk, Belgium.
   ITC, Banjul, Gambia.
   Univ Palermo, I-90123 Palermo, Italy.
RP Manirakiza, P (reprint author), Univ Instelling Antwerp, Toxicol Ctr, Univ Pl 1, B-2610 Wilrijk, Belgium.
RI Covaci, Adrian/A-9058-2008
OI Covaci, Adrian/0000-0003-0527-1136
CR Abbassy MS, 2001, B ENVIRON CONTAM TOX, V67, P225
   Aguilar C, 1997, J CHROMATOGR A, V771, P221, DOI 10.1016/S0021-9673(97)00091-5
   AKINBAMIJO O, 2000, SEM INT AL SANT PROD
   AKINBAMIJO OO, 2000, 0393497002101 ISRA I
   AKINBAMIJO OO, 2001, GARDENING CITIES W A
   Baez ME, 1996, HRC-J HIGH RES CHROM, V19, P559
   Bailey G W, 1970, Residue Rev, V32, P29
   CHU SC, 1999, SCI TOTAL ENVIRON, V244, P119
   Doong RA, 1999, ANALYST, V124, P1287, DOI 10.1039/a902722j
   DORFLER U, 1991, CHEMOSPHERE, V23, P485, DOI 10.1016/0045-6535(91)90199-N
   *EEC, 1998, OFF J
   *FAO, 1997, AFRICA RECOVERY, V11
   FONT G, 1993, J CHROMATOGR, V642, P135, DOI 10.1016/0021-9673(93)80083-K
   Gevao B, 2000, ENVIRON POLLUT, V108, P3, DOI 10.1016/S0269-7491(99)00197-9
   Hayes W.J., 1991, HDB PESTICIDE TOXICO
   HULSTER A, 1994, ENVIRON SCI TECHNOL, V28, P1110, DOI 10.1021/es00055a021
   KANJA LW, 1992, ARCH ENVIRON CON TOX, V22, P21
   KANNAN K, 1992, J AGR FOOD CHEM, V40, P518, DOI 10.1021/jf00015a032
   KANNAN K, 1992, ARCH ENVIRON CON TOX, V22, P367, DOI 10.1007/BF00212555
   Manirakiza P, 2001, INT J ENVIRON AN CH, V81, P25, DOI 10.1080/03067310108044356
   Mbakaya C. F. L., 1994, African Journal of Health Sciences, V1, P37
   McLachlan MS, 1996, ENVIRON SCI TECHNOL, V30, P252, DOI 10.1021/es9502738
   MUIR DCG, 1988, ENVIRON SCI TECHNOL, V22, P1071, DOI 10.1021/es00174a012
   Ntow WJ, 2001, ARCH ENVIRON CON TOX, V40, P557, DOI 10.1007/s002440010210
   PATERSON S, 1991, CHEMOSPHERE, V23, P539, DOI 10.1016/0045-6535(91)90203-P
   SCHMITT CJ, 1990, ARCH ENVIRON CON TOX, V19, P748, DOI 10.1007/BF01183992
   SCHROLL R, 1994, CHEMOSPHERE, V28, P297, DOI 10.1016/0045-6535(94)90126-0
   SIMONICH SL, 1995, ENVIRON SCI TECHNOL, V29, P2905, DOI 10.1021/es00012a004
   Singh RP, 2001, B ENVIRON CONTAM TOX, V67, P126, DOI 10.1007/s00128-001-0100-4
   STEVENSON FJ, 1976, ACS SYM SER, P180
   Strandberg B, 1998, ENVIRON SCI TECHNOL, V32, P1754, DOI 10.1021/es970789m
   SWACKHAMER DL, 1988, ENVIRON SCI TECHNOL, V22, P543, DOI 10.1021/es00170a010
   TRAPP S, 1995, ENVIRON SCI TECHNOL, V29, P2333, DOI 10.1021/es00009a027
   UNEP/FAO/VVHO, 1989, GUID PRED DIET INT P, P24
NR 34
TC 20
Z9 20
U1 0
U2 7
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0090-4341
J9 ARCH ENVIRON CON TOX
JI Arch. Environ. Contam. Toxicol.
PD FEB
PY 2003
VL 44
IS 2
BP 171
EP 179
DI 10.1007/s00244-002-2006-5
PG 9
WC Environmental Sciences; Toxicology
SC Environmental Sciences & Ecology; Toxicology
GA 634CD
UT WOS:000180321700004
PM 12520389
OA No
DA 2017-08-15
ER

PT J
AU Kaye, S
AF Kaye, S
TI Simple PCR-based method for synthesis of molecular calibrators and
   controls
SO CLINICAL CHEMISTRY
LA English
DT Letter
ID POLYMERASE CHAIN-REACTION; RNA; QUANTIFICATION; INFECTION; PLASMA; ASSAY
C1 MRC Labs, Banjul, Gambia.
RP Kaye, S (reprint author), MRC Labs, Atlantic Rd,POB 273, Banjul, Gambia.
CR BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   BROWN RA, 1977, GENETIC ENG PCR, P57
   DUBOIS DB, 1999, PCR APPL PROTOCOLS F, P197, DOI 10.1016/B978-012372185-3/50014-6
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   MULDER J, 1994, J CLIN MICROBIOL, V32, P292
   Parks CL, 2001, J VIROL, V75, P910, DOI 10.1128/JVI.75.2.910-920.2001
   Tang YW, 1997, CLIN CHEM, V43, P2021
   VANGEMEN B, 1993, J VIROL METHODS, V43, P177, DOI 10.1016/0166-0934(93)90075-3
   Verhaegen M, 1998, CLIN CHEM, V44, P1170
   WHITBY K, 1995, J VIROL METHODS, V51, P75, DOI 10.1016/0166-0934(94)00144-6
NR 11
TC 2
Z9 5
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD FEB
PY 2003
VL 49
IS 2
BP 325
EP 327
DI 10.1373/49.2.325
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 639WY
UT WOS:000180654100022
PM 12560363
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
AF van der Sande, MAB
TI Cardiovascular disease in sub-Saharan Africa: a disaster waiting to
   happen
SO NETHERLANDS JOURNAL OF MEDICINE
LA English
DT Review
ID IMPAIRED GLUCOSE-TOLERANCE; URBAN GAMBIAN COMMUNITIES; RISK-FACTORS;
   RURAL TANZANIA; HYPERTENSION; PREVALENCE; POPULATIONS; OBESITY;
   EMERGENCE; NIGERIA
AB The looming threat posed by the emergence of cardiovascular disease (CVD) in sub-Saharan Africa (sSA) is underestimated and often denied. The health services and societies struggle to cope with the direct effects of poverty, war, fragile social and economic structures and AIDS. The threat of CVD seems less direct and. few reliable data are available. This has resulted in neglecting serious warning signs on the emergence of CVD in sSA. This short review deals with the strong increase in a number of risk factors for CVD in certain areas, necessitating preventive measures to lighten the 'double burden of disease' in this part of the world.
C1 MRC Labs, Banjul, Gambia.
RP van der Sande, MAB (reprint author), MRC Labs, POB 274, Banjul, Gambia.
EM mvdsande@mrc.gm
CR ASTAGNEAU P, 1992, J HYPERTENS, V10, P1095
   BARKER DJP, 1995, EUR J CLIN INVEST, V25, P457, DOI 10.1111/j.1365-2362.1995.tb01730.x
   Ceesay MM, 1997, TROP MED INT HEALTH, V2, P272, DOI 10.1046/j.1365-3156.1997.d01-265.x
   CHATURVEDI N, 1993, HYPERTENSION, V22, P90
   Coleman R, 1998, B WORLD HEALTH ORGAN, V76, P633
   Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160
   Cooper RS, 1998, BRIT MED J, V316, P614
   Donnison CP, 1929, LANCET, V1, P6
   DOWSE GK, 1995, BRIT MED J, V311, P1255
   Forrester T, 1998, BRIT MED BULL, V54, P463
   Gwatkin DR, 1997, BRIT MED J, V315, P497
   Kaufman JS, 1999, HUM BIOL, V71, P641
   Kaufman JS, 1996, J HUM HYPERTENS, V10, P461
   KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157
   MCLARTY DG, 1989, LANCET, V1, P871
   MENSAH GA, 1994, J HUM HYPERTENS, V8, P799
   Mosley W. H., 1993, DIS CONTROL PRIORITI, P673
   Neel JV, 1998, PERSPECT BIOL MED, V42, P44
   Njelekela M, 2001, ACTA TROP, V79, P231, DOI 10.1016/S0001-706X(01)00134-6
   NYAN OA, UNPUB PREVALENCE DIA
   Okosun IS, 1999, OBES RES, V7, P453
   POBEE JOM, 1977, T ROY SOC TROP MED H, V71, P66, DOI 10.1016/0035-9203(77)90211-5
   Poulter NR, 1985, J Hypertens, V3, P5375
   ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32
   ROTIMI C, 1995, OBESITY RES S2, V3, P95
   Seedat YK, 2000, J HUM HYPERTENS, V14, P739, DOI 10.1038/sj.jhh.1001059
   SEEDAT YK, 1982, J EPIDEMIOL COMMUN H, V36, P256, DOI 10.1136/jech.36.4.256
   Sobngwi E, 2002, INT J OBESITY, V26, P1009, DOI 10.1038/sj.ijo.0802008
   Sobngwi E, 2001, DIABETES METAB, V27, P628
   SWAI ABM, 1991, DIABETES, V40, P516, DOI 10.2337/diabetes.40.4.516
   SWAI ABM, 1993, INT J EPIDEMIOL, V22, P651, DOI 10.1093/ije/22.4.651
   TRUSWELL AS, 1972, AM HEART J, V84, P5, DOI 10.1016/0002-8703(72)90299-2
   Unwin N, 2001, B WORLD HEALTH ORGAN, V79, P947
   van der Sande MAB, 2001, B WORLD HEALTH ORGAN, V79, P133
   van der Sande MAB, 2001, AM J PUBLIC HEALTH, V91, P1641, DOI 10.2105/AJPH.91.10.1641
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   Vorster HH, 2002, PUBLIC HEALTH NUTR, V5, P239, DOI 10.1079/PHN2001299
   Walker ARP, 2002, NUTRITION, V18, P71, DOI 10.1016/S0899-9007(01)00694-3
   WALKER R, 1994, T ROY SOC TROP MED H, V88, P609, DOI 10.1016/0035-9203(94)90193-7
   Walraven GEL, 2001, CLIN EXP ALLERGY, V31, P1679, DOI 10.1046/j.1365-2222.2001.01094.x
   Wilks R, 1996, CIBA F SYMP, V201, P37
   World Bank, 1993, WORLD DEV REP 1993
NR 42
TC 22
Z9 22
U1 3
U2 3
PU VAN ZUIDEN COMMUNICATIONS
PI ALPHEN AAN DE RIJN
PA HENRY DUNANTWEG 40A, 2402 NR ALPHEN AAN DE RIJN, NETHERLANDS
SN 0300-2977
J9 NETH J MED
JI Neth. J. Med.
PD FEB
PY 2003
VL 61
IS 2
BP 32
EP 36
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 658UQ
UT WOS:000181739200002
PM 12735418
OA No
DA 2017-08-15
ER

PT J
AU Halton, K
   Ratcliffe, AA
   Morison, L
   West, B
   Shaw, M
   Bailey, R
   Walraven, G
AF Halton, K
   Ratcliffe, AA
   Morison, L
   West, B
   Shaw, M
   Bailey, R
   Walraven, G
TI Herpes simplex 2 risk among women in a polygynous setting in rural West
   Africa
SO AIDS
LA English
DT Article
DE herpes simplex virus 2; risk factors; behaviour change programmes;
   transmission within marriage; epidemiology
ID VIRUS TYPE-2 INFECTION; HIV-INFECTION; ANTIBODY; DISEASE; GAMBIA;
   SEROPREVALENCE; INTERVENTIONS; PREVENTION; POPULATION; PREVALENCE
AB Objectives: To determine risk factors for herpes simplex 2 (HSV2) infection in women in a polygynous rural Gambian population.
   Methods: Data from women who participated in a cross-sectional survey of reproductive health were matched to their own and, for women who had been or were married (ever-married), their spouses' data collected in a cross-sectional survey of fertility interests, including information on marital histories.
   Results: Data were available on 150 never-married and 525 ever-married women. HSV2 prevalence was 16% amongst never-married women and 36% amongst ever-married women. For ever-married women, their own personal characteristics (age, ethnicity and genital cutting status) and events from their husbands' marriage history were important determinants of HSV2 infection. Women whose husbands married for the first time over age 35 were at greater risk than women whose husbands married by age 24 [odds ratio (OR) 2.72, 95% confidence interval (CI) 1.20-6.10]. Women whose husband reported interest in a new marriage were more likely to be HSV2 positive (OR 1.91, 95% CI 1.18-3.09). Women whose husbands were currently monogamous but had had previous marriages (OR 2.76, 95% CI 1.30-5.88) and women in currently polygynous marriages (OR 2.88, 95% CI 1.66-5.01) were three times as likely to be HSV2 positive as women who were their husband's only wife ever.
   Conclusion: Much transmission of HSV2 in this setting occurs within marriage where opportunity for personal protection is limited. High levels of transmission within marriage may undermine the impact of sexual behaviour change programmes aiming to reduce HSV2 and HIV incidence and complicate their evaluation. (C) 2003 Lippincott Williams Wilkins.
C1 MRC Labs, Farafenni Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Walraven, G (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
RI Halton, Kate/I-9964-2012; Morison, Linda/H-9738-2013
OI Halton, Kate/0000-0001-9785-1458
CR ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0
   Auvert B, 2001, AIDS, V15, P885, DOI 10.1097/00002030-200105040-00009
   Bonell C, 2001, BRIT MED BULL, V58, P155, DOI 10.1093/bmb/58.1.155
   Chen CY, 2000, SEX TRANSM DIS, V27, P21, DOI 10.1097/00007435-200001000-00005
   COWAN FM, 1994, BRIT MED J, V309, P1325
   Cusini M, 2000, SEX TRANSM DIS, V27, P292, DOI 10.1097/00007435-200005000-00011
   Fishbein M, 2000, SEX TRANSM DIS, V27, P101, DOI 10.1097/00007435-200002000-00008
   Fleiss JL, 1981, STAT METHODS RATES P
   Gopal R, 2000, J VIROL METHODS, V87, P71, DOI 10.1016/S0166-0934(00)00149-X
   Gregson S, 2001, INT J STD AIDS, V12, P189, DOI 10.1258/0956462011917009
   GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048
   Kamali A, 1999, SEX TRANSM INFECT, V75, P98
   Marsden HS, 1998, J MED VIROL, V56, P79, DOI 10.1002/(SICI)1096-9071(199809)56:1<79::AID-JMV13>3.0.CO;2-R
   Mbizvo EM, 2002, INT J STD AIDS, V13, P343, DOI 10.1258/0956462021925171
   Mbopi-Keou FX, 2000, J INFECT DIS, V182, P1090, DOI 10.1086/315836
   Morison L, 2001, TROP MED INT HEALTH, V6, P643, DOI 10.1046/j.1365-3156.2001.00749.x
   Morris M, 1997, AIDS, V11, P641, DOI 10.1097/00002030-199705000-00012
   Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19
   OATES JK, 1990, SEXUALLY TRANSMITTED, P129
   Obasi A, 1999, J INFECT DIS, V179, P16, DOI 10.1086/314555
   Oladepo DK, 2000, J VIROL METHODS, V87, P63, DOI 10.1016/S0166-0934(00)00152-X
   OPPONG C, 1992, FAMILY SYSTEMS CULTU
   Pequegnat W, 2000, SEX TRANSM DIS, V27, P127, DOI 10.1097/00007435-200003000-00001
   PICTET G, 1999, ANN M POP ASS AM NEW
   PISON G, 1986, POPULATION, V41, P93, DOI 10.2307/1533182
   RATCLIFFE A, 2000, THESIS HARVARD U
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   Slomka M J, 2000, Clin Lab, V46, P591
   Stata Corportation, 1999, STAT STAT SOFTW REL
   Stephenson JM, 2000, AIDS, V14, pS115
   van de Laar MJW, 1998, INT J EPIDEMIOL, V27, P127, DOI 10.1093/ije/27.1.127
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   Weiss HA, 2001, AIDS, V15, pS97, DOI 10.1097/00002030-200108004-00011
NR 36
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JAN 3
PY 2003
VL 17
IS 1
BP 97
EP 103
DI 10.1097/01.aids.0000042937.55529.05
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 634YF
UT WOS:000180369500013
PM 12478074
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Goldblatt, D
   Bates, CJ
   Prentice, AM
AF Moore, SE
   Goldblatt, D
   Bates, CJ
   Prentice, AM
TI Impact of nutritional status on antibody responses to different vaccines
   in undernourished Gambian children
SO ACTA PAEDIATRICA
LA English
DT Article
DE nutritional status; pneumococcus; rabies; The Gambia; vaccine response
ID PROTEIN-CALORIE MALNUTRITION; MALNOURISHED CHILDREN; NEUTRALIZING
   ANTIBODY; BIRTH-WEIGHT; SERUM; VACCINATION; STANDARD
AB Aim: To test the efficacy of T-cell-dependent and T-cell-independent vaccines in rural Gambian children suffering from a range of energy/protein and micronutrient deficiencies. Methods: Nutritional status (anthropometry, haemoglobin, plasma leptin and micronutrient status) and response to two vaccinations (23 valent pneumococcal capsular polysaccharide vaccine, Pneumovax(R) and the Human Diploid-Cell Rabies Vaccine) were assessed in 472 children aged 6 1/2 to 9 1/2 y. Results: Anthropometry and micronutrient status (as z-scores against European reference values) indicated a range from moderate to severe levels of undernutrition [mean (interquartile range): weight-for-age z-score -1.58 (-2.18 to -0.95); height-for-age z-score -0.94 (-1.51 to -0.35); body-mass-index-for-age z-score -1.43 (-2.05 to -0.84); mid-upper arm circumference -1.41 (=1.72 to -1.13); leptin -1.06 (-1.10 to -1.03); haemoglobin (Hb) -0.30 (-1.18 to 0.79); zinc -1.29 (-2.42 to -0.55); vitamin C -0.01 (-1.18 to 1.15); retinol -1.33 (-1.97 to -0.77)]. A seasonal effect was observed in haemoglobin levels and in all micronutrients (with the exception of zinc and retinol) and in the response to vaccination. After adjusting for seasonality, age and gender, no consistent associations were found between any of the measures of nutritional status and the effectiveness of seroconversion to either of the vaccines.
   Conclusion: The successful short-term seroconversion to whole inactivated viral and bacterial polysaccharide vaccines indicates that the processes leading to antibody secretion remain intact over a wide range of single and combined nutrient deficiencies.
C1 London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, London WC1B 3DP, England.
   MRC Labs, MRC Keneba, Keneba, Gambia.
   Inst Child Hlth, Immunobiol Unit, London, England.
   MRC, Human Nutr Res, Cambridge, England.
RP Moore, SE (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, 49-51 Bedford Sq, London WC1B 3DP, England.
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
CR BEACH RS, 1982, SCIENCE, V218, P469, DOI 10.1126/science.7123244
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005
   Department of Health, 1991, DIET REF VAL FOOD EN
   Falorni A, 1998, INT J OBESITY, V22, P1197, DOI 10.1038/sj/ijo/0800746
   Fata FT, 1996, ANN INTERN MED, V124, P299
   FREEMAN JV, 1990, ARCH DIS CHILD, V73, P17
   GREENWOOD BM, 1986, ANN TROP MED PARASIT, V80, P537
   Gregory J., 2000, NATL DIET NUTR SURVE
   Lakshmi G, 2000, VACCINE, V18, P2009, DOI 10.1016/S0264-410X(99)00529-0
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9
   NEUMANN CG, 1975, AM J CLIN NUTR, V28, P89
   NICHOLSON KG, 1979, J INFECT DIS, V140, P176
   PAPPAIOANOU M, 1986, NEW ENGL J MED, V314, P280, DOI 10.1056/NEJM198601303140504
   PHILLIPS DIW, 1993, Q J MED, V86, P247
   Powell G M, 1982, Ann Trop Paediatr, V2, P143
   Prentice A. M., 2001, BNF Nutrition Bulletin, V26, P13, DOI 10.1046/j.1467-3010.2001.00100.x
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590
   Read AF, 2000, SCIENCE, V290, P1104, DOI 10.1126/science.290.5494.1104
   REDDY V, 1976, ARCH DIS CHILD, V51, P871
   SELVARAJ RJ, 1972, AM J CLIN NUTR, V25, P166
   SIRISINHA S, 1973, LANCET, V1, P1016
   SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535
   SMYTHE PM, 1971, LANCET, V2, P939
   THURNHAM DI, 1988, CLIN CHEM, V34, P377
   WATSON CE, 1970, ARCH DIS CHILD, V45, P282
NR 30
TC 38
Z9 40
U1 6
U2 7
PU TAYLOR & FRANCIS AS
PI OSLO
PA CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PY 2003
VL 92
IS 2
BP 170
EP 176
PG 7
WC Pediatrics
SC Pediatrics
GA 663QD
UT WOS:000182015500008
PM 12710642
OA No
DA 2017-08-15
ER

PT J
AU Alloueche, A
   Milligan, P
   Conway, DJ
   Pinder, M
   Bojang, K
   Doherty, T
   Tornieporth, N
   Cohen, J
   Greenwood, BM
AF Alloueche, A
   Milligan, P
   Conway, DJ
   Pinder, M
   Bojang, K
   Doherty, T
   Tornieporth, N
   Cohen, J
   Greenwood, BM
TI Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria
   vaccine is not strain specific
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CIRCUMSPOROZOITE PROTEIN VACCINE; IMMUNE-RESPONSES; TRIAL; IMMUNIZATION;
   CHILDREN
AB RTS,S/AS02 is a recombinant protein malaria vaccine that contains a large portion of the C-terminal of the circumsporozoite protein (CSP) sequence of the NF54 isolate of Plasmodium falciparum fused to the hepatitis B virus surface antigen. It has been shown to induce significant protection to challenge infection with a homologous parasite strain in American volunteers. In a recently completed trial in semi-immune Gambian adults, vaccine efficacy against natural infection was 34% (95% confidence interval = 8-53%, P = 0.014) during the malaria season following vaccination. Breakthrough P. falciparum parasites sampled from vaccinated subjects and from controls were genotyped at two polymorphic regions of the csp gene encoding T cell epitopes (csp-th2r and csp-th3r) to determine if the vaccine conferred a strain-specific effect. The overall distribution of csp allelic variants was similar in infections occurring in vaccine and control groups. Also, the mean number of genotypes per infection in the RTS,S/AS02 group was not reduced compared with the controls.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   GlaxoSmithKline Biol, B-1330 Rixensart, Belgium.
RP Alloueche, A (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Conway, David/0000-0002-8711-3037
CR Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2
   Beck HP, 1997, J INFECT DIS, V175, P921, DOI 10.1086/513991
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112
   CUZICK J, 1985, BIOMETRICS, V41, P609, DOI 10.2307/2531281
   GRAVES P, 2001, COCHRANE LIB, V1
   GUIGUEMDE TR, 1990, B SOC PATHOL EXOT, V8, P217
   Haywood M, 1999, Trans R Soc Trop Med Hyg, V93 Suppl 1, P65, DOI 10.1016/S0035-9203(99)90330-9
   HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351
   REBERLISKE R, 1995, TROP GEOGR MED, V47, P61
   Sherwood JA, 1996, VACCINE, V14, P817, DOI 10.1016/0264-410X(95)00221-L
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
   ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947
NR 18
TC 58
Z9 59
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JAN
PY 2003
VL 68
IS 1
BP 97
EP 101
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 632YV
UT WOS:000180253200018
PM 12556156
OA No
DA 2017-08-15
ER

PT J
AU Deen, JL
   Funk, M
   Guevara, VC
   Saloojee, H
   Doe, JY
   Palmer, A
   Weber, MW
AF Deen, JL
   Funk, M
   Guevara, VC
   Saloojee, H
   Doe, JY
   Palmer, A
   Weber, MW
TI Implementation of WHO guidelines on management of severe malnutrition in
   hospitals in Africa
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE child nutrition disorders/therapy; infant nutrition disorders/therapy;
   hypothermia/therapy; hypoglycemia/therapy; fluid therapy; diet therapy;
   hospitals; World Health Organization; practice guidelines; guideline
   adherence; Africa (source : MeSH, NLM)
ID MALNOURISHED CHILDREN; MORTALITY; DIARRHEA
AB Objective To investigate the problems, benefits, feasibility, and sustainability of implementation of WHO guidelines on management of severe malnutrition. ,
   Methods A postal survey invited staff from 12 African hospitals to participate in the study. Five hospitals were evaluated and two were, selected to take part in the study: a district hospital in South Africa and a mission hospital in Ghana. At an initial visit, an experienced paediatrician reviewed the situation in the hospitals and introduced the principles of the guidelines through a participatory.:approach. During a second visit about six months later, the paediatrician reviewed the feasibility and sustainability of the introduced changes and. helped find solutions to problems. At a final visit after, one year, the paediatrician reassessed the overall situation.
   Findings Malnutrition management practices improved at both hospitals: Measures against hypoglycaemia, hypothermia, and infection were strengthened. Early; frequent feeding was established as a routine practice. Some micronutrients for inclusion in the diet were not locally available: and.: needed to be imported. Problems Were encountered with monitoring of weight gain and introducing a rehydration solution for malnutrition.
   Conclusion Implementation of the main principles of the WHO guidelines on severe malnutrition was feasible; affordable, and, sustainable at two African hospitals.. The guidelines could be improved by. including suggestions on how to adapt specific recommendations to local situations. The guidelines are well supported by experience and published reports, but more information-is. needed about some components and their impact on mortality.
C1 Int Vaccine Inst, Kwanka Ku, Seoul 151742, South Korea.
   UN, Childrens Fund, Banjul, Gambia.
   Univ Witwatersrand, Johannesburg, South Africa.
   Mapulaneng Hosp, Bushbuckridge, Northern Provin, South Africa.
   Catholic Hosp, Battor, Ghana.
   So Isl Med Ctr, Cebu, Philippines.
RP Deen, JL (reprint author), Int Vaccine Inst, Kwanka Ku, Seoul Natl Univ Campus, Seoul 151742, South Korea.
RI Doe, Jane/B-8500-2015
CR Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6
   BREWSTER D, 1995, LANCET, V345, P453, DOI 10.1016/S0140-6736(95)90435-2
   Cavalcante AAM, 1998, TROP DOCT, V28, P95
   KHANUM S, 1994, LANCET, V344, P1728
   MANARY MJ, 2000, ACTA PEDIAT, V89, P201
   Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X
   Puoane T, 2001, S AFR MED J, V91, P137
   SANDERS D, 2001, 17 INT C NUTR 2001 A
   Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223
   Stetson V., 1999, HLTH ED PRIMARY HLTH
   Waterlow J, 1999, LANCET, V354, P1142, DOI 10.1016/S0140-6736(99)00329-3
   WHO, 2000, MAN CHILD SER INF SE
   World Health Organization, 1999, MAN SEV MALN MAN PHY
   Wilkinson D, 1996, J TROP PEDIATRICS, V42, P114, DOI 10.1093/tropej/42.2.114
NR 14
TC 51
Z9 56
U1 0
U2 1
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2003
VL 81
IS 4
BP 237
EP 243
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 672AE
UT WOS:000182497600003
PM 12764489
OA No
DA 2017-08-15
ER

PT J
AU Ackerman, H
   Usen, S
   Mott, R
   Richardson, A
   Sisay-Joof, F
   Katundu, P
   Taylor, T
   Ward, R
   Molyneux, M
   Pinder, M
   Kwiatkowski, DP
AF Ackerman, H
   Usen, S
   Mott, R
   Richardson, A
   Sisay-Joof, F
   Katundu, P
   Taylor, T
   Ward, R
   Molyneux, M
   Pinder, M
   Kwiatkowski, DP
TI Haplotypic analysis of the TNF locus by association efficiency and
   entropy
SO GENOME BIOLOGY
LA English
DT Article
ID HUMAN LIPOPROTEIN-LIPASE; ALPHA GENE PROMOTER; CEREBRAL MALARIA; HUMAN
   GENOME; POLYMORPHISM; REGION; DISEASE; SUSCEPTIBILITY; COMPLEX; BINDING
AB Background: To understand the causal basis of TNF associations with disease, it is necessary to understand the haplotypic structure of this locus. We genotyped 12 single-nucleotide polymorphisms ( SNPs) distributed over 4.3 kilobases in 296 healthy, unrelated Gambian and Malawian adults. We generated 592 high-quality haplotypes by integrating family- and population-based reconstruction methods.
   Results: We found 32 different haplotypes, of which 13 were shared between the two populations. Both populations were haplotypically diverse ( gene diversity = 0.80, Gambia; 0.85, Malawi) and significantly differentiated ( p < 10(-5) by exact test). More than a quarter of marker pairs showed evidence of intragenic recombination (29% Gambia; 27% Malawi). We applied two new methods of analyzing haplotypic data: association efficiency analysis ( AEA), which describes the ability of each SNP to detect every other SNP in a case-control scenario; and the entropy maximization method (EMM), which selects the subset of SNPs that most effectively dissects the underlying haplotypic structure. AEA revealed that many SNPs in TNF are poor markers of each other. The EMM showed that 8 of 12 SNPs ( Gambia) and 7 of 12 SNPs ( Malawi) are required to describe 95% of the haplotypic diversity.
   Conclusions: The TNF locus in the Gambian and Malawi sample is haplotypically diverse and has a rich history of intragenic recombination. As a consequence, a large proportion of TNF SNPs must be typed to detect a disease-modifying SNP at this locus. The most informative subset of SNPs to genotype differs between the two populations.
C1 Inst Biol Anthropol, Oxford OX2 9QS, England.
   Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
   Univ Malawi, Coll Med, Malaria Project, Blantyre, Malawi.
   Univ Malawi, Welcome Trust Res Labs, Blantyre, Malawi.
   Wellcome Trust Human Genet, Oxford OX3 7BN, England.
RP Ackerman, H (reprint author), Harvard Univ, Sch Med, 64 Linnaean St, Cambridge, MA 02138 USA.
CR CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   Dunstan SJ, 2001, J INFECT DIS, V183, P261, DOI 10.1086/317940
   Fernandez-Arquero M, 1999, NEUROLOGY, V53, P1361
   Fullerton SM, 2000, AM J HUM GENET, V67, P881, DOI 10.1086/303070
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Hartl D. L., 1997, PRINCIPLES POPULATIO
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649
   Knight JC, 1999, P ASSOC AM PHYSICIAN, V111, P290, DOI 10.1046/j.1525-1381.1999.99237.x
   LEWONTIN RC, 1964, GENETICS, V49, P49
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551
   MullerMyhsok B, 1997, SCIENCE, V275, P1328
   Nadel S, 1996, J INFECT DIS, V174, P878
   Negoro K, 1999, GASTROENTEROLOGY, V117, P1062, DOI 10.1016/S0016-5085(99)70390-2
   NEI M, 1974, GENETICS, V76, P379
   Nei M., 1987, MOL EVOLUTIONARY GEN
   Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789
   Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223
   ROUSSET F, 1995, GENETICS, V140, P1413
   Schneider S, 2000, ARLEQUIN VER 2 000 S
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Templeton AR, 2000, AM J HUM GENET, V66, P69, DOI 10.1086/302699
   THOMPSON EA, 1988, AM J HUM GENET, V42, P113
   Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000
   Wright S, 1931, GENETICS, V16, P0097
   Zhang K, 2002, P NATL ACAD SCI USA, V99, P7335, DOI 10.1073/pnas.102186799
NR 31
TC 42
Z9 45
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1465-6914
J9 GENOME BIOL
JI Genome Biol.
PY 2003
VL 4
IS 4
AR R24
DI 10.1186/gb-2003-4-4-r24
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 675LK
UT WOS:000182696200006
PM 12702205
OA gold
DA 2017-08-15
ER

PT J
AU Herberts, CA
   van Gans-van den Brink, J
   van der Heeft, E
   van Wijk, M
   Hoekman, J
   Jaye, A
   Poelen, MCM
   Boog, CJP
   Roholl, PJM
   Whittle, H
   de Jong, APJM
   van Els, CACM
AF Herberts, CA
   van Gans-van den Brink, J
   van der Heeft, E
   van Wijk, M
   Hoekman, J
   Jaye, A
   Poelen, MCM
   Boog, CJP
   Roholl, PJM
   Whittle, H
   de Jong, APJM
   van Els, CACM
TI Autoreactivity against induced or upregulated abundant self-peptides in
   HLA-A*0201 following measles virus infection
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE measles virus; autoimmunity; MHC class I epitopes
ID CD8(+) T-CELLS; MHC CLASS-I; ENDOGENOUS INHIBITOR; TOLERANCE INDUCTION;
   MULTIPLE-SCLEROSIS; AUTOIMMUNE-DISEASE; MASS-SPECTROMETRY;
   ALPHA-INTERFERONS; IDENTIFICATION; ANTIGEN
AB Infectious agents have been implied as causative environmental factors in the development of autoimmunity. However, the exact nature of their involvement remains unknown. We describe a possible mechanism for the activation of autoreactive T cells induced by measles virus (MV) infection. The display of HLA-A*0201 associated peptides obtained from MV infected cells was compared with that from uninfected cells by mass spectrometry. We identified two abundant self peptides, IFI-6-16(74-82) and Hsp90beta(570-578), that were induced or upregulated, respectively, following infection. Their parental proteins, the type I interferon inducible protein IFI-6-16, and the beta chain of heat shock protein 90, have not been involved in MV pathogenesis. MV infection caused minor and major changes in the intracellular expression patterns of these proteins, possibly leading to altered peptide processing. CD8(+) T cells capable of recognizing the self-peptides in the context of HLA-A*0201 were detectable at low basal levels in the neonatal and adult human T cell repertoire, but were functionally silent. In contrast, peptide-specific producing IFN-gamma producing effector cells were present in MV patients during acute infection. Thus, MV infection induces an enhanced display of self-peptides in MHC class 1, which may lead to the temporary activation of autoreactive T cells. (C) American Society for Histocompatibility and Immunogenetics, 2003. Published by Elsevier Science Inc.
C1 Natl Inst Publ Hlth & Environm, Labs Vaccine Res, NL-3720 BA Bilthoven, Netherlands.
   Natl Inst Publ Hlth & Environm, Labs Organ Analyt Chem, NL-3720 BA Bilthoven, Netherlands.
   Natl Inst Publ Hlth & Environm, Labs Pathol & Immunobiol, NL-3720 BA Bilthoven, Netherlands.
   MRC Labs, Fajara, Gambia.
RP van Els, CACM (reprint author), Natl Inst Publ Hlth & Environm, Labs Vaccine Res, POB 1, NL-3720 BA Bilthoven, Netherlands.
CR Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4
   Bolt G, 2002, J GEN VIROL, V83, P1157
   Buchner J, 1996, FASEB J, V10, P10
   Cardenas MS, 1997, RAPID COMMUN MASS SP, V11, P1271
   Crotzer VL, 2000, J IMMUNOL, V164, P6120
   DHIBJALBUT SS, 1993, J IMMUNOL, V151, P6248
   Ehl S, 1998, J EXP MED, V187, P763, DOI 10.1084/jem.187.5.763
   FERBER I, 1994, SCIENCE, V263, P674, DOI 10.1126/science.8303275
   FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8
   GRIFFIN DE, 1996, FIELDS VIROLOGY
   Herberts CA, 2001, J GEN VIROL, V82, P2131
   Hiemstra HS, 2001, P NATL ACAD SCI USA, V98, P3988, DOI 10.1073/pnas.071050898
   HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328
   JACOBSON S, 1982, J GEN VIROL, V63, P351, DOI 10.1099/0022-1317-63-2-351
   JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301
   Kammer AR, 1999, J EXP MED, V190, P169, DOI 10.1084/jem.190.2.169
   Kamradt T, 2001, NEW ENGL J MED, V344, P655
   KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x
   KELLY JM, 1986, EMBO J, V5, P1601
   Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92
   LIEBERT UG, 1993, J NEUROIMMUNOL, V46, P217, DOI 10.1016/0165-5728(93)90252-T
   LINK H, 1992, J NEUROIMMUNOL, V38, P63, DOI 10.1016/0165-5728(92)90091-X
   Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754
   Marrack P, 2001, NAT MED, V7, P899, DOI 10.1038/90935
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133
   Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209
   NIJMAN HW, 1993, EUR J IMMUNOL, V23, P1215, DOI 10.1002/eji.1830230603
   Ohteki T, 1999, EUR J IMMUNOL, V29, P2886, DOI 10.1002/(SICI)1521-4141(199909)29:09<2886::AID-IMMU2886>3.0.CO;2-A
   Ovsyannikova IG, 2000, J IMMUNOL METHODS, V246, P1, DOI 10.1016/S0022-1759(00)00278-7
   Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X
   Rose NR, 2001, J CLIN INVEST, V107, P943, DOI 10.1172/JCI12673
   ROTT O, 1994, MED MICROBIOL IMMUN, V183, P195
   SALEMI S, 1995, J EXP MED, V181, P2253, DOI 10.1084/jem.181.6.2253
   Sandberg JK, 2000, J IMMUNOL, V165, P25
   Santori FR, 2001, J IMMUNOL, V166, P5416
   SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S
   Sercarz EE, 2002, NAT IMMUNOL, V3, P110, DOI 10.1038/ni0202-110
   SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595
   Tan LC, 1999, J IMMUNOL, V162, P1827
   TERMEULEN V, 1993, INTERVIROLOGY, V35, P86
   TSUBUKI S, 1994, FEBS LETT, V344, P229, DOI 10.1016/0014-5793(94)00388-2
   van der Heeft E, 1998, ANAL CHEM, V70, P3742, DOI 10.1021/ac9801014
   van Eden W, 1998, IMMUNOL TODAY, V19, P303, DOI 10.1016/S0167-5699(98)01283-3
   van Els CACM, 2000, EUR J IMMUNOL, V30, P1172, DOI 10.1002/(SICI)1521-4141(200004)30:4<1172::AID-IMMU1172>3.0.CO;2-J
   van Sechel AC, 1999, J IMMUNOL, V162, P129
   Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907
   Veronese FD, 1996, J EXP MED, V183, P2509
   WAGNER BJ, 1995, ARCH BIOCHEM BIOPHYS, V323, P455, DOI 10.1006/abbi.1995.0067
NR 49
TC 24
Z9 24
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD JAN
PY 2003
VL 64
IS 1
BP 44
EP 55
AR PII S0198-8859(02)00707-3
DI 10.1016/S0198-8859(02)00707-3
PG 12
WC Immunology
SC Immunology
GA 636EU
UT WOS:000180442200006
PM 12507814
OA No
DA 2017-08-15
ER

PT S
AU Fall, A
   Fall, A
   Diack, A
   Dia, F
AF Fall, A
   Fall, A
   Diack, A
   Dia, F
BE Pearson, RA
   Lhoste, P
   Saastamoinen, M
   MartinRosset, W
TI The role of work animals in semi-arid West Africa: current use and their
   potential for future contributions
SO WORKING ANIMALS IN AGRICULTURE AND TRANSPORT: A COLLECTION OF SOME
   CURRENT RESEARCH AND DEVELOPMENT OBSERVATIONS
SE EAAP EUROPEAN ASSOCIATION FOR ANIMAL PRODUCTION TECHNICAL SERIES
LA English
DT Proceedings Paper
CT Seminar on Working Animals in Agriculture and Transport
CY SEP 03, 2002
CL CAIRO, EGYPT
SP European Assoc Anim Product
DE work animals; semi-arid areas; animal traction; equines; draught cows
AB This paper presents an analysis of the current and future contributions of work animals in West African semi-arid areas. The study is based on literature review and surveys conducted in the Senegalese groundnut basin. The number of work animals in semi-arid areas has increased over the years reflecting increased contributions of draught animal power in cultivation and transport. Climate and policy changes have caused changes in the pattern of use of work animals. More equines are being used for light work. The use of draught oxen has changed little. Policy reforms and reduced farm profits have negatively affected the level of adoption of animal power. Equines and draught cows are likely to play a greater role in the future to meet farm energy needs for cultivation and transport. However, to optimise the use of these resources it is essential that technical and socio-economic constraints be addressed.
C1 ITC, Banjul, Gambia.
RP Fall, A (reprint author), ITC, PMB 14, Banjul, Gambia.
CR CAMPBELL J, 1990, DIPPLE STICKS DONKEY
   *CIRAD, 1996, AGR AFR TRACT AN TEC
   DEHOUX JP, 1996, AGRI, V20, P35
   FALL A, 1997, UNPUB METHODOLOGY EV, V1
   FALL A, 1997, UNPUB METHODOLOGY EV, V2
   HAVARD M, 1998, SUSTAINABLE FARMING
   HAVARD M, 1997, TRACTION ANIMALE AFR
   JABBAR MA, 1993, RES DEV ANIMALS TRAC
   LHOSTE P, 1986, THESIS I NATL AGRONO
   MATTHEWMAN R, 1993, RES DEV ANIMALS TRAC
   NDAO T, 2001, SYNTHESE TRAVAUX RAL
   NDIAME F, 1988, DIAGNOSTIQUE CONTRAI
   NDIAME F, 1986, ISRA MEMOIRE TITULAR
   PANIN A, 1994, IMPROVING ANIMAL TRA
   PEARSON RA, 1998, 3 C INT EQ TRAB MEX
   Pingali P. L., 1987, AGR MECH EVOLUTION F
   SENE M, 1990, ANIMAL TRACTION AGR
   SOWE JM, 1993, RES DEV ANIMAL TRACT
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WAGENINGEN ACADEMIC PUBLISHERS
PI WAGENINGEN
PA POSTBUS 220, 6700 AE WAGENINGEN, NETHERLANDS
SN 1570-7318
BN 90-76998-25-6
J9 EAAP TECH
PY 2003
IS 6
BP 27
EP 37
PG 11
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA BX82C
UT WOS:000186522200002
OA No
DA 2017-08-15
ER

PT S
AU Akinbamijo, OO
   Pearson, RA
   Fall, A
AF Akinbamijo, OO
   Pearson, RA
   Fall, A
BE Pearson, RA
   Lhoste, P
   Saastamoinen, M
   MartinRosset, W
TI Management strategies for trypanotolerant draught animals in West Africa
SO WORKING ANIMALS IN AGRICULTURE AND TRANSPORT: A COLLECTION OF SOME
   CURRENT RESEARCH AND DEVELOPMENT OBSERVATIONS
SE EAAP EUROPEAN ASSOCIATION FOR ANIMAL PRODUCTION TECHNICAL SERIES
LA English
DT Proceedings Paper
CT Seminar on Working Animals in Agriculture and Transport
CY SEP 03, 2002
CL CAIRO, EGYPT
SP European Assoc Anim Product
DE hypanotolerance; cattle; draught; feeding strategies; work
ID TRYPANOSOMA-CONGOLENSE INFECTION; GOBRA-ZEBU BULLS; LIVEWEIGHT CHANGES;
   BORAN CATTLE; NDAMA; SUSCEPTIBILITY; NUTRITION; ANEMIA; WORK
AB This paper identifies the problems in using trypanotolerant cattle for work in the tsetse-infested ecological zones in sub-Saharan Africa (SSA). The interactions that occur between nutrition, work and tolerance in various types of infection are reviewed. The current feeding resources and practices that are available are identified. With the basic nutrition offered by natural pastures in SSA, most working animals will barely meet their maintenance requirements without the additional needs for work. Nutritional supplementation in itself may not prevent weight loss when the animals are working, but can maintain work output, important for food crop production. A realistic balancing of work load commensurate with the nutrition available can help to reduce the debilitating effects of trypanosomosis. The synergistic effects of work and the physiological demands of disease resistance can have a significant effect on the host metabolism even during sub-clinical infections. While quantitative nutritional thresholds are suggested in this paper (daily digestible organic matter intakes, DOMI, of at least 9g/kg live weight), chemo-prophylactic measures are also considered beneficial to trypanotolerant draught animals especially during work and high disease prevalence periods. The aim in feeding is to make the best out of the natural resources available by judicious use of animal power and feeding management.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP Akinbamijo, OO (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   Akinbamijo OO, 1997, ANIM SCI, V65, P151
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P379
   Akinbamijo OO, 1998, ACTA TROP, V69, P181, DOI 10.1016/S0001-706X(97)00123-X
   AKINBAMIJO OO, 2000, P WORKSH AN TRACT NE, P169
   AKINBAMIJO OO, 1999, R6402 DFID
   AKINBAMIJO OO, 1994, THESIS WAGENINGEN AG
   AKINBAMIJO OO, 1988, THESIS OBAFEMI AWOLO
   ALFORD RJ, 1994, THESIS U EDINBURGH
   AUTHIE E, 1993, PARASITE IMMUNOL, V15, P101, DOI 10.1111/j.1365-3024.1993.tb00589.x
   BARACOS VE, 1987, CAN J PHYSIOL PHARM, V65, P1248
   BARTHOLOMEW PW, 1994, TROP ANIM HEALTH PRO, V26, P58, DOI 10.1007/BF02241135
   Bennison JJ, 1998, ANIM SCI, V66, P595
   BENNISON JJ, 1997, THESIS U LONDOMN
   DARGIE JD, 1979, PARASITOLOGY, V78, P271
   DIJKMAN JT, 1993, THESIS U EDINBURGH
   Fall A., 1997, FEEDING WORKING STRA
   FAO (Food and Agriculture Organization), 1987, AFR AGR NEXT 25 YEAR
   *INT LAB RES AN DI, 1993, EST COST ANIM TRYP A
   LAWRENCE P, 1999, FEEDING STANDARDS CA
   LAWRENCE PR, 1985, ACIAR P SERIES, V10, P59
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   MURRAY M, 1988, ACTA TROP, V45, P389
   MURRAY M, 1982, ADV PARASIT, V21, P2
   OASER S, 1999, THESIS U UTRECHT NET
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   Pearson RA, 1999, ANIM SCI, V68, P1
   PEARSON RA, 1996, WORLS ANIM REV, V97, P45
   Pearson R.A., 1993, ANIMAL PRODUCTION DE, P57
   Starkey P., 1989, HARNESSING IMPLEMENT
   STARKEY PH, 1994, P 1 WORKSH AN TRACT, P66
NR 32
TC 0
Z9 0
U1 0
U2 0
PU WAGENINGEN ACADEMIC PUBLISHERS
PI WAGENINGEN
PA POSTBUS 220, 6700 AE WAGENINGEN, NETHERLANDS
SN 1570-7318
BN 90-76998-25-6
J9 EAAP TECH
PY 2003
IS 6
BP 113
EP 122
PG 10
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA BX82C
UT WOS:000186522200010
OA No
DA 2017-08-15
ER

PT J
AU Awomoyi, AA
   Marchant, A
   Howson, JMM
   McAdam, KPWJ
   Blackwell, JM
   Newport, MJ
AF Awomoyi, AA
   Marchant, A
   Howson, JMM
   McAdam, KPWJ
   Blackwell, JM
   Newport, MJ
TI Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and
   susceptibility to tuberculosis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID INTERFERON-GAMMA-RECEPTOR; MESSENGER-RNA STABILITY;
   MYCOBACTERIUM-TUBERCULOSIS; NATURAL-RESISTANCE; INTRACELLULAR PARASITES;
   CYTOKINE PRODUCTION; GENE; INFECTION; MACROPHAGES; EXPRESSION
AB Host genetic factors are major determinants of susceptibility to tuberculosis, and an understanding of the molecular basis of this observation has major implications for the development of novel therapies and vaccines. Slc11a1 (formerly Nramp1), the first murine infection susceptibility locus identified, regulates early innate responses to intracellular pathogens. Variation in the human homologue SLC11A1 is associated with and linked to tuberculosis in genetically different populations. In a case-control study of 329 tuberculosis case patients and 324 control subjects, the association between allele 2 of a functional SLC11A1 polymorphism and tuberculosis has been reproduced. This variant is associated with higher lipopolysaccharide-induced production of the macrophage-deactivating cytokine interleukin-10. Furthermore, monocytes from persons who develop tuberculosis innately produce more interleukin-10 than do monocytes from healthy control subjects. These data therefore confirm the importance of SLC11A1 in tuberculosis susceptibility in humans and suggest that SLC11A1 influences tuberculosis susceptibility by regulation of interleukin-10.
C1 Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England.
   MRC Labs, Banjul, Gambia.
   Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC,Human Immunol Unit, Oxford OX3 9DU, England.
RP Newport, MJ (reprint author), Addenbrookes Hosp, Cambridge Inst Med Res, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.
RI Blackwell, Jenefer/H-3015-2015
FU Wellcome Trust [065642]
CR Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830
   BARNES PF, 1992, J IMMUNOL, V149, P541
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Blackwell JM, 2000, MICROBES INFECT, V2, P317, DOI 10.1016/S1286-4579(00)00295-1
   BLACKWELL JM, 1995, MOL MED, V1, P194
   Blackwell JM, 2001, CELL MICROBIOL, V3, P773, DOI 10.1046/j.1462-5822.2001.00150.x
   BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549
   Brown DH, 1997, INFECT IMMUN, V65, P597
   Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851
   Cervino ACL, 2000, ANN HUM GENET, V64, P507, DOI 10.1046/j.1469-1809.2000.6460507.x
   DE WMR, 1991, J EXP MED, V174, P1209
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   Eskdale J, 1998, P NATL ACAD SCI USA, V95, P9465, DOI 10.1073/pnas.95.16.9465
   Fine PEM, 2001, SCAND J INFECT DIS, V33, P243, DOI 10.1080/003655401300077144
   Fulton SA, 1998, J INFECT DIS, V178, P1105, DOI 10.1086/515698
   Gao PS, 2000, CLIN GENET, V58, P74, DOI 10.1034/j.1399-0004.2000.580113.x
   Gong JH, 1996, INFECT IMMUN, V64, P913
   Goswami T, 2001, BIOCHEM J, V354, P511, DOI 10.1042/0264-6021:3540511
   Greenwood CMT, 2000, AM J HUM GENET, V67, P405, DOI 10.1086/303012
   GROS P, 1981, J IMMUNOL, V127, P2417
   HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N
   Holland S M, 2000, Adv Intern Med, V45, P431
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   Lafuse WP, 2000, BIOCHEM J, V351, P687, DOI 10.1042/0264-6021:3510687
   LIU J, 1995, AM J HUM GENET, V56, P845
   MALEFYT RD, 1991, J EXP MED, V174, P915
   Meisner SJ, 2001, AM J TROP MED HYG, V65, P733
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Nunn P, 2001, SCAND J INFECT DIS, V33, P329, DOI 10.1080/003655401750173887
   Pie S, 1996, INFECT IMMUN, V64, P849
   Rojas M, 1999, J IMMUNOL, V162, P6122
   Ryu S, 2000, INT J TUBERC LUNG D, V4, P577
   Sambrook J., 1989, MOL CLONING LAB MANU, V2
   Sanjeevi CB, 2000, ARTHRITIS RHEUM, V43, P1397, DOI 10.1002/1529-0131(200006)43:6<1397::AID-ANR25>3.0.CO;2-6
   Searle S, 1999, J MED GENET, V36, P295
   Searle S, 1998, J CELL SCI, V111, P2855
   Sterling TR, 2001, CLIN INFECT DIS, V33, P976, DOI 10.1086/322670
   VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D
   Westendorp RGJ, 1997, LANCET, V349, P1912, DOI 10.1016/S0140-6736(05)63910-4
   *WHO INT UN LUNG T, 2000, 2WHOCDSTB2000278
   Wyllie S, 2002, MICROBES INFECT, V4, P351, DOI 10.1016/S1286-4579(02)01548-4
   Zhang M, 1999, J INFECT DIS, V179, P1213, DOI 10.1086/314738
   ZHANG M, 1994, J CLIN INVEST, V94, P2435, DOI 10.1172/JCI117611
NR 46
TC 93
Z9 101
U1 1
U2 5
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 15
PY 2002
VL 186
IS 12
BP 1808
EP 1814
DI 10.1086/345920
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 617ZW
UT WOS:000179392800014
PM 12447767
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, CJ
   Alloueche, A
   Curtis, J
   Drakeley, CJ
   Ord, R
   Duraisingh, M
   Greenwood, BM
   Pinder, M
   Warhurst, D
   Targett, GAT
AF Sutherland, CJ
   Alloueche, A
   Curtis, J
   Drakeley, CJ
   Ord, R
   Duraisingh, M
   Greenwood, BM
   Pinder, M
   Warhurst, D
   Targett, GAT
TI Gambian children successfully treated with chloroquine can harbor and
   transmit Plasmodium falciparum gametocytes carrying resistance genes
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID UNCOMPLICATED MALARIA; MOLECULAR MARKER; PYRIMETHAMINE-SULFADOXINE;
   LINKAGE DISEQUILIBRIUM; PFMDR1 GENE; PFCRT; POLYMORPHISMS;
   RECRUDESCENCE; ARTESUNATE; MUTATIONS
AB Polymorphisms in two genes of Plasmodium falciparum (P. falciparum multidrug resistance 1 [pfmdr1] and P. falciparum chloroquine [CQ] resistance transporter [pfcrt]) are associated with CQ treatment failure. We found significant linkage disequilibrium between these loci among isolates from symptomatic Gambian children (P = 0.026) and strong selection for the resistance-associated alleles pfmdr1-86Tyr and pfcrt-76Thr in children with persistent or re-emerging P. falciparum trophozoites during post-treatment follow-up (P = 1.9 X 10(-7)). Therefore, this genotype is characteristic of resistant infections among our study population. Since the long-term public health impact of parasites carrying such resistant genotypes depends upon their transmissibility, we examined the prevalence of pfmdr1-86Tyr and pfcrt-76Thr among Gambian children harboring sexual stage parasites during post-treatment follow-up. Gametocytes that emerged after successful treatment with CQ were significantly more likely to be of this genotype than were those emerging after other treatments (P = 4.83 x 10(-4)), and were infective to Anopheles mosquitoes. Therapeutic success may thus be accompanied by public health failure as cured children pass resistance genes on to mosquitoes at an enhanced rate.
C1 Univ London London Sch Hyg & Trop Med, Immunol Unit, Dept Infect & Trop Med, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Sutherland, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Immunol Unit, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.
CR Adagu IS, 2001, PARASITOLOGY, V123, P219, DOI 10.1017/S0031182001008344
   Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2
   BABIKER H, 1994, T ROY SOC TROP MED H, V88, P328, DOI 10.1016/0035-9203(94)90103-1
   Babiker HA, 2001, J INFECT DIS, V183, P1535, DOI 10.1086/320195
   Basco LK, 2000, AM J TROP MED HYG, V63, P215
   Basco LK, 2001, J INFECT DIS, V183, P1828, DOI 10.1086/320726
   Brockman A, 1999, AM J TROP MED HYG, V60, P14
   BRUCECHWATT LJ, 1986, WHO MONOGRAPH, V27
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
   Djimde A, 2001, LANCET, V358, P890, DOI 10.1016/S0140-6736(01)06040-8
   Dollery C., 1999, THERAPEUTIC DRUGS
   Duraisingh MT, 1997, PARASITOLOGY, V114, P205, DOI 10.1017/S0031182096008487
   Duraisingh MT, 2000, PARASITOLOGY, V121, P1, DOI 10.1017/S0031182099006022
   Durand R, 2001, MOL BIOCHEM PARASIT, V114, P95, DOI 10.1016/S0166-6851(01)00247-X
   Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(00)00084-8
   Flueck TP, 2000, TROP MED INT HEALTH, V5, P174, DOI 10.1046/j.1365-3156.2000.00543.x
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   Mehlotra RK, 2001, P NATL ACAD SCI USA, V98, P12689, DOI 10.1073/pnas.221440898
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   Pillai DR, 2001, J INFECT DIS, V183, P789, DOI 10.1086/318836
   Povoa MM, 1998, EXP PARASITOL, V88, P64, DOI 10.1006/expr.1998.4195
   Price RN, 1999, ANTIMICROB AGENTS CH, V43, P2943
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   RANFORDCARTWRIG.LC, 1997, T R SOC TROP MED HYG, V91, P710
   Snounou G, 1998, PARASITOL TODAY, V14, P462, DOI 10.1016/S0169-4758(98)01340-4
   Sutherland CJ, 2002, AM J TROP MED HYG, V66, P700
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x
   vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9
   Warhurst D, 2001, DRUG RESIST UPDATE, V4, P141, DOI 10.1054/drup.2001.0194
   Warhurst DC, 2001, NEW ENGL J MED, V344, P299, DOI 10.1056/NEJM200101253440411
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
   *WHO REG OFF AFR, 1999, PRACT HDB ANT DRUG T
NR 37
TC 84
Z9 84
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2002
VL 67
IS 6
BP 578
EP 585
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 628QJ
UT WOS:000180007500005
PM 12518847
OA No
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Wesumperuma, HL
   Fern, J
   Yamuah, LK
   Hart, CA
AF Okoko, BJ
   Wesumperuma, HL
   Fern, J
   Yamuah, LK
   Hart, CA
TI The transplacental transfer of IgG subclasses: influence of prematurity
   and low birthweight in the Gambian population
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID PLACENTAL-TRANSFER; IMMUNOGLOBULIN-G; GESTATIONAL-AGE; HUMAN-PREGNANCY;
   HYPERGAMMAGLOBULINEMIA; DEFICIENCY; RECEPTORS; FEATURES
AB Having established previously that prematurity in The Gambia is associated with impaired materno-fetal transfer of some specific antibodies, we investigated the influence of low birthweight and prematurity on placental transfer of IgG subclasses in 180 Gambian mothers and their newborn babies. A physician-blinded, cross-sectional study of 180 mother-baby pairs was carried out in the labour ward of Bansang Hospital, The Gambia. Paired maternal and cord serum samples were collected from mothers and their newborns. Serum IgG subclass levels were measured by laser nephelometry. Placental transfer of all IgG subclasses was significantly reduced in preterm newborns compared with term newborns (p < 0.01). In low birthweight (LBW) babies, the transfer of IgG(1) (p = 0.03) and IgG(2) (p < 0.01) subclasses, but not IgG(3) and IgG(4), was significantly reduced. In preterm. neonates with an adequate birthweight and term neonates with a low birthweight, all IgG subclasses were transferred with reduced efficiency, but IgG(1) and IgG(2) subclasses were transferred with significantly less efficiency than IgG(3) and IgG(4). These results confirm that prematurity and low birthweight are associated with impaired placental transfer of IgG(1) and IgG(2) subclasses in this Gambian population. This impairment might explain the susceptibility of these newborns to certain polysaccharide-encapsulated organisms.
C1 MRC, Fajara, Gambia.
   Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England.
RP Okoko, BJ (reprint author), MRC, Pneumococcal Vaccine Trial, POB 273, Banjul, Gambia.
CR BATTAGLIA FC, 1970, J PEDIATR-US, V76, P812, DOI 10.1016/S0022-3476(70)80319-5
   Beebe LA, 1996, OBSTET GYNECOL, V87, P771, DOI 10.1016/0029-7844(95)00483-1
   Catty D, 1979, PROTEIN TRANSMISSION, P37
   CostaCarvalho BT, 1996, BRAZ J MED BIOL RES, V29, P201
   deMoraesPinto I, 1997, BRIT J HOSP MED, V58, P317
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Ferrante A, 1990, PEDIAT INFECT DIS S, V9, P16
   GAIRDNER D, 1988, CRAIGS CARE NEWLY BO, P115
   GARTY BZ, 1994, CLIN DIAGN LAB IMMUN, V1, P667
   Gunsolley JC, 1997, J PERIODONTAL RES, V32, P381, DOI 10.1111/j.1600-0765.1997.tb00548.x
   Hashira S, 2000, PEDIATR INT, V42, P337, DOI 10.1046/j.1442-200x.2000.01245.x
   HAY FC, 1971, CLIN EXP IMMUNOL, V9, P355
   JEFFERIS R, 1990, CLIN EXP IMMUNOL, V81, P357
   KAMEDA T, 1991, PLACENTA, V12, P15, DOI 10.1016/0143-4004(91)90506-B
   LEE SI, 1986, MONOGR ALLERGY, V19, P108
   MALEK A, 1994, AM J REPROD IMMUNOL, V32, P8
   Okoko BJ, 2001, VACCINE, V20, P647, DOI 10.1016/S0264-410X(01)00418-2
   Okoko BJ, 2001, J INFECT DIS, V184, P627, DOI 10.1086/322808
   PITCHERWILMOTT RW, 1980, CLIN EXP IMMUNOL, V41, P303
   Praetor A, 1999, J CELL SCI, V112, P2291
   SAJI F, 1994, PLACENTA, V15, P453, DOI 10.1016/S0143-4004(05)80415-1
   Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/ror.0.0040081
   SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1049, DOI 10.1016/0002-9378(95)91325-4
   SCHUR PH, 1987, ANN ALLERGY, V58, P89
   SHIELD JPH, 1992, LANCET, V340, P448
NR 25
TC 13
Z9 14
U1 0
U2 0
PU MANEY PUBLISHING
PI LEEDS
PA HUDSON RD, LEEDS LS9 7DL, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD DEC
PY 2002
VL 22
IS 4
BP 325
EP 332
DI 10.1179/027249302125001985
PG 8
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 632LQ
UT WOS:000180225100004
PM 12530282
OA No
DA 2017-08-15
ER

PT J
AU Somda, J
   Nianogo, AJ
   Nassa, S
   Sanou, S
AF Somda, J
   Nianogo, AJ
   Nassa, S
   Sanou, S
TI Soil, fertility management and socio-economic factors in crop-livestock
   systems in Burkina Faso: a case study of composting technology
SO ECOLOGICAL ECONOMICS
LA English
DT Article
DE compost technology; adoption model; farmers' characteristics; Burkina
   Faso
ID FARMERS PERCEPTIONS; ADOPTION
AB The relation between technology adoption and farmers' socio-economic characteristics has increasingly been given attention in developing countries. However, most of the studies conducted by economists dealt with the adoption of external technologies. Here, we test the determinants of compost adoption, an alternative indigenous technology for soil fertility management. The results of analysis of data from Burkina Faso, using Logit model, strongly support the hypothesis that farmers' socio-economic characteristics and their agro-ecological location significantly affect their adoption decisions. There are two main conclusions of this study: first, the agro-ecological location of farmers influence their decision to widely adopt compost technology. Second, among farmers' characteristics affecting compost adoption, three groups can be distinguished. The most important socio-economic characteristics are farmers' age, their comparative perception on the yield effect of compost with regards to other fertilizers and their annual agricultural income. A second group of characteristics include the institutional factors, which are represented by the farmers' participation in extension workshops. A third group of factors comprises the farmer's labor force participating rate, the number of ruminants owned and farmers gender. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   UICN, Ouagadougou, Burkina Faso.
   INERA, Ouagadougou, Burkina Faso.
RP Somda, J (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR ADESINA AA, 1995, AGR ECON, V13, P1, DOI 10.1016/0169-5150(95)01142-8
   ADESINA AA, 1993, AGR ECON, V9, P297, DOI 10.1016/0169-5150(93)90019-9
   Allan W., 1965, AFRICAN HUSBANDMAN
   BaiduForson J, 1997, AGR SYST, V54, P463, DOI 10.1016/S0308-521X(96)00094-7
   CAMPBELL BM, 1997, TSBF BIOL MANAGEMENT, P150
   CHAMBERS R, 1991, MAKE FLIP STRATEGIES
   Chuma E., 2000, NUTR MOVE SOIL FERTI, P45
   *DPA, 1997, DIAGN PART SYST PROD
   DUFUMIER M, 1994, JP S INT RECH SYST A, P12
   Hilhorst T, 2000, NUTR MOVE SOIL FERTI, P1
   Kebede Y., 1990, Agricultural Economics, V4, P27, DOI 10.1016/0169-5150(90)90018-V
   LANCASTER KJ, 1966, J POLIT ECON, V74, P132, DOI 10.1086/259131
   LOMPO F, 2000, NUTR MOVE SOIL FERTI, P103
   NAGASSA A, 1997, ETHIOPIAN J AGR EC, V115, P267
   NAGY JG, 1987, CEREAL TECHNOLOGY DE
   NORMAN D, 1981, RES B ICRISAT, V4
   Oucho J.O., 1998, WORKING PAPER SERIES, V28
   PIERCE JT, 1990, FOOD RESOURCE
   PIGEONNIERE LA, 1998, ATLAS BURKINA FASO
   Pingali P. L., 1987, AGR MECH EVOLUTION F
   PRUDENCIO YC, 1983, THESIS U ARIZONA
   Savadogo K, 1998, AGR SYST, V58, P441, DOI 10.1016/S0308-521X(98)00040-7
   White KJ, 1993, SHAZAM ECONOMETRICS
   WHYTE WF, 1981, PARTICIPATORY APPROA
NR 24
TC 39
Z9 40
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8009
J9 ECOL ECON
JI Ecol. Econ.
PD DEC
PY 2002
VL 43
IS 2-3
BP 175
EP 183
AR PII S0921-8009(02)00208-2
DI 10.1016/S0921-8009(02)00208-2
PG 9
WC Ecology; Economics; Environmental Sciences; Environmental Studies
SC Environmental Sciences & Ecology; Business & Economics
GA 627KP
UT WOS:000179932600005
OA No
DA 2017-08-15
ER

PT J
AU Drammeh, BS
   Marquis, GS
   Funkhouser, E
   Bates, C
   Eto, I
   Stephensen, CB
AF Drammeh, BS
   Marquis, GS
   Funkhouser, E
   Bates, C
   Eto, I
   Stephensen, CB
TI A randomized, 4-month mango and fat supplementation trial improved
   vitamin A status among young Gambian children
SO JOURNAL OF NUTRITION
LA English
DT Article
DE vitamin A deficiency; carotenoids; beta-carotene; mango; The Gambia
ID GREEN LEAFY VEGETABLES; BETA-CAROTENE; A STATUS; SERUM RETINOL;
   DARK-GREEN; XEROPHTHALMIA; CONSUMPTION
AB Supplementation with carotene-rich fruits may be an effective and sustainable approach to prevent vitamin A deficiency. To test the effectiveness of mango supplementation, 176 Gambian children, aged 2 to 7 y, were randomly assigned to one of four treatments: 75 g of dried mango containing similar to150 mug retinol activity equivalents with (MF) or without (M) 5 g of fat, 5 d/wk for 4 mo or 60,000 mug of vitamin A (A) or placebo (P) capsule at baseline. After 4 mo, plasma beta-carotene was greater in both the M (P < 0.05) and MF (P = 0.07) groups compared with the P group. After controlling for baseline plasma retinol, elevated acute phase proteins and age, plasma retinol concentrations in the A and MF, but not M, groups were higher than in the P group at the end of the study (P < 0.01). Increases in retinol concentrations, however, were small in both groups. These results support the use of dietary supplementation with dried mangoes and a source of fat as one of several concurrent strategies that can be used to help maintain vitamin A status of children in developing countries where there is a severe seasonal shortage of carotenoid-rich foods.
C1 Iowa State Univ, Dept Food Sci & Human Nutr, Ames, IA 50011 USA.
   Univ Alabama, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
   MRC, Keneba, Gambia.
   MRC, Human Nutr Res, Cambridge CB2 2QH, England.
   Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA.
   USDA, Western Human Nutr Res Ctr, Davis, CA 95616 USA.
   Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.
RP Marquis, GS (reprint author), Iowa State Univ, Dept Food Sci & Human Nutr, Ames, IA 50011 USA.
CR BATES CJ, 1984, T ROY SOC TROP MED H, V78, P814, DOI 10.1016/0035-9203(84)90028-2
   BULUX J, 1994, AM J CLIN NUTR, V59, P1369
   de Pee S, 1998, AM J CLIN NUTR, V68, P1058
   DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7
   Erlinger TP, 2001, ARCH INTERN MED, V161, P1903, DOI 10.1001/archinte.161.15.1903
   *FAO WHO, 1988, FAO FOOD NUTR SER, V23, P25
   Food and Nutrition Board Institute of Medicine, 2002, DIET REF INT VIT A V, P82
   GODOY HT, 1987, INT J FOOD SCI TECH, V22, P451
   Hamill PVV, 1977, DHEW PUBLICATION, V(PHS) 78-1650
   Jalal F, 1998, AM J CLIN NUTR, V68, P623
   JAYARAJAN P, 1980, INDIAN J MED RES, V71, P53
   KIRK RE, 1995, EXPT DESIGN PROCEDUR, P62
   LALA VR, 1970, AM J CLIN NUTR, V23, P110
   MARGETTS BM, 1991, DESIGN CONCEPTS NUTR, P34
   MARIATH JGR, 1989, AM J CLIN NUTR, V49, P849
   MCCRAE JE, 1996, FOODS RURAL GAMBIA M, P79
   NATHANAIL L, 1992, ANN TROP PAEDIATR, V12, P67
   PITTIGLIO DH, 1987, CLIN HEMATOLOGY FUND, P35
   PRINCE MR, 1993, AM J CLIN NUTR, V57, P175
   Rahman MM, 1996, J NUTR, V126, P628
   RANKINS J, 1989, ECOL FOOD NUTR, V23, P131
   RANKINS J, 1989, J NUTR EDUC, V24, P192
   Semba RD, 2000, AM J CLIN NUTR, V72, P146
   Stephensen CB, 2000, AM J CLIN NUTR, V72, P1170
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   Takyi EEK, 1999, J NUTR, V129, P1549
   Tang G, 1999, AM J CLIN NUTR, V70, P1069
   Tanumihardjo SA, 2001, J NUTR, V131, P3316
   UNDERWOOD BA, 1994, RETINOIDS BIOL CHEM, P219
   VILLARD L, 1987, HUM NUTR-APPL NUTR, V41A, P135
   Wadhwa A., 1994, Food and Nutrition Bulletin, V15, P53
   *WHO, 1990, M PREV CHILDH BLINDN
NR 32
TC 16
Z9 17
U1 1
U2 1
PU AMER INST NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD DEC
PY 2002
VL 132
IS 12
BP 3693
EP 3699
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 625UB
UT WOS:000179833000021
PM 12468609
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Simondon, F
   Samb, B
   Cisse, B
   Jensen, H
   Lisse, IM
   Soumare, M
   Whittle, H
AF Aaby, P
   Simondon, F
   Samb, B
   Cisse, B
   Jensen, H
   Lisse, IM
   Soumare, M
   Whittle, H
TI Low mortality after mild measles infection compared to uninfected
   children in rural west Africa
SO VACCINE
LA English
DT Article
DE beneficial immune stimulation; long-term excess mortality; mortality;
   measles infection; measles immunisation; sub-clinical measles
ID RESPIRATORY SYNCYTIAL VIRUS; GUINEA-BISSAU; EXCESS MORTALITY;
   CASE-FATALITY; VACCINATION; SENEGAL; IMMUNIZATION; COMMUNITY; TITER;
   IMMUNITY
AB Background: It has been assumed that measles infection may be associated with persistent immune suppression and long-term excess mortality. However, few community studies of mortality after measles infection have been carried out. We examined long-term mortality for measles cases, sub-clinical measles cases, and uninfected contacts after an epidemic in rural Senegal.
   Methods: The study was carried out in Niakhar, a rural area of Senegal. Index cases of measles were identified and children less than 7 years of age exposed to measles in the same compound had acute and convalescent blood samples collected. Clinically diagnosed measles cases were serologically confirmed. Children without clinical symptoms were classified as sub-clinical cases if they had a four-fold or greater change in antibody levels between samples collected at exposure and 1 month later and as uninfected if there was no or a two-fold change in antibody levels.
   Results: There were 31 index cases, and among 184 exposed contacts, 35 (19%) children developed clinical measles. Among contacts that did not develop clinical measles, 45% had sub-clinical infection. Measles cases, sub-clinical cases, and uninfected contacts did not differ with respect to nutritional status. However, uninfected children without clinical symptoms and change in antibody level had higher initial measles specific IgG antibody levels and less intensive exposure to the index case. No index or secondary case of measles died in the acute phase of infection nor did any of the children exposed to measles die in the first 2 months after exposure. Exposed children developing clinical measles had lower age-adjusted mortality over the next 4 years than exposed children who did not develop clinical measles (P < 0.05). Sub-clinical measles cases tended to have low mortality and compared with uninfected children, exposed children with clinical or sub-clinical measles had lower age-adjusted mortality (mortality ratio (MR) = 0.20 (0.06-0.74)). Controlling for background factors had no impact of the estimates.
   Conclusions: When measles infection is mild, clinical measles has no long-term excess mortality and may be associated with better overall survival than no clinical measles infection. Sub-clinical measles is common among immunised children and is not associated with excess mortality. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 IRD, Unite Rech Malad Infect & Parasitaires, Dakar, Senegal.
   Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark.
   IRD, Montpellier, France.
   Univ Cheikh Anta Diop, Dakar, Senegal.
   MRC Labs, Banjul, Gambia.
RP Aaby, P (reprint author), IRD, Unite Rech Malad Infect & Parasitaires, Dakar, Senegal.
CR AABY P, 1989, PEDIATR INFECT DIS J, V8, P197
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1990, AM J EPIDEMIOL, V132, P211
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 1996, AM J EPIDEMIOL, V143, P1035
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   Aaby P, 1996, PEDIATR INFECT DIS J, V15, P39, DOI 10.1097/00006454-199601000-00009
   AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443
   AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X
   AABY P, INT J EPIDEMIOL
   Adkins P, 2001, J IMMUNOL, V166, P918
   CHAHNAZARIAN A, 1992, POPULATION SANTE NIA
   CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185
   CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330
   Cox D. R., 1984, ANAL SURVIVAL DATA
   Dollimore N, 1997, AM J EPIDEMIOL, V146, P646
   Fischer JE, 2000, J INFECT DIS, V182, P1029, DOI 10.1086/315806
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GRAHAM BS, 1993, J IMMUNOL, V151, P2032
   HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002
   HULL HF, 1983, LANCET, V1, P972
   Ito M, 1997, CLIN IMMUNOL IMMUNOP, V83, P281, DOI 10.1006/clin.1997.4344
   Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   LEON ME, 1993, J INFECT DIS, V168, P1097
   Lisse I, 1998, SCAND J INFECT DIS, V30, P17
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Moran TM, 1999, J INFECT DIS, V180, P579, DOI 10.1086/314952
   Pabst HF, 1997, VACCINE, V15, P10, DOI 10.1016/S0264-410X(96)00124-7
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P695, DOI 10.1097/00006454-199508000-00009
   Schnorr JJ, 2001, VACCINE, V19, P1503, DOI 10.1016/S0264-410X(00)00349-2
   Simondon F, 1997, VACCINE, V15, P1606, DOI 10.1016/S0264-410X(97)00100-X
   Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537
   WHITTLE HC, 1988, LANCET, V1, P963
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
NR 36
TC 13
Z9 13
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD NOV 22
PY 2002
VL 21
IS 1-2
BP 120
EP 126
AR PII S0264-410X(02)00430-9
DI 10.1016/S0264-410X(02)00430-9
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 623VP
UT WOS:000179723800015
PM 12443670
OA No
DA 2017-08-15
ER

PT J
AU Colebunders, R
   Mariage, JL
   Coche, JC
   Pirenne, B
   Kempinaire, S
   Hantson, P
   Van Gompel, A
   Niedrig, M
   Van Esbroeck, M
   Bailey, R
   Drosten, C
   Schmitz, H
AF Colebunders, R
   Mariage, JL
   Coche, JC
   Pirenne, B
   Kempinaire, S
   Hantson, P
   Van Gompel, A
   Niedrig, M
   Van Esbroeck, M
   Bailey, R
   Drosten, C
   Schmitz, H
TI A Belgian traveler who acquired yellow fever in the Gambia
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID VACCINATION; SENEGAL
AB A 47-year-old Belgian woman acquired yellow fever during a 1-week vacation in The Gambia; she had never been vaccinated against yellow fever. She died of massive gastrointestinal bleeding 7 days after the onset of the first symptoms. This dramatic case demonstrates that it is important for persons to be vaccinated against yellow fever before they travel to countries where yellow fever is endemic, even if the country, like The Gambia, does not require travelers to be vaccinated.
C1 Inst Trop Med, B-2000 Antwerp, Belgium.
   Univ Antwerp Hosp, Antwerp, Belgium.
   Clin St Pierre, Ottignies, Belgium.
   Univ Catholique Louvain, St Luc Hosp, B-1200 Brussels, Belgium.
   Robert Koch Inst, D-1000 Berlin, Germany.
   Bernhard Nocht Inst Trop Med, Hamburg, Germany.
   MRC, Clin Serv, Fajara, Gambia.
RP Colebunders, R (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.
CR Centers for Disease Control and Prevention (CDC), 2000, MMWR-MORBID MORTAL W, V49, P303
   Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P324
   Chan RC, 2001, LANCET, V358, P121, DOI 10.1016/S0140-6736(01)05341-7
   DIGOUTTE JP, 1981, B WORLD HEALTH ORGAN, V59, P759
   GERMAIN M, 1980, AM J TROP MED HYG, V29, P929
   MARRIANNEAU P, 2001, LANCET, V358, P84
   Martin M, 2001, LANCET, V358, P98, DOI 10.1016/S0140-6736(01)05327-2
   McFarland JM, 1997, CLIN INFECT DIS, V25, P1143, DOI 10.1086/516111
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2002, CLIN INFECT DIS, V34, P1369, DOI 10.1086/340104
   NOLLASALAS J, 1989, LANCET, V2, P1275
   Teichmann D, 1999, LANCET, V354, P1608, DOI 10.1016/S0140-6736(99)09233-8
   Thonnon J, 1998, AM J TROP MED HYG, V59, P108
   Van der Stuyft P, 1999, LANCET, V353, P1558, DOI 10.1016/S0140-6736(99)03291-2
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
   WACLAWSKI ER, 1987, LANCET, V1, P100
   *WHO, 2002, INT TRAV HLTH
   *WHO, 1996, WKLY EPIDEMIOL REC, V71, P342
   *WHO, 2001, WKLY EPIDEMIOL REC, V76, P373
   World Health Organization, 2000, WKLY EPIDEM REC, V75, P322
   *WHO COMM DIS SURV, 2001, DIS OUTBR REP YELL F
NR 21
TC 18
Z9 19
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 15
PY 2002
VL 35
IS 10
BP E113
EP E116
DI 10.1086/344180
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 611PM
UT WOS:000179027000025
PM 12410495
OA No
DA 2017-08-15
ER

PT J
AU Li, CM
   Campbell, SJ
   Kumararatne, DS
   Bellamy, R
   Ruwende, C
   McAdam, KPWJ
   Hill, AVS
   Lammas, DA
AF Li, CM
   Campbell, SJ
   Kumararatne, DS
   Bellamy, R
   Ruwende, C
   McAdam, KPWJ
   Hill, AVS
   Lammas, DA
TI Association of a polymorphism in the P2X(7) gene with tuberculosis in a
   Gambian population
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 3rd International Symposium on Nucleotides and Nucleosides
CY JUL 09-13, 2000
CL MADRID, SPAIN
ID VIRULENT MYCOBACTERIUM-TUBERCULOSIS; PHAGOSOME-LYSOSOME FUSION;
   HEPATITIS-B VIRUS; HUMAN MACROPHAGES; CALMETTE-GUERIN; RECEPTOR;
   AFRICANS; DEATH
AB Adenosine triphosphate (ATP) ligation of P2X(7) receptors expressed on human macrophages that are infected with mycobacteria induces cell death and subsequent loss of intracellular bacterial viability. Marked heterogeneity observed in cell donor ATP responsiveness suggests that this antimycobacterial mechanism may be genetically regulated. Five single-nucleotide polymorphisms (SNPs) previously identified in a putative 1.8-kb promoter region upstream of P2RX7 exon 1 were screened for associations with clinical tuberculosis. The frequencies of these promoter SNPs and a polymorphism in P2RX7 exon 13 at position 1513 were compared among >300 Gambian patients with tuberculosis and 1 160 ethnically matched control subjects by sequence-specific oligonucleotide hybridization and ligation detection reaction analysis. A significant protective association against tuberculosis was found for 1 promoter SNP, at nucleotide position -762 (odds ratio [OR] for variant C allele, 0.70; 95% confidence interval [CI], 0.54-0.89; P = .003; OR for CC genotype, 0.545; 95% CI, 0.318-0.934; P = .027). This association supports a role for ATP/P2X(7)-mediated host regulation of Mycobacterium tuberculosis infection.
C1 Univ Birmingham, Div Infect & Immun, MRC, Ctr Immune Regulat,Med Sch, Birmingham B15 2TT, W Midlands, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England.
   Johns Hopkins Univ, Dept Cardiovasc Med, Sch Med, Baltimore, MD USA.
   MRC Labs, Fajara, Gambia.
RP Lammas, DA (reprint author), Univ Birmingham, Div Infect & Immun, MRC, Ctr Immune Regulat,Med Sch, Birmingham B15 2TT, W Midlands, England.
RI HILL, Adrian/C-1306-2008
CR Akiyama Y, TFSEARCH SEARCHING T
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bloom BR, 1998, NEW ENGL J MED, V338, P677, DOI 10.1056/NEJM199803053381008
   Buell GN, 1998, RECEPTOR CHANNEL, V5, P347
   DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226
   DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X
   Fairbairn IP, 2001, J IMMUNOL, V167, P3300
   GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131
   Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Kusner DJ, 2001, J IMMUNOL, V167, P3308
   Kusner DJ, 2000, J IMMUNOL, V164, P379
   Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7
   LAMMAS DA, 1998, CLIN MYCOBACTERIOLOG, P107
   LI CM, IN PRESS FEBS LETT
   LI CM, 2000, DRUG DEV RES S, V50, P55
   MERIKA M, 1993, MOL CELL BIOL, V13, P3999
   MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499
   Rockett KA, 1998, INFECT IMMUN, V66, P5314
   SEKIDO R, 1994, MOL CELL BIOL, V14, P5692
   Sly LM, 2001, J BIOL CHEM, V276, P35482, DOI 10.1074/jbc.M102876200
   SNIDER DE, 1994, J INFECT DIS, V169, P1189
   Solini A, 1999, J CELL SCI, V112, P297
   Stober CB, 2001, J IMMUNOL, V166, P6276
   STOBER CB, 2000, THESIS U BIRMINGHAM
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
NR 27
TC 91
Z9 94
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2002
VL 186
IS 10
BP 1458
EP 1462
DI 10.1086/344351
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 609EQ
UT WOS:000178891000010
PM 12404161
OA No
DA 2017-08-15
ER

PT J
AU Berry, N
   Jaffar, S
   Van der Loeff, MS
   Ariyoshi, K
   Harding, E
   N'Gom, PT
   Dias, F
   Wilkins, A
   Ricard, D
   Aaby, P
   Tedder, R
   Whittle, H
AF Berry, N
   Jaffar, S
   Van der Loeff, MS
   Ariyoshi, K
   Harding, E
   N'Gom, PT
   Dias, F
   Wilkins, A
   Ricard, D
   Aaby, P
   Tedder, R
   Whittle, H
TI Low level viremia and high CD4% predict normal survival in a cohort of
   HIV type-2-infected villagers
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-2 VIRAL LOAD; GUINEA-BISSAU;
   WEST-AFRICA; LYMPHOCYTE COUNTS; PROVIRAL LOAD; HIV-2-INFECTED PATIENTS;
   RURAL AREA; RNA LEVELS; AIDS
AB A community-based study of human immunodeficiency virus type 2 (HIV-2) infection was conducted in a rural village in northern Guinea Bissau, West Africa to assess the relationship between plasma HIV-2 RNA levels, CD4 lymphocyte percentage, and survival over an 8-year period. The cohort of 133 HIV-2-infected individuals and 160 HIV-uninfected controls enrolled in 1991 were followed up at home until 1998. Thirty-one (23%) HIV-2-infected and 24 (16%) HIV-uninfected individuals died over the follow-up period (mortality hazard ratio 1.7, 95% CI 1.0, 2.9; p = 0.06). In HIV-2-infected individuals, the median HIV-2 RNA level was 347 copies/ml and the mean CD4% was 28.6. Both plasma viremia and CD4% were independent predictors of survival, with hazard ratios increasing by 1.6 (95% CI, 1.1, 2.3) for each log(10) increase of plasma viremia and 1.7 (1.1, 2.6) for each 10% decrease of CD4%. Infected subjects with a plasma viral load ? the median (347 copies/ml) and a CD4% less than or equal to the mean (28.6%) had a mortality hazard ratio of 3.1 (95% CI 1.7, 5.8) compared to uninfected controls, whereas the remaining infected subjects had a mortality rate similar to uninfected controls, the mortality hazard ratio being 1.0 (95% CI, 0.5, 2.1.) In those who survived between 1991 and 1996, HIV-2 RNA levels were unchanged overall and CD4 lymphocyte counts remained high. In conclusion, baseline HIV-2 RNA levels predicted a normal survival for the majority, with low and stable levels of plasma viremia characterizing HIV-2 infections in this rural West African community.
C1 MRC Labs, Banjul, Gambia.
   UCL Royal Free & Univ Coll Med Sch, Dept Virol, London, England.
   Natl Inst Biol Stand & Controls, Div Retrovirol, S Mimms, Herts, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan.
   MINSAP, Lab Nacl Saude Publ, Bissau, Guinea Bissau.
   Statens Serum Inst, Danish Epidemiol Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
RP Whittle, H (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM hwhittle@mrc.gm
CR Aaby P, 1996, AIDS, V10, P1585
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 1998, AIDS, V12, P2504
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Babiker A, 2000, LANCET, V355, P1131
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Boerma JT, 1998, AIDS, V12, pS3
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Desrosiers RC, 1999, NAT MED, V5, P723, DOI 10.1038/10439
   deWolf F, 1997, AIDS, V11, P1799, DOI 10.1097/00002030-199715000-00003
   Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1
   Grassly NC, 1998, J VIROL, V72, P7895
   Kim S, 2000, AIDS RES HUM RETROV, V16, P645, DOI 10.1089/088922200308873
   Kimata JT, 1999, NAT MED, V5, P535
   Lisse IM, 1996, J ACQ IMMUN DEF SYND, V13, P355
   LOVEDAY C, 1995, LANCET, V345, P790, DOI 10.1016/S0140-6736(95)90668-1
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Morgan D, 1997, LANCET, V350, P245, DOI 10.1016/S0140-6736(97)01474-8
   Norrgren H, 1997, J ACQ IMMUN DEF SYND, V16, P31
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Sarr AD, 1999, J HUMAN VIROL, V2, P45
   Todd J, 1997, AIDS, V11, P801, DOI 10.1097/00002030-199706000-00013
   van der Loeff MFS, 1999, AIDS, V13, pS69
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 34
TC 51
Z9 53
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2002
VL 18
IS 16
BP 1167
EP 1173
DI 10.1089/08892220260387904
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 612FD
UT WOS:000179063100001
PM 12487822
OA No
DA 2017-08-15
ER

PT J
AU Campbell, DI
   Lunn, PG
   Elia, M
AF Campbell, DI
   Lunn, PG
   Elia, M
TI Age-related association of small intestinal mucosal enteropathy with
   nutritional status in rural Gambian children
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE growth; intestinal permeability; enteropathy; tropical; The Gambia
ID CHRONIC DIARRHEA; PERMEABILITY; GROWTH; MALNUTRITION
AB Small bowel enteropathy (assessed by the lactulose (L) : mannitol (M) permeability test) is a major factor in infant growth faltering and malnutrition in The Gambia. However, little is known about its persistence and nutritional effect beyond 2 years of age. This was addressed by two cross-sectional studies of intestinal permeability and nutritional status in 162 residents, aged 2-60 years, living in three villages in rural Gambia. L:M ratio was found to be highest in the youngest children and although there was a significant improvement with age (P<0.0001), values were always greater than the range found in UK counterparts. M recovery (mean value 5.68 (se 0.12) %) was at all times between one-third and one-half of expected UK values and showed no improvement with age. Gut barrier function, assessed by L uptake, improved with age (P<0.001) and fell within the UK normal range beyond age 10 years. Both the L:M permeability ratio and L recovery were significantly associated with height-for-age z-scores (r-0.31 and -0.22 respectively, P<0.001), a relationship that persisted throughout childhood and into adulthood. Change in height-for-age z-score beween the two visits was also related to the L:M ratio (r-0.24,P=0.018). The close within-subject correlation of permeability variabilities between the two visits suggests a long-term persistence of enteropathy within individuals. It appears that the small bowel enteropathy previously described in Gambian infants persists through to adulthood. Although the lesion improves with age, the relationship between attained height and L:M permeability raises the possibility that enteropathy may continue to limit growth throughout childhood and puberty.
C1 MRC, Keneba, Gambia.
   Univ Cambridge, Dept Biol Anthropol, Cambridge CB2 3DZ, England.
   Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
RP Campbell, DI (reprint author), MRC, Keneba, Gambia.
CR BAKER SJ, 1972, AM J CLIN NUTR, V25, P1047
   BEHRENS RH, 1987, AM J CLIN NUTR, V45, P1433
   COOK GC, 1980, TROPICAL GASTROENTER, P271
   FORD RPK, 1985, J PEDIATR GASTR NUTR, V4, P568, DOI 10.1097/00005176-198508000-00012
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   LINDENBA.J, 1973, GASTROENTEROLOGY, V64, P637
   LINDENBAUM J, 1966, BMJ-BRIT MED J, V2, P1616
   LUNN PG, 1992, CLIN CHIM ACTA, V205, P151, DOI 10.1016/S0009-8981(05)80011-7
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Menzies IS, 1999, GUT, V44, P483
   MENZIES IS, 1979, LANCET, V2, P1107
   NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N
   PRENTICE AM, 1994, P NUTR SOC, V53, P509, DOI 10.1079/PNS19940061
   SULLIVAN PB, 1991, J PEDIATR GASTR NUTR, V12, P195, DOI 10.1097/00005176-199102000-00010
   TRAVIS S, 1992, CLIN SCI, V82, P471
NR 17
TC 36
Z9 36
U1 0
U2 2
PU C A B I PUBLISHING
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, WALLINGFORD OX10 8DE, OXON, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD NOV
PY 2002
VL 88
IS 5
BP 499
EP 505
DI 10.1079/BJN2002697
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 614FU
UT WOS:000179178300007
PM 12425730
OA No
DA 2017-08-15
ER

PT J
AU Kouomou, DW
   Nerrienet, E
   Mfoupouendoun, J
   Tene, G
   Whittle, H
   Wild, TF
AF Kouomou, DW
   Nerrienet, E
   Mfoupouendoun, J
   Tene, G
   Whittle, H
   Wild, TF
TI Measles virus strains circulating in central and West Africa:
   Geographical distribution of two B3 genotypes
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE epidemiology; Cameroon; vaccination
ID MOLECULAR EPIDEMIOLOGY; MONOCLONAL-ANTIBODIES; FUSION PROTEIN; RURAL
   SENEGAL; IMMUNITY; VACCINE; ELIMINATION; NEUTRALIZATION; IDENTIFICATION;
   HEMAGGLUTININ
AB Africa remains one of the major reservoirs of measles infection. Molecular epidemiological studies have permitted different measles virus isolates to be grouped into clades and genotypes; the major group, which has been identified as indigenous to Africa, is clade B. The viruses from epidemics in the Gambia (1993) and in the Cameroon (2001) were examined. In both studies, the homogeneity of the virus isolates within the epidemic as shown by sequence analysis revealed less than 0.2% variation of nucleotides between isolates. The measles viruses isolated in 1983 in Yaounde, Cameroon, were designated as the 131 genotype. However, in 2001 only viruses belonging to the B3 genotype were found in this city. The viruses in the Gambia (1993) were also of the B3 genotype. However, these viruses could be distinguished from each other at the antigenic level and by comparative sequence analysis. The B3 Cameroon (2001) viruses were related to the proposed B3.1 subgroup, whereas the Gambian (1993) isolates corresponded to the B3.2 subgroup. The geographical distribution for the period 1993-2001 of these two viruses shows that B3.1 is found from the Sudan to Nigeria and Ghana extending south to the Cameroon, whereas the B3.2 genotype is found in West Africa. In Nigeria and Ghana, the viruses co-circulate. The identification of these viruses will permit more meaningful epidemiological studies after the proposed. increase in measles vaccination coverage. (C) 2002 Wiley-Liss, Inc.
C1 INSERM U404, CERVI 21, F-69365 Lyon 03, France.
   Ctr Pasteur Cameroun, Yaounde, Cameroon.
   Hop Cent Yaounde, Fdn Chantal Biya, Ctr Mere Enfant, Yaounde, Cameroon.
   MRC Labs, Banjul, Gambia.
RP Wild, TF (reprint author), INSERM U404, CERVI 21, Ave Tony Garnier, F-69365 Lyon 03, France.
CR Bellini WJ, 1998, EMERG INFECT DIS, V4, P29
   CHRISTENSON B, 1994, VACCINE, V12, P129, DOI 10.1016/0264-410X(94)90049-3
   Cisse B, 1999, AM J EPIDEMIOL, V149, P295
   deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224
   EDMONSON MB, 1990, JAMA-J AM MED ASSOC, V263, P2467, DOI 10.1001/jama.263.18.2467
   El Mubarak HS, 2002, J GEN VIROL, V83, P1437
   Fayolle JL, 1999, J VIROL, V73, P787
   Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527
   GIRAUDON P, 1985, VIROLOGY, V144, P46, DOI 10.1016/0042-6822(85)90303-4
   GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303
   Hanses F, 1999, J GEN VIROL, V80, P871
   Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7
   Klingele M, 2000, J MED VIROL, V62, P91, DOI 10.1002/1096-9071(200009)62:1<91::AID-JMV14>3.0.CO;2-B
   KOBUNE F, 1990, J VIROL, V64, P700
   Kouomou DW, 2002, J VIROL, V76, P1505, DOI 10.1128/JVI.76.3.1505-1509.2002
   Kreis S, 1997, J GEN VIROL, V78, P1581
   MALVOISIN E, 1990, J VIROL, V64, P5160
   MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008
   MATHIAS RG, 1989, AM J PUBLIC HEALTH, V79, P475, DOI 10.2105/AJPH.79.4.475
   Nigatu W, 2001, J MED VIROL, V65, P373, DOI 10.1002/jmv.2044
   PEDERSEN IR, 1989, VACCINE, V7, P345, DOI 10.1016/0264-410X(89)90199-0
   RIMA BK, 1995, J GEN VIROL, V76, P1173, DOI 10.1099/0022-1317-76-5-1173
   Rota JS, 1996, J INFECT DIS, V173, P32
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   Siqueira MM, 2001, J MED VIROL, V63, P299, DOI 10.1002/1096-9071(200104)63:4<299::AID-JMV1005>3.0.CO;2-3
   Truong AT, 1999, VIRUS RES, V62, P89, DOI 10.1016/S0168-1702(99)00072-6
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WHO, 1998, WKLY EPIDEMIOL REC, V73, P265
   WHO, 2001, WKLY EPIDEMIOL REC, V76, P242
NR 29
TC 35
Z9 37
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2002
VL 68
IS 3
BP 433
EP 440
DI 10.1002/jmv.10222
PG 8
WC Virology
SC Virology
GA 597RD
UT WOS:000178233800020
PM 12226833
OA No
DA 2017-08-15
ER

PT J
AU Bogh, C
   Clarke, SE
   Walraven, GEL
   Lindsay, SW
AF Bogh, C
   Clarke, SE
   Walraven, GEL
   Lindsay, SW
TI Zooprophylaxis, artefact or reality? A paired-cohort study of the effect
   of passive zooprophylaxis on malaria in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; Anopheles gambiae; zooprophylaxis;
   cattle; socio-economic status; The Gambia
ID ENTOMOLOGICAL RISK-FACTORS; CATTLE OWNERSHIP; TRANSMISSION; CHLOROQUINE;
   PAKISTAN; CHILDREN; ELISA; URINE
AB The World Health Organization has recommended the use of cattle for zooprophylaxis as a protective measure against malaria since 1982. However, concern has been raised about this practice, since some studies have shown that the presence of cattle may instead increase malaria prevalence. This study was designed to investigate the effect of passive zooprophylaxis on malaria in an area of moderate seasonal transmission in The Gambia, West Africa. The study was based on a paired-cohort of 204 children aged < 7 years, sleeping < 20 m or > 50 m from cattle, and surveys were done from 14 October to 2 December 1997. Entomological investigations showed that the presence of cattle did not alter the risk of malaria transmission in nearby houses. There was also no significant difference in the prevalence of Plasmodium falciparum between the 2 groups. Although the presence of cattle appeared to be protective against high parasitaemia, cattle were also associated with greater wealth of the children's families. Conditional logistic regression analysis showed that the decreased risk of high parasitaemia in the group with cattle present was an artefact associated with the higher general wealth of the cattle owners. We concluded that zooprophylaxis is not an effective intervention method against malaria in settings similar to The Gambia.
C1 Danish Bilharziasis Lab, DK-2920 Charlottenlund, Denmark.
   MRC Labs, Farafenni Field Stn, Fajara, Gambia.
   Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
RP Bogh, C (reprint author), App 505,Apartment Menteng Regency,Jalan Suroso 10, Jakarta 10310, Indonesia.
CR ADIAMAH JH, 1993, ANN TROP MED PARASIT, V87, P491
   ALONSO PL, 1993, T ROYAL SOC TROPI S2, V87
   Bogh C, 2001, J MED ENTOMOL, V38, P822
   BOUMA M, 1995, T ROY SOC TROP MED H, V89, P351, DOI 10.1016/0035-9203(95)90004-7
   BRUMPT E., 1944, Ann. Parasit. hum. comp., V20, P191
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   CLARKE SE, 2001, THESIS U COPENHAGEN, P3
   FERMI C, 1928, MALARIOLOGIA, V2, P6
   Ghebreyesus TA, 2000, T ROY SOC TROP MED H, V94, P17, DOI 10.1016/S0035-9203(00)90424-3
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hackett LW, 1937, MALARIA IN EUROPE
   HEWITT S, 1994, MED VET ENTOMOL, V8, P160, DOI 10.1111/j.1365-2915.1994.tb00156.x
   LENGELER C, 1998, COCHRANE LIB
   LINDSAY SW, 1993, T ROYAL SOC TROPI S2, V87
   MULLER O, 1994, LANCET, V344, P1699, DOI 10.1016/S0140-6736(94)90481-2
   SERVICE MW, 1991, REV SAUDE PUBL, V25, P165
   SHENTON FC, 1988, T ROY SOC TROP MED H, V82, P216, DOI 10.1016/0035-9203(88)90415-4
   SHIFF CJ, 1993, T ROY SOC TROP MED H, V87, P646, DOI 10.1016/0035-9203(93)90273-S
   Snow RW, 1998, T ROY SOC TROP MED H, V92, P381, DOI 10.1016/S0035-9203(98)91056-2
   *WHO, 1982, MAN ENV MAN MOSQ CON, P3
   World Health Organization, 1999, WORLD HLTH REP 1999
   WITTE AMC, 1990, T ROY SOC TROP MED H, V84, P521, DOI 10.1016/0035-9203(90)90024-9
NR 23
TC 17
Z9 17
U1 3
U2 18
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 2002
VL 96
IS 6
BP 593
EP 596
DI 10.1016/S0035-9203(02)90320-2
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 648RW
UT WOS:000181165200004
PM 12625129
OA No
DA 2017-08-15
ER

PT J
AU Lindsay, SW
   Emerson, PM
   Charlwood, JD
AF Lindsay, SW
   Emerson, PM
   Charlwood, JD
TI Reducing malaria by mosquito-proofing houses
SO TRENDS IN PARASITOLOGY
LA English
DT Article
ID ENTOMOLOGICAL RISK-FACTORS; PERIURBAN AREA; WEST-AFRICA; GAMBIA;
   CHILDREN; VECTORS
AB Sometimes, valuable lessons from history are forgotten, remain unknown, or worse, are ignored. This article reminds us of the pioneering work of Angelo Celli at the end of the 19th century, who demonstrated that people could be protected from malaria by screening their homes against mosquitoes. Since then, public health scientists have continued to show that simple changes in house design have the potential for protecting people against this life-threatening disease. Yet today, this type of intervention remains virtually ignored. The literature reviewed here demonstrates the enormous potential of these methods to reduce malaria, in the hope that it will stimulate scientific debate and further research.
C1 Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   Univ Durham, Fajara, Gambia.
   Med Res Councils Labs, Fajara, Gambia.
   Danish Bilharziasis Lab, DK-2920 Charlottenlund, Denmark.
RP Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, S Rd, Durham DH1 3LE, England.
CR ADIAMAH JH, 1993, ANN TROP MED PARASIT, V87, P491
   BOYD MARK F., 1926, AMER JOUR TROP MED, V6, P157
   BUTRAPORN P, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P386
   Byrd I, 1914, NEW ORLEANS MED SUR, V67, P1417
   Celli A, 1900, J SANIT I, V21, P617
   CHARLWOOD JD, 1984, T ROY SOC TROP MED H, V78, P141, DOI 10.1016/0035-9203(84)90204-9
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   CLARKE SE, IN PRESS T R SOC TRO
   Fullerton H. R., 1933, SOUTH MED J, V26, P465
   GAMAGEMENDIS AC, 1991, AM J TROP MED HYG, V45, P77
   Ghebreyesus TA, 2000, T ROY SOC TROP MED H, V94, P17, DOI 10.1016/S0035-9203(00)90424-3
   GILLIES MT, 1976, B ENTOMOL RES, V66, P5
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   Gunawardena DM, 1998, AM J TROP MED HYG, V58, P533
   Guthmann JP, 2001, T ROY SOC TROP MED H, V95, P577, DOI 10.1016/S0035-9203(01)90084-7
   HANAFIN JB, 1928, J R ARMY MED CORPS, V51, P127
   Marineola J., 1996, HERODOTUS HIST
   Kiker C. C., 1941, S HUM MAL AM ASS ADV, V15, P308
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   Le Prince JAA, 1916, MOSQUITO CONTROL PAN
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P97, DOI 10.1111/j.1365-2915.1989.tb00481.x
   LINDSAY SW, 1988, T ROY SOC TROP MED H, V82, P645, DOI 10.1016/0035-9203(88)90546-9
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   MCKEOWN E, 1976, MODERN RISE POPULATI
   Orenstein A. J., 1912, P CANAL ZONE MED ASS, V5, P12
   Pampana E, 1969, TXB MALARIA ERADICAT
   Rutherford N. J. C., 1928, J ROY ARMY MED CORPS, V50, P316
   SCHOFIELD CJ, 1984, T ROY SOC TROP MED H, V78, P285, DOI 10.1016/0035-9203(84)90097-X
   Snow RW, 1998, T ROY SOC TROP MED H, V92, P381, DOI 10.1016/S0035-9203(98)91056-2
   SNOW WF, 1987, MED VET ENTOMOL, V1, P9, DOI 10.1111/j.1365-2915.1987.tb00318.x
   SNOW WF, 1975, B ENTOMOL RES, V65, P269
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   WATSON RB, 1949, MALARIOLOGY COMPREHE, V2, P1184
   Webb D J, 1985, Parasitol Today, V1, P65, DOI 10.1016/0169-4758(85)90120-6
   WHITE GB, 1969, FACTORS INFLUENCING
   WHO, 1982, WHO OFFS PUBL, V66
NR 37
TC 90
Z9 92
U1 1
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4922
J9 TRENDS PARASITOL
JI Trends Parasitol.
PD NOV
PY 2002
VL 18
IS 11
BP 510
EP 514
AR PII S1471-4922(02)02382-6
DI 10.1016/S1471-4922(02)02382-6
PG 5
WC Parasitology
SC Parasitology
GA 607MT
UT WOS:000178795900010
PM 12473368
OA No
DA 2017-08-15
ER

PT J
AU Awomoyi, AA
   Newport, M
   Sirugo, G
   McAdam, K
   Tishkoff, S
AF Awomoyi, AA
   Newport, M
   Sirugo, G
   McAdam, K
   Tishkoff, S
TI Microsatellite and SNP haplotype variability at the SLC11A1 locus in
   globally diverse human populations - SCL11A1
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Human-Genetics
CY OCT 15-19, 2002
CL BALTIMORE, MARYLAND
SP Amer Soc Human Genet, NICHHD, NCI, NIMH, Affymetrix Inc, Gentra Syst, NIDCD
C1 Univ Maryland, Dept Biol, College Pk, MD 20742 USA.
   Addenbrookes Hosp, CIMR, Cambridge CB2 2XY, England.
   MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT
PY 2002
VL 71
IS 4
SU S
MA 1062
BP 354
EP 354
PG 1
WC Genetics & Heredity
SC Genetics & Heredity
GA 594AC
UT WOS:000178025801058
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Kidd, IM
   Goetghebuer, T
   Martynoga, RA
   Magnusen, A
   Allen, S
   Weber, MW
   Fielding, KL
   Marchant, A
   Whittle, HC
AF van der Sande, MAB
   Kidd, IM
   Goetghebuer, T
   Martynoga, RA
   Magnusen, A
   Allen, S
   Weber, MW
   Fielding, KL
   Marchant, A
   Whittle, HC
TI Severe respiratory syncytial virus infection in early life is associated
   with increased type 2 cytokine production in Gambian children
SO CLINICAL AND EXPERIMENTAL ALLERGY
LA English
DT Article
DE RSV infection; cohort study; type 2 cytokines; atopy; wheeze; The Gambia
ID INTERRUPTER TECHNIQUE; ASTHMA; INFANTS; DISEASE; BRONCHIOLITIS; ATOPY;
   PREVALENCE; WHEEZE; CELLS; URBAN
AB Background Severe respiratory syncytial virus (RSV) infection in early childhood has been associated with subsequent wheezing and atopy. The aim of this study was to test if severe RSV infection in early life was associated with an increase in type 2 cytokine production and atopy in Gambian children 5 years later.
   Methods A cohort of children with severe RSV infection during the first year of life ('cases', n = 66) and without ('controls', n = 122) was followed-up at 5 years of age. Immediate hypersensitivity to common allergens, airway reactivity, serum IgE concentration and the production of IFN-gamma, IL-5 and IL-13 by lymphocytes activated in vitro with RSV F-G or control antigens was determined.
   Results After adjustment for confounders, cases produced significantly higher concentrations of IL-13 in response to RSV F-G and of IL-5 and IL-13 in response to tuberculin. Cases were more likely to have presented with a wheezy lower respiratory tract infection in the first 3 years of life (adjusted odds ratio = 9.9; 95% CI 1.6-61.0), but not thereafter. Cases and controls had similar skin response to allergens, airway reactivity and serum IgE concentrations.
   Conclusion Severe RSV infection in early life is associated with a higher production of type 2 cytokines in Gambian children at 5 years of age. However this does not appear to result in increased risk of atopy or clinical allergy at that age.
C1 MRC Labs, Fajara, Gambia.
   WHO, CH-1211 Geneva, Switzerland.
   London Sch Hyg & Trop Med, London WC1, England.
RP van der Sande, MAB (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263
   ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81
   Bendelja K, 2000, CLIN EXP IMMUNOL, V121, P332, DOI 10.1046/j.1365-2249.2000.01297.x
   Bridge PD, 1996, EUR RESPIR J, V9, P1368, DOI 10.1183/09031936.96.09071368
   Bridge PD, 1999, EUR RESPIR J, V13, P792, DOI 10.1034/j.1399-3003.1999.13d16.x
   Faniran AO, 1999, THORAX, V54, P606
   Hussell T, 1999, CURR OPIN MICROBIOL, V2, P410, DOI 10.1016/S1369-5274(99)80072-1
   Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217
   MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301
   Matsuse H, 2000, J IMMUNOL, V164, P6583
   Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x
   OSUNDWA VM, 1993, EUR J PEDIATR, V152, P1001, DOI 10.1007/BF01957225
   Pala Pietro, 1999, Immunology, V98, P5
   PULLAN CR, 1982, BRIT MED J, V284, P1665
   Renzi PM, 1997, J PEDIATR-US, V130, P584, DOI 10.1016/S0022-3476(97)70243-9
   Roman M, 1997, AM J RESP CRIT CARE, V156, P190
   SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034
   SIGURS N, 1995, PEDIATRICS, V95, P500
   Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3
   Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5
   Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x
   Weber MW, 1999, INT J EPIDEMIOL, V28, P157, DOI 10.1093/ije/28.1.157
   Weber MW, 1999, J PEDIATR-US, V135, P683, DOI 10.1016/S0022-3476(99)70085-5
   Welliver RC, 1999, J PEDIATR-US, V135, pS14
   Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579
   Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3
NR 26
TC 15
Z9 15
U1 0
U2 1
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0954-7894
J9 CLIN EXP ALLERGY
JI Clin. Exp. Allergy
PD OCT
PY 2002
VL 32
IS 10
BP 1430
EP 1435
DI 10.1046/j.1365-2745.2002.01521.x
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 601ZJ
UT WOS:000178479300008
PM 12372121
OA No
DA 2017-08-15
ER

PT J
AU Garton, NJ
   Christensen, H
   Minnikin, DE
   Adegbola, RA
   Barer, MR
AF Garton, NJ
   Christensen, H
   Minnikin, DE
   Adegbola, RA
   Barer, MR
TI Intracellular lipophilic inclusions of mycobacteria in vitro and in
   sputum
SO MICROBIOLOGY-SGM
LA English
DT Article
DE mycobacterial lipids; triacylglycerols; storage lipids; nitrogen and
   carbon limitation; cytochemistry
ID STREPTOMYCES
AB Although most mycobacterial lipids are thought to be associated with the cell envelope, the authors previously observed substantial deposits of intracellular lipophilic material. A Nile-red-based cytological assay was used to determine factors which affect the presence and natural history of intracellular lipophilic inclusions (ILIs) in Mycobacterium smegmatis. Development of ILIs was associated with stationary-phase cultures in broth and with aged (6 days). colonies on agar. Using variants of Youmans' defined medium, the frequency and size of ILIs was observed to be minimal in carbon-poor medium. ILIs were observed to form within 15 min after provision of fatty acids to the medium and after a period of several days in nitrogen-poor medium. Analysis of the non-polar lipid extracts of ILI-rich and -poor preparations indicated that the triacylglycerols (TAGs) were a major component of the inclusions. The acyl substituents of the TAGs varied according to whether they were formed in Middlebrook 7H9 broth, in low-nitrogen Youmans' broth or rapidly after oleic acid supplementation of Youmans' broth. These studies support a storage function for TAGs in mycobacteria in addition to their previously suggested occurrence as components of the cell envelope. To assess a possible role for ILIs in Mycobacterium tuberculosis, a combined acid-fast (Auramine)/Nile red assay was applied to heavily positive sputum samples from patients with tuberculosis. Strong intracellular Nile red signals were obtained from acid-fast cells, indicating that ILI occur in M. tuberculosis in vivo. This may reflect a distinct physiological state of these cells, which it has not been possible to reproduce in vitro. These findings indicate that the uptake of long-chain fatty acids and TAG biosynthetic and degradative pathways are important aspects of mycobacterial lipid metabolism, meriting further investigation.
C1 Univ Newcastle Upon Tyne, Dept Immunol & Microbiol, Newcastle Upon Tyne, Tyne & Wear, England.
   Univ Newcastle Upon Tyne, Dept Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   MRC Labs, Banjul, Gambia.
RP Garton, NJ (reprint author), Univ Leicester, Dept Immunol & Microbiol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.
CR Alvarez HM, 2000, APPL MICROBIOL BIOT, V54, P218, DOI 10.1007/s002530050012
   Alvarez HM, 1996, ARCH MICROBIOL, V165, P377, DOI 10.1007/s002030050341
   BARKSDALE L, 1977, BACTERIOL REV, V41, P217
   BRAUNEGG G, 1978, EUR J APPL MICROBIOL, V6, P29, DOI 10.1007/BF00500854
   BRIEGER E M, 1956, Tubercle, V37, P195, DOI 10.1016/S0041-3879(56)80041-X
   BURDON KL, 1946, J BACTERIOL, V57, P679
   Christensen H, 1999, MOL MICROBIOL, V31, P1561, DOI 10.1046/j.1365-2958.1999.01304.x
   Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131
   Dawes E A, 1973, Adv Microb Physiol, V10, P135, DOI 10.1016/S0065-2911(08)60088-0
   DOBSON G, 1985, SOC APPL BACTERIOLOG, V20, P237
   DRAPER P, 1982, BIOL MYCOBACTERIA, P9
   GALE GR, 1963, J BACTERIOL, V86, P749
   GOODFELLOW M, 1991, ZBL BAKT-INT J MED M, V275, P162
   KNAYSI G, 1950, J BACTERIOL, V60, P423
   Koval'schuk LP, 1973, MIKROBIOL INT, V42, P567
   MCCARTHY C, 1971, INFECT IMMUN, V4, P199
   Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95
   OLUKOSHI ER, 1994, MICROBIOL-UK, V140, P931
   Packter NM, 1995, ARCH MICROBIOL, V164, P420, DOI 10.1007/BF02529740
   PIERINGER RA, 1989, MICROBIAL LIPIDS, V2, P51
   Ratledge C, 1984, BIOTECHNOLOGY OILS F, P119
   SCHAEFER WB, 1965, J BACTERIOL, V90, P1438
   SCOTT CCL, 1976, J GEN MICROBIOL, V94, P342
   Sommers HM, 1985, MANUAL CLIN MICROBIO, P216
   SUBRAHMANYAM D, 1964, CAN J BIOCHEM PHYS, V42, P1195
   THIELE OW, 1972, EUR J BIOCHEM, V29, P224, DOI 10.1111/j.1432-1033.1972.tb01979.x
   VANBOXTEL RM, 1990, APMIS, V98, P901
   WALKER RW, 1970, LIPIDS, V5, P684, DOI 10.1007/BF02531435
   Waltermann M, 2000, MICROBIOL-UK, V146, P1143
   WEIR MP, 1972, AM REV RESPIR DIS, V106, P450
   Wheeler Paul R., 1994, P353
   White G. Edward, 1971, U CHICAGO LAW REV, V39, P51, DOI 10.2307/1598926
NR 32
TC 122
Z9 125
U1 2
U2 11
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD OCT
PY 2002
VL 148
BP 2951
EP 2958
PN 10
PG 8
WC Microbiology
SC Microbiology
GA 603YF
UT WOS:000178588300005
PM 12368428
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Moore, SE
   Collinson, AC
   O'Connell, MA
AF Prentice, AM
   Moore, SE
   Collinson, AC
   O'Connell, MA
TI Leptin and undernutrition
SO NUTRITION REVIEWS
LA English
DT Article; Proceedings Paper
CT 19th Marabou Symposium Leptin - A Key Regulator in Nutrition
CY JUN 15-17, 2001
CL SUNDBYBERG, SWEDEN
SP 4
ID CORD-BLOOD LEPTIN; ANOREXIA-NERVOSA; OBESE GENE; RECOMBINANT LEPTIN;
   MISSENSE MUTATION; BODY-COMPOSITION; HUMAN-PREGNANCY; PLASMA LEPTIN;
   WEIGHT-GAIN; OB/OB MICE
C1 London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1B 3DP, England.
   MRC Keneba, Banjul, Gambia.
   MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, 49-51 Bedford Sq, London WC1B 3DP, England.
CR Brogan RS, 1999, ENDOCRINOLOGY, V140, P2621, DOI 10.1210/en.140.6.2621
   Butte NF, 1999, AM J CLIN NUTR, V69, P299
   Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X
   CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087
   CHEHAB F, 2002, NUTR REV, V10, pS39
   Clement K, 1998, NATURE, V392, P398
   COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857
   Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503
   Darwin C., 1859, ORIGIN SPECIES MEANS
   Fagan B., 2000, FLOODS FAMINES EMPER
   Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204
   Flier JS, 2000, J CLIN INVEST, V105, P859, DOI 10.1172/JCI9725
   Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407
   FRIEDMAN J, 2002, NUTR REV, V10, pS1
   Friedman J M, 1997, Eur J Med Res, V2, P7
   FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949
   Fruhbeck G, 2001, FASEB J, V15, P1996, DOI 10.1096/fj.00-0829hyp
   Fruhbeck G, 1998, CLIN PHYSIOL, V18, P399, DOI 10.1046/j.1365-2281.1998.00129.x
   Galtier-Dereure F, 2000, AM J CLIN NUTR, V71, p1242S
   Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3861, DOI 10.1210/jc.81.11.3861
   HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777
   Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568
   Hoggard N, 2001, BIOCHEM SOC T, V29, P57, DOI 10.1042/0300-5127:0290057
   Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762
   Jebb S. A., 2000, International Journal of Obesity, V24, pS23
   KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009
   Keys A, 1950, BIOL HUMAN STARVATIO
   Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857
   Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511
   Kolaczynski JW, 1996, J CLIN ENDOCR METAB, V81, P4162, DOI 10.1210/jc.81.11.4162
   Legradi G, 1998, NEUROENDOCRINOLOGY, V68, P89, DOI 10.1159/000054354
   LEIBEL R, 2002, NUTR REV, V10, pS15
   Levi P., 1979, IF THIS IS MAN
   LORD G, 2002, NUTR REV, V10, pS35
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   LUNN PG, 1984, AM J CLIN NUTR, V39, P227
   MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155
   Mantzoros C, 1997, J CLIN ENDOCR METAB, V82, P1845, DOI 10.1210/jc.82.6.1845
   Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P2856, DOI 10.1210/jc.82.9.2856
   Matsuda J, 1999, PEDIATR RES, V45, P71, DOI 10.1203/00006450-199901000-00012
   Montague CT, 1997, NATURE, V387, P903
   Moore SE, 2002, ARCH DIS CHILD, V87, P192, DOI 10.1136/adc.87.3.192
   MOORE SE, IN PRESS INT J OBES
   Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9
   Mostyn A, 2001, P NUTR SOC, V60, P187, DOI 10.1079/PNS200086
   Mounzih K, 1998, ENDOCRINOLOGY, V139, P5259, DOI 10.1210/en.139.12.5259
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   Ong KKL, 2000, J PEDIATR ENDOCR MET, V13, P1419
   Ong KKL, 1999, J CLIN ENDOCR METAB, V84, P1145, DOI 10.1210/jc.84.3.1145
   Ozata M, 1999, J CLIN ENDOCR METAB, V84, P3686, DOI 10.1210/jc.84.10.3686
   PAYNE PR, 1967, NATURE, V215, P849, DOI 10.1038/215849a0
   PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776
   Polito A, 2000, AM J CLIN NUTR, V71, P1495
   Pond C. M., 1998, FATS LIFE
   POPPITT SD, 1994, AM J OBSTET GYNECOL, V171, P118
   Prentice A M, 2001, Obes Rev, V2, P141, DOI 10.1046/j.1467-789x.2001.00031.x
   Prentice A. M., 2001, BNF Nutrition Bulletin, V26, P13, DOI 10.1046/j.1467-3010.2001.00100.x
   PRENTICE AM, 1991, P NUTR SOC, V50, P441, DOI 10.1079/PNS19910055
   PRENTICE AM, 1994, EUR J CLIN NUTR, V48, pS78
   Prentice AM, 1995, HUM REPROD UPDATE, V1, P149, DOI 10.1093/humupd/1.2.149
   Prentice AM, 2000, AM J CLIN NUTR, V71, p1226S
   Prentice AM, 1987, S ZOOLOGICAL SOC LON, V57, P275
   PRENTICE AM, 1994, NUTR REGULATION PREG, V352, P11
   Short R V, 1976, Ciba Found Symp, P73
   Simon J., 1845, PHYSL ESSAY THYMUS G
   Soliman AT, 2000, METABOLISM, V49, P819, DOI 10.1053/meta.2000.6745
   Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/881
   WEIGLE DS, 1994, FASEB J, V8, P302
   Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P561, DOI 10.1210/jc.82.2.561
   WHITEHEAD RG, 1977, T ROY SOC TROP MED H, V71, P189, DOI 10.1016/0035-9203(77)90004-9
   Woodside B, 2000, HORM BEHAV, V37, P353, DOI 10.1006/hbeh.2000.1598
   Yura S, 1998, AM J OBSTET GYNECOL, V178, P926, DOI 10.1016/S0002-9378(98)70525-3
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
NR 73
TC 25
Z9 26
U1 0
U2 0
PU INT LIFE SCIENCES INST
PI LAWRENCE
PA 810 EAST 10TH ST SUBSCRIPTION OFFICE, LAWRENCE, KS 66044 USA
SN 0029-6643
J9 NUTR REV
JI Nutr. Rev.
PD OCT
PY 2002
VL 60
IS 10
BP S56
EP S67
PN 2
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 602VB
UT WOS:000178524200008
PM 12403085
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
   Enwere, GC
   Deloria, M
   Jaffar, S
   Goldblatt, D
   Brainsby, K
   Hallander, H
   McInnes, P
   Greenwood, BM
   McAdam, KPWJ
AF Obaro, SK
   Enwere, GC
   Deloria, M
   Jaffar, S
   Goldblatt, D
   Brainsby, K
   Hallander, H
   McInnes, P
   Greenwood, BM
   McAdam, KPWJ
TI Safety and immunogenicity of pneumococcal conjugate vaccine in
   combination with diphtheria, tetanus toxoid, pertussis and Haemophilus
   influenzae type b conjugate vaccine
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article; Proceedings Paper
CT 2nd International Symposium on Pneumococci and Pneumococcal Diseases
CY MAR 19-23, 2000
CL SUN CITY, SOUTH AFRICA
DE pneumococcal conjugate vaccine; TETRAMUNE; safety; immunogenicity;
   African infant
ID GAMBIAN INFANTS; SERUM
AB Background. Pneumococcal polysaccharide/protein conjugate vaccines (PnCV) are immunogenic and effective in infancy. However, an addition to the nine currently recommended vaccine injections during the first year of life of African children may be a deterrent to participation in a PnCV program. Thus we have evaluated the safety and immunogenicity of a 9-valent PnCV (Wyeth Lederle Pediatrics and Vaccines) mixed with diphtheria, tetanus toxoid, cell pertussis and Haemophilus influenzae type b (TETRAMUNE).
   Methods. Healthy Gambian infants were randomized at the age of 2 months to receive three doses 1 month apart of either (1) placebo reconstituted in TETRAMUNE in the right thigh (control) or (2) PnCV in the left thigh and TETRAMUNE in the right thigh (separate) or (3) PnCV reconstituted in TETRAMUNE as a single injection in the right thigh (combined). The vaccines were given together with routine Expanded Program on Immunization vaccines. Adverse reactions were recorded after vaccination, and antibody concentrations were measured by enzyme-linked immunosorbent assays.
   Results. Local induration and tenderness were observed more commonly at the site of injection of TETRAMUNE than at the site of injection with PnCV after each dose of vaccination. Swelling at the site of injection was encountered more frequently at the site of administration of TETRAMUNE than at the site of administration PnCV (P < 0.00001 for Doses 1 and 2 and P < 0.0009 for Dose 3). Swelling at the site of administration of TETRAMUNE mixed with PnCV was comparable with that observed for TETRAMUNE alone. Although most mothers reported that the babies "felt hot" 24 h after each injection, febrile reactions (temperature, greater than or equal to38degreesC) were infrequent and resolved with antipyretics. Geometric mean titer for anti-polyribosylribitol phosphate antibody was 11.6 mug/ml [95% confidence limits (95% CI), 9.2, 14.6] in the control group and comparable with 13.3 mug/ml (95% CI 11.0, 16.0) in the combined group and significantly higher at 17.9 mug/ml (95% CI 14.7, 21.9; P = 0.01) in the separate group. Geometric mean concentrations of serotype-specific pneumococcal antibodies were higher in the combined group than the separate group for all nine serotypes. Antibody responses to diphtheria and pertussis antigens were similar in all groups. Anti-tetanus toxoid antibody concentrations were lowest in the combined group (6.66 IU/ml, 95% CI 5.77, 7.68 in the control group; 5.15 IU/ml, 95% CI 4.39, 6.03 in the combined group; P = 0.02). However, all vaccinees achieved protective antibody values.
   Conclusion. The combination of TETRAMUNE and PnCV is safe and immunogenic.
C1 Univ London Imperial Coll Sci Technol & Med, Sch Med, London, England.
   London Sch Hyg & Trop Med, London WC1, England.
   Inst Child Hlth, London, England.
   MRC Labs, Fajara, Gambia.
   NIH, Bethesda, MD 20892 USA.
   Swedish Inst Infect Dis Control, Stockholm, Sweden.
RP Obaro, SK (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Med, London, England.
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
CR Choo S, 2000, PEDIATR INFECT DIS J, V19, P854, DOI 10.1097/00006454-200009000-00009
   Dagan R, 1998, INFECT IMMUN, V66, P2093
   FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208
   *GAMB PNEUM VACC T, 2000, 2 INT S PNEUM PNEUM
   Leach A, 1996, PEDIATR INFECT DIS J, V15, P333, DOI 10.1097/00006454-199604000-00010
   Manclark CR, 1986, MANUAL CLIN LABORATO, P388
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   Obaro SK, 1997, PEDIATR INFECT DIS J, V16, P1135, DOI 10.1097/00006454-199712000-00007
   OBARO SK, 2000, 40 INT C ANT CHEM TO
   PARADISO PR, 1993, PEDIATRICS, V92, P827
   PHIPPS DC, 1990, J IMMUNOL METHODS, V135, P121, DOI 10.1016/0022-1759(90)90264-V
   QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590
   Shinefield HR, 1999, PEDIATR INFECT DIS J, V18, P757, DOI 10.1097/00006454-199909000-00004
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
NR 15
TC 22
Z9 23
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 2002
VL 21
IS 10
BP 940
EP 946
DI 10.1097/01.inf.0000034245.88174.3c
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 605AY
UT WOS:000178654300010
PM 12394817
OA No
DA 2017-08-15
ER

PT J
AU Whittle, H
   Jaffar, S
   Wansbrough, M
   Mendy, M
   Dumpis, U
   Collinson, A
   Hall, A
AF Whittle, H
   Jaffar, S
   Wansbrough, M
   Mendy, M
   Dumpis, U
   Collinson, A
   Hall, A
TI Observational study of vaccine efficacy 14 years after trial of
   hepatitis B vaccination in Gambian children
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID LONG-TERM EFFICACY; 12-YEAR FOLLOW-UP; VIRUS-INFECTION; VILLAGES
AB Objective To determine the duration of protection from hepatitis B vaccine given in-infancy and early childhood.
   Design Cross sectional serological study of hepatitis B virus infection in children of various ages 14 years after the start of a trial of vaccination regimens.
   Setting Two villages in the Gambia.
   Participants Children and adolescents given hepatitis B vaccine in infancy or early childhood: 232 were aged 1-5 years, 225 aged 5-9 years, 220 aged 10-14 years, and 175 aged 15-19 years.
   Main outcome measures Vaccine efficacy against infection and against chronic infection in the different age groups.
   Results Vaccine efficacy against chronic hepatitis B virus carriage was 94% (95% confidence interval 89% to 97%) which did not vary significantly between the age groups. Efficacy against infection was 80% (76% to 84%). This, was significantly lower in the oldest age group (65%, 56 to 73). Of the uninfected participants in this age group, 36% had no detectable hepatitis B virus surface antibody. Time since vaccination and a low peak antibody response were the most powerful risk factors for breakthrough infection (P < 0.001 in each case). Low peak antibody response was also a risk factor for chronic carriage (odds ratio 95, 19 to 466).
   Conclusions Children vaccinated in infancy are at increased risk of hepatitis B virus infection in the late teens. The risk of chronic carriage after sexual exposure needs further assessment to determine if booster vaccines are necessary.
C1 MRC Labs, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Whittle, H (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Banatvala J, 2000, LANCET, V355, P561
   Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906
   COURSAGET P, 1994, J HEPATOL, V21, P250, DOI 10.1016/S0168-8278(05)80404-0
   *GAMB HEP INV STUD, 1996, ANN REP 1996, P12
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Kane M, 1993, DIS CONTROL PRIORITI, P321
   Liao SS, 1999, VACCINE, V17, P2661, DOI 10.1016/S0264-410X(99)00031-6
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Vall MM, 1990, LANCET, V336, P1107
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1987, ANN TROP PAEDIATR, V7, P6
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   WHITTLE HC, 1983, LANCET, V1, P1203
   *WHO SCI GROUP PRE, 1983, LANCET, V1, P463
   Yuen MF, 1999, HEPATOLOGY, V29, P924, DOI 10.1002/hep.510290327
NR 18
TC 86
Z9 93
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD SEP 14
PY 2002
VL 325
IS 7364
BP 569
EP 572
DI 10.1136/bmj.325.7364.569
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 595JJ
UT WOS:000178105200016
PM 12228132
OA No
DA 2017-08-15
ER

PT J
AU Faye, D
   Osaer, S
   Goossens, B
   Van Winghem, J
   Dorny, P
   Lejon, V
   Losson, B
   Geerts, S
AF Faye, D
   Osaer, S
   Goossens, B
   Van Winghem, J
   Dorny, P
   Lejon, V
   Losson, B
   Geerts, S
TI Susceptibility of trypanotolerant West African Dwarf goats and F1
   crosses with the susceptible Sahelian breed to experimental Trypanosoma
   congolense infection and interactions with helminth infections and
   different levels of diet
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE goat; breed influence; Trypanosoma congolense; nutrition; helminth; WAD;
   Sahelian; genetic resistance
ID REPRODUCTIVE-PERFORMANCE; HAEMONCHUS-CONTORTUS; DJALLONKE SHEEP; SMALL
   RUMINANTS; ZEBU CATTLE; LIVESTOCK; RESPONSES; DIAGNOSIS; NDAMA; EWES
AB dForty pure West African Dwarf (WAD) goats and 35 of its F1 crosses with the Sahelian breed were used in a multifactorial experimental design to evaluate the effects of an experimental Trypanosoma congolense infection and interactions with natural helminth infections and different levels of diet on health and productivity of these two breeds. Trypanosome infection caused a severe drop in packed cell volume (PCV), but this was not significantly affected by breed. Neither deworming nor diet had any effect on the course of anaemia after trypanosome infection. The mean score of parasitaemia tended to be higher in crossbreeds than in WAD goats although this was not significant (P > 0.05). Similarly, the antibody response to trypanosome infection was not significantly different between breeds. Parasitaemia level was significantly influenced by the level of diet with the group under high supplementation having a higher mean parasitaemia score than the group under low supplementation. Weight loss due to trypanosome infection tended to be greater in crossbreeds than in WAD goats (P > 0.05).
   During this study, there was no difference in mean helminth egg output between crossbred and WAD goats. However, between weeks 4 and 10 after trypanosome infection (corresponding to a period of heavy rainfall and highly infective pastures), the mean egg output was higher in the crossbreeds.
   The immunosuppressive effect of trypanosome infections was revealed by a lower antibody response to Haemonchus contortus in infected animals compared to the uninfected controls.Trypanosome infection tended to increase strongyle egg output. This study did no reveal any superior trypanotolerance of WAD goats compared to crossbreeds. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med, B-2000 Antwerp, Belgium.
   Univ Liege, Fac Vet Med, B-4000 Sart Tilman Par Liege, Belgium.
RP Faye, D (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR ADAH MI, 1993, VET PARASITOL, V47, P177, DOI 10.1016/0304-4017(93)90020-N
   BENGALY Z, 1991, ETUDE PATHOLOGIE TRY
   d'leteren G. D. M., 1998, REV SCI TECH OIE, V17, P154
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1999, VET PARASITOL, V85, P25, DOI 10.1016/S0304-4017(99)00087-4
   Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GRAY DG, 1987, PARASITOL TODAY, V8, P253
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   HENNESSY DR, 1994, ACTA TROP, V56, P125, DOI 10.1016/0001-706X(94)90059-0
   HILL E, 2001, P WORKSH ID ENH MECH
   HUNTLEY JF, 1995, RES VET SCI, V58, P5, DOI 10.1016/0034-5288(95)90080-2
   *ITC DLS, 1993, COUNTR LIV SURV GAMB
   Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   LUCKINS AG, 1992, BRIT VET J, V148, P471
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   Mawuena K, 1986, Rev Elev Med Vet Pays Trop, V39, P307
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Osaer S, 1998, RES VET SCI, V65, P65, DOI 10.1016/S0034-5288(98)90029-7
   OSAER S, 1999, ACTA TROP, V74, P13
   PARIS J, 1982, ACTA TROP, V39, P307
   Rebeski DE, 2000, VET PARASITOL, V89, P187, DOI 10.1016/S0304-4017(00)00194-1
   ROWLANDS GJ, 1993, P WORKSH AN DIS INT
   *SAS I INC, 1998, SAS VERS 6 12
   SCHALLIG HDFH, 1994, PARASITOLOGY, V108, P351
   Shavulimo R. S., 1988, Bulletin of Animal Health and Production in Africa, V36, P233
   THIENPONT D, 1995, DIAGNOSTIC VERMINOSE
   TOURE SM, 1981, TRYPANOTOLERANCE STU
   WHITELAW DD, 1985, TROP ANIM HEALTH PRO, V17, P155, DOI 10.1007/BF02355876
NR 35
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP 10
PY 2002
VL 108
IS 2
BP 117
EP 136
AR PII S0304-4017(02)00184-X
DI 10.1016/S0304-4017(02)00184-X
PG 20
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 596HE
UT WOS:000178158200003
PM 12208040
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Jaffar, S
   Aveika, AA
   Sabally, S
   Corrah, T
   Harding, E
   Alabi, A
   Bayang, A
   Ariyoshi, K
   Whittle, HC
AF van der Loeff, MFS
   Jaffar, S
   Aveika, AA
   Sabally, S
   Corrah, T
   Harding, E
   Alabi, A
   Bayang, A
   Ariyoshi, K
   Whittle, HC
TI Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a
   clinic-based cohort in The Gambia
SO AIDS
LA English
DT Article; Proceedings Paper
CT 13th World AIDS Conference
CY JUL, 2000
CL DURBAN, SOUTH AFRICA
DE Africa; cohort study; HIV-1; HIV-2; mortality rate; natural history;
   survival
ID GUINEA-BISSAU; DISEASE PROGRESSION; TRANSMISSION RATES; AIDS;
   POPULATION; INDIVIDUALS; COMMUNITY; MARKERS; WORKERS; TYPE-2
AB Objective: To assess and compare the mortality rates of patients with HIV-1, HIV-2 or both infections (HIV-D) in the same population.
   Design: Clinic-based cohort study.
   Methods: HIV-seropositive patients aged 15 years and older who attended the Medical Research Council clinics in Fajara between May 1986 and September 1997 were recruited. Clinical assessment using the Karnofsky score, CDC cell staging, WHO staging, and CD4 cell counts was performed at baseline. Patients attended clinic every 3 months; if they did not attend, they were visited at home by field workers to ascertain survival status. No patient was on antiretroviral therapy during the study period.
   Results: Data from 1519 HIV-positive adult patients were analysed. A total of 746 patients had HIV-1, 666 HIV-2, and 107 patients had HIV-D. A total of 828 patients (55%) died, and 161 (11%) were lost to follow-up. The median follow-up was 12 months (range 0-128). CD4 cell counts were available for 894 patients. Compared with HIV-1, the adjusted hazards ratio for mortality in the CD4 cell count category 500 cells/mul or greater was 0.50 for HIV-2 (95% CI 0.28-0.88) and 1.27 (95% CI 0.51-3.7) for HIV-D. Among those with CD4 cell counts less than 500 cells/mul the mortality rates in HIV-2 and HIV-D were similar to those in HIV-1.
   Discussion: HIV-2-infected patients with CD4 cell counts of 500 cells/mul and greater had a significantly lower mortality rate than HIV-1-infected patients. HIV-2-infected patients with advanced disease had the same poor prognosis as patients with HIV-1. Dually infected patients had mortality rates similar to HIV-1. (C) 2002 Lippincott Williams Wilkins.
C1 Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP van der Loeff, MFS (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
CR ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   ANCELLE R, 1987, LANCET, V1, P688
   Ariyoshi K, 1998, AIDS, V12, P2504
   Babiker A, 2000, LANCET, V355, P1131
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   BROOKMEYER R, 1987, BIOMETRICS, V43, P739, DOI 10.2307/2531529
   Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V41, P1
   DIENGSARR A, 1998, AIDS, V12, P131
   DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671
   KAMOFSKY DA, 1948, CANCER, V2, P634
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Kassa E, 1999, AIDS, V13, P381, DOI 10.1097/00002030-199902250-00011
   KASSIM S, 2000, 13 WORLD AIDS C DURB
   KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   Matheron S, 1997, AIDS, V11, P934
   Morgan D, 1997, LANCET, V350, P245, DOI 10.1016/S0140-6736(97)01474-8
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   Nkengasong JN, 2000, AIDS RES HUM RETROV, V16, P1371, DOI 10.1089/08892220050140919
   Norrgren H, 1998, SCAND J INFECT DIS, V30, P323
   Nunn AJ, 1997, BRIT MED J, V315, P767
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   PHILLIPS AN, 1994, AIDS, V8, P1299, DOI 10.1097/00002030-199409000-00013
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Senkoro KP, 2000, J ACQ IMMUN DEF SYND, V23, P194
   SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011
   Todd J, 1997, AIDS, V11, P801, DOI 10.1097/00002030-199706000-00013
   vanderEnde ME, 1996, AIDS, V10, P1649
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   World Health Organization, 1990, WKLY EPIDEMIOL REC, V65, P221
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
NR 33
TC 69
Z9 70
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD SEP 6
PY 2002
VL 16
IS 13
BP 1775
EP 1783
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 594AZ
UT WOS:000178027800009
PM 12218389
OA No
DA 2017-08-15
ER

PT J
AU Dibba, B
   Prentice, A
   Ceesay, M
   Mendy, M
   Darboe, S
   Stirling, DM
   Cole, TJ
   Poskitt, EME
AF Dibba, B
   Prentice, A
   Ceesay, M
   Mendy, M
   Darboe, S
   Stirling, DM
   Cole, TJ
   Poskitt, EME
TI Bone mineral contents and plasma osteocalcin concentrations of Gambian
   children 12 and 24 mo after the withdrawal of a calcium supplement
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE bone mineral accretion; calcium; children; Gambia; osteocalcin;
   osteoporosis
ID ADOLESCENT GIRLS; DOUBLE-BLIND; DENSITY; ACQUISITION; ACCRETION; MASS;
   TRIAL; PRODUCTS; GROWTH; DIET
AB Background: Our randomized, placebo-controlled supplementation study of 160 rural Gambian children aged 8.3-11.9 y showed that an increase in calcium intake of 714 mg/d for 12 mo resulted in a 5% increase in forearm bone mineral acquisition and a 22% decrease in plasma osteocalcin concentration, a bone formation marker, but had no effect on height or bone dimensions.
   Objective: We investigated whether these results were sustained after supplement withdrawal.
   Design: All participants were followed up 12 (FU1) and 24 (FU2) mo after supplementation ended. Bone mineral content (BMC), bone mineral density (BMD), and BMC adjusted for bone width, body weight, and height (size-adjusted BMC) were measured at the midshaft and distal radius. Plasma osteocalcin concentration was measured at FU1.
   Results: At follow-up, the calcium group had greater bone mineral status than did the placebo group at the midshaft radius (mean difference +/- SE), FU1: BMC (4.7 +/- 1.6%; P = 0.004), BMD (5.1 +/- 1.1%; P less than or equal to 0.0001), size-adjusted BMC (5.0 +/- 1.1%; P less than or equal to 0.0001); FU2: BMC (3.8 +/- 1.6%; P = 0.02), BMD (2.7 +/- 1.3%; P less than or equal to 0.04), size-adjusted BMC (2.5 less than or equal to 1.3%; P = 0.06). Similar differentials were observed at the distal radius but were not significant. No significant differences in plasma osteocalcin concentrations (FU1: -0.5 +/- 6.5%; P = 0.9) were observed between groups.
   Conclusion: Although some of the effects of calcium supplementation were still evident at follow-up, further studies are required to determine whether short-term increases in calcium intake have lasting benefits for Gambian children.
C1 MRC, Keneba, Gambia.
   MRC, Cambridge, England.
RP Dibba, B (reprint author), MRC, POB 273, Keneba, Gambia.
OI Cole, Tim/0000-0001-5711-8200
FU Medical Research Council [G9827821, G9827821(62595)]
CR Bonjour JP, 1997, J CLIN INVEST, V99, P1287, DOI 10.1172/JCI119287
   Cadogan J, 1997, BRIT MED J, V315, P1255
   CHAN GM, 1995, J PEDIATR-US, V126, P551, DOI 10.1016/S0022-3476(95)70348-9
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   Cole TJ, 1997, ARCH DIS CHILD, V76, P47
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   EISMAN JA, 1993, OSTEOP INT S, pS56
   GOSLINGS WRO, 1995, ACTA PAEDIATR, V84, P383, DOI 10.1111/j.1651-2227.1995.tb13655.x
   HEANEY RP, 1994, J BONE MINER RES, V9, P1515
   JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204
   LEE WTK, 1995, BRIT J NUTR, V74, P125, DOI 10.1079/BJN19950112
   Lee WTK, 1996, AM J CLIN NUTR, V64, P71
   LEE WTK, 1994, AM J CLIN NUTR, V60, P744
   Lee WTK, 1997, ACTA PAEDIATR, V86, P570, DOI 10.1111/j.1651-2227.1997.tb08936.x
   LLOYD T, 1993, JAMA-J AM MED ASSOC, V270, P841, DOI 10.1001/jama.270.7.841
   Parsons TJ, 1996, J BONE MINER RES, V11, P264
   Pratt JH, 1996, J LAB CLIN MED, V127, P67, DOI 10.1016/S0022-2143(96)90167-5
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   Prentice A, 1997, P NUTR SOC, V56, P357, DOI 10.1079/PNS19970038
   SHAW NJ, 1995, ARCH DIS CHILD, V72, P177
   Slemenda CW, 1997, J BONE MINER RES, V12, P676, DOI 10.1359/jbmr.1997.12.4.676
   Tanner JM, 1962, GROWTH ADOLESCENCE
   Wastney ME, 2000, J CLIN ENDOCR METAB, V85, P4470, DOI 10.1210/jc.85.12.4470
   WHO, 1994, WHO TECHN REP SER, P843
NR 26
TC 30
Z9 32
U1 0
U2 1
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD SEP
PY 2002
VL 76
IS 3
BP 681
EP 686
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 586LZ
UT WOS:000177586600031
PM 12198018
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Morgan, G
   Collinson, AC
   Swain, JA
   O'Connell, MA
   Prentice, AM
AF Moore, SE
   Morgan, G
   Collinson, AC
   Swain, JA
   O'Connell, MA
   Prentice, AM
TI Leptin, malnutrition, and immune response in rural Gambian children
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID BODY-MASS INDEX; INTESTINAL PERMEABILITY PROBES; RHEUMATOID-ARTHRITIS
   PATIENTS; AUTOMATED ENZYMATIC ASSAYS; SERUM LEPTIN; GENETICALLY-OBESE;
   CHRONIC DIARRHEA; MICE; ACTIVATION; DEFICIENCY
AB Background: The adipocyte derived hormone, leptin, has cytokine like function and may mediate the effects of starvation on immunity. Mice with congenital leptin deficiency (ob/ob) have small hypocellular thymuses and impaired cellular immunity. In humans leptin influences the differentiation of naive and memory cells in vitro, and genetic leptin deficiency has been associated with an ill defined susceptibility to infection.
   Aims: To describe the in vivo relation of leptin and immune function in children.
   Methods: Fasting plasma leptin concentrations, immune function (T and B cell mediated vaccine responses and delayed type hypersensitivity), and mucosal function (dual sugar permeability test and salivary sIgA concentrations) were measured in a cohort of 472 moderately undernourished rural Gambian children.
   Results: Leptin concentrations correlated with body fat assessed by mid upper arm circumference or BMI for age Z scores, and were very low compared to well nourished European norms (males 1.8 v 11.1 ng/ml; females 2.4 v 13.8 ng/ml). No detectable relations were found between leptin concentrations and any of the measures of immune or mucosal function.
   Conclusions: The data confirm that leptin acts as a peripheral signal of energy restriction, but do not support an association between fasting plasma leptin levels and immune function in children of this age.
C1 London Sch Hyg & Trop Med, Int Nutr Grp, Publ Hlth Nutr Unit, MRC, London WC1B 3DP, England.
   MRC Keneba, MRC Labs, Keneba, Gambia.
   MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9LR, England.
RP Moore, SE (reprint author), London Sch Hyg & Trop Med, Int Nutr Grp, Publ Hlth Nutr Unit, MRC, 49-51 Bedford Sq, London WC1B 3DP, England.
CR BEHRENS RH, 1984, CLIN CHIM ACTA, V137, P361, DOI 10.1016/0009-8981(84)90125-6
   BLACK PL, 1983, LIFE SCI, V33, P715, DOI 10.1016/0024-3205(83)90602-1
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   CHANDRA RK, 1980, AM J CLIN NUTR, V33, P13
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005
   Ellis KJ, 1997, PEDIATR RES, V42, P484, DOI 10.1203/00006450-199710000-00010
   Falorni A, 1998, INT J OBESITY, V22, P1197, DOI 10.1038/sj/ijo/0800746
   Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204
   Fraser DA, 1999, CLIN RHEUMATOL, V18, P394, DOI 10.1007/s100670050125
   Fraser DA, 2000, CLIN EXP RHEUMATOL, V18, P209
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Fruhbeck G, 1998, CLIN PHYSIOL, V18, P399, DOI 10.1046/j.1365-2281.1998.00129.x
   Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564
   Hanson L A, 2000, Lakartidningen, V97, P1823
   Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762
   Klein KO, 1998, J CLIN ENDOCR METAB, V83, P3469, DOI 10.1210/jc.83.10.3469
   Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386
   Loffreda S, 1998, FASEB J, V12, P57
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   LUNN PG, 1989, CLIN CHIM ACTA, V183, P163, DOI 10.1016/0009-8981(89)90332-X
   LUNN PG, 1992, CLIN CHIM ACTA, V205, P151, DOI 10.1016/S0009-8981(05)80011-7
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Ma ZM, 1996, CLIN CHEM, V42, P942
   Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P3408, DOI 10.1210/jc.82.10.3408
   Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594
   MEADE CJ, 1979, INT ARCH ALLER A IMM, V58, P121
   Mikhail AA, 1997, BLOOD, V89, P1507
   Montague CT, 1997, NATURE, V387, P903
   Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9
   NICHOLS WK, 1978, DIABETOLOGIA, V14, P343, DOI 10.1007/BF01223027
   NICHOLSON KG, 1990, MODERN VACCINES, P113
   NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N
   Ozata M, 1999, J CLIN ENDOCR METAB, V84, P3686, DOI 10.1210/jc.84.10.3686
   PRENTICE A, 1991, ARCH DIS CHILD, V66, P223
   PRENTICE A, 1984, ACTA PAEDIATR SCAND, V73, P803, DOI 10.1111/j.1651-2227.1984.tb17779.x
   Prentice AM, 1999, BRIT J NUTR, V81, P345
   RICARDO V, 1997, J CLIN ENDOCR METAB, V82, P2849
   Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171
   SHEENA J, 1978, INT ARCH ALLER A IMM, V57, P263
   SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535
   THOMPSON CI, 1983, SCIENCE, V220, P1183, DOI 10.1126/science.6602379
   Wiedenhoft A, 1999, J CLIN ENDOCR METAB, V84, P3021, DOI 10.1210/jc.84.9.3021
   Wong WW, 1998, J CLIN ENDOCR METAB, V83, P3574, DOI 10.1210/jc.83.10.3574
   Zumbach MS, 1997, J CLIN ENDOCR METAB, V82, P4080, DOI 10.1210/jc.82.12.4080
NR 46
TC 27
Z9 28
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD SEP
PY 2002
VL 87
IS 3
BP 192
EP 197
DI 10.1136/adc.87.3.192
PG 6
WC Pediatrics
SC Pediatrics
GA 589QC
UT WOS:000177770700007
PM 12193424
OA No
DA 2017-08-15
ER

PT J
AU Clarke, SE
   Bogh, C
   Brown, RC
   Walraven, GEL
   Thomas, CJ
   Lindsay, SW
AF Clarke, SE
   Bogh, C
   Brown, RC
   Walraven, GEL
   Thomas, CJ
   Lindsay, SW
TI Risk of malaria attacks in Gambian children is greater away from malaria
   vector breeding sites
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; children; entomological inoculation
   rate; clinical attack prevalence; The Gambia
ID PLASMODIUM-FALCIPARUM; WEST-AFRICA; TRANSMISSION INTENSITY; BED-NETS;
   MORBIDITY; AREA; MORTALITY; EPIDEMIOLOGY; DENSITY; PREVALENCE
AB The causes of local variation in the prevalence of malaria were investigated in rural Gambia. Cross-sectional prevalence surveys were carried out among 1184 young children (aged 6 months-5 years) in 48 villages, at the end of the transmission season in 1996. Villages were categorized according to distance from the nearest vector breeding sites, and the patterns of malaria transmission, infection and disease compared. Children living in villages within 3 km of breeding sites experienced more infective bites, and higher prevalences of parasitaemia and spleen enlargement than less-exposed children living further away. Clinical illness, in contrast, was more common among infected children who were less exposed. Infected children living 3 km or more from breeding sites were more likely to have high-density parasitaemia (odds ratio [OR] = 1.98), fever (OR = 2.60) and high-density parasitaemia together with fever (OR = 3.17). Clinical attacks did not decline in older children, as seen amongst children who were more exposed. These findings show that significant differences in the risk of infection and clinical attacks can occur over very short distances. The age at which protective immunity is acquired may be delayed in villages where transmission intensity is lower, thus increasing the risk of a clinical attack following infection. Communities with the lowest vector densities may be those at greatest risk of disease.
C1 Danish Bilharziasis Lab, DK-2920 Charlottenlund, Denmark.
   Farafenni & Fajara, Med Res Council Labs, Banjul, Gambia.
   Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
RP Clarke, SE (reprint author), London Sch Hyg & Trop Med, 50 Bedford Sq, London WC1B 3DP, England.
CR AIKINS MK, 1993, T ROYAL SOC TROPI S2, V87
   Armstrong Schellenberg J. R. M., 1994, Parasitology Today, V10, P439
   BOGH C, 1999, THESIS U COPENHAGEN, P20
   BOGH C, 1999, THESIS U COPENHAGEN
   BOGH C, 1999, THESIS U COPENHAGEN, P40
   Boyd MF., 1949, MALARIOLOGY COMPREHE
   BRADLEY AK, 1986, LANCET, V2, P204
   Browne ENL, 2000, ANN TROP MED PARASIT, V94, P15, DOI 10.1080/00034980057572
   Carter R, 2000, B WORLD HEALTH ORGAN, V78, P1401
   CATTANI JA, 1986, PAPUA NEW GUINEA MED, V29, P11
   CLARKE S, 2001, THESIS U COPENHAGEN
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   CLARKE SE, 2001, VARIATION MALARIA RI, P27
   CLARKE SE, 2001, THESIS U COPENHAGEN, P85
   CLARKE SE, 2001, THESIS U COPENHAGEN, P3
   *DOS, 1976, GAMB
   GILLIES MT, 1961, B ENTOMOL RES, V52, P92
   Goncalves A, 1996, MEM I OSWALDO CRUZ, V91, P11
   Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1987, ANN TROP MED PARASIT, V81, P345
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   LINDSAY SW, 1993, T ROYAL SOC TROPI S2, V87
   MANGA L, 1993, J MED ENTOMOL, V30, P936
   *MARA ARMA, 1998, ATL MAL RISK AFR
   Marsh K, 1997, PHILOS T ROY SOC B, V352, P1385
   Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206
   Molineaux Louis, 1980, GARKI PROJECT RES EP
   MOTT KE, 1995, B WORLD HEALTH ORGAN, V73, P247
   MULLER O, 1994, LANCET, V344, P1699, DOI 10.1016/S0140-6736(94)90481-2
   SCHELLENBERG JRMA, 1994, T ROY SOC TROP MED H, V88, P429, DOI 10.1016/0035-9203(94)90416-2
   SMITH T, 1995, ACTA TROP, V59, P1, DOI 10.1016/0001-706X(94)00082-C
   Smith TA, 2001, TRENDS PARASITOL, V17, P145, DOI 10.1016/S1471-4922(00)01814-6
   SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624
   Snow RW, 1996, PARASITOL TODAY, V12, P455, DOI 10.1016/S0169-4758(96)30032-X
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   Thompson R, 1997, AM J TROP MED HYG, V57, P550
   Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   THOMSON MC, 1995, MED VET ENTOMOL, V9, P413, DOI 10.1111/j.1365-2915.1995.tb00015.x
   TRAPE JF, 1992, AM J TROP MED HYG, V47, P181
   Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6
   vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9
   World Health Organisation, 1993, GLOB STRAT MAL CONTR
   Wright E, 1997, STATA TECH B, V38, P4
NR 50
TC 56
Z9 56
U1 0
U2 3
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 2002
VL 96
IS 5
BP 499
EP 506
DI 10.1016/S0035-9203(02)90419-0
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 621UQ
UT WOS:000179609800009
PM 12474476
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Herman, J
   Jaffar, S
   Usen, S
   Oparaugo, A
   Omosigho, C
   Adegbola, RA
   Greenwood, BM
   Mulholland, EK
AF Weber, MW
   Herman, J
   Jaffar, S
   Usen, S
   Oparaugo, A
   Omosigho, C
   Adegbola, RA
   Greenwood, BM
   Mulholland, EK
TI Clinical predictors of bacterial meningitis in infants and young
   children in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE meningitis; clinical signs; Integrated Management of Childhood Illness;
   child; developing countries
ID INFLUENZAE TYPE-B; CONJUGATE; PNEUMONIA; CHILDHOOD; SIGNS
AB BACKGROUND Bacterial meningitis is an important cause of childhood morbidity and mortality world-wide. In the developing world, where the burden of acute meningitis and its long-term sequelae are especially high, staff with limited training at primary health care facilities must be able to recognize the symptoms and signs of meningitis, so that suspected cases can be referred urgently to hospitals.
   METHODS Children who presented with possible invasive bacterial infection to health facilities in The Gambia, West Africa, between 1993 and 1995 were investigated in a standardized manner and clinical findings were documented. Bacterial meningitis was defined as the growth of bacteria from the cerebrospinal fluid. Clinical findings were compared between cases of meningitis and other children.
   RESULTS Of 2097 children between 2 months and 3 years of age investigated, 51 had a confirmed diagnosis of bacterial meningitis. In multivariate analysis using a model adjusting for age but not including respiratory signs, the variables associated independently with meningitis were appearance of being very sick (odds ratio for meningitis vs. no meningitis or no lumbar puncture performed (OR) 4.1, 95% CI 1.5-11.1), being lethargic or unconscious (OR 5.2, 95% CI 2.1-13), a stiff neck (OR 29.3, 95% CI 12.2-70.3), a bulging fontanel (OR 3.2, 95% CI 1.2-8.5) and reduced feeding as a prompted complaint (OR 2.9, 95% CI 1.3-6.7). A combination model of a history of convulsions, or being lethargic or unconscious, or having a stiff neck, as used in the WHO-Integrated Management of Childhood Illness (IMCI) guidelines, had a sensitivity of 98% and a specificity of 72% to predict meningitis.
   CONCLUSIONS A combination of a limited number of signs is sufficient to predict meningitis with high sensitivity, without a large number of children who do not have meningitis being unnecessarily referred.
C1 MRC Labs, Fajara, Gambia.
   Hannover Med Sch, Childrens Hosp, D-3000 Hannover, Germany.
   London Sch Hyg & Trop Med, London WC1, England.
   Brooklyn Hosp Med Ctr, Dept Pediat, New York, NY USA.
   WHO, CAH, CH-1211 Geneva, Switzerland.
RP Weber, MW (reprint author), WHO, CAH, CH-1211 Geneva 27, Switzerland.
CR Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   Andersen W, 1997, ANN PHYS-NEW YORK, V255, P34, DOI 10.1006/aphy.1996.5648
   CHOO KE, 1990, ANN TROP PAEDIATR, V10, P89
   Chotpitayasunondh Tawee, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P107
   GEISELER PJ, 1980, REV INFECT DIS, V2, P725
   Goetghebuer T, 2000, TROP MED INT HEALTH, V5, P207, DOI 10.1046/j.1365-3156.2000.00535.x
   HENSEL M, 1992, KLIN PADIATR, V204, P163, DOI 10.1055/s-2007-1025344
   KIRKPATRICK B, 1994, J INFECTION, V29, P171, DOI 10.1016/S0163-4453(94)90698-X
   Lehmann D, 1999, ANN TROP PAEDIATR, V19, P21, DOI 10.1080/02724939992608
   Molyneux E, 1998, TROP MED INT HEALTH, V3, P610
   MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51
   Rosenberg N M, 1988, Pediatr Emerg Care, V4, P5, DOI 10.1097/00006565-198803000-00002
   Tikhomirov Eugene, 1997, World Health Statistics Quarterly, V50, P170
   TUGWELL P, 1976, Q J MED, V45, P583
   Tulloch J, 1999, LANCET S2, V354, P16
   VALMARI P, 1987, EUR J PEDIATR, V146, P515, DOI 10.1007/BF00441607
   WALSHKELLY C, 1992, ANN EMERG MED, V21, P910, DOI 10.1016/S0196-0644(05)82926-9
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS23
   ZIAI M, 1958, NEW ENGL J MED, V259, P314, DOI 10.1056/NEJM195808142590702
NR 21
TC 21
Z9 24
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2002
VL 7
IS 9
BP 722
EP 731
DI 10.1046/j.1365-3156.2002.00926.x
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 592RN
UT WOS:000177950800002
PM 12225501
OA No
DA 2017-08-15
ER

PT J
AU Sabeti, P
   Usen, S
   Farhadian, S
   Jallow, M
   Doherty, T
   Newport, M
   Pinder, M
   Ward, R
   Kwiatkowski, D
AF Sabeti, P
   Usen, S
   Farhadian, S
   Jallow, M
   Doherty, T
   Newport, M
   Pinder, M
   Ward, R
   Kwiatkowski, D
TI CD40L association with protection from severe malaria
SO GENES AND IMMUNITY
LA English
DT Article
DE CD40L; severe malaria
ID HYPER-IGM SYNDROME; MOLECULAR ANALYSIS; LIGAND; REGION; CELLS;
   SUSCEPTIBILITY; DISEQUILIBRIUM; RESISTANCE; COMPLEX; GENE
AB CD40 ligand (CD40L), a glycoprotein involved in B cell proliferation, antigen presenting cell activation, and Ig class switching, is important in the immune response to infection. Rare coding mutations in CD40L can lead to life-threatening immunodeficiency but the potential for common variants to alter disease susceptibility remains to be explored. To identify polymorphisms in CD40L, we sequenced 2.3 kb of the 5' flanking region and the first exon of the gene in DNA samples from 36 Gambian females and one chimpanzee. Diversity was lower than the average reported for other areas of the X chromosome, and only two polymorphisms were identified. The polymorphisms were genotyped in DNA samples from 957 Gambian individuals, cases and controls from a study of severe malaria. A significant reduction in risk for severe malaria (OR = 0.52, P = 0.002) was associated with males hemizygous for the CD40L-726C. Analysis by transmission disequilibrium test of 371 cases, for whom DNA from both parents was also available, confirmed the result was not due to stratification (P = 0.04). A similar but non-significant trend was found in females. This preliminary association of a common variant in CD40L with a malaria resistance phenotype encourages further genetic characterization of the role of CD40L in infectious disease.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   MRC Labs, Fajara, Gambia.
   Univ Oxford, Inst Biol Anthropol, Oxford, England.
   Royal Victoria Hosp, Banjul, Gambia.
RP Kwiatkowski, D (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
CR Anagnostopoulos T, 1999, AM J HUM GENET, V64, P508, DOI 10.1086/302250
   Cargill M, 1999, NAT GENET, V22, P231
   DEAN AG, 1991, AM J PREV MED, V7, P178
   DURIE FH, 1994, IMMUNOL TODAY, V15, P406, DOI 10.1016/0167-5699(94)90269-0
   GAUCHAT JF, 1995, EUR J IMMUNOL, V25, P863, DOI 10.1002/eji.1830250335
   GRAMMER AC, 1995, J IMMUNOL, V154, P4996
   Hartl D. L., 1997, PRINCIPLES POPULATIO
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Hill AVS, 1999, P ASSOC AM PHYSICIAN, V111, P272, DOI 10.1046/j.1525-1381.1999.99234.x
   Karpusas M, 1995, STRUCTURE, V3, P1426
   Kornbluth RS, 2000, J LEUKOCYTE BIOL, V68, P373
   Kutsche K, 2000, NAT GENET, V26, P247
   Kwiatkowski D, 2000, CURR OPIN GENET DEV, V10, P320, DOI 10.1016/S0959-437X(00)00087-3
   LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226
   Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9
   LEWONTIN RC, 1964, GENETICS, V49, P49
   Li WH, 1997, MOL EVOLUTION
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Miller RD, 2001, GENOMICS, V71, P78, DOI 10.1006/geno.2000.6417
   NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101
   Pinchuk LM, 1996, J IMMUNOL, V157, P4363
   Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878
   Schaid DJ, 1998, AM J HUM GENET, V63, P935, DOI 10.1086/302077
   SHIMADZU M, 1995, BBA-GENE STRUCT EXPR, V1260, P67, DOI 10.1016/0167-4781(94)00179-7
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Tsytsykova AV, 1996, J BIOL CHEM, V271, P3763
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2
NR 27
TC 45
Z9 47
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD AUG
PY 2002
VL 3
IS 5
BP 286
EP 291
DI 10.1038/sj.gene.636877
PG 6
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 582ZA
UT WOS:000177380000006
PM 12140747
OA No
DA 2017-08-15
ER

PT J
AU Prynne, CJ
   Paul, AA
   Dibba, B
   Jarjou, LMA
AF Prynne, CJ
   Paul, AA
   Dibba, B
   Jarjou, LMA
TI Gambian food records: A new framework for computer coding
SO JOURNAL OF FOOD COMPOSITION AND ANALYSIS
LA English
DT Article
DE Gambian; coding; database; foods; composition; calcium
ID WOMEN
AB Gambian weighed dietary records have been collected over many years as part of health-related studies and an extensive database of Gambian foods has been established. The diet of rural Gambians is relatively limited consisting of rice, accompanied by sauces, based on groundnuts, leaves and fish. However, there are several extra ingredients that, although present in very small quantities, are rich sources of micro-nutrients such as calcium. A coding problem arises when the weighed meal consists of a sauce containing pre-mixed additional ingredients and when rice and sauce are weighed together. Previously, all records had to be coded manually which was slow with potential for error. The computerized coding system, Diet in, Data out (DIDO) previously set up for U.K. records, has been adapted to the Gambian diet. The DIDO menu is arranged in a pyramidal structure where the principal menu lists 20 food groups, each of which has a series of submenus. A particular feature is the inclusion of a wide range of prepared dishes. The entire menu offers 500 foods. A comparative study of coding by Gambian and British researchers identified particular foods where coding was inconsistent due to lack of food detail. This has highlighted the importance of adequate identification of food items and the need to develop a strategy for standardized default codes for these foods. (C) 2002 Elsevier Science Ltd. All sights reserved.
C1 MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   MRC, Keneba, Gambia.
RP Prynne, CJ (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
CR BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   BLAND JM, 1986, LANCET, V1, P307
   DAY KC, 1980, J HUM NUTR, V34, P181
   DIBBA B, 1999, THESIS OPEN U
   HUDSON GJ, 1995, BRIT J NUTR, V73, P551, DOI 10.1079/BJN19950058
   HUDSON GJ, 1980, ECOL FOOD NUTR, V10, P9
   Jarjou L. M. A., 1993, Proceedings of the Nutrition Society, V52, p349A
   McCrae JE, 1996, FOODS RURAL GAMBIA
   Paul AA, 1998, INT J FOOD SCI NUTR, V49, P141, DOI 10.3109/09637489809089394
   PAUL AA, 1980, MATERNAL NUTRITION P, P105
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Price GM, 1995, J HUM NUTR DIET, V8, P417, DOI 10.1111/j.1365-277X.1995.tb00337.x
   VILLARD L, 1987, HUM NUTR-APPL NUTR, V41A, P135
   WHITEHEAD RG, 1979, UNU FOOD NUTR B, V1, P36
NR 15
TC 4
Z9 4
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1575
J9 J FOOD COMPOS ANAL
JI J. Food Compos. Anal.
PD AUG
PY 2002
VL 15
IS 4
BP 349
EP 357
DI 10.1006/jfca.2002.1074
PG 9
WC Chemistry, Applied; Food Science & Technology
SC Chemistry; Food Science & Technology
GA 601GF
UT WOS:000178437600003
OA No
DA 2017-08-15
ER

PT J
AU West, B
   Walraven, G
   Morison, L
   Brouwers, J
   Bailey, R
AF West, B
   Walraven, G
   Morison, L
   Brouwers, J
   Bailey, R
TI Performance of the rapid plasma reagin and the rapid syphilis screening
   tests in the diagnosis of syphilis in field conditions in rural Africa
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
ID PREVALENCE; WOMEN
AB Objectives: To assess the rapid plasma reagin (RPR) test performance in the field and to;evaluate a new rapid syphilis test (RST) as a primary screen for syphilis.
   Methods: 1325 women of reproductive age from rural communities in the Gambia were tested for syphilis seropositivity using a RPR 18 mm circle card and a RST strip. Within 1 week a repeat RPR and a TPHA test were carried out using standard techniques in the laboratory.
   Results: Comparing field tests to a diagnosis of "active" syphilis defined as laboratory RPR and TPHA positive, the RPR test was 77.5% sensitive and 94.1% specific; the RST was 75.0% sensitive and 95.2% specific. The RST was easier to use and interpret than the RPR test especially where field conditions were difficult. In this setting with a low prevalence of syphilis in the community (3%), the chance of someone with a positive test being confirmed as having serologically active syphilis was less than 50% for both tests.
   Conclusions: The appropriateness of syphilis screening using RPR testing in antenatal clinics and health centres should be questioned if there is a low prevalence in the population, conditions for testing are poor, and resources limited. There is still an urgent need for an appropriate rapid syphilis test for field use.
C1 MRC Labs, Reprod Hlth Programme, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP West, B (reprint author), MRC Labs, Reprod Hlth Programme, Farafenni & Fajara,POB 273, Banjul, Gambia.
RI Morison, Linda/H-9738-2013
CR BERKOWITZ K, 1990, AM J OBSTET GYNECOL, V163, P975
   CREIGHTON ET, 1990, MANUAL TESTS SYPHILI, P100
   DELPORT SD, 1993, S AFR MED J, V83, P723
   EGGLESTONE S, 1997, 12 M INT SOC SEX TRA
   ELZAATARI MM, 1994, SEX TRANSM DIS, V21, P243, DOI 10.1097/00007435-199409000-00001
   Hawkes S, 1999, LANCET, V354, P1776, DOI 10.1016/S0140-6736(99)02463-0
   JENNISKENS F, 1995, INT J GYNECOL OBSTET, V48, pS121, DOI 10.1016/0020-7292(95)02326-8
   LARSEN SA, 1995, CLIN MICROBIOL REV, V8, P1
   Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P69
   SANKE GS, 1999, CURR OPIN UROL, V9, P31
   Schmidt BL, 2000, J CLIN MICROBIOL, V38, P1279
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   VANDYCK E, 1993, SEX TRANSM DIS, V20, P194
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   World Health Organization, 1982, WHO TECHN REP SER, V674
   Young H, 2000, SEX TRANSM INFECT, V76, P403, DOI 10.1136/sti.76.5.403
   YOUNG H, 1992, INT J STD AIDS, V3, P913
NR 17
TC 35
Z9 39
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD AUG
PY 2002
VL 78
IS 4
BP 282
EP 285
DI 10.1136/sti.78.4.282
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA 586WV
UT WOS:000177609900013
PM 12181468
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Burton, KJ
   Chuka-Okosa, CM
   Bailey, RL
AF Burton, MJ
   Burton, KJ
   Chuka-Okosa, CM
   Bailey, RL
TI Plummeting lenses in the TB clinic
SO LANCET
LA English
DT Editorial Material
C1 MRC Labs, Fajara, Gambia.
   Royal Victoria Hosp, Banjul, Gambia.
RP Burton, MJ (reprint author), MRC Labs, Fajara, Gambia.
CR AICARDI J, 1998, DIS NERVOUS SYSTEM C, P274
   Franco RF, 1998, HUM HERED, V48, P338, DOI 10.1159/000022826
   HANDMAN J, 1996, GOODMAN GILMANS PHAR, P1561
   MCKUSICK VA, 2002, ONLINE MENDELIAN INH
   SHULMAN D, 1977, S AFR MED J, V52, P127
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 13
PY 2002
VL 360
IS 9327
BP 138
EP 138
DI 10.1016/S0140-6736(02)09415-1
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 573PB
UT WOS:000176839100014
PM 12126825
OA No
DA 2017-08-15
ER

PT J
AU Cervino, ACL
   Lakiss, S
   Sow, O
   Bellamy, R
   Beyers, N
   Hoal-van Helden, E
   van Helden, P
   McAdam, KPWJ
   Hill, AVS
AF Cervino, ACL
   Lakiss, S
   Sow, O
   Bellamy, R
   Beyers, N
   Hoal-van Helden, E
   van Helden, P
   McAdam, KPWJ
   Hill, AVS
TI Fine mapping of a putative tuberculosis-susceptibility locus on
   chromosome 15q11-13 in African families
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PRADER-WILLI SYNDROMES; PARENTAL ORIGIN; PULMONARY TUBERCULOSIS;
   NATURAL-RESISTANCE; GENE; ASSOCIATION; ANGELMAN; TRANSMISSION; HLA;
   DISEQUILIBRIUM
AB Host genetics plays an important role in individual susceptibility and resistance to infectious diseases, but no genes have yet been identified using genome-wide screens. Twin studies have indicated that tuberculosis susceptibility has a significant host genetic component, and several genes appear to be involved. Recently, a genome-wide linkage analysis of 136 African families identified chromosome 15q11-13 as a region with suggestive evidence of linkage, with a LOD score of 2.0. We tested 10 microsatellite markers and 5 positional candidate genes in this chromosomal region for deviation from random transmission from parents to affected offspring. The polymorphisms, lying in a region of 14 cM, were initially typed in the same 79 Gambian families used in the genome screen. A borderline significant association with a 7 bp deletion in UBE3A (P=0.01) was found. This polymorphism was then evaluated further in a larger series of families with tuberculosis, including 44 Guinean families and 57 families from South Africa. Testing for association between the deletion and tuberculosis across all the families using the exact symmetry test further supported the association (overall P=0.002). These fine-mapping data suggest that UBE3A or a closely flanking gene may be a tuberculosis-susceptibility locus.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Hop Ignace Deen, Conakry, Guinea.
   Univ Stellenbosch, Dept Paediat & Child Hlth, ZA-7600 Stellenbosch, South Africa.
   Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7600 Stellenbosch, South Africa.
   Univ Stellenbosch, Dept Med Biochem, ZA-7600 Stellenbosch, South Africa.
   MRC Labs, Banjul, Gambia.
RP Hill, AVS (reprint author), John Radcliffe Hosp, Room 7501,Level 7, Oxford OX3 9DU, England.
RI HILL, Adrian/C-1306-2008
OI Hoal, Eileen/0000-0002-6444-5688
CR Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   BOTHAMLEY GH, 1989, J INFECT DIS, V159, P549
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   Cervino ACL, 2000, ANN HUM GENET, V64, P507, DOI 10.1046/j.1469-1809.2000.6460507.x
   Cervino ACL, 2000, AM J HUM GENET, V67, P120, DOI 10.1086/302992
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Cleves MA, 1997, GENET EPIDEMIOL, V14, P337, DOI 10.1002/(SICI)1098-2272(1997)14:4<337::AID-GEPI1>3.0.CO;2-0
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   DIEHL K, 1936, ERBEINFLUSS TUBERKUL
   GLATT K, 1994, GENOMICS, V19, P157, DOI 10.1006/geno.1994.1027
   Hackam DJ, 1998, J EXP MED, V188, P351, DOI 10.1084/jem.188.2.351
   Jabado N, 2000, J EXP MED, V192, P1237, DOI 10.1084/jem.192.9.1237
   Reisner D, 1942, AM REV TUBERC, V47, P549
   KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235
   LEE ST, 1995, GENOMICS, V26, P354, DOI 10.1016/0888-7543(95)80220-G
   MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307
   NEWPORT MJ, 1997, BAILLIERES CLIN INFE, V2, P207
   Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557
   Pospelov LE, 1996, TUBERCLE LUNG DIS, V77, P77, DOI 10.1016/S0962-8479(96)90080-5
   Puri N, 2000, J INVEST DERMATOL, V115, P607, DOI 10.1046/j.1523-1747.2000.00108.x
   Rajalingam R, 1996, J INFECT DIS, V173, P669
   Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15
   Rougeulle C, 1997, NAT GENET, V17, P14, DOI 10.1038/ng0997-14
   Sawabe T, 2001, INT J MOL MED, V7, P609
   SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3
   Simonds B, 1963, TUBERCULOSIS TWINS, P81
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Veenstra-VanderWeele J, 1999, MOL PSYCHIATR, V4, P64, DOI 10.1038/sj.mp.4000472
   VU TH, 1997, NAT GENET, V17, P121
   WOOD GW, 1994, IMMUNOL TODAY, V15, P15, DOI 10.1016/0167-5699(94)90020-5
   ZORI R, 1990, AM J MED GENET, V37, P294, DOI 10.1002/ajmg.1320370233
NR 34
TC 41
Z9 43
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2002
VL 11
IS 14
BP 1599
EP 1603
DI 10.1093/hmg/11.14.1599
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 569MN
UT WOS:000176606300002
PM 12075004
OA No
DA 2017-08-15
ER

PT J
AU Holmgren, B
   Andersson, S
   Harding, E
   van der Loeff, MS
   Vastrup, P
   Aaby, P
   Ariyoshi, K
   Whittle, H
AF Holmgren, B
   Andersson, S
   Harding, E
   van der Loeff, MS
   Vastrup, P
   Aaby, P
   Ariyoshi, K
   Whittle, H
TI Increased prevalence of HTLV-1 among HIV-2-infected women but not
   HIV-2-infected men in rural Guinea-Bissau
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-2; HTLV-1; female; prevalence; risk factors; community study
ID VIRUS TYPE-I; CELL LEUKEMIA-VIRUS; WESTERN EQUATORIAL AFRICA; TO-CHILD
   TRANSMISSION; HIV-1 INFECTION; GENITAL-TRACT; PROTECTION; MOTHER; I/II;
   RISK
AB Objective: To assess the prevalence of HTLV infection and its association with HIV and other potential risk factors.
   Design and Setting: A cross-sectional survey and a case-control study in a rural community in Guinea-Bissau.
   Methods: A total of 2770 people were included in an HIV and HTLV seroepidemiologic survey. Three hundred of these participants were selected for a case-control study on HIV-2. Sera from both studies were tested for HTLV.
   Results: In all, 2501 and 298 subjects in the survey and case-control study, respectively. were tested for HTLV. Overall HTLV-1 prevalence was 5.2% and it was higher in women (odds ratio [OR]. 1.36 confidence interval [CI], 0.92-2.02). Apart from an infected spouse, no significant risk factors could be identified for men, In women. HIV-2 infection (adjusted OR, 5.58 Cl, 3.09-10.1). having an infected spouse. and area of residence were significantly associated with HTLV- I infection. The association between HTLV- I and HIV-2 was significantly different for men and women (test of interaction, p = .002).
   Conclusions: In women, the most important determinant of HTLV-1 seropositivity was HIV-2 infection. Because the pattern was significantly different for men an women, common sexual risk factors may not be sufficient to explain file co-occurrence of HIV-2 and HTLV-1 in women. These observations may have implications in geographic areas where both types of retroviruses are prevalent.
C1 Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark.
   Danish Epidemiol Sci Ctr, Bandim Hlth Project, Bissau, Guinea Bissau.
   Swedish Inst Infect Dis Control, Stockholm, Sweden.
   MRC Labs, Fajara, Gambia.
RP Holmgren, B (reprint author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
CR Andersson S, 1999, TRANSFUSION, V39, P845, DOI 10.1046/j.1537-2995.1999.39080845.x
   ANDO Y, 1987, JPN J CANCER RES, V78, P322
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   BIGGAR RJ, 1993, AIDS RES HUM RETROV, V9, P505, DOI 10.1089/aid.1993.9.505
   DELAPORTE E, 1989, LANCET, V2, P1226
   DELAPORTE E, 1988, INT J CANCER, V42, P687, DOI 10.1002/ijc.2910420509
   DELMISTRO A, 1994, AIDS RES HUM RETROV, V10, P617, DOI 10.1089/aid.1994.10.617
   DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x
   DUMAS M, 1991, AIDS RES HUM RETROV, V7, P447, DOI 10.1089/aid.1991.7.447
   DURAND JP, 1995, AIDS RES HUM RETROV, V11, P985, DOI 10.1089/aid.1995.11.985
   Fouchard N, 1998, LEUKEMIA, V12, P578, DOI 10.1038/sj.leu.2400956
   JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102
   KAJIYAMA W, 1986, AM J EPIDEMIOL, V123, P41
   KAJIYAMA W, 1986, J INFECT DIS, V154, P851
   Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193
   Kokkotou EG, 2000, P NATL ACAD SCI USA, V97, P6797, DOI 10.1073/pnas.97.12.6797
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   Larsen O, 2000, J ACQ IMMUN DEF SYND, V25, P157, DOI 10.1097/00126334-200010010-00010
   Mauclere P, 1997, J INFECT DIS, V176, P505
   Melbye M, 1998, INT J CANCER, V76, P293, DOI 10.1002/(SICI)1097-0215(19980504)76:3<293::AID-IJC1>3.0.CO;2-Q
   Michel P, 1996, Med Trop (Mars), V56, P249
   MIYAZAKI K, 1991, OBSTET GYNECOL, V77, P107
   MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114
   MURPHY EL, 1989, ANN INTERN MED, V111, P555
   NAUCLER A, 1992, AIDS, V6, P510
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014
   Nyambi PN, 1996, J ACQ IMMUN DEF SYND, V12, P187
   Olaitan A, 1998, CLIN EXP IMMUNOL, V112, P100
   Olaitan A, 1996, AIDS, V10, P759, DOI 10.1097/00002030-199606001-00010
   Olaleye OD, 1996, ARCH VIROL, V141, P345, DOI 10.1007/BF01718404
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   STRICKLER HD, 1995, INT J CANCER, V61, P23, DOI 10.1002/ijc.2910610105
   STUVER SO, 1992, J ACQ IMMUN DEF SYND, V5, P12
   STUVER SO, 1993, J INFECT DIS, V167, P57
   TAKAHASHI K, 1991, INT J CANCER, V49, P673, DOI 10.1002/ijc.2910490508
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   TUKE PW, 1992, J VIROL METHODS, V40, P163, DOI 10.1016/0166-0934(92)90065-L
   VALLAT JM, 1993, J NEUROL SCI, V119, P141, DOI 10.1016/0022-510X(93)90126-J
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   VERDIER M, 1989, J INFECT DIS, V160, P363
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   WILLIAMS CKO, 1994, LEUKEMIA, V8, pS77
NR 44
TC 12
Z9 12
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr.
PD JUL 1
PY 2002
VL 30
IS 3
BP 342
EP 350
DI 10.1097/01.QAI.0000013943.86473.3E
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 575BG
UT WOS:000176925500011
PM 12131572
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Bennett, S
   Del Prete, G
   Bah-Sow, O
   Newport, M
   Gustafson, P
   Manneh, K
   Gomes, V
   Hill, A
   McAdam, K
AF Lienhardt, C
   Bennett, S
   Del Prete, G
   Bah-Sow, O
   Newport, M
   Gustafson, P
   Manneh, K
   Gomes, V
   Hill, A
   McAdam, K
TI Investigation of environmental and host-related risk factors for
   tuberculosis in Africa. I. Methodological aspects of a combined design
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE epidemiologic methods; genetics; infection; Mycobacterium tuberculosis;
   research design; risk factors; tuberculosis
ID CD4(+) T-CELLS; SUSCEPTIBILITY; ASSOCIATION; MYCOBACTERIAL;
   TRANSMISSION; DEFICIENCY; EXPRESSION; INFECTIONS; CHILDHOOD; CYTOKINES
AB Host-related and environmental factors for tuberculosis have usually been investigated separately using different study designs. Joint investigation of the genetic, immunologic, and environmental factors at play in susceptibility to tuberculosis represents an innovative goal for obtaining a better understanding of the pathogenesis of the disease. In this paper, the authors describe methods being used to investigate these points in a West African study combining several designs. Patients with newly diagnosed smear-positive cases of tuberculosis are recruited. The effect of host-related factors is assessed by comparing each case with a healthy control from the case's household. The role of environmental factors is estimated by comparing cases with randomly selected community controls. The frequencies of candidate gene variants are compared between cases and community controls, and results are validated through family-based association studies. Members of the households of cases and community controls are being followed prospectively to determine the incidence of "secondary" tuberculosis and to evaluate the influence of geographic and genetic proximity to the index case. This type of design raises important methodological issues that may be useful to consider in studies investigating the natural history of infectious diseases and in attempts to disentangle the effects of environmental and genetic factors in response to infection.
C1 Inst Rech Dev, Dakar, Senegal.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Fajara, Gambia.
   Univ Florence, Fac Med, Dept Internal Med, Florence, Italy.
   CHU Ignace Deen, Programme Natl Lutte Anti TB, Conakry, Guinea.
   Wellcome Trust Ctr Mol Mech Dis, Cambridge, England.
   Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau.
   Minist Hlth, Natl Leprosy TB Control Programme, Banjul, Gambia.
   Hop Raoul Follereau, Bissau, Guinea Bissau.
   Wellcome Trust Ctr Human Genet, Oxford, England.
RP Lienhardt, C (reprint author), Inst Rech Dev, BP 1386, Dakar, Senegal.
RI HILL, Adrian/C-1306-2008
CR Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432
   American Thoracic Society, 1981, AM REV RESPIR DIS, V123, P343
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   ANDERSEN S, 1960, Bull World Health Organ, V22, P39
   Annunziato F, 1996, FASEB J, V10, P769
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   Bentwich Z, 2000, PARASITOL TODAY, V16, P312, DOI 10.1016/S0169-4758(00)01693-8
   BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7
   Talent JM, 1997, INT J TUBERC LUNG D, V1, P31
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131
   COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   de Jong R, 1998, SCIENCE, V280, P1435
   DELPRETE G, 1995, FASEB J, V9, P81
   DOHERTY T, 2000, CURR OPIN PULM MED, V3, P203
   DONALD PR, 1999, TUBERCULOSIS CHILDRE
   ENARSON DA, 1994, CLIN TUBERCULOSIS
   Falk A, 1969, DIAGNOSTIC STANDARDS
   FINE PEM, 1981, INT J LEPROSY, V49, P437
   Fine PEM, 1998, NOVART FDN SYMP, V217, P57, DOI 10.1002/0470846526.ch5
   Fourie PB, 1998, INT J TUBERC LUNG D, V2, P116
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406
   Frost WH, 1933, AM J PUBLIC HEALTH N, V23, P426, DOI 10.2105/AJPH.23.5.426
   Galli G, 2000, EUR J IMMUNOL, V30, P204, DOI 10.1002/1521-4141(200001)30:1<204::AID-IMMU204>3.3.CO;2-7
   GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S
   Glynn JR, 1998, B WORLD HEALTH ORGAN, V76, P295
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90
   Hartl D. L., 1997, PRINCIPLES POPULATIO
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288
   LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109
   MADICO G, 1995, LANCET, V345, P416, DOI 10.1016/S0140-6736(95)90401-8
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6
   NARAIN R, 1996, B WORLD HEALTH ORGAN, V34, P639
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   OBRIEN R, 1994, TUBERCULOSIS BACK FU
   Orme IM, 1997, INT J TUBERC LUNG D, V1, P95
   OSBORNE CM, 1995, ARCH DIS CHILD, V72, P369
   PIESSENS WF, 2000, TUBERCULOSIS COMPREH
   Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1
   RISCH N, 1990, AM J HUM GENET, V46, P229
   RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205
   ROUILLON A, 1976, TUBERCLE, V57, P275
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   SIMMONDS B, 1963, TUBERCULOSIS TWINS
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   Smith P., 1994, TUBERCULOSIS PATHOGE
   STYBLO K, 1978, Bulletin of the International Union Against Tuberculosis, V53, P141
   STYBLO K, 1991, SELECTED PAPERS ROYA, V24
   Sutherland I, 1976, Adv Tuberc Res, V19, P1
   Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247
   Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
NR 58
TC 35
Z9 37
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2002
VL 155
IS 11
BP 1066
EP 1073
DI 10.1093/aje/155.11.1066
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 557MY
UT WOS:000175913400011
PM 12034586
OA No
DA 2017-08-15
ER

PT J
AU Bennett, S
   Lienhardt, C
   Bah-Sow, O
   Gustafson, P
   Manneh, K
   Del Prete, G
   Gomes, V
   Newport, M
   McAdam, K
   Hill, A
AF Bennett, S
   Lienhardt, C
   Bah-Sow, O
   Gustafson, P
   Manneh, K
   Del Prete, G
   Gomes, V
   Newport, M
   McAdam, K
   Hill, A
TI Investigation of environmental and host-related risk factors for
   tuberculosis in Africa. II. Investigation of host genetic factors
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE epidemiologic methods; genetics; infection; Mycobacterium tuberculosis;
   research design; risk factors; tuberculosis
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; VITAMIN-D DEFICIENCY;
   TRANSMISSION/DISEQUILIBRIUM TEST; PULMONARY TUBERCULOSIS; LINKAGE
   DISEQUILIBRIUM; ASSOCIATION; SUSCEPTIBILITY; HLA; EPIDEMIOLOGY;
   INFECTION
AB In an accompanying paper (Am J Epidemiol 2002;155:1066-73), the authors describe the design of a large multicenter study being carried out in three West African countries for investigation of the roles of environmental and host-related factors in the development of tuberculosis. In this paper, the authors review some evidence that host genetic factors play a role in susceptibility to tuberculosis. They describe the three components of the study that are designed to investigate the effect of host genetic factors on the development of tuberculosis: case-control and family-based association studies of candidate genes and analysis of affected relative pairs to screen the human genome for areas of linkage to the disease. The authors also address a number of methodological issues that arise, such as the effects of consanguinity, half-siblings, and nonpaternity. Lastly, they review opportunities to assess gene-environment interaction in the framework of the study, in light of current methodological knowledge. Consideration of these issues may be useful in the design of other studies of genetic susceptibility to infectious diseases, particularly those to be carried out in developing countries.
C1 Inst Rech Dev, Dakar, Senegal.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Fajara, Gambia.
   CHU Ignace Deen, Programme Natl Lutte Anti TB, Conakry, Guinea.
   Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau.
   Minist Hlth, Natl Leprosy TB Control Programme, Banjul, Gambia.
   Univ Florence, Fac Med, Dept Internal Med, Florence, Italy.
   Hop Raoul Follereau, Bissau, Guinea Bissau.
   Wellcome Trust Ctr Mol Mech Dis, Cambridge, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
RP Lienhardt, C (reprint author), Inst Rech Dev, BP 1386, Dakar, Senegal.
RI HILL, Adrian/C-1306-2008
CR Abel L, 1998, EMERG INFECT DIS, V4, P593
   Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Bennett S, 2001, GENET EPIDEMIOL, V21, P68, DOI 10.1002/gepi.1019
   BLACKWELL JM, 1989, RES IMMUNOL, V140, P767, DOI 10.1016/0923-2494(89)90029-1
   BLACKWELL JM, 1995, MOL MED, V1, P194
   BOTHAMLEY GH, 1989, J INFECT DIS, V159, P549
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8
   Cervino ACL, 2000, AM J HUM GENET, V67, P120, DOI 10.1086/302992
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   de Jong R, 1998, SCIENCE, V280, P1435
   Garcia-Closas M, 1999, AM J EPIDEMIOL, V149, P689
   GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269
   Horvath S, 1998, AM J HUM GENET, V63, P1886, DOI 10.1086/302137
   HWANG SJ, 1994, AM J EPIDEMIOL, V140, P1029
   KHOMENKO AG, 1990, TUBERCLE, V71, P187, DOI 10.1016/0041-3879(90)90074-I
   Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   NEWPORT MJ, 1997, MYCOBACTERIAL INFECT
   North RJ, 1999, INFECT IMMUN, V67, P5811
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Siddiqui MR, 2001, NAT GENET, V27, P439, DOI 10.1038/86958
   SIMMONDS B, 1963, TUBERCULOSIS TWINS
   SINGH SPN, 1983, J INFECT DIS, V148, P676
   SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Stene LC, 2000, LANCET, V356, P73, DOI 10.1016/S0140-6736(05)73407-3
   STYBLO K, 1991, SELECTED PAPERS ROYA, V24
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D
   Weinberg CR, 2000, AM J EPIDEMIOL, V152, P197, DOI 10.1093/aje/152.3.197
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
   Yang QH, 1997, EPIDEMIOL REV, V19, P33
NR 41
TC 26
Z9 28
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2002
VL 155
IS 11
BP 1074
EP 1079
DI 10.1093/aje/155.11.1074
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 557MY
UT WOS:000175913400012
PM 12034587
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, CJ
   Alloueche, A
   McRobert, L
   Ord, R
   Leggat, J
   Snounou, G
   Pinder, M
   Targett, GAT
AF Sutherland, CJ
   Alloueche, A
   McRobert, L
   Ord, R
   Leggat, J
   Snounou, G
   Pinder, M
   Targett, GAT
TI Genetic complexity of Plasmodium falciparum gametocytes isolated from
   the peripheral blood of treated Gambian children
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLUS PYRIMETHAMINE; MALARIA; TRANSMISSION; POPULATIONS; RECOMBINATION;
   SULFADOXINE; VIRULENCE; PATTERNS; PFS16; AREA
AB The genetic complexity of Plasmodium falciparum gametocytes isolated from Gambian children participating in a controlled trial of anti-malarial therapy was investigated. RNA and DNA were prepared from gametocyte-positive blood, which was also used in transmission experiments with Anopheles gambiae mosquitoes. Amplification by a reverse transcriptase-polymerase chain reaction (RT-PCR) of transcripts from the genes for the ring-infected erythrocyte surface antigen and the 16-kD antigen, which exhibit asexual and sexual stage-specific expression, was used to identify 30 post-treatment gametocyte isolates in which trophozoites persisted below the threshold of detection by microscopy. These included isolates from children who received sulfadoxine/pyrimethamine plus artesunate. Twenty-nine gametocyte-positive isolates that were free of subpatent trophozoites were examined further by PCR amplification of polymorphic genomic loci. We estimate that an average minimum of 2.3 genotypes occurred in these gametocyte-only isolates, and many of these were shown to be infective to mosquitoes. Thus, meiotic recombination between different genotypes is predicted to be a common event in this study area.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Inst Pasteur, Unite Parasitol Bio Med, F-75015 Paris, France.
RP Sutherland, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, Keppel St, London WC1E 7HT, England.
RI Snounou, Georges/F-3352-2011
OI Snounou, Georges/0000-0002-6133-6398
CR BABIKER HA, 1994, PARASITOLOGY, V109, P413
   Babiker HA, 1999, MOL BIOCHEM PARASIT, V99, P143, DOI 10.1016/S0166-6851(98)00175-3
   BAKER DA, 1994, PARASITOLOGY, V108, P129
   Contamin H, 1996, AM J TROP MED HYG, V54, P632
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Daubersies P, 1996, AM J TROP MED HYG, V54, P18
   Drakeley CJ, 2000, ANN TROP MED PARASIT, V94, P399
   Farnert A, 1997, AM J TROP MED HYG, V56, P538
   FAVALORO JM, 1986, NUCLEIC ACIDS RES, V14, P8265, DOI 10.1093/nar/14.21.8265
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Hayward RE, 1999, P NATL ACAD SCI USA, V96, P4563, DOI 10.1073/pnas.96.8.4563
   JANSE CJ, 1993, PARASITOL TODAY, V9, P19, DOI 10.1016/0169-4758(93)90158-C
   Jarra W, 1998, INFECT IMMUN, V66, P3783
   Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0
   MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V46, P311, DOI 10.1016/0166-6851(91)90056-C
   PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897
   Robert V, 2000, AM J TROP MED HYG, V62, P210
   Rogers NJ, 2000, INFECT IMMUN, V68, P3455, DOI 10.1128/IAI.68.6.3455-3462.2000
   SHUTE PG, 1951, T ROY SOC TROP MED H, V44, P421, DOI 10.1016/S0035-9203(51)80020-8
   Smalley M E, 1981, Trans R Soc Trop Med Hyg, V75, P103
   Snounou G., 1999, T ROY SOC TROP MED H, V93, P1
   Tami A, 2002, PARASITOLOGY, V124, P569, DOI 10.1017/S0031182002001713
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   TIBAYRENC M, 1991, PARASITOL TODAY, V7, P228, DOI 10.1016/0169-4758(91)90234-F
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
NR 25
TC 13
Z9 13
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2002
VL 66
IS 6
BP 700
EP 705
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 587UB
UT WOS:000177660700012
PM 12224577
OA No
DA 2017-08-15
ER

PT J
AU Ismaili, J
   Olislagers, V
   Poupot, R
   Fournie, JJ
   Goldman, M
AF Ismaili, J
   Olislagers, V
   Poupot, R
   Fournie, JJ
   Goldman, M
TI Human gamma delta T cells induce dendritic cell maturation
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE gamma delta T cells; dendritic cells; phosphoantigens
ID BACTERIAL LIPOPOLYSACCHARIDE; LISTERIA-MONOCYTOGENES; IMMUNE-RESPONSE;
   ALPHA-BETA; IN-VIVO; INFECTION; PYROPHOSPHATE; STIMULATION; EXPRESSION;
   ACTIVATION
AB gammadelta T cells are known to be involved in the innate immune defenses against infectious microorganisms. Herein, we considered that gammadelta T cells could also influence adaptative immunity by interacting with dendritic cells (DC) in the early phase of the immune response. To investigate this hypothesis, gammadelta T cells isolated from the peripheral blood of healthy volunteers were cocultured with autologous monocyte-derived dendritic cells, which were subsequently analyzed for their expression of key surface molecules and for their production of IL-12. First, we found that gammadelta T cells induced the upregulation of HLA-DR, CD86, and CD83 on DC. This effect did not require cell to cell contact and could be blocked by a neutralizing anti-TNF antibody. We then observed that gammadeltaT cells activated by the synthetic phosphoantigen bromohydrin pyrophosphate (BrHPP) induced the production of IL-12 (p40) and IL-12 (p70) by DC, an effect that involved IFN-gamma production. The relevance of this finding to DC function was demonstrated by the increased production of IFN-gamma by alloreactive T cells when stimulated in a mixed leucocyte reaction with DC preincubated with activated gammadelta T cells. We conclude that gammadelta T cell activation might result in DC maturation and thereby in enhanced alphabeta T cell responses. (C) 2002 Eisevier Science (USA).
C1 Free Univ Brussels, Expt Immunol Lab, Brussels, Belgium.
   CHU Purpan, INSERM, U395, Toulouse, France.
RP Ismaili, J (reprint author), MRC Labs, Banjul, Gambia.
RI Fournie, jean-jacques/J-7805-2013
OI Fournie, jean-jacques/0000-0001-6542-6908
CR Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   BARNES PF, 1993, INFECT IMMUN, V61, P197
   Bendelac A, 2002, J EXP MED, V195, pF19, DOI 10.1084/jem.20020073
   de Jong EC, 2002, J IMMUNOL, V168, P1704
   DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413
   Espinosa E, 2001, J BIOL CHEM, V276, P18337, DOI 10.1074/jbc.M100495200
   FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0
   Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938
   Gonzalez-Aseguinolaza G, 2002, J EXP MED, V195, P617, DOI 10.1084/jem.20011889
   Goriely S, 2001, J IMMUNOL, V166, P2141
   HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49
   HOLOSHITZ J, 1993, INT IMMUNOL, V5, P1437, DOI 10.1093/intimm/5.11.1437
   Kato K, 2001, J LEUKOCYTE BIOL, V70, P941
   LANG F, 1995, J IMMUNOL, V154, P5986
   LECLERCQ G, 1995, J IMMUNOL, V154, P5313
   Marchant A, 1999, J IMMUNOL, V163, P2249
   MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0
   MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7
   NITTA T, 1994, J ENDOTOXIN RES, V1, P101
   OHGA S, 1990, EUR J IMMUNOL, V20, P533, DOI 10.1002/eji.1830200311
   RAZIUDDIN S, 1992, EUR J IMMUNOL, V22, P309, DOI 10.1002/eji.1830220204
   Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175
   Rescigno M, 1997, J LEUKOCYTE BIOL, V61, P415
   Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819
   Sireci G, 1997, HUM IMMUNOL, V58, P70, DOI 10.1016/S0198-8859(97)00211-5
   SKEEN MJ, 1993, J EXP MED, V178, P971, DOI 10.1084/jem.178.3.971
   Verhasselt V, 1997, J IMMUNOL, V158, P2919
NR 27
TC 102
Z9 104
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
BP 296
EP 302
DI 10.1006/clim.2002.5218
PN 1
PG 7
WC Immunology
SC Immunology
GA 565KX
UT WOS:000176370300009
PM 12173304
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Azzurri, A
   Amedei, A
   Fielding, K
   Sillah, J
   Sow, OY
   Bah, B
   Benagiano, M
   Diallo, A
   Manetti, R
   Manneh, K
   Gustafson, P
   Bennett, S
   D'Elios, MM
   McAdam, K
   Del Prete, G
AF Lienhardt, C
   Azzurri, A
   Amedei, A
   Fielding, K
   Sillah, J
   Sow, OY
   Bah, B
   Benagiano, M
   Diallo, A
   Manetti, R
   Manneh, K
   Gustafson, P
   Bennett, S
   D'Elios, MM
   McAdam, K
   Del Prete, G
TI Active tuberculosis in Africa is associated with reduced Th1 and
   increased Th2 activity in vivo
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE tuberculosis; Th1/Th2 activity; lymphocyte activation gene-3 (LAG-3);
   IgE; soluble CD30
ID CD4(+) T-CELLS; IFN-GAMMA PRODUCTION; INTERFERON-GAMMA;
   MYCOBACTERIUM-TUBERCULOSIS; CHEMOKINE PRODUCTION; CD30 EXPRESSION; SERUM
   IGE; IN-VITRO; RESPONSES; HELPER
AB Activation of Th1 lymphocytes, IFN-gamma production and macrophage activation are crucial in defense against Mycobacteria. In developing countries, Th2 activation and IL-4 production have been associated in vitro with tuberculosis and with poor clinical outcome after treatment. Serological markers of Th1 [soluble lymphocyte activation gene (LAG)-3] and Th2 (IgE, soluble CD30, and CCL22/macrophage-derived chemokine) activity were measured in 414 HIV-negative tuberculosis patients from The Gambia and Guinee and in 414 healthy household and community controls. Measurements were repeated during treatment to assess the effect of therapy on Th1/Th2 ratio. At diagnosis, sLAG-3 levels were lower in patients than in community controls (p<0.0001), but were higher in household controls exposed to contact with patients than in community controls (p<0.0001). In comparison with community controls, patients had consistently higher levels of IgE, sCD30, and CCL22 (p<0.0001), whereas household controls had lower levels of indicators of Th2 activity (P<0.0001). After treatment, cured patients had higher levels of Th1 (p<0.0001) and lower levels of Th2 (p<0.0001) activity than patients who were not successfully treated or interrupted therapy. In Africa, tuberculosis is associated with low Th1 and high Th2 activity in vivo, whereas close exposure to tuberculosis is associated with a high Th1/Th2 ratio. Patients with favorable outcome after treatment exhibit a higher Th1/Th2 ratio compared to patients with poor clinical outcome.
C1 Univ Florence, Dept Internal Med, I-50134 Florence, Italy.
   MRC Labs, Fajara, Gambia.
   Inst Rech Dev, Dakar, Senegal.
   London Sch Hyg & Trop Med, London WC1, England.
   Malmo Univ Hosp, Malmo, Sweden.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Copenhagen, Denmark.
RP Del Prete, G (reprint author), Univ Florence, Dept Internal Med, Viale Morgagni 85, I-50134 Florence, Italy.
RI Amedei, Amedeo/G-5378-2011
OI Amedei, Amedeo/0000-0002-6797-9343
CR Adams JFA, 1999, LANCET, V353, P2030, DOI 10.1016/S0140-6736(98)08510-9
   ALZONA M, 1995, J IMMUNOL, V154, P9
   Amedei A, 2001, EUR J IMMUNOL, V31, P1927, DOI 10.1002/1521-4141(200106)31:6<1927::AID-IMMU1927>3.0.CO;2-D
   Annunziato F, 1996, FASEB J, V10, P769
   Bentwich Z, 1999, IMMUNOL TODAY, V20, P485, DOI 10.1016/S0167-5699(99)01499-1
   Bonecchi R, 1998, BLOOD, V92, P2668
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918
   COOPER AM, 1993, J EXP MED, V178, P2249
   Das G, 1999, CLIN EXP IMMUNOL, V115, P324, DOI 10.1046/j.1365-2249.1999.00755.x
   DElios MM, 1997, J LEUKOCYTE BIOL, V61, P539
   DELPRETE G, 1995, FASEB J, V9, P81
   DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300
   Doffinger R, 2000, J INFECT DIS, V181, P379, DOI 10.1086/315197
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Galli G, 2000, EUR J IMMUNOL, V30, P204, DOI 10.1002/1521-4141(200001)30:1<204::AID-IMMU204>3.3.CO;2-7
   Gong JH, 1996, INFECT IMMUN, V64, P913
   Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193
   Hirsch CS, 1999, J INFECT DIS, V179, P945, DOI 10.1086/314667
   Jouanguy E, 1999, CURR OPIN IMMUNOL, V11, P346, DOI 10.1016/S0952-7915(99)80055-7
   LADEL CH, 1995, EUR J IMMUNOL, V25, P2877, DOI 10.1002/eji.1830251025
   LIENHARDT C, 2002, IN PRESS AM J EPIDEM
   Marchant A, 2001, AM J RESP CELL MOL, V24, P187
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   Nakamura T, 1997, J IMMUNOL, V158, P2090
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200
   Seah GT, 2001, SCAND J INFECT DIS, V33, P106, DOI 10.1080/003655401750065472
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   VILCEK J, 1986, J CLIN IMMUNOL, V6, P146, DOI 10.1007/BF00918747
   Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837
NR 33
TC 123
Z9 134
U1 2
U2 6
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JUN
PY 2002
VL 32
IS 6
BP 1605
EP 1613
DI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6
PG 9
WC Immunology
SC Immunology
GA 563RH
UT WOS:000176269000011
PM 12115643
OA No
DA 2017-08-15
ER

PT J
AU Koch, O
   Awomoyi, A
   Usen, S
   Jallow, M
   Richardson, A
   Hull, J
   Pinder, M
   Newport, M
   Kwiatkowski, D
AF Koch, O
   Awomoyi, A
   Usen, S
   Jallow, M
   Richardson, A
   Hull, J
   Pinder, M
   Newport, M
   Kwiatkowski, D
TI IFNGR1 gene promoter polymorphisms and susceptibility to cerebral
   malaria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; INTERFERON-GAMMA RECEPTOR; INFECTION;
   AMPLIFICATION; TRANSMISSION; IMMUNITY
AB Interferon (IFN)-gamma is a critical mediator of immunity to malaria. This study explored the relationship between polymorphisms in the promoter region of the gene encoding IFN-gamma receptor 1 (IFNGR1) and susceptibility to malaria in African children. Four polymorphisms were found in the region between -1400 and +100 nt of the translational start site by sequencing, and analysis of 562 nuclear families revealed 6 haplotypes. Case-control analysis of 562 Gambian children with severe malaria and 569 umbilical cord blood samples (controls) showed that in Mandinka, the major Gambian ethnic group, heterozygotes for the IFNGR1-56 polymorphism were protected against cerebral malaria (odds ratio, 0.54; P=.016) and against death resulting from cerebral malaria (odds ratio, 0.22; P=.006). Analysis of a family study by transmission disequilibrium testing revealed a similar result. Further data are needed to validate this finding, but these results are reminiscent of those for other well-established heterozygote advantages, such as that associated with hemoglobin S.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Oxford, Dept Pediat, Oxford OX3 7BN, England.
   MRC Labs, Fajara, Gambia.
   Royal Victoria Hosp, Banjul, Gambia.
RP Koch, O (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
RI Koch, Oliver/A-9480-2016
CR Altare F, 1998, CURR OPIN IMMUNOL, V10, P413, DOI 10.1016/S0952-7915(98)80114-3
   Amani V, 2000, EUR J IMMUNOL, V30, P1646, DOI 10.1002/1521-4141(200006)30:6<1646::AID-IMMU1646>3.0.CO;2-0
   Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563
   BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526
   GREENWOOD BM, 1987, ANN TROP MED PARASIT, V81, P345
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   Merlin G, 1997, IMMUNOGENETICS, V45, P413, DOI 10.1007/s002510050223
   Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P10700, DOI 10.1073/pnas.91.22.10700
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 15
TC 69
Z9 72
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2002
VL 185
IS 11
BP 1684
EP 1687
DI 10.1086/340516
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 556LK
UT WOS:000175850800022
PM 12023780
OA No
DA 2017-08-15
ER

PT J
AU Bates, CJ
   Matthews, N
   West, B
   Morison, L
   Walraven, G
AF Bates, CJ
   Matthews, N
   West, B
   Morison, L
   Walraven, G
TI Plasma carotenoid and vitamin E concentrations in women living in a
   rural West African (Gambian) community
SO INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH
LA English
DT Article
DE carotenoids; vitamin E; tocopherol; plasma; The Gambia; West Africa;
   women; pregnancy; season; ethnic group
ID PALM OIL CAROTENOIDS; SERUM CAROTENOIDS; LUNG-CANCER; ANTIOXIDANT
   VITAMINS; DIETARY CAROTENOIDS; SEASONAL-VARIATIONS; DISEASE; TOCOPHEROL;
   POPULATION; RETINOL
AB Vitamin E and carotenoid pigments are important nutrients for the maintenance of health and protection of tissues against free radical damage. They also play a potential role in disease-risk-prediction and -protection, but little is known about their physiological and sociodemographic correlates and determinants, especially in a West African context. As part of a study of reproductive health in rural Gambian women. blood samples were obtained from 1286 women aged 15 to 54 years, living in the Farafenni area of The Gambia. Measurement of two forms of vitamin E and six carotenoids in plasma was performed by high performance liquid chromatography. All eight components, but especially the carotenoids: lycopene, alpha- and P-carotene, exhibited a major seasonal variation, with maximum levels between May and July, corresponding to the end of the "mango" season and the beginning of the "rainy" season. Only the tocopherols varied significantly (increasiner) with age. Several unexpected ethnic group differences were observed, and canthaxanthin was present at lower concentrations in women with manual occupations, compared to those with non-manual occupations. There were also significant differences associated with pregnancy and the postpartum period, especially for the tocopherols, but fewer differences associated with marital status. The observed patterns confirm that there are important seasonal, physiological, possibly genetic, and sociodemographic determinants of these nutrients in blood plasma, which may have significance for health and longevity.
C1 MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   Farafenni & Fajara, Med Res Council Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Bates, CJ (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
RI Morison, Linda/H-9738-2013
CR ADAMSCAMPBELL LL, 1992, J NUTR BIOCHEM, V3, P58, DOI 10.1016/0955-2863(92)90091-V
   BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   BATES CJ, 1984, T ROY SOC TROP MED H, V78, P814, DOI 10.1016/0035-9203(84)90028-2
   BATES CJ, 1983, P NUTR SOC, V42, P65, DOI 10.1079/PNS19830008
   Bertram JS, 1999, NUTR REV, V57, P182
   Cooper DA, 1999, NUTR REV, V57, P133
   Cooper DA, 1999, NUTR REV, V57, P201
   ESTERBAUER H, 1991, ANN MED, V23, P573, DOI 10.3109/07853899109150520
   Finch S., 1998, NATL DIET NUTR SURVE, V1
   Ford Earl S., 2000, Ethnicity and Disease, V10, P208
   Ford ES, 1999, AM J EPIDEMIOL, V150, P290
   Gregory J, 1990, DIET NUTR SURVEY BRI
   Gregory J., 2000, NATL DIET NUTR SURVE
   Heber D, 2000, AM J CLIN NUTR, V72, P901
   Kritchevsky SB, 2000, AM J EPIDEMIOL, V152, P1065, DOI 10.1093/aje/152.11.1065
   Lietz G, 2001, AM J CLIN NUTR, V74, P501
   MCGREGOR IA, 1976, OIKOS, V27, P180, DOI 10.2307/3543897
   Mercadante AZ, 1997, J AGR FOOD CHEM, V45, P120, DOI 10.1021/jf960276j
   Michaud DS, 2000, AM J CLIN NUTR, V72, P990
   Nagata C, 1999, BRIT J CANCER, V81, P1234, DOI 10.1038/sj.bjc.6690834
   NG JH, 1988, J CHROMATOGR SCI, V26, P463
   Olmedilla B, 2001, BRIT J NUTR, V85, P227, DOI 10.1079/BJN2000248
   Packer L., 1993, VITAMIN E HLTH DIS
   Rock CL, 1999, J NUTR, V129, P855
   Rock CL, 1997, AM J CLIN NUTR, V65, P844
   SLATTERY ML, 1995, J AM COLL NUTR, V14, P635
   Thurnham DI, 1997, P NUTR SOC, V56, P421, DOI 10.1079/PNS19970043
   THURNHAM DI, 1986, ANN CLIN BIOCHEM, V23, P514
   THURNHAM DI, 1988, CLIN CHEM, V34, P337
   Tsubono Y, 1999, NUTR CANCER, V34, P56, DOI 10.1207/S15327914NC340108
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   van het Hof KH, 1999, J AGR FOOD CHEM, V47, P1582, DOI 10.1021/jf981091a
   VILLARD L, 1987, HUM NUTR-APPL NUTR, V41A, P135
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   WinklhoferRoob BM, 1997, CLIN CHEM, V43, P146
NR 35
TC 1
Z9 1
U1 0
U2 4
PU VERLAG HANS HUBER
PI BERN 9
PA LANGGASS-STRASSE 76, CH-3000 BERN 9, SWITZERLAND
SN 0300-9831
J9 INT J VITAM NUTR RES
JI Int. J. Vitam. Nutr. Res.
PD MAY
PY 2002
VL 72
IS 3
BP 133
EP 141
DI 10.1024/0300-9831.72.3.133
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 561HT
UT WOS:000176134700003
PM 12098880
OA No
DA 2017-08-15
ER

PT J
AU Kakonge, JO
AF Kakonge, JO
TI Application of chaos theory to solving the problems of social and
   environmental decline in Lesotho
SO JOURNAL OF ENVIRONMENTAL MANAGEMENT
LA English
DT Article
DE land tenure system; overgrazing; soil erosion; land degradation;
   carrying capacity
AB This paper examines the definition of chaos theory and its use in different circumstances. The paper explains that environmental crisis is complex, chaotic and unstable and will remain so unless actions are taken to reverse the trend. It further suggests that chaos theory could be used to interpret the crisis and help identify solutions. By recommending the application of chaos theory to the environmental problems in Lesotho, the paper explores some of the key issues that contribute to and perpetuate the environmental situation, for example, the current land tenure system and the problem of overgrazing. In addition, it identifies appropriate and realistic government policies that could be implemented to address the environmental degradation in the country. The paper concludes that the application of chaos theory may be unable to help solve the environmental crisis in Lesotho unless there is political will and commitment and collective effort from all stakeholders, coupled with an attitudinal change. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 United Nations Dev Programme, Banjul, Gambia.
RP Kakonge, JO (reprint author), United Nations Dev Programme, POB 553, Banjul, Gambia.
EM john.o.kakonge@undp.org
CR AGNEW CT, 1995, PEOPLE ENV AFRICA
   ALLEN PM, 1993, MODELLING COMPLEXITY
   Ghai D., 1995, GRASSROOTS ENV ACTIO
   GIRT J, 1990, DRYLAND MANAGEMENT E
   *GOV LES, 1994, BUR STAT LES AGR SIT
   *GOV LES, 1988, NAT CONS PLAN LES CO
   *GOV LES, 1992, NAT PAP UN C ENV DEV
   *GOV LES, 1986, BUR STAT POP CENS AN, V3
   *GOV LES, 1989, NAT ENV ACT PLAN
   *GOV LES, 1986, LES EN MAST PLAN
   *IUCN, 1991, INT UN CONS NAT NAT
   KAKONGE JO, 1999, HDB ENV IMPACT ASSES
   MCLEOD GA, 1988, CERTIFICATE GEOGRAPH
   MOTSAMI B, 1988, INT C ENV DEV LES HE
   *NAT ENV SECR, 1999, STAT ENV LES
   NORSTROM K, 1988, UNPUB GULLY EROSION
   READ PL, 1993, NATURE CHAOS
   RENGASAMY S, 1999, PLA NOTES, V34
   Sardar Z, 1999, INTRO CHAOS
   *SECH CONS, 1995, LES LONG JOURN
   STROMQUIST L, 1988, 68 UNGI UPPS U
   STROMQUIST L, 1986, 64 UNGI UPPS U
   *UNDP, 1993, UNPUB REV AN LAND TE
   *UNDP, 1995, UNPUB POV ENV STUD
   WITZCH G, 1992, LESOTHO ENV ENV LAW
NR 25
TC 1
Z9 1
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0301-4797
EI 1095-8630
J9 J ENVIRON MANAGE
JI J. Environ. Manage.
PD MAY
PY 2002
VL 65
IS 1
BP 63
EP 78
DI 10.1006/jema.2001.0519
PG 16
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 573UJ
UT WOS:000176849600005
PM 12173423
OA No
DA 2017-08-15
ER

PT J
AU Aucan, C
   Walley, AJ
   Greenwood, BM
   Hill, AVS
AF Aucan, C
   Walley, AJ
   Greenwood, BM
   Hill, AVS
TI Haptoglobin genotypes are not associated with resistance to severe
   malaria in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; haptoglobin; gene polymorphisms;
   pathogenesis; The Gambia
ID FALCIPARUM-MALARIA; POLYMORPHISM; MORTALITY; AFRICA
AB The influence of haptoglobin polymorphisms on severe malaria occurrence was assessed in 1183 individuals from The Gambia. No significant association was found between severe malaria and either haptoglobin genotypes or phenotypes. The advantages of using a deoxyribomicleic acid-based haptoglobin typing method are discussed.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   London Sch Hyg & Trop Med, London WC1B 3DP, England.
   MRC Labs, Banjul, Gambia.
RP Aucan, C (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
RI HILL, Adrian/C-1306-2008
OI Walley, Andrew/0000-0001-7707-7549
CR BOREHAM PFL, 1981, T ROY SOC TROP MED H, V75, P193, DOI 10.1016/0035-9203(81)90316-3
   Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009
   Elagib AA, 1998, T ROY SOC TROP MED H, V92, P309, DOI 10.1016/S0035-9203(98)91025-2
   HILL AVS, 1987, T ROY SOC TROP MED H, V81, P573, DOI 10.1016/0035-9203(87)90412-3
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1986, AM J HUM GENET, V38, P382
   HURT N, 1994, T ROY SOC TROP MED H, V88, P182, DOI 10.1016/0035-9203(94)90287-9
   Kasvosve I, 2000, INT J TUBERC LUNG D, V4, P771
   Langlois MR, 1996, CLIN CHEM, V42, P1589
   Louagie HK, 1996, J HEPATOL, V25, P10, DOI 10.1016/S0168-8278(96)80321-7
   Quaye IKE, 2000, T ROY SOC TROP MED H, V94, P216, DOI 10.1016/S0035-9203(00)90281-5
   ROUGEMONT A, 1988, LANCET, V2, P709
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P430, DOI 10.1016/0035-9203(85)90053-7
   TRAPE JF, 1988, AM J EPIDEMIOL, V127, P1282
   Yano A, 1998, ACTA MED OKAYAMA, V52, P173
NR 15
TC 34
Z9 35
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 2002
VL 96
IS 3
BP 327
EP 328
DI 10.1016/S0035-9203(02)90114-8
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 579DV
UT WOS:000177161900024
PM 12174790
OA No
DA 2017-08-15
ER

PT J
AU Benn, CS
   Balde, A
   George, E
   Kidd, M
   Whittle, H
   Lisse, IM
   Aaby, P
AF Benn, CS
   Balde, A
   George, E
   Kidd, M
   Whittle, H
   Lisse, IM
   Aaby, P
TI Effect of vitamin A supplementation on measles-specific antibody levels
   in Guinea-Bissau
SO LANCET
LA English
DT Article
AB We have previously reported that vitamin A supplementation with measles vaccine at age 9 months increases measles-specific antibody concentrations In children at age 18 months compared with placebo. We examined these children when they reached age 6-8 years. Fewer vitamin A-supplemented children had non-protective antibody concentrations (p=0.0095); among children with protective antibody levels, vitamin A-supplemented children tended to have higher geometric mean antibody titres (p=0.09). Thus, simultaneous administration of vitamin A and measles vaccine at age 9 months had a long-term effect on measles-specific antibody levels and may contribute to Improved measles control In less-developed countries.
C1 State Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark.
   MRC Labs, Fajara, Gambia.
CR Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   CHEN RT, 1990, J INFECT DIS, V162, P1036
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   *UNICEF TUL U, 1998, PROGR CONTR VIT A DE
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
NR 5
TC 37
Z9 39
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 13
PY 2002
VL 359
IS 9314
BP 1313
EP 1314
DI 10.1016/S0140-6736(02)08274-0
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 541NB
UT WOS:000174989700017
PM 11965280
OA No
DA 2017-08-15
ER

PT J
AU Scherf, C
   Morison, L
   Fiander, A
   Ekpo, G
   Walraven, G
AF Scherf, C
   Morison, L
   Fiander, A
   Ekpo, G
   Walraven, G
TI Epidemiology of pelvic organ prolapse in rural Gambia, West Africa
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article
ID GENITAL PROLAPSE; WOMEN; INCONTINENCE; DYSFUNCTION; POPULATION; FLOOR;
   YOUNG; EGYPT
AB Objectives To investigate the prevalence of pelvic organ prolapse in rural Gambia.
   Design Community-based reproductive health survey.
   Population 1348 women residing in 20 villages in rural Gambia.
   Methods Health questionnaire and standard gynaecological examination to detect symptoms and signs of pelvic organ prolapse and other reproductive diseases. Association between prolapse, socio-demographic data and other morbidities was examined.
   Main outcome measures Presence and degree of pelvic organ prolapse.
   Results Out of 1067 women consenting to speculum examination 488 (46%) were found to have some degree of prolapse. In 152 women (14%) the prolapse was severe enough to warrant surgical intervention. After adjustment for confounders the likelihood of pelvic organ prolapse increased with parity and age and was higher in women of the Wolof tribe, pregnant women, those with insufficient perineum, and moderately and severely anaemic women. Only 13% of women with moderate or severe prolapse reported symptoms on direct questioning.
   Conclusions Pelvic organ prolapse has a high prevalence in this first community-based study of prolapse in West Africa. Many of those affected did not complain about their problem, thus increasing the large, silent burden of reproductive morbidity in this population. Parity was confirmed to be the strongest risk factor followed by age and anaemia. Ethnic origin was a previously unknown risk factor suggesting possible genetic factors in the pathogenesis of prolapse.
C1 Univ Wales Coll Cardiff, Coll Med, Dept Obstet & Gynaecol, Cardiff CF1 3NS, S Glam, Wales.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Farafenni Field Stn, Banjul, Gambia.
RP Scherf, C (reprint author), Chelsea & Westminster Hosp, Dept Obstet & Gynaecol, 396 Fulham Rd, London SW10 9NH, England.
RI Morison, Linda/H-9738-2013
CR BANG RA, 1989, LANCET, V1, P85
   Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0
   Chiaffarino F, 1999, EUR J OBSTET GYN R B, V82, P63, DOI 10.1016/S0301-2115(98)00175-4
   Dia A, 1991, Dakar Med, V36, P39
   Handa VL, 1996, OBSTET GYNECOL, V88, P470, DOI 10.1016/0029-7844(96)00151-2
   LUKMAN Y, 1995, E AFR MED J, V72, P2
   Mant J, 1997, BRIT J OBSTET GYNAEC, V104, P579, DOI 10.1111/j.1471-0528.1997.tb11536.x
   NORTON PA, 1995, OBSTET GYNECOL, V85, P225, DOI 10.1016/0029-7844(94)00386-R
   Olsen AL, 1997, OBSTET GYNECOL, V89, P501, DOI 10.1016/S0029-7844(97)00058-6
   OTUBU JA, 1982, E AFR MED J, V59, P605
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Samuelsson EC, 1999, AM J OBSTET GYNECOL, V180, P299, DOI 10.1016/S0002-9378(99)70203-6
   SPENCEJONES C, 1994, BRIT J OBSTET GYNAEC, V101, P147, DOI 10.1111/j.1471-0528.1994.tb13081.x
   Strohbehn K, 1997, OBSTET GYNECOL, V90, P33, DOI 10.1016/S0029-7844(97)00218-4
   Swift SE, 2000, AM J OBSTET GYNECOL, V183, P277, DOI 10.1067/mob.2000.107583
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   *WORLD BANK, 1993, WOLRD DEV REP
   YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232
   ZURAYK H, 1995, STUD FAMILY PLANN, V26, P14, DOI 10.2307/2138047
NR 19
TC 20
Z9 22
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1470-0328
J9 BJOG-INT J OBSTET GY
JI BJOG
PD APR
PY 2002
VL 109
IS 4
BP 431
EP 436
AR PII S1470-0328(02)01109-6
DI 10.1111/j.1471-0528.2002.01109.x
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 614YX
UT WOS:000179220000012
PM 12013164
OA No
DA 2017-08-15
ER

PT J
AU Enwere, GC
AF Enwere, GC
TI Appropriate definition of hypoxaemia needed to determine its clinical
   correlates
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Letter
ID RESPIRATORY-TRACT INFECTION; HYPOXEMIA; PREDICTORS; CHILDREN
C1 MRC Labs, Banjul, Gambia.
RP Enwere, GC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR DYKE T, 1994, BRIT MED J, V308, P119
   ONYANGO FE, 1993, BRIT MED J, V306, P612
   Usen S, 2001, INT J TUBERC LUNG D, V5, P505
   Usen S, 1999, BRIT MED J, V318, P86
   Weber MW, 1997, ARCH DIS CHILD, V76, P310
NR 5
TC 0
Z9 0
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD APR
PY 2002
VL 6
IS 4
BP 366
EP 367
PG 2
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 537TW
UT WOS:000174776500016
PM 11936749
OA No
DA 2017-08-15
ER

PT J
AU Bowman, RJC
   Faal, H
   Jatta, B
   Myatt, M
   Foster, A
   Johnson, GJ
   Bailey, RL
AF Bowman, RJC
   Faal, H
   Jatta, B
   Myatt, M
   Foster, A
   Johnson, GJ
   Bailey, RL
TI Longitudinal study of trachomatous trichiasis in the Gambia: Barriers to
   acceptance of surgery
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID TRIAL; WOMEN
AB PURPOSE. Investigation of compliance with surgery for trachomatous trichiasis has become a priority of the World Health Organization. This study was conducted to investigate attitudes toward trichiasis and its treatment and to deter-mine the rate of surgical uptake in The Gambia.
   METHODS. A 1-year longitudinal study was performed in 190 subjects with trichiasis. Persons with major trichiasis (involving five lashes or more) were referred for surgery, and those with minor trichiasis were advised to epilate. Outcome measures included attitudes toward trichiasis and its treatment, reported barriers to surgical uptake, acceptance rates for surgery, and factors affecting acceptance.
   RESULTS. Twenty-three percent (95% confidence interval [CI] 16.5%-30.6%) Of Subjects with major trichiasis attended for surgery during the year. Degree of ignorance about surgery, symptoms impeding work, and a multiple income source for the head of household predicted attendance. Reported lack of time predicted nonattendance. Sixty-eight percent of patients who had undergone surgery were trichiasis free at last follow-up.
   CONCLUSIONS. Poor attendance for surgery remains a problem in The Gambia. Barriers include ignorance and lack of time and money. Health education and surgical delivery strategies are needed to overcome these barriers. Regular audit of surgical results is necessary, with retraining where indicated.
C1 Int Ctr Eye Hlth, London EC1V 9EL, England.
   Natl Eye Care Program Gambia, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Bowman, RJC (reprint author), Int Ctr Eye Hlth, 11-43 Bath St, London EC1V 9EL, England.
CR BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   Bowman RJC, 2000, TROP MED INT HEALTH, V5, P528, DOI 10.1046/j.1365-3156.2000.00605.x
   COURTRIGHT P, 1994, E AFR MED J, V71, P803
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   *GLOB IN EL AV BLI, WHO PUBL, V9761
   OLIVA MS, 1998, INT OPHTHALMOL, V21, P235
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   SHAMANNA BR, 2001, COMMUN EYE HLTH, V37, P7
   WEST S, 1994, INT OPHTHALMOL, V18, P105, DOI 10.1007/BF00919249
   *WHO, 1996, GLOB SCI M GEN SWITZ
   *WORLD HLTH ASS, 1998, GLOB IN EL AV BLINDN
NR 11
TC 31
Z9 31
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2002
VL 43
IS 4
BP 936
EP 940
PG 5
WC Ophthalmology
SC Ophthalmology
GA 536LE
UT WOS:000174700900005
PM 11923231
OA No
DA 2017-08-15
ER

PT J
AU Doherty, CP
   Weaver, LT
   Prentice, AM
AF Doherty, CP
   Weaver, LT
   Prentice, AM
TI Micronutrient supplementation and infection: A double-edged sword?
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Review
ID BLOOD MONONUCLEAR-CELLS; ZINC SUPPLEMENTATION; IRON OVERLOAD; CHILDREN;
   METABOLISM; GROWTH; SUSCEPTIBILITY; TUBERCULOSIS; HEMODIALYSIS;
   TRANSPORTER
C1 Univ Glasgow, Dept Child Hlth, Glasgow, Lanark, Scotland.
   London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC1, England.
   MRC, Keneba, Gambia.
RP Univ Glasgow, Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland.
EM cd1c@clinmed.gla.ac.uk
CR Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830
   Agranoff D, 1999, J EXP MED, V190, P717, DOI 10.1084/jem.190.5.717
   Agranoff DD, 1998, MOL MICROBIOL, V28, P403, DOI 10.1046/j.1365-2958.1998.00790.x
   AKBAR AN, 1986, J IMMUNOL, V136, P1635
   BARRY DMJ, 1977, PEDIATRICS, V60, P908
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   BREMNER I, 1995, P NUTR SOC, V54, P489, DOI 10.1079/PNS19950017
   BROCK JH, 1981, IMMUNOLOGY, V43, P387
   BROCK JH, 1986, IMMUNOLOGY, V57, P105
   BROWN KH, 1993, AM J CLIN NUTR, V58, P549
   BURKITT MJ, 1991, P NATL ACAD SCI USA, V88, P8440, DOI 10.1073/pnas.88.19.8440
   CARTWRIGHT GE, 1971, BRIT J HAEMATOL, V21, P147, DOI 10.1111/j.1365-2141.1971.tb03424.x
   CELADA A, 1979, BRIT J HAEMATOL, V43, P457, DOI 10.1111/j.1365-2141.1979.tb03773.x
   CHANDRA RK, 1984, JAMA-J AM MED ASSOC, V252, P1443, DOI 10.1001/jama.252.11.1443
   CHAVPIL M, 1977, J LAB CLIN MED, V89, P135
   CHAVPIL M, 1976, MED CLIN N AM, V60, P799
   CLOHESSY PA, 1995, SCAND J IMMUNOL, V42, P551, DOI 10.1111/j.1365-3083.1995.tb03695.x
   COUSINS RJ, 1988, FASEB J, V2, P2884
   De Voss JJ, 1999, J BACTERIOL, V181, P4443
   Doherty CP, 1998, AM J CLIN NUTR, V68, P742
   DRIESSEN C, 1994, LYMPHOKINE CYTOK RES, V13, P15
   ELIN RJ, 1977, BLOOD, V49, P147
   FAIRWEATHERTAIT SJ, 1995, P NUTR SOC, V54, P465, DOI 10.1079/PNS19950015
   FARTHING MJG, 1989, ACTA PAEDIATR SCAND, P44
   Gaetke LM, 1997, AM J PHYSIOL-ENDOC M, V272, pE952
   GOLDEN MHN, 1977, LANCET, V2, P1057
   Govoni G, 1996, INFECT IMMUN, V64, P2923
   Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343
   Hoen B, 1998, J AM SOC NEPHROL, V9, P869
   HOFFBRAND AV, 1976, BRIT J HAEMATOL, V33, P517, DOI 10.1111/j.1365-2141.1976.tb03570.x
   JENSEN SE, 1980, J BACTERIOL, V144, P844
   KELLY DA, 1987, J PEDIATR GASTR NUTR, V6, P643, DOI 10.1097/00005176-198707000-00027
   KLASING KC, 1984, AM J PHYSIOL, V247, pR901
   Kochan I, 1973, Curr Top Microbiol Immunol, V60, P1
   LENNARD ES, 1974, J SURG RES, V16, P286, DOI 10.1016/0022-4804(74)90045-6
   MCFARLANE H, 1970, BMJ-BRIT MED J, V4, P268
   MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946
   MURATA R, 1969, JPN J MED SCI BIOL, V22, P133
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   Rink L, 2000, P NUTR SOC, V59, P541, DOI 10.1017/S0029665100000781
   SAZAWAL S, 1995, NEW ENGL J MED, V333, P839, DOI 10.1056/NEJM199509283331304
   SCHLESINGER L, 1992, AM J CLIN NUTR, V56, P491
   SCHLESINGER L, 1993, ACTA PAEDIATR, V82, P734, DOI 10.1111/j.1651-2227.1993.tb12548.x
   Sempertegui F, 1996, EUR J CLIN NUTR, V50, P42
   SUGARMAN B, 1983, REV INFECT DIS, V5, P137
   TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310
   Umeta M, 2000, LANCET, V355, P2021, DOI 10.1016/S0140-6736(00)02348-5
   VANASBECK BS, 1984, J IMMUNOL, V132, P851
   WATERLOT Y, 1985, BRIT MED J, V291, P501
   Wellinghausen N, 1996, CELL IMMUNOL, V171, P255, DOI 10.1006/cimm.1996.0201
   Wellinghausen N, 1997, EUR J IMMUNOL, V27, P2529, DOI 10.1002/eji.1830271010
   Wellinghausen N, 1996, CYTOKINE, V8, P767, DOI 10.1006/cyto.1996.0102
   World Health Organization, 1999, MAN SEV MALN MAN PHY
   Zwilling BS, 1999, INFECT IMMUN, V67, P1386
NR 54
TC 19
Z9 20
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-2116
EI 1536-4801
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD APR
PY 2002
VL 34
IS 4
BP 346
EP 352
DI 10.1097/00005176-200204000-00004
PG 7
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 538JW
UT WOS:000174813700004
PM 11930086
OA No
DA 2017-08-15
ER

PT J
AU Deen, JL
   Walraven, GEL
   von Seidlein, L
AF Deen, JL
   Walraven, GEL
   von Seidlein, L
TI Increased risk for malaria in chronically malnourished children under 5
   years of age in rural gambia
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID NUTRITIONAL-STATUS; MORBIDITY; COMMUNITY; AFRICA
AB Malaria and malnutrition cause high morbidity and mortality in rural sub-Saharan Africa. To explore the relationship between nutritional status and malaria, a cohort of Gambian children under 5 years of age was followed weekly during one malaria season. Anthropometric measurements were made at the beginning and at the end of the season. A total of 55/107 (51.4 per cent) children with baseline stunting, defined as having a height-for-age z-score below -2 standard deviations, subsequently experienced malaria episodes, compared to 145/380 (38.2 per cent) children who were not stunted (RR = 1.35; 95 per cent CI, 1.08-1.69; p value = 0.01). Neither wasting (weight-for-height z-score below -2 standard deviations) nor undernutrition (weight-for-age z-score below -2 standard deviations) influenced susceptibility to malaria. Adjustment for characteristics of age, sex, and ethnicity did not significantly change the risk ratios. Malaria had no effect on the nutritional status from the beginning to the end of the malaria season. Our findings suggest that chronically malnourished children may be at higher risk for developing malaria episodes.
C1 MRC Labs, Farafenni Field Stn, Fajara, Gambia.
RP von Seidlein, L (reprint author), Int Vaccine Inst, Kwanak POB 14, Seoul 151600, South Korea.
CR ASHWORTH A, 1991, DIS MORTALITY SUBSAH, P122
   BRADLEYMOORE AM, 1985, ANN TROP MED PARASIT, V79, P575
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   DALLESANDRO U, 1995, LANCET, V345, P479
   ELSAMANI FZ, 1987, J TROP MED HYG, V90, P69
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HENDRICKSE RG, 1971, ANN TROP MED PARASIT, V65, P1
   Ibrahim MM, 1998, ANN TROP PAEDIATR, V18, P145
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   Man WDC, 1998, TROP MED INT HEALTH, V3, P678
   McGregor IA, 1991, DIS MORTALITY SUBSAH, P306
   Ota MOC, 2000, AIDS, V14, P435, DOI 10.1097/00002030-200003100-00018
   Poskitt EME, 1999, ARCH DIS CHILD, V80, P115
   ROWLAND MGM, 1997, BR J NUTR, V37, P441
   SCHIFF C, 1996, T ROY SOC TROP MED H, V90, P262
   SMITH PG, 1996, FIELD TRIALS HLTH IN, P157
   SNOW RW, 1991, T ROY SOC TROP MED H, V85, P584, DOI 10.1016/0035-9203(91)90351-X
   SNOW RW, 1999, B WORLD HEALTH ORGAN, V77, P617
   TOMKINS AM, 1989, T ROY SOC TROP MED H, V83, P282, DOI 10.1016/0035-9203(89)90681-0
   Tonglet R, 1999, TROP MED INT HEALTH, V4, P120, DOI 10.1046/j.1365-3156.1999.00366.x
   World Health Organization, 1995, WHO TECHN REP SER, V854
NR 21
TC 44
Z9 45
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD APR
PY 2002
VL 48
IS 2
BP 78
EP 83
DI 10.1093/tropej/48.2.78
PG 6
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 544MB
UT WOS:000175163200004
PM 12022433
OA No
DA 2017-08-15
ER

PT J
AU Emerson, PM
   Lindsay, SW
   Walraven, GEL
   Dibba, SM
   Lowe, KO
   Bailey, RL
AF Emerson, PM
   Lindsay, SW
   Walraven, GEL
   Dibba, SM
   Lowe, KO
   Bailey, RL
TI The flies and eyes project
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE trachoma prevention; flies; Musca sorbens; SAFE strategy; sanitation;
   latrines; underdeveloped countries; The Gambia
ID TRACHOMA; EPIDEMIOLOGY; SIMULATION; TANZANIA; RISK
AB The Flies and Eyes project is a community-based, cluster-randomised, intervention trial based in a rural area of The Gambia. It was designed to prove whether flies are mechanical vectors of trachoma; to quantify the relative importance of flies as vectors of trachoma and to test the effectiveness of insecticide spraying and the provision of latrines in trachoma control. A total Of 21 clusters, each composed Of 300-550 people, are to be recruited in groups of three. One cluster from each group is randomly allocated to receive insecticide spraying, one to receive pit latrines and the remaining to act as a control. The seven groups of clusters are recruited on a step-wise basis separated by two months to aid logistics and allow all seasons to be covered. Standardised, validated trachoma surveys are conducted for people of all ages and both sexes at baseline and six months post intervention. The Muscid fly population is monitored using standard traps and fly-eye contact is measured with catches of flies direct from children's faces. The Flies and Eyes project has been designed to strengthen the evidence base for the 'E' component of the SAFE strategy for trachoma control. The results will assist programme planners and country co-ordinators to make informed decisions on the environmental aspects of trachoma control.
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
   Univ Durham, Durham, England.
   Natl Eye Care Programme, Banjul, Gambia.
RP Emerson, PM (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
CR Bowman RJC, 2000, EYE, V14, P864
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Briggs AH, 1999, STAT MED, V18, P3245, DOI 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2
   COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   Crosskey R. W., 1993, MED INSECTS ARACHNID
   CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1
   DINWOODY C, 1996, PRINCIPLES COST BENE
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   EMERSON PM, 2000, TROP MED INT HEALTH, V5, P250
   GROUP WB, 1996, WORLD DEV REPORT
   Hafez M., 1941, B SOC FOUAD IER ENT, V25, P99
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P83
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P275
   Jan S, 2000, HEALTH ECON, V9, P631, DOI 10.1002/1099-1050(200010)9:7<631::AID-HEC531>3.0.CO;2-N
   JONES BR, 1980, T OPHTHAL SOC UK, V100, P25
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   LUNA EJA, 1992, INT J EPIDEMIOL, V21, P169, DOI 10.1093/ije/21.1.169
   MAU RFL, 1978, ANN ENTOMOL SOC AM, V71, P635
   Munoz B, 1997, EPIDEMIOL REV, V19, P205
   Pont A.C., 1991, Fauna of Saudi Arabia, V12, P312
   Pruss A, 2000, B WORLD HEALTH ORGAN, V78, P258
   Raikou M, 2000, HEALTH ECON, V9, P191, DOI 10.1002/(SICI)1099-1050(200004)9:3<191::AID-HEC510>3.0.CO;2-1
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   TIELSCH JM, 1988, AM J TROP MED HYG, V38, P393
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   [Anonymous], 1997, 1 M WHO ALL GLOB EL
   Zerihun N, 1997, TROP MED INT HEALTH, V2, P1115, DOI 10.1046/j.1365-3156.1997.d01-211.x
   Zimin LS, 1948, OPRED FAUNA USSR, V28, P1
   ZUMPT F, 1956, EXPLORATION PARC NAT
NR 32
TC 10
Z9 10
U1 1
U2 3
PU SWETS ZEITLINGER PUBLISHERS
PI LISSE
PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS
SN 0928-6586
J9 OPHTHALMIC EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2002
VL 9
IS 2
BP 105
EP 117
DI 10.1076/opep.9.2.105.1522
PG 13
WC Ophthalmology
SC Ophthalmology
GA 606EY
UT WOS:000178722200003
PM 11821976
OA No
DA 2017-08-15
ER

PT J
AU McConkey, SJ
AF McConkey, SJ
TI Case series of acute abdominal surgery in rural Sierra Leone
SO WORLD JOURNAL OF SURGERY
LA English
DT Article
AB In many poor countries of the world the need for surgical treatment:of acute abdominal emergencies is largely unmet. In some cases this service is provided by physicians with little postgraduate surgical training, and there is a paucity of published data on the outcomes of this service. This series of sequential cases of acute abdominal surgical emergencies from a hospital in rural Sierra Leone illustrates the causes, outcomes, and challenges in this setting. All patients with an acute abdomen from September 1992 until September 1994 who required surgery were identified by review of theater records, ward books, and patients' notes. Altogether, 173 cases were identified. Operative diagnoses included ectopic pregnancy (n = 43), strangulated hernia (n = 45) 15 of which required bowel resection, appendicitis (n = 15), normal appendix (n = 4), uterine rupture (n 9), perforated ulcer (n = 8), tubal or pelvic abscess (n = 7), volvulus (n 6), and others. Ninety percent survived to discharge after a median postoperative stay of 9.2 days (range 7-127 days). Of the 18 deaths, 83% occurred during the first 3 days. Factors associated with poor outcome were ileal perforation due to typhoid fever and resection of bowel after a strangulated hernia. These results show that acute abdominal surgery can be done at the district level in poor countries using limited facilities by staff without extensive surgical training. The outcomes are comparable to those from larger centers.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
RP McConkey, SJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
CR BADOE E A, 1968, West African Medical Journal and Nigerian Practitioner, V17, P194
   BANG RA, 1989, LANCET, V1, P85
   DEAN AD, 1990, EPI INFO VERSION 5 W, P1
   Goldner T E, 1993, MMWR CDC Surveill Summ, V42, P73
   LONGOMBE AO, 1994, TROP DOCT, V24, P90
   Naaeder S B, 1993, West Afr J Med, V12, P82
   SOLANKE T F, 1968, West African Medical Journal and Nigerian Practitioner, V17, P191
   WRIGHT DH, 1967, J PEDIATR-US, V71, P264, DOI 10.1016/S0022-3476(67)80086-6
   1995, MMMWR MORB MORTAL WK, V44, P46
NR 9
TC 25
Z9 26
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0364-2313
J9 WORLD J SURG
JI World J.Surg.
PD APR
PY 2002
VL 26
IS 4
BP 509
EP 513
DI 10.1007/s00268-001-0258-2
PG 5
WC Surgery
SC Surgery
GA 539MD
UT WOS:000174873200021
PM 11910489
OA No
DA 2017-08-15
ER

PT J
AU Ezedani, E
   Chukwuemeka, B
   Egbuchulem, VP
AF Ezedani, E
   Chukwuemeka, B
   Egbuchulem, VP
TI Concurrent herbal extract-pyrimethamine regimen substantially abolishes
   intra-seasonal relapse of P. vivax and P. ovale malaria
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 New Era Sch, Pharmacol Programme, Serre Kunda, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 20
PY 2002
VL 16
IS 4
BP A178
EP A178
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 533MG
UT WOS:000174533600990
OA No
DA 2017-08-15
ER

PT J
AU Bowman, RJC
   Faal, H
   Myatt, M
   Adegbola, R
   Foster, A
   Johnson, GJ
   Bailey, RL
AF Bowman, RJC
   Faal, H
   Myatt, M
   Adegbola, R
   Foster, A
   Johnson, GJ
   Bailey, RL
TI Longitudinal study of trachomatous trichiasis in the Gambia
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CONTROLLED TRIAL; SURGERY; AZITHROMYCIN
AB Aim: Investigation of the natural history of trachomatous trichiasis in the Gambia and of the outcome of self epilation and surgery for the condition.
   Methods: A 1 year longitudinal study of 190 subjects with trichiasis was performed. Major trichiasis cases (five lashes or more) were referred for surgery and minor trichiasis cases were advised to epilate. Outcome measures included progression of trichiasis and corneal scarring; attendance for and results of surgery.
   Results: 34 of 148 (23%, 95% CI 16 to 31) subjects with major trichiasis attended for surgery over the year. Progression from minor to major trichiasis occurred in 18 of 55 subjects (33%, 95% CI 21 to 47). Progression of corneal scarring occurred in 60 of 167 patients (36%, 95% CI 29 to 44). Clinically active trachoma and conjunctival bacterial isolation predicted progression of corneal opacity. Surgery was successful in 39 of 54 (72%) eyes.
   Conclusions: Despite the overall decline in trachoma in the Gambia, patients with both minor and major trichiasis remain at risk of developing corneal opacity. Active trachomatous inflammation and additional infection with bacteria may accelerate this process. Antibiotic treatment for trichiasis patients (in addition to surgery) should be investigated. Surgery for minor trichiasis may be indicated. Regular audit of surgical results is necessary with retraining where needed.
C1 Int Ctr Eye Hlth, London EC1V 9EL, England.
   Natl Eye Care Program Gambia, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Bowman, RJC (reprint author), Int Ctr Eye Hlth, 11-43 Bath St, London EC1V 9EL, England.
CR BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   Bowman RJC, 2001, OPHTHALMOLOGY, V108, P2219, DOI 10.1016/S0161-6420(01)00645-5
   CHEM KC, 1999, BR J OPHTHALMOL, V83, P1332
   COURTRIGHT P, 1994, E AFR MED J, V71, P803
   DAWSON CR, GUIDE TRACHOMA CONTR
   DETELS R, 1966, AM J EPIDEMIOL, V84, P81
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Girard AE, 1996, J ANTIMICROB CHEMOTH, V37, P9
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   JONES BR, 1976, BRIT J OPHTHALMOL, V60, P492, DOI 10.1136/bjo.60.7.492
   Khandekar R, 2001, Ophthalmic Epidemiol, V8, P155, DOI 10.1076/opep.8.2.155.4165
   OLIVA MS, 1998, INT OPHTHALMOL, V21, P235
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   *WHO, 1998, 5111 WHA WHO
   *WHO, 1996, GOB SCI M GEN WHO 17
   World Health Organization, WHOPBL9761
NR 19
TC 38
Z9 38
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2002
VL 86
IS 3
BP 339
EP 343
DI 10.1136/bjo.86.3.339
PG 5
WC Ophthalmology
SC Ophthalmology
GA 529CK
UT WOS:000174282300024
PM 11864895
OA No
DA 2017-08-15
ER

PT J
AU Vekemans, J
   Ota, MOC
   Wang, ECY
   Kidd, M
   Borysiewicz, LK
   Whittle, H
   McAdam, KPWJ
   Morgan, G
   Marchant, A
AF Vekemans, J
   Ota, MOC
   Wang, ECY
   Kidd, M
   Borysiewicz, LK
   Whittle, H
   McAdam, KPWJ
   Morgan, G
   Marchant, A
TI T cell responses to vaccines in infants: defective IFN gamma production
   after oral polio vaccination
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE cellular immunity; infant; poliomyelitis; vaccination
ID BORDETELLA-PERTUSSIS; GUERIN VACCINATION; INTERFERON-GAMMA; INFECTION;
   MICE; INDUCTION; EXPRESSION; IMMUNITY; TYPE-1
AB The immaturity of the neonatal immune system is associated with an increased susceptibility to infections. Studies in mice indicate that neonatal immune responses are biased towards the T helper 2 type, but little is known about helper T cell responses in human newborns. In this study, the oral polio vaccine was used as a model of early immunization to investigate the capacity of young infants to develop cellular immune responses. We show that neonatal immunization with oral polio vaccine induces the production of high titres of neutralizing antibodies but reduced proliferative and IFNgamma responses to polio antigens compared to immune adults. These data suggest that specific strategies will be required to immunize newborns against pathogens controlled by Th1 type immune responses.
C1 Free Univ Brussels, Expt Immunol Lab, B-1070 Brussels, Belgium.
   MRC Labs, Fajara, Gambia.
   Univ Wales Coll Med, Dept Med, Cardiff CF4 4XN, S Glam, Wales.
RP Vekemans, J (reprint author), Free Univ Brussels, Expt Immunol Lab, CP 615, Route Lennik 808, B-1070 Brussels, Belgium.
CR Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263
   Adkins B, 2001, J Immunol, V166, P918
   Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   Ausiello CM, 1997, INFECT IMMUN, V65, P2168
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   BURCHETT SK, 1992, J INFECT DIS, V165, P813
   Douek DC, 1998, NATURE, V396, P690
   Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728
   Goriely S, 2001, J IMMUNOL, V166, P2141
   GRAHAM S, 1993, J VIROL, V67, P1627
   INABA K, 1993, J EXP MED, V178, P479, DOI 10.1084/jem.178.2.479
   MAHON BP, 1995, J EXP MED, V181, P1285, DOI 10.1084/jem.181.4.1285
   Mahon BP, 1996, INFECT IMMUN, V64, P5295
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Ryan M, 1997, J INFECT DIS, V175, P1246
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Sutter RW, 1999, VACCINES, P364
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   [Anonymous], 1997, MAN VIR INV POL
NR 19
TC 51
Z9 51
U1 0
U2 5
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAR
PY 2002
VL 127
IS 3
BP 495
EP 498
DI 10.1046/j.1365-2249.2002.01788.x
PG 4
WC Immunology
SC Immunology
GA 548KJ
UT WOS:000175386900013
PM 11966766
OA No
DA 2017-08-15
ER

PT J
AU Lee, EAM
   Palmer, DR
   Flanagan, KL
   Reece, WHH
   Odhiambo, K
   Marsh, K
   Pinder, M
   Gravenor, MB
   Keitel, WA
   Kester, KE
   Diggs, C
   Kaslow, D
   Apostolopoulos, V
   Ballou, WR
   Hill, AVS
   Krzych, U
   Plebanski, M
AF Lee, EAM
   Palmer, DR
   Flanagan, KL
   Reece, WHH
   Odhiambo, K
   Marsh, K
   Pinder, M
   Gravenor, MB
   Keitel, WA
   Kester, KE
   Diggs, C
   Kaslow, D
   Apostolopoulos, V
   Ballou, WR
   Hill, AVS
   Krzych, U
   Plebanski, M
TI Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite
   surface protein 1 in vaccinated healthy volunteers and adults naturally
   exposed to malaria
SO INFECTION AND IMMUNITY
LA English
DT Article
ID HUMORAL IMMUNE-RESPONSES; B-CELL EPITOPES; PLASMODIUM-FALCIPARUM;
   TERMINAL FRAGMENT; DISULFIDE BONDS; BLOOD STAGES; ANTIGEN; ANTIBODIES;
   AFRICANS; HUMANS
AB Plasmodium falciparum malaria is a major cause of death in the tropics. The 19-kDa subunit of P. falciparum merozoite surface protein I (MSP-1(19)), a major blood stage vaccine candidate, is the target of cellular and humoral immune responses in animals and humans. In this phase I trial of MSP-119, immunization of nonexposed human volunteers with either of the two allelic forms of recombinant MSP-1(19) induced high levels of antigen-specific Th1 (gamma interferon) and Th2 (interleukin 4 [IL-4] and IL-10) type lymphokines. The adjustment of the antigen dose and number of immunizations regulated the level of specificity of immune responses and Th1/Th2 bias of responses induced by vaccination. Novel conserved and allelic T-cell epitopes which induced cross-strain immune responses were identified. Importantly, responses to many of these novel epitopes were also present in adults exposed to malaria, both in east (Kenya) and west Africa (The Gambia). These data suggest that epitope-specific naturally acquired MSP-1(19) immune responses in endemic populations can be boosted by vaccination.
C1 Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Med,Mol Immunol Grp, Oxford OX3 9DU, England.
   Inst Anim Hlth, Compton RG20 7NN, Berks, England.
   Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Immunol, Washington, DC 20307 USA.
   US Agcy Int Dev, Malaria Vaccine Dev Program, Washington, DC 20523 USA.
   Kilifi Dist Hosp, KEMRI Ctr Geog Med Res Coast, Kilifi, Kenya.
   MRC Labs, Banjul, Gambia.
   Baylor Coll Med, Dept Mol Virol & Microbiol & Med, Houston, TX 77030 USA.
   NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Lee, EAM (reprint author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Med,Mol Immunol Grp, Oxford OX3 9DU, England.
EM elee@enterprise.molbiol.ox.ac.uk
RI HILL, Adrian/C-1306-2008; Kester, Kent/A-2114-2011
OI Kester, Kent/0000-0002-5056-0802
FU NIAID NIH HHS [N01-AI-25135]
CR AlYaman F, 1996, AM J TROP MED HYG, V54, P443
   Bergmann ES, 1997, CELL IMMUNOL, V180, P143, DOI 10.1006/cimm.1997.1186
   BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633
   BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409
   Brewer JM, 1999, J IMMUNOL, V163, P6448
   COLLINS DS, 1991, J IMMUNOL, V147, P4054
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   Egan A, 1997, INFECT IMMUN, V65, P3024
   Egan AF, 1996, J INFECT DIS, V173, P765
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9
   HERRERA MA, 1992, INFECT IMMUN, V60, P154
   Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593
   HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277
   Holder AA, 1999, P NATL ACAD SCI USA, V96, P1167, DOI 10.1073/pnas.96.4.1167
   Keitel WA, 1999, VACCINE, V18, P531, DOI 10.1016/S0264-410X(99)00221-2
   Lee EAM, 2001, AM J TROP MED HYG, V64, P194
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3
   Plebanski M, 1997, PARASITOLOGY, V115, pS55
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729
   SOKAL RR, 1995, ANAL PROPORTION
   UDHAYAKUMAR V, 1995, J IMMUNOL, V154, P6022
NR 25
TC 33
Z9 34
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 2002
VL 70
IS 3
BP 1417
EP 1421
DI 10.1128/IAI.70.3.1417-1421.2002
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 522EQ
UT WOS:000173883100049
PM 11854228
OA No
DA 2017-08-15
ER

PT J
AU Reece, WHH
   Plebanski, M
   Akinwunmi, P
   Gothard, P
   Flanagan, KL
   Lee, EAM
   Cortina-Borja, M
   Hill, AVS
   Pinder, M
AF Reece, WHH
   Plebanski, M
   Akinwunmi, P
   Gothard, P
   Flanagan, KL
   Lee, EAM
   Cortina-Borja, M
   Hill, AVS
   Pinder, M
TI Naturally exposed populations differ in their T1 and T2 responses to the
   circumsporozoite protein of Plasmodium falciparum
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MALARIA ENDEMIC AREA; BERGHEI INFECTION; LEISHMANIA-MAJOR; CELLS;
   RECOGNITION; VACCINE; GAMMA; LYMPHOCYTES; PROTECTION; INTERFERON
AB T-cell responses directed against the circumsporozoite protein (CS) of Plasmodium falciparum can mediate protection against malaria. We determined the frequency of T cells reactive to different regions of the CS in the blood of donors naturally exposed to P. falciparum by examining T1 (gamma interferon ( IFN-gamma ELISPOT assay), T2 (interleukin 4 [IL-4] ELISPOT assay), and proliferative T-cell responses. The proliferative responses were weak, which confirmed previous observations. The responses to the CS in the IL-4 and IFN-gamma ELISPOT assays were also weak (<40 responding cells per 10(6) cells), much weaker than the response to the purified protein derivative of Mycobacterium tuberculosis in the same donors. Moreover, a response in one assay could not be used to predict a response in either of the other assays, suggesting that although these assays may measure different responding cells, all of the responses are weakly induced by natural exposure. Interestingly, the two different study populations used bad significantly different T1 and T2 biases in their responses in the C terminus of the protein, suggesting that the extent of P. falciparum exposure can affect regulation of the immune system.
C1 Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Med,Mol Immunol Grp, Oxford OX3 9DU, England.
   Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   MRC Labs, Fajara, Gambia.
RP Reece, WHH (reprint author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Med,Mol Immunol Grp, Oxford OX3 9DU, England.
RI HILL, Adrian/C-1306-2008; Cortina Borja, Mario/A-3847-2009
CR AlYaman F, 1997, PARASITE IMMUNOL, V19, P249, DOI 10.1046/j.1365-3024.1997.d01-204.x
   BANCROFT AJ, 1994, EUR J IMMUNOL, V24, P3113, DOI 10.1002/eji.1830241230
   Bebo BF, 1999, J IMMUNOL, V162, P35
   BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   BROWN AJ, 1997, CHARACTERIZATION POR, V4, P1
   CASPERS P, 1989, MOL BIOCHEM PARASIT, V35, P185, DOI 10.1016/0166-6851(89)90121-7
   Doherty TM, 1996, EXP PARASITOL, V84, P124, DOI 10.1006/expr.1996.0098
   DOOLAN DL, 1994, PARASITE IMMUNOL, V16, P129, DOI 10.1111/j.1365-3024.1994.tb00332.x
   ELGHAZALI G, 1995, SCAND J IMMUNOL, V42, P39, DOI 10.1111/j.1365-3083.1995.tb03623.x
   ESPOSITO F, 1992, IMMUNOL LETT, V33, P187, DOI 10.1016/0165-2478(92)90046-Q
   GLOBERSON A, 1995, INT ARCH ALLERGY IMM, V107, P491
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579
   Kurtis JD, 1999, INFECT IMMUN, V67, P3424
   LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X
   MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300
   Menon JN, 1998, EUR J IMMUNOL, V28, P4020, DOI 10.1002/(SICI)1521-4141(199812)28:12<4020::AID-IMMU4020>3.0.CO;2-3
   MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P45, DOI 10.1016/0022-1759(94)00327-S
   Moreno EC, 1991, BIOFOULING, V4, P3
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   NARDIN E, 1992, MEM I OSWALDO CRUZ S, V87, P3223
   NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283
   Paludan SR, 1998, SCAND J IMMUNOL, V48, P459
   Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P
   Reed RC, 1996, VACCINE, V14, P828, DOI 10.1016/0264-410X(95)00175-Z
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   ROMERO P, 1990, IMMUNOL LETT, V25, P27, DOI 10.1016/0165-2478(90)90086-6
   SATO K, 1995, JPN J FOOD CHEM, V2, P1
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   Vonesh EF, 1997, LINEAR NONLINEAR MOD
   Zeidner NS, 1999, PARASITE IMMUNOL, V21, P35, DOI 10.1046/j.1365-3024.1999.00199.x
NR 33
TC 14
Z9 14
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 2002
VL 70
IS 3
BP 1468
EP 1474
DI 10.1128/IAI.70.3.1468-1474.2002
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 522EQ
UT WOS:000173883100055
PM 11854234
OA No
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Ota, MO
   Yamuah, LK
   Idiong, D
   Mkpanam, SN
   Avieka, A
   Banya, WAS
   Osinusi, K
AF Okoko, BJ
   Ota, MO
   Yamuah, LK
   Idiong, D
   Mkpanam, SN
   Avieka, A
   Banya, WAS
   Osinusi, K
TI Influence of placental malaria infection on foetal outcome in the
   Gambia: Twenty years after Ian McGregor
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article; Proceedings Paper
CT 11th European Congress of Clinical Microbiology and Infectious Diseases
   (ECCMID)
CY APR 01-04, 2001
CL ISTANBUL, TURKEY
SP European Soc Clin Microbiol & Infectious Dis, European Study Grp Antimicrobial Policies
DE malaria; disease transmission; the Gambia
ID INTRAUTERINE GROWTH-RETARDATION; RURAL MALAWI; BIRTH-WEIGHT;
   PERINATAL-MORTALITY; GESTATIONAL-AGE; PREGNANCY; AFRICA
AB Malaria infection in pregnancy has serious health consequences among mothers and offspring. The influence of placental malaria infection on foetal outcome was studied in a Gambian rural setting where few pregnant women take antimalarial chemoprophylaxis. During July-December 1997, three hundred thirteen mother-newborn pairs (singletons only) were consecutively recruited into a study of the effects of placental malaria infection on the outcome of pregnancy. Placental blood and tissue were collected at delivery. Babies were clinically assessed until discharge. The overall prevalence of placental malaria infection was 51.1% by placental histology and 37.1% by blood smear. The primigravid women were more susceptible to placental malaria than the multigravidae (65.3% vs 44.7%, p=0.01). Placental malaria was significantly associated with pre-term delivery and intrauterine growth retardation (p<0.01), and there was a four-fold risk of delivering low-birth-weight babies if mothers had parasitized placentae [OR=4.42, 95% confidence interval (CI) 2.10-9.27]. A reduction of mean birth-weight of babies by 320 g was associated with placental malaria infection (p<0.001). Similarly, a two-fold risk of stillbirth delivery (OR=2.22, 95% Cl 1.04-4.72) was observed among the infected mothers. The findings showed that there was still an overall poor foetal outcome associated with placental malaria infection. The findings of this study confirm the findings of an earlier study by McGregor in the Gambia that the low birth-weight rate is significantly higher if the placenta is parasitized. In addition, this study observed that the high stillbirth and prematurity rates were associated with placental malaria infection. The findings of the present study suggest undertaking of effective malaria-control strategies during pregnancy, such as use of insecticide-impregnated bednets, intermittent and early treatment for malaria, and antimalarial chemoprophylaxis, in the Gambia.
C1 MRC Labs, Fajara, Gambia.
   Univ Coll Ibadan Hosp, Ibadan, Nigeria.
RP Okoko, BJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR BATTAGLI.FC, 1967, J PEDIATR-US, V71, P159, DOI 10.1016/S0022-3476(67)80066-0
   Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582
   Brabin B, 1997, Afr Health, V19, P19
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570
   GALBRAITH RM, 1980, T ROY SOC TROP MED H, V74, P52, DOI 10.1016/0035-9203(80)90011-5
   GARNER P, 1994, B WORLD HEALTH ORGAN, V72, P89
   GREENWOOD AM, 1994, T ROY SOC TROP MED H, V88, P311, DOI 10.1016/0035-9203(94)90094-9
   IBHANESEBHOR SE, 1992, INT J GYNECOL OBSTET, V37, P247, DOI 10.1016/0020-7292(92)90324-C
   Kulmala T, 2000, PAEDIATR PERINAT EP, V14, P219, DOI 10.1046/j.1365-3016.2000.00270.x
   LAWOYIN TO, 1991, J TROP PEDIATRICS, V37, P166
   MATEELLI A, 1996, ANN TROP MED PARASIT, V90, P125
   McDermott JM, 1996, AM J TROP MED HYG, V55, P61
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449
   Moormann AM, 1999, J INFECT DIS, V180, P1987, DOI 10.1086/315135
   Steketee RW, 1996, AM J TROP MED HYG, V55, P2
   Steketee RW, 1996, AM J TROP MED HYG, V55, P33
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   Tomlinson AJ, 1997, TROP DOCT, V27, P172
   Verhoeff FH, 2001, EUR J CLIN NUTR, V55, P682, DOI 10.1038/sj.ejcn.1601200
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
NR 25
TC 36
Z9 38
U1 0
U2 0
PU I C D D R B-CENTRE HEALTH POPULATION RESEARCH
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD MAR
PY 2002
VL 20
IS 1
BP 4
EP 11
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 548WG
UT WOS:000175412400002
PM 12022158
OA No
DA 2017-08-15
ER

PT J
AU Fox-Marsh, A
   Harrison, LC
AF Fox-Marsh, A
   Harrison, LC
TI Emerging evidence that molecules expressed by mammalian tissue grafts
   are recognized by the innate immune system
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Review
DE PAMP; macrophage; neutrophil; NK cell; complement
ID NATURAL-KILLER-CELLS; TOLL-LIKE RECEPTOR-2; PORCINE ENDOTHELIAL-CELLS;
   MACROPHAGE MANNOSE RECEPTOR; ISLET XENOGRAFT REJECTION; NONOBESE
   DIABETIC MICE; HUMAN T-LYMPHOCYTES; FETAL PIG PANCREAS; ANTI-GAL
   ANTIBODY; PATTERN-RECOGNITION
AB The innate immune system existed prior to the emergence of adaptive immunity in sharks and higher vertebrates. Homologues of many mammalian innate immune-system elements such as the toll-like receptors exist in species as distant as Drosophila. Selective pressure has led to the development of highly conserved, soluble, and cell-surface receptors that recognize functionally essential molecules shared by microbial pathogens. It is thought that molecular patterns that exquisitely distinguish pathogenic cells from mammalian cells are recognized. Therefore, it would seem unlikely that innate immune-system elements should recognize mammalian tissues. However, there is increasing evidence to suggest that this is the case and that innate immunity promotes rejection of transplanted mammalian tissues, particularly those from other species (xenografts). Evidence for innate recognition of mammamian grafts, the nature of this recognition, and the hi-directional interactions between innate and adaptive immunity that contribute to graft rejection are discussed in this review, with the emphasis on nonvascular xenografts.
C1 Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Parkville, Vic, Australia.
RP Fox-Marsh, A (reprint author), MRC Labs, Altantic Blvd,POB 273, Banjul, Gambia.
RI Tang, Amy/L-3226-2016
OI Tang, Amy/0000-0002-5772-2878; Fox, Annette/0000-0002-0565-7146
CR AlMohanna F, 1997, AM J PATHOL, V151, P111
   AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001
   BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x
   Badolato R, 2000, J LEUKOCYTE BIOL, V67, P381
   Baldwin WM, 2001, IMMUNITY, V14, P369, DOI 10.1016/S1074-7613(01)00117-0
   Bennet W, 1999, DIABETES, V48, P1907, DOI 10.2337/diabetes.48.10.1907
   Bennet W, 2000, TRANSPLANTATION, V69, P711
   Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732
   Campos MA, 2001, J IMMUNOL, V167, P416
   CELADA A, 1994, IMMUNOL TODAY, V15, P100, DOI 10.1016/0167-5699(94)90150-3
   Chaudhary PM, 1998, BLOOD, V91, P4020
   COOPER DKC, 1994, IMMUNOL REV, V141, P31, DOI 10.1111/j.1600-065X.1994.tb00871.x
   De Moraes-Vasconcelos D, 2001, CLIN EXP IMMUNOL, V123, P247, DOI 10.1046/j.1365-2249.2001.01430.x
   Denkers EY, 1998, IMMUNOLOGIST, V6, P116
   Dilulio NA, 1999, EUR J IMMUNOL, V29, P3485, DOI 10.1002/(SICI)1521-4141(199911)29:11<3485::AID-IMMU3485>3.0.CO;2-B
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50
   Fijen CAP, 2000, CLIN EXP IMMUNOL, V120, P338, DOI 10.1046/j.1365-2249.2000.01208.x
   Flo TH, 2000, J IMMUNOL, V164, P2064
   Fox A, 1998, TRANSPLANTATION, V66, P1407, DOI 10.1097/00007890-199812150-00002
   Fox A, 2000, IMMUNOL REV, V173, P141, DOI 10.1034/j.1600-065X.2000.917313.x
   Fox A, 2001, J IMMUNOL, V166, P2133
   Fox A, 2000, IMMUNOLOGIST, V8, P37
   FOX A, 2001, IN PRESS XENOTRANSPL
   Fraser IP, 1998, SEMIN IMMUNOL, V10, P363, DOI 10.1006/smim.1998.0141
   Fryer JP, 1997, XENOTRANSPLANTATION, V4, P40, DOI 10.1111/j.1399-3089.1997.tb00163.x
   Gadjeva M, 2001, CURR OPIN IMMUNOL, V13, P74, DOI 10.1016/S0952-7915(00)00185-0
   GALILI U, 1993, BLOOD, V82, P2485
   GALILI U, 1995, TRANSPLANTATION, V59, P1549, DOI 10.1097/00007890-199506150-00008
   GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155
   GHINAN I, 2000, J EXP MED, V192, P1797
   Godaly G, 2001, J LEUKOCYTE BIOL, V69, P899
   Goodman DJ, 1996, TRANSPLANTATION, V61, P763, DOI 10.1097/00007890-199603150-00016
   Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X
   Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106
   Heine H, 1999, J IMMUNOL, V162, P6971
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021
   Itescu S, 1998, HUM IMMUNOL, V59, P275, DOI 10.1016/S0198-8859(98)00026-3
   Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x
   JANEWAY CAJ, 1992, IMMUNOL TODAY, V12, P11
   JANKOVIC D, 2001, TRENDS IMMUNOL, V22, P540
   Kaiser V, 2000, J LEUKOCYTE BIOL, V68, P779
   Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1
   KarlssonParra A, 1996, TRANSPLANTATION, V61, P1313, DOI 10.1097/00007890-199605150-00005
   Koga S, 1999, J IMMUNOL, V163, P4878
   Kondo T, 2000, TRANSPLANTATION, V69, P969
   Kondo T, 1996, TRANSPLANTATION, V61, P1750, DOI 10.1097/00007890-199606270-00015
   Korsgren O, 1999, XENOTRANSPLANTATION, V6, P271, DOI 10.1034/j.1399-3089.1999.00032.x
   Krieg AM, 1998, J IMMUNOL, V161, P2428
   Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006
   Krutzik SR, 2001, CURR OPIN IMMUNOL, V13, P104, DOI 10.1016/S0952-7915(00)00189-8
   KURASHIMA C, 1991, INFECT IMMUN, V59, P216
   Lanier L L, 1995, Semin Immunol, V7, P75, DOI 10.1006/smim.1995.0011
   Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359
   Levy O, 1999, PEDIATRICS, V104, P1327, DOI 10.1542/peds.104.6.1327
   MACKANESS GB, 1969, J EXP MED, V129, P973, DOI 10.1084/jem.129.5.973
   Mackay CR, 1999, IMMUNOLOGIST, V7, P112
   Magee J C, 1994, Ther Immunol, V1, P45
   Maier S, 2001, NAT MED, V7, P557, DOI 10.1038/87880
   MANDEL TE, 1995, AM J PATHOL, V147, P834
   Mandel TE, 1997, XENOTRANSPLANTATION, V4, P2, DOI 10.1111/j.1399-3089.1997.tb00158.x
   MANGAN DF, 1989, INFECT IMMUN, V57, P3601
   Manilay JO, 1998, CURR OPIN IMMUNOL, V10, P532, DOI 10.1016/S0952-7915(98)80219-7
   MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0
   Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   Means TK, 1999, J IMMUNOL, V163, P3920
   Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5
   Medzhitov R, 1997, NATURE, V388, P394
   Millan MT, 1997, TRANSPLANTATION, V63, P421, DOI 10.1097/00007890-199702150-00016
   Morita K, 2001, J IMMUNOL, V167, P2979
   Mullighan CG, 2000, SCAND J IMMUNOL, V51, P111
   Mullin NP, 1997, J BIOL CHEM, V272, P5668
   Muzio M, 2000, J IMMUNOL, V164, P5998
   NADEAU KC, 1995, P NATL ACAD SCI USA, V92, P8729, DOI 10.1073/pnas.92.19.8729
   ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Platt JL, 1998, XENOTRANSPLANTATION, V5, P169, DOI 10.1111/j.1399-3089.1998.tb00024.x
   Risso A, 2000, J LEUKOCYTE BIOL, V68, P785
   Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588
   ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J
   ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685
   SANDBERG AL, 1995, INFECT IMMUN, V63, P2625
   SATAKE M, 1994, TRANSPLANT P, V26, P1122
   Satake Mashairo, 1994, Xenotransplantation, V1, P89, DOI 10.1111/j.1399-3089.1994.tb00054.x
   Schaapherder AFM, 1996, TRANSPLANTATION, V62, P29, DOI 10.1097/00007890-199607150-00006
   Schilling JD, 2001, J IMMUNOL, V166, P1148
   SCHMARC M, 2001, NAT IMMUNOL, V2, P947
   SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188
   Seebach JD, 1997, XENOTRANSPLANTATION, V4, P201, DOI 10.1111/j.1399-3089.1997.tb00184.x
   Seebach JD, 1997, J IMMUNOL, V159, P3655
   Sheikh S, 2000, TRANSPLANTATION, V70, P917, DOI 10.1097/00007890-200009270-00009
   Shoker AS, 1996, PHARMACOTHERAPY, V16, P562
   SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0
   STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V
   STEIN M, 1992, CLIN EXP ALLERGY, V22, P19, DOI 10.1111/j.1365-2222.1992.tb00110.x
   Sugawara S, 2001, INFECT IMMUN, V69, P4951, DOI 10.1128/IAI.69.8.4951-4957.2001
   Suzuki N, 1996, J IMMUNOL, V156, P128
   Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0
   Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   TANOUE M, 1993, INT ARCH ALLERGY IMM, V101, P47
   Taub DD, 1996, BLOOD, V87, P1423
   Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625
   THOMPSON SC, 1990, TRANSPLANTATION, V49, P571, DOI 10.1097/00007890-199003000-00019
   THORNHILL MH, 1991, J IMMUNOL, V146, P592
   Travis SM, 2001, CURR OPIN IMMUNOL, V13, P89, DOI 10.1016/S0952-7915(00)00187-4
   Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451
   Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000
   Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1
   Underhill DM, 1999, NATURE, V401, P811
   Ushio-Umeda Y, 1997, MICROBIOL IMMUNOL, V41, P981
   VERCELLOTTI GM, 1991, J IMMUNOL, V146, P730
   Wennberg L, 1997, TRANSPLANTATION, V63, P1234, DOI 10.1097/00007890-199705150-00008
   Womer KL, 2001, PHILOS T ROY SOC B, V356, P727, DOI 10.1098/rstb.2001.0852
   Wu GS, 2000, XENOTRANSPLANTATION, V7, P214, DOI 10.1034/j.1399-3089.2000.00071.x
   Yamashiro S, 2001, J LEUKOCYTE BIOL, V69, P698
   Yang RB, 1998, NATURE, V395, P284
   Yoshimura A, 1999, J IMMUNOL, V163, P1
   Yu XZ, 2001, LANCET, V357, P1959, DOI 10.1016/S0140-6736(00)05068-6
   ZIJLSTRA M, 1992, J EXP MED, V175, P885, DOI 10.1084/jem.175.4.885
NR 123
TC 8
Z9 8
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD MAR
PY 2002
VL 71
IS 3
BP 401
EP 409
PG 9
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 529BG
UT WOS:000174279700004
PM 11867677
OA No
DA 2017-08-15
ER

PT J
AU Ansell, J
   Hamilton, KA
   Pinder, M
   Walraven, GEL
   Lindsay, SW
AF Ansell, J
   Hamilton, KA
   Pinder, M
   Walraven, GEL
   Lindsay, SW
TI Short-range attractiveness of pregnant women to Anopheles gambiae
   mosquitoes
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; pregnancy; transmission; Anopheles gambiae; The Gambia
ID UNTREATED BEDNETS; MALARIA INFECTION; HUMAN PLACENTA; BIRTH-WEIGHT;
   AREA; CULICIDAE; EXPOSURE; CHILDREN; VECTORS; DIPTERA
AB Malaria is a major cause of illness and an indirect cause of mortality in pregnant women. It can also cause stillbirths and low-birthweight babies. We have shown previously that pregnant women attracted twice as many Anopheles gambiae mosquitoes, the principal African malaria vector, as their non-pregnant counterparts over distances of about 15 in. In the current study (in 1998/99) we compared the short-range attractiveness of both pregnant and non-pregnant women sleeping under untreated bednets in Gambian villages. First, we measured the rate of mosquito entry under bednets and, second, we calculated the proportion of mosquitoes biting mothers under each bednet compared to their children. The feeding preference of An. gambiae collected under nets was determined by DNA fingerprinting blood samples from human subjects sleeping under each bednet and comparing these to fingerprints obtained from mosquito bloodmeals. Pregnant women were more attractive to An. gambiae mosquitoes than nonpregnant women under an untreated bednet. The number of mosquitoes entering bednets each night was 1.7-4.5 times higher in the pregnant group (P = 0.02) and pregnant women also received a higher proportion of bites under the bednets than did non-pregnant women (70% vs 52%, P = 0.001). This study clearly demonstrates that pregnant women are more exposed to malaria parasites than other women, which contributes to the greater vulnerability of pregnant women to malaria.
C1 Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   MRC Labs, Fajara, Gambia.
RP Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.
RI Ansell, Juliet/A-7769-2014
CR Ansell J, 2000, T ROY SOC TROP MED H, V94, P572, DOI 10.1016/S0035-9203(00)90092-0
   BARKER DJP, 1990, BRIT MED J, V301, P1111
   BOGH C, 2000, THESIS U COPENHAGEN
   Brabin B, 1997, ANN HUM BIOL, V24, P547, DOI 10.1080/03014469700005312
   BRABIN BJ, 1983, POSTGRADUATE DOCTOR, V11, P57
   Braks MAH, 1999, PARASITOL TODAY, V15, P409, DOI 10.1016/S0169-4758(99)01514-8
   BRUNNER DP, 1994, SLEEP, V17, P576
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   Clements A.N., 1999, BIOL MOSQUITOES SENS
   Fried M, 1998, J IMMUNOL, V160, P2523
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   HEALY TP, 1995, MED VET ENTOMOL, V9, P331, DOI 10.1111/j.1365-2915.1995.tb00143.x
   HERTZ G, 1992, SLEEP, V15, P246
   Knols BGJ, 1996, PARASITOL TODAY, V12, P159, DOI 10.1016/0169-4758(96)10002-8
   Lee KA, 2000, OBSTET GYNECOL, V95, P14, DOI 10.1016/S0029-7844(99)00486-X
   Lindsay S, 2000, LANCET, V355, P1972, DOI 10.1016/S0140-6736(00)02334-5
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   LINES JD, 1987, MED VET ENTOMOL, V1, P37, DOI 10.1111/j.1365-2915.1987.tb00321.x
   MAIBACH HI, 1966, JAMA-J AM MED ASSOC, V196, P173
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0
   PORT GR, 1980, B ENTOMOL RES, V70, P133
   SCHWEIGER MS, 1972, AM J OBSTET GYNECOL, V114, P879
   Shulman CE, 1999, ANN TROP MED PARASIT, V93, pS59, DOI 10.1080/00034989957745
   Silver HM, 1997, INFECT DIS CLIN N AM, V11, P99, DOI 10.1016/S0891-5520(05)70344-5
   Takken W, 1997, J INSECT BEHAV, V10, P395, DOI 10.1007/BF02765606
   Takken W., 1990, Proceedings of the Section Experimental and Applied Entomology of the Netherlands Entomological Society (N.E.V.), V1, P121
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   Verhoeff FH, 1999, ANN TROP MED PARASIT, V93, pS25, DOI 10.1080/00034989957718
NR 32
TC 44
Z9 45
U1 1
U2 13
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 2002
VL 96
IS 2
BP 113
EP 116
DI 10.1016/S0035-9203(02)90271-3
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 605DW
UT WOS:000178661000001
PM 12055794
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
AF Walraven, G
TI Rural Africa
SO LANCET
LA English
DT Editorial Material
C1 MRC Labs, Farafenni Field Stn, Farafenni, Gambia.
RP Walraven, G (reprint author), MRC Labs, Farafenni Field Stn, Farafenni, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 2
PY 2002
VL 359
IS 9304
BP 401
EP 401
DI 10.1016/S0140-6736(02)07601-8
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 518UP
UT WOS:000173686500012
PM 11844512
OA No
DA 2017-08-15
ER

PT J
AU Klein, MR
   Hammond, AS
   Smith, SM
   Jaye, A
   Lukey, PT
   McAdam, KPWJ
AF Klein, MR
   Hammond, AS
   Smith, SM
   Jaye, A
   Lukey, PT
   McAdam, KPWJ
TI HLA-B*35-restricted CD8(+)-T-cell epitope in Mycobacterium tuberculosis
   Rv2903c
SO INFECTION AND IMMUNITY
LA English
DT Article
ID CLASS-I MOLECULES; CD8(+) T-CELLS; INTERFERON-GAMMA; PEPTIDES; BINDING
AB Few human CD8(+) T-cell epitopes in mycobacterial antigens have been described to date. Here we have identified a novel HLA-B*35-restricted CD8(+) T-cell epitope in Mycobacterium tuberculosis Rv2903c based on a reverse immunogenetics approach. Peptide-specific CD8 T cells were able to kill M. tuberculosis-infected macrophages and produce gamma interferon and tumor necrosis factor alpha.
C1 GlaxoSmithKline R&D, Med Res Ctr, Resp Syst, Stevenage, Herts, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Med, Immunol Unit, London WC1, England.
   MRC Labs, TB Res Programme, Fajara, Gambia.
RP Klein, MR (reprint author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Beckman Ctr B239,Schoolnik Lab, 279 Campus Dr, Stanford, CA 94305 USA.
RI Hammond, Abdulrahman/F-1541-2011
CR ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497
   Cole ST, 1998, NATURE, V393, P537
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530
   Kern F, 1998, NAT MED, V4, P975, DOI 10.1038/nm0898-975
   Klein Michel R., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P313
   Klein MR, 2001, J INFECT DIS, V183, P928, DOI 10.1086/319267
   Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Lewinsohn DM, 2001, J IMMUNOL, V166, P439
   Paetzel M, 1998, NATURE, V396, P186
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Smith SM, 2000, J IMMUNOL, V165, P7088
   Smith SM, 1999, INFECT IMMUN, V67, P5223
   Smith SM, 2000, INFECT IMMUN, V68, P7144, DOI 10.1128/IAI.68.12.7144-7148.2000
   Smith SM, 2000, IMMUNOL CELL BIOL, V78, P325, DOI 10.1046/j.1440-1711.2000.00936.x
   TAKAMIYA Y, 1994, INT IMMUNOL, V6, P255
   vanderBurg SH, 1996, J IMMUNOL, V156, P3308
   vanderBurg SH, 1995, HUM IMMUNOL, V44, P189, DOI 10.1016/0198-8859(95)00105-0
NR 21
TC 14
Z9 14
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 2002
VL 70
IS 2
BP 981
EP 984
DI 10.1128/IAI.70.2.981-984.2002
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 516LY
UT WOS:000173555800069
PM 11796635
OA No
DA 2017-08-15
ER

PT J
AU Obaro, S
   Adegbola, R
AF Obaro, S
   Adegbola, R
TI The pneumococcus: carriage, disease and conjugate vaccines
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Review
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   HAEMOPHILUS-INFLUENZAE; SEROTYPE REPLACEMENT; COLONIAL MORPHOLOGY;
   GAMBIAN CHILDREN; IMMUNOGENICITY; CELLS; VACCINATION; INFECTIONS
AB Modern biotechnology has made possible the rapid development and introduction into clinical care of a wide spectrum of potent antimicrobial agents. However, the battle against Streptococcus pneumoniae (pneumococcus) has remained fierce, as acquisition of resistance is even more rapid and these antimicrobial agents are rendered ineffective. Obtaining appropriate antibiotic treatment for severe invasive pneumococcal infections is now a major challenge in many regions of the world. The ground-breaking success of Haemophilus influenzae type b (Hib) conjugate vaccine has brought hope for the conquest of other capsulate bacteria. Recent results of efficacy trials of a heptavalent pneumococcal conjugate vaccine bring hope that protein conjugate vaccines will have a similar impact on pneumococcal disease. These multivalent vaccine formulations include pneumococcal serotypes that most often acquire antibiotic resistance and there is hope that the widespread application of these vaccines will decrease the incidence of multidrug-resistant infections. The potential reduction of pneumococcal disease could even extend to unimmunised younger siblings and the elderly residing with immunised young children, through its herd effect. However, in view of the multiplicity of serotypes and the biology of the pneumococcus, optimism must be tempered by caution.
C1 St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, London W2 1PG, England.
   MRC Labs, Fajara, Gambia.
RP Obaro, S (reprint author), St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, Norfolk Pl, London W2 1PG, England.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   ANDERSSON B, 1983, J EXP MED, V158, P559, DOI 10.1084/jem.158.2.559
   AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35
   AUSTRIAN R, 1986, CHEST, V90, P738, DOI 10.1378/chest.90.5.738
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   BLACK S, 2000, 2 INT S PNEUM PNEUM
   BRONSDON MA, 2000, 2 INT S PNEUM PNEUM
   BRUYN GAW, 1992, CLIN INFECT DIS, V14, P251
   BUSSE WW, 1991, REV INFECT DIS, V13, pS477
   CONVERSE GM, 1977, J CLIN MICROBIOL, V5, P293
   *CTR DIS CONTR, 1997, MMWR, V46
   CUNDELL DR, 1994, MICROB PATHOGENESIS, V17, P361, DOI 10.1006/mpat.1994.1082
   CUNDELL DR, 1995, INFECT IMMUN, V63, P757
   CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0
   Dagan R, 1997, PEDIATR INFECT DIS J, V16, P1060, DOI 10.1097/00006454-199711000-00011
   DAGAN R, 2000, 40 INT C ANT AG CHEM
   Eskola J, 2000, PEDIATR INFECT DIS J, V19, P388, DOI 10.1097/00006454-200004000-00035
   ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P3323, DOI 10.1001/jama.268.23.3323
   FREDERIKSEN B, 1988, J TROP PEDIATRICS, V34, P114
   GILLESPIE SH, 1989, J MED MICROBIOL, V28, P237
   GRATTEN M, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P501
   GRAY BM, 1980, J INFECT DIS, V142, P923
   HANSMAN D, 1974, MED J AUSTRALIA, V2, P436
   HEILMANN C, 1988, J IMMUNOL, V140, P1496
   HOLLIDAY MG, 1985, J HOSP INFECT, V6, P110, DOI 10.1016/S0195-6701(85)80029-3
   JOHNSTON RB, 1991, REV INFECT DIS, V13, pS509
   KILPI T, 2000, 2 INT S PNEUM PNEUM
   Kontiokari T, 2000, APMIS, V108, P734, DOI 10.1034/j.1600-0463.2000.d01-22.x
   KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157
   LAFONG AC, 1988, J CLIN PATHOL, V41, P230, DOI 10.1136/jcp.41.2.230
   LANKINEN KS, 1994, J CLIN MICROBIOL, V32, P2948
   Lipsitch M, 1999, EMERG INFECT DIS, V5, P336
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   MULHOLLAND EK, 1997, REPORT PREPARED SCI
   MUSHER DM, 1992, CLIN INFECT DIS, V14, P801
   O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885
   Park MK, 2000, CLIN DIAGN LAB IMMUN, V7, P486, DOI 10.1128/CDLI.7.3.486-489.2000
   PLOTKOWSKI MC, 1986, AM REV RESPIR DIS, V134, P1040
   PUKANDER J, 1982, ACTA OTO-LARYNGOL, V93, P447, DOI 10.3109/00016488209130903
   Rapola S, 1997, J CLIN MICROBIOL, V35, P1077
   Rennels MB, 1998, PEDIATRICS, V101, P604, DOI 10.1542/peds.101.4.604
   REYNOLDS HY, 1988, MAYO CLIN PROC, V63, P161
   Spratt BG, 2000, LANCET, V356, P1210, DOI 10.1016/S0140-6736(00)02779-3
   TARKOWSKI A, 1990, J IMMUNOL, V144, P3770
   WEISER JN, 1994, INFECT IMMUN, V62, P2582
   ZIEGLERHEITBROCK HWL, 1992, INFECT IMMUN, V60, P1692
NR 50
TC 100
Z9 109
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD FEB
PY 2002
VL 51
IS 2
BP 98
EP 104
PG 7
WC Microbiology
SC Microbiology
GA 520LU
UT WOS:000173784000002
PM 11863272
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
AF Walraven, G
TI Commentary: Involving traditional birth attendants in prevention of HIV
   transmission needs careful consideration
SO BRITISH MEDICAL JOURNAL
LA English
DT Editorial Material
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
RP Walraven, G (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
CR DEVAATE B, IN PRESS MIDWIFERY
   HABIMANA P, 1994, AIDS, V8, P701, DOI 10.1097/00002030-199405000-00020
   MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7
   Walraven G, 1999, TROP MED INT HEALTH, V4, P527, DOI 10.1046/j.1365-3156.1999.00441.x
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
NR 5
TC 4
Z9 4
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD JAN 26
PY 2002
VL 324
IS 7331
BP 224
EP 225
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 517HJ
UT WOS:000173604800025
PM 11831205
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Vekemans, J
   Schlegel-Haueter, SE
   Fielding, K
   Sanneh, M
   Kidd, M
   Newport, MJ
   Aaby, P
   Whittle, H
   Lambert, PH
   McAdam, KPWJ
   Siegrist, CA
   Marchant, A
AF Ota, MOC
   Vekemans, J
   Schlegel-Haueter, SE
   Fielding, K
   Sanneh, M
   Kidd, M
   Newport, MJ
   Aaby, P
   Whittle, H
   Lambert, PH
   McAdam, KPWJ
   Siegrist, CA
   Marchant, A
TI Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody
   and cytokine responses to human neonatal vaccination
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID EARLY BCG VACCINATION; DENDRITIC CELLS; GUINEA-BISSAU; T-LYMPHOCYTES;
   IN-VIVO; TUBERCULOSIS; IMMUNIZATION; ACTIVATION; PREVENTION; NEWBORNS
AB The immaturity of the immune system increases the susceptibility of young infants to infectious diseases and prevents the induction of protective immune responses by vaccines. We previously reported that Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination induces a potent Th1 response to mycobacterial Ags in newborns. In this study, we evaluated the influence of BCG on the response to unrelated vaccines given in early life. Newborns were randomly allocated to one of three study groups receiving BCG at birth, when infants received their first dose of hepatitis B and oral polio vaccines; at 2 mo of age, when infants received their first dose of diphtheria and tetanus vaccines; or at 4.5 mo of age, when immune responses to vaccines were measured. Administration of BCG at the time of priming markedly increased the cellular and Ab responses to the hepatitis B vaccine, but had only a limited influence on the cytokine response to tetanus toxoid and no effect on the Ab responses to tetanus and diphtheria toxoids. Although BCG induced a potent Th1-type response to mycobacterial Ags, it promoted the production of both Th1- and Th2-type cytokines in response to unrelated vaccines. The effect of BCG was apparent at the systemic level, as it increased the Ab response to oral polio vaccine. These results demonstrate that BCG influences the immune response to unrelated Ags in early life, likely through its influence on the maturation of dendritic cells.
C1 MRC Labs, Banjul, Gambia.
   Univ Geneva, Sch Med, WHO, Ctr Vaccinol & Neonatal Immunol, CH-1211 Geneva, Switzerland.
   London Sch Hyg & Trop Med, London WC1, England.
   Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge, England.
   Danish Epidemiol Sci Ctr, Copenhagen, Denmark.
RP Marchant, A (reprint author), Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.
CR Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   Borkow G, 2000, J CLIN INVEST, V106, P1053, DOI 10.1172/JCI10182
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   De Smedt T, 1998, J IMMUNOL, V161, P4476
   Goriely S, 2001, J IMMUNOL, V166, P2141
   Gruber C, 2001, PEDIATRICS, V107, pE36, DOI 10.1542/peds.107.3.e36
   Henderson RA, 1997, J IMMUNOL, V159, P635
   INABA K, 1993, J EXP MED, V178, P479, DOI 10.1084/jem.178.2.479
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Marchant A, 2000, CURR OPIN INFECT DIS, V13, P241
   Mulholland K, 1996, JAMA-J AM MED ASSOC, V275, P1182
   Ohshima Y, 1997, J IMMUNOL, V158, P629
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Simondon F, 1999, EUR J CLIN MICROBIOL, V18, P23, DOI 10.1007/s100960050221
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   *WHO, 1997, MAN VIR INV POL, P44
   Zhu YD, 1997, J INFECT DIS, V176, P1445
NR 23
TC 163
Z9 165
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JAN 15
PY 2002
VL 168
IS 2
BP 919
EP 925
PG 7
WC Immunology
SC Immunology
GA 510DP
UT WOS:000173193700047
PM 11777990
OA No
DA 2017-08-15
ER

PT J
AU Ismaili, J
   Rennesson, J
   Aksoy, E
   Vekemans, J
   Vincart, B
   Amraoui, Z
   Van Laethem, F
   Goldman, M
   Dubois, PM
AF Ismaili, J
   Rennesson, J
   Aksoy, E
   Vekemans, J
   Vincart, B
   Amraoui, Z
   Van Laethem, F
   Goldman, M
   Dubois, PM
TI Monophosphoryl lipid A activates both human dendritic cells and T cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTOR-2; ANTIGEN-PRESENTING CELLS; BACTERIAL
   LIPOPOLYSACCHARIDE; INTRACELLULAR CALCIUM; ADJUVANT; PROTEIN;
   MATURATION; QS21; EXPRESSION; INCREASE
AB The induction of dendritic cell (DC) maturation is critical for the induction of Ag-specific T lymphocyte responses and may be essential for the development of human vaccines relying on T cell immunity. In this study, we have investigated the effects of monophosphoryl lipid A (MPL) on human monocyte-derived DC as well as peripheral blood T cells. Calcium mobilization, mitogen-activated protein kinase activation, and the NF-kappaB transcription factor were induced after MPL stimulation of DC and required high doses of MPL (100 mug/ml). Maturation parameters such as production of IL-12 and increases in cell surface expression of HLA-DR, CD80, CD86, CD40, and CD83 were observed following DC treatment with MPL. However, lower levels of IL-12 were induced by MPL when compared with lipopolysaccharide. This is likely to be related to differences in the kinetics of extracellular signal-related kinase 1/2 and p-38 phosphorylation induced by both molecules. Although maturation induced by MPL was weaker when compared with lipopolysaccharide, it appeared to be sufficient to support optimal activation of allogeneic naive CD45RA(+) T cell and anti-tetanus toxoid CD4 T cells. MPL at low doses (5 mug/ml) had no impact on DC maturation, while its addition to DC-T cell cocultures induced full T cell activation. The observed effect was related to the fact that NIPI. also acts directly on T cells, likely through their Toll-like receptors, by increasing their intracellular calcium and up-regulating their CD40 ligand expression. Together, these data support a model where MPL enhances T cell responses by having an impact on DC and T cells.
C1 Free Univ Brussels, Fac Med, Expt Immunol Lab, Brussels, Belgium.
   Inst Biol & Med Mol, Lab Anim Physiol, Gosselies, Belgium.
   GlaxoSmithKline, Rixensart, Belgium.
RP Ismaili, J (reprint author), MRC Labs, POb 273, Fajara, WA, Gambia.
CR Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Chien EJ, 2000, J CELL BIOCHEM, V76, P404, DOI 10.1002/(SICI)1097-4644(20000301)76:3<404::AID-JCB8>3.0.CO;2-E
   Cunningham MD, 2000, J IMMUNOL, V164, P3255
   De Becker G, 2000, INT IMMUNOL, V12, P807, DOI 10.1093/intimm/12.6.807
   DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413
   Hacker H, 1999, EMBO J, V18, P6973, DOI 10.1093/emboj/18.24.6973
   Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091
   Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541
   Matsuguchi T, 2000, BLOOD, V95, P1378
   May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3
   Mikloska Z, 2000, J IMMUNOL, V164, P5167
   Moore A, 1999, VACCINE, V17, P2517, DOI 10.1016/S0264-410X(99)00062-6
   Muzio M, 2000, J IMMUNOL, V164, P5998
   Nusslein HG, 1996, EUR J IMMUNOL, V26, P846, DOI 10.1002/eji.1830260418
   Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175
   Rescigno M, 1997, J LEUKOCYTE BIOL, V61, P415
   RIBI E, 1986, ADV CARRIERS ADJUVAN, P35
   RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8
   Schletter J, 1995, ARCH MICROBIOL, V164, P383
   Silla S, 1999, EUR CYTOKINE NETW, V10, P181
   Ulrich J T, 1995, Pharm Biotechnol, V6, P495
   VOGEL SN, 1983, J IMMUNOL, V130, P1774
   Yang RB, 1999, J IMMUNOL, V163, P639
NR 23
TC 116
Z9 119
U1 1
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JAN 15
PY 2002
VL 168
IS 2
BP 926
EP 932
PG 7
WC Immunology
SC Immunology
GA 510DP
UT WOS:000173193700048
PM 11777991
OA No
DA 2017-08-15
ER

PT J
AU Mayaud, P
   West, B
   Lloyd-Evans, N
   Seck, K
AF Mayaud, P
   West, B
   Lloyd-Evans, N
   Seck, K
TI GASP-WAR: west African network to tackle gonorrhoea
SO LANCET
LA English
DT Letter
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Natl Hlth Labs, Banjul, Gambia.
   MRC Labs, Fajara, Gambia.
   Programme Natl Lutte SIDA & MST, Dakar, Senegal.
RP Mayaud, P (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   ISON CA, 1998, LANCET S3, V381, P8
   Tapsall JW, 1997, GENITOURIN MED, V73, P355
   World Health Organization, 1999, WHOCDS991
   World Health Organization, 1990, WHOVDT90452
NR 5
TC 5
Z9 5
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 12
PY 2002
VL 359
IS 9301
BP 173
EP 173
DI 10.1016/S0140-6736(02)07359-2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 510MT
UT WOS:000173212400057
PM 11809300
OA No
DA 2017-08-15
ER

PT J
AU Kock, D
   Barnett, L
   Fahr, J
   Emms, C
AF Kock, D
   Barnett, L
   Fahr, J
   Emms, C
TI On a collection of bats (Mammalia : Chiroptera) from The Gambia
SO ACTA CHIROPTEROLOGICA
LA English
DT Article
DE Gambia; Chiroptera; taxonomy; distribution; ecology; biology
ID MOUNT NIMBA; AFRICA; ECHOLOCATION; STRATEGIES; LIBERIA; SENEGAL;
   DIPTERA; RECORDS; MALAWI
AB A recent collection of bats from The Gambia presented in this publication comprises 17 species, four of which (Lissonycteris angolensis, Pipistrellus (P.) rusticus, P (Neoromicia) guineensis, and Scotoecus hirundo) represent new records for The Gambia, raising the total number of known species from 27 to 31. Notes on taxonomy, distribution, ecology and biology are presented.
C1 Forsch Inst Senckenberg, D-60325 Frankfurt, Germany.
   Dept Pk & Wildlife Manaagement, Res & Dev Unit, Serrekunda, Gambia.
   Univ Ulm, Dept Exptl Ecol Bio 3, D-89069 Ulm, Germany.
RP Kock, D (reprint author), Forsch Inst Senckenberg, Senckenberganlage 25, D-60325 Frankfurt, Germany.
EM dkock@sng.uni-frankfurt.de
RI Fahr, Jakob/E-8831-2012
OI Fahr, Jakob/0000-0002-9174-1204
CR ADAM F, 1972, Mammalia, V36, P59, DOI 10.1515/mamm.1972.36.1.59
   ADANSON M, 1773, NACHRICHT SEINER REI
   Aellen V., 1956, Mem Inat franc Afr Noire Ifan-Dakar, VNo. 48, P23
   ALLEN GLOVER M., 1939, BULL MUS COMP ZOOLOGY, V83, P1
   Allen JA, 1917, B AM MUS NAT HIST, V37, P405
   Andersen K., 1907, Annals & Magazine of Natural History Series 7, V19
   Andersen K., 1912, Annals & Magazine of Natural History Series 8, V10
   Andersen K, 1912, CATALOGUE CHIROPTERA
   Ansell W. F. H., 1963, Puku Occasional Papers of the Department of Game and Fisheries Northern Rhodesia, V1, P9
   Ansell WFH, 1969, PUKU, V5, P1
   BENETT ET, 1836, P ZOOLOGICAL SOC, V3, P149
   BENNETT ET, 1841, T ZOOLOGICAL SOC LON, V2, P31
   BERGMANS W, 1988, Beaufortia, V38, P75
   BERGMANS W, 1990, Beaufortia, V40, P111
   BERGMANS W, 1989, Beaufortia, V39, P89
   BOCAGE BJ, 1889, J SCI MATH FISICAS N, V1, P1
   Bourliere F., 1955, Bull Inst franY Afr N, V17A, P918
   BRAY RS, 1984, J PROTOZOOL, V31, P577, DOI 10.1111/j.1550-7408.1984.tb05507.x
   Burgess N.D., 2000, COASTAL FORESTS E AF, P173
   Cosson Jean-Francois, 1996, Journal of African Zoology, V110, P369
   Cotterill F. P. D., 1996, Arnoldia Zimbabwe, V10, P71
   Cotterill F.P.D., 2001, Durban Museum Novitates, V26, P53
   Dobson GE, 1878, CATALOGUE CHIROPTERA
   EDBERG E, 1982, NATURALISTS GUIDE GA
   Eisentraut M., 1960, Stuttgarter Beitraege zur Naturkunde, VNo. 39, P1
   EISENTRAUT M, 1965, BONNER ZOOLOGISCHE B, V16, P1
   FAIN A, 1953, REV ZOOLOGIE BOT AFR, V48, P89
   FUNAIOLI U, 1968, Monitore Zoologico Italiano, V2, P199
   GRUBB P, 1999, MAMMALS GHANA SIERRA
   GRUBB P, 1996, NIGERIAN FIELD, V61, P164
   HAPPOLD DCD, 1987, MAMMALIA, V51, P337, DOI 10.1515/mamm.1987.51.3.337
   HAPPOLD DCD, 1990, J ZOOL, V222, P557
   Happold M, 1997, J NAT HIST, V31, P805, DOI 10.1080/00222939700770401
   Hayman R. W, 1971, P1
   HERHOLDT EM, 1989, S AFR J WILDL RES, V19, P86
   HILL J E, 1976, Revue de Zoologie Africaine, V90, P626
   Hill J E., 1974, Bulletin Br. Mus. nat. Hist. (Zool.), V27, P169
   HILL JE, 1982, MAMMALIA, V46, P116
   Hill J. E., 1987, B BRIT MUS NAT HIST, V52, P225
   HIRST S, 1923, P ZOOLOGICAL SOC, P971
   HUBERT B, 1973, THESIS U PARIS PARIS
   HUTTON J M, 1986, Cimbebasia Series A, V8, P219
   JONES G, 1993, J ZOOL, V230, P385
   JONES S, 1992, S W HERPETOLOGICAL S, V2, P11
   Kershaw P. S., 1922, Annals & Magazine of Natural History Series 9, V10, P177
   KOCH-WESER S, 1984, Senckenbergiana Biologica, V64, P255
   Kock D., 1969, Abhandlungen der Senckenbergischen Naturforschenden Gesellschaft, VNo. 521, P1
   KOOPMAN K F, 1975, Bulletin of the American Museum of Natural History, V154, P353
   KOOPMAN KARL F., 1965, AMER MUS NOVITATES, V2219, P1
   Koopman Karl P., 1993, P137
   KOOPMAN KF, 1994, HDB ZOOLOGY, V8, P60
   KOOPMAN KF, 1995, AM MUS NOVIT, P11
   LANZA B, 1972, Universo (Florence), V52, P1035
   LARGEN M J, 1974, Monitore Zoologico Italiano Supplemento, V5, P221
   Lopes F.J., 1992, GARCIA ORTA ZOOLOGIC, V17, P1
   MAA TC, 1968, J MED ENTOMOL, V5, P238
   Meinig Holger, 1999, Bonner Zoologische Beitraege, V49, P101
   MONTICELLI FA, 1887, ANN MUSEO CIVICO STO, V5, P517
   Morel P. C., 1961, Memoires de l'Institut Francais d'Afrique Noire Dakar, Vno. 62, P275
   OGILBY W, 1835, P ZOOL SOC LOND, P97
   OSHEA TJ, 1980, Z TIERPSYCHOL, V53, P171
   OWEN RD, 1987, Z SAUGETIERKD, V52, P329
   PALACKY J, 1901, VESTNIK KRALOVSKE CE, P1
   PETERS W, 1868, FORTSETZUNG SCHLUSS, P865
   PETERSON R. L., 1995, FAUNE MADAGASCAR, V84
   POCHE R M, 1975, Mammalia, V39, P39, DOI 10.1515/mamm.1975.39.1.39
   RAINHO A, 1999, MORCEGOS GUINE BISSA
   Rautenbach I. L., 1993, Koedoe, V36, P87
   ROBBINS CB, 1980, MAMMALIA, V44, P83, DOI 10.1515/mamm.1980.44.1.83
   ROBBINS CB, 1985, MUSEE ROYALE AFRIQUE, V246, P53
   ROCHEBRUNE A. T., 1883, ACTES SOC LINNEENNE, V37, P49
   Rosevear D. R., 1965, BATS W AFRICA
   RUDNICK ALBERT, 1960, UNIV CALIFORNIA PUBL ENT, V17, P157
   Sanborn C. C., 1936, Field Museum Publications Chicago Zoological Series, V20, P107
   SCHMUTTERER H, 1992, ANZ SCHADLINGSKD PFL, V65, P1, DOI 10.1007/BF01905973
   Sylla M, 1997, ACAROLOGIA, V38, P239
   Taylor PJ, 1999, S AFR J ZOOL, V34, P114
   THEODOR O, 1956, PARASITOLOGY, V46, P353
   Thomas Nikky M., 1994, Bonner Zoologische Beitraege, V45, P17
   Thomas O., 1896, Proceedings of the Zoological Society of London, P788
   Thompson L, 2000, J EXP PSYCHOL-APPL, V6, P3, DOI 10.1037//0278-7393.6.1.3
   TOMES RF, 1860, P ZOOLOGICAL SOC, P42
   True F. W, 1893, P US NATL MUS, V16, P601
   Van Cakenberghe Victor, 1998, Bonner Zoologische Beitraege, V48, P123
   Van Cakenberghe Victor, 1993, Bonner Zoologische Beitraege, V44, P299
   VANCAKENBERGHE V, 1985, AFRICAN VERTEBRATES, P53
   VEIGAFERREIRA MC, 1948, ANN JUNTA INVESTIGAC, V3, P57
   VERSCHUREN J, 1957, EXPLOR PARC NAT GARA, V7, P1
   Verschuren J, 1982, MEM I FONDAMENTAL AF, V92, P307
   VIELLARD J, 1974, Revue Suisse de Zoologie, V81, P975
   VONLEHMANN E, 1964, A KOENIGS REISEN NIL, P71
   WARD R, 1994, BIRDWATCHERS GUIDE G
   *WILDL CONS DEP, 1978, 50 TREES AB NAT RES
   WOLTON RJ, 1982, MAMMALIA, V46, P419, DOI 10.1515/mamm.1982.46.4.419
NR 94
TC 4
Z9 5
U1 0
U2 5
PU MUSEUM & INST ZOOLOGY PAS-POLISH ACAD SCIENCES
PI WARSAW
PA WILCZA STREET 64, 00-679 WARSAW, POLAND
SN 1508-1109
J9 ACTA CHIROPTEROL
JI Acta Chiropt.
PY 2002
VL 4
IS 1
BP 77
EP 97
PG 21
WC Zoology
SC Zoology
GA 578NQ
UT WOS:000177124900007
OA No
DA 2017-08-15
ER

PT J
AU Mahdi, OSM
AF Mahdi, OSM
TI Impact of host genetics on susceptibility to human Chlamydia trachomatis
   disease
SO BRITISH JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Review
DE Chlamydia trachomatis; disease susceptibility; genetics; infection
ID NECROSIS-FACTOR-ALPHA; PELVIC INFLAMMATORY DISEASE; HEAT-SHOCK-PROTEIN;
   II DQ ALLELES; SCARRING TRACHOMA; ENDEMIC POPULATION; TUBAL INFERTILITY;
   HLA ANTIGENS; RISK-FACTORS; POLYMORPHISM
AB Evidence that host genetic factors play a major role in susceptibility or resistance to many infectious diseases is increasing, due to major advances in genetic epidemiological methodology. Recent human genome mapping information and the identification of a large number of candidate genes provide the tools for such studies. The information obtained is important for understanding the pathogenesis of disease and for the design of preventive and therapeutic strategies. In the study of Chlamydia trachomatis disease pathogenesis, much research focuses on how bacterial factors modulate the immune response and thus contribute to the disease process. It is likely, however, that host factors also play a role, and therefore susceptibility to disease is the result of an environmental effect set against a background of genetic factors. This review outlines the evidence for the contribution of host genetic factors to susceptibility to C. trachomatis disease in humans.
C1 MRC Labs, Banjul, Gambia.
RP Mahdi, OSM (reprint author), Univ Wisconsin, Dept Med Microbiol & Immunol, 436 SMI,1300 Univ Ave, Madison, WI 53706 USA.
CR BARENFANGER J, 1975, AM J TROP MED HYG, V24, P509
   BEATTY WL, 1993, P NATL ACAD SCI USA, V90, P3998, DOI 10.1073/pnas.90.9.3998
   Bouma G, 1996, SCAND J IMMUNOL, V43, P456, DOI 10.1046/j.1365-3083.1996.d01-65.x
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   BREWERTON DA, 1973, LANCET, V2, P996
   Brinkman BMN, 1996, J INFLAMM, V46, P32
   BRUNHAM RC, 1990, AM J EPIDEMIOL, V132, P946
   BRUNHAM RC, 1994, INFECT AGENT DIS, V3, P218
   BRUNHAM RC, 1992, J INFECT DIS, V165, P1076
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   CHAKRAVARTTI MR, 1973, TWIN STUDY LEPROSY, V1
   Cohen CR, 2000, OBSTET GYNECOL, V95, P72, DOI 10.1016/S0029-7844(99)00541-4
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Conway DJ, 1996, J INFECT DIS, V174, P643
   DETELS R, 1966, AM J EPIDEMIOL, V84, P81
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Eckert LO, 1997, J INFECT DIS, V175, P1453
   Gaur LK, 1999, J INFECT DIS, V180, P234, DOI 10.1086/314838
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Hohler T, 1998, CLIN EXP IMMUNOL, V111, P579
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   JONES BR, 1975, T OPHTHAL SOC UK, V95, P16
   Kimani J, 1996, J INFECT DIS, V173, P1437
   LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226
   Lichtenwalner AB, 1997, INFECT IMMUN, V65, P2250
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Morrison R P, 1991, Semin Immunol, V3, P25
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Peeling RW, 1998, J INFECT DIS, V177, P256, DOI 10.1086/517367
   RANI R, 1993, TISSUE ANTIGENS, V42, P133, DOI 10.1111/j.1399-0039.1993.tb02179.x
   Sartakova ML, 1999, TERAPEVT ARKH, V71, P41
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   Schachter J, 1978, HUMAN CHLAMYDIAL INF
   SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202
   STEEL CM, 1988, LANCET, V1, P1185
   Stuber F, 1996, J INFLAMM, V46, P42
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
   TIELSCH JM, 1988, AM J TROP MED HYG, V38, P393
   TOYE B, 1993, J INFECT DIS, V168, P1236
   TUFFREY M, 1992, J REPROD FERTIL, V95, P31
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   TURNER VM, 1993, INT J EPIDEMIOL, V22, P341, DOI 10.1093/ije/22.2.341
   Ward ME, 1999, CHLAMYDIA, P171
   White AG, 1997, BRIT J OPHTHALMOL, V81, P431, DOI 10.1136/bjo.81.6.431
   *WHO, 1995, WHO64
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   ZHONG GM, 1992, INFECT IMMUN, V60, P3143
NR 50
TC 1
Z9 2
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0967-4845
J9 BRIT J BIOMED SCI
JI Br. J. Biomed. Sci.
PY 2002
VL 59
IS 2
BP 128
EP 132
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 610UJ
UT WOS:000178979300015
PM 12113404
OA No
DA 2017-08-15
ER

PT J
AU Moorthy, V
   Hill, AVS
AF Moorthy, V
   Hill, AVS
TI Malaria vaccines
SO BRITISH MEDICAL BULLETIN
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; CIRCUMSPOROZOITE PROTEIN VACCINE;
   TRANSMISSION-BLOCKING VACCINES; C-TERMINAL FRAGMENT; T-CELL INDUCTION;
   IMMUNE-RESPONSES; CLINICAL MALARIA; VIRUS ANKARA; DNA VACCINE;
   SPOROZOITES
AB Malaria kills one child in Africa every 30 s. After summarising the burden of malaria, the life-cycle of this parasite in humans and female Anopheles mosquitoes is outlined. Important differences between natural immunity and that induced by current candidate vaccines are discussed. In the main part of the review, the recent rapid expansion in evaluation of candidate malaria vaccines in clinical trials across the world is discussed. Subunit vaccine technologies are progressing rapidly with new delivery systems, vectors and antigens under evaluation as well as new polyepitope approaches. Combination vaccination regimens, improved adjuvants and genetic engineering of antigens are all improving the immunogenicity of candidate vaccines. We also discuss particular difficulties in vaccination against malaria, the conduct of field trials of malaria vaccines in non-inclustrialised countries and the need for even greater cooperation between researchers. Finally, the important concept of iterative vaccine development is raised and the prospects for effective malaria vaccination are discussed.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
RP Hill, AVS (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
RI HILL, Adrian/C-1306-2008
CR Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Amukoye E, 1997, ANTIMICROB AGENTS CH, V41, P2261
   BALLOU WR, 1987, LANCET, V1, P1277
   BARNES DA, 1995, EXP PARASITOL, V81, P79, DOI 10.1006/expr.1995.1095
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Carter R, 2000, NAT MED, V6, P241, DOI 10.1038/73062
   CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Daubersies P, 2000, NAT MED, V6, P1258
   Doolan DL, 2001, INT J PARASITOL, V31, P753, DOI 10.1016/S0020-7519(01)00184-9
   Duffy PE, 1997, INFECT IMMUN, V65, P1109
   EDELMAN R, 1993, J INFECT DIS, V168, P1066
   Egan AF, 1996, J INFECT DIS, V173, P765
   Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x
   FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Genton B, 2000, VACCINE, V18, P2504, DOI 10.1016/S0264-410X(00)00036-0
   Gilbert SC, 1999, BIOL CHEM, V380, P299, DOI 10.1515/BC.1999.041
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   Gozar MMG, 2001, EXP PARASITOL, V97, P61, DOI 10.1006/expr.2000.4580
   Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001
   HOFFMAN SL, 1994, VACCINE, V12, P1529, DOI 10.1016/0264-410X(94)90078-7
   Holder A. A., 1999, Parassitologia (Rome), V41, P409
   Keitel WA, 1999, VACCINE, V18, P531, DOI 10.1016/S0264-410X(99)00221-2
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Krzych U, 2000, IMMUNOL REV, V174, P123, DOI 10.1034/j.1600-0528.2002.00013h.x
   Kurtis JD, 2001, TRENDS PARASITOL, V17, P219, DOI 10.1016/S0169-4758(00)01862-7
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   leSueur D, 1996, S AFR MED J, V86, P936
   LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X
   Mayr A, 1999, BERL MUNCH TIERARZTL, V112, P322
   MCCONKEY SJ, 2002, UNPUB
   MOORTHY VS, 2002, UNPUB SAFETY IMMUNOG
   MOORTHY VS, 2002, UNPUB
   NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20
   Nardin EH, 2001, J IMMUNOL, V166, P481
   NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351
   Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871
   Nevill CG, 1996, TROP MED INT HEALTH, V1, P139
   NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0
   O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403
   Oeuvray C, 2000, INFECT IMMUN, V68, P2617, DOI 10.1128/IAI.68.5.2617-2620.2000
   OEUVRAY C, 1994, BLOOD, V84, P1594
   Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P
   PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N
   REECE WHH, 2002, UNPUB
   ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0
   ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G
   Russell P., 1955, MANS MASTERY MALARIA
   SACHS J, 1999, EC MALARIA
   Saul A, 1999, VACCINE, V17, P3145, DOI 10.1016/S0264-410X(99)00175-9
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Schneider J, 1999, IMMUNOL REV, V170, P29, DOI 10.1111/j.1600-065X.1999.tb01326.x
   Sedegah M, 2000, J IMMUNOL, V164, P5905
   Shanks GD, 2000, T ROY SOC TROP MED H, V94, P253, DOI 10.1016/S0035-9203(00)90310-9
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   STURCHLER D, 1989, PARASITOL TODAY, V5, P39
   SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1
   Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   *WHO, 1996, 94 WHO
   *WHO, 2000, MAL GLOB CRIS
NR 67
TC 28
Z9 29
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-1420
J9 BRIT MED BULL
JI Br. Med. Bull.
PY 2002
VL 62
BP 59
EP 72
DI 10.1093/bmb/62.1.59
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 581LT
UT WOS:000177294400005
PM 12176850
OA No
DA 2017-08-15
ER

PT J
AU Coleman, R
   Loppy, L
   Walraven, G
AF Coleman, R
   Loppy, L
   Walraven, G
TI The treatment gap and primary health care for people with epilepsy in
   rural Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE epilepsy/epidemiology/therapy; seizures/therapy; patient acceptance of
   health care/othnology; attitude/ethnology; choice behavior; primary
   health care; medicine, traditional; Gambia
ID MORTALITY; COMMUNITY; AFRICA; KENYA; INDIA
AB Objective To study primary-level management for people with epilepsy in rural Gambia by means of community surveys,
   Methods After population screening was carried out, visits were made by a physician who described the epidemiology of epilepsy and its management, Gaps between required management and applied management were investigated by conducting interviews and discussions With people with epilepsy and their communities.
   Findings The lifetime prevalence of epilepsy was 4.9/1000 and the continuous treatment rate was less than 10%. The choice of treatment was shaped by beliefs in an external spiritual cause of epilepsy and was commonly expected to be curative but not preventive. Treatment rarely led to the control of seizures, although when control was achieved, the level Of community acceptance of people with epilepsy increased. Every person with epilepsy had sought traditional treatment, Of the 69 people with active epilepsy, 42 (61%) said they would like to receive preventive biomedical treatment if it were available in their local community. Key programme factors included the local provision of effective treatment and community information with, in parallel, clarification of the use of preventive treatment and genuine integration with current traditional sources of treatment and advice.
   Conclusion Primary-level management of epilepsy could be integrated into a chronic disease programme covering hypertension, diabetes, asthma and mental health. Initial diagnosis and prescribing could take place away from the periphery but recurrent dispensing would be conducted locally, Probable epilepsy etiologies suggest that there is scope for primary prevention through the strengthening of maternal and child health services.
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
RP Coleman, R (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
CR Coleman R, 1998, B WORLD HEALTH ORGAN, V76, P633
   FEKSI AT, 1991, LANCET, V337, P406, DOI 10.1016/0140-6736(91)91176-U
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   Commission on Classification and Terminology of the International League against Epilepsy, 1993, EPILEPSIA, V34, P592
   JilekAall L, 1997, SOC SCI MED, V45, P783, DOI 10.1016/S0277-9536(96)00414-5
   JILEKAALL L, 1992, EPILEPSIA, V33, P645, DOI 10.1111/j.1528-1157.1992.tb02341.x
   Kale R, 1997, BRIT MED J, V315, P2
   LISK DR, 1992, J SIERRA LEONE MED D, V6, P9
   MANI KS, 1994, TROP GEOGR MED, V46, pS34
   MATUJA WBP, 1990, TROP GEOGR MED, V42, P359
   Meinardi H, 2001, EPILEPSIA, V42, P136, DOI 10.1046/j.1528-1157.2001.32800.x
   Mendizabal JE, 1996, EPILEPSIA, V37, P373, DOI 10.1111/j.1528-1157.1996.tb00574.x
   Nilsson L, 1999, LANCET, V353, P888, DOI 10.1016/S0140-6736(98)05114-9
   Pal DK, 1998, INT J EPIDEMIOL, V27, P672, DOI 10.1093/ije/27.4.672
   Pal DK, 1999, LANCET, V353, P1817, DOI 10.1016/S0140-6736(99)00189-0
   PLACENCIA M, 1992, BRAIN, V115, P783, DOI 10.1093/brain/115.3.783
   REIS R, 1994, TROP GEOGR MED, V46, pS37
   Scott RA, 2001, B WORLD HEALTH ORGAN, V79, P344
   Shaba B, 1993, Cent Afr J Med, V39, P165
   Shorvon SD, 1988, EPILEPSIA S1, V29, P36
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   WHO (World Health Organization), 1998, PRIM PREV MENT NEUR
   Whyte S. R., 1995, DISABILITY CULTURE, P226
NR 23
TC 38
Z9 38
U1 4
U2 9
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2002
VL 80
IS 5
BP 378
EP 383
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 555NR
UT WOS:000175800600007
PM 12077613
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Milligan, P
   Sanneh, M
   Awemoyi, A
   Dakour, ER
   Schneider, G
   Palmer, A
   Jallow, M
   Oparaogu, A
   Whittle, H
   Mulholland, EK
   Greenwood, BM
AF Weber, MW
   Milligan, P
   Sanneh, M
   Awemoyi, A
   Dakour, ER
   Schneider, G
   Palmer, A
   Jallow, M
   Oparaogu, A
   Whittle, H
   Mulholland, EK
   Greenwood, BM
TI An epidemiological study of RSV infection in the Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE respiratory syncytial virus; human/pathogenicity; respiratory syncytial
   virus infections/epidemiology; respiratory tract infections/etiology;
   anoxemia; patient admission; hospitals; measles; epidemiologic factors;
   health services accessibility; households; epidemiologic studies; Gambia
ID RESPIRATORY-SYNCYTIAL-VIRUS; TRACT INFECTIONS; CHILDREN; DISEASE;
   WASHINGTON; HOSPITALIZATIONS; COMMUNITY; ETIOLOGY; DISTANCE; ILLNESS
AB Objective To describe the epidemiology of respiratory syncytial virus (RSV) infection in a developing country.
   Methods The work was carried out in three hospitals for primary cases and in the community for secondary cases in the western region of the Gambia, West Africa. RSV infection was diagnosed by immunofluorescence of nasopharyngeal aspirate samples in children younger than two years admitted to hospital with acute lower respiratory infection (ALRI). Routine records of all children with ALRI were analysed, and the incidence rates of ALRI, severe RSV-associated respiratory illness and hypoxaemic RSV infections were compared. A community-based study was undertaken to identify secondary cases and to obtain information about spread of the virus.
   Findings 4799 children with ALRI who were younger than two years and lived in the study area were admitted to the study hospitals: 421 had severe RSV-associated respiratory illness; 55 of these were hypoxaemic. Between 1994 and 1996, the observed incidence rate for ALRI in 100 children younger than one year living close to hospital was 9.6 cases per year; for severe RW-associated respiratory illness 0.83; and for hypoxaemic RSV-associated respiratory illness 0.089. The proportion of all ALRI admissions due to RSV was 19%. Overall, 41% of children younger than five years in compounds in which cases lived and 42% in control compounds had evidence of RSV infection during the surveillance period.
   Conclusion RSV is an important cause of ALRI leading to hospital admission in the Gambia. Morbidity is considerable and efforts at prevention are worthwhile.
C1 MRC Labs, Fajara, Gambia.
   Hannover Med Sch, Childrens Hosp, D-3000 Hannover, Germany.
   Royal Victoria Hosp, Banjul, Gambia.
   WEC Mission Hosp, Sibanor, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Weber, MW (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR BERMAN S, 1983, PEDIATRICS, V71, P210
   BORRERO I, 1990, REV INFECT DIS, V12, pS950
   BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355
   Collins PL, 1996, FIELDS VIROLOGY, P1313
   DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006
   DENNY FW, 1977, PEDIATR RES, V11, P234
   FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543
   GLEZEN WP, 1977, PEDIATR RES, V11, P239
   GLEZEN WP, 1971, J PEDIATR-US, V78, P397, DOI 10.1016/S0022-3476(71)80218-4
   GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005
   HALL CB, 1976, NEW ENGL J MED, V294, P414, DOI 10.1056/NEJM197602192940803
   HAYES EB, 1989, AM J DIS CHILD, V143, P316
   Henderson F W, 1987, Semin Respir Infect, V2, P112
   HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004
   Hijazi Z, 1996, J TROP PEDIATRICS, V42, P276, DOI 10.1093/tropej/42.5.276
   KIM HW, 1973, AM J EPIDEMIOL, V98, P216
   LAVIA WV, 1992, J PEDIATR-US, V121, P503
   LAVIA WV, 1993, CLIN PEDIATR, V32, P450, DOI 10.1177/000992289303200801
   LEHMANN D, 1991, PAPUA NEW GUINEA MED, V34, P174
   MONTO AS, 1971, AM J EPIDEMIOL, V94, P290
   Muller I, 1998, INT J EPIDEMIOL, V27, P878, DOI 10.1093/ije/27.5.878
   PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289
   PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3
   SALOMON HE, 1989, J MED VIROL, V28, P159, DOI 10.1002/jmv.1890280310
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Shryock H. S., 1976, METHODS MAT DEMOGRAP
   SIMS DG, 1976, BRIT MED J, V2, P1095
   SINGLETON RJ, 1995, PEDIATR INFECT DIS J, V14, P26, DOI 10.1097/00006454-199501000-00005
   STOCK R, 1983, SOC SCI MED, V17, P563, DOI 10.1016/0277-9536(83)90298-8
   SUTMOLLER F, 1995, CLIN INFECT DIS, V20, P854
   TUPASI TE, 1990, REV INFECT DIS, V12, pS940
   *US AG INT DEV UN, 1994, POP AN MICR
   WAFULA EM, 1990, REV INFECT DIS, V12, pS1035
   Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232
NR 37
TC 48
Z9 50
U1 0
U2 1
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2002
VL 80
IS 7
BP 562
EP 568
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 574VZ
UT WOS:000176911400007
PM 12163920
OA No
DA 2017-08-15
ER

PT J
AU Akramuzzaman, SM
   Cutts, FT
   Hossain, MJ
   Wahedi, OK
   Nahar, N
   Islam, D
   Shaha, NC
   Mahalanabis, D
AF Akramuzzaman, SM
   Cutts, FT
   Hossain, MJ
   Wahedi, OK
   Nahar, N
   Islam, D
   Shaha, NC
   Mahalanabis, D
TI Measles vaccine effectiveness and risk factors for measles in Dhaka,
   Bangladesh
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE measles vaccine/therapeutic use; measles/etiology; cross infection;
   immunization; risk factors; socioeconomic factors; case-control studies;
   odds ratio; Bangladesh
ID NOSOCOMIAL DIARRHEA; MEDICAL SETTINGS; FIELD-EVALUATION; GUINEA-BISSAU;
   EFFICACY; OUTBREAK; TRANSMISSION; COMMUNITY; MORTALITY; EPIDEMIC
AB Objective To evaluate vaccine effectiveness and to assess risk factor's for measles in Dhaka, Bangladesh.
   Method A case-control study, involving 198 cases with 783 age-matched neighbourhood controls and 120 measles cases with 365 age-matched hospital controls, was conducted in. 1995-96 in three large hospitals in Dhaka.
   Findings Measles vaccine effectiveness was estimated at 80% (95% confidence interval (CI) = 60-90%) using neighbourhood controls; very similar results were obtained using. hospital controls. Visits to a health facility 7-21 days before onset of any symptoms were associated with increased risk of measles compared with neighbourhood (adjusted odds ratio.(OR) = 7.0, 95% CI = 4.2-11.6) or hospital (adjusted OR. 1.7, 95% CI = 1.01-2.8) controls. Cases were more likely than controls to come from a household where more than one child lived (adjusted OR = 1.6, 95% CI = 1.1-2.5 versus neighbourhood controls; adjusted OR = 1.8, 95% CI = 1.02-3.0 versus,hospital control).
   Conclusions To improve measles' control in urban Dhaka missed immunization opportunities must be reduced in all health care facilities by following WHO guidelines. For measles, elimination, more than one dose of vaccine would be required.
C1 MRC Labs, Banjul, Gambia.
   Ctr Hlth & Populat Res, ICDDR B, Int Ctr Diarrhoeal Dis Res, Div Clin Sci, Dhaka, Bangladesh.
   London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
   Dhaka Shishu Children Hosp, Dhaka, Bangladesh.
   Dhaka Med Coll Hosp, Dept Pediat, Dhaka, Bangladesh.
RP Akramuzzaman, SM (reprint author), MRC Labs, Atlantic Blvd,Fajara,POB 273, Banjul, Gambia.
CR AABY P, 1986, J INFECT DIS, V154, P858
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1984, J TROP PEDIATRICS, V30, P164
   AABY P, 1985, J EPIDEMIOL COMMUN H, V39, P113, DOI 10.1136/jech.39.2.113
   Akramuzzaman SM, 2000, AM J EPIDEMIOL, V151, P723
   Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775
   Biellik RJ, 1997, B WORLD HEALTH ORGAN, V75, P367
   BURSTROM B, 1992, E AFR MED J, V69, P419
   CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185
   Clayton D, 1996, STAT MODELS EPIDEMIO
   Cunha BA, 1998, CRIT CARE CLIN, V14, P329, DOI 10.1016/S0749-0704(05)70398-5
   CUTTS FT, 1990, AM J EPIDEMIOL, V131, P349
   DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295
   de Swart RL, 2000, LANCET, V355, P201, DOI 10.1016/S0140-6736(99)04652-8
   DEAN AG, 1995, EPI INFO VERS 6 WORL
   Desmet M., 1998, ILLNESS PROFILE HLTH
   *DIR HLTH GOV BANG, 2001, EXP PROGR IMM NAT IM
   FARIZO KM, 1991, PEDIATRICS, V87, P74
   Guyer B, 1976, MED TROPICALE, V36, P451
   HULL HF, 1983, LANCET, V1, P972
   KILLEWO J, 1991, INT J EPIDEMIOL, V20, P508, DOI 10.1093/ije/20.2.508
   KLEINZABBAN ML, 1987, B WORLD HEALTH ORGAN, V65, P197
   MALFAIT P, 1994, PEDIATR INFECT DIS J, V13, P38, DOI 10.1097/00006454-199401000-00009
   MASON WH, 1993, PEDIATR INFECT DIS J, V12, P42, DOI 10.1097/00006454-199301000-00010
   MCGRATH D, 1992, PEDIATR INFECT DIS J, V11, P385, DOI 10.1097/00006454-199205000-00009
   MIRANDA AC, 1994, INT J EPIDEMIOL, V23, P843, DOI 10.1093/ije/23.4.843
   MORLEY D, 1963, J HYG-CAMBRIDGE, V61, P115
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   OZANNE G, 1992, J CLIN MICROBIOL, V30, P564
   Perry H, 1998, B WORLD HEALTH ORGAN, V76, P565
   PORTER JDH, 1990, INT J EPIDEMIOL, V19, P1072, DOI 10.1093/ije/19.4.1072
   SCRIMSHAW NS, 1966, AM J TROP MED HYG, V15, P625
   SIENKO DG, 1987, AM J PUBLIC HEALTH, V77, P1222, DOI 10.2105/AJPH.77.9.1222
   *STAT CORP, 2000, INT STAT 6 0 WIND 98
   Unicomb LE, 1998, PEDIATR INFECT DIS J, V17, P611, DOI 10.1097/00006454-199807000-00007
   *WHO, 1992, MEASL CONTR 1990S PL
   World Health Organization, 1999, WORLD HLTH REP 1999
NR 37
TC 9
Z9 10
U1 0
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2002
VL 80
IS 10
BP 776
EP 782
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 607DR
UT WOS:000178776800004
PM 12471397
OA No
DA 2017-08-15
ER

PT J
AU von Seidlein, L
   Clarke, S
   Alexander, N
   Manneh, F
   Doherty, T
   Pinder, M
   Walraven, G
   Greenwood, B
AF von Seidlein, L
   Clarke, S
   Alexander, N
   Manneh, F
   Doherty, T
   Pinder, M
   Walraven, G
   Greenwood, B
TI Treatment uptake by individuals infected with Plasmodium falciparum in
   rural Gambia, West Africa
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE malaria; Falciparum/drug therapy/diagnosis; Plasmodium
   falciparum/pathogenicity; parasitemia/epidemiology;
   antimalarials/therapeutic use; patient acceptance of health-care; self
   medication; households; rural population; cross-sectional studies;
   Gambia
ID HOME TREATMENT; ANTIMALARIAL-DRUGS; LONGITUDINAL DATA; MALARIA;
   CHILDREN; AREA; ARTEMISININ; POPULATION; DISTRICT; MOTHERS
AB Objective-To find out what proportion of Plasmodium falciparum infections are treated in rural Gambia.
   Methods Subjects from four villages in the Gambia were followed over nine, months through visits to village health workers. Monthly cross-sectional malaria surveys measured the prevalence of P. falciparum infection. Linked databases were searched for treatment requests. Treated cases were individuals with parasitaemia who requested treatment during narrow or extended periods (14 or 28 days, respectively) before or after a positive blood film was obtained.
   Findings Parasite prevalence peaked in November 1998, when 399/653 (61%) individuals had parasitaemia. Parasite prevalence was highest throughout the study in children aged 5-10 years. Although access to treatment was better than in most of sub-Saharan Africa, only 20% of infected individuals sought medical treatment up to 14 days before or after a positive, blood film. Within two months of a positive blood film, 199/726 (27%) individuals with parasitaemia requested treatment. Despite easy access to health care, less than half (42%) of those with parasite densities consistent with malaria attacks (>5000/mul) requested treatment. High parasite density and infection during October-November were associated With more frequent treatment requests. Self-treatment was infrequent in study villages: in 3/120 (2.5%) households antimalarial drugs had been used in the preceding malaria season.
   Conclusion Many P. falciparum infections may be untreated because of their subdinical nature. Intermittent presumptive treatment may reduce morbidity and mortality. It is likely that not all untreated infections were asymptomatic. Qualitative research should explore barriers to treatment uptake, to allow educational interventions to be planned.
C1 MRC Labs, Malaria Lab, Banjul, Gambia.
   Int Vaccine Inst, Seoul, South Korea.
   London Sch Hyg & Trop Med, London WC1, England.
   Minist Hlth, Banjul, Gambia.
   MRC Labs, Farafenni Field Stn, Banjul, Gambia.
RP von Seidlein, L (reprint author), MRC Labs, Malaria Lab, Banjul, Gambia.
CR Ahorlu CK, 1997, TROP MED INT HEALTH, V2, P488, DOI 10.1046/j.1365-3156.1997.d01-298.x
   CLARK S, 2001, THESIS U COPENHAGEN
   DEMARTIN S, 1999, THESIS LONDON SCH HY
   DEMING MS, 1989, B WORLD HEALTH ORGAN, V67, P695
   Diallo AB, 2001, B WORLD HEALTH ORGAN, V79, P28
   Fawole O I, 2001, West Afr J Med, V20, P152
   GIESECKE J, 1994, MODER INFECT DIS EPI
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hamel MJ, 2001, B WORLD HEALTH ORGAN, V79, P1014
   Julvez J., 1995, Cahiers d'Etudes et de Recherches Francophones/Sante, V5, P307
   Kaneko A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5
   KASEJE D C O, 1987, Annals of Tropical Medicine and Parasitology, V81, P77
   Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0
   Luxemburger C, 1996, T ROY SOC TROP MED H, V90, P105, DOI 10.1016/S0035-9203(96)90102-9
   Madge C, 1998, HEALTH PLACE, V4, P293, DOI 10.1016/S1353-8292(98)00033-1
   MENON A, 1988, J TROP MED HYG, V91, P49
   Meshnick SR, 1996, MICROBIOL REV, V60, P301
   MNYIKA KS, 1995, TROP GEOGR MED, V47, P32
   Molineaux Louis, 1980, GARKI PROJECT RES EP
   Pagnoni F, 1997, T ROY SOC TROP MED H, V91, P512, DOI 10.1016/S0035-9203(97)90006-7
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   RUEBUSH TK, 1995, B WORLD HEALTH ORGAN, V73, P229
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624
   Thera MA, 2000, TROP MED INT HEALTH, V5, P876, DOI 10.1046/j.1365-3156.2000.00652.x
   TRAPE JF, 1994, AM J TROP MED HYG, V51, P123
   VONSEIDLEIN L, 2002, THESIS LONDON SCH HY
   World Health Organization, 1993, IMPL GLOB MAL CONTR
   ZEGER SL, 1992, STAT MED, V11, P1825, DOI 10.1002/sim.4780111406
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 30
TC 19
Z9 19
U1 0
U2 5
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2002
VL 80
IS 10
BP 790
EP 796
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 607DR
UT WOS:000178776800006
PM 12471399
OA No
DA 2017-08-15
ER

PT J
AU Manirakiza, P
   Akimbamijo, O
   Covaci, A
   Adediran, SA
   Cisse, I
   Fall, ST
   Schepens, P
AF Manirakiza, P
   Akimbamijo, O
   Covaci, A
   Adediran, SA
   Cisse, I
   Fall, ST
   Schepens, P
TI Persistent chlorinated pesticides in fish and cattle fat and their
   implications for human serum concentrations from the Sene-Gambian region
SO JOURNAL OF ENVIRONMENTAL MONITORING
LA English
DT Article
ID MATERNAL ADIPOSE-TISSUE; UMBILICAL BLOOD-SERUM; ORGANOCHLORINE
   PESTICIDES; MALARIA CONTROL; RESIDUES; DDT; INSECTICIDES; INHABITANTS;
   VERACRUZ; PLASMA
AB The concentrations of organochlorine pesticides (OCPs) in fish, shrimps, cattle fat and human serum samples from the Sene-Gambian region were measured using validated analytical methodologies. The results obtained were compared with those of other existing African studies and with data from other developing countries. In fish samples, p, p'-dichlorodiphenyldichloroethylene (p, p'-DDE) and HCB were detected with a frequency of 100%, whereas p, p'-dichlorodiphenyltrichloroethane (p, p'-DDT) was detected in eight, heptachlorepoxide in six and endosulfansulfate in five of the nine fish samples. Relatively low concentrations of OCPs were found in cattle and shrimp fat samples. p, p'-DDE and alpha-hexachlorocyclohexane (alpha-HCH) were the most frequently identified. The sum of HCHs ranged from undetected to 13.3 ng g(-1) fat, the sum of DDTs from 11.1 to 199.2 ng g(-1) fat and the sum of endosulfans from not detected to 49.7 ng g(-1) fat in fish and shrimps. In serum samples, alpha-HCH, p,p'-DDE, o,p'-DDT and p,p'-DDT were detected in all 16 pooled serum samples, whereas endosulfansulfate, methoxychlor, mirex, heptachlorepoxide and endrin were detected in 15 samples with most of the concentrations below 10 ng mL(-1). The concentrations of OCPs in human serum were given on a serum lipid and whole serum volume basis. The implications for the human diet of these OCP concentrations in serum were investigated by means of biomagnification factors related to the log K-ow values of the targeted compounds. The current use of HCH mixtures was suggested to explain the unusually high alpha-HCH concentration. The distribution pattern of these OCPs in humans was also discussed and compared with that in other studies.
C1 Univ Antwerp, Toxicol Ctr, B-2610 Wilrijk, Belgium.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Senegalais Rech Agr, Dakar, Senegal.
RP Manirakiza, P (reprint author), Univ Antwerp, Toxicol Ctr, Univ Pl 1, B-2610 Wilrijk, Belgium.
RI Covaci, Adrian/A-9058-2008
OI Covaci, Adrian/0000-0003-0527-1136
CR ABRAHAM K, 1994, ORGANOHALOGEN COMP, V21, P163
   BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141
   BROWN JF, 1984, B ENVIRON CONTAM TOX, V33, P277
   Buckland S., 2001, CONCENTRATIONS SELEC
   CHEEK CS, 1969, CLIN CHEM, V15, P102
   DeLorenzo ME, 2002, ARCH ENVIRON CON TOX, V42, P173, DOI 10.1007/s00244-001-0008-3
   DUA VK, 1996, B ENVIRON CONTAM TOX, V22, P21
   GOSSEL TA, 1990, PRINC CLIN TOXICOL
   Grimvall E, 1997, ARCH ENVIRON CON TOX, V32, P329, DOI 10.1007/s002449900193
   KANJA LW, 1992, ARCH ENVIRON CON TOX, V22, P21
   Larsson P, 1995, NATURWISSENSCHAFTEN, V82, P559, DOI 10.1007/s001140050233
   LONDON L, 1995, AM J IND MED, V27, P1, DOI 10.1002/ajim.4700270102
   Mackay D, 2000, ENVIRON POLLUT, V110, P375, DOI 10.1016/S0269-7491(00)00162-7
   MACKAY D, 1982, ENVIRON SCI TECHNOL, V16, P274, DOI 10.1021/es00099a008
   MALIWAL BP, 1981, CHEM-BIOL INTERACT, V35, P177, DOI 10.1016/0009-2797(81)90141-1
   Manirakiza P, 2002, ENVIRON POLLUT, V117, P447, DOI 10.1016/S0269-7491(01)00188-9
   Manirakiza P, 2002, CHROMATOGRAPHIA, V55, P353, DOI 10.1007/BF02491672
   Manirakiza P, 2001, J FOOD COMPOS ANAL, V14, P93, DOI 10.1006/jfca.2000.0972
   MANIRAKIZA P, IN PRESS ARCH ENV CO
   MATHIES M, 1991, PESTICIDE CHEM, P433
   Minelli EV, 1996, B ENVIRON CONTAM TOX, V57, P691
   Ntow WJ, 2001, ARCH ENVIRON CON TOX, V40, P557, DOI 10.1007/s002440010210
   Osibanjo O, 1997, B ENVIRON CONTAM TOX, V58, P206, DOI 10.1007/s001289900321
   Pauwels AN, 1998, INT J ENVIRON AN CH, V71, P105, DOI 10.1080/03067319808032621
   PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495
   Snedeker S M, 2001, Environ Health Perspect, V109 Suppl 1, P35
   TANABE S, 1990, J AGR FOOD CHEM, V38, P899, DOI 10.1021/jf00093a066
   Tomlin C., 1997, PESTICIDE MANUAL
   Trigg PI, 1998, B WORLD HEALTH ORGAN, V76, P11
   Waliszewski SM, 1999, B ENVIRON CONTAM TOX, V62, P397, DOI 10.1007/s001289900888
   Waliszewski SM, 2001, ARCH ENVIRON CON TOX, V40, P432, DOI 10.1007/s002440010194
   WALISZEWSKI SM, 1993, ENVIRON POLLUT, V82, P289, DOI 10.1016/0269-7491(93)90131-7
   Waliszewski SM, 2000, B ENVIRON CONTAM TOX, V65, P293, DOI 10.1007/s001280000127
   World Health Organization, 1984, CHEM METH CONTR ARTH
   Wiktelius S, 1999, AGR ECOSYST ENVIRON, V75, P121, DOI 10.1016/S0167-8809(99)00076-6
   WYLIE P, 2001, LABPLUS INT      SEP, P22
NR 36
TC 17
Z9 17
U1 0
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1464-0325
J9 J ENVIRON MONITOR
JI J. Environ. Monit.
PY 2002
VL 4
IS 4
BP 609
EP 617
DI 10.1039/b202932b
PG 9
WC Chemistry, Analytical; Environmental Sciences
SC Chemistry; Environmental Sciences & Ecology
GA 578HJ
UT WOS:000177111100028
PM 12196010
OA No
DA 2017-08-15
ER

PT B
AU Ekpo, G
   Scherf, C
   West, B
   Morison, L
   Walraven, G
AF Ekpo, G
   Scherf, C
   West, B
   Morison, L
   Walraven, G
BE BenRafael, Z
   Lobo, R
   Shoham, Z
TI Level of male participation in infertility evaluation in a rural
   community - Should we re-define infertility?
SO THIRD WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS GYNECOLOGY &
   INFERTILITY, FREE PAPERS
LA English
DT Proceedings Paper
CT 3rd World Congress on Controversies in Obstetrics, Gynecology and
   Infertility
CY JUN 20-23, 2002
CL WASHINGTON, D.C.
AB This community based case-control study in infertility was carried out with the objective to assess the willingness of men to participate in infertility evaluation. One hundred and seven infertile couples were eligible for the study. The consenting cases and their controls were served a reproductive health questionnaire. Clinical examination, serological tests, swab examinations and semen analysis were carried out. The infertile females also had hysterosalpingography. The response rate was fairly similar in both males and female (86% vs. 84% respectively). 73.5% male and 83.2% female cases accepted clinical examination. Many more females (83.2%) compared to males (54.4%) had serological tests. Only 17.6% of the male cases were willing to give semen for analysis. 70% of the female cases had hysterosalpingography.
   We propose that treatment for infertility be reconsidered. It should be treated in any one that has an unfulfilled desire for conception.
C1 MRC, Banjul, Gambia.
RP Ekpo, G (reprint author), MRC, Banjul, Gambia.
RI Morison, Linda/H-9738-2013
CR CATES W, 1985, LANCET, V2, P596
   Rowe PC, 1993, WHO MANUAL STANDARDI
   Rowe P. J., 1999, REPROD HEALTH MATTER, V7, P103, DOI 10.1016/S0968-8080(99)90119-2
   Sundby J, 1997, PATIENT EDUC COUNS, V31, P29, DOI 10.1016/S0738-3991(97)01006-9
   TEMPLETON AA, 1999, RCOG MANAGEMENT GUID
NR 5
TC 0
Z9 0
U1 0
U2 1
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 88-323-2621-3
PY 2002
BP 19
EP 23
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA BX07V
UT WOS:000184198900005
OA No
DA 2017-08-15
ER

PT J
AU Smith, SM
   Klein, MR
   Malin, AS
   Sillah, J
   McAdam, KPWJ
   Dockrell, HM
AF Smith, SM
   Klein, MR
   Malin, AS
   Sillah, J
   McAdam, KPWJ
   Dockrell, HM
TI Decreased IFN-gamma and increased IL-4 production by human CD8(+) T
   cells in response to Mycobacterium tuberculosis in tuberculosis patients
SO TUBERCULOSIS
LA English
DT Article
ID BLOOD MONONUCLEAR-CELLS; CYTOKINE RESPONSES; IMMUNE-RESPONSE; PULMONARY
   TUBERCULOSIS; SCHISTOSOMA-MANSONI; HUMAN INFECTION; IN-VITRO;
   RESISTANCE; ANTIGENS; MICE
AB To investigate the role of MHC class I restricted CD8(+) T cells in host defense to M. tuberculosis, peripheral blood mononuclear cells (PBMC) from healthy BCG-vaccinated donors and untreated pulmonary tuberculosis (TB) patients in The Gambia were stimulated for 6 days with M. bovis BCG or M. tuberculosis and the CD8(+) T cell response analyzed. Intracellular FACS analysis of cytokine production by CD8(+) T cells showed that IFN-gamma and TNF-alpha production were greatly reduced in TB patients compared to healthy controls. IL-4-producing CD8(+) T cells were detected in TB patients, a phenotype absent in controls. Collectively, these data suggest that an alteration in the type 1/ type 2 cytokine balance occurs in CD8(+) T cells during clinical tuberculosis, and that this may provide a surrogate marker for disease. (C) 2002, Elsevier Science Ltd. All rights reserved.
C1 Univ London London Sch Hyg & Trop Med, Immunol Unit, London WC1E 7HT, England.
   MRC Labs, TB Res Programme, Fajara, Gambia.
RP Dockrell, HM (reprint author), Univ London London Sch Hyg & Trop Med, Immunol Unit, Keppel St, London WC1E 7HT, England.
CR Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633
   Baliko Z, 1998, FEMS IMMUNOL MED MIC, V22, P199, DOI 10.1111/j.1574-695X.1998.tb01207.x
   Bhattacharyya S, 1999, INFECT IMMUN, V67, P5597
   Bleed D, 2000, Curr Opin Pulm Med, V6, P174, DOI 10.1097/00063198-200005000-00002
   CANADAY DH, 1999, J IMMUNOL, V162, P327
   Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830
   Dlugovitzky D, 1999, SCAND J IMMUNOL, V49, P210, DOI 10.1046/j.1365-3083.1999.00492.x
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706
   Feng CG, 1999, INFECT IMMUN, V67, P3242
   Feng CG, 2000, J IMMUNOL, V164, P4853
   FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   GIRARDI F, 2000, AIDS, pS47
   KULLBERG MC, 1992, J IMMUNOL, V148, P3264
   LADEL CH, 1995, EUR J IMMUNOL, V25, P377, DOI 10.1002/eji.1830250211
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Lewinsohn DM, 1998, J EXP MED, V187, P1633, DOI 10.1084/jem.187.10.1633
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271
   PEARLMAN E, 1993, J IMMUNOL, V151, P4857
   Sabin EA, 1996, J INFECT DIS, V173, P269
   SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588
   SANCHEZ FO, 1994, INFECT IMMUN, V62, P5673
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200
   Serbina NV, 1999, INFECT IMMUN, V67, P3980
   Smith SM, 2000, J IMMUNOL, V165, P7088
   Smith SM, 1999, INFECT IMMUN, V67, P5223
   Smith SM, 2000, INFECT IMMUN, V68, P7144, DOI 10.1128/IAI.68.12.7144-7148.2000
   Sousa AO, 2000, P NATL ACAD SCI USA, V97, P4204, DOI 10.1073/pnas.97.8.4204
   Stewart GR, 1999, CLIN EXP IMMUNOL, V117, P517
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171
   Tan JS, 1997, J IMMUNOL, V159, P290
   Tascon RE, 1998, INFECT IMMUN, V66, P830
   Torres M, 1998, INFECT IMMUN, V66, P176
   Turner J, 2001, AM J RESP CELL MOL, V24, P203
   Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325
   ZHANG M, 1995, INFECT IMMUN, V63, P3231
NR 37
TC 38
Z9 41
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1472-9792
J9 TUBERCULOSIS
JI Tuberculosis
PY 2002
VL 82
IS 1
BP 7
EP 13
DI 10.1054/tube.2001.0317
PG 7
WC Immunology; Microbiology; Respiratory System
SC Immunology; Microbiology; Respiratory System
GA 545UL
UT WOS:000175235900002
PM 11914057
OA No
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Wesumperuma, LH
   Hart, AC
AF Okoko, BJ
   Wesumperuma, LH
   Hart, AC
TI Materno-foetal transfer of H-influenzae and pneumococcal antibodies is
   influenced by prematurity and low birth weight: implications for
   conjugate vaccine trials
SO VACCINE
LA English
DT Article
DE Pneumococcus; Haemophilus influenza; prematurity
ID PLACENTAL MALARIA; LOCALIZATION; INFANT; FCRN
AB The influence of prematurity and low birth weight (LBW) on transplacental. transfer of Haemophilus influenza type B and Streptococcus pneumoniae antibodies was assessed in 213 mothers and their neonates from Gambia. Paired maternal and cord serum samples were tested for specific IgG antibody titres for H. influenza and S. pneumococcus antigens using enzyme linked immunosorbent assay. Prematurity and LBW was significantly associated with reduced placental antibody transfer for these antigens.
   The reduced materno-foetal transfer of these antibodies in this vulnerable population of babies may further predispose them to more bacterial infections. These findings are of practical importance to the vaccination strategies. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 MRC Labs, Banjul, Fajara, Gambia.
   Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England.
RP Okoko, BJ (reprint author), MRC Labs, POB 273, Banjul, Fajara, Gambia.
CR BARROS FC, 1987, ARCH DIS CHILD, V62, P487
   Becken ET, 2001, ARCH OTOLARYNGOL, V127, P517
   de Moraes-Pinto MI, 1998, ARCH DIS CHILD, V79, pF202
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   GAIRDNER D, CRAIGS CARE NEWLY BO, V8, P115
   IBHANESEBHOR SE, 1992, INT J GYNECOL OBSTET, V37, P247, DOI 10.1016/0020-7292(92)90324-C
   KAMAT M, 1994, ARCH PEDIAT ADOL MED, V148, P694
   KAMEDA T, 1991, PLACENTA, V12, P15, DOI 10.1016/0143-4004(91)90506-B
   Leach JL, 1996, J IMMUNOL, V157, P3317
   MARGARITA G, 1999, PAEDIAT INFECT DIS, V18, P1014
   Obaro SK, 2000, ACTA TROP, V75, P141, DOI 10.1016/S0001-706X(99)00094-7
   OKOKO JB, 1999, THESIS W AFRICAN COL
   Plikaytis BD, 2000, J CLIN MICROBIOL, V38, P2043
   Praetor A, 1999, J CELL SCI, V112, P2291
   Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/ror.0.0040081
   SIMISTER NE, HUMAN IGG RECEPTORS, P1
   TAFARI N, 1991, PAEDIAT TROPICS, P198
   TOIVANEN P, 1968, IMMUNOLOGY, V15, P395
   VOLLER A, 1978, J CLIN PATHOL, V31, P507, DOI 10.1136/jcp.31.6.507
   Wesumperuma HL, 1999, ANN TROP MED PARASIT, V93, P169
   *WHO STUD GROUP, 1999, INFECT DIS J, V18, pS17
   Yoon JK, 2001, J KOREAN MED SCI, V16, P9
NR 22
TC 14
Z9 14
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD DEC 12
PY 2001
VL 20
IS 5-6
BP 647
EP 650
DI 10.1016/S0264-410X(01)00418-2
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 504TJ
UT WOS:000172871700004
PM 11738729
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Whittle, H
   Cisse, B
   Samb, B
   Jensen, H
   Simondon, F
AF Aaby, P
   Whittle, H
   Cisse, B
   Samb, B
   Jensen, H
   Simondon, F
TI The frailty hypothesis revisited: mainly weak children die of measles
SO VACCINE
LA English
DT Article
DE frailty hypothesis; measles; frail children
ID RURAL SENEGAL; DEVELOPING-COUNTRIES; CASE-FATALITY; WEST-AFRICA;
   MORTALITY; IMMUNIZATION; INFECTION; VACCINATION; COMMUNITY; EXPOSURE
AB It has been suggested that measles infection mainly kills frail children who are likely to die anyhow of other infections. If that were true, the proportion of frail children should increase after the introduction of measles vaccination and post-measles mortality compared with mortality in uninfected children should increase when the case fatality declines and frail children are no longer dying of measles. The latter deduction was investigated in Niakhar, Senegal, where the measles case fatality has declined markedly. Measles has been studied in Niakhar during 12 years from 1983 to 1994. We compared long-term mortality after measles infection in periods with both high and low case fatality. The acute measles case fatality rate (CFR) declined from 6.5% in 1983-1986 to 1.5% in 1987-1994, an age-adjusted decline of 66% (RR = 0.34 (0.19-0.58)). Between 1983-1986 and 1987-1994, mortality in the first year after measles infection declined by 35% (RR = 0.65 (0.37-1.16)), the pattern being the same in the second and third year after infection (RR = 0.63 (0.33-1.21)). This reduction could not be related to introduction of immunization, treatment of measles with Vitamin A, or prophylactic use of antibiotics. Controlling for age, immunization, and season, the decline in post-measles mortality was similar to the fall in non-measles-related mortality between the two periods (mortality rate ratio = 0.72 (0.64-0.80)). Since the mortality decline in survivors of measles was as large as the decline in mortality among uninfected children, reduction in acute measles mortality did not lead to accumulation of frail children. We doubt measles infection ever eliminated mainly weak children; it always killed a broad spectrum of children, most of whom were "fit to survive". Hence, it seems unlikely that measles vaccination has contributed to the survival of more frail children. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Projecto Saude Bandim, Bissau, Guinea Bissau.
   IRD, Infect Dis Res Unit, Dakar, Senegal.
   MRC Labs, Banjul, Gambia.
RP Aaby, P (reprint author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen, Denmark.
CR AABY P, 1988, REV INFECT DIS, V10, P478
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 1996, AM J EPIDEMIOL, V143, P1035
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443
   CHAHNAZARIAN A, 1992, POPULATION SANTE NIA
   CHRISTENSEN PE, 1953, ACTA MED SCAND, V144, P430
   CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330
   Cox D. R., 1984, ANAL SURVIVAL DATA
   DELAUNAY V, 1998, SITUATION DEMOGRAPHI
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GARENNE M., 1987, RISQUES DECES ASSOCI
   Garenne ML, 1982, THESIS U PENNSYLVANI
   HENDRICKSE RG, 1975, T ROY SOC TROP MED H, V69, P31, DOI 10.1016/0035-9203(75)90007-3
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Montgomery SM, 1997, LANCET, V349, P472, DOI 10.1016/S0140-6736(05)61183-X
   MOSLEY W. H., 1985, HLTH POLICY SOCIAL P, P103
   POULSEN AG, 1989, LANCET, V1, P827
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P695, DOI 10.1097/00006454-199508000-00009
   Samb B, 1997, AM J EPIDEMIOL, V145, P51
   Simondon F, 1997, VACCINE, V15, P1606, DOI 10.1016/S0264-410X(97)00100-X
   SINHA DP, 1977, TROP GEOGR MED, V29, P125
   VANBALEN H, 1981, LANCET, V1, P764
NR 24
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD DEC 12
PY 2001
VL 20
IS 5-6
BP 949
EP 953
DI 10.1016/S0264-410X(01)00390-5
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 504TJ
UT WOS:000172871700037
PM 11738762
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Milligan, PJM
   Pinder, M
   Vigneron, L
   Alloueche, A
   Kester, KE
   Ballou, WR
   Conway, DJ
   Reece, WHH
   Gothard, P
   Yamuah, L
   Delchambre, M
   Voss, G
   Greenwood, BM
   Hill, A
   McAdam, KPWJ
   Tornieporth, N
   Cohen, JD
   Doherty, T
AF Bojang, KA
   Milligan, PJM
   Pinder, M
   Vigneron, L
   Alloueche, A
   Kester, KE
   Ballou, WR
   Conway, DJ
   Reece, WHH
   Gothard, P
   Yamuah, L
   Delchambre, M
   Voss, G
   Greenwood, BM
   Hill, A
   McAdam, KPWJ
   Tornieporth, N
   Cohen, JD
   Doherty, T
CA RTS,S Malaria Vaccine Trial Team
TI Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum
   infection in semi-immune adult men in The Gambia: a randomised trial
SO LANCET
LA English
DT Article
ID CIRCUMSPOROZOITE-PROTEIN; SPF66 VACCINE; WEST-AFRICA; SAFETY;
   IMMUNOGENICITY; SPOROZOITES; HETEROGENEITY; IMMUNIZATION; RTS,S/SBAS2;
   PROTECTION
AB Background RTS,S/AS02 is a pre-erythrocytic malaria vaccine based on the circumsporozoite surface protein of Plasmodium falciparum fused to HBsAg, incorporating a new adjuvant (AS02). We did a randomised trial of the efficacy of RTS,S/AS02 against natural P falciparum infection in semi-immune adult men in The Gambia.
   Methods 306 men aged 18-45 years were randomly assigned three doses of either RTS,S/AS02 or rabies vaccine (control). Volunteers were given sulfadoxine/pyrimethamine 2 weeks before dose 3, and kept under surveillance throughout the malaria transmission season. Blood smears were collected once a week and whenever a volunteer developed symptoms compatible with malaria. The primary endpoint was time to first infection with P falciparum. Analysis was per protocol.
   Findings 250 men (131 in the RTS,S/AS02 group and 119 in the control group) received three doses of vaccine and were followed up for 15 weeks. RTS,S/AS02 was safe and well tolerated. P falciparum infections occurred significantly earlier in the control group than the RTS,S/AS02 group (Wilcoxon's test p=0.018). Vaccine efficacy, adjusted for confounders, was 34% (95% CI 8.0-53, p=0.014). Protection seemed to wane: estimated efficacy during the first 9 weeks of follow-up was 71% (46-85), but decreased to 0% (-52 to 34) in the last 6 weeks. Vaccination induced strong antibody responses to circumsporozoite protein and strong T-cell responses. Protection was not limited to the NF54 parasite genotype from which the vaccine was derived. 158 men received a fourth dose the next year and were followed up for 9 weeks; during this time, vaccine efficacy was 47% (4-71, p=0.037).
   Interpretation RTS,S/AS02 is safe, immunogenic, and is the first pre-erythrocytic vaccine to show significant protection against natural P falciparum infection.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England.
   Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA.
   GlaxoSmithKline Biol, Rixensart, Belgium.
RP Bojang, KA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI HILL, Adrian/C-1306-2008; Kester, Kent/A-2114-2011; Milligan,
   Paul/D-8985-2017
OI Kester, Kent/0000-0002-5056-0802; Milligan, Paul/0000-0003-3430-3395;
   Conway, David/0000-0002-8711-3037
CR AALEN OO, 1988, STAT MED, V7, P1121, DOI 10.1002/sim.4780071105
   Acosta CJ, 1999, TROP MED INT HEALTH, V4, P368, DOI 10.1046/j.1365-3156.1999.00406.x
   Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2
   ALONSO PL, 1994, LANCET, V344, P1175
   BALLOU WR, 1987, LANCET, V1, P1277
   BROWN AE, 1988, J CLIN IMMUNOL, V8, P342, DOI 10.1007/BF00917149
   Collet D, 1994, MODELING SURVIVAL DA
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   Doherty JF, 1999, AM J TROP MED HYG, V61, P865
   Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739
   Durham LK, 1999, J ROY STAT SOC C-APP, V48, P395, DOI 10.1111/1467-9876.00160
   ETLINGER HM, 1988, J IMMUNOL, V140, P626
   GORDON DM, 1995, J INFECT DIS, V171, P1576
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0
   HOFFMANN SL, 1990, MALARIA VACCINE DEV
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   LENGELOR C, 1998, COCHRANE LIB
   Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520
   NNOYA O, 1994, J INFECT DIS, V170, P396
   Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0
   SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066
   SCHUMACHER M, 1987, STAT MED, V6, P773, DOI 10.1002/sim.4780060708
   SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657
   Therneau TM, 2000, MODELING SURVIVAL DA
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W
   WEBSTER HK, 1988, J CLIN MICROBIOL, V26, P923
NR 32
TC 356
Z9 366
U1 1
U2 21
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD DEC 8
PY 2001
VL 358
IS 9297
BP 1927
EP 1934
DI 10.1016/S0140-6736(01)06957-4
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 500HZ
UT WOS:000172622200008
PM 11747915
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Collinson, AC
   Prentice, AM
AF Moore, SE
   Collinson, AC
   Prentice, AM
TI Immune function in rural Gambian children is not related to season of
   birth, birth size, or maternal supplementation status
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article; Proceedings Paper
CT Summer Meeting of the Nutrition-Society
CY JUN 27-30, 2000
CL UNIV COLL, CORK, IRELAND
SP Nutrit Soc
HO UNIV COLL
DE fetal programming; immune function; maternal supplementation; pregnancy;
   children; birth weight; rabies vaccine; pneumococcus vaccine; The Gambia
ID INTESTINAL PERMEABILITY PROBES; AUTOMATED ENZYMATIC ASSAYS; FETAL
   GROWTH; CHRONIC DIARRHEA; INDIAN CHILDREN; SOUTH-INDIA; WEIGHT;
   INFECTION; MORTALITY; DISEASE
AB Background: We previously showed that mortality from infectious diseases among young adults in rural Gambia is strongly correlated with the season of their birth. This suggests that early life insults that involve fetal malnutrition, exposure to natural toxins, or highly seasonal infections affecting the infant or pregnant mother cause permanent damage to the immune system. Excess mortality begins after puberty and has a maximal odds ratio of > 10 for deaths between ages 25 and 50 y.
   Objective: We investigated the immune function of children according to birth weight, season of birth, and exposure to maternal dietary supplementation during pregnancy.
   Design: Immune function was measured in 472 prepubertal children aged 6.5-9.5 y from 28 villages in rural Gambia. The mothers of these children had been randomly assigned to a high-energy prenatal supplementation program, which significantly increased birth weight. This permitted supplementation status, birth weight, and season of birth to be investigated as exposure variables. The outcome variables tested were naive responses to rabies and pneumococcus vaccines, delayed-type hypersensitivity skin reactions, and mucosal defense (secretory immunoglobulin A and dual-sugar permeability).
   Results: Immune responses were strongly related to current age and sex, suggesting a high level of sensitivity, but were not consistently related to birth weight, season of birth, or maternal supplementation (control compared with intervention).
   Conclusion: Events in early life did not predict a measurable defect in immune response within this cohort of rural Gambian children. It is possible that the early programming of immune function may be mediated through a defect in immunologic memory or early senescence rather than through impairment of early responses.
C1 London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC1B 3DP, England.
   MRC, Keneba, Gambia.
   MRC, Cambridge, England.
RP Moore, SE (reprint author), London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, 49-51 Bedford Sq, London WC1B 3DP, England.
CR ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P426, DOI 10.1016/0035-9203(92)90253-9
   Aspinall R, 1997, J IMMUNOL, V158, P3037
   Aspinall R, 2000, BIOCHEM SOC T, V28, P250
   Barker DJP, 1999, ARCH DIS CHILD, V80, P305
   Barker DJP, 1994, MOTHERS BABIES DIS L
   Bavdekar A, 1999, DIABETES, V48, P2422, DOI 10.2337/diabetes.48.12.2422
   BEHRENS RH, 1984, CLIN CHIM ACTA, V137, P361, DOI 10.1016/0009-8981(84)90125-6
   BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J
   CAMPBELL DI, IN PRESS J PEDIAT GA
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087
   CHANDRA RK, 1975, SCIENCE, V190, P189
   CHAPOT B, 1991, TECHNIQUES DIAGNOSTI, P135
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005
   Fall CHD, 1998, DIABETIC MED, V15, P220, DOI 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.3.CO;2-F
   Forrester TE, 1996, BRIT MED J, V312, P156
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Godfrey K, 1996, BRIT MED J, V312, P410
   GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x
   Hall A.J., 1994, TOXICOLOGY AFLATOXIN, P233
   KOCHANOWSKI BA, 1985, AM J CLIN NUTR, V41, P278
   Lisse IM, 1997, J PEDIATR-US, V130, P77, DOI 10.1016/S0022-3476(97)70313-5
   LUNN PG, 1989, CLIN CHIM ACTA, V183, P163, DOI 10.1016/0009-8981(89)90332-X
   LUNN PG, 1992, CLIN CHIM ACTA, V205, P151, DOI 10.1016/S0009-8981(05)80011-7
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Moore SE, 2001, DIABETIC MED, V18, P646, DOI 10.1046/j.1464-5491.2001.00565.x
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N
   Owens JA, 1989, ADV FETAL PHYSL, P263
   PHILLIPS DIW, 1993, Q J MED, V86, P247
   PRENTICE A, 1991, ARCH DIS CHILD, V66, P223
   PRENTICE A, 1984, ACTA PAEDIATR SCAND, V73, P803, DOI 10.1111/j.1651-2227.1984.tb17779.x
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Shaheen SO, 1996, BRIT MED J, V313, P969
   SINGH J, 1989, BRIT J NUTR, V62, P315, DOI 10.1079/BJN19890033
   SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535
   Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3
   THURNHAM DI, 1988, CLIN CHEM, V34, P377
   VICTORA CG, 1988, PEDIATRICS, V81, P807
   VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25
   WHITELAW A, 1988, BRIT MED BULL, V44, P1037
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   YAJNIK CS, 1995, DIABETIC MED, V12, P330
NR 49
TC 32
Z9 32
U1 0
U2 5
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC
PY 2001
VL 74
IS 6
BP 840
EP 847
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 495FB
UT WOS:000172328600021
PM 11722967
OA No
DA 2017-08-15
ER

PT J
AU Meisner, SJ
   Mucklow, S
   Warner, G
   Sow, SO
   Lienhardt, C
   Hill, AVS
AF Meisner, SJ
   Mucklow, S
   Warner, G
   Sow, SO
   Lienhardt, C
   Hill, AVS
TI Association of NRAMP1 polymorphism with leprosy type but not
   susceptibility to leprosy per se in West Africans
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID NATURAL-RESISTANCE; GENETIC EPIDEMIOLOGY; NO EVIDENCE; INFECTION;
   TUBERCULOSIS; SEGREGATION; ACTIVATION; PATHOGENS; RESPONSES; PROTEIN
AB Twin and family studies indicate that host genetic factors influence susceptibility to leprosy and, possibly, leprosy type. Murine studies have suggested a role for the natural resistance-associated macrophage protein I (Nramp1) gene, which can influence cellular immune responses to intracellular pathogens. We evaluated a variation in the human homolog, NRAMP1, recently associated with tuberculosis susceptibility in West Africa. A total of 273 patients with leprosy and 201 controls from Mali were genotyped for NRAMP1 polymorphisms previously associated with tuberculosis. No association was found with leprosy per se (P = 0.83), but the NRAMP1 3'-untranslated region 4-bp insertion/deletion polymorphism was associated with leprosy type (P = 0.007). Heterozygotes were more frequent among multibacillary than paucibacillary leprosy cases. Thus, variation in or near the NRAMP1 gene may exert an influence on the clinical presentation of leprosy, possibly by influencing cellular immune response type.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Inst Marchoux, Bamako, Mali.
   MRC Labs, Fajara, Gambia.
RP Hill, AVS (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
RI HILL, Adrian/C-1306-2008
CR Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830
   ABEL L, 1988, AM J HUM GENET, V42, P256
   ABEL L, 1995, GENET EPIDEMIOL, V12, P63, DOI 10.1002/gepi.1370120107
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   BLACKWELL JM, 1991, IMMUNOL LETT, V30, P241, DOI 10.1016/0165-2478(91)90032-6
   CHAKRAVARTI MR, 1973, TOPICS HUMAN GENETIC, V1
   FEITOSA MF, 1995, AM J HUM GENET, V56, P1179
   Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717
   Hackam DJ, 1998, J EXP MED, V188, P351, DOI 10.1084/jem.188.2.351
   LIU J, 1995, AM J HUM GENET, V56, P845
   North RJ, 1998, TRENDS MICROBIOL, V6, P441, DOI 10.1016/S0966-842X(98)01364-X
   RANI R, 1993, TISSUE ANTIGENS, V42, P133, DOI 10.1111/j.1399-0039.1993.tb02179.x
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Roger M, 1997, INT J LEPROSY, V65, P197
   Roy S, 1997, J INFECT DIS, V176, P530
   Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536
   Searle S, 1998, J CELL SCI, V111, P2855
   SHAW MA, 1993, ANN HUM GENET, V57, P251, DOI 10.1111/j.1469-1809.1993.tb00899.x
   SHIELDS ED, 1987, J CLIN INVEST, V79, P1139, DOI 10.1172/JCI112930
   SKAMENE E, 1984, IMMUNOGENETICS, V19, P117, DOI 10.1007/BF00387854
   Skamene E, 1998, ANNU REV MED, V49, P275
   Soo SS, 1998, INFECT IMMUN, V66, P1910
   TODD JR, 1990, REV INFECT DIS, V12, P63
   VANEDEN W, 1980, J INFECT DIS, V141, P693
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D
   *WHO, 1982, TECHN REP SER WHO, V675
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
NR 28
TC 50
Z9 53
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2001
VL 65
IS 6
BP 733
EP 735
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 508YJ
UT WOS:000173117100013
PM 11791966
OA No
DA 2017-08-15
ER

PT J
AU Casals-Pascual, C
   Allen, S
   Allen, A
   Kai, O
   Lowe, B
   Pain, A
   Roberts, DJ
AF Casals-Pascual, C
   Allen, S
   Allen, A
   Kai, O
   Lowe, B
   Pain, A
   Roberts, DJ
TI Short report: Codon 125 polymorphism of CD31 and susceptibility to
   malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CHILDREN; DISEASE
AB Platelet-endothelial cell adhesion molecule 1 (PECAM-1/CD31) has been identified as an endothelial cell receptor of Plasmodium falciparum-infected erythrocytes. The significance of adhesion of infected erythrocytes to this receptor in malaria infection has not been determined. We have therefore studied the association of the functional mutation CTG-->GTG (Leu-->Val) in codon 125 of the C,131 gene with severe disease in 2 case-control studies of malaria in Madang Hospital, Papua New Guinea, and in Kilifi District Hospital, Kenya. We analyzed data from 442 cases and controls from Papua New Guinea and data from 396 cases and controls from Kenya. The codon 125 polymorphism was not associated with severe malaria in either study. We conclude that the presence of CTG-->GTG (Leu-->Wal) substitution in codon 125 in CD31 is not associated with protection from severe malaria, and we suggest that selective forces other than malaria may maintain this high-frequency polymorphism.
C1 John Radcliffe Hosp, Oxford Ctr, Natl Blood Serv, Blood Res Lab, Oxford OX3 9DU, England.
   John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.
   KEMRI Ctr Geog Med, Kilifi, Kenya.
   MRC, Unit Trop Med, Banjul, Gambia.
RP Roberts, DJ (reprint author), John Radcliffe Hosp, Oxford Ctr, Natl Blood Serv, Blood Res Lab, Oxford OX3 9DU, England.
RI Pain, Arnab/L-5766-2015
OI Pain, Arnab/0000-0002-1755-2819
CR Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736
   Behar E, 1996, NEW ENGL J MED, V334, P286, DOI 10.1056/NEJM199602013340502
   Chen QJ, 2000, CLIN MICROBIOL REV, V13, P439, DOI 10.1128/CMR.13.3.439-450.2000
   Gumina RJ, 1997, BLOOD, V89, P1260
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Maruya E, 1998, BLOOD, V92, P2169
   NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453
   Treutiger CJ, 1997, NAT MED, V3, P1405, DOI 10.1038/nm1297-1405
NR 8
TC 11
Z9 13
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2001
VL 65
IS 6
BP 736
EP 737
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 508YJ
UT WOS:000173117100014
PM 11791967
OA No
DA 2017-08-15
ER

PT J
AU Falade, AG
   Adegbola, RA
   Mulholland, EK
   Greenwood, BM
AF Falade, AG
   Adegbola, RA
   Mulholland, EK
   Greenwood, BM
TI Respiratory rate as a predictor of positive lung aspirates in young
   Gambian children with lobar pneumonia
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID ETIOLOGY; BLOOD
AB Clinical predictors of a positive bacterial culture from lung aspirate or blood culture were investigated in 90 children under 5 years of age with lobar pneumonia on whom both lung aspiration and blood culture were performed. Of the 66 children with a respiratory rate of greater than or equal to 50 breaths/ min, 35 (53%) had positive bacterial lung aspirates compared with only five (21.7%) of 23 children with a respiratory rate of <50 breaths/ min (odds ratio [OR] 4.06, 95% confidence interval [CI] 1.24-15.46, p = 0.02). Of the 41 children with positive lung aspirates, 31 (76%) had negative blood cultures. In contrast with children with positive lung aspirates, there were no clinical predictors of a positive blood culture. A respiratory rate of <greater than or equal to>50 breaths/ min in children with radiological evidence of lobar pneumonia would support lung aspiration as a positive result is significantly more likely than in children with a lower respiratory rate.
C1 MRC Labs, Fajara, Gambia.
RP Falade, AG (reprint author), Univ Coll Ibadan Hosp, Dept Paediat, Ibadan, Nigeria.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Adegbola RA, 2000, ANN TROP MED PARASIT, V94, P197
   BALE JR, 1990, REV INFECT DIS, V12, pS861
   Banya WAS, 1996, PEDIATR INFECT DIS J, V15, P292, DOI 10.1097/00006454-199604000-00003
   *CDC WHO, 1994, EP INF VERS 6 WORD P
   Falade AG, 1997, ANN TROP PAEDIATR, V17, P315
   FALADE AG, 1995, B WORLD HEALTH ORGAN, V73, P299
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
NR 8
TC 2
Z9 2
U1 0
U2 0
PU CARFAX PUBLISHING
PI BASINGSTOKE
PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD DEC
PY 2001
VL 21
IS 4
BP 293
EP 297
DI 10.1080/07430170120093472
PG 5
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 490HE
UT WOS:000172044300002
PM 11732146
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Coleman, RL
   van der Loeff, MFS
   McAdam, KPWJ
   Nyan, OA
   Thien, T
   Dolmans, WM
   El Walraven, G
AF van der Sande, MAB
   Coleman, RL
   van der Loeff, MFS
   McAdam, KPWJ
   Nyan, OA
   Thien, T
   Dolmans, WM
   El Walraven, G
TI A template for improved prevention and control of cardiovascular disease
   in sub-Saharan Africa
SO HEALTH POLICY AND PLANNING
LA English
DT Article
ID DEPENDENT DIABETES-MELLITUS; RURAL SOUTH-AFRICA; CHLAMYDIA-PNEUMONIAE;
   BLOOD-PRESSURE; INTERVENTION PROGRAM; COST-EFFECTIVENESS; RISK FACTOR;
   HYPERTENSION; ATHEROSCLEROSIS; HEALTH
AB Cardiovascular disease (CVD) is rapidly becoming an important public health problem in sub-Saharan Africa, yet the response so far is often minimal and inadequate. While there is, undoubtedly, a 'double burden of disease' (persisting infectious diseases co-existing with emerging non-communicable disease), this is hardly reflected in current health planning, possibly due to a limited appreciation of the changing pattern of CVD and CVD risk factor exposure. In a situation where there are also considerable budget constraints and well-established infectious disease priorities, it is difficult to implement effective interventions for prevention or treatment of CVD. Yet such planning is urgently needed and a template for a comprehensive programme, adaptable to local situations, is presented here. The first step is to raise awareness and create evidence-based commitment among policy-makers, which could lead to the establishment of a multi-sectoral CVD unit at national level. Programmes need to focus on prevention of modifiable risk factors at population level, involving a wide range of institutions and individuals. Recommended strategies include decentralizing the design and implementation of programmes, with appropriate standardized surveillance of major risk factors, all complemented by operational, epidemiological and basic research.
C1 MRC Labs, Fajara, Gambia.
   WHO, CH-1211 Geneva, Switzerland.
   Dept Gen Internal Med, Nijmegen, Netherlands.
RP van der Sande, MAB (reprint author), Med Res Council Fajara, POB 273, Banjul, Gambia.
CR ALLEMANN Y, 1995, J HYPERTENS, V13, P163
   BARKER DJP, 1995, EUR J CLIN INVEST, V25, P457, DOI 10.1111/j.1365-2362.1995.tb01730.x
   Chalmers J, 1999, J HYPERTENS, V17, P151
   Coleman R, 1998, B WORLD HEALTH ORGAN, V76, P633
   Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160
   Cooper R, 1998, BRIT MED J, V317, P77
   Cooper RS, 1998, BRIT MED J, V316, P614
   Cooper R, 1997, BLOOD PRESS MONIT, V2, P35
   DOWSE GK, 1995, BRIT MED J, V311, P1255
   Edwards PR, 1998, S AFR MED J, V88, P549
   EZENWAKA CE, 1993, DIABETES RES CLIN PR, V20, P175, DOI 10.1016/0168-8227(93)90075-G
   Forrester T, 1998, BRIT MED BULL, V54, P463
   Gwatkin DR, 1999, LANCET, V354, P586, DOI 10.1016/S0140-6736(99)02108-X
   HARRIS MI, 1995, CLIN INVEST MED, V18, P231
   High KP, 1999, CLIN INFECT DIS, V28, P746, DOI 10.1086/515216
   Howson CP, 1998, LANCET, V351, P586, DOI 10.1016/S0140-6736(97)11452-0
   KAPLAN NM, 1994, LANCET, V344, P450, DOI 10.1016/S0140-6736(94)91774-4
   Kaufman Jay, 1993, Ethnicity and Disease, V3, pS83
   Kaufman JS, 1996, J HUM HYPERTENS, V10, P461
   Korner I, 1999, VASA-J VASCULAR DIS, V28, P259, DOI 10.1024/0301-1526.28.4.259
   Metcalf CA, 1996, J HUM HYPERTENS, V10, P21
   MILLS A, 1992, EPC PUBLICATIONS SER
   Montgomery RW, 1998, BRIT MED J, V317, P76
   Mufunda T, 2000, J HUM HYPERTENS, V14, P65
   MULDOON MF, 1993, AM J HYPERTENS, V6, P76
   Port S, 2000, LANCET, V355, P175, DOI 10.1016/S0140-6736(99)07051-8
   Poulter NR, 1985, J Hypertens, V3, P5375
   Razum O., 1996, Central African Journal of Medicine, V42, P120
   ROLFE M, 1992, DIABETIC MED, V9, P484
   ROSE G, 1981, BRIT MED J, V282, P1847
   ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32
   ROSSOUW JE, 1993, INT J EPIDEMIOL, V22, P428, DOI 10.1093/ije/22.3.428
   Schmidt MI, 1999, LANCET, V353, P1649, DOI 10.1016/S0140-6736(99)01046-6
   Seedat YK, 2000, J HUM HYPERTENS, V14, P739, DOI 10.1038/sj.jhh.1001059
   Shor A, 1999, JAMA-J AM MED ASSOC, V282, P2071, DOI 10.1001/jama.282.21.2071
   van der Sande MAB, 2001, B WORLD HEALTH ORGAN, V79, P321
   van der Sande MAB, 2001, B WORLD HEALTH ORGAN, V79, P133
   van der Sande MAB, 1999, TROP MED INT HEALTH, V4, P506
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   VANDERSANDE MAB, 2001, IN PRESS J HUMAN HYP
   VAUGHAN P, 1989, HEALTH POLICY PLANN, V4, P97, DOI 10.1093/heapol/4.2.97
   Walt G, 1998, LANCET, V351, P434, DOI 10.1016/S0140-6736(97)05546-3
   WELBOURNE A, 1995, STEPPING STONES PACK
   Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094
   Wilkinson D, 1997, S AFR MED J, V87, P451
   World Bank, 1993, WORLD DEV REP 1993 I
NR 47
TC 7
Z9 7
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1080
J9 HEALTH POLICY PLANN
JI Health Policy Plan.
PD DEC
PY 2001
VL 16
IS 4
BP 345
EP 350
DI 10.1093/heapol/16.4.345
PG 6
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 504QH
UT WOS:000172867000002
PM 11739358
OA No
DA 2017-08-15
ER

PT J
AU Jepson, A
   Fowler, A
   Banya, W
   Singh, M
   Bennett, S
   Whittle, H
   Hill, AVS
AF Jepson, A
   Fowler, A
   Banya, W
   Singh, M
   Bennett, S
   Whittle, H
   Hill, AVS
TI Genetic regulation of acquired immune responses to antigens of
   Mycobacterium tuberculosis: a study of twins in West Africa (vol 69, pg
   3989, 2001)
SO INFECTION AND IMMUNITY
LA English
DT Correction
C1 Wellcome Trust Ctr Human Genet, Oxford, England.
   London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1, England.
   GBF, D-38124 Braunschweig, Germany.
   MRC Labs, Fajara, Gambia.
RP Jepson, A (reprint author), Wellcome Trust Ctr Human Genet, Oxford, England.
RI HILL, Adrian/C-1306-2008
CR Jepson A, 2001, INFECT IMMUN, V69, P3989, DOI 10.1128/IAI.69.6.3989-3994.2001
NR 1
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2001
VL 69
IS 12
BP 7964
EP 7964
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 494QP
UT WOS:000172297600101
OA No
DA 2017-08-15
ER

PT J
AU Dumpis, U
   Mendy, M
   Hill, A
   Thursz, M
   Hall, A
   Whittle, H
   Karayiannis, P
AF Dumpis, U
   Mendy, M
   Hill, A
   Thursz, M
   Hall, A
   Whittle, H
   Karayiannis, P
TI Prevalence of HBV core promoter/precore/core mutations in Gambian
   chronic carriers
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis B virus; genotype; genomic mutations; basic core promoter;
   precore/core
ID HEPATITIS-B-VIRUS; SURFACE-ANTIGEN; NUCLEOTIDE-SEQUENCE; INFECTION;
   FULMINANT; GENE; RELATEDNESS; GENOTYPES; VARIANTS; STRAINS
AB One hundred forty-two precore/core sequences were obtained from Gambian chronic hepatitis B virus (HBV) carriers and the predominant variants defined. The two point mutations, from A to T and G to A at nt positions 1762 and 1764 in the basic core promoter region, were found in only 7/99 (7%) of the samples where this region was sequenced. These mutations were found in both HBeAg-positive and -negative patients. The precore stop-codon mutation at nt position 1896 was found in 14/51 (27%) of HBeAg-negative samples, which is a lower prevalence rate in comparison with other parts of the world with high carrier rates. In HBeAg-positive patients the core amino acid sequences were conserved, but after seroconversion to anti-HBe significantly more changes were apparent. Several of the amino acid substitutions found have been described previously been in wild-type viruses of other genotypes. (C) 2001 Wiley-Liss, Inc.
C1 Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med A, London W2 1NY, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Karayiannis, P (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med A, St Marys Campus,S Wharf Rd, London W2 1NY, England.
RI HILL, Adrian/C-1306-2008
CR AKARCA US, 1995, HEPATOLOGY, V22, P50, DOI 10.1016/0270-9139(95)90352-6
   Alexopoulou A, 1997, J HEPATOL, V26, P748, DOI 10.1016/S0168-8278(97)80238-3
   Bozkaya H, 1997, J HEPATOL, V26, P508, DOI 10.1016/S0168-8278(97)80415-1
   CARMAN WF, 1995, J VIRAL HEPATITIS, V2, P77, DOI 10.1111/j.1365-2893.1995.tb00010.x
   Carman WF, 1997, J INFECT DIS, V175, P1093
   CARMAN WF, 1989, LANCET, V2, P588
   CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29
   CHUANG WL, 1993, GASTROENTEROLOGY, V104, P263
   DUMPIS U, 2001, J HEPATOL, V35, P94
   EHATA T, 1992, J CLIN INVEST, V89, P332, DOI 10.1172/JCI115581
   Fujiwara K, 1998, DIGEST DIS SCI, V43, P368, DOI 10.1023/A:1018870709286
   Hannoun C, 2000, J GEN VIROL, V81, P75
   INSKIP HM, 1991, INT J EPIDEMIOL, V20, P770, DOI 10.1093/ije/20.3.770
   KANEKO M, 1995, J MED VIROL, V47, P204, DOI 10.1002/jmv.1890470304
   Karasawa T, 1997, J GASTROENTEROL, V32, P611, DOI 10.1007/BF02934110
   Karayiannis P, 1995, HEPATOLOGY, V22, P1628, DOI 10.1016/0270-9139(95)90183-3
   KIDDLJUNGGREN K, 1995, J GEN VIROL, V76, P2119, DOI 10.1099/0022-1317-76-9-2119
   Kramvis A, 1997, HEPATOLOGY, V25, P235, DOI 10.1002/hep.510250143
   LASKUS T, 1995, GASTROENTEROLOGY, V109, P1618, DOI 10.1016/0016-5085(95)90651-7
   Lindh M, 1997, J INFECT DIS, V175, P1285
   NORDER H, 1992, J GEN VIROL, V73, P1201, DOI 10.1099/0022-1317-73-5-1201
   NORDER H, 1993, J GEN VIROL, V74, P1341, DOI 10.1099/0022-1317-74-7-1341
   NORDER N, 1993, ARCH VIROL, V8, pS189
   OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575
   RodriguezFrias F, 1995, HEPATOLOGY, V22, P1641, DOI 10.1016/0270-9139(95)90185-X
   Stuyver L, 2000, J GEN VIROL, V81, P67
   Vall MM, 1990, LANCET, V336, P1107
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
NR 28
TC 21
Z9 28
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2001
VL 65
IS 4
BP 664
EP 670
DI 10.1002/jmv.2088
PG 7
WC Virology
SC Virology
GA 489LY
UT WOS:000171993900006
PM 11745929
OA No
DA 2017-08-15
ER

PT J
AU Bowman, RJC
   Jatta, B
   Cham, B
   Bailey, RL
   Faal, H
   Myatt, M
   Foster, A
   Johnson, GJ
AF Bowman, RJC
   Jatta, B
   Cham, B
   Bailey, RL
   Faal, H
   Myatt, M
   Foster, A
   Johnson, GJ
TI Natural history of trachomatous scarring in The Gambia - Results of a
   12-year longitudinal follow-up
SO OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT Meeting of the WHO Alliance for the Global Elimination of Trachoma
CY DEC, 1999
CL GENEVA, SWITZERLAND
SP WHO
ID TRICHIASIS
AB Purpose: The sight-threatening complications of trachoma are trichiasis and corneal opacity, and these remain the world's most common cause of preventable blindness. The aim of the study was to investigate the rate of progression of trachomatous conjunctival scarring to trichiasis and corneal opacity and to investigate risk factors for such progression.
   Design: A 12-year, longitudinal study of the incidence and risk factors for the development of trichiasis and corneal opacity in a cohort of patients initially identified with trachomatous scarring in The Gambia.
   Participants: Six hundred thirty-nine subjects with some degree of trachomatous scarring were identified from the 1986 survey, and attempts were made to trace all these subjects.
   Methods: Successfully traced subjects were interviewed, examined, and graded for trachoma.
   Main Outcome Measures: (1) Twelve-year rates of progression. (2) Risk factors for progression of disease.
   Results: Three hundred twenty-six of six hundred thirty-nine (51%) subjects were traced and examined, 108 (17%) had died, and 205 (32%) were lost to follow-up. After 12 years, 6.4% (95% confidence interval [CI], 4.0-9.97) of scarred subjects had trichiasis develop, 5.96% (95% CI, 3.67-9.42) had corneal opacity develop, 16.51% (95% CI, 12.71-21.13) had visual impairment/blindness develop, and 2.5% (95% CI, 1.2-5.0) had corneal visual impairment/blindness develop. Mandinka ethnicity was a risk factor for trichiasis (odds ratio [OR], 4.3; 95% CI, 1.3-14.4), and trichiasis at baseline was a risk factor for corneal opacity (OR, 8.4; 95% CI, 1.8-39.2). History of lid surgery for trichiasis was associated with corneal opacity at follow-up (OR, 4.4; 95% CI, 1.4-14.0). Older age was a significant risk factor for development of trichiasis, corneal opacity, and visual loss (OR, 1.07; 95% CI, 1.01-1.12). Bilateral cataract was present in 40% of traced subjects and was associated with the incidence of visual impairment/blindness (OR, 9.4; 95% CI; 4.5-19.6)
   Conclusions: This is the first study to demonstrate the link between trichiasis and future corneal opacity, and it provides the rationale for performing lid rotation surgery on patients with trichiasis who do not yet have corneal opacity. The association between corneal opacity at follow-up and previous surgery among trichiasis patients suggests late presentation as a problem. The planning of surgical services will be aided by the incidence figures generated by this study. (C) 2001 by the American Academy of Ophthalmology.
C1 Int Ctr Eye Hlth, London, England.
   Natl Eye Care Program Gambia, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel, England.
RP Bowman, RJC (reprint author), Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.
CR AJEWOLE JF, 1998, THESIS INT CTR EYE H
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   DAWSON CR, 1989, EYE, V3, P204
   DAWSON CR, 1981, GUIDE TRACHOMA CONTR, P43
   DETELS R, 1966, AM J EPIDEMIOL, V84, P81
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   JONES LT, 1960, AM J OPHTHALMOL, V49, P29
   LEWALLEN S, 1991, BRIT J OPHTHALMOL, V75, P713, DOI 10.1136/bjo.75.12.713
   Munoz B, 1997, TROP MED INT HEALTH, V2, P1030, DOI 10.1046/j.1365-3156.1997.d01-186.x
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   RUTTEN G, 1995, THESIS INT CTR EYE H
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   *WHO PBL, 1997, WHOPBL9761
NR 16
TC 37
Z9 37
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2001
VL 108
IS 12
BP 2219
EP 2224
DI 10.1016/S0161-6420(01)00645-5
PG 6
WC Ophthalmology
SC Ophthalmology
GA 496VM
UT WOS:000172417800034
PM 11733262
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Aaby, P
   Aryioshi, K
   Vincent, T
   Awasana, AA
   Da Costa, C
   Pembrey, L
   Dias, F
   Harding, E
   Weiss, HA
   Whittle, HC
AF van der Loeff, MFS
   Aaby, P
   Aryioshi, K
   Vincent, T
   Awasana, AA
   Da Costa, C
   Pembrey, L
   Dias, F
   Harding, E
   Weiss, HA
   Whittle, HC
TI HIV-2 does not protect against HIV-1 infection in a rural community in
   Guinea-Bissau
SO AIDS
LA English
DT Article; Proceedings Paper
CT 13th International AIDS Conference
CY JUL 09-14, 2000
CL DURBAN, SOUTH AFRICA
DE HIV-2; Africa; cross-protection; incidence rate; sex workers;
   Guinea-Bissau
ID WEST-AFRICA; NATURAL PROTECTION; VIRUS TYPE-2; LOAD; AIDS; AREA
AB Objective: To examine the putative protective effect of HIV-2 infection against subsequent HIV-1 infection.
   Design: Retrospective analysis of data from two cross-sectional surveys in the same community.
   Methods: Two surveys between 1989 and 1998 in a rural area in northwestern Guinea-Bissau provided data from residents aged 15-59 years. HIV testing was done in the first survey. in the second survey, tests were made for both HIV and syphilis, and data on sociodemographic factors and sexual behaviour, including commercial sex work, were gathered. Qualitative polymerase chain reaction amplification of HIV-1 and HIV-2 viral DNA was performed on serologically dually reactive samples.
   Results: Of the 2276 eligible adult villagers initially tested, 60% (1360) provided a second sample. Of 110 HIV-2-infected subjects, 17 became additionally infected with HIV-1 [incidence rate (IR), 26.3/1000 person-years observation]. Of the 1250 HIVseronegative subjects, 24 became infected with HIV-1 (IR, 2.8/1000 person-years observation). The incidence rate ratio (IRR), comparing the incidence rate in HIV-2-infected people with the rate in HIV-seronegative subjects, was > 1 in all three 'risk groups': men, female commercial sexworkers, and other women, The overall estimate of the IRR, adjusted forage group and risk group, was 3.24 (confidence interval, 1.5-7.1).
   Conclusions: There was no protective effect of HIV-2 in this population. HIV-2 cannot be regarded as a vaccine, but, instead, may be a risk factor for HIV-1 infection. (C) 2001 Lippincott Williams Wilkins.
C1 London Sch Hyg & Trop Med, London WC1, England.
   Minist Saude Publ, Bissau, Guinea Bissau.
   Projecto Saude Bandim, Bissau, Guinea Bissau.
   MRC Labs, Banjul, Gambia.
RP van der Loeff, MFS (reprint author), POB 273, Banjul, Gambia.
CR Aaby P, 1997, AIDS, V11, P939
   Aaby P, 1996, AIDS, V10, P1585
   Ariyoshi K, 1997, AIDS, V11, P1053
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   BRUNVEZINET F, 1987, LANCET, V1, P128
   BUCKNER M, 1999, VIVRE PENSER SIDA AF, P391
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Greenberg AE, 1996, SCIENCE, V272, P1959
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Kanki PJ, 1996, SCIENCE, V272, P1959
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Norrgren H, 1997, J ACQ IMMUN DEF SYND, V16, P31
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Sarr AD, 2000, AIDS RES HUM RETROV, V16, P295, DOI 10.1089/088922200309395
   TEDDER RS, 1988, LANCET, V2, P927
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   VANDERLOEFF MFS, 1999, 11 INT C STD AIDS AF
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Xiang Z, 1997, AIDS RES HUM RETROV, V13, P501, DOI 10.1089/aid.1997.13.501
NR 24
TC 35
Z9 37
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV 23
PY 2001
VL 15
IS 17
BP 2303
EP 2310
DI 10.1097/00002030-200111230-00012
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 555GW
UT WOS:000175787200012
OA No
DA 2017-08-15
ER

PT J
AU Garly, ML
   Bale, C
   Martins, CL
   Balde, MA
   Hedegaard, KL
   Whittle, HC
   Aaby, P
AF Garly, ML
   Bale, C
   Martins, CL
   Balde, MA
   Hedegaard, KL
   Whittle, HC
   Aaby, P
TI BCG vaccination among West African infants is associated with less
   anergy to tuberculin and diphtheria-tetanus antigens
SO VACCINE
LA English
DT Article
DE BCG vaccine; diphtheria-tetanus-pertussis vaccine; anergy
ID CELL-MEDIATED-IMMUNITY; GUINEA-BISSAU; BANGLADESHI CHILDREN; SKIN-TEST;
   HYPERSENSITIVITY; MEASLES; REACTIVITY; MORTALITY; RESPONSES; ATOPY
AB To examine risk factors for anergy. delayed-type hypersensitivity was assessed among 884 infants participating in a vaccine trial in Guinea-Bissau. The infants were skin-tested at 7.5 months of age with a panel of seven intradermal antigens. Risk factors for anergy to tuberculin or anergy to both the diphtheria and tetanus antigens were determined in relation to Bacillus Calmette-Guerin (BCG) vaccination, diphtheria-tetanus-pertussis (DTP) vaccination, and measles vaccination. We found sick children to be more anergic to tuberculin and diphtheria-tetanus antigens than healthy children (OR = 2.49 (95% confidence interval 1.40-4.55)). There was a higher prevalence of anergy to tuberculin in the rainy season than in the dry season (OR = 1.67 (1.25-2.23)). Children who had taken antimalarials within the last week had a higher prevalence of anergy to tuberculin (OR = 1.41 (1.02-1.92)). BCG vaccination was significantly associated with less anergy to tuberculin and diphtheria-tetanus antigens (OR = 0.42 (0.28-0.63), OR = 0.77 (0.60-0.99), respectively). Children vaccinated with BCG before I month of age were more anergic to tuberculin than children vaccinated after I month (OR = 1.61 (1.19-2.19)). DTP vaccination was associated with less anergy to diphtheria-tetanus antigens (OR = 0.40 (0.32-0.49)), but not to tuberculin. Children with a positive reaction to tuberculin were less likely to be anergic to diphtheria-tetanus antigens (OR = 0.36 (0.26-0.49)) than children with a negative tuberculin reaction. Children who were vaccinated with BCG before they received their last DTP vaccine were less anergic to diphtheria-tetanus antigens (OR = 0.40 (0.16-0.88)) than other DTP-vaccinated children. In conclusion. current disease. rainy season, age below I month of age at the time of BCG vaccination. and administration of chloroquine or quinimax within the last 7 days were risk factors for anergy to tuberculin among 7.5-month-old infants. BCG vaccination and a positive tuberculin reaction were associated with a lower prevalence of anergy to both tuberculin and diphtheria-tetanus. Thus. BCG vaccination may contribute to better cell-mediated immune responses among infants. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Projecto Saude Bandim, Bissau, Guinea Bissau.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
   Med Res Council Labs, Fajara, Gambia.
RP Garly, ML (reprint author), Projecto Saude Bandim, Apartado 861, Bissau, Guinea Bissau.
CR Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   BANDIM AP, 1997, PROSPECTIVE COMMUNIT, P276
   BAQUI AH, 1993, AM J EPIDEMIOL, V137, P355
   BERKOVICH S, 1966, NEW ENGL J MED, V274, P67, DOI 10.1056/NEJM196601132740203
   BLACK RE, 1989, PEDIATR INFECT DIS J, V8, P210
   BRODY JA, 1964, AM REV RESPIR DIS, V90, P607
   CHRISTOU NV, 1989, ANN SURG, V210, P69, DOI 10.1097/00000658-198907000-00011
   DELPRETE G, 1992, ALLERGY, V47, P450
   Desnues P, 1967, Rev Tuberc Pneumol (Paris), V31, P1154
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   GARLY ML, 1999, THESIS U COPENHAGEN
   HARLAND PSE, 1965, LANCET, V2, P719
   HILDRETH EA, 1963, T AM CLIN CLIMAT ASS, V75, P37
   ILDIRIM I, 1992, ARCH DIS CHILD, V67, P80
   KNIKER WT, 1985, AM J DIS CHILD, V139, P840
   KOSTER FT, 1987, AM J CLIN NUTR, V46, P115
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   LIU AY, 1993, CHEST, V104, P1668, DOI 10.1378/chest.104.6.1668
   Madhi SA, 1999, PEDIATR INFECT DIS J, V18, P800, DOI 10.1097/00006454-199909000-00011
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2
   Rani S H, 1998, Indian Pediatr, V35, P123
   Schnorr JJ, 2001, VACCINE, V19, P1503, DOI 10.1016/S0264-410X(00)00349-2
   Shaheen SO, 1996, BRIT MED J, V313, P969
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   Simondon F, 1999, EUR J CLIN MICROBIOL, V18, P23, DOI 10.1007/s100960050221
   Sivarajah N, 1990, Ceylon Med J, V35, P75
   Slovis BS, 2000, JAMA-J AM MED ASSOC, V283, P2003, DOI 10.1001/jama.283.15.2003
   SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013
   STARR S, 1964, NEW ENGL J MED, V270, P386, DOI 10.1056/NEJM196402202700802
   Vredevoe DL, 1998, AM J CARDIOL, V82, P323, DOI 10.1016/S0002-9149(98)00334-8
   Wayne S.J., 1990, J GERONTOL, V45, P45
   Zaman K, 1996, EUR J CLIN NUTR, V50, P309
   ZWEIMAN B, 1971, INT ARCH ALLER A IMM, V40, P834
   1991, MMWR MORB MORTAL WKL, V40, P833
NR 35
TC 33
Z9 33
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD NOV 12
PY 2001
VL 20
IS 3-4
BP 468
EP 474
DI 10.1016/S0264-410X(01)00339-5
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 492DP
UT WOS:000172153400024
PM 11672911
OA No
DA 2017-08-15
ER

PT J
AU Faye, D
   de Almeida, PJLP
   Goossens, B
   Osaer, S
   Ndao, M
   Berkvens, D
   Speybroeck, N
   Nieberding, F
   Geerts, S
AF Faye, D
   de Almeida, PJLP
   Goossens, B
   Osaer, S
   Ndao, M
   Berkvens, D
   Speybroeck, N
   Nieberding, F
   Geerts, S
TI Prevalence and incidence of trypanosomosis in horses and donkeys in the
   Gambia
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE horse; donkey; Trypanosoma spp.; buffy-coat; PCR; the Gambia
ID POLYMERASE CHAIN-REACTION; PARASITOLOGICAL TECHNIQUES; AFRICAN
   TRYPANOSOMIASIS; DIAGNOSTIC EVALUATION; CATTLE; PCR; GOATS; VIVAX;
   CHALLENGE; TSETSE
AB In a study of the prevalence and incidence of trypanosomosis in horses and donkeys in two regions of the Gambia, surveys were carried out at Niamina east and Bansang south with a high and low to moderate tsetse challenge, respectively. Eleven horses and 67 donkeys were sampled monthly from August 1997 to September 1998. Blood samples were examined for trypanosomes using the buffy-coat (BC) method and polymerase chain reaction (PCR). Three primer sets were used, specific for either Trypanosoma vivax (TVW), Trypanosoma congolense (GOL) or Trypanosoma brucei (ORPHON5J).
   The BC results showed that the prevalence (August 1997) and the average monthly incidence (September 1997-1998) of trypanosome infections in horses (45.5 and 16%, respectively) were significantly higher than in donkeys (6.2 and 9%, respectively). Using PCR, the number of detected cases was seven times higher than using the BC. T congolense was the most frequently observed species, followed by T vivax and T brucei. This study confirms earlier observations by other authors that donkeys, which are exposed to a similar tsetse challenge as horses, are significantly less infected with trypanosomes than the latter. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med, B-2000 Antwerp, Belgium.
RP Faye, D (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR BARROWMAN PR, 1991, DONKEYS, MULES AND HORSES IN TROPICAL AGRICULTURAL DEVELOPMENT, P106
   de Almeida PJLP, 1998, VET PARASITOL, V80, P111
   de Almeida PP, 1998, ACTA TROP, V70, P269, DOI 10.1016/S0001-706X(98)00031-X
   deAlmeida PJLP, 1997, ACTA TROP, V66, P45, DOI 10.1016/S0001-706X(97)00677-3
   DEBRUJIN MHL, 1993, TROP MED PARASITOL, V44, P201
   Desquesnes M, 1997, ACTA TROP, V65, P139, DOI 10.1016/S0001-706X(96)00643-2
   *DLS ITC, 1993, NAT LIV CENS REP LIV
   Hoare C, 1972, TRYPANOSOMES MAMMALS
   LEPERRE P, 1994, TROP ANIM HEALTH PRO, V26, P139, DOI 10.1007/BF02241070
   MacLennan K. J. R., 1970, P751
   Masake RA, 1997, EXP PARASITOL, V85, P193, DOI 10.1006/expr.1996.4124
   MATTILI RC, 1994, TROP ANIM HEALTH PRO, V26, P102, DOI 10.1007/BF02239909
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   PARIS J, 1982, ACTA TROP, V39, P307
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   ROGERS DJ, 1985, ACTA TROP, V42, P5
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   STARKEY P, 1990, P 3 WORKSH W AFR AN, P90
   Sumberg J., 1992, African Livestock Research, V1, P1
   SWALLO BM, 1997, P 24 INT SCI COUNC T, P515
   Van Hoeve K., 1964, Veterinary Record, V76, P260
NR 21
TC 14
Z9 16
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV 5
PY 2001
VL 101
IS 2
BP 101
EP 114
DI 10.1016/S0304-4017(01)00503-9
PG 14
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 495ZF
UT WOS:000172369700003
PM 11587839
OA No
DA 2017-08-15
ER

PT J
AU Enwere, GE
   Obaro, SK
AF Enwere, GE
   Obaro, SK
TI Diagnosis of bacterial meningitis
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Obaro, SK (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507
CR Arditi M, 1998, PEDIATRICS, V102, P1087, DOI 10.1542/peds.102.5.1087
   Berkley JA, 2001, LANCET, V357, P1753, DOI 10.1016/S0140-6736(00)04897-2
   RADETSKY M, 1992, PEDIATR INFECT DIS J, V11, P694, DOI 10.1097/00006454-199209000-00002
NR 3
TC 2
Z9 2
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 3
PY 2001
VL 358
IS 9292
BP 1549
EP 1549
DI 10.1016/S0140-6736(01)06598-9
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 490MN
UT WOS:000172055800046
PM 11705597
OA No
DA 2017-08-15
ER

PT J
AU von Seidlein, L
   Drakeley, C
   Greenwood, B
   Walraven, G
   Targett, G
AF von Seidlein, L
   Drakeley, C
   Greenwood, B
   Walraven, G
   Targett, G
TI Risk factors for gametocyte carriage in Gambian children
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM; MALARIA
AB A widespread reduction in Plasmodium falciparum gametocyte prevalence could reduce malaria transmission. After infection with P. falciparum, a variable proportion of people are found to be gametocytemic. We analyzed risk factors associated with gametocytemia at presentation and 7 days later. We enrolled 1,198 children in 2 antimalarial. drug trials between September and December 1998. The children were assigned to 1 of 4 treatment groups: chloroquine only; pyrimethamine-sulfadoxine (PSD) only; PSD combined with 1 dose of artesunate; and PSD combined with 3 doses of artesunate. By the time of enrollment, 200 (17%) of 1,198 children were gametocyte carriers. Three independent risk factors were associated with gametocytemia at enrollment. Children with anemia were more likely to carry gametocytes, whereas children with fever (> 37.4 degreesC) or high parasite densities (> 100,000 parasites/muL) were less frequently gametocyte carriers. Children with at least 2 of the risk factors were 4 times more likely to be gametocytemic than children with < 2 risk factors (odds ratio [OR], 4.4; 95% confidence interval [CI], 2.7-7.1). Seven days after the start of treatment, 355 (37%) of 466 assessable children were found to be gametocyte carriers. Children treated with PSD alone had a significantly higher risk of being gametocytemic by Day 7 compared with children in the other 3 treatment groups. In the subgroup of children who had no detectable gametocytes on enrollment, the effect of treatment with PSD + 3 doses of artesunate was most marked. Nineteen (10%) of 198 children treated with PSD + 3 doses of artesunate became gametocytemic, in contrast to 184 (57%) of 321 children treated with PSD alone (OR, 12.7; 95% CI, 7.3-22.1). Early treatment with highly effective antimalarial therapy has the greatest chance of preventing gametocytemia. The choice of a first-line antimalarial drug for uncomplicated malaria should not only take into consideration the ablation asexual parasitemia but also the suppression of gametocytemia.
C1 MRC Labs, Fajara, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP von Seidlein, L (reprint author), Int Vaccine Inst, POB 14 Kwanak, Seoul, South Korea.
CR Akim NIJ, 2000, AM J TROP MED HYG, V63, P199
   Behrman RE, 1996, NELSON TXB PEDIAT
   Butcher GA, 1997, INT J PARASITOL, V27, P975, DOI 10.1016/S0020-7519(97)00079-9
   Collins WE, 1999, AM J TROP MED HYG, V61, P36
   David W. H., 1989, APPL LOGISTIC REGRES
   KUMAR N, 1990, PARASITOL RES, V76, P214, DOI 10.1007/BF00930817
   NAOTUNNE TD, 1991, J EXP MED, V173, P523, DOI 10.1084/jem.173.3.523
   Price R, 1999, AM J TROP MED HYG, V60, P1019
   Robert V, 1996, AM J TROP MED HYG, V55, P350
   SCHNEWEIS S, 1991, PARASITOL RES, V77, P458, DOI 10.1007/BF00931646
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Trager W, 1999, EXP PARASITOL, V91, P115, DOI 10.1006/expr.1998.4347
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x
NR 14
TC 63
Z9 64
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2001
VL 65
IS 5
BP 523
EP 527
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 491ZD
UT WOS:000172139700021
PM 11716108
OA No
DA 2017-08-15
ER

PT J
AU Nyan, OA
   Walraven, GEL
   Banya, WAS
   Milligan, P
   Van der Sande, M
   Ceesay, SM
   Del Prete, G
   McAdam, KPWJ
AF Nyan, OA
   Walraven, GEL
   Banya, WAS
   Milligan, P
   Van der Sande, M
   Ceesay, SM
   Del Prete, G
   McAdam, KPWJ
TI Atopy, intestinal helminth infection and total serum IgE in rural and
   urban adult Gambian communities
SO CLINICAL AND EXPERIMENTAL ALLERGY
LA English
DT Article
DE atopy; intestinal helminths; IgE; adult Gambian; asthma
ID ASTHMA; PREVALENCE; MITE
AB Background The rarity of atopy in traditional societies has been attributed to high parasite-driven blocking IgE concentrations. Information is lacking on the relationship between atopy, IgE and intestinal helminth infection in African populations.
   Objective To determine the prevalence of atopy and intestinal helminth infection and to relate these to wheeze history and serum total IgE in a community sample of adults from an urban (Banjul) and a rural (Farafenni) area of the Gambia.
   Methods Six hundred and ninety-three adults were interviewed about respiratory symptoms using a modified version of the IUTLD questionnaire, and had skin prick testing using four allergens. Stools were examined after formol-ether concentration. Total serum IgE concentration was measured in a subset of participants.
   Results The prevalence of atopy (mean weal diameter > = 3 mm) in the urban and rural area was 35.3% and 22.5% (P=0.05); D. pteronyssinus and Mold mix being the common sensitizing allergens. Prevalence of wheeze in the previous 12 months was 4.4% and 3.5% for the urban and rural areas, respectively. Wheezing was not significantly associated with atopy. Seventeen per cent of urban and 8.2% of rural subjects had helminths detected in stools. There was an inverse association between atopy and intestinal helminth infection; 7% of atopic subjects had helminths, compared to 13% of non-atopic subjects (unadjusted odds ratio 0.51, 95%CI 0.24-1.1, P=0.09; adjusted odds ratio 0.37, 95%CI 0.15-0.92, P=0.03). Non-atopics had total serum IgE concentrations about 2.5 times the upper limit of the reference range in non-atopic Western populations. Geometric mean total serum IgE concentration was significantly higher among atopic subjects (570 IU/mL, IQR 91-833) than non-atopic subjects (259 IU/mL, IQR 274-1303) (P<0.001). IgE concentration was not associated with the presence of helminth infection.
   Conclusion Further studies are needed to clarify why asthma is still relatively uncommon in spite of the prevalence of atopy in Gambian adults. Our data are also compatible with the idea that atopy might protect against helminth infection.
C1 Univ Florence, Florence, Italy.
   MRC Labs, Banjul, Gambia.
RP Nyan, OA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ARLIAN LG, 1991, J INVEST DERMATOL, V96, P349, DOI 10.1111/1523-1747.ep12465257
   BORROWS B, 1989, NEW ENGL J MED, V320, P271
   BURNEY PGJ, 1989, EUR RESPIR J, V2, P940
   CDC, 1979, INT PAR SURV ANN SUM
   Crimi E, 1998, AM J RESP CRIT CARE, V157, P4
   Faniran AO, 1999, THORAX, V54, P606
   Finkelman F. D., 1991, IMMUNOL TODAY, V12, P62
   GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x
   HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0
   HAGAN P, 1993, PARASITE IMMUNOL, V15, P1, DOI 10.1111/j.1365-3024.1993.tb00565.x
   JOHANSSON SG, 1968, LANCET, V1, P1118
   Kang G, 1998, TROP MED INT HEALTH, V3, P70, DOI 10.1046/j.1365-3156.1998.00175.x
   KNIGHT R, 1981, ANN TROP MED PARASIT, V75, P299
   LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z
   LYNCH NR, 1992, PARASITOL TODAY, V8, P166, DOI 10.1016/0169-4758(92)90011-P
   Morgan MS, 1997, AM J TROP MED HYG, V57, P190
   OHMAN JL, 1993, J ALLERGY CLIN IMMUN, V91, P752, DOI 10.1016/0091-6749(93)90195-L
   PRITCHARD DI, 1997, PARASITOLOGY, V115, P1
   Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7
   Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5
   *STAT, 1999, STAT STAT SOFTW REL
   Strachan D, 1996, TOXICOL LETT, V86, P199, DOI 10.1016/0378-4274(96)03691-0
   SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3
   Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3
NR 24
TC 108
Z9 113
U1 1
U2 5
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0954-7894
J9 CLIN EXP ALLERGY
JI Clin. Exp. Allergy
PD NOV
PY 2001
VL 31
IS 11
BP 1672
EP 1678
DI 10.1046/j.1365-2222.2001.00987.x
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 496XF
UT WOS:000172423100006
PM 11696042
OA No
DA 2017-08-15
ER

PT J
AU Walraven, GEL
   Nyan, OA
   Van der Sande, MAB
   Banya, WAS
   Ceesay, SM
   Milligan, PJM
   McAdam, KPWJ
AF Walraven, GEL
   Nyan, OA
   Van der Sande, MAB
   Banya, WAS
   Ceesay, SM
   Milligan, PJM
   McAdam, KPWJ
TI Asthma, smoking and chronic cough in rural and urban adult communities
   in The Gambia
SO CLINICAL AND EXPERIMENTAL ALLERGY
LA English
DT Article
DE adult Gambians; asthma; chronic cough; epidemiology; smoking
ID PREVALENCE; CHILDREN; CHILDHOOD; SYMPTOMS
AB Background Asthma is reported to be rare in traditional rural communities, but is thought to be increasing as lifestyles become more urbanized or 'western'.
   Objectives A community-based survey of non-communicable diseases was conducted from October 1996 to June 1997, and included comparison of the prevalence of asthma, smoking and chronic cough in rural and urban Gambia.
   Methods A cluster sample survey was conducted in a random sample of rural and urban adults (greater than or equal to 15 years of age). Subjects were asked about respiratory symptoms using a locally adapted version based on the IULTD questionnaire. Spirometry (basal, methacholine provocation and reversibility with a bronchodilator) and skin prick tests were performed an a randomly selected subsample of all subjects and those who, when interviewed, said they wheezed or had been diagnosed as asthmatic by a doctor.
   Results Out of 2166 participants in the urban population, 4.1% reported having had wheezing or whistling in the chest in the previous 12 months, 3.6% reported doctor-diagnosed asthma, and 0.6% chronic cough. In the rural population with 3223 participants these figures were 3.3%, 0.7% and 1.2%, respectively. Wheeze was more common in women, cough for 3 months of the year was more common in the age-groups 45+. Those who reported that they currently smoked accounted for 34% in urban and 42% in rural men. Figures were much lower for women (1.5% and 6.0%). Seven out of 574 randomly selected subjects (1.4%) exhibited bronchial hyper-responsiveness to methacholine challenge. Four of 133 (3.0%) people with self-reported wheeze and 3/69 (4.3%) participants with doctor-diagnosed asthma reacted positively on bronchial provocation with methacholine. There was a remarkably high prevalence of positive skin prick tests to aeroallergens: 38% in participants with a history of wheeze and 27% in those without.
   Conclusion The prevalence of wheeze (particularly in association with bronchial hyperresponsiveness) vas low in both rural and urban Gambia. This is in contrast to the relatively high prevalence of positive skin prick tests to aeroallergens (in both wheezers and non-wheezers), questioning the mechanisms of interaction between allergy and asthma and the presence of protective factors against asthma in this West African population. The high smoking rates justify international concern about tobacco marketing in developing societies.
C1 MRC Labs, Banjul, Gambia.
RP Walraven, GEL (reprint author), MRC Labs, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Becklake MR, 1997, LANCET, V350, P10
   BURNEY PGJ, 1989, EUR RESPIR J, V2, P940
   *CENTR STAT DEP, 1995, 1993 1994 HOUS ED HL
   *CENTR STAT DEP, 1994, 1993 HOUS EC SURV RE
   CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303
   Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41
   Dagli E, 1999, INT J TUBERC LUNG D, V3, P113
   DOWSE GK, 1986, CLIN ALLERGY, V16, P17
   FLOREY C, 1981, EUROPEAN SERIES WHO, V12
   GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x
   Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x
   INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834
   KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549
   Marchant A, 1999, J IMMUNOL, V163, P2249
   MARTINEZ FD, 1998, CLIN EXP ALLERGY, V28, P136
   NEWMANTAYLOR A, 1995, LANCET, V345, P296
   Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x
   OBYRNE PM, 1995, MANUAL ASTHMA MANAGE
   PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549
   Sears MR, 1997, LANCET, V350, P1
   STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693
   STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x
   VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319
   vonMutius E, 1997, LANCET, V350, P14
   WOOLCOCK AJ, 1994, TXB RESP MED, P1288
   Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3
NR 26
TC 27
Z9 28
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0954-7894
J9 CLIN EXP ALLERGY
JI Clin. Exp. Allergy
PD NOV
PY 2001
VL 31
IS 11
BP 1679
EP 1685
DI 10.1046/j.1365-2222.2001.01094.x
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 496XF
UT WOS:000172423100007
PM 11696043
OA No
DA 2017-08-15
ER

PT J
AU Crampin, AC
   Floyd, S
   Mwaungulu, F
   Black, G
   Ndhlovu, R
   Mwaiyeghele, E
   Glynn, JR
   Warndorff, DK
   Fine, PEM
AF Crampin, AC
   Floyd, S
   Mwaungulu, F
   Black, G
   Ndhlovu, R
   Mwaiyeghele, E
   Glynn, JR
   Warndorff, DK
   Fine, PEM
TI Comparison of two versus three smears in identifying culture-positive
   tuberculosis patients in a rural African setting with high HIV
   prevalence
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculosis; diagnosis; smears; HIV; Africa
ID PULMONARY TUBERCULOSIS; SPUTUM SMEARS; DIAGNOSIS; MICROSCOPY; INFECTION;
   YIELD
AB SETTING: Karonga district, northern Malawi.
   OBJECTIVE: To compare the sensitivity and specificity of two versus three smears for the diagnosis of pulmonary tuberculosis in a setting, with high HIV prevalence.
   DESIGN: A total of 1992 pulmonary tuberculosis suspects with three sputum smears taken over a 2-7 day period and at least one culture result were studied. Smears were auramine stained and examined using fluorescence microscopy, and positives were confirmed with Ziehl-Neelsen staining and light microscopy. Cultures were set up on Lowenstein-jensen media. True negative and positive status was defined on the basis of culture. The sensitivity, specificity, and positive and negative predictive values of two and three smears were compared.
   RESULTS: Compared to culture, the sensitivity, specificity, and positive and negative predictive values of three smears were 70%, 98%, 92%, and 92%, respectively. Restriction to the first two smears gave similar results. Of those detected as smear-positive using three smears, at least 97% would have been detected by two. Among those with HIV serology results available, the sensitivity of two smears for detecting culture-positive tuberculosis was identical to that using three.
   CONCLUSION: In this setting, using fluorescence and light microscopy, collecting two smears rather than three would only marginally reduce sensitivity and would slightly improve the specificity of diagnosis of tuberculosis; this is unaffected by HIV status. The potential for improving specificity is important because of the costs of misdiagnosis. In practice, both sensitivity and specificity may be increased due to the time saved by examining two rather than three smears.
C1 Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Karonga Prevent Study, Chilumba, Malawi.
   MRC Labs, Fajara, Gambia.
RP Fine, PEM (reprint author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR BLAIR EB, 1976, AM REV RESPIR DIS, V113, P427
   Cauthen GM, 1996, AM J EPIDEMIOL, V144, P69
   DeCock KM, 1996, AM J PUBLIC HEALTH, V86, P1071, DOI 10.2105/AJPH.86.8_Pt_1.1071
   Dujardin B, 1997, AM J PUBLIC HEALTH, V87, P1234, DOI 10.2105/AJPH.87.7.1234-a
   ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U
   Enarson DA, 1996, TUBERCULOSIS GUIDE L
   Fine PEM, 2001, EPIDEMIOL INFECT, V126, P379
   Glynn JR, 1998, B WORLD HEALTH ORGAN, V76, P295
   Harries AD, 1996, LANCET, V347, P834, DOI 10.1016/S0140-6736(96)90915-0
   Harries AD, 2000, INT J TUBERC LUNG D, V4, P36
   Ipuge YAI, 1996, T ROY SOC TROP MED H, V90, P258, DOI 10.1016/S0035-9203(96)90239-4
   KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190
   LONG R, 1991, AM J PUBLIC HEALTH, V81, P1326, DOI 10.2105/AJPH.81.10.1326
   Nair SS, 1976, INDIAN J TUBERC, V23, P152
   NARAIN R, 1971, AM REV RESPIR DIS, V103, P761
   NARAIN R, 1968, B WORLD HEALTH ORGAN, V39, P701
   SMITH RL, 1994, CHEST, V106, P684, DOI 10.1378/chest.106.3.684
   Toman K, 1979, TUBERCULOSIS CASE FI
   URBANCZIK R, 1985, ZBL BAKT-INT J MED M, V260, P81
   Walker D, 2000, INT J TUBERC LUNG D, V4, P246
NR 20
TC 35
Z9 35
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD NOV
PY 2001
VL 5
IS 11
BP 994
EP 999
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 489WD
UT WOS:000172014700003
PM 11716350
OA No
DA 2017-08-15
ER

PT J
AU Flanagan, KL
   Lee, EAM
   Gravenor, MB
   Reece, WHH
   Urban, BC
   Doherty, T
   Bojang, KA
   Pinder, M
   Hill, AVS
   Plebanski, M
AF Flanagan, KL
   Lee, EAM
   Gravenor, MB
   Reece, WHH
   Urban, BC
   Doherty, T
   Bojang, KA
   Pinder, M
   Hill, AVS
   Plebanski, M
TI Unique T cell effector functions elicited by Plasmodium falciparum
   epitopes in malaria-exposed Africans tested by three T cell assays
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMORAL IMMUNE-RESPONSES; NATURALLY ACQUIRED ANTIBODIES;
   CIRCUMSPOROZOITE PROTEIN; GAMMA-INTERFERON; MYCOBACTERIUM-LEPRAE;
   VACCINE DEVELOPMENT; SPOROZOITE VACCINE; LEPROSY PATIENTS; DEFICIENT
   MICE; KUPFFER CELLS
AB Natural immunity to malaria Is characterized by low level CD4 T cell reactivity detected by either lymphoproliferation or IFN-gamma secretion. Here we show a doubling in the detection rate of responders to the carboxyl terminus of circumsporozoite protein (CS) of Plasmodium falciparum by employing three T cell assays simultaneously: rapid IFN-T secretion (ex vivo ELISPOT), IFN-gamma secretion after reactivation of memory T cells and expansion in vitro (cultured ELISPOT), and lymphoproliferation. Remarkably, for no individual peptide did a positive response for one T cell effector function correlate with any other. Thus these CS epitopes elicited unique T cell response patterns in malaria-exposed donors. Novel or important epitope responses may therefore be missed if only one T cell assay is employed. A borderline correlation was found between anti-CS Ab levels and proliferative responses, but no correlation was found with ex vivo or cultured IFN-gamma responses. This suggested that the proliferating population, but not the IFN-gamma -secreting cells, contained cells that provide help for Ab production. The data suggest that natural immunity to malaria is a complex function of T cell subgroups with different effector functions and has important implications for future studies of natural T cell immunity.
C1 Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
   MRC Labs, Malaria Lab, Fajara, Gambia.
   Austin & Repatriat Med Ctr, Austin Res Inst, Vaccine & Infect Dis Unit, Melbourne, Vic, Australia.
RP Flanagan, KL (reprint author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
RI HILL, Adrian/C-1306-2008
CR AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2
   BALLOU WR, 1987, LANCET, V1, P1277
   CASPERS P, 1989, MOL BIOCHEM PARASIT, V35, P185, DOI 10.1016/0166-6851(89)90121-7
   CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7
   CHAROENVIT Y, 1995, EXP PARASITOL, V80, P419, DOI 10.1006/expr.1995.1054
   CHEN DH, 1977, J IMMUNOL, V118, P1322
   CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002
   DANFORTH HD, 1980, J PROTOZOOL, V27, P193, DOI 10.1111/j.1550-7408.1980.tb04680.x
   DEGROOT AS, 1989, J IMMUNOL, V142, P4000
   DELACRUZ VF, 1989, J IMMUNOL, V142, P3568
   Doolan DL, 1999, J IMMUNOL, V163, P884
   DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511
   Doolan DL, 1997, PARASITOL TODAY, V13, P171, DOI 10.1016/S0169-4758(97)01040-5
   EGAN JE, 1987, SCIENCE, V236, P453, DOI 10.1126/science.3551073
   FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HOFFMAN SL, 1989, J IMMUNOL, V142, P1299
   HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709
   HOFFMAN SL, 1986, NEW ENGL J MED, V315, P601, DOI 10.1056/NEJM198609043151001
   HOLLSBERG P, 1995, P NATL ACAD SCI USA, V92, P4036, DOI 10.1073/pnas.92.9.4036
   HVIID L, 1990, APMIS, V98, P594
   JANSON AAM, 1991, J IMMUNOL, V147, P3530
   KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0
   Kwiatkowski D, 1997, LANCET, V350, P1696, DOI 10.1016/S0140-6736(97)03256-X
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   LANGHORNE J, 1995, INT IMMUNOL, V7, P1005, DOI 10.1093/intimm/7.6.1005
   LINK HT, 1993, EUR J IMMUNOL, V23, P2263, DOI 10.1002/eji.1830230932
   MAHESHWARI RK, 1986, INFECT IMMUN, V53, P628
   MEIS JFGM, 1983, PARASITOLOGY, V86, P231
   MELLOUK S, 1987, J IMMUNOL, V139, P4192
   Milich DR, 1997, J VIROL, V71, P2192
   Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520
   MORENO A, 1993, J IMMUNOL, V151, P489
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145
   Moudgil KD, 1998, J IMMUNOL, V161, P6046
   MUTIS T, 1993, J IMMUNOL, V150, P4641
   NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0
   NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5
   Plebanski M, 1997, J IMMUNOL, V158, P2849
   PLEBANSKI M, 1998, EUR J IMMUNOL, V28, P1
   POMBO D, 1988, J IMMUNOL, V140, P3594
   POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504
   RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1988, CLIN EXP IMMUNOL, V71, P377
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   Rzepczyk CM, 1997, INT J PARASITOL, V27, P191, DOI 10.1016/S0020-7519(96)00149-X
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   SHI YP, 1992, AM J TROP MED HYG, V47, P844
   SINDEN RE, 1982, ACTA TROP, V39, P11
   SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0
   SINIGAGLIA F, 1988, EUR J IMMUNOL, V18, P633, DOI 10.1002/eji.1830180422
   SPITALNY GL, 1977, EXP PARASITOL, V42, P73, DOI 10.1016/0014-4894(77)90063-7
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   STREET NE, 1991, FASEB J, V5, P171
   SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x
   TROYEBLOMBERG M, 1990, P NATL ACAD SCI USA, V87, P5484, DOI 10.1073/pnas.87.14.5484
   TROYEBLOMBERG M, 1989, J IMMUNOL, V25, P1002
   TSUJI M, 1994, P NATL ACAD SCI USA, V91, P345, DOI 10.1073/pnas.91.1.345
   VANDERBERG JP, 1990, J PROTOZOOL, V37, P528, DOI 10.1111/j.1550-7408.1990.tb01260.x
   Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778
   VERHAVE JP, 1978, J IMMUNOL, V121, P1031
   VREDEN SGS, 1994, PARASITOL TODAY, V10, P304, DOI 10.1016/0169-4758(94)90084-1
   ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595
   ZEVERING Y, 1990, INT IMMUNOL, V2, P945, DOI 10.1093/intimm/2.10.945
   Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837
NR 75
TC 48
Z9 48
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2001
VL 167
IS 8
BP 4729
EP 4737
PG 9
WC Immunology
SC Immunology
GA 487DL
UT WOS:000171858300073
PM 11591804
OA No
DA 2017-08-15
ER

PT J
AU Greenwood, B
   Corrah, T
AF Greenwood, B
   Corrah, T
TI Systemic lupus erythematosus in African immigrants
SO LANCET
LA English
DT Letter
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Greenwood, B (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR Brown MA, 1997, ANN RHEUM DIS, V56, P68, DOI 10.1136/ard.56.1.68
   GREENWOO.BM, 1968, LANCET, V2, P380
   HOLLIGAN S, 1991, BR J RHEUMATOL S2, V9, P30
   Molokhia M, 2001, LANCET, V357, P1414, DOI 10.1016/S0140-6736(00)04580-3
NR 4
TC 7
Z9 7
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 6
PY 2001
VL 358
IS 9288
BP 1182
EP 1182
DI 10.1016/S0140-6736(01)06281-X
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 479HM
UT WOS:000171399000044
PM 11597702
OA No
DA 2017-08-15
ER

PT J
AU Awomoyi, AA
   Marchant, A
   Sirugo, G
   McAdam, K
   Tishkoff, SA
   Blackwell, J
   Newport, M
AF Awomoyi, AA
   Marchant, A
   Sirugo, G
   McAdam, K
   Tishkoff, SA
   Blackwell, J
   Newport, M
TI Identifying tuberculosis disease resistance genes using Quantitative
   Phenotype Analysis.
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Meeting Abstract
C1 Univ Maryland, Dept Biol, College Pk, MD 20742 USA.
   Inst Mol Med, Oxford, England.
   MRC Labs, Fajara, Gambia.
   Cambridge Inst Med Res, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT
PY 2001
VL 69
IS 4
SU 1
MA 1282
BP 401
EP 401
PG 1
WC Genetics & Heredity
SC Genetics & Heredity
GA 483RD
UT WOS:000171648901282
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Ceesay, SM
   Milligan, PJM
   Nyan, OA
   Banya, WAS
   Prentice, A
   McAdam, KPWJ
   Walraven, GEL
AF van der Sande, MAB
   Ceesay, SM
   Milligan, PJM
   Nyan, OA
   Banya, WAS
   Prentice, A
   McAdam, KPWJ
   Walraven, GEL
TI Obesity and undernutrition and cardiovascular risk factors in rural and
   urban Gambian communities
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID NUTRITIONAL-STATUS; HYPERTENSION; ADULTS; PREVALENCE; DISEASE; AFRICA
AB Objectives. This study documented the prevalence of and cardiovascular risk factors associated with obesity and undernutrition in the Gambia.
   Methods. Adults (greater than or equal to 15 years; N = 5373) from rural and urban areas completed a questionnaire; their height, weight, and waist and hip circumferences were measured, and their cardiovascular risk factors were assessed,
   Results. Prevalence of undernutrition (body mass index < 18 kg/m(2)) was 18.0%; all strata of society were affected. Prevalence of obesity (body mass index greater than or equal to 30 kg/m(2)) was 4.0% but was higher (32.6%) among urban women 35 years or older. Cardiovascular risk factors were more prevalent among obese participants.
   Conclusions. Undernutrition coexists with obesity, demonstrating a "double burden of disease." Differential interventions should focus on high-risk groups; prevention needs a multisectorial approach.
C1 MRC Labs, Fajara, Gambia.
   MRC, Dunn Nutr Unit, Cambridge CB4 1XJ, England.
RP van der Sande, MAB (reprint author), MRC, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ALEMU T, 1995, INT J EPIDEMIOL, V24, P977, DOI 10.1093/ije/24.5.977
   Bailey KV, 1995, B WORLD HEALTH ORGAN, V73, P673
   Cameron N., 1984, MEASUREMENT HUMAN GR
   DETTWYLER KA, 1992, AM J PHYS ANTHROPOL, V88, P309, DOI 10.1002/ajpa.1330880306
   DOWSE GK, 1995, BRIT MED J, V311, P1255
   HODGE AM, 1994, BAILLIERE CLIN ENDOC, V8, P577, DOI 10.1016/S0950-351X(05)80287-3
   Igbedioh S. O., 1993, Nutrition and Health (Bicester), V9, P1
   Kaufman JS, 1996, EPIDEMIOLOGY, V7, P398, DOI 10.1097/00001648-199607000-00010
   LAWS A, 1993, BAILLIERE CLIN ENDOC, V7, P1063, DOI 10.1016/S0950-351X(05)80245-9
   O'Brien E, 1996, BLOOD PRESS MONIT, V1, P55
   Okosun IS, 1998, DIABETES CARE, V21, P1836, DOI 10.2337/diacare.21.11.1836
   SWAI AB, 1992, BRIT MED J, V305, P1057
   van der Sande MAB, 1999, TROP MED INT HEALTH, V4, P506
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   WALKER ARP, 1990, J ROY SOC HEALTH, V110, P101, DOI 10.1177/146642409011000311
   Wilks R, 1996, CIBA F SYMP, V201, P37
NR 17
TC 47
Z9 47
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD OCT
PY 2001
VL 91
IS 10
BP 1641
EP 1644
DI 10.2105/AJPH.91.10.1641
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 476JD
UT WOS:000171221800032
PM 11574327
OA No
DA 2017-08-15
ER

PT J
AU Richardson, A
   Sisay-Joof, F
   Ackerman, H
   Usen, S
   Katundu, P
   Taylor, T
   Molyneux, M
   Pinder, M
   Kwiatkowski, D
AF Richardson, A
   Sisay-Joof, F
   Ackerman, H
   Usen, S
   Katundu, P
   Taylor, T
   Molyneux, M
   Pinder, M
   Kwiatkowski, D
TI Nucleotide diversity of the TNF gene region in an African village
SO GENES AND IMMUNITY
LA English
DT Article
DE The Gambia; TNF gene; Malawi
ID PROMOTER REGION; ALPHA PROMOTER; MENINGOCOCCAL DISEASE; 5'-FLANKING
   REGION; CEREBRAL MALARIA; CROHNS-DISEASE; POLYMORPHISM; SUSCEPTIBILITY;
   ALLELE
AB The wide variety of disease associations reported at the TNF locus raises the question of how much variation exists within a single population. To address this question, we sequenced the entire TNF gene in 72 chromosomes from healthy residents of a village in The Gambia, West Africa. We found 12 polymorphisms in 4393 nucleotides, of which five have not been previously described, giving an estimated nucleotide diversity (theta) of 5.6 x 10(-4). A significantly higher frequency of polymorphisms was found in the promoter region than in the coding region (8/1256 vs 0/882 nucleotides, P = 0.02). All polymorphisms with the exception of one rare allele were found to be present in Malawi, which is both geographically and genetically distant from The Gambia. Genotyping of 424 Gambian and 121 Malawian adults showed a significant frequency difference between the two populations for eight of the 12 polymorphisms, but the average fixation index across the variable sites was relatively low (F-ST = 0.007). We conclude that, at the TNF locus, the nucleotide diversity found within a single African village is similar to the global value for human autosomal genes sampled across different continents.
C1 Wellcome Trust Ctr Human Genet, Oxford, England.
   MRC Labs, Fajara, Gambia.
   Univ Malawi, Coll Med, Wellcome Trust Res Labs, Blantyre, Malawi.
   Univ Malawi, Coll Med, Malawi Project, Blantyre, Malawi.
RP Kwiatkowski, D (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford, England.
CR Abraham LJ, 1999, J LEUKOCYTE BIOL, V66, P562
   Beck S, 1999, NATURE, V401, P921
   Brinkman B M, 1995, J Inflamm, V46, P32
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Cargill M, 1999, NAT GENET, V22, P231
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Fernandez-Arquero M, 1999, NEUROLOGY, V53, P1361
   Goddard KAB, 2000, AM J HUM GENET, V66, P216, DOI 10.1086/302727
   Halushka MK, 1999, NAT GENET, V22, P239
   Higuchi T, 1998, TISSUE ANTIGENS, V51, P605, DOI 10.1111/j.1399-0039.1998.tb03002.x
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277
   Hohjoh H, 2001, GENES IMMUN, V2, P105, DOI 10.1038/sj.gene.6363721
   Kawasaki A, 2000, GENES IMMUN, V1, P351, DOI 10.1038/sj.gene.6363689
   Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649
   Knight JC, 1999, P ASSOC AM PHYSICIAN, V111, P290, DOI 10.1046/j.1525-1381.1999.99237.x
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551
   Nadel S, 1996, J INFECT DIS, V174, P878
   NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611
   Negoro K, 1999, GASTROENTEROLOGY, V117, P1062, DOI 10.1016/S0016-5085(99)70390-2
   Skoog T, 1999, HUM MOL GENET, V8, P1443, DOI 10.1093/hmg/8.8.1443
   Stuber F, 1996, J INFLAMM, V46, P42
   Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000
   Uglialoro AM, 1998, TISSUE ANTIGENS, V52, P359, DOI 10.1111/j.1399-0039.1998.tb03056.x
   Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   Wright S, 1921, GENETICS, V6, P111
NR 29
TC 35
Z9 44
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD OCT
PY 2001
VL 2
IS 6
BP 343
EP 348
DI 10.1038/sj.gene.6363789
PG 6
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 479FW
UT WOS:000171395200008
PM 11607791
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Lesi, F
   Hainaut, P
   Mendy, M
   Goedert, J
   Montesano, R
AF Kirk, GD
   Lesi, F
   Hainaut, P
   Mendy, M
   Goedert, J
   Montesano, R
TI Hepatitis B and C infection and aflatoxin exposure in hepatocellular
   carcinoma: A case-control study from the Gambia, West Africa.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 NCI, Rockville, MD USA.
   NIH, NIAID, Rockville, MD USA.
   Gambia Hepatitis Intervent Study, Banjul, Gambia.
   Int Agcy Res Canc, F-69372 Lyon, France.
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2001
VL 34
IS 4
SU S
MA 1978
BP 666A
EP 666A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476KE
UT WOS:000171224701969
OA No
DA 2017-08-15
ER

PT J
AU Vekemans, J
   Lienhardt, C
   Sillah, JS
   Wheeler, JG
   Lahai, GP
   Doherty, MT
   Corrah, T
   Andersen, P
   McAdam, KPWJ
   Marchant, A
AF Vekemans, J
   Lienhardt, C
   Sillah, JS
   Wheeler, JG
   Lahai, GP
   Doherty, MT
   Corrah, T
   Andersen, P
   McAdam, KPWJ
   Marchant, A
TI Tuberculosis contacts but not patients have higher gamma interferon
   responses to ESAT-6 than do community controls in The Gambia
SO INFECTION AND IMMUNITY
LA English
DT Article
ID T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS; MORTALITY
AB The Mycobacterium tuberculosis antigen ESAT-6 has been proposed for tuberculosis immunodiagnosis. In The Gambia, 30% of community controls produced gamma interferon (IFN-gamma) in response to ESAT-6. Increased proportions of responders and intensities of responses were found in household contacts. Responses that were initially low in tuberculosis patients increased after treatment. An ESAT-6 IFN-gamma assay will be of limited use in the diagnosis of tuberculosis in countries where tuberculosis is endemic. Its role in contact tracing should be evaluated further.
C1 Statens Serum Inst, DK-2300 Copenhagen, Denmark.
   London Sch Hyg & Trop Med, London WC1, England.
   Free Univ Brussels, Brussels, Belgium.
   Natl TB Control Programme, Banjul, Gambia.
   Med Res Counciol Labs, Fajara, Senegal.
RP Vekemans, J (reprint author), Fac Med, Lab Immunol Expt, Batiment GE,808 Route Lennik, B-1070 Brussels, Belgium.
CR Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   Demissie A, 1999, INFECT IMMUN, V67, P5967
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   LEITCH AG, 1992, RESP MED, V86, P371, DOI 10.1016/S0954-6111(06)80003-X
   *MIN HLTH SOC WELF, 1992, EXP PROGR IMM CLUST
   NYBOE J, 1960, Bull World Health Organ, V22, P5
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640
   RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9
   SCHOEL B, 1992, INFECT IMMUN, V60, P1717
   Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W
   Ulrichs T, 2000, INFECT IMMUN, V68, P6073, DOI 10.1128/IAI.68.10.6073-6076.2000
   *WHO, 2000, WHOCDSTB200275
NR 18
TC 86
Z9 89
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD OCT
PY 2001
VL 69
IS 10
BP 6554
EP 6557
DI 10.1128/IAI.69.10.6554-6557.2001
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 474RR
UT WOS:000171121100076
PM 11553606
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Milligan, PJM
   Walraven, GEL
   Dolmans, WMV
   Newport, M
   Nyan, OA
   Banya, WAS
   Thien, T
   Ward, R
   McAdam, KPWJ
AF van der Sande, MAB
   Milligan, PJM
   Walraven, GEL
   Dolmans, WMV
   Newport, M
   Nyan, OA
   Banya, WAS
   Thien, T
   Ward, R
   McAdam, KPWJ
TI Geographical variation in prevalence of hypertension within The Gambia
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Article
DE hypertension prevalence; geographical variation; community randomised
   trials; sub-Sahara Africa
ID BLOOD-PRESSURE; NONCOMMUNICABLE DISEASES; RISK FACTOR; INTERVENTION;
   EPIDEMIOLOGY; POPULATIONS; PROGRAM; AFRICA; DESIGN; TRIALS
AB Hypertension has become an important public health problem for sub-Sahara Africa. In a previous nationwide study, we observed a high degree of geographical variation in the prevalence of diastolic hypertension. Geographical variation provides essential background information for the development of community randomised trials could suggest aetiological mechanisms, inform control strategies and prompt further research questions. We designed a follow-up study from the nine high-prevalence communities, and from 18 communities where hypertension was found least prevalent (controls). In each community, 50 households were randomly selected. In each household, an (unrelated) man and woman were enrolled. The risk for hypertension (blood pressure greater than or equal to 160/95 mm Hg) was higher in the high prevalence communities compared to the control villages (adjusted OR = 1.7, 95% Cl 1.3-2.2). The observed coefficient of variation in hypertension prevalence, k, was 0.30. Thus we confirmed significant geographical variation in prevalence of hypertension over time, which has implications for planning of interventions.
C1 MRC Labs, Fajara, Gambia.
RP van der Sande, MAB (reprint author), MRC, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Bakx JC, 1999, HUISARTS WETENSCHAP, V42, P53
   BEEGOM R, 1995, INT J CARDIOL, V51, P183, DOI 10.1016/0167-5273(95)02402-I
   BEEVERS DG, 1991, T ROY SOC TROP MED H, V85, P324, DOI 10.1016/0035-9203(91)90276-5
   BENNETT S, 1992, J HUM HYPERTENS, V6, P271
   *CENTR STAT DEP, 1998, POP HOUS CENS 1993 M
   Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160
   Cooper RS, 1998, BRIT MED J, V316, P614
   DOWSE GK, 1995, BRIT MED J, V311, P1255
   Forrester T, 1998, BRIT MED BULL, V54, P463
   Grim Clarence E., 1995, P171
   HANNAN PJ, 1994, EPIDEMIOLOGY, V5, P88
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   KATZ J, 1993, AM J EPIDEMIOL, V138, P994
   Kaufman Jay, 1993, Ethnicity and Disease, V3, pS83
   Kaufman JS, 1996, J HUM HYPERTENS, V10, P461
   KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1
   MENSAH GA, 1994, J HUM HYPERTENS, V8, P799
   O'Brien E, 1996, BLOOD PRESS MONIT, V1, P55
   POULTER NR, 1985, J HYPERTENS, V3, pS375
   ROSE G, 1981, BRIT MED J, V282, P1847
   ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32
   ROSSOUW JE, 1993, INT J EPIDEMIOL, V22, P428, DOI 10.1093/ije/22.3.428
   Rotimi CN, 1999, HYPERTENSION, V33, P874
   SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202
   STAMLER R, 1992, HYPERTENSION, V19, P237
   van der Sande MAB, 2001, B WORLD HEALTH ORGAN, V79, P321
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   Ward Ryk, 1995, P67
   WHELTON PK, 1994, LANCET, V344, P101, DOI 10.1016/S0140-6736(94)91285-8
NR 30
TC 12
Z9 12
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 0950-9240
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
PD OCT
PY 2001
VL 15
IS 10
BP 733
EP 739
DI 10.1038/sj.jhh.1001259
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 491CU
UT WOS:000172091100013
PM 11607805
OA No
DA 2017-08-15
ER

PT J
AU Shaw, M
   van der Sande, M
   West, B
   Paine, K
   Ceesay, S
   Bailey, R
   Walraven, G
   Morison, L
   McAdam, K
AF Shaw, M
   van der Sande, M
   West, B
   Paine, K
   Ceesay, S
   Bailey, R
   Walraven, G
   Morison, L
   McAdam, K
TI Prevalence of herpes simplex type 2 and syphilis serology among young
   adults in a rural Gambian community
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
DE seroepidemiological studies; Africa; herpes simplex virus
ID SEXUALLY-TRANSMITTED DISEASES; HIV-INFECTION; VIRUS TYPE-2; AFRICA;
   PREVENTION; TANZANIA; BEHAVIOR; IMPACT; RISK
AB Objectives: To estimate prevalence and risk factors for herpes simplex 2 (HSV2) positivity, syphilis and Chlamydia trachomatis infection among rural people aged 15-34 in the Gambia.
   Methods: Questionnaires and serum samples were collected from 1076 men and women aged 15-34 during a cross sectional prevalence survey in a rural area of the Gambia. Sera were screened for antibodies to herpes simplex virus type 2 (HSV2), and for syphilis using Treponema pallidum haemagglutination assay (TPHA) and rapid plasma reagin (RPR) tests. Urine was tested by polymerase chain reaction (PCR) for C trachomatis infection.
   Results: 28% of women and 5% of men were HSV2 ELISA positive; 10% of women and 2% of men were TPHA positive; and 7% of women and 1% of men were both RPR and TPHA positive. Out of 1030 urine sample tested only six were positive for C trachomatis. 7% of those who reported never having sex were positive for one or other of these tests. Prevalences of all STIs increased with age and were higher in women than men. Women were much less likely than men to seek treatment for STI symptoms at a health centre. Married people were at increased risk of an STI compared with single people. Jola and Fula women had a higher prevalence of HSV2 than women from other ethnic groups, and Fulas also had a higher prevalence of RPR/TPHA positivity. The limited number of sexual behaviour questions were not significantly associated with STIs after adjustment for age, marital status, and ethnic group.
   Conclusions: The prevalences of the ulcerative infections HSV2 and syphilis in this population are a cause for concern. In a setting where HIV I prevalence remains low this indicates an urgent need for STI control and behaviour change programmes to prevent an HIV epidemic. Concerns about the validity of reported sexual behaviour data high light the necessity of biological markers in the evaluation of behaviour change programmes.
C1 MRC, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Shaw, M (reprint author), MRC, POB 273, Banjul, Gambia.
RI Morison, Linda/H-9738-2013
CR ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0
   Auvert B, 2001, AIDS, V15, P885, DOI 10.1097/00002030-200105040-00009
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   Bertherat E, 1998, INT J STD AIDS, V9, P31
   Colvin M, 2000, SEX TRANSM INFECT, V76, P39, DOI 10.1136/sti.76.1.39
   *FAM HLTH INT AIDS, 1998, FIN REP AIDSCAP PROG
   Fishbein M, 2000, SEX TRANSM DIS, V27, P452, DOI 10.1097/00007435-200009000-00005
   GREENWOOD AM, 1992, J INFECT DIS, V166, P842
   Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9
   GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   HAWKES S, 1999, LANCET, V354, P1176
   Huygens P, 1996, SOC SCI MED, V42, P221, DOI 10.1016/0277-9536(95)00088-7
   Marsden HS, 1998, J MED VIROL, V56, P79, DOI 10.1002/(SICI)1096-9071(199809)56:1<79::AID-JMV13>3.0.CO;2-R
   McFarland W, 1999, J INFECT DIS, V180, P1459, DOI 10.1086/315076
   Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018
   Morison L, 2001, TROP MED INT HEALTH, V6, P643, DOI 10.1046/j.1365-3156.2001.00749.x
   Nelson KE, 1997, J ACQ IMMUN DEF SYND, V16, P293
   Obasi A, 1999, J INFECT DIS, V179, P16, DOI 10.1086/314555
   PAINE K, UNPUB BEFORE WE WERE
   Pickering H., 1988, Health Policy and Planning, V3, P237, DOI 10.1093/heapol/3.3.237
   SKRAMSTAD H, 1993, PROSTITUTE METAPHOR
   UNAIDS, 2000, REP GLOB HIV AIDS EP
   *UNAIDS, 2000, EP FACT SHEET HIV AI
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   WEISS H, 2000, 13 M INT SOC STD RES
   Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018
   WHITTLE H, 1998, INT C AIDS, V12, P373
   *WHO, 1991, REP WHOT STUD GROUP
   2000, 7 INT C AIDS DURB 7
   1999, 13 M INT SOC STD RES
NR 30
TC 25
Z9 25
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD OCT
PY 2001
VL 77
IS 5
BP 358
EP 365
DI 10.1136/sti.77.5.358
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 482FH
UT WOS:000171564800019
PM 11588283
OA No
DA 2017-08-15
ER

PT J
AU Greiner, M
   Mattioli, RC
   Faye, J
   Rebeski, D
   Winger, E
   Mehlitz, D
AF Greiner, M
   Mattioli, RC
   Faye, J
   Rebeski, D
   Winger, E
   Mehlitz, D
TI A survival analysis of trypanosomosis diagnostic-test performance under
   natural infection challenge
SO PREVENTIVE VETERINARY MEDICINE
LA English
DT Article; Proceedings Paper
CT Conference of the
   Society-for-Veterinary-Epidemiology-and-Preventive-Medicine
CY MAR 29-31, 2000
CL UNIV EDINBURGH, EDINBURGH, SCOTLAND
SP Univ Edinburgh, Off Int Epizooties, Lothian Enterprise Ltd, Edinburgh Enterprise Ltd
HO UNIV EDINBURGH
DE trypanosomosis; cattle; The Gambia; ELISA; survival analysis
ID SUSCEPTIBILITY
AB Little is known about the time-to-first detection and the time difference (TD) between first parasitological and first serological diagnosis of Trypanosoma spp. infections under natural infection challenge in cattle. The objective of our study was to estimate these measures of "longitudinal aspects" of diagnostic performance and to investigate potential biological factors. Emphasis was on diagnosis at the genus level (Trypanosoma spp.). Twelve N'Dama, 12 Gobra zebu and 12 N'Dama x Gobra (Fl) crossbred cattle (all animals non-infected at the start of the experiment, six male and six female animals in each cohort) were exposed to natural high tsetse challenge in the Niamina East area in The Gambia [Acta Trop. 71 (1998) 57]. The animals were investigated parasitologically (detection of trypanosomes by buffy-coat technique), serologically (detection of T brucei, T congolense and T vivax antigen by enzyme-linked immunosorbent assay (ELISA)) and clinically (packed-cell volume, PCV) over a period of 180 days. The time-to-first detection of trypanosomes, trypanosomal antigen (cut-off as suggested by test supplier) and drop in PCV (subject-based cut-off values) were recorded as outcomes of interest. Thus, incidence was both parasitologically (I-p), serologically (I-s) and clinically (I-c). Recurrent events were not considered. The TD between first parasitological and first serological detection was established as I-s time minus I-p time. The effect of breed and sex on the time-to-first detection and on TD was investigated using Cox (proportional hazard) regression and ANOVA, respectively.
   We found that time-to-first parasitological detection of trypanosomosis in N'Dama animals was significantly longer than in the two other breeds (Cox regression, P = 0.002). A similar but less-strong (P = 0.063) effect of breed on time-to-first detection of trypanosomal. antigen was found, whereas no breed effect was observed for clinical detection (P = 0.432). Sex had no effect in all detection systems. The TD varied between -56 and 115 (mean 28). Marked differences among breeds and between sexes were not observed (ANOVA, P = 0.8). We suggest that incidence studies are more suitable for detecting risk factors for animal trypanosomosis than prevalence-based (cross-sectional) studies because the latter often result in misinterpretation of factors that increase the survival time with infection as risk factors. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Free Univ Berlin, Inst Parasitol & Trop Vet Med, Dept Int Anim Hlth, D-14163 Berlin, Germany.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Int Atom Energy Agcy Labs, A-2444 Seibersdorf, Austria.
RP Greiner, M (reprint author), Free Univ Berlin, Inst Parasitol & Trop Vet Med, Dept Int Anim Hlth, Konigsweg 67, D-14163 Berlin, Germany.
RI Greiner, Matthias/D-2812-2013
OI Greiner, Matthias/0000-0003-4974-5970
CR CLAUSEN PH, 1989, P 6 INT C I TROP VET, P318
   Connor R. J., 1994, INFECT DIS LIVESTOCK, P167
   DWINGER RH, 1994, VET QUART, V16, P81
   Greiner M, 2000, PREV VET MED, V45, P3, DOI 10.1016/S0167-5877(00)00114-8
   Kalbfleisch J. D, 1980, STAT ANAL FAILURE TI
   Mattioli RC, 1998, ACTA TROP, V71, P57, DOI 10.1016/S0001-706X(98)00051-5
   MOZARIA S, 1998, P WORKSH HELD ILRI N
   Murray M., 1979, P121
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   NANTULYA VM, 1987, PARASITE IMMUNOL, V9, P421, DOI 10.1111/j.1365-3024.1987.tb00520.x
   Sahai H., 1995, STAT EPIDEMIOLOGY
   *STAT, 1997, STAT STAT SOFTW REL
NR 12
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-5877
J9 PREV VET MED
JI Prev. Vet. Med.
PD SEP 20
PY 2001
VL 51
IS 1-2
BP 51
EP 62
DI 10.1016/S0167-5877(01)00206-9
PG 12
WC Veterinary Sciences
SC Veterinary Sciences
GA 472GF
UT WOS:000170974800005
PM 11530194
OA No
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Wesumperuma, LH
   Ota, MOC
   Pinder, M
   Banya, W
   Gomez, SF
   McAdam, KPJ
   Hart, AC
AF Okoko, BJ
   Wesumperuma, LH
   Ota, MOC
   Pinder, M
   Banya, W
   Gomez, SF
   McAdam, KPJ
   Hart, AC
TI The influence of placental malaria infection and maternal
   hypergammaglobulinemia on transplacental transfer of antibodies and IgG
   subclasses in a rural West African population
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IMMUNIZATION; INFANT; IMMUNOGLOBULINS; IMMUNITY; VACCINES; MEASLES; FCRN
AB Two hundred thirteen mother-baby pairs in The Gambia were studied to determine the influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental antibody transfer. Antibody transfer for herpes simplex virus 1 (HSV-1), respiratory syncytial virus (RSV), and varicella-zoster virus (VZV) was significantly reduced by placental malaria infection by 69%, 58%, and 55%, respectively. Maternal hypergammaglobulinemia was associated with a significant reduction in antibody transfer for HSV-1, RSV, VZV, and pneumococcus by 89%, 90%, 91%, and 88%, respectively. In addition, placental malaria infection was associated with a significant reduction in transfer of IgG1, IgG2, and IgG4 (P < .01, P = .01, and P = .03, respectively) but not of IgG3 (P = .59). Maternal hypergammaglobulinemia significantly impaired the transfer of IgG1 and IgG2 (P = .01) but not of IgG3 or IgG4 (P = .62 and P = .59, respectively). Placental malaria infection and maternal hypergammaglobulinemia were associated with reduction in the transplacental transfer of these specific antibodies, IgG1, and IgG2 in this Gambian population.
C1 MRC Labs, Fajara, Senegal.
   Royal Victoria Hosp, Pathol Unit, Banjul, Gambia.
   Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England.
RP Okoko, BJ (reprint author), MRC, Vaccine Trial Unit, POB 273, Banjul, Gambia.
CR ADA G, 1995, INT ARCH ALLERGY IMM, V108, P304
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   Brambell FWR, 1970, FRONT BIOL, P18
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x
   de Moraes-Pinto MI, 1998, ARCH DIS CHILD, V79, pF202
   deMoraesPinto I, 1997, BRIT J HOSP MED, V58, P317
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   EINHORN MS, 1987, J PEDIATR-US, V111, P783, DOI 10.1016/S0022-3476(87)80268-8
   ENGLUND JA, 1995, J INFECT DIS, V171, P99
   GALBRAITH RM, 1980, T ROY SOC TROP MED H, V74, P52, DOI 10.1016/0035-9203(80)90011-5
   GENDREL D, 1988, PRESSE MED, V17, P1633
   HOOD N, 1994, ANN TROP PAEDIATR, V14, P179
   JEFFERIS R, 1990, CLIN EXP IMMUNOL, V81, P357
   LANDOR M, 1995, ANN ALLERG ASTHMA IM, V74, P279
   Leach JL, 1996, J IMMUNOL, V157, P3317
   LEE SI, 1986, MONOGR ALLERGY, V19, P108
   Leopardi O, 1996, PATHOL RES PRACT, V192, P892
   LOGIE DE, 1973, B WORLD HEALTH ORGAN, V49, P547
   MOHAN M, 1981, Indian Pediatrics, V18, P631
   Praetor A, 1999, J CELL SCI, V112, P2291
   Rogerson SJ, 1999, ANN TROP MED PARASIT, V93, pS35, DOI 10.1080/00034989957727
   SAJI F, 1994, PLACENTA, V15, P453, DOI 10.1016/S0143-4004(05)80415-1
   Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/ror.0.0040081
   SATO H, 1979, AM J DIS CHILD, V133, P1240
   Wesumperuma HL, 1999, ANN TROP MED PARASIT, V93, P169
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS17, DOI DOI 10.1097/00006454-199910001-00004
NR 29
TC 43
Z9 43
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2001
VL 184
IS 5
BP 627
EP 632
DI 10.1086/322808
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 462PR
UT WOS:000170429400015
PM 11494168
OA No
DA 2017-08-15
ER

PT J
AU Emerson, PM
   Bailey, RL
   Walraven, GEL
   Lindsay, SW
AF Emerson, PM
   Bailey, RL
   Walraven, GEL
   Lindsay, SW
TI Human and other faeces as breeding media of the trachoma vector Musca
   sorbens
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE Chlamydia trachomatis; Musca sorbens; blindness; faeces; flies; fly
   breeding media; fly control; human eye infection; sanitation; trachoma;
   The Gambia
AB The fly Musca sorbens Wiedemann (Diptera: Muscidae) apparently transmits Chlamydia trachomatis, causing human trachoma. The literature indicates that M. sorbens breeds predominantly in isolated human faeces on the soil surface, but not in covered pit latrines. We sought to identify breeding media of M. sorbens in a rural Gambian villa-e endemic for trachoma. Test breeding media were presented for oviposition on soil-filled buckets and monitored for adult emergence. Musca sorbens emerged from human (6/9 trials), calf (3/9), cow (3/9), dog (2/9) and goat (1/9) faeces, but not from horse faeces, composting kitchen scraps or a soil control (0/9 of each). After adjusting for mass of medium, the greatest number of flies emerged from human faeces ( 1426 flies/kg). Median time for emergence was 9 (inter quartile range = 8-9.75) days post-oviposition. Of all flies emerging from faeces 81% were M. sorbens. Male and female flies emerging from human faeces were significantly larger than those from other media, suggesting that they would be more fecund and live longer than smaller flies from other sources. Female flies caught from children's eyes were of a similar size to those from human faeces, but significantly larger than those from other media. We consider that human faeces are the best larval medium for M. sorbens, although some breeding also occurs in animal faeces. Removal of human faeces from the environment, through the provision of basic sanitation, is likely to greatly reduce fly density, eye contact and hence trachoma transmission, but if faeces of other animals are present M. sorbens will persist.
C1 MRC Labs, Banjul, Gambia.
   Univ Durham, Sch Biol & Biomed Sci, Durham, England.
RP Emerson, PM (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Crosskey R. W., 1993, P403
   CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   GREENHAM PM, 1972, J ANIM ECOL, V41, P153, DOI 10.2307/3510
   Hafez M., 1941, B SOC FOUAD IER ENT, V25, P99
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P83
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P275
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P123
   HUGHES R D, 1972, Journal of the Australian Entomological Society, V11, P311
   HUGHES RD, 1970, J ANIM ECOL, V39, P691, DOI 10.2307/2860
   Legner E. F., 1974, Bulletin of the Society of Vector Ecologists, V1, P1
   MAU RFL, 1978, ANN ENTOMOL SOC AM, V71, P635
   MENG CH, 1944, CHINESE MED J, V62, P77
   PEFFLY RL, 1953, J EGYPTIAN PUBLIC HL, V28, P167
   Pont A.C., 1991, Fauna of Saudi Arabia, V12, P312
   SABROSKY CW, 1952, AM J TROP MED HYG, V1, P333
   Skidmore P., 1985, BIOL MUSCIDAE WORLD
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   TOYAMA GM, 1976, P HAWAII ENTOMOL SOC, V22, P353
   TYNDALEBISCOE M, 1968, B ENTOMOL RES, V59, P129
   West LS, 1951, HOUSEFLY ITS NATURAL
   Zimin LS, 1948, OPRED FAUNA USSR, V28, P1
NR 23
TC 60
Z9 60
U1 1
U2 8
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD SEP
PY 2001
VL 15
IS 3
BP 314
EP 320
DI 10.1046/j.0269-283x.2001.00318.x
PG 7
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA 474VM
UT WOS:000171127600012
PM 11583450
OA No
DA 2017-08-15
ER

PT J
AU Clarke, SE
   Bogh, C
   Brown, RC
   Pinder, M
   Walraven, GEL
   Lindsay, SW
AF Clarke, SE
   Bogh, C
   Brown, RC
   Pinder, M
   Walraven, GEL
   Lindsay, SW
TI Do untreated bednets protect against malaria?
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; disease control; vector control;
   bednets; children; poverty; The Gambia
ID TREATED BED NETS; MOSQUITO-NETS; WEST-AFRICA; RURAL AREA; TARGETED
   CHEMOPROPHYLAXIS; GAMBIAN CHILDREN; INSECTICIDE; MORBIDITY; TRIAL;
   IMPACT
AB Bednets are thought to offer little, if any, protection against malaria, unless treated with insecticide. There is also concern that the use of untreated nets will cause people sleeping without nets to receive more mosquito bites, and thus increase the malaria risk for other community members. Regular retreatment of nets is therefore viewed as critical for malaria control. However, despite good uptake of nets, many control programmes in Africa have reported low re-treatment rates. We investigated whether untreated bednets had any protective benefit (in October and November 1996) in The Gambia where nets, although widely used, are mostly untreated. Cross-sectional prevalence surveys were carried out in 48 villages and the risk of malaria parasitaemia was compared in young children sleeping with or without nets. Use of an untreated bednet in good condition was associated with a significantly lower prevalence of Plasmodium falciparum infection (51% protection [95% CI 34-64%], P < 0.001). This finding was only partly explained by differences in wealth between households, and children in the poorest households benefited most from sleeping under an untreated net (62% protection [14-83%1, P = 0-018). There was no evidence that mosquitoes were diverted to feed on children sleeping without nets. These findings suggest that an untreated net, provided it is in relatively good condition, can protect against malaria. Control programmes should target the poorest households as they may have the most to gain from using nets.
C1 Danish Bilharziasis Lab, DK-2920 Charlottenlund, Denmark.
   MRC Labs, Banjul, Gambia.
   Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
RP Clarke, SE (reprint author), Danish Bilharziasis Lab, Faegersborg Alle 1D, DK-2920 Charlottenlund, Denmark.
CR AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   BOGH C, 1999, THESIS U COPENHAGEN, P20
   BOGH C, 1999, THESIS U COPENHAGEN, P40
   BRADLEY AK, 1986, LANCET, V2, P204
   BURKOT TR, 1990, T ROY SOC TROP MED H, V84, P773, DOI 10.1016/0035-9203(90)90073-N
   CAMPBELL H, 1987, LANCET, V1, P859
   CARNEVALE P, 1992, T ROY SOC TROP MED H, V86, P362, DOI 10.1016/0035-9203(92)90219-3
   Cham MK, 1997, HEALTH POLICY PLANN, V12, P240, DOI 10.1093/heapol/12.3.240
   CLARKE SE, 1999, THESIS U COPENHAGEN, P104
   DAlessandro U, 1995, T ROY SOC TROP MED H, V89, P596, DOI 10.1016/0035-9203(95)90401-8
   DAVEYSMITH G, 1992, LANCET, V340, P709, DOI 10.1016/0140-6736(92)92242-8
   DELACOLLETTE C, 1993, ANN TROP MED PARASIT, V87, P537
   GENTON B, 1994, ANN TROP MED PARASIT, V88, P263
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   LENGELER C, 1998, COCHRANE LIB
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1988, PARASITOL TODAY, V4, P270, DOI 10.1016/0169-4758(88)90017-8
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   LINES JD, 1987, MED VET ENTOMOL, V1, P37, DOI 10.1111/j.1365-2915.1987.tb00321.x
   Maxwell CA, 1999, T ROY SOC TROP MED H, V93, P4, DOI 10.1016/S0035-9203(99)90158-X
   MULLER O, 1994, LANCET, V344, P1699, DOI 10.1016/S0140-6736(94)90481-2
   NEVILL CG, 1988, BRIT MED J, V297, P401
   PORT GR, 1982, B ENTOMOL RES, V72, P483
   SCHELLENBERG JRMA, 1994, T ROY SOC TROP MED H, V88, P429, DOI 10.1016/0035-9203(94)90416-2
   Snow RW, 1999, HEALTH POLICY PLANN, V14, P18, DOI 10.1093/heapol/14.1.18
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   Winch PJ, 1997, TROP MED INT HEALTH, V2, P760, DOI 10.1046/j.1365-3156.1997.d01-376.x
NR 30
TC 92
Z9 93
U1 0
U2 14
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 2001
VL 95
IS 5
BP 457
EP 462
DI 10.1016/S0035-9203(01)90001-X
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 489GZ
UT WOS:000171984800001
PM 11706649
OA No
DA 2017-08-15
ER

PT J
AU Hull, J
   Ackerman, H
   Isles, K
   Usen, S
   Pinder, M
   Thomson, A
   Kwiatkowski, D
AF Hull, J
   Ackerman, H
   Isles, K
   Usen, S
   Pinder, M
   Thomson, A
   Kwiatkowski, D
TI Unusual haplotypic structure of IL8, a susceptibility locus for a common
   respiratory virus
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENE REGION; BRONCHIOLITIS
AB Interleukin-8 (IL8) is believed to play a role in the pathogenesis of bronchiolitis, a common viral disease of infancy, and a recent U.K. family study identified an association between this disease and the IL8-251A allele. In the present study we report data, from a different set of families, which replicate this finding; combined analysis of 194 nuclear families through use of the transmission/disequilibrium test gives. To explore the underlying genetic cause, we identified nine single-nucleotide polymorphisms (SNPs) in a 7.6-kb segment spanning the IL8 gene and its promoter region and used six of these SNPs to define the haplotypic structure of the IL8 locus. The IL8-251A allele resides on two haplotypes, only one of which is associated with disease, suggesting that this may not be the functional allele. Europeans show an unusual haplotype genealogy that is dominated by two common haplotypes differing at multiple sites, whereas Africans have much greater haplotypic diversity. These marked haplotype-frequency differences give an F-ST of .25, and, in the European sample, both Tajima's D statistic (D = 2.58, P = .007) and the Hudson/Kreitman/Aguade test (chi (2) = 4.9, P = .03) reject neutral equilibrium, suggesting that selective pressure may have acted on this locus.
C1 Univ Oxford, Dept Paediat, Oxford OX3 9DU, England.
   Wellcome Trust Ctr Human Genet, Oxford, England.
   MRC Labs, Fajara, Gambia.
RP Hull, J (reprint author), Univ Oxford, Dept Paediat, Oxford OX3 9DU, England.
CR Abu-Harb M, 1999, EUR RESPIR J, V14, P139, DOI 10.1034/j.1399-3003.1999.14a23.x
   Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN
   Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977
   Fiedler MA, 1996, AM J PHYSIOL-LUNG C, V271, pL963
   GRIFFITHS RC, 1994, STAT SCI, V9, P307, DOI 10.1214/ss/1177010378
   Hamblin MT, 2000, AM J HUM GENET, V66, P1669, DOI 10.1086/302879
   HUDSON RR, 1987, GENETICS, V116, P153
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Modi WS, 1998, GENOMICS, V47, P136, DOI 10.1006/geno.1997.5100
   Nei M., 1987, MOL EVOLUTIONARY GEN
   NOAH TL, 1995, J INFECT DIS, V171, P584
   Smyth RL, 2000, ARCH DIS CHILD S, V82, pA4
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   TAJIMA F, 1989, GENETICS, V123, P585
   Wright S, 1931, GENETICS, V16, P0097
NR 16
TC 142
Z9 150
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD AUG
PY 2001
VL 69
IS 2
BP 413
EP 419
DI 10.1086/321291
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 456XN
UT WOS:000170108200015
PM 11431705
OA No
DA 2017-08-15
ER

PT J
AU Erskine, J
AF Erskine, J
TI Prescribing for lower respiratory tract infection
SO BRITISH JOURNAL OF GENERAL PRACTICE
LA English
DT Letter
C1 WEC Int, Banjul, Gambia.
RP Erskine, J (reprint author), WEC Int, POB 86, Banjul, Gambia.
CR Holmes WF, 2001, BRIT J GEN PRACT, V51, P177
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ROYAL COLL GENERAL PRACTITIONERS
PI LONDON
PA 14 PRINCES GATE, HYDE PARK, LONDON SW7 1PU, ENGLAND
SN 0960-1643
J9 BRIT J GEN PRACT
JI Br. J. Gen. Pract.
PD AUG
PY 2001
VL 51
IS 469
BP 672
EP 673
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 461LD
UT WOS:000170365000017
PM 11510401
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Halsall, I
   Howarth, D
   Poskitt, EME
   Prentice, AM
AF Moore, SE
   Halsall, I
   Howarth, D
   Poskitt, EME
   Prentice, AM
TI Glucose, insulin and lipid metabolism in rural Gambians exposed to early
   malnutrition
SO DIABETIC MEDICINE
LA English
DT Article
DE early malnutrition; glucose tolerance; cardiovascular disease; Gambia
ID PROTEIN-CALORIE MALNUTRITION; CORONARY-HEART-DISEASE; THRIFTY PHENOTYPE
   HYPOTHESIS; FETAL-GROWTH; SECRETORY RESPONSE; DIABETES-MELLITUS;
   BIRTH-WEIGHT; PERSISTENT IMPAIRMENT; RESISTANCE SYNDROME;
   ENERGY-EXPENDITURE
AB Aims There is now substantial evidence to suggest that susceptibility to certain non-communicable diseases may be increased by early undernutrition. In rural Gambia, an annual hungry season reduces birth weight by 200-300 g and increases the prevalence of low birth weight (< 2500 g) from 11 % to 24 %. The aim of this study was to investigate whether fetal nutritional stress (using season of birth as a proxy measure for prenatal growth retardation) or early childhood malnutrition (using historical anthropometric records) had a residual influence on risk factors for cardiovascular disease in a cohort of rural Gambian adults.
   Methods Two hundred and nineteen adults (mean age = 35.8 years; mean body mass index = 21.3 kg/m(2); women = 181) for whom month of birth and infant anthropometric records were available participated in this study. Risk factors for cardiovascular disease were measured.
   Results No differences were found between season of birth groups (hungry vs. harvest) and fasting measures of glucose, insulin, lipids, fibrinogen or cortisol, or against 30 and 120 min glucose and insulin levels following an oral glucose tolerance test, or blood pressure. Similarly, these risk factors for adult disease were not related to the subjects' weight-for-age as children.
   Conclusions Moderate-to-severe fetal and childhood malnutrition in rural Gambia caused no detectable impairment of the glucose/insulin axis, or of other cardiovascular disease risk factors in adults remaining lean and fit on a low-fat diet.
C1 London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC18 3DP, England.
   MRC Keneba, Keneba, Gambia.
   Addenbrookes NHS Trust, Dept Clin Biochem, Cambridge CB2 2QQ, England.
   St Bartholomews Hosp, Wolfson Inst Preventat Med, London, England.
RP Moore, SE (reprint author), London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, 49-51 Bedford Sq, London WC18 3DP, England.
EM Sophie.Moore@LSHTM.ac.uk
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Barker DJP, 1999, ANN INTERN MED, V130, P322
   BARKER DJP, 1995, BRIT MED J, V311, P171
   Barker DJP, 1994, MOTHERS BABIES DIS L
   Bavdekar A, 1999, DIABETES, V48, P2422, DOI 10.2337/diabetes.48.12.2422
   BECKER DJ, 1971, DIABETES, V20, P542
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
   COLE TJ, 1993, SOC ST HUM, V35, P89, DOI 10.1017/CBO9780511600517.008
   COOK GC, 1967, NATURE, V215, P1295, DOI 10.1038/2151295a0
   CRACE CJ, 1991, UPSALA J MED SCI, V96, P177
   Dunger DB, 1998, NAT GENET, V19, P98, DOI 10.1038/ng0598-98
   Eriksson JG, 1999, BRIT MED J, V318, P427
   ESCRIVA F, 1991, DIABETOLOGIA, V34, P559, DOI 10.1007/BF00400273
   Fall CHD, 1998, DIABETIC MED, V15, P220, DOI 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.3.CO;2-F
   Forrester TE, 1996, BRIT MED J, V312, P156
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x
   HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248
   Hales CN, 1997, DIABETIC MED, V14, P189
   HATTERSLEY AT, 1998, NAT GENET, V19, P269
   JAMES WPT, 1970, AM J CLIN NUTR, V23, P386
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   MCGREGOR IA, 1952, T ROY SOC TROP MED H, V46, P403, DOI 10.1016/0035-9203(52)90058-8
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   NYAN OA, 1997, MED RES TROPICS 1997
   ODEA K, 1988, MED J AUSTRALIA, V148, P177
   Phillips DIW, 1998, J CLIN ENDOCR METAB, V83, P757, DOI 10.1210/jc.83.3.757
   POPPITT SD, 1994, AM J OBSTET GYNECOL, V171, P118
   POPPITT SD, 1993, AM J CLIN NUTR, V57, P353
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   PRENTICE AM, 1984, ENERGY INTAKE ACTIVI, P3
   PRESCOTTCLARK P, 1999, HLTH SURVEY ENGLAND
   RAMACHANDRAN A, 1992, DIABETES CARE, V15, P1348, DOI 10.2337/diacare.15.10.1348
   RAO RH, 1988, ENDOCR REV, V9, P189
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
   SINGH J, 1989, BRIT J NUTR, V62, P315, DOI 10.1079/BJN19890033
   Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3
   SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454
   SWENNE I, 1988, J ENDOCRINOL, V118, P295, DOI 10.1677/joe.0.1180295
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   Wareham N J, 1995, Diabet Med, V12, P931
   Wareham NJ, 1998, BRIT J NUTR, V80, P235
   Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681
   *WHO, 1992, SOFTW CALC PAED ANTH
   World Health Organization, 1985, TECHN REP SER WHO, V727
   YAJNIK CS, 1995, DIABETIC MED, V12, P330
NR 50
TC 52
Z9 55
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD AUG
PY 2001
VL 18
IS 8
BP 646
EP 653
DI 10.1046/j.1464-5491.2001.00565.x
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 475UK
UT WOS:000171186300007
PM 11553202
OA No
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Ota, MOC
   Arowolo, JO
   Whittle, HC
AF Okoko, BJ
   Ota, MOC
   Arowolo, JO
   Whittle, HC
TI Peripheral gangrene complicating Salmonella typhi septicaemia in a
   Gambian infant
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID CHILDREN
AB A 1-year-old malnourished boy, who presented with Salmonella typhi septicaemia with a 4-day history of febrile illness, dehydration and severe anaemia, developed bilateral dry gangrene of the hands and feet. Although he improved appreciably, he suffered auto-amputation of the distal phalanges of the left foot after 3 weeks of illness. A high index of suspicion and prompt treatment is highly critical in the treatment of septicaemia in young children.
C1 MRC, Fajara, Gambia.
   Royal Victoria Hosp, Dept Paediat, Banjul, Gambia.
RP Okoko, BJ (reprint author), MRC, Box 273, Banjul, Gambia.
CR CHAUDHURI AKR, 1970, BRIT MED J, V4, P678
   COLMAN RW, 1972, AM J MED, V52, P679, DOI 10.1016/0002-9343(72)90058-7
   CORRIGAN JJ, 1968, NEW ENGL J MED, V279, P879
   LOWENTHAL MN, 1967, BMJ-BRIT MED J, V2, P700
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   ONYEMELUKWE GC, 1997, TROP GEOGR MED, V31, P297
NR 7
TC 3
Z9 3
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD AUG
PY 2001
VL 47
IS 4
BP 250
EP 251
DI 10.1093/tropej/47.4.250
PG 2
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 469DP
UT WOS:000170798700014
PM 11523769
OA No
DA 2017-08-15
ER

PT J
AU Weber, A
   Weber, M
   Milligan, P
AF Weber, A
   Weber, M
   Milligan, P
TI Modeling epidemics caused by respiratory syncytial virus (RSV)
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE respiratory syncytial virus (RSV); SIRS model; SEIRS model; parameter
   estimates; threshold conditions; transmission
ID MATERNAL ANTIBODY; YOUNG-CHILDREN; GROUP-A; GROUP-B; INFECTION; INFANTS;
   DISEASE; RISK; TRANSMISSION; REINFECTION
AB Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection in children. In this paper we use models of RSV transmission to interpret the pattern of seasonal epidemics of RSV disease observed in different countries, and to estimate epidemic and eradication thresholds for RSV infection. We compare the standard SIRS model with a more realistic model of RSV transmission in which individuals acquire immunity gradually after repeated exposure to infection. The models are fitted to series of monthly hospital case reports of RSV disease from developed and developing countries. The models can explain many of the observed patterns: regular yearly outbreaks in some countries, and in other countries cycles of alternating larger and smaller annual epidemics, with shifted maxima in alternate years. Previously these patterns have been attributed to the transmission of different strains of RSV. In some countries the timing of epidemics is not consistent with increased social contact among school children during term time being the major driving mechanism. Climatic factors appear to be more important. Qualitatively different models gave equally good fits to the data series, but estimates of the transmission parameter were different by a factor of 4. Estimates of the basic reproduction number (R-0) ranged from 1.2 to 2.1 with the SIRS model, and from 5.4 to 7.1 with the model with gradual acquisition of partial immunity. (C) 2001 Elsevier Science Inc. All rights reserved.
C1 Univ Bonn, Inst Informat 2, D-53117 Bonn, Germany.
   WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland.
   MRC Labs, Fajara, Gambia.
   Univ Tubingen, Dept Comp Sci, Symbol Computat Grp, D-72074 Tubingen, Germany.
RP Weber, A (reprint author), Univ Bonn, Inst Informat 2, Romerstr 164, D-53117 Bonn, Germany.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Weber, Andreas/0000-0001-5624-3368
CR Anderson R.M., 1992, INFECT DIS HUMANS DY
   BELSHE RB, 1983, AM J EPIDEMIOL, V117, P467
   BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355
   Cane PA, 1999, EPIDEMIOL INFECT, V122, P155, DOI 10.1017/S0950268896001872
   Chew FT, 1998, EPIDEMIOL INFECT, V121, P121, DOI 10.1017/S0950268898008905
   Dietz K, 1976, LECTURE NOTES BIOMAT, V11, P1
   DITCHBURN RK, 1971, BMJ-BRIT MED J, V3, P671
   Earn DJD, 2000, SCIENCE, V287, P667, DOI 10.1126/science.287.5453.667
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708
   GLEZEN WP, 1977, PEDIATR RES, V11, P239
   GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005
   GOLLER M, 1998, NUMCODE GENERATING M
   GRENFELL BT, 1995, EPIDEMIC MODELS THEI, P248
   Grossman Z., 1977, NONLINEAR SYSTEMS AP, P525
   HALL CB, 1980, J INFECT DIS, V141, P98
   HALL CB, 1976, J PEDIATR-US, V89, P11, DOI 10.1016/S0022-3476(76)80918-3
   HALL CB, 1976, NEW ENGL J MED, V294, P414, DOI 10.1056/NEJM197602192940803
   HALL CB, 1990, J INFECT DIS, V162, P1283
   HALL CB, 1991, J INFECT DIS, V163, P693
   HALL CB, 1981, J PEDIATR-US, V99, P100, DOI 10.1016/S0022-3476(81)80969-9
   Hall CB, 1992, TXB PEDIAT INFECT DI, P1633
   Halstead DC, 1998, SOUTHERN MED J, V91, P433
   HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004
   HETHCOTE H W, 1976, Mathematical Biosciences, V28, P335, DOI 10.1016/0025-5564(76)90132-2
   HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135
   KIM HW, 1973, AM J EPIDEMIOL, V98, P216
   KRAVETZ HM, 1961, JAMA-J AM MED ASSOC, V176, P657
   MARTIN AJ, 1978, LANCET, V2, P1035
   MONTO AS, 1971, AM J EPIDEMIOL, V94, P290
   MORLEY D, 1969, BRIT MED J, V1, P297
   MUELENAER PM, 1991, J INFECT DIS, V164, P15
   MUFSON MA, 1987, J CLIN MICROBIOL, V25, P1535
   OGILVIE MM, 1981, J MED VIROL, V7, P263, DOI 10.1002/jmv.1890070403
   OLSEN LF, 1988, THEOR POPUL BIOL, V33, P344, DOI 10.1016/0040-5809(88)90019-6
   OLSEN LF, 1990, SCIENCE, V249, P248
   SCHWARTZ IB, 1992, J MATH BIOL, V30, P473, DOI 10.1007/BF00160532
   Spencer N, 1996, ARCH DIS CHILD, V74, P50
   Sullender WM, 2000, CLIN MICROBIOL REV, V13, P1
   UNICEF, 1999, STAT WORLDS CHILDR
   WARIS M, 1991, J INFECT DIS, V163, P464
   Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   1978, BR MED J, V2, P796
NR 44
TC 75
Z9 75
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0025-5564
J9 MATH BIOSCI
JI Math. Biosci.
PD AUG
PY 2001
VL 172
IS 2
BP 95
EP 113
DI 10.1016/S0025-5564(01)00066-9
PG 19
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 471HX
UT WOS:000170924900003
PM 11520501
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
AF Obaro, SK
TI Protein conjugate vaccines - how much is enough?
SO TRENDS IN MICROBIOLOGY
LA English
DT Letter
ID INFLUENZAE TYPE-B; CAPSULAR POLYSACCHARIDE; PROTECTIVE LEVEL; SERUM
   ANTIBODIES; RANDOMIZED TRIAL; VACCINATION; TETANUS; IMMUNOGENICITY;
   IMMUNIZATION; DIPHTHERIA
C1 MRC Labs, Fajara, Gambia.
RP Obaro, SK (reprint author), MRC Labs, POB 273, Fajara, Gambia.
CR Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   Ahman H, 1999, VACCINE, V17, P2726
   ANDERSON P, 1984, J INFECT DIS, V149, P1034
   Booy R, 1997, LANCET, V349, P1197, DOI 10.1016/S0140-6736(96)06392-1
   Eskola J, 1996, LANCET, V348, P1688, DOI 10.1016/S0140-6736(96)04356-5
   Goldblatt D, 1999, J INFECT DIS, V180, P538, DOI 10.1086/314901
   Goldblatt D, 1998, J MED MICROBIOL, V47, P563
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   Lagos R, 1998, LANCET, V351, P1472, DOI 10.1016/S0140-6736(97)07456-4
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   PETER G, 1997, REDBOOK REPORT COMMI, P4
   Richmond P, 2001, J INFECT DIS, V183, P160, DOI 10.1086/317646
   Weycker D, 2000, AM J MANAG CARE, V6, pS526
NR 15
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0966-842X
J9 TRENDS MICROBIOL
JI Trends Microbiol.
PD AUG
PY 2001
VL 9
IS 8
BP 364
EP 365
DI 10.1016/S0966-842X(01)02076-5
PG 2
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA 463DV
UT WOS:000170462300004
PM 11519529
OA No
DA 2017-08-15
ER

PT J
AU Morison, L
   Scherf, C
   Ekpo, G
   Paine, K
   West, B
   Coleman, R
   Walraven, G
AF Morison, L
   Scherf, C
   Ekpo, G
   Paine, K
   West, B
   Coleman, R
   Walraven, G
TI The long-term reproductive health consequences of female genital cutting
   in rural Gambia: a community-based survey
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE female genital cutting; female genital mutilation; female circumcision;
   Gambia; Africa; reproductive health
ID BACTERIAL VAGINOSIS; FERTILITY; MORTALITY; INFECTION
AB This paper examines the association between traditional practices of female genital cutting (FGC) and adult women's reproductive morbidity in rural Gambia. In 1999, we conducted a cross-sectional community survey of 1348 women aged 15-54 years, to estimate the prevalence of reproductive morbidity on the basis of women's reports, a gynaecological examination and laboratory analysis of specimens. Descriptive statistics and logistic regression were used to compare the prevalence of each morbidity between cut and uncut women adjusting for possible confounders. A total of 1157 women consented to gynaecological examination and 58% had signs of genital cutting. There was a high level of agreement between reported circumcision status and that found on examination (97% agreement). The majority of operations consisted of clitoridectomy and excision of the labia minora (W-HO classification type II) and were performed between the ages of 4 and 7 years. The practice of genital cutting was highly associated with ethnic group for two of the three main ethnic groups, making the effects of ethnic group and cutting difficult to distinguish. Women who had undergone FGC had a significantly higher prevalence of bacterial vaginosis (BV) [adjusted odds ratio (OR) = 1.66; 95% confidence interval (CI) 1.25-2.18] and a substantially higher prevalence of herpes simplex virus 2 (HSV2) [adjusted OR = 4.71; 95% CI 3.46-6.421. The higher prevalence of HSV2 suggests that cut women may be at increased risk of HIV infection. Commonly cited negative consequences of FGC such as damage to the perineum or anus, vulval tumours (such as Bartholin's cysts and excessive keloid formation), painful sex, infertility, prolapse and other reproductive tract infections (RTIs) were not significantly more common in cut women. The relationship between FGC and long-term reproductive morbidity remains unclear, especially in settings where type II cutting predominates. Efforts to eradicate the practice should incorporate a human rights approach rather than rely solely on the damaging health consequences.
C1 Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Infect Dis Epidemiol Grp, London WC1E 7HT, England.
   Univ Wales Coll Cardiff, Dept Obstet & Gynaecol, Cardiff CF1 3NS, S Glam, Wales.
   MRC Labs, Farafenni, Gambia.
   MRC Labs, Fajara, Gambia.
RP Morison, L (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Infect Dis Epidemiol Grp, Keppel St, London WC1E 7HT, England.
RI Morison, Linda/H-9738-2013
CR Adinma J I, 1997, West Afr J Med, V16, P227
   BALLARD R, 1998, WHO UNAIDS CONS OCT
   BLEDSOE CH, 1994, POPUL DEV REV, V20, P81, DOI 10.2307/2137631
   Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802
   Carr Dara, 1997, FEMALE GENITAL CUTTI
   *EGYPT FERT CAR SO, 1996, CLIN BAS INV TYP SEL
   Filippi V, 1997, TROP MED INT HEALTH, V2, P47, DOI 10.1046/j.1365-3156.1997.d01-126.x
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   Jones H, 1999, STUD FAMILY PLANN, V30, P219, DOI 10.1111/j.1728-4465.1999.00219.x
   Kun KE, 1997, INT J GYNECOL OBSTET, V59, P153, DOI 10.1016/S0020-7292(97)00201-4
   KURKI T, 1992, OBSTET GYNECOL, V80, P173
   Larsen U, 2000, DEMOGRAPHY, V37, P313, DOI 10.2307/2648044
   Marsden HS, 1998, J MED VIROL, V56, P79, DOI 10.1002/(SICI)1096-9071(199809)56:1<79::AID-JMV13>3.0.CO;2-R
   Obermeyer CM, 1999, MED ANTHROPOL Q, V13, P79, DOI 10.1525/maq.1999.13.1.79
   Odujinrin O M, 1989, West Afr J Med, V8, P183
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5
   SINGHATEH SK, 1985, FEMALE CIRCUMCISION
   Snow RC, 2001, TROP MED INT HEALTH, V6, P89, DOI 10.1046/j.1365-3156.2001.00692.x
   Toubia N, 1993, FEMALE GENITAL MUTIL
   TOUBIA N, 1996, FEMALE GENITAL MUTIL
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   WEISS HA, 2001, IN PRESS AIDS S5, V15
   *WHO, 1995, WHOFRHWHD96
NR 25
TC 82
Z9 84
U1 0
U2 11
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2001
VL 6
IS 8
BP 643
EP 653
DI 10.1046/j.1365-3156.2001.00749.x
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 469DC
UT WOS:000170797600008
PM 11555430
OA No
DA 2017-08-15
ER

PT J
AU Dumpis, U
   Holmes, EC
   Mendy, M
   Hill, A
   Thursz, M
   Hall, A
   Whittle, H
   Karayiannis, P
AF Dumpis, U
   Holmes, EC
   Mendy, M
   Hill, A
   Thursz, M
   Hall, A
   Whittle, H
   Karayiannis, P
TI Transmission of hepatitis B virus infection in Gambian families revealed
   by phylogenetic analysis
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE hepatitis B virus; chronic carriers; intrafamilial transmission;
   phylogenetic tree analysis; pre-core/core region; Gambia
ID HORIZONTAL TRANSMISSION; RISK-FACTORS; E-ANTIGEN; CHILDREN; VILLAGES;
   MUTANTS; MEMBERS; VARIANT
AB Background/Aims: Transmission of hepatitis B virus (HBV) in Africa occurs horizontally, with most people becoming infected between the ages of 1 and 5 years. The index cases in such events have been assumed to come from within the family unit or from sources outside the immediate family, such as other families or inhabitants of the same compound or village. Here, we define these routes of transmission by phylogenetic tree analysis of sequences from the entire pre-core/core region of the virus, in Gambian chronic carriers.
   Methods: Amplification by polymerase chain reaction of serum extracted HBV-DNA was followed by direct sequencing of the target region. Following editing and alignment of these sequences, phylogenetic tree analysis was performed using the neighbour-joining and maximum-likelihood methods.
   Results: Despite the overall conserved nature of the sequences of the pre-core/core region from 142 chronic carriers, distinct clusters were easily defined at the family and village level, but not on a wider geographical separation.
   Conclusions: Phylogenetic tree analysis of sequences obtained from family members provided strong evidence of intrafamilial transmission of HBV in at least two-thirds of the families studied from Gambia, (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
C1 Imperial Coll Sch Med, Dept Med A, London W2 1NY, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   Univ Oxford, Dept Zool, Oxford OX1 3PS, England.
   MRC Labs, Gambia Hepatitis Intervent Scheme, Fajara, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Karayiannis, P (reprint author), Imperial Coll Sch Med, Dept Med A, St Marys Campus,S Wharf Rd, London W2 1NY, England.
RI HILL, Adrian/C-1306-2008
OI Holmes, Edward/0000-0001-9596-3552
CR AKARCA US, 1994, HEPATOLOGY, V19, P1366
   BARLET V, 1994, J HEPATOL, V21, P797, DOI 10.1016/S0168-8278(94)80242-4
   Bozkaya H, 1997, J HEPATOL, V26, P508, DOI 10.1016/S0168-8278(97)80415-1
   CARMAN WF, 1989, LANCET, V2, P588
   DAVIS LG, 1989, LANCET, V1, P889
   FOSTER O, 1984, LANCET, V1, P576
   Hannoun C, 2000, J GEN VIROL, V81, P75
   HO MS, 1995, CLIN DIAGN LAB IMMUN, V2, P760
   INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764
   Karayiannis P, 1995, HEPATOLOGY, V22, P1628, DOI 10.1016/0270-9139(95)90183-3
   LIN HJ, 1990, LANCET, V336, P208, DOI 10.1016/0140-6736(90)91735-S
   Martinson FEA, 1998, AM J EPIDEMIOL, V147, P478
   MAYANS MV, 1990, LANCET, V336, P1107
   MAYANS MV, 1994, LANCET, V344, P962
   Santantonio T, 1997, J HEPATOL, V26, P221, DOI 10.1016/S0168-8278(97)80034-7
   TABOR E, 1985, J MED VIROL, V15, P113, DOI 10.1002/jmv.1890150203
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1983, LANCET, V1, P1203
NR 19
TC 66
Z9 67
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD JUL
PY 2001
VL 35
IS 1
BP 99
EP 104
DI 10.1016/S0168-8278(01)00064-2
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 455HN
UT WOS:000170021600017
PM 11495049
OA No
DA 2017-08-15
ER

PT J
AU Atabani, SF
   Byrnes, AA
   Jaye, A
   Kidd, IM
   Magnusen, AF
   Whittle, H
   Karp, CL
AF Atabani, SF
   Byrnes, AA
   Jaye, A
   Kidd, IM
   Magnusen, AF
   Whittle, H
   Karp, CL
TI Natural measles causes prolonged suppression of interleukin-12
   production
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Joint Annual Meeting of the
   American-Association-of-Immunologists/Clincal Immunology-Society
CY MAY, 2000
CL SEATTLE, WASHINGTON
SP Amer Assoc Immunol, Clin Immunol Soc
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-MEDIATED-IMMUNITY; HUMAN DENDRITIC
   CELLS; INTERFERON-GAMMA; HUMAN MONOCYTES; SELECTIVE SUPPRESSION; SOLUBLE
   FACTOR; IFN-GAMMA; T-CELLS; INFECTION
AB Among vaccine-preventable diseases, measles is the preeminent killer of children worldwide. Infection with measles virus (MV) is associated with prolonged suppression of cell-mediated immune responses, a phenomenon that is thought to underlie the susceptibility to secondary infections that accounts for most measles-related mortality. Interleukin (IL)-12 is critical for the orchestration of cellular immunity. MV specifically ablates IL-12 production by monocyte/macrophages in vitro through binding to CD46, a complement regulatory protein that is an MV receptor. To address the effect of MV on IL-12 responses in vivo, cytokine production was examined in Gambian patients with measles. IL-12 production by peripheral blood monocytes from such patients is markedly suppressed, which provides a unifying mechanism for many of the immunologic abnormalities associated with measles. This suppression is prolonged, with significant, stimulus-specific inhibition of IL-12 production demonstrable months after recovery from acute infection. However, despite this suppression, IL-12 responsiveness remains intact.
C1 Med Res Council Labs, Banjul, Gambia.
   Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
RP Karp, CL (reprint author), Childrens Hosp Res Fdn, Mol Immunol Sect, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
FU NIAID NIH HHS [AI-40507]
CR Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950
   ANDERSON R, 1976, J PEDIATR-US, V89, P27, DOI 10.1016/S0022-3476(76)80921-3
   Auwaerter PG, 1996, J VIROL, V70, P3734
   BAZIL V, 1991, J IMMUNOL, V147, P1567
   Bont L, 2000, J INFECT DIS, V181, P1772, DOI 10.1086/315433
   Braun MC, 2000, J IMMUNOL, V164, P3009
   CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361
   Chougnet C, 1996, J INFECT DIS, V174, P46
   Chougnet C, 2000, J INFECT DIS, V181, P1590, DOI 10.1086/315458
   Ciurea A, 1999, P NATL ACAD SCI USA, V96, P11964, DOI 10.1073/pnas.96.21.11964
   CLEMENTS CJ, 1995, CURR TOP MICROBIOL, V191, P13
   Comabella M, 1998, J CLIN INVEST, V102, P671, DOI 10.1172/JCI3125
   Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315
   ESOLEN LM, 1993, J INFECT DIS, V168, P47
   FLESCH IEA, 1995, J EXP MED, V181, P1615, DOI 10.1084/jem.181.5.1615
   FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813
   Fujinami RS, 1998, J VIROL, V72, P9421
   Gans HA, 1999, J IMMUNOL, V162, P5569
   GRIFFIN DE, 1990, CLIN EXP IMMUNOL, V81, P218
   GRIFFIN DE, 1995, CURR TOP MICROBIOL, V191, P117
   GRIFFIN DE, 1993, J INFECT DIS, V168, P275
   Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801
   Hoffmann KF, 1999, J IMMUNOL, V163, P927
   JANEWAY CA, 1948, T ASSOC AM PHYSICIAN, V108, P108
   Jaye A, 1998, J CLIN INVEST, V102, P1969, DOI 10.1172/JCI3290
   Karp CL, 1999, IMMUNOL REV, V168, P91, DOI 10.1111/j.1600-065X.1999.tb01285.x
   Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228
   Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759
   Kreutz M, 1997, IMMUNOLOGY, V92, P396, DOI 10.1046/j.1365-2567.1997.00365.x
   Luty AJF, 2000, INFECT IMMUN, V68, P3909, DOI 10.1128/IAI.68.7.3909-3915.2000
   Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6
   Manchester M, 2000, VIROLOGY, V274, P5, DOI 10.1006/viro.2000.0469
   MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161
   Manchester M, 2000, J VIROL, V74, P3967, DOI 10.1128/JVI.74.9.3967-3974.2000
   MANTHEY CL, 1992, J IMMUNOL, V149, P2459
   Marshall JD, 1999, BLOOD, V94, P1003
   Marth T, 1997, J EXP MED, V185, P1987, DOI 10.1084/jem.185.11.1987
   MCCHESNEY MB, 1987, ANNU REV IMMUNOL, V5, P279, DOI 10.1146/annurev.immunol.5.1.279
   McIntyre KW, 1996, EUR J IMMUNOL, V26, P2933, DOI 10.1002/eji.1830261219
   MOENCH TR, 1988, J INFECT DIS, V158, P433
   Naniche D, 2000, J VIROL, V74, P7478, DOI 10.1128/JVI.74.16.7478-7484.2000
   PAYNE JB, 1992, J INTERFERON RES, V12, P307, DOI 10.1089/jir.1992.12.307
   Pignata C, 1998, PEDIATR RES, V43, P77, DOI 10.1203/00006450-199801000-00012
   Schlender J, 1996, P NATL ACAD SCI USA, V93, P13194, DOI 10.1073/pnas.93.23.13194
   Schnorr JJ, 1997, P NATL ACAD SCI USA, V94, P5326, DOI 10.1073/pnas.94.10.5326
   Servet-Delprat C, 2000, J VIROL, V74, P4387, DOI 10.1128/JVI.74.9.4387-4393.2000
   Servet-Delprat C, 2000, J IMMUNOL, V164, P1753
   Steineur MP, 1998, EUR J DERMATOL, V8, P413
   Sun XM, 1998, VIROLOGY, V246, P24, DOI 10.1006/viro.1998.9186
   Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977
   TAMASHIRO VG, 1987, PEDIATR INFECT DIS J, V6, P451, DOI 10.1097/00006454-198705000-00007
   Tatsuo H, 2000, NATURE, V406, P893
   Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9
   Valentin H, 1999, J VIROL, V73, P2212
   VONPIRQUET C, 1908, DEUT MED WOCHENSCHR, V30, P1297
   WATSON T, 1844, MEASLES LECT PRINCIP, P876
   WHITTLE HC, 1988, LANCET, V1, P963
   WHITTLE HC, 1978, J CLIN INVEST, V62, P678, DOI 10.1172/JCI109175
   1992, WKLY EPIDEMIOL REC, V67, P50
   [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1049
   1998, REPORT GLOBAL HIV AI
NR 61
TC 67
Z9 67
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2001
VL 184
IS 1
BP 1
EP 9
DI 10.1086/321009
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 447DL
UT WOS:000169554400001
PM 11398102
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Obaro, SK
   Biney, E
   Greenwood, BM
AF Adegbola, RA
   Obaro, SK
   Biney, E
   Greenwood, BM
TI Evaluation of Binax NOW Streptococcus pneumoniae urinary antigen test in
   children in a community with a high carriage rate of pneumococcus
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE Streptococcus pneumoniae; nasopharyngeal colonization; urinary antigen
   detection; Binax NOW
ID GAMBIAN CHILDREN; ETIOLOGY
AB Pneumococcal antigen was present in urine from 49 of 102 well Gambian children. Eighty-nine of the 102 were nasopharyngeal carriers of pneumococci. The positive predictive value for carriage was 96%, and the negative predictive value was 22%. The test is not useful for predicting etiology of disease in populations with a high rate of nasopharyngeal carriage of pneumococci.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Adegbola, RA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Dowell SF, 2001, CLIN INFECT DIS, V32, P824, DOI 10.1086/319205
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Leowski J, 1986, World Health Stat Q, V39, P138
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   Ruiz-Gonzalez A, 1999, AM J MED, V106, P385, DOI 10.1016/S0002-9343(99)00050-9
NR 7
TC 47
Z9 49
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUL
PY 2001
VL 20
IS 7
BP 718
EP 719
DI 10.1097/00006454-200107000-00018
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 452JV
UT WOS:000169855300018
PM 11465850
OA No
DA 2017-08-15
ER

PT J
AU Deen, JL
   von Seidlein, L
   Pinder, M
   Walraven, GEL
   Greenwood, BM
AF Deen, JL
   von Seidlein, L
   Pinder, M
   Walraven, GEL
   Greenwood, BM
TI The safety of the combination artesunate and pyrimethamine-sulfadoxine
   given during pregnancy
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; chemotherapy; artesunate;
   pyrimethamine-sulfadoxine; primagravida; pregnancy; teratogenicity; The
   Gambia
ID BIRTH-WEIGHT; PLASMODIUM-FALCIPARUM; MALARIA; MALAWI; CHEMOPROPHYLAXIS;
   CHLOROQUINE; ARTEMISININ; PREVENTION; RESISTANCE; EFFICACY
AB Malaria during pregnancy is associated with an increased risk of severe anaemia and low-birthweight babies. Effective intermittent therapy with pyrimethamine-sulfadoxine (PSD) decreases parasitaemia and severe anaemia and improves birthweight in areas where Plasmodium falciparum is sensitive to this drug. Increasing resistance to PSD is a concern and alternative antimalarial regimens during pregnancy are needed. Artesunate with PSD is a promising antimalarial combination but few data are available on the safety of artemisinins when taken during pregnancy. Outcome of pregnancy was evaluated for 287 women in The Gambia who were exposed in June 1999 to a single dose of the combination artesunate and PSD during a mass drug administration and 172 women who were not exposed. Women who received placebo (40) and those who did not participate in the mass drug administration (132) comprised the non-exposed group. There was no difference in the proportion of abortions, stillbirths, or infant deaths among those exposed or not exposed to the drugs. The mean weight of 18 infants born to mothers who had received artesunate and PSD during the third trimester was 3.10 kg compared to a mean weight of 2.62 kg of the 10 infants of untreated mothers (adjusted P value = 0.05). We found no evidence of a teratogenic or otherwise harmful effect of gestational exposure to artesunate and PSD. Treatment of a self-selected group of pregnant women with PSD and artesunate during pregnancy was associated with a greater birthweight, which may have resulted from clearance of malaria parasites. However, the influence of confounding factors cannot be excluded.
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP von Seidlein, L (reprint author), Int Vaccine Inst, POB 14, Seoul 151600, South Korea.
CR Brewer T G, 1994, Trans R Soc Trop Med Hyg, V88 Suppl 1, pS33
   FLEMING AF, 1986, ANN TROP MED PARASIT, V80, P211
   GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   HEYMANN DL, 1990, T ROY SOC TROP MED H, V84, P496, DOI 10.1016/0035-9203(90)90011-3
   McGready R, 1998, T ROY SOC TROP MED H, V92, P430, DOI 10.1016/S0035-9203(98)91081-1
   Meshnick SR, 1996, MICROBIOL REV, V60, P301
   MORLEY D, 1964, BRIT MED J, V1, P667
   MUTABINGWA TK, 1993, TROP GEOGR MED, V45, P49
   Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Steketee RW, 1996, AM J TROP MED HYG, V55, P33
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
NR 14
TC 58
Z9 60
U1 0
U2 2
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL-AUG
PY 2001
VL 95
IS 4
BP 424
EP 428
DI 10.1016/S0035-9203(01)90204-4
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 478GJ
UT WOS:000171336900020
PM 11579889
OA No
DA 2017-08-15
ER

PT J
AU Okoko, JB
   Wesumperuma, HL
   Hart, CA
AF Okoko, JB
   Wesumperuma, HL
   Hart, CA
TI The influence of prematurity and low birthweight on transplacental
   antibody transfer in a rural West African population
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article; Proceedings Paper
CT 11th European Congress on Clinical Microbiology and Infectious Diseases
   (ECCSMID 2001)
CY APR 01-04, 2001
CL ISTANBUL, TURKEY
DE maternal antibody transfer; neonates; prematurity; low birthweight; The
   Gambia
ID LOW-BIRTH-WEIGHT; PLACENTAL-TRANSFER; INFECTION; MALARIA; IMMUNIZATION;
   SUBCLASSES; IMMUNITY; MEASLES; INFANT; MOTHER
AB OBJECTIVE To determine the influence of prematurity and low birthweight (LBW) on transplacental antibody transfer.
   METHOD in a physician-blinded, cross-sectional study of 213 mother-baby pairs in the labour ward of Bansang Hospital, The Gambia, paired maternal and cord serum samples were tested for specific IgG antibody titres for measles virus (MeV), herpes simplex virus type 1 (HSV1), respiratory syncytial virus (RSV), varicella-zoster virus (VZV), tetanus toroid ITT) and diphtheria toroid (DT) antigens using enzyme linked immunosorbent assay (ELISA).
   RESULTS Prematurity was significantly associated with reduced placental antibody transfer for MeV, HSV1, TT, DT, RSV and VZV. Maternal antibody transfer for MeV. HSV1, TT, DT. RSV and VZV was significantly lower in neonates with LBW than in babies with adequate birthweight (ABW).
   CONCLUSION Materno-foetal transfer of antibodies is impaired in prematurity and LBW babies in this Gambian population. Reduction in antibody transfer may further predispose these already vulnerable neonates to bacteria and viral infections. Therefore, alternative vaccination strategies, including earlier vaccination schedules, are needed to provide better protection to these young infants.
C1 Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England.
   MRC, Fajara, Gambia.
RP Okoko, JB (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR ADA G, 1995, INT ARCH ALLERGY IMM, V108, P304
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x
   CostaCarvalho BT, 1996, BRAZ J MED BIOL RES, V29, P201
   de Moraes-Pinto MI, 1998, ARCH DIS CHILD, V79, pF202
   deMoraesPinto I, 1997, BRIT J HOSP MED, V58, P317
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077
   DREWS MB, 1995, J HOSP INFECT, V30, P65, DOI 10.1016/0195-6701(95)90250-3
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   ENGLUND JA, 1995, J INFECT DIS, V171, P99
   Ferrante A, 1990, PEDIAT INFECT DIS S, V9, P16
   Fried M, 1998, J IMMUNOL, V160, P2523
   GAIRDNER D, 1988, CRAIGS CARE NEWLY BO, P115
   GARTY BZ, 1994, CLIN DIAGN LAB IMMUN, V1, P667
   IBANESEBHOR SE, 1992, INT J GYNECOL OBSTET, V37, P247
   KAMAT M, 1994, ARCH PEDIAT ADOL MED, V148, P694
   KAMEDA T, 1991, PLACENTA, V12, P15, DOI 10.1016/0143-4004(91)90506-B
   Leach JL, 1996, J IMMUNOL, V157, P3317
   MCGEGOR IA, 1983, T ROY SOC TROP MED H, V77, P19
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   OKOKO JB, 1999, THESIS W AFRICAN COL
   SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1049, DOI 10.1016/0002-9378(95)91325-4
   SATO H, 1979, AM J DIS CHILD, V133, P1240
   TAFARI N, 1991, PAEDIAT TROPICS, P198
   TOIVANEN P, 1968, IMMUNOLOGY, V15, P395
   Wesumperuma HL, 1999, ANN TROP MED PARASIT, V93, P169
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS17, DOI DOI 10.1097/00006454-199910001-00004
NR 27
TC 28
Z9 28
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2001
VL 6
IS 7
BP 529
EP 534
DI 10.1046/j.1365-3156.2001.00741.x
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 455AR
UT WOS:000170005800007
PM 11469946
OA No
DA 2017-08-15
ER

PT J
AU Eisler, MC
   Brandt, J
   Bauer, B
   Clausen, PH
   Delespaux, V
   Holmes, PH
   Ilemobade, A
   Machila, N
   Mbwambo, H
   McDermott, J
   Mehlitz, D
   Murilla, G
   Ndung'u, JM
   Peregrine, AS
   Sidibe, I
   Sinyangwe, L
   Geerts, S
AF Eisler, MC
   Brandt, J
   Bauer, B
   Clausen, PH
   Delespaux, V
   Holmes, PH
   Ilemobade, A
   Machila, N
   Mbwambo, H
   McDermott, J
   Mehlitz, D
   Murilla, G
   Ndung'u, JM
   Peregrine, AS
   Sidibe, I
   Sinyangwe, L
   Geerts, S
TI Standardised tests in mice and cattle for the detection of drug
   resistance in tsetse-transmitted trypanosomes of African domestic cattle
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE cattle-protozoa; drug resistance; trypanocides; Trypanosoma spp.
ID LINKED-IMMUNOSORBENT-ASSAY; ISOMETAMIDIUM CHLORIDE; BOVINE
   TRYPANOSOMIASIS; CONGOLENSE RESISTANT; DIMINAZENE ACETURATE; HOMIDIUM;
   CHEMOTHERAPY; POPULATIONS; DIAGNOSIS; ETHIOPIA
AB Resistance to the drugs used to control African animal trypanosomosis is increasingly recognised as a constraint to livestock production in sub-Saharan Africa. The most commonly used tests for detection of trypanocidal drug resistance are tests using mice or ruminants, but these suffer from lack of standardisation and hence it may be difficult to compare the results of different investigators. Tests in mice are less expensive than tests in ruminants, but while tests in mice they may be useful as a general guide to resistance in a geographic area they should not be extrapolated to cattle on an individual trypanosome level. Moreover, the commonly used protocols are too laborious for their application to large number of trypanosome isolates on an area-wide basis. This paper presents guidelines for standardised testing of trypanocidal drugs in vivo, and introduces a simplified single-dose test for use in mice, which is convenient for use in areas with limited laboratory facilities. The single-dose test is appropriate for characterisation of geographic areas in terms of trypanocidal drug resistance using large numbers of trypanosome isolates, for making comparisons between areas, and for monitoring changes in trypanocidal drug resistance over time. Multiple-dose tests may be used to determine the degree of resistance of individual stabilates to be determined precisely in mice are also described, but for logistical reasons these will rarely be conducted on more than a few stabilates, and testing of a larger number of stabilates in the single-dose test will generally provide more useful information. Finally, we describe tests in cattle that may be used to determine the efficacy of recommended curative doses of trypanocidal drugs for the treatment of infection with individual trypanosome isolates, including Trypanosoma vivax, which is rarely infective for mice. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Glasgow, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland.
   OAU, IBAR, Nairobi, Kenya.
   Inst Trop Med, B-2000 Antwerp, Belgium.
   Inst Parasitol & Trop Vet Med, D-14163 Berlin, Germany.
   Univ Edinburgh, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland.
   Anim Dis Res Inst, Dar Es Salaam, Tanzania.
   Int Livestock Res Inst, Nairobi, Kenya.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Kenya Trypanosomiasis Res Inst, Kikuyu, Kenya.
   Univ Guelph, Ontario Vet Coll, Guelph, ON N1G 2W1, Canada.
   CIRDES, Bobo Dioulasso 01, Burkina Faso.
   Cent Vet Res Inst, Lusaka, Zambia.
RP Eisler, MC (reprint author), Univ Glasgow, Dept Vet Clin Studies, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.
RI DELESPAUX, Vincent/C-3160-2009
CR AINANSHE OA, 1992, TROP ANIM HEALTH PRO, V24, P65, DOI 10.1007/BF02356946
   CODJIA V, 1993, ACTA TROP, V53, P151, DOI 10.1016/0001-706X(93)90026-8
   Eisler MC, 1997, J VET PHARMACOL THER, V20, P173, DOI 10.1111/j.1365-2885.1997.tb00092.x
   Eisler MC, 1996, DRUG METAB DISPOS, V24, P1355
   Eisler MC, 1996, THER DRUG MONIT, V18, P73, DOI 10.1097/00007691-199602000-00012
   EISLER MC, 2000, P 9 ISVEE S BRECK CO
   GEERTS S, 1999, P 25 ISCTRC C MOMB
   Geerts S., 1998, PAAT TECHNICAL SCI S, V1, P31
   HAWKING F, 1963, ANN TROP MED PARASIT, V57, P262
   *ICPTV, 2000, WORKSH DRUG DEL RES, P3
   JENNINGS FW, 1977, PARASITOLOGY, V75, P143
   JENNINGS FW, 1977, VET REC, V100, P367
   KONE P, 1999, THESIS I TROP MED, P46
   LUCKINS AG, 1978, TROP ANIM HEALTH PRO, V10, P149, DOI 10.1007/BF02235328
   MAMMAN M, 1995, ANTIMICROB AGENTS CH, V39, P1107
   MCDERMOTT JJ, 1999, P INT SCI COUNC TRYP
   MCDERMOTT JJ, 2000, FIELD STUDIES DEV IM, P18
   MDACHI RE, 1999, THESIS U GLASGOW, P366
   Mulugeta W, 1997, ACTA TROP, V64, P205, DOI 10.1016/S0001-706X(96)00645-6
   Murilla GA, 1999, J VET PHARMACOL THER, V22, P295, DOI 10.1046/j.1365-2885.1999.00215.x
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   NDOUTAMIA G, 1993, ANTIMICROB AGENTS CH, V37, P1163
   NDUNGU JM, 1999, P INT SCI COUNC TRYP
   PEREGRINE AS, 1994, VET PARASITOL, V54, P223, DOI 10.1016/0304-4017(94)90092-2
   PEREGRINE AS, 1991, PARASITOLOGY, V102, P93
   PEREGRINE AS, 2000, LONG TERM OCCURRENCE, P22
   SONES KR, 1988, ACTA TROP, V45, P153
   SONES KR, 1992, ACTA TROP, V51, P213, DOI 10.1016/0001-706X(92)90039-Z
   WHITESIDE EF, 1958, P 7 M INT SCI COMM T, P83
NR 29
TC 40
Z9 41
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUN 12
PY 2001
VL 97
IS 3
BP 171
EP 182
DI 10.1016/S0304-4017(01)00415-0
PG 12
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 444UG
UT WOS:000169418000001
PM 11390069
OA No
DA 2017-08-15
ER

PT J
AU Obaro, S
AF Obaro, S
TI Differences in invasive pneumococcal serotypes
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Obaro, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Alpern ER, 2000, PEDIATRICS, V106, P505, DOI 10.1542/peds.106.3.505
   Harrison LH, 2000, ARCH INTERN MED, V160, P89, DOI 10.1001/archinte.160.1.89
   Hausdorff WP, 2001, LANCET, V357, P950, DOI 10.1016/S0140-6736(00)04222-7
   Hedlund J, 1997, LANCET, V349, P371, DOI 10.1016/S0140-6736(97)80003-7
   SNIADACK DH, 1995, PEDIATR INFECT DIS J, V14, P503, DOI 10.1097/00006454-199506000-00007
NR 5
TC 4
Z9 4
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 2
PY 2001
VL 357
IS 9270
BP 1800
EP 1801
DI 10.1016/S0140-6736(00)04915-1
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 440BN
UT WOS:000169156200046
PM 11407384
OA No
DA 2017-08-15
ER

PT J
AU Schneider, G
AF Schneider, G
TI Oxygen supply in rural Africa: a personal experience
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE oxygen supply; oxygen concentrator; Africa
AB Oxygen is one of the essential medical supplies in any hospital setting. However, in some rural African settings without regular electricity and with logistical problems in the transport of oxygen cylinders, the delivery of oxygen can be difficult. This paper compares the costs incurred using oxygen cylinders with a solar operated oxygen concentrator in a rural Gambian setting. The paper shows that a solar operated system has a high capital investment initially, but that running costs and maintenance are minimal. The system becomes cost effective if a rural hospital needs more than G treatment days (1 l/min) of oxygen per month and can be considered in a setting where 6 hours of sunlight per day can be guaranteed.
C1 WEC Int, Banjul, Gambia.
RP Schneider, G (reprint author), WEC Int, Box 86, Banjul, Gambia.
CR Dobson M., 1991, ANAESTHESIA, V146, P217
   PEDERSEN J, 1991, BRIT J ANAESTH, V66, P264, DOI 10.1093/bja/66.2.264
   *WHO, 1993, OX THER AC RESP TRAC
NR 3
TC 17
Z9 18
U1 0
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD JUN
PY 2001
VL 5
IS 6
BP 524
EP 526
PG 3
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 439GF
UT WOS:000169101900006
PM 11409578
OA No
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Wesuperuma, LH
   Ota, MOC
   Banya, WAS
   Pinder, M
   Gomez, FS
   Osinusi, K
   Hart, AC
AF Okoko, BJ
   Wesuperuma, LH
   Ota, MOC
   Banya, WAS
   Pinder, M
   Gomez, FS
   Osinusi, K
   Hart, AC
TI Influence of placental malaria infection and maternal
   hypergammaglobulinaemia on materno-foetal transfer of measles and
   tetanus antibodies in a rural west African population
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article
DE malaria; hypergammaglobulinaemia; measles; antibodies; tetanus; the
   Gambia; West Africa
ID NEONATAL TETANUS; IMMUNIZATION; VACCINATION; PREGNANCY; IMMUNITY;
   VACCINES; GAMMA
AB Placental malaria infection jeopardizes pregnancy outcome, and its influence may also impair the transplacental transfer of some antibodies. Two hundred and thirteen Gambian mother-baby pairs were studied to determine the influence of placental malaria infection and maternal hypergammaglobulinaemia on transplacental transfer of measles and tetanus antibodies in Gambian population. Placental blood and tissue were collected for placental malaria diagnosis. Cord and maternal sera were tested for total IgG concentration by laser nephelometry and for IgG antibody to tetanus toxoid and measles by ELISA. The prevalence of placental malaria infection was 51.1 %. Mothers whose placentae were parasitized had a significantly higher mean total serum IgG (22.0 g/L vs 11.3 g/L, p <0.001) and measles antibody level (4.02 IU/mL vs 1.21 IU/mL, p <0.01), but not tetanus antibody, than mothers with non-parasitized placentae. Results of multiple regression analysis showed that placental malaria infection and maternal hypergammaglobulinaemia were associated with the reduction of 72% (95% CI 67,84)and 86% (95 % CI 76,91) in transplacental transfer of measles antibody respectively but did not influence the transfer of tetanus antibody. It is concluded that the combined influence of placental malaria infection and maternal hypergammaglobulinaemia is significantly associated with the transfer of impaired measles antibody in this population.
C1 MRC, Fajara, Gambia.
   Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England.
   Royal Victoria Hosp, Dept Pathol, Banjul, Gambia.
   Univ Coll Ibadan Hosp, Dept Paediat, Ibadan, Nigeria.
RP Okoko, BJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR ADA G, 1995, INT ARCH ALLERGY IMM, V108, P304
   ANTIAOBONG OE, 1993, ANN TROP PAEDIATR, V13, P7
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   BRAMBEL FWR, 1970, TRANSMISSION PASSIVE, P1
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   de Moraes-Pinto MI, 1998, ARCH DIS CHILD, V79, pF202
   deMoraesPinto I, 1997, BRIT J HOSP MED, V58, P317
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077
   Egemen A, 1996, J TROP PEDIATRICS, V42, P299, DOI 10.1093/tropej/42.5.299
   ENGLUND JA, 1995, J INFECT DIS, V171, P99
   FERRANTE A, 1990, PEDIATR INFECT DIS J, V9, pS16
   Fried M, 1998, J IMMUNOL, V160, P2523
   GENDREL D, 1988, PRESSE MED, V17, P1633
   GENDREL D, 1990, J TROP PEDIATRICS, V36, P279
   HOOD N, 1994, ANN TROP PAEDIATR, V14, P174
   KAMEDA T, 1991, PLACENTA, V12, P15, DOI 10.1016/0143-4004(91)90506-B
   LOGIE DE, 1973, B WORLD HEALTH ORGAN, V49, P547
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145
   OWA JA, 1990, TROP DOCT, V20, P156
   Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/ror.0.0040081
   SATO H, 1979, AM J DIS CHILD, V133, P1240
   SCHUR PH, 1987, ANN ALLERGY, V58, P89
   Wesumperuma HL, 1999, ANN TROP MED PARASIT, V93, P169
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS17, DOI DOI 10.1097/00006454-199910001-00004
NR 25
TC 28
Z9 29
U1 0
U2 0
PU I C D D R B-CENTRE HEALTH POPULATION RESEARCH
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD JUN
PY 2001
VL 19
IS 2
BP 59
EP 65
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 459VY
UT WOS:000170273200003
PM 11503348
OA No
DA 2017-08-15
ER

PT J
AU De Martin, S
   von Seidlein, L
   Deen, JL
   Pinder, M
   Walraven, G
   Greenwood, B
AF De Martin, S
   von Seidlein, L
   Deen, JL
   Pinder, M
   Walraven, G
   Greenwood, B
TI Community perceptions of a mass administration of an antimalarial drug
   combination in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE knowledge; attitude; practice; KAP; mass drug administration (MDA);
   compliance; malaria; Africa; The Gambia
ID MALARIA
AB To test the hypothesis that widespread treatment with artemisinin derivatives can reduce malaria transmission, a mass drug administration (MDA) campaign was undertaken in an area of The Gambia in 1999. Coverage of 85% of the target population was achieved, but the intervention did not reduce overall malaria transmission. We studied the perceptions, knowledge and attitudes of the community to the MDA campaign, A validated questionnaire was administered to randomly selected MDA participants (n = 90) and MDA refusers (n = 71). Individuals who believed in the importance of the MDA (adjusted OR 58.3%; 95% CI 17.4-195.8) and those who were aware that a high level of participation was needed for the MDA to be successful (adjusted OR 28.1; 95% CI 10.3-75.9) were more likely to participate. Understanding that the purpose of the MDA was to reduce malaria (adjusted OR 13.9; 95% CI 5.5-35.1) and knowledge of the fact that malaria is transmitted by mosquitoes and of the clinical signs of malaria (adjusted OR 3.4; 95% CI 3.1-9.0) were associated with participation. Individuals who discussed the MDA with other villagers (adjusted OR 5.5; 95% CI 2.2-13.5) and those who attended the sensitization meeting (adjusted OR 2.6; 95% CI 1.1-6.0) were also more likely to participate. Women were significantly more likely to participate in the MDA than men (adjusted OR 3.1; 95% CI 1.5-6.2). Individuals who refused to participate were unlikely to plan participation in future MDAs. One of the most difficult challenges in the implementation of a mala;ia control strategy such as an MDA is to convince villagers to participate and to make them aware that a high level of participation by the community is needed for success. We found that our sensitization meetings could be improved by giving more information on how the MDA works and finding means to generate small group discussions after the meeting.
C1 London Sch Hyg & Trop Med, London WC1, England.
   Farafenni Field Stn, MRC Labs, Fajara, Gambia.
RP von Seidlein, L (reprint author), Int Vaccine Inst, Kwanak POB 14, Seoul 151600, South Korea.
CR AGER A, 1992, TROP MED PARASITOL, V43, P234
   AGYEPONG IA, 1994, ACTA TROP, V58, P317, DOI 10.1016/0001-706X(94)90025-6
   DE ZULUETA J., 1964, East African Medical Journal, V41, P102
   DOI H, 1989, J TROPICAL MED PUBLI, V20, P341
   GARFIELD RM, 1983, LANCET, V2, P500
   Kaneko A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5
   Kaneko Akira, 1994, Japanese Journal of Parasitology, V43, P358
   Molineaux Louis, 1980, GARKI PROJECT RES EP
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   SMITH PG, 1996, FIELD TRIALS HLTH IN
   Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624
   Thera MA, 2000, TROP MED INT HEALTH, V5, P876, DOI 10.1046/j.1365-3156.2000.00652.x
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   Wongsrichanalai C, 2000, LANCET, V355, P2245, DOI 10.1016/S0140-6736(00)02416-8
NR 14
TC 14
Z9 14
U1 3
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2001
VL 6
IS 6
BP 442
EP 448
DI 10.1046/j.1365-3156.2001.00723.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 446DE
UT WOS:000169497000005
PM 11422958
OA No
DA 2017-08-15
ER

PT J
AU Bah, E
   Parkin, DM
   Hall, AJ
   Jack, AD
   Whittle, H
AF Bah, E
   Parkin, DM
   Hall, AJ
   Jack, AD
   Whittle, H
TI Cancer in the Gambia: 1988-97
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE incidence; cancer; registration; hepatitis B; immunization
ID HEPATITIS-B INFECTION; AFLATOXIN EXPOSURE; WEST-AFRICA; REGISTRY;
   POPULATION; PATTERN; RISK
AB We describe the incidence of cancer in The Gambia over a 10-year period using data collected through the Gambian National Cancer Registry. Major problems involved with cancer registration in a developing country, specifically in Africa are discussed. The data accumulated show a low overall rate of cancer incidence compared to more developed parts of the world. The overall age standardized incidence rates (ASR) were 61.0 and 55.7 per 100 000 for males and females, respectively. In males, liver cancer was most frequent, comprising 58% of cases (ASR 35.7) followed by non-Hodgkin lymphoma, 5.4% (ASR 2.4), lung 4.0%, (ASR 2.8) and prostate 3.3% (ASR 2.5) cancers. The most frequent cancers in females were cervix uteri 34.0% (ASR 18.9), liver 19.4% (ASR 11.2), breast 9.2% (ASR 5.5) and ovary 3.2% (ASR 1.6). The data indicate that cancers of the liver and cervix are the most prevalent cancers, and are likely to be due to infectious agents. It is hoped that immunization of children under 1 year against hepatitis B will drastically reduce the incidence of liver cancer in The Gambia. (C) 2001 Cancer Research Campaign.
C1 MRC Labs, Gambia Hepatitis Intervent Study, Int Agcy Res Canc, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   Int Agcy Res Canc, F-69372 Lyon, France.
   WHO, Representat Off, Gaborone, Botswana.
RP Bah, E (reprint author), MRC Labs, Gambia Hepatitis Intervent Study, Int Agcy Res Canc, POB 273, Banjul, Gambia.
CR ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P426, DOI 10.1016/0035-9203(92)90253-9
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486
   Chokunonga E, 2000, INT J CANCER, V85, P54, DOI 10.1002/(SICI)1097-0215(20000101)85:1<54::AID-IJC10>3.3.CO;2-4
   COOKE A, 1998, 9803 INT AG RES CANC
   DESANJOSE S, 1994, INT J CANCER, V56, P358, DOI 10.1002/ijc.2910560311
   Doll R, 1966, CANC INC 5 CONT, Vi
   Echimane AK, 2000, CANCER, V89, P653, DOI 10.1002/1097-0142(20000801)89:3<653::AID-CNCR22>3.0.CO;2-Z
   HALL A J, 1987, Cancer Research, V47, P5782
   Herrero R, 1999, CANCER SURV, V33, P75
   [Anonymous], 1994, IARC MON EV CARC RIS, V59
   *IARC, 1998, IARC MON EV CARC RIS, V70
   JAYANT K, 1997, IARC SCI PUBLICATION, V143
   Kew MC, 1975, MODERN TRENDS GASTRO, V5, P91
   Koulibaly M, 1997, INT J CANCER, V70, P39, DOI 10.1002/(SICI)1097-0215(19970106)70:1<39::AID-IJC6>3.0.CO;2-7
   Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0
   Meda N, 1997, GENITOURIN MED, V73, P188
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   OETTLE AG, 1962, ACTA UICC, V18, P17
   Parkin DM, 1994, 19 IARC
   Parkin D.M., 1997, IARC SCI PUBLICATION, VVII
   Percy C, 1990, INT CLASSIFICATION D
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   Rajkumar R, 2000, CANCER CAUSE CONTROL, V11, P433, DOI 10.1023/A:1008900425151
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   Smith P., 1992, IARC SCI PUBL, VVI, P865
   TORTEY E, 1985, LANCET, V1, P514
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Wabinga HR, 2000, BRIT J CANCER, V82, P1585
   WATERHOUSE JAH, 1982, IARC SCI PUBL, V42, P210
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P1
NR 34
TC 49
Z9 49
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 4
PY 2001
VL 84
IS 9
BP 1207
EP 1214
DI 10.1054/bjoc.2001.1730
PG 8
WC Oncology
SC Oncology
GA 433UQ
UT WOS:000168779100013
PM 11336472
OA No
DA 2017-08-15
ER

PT J
AU Vekemans, J
   Amedei, A
   Ota, MO
   D'Elios, MM
   Goetghebuer, T
   Ismaili, J
   Newport, MJ
   Del Prete, G
   Goldman, M
   McAdam, KPWJ
   Marchant, A
AF Vekemans, J
   Amedei, A
   Ota, MO
   D'Elios, MM
   Goetghebuer, T
   Ismaili, J
   Newport, MJ
   Del Prete, G
   Goldman, M
   McAdam, KPWJ
   Marchant, A
TI Neonatal bacillus Callmette-Guerin vaccination induces adult-like
   IFN-gamma production by CD4(+) T lymphocytes
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE neonatal immunology; vaccination; Th1; Th2
ID DENDRITIC CELLS; CALMETTE-GUERIN; MYCOBACTERIUM-TUBERCULOSIS; RESPONSES;
   TOLERANCE; ANTIGENS; PROFILE
AB The immaturity of the neonatal immune system in mice is associated with defective IFN-gamma production and The-biased immune responses. In this study, infants vaccinated at birth with BCG produced similar concentrations of IFN-gamma in response to PPD and showed similar frequencies of IFN-gamma -producing lymphocytes as compared to immune adults. Infants and adults produced only low concentrations of IL-4 and IL-5. CD4(+) T lymphocytes were the main source of IFN-gamma. Similar proportions of Th1 and Th0 PPD-specific T cell clones were observed in infants and adults. This study demonstrates that the human neonatal immune response to BCG is not biased towards Th2 and is characterized by the predominant production of lFN-gamma by CD4(+) T lymphocytes.
C1 Free Univ Brussels, Brussels, Belgium.
   Addenbrookes Hosp, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge, England.
   Univ Florence, Dept Internal Med, Florence, Italy.
   Med Res Council Labs, Banjul, Gambia.
RP Vekemans, J (reprint author), Free Univ Brussels, 808 Route Lennik, Brussels, Belgium.
RI Amedei, Amedeo/G-5378-2011
OI Amedei, Amedeo/0000-0002-6797-9343
CR Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   Barrios C, 1996, EUR J IMMUNOL, V26, P2666, DOI 10.1002/eji.1830261118
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   Delespesse G, 1998, VACCINE, V16, P1415, DOI 10.1016/S0264-410X(98)00101-7
   DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300
   Flamand V, 1998, J IMMUNOL, V160, P4666
   GORIELLI S, IN PRESS J IMMUNOL
   Henderson RA, 1997, J IMMUNOL, V159, P635
   HUNT DWC, 1994, BLOOD, V84, P4333
   Kovarik J, 1999, J IMMUNOL, V162, P1611
   Lambert PH, 1997, BRIT MED J, V315, P1595
   LEWIS DB, 1991, J CLIN INVEST, V87, P194, DOI 10.1172/JCI114970
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Prescott SL, 1998, J IMMUNOL, V160, P4730
   Ravn P, 1997, J IMMUNOL, V158, P1949
   Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723
   Siegrist C A, 2000, Int Rev Immunol, V19, P195, DOI 10.3109/08830180009088505
NR 18
TC 120
Z9 124
U1 1
U2 4
PU WILEY-V C H VERLAG GMBH
PI BERLIN
PA PO BOX 10 11 61, D-69451 BERLIN, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAY
PY 2001
VL 31
IS 5
BP 1531
EP 1535
DI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
PG 5
WC Immunology
SC Immunology
GA 434KY
UT WOS:000168814900027
PM 11465110
OA No
DA 2017-08-15
ER

PT J
AU Mozzato-Chamay, N
   Corbett, EL
   Bailey, RL
   Mabey, DCW
   Raynes, J
   Conway, DJ
AF Mozzato-Chamay, N
   Corbett, EL
   Bailey, RL
   Mabey, DCW
   Raynes, J
   Conway, DJ
TI Polymorphisms in the I kappa B-alpha promoter region and risk of
   diseases involving inflammation and fibrosis
SO GENES AND IMMUNITY
LA English
DT Article
DE I kappa B-alpha (IkappaB-alpha gene); promoter; single nucleotide
   polymorphism (SNP); fibrosis; trachoma; silicosis
ID GENE; INHIBITOR; TRACHOMA
AB The transcription factor NF kappaB regulates inflammatory and other cellular responses. In non-stimulated cells, NF kappaB is linked to its inhibitor I kappaB, which plays a major role in controlling NF kappaB activity. Here, the gene promoter region of the major inducible I kappaB component (I kappaB-alpha) was studied to identify single nucleotide polymorphisms (SNPs), and to test if these are associated with risk of two diseases involving inflammation and fibrosis (trachoma and silicosis). Three SNPs were identified at positions -881, -826 and -297 relative to the transcription start site. The position -297 is close to two NF kappaB binding sites, kappa B2 and kappa B3, but the alleles were not associated with either disease. Alleles at positions -881 and -826 were in complete linkage disequilibrium with each other, and the rare haplotype was significantly less frequent among patients with trachoma compared to controls, although there was no difference in frequencies between silicosis patients and controls.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Med Res Council Labs, Banjul, Gambia.
RP Conway, DJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI Raynes, John/G-7932-2011
OI Raynes, John/0000-0002-8536-1328
CR BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532
   CONWAY DJ, 1997, INFECT IMMUN, V65, P1000
   CORBETT EL, UNPUB
   Emmerich F, 1999, BLOOD, V94, P3129
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787
   LEBAIL O, 1993, EMBO J, V12, P5043
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Tojima Y, 2000, NATURE, V404, P778
   Wagner GR, 1997, LANCET, V349, P1311, DOI 10.1016/S0140-6736(96)07336-9
NR 11
TC 31
Z9 31
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD MAY
PY 2001
VL 2
IS 3
BP 153
EP 155
DI 10.1038/sj.gene.6363753
PG 3
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 436UT
UT WOS:000168954800005
PM 11426324
OA No
DA 2017-08-15
ER

PT J
AU Sear, R
   Shanley, D
   McGregor, IA
   Mace, R
AF Sear, R
   Shanley, D
   McGregor, IA
   Mace, R
TI The fitness of twin mothers: evidence from rural Gambia
SO JOURNAL OF EVOLUTIONARY BIOLOGY
LA English
DT Article
DE anthropometric status; fertility; polyovulation; twins
ID CHILD-MORTALITY; VANISHING TWIN; MATERNAL AGE; DETERMINANTS; HUMANS;
   PREGNANCIES; SINGLETONS; FERTILITY; LACTATION; NUTRITION
AB We used a longitudinal database from a natural fertility population in rural Gambia to compare the overall fertility of mothers who had given birth to twins at some point in their reproductive history and mothers who had only ever given birth to singletons. We found that twin mothers had shorter birth intervals, higher age-specific fertility and more surviving children than singleton mothers. This suggests that, despite the considerably higher mortality of twins found in this population, twin mothers have a fitness advantage over singleton mothers, even in the absence of modern medical care. We ran a simple simulation model to estimate the relative fitness of twin and singleton mothers, and found that the model also estimated higher fitness for twin mothers. Further, girls who went on to become twin mothers were of higher anthropometric status during their teenage years than those who became singleton mothers.
C1 UCL, Dept Anthropol, London WC1E 6BT, England.
   Univ Newcastle Upon Tyne, Dept Gerontol, Wolfson Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   MRC Keneba, Keneba, Gambia.
RP Sear, R (reprint author), UCL, Dept Anthropol, Gower St, London WC1E 6BT, England.
EM r.sear@ucl.ac.uk
OI Mace, Ruth/0000-0002-6137-7739
CR ALLEN G, 1971, Social Biology, V18, P18
   ANDERSON DJ, 1990, EVOLUTION, V44, P438, DOI 10.1111/j.1558-5646.1990.tb05211.x
   Ball HL, 1999, J BIOSOC SCI, V31, P245, DOI 10.1017/S002193209900245X
   Beiguelman B, 2000, GENET MOL BIOL, V23, P15, DOI 10.1590/S1415-47572000000100003
   Bentley GR, 1999, EVOL ANTHROPOL, V7, P175
   BILLEWICZ WZ, 1982, ANN HUM BIOL, V9, P309, DOI 10.1080/03014468200005811
   BLUMENFELD Z, 1992, BRIT J OBSTET GYNAEC, V99, P333, DOI 10.1111/j.1471-0528.1992.tb13734.x
   BOKLAGE CE, 1990, INT J FERTIL, V35, P75
   BULMER MG, 1959, ANN HUM GENET, V23, P454, DOI 10.1111/j.1469-1809.1959.tb01486.x
   BULMER MG, 1959, BRIT MED J, V1, P29
   Bulmer M. G., 1970, BIOL TWINNING MAN
   CAMPBELL DM, 1974, J BIOSOC SCI, V6, P463
   CANTRELLE P, 1971, POP STUD-J DEMOG, V25, P505, DOI 10.1080/00324728.1971.10405821
   CORNEY G, 1981, TWIN RES A, V3, P107
   Curtis SL, 1996, J BIOSOC SCI, V28, P141
   DASGUPTA M, 1990, POP STUD-J DEMOG, V44, P489
   ERIKSSON AW, 1967, HEREDITAS, V47, P395
   Forbes LS, 1997, TRENDS ECOL EVOL, V12, P446, DOI 10.1016/S0169-5347(97)01179-8
   GABLER S, 1994, HUM BIOL, V66, P699
   Goldstein H, 1998, USERS GUIDE MLWIN
   Goldstein H, 1995, MULTILEVEL STAT MODE
   GRAHAM W, 1989, STUD FAMILY PLANN, V20, P125, DOI 10.2307/1966567
   GREENWOOD AM, 1987, B WORLD HEALTH ORGAN, V65, P635
   GUO G, 1993, POP STUD-J DEMOG, V47, P495, DOI 10.1080/0032472031000147266
   HAUKIOJA E, 1989, AM NAT, V133, P572, DOI 10.1086/284936
   HOFFMANS MDAF, 1988, HUM BIOL, V60, P237
   HOGBERG U, 1992, J BIOSOC SCI, V24, P487
   KELLY MP, 1991, FERTIL STERIL, V56, P221
   KLOSS RJ, 1992, ETHOL SOCIOBIOL, V13, P283, DOI 10.1016/0162-3095(92)90027-2
   Krackow S, 1998, TRENDS ECOL EVOL, V13, P156, DOI 10.1016/S0169-5347(98)01338-X
   LAMB WH, 1984, LANCET, V2, P912
   LANDY HJ, 1982, ACTA GENET MED GEMEL, V31, P179
   Lummaa V, 1998, NATURE, V394, P533, DOI 10.1038/28977
   Lummaa V, 1999, J EVOLUTION BIOL, V12, P806
   MADISE NJ, 1995, J BIOSOC SCI, V27, P95
   MADRIGAL L, 1995, HUM BIOL, V67, P779
   MCDERMOTT JM, 1995, INT J EPIDEMIOL, V24, P413, DOI 10.1093/ije/24.2.413
   McGregor IA, 1991, DIS MORTALITY SUBSAH, P306
   NYLANDER PP, 1969, ANN HUM GENET, V33, P41, DOI 10.1111/j.1469-1809.1969.tb01627.x
   PHILIPPE P, 1989, HUM BIOL, V61, P599
   Pison Gilles, 1992, MORTALITY SOC SUBSAH, P253
   POPKIN BM, 1993, DEMOGRAPHY, V30, P333, DOI 10.2307/2061644
   SCHMIDT HD, 1983, ANN HUM BIOL, V10, P371, DOI 10.1080/03014468300006541
   STEIN Z, 1986, LANCET, V1, P944
   THOMPSON EDB, 1965, THESIS U ABERDEEN AB
   Tracer DP, 1996, HUM BIOL, V68, P277
   VANGINNEKEN JK, MATERNAL CHILD HLTH
   VOLAND E, 1994, NATURWISSENSCHAFTEN, V81, P224, DOI 10.1007/s001140050060
   Warburton D, 1998, TRENDS ECOL EVOL, V13, P157, DOI 10.1016/S0169-5347(98)01342-1
   WEAVER LT, 1993, LANCET, V341, P1327, DOI 10.1016/0140-6736(93)90827-4
   WYSHAK G, 1965, AM J PUBLIC HEALTH N, V55, P1586, DOI 10.2105/AJPH.55.10.1586
   WYSHAK G, 1981, TWIN RES, V3, P95
NR 52
TC 26
Z9 26
U1 2
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1010-061X
J9 J EVOLUTION BIOL
JI J. Evol. Biol.
PD MAY
PY 2001
VL 14
IS 3
BP 433
EP 443
DI 10.1046/j.1420-9101.2001.00287.x
PG 11
WC Ecology; Evolutionary Biology; Genetics & Heredity
SC Environmental Sciences & Ecology; Evolutionary Biology; Genetics &
   Heredity
GA 446DH
UT WOS:000169497300009
OA No
DA 2017-08-15
ER

PT J
AU Collinson, A
   Laskey, M
   Dibba, B
   Prentice, A
AF Collinson, A
   Laskey, M
   Dibba, B
   Prentice, A
TI Dual-energy X-ray absorptiometry: A new insight into geophagy
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
C1 MRC, Int Nutr Grp, London, England.
   MRC, Kaneba, Gambia.
   MRC, Elsie Widdowson Lab, Cambridge, England.
RP Collinson, A (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, 49-51 Bedford Sq, London WC1B 3DP, England.
CR BATES CJ, 1994, BRIT J NUTR, V72, P601, DOI 10.1079/BJN19940062
   Laskey MA, 1996, NUTRITION, V12, P45, DOI 10.1016/0899-9007(95)00017-8
   Reid R M, 1992, Med Anthropol, V13, P337
   Simon SL, 1998, HEALTH PHYS, V74, P647, DOI 10.1097/00004032-199806000-00003
   STANEK EJ, 1995, ENVIRON HEALTH PERSP, V103, P277
NR 5
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD MAY
PY 2001
VL 32
IS 5
BP 615
EP 616
DI 10.1097/00005176-200105000-00027
PG 2
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 449DJ
UT WOS:000169668800027
PM 11429530
OA No
DA 2017-08-15
ER

PT J
AU Jaitner, J
   Sowe, J
   Secka-Njie, E
   Dempfle, L
AF Jaitner, J
   Sowe, J
   Secka-Njie, E
   Dempfle, L
TI Ownership pattern and management practices of small ruminants in The
   Gambia - implications for a breeding programme
SO SMALL RUMINANT RESEARCH
LA English
DT Article
DE Djallonke sheep; West African dwarf goats; ownership pattern; breeding
   programme
ID AFRICAN DWARF GOATS; DJALLONKE SHEEP; TRYPANOSOMOSIS RISK; PRODUCTIVITY
AB In the framework of a genetic improvement scheme a countrywide survey of small ruminant owners was conducted in The Gambia to obtain information about the ownership pattern, reasons for keeping and especially about breeding and management practices including housing and feeding. The main results were the following: women play a major role in small ruminant production, representing 52% of the owners of sheep, 67% of the owners of goats and 43% of the owners of both sheep and goats. The average number of animals owned is quire low (about six head of sheep and goats each, out of which about three are breeding females). Most of the breeding males are born in their respective flock and there are fewer breeding bucks than bleeding rams. However, there are sufficient numbers of breeding males around. Animals are mainly left free to roam around during the dry season, and are either tethered or herded in the rainy season. During night animals are housed or tied under a shelter. Supplementary feeding is not common and vaccination against Pest des Petit Ruminants (PPR) and Pasteurellosis is only partly carried out. Implications for the establishment and structure of a multiplication tier within a three tier breeding scheme, nucleus --> multipliers --> farmers are discussed. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Dept Livestock Serv, Abuko, Gambia.
   Tech Univ Munich, Inst Tierwissensch, D-85350 Freising, Germany.
RP Jaitner, J (reprint author), Zeiterweg 17, D-89335 Ichenhausen, Germany.
CR Agyemang K., 1991, Bulletin of Animal Health and Production in Africa, V39, P129
   Ankers P, 1998, PREV VET MED, V34, P215, DOI 10.1016/S0167-5877(97)00037-8
   Bennison JJ, 1997, AGR SYST, V55, P425, DOI 10.1016/S0308-521X(97)00002-4
   *DLS ITC, 1993, LIV CENS
   Itty P., 1997, Quarterly Journal of International Agriculture, V36, P153
   *NASS, 1989, DEP PLANN TECHN B N, V895
   Osaer S, 1999, VET PARASITOL, V82, P101, DOI 10.1016/S0304-4017(99)00011-4
   Osaer S, 2000, ACTA TROP, V74, P13, DOI 10.1016/S0001-706X(99)00042-X
   RAWLINGS P, 1992, AFR LIVESTOCK RES, V2, P50
   SOLKNER J, 1998, LIVEST PROD, V25, P273
   SUMBERG J, 1988, NOTES CATTLE SHEEP G
   *WID, 1993, SHEEP GOATS SURV WOM
NR 12
TC 34
Z9 34
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-4488
J9 SMALL RUMINANT RES
JI Small Ruminant Res.
PD MAY
PY 2001
VL 40
IS 2
BP 101
EP 108
DI 10.1016/S0921-4488(00)00221-2
PG 8
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 424DG
UT WOS:000168216400001
OA No
DA 2017-08-15
ER

PT J
AU Zhu, PX
   van der Ende, A
   Falush, D
   Brieske, N
   Morelli, G
   Linz, B
   Popovic, T
   Schuurman, IGA
   Adegbola, RA
   Zurth, K
   Gagneux, S
   Platonov, AE
   Riou, JY
   Caugant, DA
   Nicolas, P
   Achtman, M
AF Zhu, PX
   van der Ende, A
   Falush, D
   Brieske, N
   Morelli, G
   Linz, B
   Popovic, T
   Schuurman, IGA
   Adegbola, RA
   Zurth, K
   Gagneux, S
   Platonov, AE
   Riou, JY
   Caugant, DA
   Nicolas, P
   Achtman, M
TI Fit genotypes and escape variants of subgroup III Neisseria meningitidis
   during three pandemics of epidemic meningitis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE genetic variation; clonal descent; intercontinental spread; population
   structure; microevolution
ID SEROGROUP-A; WEST-AFRICA; POPULATION; CARRIAGE; DISEASE
AB The genetic variability at six polymorphic loci was examined within a global collection of 502 isolates of subgroup ill, serogroup A Neisseria meningitidis. Nine "genoclouds" were identified, consisting of genotypes that were isolated repeatedly plus 48 descendent genotypes that were isolated rarely. These genoclouds have caused three pandemic waves of disease since the mid-1960s, the most recent of which was imported from East Asia to Europe and Africa in the mid-1990s, Many of the genotypes are escape variants, resulting from positive selection that we attribute to herd immunity. Despite positive selection, most escape variants are less fit than their parents and are lost because of competition and bottlenecks during spread from country to country, Competition between fit genotypes results in dramatic changes in population composition over short time periods.
C1 Max Planck Inst Mol Genet, D-14195 Berlin, Germany.
   Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands.
   Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Atlanta, GA 30333 USA.
   Swiss Trop Inst, CH-4002 Basel, Switzerland.
   Med Res Council Labs, Fajara, Gambia.
   Cent Res Inst Epidemiol, Moscow 111123, Russia.
   Inst Pasteur, F-75724 Paris 15, France.
   Natl Publ Hlth Inst, WHO, Collaborating Ctr Ref & Res Meningococci, N-0403 Oslo, Norway.
   WHO, Collaborating Ctr Ref & Res Meningococci, Inst Med Trop, Serv Sante Armees, F-13998 Marseille, France.
RP Achtman, M (reprint author), Max Planck Inst Infekt Biol, Schumannstr 21-22, D-10017 Berlin, Germany.
RI van der Ende, Arie/A-4346-2012
OI Platonov, Alexander/0000-0001-7450-0081; Achtman,
   Mark/0000-0001-6815-0070; Gagneux, Sebastien/0000-0001-7783-9048
CR ACHTMAN M, 1992, J INFECT DIS, V165, P53
   ACHTMAN M, 2001, IN PRESS EMERG INFEC
   ACHTMAN M, 1990, REV MED MICROBIOL, V1, P29
   Bart A, 1998, J CLIN MICROBIOL, V36, P1746
   BLAKEBROUGH IS, 1982, J INFECT DIS, V146, P626
   CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323
   Caugant DA, 1998, APMIS, V106, P505
   CROWE BA, 1989, J INFECT DIS, V159, P686
   Eigen M, 1996, TRENDS MICROBIOL, V4, P216, DOI 10.1016/0966-842X(96)20011-3
   Gagneux S, 2000, TROP MED INT HEALTH, V5, P280, DOI 10.1046/j.1365-3156.2000.00550.x
   Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68
   Kwara A, 1998, TROP MED INT HEALTH, V3, P742
   Lapeyssonnie L., 1963, B WHO S, V28, P53
   Linz B, 2000, MOL MICROBIOL, V36, P1049, DOI 10.1046/j.1365-2958.2000.01932.x
   Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140
   Malorny B, 1998, J BACTERIOL, V180, P1323
   MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686
   Morelli G, 1997, MOL MICROBIOL, V25, P1047, DOI 10.1046/j.1365-2958.1997.5211882.x
   NICOLAS P, 2001, IN PRESS EMERG INFEC
   SCHOLTEN RJPM, 1993, CLIN INFECT DIS, V16, P237
   SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x
   Smith JM, 2000, BIOESSAYS, V22, P1115, DOI 10.1002/1521-1878(200012)22:12<1115::AID-BIES9>3.3.CO;2-I
   Tikhomirov Eugene, 1997, World Health Statistics Quarterly, V50, P170
   VIEUSSEUX M, 1806, J MED CHIRURG PHARM, V11, P163
   WANG FJ, 1992, INFECT IMMUN, V60, P5267
   Zhu PX, 1999, MOL MICROBIOL, V33, P635, DOI 10.1046/j.1365-2958.1999.01514.x
   1995, WEEKLY EPIDEMIO 1006, P281
NR 27
TC 91
Z9 93
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 24
PY 2001
VL 98
IS 9
BP 5234
EP 5239
DI 10.1073/pnas.061386098
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 425VC
UT WOS:000168311500078
PM 11287631
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
   Scherf, C
   West, B
   Ekpo, G
   Paine, K
   Coleman, R
   Bailey, R
   Morison, L
AF Walraven, G
   Scherf, C
   West, B
   Ekpo, G
   Paine, K
   Coleman, R
   Bailey, R
   Morison, L
TI The burden of reproductive-organ disease in rural women in The Gambia,
   West Africa
SO LANCET
LA English
DT Article
ID TRADITIONAL BIRTH ATTENDANTS; SIMPLEX VIRUS TYPE-2; CONTROLLED TRIAL;
   PREGNANCY; INFERTILITY; PREVALENCE; INFECTION; WORLDWIDE; MORTALITY;
   MALARIA
AB Background Data on the epidemiology of reproductive-organ morbidity are needed to guide effective interventions, to set health-care priorities, and to target future research. This study aimed to find out the prevalence of reproductive-organ disease in a sample of rural Gambian women.
   Methods A questionnaire on reproductive health was administered by fieldworkers to women aged 15-54 years living in a rural area under demographic surveillance. A female gynaecologist questioned and examined the women (including speculum and bimanual pelvic examinations). Vaginal swabs were taken to test for Trichomonas vaginalis, Candida albicans, and bacterial vaginosis, cervical smears for cytology, cervical swabs for Chlamydia trachomatis PCR and Neisseria gonorrhoeae culture, and venous blood for haemoglobin, HIV, herpes simplex virus 2, and syphilis serology,
   Findings 1348 (72.0%) of 1871 eligible women took part. Reproductive-organ symptoms were more likely to be reported to the gynaecologist (52.7% of women) than to the fieldworker (26.5%). Menstrual problems, abnormal vaginal discharge, and vaginal itching were the most commonly reported symptoms. A minority of women said they had sought health care for their symptoms. The frequencies of reproductive-organ morbidity were high: menstrual dysfunction 34.1% (95% CI 29.6-39.1), infertility 9.8% (8.2-11.6), reproductive-tract infections 47.3% (43.7-51.0), pelvic tenderness 9.8% ((7.0-13.5), cervical dysplasia 6.7% (5.2-8.4), masses 15.9% (12.5-20.1), and childbirth-related damage to pelvic structures 46.1% (40.1-52.3). 948 (70.3%) women had at least one reproductive-organ disorder.
   Interpretation For these rural women, whose lives depend heavily on their reproductive function, reproductive-organ disease is a large burden. In inadequately resourced rural areas, with poor education,;heavy agricultural and domestic labour, and limited access to quality health care, many women are not able to attain and maintain reproductive health and wellbeing.
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
   Univ Wales Coll Med, Dept Obstet & Gynaecol, Cardiff CF4 4XN, S Glam, Wales.
   London Sch Hyg & Trop Med, London WC1, England.
RP Walraven, G (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
RI Morison, Linda/H-9738-2013
CR BAILEY RL, 1994, J INFECT DIS, V170, P709
   BANG RA, 1989, LANCET, V1, P85
   [Anonymous], 1993, ACTA CYTOL, V37, P115
   BLEDSOE CH, 1994, POPUL DEV REV, V20, P81, DOI 10.2307/2137631
   BRABIN L, 1995, LANCET, V345, P300, DOI 10.1016/S0140-6736(95)90281-3
   Bulut A, 1997, STUD FAMILY PLANN, V28, P35, DOI 10.2307/2137969
   CATES W, 1985, LANCET, V2, P596
   FATHALLA MF, 1988, RES NEEDS HUMAN REPR
   Favot I, 1997, INT J EPIDEMIOL, V26, P414, DOI 10.1093/ije/26.2.414
   FILLIPPI V, 1997, TROP MED INT HEALTH, V2, P47
   GRAHAM WJ, 1995, ASKING QUESTIONS WOM
   GREENWOOD AM, 1992, J INFECT DIS, V166, P842
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   Harrison KA, 1997, LANCET, V349, P644, DOI 10.1016/S0140-6736(97)02192-2
   Hawkes S, 1999, LANCET, V354, P1776, DOI 10.1016/S0140-6736(99)02463-0
   HERRERO R, 1997, PAN AM J PUBLIC HLTH, V1, P362
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   INHORN MC, 1994, SOC SCI MED, V39, P459, DOI 10.1016/0277-9536(94)90089-2
   Lancaster EJ, 1999, E AFR MED J, V76, P101
   Marsden HS, 1998, J MED VIROL, V56, P79, DOI 10.1002/(SICI)1096-9071(199809)56:1<79::AID-JMV13>3.0.CO;2-R
   MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Obasi A, 1999, J INFECT DIS, V179, P16, DOI 10.1086/314555
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.3.CO;2-D
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   TSUI AO, 1997, REPROD HLTH DEV COUN, P178
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   Wawer MJ, 1998, AIDS, V12, P1211, DOI 10.1097/00002030-199810000-00014
   WOLFENDALE MR, 1987, BRIT MED J, V294, P33
   YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232
   ZURAYK H, 1995, STUD FAMILY PLANN, V26, P14, DOI 10.2307/2138047
NR 34
TC 77
Z9 77
U1 0
U2 7
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 14
PY 2001
VL 357
IS 9263
BP 1161
EP 1167
DI 10.1016/S0140-6736(00)04333-6
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 423RX
UT WOS:000168192100010
PM 11323043
OA No
DA 2017-08-15
ER

PT J
AU Jawara, M
   Pinder, M
   Cham, B
   Walraven, G
   Rowley, J
AF Jawara, M
   Pinder, M
   Cham, B
   Walraven, G
   Rowley, J
TI Comparison of deltamethrin tablet formulation with liquid deltamethrin
   and permethrin for bednet treatment in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE deltamethrin; permethrin; insecticide formulation; impregnated bednets;
   The Gambia; effectiviness; acceptability
ID ANOPHELES-GAMBIAE; MALARIA; MOSQUITOS; CHILDREN; TRIAL; AREA
AB The study aim was to compare three formulations, tablet deltamethrin, liquid deltamethrin and liquid permethrin, for their impact on vector behaviour and persistence. Product acceptance, perceived side-effects and user's perceptions of effectiveness were also investigated. At the beginning of the 1998 rainy season, 255 nets in a Gambian village were dipped in one of the three insecticides. Chemical residue analysis immediately after dipping showed that the target doses were reached for the liquid insecticides, but tablet deltamethrin deposited significantly less. Insecticide persistence at 5 months, however, was highest for the tablet formulation. Susceptibility tests established that Anophelines in this area were sensitive to both insecticides. All three formulations appeared effective as very few live Anophelines, or other mosquitoes, were caught under the treated nets. This conclusion was supported by the bioassay data with both deltamethrin formulations giving over 90% mortality soon after dipping and at 3 months, and at 5 months 70.8 and 79.6% were obtained for deltametrin liquid and tablet, respectively. Permethrin appeared less effective at all times (72.4, 86.8, 59.0%). There were no serious side-effects reported by the villagers following dipping. All three treatments were perceived as effective by the majority (92%) of users and most (93%) wanted to use the insecticide again. Deltamethrin tablets thus appear as good as permethrin for treating bednets in The Gambia. In addition, a tablet formulation is considerable easier to pack and distribute.
C1 Med Res Council Labs, Fajara, Senegal.
   Natl Malaria Control Programme, Banjul, Gambia.
RP Jawara, M (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Curtis CF, 1996, MED VET ENTOMOL, V10, P1, DOI 10.1111/j.1365-2915.1996.tb00075.x
   DALESSANDRO U, 1994, B WORLD HEALTH ORGAN, V72, P391
   HEMMINGWAY J, 1995, B ENTOMOL RES, V85, P229
   Jawara M, 1998, MED VET ENTOMOL, V12, P60
   JONES COH, 1997, FIELD TRIAL ACCEPTAB
   LENGELER C, 1998, COCHRANE LIB, V3
   LINDGREN F, 1993, J CHEMOMETR, V7, P45, DOI 10.1002/cem.1180070104
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   LINDSAY SW, 1991, PESTIC SCI, V32, P397, DOI 10.1002/ps.2780320402
   MILLER JE, 1995, MED VET ENTOMOL, V9, P43, DOI 10.1111/j.1365-2915.1995.tb00115.x
   NJAU RJA, 1993, INSECT SCI APPL, V14, P575
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   *WHO, 1999, WHOCDSWHOPES995
NR 14
TC 15
Z9 16
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD APR
PY 2001
VL 6
IS 4
BP 309
EP 316
DI 10.1046/j.1365-3156.2001.00706.x
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 436XD
UT WOS:000168960400010
PM 11348522
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
AF van der Loeff, MFS
TI Untitled
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP van der Loeff, MFS (reprint author), MRC Labs, Banjul, Gambia.
CR *CDCP, 1997, EP INF 6
   Hennekens CH, 1987, EPIDEMIOLOGY MED, P327
   van Hoogstraten MJ, 2000, TROP MED INT HEALTH, V5, P668
NR 3
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD APR
PY 2001
VL 6
IS 4
BP 325
EP 325
DI 10.1046/j.1365-3156.2001.0719b.x
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 436XD
UT WOS:000168960400013
OA No
DA 2017-08-15
ER

PT J
AU Klein, MR
   Smith, SM
   Hammond, AS
   Ogg, GS
   King, AS
   Vekemans, J
   Jaye, A
   Lukey, PT
   McAdam, KPWJ
AF Klein, MR
   Smith, SM
   Hammond, AS
   Ogg, GS
   King, AS
   Vekemans, J
   Jaye, A
   Lukey, PT
   McAdam, KPWJ
TI HLA-B*35-restricted CD8 T cell epitopes in the antigen 85 complex of
   Mycobacterium tuberculosis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CLASS-I MOLECULES; PEPTIDE-BINDING; ANTIMICROBIAL ACTIVITY; INFECTION;
   IDENTIFICATION; LYMPHOCYTES; MICE; VACCINATION; RESISTANCE; PROTECTION
AB Few target epitopes have been described for human CD8 T lymphocytes in antigens of Mycobacterium tuberculosis. By use of a reverse immunogenetics approach, 23 motif-bearing peptides of the Ag85 complex were tested for binding to HLA-B*35, one of the common B-types in West Africa. Three 9-mer peptides bound with high affinity to HLA-B*3501 and displayed low dissociation rates of peptide-major histocompatibility complexes (MHCs). IC50 and half-life values of peptide-MHC class I complexes were in the same range as reported earlier for other immunogenic peptides. Immune responses against peptide Ag85C (aa 204-212) WPTLIGLAM were characterized in detail. Peptide-stimulated effector cells were able to kill macrophages infected with M. tuberculosis or bacille Calmette-Guerin. Peptide-specific CD8 T cells could be visualized by using HLA-B*3501 tetramers and were shown to produce interferon-gamma and tumor necrosis factor-alpha. Together with other published epitopes, these peptides can be used to study more closely the role of CD8 T cells in mycobacterial infection and tuberculosis.
C1 MRC Labs, TB Res Programme, Fajara, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1, England.
   Inst Mol Med, MRC, Human Immunol Unit, Oxford, England.
   GlaxoSmithKline Res & Dev, Resp Syst, Stevenage, Herts, England.
RP Klein, MR (reprint author), MRC Labs, TB Res Programme, Atlantic Rd,POB 273, Banjul, Gambia.
RI Hammond, Abdulrahman/F-1541-2011
CR ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   BLEED D, 2000, WHOCDSTB2000275
   Bonato VLD, 1998, INFECT IMMUN, V66, P169
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Canaday DH, 1999, J IMMUNOL, V162, P372
   Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497
   Cole ST, 1998, NATURE, V393, P537
   DeGroot AS, 1997, AIDS RES HUM RETROV, V13, P529, DOI 10.1089/aid.1997.13.529
   Denis O, 1998, INFECT IMMUN, V66, P1527
   DIBRINO M, 1993, J IMMUNOL, V151, P5930
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   Geluk A, 2000, J IMMUNOL, V165, P6463
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530
   KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3
   Kern F, 1998, NAT MED, V4, P975, DOI 10.1038/nm0898-975
   Klein Michel R., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P313
   KORBER B, 2000, HIV MOL IMMUNOLOGY D
   LADEL CH, 1995, EUR J IMMUNOL, V25, P377, DOI 10.1002/eji.1830250211
   Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Lewinsohn DM, 1998, J EXP MED, V187, P1633, DOI 10.1084/jem.187.10.1633
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Pathan AA, 2000, EUR J IMMUNOL, V30, P2713, DOI 10.1002/1521-4141(200009)30:9<2713::AID-IMMU2713>3.0.CO;2-4
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   SCHONBACH C, 1995, J IMMUNOL, V154, P5951
   Sidney J, 1996, J IMMUNOL, V157, P3480
   Smith SM, 2000, J IMMUNOL, V165, P7088
   Smith SM, 1999, INFECT IMMUN, V67, P5223
   Smith SM, 2000, INFECT IMMUN, V68, P7144, DOI 10.1128/IAI.68.12.7144-7148.2000
   Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121
   TAKAMIYA Y, 1994, INT IMMUNOL, V6, P255
   Tascon RE, 1998, INFECT IMMUN, V66, P830
   Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x
   vanderBurg SH, 1996, J IMMUNOL, V156, P3308
   vanderBurg SH, 1995, HUM IMMUNOL, V44, P189, DOI 10.1016/0198-8859(95)00105-0
   Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833
NR 41
TC 31
Z9 32
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 15
PY 2001
VL 183
IS 6
BP 928
EP 934
DI 10.1086/319267
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 404RM
UT WOS:000167114500013
PM 11237810
OA No
DA 2017-08-15
ER

PT J
AU Lee, EAM
   Flanagan, KL
   Odhiambo, K
   Reece, WHH
   Potter, C
   Bailey, R
   Marsh, K
   Pinder, M
   Hill, AVS
   Plebanski, M
AF Lee, EAM
   Flanagan, KL
   Odhiambo, K
   Reece, WHH
   Potter, C
   Bailey, R
   Marsh, K
   Pinder, M
   Hill, AVS
   Plebanski, M
TI Identification of frequently recognized dimorphic T-cell epitopes in
   Plasmodium falciparum merozoite surface protein-1 in West and East
   Africans: Lack of correlation of immune recognition and allelic
   prevalence
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID C-TERMINAL FRAGMENT; GAMMA-INTERFERON; NATURAL-SELECTION; SERUM
   ANTIBODIES; HUMAN MALARIA; BLOOD STAGES; IFN-GAMMA; RESPONSES; PARASITE;
   INFECTION
AB The: merozoite surface protein-1 (MSP1) is the most studied malaria blood-stage vaccine candidate. Lymphokines such as interferon gamma (IFN-gamma) and interleukin 4 (IL-4) may mediate blood-stage specific protection Here we identify Plasmodium falciparum MSP1 T-cell epitopes capable of rapid induction of IFN-gamma and/or IL-4 from peripheral blood mononuclear cells of East and West African donors. Both allelic forms of these novel MSP1 T-cell epitopes were stimulatory. An unusually high numbers of Gambian responders (> 80%) to these epitopes were observed, suggesting that MSP1 reactivity may have been underestimated previously in this population. Surprisingly, IFN-gamma responses to allelic T-cell epitopes failed to correlate with differential antigenic exposure in The Gambia compared to Kenya. These results suggest an unexpected level of immunoregulation of IFN-gamma response with variable allelic T-cell reactivity independent of the level of antigenic exposure. Further analysis of the mechanisms determining this response pattern may be required if vaccines are to overcome this allelic reactivity bias in malaria-exposed populations.
C1 Univ Oxford, John Radcliffe Hosp, Mol Immunol Grp, Inst Mol Med,Nuffield Dept Med, Oxford OX3 9DU, England.
   Med Res Council Labs, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Kenya Med Res Inst, Kilifi Res Unit, Kilifi, Kenya.
RP Lee, EAM (reprint author), Univ Oxford, John Radcliffe Hosp, Mol Immunol Grp, Inst Mol Med,Nuffield Dept Med, Oxford OX3 9DU, England.
RI HILL, Adrian/C-1306-2008
CR BABIKER HA, 1991, T ROY SOC TROP MED H, V85, P572, DOI 10.1016/0035-9203(91)90347-2
   BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633
   BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409
   Chang SP, 1996, INFECT IMMUN, V64, P253
   CLARK IA, 1990, IMMUNOL LETT, V25, P195, DOI 10.1016/0165-2478(90)90114-6
   CONWAY DJ, 1992, INFECT IMMUN, V60, P1122
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   CRISANTI A, 1990, IMMUNOL LETT, V25, P143, DOI 10.1016/0165-2478(90)90106-Z
   CRISANTI A, 1988, SCIENCE, V240, P1324, DOI 10.1126/science.2453924
   DALY TM, 1995, J IMMUNOL, V155, P236
   DAVENPORT MP, 1995, IMMUNOGENETICS, V42, P392
   DAVENPORT MP, 1995, P NATL ACAD SCI USA, V92, P6567, DOI 10.1073/pnas.92.14.6567
   DELORON P, 1991, J CLIN MICROBIOL, V29, P1757
   Druilhe P, 1997, ANN TROP MED PARASIT, V91, pS37
   Egan A, 1997, INFECT IMMUN, V65, P3024
   EGAN AF, 1995, INFECT IMMUN, V63, P456
   Egan AF, 1996, J INFECT DIS, V173, P765
   ETLINGER HM, 1991, INFECT IMMUN, V59, P3498
   FERRANTE A, 1990, IMMUNOL LETT, V25, P179, DOI 10.1016/0165-2478(90)90112-4
   Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173
   Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HO M, 1989, PARASITE IMMUNOL, V11, P105, DOI 10.1111/j.1365-3024.1989.tb00652.x
   HOLDER AA, 1994, PARASITOL TODAY, V10, P182, DOI 10.1016/0169-4758(94)90025-6
   HUGHES AL, 1992, MOL BIOL EVOL, V9, P381
   HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2
   KING CL, 1993, J IMMUNOL, V151, P458
   KUMARATILAKE LM, 1994, RES IMMUNOL, V145, P423, DOI 10.1016/S0923-2494(94)80172-X
   LING IT, 1995, PARASITE IMMUNOL, V17, P425, DOI 10.1111/j.1365-3024.1995.tb00910.x
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   MAHESHWARI RK, 1986, INFECT IMMUN, V53, P628
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520
   NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134
   OCKENHOUSE CF, 1984, J IMMUNOL, V133, P1601
   Plebanski M, 1999, NAT MED, V5, P565, DOI 10.1038/8444
   Plebanski M, 1997, PARASITOLOGY, V115, pS55
   QUAKYI IA, 1994, J IMMUNOL, V153, P2082
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   ROBINSON AWT, 1993, PARASITE IMMUNOL, V15, P301
   Shi YP, 1996, INFECT IMMUN, V64, P2716
   SHIRAI A, 1993, J IMMUNOL, V150, P793
   SIMITSEK PD, 1990, EUR J IMMUNOL, V20, P1755, DOI 10.1002/eji.1830200820
   SINIGAGLIA F, 1988, J IMMUNOL, V140, P3568
   SOKAL RR, 1995, BIOMETRY PRINCIPLES, P68
   STEVENSON MM, 1989, PARASITE IMMUNOL, V11, P529, DOI 10.1111/j.1365-3024.1989.tb00687.x
   STEVENSON MM, 1995, J IMMUNOL, V155, P2545
   STEVENSON MM, 1993, CLIN EXP IMMUNOL, V92, P77
   TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8
   TAYLORROBINSON AW, 1994, INFECT IMMUN, V62, P2490
   TRAPE JF, 1992, AM J TROP MED HYG, V47, P181
   UDHAYAKUMAR V, 1995, J IMMUNOL, V154, P6022
NR 55
TC 21
Z9 21
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAR-APR
PY 2001
VL 64
IS 3-4
BP 194
EP 203
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 445UA
UT WOS:000169475900015
PM 11442217
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Rowley, J
   Manneh, K
   Lahai, G
   Needham, D
   Milligan, P
   McAdam, KPWJ
AF Lienhardt, C
   Rowley, J
   Manneh, K
   Lahai, G
   Needham, D
   Milligan, P
   McAdam, KPWJ
TI Factors affecting time delay to treatment in a tuberculosis control
   programme in a sub-Saharan African country: the experience of The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculosis; diagnosis; delay; TB control
ID PULMONARY TUBERCULOSIS
AB SETTING: Rural and urban health centres in The Gambia, West Africa.
   OBJECTIVES: To estimate the time delay between onset of symptoms and initiation of treatment and identify the risk factors influencing the delay in patients with tuberculosis (TB).
   DESIGN: Structured interviews with newly diagnosed TB patients aged over 15 years presenting to TB control staff in four health centres.
   RESULTS: A total of 152 TB patients were interviewed. The median delay from onset of symptoms to commencement of treatment was 8.6 weeks (range 5-17). Delay to treatment was independent. of sex, but was shorter in young TB patients. The median delay was longer in rural than in urban areas (12 weeks [range 8.5-17] vs. 8 [4-12], P < 0.01) and in those who did not attend school, but this effect disappeared after adjusting for age and area of residence. Patients who reported haemoptysis as one of their initial symptoms had shorter delays to treatment. There was no relation between duration of delay to treatment and cure rate, but longer delay did increase the risk of death.
   CONCLUSION: Starting TB patients on treatment as early as possible plays a major role in reducing disease transmission in the community. Key to this is increasing awareness of the signs and symptoms of TB and ensuring easy access to diagnostic facilities and treatment.
C1 Med Res Council Labs, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Natl TB & Leprosy Control Programme, Minist Hlth, Banjul, Gambia.
   Univ Toronto, Internal Med Residency Program, Toronto, ON, Canada.
RP Lienhardt, C (reprint author), Inst Rech Dev, BP 1386, Dakar, Senegal.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Enarson DA, 1996, TUBERCULOSIS GUIDE L
   Enwere GC, 1999, ANN TROP MED PARASIT, V93, P669, DOI 10.1080/00034989957907
   KANGANGI J, 1995, LUNG DIS S2, V76, P33
   Lawn SD, 1998, INT J TUBERC LUNG D, V2, P635
   Liefooghe R, 1997, TROP MED INT HEALTH, V2, P809, DOI 10.1046/j.1365-3156.1997.d01-380.x
   Lienhardt C, 1998, INT J TUBERC LUNG D, V2, P712
   LIENHARDT C, 1997, INT J TUBERC LUNG S1, V1, pS145
   MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306
   MORI T, 1992, TUBERCLE LUNG DIS, V73, P225, DOI 10.1016/0962-8479(92)90091-W
   Pirkis JE, 1996, TUBERCLE LUNG DIS, V77, P401, DOI 10.1016/S0962-8479(96)90111-2
   RAMAKRISHNA C, 1961, B WORLD HEALTH ORGAN, V25, P361
   Steen TW, 1998, INT J TUBERC LUNG D, V2, P627
   VANBAWEL JAC, 1997, 6 KNCV
   World Health Organization, 1994, WHOTB94179
NR 14
TC 102
Z9 112
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD MAR
PY 2001
VL 5
IS 3
BP 233
EP 239
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 426QF
UT WOS:000168359300007
PM 11326822
OA No
DA 2017-08-15
ER

PT J
AU Garly, ML
   Bale, C
   Martins, CL
   Monteiro, M
   George, E
   Kidd, M
   Dias, F
   Aaby, P
   Whittle, HC
AF Garly, ML
   Bale, C
   Martins, CL
   Monteiro, M
   George, E
   Kidd, M
   Dias, F
   Aaby, P
   Whittle, HC
TI Measles antibody responses after early two dose trials in Guinea-Bissau
   with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better
   antibody increase from booster dose of the Edmonston-Zagreb vaccine
SO VACCINE
LA English
DT Article
DE measles antibodies; boosting; two-dose schedule; Guinea-Bissau; Africa
ID 6-MONTH-OLD INFANTS; AIK-C; GAMBIAN CHILDREN; IMMUNE-RESPONSE; YOUNG
   INFANTS; IMMUNIZATION; AGE; STRAINS; IMMUNOGENICITY; REVACCINATION
AB In Guinea-Bissau, children were randomised at 6 months of age to receive either two doses of standard-titre measles vaccine at 6 and 9 months of age or an inactivated polio vaccine at 6 months and standard-titre measles vaccine at 9 months of age. During the first 5 months, children received Edmonston-Zagreb (EZ) vaccine and during the following 11 months, the Schwarz (SW) vaccine. Five percent of the mothers, 74% of children at 6 months of age, and 92% of unvaccinated children at 9 months of age had unprotective levels ( < 125 mIU/ml) of measles antibodies. Among children receiving EZ vaccine, 1%, were unprotected at 18 months of age after either two (3/240) or one (3/211) doses of vaccine, the geometric mean measles antibody titre (GMT) being <similar to> 1550 mIU/ml in both groups. Among those receiving SW vaccine 9% (34/365) and 3% (9/310) were unprotected at 18 months of age in the two-dose and the one-dose groups (RR = 3.21 (95% confidence interval (CI) 1.56-6.58)), respectively. The GMT was higher after one dose of SW vaccine at 9 months of age (2491 mIU/ml) than after two doses of SW vaccine (1125 mIU) (P < 0.001). In the EZ vaccine group, there was no significant difference in antibody level for children vaccinated in the presence of high or low levels of maternal antibodies, whereas there was a marked difference in the SW group. The second EZ vaccine induced a significant antibody increase between 9 months of age (1191 mIU) and Is months of age (1602 mIU, P = 0.011), whereas antibody levels tended to decline from 9 months (1243 mIU) to 18 months of age (998 mIU, P = 0.124) after the second dose of SW vaccine. Conclusively, after two doses of EZ measles vaccine more children were protected at 18 months of age than after two doses of SW. One dose of SW provided the highest antibody response, but a higher proportion of unprotected than one or two doses of EZ. The EZ vaccine was less sensitive to maternal antibodies, and able to increase the antibody response by revaccination, while the second SW vaccine resulted in an unchanged or lower antibody response. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Projecto Saude Bandim, Bissau 1004, Guinea Bissau.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
   Lab Nacl Saude Publ, Bissau, Guinea Bissau.
   MRC Labs, Fajara, Gambia.
RP Garly, ML (reprint author), Projecto Saude Bandim, Apartado 861, Bissau 1004, Guinea Bissau.
CR AABY P, 1993, BRIT MED J, V307, P1308
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 1999, AM J EPIDEMIOL, V149, P304
   ABANAMY A, 1992, ANN SAUDI MED, V12, P110
   Bennett JV, 1999, PEDIATRICS, V104, P1123, DOI 10.1542/peds.104.5.1123
   BERRY S, 1992, PEDIATR INFECT DIS J, V11, P822, DOI 10.1097/00006454-199210000-00003
   BLACK FL, 1984, B WORLD HEALTH ORGAN, V62, P315
   BOLOTOVSKI VM, 1994, INT J EPIDEMIOL, V23, P1069, DOI 10.1093/ije/23.5.1069
   BOTTIGER M, 1973, J BIOL STAND, V1, P225, DOI 10.1016/0092-1157(73)90016-4
   CLEMENTS CJ, 1995, CURR TOP MICROBIOL, V191, P13
   CUTTS FT, 1994, VACCINE, V12, P1311, DOI 10.1016/S0264-410X(94)80057-7
   CUTTS FT, 1995, BIOLOGICALS, V23, P95
   Dilraj A, 2000, LANCET, V355, P798, DOI 10.1016/S0140-6736(99)95140-1
   Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   GARLY ML, 1999, THESIS U COPENHAGEN
   *HONG KONG MEASL V, 1968, MED J AUSTRALIA, V1, P489
   Jaye A, 1998, J CLIN INVEST, V102, P1969, DOI 10.1172/JCI3290
   KHANUM S, 1987, LANCET, P150
   KIEPIELA P, 1991, B WORLD HEALTH ORGAN, V69, P221
   LENNETTE EH, 1959, DIAGNOSTIC PROCEDURE, P100
   LINNEMANN CC, 1982, PEDIATRICS, V69, P332
   MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903
   MARKOWITZ LE, 1987, PEDIATR INFECT DIS J, V6, P809, DOI 10.1097/00006454-198709000-00001
   MURPHY MD, 1984, PEDIATRICS, V74, P90
   NDUMBE PM, 1995, VACCINE, V13, P276, DOI 10.1016/0264-410X(95)93314-Y
   Pabst HF, 1999, VACCINE, V17, P1910, DOI 10.1016/S0264-410X(98)00472-1
   ROGERS S, 1991, J TROP MED HYG, V94, P88
   ROSENTHAL SR, 1993, B WORLD HEALTH ORGAN, V71, P421
   ROTA JS, 1994, VIRUS RES, V31, P317, DOI 10.1016/0168-1702(94)90025-6
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   WARD BJ, 1995, J INFECT DIS, V172, P1591
   Whistler T, 1996, VIROLOGY, V220, P480, DOI 10.1006/viro.1996.0335
   White CR, 1999, SEMIN CUTAN MED SURG, V18, P1, DOI 10.1016/S1085-5629(99)80002-9
   WHITTLE H, 1988, LANCET, V2, P811
   WHITTLE HC, 1988, LANCET, V1, P963
   WHITTLE HC, 1984, LANCET, V2, P834
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
   WHITTLE HC, 2000, UNPUB LANCET
   WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6
NR 41
TC 24
Z9 24
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2001
VL 19
IS 15-16
BP 1951
EP 1959
DI 10.1016/S0264-410X(00)00431-X
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 412DF
UT WOS:000167538200014
PM 11228365
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Faye, JA
   Jaitner, J
AF Mattioli, RC
   Faye, JA
   Jaitner, J
TI Estimation of trypanosomal status by the buffy coat technique and an
   antibody ELISA for assessment of the impact of trypanosomosis on health
   and productivity of N'Dama cattle in The Gambia
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE cattle-protozoa; Trypanosoma spp.; diagnosis-protozoa
ID LINKED-IMMUNOSORBENT-ASSAY; GLOSSINA-MORSITANS-SUBMORSITANS; AFRICAN
   ANIMAL TRYPANOSOMOSIS; CROSSBRED CATTLE; ZEBU CATTLE; GOBRA-ZEBU;
   SUSCEPTIBILITY; CONGOLENSE; TSETSE; CHALLENGE
AB The buffy coat/dark ground phase contrast technique (BCT) and an indirect antibody enzyme immunoassay (ELISA) were employed to assess the trypanosomal status of 32 N'Dama cattle, aged 19-28 months, exposed to natural challenge of Glossina morsitans submorsitans and C. palpalis gambiensis. Prior to the start of the investigation animals experienced 9-16 months of tsetse challenge in the study area. Blood and corresponding serum samples were examined monthly for a period of 8 months for patent parasitaemia by BCT and presence of Trypanosoma vivax and T. congolense antibodies by ELISA. In the ELISA, the reactivity of sera to anti-trypanosomal antibodies was expressed in percent positivity (pp). Packed cell volumes (PCV) and body weights were also recorded monthly, and daily weight gain (DWG) computed to assess the impact of trypanosomal status on health and productivity. During the study period, the overall parasitaemic trypanosome prevalence was 3% (6/199), while the serological prevalence was 54.7% (109/199). Both diagnostic tests revealed a predominance of T. vivax over T. congolense infections in N'Dama cattle. Sensitivity of the immunoassay was 83.3%. In ir: vivax-parasitaemic cattle, antibodies persisted for 4-6 months after the parasite was detected by BCT. A significantly higher overall mean PCV level was observed in blood samples obtained from cattle found, in any particular month, negative by BCT and ELISA, compared with those blood samples from animals responding serologically positively for anti-trypanosome antibodies. Likewise, mean DWG was significantly higher in cattle found negative for both tests in comparison to animals presenting detectable anti-trypanosome antibodies and those detected positive by both tests. A significant negative relationship was observed between pp values and PCV levels in animals seropositive for T. vivax and/or T. congolense. Similarly, a negative relationship was observed between DWGs and pp values. PCV levels were significantly positively correlated with DWGs. It was concluded that serological screening could provide useful information complementary to that obtained by the use of BCT not only to assess more accurately the trypanosomal status of cattle populations, but also to evaluate the effects of trypanosome infection on animal health and productivity and estimate the trypanosomosis risk. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR AUTHIE E, 1993, PARASITE IMMUNOL, V15, P101, DOI 10.1111/j.1365-3024.1993.tb00589.x
   Bauer B, 1999, TROP ANIM HEALTH PRO, V31, P89, DOI 10.1023/A:1005115707181
   BOCQUENTIN R, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P479
   CLAXTON JR, 1992, ACTA TROP, V50, P219, DOI 10.1016/0001-706X(92)90078-C
   CONNOR RJ, 1987, TROP ANIM HEALTH PRO, V19, P165, DOI 10.1007/BF02239713
   DEHOUX J P, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P337
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   Hopkins JS, 1998, PREV VET MED, V37, P91, DOI 10.1016/S0167-5877(98)00101-9
   Hursey B. S., 1995, World Animal Review, P67
   Itty P, 1996, AGR ECON, V14, P33, DOI 10.1016/0169-5150(95)01170-6
   JONGEJAN F, 1988, VET QUART, V10, P42
   Jordan A.M., 1986, TRYPANOSOMIASIS CONT
   LEPERRE P, 1994, TROP ANIM HEALTH PRO, V26, P139, DOI 10.1007/BF02241070
   LUCKINS AG, 1978, TROP ANIM HEALTH PRO, V10, P149, DOI 10.1007/BF02235328
   LUCKINS AG, 1977, TROP ANIM HEALTH PRO, V9, P53, DOI 10.1007/BF02297393
   Mattioli R. C., 1994, Parassitologia (Rome), V36, P305
   Mattioli RC, 1999, VET PARASITOL, V86, P83, DOI 10.1016/S0304-4017(99)00117-X
   Mattioli RC, 1996, ACTA TROP, V62, P71, DOI 10.1016/S0001-706X(96)00033-2
   Mattioli RC, 1998, ACTA TROP, V71, P57, DOI 10.1016/S0001-706X(98)00051-5
   MILLIGAN PJM, 1988, PARASITOLOGY, V96, P211
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   Nantulya V.M., 1990, Revue Scientifique et Technique Office International des Epizooties, V9, P357
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   PINDER M, 1988, VET IMMUNOL IMMUNOP, V18, P245, DOI 10.1016/0165-2427(88)90069-4
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   Rebeski DE, 2000, VET PARASITOL, V89, P187, DOI 10.1016/S0304-4017(00)00194-1
   Rebeski DE, 1999, MEM I OSWALDO CRUZ, V94, P249
   Snow WF, 1999, PREV VET MED, V42, P67, DOI 10.1016/S0167-5877(99)00072-0
   TRAIL JCM, 1992, VET PARASITOL, V42, P213, DOI 10.1016/0304-4017(92)90063-F
   TRAIL JCM, 1993, VET PARASITOL, V45, P241, DOI 10.1016/0304-4017(93)90079-3
   WACHER TJ, 1994, PARASITOLOGY, V109, P149
   WILSON A J, 1971, Tropical Animal Health and Production, V3, P133, DOI 10.1007/BF02360742
   Wright P F, 1993, Rev Sci Tech, V12, P435
NR 35
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB 5
PY 2001
VL 95
IS 1
BP 25
EP 35
DI 10.1016/S0304-4017(00)00411-8
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 395FL
UT WOS:000166569500003
PM 11163695
OA No
DA 2017-08-15
ER

PT J
AU Berry, N
   Ariyoshi, K
   Balfe, P
   Tedder, R
   Whittle, H
AF Berry, N
   Ariyoshi, K
   Balfe, P
   Tedder, R
   Whittle, H
TI Sequence specificity of the human immunodeficiency virus type 2 (HIV-2)
   long terminal repeat U3 region in vivo allows subtyping of the principal
   HIV-2 viral subtypes A and B
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; SP1 BINDING-ELEMENTS; RURAL GUINEA-BISSAU;
   NF-KAPPA-B; LOAD; VARIABILITY; ENHANCER; DNA; PATHOGENICITY; REPLICATION
AB Sequences from the nef/LTR overlap region of the human immunodeficiency virus type 2 (HIV-2) genome were amplified from uncultured peripheral blood mononuclear cells (PBMCs) from 40 HIV-2-infected individuals in The Gambia, West Africa. Additional sequences from the plasma of three blood donors were also derived. Analysis of HIV-2 U3 LTR transcription factor elements (PuB-1, p-ets, PuB-2, peri-kappaB, and NF-kappaB sites) indicated a relatively high level of conservation in vivo. The region immediately 3' of the nef termination codon, which exhibits clade-dependent specificity, was targeted by PCR to differentiate HIV-2 subtype A from subtype B infections, the two principal clinical HIV-2 subtypes. All clinical samples analyzed (n = 43) from The Gambia were identified as HIV-2 subtype A by a combination of LTR sequence analysis and subtype-specific amplification of subtypes A and B. Differential PCR amplification of the HIV-2 U3 LTR region represents a rapid means of differentiating subtype A from subtype B infections, the two dominant HIV-2 subtypes that are important in human disease.
C1 UCL Royal Free & Univ Coll Med Sch, Windeyer Inst Med Sci, Dept Virol, London W1P 6DB, England.
   MRC Labs, Banjul, Gambia.
RP Berry, N (reprint author), Natl Inst Biol Stand & Controls, Div Retrovirol, Blanche Lane S Mimms, Potters Bar EN6 3QG, Herts, England.
EM nberry@nibsc.ac.uk
CR Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   BOERI E, 1992, J VIROL, V66, P4546
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Chen ZW, 1997, J VIROL, V71, P3953
   CLARK NM, 1995, J VIROL, V69, P4854
   Damond F, 1998, J CLIN MICROBIOL, V36, P809
   GAO F, 1994, J VIROL, V68, P7433
   GAO F, 1992, NATURE, V358, P395
   GRANKVIST O, 1992, J ACQ IMMUN DEF SYND, V5, P286
   Grassly NC, 1998, J VIROL, V72, P7895
   Ilyinskii PO, 1996, J VIROL, V70, P3118
   MARKOVITZ DM, 1992, J VIROL, V66, P5479
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Norrgren H, 1997, J ACQ IMMUN DEF SYND, V16, P31
   Peeters M, 1998, AIDS RES HUM RETROV, V14, P51, DOI 10.1089/aid.1998.14.51
   Pieniazek D, 1999, AIDS RES HUM RETROV, V15, P603, DOI 10.1089/088922299311132
   Pohlmann S, 1998, J VIROL, V72, P5589
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   SANKALE JL, 1995, AIDS RES HUM RETROV, V11, P617, DOI 10.1089/aid.1995.11.617
   SCHULZ TF, 1990, J VIROL, V64, P5177
   van der Loeff MFS, 1999, AIDS, V13, pS69
   Walther L, 1996, AIDS RES HUM RETROV, V12, P1077, DOI 10.1089/aid.1996.12.1077
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   Xiang Z, 1997, AIDS RES HUM RETROV, V13, P501, DOI 10.1089/aid.1997.13.501
   Yamaguchi J, 2000, AIDS RES HUM RETROV, V16, P925
NR 27
TC 18
Z9 19
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB
PY 2001
VL 17
IS 3
BP 263
EP 267
DI 10.1089/088922201750063197
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 400DL
UT WOS:000166856500010
PM 11177410
OA No
DA 2017-08-15
ER

PT J
AU Marchant, A
   Amedei, A
   Azzurri, A
   Vekemans, J
   Benagiano, M
   Tamburini, C
   Lienhardt, C
   Corrah, T
   McAdam, KPW
   Romagnani, S
   D'Elios, MM
   Del Prete, G
AF Marchant, A
   Amedei, A
   Azzurri, A
   Vekemans, J
   Benagiano, M
   Tamburini, C
   Lienhardt, C
   Corrah, T
   McAdam, KPW
   Romagnani, S
   D'Elios, MM
   Del Prete, G
TI Polarization of PPD-specific T-cell response of patients with
   tuberculosis from Th0 to Th1 profile after successful antimycobacterial
   therapy or in vitro conditioning with interferon-alpha or interleukin-12
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
ID ACTIVATION-INDUCED CELL; PULMONARY TUBERCULOSIS;
   MYCOBACTERIUM-TUBERCULOSIS; CYTOKINE PRODUCTION; DIFFERENTIAL ABILITY;
   IMMUNE-RESPONSES; GAMMA; HELPER; APOPTOSIS; INFECTION
AB The T helper (Th) 1/Th2 balance in the T-lymphocyte response to purified protein derivative (PPD) was evaluated at the clonal level in six Italian and five Gambian patients with pulmonary tuberculosis (TB) before and after antimycobacterial therapy, as well as in five Gambian and four Italian healthy immune control subjects. In untreated patients, most PPD-specific clones derived from either peripheral blood or pleural effusions showed a Th0 cytokine profile (production of both interferon [IFN]-gamma and interleukin [IL]-4/IL-5). After 6 mo of therapy and clinical healing, most PPD-specific clones showed a polarized Th1 profile (production of IFN-gamma but not IL-4/IL-5) in both Italian and Gambian patients. The Th1 polarization was less marked in Gambian than in Italian patients and failed to occur in another group of four Italian patients who experienced treatment failure. The cytokine profile observed after successful therapy in patients with TB was similar to that found in healthy control subjects, T-cell clones of undefined specificity generated from PPD-stimulated cultures showed a similar Th0/Th2 bias in Gambian individuals and Italian patients with treatment failure. The Th0/Th2-biased responses in Gambian patients before therapy could be modulated in vitro by IFN-alpha or IL-12, which induced a Th1 polarization of both PPD-specific and bystander T cells. Our data show that active TB associates with a predominant Th0 response to mycobacterial antigens that could play a role in the pathogenesis of the disease. Adjunctive immunotherapy using Th1-polarizing cytokines could increase host defense against mycobacteria and accelerate healing.
C1 Univ Florence, Dept Internal Med, I-50134 Florence, Italy.
   Med Res Council Labs, Fajara, Gambia.
RP Del Prete, G (reprint author), Univ Florence, Dept Internal Med, Viale Morgagni 85, I-50134 Florence, Italy.
RI Amedei, Amedeo/G-5378-2011
OI Amedei, Amedeo/0000-0002-6797-9343
CR Adams JFA, 1999, LANCET, V353, P2030, DOI 10.1016/S0140-6736(98)08510-9
   BARNES PF, 1989, J IMMUNOL, V142, P1114
   Bentwich Z, 1999, IMMUNOL TODAY, V20, P485, DOI 10.1016/S0167-5699(99)01499-1
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918
   BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655
   Carter LL, 1997, CURR OPIN IMMUNOL, V9, P177, DOI 10.1016/S0952-7915(97)80132-X
   Daniel Thomas M., 1994, P13
   Das G, 1999, CLIN EXP IMMUNOL, V115, P324, DOI 10.1046/j.1365-2249.1999.00755.x
   DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707
   DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300
   Doffinger R, 2000, J INFECT DIS, V181, P379, DOI 10.1086/315197
   Giosue S, 1998, AM J RESP CRIT CARE, V158, P1156
   Gong JH, 1996, INFECT IMMUN, V64, P913
   Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193
   Hirsch CS, 1999, J INFECT DIS, V179, P945, DOI 10.1086/314667
   Holland S M, 2000, Adv Intern Med, V45, P431
   Jouanguy E, 1999, CURR OPIN IMMUNOL, V11, P346, DOI 10.1016/S0952-7915(99)80055-7
   LAUNOIS P, 1994, INFECT IMMUN, V62, P3679
   Lin YG, 1996, INFECT IMMUN, V64, P1351
   MANCA F, 1991, INFECT IMMUN, V59, P503
   MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   MUTIS T, 1993, J IMMUNOL, V150, P4641
   Palmero D, 1999, INT J TUBERC LUNG D, V3, P214
   PARRONCHI P, 1992, J IMMUNOL, V149, P2977
   RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325
   Vanham G, 1997, TUBERCLE LUNG DIS, V78, P145, DOI 10.1016/S0962-8479(97)90021-6
   Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778
   VILCEK J, 1986, J CLIN IMMUNOL, V6, P146, DOI 10.1007/BF00918747
   ZHANG M, 1995, INFECT IMMUN, V63, P3231
   Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837
NR 36
TC 49
Z9 50
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD FEB
PY 2001
VL 24
IS 2
BP 187
EP 194
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 405JV
UT WOS:000167157000012
PM 11159053
OA No
DA 2017-08-15
ER

PT J
AU von Seidlein, L
   Jawara, M
   Coleman, R
   Doherty, T
   Walraven, G
   Targett, G
AF von Seidlein, L
   Jawara, M
   Coleman, R
   Doherty, T
   Walraven, G
   Targett, G
TI Parasitaemia and gametocytaemia after treatment with chloroquine,
   pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with
   artesunate in young Gambians with uncomplicated malaria
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE P. faliciparum; malaria; Africa; The Gambia; artemisinin; artesunate;
   sulfadoxine-pyrimethamine; PSD; combination; gametocytes; chloroquine
ID RESISTANT FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM;
   SULFADOXINE-PYRIMETHAMINE; DRUG-RESISTANCE; CHILDREN; TRIAL;
   SENSITIVITY; EFFICACY; TANZANIA; AFRICA
AB As part of a study to assess the infectivity of gametocytes after treatment with four antimalarial regimens, the efficacy of each treatment was also determined. From September to December 1998, 598 children with uncomplicated malaria were treated; 135 received chloroquine (CQ) alone, 276 received pyrimethamine/sulfadoxine (Fansidar(C), PSD) alone, 113 received PSD with a single dose of artesunate (PSD + 1ART) and 74 received PSD combined with three doses of artesunate (PSD + 3ART). On day 28 19/63 (30.2%; 95% C.I. 19.2% to 43.1%) of children treated with CQ alone, 5/134 (3.7%; 95% C.I. 1.2% to 8.5%) treated with PSD alone, 1/71 (1.4%, 95% C.I. 0.0% to 7.9%) treated with PSD + 1ART and 0/45 (0.0%; 95% C.I. 0.0% to 7.9%) treated with PSD + 3ART were parasitaemic. The proportion of children with gametocytes on day 7 after treatment with CQ alone was 16/89 (18.0%; 95% C.I. 10.6% to 27.6%), 98/174 (56.3%; 95% C.I. 48.6% to 63.8%) after treatment with PSD alone, 8/70 (11.4%; 95% C.I. 5.1% to 21.3%) after treatment with PSD + 1ART and 4/46 (8.7%; 95% C.I., 2.4% to 20.8%) after treatment with PSD + 3ART. CQ thus has a lower efficacy than PSD or either of the PSD and artesunate combinations. Use of PSD alone as an alternative first line treatment results in a very high post-treatment gametocyte prevalence that is likely to enhance transmission. There would be greater and more sustainable benefits from using PSD and artesunate combinations.
C1 Med Res Council Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP von Seidlein, L (reprint author), Int Vaccine Inst, POB 14 Kwanak, Seoul 151600, South Korea.
CR BASCO LK, 1993, TROP MED PARASITOL, V44, P111
   Bojang KA, 1998, T ROY SOC TROP MED H, V92, P73, DOI 10.1016/S0035-9203(98)90962-2
   Bouvier P, 1997, AM J EPIDEMIOL, V145, P850
   BRANDICOURT O, 1986, AM J TROP MED HYG, V35, P717
   Brasseur P, 1999, T ROY SOC TROP MED H, V93, P645, DOI 10.1016/S0035-9203(99)90083-4
   BURCHARD GD, 1984, TROPENMED PARASITOL, V35, P1
   Collins WE, 1999, AM J TROP MED HYG, V61, P20
   Doherty JF, 1999, T ROY SOC TROP MED H, V93, P543, DOI 10.1016/S0035-9203(99)90376-0
   Ekvall H, 1998, T ROY SOC TROP MED H, V92, P556, DOI 10.1016/S0035-9203(98)90913-0
   Ezedinachi E. N. U., 1996, Central African Journal of Medicine, V42, P109
   KYRONSEPPA H, 1984, LANCET, V1, P1244
   LEBRAS J, 1986, LANCET, V2, P1043
   LI GQ, 1984, LANCET, V2, P1360
   MENON A, 1987, LANCET, V1, P1029
   Meshnick SR, 1996, MICROBIOL REV, V60, P301
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   NEEQUAYE J, 1986, LANCET, V1, P153
   Premji Z, 1999, B WORLD HEALTH ORGAN, V77, P740
   Rogier C, 1996, AM J TROP MED HYG, V54, P613
   Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7
   SANSONETTI PJ, 1985, LANCET, V1, P1154
   TARGETT G, 2000, IN PRESS J INFECT DI
   TOPLEY E, 1968, T ROY SOC TROP MED H, V62, P602, DOI 10.1016/0035-9203(68)90109-0
   Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   Warsame M, 1999, T ROY SOC TROP MED H, V93, P312, DOI 10.1016/S0035-9203(99)90034-2
   WHITE N, 1999, TROP MED INT HEALTH, V4, P468
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
   White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2
   *WHO, 1997, WHOMAL97
   Williams HA, 1999, TROP MED INT HEALTH, V4, P641, DOI 10.1046/j.1365-3156.1999.00471.x
NR 31
TC 52
Z9 52
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 2001
VL 6
IS 2
BP 92
EP 98
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 415RN
UT WOS:000167736600002
PM 11251903
OA No
DA 2017-08-15
ER

PT J
AU Erskine, J
AF Erskine, J
TI Terra breech trial
SO LANCET
LA English
DT Letter
RP Erskine, J (reprint author), POB 86, Banjul, Gambia.
CR Hannah ME, 2000, LANCET, V356, P1375, DOI 10.1016/S0140-6736(00)02840-3
NR 1
TC 3
Z9 3
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 20
PY 2001
VL 357
IS 9251
BP 228
EP 228
DI 10.1016/S0140-6736(05)71324-6
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 395QX
UT WOS:000166593700044
PM 11213119
OA No
DA 2017-08-15
ER

PT J
AU Tchilian, EZ
   Wallace, DL
   Wells, RS
   Flower, DR
   Morgan, G
   Beverley, PCL
AF Tchilian, EZ
   Wallace, DL
   Wells, RS
   Flower, DR
   Morgan, G
   Beverley, PCL
TI A deletion in the gene encoding the CD45 antigen in a patient with SCID
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LEUKOCYTE-COMMON ANTIGEN; SEVERE COMBINED IMMUNODEFICIENCY; T-CELLS;
   POINT MUTATION; EXPRESSION; DEFICIENCY; RECEPTOR; ISOFORM;
   LYMPHOHISTIOCYTOSIS; ACTIVATION
AB SCID is a heterogeneous group of hereditary diseases. Mutations in the common gamma -chain (gamma (c)) of cytokine receptors, including those for IL-2, IL-4, IL-7, IL-9, and IL-15, are responsible for an X-linked form of the disease, while mutations of several other genes, including Janus-associated kinase-3, may cause autosomal recessive forms of SCID. We investigated the first SCID patient to be described with minimal cell surface expression of the leukocyte common (CD45) Ag. CD45 is an abundant transmembrane tyrosine phosphatase, expressed on all leukocytes, and is required for efficient lymphocyte signaling. CD45-deficient mice are severely immunodeficient and have very few peripheral T lymphocytes. We report here that a homozygous 6-bp deletion in the gene encoding CD45 (PTPRC, gene map locus 1q31-32), which results in a loss of glutamic acid 339 and tyrosine 340 in the first fibronectin type III module of the extracellular domain of CD45, is associated with failure of surface expression of CD45 and SCID. Molecular modeling suggests that tyrosine 340 is crucial for the structural integrity of CD45 protein. This is the second description of a clinically relevant CD45 mutation, provides direct evidence for the importance of CD45 in immune function in humans, and suggests that abnormalities in CD45 expression are a possible cause of SCID in humans.
C1 Edward Jenner Inst Vaccine Res, Compton RG20 7NN, Berks, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Imperial Canc Res Fund, Oxford, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Immunogenet Lab, Oxford, England.
   MRC Labs, Fajara, Gambia.
RP Tchilian, EZ (reprint author), Edward Jenner Inst Vaccine Res, Compton RG20 7NN, Berks, England.
RI Flower, Darren/F-1263-2010
OI Flower, Darren/0000-0002-8542-7067
CR AKBAR AN, 1988, J IMMUNOL, V140, P2171
   ALEXANDER DR, 1997, LYMPHOCYTE SIGNALLIN, P107
   ARNAIZVILLENA A, 1992, NEW ENGL J MED, V327, P529, DOI 10.1056/NEJM199208203270805
   Beverley PCL, 1996, CURR OPIN IMMUNOL, V8, P327, DOI 10.1016/S0952-7915(96)80120-8
   BUJAN W, 1993, LANCET, V342, P1296, DOI 10.1016/0140-6736(93)92385-7
   BYTGH KF, 1996, J EXP MED, V183, P170
   Cale CM, 1997, ARCH DIS CHILD, V76, P163
   GIBLETT ER, 1972, LANCET, V2, P1067
   HALL LR, 1988, J IMMUNOL, V141, P2781
   KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7
   KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9
   Kung C, 2000, NAT MED, V6, P343
   LEE WT, 1990, J IMMUNOL, V144, P3288
   Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2
   Liao HX, 2000, J IMMUNOL, V165, P148
   MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0
   MASON D, 1992, BIOCHEM SOC T, V20, P188
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O
   Ochs HD, 1999, PRIMARY IMMUNODEFICI
   Okumura M, 1996, J IMMUNOL, V157, P1569
   PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7
   Poupon A, 1998, PROTEINS, V33, P329, DOI 10.1002/(SICI)1097-0134(19981115)33:3<329::AID-PROT3>3.0.CO;2-E
   ROGERS PR, 1992, J IMMUNOL, V148, P4054
   ROIFMAN CM, 1995, J CLIN IMMUNOL, V15, pS52, DOI 10.1007/BF01540894
   SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940
   STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548
   STREULI M, 1988, J IMMUNOL, V141, P3910
   SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377
   SYMMONS A, 1999, PROTEIN ENG, V12, P885
   TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.immunol.12.1.85
   Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8
   WAGNER R, 1995, CLIN EXP IMMUNOL, V99, P216
   Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888
   Zilch CF, 1998, EUR J IMMUNOL, V28, P22, DOI 10.1002/(SICI)1521-4141(199801)28:01<22::AID-IMMU22>3.0.CO;2-7
NR 35
TC 107
Z9 113
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JAN 15
PY 2001
VL 166
IS 2
BP 1308
EP 1313
PG 6
WC Immunology
SC Immunology
GA 389VP
UT WOS:000166259600074
PM 11145714
OA No
DA 2017-08-15
ER

PT J
AU Holmgren, B
   Andersson, S
   Ariyoshi, K
   Aaby, P
   Whittle, H
AF Holmgren, B
   Andersson, S
   Ariyoshi, K
   Aaby, P
   Whittle, H
TI Increased Prevalence of HTLV-1 Infection among HIV-2 positive women, but
   not men, in rural Guinea-Bissau
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
C1 Statens Serum Inst, DK-2300 Copenhagen, Denmark.
   Bandim Hlth Project, Bissau, Guinea Bissau.
   Swedish Inst Infect Dis Control, Stockholm, Sweden.
   MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 2001
VL 17
SU 1
BP S10
EP S10
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 446EE
UT WOS:000169499300022
OA No
DA 2017-08-15
ER

EF